PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Lesch, KP; Bengel, D; Heils, A; Sabol, SZ; Greenberg, BD; Petri, S; Benjamin, J; Muller, CR; Hamer, DH; Murphy, DL				Lesch, KP; Bengel, D; Heils, A; Sabol, SZ; Greenberg, BD; Petri, S; Benjamin, J; Muller, CR; Hamer, DH; Murphy, DL			Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region	SCIENCE			English	Article							ANGIOTENSIN-CONVERTING ENZYME; UNIFIED BIOSOCIAL THEORY; H-3 PAROXETINE BINDING; MYOCARDIAL-INFARCTION; QUANTITATIVE TRAITS; PERSONALITY-DISORDERS; SEXUAL ORIENTATION; MAJOR DEPRESSION; MARKERS; LINKAGE	Transporter-facilitated uptake of serotonin (5-hydroxytryptamine or 5-HT) has been implicated in anxiety in humans and animal models and is the site of action of widely used uptake-inhibiting antidepressant and antianxiety drugs. Human 5-HT transporter (5-HTT) gene transcription is modulated by a common polymorphism in its upstream regulatory region. The short variant of the polymorphism reduces the transcriptional efficiency of the 5-HTT gene promoter, resulting in decreased 5-HTT expression and 5-HT uptake in lymphoblasts. Association studies in two independent samples totaling 505 individuals revealed that the 5-HTT polymorphism accounts for 3 to 4 percent of total variation and 7 to 9 percent of inherited variance in anxiety-related personality traits in individuals as well as sibships.	NIMH,CLIN SCI LAB,NIH,BETHESDA,MD 20892; NCI,BIOCHEM LAB,NIH,BETHESDA,MD 20892; UNIV WURZBURG,INST HUMAN GENET,D-97074 WURZBURG,GERMANY	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Wurzburg	Lesch, KP (corresponding author), UNIV WURZBURG,DEPT PSYCHIAT,FUCHSLEINSTR 15,D-97080 WURZBURG,GERMANY.		Hamer, Dean H/L-1248-2015; Petri, Susanne/AID-7665-2022; Lesch, Klaus-Peter/J-4906-2013	Hamer, Dean H/0000-0002-6211-5781; Lesch, Klaus-Peter/0000-0001-8348-153X; Lagrange, hugues/0000-0002-2180-5284				Altemus M, 1996, AM J MED GENET, V67, P409, DOI 10.1002/(SICI)1096-8628(19960726)67:4<409::AID-AJMG16>3.0.CO;2-N; ANDREWS G, 1990, J AFFECT DISORDERS, V19, P23, DOI 10.1016/0165-0327(90)90005-S; [Anonymous], 1990, PERSONALITY ADULTHOO; ARBUSTINI E, 1995, BRIT HEART J, V74, P584; BEASLEY CM, 1992, PSYCHOPHARMACOLOGY, V107, P1, DOI 10.1007/BF02244958; Benjamin J, 1996, NAT GENET, V12, P81, DOI 10.1038/ng0196-81; BENKERT O, 1993, INT CLIN PSYCHOPHARM, V8, P3, DOI 10.1097/00004850-199309001-00001; BERGEMAN CS, 1988, PSYCHOL AGING, V3, P399, DOI 10.1037/0882-7974.3.4.399; BLIER P, 1994, TRENDS PHARMACOL SCI, V15, P220, DOI 10.1016/0165-6147(94)90315-8; BOJA JW, 1994, DOPAMINE RECEPTORS T, P611; CAMBIEN F, 1994, CLIN GENET, V46, P94; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; Cattell R.B., 1946, DESCRIPTION MEASUREM; Cattell RB, 1943, J ABNORM SOC PSYCH, V38, P476, DOI 10.1037/h0054116; CHEEK J, IN PRESS; CHEN HT, 1992, J PHARMACOL TOXICOL, V27, P209, DOI 10.1016/1056-8719(92)90043-Z; Cloninger C.R., 1986, PSYCHIATRIC DEV, V3, P167; CLONINGER CR, 1987, ARCH GEN PSYCHIAT, V44, P573; CLONINGER CR, 1988, PSYCHIAT DEV, V6, P83; COLLIER D, IN PRESS MOL PSYCHIA; Collier DA, 1996, NEUROREPORT, V7, P1675, DOI 10.1097/00001756-199607080-00030; COOK EH, 1994, NEUROREPORT, V5, P1745, DOI 10.1097/00001756-199409080-00014; COSTA PTJ, HDB PERSONALITY INVE; DENBOER JA, 1995, INT CLIN PSYCHOPHARM, V9, P47, DOI 10.1097/00004850-199501004-00007; DIBELLA D, 1995, PSYCHIAT GENET, V5, pS100; Ebstein RP, 1996, NAT GENET, V12, P78, DOI 10.1038/ng0196-78; ELSTON RC, 1994, SAGE USERS GUIDE REL; EYSENCK HJ, 1957, HDB ABNORMAL PSYCHOL, P131; FALUDI G, 1994, J PSYCHIATR NEUROSCI, V19, P109; FARAJ BA, 1994, INT J IMMUNOPHARMACO, V16, P561, DOI 10.1016/0192-0561(94)90107-4; FLINT J, 1995, SCIENCE, V269, P1432, DOI 10.1126/science.7660127; FUXE K, 1983, NEUROPHARMACOLOGY, V22, P389, DOI 10.1016/0028-3908(83)90188-0; GARDEMANN A, 1995, CIRCULATION, V92, P2796, DOI 10.1161/01.CIR.92.10.2796; GELERNTER J, 1995, HUM GENET, V95, P677; GEORGE VT, 1987, GENET EPIDEMIOL, V4, P193, DOI 10.1002/gepi.1370040304; Gray JA, 1982, NEUROPSYCHOLOGY ANXI, DOI 10.1002/9780470720394.ch2; GRIEBEL G, 1995, PHARMACOL THERAPEUT, V65, P319, DOI 10.1016/0163-7258(95)98597-J; HAMER DH, 1993, SCIENCE, V261, P321, DOI 10.1126/science.8332896; HANDLEY SL, 1995, PHARMACOL THERAPEUT, V66, P103, DOI 10.1016/0163-7258(95)00004-Z; HEATH AC, 1994, J PERS SOC PSYCHOL, V66, P762, DOI 10.1037/0022-3514.66.4.762; Heils A, 1996, J NEUROCHEM, V66, P2621; Heils A, 1995, J NEURAL TRANSM-GEN, V102, P247, DOI 10.1007/BF01281159; Heninger George R., 1995, P471; HENSLER JG, 1994, SYNAPSE, V17, P1, DOI 10.1002/syn.890170102; HU S, 1995, NAT GENET, V11, P248, DOI 10.1038/ng1195-248; IKEN K, 1995, CELL IMMUNOL, V163, P1, DOI 10.1006/cimm.1995.1092; INY LJ, 1994, BIOL PSYCHIAT, V36, P281; KENDLER KS, 1987, ARCH GEN PSYCHIAT, V44, P451; KENDLER KS, 1993, ARCH GEN PSYCHIAT, V50, P863; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; LESCH KP, 1994, J NEURAL TRANSM-GEN, V95, P157, DOI 10.1007/BF01276434; LESCH KP, 1995, BIOL PSYCHIAT, V37, P215, DOI 10.1016/0006-3223(94)00147-U; LESCH KP, 1993, J NEURAL TRANSM-GEN, V91, P67, DOI 10.1007/BF01244919; LOEHLIN JC, 1989, AM PSYCHOL, V44, P1285, DOI 10.1037/0003-066X.44.10.1285; MACKINNON A, 1994, HDB DEPRESSION ANXIE, P71; MAJ J, 1992, J NEURAL TRANSM-GEN, V88, P143, DOI 10.1007/BF01244819; MULDER RT, 1994, COMPR PSYCHIAT, V35, P225, DOI 10.1016/0010-440X(94)90195-3; MURPHY DL, 1993, SEROTONIN CELL BIOL, V2, P223; NICK TG, 1995, GENET EPIDEMIOL, V12, P145, DOI 10.1002/gepi.1370120204; Ogilvie AD, 1996, LANCET, V347, P731, DOI 10.1016/S0140-6736(96)90079-3; Ohno T, 1996, METABOLISM, V45, P218, DOI 10.1016/S0026-0495(96)90057-8; OWENS MJ, 1994, CLIN CHEM, V40, P288; PATERSON AH, 1991, GENETICS, V127, P181; PEDERSEN NL, 1988, J PERS SOC PSYCHOL, V55, P950, DOI 10.1037/0022-3514.55.6.950; PLOMIN R, 1994, SCIENCE, V264, P1733, DOI 10.1126/science.8209254; RAMAMOORTHY JD, 1995, J BIOL CHEM, V270, P17189, DOI 10.1074/jbc.270.29.17189; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; SHUEY DL, 1992, TERATOLOGY, V46, P367, DOI 10.1002/tera.1420460407; STUBER CW, 1992, GENETICS, V132, P823; SVRAKIC DM, 1993, ARCH GEN PSYCHIAT, V50, P991; WESTENBERG HG, 1996, ADV NEUROBIOLOGY ANX; WHITAKERAZMITIA P, 1990, ANN NY ACAD SCI, V600, P4; WIGGINS JS, 1992, ANNU REV PSYCHOL, V43, P473, DOI 10.1146/annurev.ps.43.020192.002353	73	3978	4123	6	435	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1996	274	5292					1527	1531		10.1126/science.274.5292.1527	http://dx.doi.org/10.1126/science.274.5292.1527			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	VV775	8929413				2022-12-24	WOS:A1996VV77500048
J	Hotamisligil, GS; Johnson, RS; Distel, RJ; Ellis, R; Papaioannou, VE; Spiegelman, BM				Hotamisligil, GS; Johnson, RS; Distel, RJ; Ellis, R; Papaioannou, VE; Spiegelman, BM			Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA; TYROSINE PHOSPHORYLATION; ADIPOSE-TISSUE; EXPRESSION; RECEPTOR; MICE; GENE	Fatty acid binding proteins (FABPs) are small cytoplasmic proteins that are expressed in a highly tissue-specific manner and bind to fatty acids such as oleic and retinoic acid. Mice with a null mutation in aP2, the gene encoding the adipocyte FABP, were developmentally and metabolically normal. The aP2-deficient mice developed dietary obesity but, unlike control mice, they did not develop insulin resistance or diabetes. Also unlike their obese wild-type counterparts, obese aP2(-/-) animals failed to express in adipose tissue tumor necrosis factor-alpha (TNF-alpha), a molecule implicated in obesity-related insulin resistance. These results indicate that aP2 is central to the pathway that links obesity to insulin resistance, possibly by linking fatty acid metabolism to expression of TNF-alpha.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; COLUMBIA UNIV, DEPT GENET & DEV, NEW YORK, NY 10032 USA	University of California System; University of California San Diego; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Columbia University	Hotamisligil, GS (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, 665 HUNTINGTON AVE, BOSTON, MA 02115 USA.		Johnson, Randall/AAM-1189-2021	Johnson, Randall/0000-0002-4084-6639; Papaioannou, Virginia/0000-0001-7558-8601	NICHD NIH HHS [HD27295] Funding Source: Medline; NIDDK NIH HHS [DK31405] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027295] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031405, R01DK031405] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERNLOHR DA, UNPUB; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; FERRANNINI E, 1983, J CLIN INVEST, V72, P1737, DOI 10.1172/JCI111133; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HAMANN A, 1995, DIABETES, V44, P1266, DOI 10.2337/diabetes.44.11.1266; HOFMANN C, 1994, ENDOCRINOLOGY, V134, P264, DOI 10.1210/en.134.1.264; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; HOTAMISLIGIL GS, 1994, J CLIN INVEST, V94, P1543, DOI 10.1172/JCI117495; HOTAMISLIGIL GS, UNPUB; JOHNSON RS, 1989, SCIENCE, V245, P1234, DOI 10.1126/science.2506639; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; KERN PA, 1995, J CLIN INVEST, V95, P2111, DOI 10.1172/JCI117899; KRIEG P, 1993, J BIOL CHEM, V268, P17362; Kroder G, 1996, J CLIN INVEST, V97, P1471, DOI 10.1172/JCI118569; LEMONNIER D, 1975, DIABETES METAB, V1, P77; MATARESE V, 1989, PROG LIPID RES, V28, P245, DOI 10.1016/0163-7827(89)90001-5; Moller DE, 1993, INSULIN RESISTANCE; Papaioannou V., 1993, Gene targeting: a practical approach., P107; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; RANDLE PJ, 1963, LANCET, V1, P785; SALMON DMW, 1985, INT J OBESITY, V9, P443; STEPHENS JM, 1991, J BIOL CHEM, V266, P21839; STORCH J, UNPUB; STORLIEN LH, 1991, DIABETES, V40, P280, DOI 10.2337/diabetes.40.2.280; SVEDBERG J, 1990, DIABETES, V39, P570, DOI 10.2337/diabetes.39.5.570	30	620	675	0	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 22	1996	274	5291					1377	1379		10.1126/science.274.5291.1377	http://dx.doi.org/10.1126/science.274.5291.1377			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU954	8910278				2022-12-24	WOS:A1996VU95400054
J	Wang, Q; Stacy, T; Miller, JD; Lewis, AF; Gu, TL; Huang, XM; Bushweller, JH; Bories, JC; Alt, FW; Ryan, G; Liu, PP; WynshawBoris, A; Binder, M; MarinPadilla, M; Sharpe, AH; Speck, NA				Wang, Q; Stacy, T; Miller, JD; Lewis, AF; Gu, TL; Huang, XM; Bushweller, JH; Bories, JC; Alt, FW; Ryan, G; Liu, PP; WynshawBoris, A; Binder, M; MarinPadilla, M; Sharpe, AH; Speck, NA			The CBF beta subunit is essential for CBF alpha 2 (AML1) function in vivo	CELL			English	Article							ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; MOUSE EMBRYO; RUNT DOMAIN; TRANSCRIPTION FACTORS; TARGETED MUTATION; CEREBRAL-CORTEX; CHIMERIC MICE; PROTEIN RBTN2; YOLK-SAC	The CBF beta subunit is the non-DNA-binding subunit of the heterodimeric core-binding factor (CBF). CBF beta associates with DNA-binding CBF alpha subunits and increases their affinity for DNA. Genes encoding the CBF beta subunit (CBFB) and one of the CBF alpha subunits (CBFA2, otherwise known as AML1) are the most frequent targets of chromosomal translocations in acute leukemias in humans. We and others previously demonstrated that homozygous disruption of the mouse Cbfa2 (AML1) gene results in embryonic lethality at midgestation due to hemorrhaging in the central nervous system and blocks fetal liver hematopoiesis. Here we demonstrate that homozygous mutation of the Cbfb gene results in the same phenotype. Our results demonstrate that the CBF beta subunit is required for CBF alpha 2 function in vivo.	DARTMOUTH COLL,DEPT CHEM,HANOVER,NH 03755; CHILDRENS HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02215; NIH,NATL CTR HUMAN GENOME RES,BETHESDA,MD 20892; DARTMOUTH COLL SCH MED,DEPT ANAT,HANOVER,NH 03755; DARTMOUTH COLL SCH MED,DEPT PATHOL,HANOVER,NH 03755; BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215	Dartmouth College; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Dartmouth College; Dartmouth College; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Wang, Q (corresponding author), DARTMOUTH COLL SCH MED,DEPT BIOCHEM,HANOVER,NH 03755, USA.		Bories, Jean-Christophe/L-6952-2017; Liu, Paul/A-7976-2012	Liu, Paul/0000-0002-6779-025X; Bushweller, John/0000-0002-5386-1758	NCI NIH HHS [CA58343] Funding Source: Medline; NIAID NIH HHS [AI39536-01] Funding Source: Medline; NINDS NIH HHS [NS22897] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039536, R29AI039536] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022897] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDRES KH, 1967, Z ZELLFORSCH MIK ANA, V79, P272, DOI 10.1007/BF00369291; BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; BITTER MA, 1987, HUM PATHOL, V18, P211, DOI 10.1016/S0046-8177(87)80002-3; BOWIE JU, 1989, J BIOL CHEM, V264, P7596; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Golling G, 1996, MOL CELL BIOL, V16, P932; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Harlow E, 1988, ANTIBODIES LAB MANUA; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KRISCH B, 1984, CELL TISSUE RES, V238, P459; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MARINPADILLA M, 1985, J COMP NEUROL, V241, P237, DOI 10.1002/cne.902410210; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; ROSEN B, 1993, TRENDS GENET, V9, P162, DOI 10.1016/0168-9525(93)90162-B; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; SHURTLEFF SA, 1995, BLOOD, V85, P3695, DOI 10.1182/blood.V85.12.3695.bloodjournal85123695; SIMEONE A, 1995, DEV DYNAM, V203, P61, DOI 10.1002/aja.1002030107; SOLFER SJ, 1994, AM J PATHOL, V144, P60; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; THORNELL A, 1991, J VIROL, V65, P42, DOI 10.1128/JVI.65.1.42-50.1991; TSAL JY, 1994, NATURE, V371, P221; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; WONG PMC, 1986, P NATL ACAD SCI USA, V83, P3851, DOI 10.1073/pnas.83.11.3851	46	533	540	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1996	87	4					697	708		10.1016/S0092-8674(00)81389-6	http://dx.doi.org/10.1016/S0092-8674(00)81389-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VU035	8929538	hybrid			2022-12-24	WOS:A1996VU03500012
J	Fields, BA; Malchiodi, EL; Li, HM; Ysern, X; Stauffacher, CV; Schlievert, PM; Karjalainen, K; Mariuzza, RA				Fields, BA; Malchiodi, EL; Li, HM; Ysern, X; Stauffacher, CV; Schlievert, PM; Karjalainen, K; Mariuzza, RA			Crystal structure of a T-cell receptor beta-chain complexed with a superantigen	NATURE			English	Article							3-DIMENSIONAL STRUCTURE; ANTIGEN RECEPTOR; BINDING; MHC	SUPERANTIGENS (SAgs) are viral or bacterial proteins that act as potent T-cell stimulants and have been implicated in a number of human diseases, including toxic shock syndrome(1,2), diabetes mellitus(3) and multiple sclerosis(4). The interaction of SAgs with the T-cell receptor (TCR) and major histocompatibility complex (MHC) proteins results in the stimulation of a disproportionately large fraction of the T-cell population(2). We report here the crystal structures of the beta-chain of a TCR complexed with the Staphylococcus aureus enterotoxins C2 and C3 (SEC2, SEC3). These enterotoxins, which cause both toxic shock and food poisoning, bind in an identical way to the TCR beta-chain. The complementarity-determining region 2 (CDR2) of the beta-chain and, to lesser extents, CDR1 and hypervariable region 4 (HV4), bind in a cleft between the two domains of the SAgs. Thus, there is considerable overlap between the SAg-binding site and the peptide/MHC-binding sites of the TCR. A model of a TCR-SAg-MHC complex constructed from the crystal structures of (1) the beta-chain-SEC3 complex, (2) a complex between staphylococcal enterotoxin B (SEB) and an MHC molecule(5), and (3) a TCR V alpha domain(6), reveals that the SAg acts as a wedge between the TCR and MHC to displace the antigenic peptide away from the TCR combining site. In this way, the SAg is able to circumvent the normal mechanism for T-cell activation by specific peptide/MHC complexes.	UNIV MARYLAND, MARYLAND BIOTECHNOL INST, CTR ADV RES BIOTECHNOL, ROCKVILLE, MD 20850 USA; UNIV BUENOS AIRES, FAC FARM & BIOQUIM,CATEDRA IMMUNOL,CONICET, INST ESTUDIOS INMUNIDAD HUMORAL, RA-1113 BUENOS AIRES, DF, ARGENTINA; US FDA, CTR DRUG EVALUAT & RES, ROCKVILLE, MD 20857 USA; PURDUE UNIV, DEPT BIOL SCI, W LAFAYETTE, IN 47907 USA; UNIV MINNESOTA, SCH MED, DEPT MICROBIOL, MINNEAPOLIS, MN 55455 USA; BASEL INST IMMUNOL, CH-4005 BASEL, SWITZERLAND	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; US Food & Drug Administration (FDA); Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Minnesota System; University of Minnesota Twin Cities			Karjalainen, Klaus/A-2206-2011; Li, Hongmin/ABI-2439-2020	Li, Hongmin/0000-0002-8684-5308; Malchiodi, Emilio/0000-0001-7501-3330; Schlievert, Patrick/0000-0001-8314-9369; Fields, Barry/0000-0003-0628-1328				Arden Bernhard, 1995, Immunogenetics, V42, P455; Bentley GA, 1996, ANNU REV IMMUNOL, V14, P563, DOI 10.1146/annurev.immunol.14.1.563; BENTLEY GA, 1995, SCIENCE, V267, P1984, DOI 10.1126/science.7701320; BLOMSTERHAUTAMAA DA, 1988, METHOD ENZYMOL, V165, P37; BOHACH GA, 1990, CRIT REV MICROBIOL, V17, P251, DOI 10.3109/10408419009105728; BROCKE S, 1993, NATURE, V365, P642, DOI 10.1038/365642a0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CONRAD B, 1994, NATURE, V371, P351, DOI 10.1038/371351a0; DECKHUT AM, 1994, J EXP MED, V180, P1931, DOI 10.1084/jem.180.5.1931; DERINGER JR, IN PRESS MOL MICROBI; FIELDS BA, 1995, SCIENCE, V270, P1821, DOI 10.1126/science.270.5243.1821; FREMONDT DH, 1996, J SCIE, V272, P1001; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; FUREY W, IN PRESS METHODS ENZ; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; HOFFMANN ML, 1994, INFECT IMMUN, V62, P3396, DOI 10.1128/IAI.62.8.3396-3407.1994; Hong SC, 1996, J EXP MED, V183, P1437, DOI 10.1084/jem.183.4.1437; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; KIM JS, 1994, SCIENCE, V266, P1870, DOI 10.1126/science.7997880; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; KOTZIN BL, 1993, ADV IMMUNOL, V54, P99, DOI 10.1016/S0065-2776(08)60534-9; LABRECQUE N, 1994, J EXP MED, V180, P1921, DOI 10.1084/jem.180.5.1921; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MALCHIODI EL, 1995, J EXP MED, V182, P1833, DOI 10.1084/jem.182.6.1833; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PAPAGEORGIOU AC, 1995, STRUCTURE, V3, P769, DOI 10.1016/S0969-2126(01)00212-X; SETH A, 1994, NATURE, V369, P324, DOI 10.1038/369324a0; SWAMINATHAN S, 1992, NATURE, V359, P801, DOI 10.1038/359801a0; WEBB SR, 1994, CURR OPIN IMMUNOL, V6, P467, DOI 10.1016/0952-7915(94)90129-5; WOODLAND DL, 1993, IMMUNOL TODAY, V14, P208, DOI 10.1016/0167-5699(93)90164-G	31	250	263	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 14	1996	384	6605					188	192		10.1038/384188a0	http://dx.doi.org/10.1038/384188a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT336	8906797				2022-12-24	WOS:A1996VT33600071
J	Hempel, CM; Vincent, P; Adams, SR; Tsien, RY; Selverston, AI				Hempel, CM; Vincent, P; Adams, SR; Tsien, RY; Selverston, AI			Spatio-temporal dynamics of cyclic AMP signals in an intact neural circuit	NATURE			English	Article							LOBSTER STOMATOGASTRIC GANGLION; PROTEIN KINASE-A; AMINERGIC MODULATION; PYLORIC CIRCUIT; NEURONS; CAMP; ORGANIZATION; OCTOPAMINE; PROCTOLIN; PATTERN	THE functional properties of neuronal networks can be reconfigured by a variety of modulatory neurotransmitters, which may alter the excitable properties of neurons or the strengths of synaptic connections. Many of these neuromodulators act via the intracellular second messenger cyclic AMP, but their effects on the spatial distribution of cAMP concentration have never been examined in an intact neural circuit. We therefore used the cAMP-indicator dye FICRhR (refs 1, 2) to investigate the effect of several neuromodulators (octopamine, dopamine, acetylcholine, serotonin and proctolin) on cAMP distribution in identified neurons of the lobster stomatogastric ganglion (STG). When added to the bath solution, each of these neuromodulators produced a unique pattern of cAMP transients among the different neurons of the STG. Electrical stimulation of neurons innervating the STG causes synaptic release of endogenous modulators, leading within a few seconds to local increases of cAMP in fine neurite branches, the site where many modulators are thought to act(3,4). After prolonged stimulation, cAMP diffuses from the site of production to throughout the neuritic tree and eventually to the cell body. Diffusion of cAMP may explain how transient localized inputs to a neuron can produce long-range effects such as long-term changes in gene expression.	UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Hempel, CM (corresponding author), UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA.		Vincent, Pierre/A-1055-2012	Vincent, Pierre/0000-0002-8479-1908				Adams S.R., 1993, FLUORESCENT PROBES B, P133; ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; ALBERINI CM, 1995, ANN NY ACAD SCI, V758, P261, DOI 10.1111/j.1749-6632.1995.tb24833.x; BACSKAI BJ, 1993, SCIENCE, V260, P222, DOI 10.1126/science.7682336; BAL T, 1987, J NEUROSCI, P3019; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; FLAMM RE, 1986, J NEUROPHYSIOL, V55, P866, DOI 10.1152/jn.1986.55.5.866; FLAMM RE, 1987, J NEUROPHYSIOL, V58, P1370, DOI 10.1152/jn.1987.58.6.1370; FLAMM RE, 1986, J NEUROPHYSIOL, V55, P847, DOI 10.1152/jn.1986.55.5.847; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; Harris-Warrick Ronald M., 1992, P87; Hartline Daniel K., 1992, P31; HEINZEL HG, 1988, J NEUROPHYSIOL, V59, P551, DOI 10.1152/jn.1988.59.2.551; HOOPER SL, 1987, J NEUROSCI, V7, P2097; Johnson Bruce R., 1992, P1; KING DG, 1976, J NEUROCYTOL, V5, P239, DOI 10.1007/BF01181658; MAYNARD DM, 1975, J COMP PHYSIOL, V100, P161, DOI 10.1007/BF00613967; RUSSELL DF, 1979, BRAIN RES, V177, P598, DOI 10.1016/0006-8993(79)90480-3; Tsien Roger Y., 1995, P459; Tsien Roger Y., 1993, Trends in Cell Biology, V3, P242, DOI 10.1016/0962-8924(93)90124-J	20	127	129	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 14	1996	384	6605					166	169		10.1038/384166a0	http://dx.doi.org/10.1038/384166a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT336	8906791				2022-12-24	WOS:A1996VT33600065
J	Weber, DA; Evavold, BD; Jensen, PE				Weber, DA; Evavold, BD; Jensen, PE			Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM	SCIENCE			English	Article							CLASS-II MHC; ANTIGEN-PROCESSING MUTANT; INVARIANT CHAIN PEPTIDES; HISTOCOMPATIBILITY MOLECULES; BINDING; CLIP; TRANSPORT; LIGANDS; HLA-DR3; RELEASE	Human leukocyte antigen (HLA)-DM is a critical participant in antigen presentation that catalyzes the release of class II-associated invariant chain-derived peptides (CLIP) from newly synthesized class II histocompatibility molecules, freeing the peptide-binding site for acquisition of antigenic peptides. The mechanism for the selective release of CLIP but not other peptides is unknown. DM was found to enhance the rate of peptide dissociation to an extent directly proportional to the intrinsic rate of peptide dissociation from HLA-DR, regardless of peptide sequence. Thus, CLIP is rapidly released in the presence of DM, because its intrinsic rate of dissociation is relatively high. In antigen presentation, DM has the potential to markedly enhance the rate of peptide exchange, favoring the presentation of peptides with slower intrinsic rates of dissociation.	EMORY UNIV,SCH MED,DEPT PATHOL & LAB MED,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,ATLANTA,GA 30322	Emory University; Emory University				Evavold, Brian/0000-0002-3561-3494	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI033614, R21AI030554, R01AI033614, R01AI030554] Funding Source: NIH RePORTER; NIAID NIH HHS [AI30554, AI33614] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; FLING SP, 1994, NATURE, V368, P554, DOI 10.1038/368554a0; GELUK A, 1994, J IMMUNOL, V152, P5742; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; JENSEN PE, 1991, J EXP MED, V174, P1111, DOI 10.1084/jem.174.5.1111; KROPSHOFER H, 1995, SCIENCE, V270, P1357, DOI 10.1126/science.270.5240.1357; MALCHEREK G, 1994, J IMMUNOL, V153, P1141; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; SETTE A, 1992, SCIENCE, V258, P1801, DOI 10.1126/science.1465617; SHERMAN MA, 1995, IMMUNITY, V3, P197, DOI 10.1016/1074-7613(95)90089-6; SLOAN VS, 1995, NATURE, V375, P802, DOI 10.1038/375802a0; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; WITT SN, 1991, P NATL ACAD SCI USA, V88, P8164, DOI 10.1073/pnas.88.18.8164	20	251	258	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 25	1996	274	5287					618	620		10.1126/science.274.5287.618	http://dx.doi.org/10.1126/science.274.5287.618			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN919	8849454				2022-12-24	WOS:A1996VN91900052
J	Zhou, QA; Sharp, PA				Zhou, QA; Sharp, PA			Tat-SF1: Cofactor for stimulation of transcriptional elongation by HIV-1 Tat	SCIENCE			English	Article							RNA-POLYMERASE-II; TUMOR-SUPPRESSOR PROTEIN; LONG TERMINAL REPEAT; ACTIVATION DOMAIN; TRANS-ACTIVATION; GENE-EXPRESSION; BINDING PROTEIN; SEQUENCE; FUSION; TRANSLOCATION	Tat may stimulate transcriptional elongation by recruitment of a complex containing Tat-SF1 and a kinase to the human immunodeficiency virus-type 1 (HIV-1) promoter through a Tat-TAR interaction. A complementary DNA for the cellular activity, Tat-SF1, has been isolated. This factor is required for Tat trans-activation and is a substrate of an associated cellular kinase, Cotransfection with the complementary DNA for Tat-SF1 specifically modulates Tat activation. Tat-SF1 contains two RNA recognition motifs and a highly acidic carboxyl-terminal half. It is distantly related to EWS and FUS/TLS, members of a family of putative transcription factors with RNA recognition motifs that are associated with sarcomas.	MIT, CTR CANC RES, CAMBRIDGE, MA 02139 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)					NATIONAL CANCER INSTITUTE [P30CA014051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032486] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034277, R01GM034277] Funding Source: NIH RePORTER; NCI NIH HHS [CA14051] Funding Source: Medline; NIAID NIH HHS [AI32486] Funding Source: Medline; NIGMS NIH HHS [GM34277] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BLAIR WS, 1996, EMBO J, V15, P101; Blau J, 1996, MOL CELL BIOL, V16, P2044; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; CULLEN BR, 1994, INFECT AGENT DIS, V3, P68; DAHMUS ME, 1995, BBA-GENE STRUCT EXPR, V1261, P171, DOI 10.1016/0167-4781(94)00233-S; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; Frankel AD, 1992, CURR OPIN GENET DEV, V2, P293, DOI 10.1016/S0959-437X(05)80287-4; GARCIA JA, 1989, EMBO J, V8, P765, DOI 10.1002/j.1460-2075.1989.tb03437.x; GAYNOR RB, 1995, CURR TOP MICROBIOL, V193, P51; GENDELMAN HE, 1986, P NATL ACAD SCI USA, V83, P9759, DOI 10.1073/pnas.83.24.9759; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; Harper SE, 1996, P NATL ACAD SCI USA, V93, P8536, DOI 10.1073/pnas.93.16.8536; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; KARN J, 1992, TRENDS GENET, V8, P365, DOI 10.1016/0168-9525(92)90284-B; KATO H, 1992, GENE DEV, V6, P655, DOI 10.1101/gad.6.4.655; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; LADANYI M, 1995, DIAGN MOL PATHOL, V4, P162, DOI 10.1097/00019606-199509000-00003; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; Liu S., UNPUB; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; MARSHAK DR, 1991, METHOD ENZYMOL, V200, P134; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MCMILLAN NAJ, 1995, VIROLOGY, V213, P413, DOI 10.1006/viro.1995.0014; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; PRASAD DDK, 1994, ONCOGENE, V9, P3717; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RICE AP, 1990, J VIROL, V64, P1864, DOI 10.1128/JVI.64.4.1864-1868.1990; SELBY MJ, 1989, GENE DEV, V3, P547, DOI 10.1101/gad.3.4.547; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; TILEY LS, 1990, VIROLOGY, V178, P560, DOI 10.1016/0042-6822(90)90354-T; TRUETT MA, 1985, DNA-J MOLEC CELL BIO, V4, P333, DOI 10.1089/dna.1985.4.333; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2; ZHOU QA, 1995, EMBO J, V14, P321, DOI 10.1002/j.1460-2075.1995.tb07006.x; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513	46	140	146	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 25	1996	274	5287					605	610		10.1126/science.274.5287.605	http://dx.doi.org/10.1126/science.274.5287.605			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN919	8849451				2022-12-24	WOS:A1996VN91900049
J	Gerber, MA; Shapiro, ED; Burke, GS; Parcells, VJ; Bell, GL				Gerber, MA; Shapiro, ED; Burke, GS; Parcells, VJ; Bell, GL			Lyme disease in children in southeastern Connecticut	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHILDHOOD; BORRELIOSIS; MANIFESTATIONS; SERODIAGNOSIS; DOXYCYCLINE; FEATURES; ASSAY; AREA	Background Although the incidence of Lyme disease is highest in children, there are few prospective data on the clinical manifestations and outcomes in children. Methods We conducted a prospective, longitudinal, community-based cohort study of children with newly diagnosed Lyme disease in an area of Connecticut in which the disease is highly endemic. We obtained clinical and demographic information and performed serial antibody tests and follow-up evaluations. Results Over a period of 20 months, 201 consecutive patients were enrolled; their median age was 7 years (range, 1 to 21). The initial clinical manifestations of Lyme disease were a single erythema migrans lesion in 66 percent, multiple erythema migrans lesions in 23 percent, arthritis in 6 percent, facial-nerve palsy in 3 percent, aseptic meningitis in 2 percent, and carditis in 0.5 percent. At presentation, 37 percent of the patients with a single erythema migrans lesion and 89 percent of those with multiple erythema migrans lesions had antibodies against Borrelia burgdorferi. All but 3 of the 201 patients were treated for two to four weeks with conventional antimicrobial therapy, which was adminis tered orally in 96 percent. All had prompt clinical responses, After four weeks, 94 percent were completely asymptomatic (including the two patients whose parents had refused to allow antimicrobial treatment), At follow-up a mean of 25.4 months later, none of the patients had evidence of either chronic or recurrent Lyme disease. Six patients subsequently had a new episode of erythema migrans. Conclusions About 90 percent of children with Lyme disease present with erythema migrans, which is an early stage of the disease. The prognosis is excellent for those with early Lyme disease who are treated promptly with conventional courses of antimicrobial agents. (C) 1996, Massachusetts Medical Society.	YALE UNIV, SCH MED, DEPT PEDIAT, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT EPIDEMIOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, CHILDRENS CLIN RES CTR, NEW HAVEN, CT 06510 USA	Yale University; Yale University; Yale University	Gerber, MA (corresponding author), UNIV CONNECTICUT, SCH MED, CONNECTICUT CHILDRENS MED CTR, DEPT PEDIAT, 282 WASHINGTON ST, HARTFORD, CT 06106 USA.							ADAMS WV, 1994, PEDIATRICS, V94, P185; AGUEROROSENFELD ME, 1993, J CLIN MICROBIOL, V31, P3090, DOI 10.1128/JCM.31.12.3090-3095.1993; BERGLUND J, 1995, NEW ENGL J MED, V333, P1319, DOI 10.1056/NEJM199511163332004; CHRISTEN HJ, 1990, ACTA PAEDIATR SCAND, V79, P1219; CHRISTEN HJ, 1993, ACTA PAEDIATR, V82, P1; DATTWYLER RJ, 1990, LANCET, V336, P1404, DOI 10.1016/0140-6736(90)93103-V; DRESSLER F, 1991, ANN INTERN MED, V115, P533, DOI 10.7326/0003-4819-115-7-533; DRESSLER F, 1994, CLIN EXP RHEUMATOL, V12, pS49; DRESSLER F, 1993, J INFECT DIS, V167, P392, DOI 10.1093/infdis/167.2.392; EICHENFIELD AH, 1986, J PEDIATR-US, V109, P753, DOI 10.1016/S0022-3476(86)80688-6; FEDER HM, 1995, J INFECT DIS, V171, P1371, DOI 10.1093/infdis/171.5.1371; GRODZICKI RL, 1988, J INFECT DIS, V157, P790, DOI 10.1093/infdis/157.4.790; JORBECK HJA, 1987, ACTA PAEDIATR SCAND, V76, P228, DOI 10.1111/j.1651-2227.1987.tb10452.x; KRAMER CY, 1956, BIOMETRICS, V12, P307, DOI 10.2307/3001469; Kramer M.S., 1988, CLIN EPIDEMIOLOGY BI; MAGNARELLI LA, 1988, AM J EPIDEMIOL, V127, P818, DOI 10.1093/oxfordjournals.aje.a114864; MARKOWITZ M, 1968, PEDIATRICS, V41, P151; MASSAROTTI EM, 1992, AM J MED, V92, P396, DOI 10.1016/0002-9343(92)90270-L; NADELMAN RB, 1992, ANN INTERN MED, V117, P273, DOI 10.7326/0003-4819-117-4-273; PETERSEN LR, 1989, YALE J BIOL MED, V62, P253; SALAZAR JC, 1993, J PEDIATR-US, V122, P591, DOI 10.1016/S0022-3476(05)83541-3; Siegel S., 1988, NONPARAMETRIC STAT B; SIGAL LH, 1990, AM J MED, V88, P577, DOI 10.1016/0002-9343(90)90520-N; STEERE AC, 1983, ANN INTERN MED, V99, P22, DOI 10.7326/0003-4819-99-1-22; Tukey JW, 1991, STAT SCI, V6, P100, DOI [DOI 10.1214/SS/1177011945, 10.1214/ss/1177011945]; WEBER K, 1986, INFECTION, V14, P32, DOI 10.1007/BF01644807; WILLIAMS CL, 1990, PEDIATR INFECT DIS J, V9, P10, DOI 10.1097/00006454-199001000-00003; [No title captured]; [No title captured]	29	228	232	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 24	1996	335	17					1270	1274		10.1056/NEJM199610243351703	http://dx.doi.org/10.1056/NEJM199610243351703			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN594	8857006				2022-12-24	WOS:A1996VN59400003
J	Chan, SSY; Zheng, H; Su, MW; Wilk, R; Killeen, MT; Hedgecock, EM; Culotti, JG				Chan, SSY; Zheng, H; Su, MW; Wilk, R; Killeen, MT; Hedgecock, EM; Culotti, JG			UNC-40, a C-elegans homolog of DCC (Deleted in Colorectal Cancer), is required in motile cells responding to UNC-6 netrin cues	CELL			English	Article							PIONEER AXON MIGRATIONS; CAENORHABDITIS-ELEGANS; IMMUNOGLOBULIN SUPERFAMILY; NEURONAL DIFFERENTIATION; POINT MUTATIONS; NERVOUS-SYSTEM; GENE-PRODUCT; GUIDES CELL; GUIDANCE; EXPRESSION	UNC-6 netrin, a laminin-related protein secreted from neuroglia and neurons along the ventral midline, orients migrating cells and pioneering growth cones on the nematode epidermis. UNC-5, a cell surface protein expressed on motile cells and pioneer axons, orients movements away from UNC-6 sources. UNC-40, a homolog of the cell surface proteins DCC (Deleted in Colorectal Cancer) and neogenin, is also expressed on motile cells and pioneer neurons. UNC-40 acts cell autonomously to orient movement toward UNC-6 sources. For cells coexpressing UNC-5, it helps orient movement away from UNC-6 sources. Finally, UNC-40 helps determine the dorsoventral position of cells undergoing purely longitudinal migrations. Together with the recent report that DCC is a netrin receptor in vertebrates, our results suggest that UNC-40 is a component of UNC-6 receptors on motile cells.	UNIV TORONTO,DEPT MOL & MED GENET,TORONTO,ON M5S 1A8,CANADA; JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218	University of Toronto; Johns Hopkins University	Chan, SSY (corresponding author), MT SINAI HOSP,SAMUEL LUNENFELD RES INST,600 UNIV AVE,TORONTO,ON M5G 1X5,CANADA.		Culotti, Joseph/G-6467-2013; Killeen, Marie/C-1131-2012	Killeen, Marie/0000-0001-9404-4845; Culotti, Joseph/0000-0001-6325-4612	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS026295, R01NS026295] Funding Source: NIH RePORTER; NINDS NIH HHS [NS26295] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; Burden-Gulley Susan M., 1995, Seminars in Developmental Biology, V6, P79, DOI 10.1016/S1044-5781(06)80017-4; CHUONG CM, 1994, DEV BIOL, V164, P383, DOI 10.1006/dbio.1994.1208; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; CULOTTI JG, 1994, CURR OPIN GENET DEV, V4, P587, DOI 10.1016/0959-437X(94)90077-G; CUNNINGHAM BA, 1995, CURR OPIN CELL BIOL, V7, P628, DOI 10.1016/0955-0674(95)80103-0; DURBIN RM, 1987, THESIS U CAMBRIDGE E; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HEDRICK L, 1992, COLD SPRING HARB SYM, V57, P345, DOI 10.1101/SQB.1992.057.01.039; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Kennedy Timothy E., 1995, Current Opinion in Neurobiology, V5, P83, DOI 10.1016/0959-4388(95)80091-3; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LAWLOR KG, 1992, CELL GROWTH DIFFER, V3, P609; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; Maniatis T., 1982, MOL CLONING; Mello C, 1995, METHOD CELL BIOL, P452; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PIERCEALL WE, 1994, DEV BIOL, V166, P654, DOI 10.1006/dbio.1994.1345; PIERCEALL WE, 1994, J CELL BIOL, V124, P1017, DOI 10.1083/jcb.124.6.1017; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SPINARDI L, 1991, NUCLEIC ACIDS RES, V19, P4009, DOI 10.1093/nar/19.14.4009; Sulston J, 1988, NEMATODE CAENORHABDI, P587; Vaughn DE, 1996, NEURON, V16, P261, DOI 10.1016/S0896-6273(00)80045-8; VIELMETTER J, 1994, J CELL BIOL, V127, P2009, DOI 10.1083/jcb.127.6.2009; Wadsworth WG, 1996, NEURON, V16, P35, DOI 10.1016/S0896-6273(00)80021-5; Wadsworth William G., 1992, Current Opinion in Neurobiology, V2, P36, DOI 10.1016/0959-4388(92)90159-I; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Zinn Kai, 1993, Seminars in Cell Biology, V4, P397, DOI 10.1006/scel.1993.1047	39	389	402	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1996	87	2					187	195		10.1016/S0092-8674(00)81337-9	http://dx.doi.org/10.1016/S0092-8674(00)81337-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VN403	8861903	hybrid			2022-12-24	WOS:A1996VN40300007
J	Draper, BW; Mello, CC; Bowerman, B; Hardin, J; Priess, JR				Draper, BW; Mello, CC; Bowerman, B; Hardin, J; Priess, JR			MEX-3 is a KH domain protein that regulates blastomere identity in early C-elegans embryos	CELL			English	Article							FRAGILE-X SYNDROME; CAENORHABDITIS-ELEGANS; RNA-BINDING; MESSENGER-RNA; CYTOPLASMIC LOCALIZATION; CLEAVAGE SPINDLE; GENE; ENCODES; FMR1; SKN-1	After the first division of the C. elegans embryo, the posterior blastomere can produce numerous muscles while the anterior blastomere cannot. We show here that maternal-effect lethal mutations in the gene mex-3 cause descendants of the anterior blastomere to produce muscles by a pattern of development similar to that of a descendant of the wild-type posterior blastomere. mex-3 encodes a probable RNA-binding protein that is distributed unequally in early embryos and that is a component of germline-specific granules called P granules. We propose that MEX-3 contributes to anterior-posterior asymmetry by regulating one or more mRNAs involved in specifying the fate of the posterior blastomere.	UNIV WASHINGTON,DEPT ZOOL,SEATTLE,WA 98195; UNIV WISCONSIN,DEPT ZOOL,MADISON,WI 53706; HOWARD HUGHES MED INST,SEATTLE,WA	University of Washington; University of Washington Seattle; University of Wisconsin System; University of Wisconsin Madison; Howard Hughes Medical Institute	Draper, BW (corresponding author), FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,1124 COLUMBIA ST,SEATTLE,WA 98109, USA.			Draper, Bruce W/0000-0002-4397-7749				ALBERTSON DG, 1984, DEV BIOL, V101, P61, DOI 10.1016/0012-1606(84)90117-9; ASHLEY CT, 1993, SCIENCE, V262, P563, DOI 10.1126/science.7692601; BLACKWELL TK, 1994, SCIENCE, V266, P621, DOI 10.1126/science.7939715; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; BOWERMAN B, 1993, CELL, V74, P443, DOI 10.1016/0092-8674(93)80046-H; BRENNER S, 1974, GENETICS, V77, P71; CHENG NN, 1995, GENETICS, V139, P549; COWAN AE, 1985, CELL, V41, P923, DOI 10.1016/S0092-8674(85)80073-8; ETEMADMOGHADAM B, 1995, CELL, V83, P743, DOI 10.1016/0092-8674(95)90187-6; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; GIBSON TJ, 1993, TRENDS BIOCHEM SCI, V18, P331, DOI 10.1016/0968-0004(93)90068-X; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Harlow E, 1988, ANTIBODIES LAB MANUA; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HUTTER H, 1994, DEVELOPMENT, V120, P2051; ITO K, 1994, NUCLEIC ACIDS RES, V22, P53, DOI 10.1093/nar/22.1.53; JONES AR, 1995, GENE DEV, V9, P1491, DOI 10.1101/gad.9.12.1491; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; KIRBY C, 1990, DEV BIOL, V142, P203, DOI 10.1016/0012-1606(90)90164-E; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LAUFER JS, 1980, CELL, V19, P569, DOI 10.1016/S0092-8674(80)80033-X; LEFFERS H, 1995, EUR J BIOCHEM, V230, P447, DOI 10.1111/j.1432-1033.1995.tb20581.x; LIN RL, 1995, CELL, V83, P599, DOI 10.1016/0092-8674(95)90100-0; LIU K, 1995, J MOL BIOL, V247, P547, DOI 10.1016/S0022-2836(05)80136-6; MAHONE M, 1995, EMBO J, V14, P2043, DOI 10.1002/j.1460-2075.1995.tb07196.x; MANGO SE, 1994, DEVELOPMENT, V120, P2305; MELLO CC, 1992, CELL, V70, P163, DOI 10.1016/0092-8674(92)90542-K; Mello CC, 1996, NATURE, V382, P710, DOI 10.1038/382710a0; Mickey KM, 1996, DEVELOPMENT, V122, P1791; MILLER DM, 1983, CELL, V34, P477, DOI 10.1016/0092-8674(83)90381-1; MORI I, 1988, GENETICS, V120, P397; MORTON DG, 1992, GENETICS, V130, P771; Musco G, 1996, CELL, V85, P237, DOI 10.1016/S0092-8674(00)81100-9; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; Schnabel R, 1996, MECH DEVELOP, V54, P133, DOI 10.1016/0925-4773(95)00466-1; Schnabel R, 1996, BIOESSAYS, V18, P591, DOI 10.1002/bies.950180711; SCHNABEL R, 1994, SCIENCE, V263, P1449, DOI 10.1126/science.8128230; SEYDOUX G, 1994, DEVELOPMENT, V120, P2823; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; STROME S, 1982, P NATL ACAD SCI-BIOL, V79, P1558, DOI 10.1073/pnas.79.5.1558; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; URLAUB H, 1995, EMBO J, V14, P4578, DOI 10.1002/j.1460-2075.1995.tb00137.x; WARING DA, 1991, NATURE, V350, P712, DOI 10.1038/350712a0	45	213	235	1	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1996	87	2					205	216		10.1016/S0092-8674(00)81339-2	http://dx.doi.org/10.1016/S0092-8674(00)81339-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VN403	8861905	Bronze			2022-12-24	WOS:A1996VN40300009
J	Holtschke, T; Lohler, J; Kanno, Y; Fehr, T; Giese, N; Rosenbauer, F; Lou, J; Knobeloch, KP; Gabriele, L; Waring, JF; Bachmann, MF; Zinkernagel, RM; Morse, HC; Ozato, K; Horak, I				Holtschke, T; Lohler, J; Kanno, Y; Fehr, T; Giese, N; Rosenbauer, F; Lou, J; Knobeloch, KP; Gabriele, L; Waring, JF; Bachmann, MF; Zinkernagel, RM; Morse, HC; Ozato, K; Horak, I			Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene	CELL			English	Article							INTERFERON REGULATORY FACTOR; SEQUENCE-BINDING-PROTEIN; FACTOR FAMILY; T-CELLS; HEMATOPOIETIC-CELLS; FACTOR-II; GAMMA; ALPHA; IFN; TRANSCRIPTION	Interferon consensus sequence binding protein (ICSBP) is a transcription factor of the interferon (IFN) regulatory factor (IRF) family. Mice with a null mutation of ICSBP exhibit two prominent phenotypes related to previously described activities of the IRF family. The fi rst is enhanced susceptibility to virus infections associated with impaired production of IFN gamma. The second is deregulated hematopoiesis in both ICSBP-/- and ICSBP+/- mice that manifests as a syndrome similar to human chronic myelogenous leukemia. The chronic period of the disease progresses to a fatal beast crisis characterized by a clonal expansion of undifferentiated cells. Normal mice injected with cells from mice in blast crisis developed acute leukemia within 6 weeks of transfer. These results suggest a novel role for ICSBP in regulating the proliferation and differentiation of hematopoietic progenitor cells.	UNIV WURZBURG,INST VIROL & IMMUNBIOL,D-8700 WURZBURG,GERMANY; UNIV HAMBURG,HEINRICH PETTE INST,HAMBURG,GERMANY; NICHHD,NATL INST HLTH,LAB MOL GROWTH REGULAT,BETHESDA,MD 20205; UNIV ZURICH,INST EXPT IMMUNOL,CH-8091 ZURICH,SWITZERLAND; NIAID,NATL INST HLTH,IMMUNOPATHOL LAB,BETHESDA,MD 20205; RES INST MOL PHARM,DEPT MOL GENET,D-12207 BERLIN,GERMANY	University of Wurzburg; Heinrich Pette Institute; University of Hamburg; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Zurich; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Gabriele, Lucia/J-8335-2016; Fehr, Thomas/AFQ-9308-2022; Kanno, Yuka/B-5802-2013	Gabriele, Lucia/0000-0002-1483-866X; Fehr, Thomas/0000-0003-1668-1800; Kanno, Yuka/0000-0001-5668-9319; Morse, Herbert/0000-0002-9331-3705				ANTALIS TM, 1991, NUCLEIC ACIDS RES, V19, P4301, DOI 10.1093/nar/19.15.4301; AU WC, 1995, P NATL ACAD SCI USA, V92, P11657, DOI 10.1073/pnas.92.25.11657; BOVOLENTA C, 1994, P NATL ACAD SCI USA, V91, P5046, DOI 10.1073/pnas.91.11.5046; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DRIGGERS PH, 1992, NUCLEIC ACIDS RES, V20, P2533, DOI 10.1093/nar/20.10.2533; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; GAZZINELLI RT, 1993, P NATL ACAD SCI USA, V90, P6115, DOI 10.1073/pnas.90.13.6115; Giese NA, 1996, IMMUNOLOGY, V87, P467, DOI 10.1046/j.1365-2567.1996.492569.x; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HAWLEY RG, 1992, J EXP MED, V176, P1149, DOI 10.1084/jem.176.4.1149; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; HWANG SY, 1995, P NATL ACAD SCI USA, V92, P11284, DOI 10.1073/pnas.92.24.11284; JOHNSON GR, 1989, EMBO J, V8, P441, DOI 10.1002/j.1460-2075.1989.tb03396.x; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; MANIATIS T, 1992, TRANSCRIPTIONAL REGU, P1193; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Nelson N, 1996, J IMMUNOL, V156, P3711; NELSON N, 1993, MOL CELL BIOL, V13, P588, DOI 10.1128/MCB.13.1.588; PALOMBELLA VJ, 1992, MOL CELL BIOL, V12, P3325, DOI 10.1128/MCB.12.8.3325; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Thornton AM, 1996, P NATL ACAD SCI USA, V93, P383, DOI 10.1073/pnas.93.1.383; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; WEISSMAN IL, 1994, IMMUNITY, V1, P529, DOI 10.1016/1074-7613(94)90042-6; WONG PMC, 1989, MOL CELL BIOL, V9, P798, DOI 10.1128/MCB.9.2.798; ZINKERNAGEL RM, 1986, J EXP MED, V164, P1057	41	530	539	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1996	87	2					307	317		10.1016/S0092-8674(00)81348-3	http://dx.doi.org/10.1016/S0092-8674(00)81348-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VN403	8861914	Bronze			2022-12-24	WOS:A1996VN40300018
J	Parker, G; Jenkins, S				Parker, G; Jenkins, S			Hepatitis B and admission to medical school: An audit of British medical school policy	BMJ-BRITISH MEDICAL JOURNAL			English	Article											Parker, G (corresponding author), UNIV MANCHESTER, SCH EPIDEMIOL & HLTH SCI, CTR OCCUPAT HLTH, MANCHESTER M13 9PT, LANCS, ENGLAND.							*COMM VIC CHANC PR, 1994, FITN PRACT MED DENT; GERLICH WH, 1994, LANCET, V343, P1572, DOI 10.1016/S0140-6736(94)92974-2; LEVER AM, 1994, BRIT MED J, V308, P870, DOI 10.1136/bmj.308.6933.870; POLAND GA, 1994, LANCET, V343, P1162, DOI 10.1016/S0140-6736(94)90267-4; *UK HLTH DEP ADV G, 1993, PROT HLTH CAR WORK P	5	5	5	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 5	1996	313	7061					856	857						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL559	8870573				2022-12-24	WOS:A1996VL55900023
J	Just, MA; Carpenter, PA; Keller, TA; Eddy, WF; Thulborn, KR				Just, MA; Carpenter, PA; Keller, TA; Eddy, WF; Thulborn, KR			Brain activation modulated by sentence comprehension	SCIENCE			English	Article							POSITRON EMISSION TOMOGRAPHY; WORKING-MEMORY; INDIVIDUAL-DIFFERENCES; RIGHT-HEMISPHERE; CORTEX	The comprehension of visually presented sentences produces brain activation that increases with the linguistic complexity of the sentence. The volume of neural tissue activated (number of voxels) during sentence comprehension was measured with echo-planar functional magnetic resonance imaging. The modulation of the volume of activation by sentence complexity was observed In a network of lour areas: the classical left-hemisphere language areas (the left laterosuperior temporal cortex, or Wernicke's area, and the left inferior frontal gyrus, or Broca's area) and their homologous right-hemisphere areas, although the right areas had much smaller volumes of activation than did the left areas. These findings generally indicate that the amount of neural activity that a given cognitive process engenders is dependent on the computational demand that the task imposes.	CARNEGIE MELLON UNIV,DEPT STAT,PITTSBURGH,PA 15213; UNIV PITTSBURGH,MED CTR,DEPT RADIOL,PITTSBURGH,PA 15213	Carnegie Mellon University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Just, MA (corresponding author), CARNEGIE MELLON UNIV,DEPT PSYCHOL,PITTSBURGH,PA 15213, USA.		Thulborn, Keith Raymond/D-9183-2015	Thulborn, Keith Raymond/0000-0001-6197-4296; Just, Marcel/0000-0003-1245-3050	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH029617, T32MH019102] Funding Source: NIH RePORTER; NIMH NIH HHS [MH-00662, MH-19102, MH-29617] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Baker SC, 1996, NEUROPSYCHOLOGIA, V34, P515, DOI 10.1016/0028-3932(95)00133-6; BANDETTINI PA, 1992, MAGNET RESON MED, V25, P390, DOI 10.1002/mrm.1910250220; BINDER JR, 1994, ANN NEUROL, V35, P662, DOI 10.1002/ana.410350606; BOTTINI G, 1994, BRAIN, V117, P1241, DOI 10.1093/brain/117.6.1241; Braver T. S., 1995, Society for Neuroscience Abstracts, V21, P274; Cohen J D, 1994, Hum Brain Mapp, V1, P293, DOI 10.1002/hbm.460010407; EDDY WF, P COMPUTATIONAL STAT; FORD M, 1983, J VERB LEARN VERB BE, V22, P203, DOI 10.1016/S0022-5371(83)90156-1; GRASBY PM, 1994, BRAIN, V117, P1271, DOI 10.1093/brain/117.6.1271; HAARMANN HH, IN PRESS BRAIN LANG; JONIDES J, 1993, NATURE, V363, P623, DOI 10.1038/363623a0; JUST MA, 1992, PSYCHOL REV, V99, P122, DOI 10.1037/0033-295X.99.1.122; JUST MA, 1993, CAN J EXP PSYCHOL, V47, P310, DOI 10.1037/h0078820; KARBE H, 1989, NEUROLOGY, V39, P1083, DOI 10.1212/WNL.39.8.1083; KEMPLER D, 1991, J NEUROLINGUIST, V6, P301; KING J, 1991, J MEM LANG, V30, P580, DOI 10.1016/0749-596X(91)90027-H; MAZOYER BM, 1993, J COGNITIVE NEUROSCI, V5, P467, DOI 10.1162/jocn.1993.5.4.467; METTER EJ, 1990, ARCH NEUROL-CHICAGO, V47, P1235, DOI 10.1001/archneur.1990.00530110097024; OGAWA S, 1993, BIOPHYS J, V64, P803, DOI 10.1016/S0006-3495(93)81441-3; PAULESU E, 1993, NATURE, V362, P342, DOI 10.1038/362342a0; Rueckert L, 1994, J Neuroimaging, V4, P67; SERGENT J, 1994, TRENDS NEUROSCI, V17, P221, DOI 10.1016/0166-2236(94)90002-7; STOIZ WA, 1967, J VERB LEARN VERB BE, V6, P867; Stromswold K, 1996, BRAIN LANG, V52, P452, DOI 10.1006/brln.1996.0024; TOMPKINS CA, 1985, BRAIN LANG, V24, P185, DOI 10.1016/0093-934X(85)90130-0; WEISSKOFF RM, 1994, MAGNET RESON MED, V31, P601, DOI 10.1002/mrm.1910310605	26	797	817	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1996	274	5284					114	116		10.1126/science.274.5284.114	http://dx.doi.org/10.1126/science.274.5284.114			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	VK748	8810246				2022-12-24	WOS:A1996VK74800060
J	Shachar, I; Flavell, RA				Shachar, I; Flavell, RA			Requirement for invariant chain in B cell maturation and function	SCIENCE			English	Article							CLASS-II MOLECULES; MICE LACKING; TRANSPORT; EXPRESSION	Previously the role of invariant chain (ii) had been described only as a chaperone that facilitates folding and transport of major histocompatability complex class II molecules; here it is shown that Ii is required for B cell development. B cells from mice lacking Ii were found to have a low response to T-independent type II antigen and could not proliferate after the mice were injected with antigen. Study of cell surface markers revealed a developmental arrest that prevented immature virgin B cells from becoming mature B cells in the periphery. This block was independent of major histocompatability complex class II expression and was an intrinsic feature of B cells that correlated with the amount of Ii. Thus, Ii participates by an unknown mechanism in B cell maturation.	YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510	Yale University; Howard Hughes Medical Institute; Yale University								BIKOFF EK, 1993, J EXP MED, V177, P1699, DOI 10.1084/jem.177.6.1699; Chan S H, 1994, Semin Immunol, V6, P241, DOI 10.1006/smim.1994.1031; Chang CH, 1996, IMMUNITY, V4, P167, DOI 10.1016/S1074-7613(00)80681-0; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; ELLIOTT EA, 1994, J EXP MED, V179, P681, DOI 10.1084/jem.179.2.681; MARKOWITZ JS, 1993, J IMMUNOL, V150, P1223; NAUJOKAS MF, 1995, IMMUNITY, V3, P359, DOI 10.1016/1074-7613(95)90120-5; SHACHAR I, 1995, IMMUNITY, V3, P373, DOI 10.1016/1074-7613(95)90121-3; van Meerwijk J P, 1994, Semin Immunol, V6, P231, DOI 10.1006/smim.1994.1030; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z	11	104	110	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1996	274	5284					106	108		10.1126/science.274.5284.106	http://dx.doi.org/10.1126/science.274.5284.106			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VK748	8810244				2022-12-24	WOS:A1996VK74800058
J	Cao, ZD; Xiong, J; Takeuchi, M; Kurama, T; Goeddel, DV				Cao, ZD; Xiong, J; Takeuchi, M; Kurama, T; Goeddel, DV			TARF6 is a signal transducer for interleukin-1	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; RING FINGER PROTEIN; FACTOR RECEPTOR; CYTOPLASMIC DOMAIN; CD40; ACTIVATION; FAMILY; INVOLVEMENT; EXPRESSION	MANY cytokines signal through different cell-surface receptors to activate the transcription factor NF-kappa B (ref. 1). Members of the TRAF protein family have been implicated in the activation of NF-kappa B by the tumour-necrosis factor (TNF)-receptor superfamily(2-5). Here we report the identification of a new TRAF family member, designated TRAF6. When overexpressed in human 293 cells, TRAF6 activates NF-kappa B. A dominant-negative mutant of TRAF6 inhibits NF-kappa B activation signalled by interleukin-1 (IL-1) but not by TNF. IL-1 treatment of 293 cells induces the association of TRAF6 with IRAK, a serine/threonine kinase that is rapidly recruited to the IL-1 receptor after IL-1 induction(6). These findings indicate that TRAF proteins may function as signal transducers for distinct receptor families and that TRAF6 participates in IL-1 signalling.	TULARIK INC,S SAN FRANCISCO,CA 94080; YAMANOUCHI PHARMACEUT CO LTD,TSUKUBA,IBARAKI 305,JAPAN	Astellas Pharmaceuticals								AUSUBEL FM, 1994, CURR PROT MOL BIOL, V1; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BERBERICH I, 1994, J IMMUNOL, V153, P4357; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CROSTON GE, 1995, J BIOL CHEM, V270, P16514, DOI 10.1074/jbc.270.28.16514; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; GRUSS HJ, 1995, BLOOD, V85, P3378, DOI 10.1182/blood.V85.12.3378.bloodjournal85123378; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HU HM, 1994, J BIOL CHEM, V269, P30069; MCDONALD PP, 1995, EUR J IMMUNOL, V25, P2870, DOI 10.1002/eji.1830251024; MESSER G, 1990, Cytokine, V2, P389, DOI 10.1016/1043-4666(90)90046-V; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SARMA V, 1995, J BIOL CHEM, V270, P12343, DOI 10.1074/jbc.270.21.12343; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; SONG HY, 1995, BIOCHEM J, V309, P825, DOI 10.1042/bj3090825; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253	28	1078	1131	4	48	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 3	1996	383	6599					443	446		10.1038/383443a0	http://dx.doi.org/10.1038/383443a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL463	8837778				2022-12-24	WOS:A1996VL46300064
J	Griffiths, TD; Rees, A; Witton, C; Shakir, RA; Henning, GB; Green, GGR				Griffiths, TD; Rees, A; Witton, C; Shakir, RA; Henning, GB; Green, GGR			Evidence for a sound movement area in the human cerebral cortex	NATURE			English	Article							POSITRON EMISSION TOMOGRAPHY; AUDITORY-CORTEX; FREQUENCY; BRAIN; LOCATION; SIGNALS; MOTION	HUMAN listeners can localize sounds by the difference in both arrival time (phase) and loudness between the two ears(1). Movement of the sound source modulates these cues, and responses to moving sounds have been detected in animals in primary auditory cortex(2,3) and in humans in other cortical areas(4). Here we show that detection of changes in the interaural phase or amplitude difference occurs through a mechanism distinct from that used to detect changes in one ear alone, Moreover, a patient with a right hemisphere stroke is unable to detect sound movement, regardless of whether it is defined by phase or by loudness cues. We propose that this deficit reflects damage to a distinct cortical area, outside the classical auditory areas, that is specialized for the detection of sound motion, The deficit is analagous to cerebral akinotopsia (motion blindness) in the visual system, and so the auditory system may, like the visual system(5), show localization of specialized functions to different cortical regions.	UNIV NEWCASTLE,SCH MED,DEPT CLIN NEUROSCI,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; INST NEUROL,WELLCOME DEPT COGNIT NEUROL,LONDON WC1N 3BG,ENGLAND; CHARING CROSS HOSP,REG NEUROSCI CTR,LONDON W6 8RF,ENGLAND; UNIV OXFORD,DEPT EXPT PSYCHOL,OXFORD OX1 3UD,ENGLAND	Newcastle University - UK; University of London; University College London; Imperial College London; University of Oxford	Griffiths, TD (corresponding author), UNIV NEWCASTLE,SCH MED,DEPT PHYSIOL SCI,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND.		Rees, Adrian/H-2200-2012; Green, Gary GR/D-3543-2009	Rees, Adrian/0000-0003-3313-8375; Green, Gary GR/0000-0003-1977-7509; Griffiths, Timothy/0000-0001-8066-4381; Witton, Caroline/0000-0002-5610-4234	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AHISSAR M, 1992, J NEUROPHYSIOL, V67, P203, DOI 10.1152/jn.1992.67.1.203; ALTMAN JA, 1986, HEARING RES, V24, P243, DOI 10.1016/0378-5955(86)90023-7; ANDERSEN RA, 1995, CEREB CORTEX, V5, P457, DOI 10.1093/cercor/5.5.457; Blauert J., 1983, SPATIAL HEARING; BNIFFITHS TD, 1994, CURR BIOL, V4, P892; GRANTHAM DW, 1979, PERCEPT PSYCHOPHYS, V26, P403, DOI 10.3758/BF03204166; JEFFRESS LA, 1948, J COMP PHYSIOL PSYCH, V41, P35, DOI 10.1037/h0061495; KAY RH, 1972, J PHYSIOL-LONDON, V225, P657, DOI 10.1113/jphysiol.1972.sp009962; LAUTER JL, 1985, HEARING RES, V20, P199, DOI 10.1016/0378-5955(85)90024-3; LAVIKAINEN J, 1994, NEUROREPORT, V6, P182, DOI 10.1097/00001756-199412300-00046; Macmillan N. A., 1991, DETECTION THEORY USE; MOORE BCJ, 1991, Q J EXP PSYCHOL-A, V43, P327, DOI 10.1080/14640749108400976; Pardo Patricia J., 1994, Society for Neuroscience Abstracts, V20, P325; PERROTT DR, 1988, J ACOUST SOC AM, V83, P1522, DOI 10.1121/1.395908; PINEK B, 1992, BRAIN COGNITION, V11, P1; RIZZO M, 1995, BRAIN, V118, P1105, DOI 10.1093/brain/118.5.1105; Strutt J., 1907, PHILOS MAG, V13, P214, DOI [DOI 10.1080/14786440709463595, 10.1080/14786440709463595]; STRYBEL TZ, 1989, PERCEPT PSYCHOPHYS, V45, P371, DOI 10.3758/BF03204951; STUMPF E, 1992, EXP BRAIN RES, V88, P158, DOI 10.1007/BF02259137; WATSON JDG, 1993, CEREB CORTEX, V3, P79, DOI 10.1093/cercor/3.2.79; WHITFIEL.IC, 1965, J NEUROPHYSIOL, V28, P655, DOI 10.1152/jn.1965.28.4.655; ZIHL J, 1983, BRAIN, V106, P313, DOI 10.1093/brain/106.2.313	22	101	103	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 3	1996	383	6599					425	427		10.1038/383425a0	http://dx.doi.org/10.1038/383425a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL463	8837772				2022-12-24	WOS:A1996VL46300058
J	Knudsen, EI; Knudsen, PF				Knudsen, EI; Knudsen, PF			Disruption of auditory spatial working memory by inactivation of the forebrain archistriatum in barn owls	NATURE			English	Article							LESIONS; SPACE	BARN owls only localize auditory stimuli with great accuracy, they also remember the locations of auditory stimuli and can use (his remembered spatial information to guide their flight and strike(1). Although the mechanisms of sound localization have been studied extensively(2,3), the neurobiological basis auditory spatial memory has not. Here we show that the ability of barn owls to orient their gaze towards and fly to the remembered location of auditory targets is lost during pharmacological inactivation of a small region in the forebrain, the anterior archistriatum. In contrast, archistriatal inactivation has no effect on stimulus-guided responses to auditory targets. The memory-dependent deficit is evident only for acoustic events that occur in the hemifield contralateral to the side that is inactivated, The data demonstrate that in the avian archistriatum, as in the mammalian frontal cortex, there exists a region that is essential for the expression of spatial working memory and that, in the barn owl, this region encodes auditory spatial memory.			Knudsen, EI (corresponding author), STANFORD UNIV,SCH MED,DEPT NEUROBIOL,FAIRCHILD SCI BLDG,STANFORD,CA 94305, USA.							Baddeley A, 1986, WORKING MEMORY; Clarey JC, 1992, MAMMALIAN AUDITORY P, P232, DOI [10.1007/978-1-4612-2838-7_5, DOI 10.1007/978-1-4612-2838-7_5]; Deng S.-Y., 1986, ADAPTIVE PROCESSES V, P201; Dias EC, 1995, J NEUROPHYSIOL, V74, P2744, DOI 10.1152/jn.1995.74.6.2744; FUNAHASHI S, 1993, J NEUROSCI, V13, P1479; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; FUSTER JM, 1986, PREFRONTAL CORTEX; GOLDMAN-RAKIC P S, 1992, Scientific American, V267, P110; GOLDMANRAKIC PS, 1995, NEURON, V14, P477, DOI 10.1016/0896-6273(95)90304-6; HIKOSAKA O, 1985, J NEUROPHYSIOL, V53, P266, DOI 10.1152/jn.1985.53.1.266; KING AJ, 1993, EXP PHYSIOL, V78, P559, DOI 10.1113/expphysiol.1993.sp003708; KNUDSEN EI, 1995, J NEUROSCI, V15, P5139; KNUDSEN EI, 1993, J NEUROSCI, V13, P2837; Knudsen EI, 1996, EXP BRAIN RES, V108, P23; KONISHI M, 1973, AM SCI, V61, P414; Neter J, 1990, APPL LINEAR STAT MOD; ZEIER H, 1971, BRAIN RES, V31, P327, DOI 10.1016/0006-8993(71)90186-7	17	51	51	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 3	1996	383	6599					428	431		10.1038/383428a0	http://dx.doi.org/10.1038/383428a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL463	8837773				2022-12-24	WOS:A1996VL46300059
J	Krauskopf, A; Blackburn, EH				Krauskopf, A; Blackburn, EH			Control of telomere growth by interactions of RAP1 with the most distal telomeric repeats	NATURE			English	Article							KLUYVEROMYCES-LACTIS; FUNCTIONAL-ANALYSIS; BINDING-PROTEIN; YEAST TELOMERES; SILENCERS; DOMAIN; END	TELOMERES, the specialized DNA-protein structures at the ends of eukaryotic chromosomes, are required for chromosomal stability and integrity(1-3). Regulation of the overall length of the telomeric DNA repeat tract is likely to be a key requirement for its various biological roles. We have studied telomere length regulation in the yeast Kluyveromyces lactis, which has long (25 base pairs) homogeneous telomeric repeat units(4) that make it highly suitable for telomere studies. In the related Saccharomyces cerevisiae, the DNA-sequence-specific duplex-binding protein RAP1 is a component of the telomeric complex(5-9). Here we show that the phenotypic severity of previously described telomerase RNA (ter1) mutations(10) is directly proportional to the loss of RAP1 binding to mutated telomeric repeats. Using a carboxy-terminal-tail mutant of K. lactis RAP1, we also show that, unexpectedly, RAP1 interaction with the most terminal telomeric repeats is crucial for telomere length control.	UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco								BERMAN J, 1986, P NATL ACAD SCI USA, V83, P3713, DOI 10.1073/pnas.83.11.3713; BLACKBURN EH, 1994, CELL, V77, P621, DOI 10.1016/0092-8674(94)90046-9; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P5086, DOI 10.1128/MCB.8.12.5086; BUCK SW, 1995, GENE DEV, V9, P370, DOI 10.1101/gad.9.3.370; CHEN XJ, 1994, MOL CELL BIOL, V14, P4501, DOI 10.1128/MCB.14.7.4501; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; FANG G, 1995, TELOMERES, P69; GILSON E, 1993, J MOL BIOL, V231, P293, DOI 10.1006/jmbi.1993.1283; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; KURTZ S, 1991, GENE DEV, V5, P616, DOI 10.1101/gad.5.4.616; LARSON GP, 1994, GENE, V150, P35, DOI 10.1016/0378-1119(94)90854-0; LIU C, 1994, GENETICS, V138, P1025; MCEACHERN MJ, 1994, P NATL ACAD SCI USA, V91, P3453, DOI 10.1073/pnas.91.8.3453; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; SHORE D, 1994, TRENDS GENET, V10, P408, DOI 10.1016/0168-9525(94)90058-2; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601	19	147	149	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 26	1996	383	6598					354	357		10.1038/383354a0	http://dx.doi.org/10.1038/383354a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VJ439	8848051				2022-12-24	WOS:A1996VJ43900050
J	Cressman, DE; Greenbaum, LE; DeAngelis, RA; Ciliberto, G; Furth, EE; Poli, V; Taub, R				Cressman, DE; Greenbaum, LE; DeAngelis, RA; Ciliberto, G; Furth, EE; Poli, V; Taub, R			Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice	SCIENCE			English	Article							EPIDERMAL GROWTH-FACTOR; NECROSIS-FACTOR RECEPTOR; FACTOR KAPPA-B; MOUSE-LIVER; TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; PARTIAL-HEPATECTOMY; RAPID ACTIVATION; SERUM LEVELS	Liver regeneration stimulated by a loss of liver mass leads to hepatocyte and nonparenchymal cell proliferation and rapid restoration of liver parenchyma. Mice with targeted disruption of the interleukin-6 (IL-6) gene had impaired liver regeneration characterized by liver necrosis and failure. There was a blunted DNA synthetic response in hepatocytes of these mice but not in nonparenchymal liver cells. Furthermore; there were discrete G(1) phase (prereplicative stage in the cell cycle) abnormalities including absence of STAT3 (signal transducer and activator of transcription protein 3) activation and depressed AP-1, Myc, and cyclin D1 expression. Treatment of IL-6-deficient mice with a single preoperative dose of IL-6 returned STAT3 binding, gene expression, and hepatocyte proliferation to near normal and prevented liver damage, establishing that IL-6 is a critical component of the regenerative response.	UNIV PENN,SCH MED,DEPT GENET & MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PATHOL,PHILADELPHIA,PA 19104; IRBM PIETRO ANGELETTI,INST RIC BIOL MOL,POMEZIA,ROMA,ITALY	University of Pennsylvania; University of Pennsylvania			Poli, Valeria/A-9215-2012; Ciliberto, Gennaro/J-4131-2017	Poli, Valeria/0000-0002-3739-3966; Ciliberto, Gennaro/0000-0003-2851-8605	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049629, P01DK049210, R01DK044237] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44237, DK49629, DK49210] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKERMAN P, 1992, AM J PHYSIOL, V263, pG579, DOI 10.1152/ajpgi.1992.263.4.G579; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ALBRECHT JH, 1995, BIOCHEM BIOPH RES CO, V209, P648, DOI 10.1006/bbrc.1995.1548; ARCONE R, 1991, EUR J BIOCHEM, V198, P541, DOI 10.1111/j.1432-1033.1991.tb16048.x; BAUER J, 1988, BLOOD, V72, P1134; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BLUETHMANN H, 1994, J LEUKOCYTE BIOL, V56, P565, DOI 10.1002/jlb.56.5.565; COFFER P, 1995, ONCOGENE, V10, P985; CORNELL RP, 1990, HEPATOLOGY, V11, P916, DOI 10.1002/hep.1840110603; CRESSMAN DE, 1995, HEPATOLOGY, V21, P1443, DOI 10.1016/0270-9139(95)90068-3; CRESSMAN DE, 1994, J BIOL CHEM, V269, P30429; CRESSMAN DE, 1994, J BIOL CHEM, V269, P26594; CRESSMAN DE, UNPUB; CZAJA MJ, 1995, GASTROENTEROLOGY, V108, P1849, DOI 10.1016/0016-5085(95)90149-3; DABEVA MD, 1993, AM J PATHOL, V143, P1606; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEVIERE J, 1989, CLIN EXP IMMUNOL, V77, P221; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; FATTORI E, 1994, J EXP MED, V180, P1243, DOI 10.1084/jem.180.4.1243; Fausto Nelson, 1994, P1059; FITZGERALD MJ, 1995, CELL GROWTH DIFFER, V6, P417; GREENBAUM LE, 1995, J CLIN INVEST, V96; GREENWEL P, 1993, LAB INVEST, V69, P210; Gressner AM, 1996, KIDNEY INT, V49, pS39; HABER BA, 1995, J CLIN INVEST, V95, P832, DOI 10.1172/JCI117733; Higgins GM, 1931, ARCH PATHOL, V12, P186; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; HSU SM, 1981, AM J CLIN PATHOL, V75, P734, DOI 10.1093/ajcp/75.5.734; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; KU NO, 1995, J CELL BIOL, V131, P1303, DOI 10.1083/jcb.131.5.1303; KUMA S, 1990, IMMUNOBIOLOGY, V180, P235, DOI 10.1016/S0171-2985(11)80331-1; LEE JY, 1994, HEPATOLOGY, V19, P656, DOI 10.1002/hep.1840190317; MCCLAIN C, 1993, SEMIN LIVER DIS, V13, P170, DOI 10.1055/s-2007-1007347; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PHUCHAREON J, 1995, CANCER LETT, V92, P203, DOI 10.1016/0304-3835(95)03780-Z; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; QIAN XB, 1995, MOL CELL BIOL, V15, P1364; RABES HM, 1977, CANCER RES, V37, P1105; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; ROKICKI M, 1993, RES EXP MED, V193, P305, DOI 10.1007/BF02576238; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; SANDGREN EP, 1991, CELL, V66, P245, DOI 10.1016/0092-8674(91)90615-6; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SCHUTTE B, 1987, J HISTOCHEM CYTOCHEM, V35, P1343, DOI 10.1177/35.11.3116075; Taub R, 1996, FASEB J, V10, P413, DOI 10.1096/fasebj.10.4.8647340; TAUB R, 1995, LIVER REGENERATION C, P71; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898; TILG H, 1992, GASTROENTEROLOGY, V103, P264, DOI 10.1016/0016-5085(92)91122-K; VANSNICK J, 1986, P NATL ACAD SCI USA, V83, P9679; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; YAMADA Y, UNPUB; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	62	1277	1338	1	77	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 22	1996	274	5291					1379	1383		10.1126/science.274.5291.1379	http://dx.doi.org/10.1126/science.274.5291.1379			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU954	8910279				2022-12-24	WOS:A1996VU95400055
J	Kannus, P; Palvanen, M; Niemi, S; Parkkari, J; Jarvinen, M; Vuori, I				Kannus, P; Palvanen, M; Niemi, S; Parkkari, J; Jarvinen, M; Vuori, I			Increasing number and incidence of osteoporotic fractures of the proximal humerus in elderly people	BRITISH MEDICAL JOURNAL			English	Article									TAMPERE UNIV HOSP,DEPT SURG,TAMPERE,FINLAND	Tampere University; Tampere University Hospital	Kannus, P (corresponding author), UKK INST HLTH PROMOT RES,ACCID & TRAUMA RES CTR,POB 30,FIN-33501 TAMPERE,FINLAND.							Aro S, 1990, Duodecim, V106, P1443; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; KANNUS P, 1995, LANCET, V346, P50, DOI 10.1016/S0140-6736(95)92679-8; LUTHJE P, 1995, ACTA ORTHOP SCAND, V66, P245; Salmela R, 1987, SAIRAALA, V49, P480	5	81	85	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 26	1996	313	7064					1051	1052						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP742	8898596				2022-12-24	WOS:A1996VP74200026
J	Aitchison, JD; Blobel, G; Rout, MP				Aitchison, JD; Blobel, G; Rout, MP			Kap104p: A karyopherin involved in the nuclear transport of messenger RNA binding proteins	SCIENCE			English	Article							PORE COMPLEX; IMPORT SUBSTRATE; SACCHAROMYCES-CEREVISIAE; LOCALIZATION SEQUENCES; CYTOSOLIC FACTORS; MEDIATED BINDING; EXPORT PATHWAY; U SNRNPS; HNRNP A1; YEAST	A cytosolic yeast karyopherin, Kap104p, was isolated and shown to function in the nuclear import of a specific class of proteins. The protein bound directly to repeat-containing nucleoporins and to a cytosolic pool of two nuclear messenger RNA (mRNA) binding proteins, Nab2p and Nab4p, Depletion of Kap104p resulted in a rapid shift of Nab2p from the nucleus to the cytoplasm without affecting the localization of other nuclear proteins tested, This finding suggests that the major function of Kap104p lies in returning mRNA binding proteins to the nucleus after mRNA export.	ROCKEFELLER UNIV, HOWARD HUGHES MED INST, CELL BIOL LAB, NEW YORK, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University			Rout, Michael/Y-7090-2018	Rout, Michael/0000-0003-2010-706X				ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Aitchison JD, 1995, J CELL BIOL, V131, P1659, DOI 10.1083/jcb.131.6.1659; AITCHISON JD, 1995, J CELL BIOL, V131, P1133, DOI 10.1083/jcb.131.5.1133; ANDERSON JT, 1993, MOL CELL BIOL, V13, P2730, DOI 10.1128/MCB.13.5.2730; ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; ARIS JP, 1988, J CELL BIOL, V107, P17, DOI 10.1083/jcb.107.1.17; BATAILLE N, 1990, J CELL BIOL, V111, P1571, DOI 10.1083/jcb.111.4.1571; BELANGER KD, 1994, J CELL BIOL, V126, P619, DOI 10.1083/jcb.126.3.619; BONIFACI N, COMMUNICATION; BOSSIE MA, 1992, MOL BIOL CELL, V3, P875, DOI 10.1091/mbc.3.8.875; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; CHOW TYK, 1992, J CELL SCI, V101, P709; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; FISCHER U, 1991, J CELL BIOL, V113, P705, DOI 10.1083/jcb.113.4.705; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FISCHER U, 1993, EMBO J, V12, P573, DOI 10.1002/j.1460-2075.1993.tb05689.x; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; Henry M, 1996, GENETICS, V142, P103; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; Iovine MK, 1995, J CELL BIOL, V131, P1699, DOI 10.1083/jcb.131.6.1699; IZAURRALDE E, 1992, J CELL BIOL, V118, P1287, DOI 10.1083/jcb.118.6.1287; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; KAMBACH C, 1992, J CELL BIOL, V118, P11, DOI 10.1083/jcb.118.1.11; KRAEMER DM, 1995, J BIOL CHEM, V270, P19017, DOI 10.1074/jbc.270.32.19017; LEE WC, 1991, J CELL BIOL, V113, P1, DOI 10.1083/jcb.113.1.1; MELCHIOR F, 1995, J CELL BIOL, V131, P571, DOI 10.1083/jcb.131.3.571; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MICHAEL WM, 1995, CELL, V83, P415; MICHAUD N, 1991, J CELL BIOL, V112, P215, DOI 10.1083/jcb.112.2.215; MICHAUD N, 1992, J CELL BIOL, V116, P851, DOI 10.1083/jcb.116.4.851; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P7059, DOI 10.1073/pnas.93.14.7059; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; NEHRBASS U, 1990, CELL, V61, P979, DOI 10.1016/0092-8674(90)90063-K; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; ROUT MP, 1993, J CELL BIOL, V123, P771, DOI 10.1083/jcb.123.4.771; ROUT MP, 1990, J CELL BIOL, V111, P1913, DOI 10.1083/jcb.111.5.1913; ROUT MP, UNPUB; WEIGHARDT F, 1995, J CELL SCI, V108, P545; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; YANO R, 1994, P NATL ACAD SCI USA, V91, P6880, DOI 10.1073/pnas.91.15.6880; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640	57	275	278	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 25	1996	274	5287					624	627		10.1126/science.274.5287.624	http://dx.doi.org/10.1126/science.274.5287.624			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN919	8849456				2022-12-24	WOS:A1996VN91900054
J	Holland, SJ; Gale, NW; Mbamalu, G; Yancopoulos, GD; Henkemeyer, M; Pawson, T				Holland, SJ; Gale, NW; Mbamalu, G; Yancopoulos, GD; Henkemeyer, M; Pawson, T			Bidirectional signalling through the EPH-family receptor Nuk and its transmembrane ligands	NATURE			English	Article							PROTEIN-TYROSINE KINASES; CLONING; DOMAIN; BRAIN; CELLS; CEK5	RECEPTOR tyrosine kinases of the EPH class have been implicated in the control of axon guidance and fasciculation(1-7), in regulating cell migration(8), and in defining compartments in the developing embryo(9-11). Efficient activation of EPH receptors generally requires that their ligands be anchored to thr cell surface, either through a transmembrane (TM) region or a glycosyl phosphatidylinositol (GPI) group(12). These observations have suggested that EPH receptors can transduce signals initiated by direct cell-cell interaction. Genetic analysis of Nuk, a murine EPH receptor that binds TM ligands, has raised the possibility that these ligands might themselves have a signalling function(6). Consistent with this, the three known TM ligands have a highly conserved cytoplasmic region, with multiple potential sites for tyrosine phosphorylation(12-17). Here we show that challenging cells that express the TM ligands Elk-L or Htk-L with the clustered ectodomain of Nuk induces phosphorylation of the ligands on tyrosine, a process that can be mimicked both in vitro and in vivo by an activated Src tyrosine kinase. Co-culture of cells expressing a TM ligand with cells expressing Nuk leads to tyrosine phosphorylation of both the ligand and Nuk. These results suggest that the TM ligands are associated with a tyrosine kinase, and are inducibly phosphorylated upon binding Nuk in a fashion reminiscent of cytokine receptors(18). Furthermore, we show that TM ligands, as well as Nuk are phosphorylated on tyrosine in mouse embryos, indicating that this is a physiological process. EPH receptors and their TM ligands therefore mediate bidirectional cell signalling.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,PROGRAMME MOL BIOL & CANC,TORONTO,ON M5G 1X5,CANADA; REGENERON PHARMACEUT INC,TARRYTOWN,NY 10804; UNIV TORONTO,DEPT MOL & MED GENET,TORONTO,ON M5S 1A8,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Regeneron; University of Toronto			Pawson, Tony J/E-4578-2013	Henkemeyer, Mark/0000-0002-7525-1061				BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BENNETT BD, 1995, P NATL ACAD SCI USA, V92, P1866, DOI 10.1073/pnas.92.6.1866; BERGEMANN AD, 1995, MOL CELL BIOL, V15, P4921; BRMABILLA R, 1995, EMBO J, V14, P3116; Cerretti DP, 1995, MOL IMMUNOL, V32, P1197, DOI 10.1016/0161-5890(95)00108-5; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Ellis C, 1996, ONCOGENE, V12, P1727; Gale NW, 1996, ONCOGENE, V13, P1343; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; LHOTAK V, 1993, MOL CELL BIOL, V13, P7071, DOI 10.1128/MCB.13.11.7071; LIU XQ, 1993, ONCOGENE, V8, P1119; NELSON P, 1976, P NATL ACAD SCI USA, V73, P123, DOI 10.1073/pnas.73.1.123; Nicola NA, 1996, GROWTH FACTORS, V13, P141, DOI 10.3109/08977199609034574; Owens T, 1996, CURR BIOL, V6, P32, DOI 10.1016/S0960-9822(02)00415-3; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; SHAO HN, 1994, J BIOL CHEM, V269, P26606; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; VANESSEN D, 1995, NATURE, V378, P620, DOI 10.1038/378620a0; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; Xu QL, 1996, NATURE, V381, P319, DOI 10.1038/381319a0; Xu QL, 1995, DEVELOPMENT, V121, P4005	29	448	462	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 24	1996	383	6602					722	725		10.1038/383722a0	http://dx.doi.org/10.1038/383722a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN918	8878483	Green Submitted			2022-12-24	WOS:A1996VN91800055
J	Zein, NN; Rakela, J; Krawitt, EL; Reddy, KR; Tominaga, T; Persing, DH; Therneau, TM; Gross, JB; Poterucha, JJ; Gossard, AA; Jeffers, LJ; Schiff, ER				Zein, NN; Rakela, J; Krawitt, EL; Reddy, KR; Tominaga, T; Persing, DH; Therneau, TM; Gross, JB; Poterucha, JJ; Gossard, AA; Jeffers, LJ; Schiff, ER			Hepatitis C virus genotypes in the United States: Epidemiology, pathogenicity, and response to interferon therapy	ANNALS OF INTERNAL MEDICINE			English	Article						hepatitis C; interferons; genotype; outcome assessment (health care); liver cirrhosis	NON-B-HEPATITIS; CHRONIC NON-A; POLYMERASE CHAIN-REACTION; RECIPIENTS; DISEASE; RNA; HOMOLOGY; SEQUENCE; SEVERITY; REGIONS	Objective: To study 1) the geographic distribution and clinical significance of hepatitis C virus (HCV) genotypes in the United States and 2) the influence of HCV genotypes on response to interferon therapy. Design: Hepatitis C virus genotype was determined in 179 stored serum samples obtained from patients who were positive for antibody to HCV and for HCV RNA by using polymerase chain reaction. Setting: Tertiary referral centers in four geographic regions of the United States. Patients: Patients who visited medical centers in the Midwest (50 patients), Northeast (42 patients), Southeast (35 patients), and West (52 patients). Measurements: Chaotropic lysis and isopropanol precipitation were used to extract RNA from serum. Polymerase chain reaction was done on the NS5 region and was followed by automated direct sequencing and genotyping of desalted amplification products. Results: 104 patients (58%) had subtype 1a; 38 (21%)had subtype 1b; 4 (2%) had subtype 2a; 23 (13%) had subtype 2b; 8 (5%) had subtype 3a; and 2 (1%) had subtype 4a. Examination of the known risk factors for acquiring HCV showed no association between genotype and mode of acquisition (blood transfusion, injection drug use, employment at a health care facility) or histologic findings at presentation (mild active hepatitis, moderately active hepatitis, or cirrhosis). Sixty-eight percent of patients with genotype 1a, 80% of patients with genotype 1b, and 37% of patients with genotype 2a or 2b had severe hepatitis. Thirteen of 46 (28%) patients with genotype 1a and 4 of 15 (26%) patients with genotype 1b had a complete biochemical response after 6 months of interferon therapy. In contrast, 10 of 14 (71%) patients with genotype 2a or 2b had a complete response to interferon therapy. Five of: 39 (13%) patients with genotype 1a, 1 of 14 (7%) patients with genotype 1b, and 2 of 11 (18%) patients with genotype 2a or 2b had a sustained biochemical response. Conclusions: In the United States, HCV genotypes 1a and 1b are the predominant genotypes in patients with ch ron ic hepatitis C. Genotype is not correlated with mode of virus acquisition or with histologic findings at presentation. Patients with HCV genotype 1a or 1b had more severe liver disease and lower rates of response to interferon therapy than did patients with HCV genotype 2a or 2b. These findings may have implications for predicting outcome and selecting patients for interferon treatment.	MAYO CLIN, ROCHESTER, MN 55905 USA; UNIV VERMONT, BURLINGTON, VT 05405 USA; UNIV MIAMI, MIAMI, FL 33101 USA	Mayo Clinic; University of Vermont; University of Miami					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032403, P01AI030548] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041497] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 32403, AI 30548] Funding Source: Medline; NIAMS NIH HHS [AR 41497] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; CAUSSE X, 1991, GASTROENTEROLOGY, V101, P497, DOI 10.1016/0016-5085(91)90030-O; CHAYAMA K, 1993, GASTROENTEROL JPN, V28, P45, DOI 10.1007/BF02989204; CHEN PJ, 1992, VIROLOGY, V188, P102, DOI 10.1016/0042-6822(92)90739-C; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; DELISSE AM, 1991, J HEPATOL, V13, pS20, DOI 10.1016/0168-8278(91)90017-6; DIBISCEGLIE AM, 1991, HEPATOLOGY, V14, P969, DOI 10.1016/0270-9139(91)90113-A; DUSHEIKO G, 1994, HEPATOLOGY, V19, P13, DOI 10.1016/0270-9139(94)90046-9; ENOMOTO N, 1990, BIOCHEM BIOPH RES CO, V170, P1021, DOI 10.1016/0006-291X(90)90494-8; GORDON FD, 1995, GASTROENTEROLOGY, V108, pA1074; HAN JH, 1991, P NATL ACAD SCI USA, V88, P1711, DOI 10.1073/pnas.88.5.1711; HIJIKATA M, 1991, BIOCHEM BIOPH RES CO, V175, P220, DOI 10.1016/S0006-291X(05)81223-9; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; KARINO Y, 1991, GASTROENTEROL JPN, V26, P234; KATO N, 1991, BIOCHEM BIOPH RES CO, V181, P279, DOI 10.1016/S0006-291X(05)81414-7; LI JS, 1991, GENE, V105, P167; LIJS, 1991, J HEPATOL S4, V13, pS33; LIN R, 1991, AUST NZ J MED, V21, P387, DOI 10.1111/j.1445-5994.1991.tb04715.x; NOUSBAUM JB, 1995, ANN INTERN MED, V122, P161, DOI 10.7326/0003-4819-122-3-199502010-00001; OKAMOTO H, 1992, J GEN VIROL, V73, P673, DOI 10.1099/0022-1317-73-3-673; OKAMOTO H, 1992, VIROLOGY, V188, P331, DOI 10.1016/0042-6822(92)90762-E; POL S, 1995, GASTROENTEROLOGY, V108, P581, DOI 10.1016/0016-5085(95)90088-8; POZZATO G, 1991, LANCET, V338, P509, DOI 10.1016/0140-6736(91)90578-D; SIMMONDS P, 1993, J GEN VIROL, V74, P2391, DOI 10.1099/0022-1317-74-11-2391; TAKADA N, 1993, GASTROENTEROL JPN, V28, P268; WEILAND O, 1993, SCAND J INFECT DIS, V25, P25, DOI 10.3109/00365549309169665; YOSHIOKA K, 1992, HEPATOLOGY, V16, P293, DOI 10.1002/hep.1840160203; ZEIN NN, 1995, MAYO CLIN PROC, V70, P449, DOI 10.4065/70.5.449; ZEIN NN, 1995, GASTROENTEROLOGY, V108, pA1208; ZEIN NN, 1995, J LIVER TRANSPLANT S, V6, P354; ZEIN NN, 1995, SEMIN GASTROINTEST D, V1, P46	31	319	331	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1996	125	8					634	+		10.7326/0003-4819-125-8-199610150-00002	http://dx.doi.org/10.7326/0003-4819-125-8-199610150-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM889	8849147				2022-12-24	WOS:A1996VM88900004
J	Dikstein, R; Zhou, S; Tjian, R				Dikstein, R; Zhou, S; Tjian, R			Human TAF(parallel to)105 is a cell type-specific TFIID subunit related to hTAF(parallel to)130	CELL			English	Article							TATA-BINDING PROTEIN; TRANSCRIPTIONAL ACTIVATION; SACCHAROMYCES-CEREVISIAE; BASAL TRANSCRIPTION; MOLECULAR-CLONING; COMPLEX; COACTIVATORS; PROMOTER; INTERACTS; GENE	We previously characterized Drosophila and human TAF subunits that make up the core TFIID complex found in all cells. Here, we report that differentiated B cells contain a novel substoichiometric TAF of 105 kDa not found associated with TFIID isolated from other cell types. The cDNA encoding hTAF(II)105 reveals a highly conserved C-terminal domain shared by hTAF(II)130 and dTAF(II)110, while the N-terminal coactivator domain has diverged significantly. All cells tested express TAF(II)105 mRNA, but only B cells contain significant levels of protein associated with TFIID. Transient overexpression of hTAF(II)105 selectively squelches the transcription of some genes in B cells. These properties suggest that TAF(II)105 is a cell type-specific subunit of TFIID that may be responsible for mediating transcription by a subset of activators in B cells.			Dikstein, R (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOL & CELL BIOL,BERKELEY,CA 94720, USA.							ATCHISON ML, 1987, CELL, V48, P121, DOI 10.1016/0092-8674(87)90362-X; ATTARDI LD, 1993, GENE DEV, V7, P1341, DOI 10.1101/gad.7.7b.1341; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; COLEMAN RA, 1995, J BIOL CHEM, V270, P13842, DOI 10.1074/jbc.270.23.13842; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KUNZLER M, 1994, EMBO J, V13, P641, DOI 10.1002/j.1460-2075.1994.tb06302.x; LUO Y, 1995, MOL CELL BIOL, V15, P4115; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; PONTICELLI AS, 1995, MOL CELL BIOL, V15, P983; POON D, 1995, P NATL ACAD SCI USA, V92, P8224, DOI 10.1073/pnas.92.18.8224; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; Taggart AKP, 1996, SCIENCE, V272, P1331, DOI 10.1126/science.272.5266.1331; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; Tang H, 1996, P NATL ACAD SCI USA, V93, P1119, DOI 10.1073/pnas.93.3.1119; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; YOKOMORI K, 1993, GENE DEV, V7, P2235, DOI 10.1101/gad.7.11.2235; YOKOMORI K, 1993, GENE DEV, V7, P2587, DOI 10.1101/gad.7.12b.2587; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	37	153	158	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1996	87	1					137	146		10.1016/S0092-8674(00)81330-6	http://dx.doi.org/10.1016/S0092-8674(00)81330-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VL695	8858156	Bronze			2022-12-24	WOS:A1996VL69500016
J	Milot, E; Strouboulis, J; Trimborn, T; Wijgerde, M; deBoer, E; Langeveld, A; TanUn, K; Vergeer, W; Yannoutsos, N; Grosveld, F; Fraser, P				Milot, E; Strouboulis, J; Trimborn, T; Wijgerde, M; deBoer, E; Langeveld, A; TanUn, K; Vergeer, W; Yannoutsos, N; Grosveld, F; Fraser, P			Heterochromatin effects on the frequency and duration of LCR-mediated gene transcription	CELL			English	Article							BETA-GLOBIN LOCUS; DOMINANT CONTROL REGION; HIGH-LEVEL EXPRESSION; TRANSGENIC MICE; HYPERSENSITIVE SITE; DEVELOPMENTAL REGULATION; ACTIVATION REGION; REPLICATION; ELEMENT; DNA	Locus control regions (LCRs) are responsible for initiating and maintaining a stable tissue-specific open chromatin structure of a locus. In transgenic mice, LCRs confer high level expression on linked genes independent of position in the mouse genome. Here we show that an incomplete LCR loses this property when integrated into heterochromatic regions. Two disruption mechanisms were observed. One is classical position-effect variegation, resulting in continuous transcription in a clonal subpopulation of cells. The other is a novel mechanism resulting in intermittent gene transcription in all cells. We conclude that only a complete LCR fully overcomes heterochromatin silencing and that it controls the level of transcription by ensuring activity in all cells at all times rather than directly controlling the rate of transcription.	NATL INST MED RES,DEPT GENE STRUCT & EXPRESS,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research	Milot, E (corresponding author), ERASMUS UNIV ROTTERDAM,DEPT CELL BIOL,CTR MED GENET,NL-3000 DR ROTTERDAM,NETHERLANDS.		Fraser, Peter/B-7549-2009; Strouboulis, John/U-4459-2019	Strouboulis, John/0000-0002-6133-2872; Fraser, Peter/0000-0002-0041-1227				ALADJEM MI, 1995, SCIENCE, V270, P815, DOI 10.1126/science.270.5237.815; Bungert J, 1995, GENE DEV, V9, P3083, DOI 10.1101/gad.9.24.3083; COLLIS P, 1990, EMBO J, V9, P233, DOI 10.1002/j.1460-2075.1990.tb08100.x; CURTIN PT, 1989, P NATL ACAD SCI USA, V86, P7082, DOI 10.1073/pnas.86.18.7082; EISSENBERG JC, 1995, CHROMATIN STRUCTURE, P147; ELLIOTT JI, 1995, EMBO J, V14, P575, DOI 10.1002/j.1460-2075.1995.tb07033.x; Festenstein R, 1996, SCIENCE, V271, P1123, DOI 10.1126/science.271.5252.1123; FLERING S, 1995, GENE DEV, V9, P2203; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; FRASER P, 1990, NUCLEIC ACIDS RES, V18, P3503, DOI 10.1093/nar/18.12.3503; FRASER P, 1993, GENE DEV, V7, P106, DOI 10.1101/gad.7.1.106; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GROSVELD F, 1993, BAILLIERE CLIN HAEM, V6, P31, DOI 10.1016/S0950-3536(05)80065-4; HANSCOMBE O, 1989, GENE DEV, V3, P1572, DOI 10.1101/gad.3.10.1572; HEINTZ E, 1928, WISS BOTANIK, V69, P762; HOLMQUIST GP, 1987, AM J HUM GENET, V40, P151; Hug BA, 1996, MOL CELL BIOL, V16, P2906; John B, 1979, Int Rev Cytol, V58, P1, DOI 10.1016/S0074-7696(08)61473-4; KARPEN GH, 1994, CURR OPIN GENET DEV, V4, P281, DOI 10.1016/S0959-437X(05)80055-3; KLOUSSIS D, 1983, NATURE, V306, P662; KULOZIK AE, 1991, J CLIN INVEST, V87, P2142, DOI 10.1172/JCI115246; LINDENBAUM MH, 1990, GENE DEV, V4, P2075, DOI 10.1101/gad.4.12a.2075; Milot E, 1996, TRENDS GENET, V12, P123, DOI 10.1016/0168-9525(96)30019-X; MORLEY BJ, 1992, MOL CELL BIOL, V12, P2057, DOI 10.1128/MCB.12.5.2057; MULDER MP, 1995, HUM GENET, V96, P133, DOI 10.1007/BF00207368; ORLANDO V, 1995, CURR OPIN GENET DEV, V5, P174, DOI 10.1016/0959-437X(95)80005-0; PHILIPSEN S, 1993, EMBO J, V12, P1077, DOI 10.1002/j.1460-2075.1993.tb05749.x; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; PILLUS L, 1995, CHROMATIN STRUCTURE, P123; PIRROTTA V, 1995, CURR OPIN GENET DEV, V5, P466, DOI 10.1016/0959-437X(95)90050-Q; PRUZINA S, 1991, NUCLEIC ACIDS RES, V19, P1413, DOI 10.1093/nar/19.7.1413; RYAN TM, 1989, GENE DEV, V3, P314, DOI 10.1101/gad.3.3.314; SCHEDL P, 1995, CHROMATIN STRUCTURE, P174; STROUBOULIS J, 1992, NUCLEIC ACIDS RES, V20, P6109, DOI 10.1093/nar/20.22.6109; STROUBOULIS J, 1992, GENE DEV, V6, P1857, DOI 10.1101/gad.6.10.1857; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TALBOT D, 1989, NATURE, V338, P352, DOI 10.1038/338352a0; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; WILSON C, 1990, ANNU REV CELL BIOL, V6, P679, DOI 10.1146/annurev.cellbio.6.1.679; ZAFARANA G, 1995, P 9 C HEM SWITCH 199, P39	42	279	289	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1996	87	1					105	114		10.1016/S0092-8674(00)81327-6	http://dx.doi.org/10.1016/S0092-8674(00)81327-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VL695	8858153	Green Published, Bronze			2022-12-24	WOS:A1996VL69500013
J	Wolthers, KC; Wisman, GBA; Otto, SA; Husman, AMD; Schaft, N; deWolf, F; Goudsmit, J; Coutinho, RA; vanderZee, AGJ; Meyaard, L; Miedema, F				Wolthers, KC; Wisman, GBA; Otto, SA; Husman, AMD; Schaft, N; deWolf, F; Goudsmit, J; Coutinho, RA; vanderZee, AGJ; Meyaard, L; Miedema, F			T cell telomere length in HIV-1 infection: No evidence for increased CD4(+) T cell turnover	SCIENCE			English	Article							HUMAN FIBROBLASTS; TERMINAL TRANSFERASE; HUMAN-LYMPHOCYTES; IMMORTAL CELLS; MITOTIC CLOCK; IN-VITRO; AIDS; INDIVIDUALS; PROGRESSION; MEMORY	Progression to acquired immunodeficiency syndrome (AIDS) has been related to exhaustion of the regenerative capacity of the immune system resulting from high T cell turnover. Analysis of telomeric terminal restriction fragment (TRF) length, a marker for cellular replicative history, showed that CD8(+) T cell TRF length decreased but CD4(+) T cell TRF length was stable during the course of human immunodeficiency Virus type-1 (HIV-1) infection, which was not explained by differential telomerase activity. This observation provides evidence that turnover in the course of HIV-1 infection can be increased considerably in CD8(+) T cells, but not in CD4(+) T cells. These results are compatible with CD4(+) T cell decline in HIV-1 infection caused by interference with cell renewal.	NETHERLANDS RED CROSS, BLOOD TRANSFUS SERV, CENT LAB, DEPT CLIN VIROIMMUNOL, NL-1066 CX AMSTERDAM, NETHERLANDS; UNIV AMSTERDAM, EXPT & CLIN IMMUNOL LAB, AMSTERDAM, NETHERLANDS; UNIV GRONINGEN, ACAD HOSP GRONINGEN, DEPT OBSTET & GYNAECOL, GRONINGEN, NETHERLANDS; UNIV AMSTERDAM, ACAD MED CTR, DEPT HUMAN RETROVIROL, NL-1105 AZ AMSTERDAM, NETHERLANDS; MUNICIPAL HLTH SERV, DEPT PUBL HLTH, AMSTERDAM, NETHERLANDS	University of Amsterdam; University of Groningen; University of Amsterdam; Academic Medical Center Amsterdam			Wolthers, Katja C./E-5140-2018; Schaft, Niels/H-3713-2011	Wolthers, Katja C./0000-0003-1617-7049; Schaft, Niels/0000-0001-8236-9298; Meyaard, Linde/0000-0003-0707-4793				Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; ALLSOPP RC, 1995, EXP CELL RES, V220, P194, DOI 10.1006/excr.1995.1306; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; ALLSOPP RC, 1995, EXP CELL RES, V219, P130, DOI 10.1006/excr.1995.1213; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Bofill M, 1996, AIDS, V10, P827, DOI 10.1097/00002030-199607000-00005; Boudet F, 1996, J IMMUNOL, V156, P2282; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; CLERICI M, 1989, J CLIN INVEST, V84, P1892, DOI 10.1172/JCI114376; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; Effros RB, 1996, AIDS, V10, pF17, DOI 10.1097/00002030-199607000-00001; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; GIORGI JV, 1987, J IMMUNOL, V138, P3725; GOUGEON ML, 1993, SCIENCE, V260, P1269, DOI 10.1126/science.8098552; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GRUTERS RA, 1991, AIDS, V5, P837, DOI 10.1097/00002030-199107000-00007; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HIYAMA K, 1995, J IMMUNOL, V155, P3711; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO HN, 1993, J IMMUNOL, V150, P3070; Holt SE, 1996, NAT BIOTECHNOL, V14, P836, DOI 10.1038/nbt0796-836; Kelleher AD, 1996, J INFECT DIS, V173, P321, DOI 10.1093/infdis/173.2.321; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; MACKALL CL, 1995, NEW ENGL J MED, V332, P143, DOI 10.1056/NEJM199501193320303; MARGOLICK JB, 1995, NAT MED, V1, P674, DOI 10.1038/nm0795-674; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; MIEDEMA F, 1988, J CLIN INVEST, V82, P1908, DOI 10.1172/JCI113809; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MOSLER DE, 1995, NATURE, V375, P193, DOI 10.1038/375193b0; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; MUROCACHO CA, 1995, J IMMUNOL, V154, P5555; Ohyashiki JH, 1996, JPN J CANCER RES, V87, P329, DOI 10.1111/j.1349-7006.1996.tb00225.x; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; PHILLIPS AN, 1995, NATURE, V375, P195, DOI 10.1038/375195a0; ROOS MTL, 1995, J INFECT DIS, V171, P531, DOI 10.1093/infdis/171.3.531; SCHELLEKENS PTA, 1992, AIDS, V6, P665, DOI 10.1097/00002030-199207000-00008; SCHNITTMAN SM, 1990, P NATL ACAD SCI USA, V87, P6058, DOI 10.1073/pnas.87.16.6058; SLAGBOOM PE, 1994, AM J HUM GENET, V55, P876; SPRENT J, 1993, CURR OPIN IMMUNOL, V5, P433, DOI 10.1016/0952-7915(93)90065-Z; TANCHOT C, 1995, EUR J IMMUNOL, V25, P2127, DOI 10.1002/eji.1830250802; Tough DF, 1996, IMMUNOL REV, V150, P129, DOI 10.1111/j.1600-065X.1996.tb00699.x; VAZIRI H, 1993, AM J HUM GENET, V52, P661; VAZIRI H, 1994, P NATL ACAD SCI USA, V91, P9857, DOI 10.1073/pnas.91.21.9857; WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Weng NP, 1996, J EXP MED, V183, P2471, DOI 10.1084/jem.183.6.2471; WENG NP, 1995, P NATL ACAD SCI USA, V92, P11091, DOI 10.1073/pnas.92.24.11091	54	245	259	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 29	1996	274	5292					1543	1547		10.1126/science.274.5292.1543	http://dx.doi.org/10.1126/science.274.5292.1543			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929418				2022-12-24	WOS:A1996VV77500053
J	Ren, PF; Lim, CS; Johnsen, R; Albert, PS; Pilgrim, D; Riddle, DL				Ren, PF; Lim, CS; Johnsen, R; Albert, PS; Pilgrim, D; Riddle, DL			Control of C-elegans larval development by neuronal expression of a TGF-beta homolog	SCIENCE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; GREEN FLUORESCENT PROTEIN; DAUER LARVA; PHEROMONE; TEMPERATURE; SUPERFAMILY; ENCODES	The Caenorhabditis elegans dauer larva is specialized for dispersal without growth and is formed under conditions of overcrowding and limited food. The daf-7 gene, required for transducing environmental cues that support continuous development with plentiful food, encodes a transforming growth factor-beta (TGF-beta) superfamily member. A daf-7 reporter construct is expressed in the ASI chemosensory neurons. Dauer-inducing pheromone inhibits daf-7 expression and promotes dauer formation, whereas food reactivates daf-7 expression and promotes recovery from the dauer state. When the food/pheromone ratio is high, the level of daf-7 mRNA peaks during the L1 larval stage, when commitment to non-dauer development is made.	UNIV MISSOURI,PROGRAM MOL BIOL,COLUMBIA,MO 65211; UNIV MISSOURI,DIV BIOL SCI,COLUMBIA,MO 65211; UNIV ALBERTA,DEPT BIOL SCI,EDMONTON,AB T6G 2E9,CANADA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Alberta			Pilgrim, David/A-2676-2014	Pilgrim, David/0000-0001-7820-7915	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD011239] Funding Source: NIH RePORTER; NICHD NIH HHS [HD11239] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARGMANN CI, 1991, SCIENCE, V251, P1243, DOI 10.1126/science.2006412; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; CASSADA RC, 1975, DEV BIOL, V46, P326, DOI 10.1016/0012-1606(75)90109-8; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; EPSTEIN HF, 1995, MODERN BIOL ANAL ORG; ESTEVEZ A, UNPUB; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; Evans A. A. F., 1976, The organization of nematodes., P383; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GOLDEN JW, 1985, MOL GEN GENET, V198, P534, DOI 10.1007/BF00332953; GOLDEN JW, 1984, P NATL ACAD SCI-BIOL, V81, P819, DOI 10.1073/pnas.81.3.819; GOLDEN JW, 1982, SCIENCE, V218, P578, DOI 10.1126/science.6896933; GOLDEN JW, 1984, DEV BIOL, V102, P368, DOI 10.1016/0012-1606(84)90201-X; Griffith DL, 1996, P NATL ACAD SCI USA, V93, P878, DOI 10.1073/pnas.93.2.878; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MORI I, 1988, GENETICS, V120, P397; PILGRIM D, 1993, GENOME, V36, P712, DOI 10.1139/g93-096; Riddle DL., 1988, NEMATODE CAENORHABDI, P393; Rushforth AM, 1996, MOL CELL BIOL, V16, P422; SAWCHENKO PE, 1988, NATURE, V334, P615, DOI 10.1038/334615a0; SCHACKWITZ WS, IN PRESS NEURON; SWANSON MM, 1981, DEV BIOL, V84, P27, DOI 10.1016/0012-1606(81)90367-5; THOMAS JH, 1993, GENETICS, V134, P1105; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056	27	414	426	2	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 22	1996	274	5291					1389	1391		10.1126/science.274.5291.1389	http://dx.doi.org/10.1126/science.274.5291.1389			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU954	8910282				2022-12-24	WOS:A1996VU95400058
J	Siegler, EL				Siegler, EL			April may be cruel, but November's pretty lousy, too	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Siegler, EL (corresponding author), BROOKLYN HOSP CTR, 121 DEKALB AVE, BROOKLYN, NY 11201 USA.			Siegler, Eugenia/0000-0001-9449-5873					0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1996	125	9					774	775		10.7326/0003-4819-125-9-199611010-00014	http://dx.doi.org/10.7326/0003-4819-125-9-199611010-00014			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ072	8929014				2022-12-24	WOS:A1996VQ07200012
J	Perseghin, G; Price, TB; Petersen, KF; Roden, M; Cline, GW; Gerow, K; Rothman, DL; Shulman, GI				Perseghin, G; Price, TB; Petersen, KF; Roden, M; Cline, GW; Gerow, K; Rothman, DL; Shulman, GI			Increased glucose transport-phosphorylation and muscle glycogen synthesis after exercise training in insulin-resistant subjects	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEPENDENT DIABETES-MELLITUS; RAT SKELETAL-MUSCLE; 1ST-DEGREE RELATIVES; PHYSICAL-ACTIVITY; INCREASED RISK; SINGLE BOUT; MEN; SENSITIVITY; METABOLISM; SYNTHASE	Background Insulin resistance in the offspring of parents with non-insulin-dependent diabetes mellitus (NIDDM) is the best predictor of development of the disease and probably plays an important part in its pathogenesis. We studied the mechanism and degree to which exercise training improves insulin sensitivity in these subjects. Methods Ten adult children of parents with NIDDM and eight normal subjects were studied before starting an aerobic exercise-training program, after one session of exercise, and after six weeks of exercise. Insulin sensitivity was measured by the hyperglycemic-hyperinsulinemic clamp technique combined with indirect calorimetry, and the rate of glycogen synthesis in muscle and the intramuscular glucose-6-phosphate concentration were measured by carbon-13 and phosphorus-31 nuclear magnetic resonance spectroscopy, respectively. Results During the base-line study, the mean (+/-SE) rate of muscle glycogen synthesis was 63+/-9 percent lower in the offspring of diabetic parents than in the normal subjects (P<0.001). The mean value increased 69+/-10 percent (P=0.04) and 62+/-11 percent (P=0.04) after the first exercise session and 102+/-11 percent (P=0.02) and 97+/-9 percent (P=0.008) after six weeks of exercise training in the offspring and the normal subjects, respectively. The increment in glucose-6-phosphate during hyperglycemic-hyperinsulinemic clamping was lower in the offspring than in the normal subjects (0.039+/-0.013 vs. 0.089+/-0.009 mol per liter, P=0.005), reflecting reduced glucose transport-phosphorylation, but this increment was normal in the offspring after the first exercise session and after exercise training. Basal and stimulated insulin secretion was higher in the offspring than the normal subjects and was not altered by the exercise training program. Conclusions Exercise increases insulin sensitivity in both normal subjects and the insulin-resistant offspring of diabetic parents because of a twofold increase in insulin-stimulated glycogen synthesis in muscle, due to an increase in insulin-stimulated glucose transport-phosphorylation. (C) 1996, Massachusetts Medical society.	YALE UNIV,SCH MED,DEPT INTERNAL MED,NEW HAVEN,CT 06520	Yale University			Roden, Michael/AAD-3843-2019; Shulman, Gerald I./P-7176-2019	Shulman, Gerald I./0000-0003-1529-5668; PERSEGHIN, Gianluca/0000-0002-3024-0457	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049230, P30DK045735] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR-00125] Funding Source: Medline; NIDDK NIH HHS [P30 DK-45735, R01 DK-49230] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSEN P, 1977, J PHYSIOL-LONDON, V270, P677, DOI 10.1113/jphysiol.1977.sp011975; BAECKE JAH, 1982, AM J CLIN NUTR, V36, P936; BECKNIELSEN H, 1994, J CLIN INVEST, V94, P1714, DOI 10.1172/JCI117518; BOGARDUS C, 1984, DIABETES, V33, P311, DOI 10.2337/diabetes.33.4.311; DEFRONZO RA, 1987, DIABETES, V36, P1379, DOI 10.2337/diabetes.36.12.1379; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; DEVLIN JT, 1987, DIABETES, V36, P434, DOI 10.2337/diabetes.36.4.434; DOUEN AG, 1990, FEBS LETT, V261, P256, DOI 10.1016/0014-5793(90)80566-2; EBELING P, 1993, J CLIN INVEST, V92, P1623, DOI 10.1172/JCI116747; ERIKSSON J, 1989, NEW ENGL J MED, V321, P337, DOI 10.1056/NEJM198908103210601; GOODYEAR LJ, 1992, DIABETES, V41, P1091, DOI 10.2337/diabetes.41.9.1091; GOODYEAR LJ, 1990, J APPL PHYSIOL, V68, P193, DOI 10.1152/jappl.1990.68.1.193; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; HOTHERNIELSEN O, 1989, ACTA ENDOCRINOL-COP, V120, P257, DOI 10.1530/acta.0.1200257; HOUMARD JA, 1991, AM J PHYSIOL, V261, pE437, DOI 10.1152/ajpendo.1991.261.4.E437; KOBBERLING J, 1971, DIABETOLOGIA, V7, P46, DOI 10.1007/BF02346253; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; Lusk G, 1924, J BIOL CHEM, V59, P41; MIKINES KJ, 1989, J APPL PHYSIOL, V66, P704, DOI 10.1152/jappl.1989.66.2.704; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; ODOHERTY RM, 1994, AM J PHYSIOL, V266, pE171; OSHIDA Y, 1989, J APPL PHYSIOL, V66, P2206, DOI 10.1152/jappl.1989.66.5.2206; ROTHMAN DL, 1992, J CLIN INVEST, V89, P1069, DOI 10.1172/JCI115686; ROTHMAN DL, 1995, P NATL ACAD SCI USA, V92, P983, DOI 10.1073/pnas.92.4.983; SCHALINJANTTI C, 1992, DIABETES, V41, P598, DOI 10.2337/diabetes.41.5.598; SEGAL KR, 1991, J APPL PHYSIOL, V71, P2402, DOI 10.1152/jappl.1991.71.6.2402; SHULMAN GI, 1990, NEW ENGL J MED, V322, P223, DOI 10.1056/NEJM199001253220403; TONINO RP, 1989, AM J PHYSIOL, V256, pE352, DOI 10.1152/ajpendo.1989.256.3.E352; VAAG A, 1992, J CLIN INVEST, V89, P782, DOI 10.1172/JCI115656; WARRAM JH, 1990, ANN INTERN MED, V113, P909, DOI 10.7326/0003-4819-113-12-909; WIDEN EIM, 1992, DIABETES, V41, P354, DOI 10.2337/diabetes.41.3.354; WOLFE RR, 1992, RADIOACTIVE STABLE I, P49	32	486	504	2	44	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 31	1996	335	18					1357	1362		10.1056/NEJM199610313351804	http://dx.doi.org/10.1056/NEJM199610313351804			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP484	8857019				2022-12-24	WOS:A1996VP48400004
J	Cruysberg, JRM; Boers, GHJ; Trijbels, JMF; Deutman, AF				Cruysberg, JRM; Boers, GHJ; Trijbels, JMF; Deutman, AF			Delay in diagnosis of homocystinuria: Retrospective study of consecutive patients	BRITISH MEDICAL JOURNAL			English	Article							SYNTHASE DEFICIENCY; CYSTATHIONINE	Objective-To assess the causes for delay in the diagnosis of homocystinuria. Design-Clinical and laboratory data were collected from patients diagnosed as having homocystinuria due to cystathionine synthase deficiency, with special reference to the ages at which the patients had their first major signs of the disease, ectopia lentis was established, and homocystinuria was diagnosed. Setting-University hospital in the Netherlands. Subjects-34 patients (18 males) in whom homocystinuria due to cystathionine synthase deficiency was diagnosed in the period 1970-94. Results-Among 34 consecutively detected homocystinuria patients the mean age at diagnosis of homocystinuria was 24 (range 1-61) years. Despite frequent ocular manifestations, serious complications in the vascular, skeletal, and central nervous systems, and repeated examinations performed in these patients by clinicians of various disciplines, there was a mean delay of 11 (0-43) years between the first major signs of the disease (at mean age 13 (1-40) years) and the ultimate diagnosis of homocystinuria. Even when ectopia lentis was diagnosed (in 26 (76%) patients, mean age 18 (1-50) years), this did not lead to adequate biochemical analysis for homocystinuria at the time of detection, causing a mean diagnostic delay of 8 (0-24) years in these patients. Conclusions-Three factors should have precipitated the diagnosis of homocystinuria: early recognition that unusual myopia (high, very high, abnormal progressive, or at young age) was caused by subluxation of the ocular lenses; awareness that the occurrence of myopia combined with systemic complications (''myopia plus'') might be due to homocystinuria; and appropriate biochemical investigations carried out in patients with ectopia lentis and in their siblings.			Cruysberg, JRM (corresponding author), UNIV NIJMEGEN HOSP,POB 9101,NL-6500 HB NIJMEGEN,NETHERLANDS.		Cruysberg, Johannes R. M./D-4313-2009	Cruysberg, Johannes R. M./0000-0002-5330-0774				APPLEGARTH DA, 1995, EUR J PEDIATR, V154, P589, DOI 10.1007/BF02074844; BLIKA S, 1982, ACTA OPHTHALMOL, V60, P894; BOERS GHJ, 1983, METABOLISM, V32, P390, DOI 10.1016/0026-0495(83)90049-5; BOERS GHJ, 1984, NETH J MED, V27, P206; BOERS GHJ, 1985, HUM GENET, V69, P164, DOI 10.1007/BF00293290; BOERS GHJ, 1986, CLIN RES SERIES, V3; BRENTON D P, 1972, Journal of Bone and Joint Surgery British Volume, V54, P277; CARSON NAJ, 1962, ARCH DIS CHILD, V37, P505, DOI 10.1136/adc.37.195.505; Cernea P, 1972, Ann Ocul (Paris), V205, P167; CROSS HE, 1973, AM J OPHTHALMOL, V75, P405, DOI 10.1016/0002-9394(73)91149-5; CROXATTO JO, 1986, OPHTHALMOLOGICA, V193, P23, DOI 10.1159/000309674; CULLOM RD, 1995, SURV OPHTHALMOL, V40, P217, DOI 10.1016/S0039-6257(95)80028-X; GARSTON JB, 1970, BRIT J OPHTHALMOL, V54, P248, DOI 10.1136/bjo.54.4.248; GERRITSEN T, 1962, BIOCHEM BIOPH RES CO, V9, P493, DOI 10.1016/0006-291X(62)90114-6; HINDLE NW, 1969, CAN J OPHTHALMOLOGY, V4, P128; JARRETT WH, 1967, ARCH OPHTHALMOL-CHIC, V78, P289, DOI 10.1001/archopht.1967.00980030291006; JOHNSTON SS, 1968, BRIT J OPHTHALMOL, V52, P251, DOI 10.1136/bjo.52.3.251; LEUENBERGER S, 1983, KLIN MONATSBL AUGENH, V182, P457, DOI 10.1055/s-2008-1054821; MATTHAUS W, 1984, KLIN MONATSBL AUGENH, V185, P253, DOI 10.1055/s-2008-1054609; MATTHAUS W, 1976, OPHTHALMOLOGICA, V173, P111, DOI 10.1159/000307862; MCKUSICK VA, 1972, HERITABLE DISORDERS, P224; Mohindra I, 1981, DOC OPHTHALMOL PROC, V28, P17; Mudd S.H., 1995, METABOLIC MOL BASES, V1, P1279; MUDD SH, 1985, AM J HUM GENET, V37, P1; MURPHREE AL, 1984, SURV OPHTHALMOL, V28, P357; Neetens A, 1980, Bull Soc Belge Ophtalmol, V191, P29; PEYMAN GA, 1979, BRIT J OPHTHALMOL, V63, P771, DOI 10.1136/bjo.63.11.771; SCHOONDERWALDT HC, 1981, CLIN NEUROL NEUROSUR, V83, P153, DOI 10.1016/0303-8467(81)90017-2; SORSBY A, 1960, BRIT MED J, V1, P1394, DOI 10.1136/bmj.1.5183.1394; SORSBY A, 1962, VISION RES, V2, P309, DOI 10.1016/0042-6989(62)90039-1; SPAETH GL, 1967, PEDIATRICS, V40, P586; SPAETH GL, 1984, SURV OPHTHALMOL, V29, P230, DOI 10.1016/0039-6257(84)90213-3; Spaeth GL, 1996, J PEDIAT OPHTHALMOL, V3, P42; WALSH FB, 1969, CLIN NEUROOPHTHALMOL, V1, P782	34	46	47	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 26	1996	313	7064					1037	1040						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP742	8898592				2022-12-24	WOS:A1996VP74200021
J	Adams, MD; Venter, JC				Adams, MD; Venter, JC			Should non-peer-reviewed raw DNA sequence data release be forced on the scientific community?	SCIENCE			English	Editorial Material							GENOME				Adams, MD (corresponding author), INST GENOM RES,MED CTR DR,ROCKVILLE,MD 20850, USA.							ADAMS MD, 1995, NATURE, V377, P3; ADAMS MD, 1991, SCIENCE, V252, P151; ANDERSON C, 1993, SCIENCE, V259, P1685, DOI 10.1126/science.259.5102.1685; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; LIPMAN D, COMMUNICATION; Marshall E, 1996, SCIENCE, V272, P477; WHITE O, 1993, NUCLEIC ACIDS RES, V21, P3829, DOI 10.1093/nar/21.16.3829	9	18	29	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 25	1996	274	5287					534	536		10.1126/science.274.5287.534	http://dx.doi.org/10.1126/science.274.5287.534			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	VN919	8928007				2022-12-24	WOS:A1996VN91900035
J	Takahashi, T; Forsythe, ID; Tsujimoto, T; BarnesDavies, M; Onodera, K				Takahashi, T; Forsythe, ID; Tsujimoto, T; BarnesDavies, M; Onodera, K			Presynaptic calcium current modulation by a metabotropic glutamate receptor	SCIENCE			English	Article							SYNAPTIC TRANSMISSION; HIPPOCAMPAL-NEURONS; TRANSMITTER RELEASE; RAT HIPPOCAMPUS; CHANNELS; SLICES; INFLUX; BRAIN; INHIBITION; SYNAPSES	Metabotropic glutamate receptors (mGluRs) regulate transmitter release at mammalian central synapses. However, because oi the difficulty of recording from mammalian presynaptic terminals, the mechanism underlying mGluR-mediated presynaptic inhibition is not known. Here, simultaneous recordings from a giant presynaptic terminal, the calyx of Held, and its postsynaptic target in the medial nucleus of the trapezoid body were obtained in rat brainstem slices. Agonists of mGluRs suppressed a high voltage-activated P/Q-type calcium conductance in the presynaptic terminal, thereby inhibiting transmitter release at this glutamatergic synapse. Because several forms of presynaptic modulation and plasticity are mediated by mGluRs, this identification of a target ion channel is a first step toward elucidation of their molecular mechanism.	UNIV LEICESTER,DEPT CELL PHYSIOL & PHARMACOL,ION CHANNEL GRP,LEICESTER LE1 9HN,LEICS,ENGLAND	University of Leicester	Takahashi, T (corresponding author), UNIV TOKYO,FAC MED,INST BRAIN RES,DEPT NEUROPHYSIOL,TOKYO 113,JAPAN.		Takahashi, Tomoyuki/G-5951-2015	Takahashi, Tomoyuki/0000-0002-8771-7666	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANWYL R, 1991, BRAIN RES REV, V16, P265, DOI 10.1016/0165-0173(91)90010-6; AUGUSTINE GJ, 1986, J PHYSIOL-LONDON, V381, P619, DOI 10.1113/jphysiol.1986.sp016347; BAMESDAVIES M, 1995, J PHYSIOL-LONDON, V488, P387; BASKYS A, 1991, J PHYSIOL-LONDON, V444, P687, DOI 10.1113/jphysiol.1991.sp018901; Borst JGG, 1995, J PHYSIOL-LONDON, V489, P825, DOI 10.1113/jphysiol.1995.sp021095; Dittman JS, 1996, J NEUROSCI, V16, P1623; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; FORSYTHE ID, 1993, P ROY SOC B-BIOL SCI, V251, P143, DOI 10.1098/rspb.1993.0021; FORSYTHE ID, 1990, J PHYSIOL-LONDON, V429, P1; FORSYTHE ID, 1994, J PHYSIOL-LONDON, V479, P381, DOI 10.1113/jphysiol.1994.sp020303; FU WM, 1991, NEURON, V6, P837, DOI 10.1016/0896-6273(91)90179-4; HAYASHI Y, 1993, NATURE, V366, P687, DOI 10.1038/366687a0; HORI Y, 1996, J PHYSIOL-LONDON, V492, P967; KATZ B, 1967, J PHYSIOL-LONDON, V192, P407, DOI 10.1113/jphysiol.1967.sp008307; KAWAI N, 1980, J PHYSIOL-LONDON, V305, P73, DOI 10.1113/jphysiol.1980.sp013350; Kobayashi K, 1996, SCIENCE, V273, P648, DOI 10.1126/science.273.5275.648; LLANO I, 1995, J PHYSIOL-LONDON, V486, P163, DOI 10.1113/jphysiol.1995.sp020800; LOVINGER DM, 1993, J NEUROPHYSIOL, V69, P1236, DOI 10.1152/jn.1993.69.4.1236; MARTIN AR, 1963, J PHYSIOL-LONDON, V168, P443, DOI 10.1113/jphysiol.1963.sp007202; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; OHISHI H, 1994, NEURON, V13, P55, DOI 10.1016/0896-6273(94)90459-6; OHISHI H, 1995, J COMP NEUROL, V360, P555, DOI 10.1002/cne.903600402; PONCER JC, 1995, J PHYSIOL-LONDON, V485, P121, DOI 10.1113/jphysiol.1995.sp020717; SAHARA Y, 1993, J NEUROSCI, V13, P3041; SCHOEPP DD, 1993, TRENDS PHARMACOL SCI, V14, P13, DOI 10.1016/0165-6147(93)90107-U; Shigemoto R, 1996, NATURE, V381, P523, DOI 10.1038/381523a0; SIEGELBAUM SA, 1982, NATURE, V299, P413, DOI 10.1038/299413a0; SIVARAMAKRISHNAN S, 1995, J NEUROSCI, V15, P6576; SLADECZEK F, 1993, P ROY SOC B-BIOL SCI, V253, P297, DOI 10.1098/rspb.1993.0117; STANLEY EF, 1991, J NEUROSCI, V11, P985; SWARTZ KJ, 1992, J NEUROSCI, V12, P458; TAKAHASHI T, 1993, NATURE, V366, P156, DOI 10.1038/366156a0; TAKAHASHI T, 1992, J PHYSIOL-LONDON, V446, pP549; WHEELER DB, 1994, SCIENCE, V264, P107, DOI 10.1126/science.7832825; WU LG, 1994, NEURON, V12, P1139, DOI 10.1016/0896-6273(94)90321-2; WU LG, 1995, J PHYSIOL-LONDON, V485, P649, DOI 10.1113/jphysiol.1995.sp020759; YAWO H, 1993, J PHYSIOL-LONDON, V460, P153, DOI 10.1113/jphysiol.1993.sp019464; Yokoi M, 1996, SCIENCE, V273, P645, DOI 10.1126/science.273.5275.645; YOSHINO M, 1995, BRAIN RES, V695, P179, DOI 10.1016/0006-8993(95)00743-A	39	333	337	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 25	1996	274	5287					594	597		10.1126/science.274.5287.594	http://dx.doi.org/10.1126/science.274.5287.594			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN919	8849448				2022-12-24	WOS:A1996VN91900046
J	Wingrove, JA; Gober, JW				Wingrove, JA; Gober, JW			Identification of an asymmetrically localized sensor histidine kinase responsible for temporally and spatially regulated transcription	SCIENCE			English	Article							CAULOBACTER-CRESCENTUS; BACTERIAL CHEMORECEPTOR; SIGNAL-TRANSDUCTION; FLAGELLAR GENES; CELL; PROTEIN; FLBD; ACTIVATOR; DIVISION; DIFFERENTIATION	Caulobacter crescentus undergoes asymmetric cell division, resulting in a stalked cell and a motile swarmer cell. The genes encoding external components of the flagellum are expressed in the swarmer compartment of the predivisional cell through the localized activation of the transcription factor FlbD. The mechanisms responsible for the temporal and spatial activation of FlbD were determined through identification of FlbE, a histidine kinase required for FlbD activity. FlbE is asymmetrically distributed in the predivisional cell. It is located at the pole of the stalked compartment and at the site of cell division in the swarmer compartment. These findings suggest that FlbE and FlbD are activated in response to a morphological change in the cell resulting from cell division events.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,INST MOL BIOL,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NIGMS NIH HHS [GM-07104, GM48417] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEX LA, 1994, TRENDS GENET, V10, P133, DOI 10.1016/0168-9525(94)90215-1; ALLEY MRK, 1992, GENE DEV, V6, P825, DOI 10.1101/gad.6.5.825; ALLEY MRK, 1993, SCIENCE, V259, P1754, DOI 10.1126/science.8456303; ARIGONI F, 1995, SCIENCE, V270, P637, DOI 10.1126/science.270.5236.637; BACKMAN K, 1981, P NATL ACAD SCI-BIOL, V78, P3743, DOI 10.1073/pnas.78.6.3743; BENSON AK, 1994, RES MICROBIOL, V145, P420, DOI 10.1016/0923-2508(94)90090-6; BENSON AK, 1994, P NATL ACAD SCI USA, V91, P4989, DOI 10.1073/pnas.91.11.4989; BRUN YV, 1994, ANNU REV BIOCHEM, V63, P419, DOI 10.1146/annurev.bi.63.070194.002223; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; CONTRERAS I, 1978, J BACTERIOL, V135, P1130, DOI 10.1128/JB.135.3.1130-1136.1978; DUNCAN L, 1995, SCIENCE, V270, P641, DOI 10.1126/science.270.5236.641; GOBER JW, 1992, MOL BIOL CELL, V3, P913, DOI 10.1091/mbc.3.8.913; GOBER JW, 1995, MICROBIOL REV, V59, P31, DOI 10.1128/MMBR.59.1.31-47.1995; GOBER JW, 1991, CELL, V64, P381, DOI 10.1016/0092-8674(91)90646-G; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; HULTQUIS.DE, 1968, BIOCHIM BIOPHYS ACTA, V153, P329, DOI 10.1016/0005-2728(68)90078-9; Jenal U, 1996, EMBO J, V15, P2393, DOI 10.1002/j.1460-2075.1996.tb00597.x; KOSHLAND DE, 1951, J AM CHEM SOC, V74, P2286; KOVACH ME, 1994, BIOTECHNIQUES, V16, P800; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MADDOCK JR, 1993, SCIENCE, V259, P1717; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; POINDEXTER JS, 1964, BACTERIOL REV, V28, P231, DOI 10.1128/MMBR.28.3.231-295.1964; Quon KC, 1996, CELL, V84, P83, DOI 10.1016/S0092-8674(00)80995-2; RAMAKRISHNAN G, 1990, P NATL ACAD SCI USA, V87, P2369, DOI 10.1073/pnas.87.6.2369; RAMAKRISHNAN G, 1994, J BACTERIOL, V176, P7587, DOI 10.1128/JB.176.24.7587-7600.1994; SCHWEIZER HP, 1992, MOL MICROBIOL, V6, P1195, DOI 10.1111/j.1365-2958.1992.tb01558.x; SWANSON RV, 1994, TRENDS BIOCHEM SCI, V19, P485, DOI 10.1016/0968-0004(94)90135-X; WINGROVE JA, 1994, GENE DEV, V8, P1839, DOI 10.1101/gad.8.15.1839; WINGROVE JA, 1993, GENE DEV, V7, P1979, DOI 10.1101/gad.7.10.1979; WINGROVE JA, UNPUB; WU JG, 1995, J BACTERIOL, V177, P3241, DOI 10.1128/jb.177.11.3241-3250.1995	33	36	37	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 25	1996	274	5287					597	601		10.1126/science.274.5287.597	http://dx.doi.org/10.1126/science.274.5287.597			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN919	8849449				2022-12-24	WOS:A1996VN91900047
J	Borst, JGG; Sakmann, B				Borst, JGG; Sakmann, B			Calcium influx and transmitter release in a fast CNS synapse	NATURE			English	Article							SQUID GIANT SYNAPSE; RAT MEDIAL NUCLEUS; NERVE-TERMINALS; TRAPEZOID BODY; ION-BINDING; CURRENTS; CHANNELS; FACILITATION; HIPPOCAMPUS; EXOCYTOSIS	CALCIUM entry through presynaptic calcium channels controls the release of neurotransmitter(1). It is not known whether the putative calcium sensor that triggers this rapid neurotransmitter release is close enough to be activated by the large increase in the Ca2+ concentration (calcium 'domain') reached within nanometres of a single calcium channel or whether many channels have to open(2), We tested this in a calyx-type synapse in the rat medial nucleus of the trapezoid body, We compared the quantal content of postsynaptic currents with the presynaptic calcium current that flows during an action potential, and the results suggest that more than 60 calcium channels open for each vesicle that is released, In addition, we dialysed terminals with the slow calcium buffer EGTA, which reduced phasic transmitter release at concentrations as low as 1 mM. These results indicate that the distance that calcium ions must diffuse to reach the calcium sensor is relatively long, and that therefore Ca2+ entry through multiple calcium channels is needed to release a vesicle.			Borst, JGG (corresponding author), MAX PLANCK INST MED RES, ZELLPHYSIOL ABT, JAHNSTR 29, D-69120 HEIDELBERG, GERMANY.							ADLER EM, 1991, J NEUROSCI, V11, P1496; Borst JGG, 1995, J PHYSIOL-LONDON, V489, P825, DOI 10.1113/jphysiol.1995.sp021095; CASEY MA, 1988, NEUROSCIENCE, V24, P189, DOI 10.1016/0306-4522(88)90322-3; COOPER RL, 1995, J NEUROSCI METH, V61, P67, DOI 10.1016/0165-0270(95)00024-O; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P574, DOI 10.1113/jphysiol.1954.sp005130; DIAMOND JS, 1995, NEURON, V15, P1097, DOI 10.1016/0896-6273(95)90098-5; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; FALKE JJ, 1994, Q REV BIOPHYS, V27, P219, DOI 10.1017/S0033583500003012; FORSYTHE ID, 1993, P ROY SOC B-BIOL SCI, V251, P151, DOI 10.1098/rspb.1993.0022; GOLLASCH M, 1992, AM J PHYSIOL, V263, pC948, DOI 10.1152/ajpcell.1992.263.5.C948; HAYDON PG, 1994, NEURON, V13, P1275, DOI 10.1016/0896-6273(94)90414-6; HERRINGTON J, 1994, PULSE CONTROL V4 0 I; HOCHNER B, 1991, NEUROSCI LETT, V125, P215, DOI 10.1016/0304-3940(91)90032-O; ISAACSON JS, 1995, NEURON, V15, P875, DOI 10.1016/0896-6273(95)90178-7; JACKSON MB, 1991, P NATL ACAD SCI USA, V88, P380, DOI 10.1073/pnas.88.2.380; JONAS P, 1993, J PHYSIOL-LONDON, V472, P615, DOI 10.1113/jphysiol.1993.sp019965; KATZ B, 1965, PROC R SOC SER B-BIO, V161, P483, DOI 10.1098/rspb.1965.0016; Katz B., 1969, RELEASE NEURAL TRANS; KORN H, 1994, ADV SEC MESS PHOSPH, V29, P301; LIM NF, 1990, NATURE, V344, P449, DOI 10.1038/344449a0; LLINAS R, 1982, P NATL ACAD SCI-BIOL, V79, P2415, DOI 10.1073/pnas.79.7.2415; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; MARTIN AR, 1964, J PHYSIOL-LONDON, V175, P1; MINTZ IM, 1995, NEURON, V15, P675, DOI 10.1016/0896-6273(95)90155-8; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; Neher E., 1986, EXPT BRAIN RES SERIE, P80; SCHWEIZER FE, 1995, NEURON, V14, P689, DOI 10.1016/0896-6273(95)90213-9; SMITH PD, 1984, ANAL BIOCHEM, V143, P188, DOI 10.1016/0003-2697(84)90575-X; STANLEY EF, 1993, NEURON, V11, P1007, DOI 10.1016/0896-6273(93)90214-C; WU LG, 1995, J NEUROPHYSIOL, V73, P1965, DOI 10.1152/jn.1995.73.5.1965	30	476	483	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 3	1996	383	6599					431	434		10.1038/383431a0	http://dx.doi.org/10.1038/383431a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL463	8837774				2022-12-24	WOS:A1996VL46300060
J	Chiang, C; Ying, LTT; Lee, E; Young, KE; Corden, JL; Westphal, H; Beachy, PA				Chiang, C; Ying, LTT; Lee, E; Young, KE; Corden, JL; Westphal, H; Beachy, PA			Cyclopia and defective axial patterning in mice lacking Sonic hedgehog gene function	NATURE			English	Article							MOTOR-NEURON INDUCTION; TERMINAL CLEAVAGE PRODUCT; FLOOR PLATE; MOUSE EMBRYO; NOTOCHORD DEVELOPMENT; SCLEROTOME INDUCTION; POLARIZING ACTIVITY; XENOPUS-LAEVIS; EXPRESSION; DROSOPHILA	Targeted gene disruption in the mouse shows that the Sonic hedgehog (Shh) gene plays a critical role in patterning of vertebrate embryonic tissues, including the brain and spinal cord, the axial skeleton and the limbs. Early defects are observed in the establishment or maintenance of midline structures, such as the notochord and the floorplate, and later defects include absence of distal limb structures, cyclopia, absence of ventral cell types within the neural tube, and absence of the spinal column and most of the ribs. Defects in all tissues extend beyond the normal sites of Shh transcription, confirming the proposed role of Shh proteins as an extracellular signal required for the tissue-organizing properties of several vertebrate patterning centres.	JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT MOL BIOL & GENET, BALTIMORE, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University	Chiang, C (corresponding author), NIH, LAB MAMMALIAN GENET & DEV, BETHESDA, MD 20892 USA.							Adelmann HB, 1936, Q REV BIOL, V11, P284, DOI 10.1086/394509; Adelmann HB, 1936, Q REV BIOL, V11, P161, DOI 10.1086/394504; ALTABA ARI, 1995, MOL CELL NEUROSCI, V6, P106, DOI 10.1006/mcne.1995.1011; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; BEDDINGTON RSP, 1994, DEVELOPMENT, V120, P613; BONCINELLI E, 1993, J NEUROBIOL, V24, P1356, DOI 10.1002/neu.480241008; CHANG DT, 1994, DEVELOPMENT, V120, P3339; CHRIST B, 1992, ANAT EMBRYOL, V186, P505; CHRIST B, 1995, ANAT EMBRYOL, V191, P381, DOI 10.1007/BF00304424; Cohn MJ, 1996, TRENDS GENET, V12, P253, DOI 10.1016/0168-9525(96)10030-5; Cossu G, 1996, TRENDS GENET, V12, P218, DOI 10.1016/0168-9525(96)10025-1; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; EKKER SC, 1995, DEVELOPMENT, V121, P2337; EKKER SC, 1995, CURR BIOL, V5, P944, DOI 10.1016/S0960-9822(95)00185-0; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; Fitz C R, 1994, Neuroimaging Clin N Am, V4, P263; HALL TMT, 1995, NATURE, V378, P212, DOI 10.1038/378212a0; HALPERN ME, 1993, CELL, V75, P99, DOI 10.1016/0092-8674(93)90682-G; Hammerschmidt M, 1996, GENE DEV, V10, P647, DOI 10.1101/gad.10.6.647; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; HERRMANN BG, 1994, TRENDS GENET, V10, P280, DOI 10.1016/0168-9525(90)90011-T; HERRMANN BG, 1991, DEVELOPMENT, V113, P913; HINCHLIFFE JR, 1981, J EMBRYOL EXP MORPH, V62, P63; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; HYNES M, 1995, NEURON, V15, P35, DOI 10.1016/0896-6273(95)90062-4; JOHNSON RL, 1994, CELL, V79, P1165, DOI 10.1016/0092-8674(94)90008-6; JOYNER AL, 1987, GENE DEV, V1, P29, DOI 10.1101/gad.1.1.29; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LAI CJ, 1995, DEVELOPMENT, V121, P2349; LAWSON KA, 1991, DEVELOPMENT, V113, P891; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LOPEZMARTINEZ A, 1995, CURR BIOL, V5, P791, DOI 10.1016/S0960-9822(95)00156-4; Macdonald R, 1996, CURR OPIN NEUROBIOL, V6, P49, DOI 10.1016/S0959-4388(96)80008-0; MACDONALD R, 1995, DEVELOPMENT, V121, P3267; MANSOURI A, 1994, J CELL SCI, P35; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NEUBUSER A, 1995, DEV BIOL, V170, P701, DOI 10.1006/dbio.1995.1248; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X; PONG TM, 1992, DEVELOPMENT, V115, P657; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; SIMEONE A, 1993, EMBO J, V12, P2735, DOI 10.1002/j.1460-2075.1993.tb05935.x; Sordino P, 1996, TRENDS ECOL EVOL, V11, P114, DOI 10.1016/0169-5347(96)81089-5; TALBOT WS, 1995, NATURE, V378, P150, DOI 10.1038/378150a0; WALLIN J, 1994, DEVELOPMENT, V120, P1109; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	51	2411	2492	2	175	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 3	1996	383	6599					407	413		10.1038/383407a0	http://dx.doi.org/10.1038/383407a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL463	8837770				2022-12-24	WOS:A1996VL46300053
J	Rossing, P; Hougaard, P; BorchJohnsen, K; Parving, HH				Rossing, P; Hougaard, P; BorchJohnsen, K; Parving, HH			Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study	BRITISH MEDICAL JOURNAL			English	Article							CLINICAL PROTEINURIA; IMPROVED SURVIVAL; MICROALBUMINURIA; NEPHROPATHY; MELLITUS; PROGNOSIS; ONSET; COMPLICATIONS; CAPTOPRIL; DEATH	Objective-To evaluate the prognostic significance of microalbuminuria and overt diabetic nephropathy and other putative risk factors for cardiovascular and all cause mortality in insulin dependent diabetes. Design-Ten year observational follow up study. Setting-Outpatient diabetic clinic in a tertiary referral centre. Subjects-All 939 adults with insulin dependent diabetes (duration of diabetes five years or more) attending the clinic in 1984; 593 had normal urinary albumin excretion (less than or equal to 30 mg/24 h), 181 persistent microalbuminuria (31-299 mg/24 h), and 165 overt nephropathy (greater than or equal to 300 mg/24 h). Main outcome measure-All cause and cardiovascular mortality. Results-Fifteen per cent of patients (90/593) with normoalbuminuria, 25% (45/181) with microalbuminuria, and 44% (72/165) with overt nephropathy at baseline died during follow up. Cox multiple regression analysis identified the following significant predictors of all cause mortality: male sex (relative risk 2.03; 95% confidence interval 1.37 to 3.02), age (1.07; 1.06 to 1.08), height (0.96; 0.94 to 0.98), smoking (1.51; 1.09 to 2.08), social class V versus social class IV (1.70; 1.25 to 2.31), log(10) urinary albumin excretion (1.45; 1.18 to 1.77), hypertension (1.63; 1.18 to 2.25), log(10) serum creatinine concentration (8.96; 3.34 to 24.08), and haemoglobin A(1c) concentration (1.11; 1.03 to 1.20). Age, smoking, microalbuminuria, overt nephropathy, and hypertension were significant predictors of cardiovascular mortality. Mortality in patients with microalbuminuria was only slightly increased compared with that in patients with normoalbuminuria. Median survival time after the onset of overt diabetic nephropathy was 13.9 years (95% confidence interval 11.8 to 17.2 years). Conclusions-Abnormally increased urinary albumin excretion and other potentially modifiable risk factors such as hypertension, smoking, poor glycaemic control, and social class predict increased mortality in insulin dependent diabetes. Microalbuminuria by itself confers only a small increase in mortality. The prognosis of patients with overt diabetic nephropathy has improved, probably owing to effective antihypertensive treatment.	NOVO NORDISK AS,STAT HRT CNS GH,HLTH CARE DEV,DK-2880 BAGSVAERD,DENMARK; GLOSTRUP UNIV HOSP,DEPT MED C,CTR PREVENT MED,GLOSTRUP,DENMARK	Novo Nordisk; University of Copenhagen	Rossing, P (corresponding author), STENO DIABET CTR,DK-2820 GENTOFTE,DENMARK.		rossing, peter/AAZ-3415-2021; rossing, peter/AAH-7879-2021	rossing, peter/0000-0002-1531-4294; 				ANDERSEN AR, 1983, DIABETOLOGIA, V25, P496; ANDERSEN PK, 1993, SPRINGER SERIES STAT, P152; BORCHJOHNSEN K, 1993, BRIT MED J, V306, P1722, DOI 10.1136/bmj.306.6894.1722; BORCHJOHNSEN K, 1985, DIABETOLOGIA, V28, P590, DOI 10.1007/BF00281993; BORCHJOHNSEN K, 1987, BMJ-BRIT MED J, V294, P1651, DOI 10.1136/bmj.294.6588.1651; COX DR, 1972, J R STAT SOC B, V34, P187; DECKERT T, 1978, DIABETOLOGIA, V14, P363, DOI 10.1007/BF01228130; FELDTRASMUSSEN B, 1991, DIABETOLOGIA, V34, P164, DOI 10.1007/BF00418270; FORSBLOM CM, 1992, BRIT MED J, V305, P1051, DOI 10.1136/bmj.305.6861.1051; GALL MA, 1995, DIABETOLOGIA, V38, pA215; GALL MA, 1995, DIABETES, V44, P1303, DOI 10.2337/diabetes.44.11.1303; GOULD MM, 1993, BMJ-BRIT MED J, V306, P240, DOI 10.1136/bmj.306.6872.240; HANSEN EJ, 1982, DISTRIBUTION LIVING, P1; Herbert PR, 1993, CIRCULATION, V88, P1437; Jarrett R J, 1984, Diabet Med, V1, P17; Knowles H C Jr, 1971, Trans Assoc Am Physicians, V84, P95; KROLEWSKI AS, 1987, AM J CARDIOL, V59, P750, DOI 10.1016/0002-9149(87)91086-1; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; MARMOT MG, 1984, LANCET, V1, P1003; MATHIESEN ER, 1989, DIABETOLOGIA, V32, P884, DOI 10.1007/BF00297455; MATHIESEN ER, 1991, BMJ-BRIT MED J, V303, P81, DOI 10.1136/bmj.303.6794.81; MESSENT JWC, 1992, KIDNEY INT, V41, P836, DOI 10.1038/ki.1992.128; MOGENSEN CE, 1985, UREMIA INVEST, V9, P85, DOI 10.3109/08860228509088195; MOGENSEN CE, 1984, NEW ENGL J MED, V311, P89, DOI 10.1056/NEJM198407123110204; MOGENSEN CE, 1984, NEW ENGL J MED, V310, P356, DOI 10.1056/NEJM198402093100605; MOSS SE, 1994, ARCH INTERN MED, V154, P2473; PARVING HH, 1989, BRIT MED J, V299, P230, DOI 10.1136/bmj.299.6693.230; PARVING HH, 1982, ACTA ENDOCRINOL-COP, V100, P550, DOI 10.1530/acta.0.1000550; PARVING HH, 1988, BMJ-BRIT MED J, V296, P156, DOI 10.1136/bmj.296.6616.156; Parving HH, 1996, KIDNEY INT, V49, P1778, DOI 10.1038/ki.1996.266; PARVING HH, 1996, KIDNEY, P1864; PEDERSEN MM, 1992, DIABETOLOGIA, V35, pA60; REICHARD P, 1993, NEW ENGL J MED, V329, P304, DOI 10.1056/NEJM199307293290502; ROSSING P, 1995, BRIT MED J, V310, P296, DOI 10.1136/bmj.310.6975.296; SAWICKI PT, 1995, J HYPERTENS, V13, P933, DOI 10.1097/00004872-199508000-00015; VIBERTI G, 1994, JAMA-J AM MED ASSOC, V271, P275, DOI 10.1001/jama.271.4.275; VIBERTI GC, 1982, LANCET, V1, P1430; 1995, BRIT MED J, V311, P973; 1993, NEW ENGL J MED, V329, P977	39	359	367	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1996	313	7060					779	784						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK566	8842069				2022-12-24	WOS:A1996VK56600021
J	Bhattacharya, S; Eckner, R; Grossman, S; Oldread, E; Arany, Z; DAndrea, A; Livingston, DM				Bhattacharya, S; Eckner, R; Grossman, S; Oldread, E; Arany, Z; DAndrea, A; Livingston, DM			Cooperation of Stat2 and p300/CBP in signalling induced by interferon-alpha	NATURE			English	Article							ADENOVIRUS E1A PROTEINS; TRANSCRIPTION FACTOR; GENE-EXPRESSION; TRANSFORMATION; INHIBITION; REPRESSION; INDUCTION; PATHWAYS; ONCOGENE; PROMOTER	THE transcription factor ISGF3 transduces interferon (IFN)-alpha signals and activates the transcription of cellular antiviral defence genes(1,2). Adenovirus EIA blocks the IFN-alpha response, allowing unhindered viral replication(3-5). ISGF3 consists of Stat1, Stat2 and p48. Here we show that p300 and/or CBP (CREB-binding protein), which are transcription adaptors targeted by E1A, interact specifically with Stat2, Binding occurs between the first cysteine-histidine-rich region of p300/CBP and the carboxy terminal segment of Stat2, a domain essential for ISGF3 function(6). We find that this domain of Stat2 has transactivation potential, which correlates with its binding to p300/CBP, Moreover, E1A represses Stat2 transactivation and IFN-alpha-activated transcription by inhibiting p300/CBP function, This provides a new mechanism for inhibition of the IFN-alpha-activated antiviral response by ELA, and supports the view that E1A binding to p300/CBP has functional significance for adenovirus replication in its natural host.	DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School			Bhattacharya, Shoumo/F-4127-2010	Bhattacharya, Shoumo/0000-0002-5571-0478				ACKRILL AM, 1991, NUCLEIC ACIDS RES, V19, P4387, DOI 10.1093/nar/19.16.4387; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BAYLEY ST, 1994, INT J ONCOL, V5, P425; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COHEN B, 1988, EMBO J, V7, P1411, DOI 10.1002/j.1460-2075.1988.tb02958.x; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; GUTCH MJ, 1991, P NATL ACAD SCI USA, V88, P7913, DOI 10.1073/pnas.88.18.7913; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KALVAKOLANU DVR, 1991, P NATL ACAD SCI USA, V88, P7459, DOI 10.1073/pnas.88.17.7459; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; KRAUS VB, 1992, MOL CELL BIOL, V12, P4391, DOI 10.1128/MCB.12.10.4391; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; KUMAR R, 1995, EXP CELL RES, V216, P143, DOI 10.1006/excr.1995.1018; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LANDOLFO S, 1995, PHARMACOL THERAPEUT, V65, P415, DOI 10.1016/0163-7258(95)98599-L; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; LUNDBLAD JR, 1995, NATURE, V374, P81; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; Qureshi SA, 1996, MOL CELL BIOL, V16, P288; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; YAN RQ, 1995, NUCLEIC ACIDS RES, V23, P459, DOI 10.1093/nar/23.3.459	29	406	414	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 26	1996	383	6598					344	347		10.1038/383344a0	http://dx.doi.org/10.1038/383344a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VJ439	8848048				2022-12-24	WOS:A1996VJ43900047
J	Lemaitre, B; Nicolas, E; Michaut, L; Reichhart, JM; Hoffmann, JA				Lemaitre, B; Nicolas, E; Michaut, L; Reichhart, JM; Hoffmann, JA			The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults	CELL			English	Article							DORSAL-VENTRAL PATTERN; NF-KAPPA-B; SIGNAL-TRANSDUCTION PATHWAY; INSECT IMMUNITY; INNATE IMMUNITY; SERINE PROTEASE; EMBRYONIC POLARITY; IL-1 RECEPTOR; HOST-DEFENSE; TOLL GENE	The cytokine-induced activation cascade of NF-KB in mammals and the activation of the morphogen dorsal in Drosophila embryos show striking structural and functional similarities (Toll/IL-1, Cactus/1-kappa B, and dorsal/NF-kappa B). Here we demonstrate that these parallels extend to the immune response of Drosophila. In particular, the intracellular components of the dorsoventral signaling pathway (except for dorsal) and the extracellular Toll ligand, spatzle, control expression of the antifungal peptide gene drosomycin in adults. We also show that mutations in the Toll signaling pathway dramatically reduce survival after fungal infection. Antibacterial genes are induced either by a distinct pathway involving the immune deficiency gene (imd) or by combined activation of both imd and dorsoventral pathways.			Lemaitre, B (corresponding author), INST BIOL MOL & CELLULAIRE,UPR 9022 CNRS,15 RUE RENE DESCARTES,F-67084 STRASBOURG,FRANCE.		Lemaitre, Bruno/T-8146-2019	Lemaitre, Bruno/0000-0001-7970-1667				ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; ANDERSON KV, 1986, GAMETOGENESIS EARLY, P177; ASLING B, 1995, INSECT BIOCHEM MOLEC, V25, P511, DOI 10.1016/0965-1748(94)00091-C; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BROEKAERT WF, 1995, PLANT PHYSIOL, V108, P1353, DOI [10.1104/pp.108.4.1353, 10.1016/j.chiabu.2021.105188]; BULET P, 1993, J BIOL CHEM, V268, P14893; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CHASAN R, 1989, CELL, V56, P391, DOI 10.1016/0092-8674(89)90242-0; DELOTTO R, 1986, NATURE, V323, P688, DOI 10.1038/323688a0; DIMARCQ JL, 1994, EUR J BIOCHEM, V221, P201, DOI 10.1111/j.1432-1033.1994.tb18730.x; DINESHKUMAR SP, 1995, P NATL ACAD SCI USA, V92, P4175, DOI 10.1073/pnas.92.10.4175; ENGSTROM Y, 1993, J MOL BIOL, V232, P327, DOI 10.1006/jmbi.1993.1392; FEHLBAUM P, 1994, J BIOL CHEM, V269, P33159; FLYG C, 1988, GENET RES, V52, P51, DOI 10.1017/S0016672300027300; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GERTTULA S, 1988, GENETICS, V119, P123; Gross I, 1996, NUCLEIC ACIDS RES, V24, P1238, DOI 10.1093/nar/24.7.1238; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HECHT PM, 1993, GENETICS, V135, P405; Heguy A., 1992, J BIOL CHEM, V267, P2604; Hetru C., 1994, PERSPECTIVES IMMUNIT, P167; HOFFMANN JA, 1995, CURR OPIN IMMUNOL, V7, P4, DOI 10.1016/0952-7915(95)80022-0; HULTMARK D, 1993, TRENDS GENET, V9, P178, DOI 10.1016/0168-9525(93)90165-E; Ip T.Y., 1993, CELL, V75, P753; IWANAGA S, 1993, CURR OPIN IMMUNOL, V5, P74, DOI 10.1016/0952-7915(93)90084-6; JIN YS, 1990, CELL, V60, P873, DOI 10.1016/0092-8674(90)90100-S; KAPPLER C, 1993, EMBO J, V12, P1561, DOI 10.1002/j.1460-2075.1993.tb05800.x; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KYLSTEN P, 1990, EMBO J, V9, P217, DOI 10.1002/j.1460-2075.1990.tb08098.x; LEMAITRE B, 1995, EMBO J, V14, P536, DOI 10.1002/j.1460-2075.1995.tb07029.x; LEMAITRE B, 1995, P NATL ACAD SCI USA, V92, P9465, DOI 10.1073/pnas.92.21.9465; LETSOU A, 1991, P NATL ACAD SCI USA, V88, P810, DOI 10.1073/pnas.88.3.810; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; Morisato D, 1995, ANNU REV GENET, V29, P371, DOI 10.1146/annurev.genet.29.1.371; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; PETERSEN UM, 1995, EMBO J, V14, P3146, DOI 10.1002/j.1460-2075.1995.tb07317.x; Reichhart J.M., 1993, CR HEBD ACAD SCI, V316, P1207; ROSETTO M, 1995, BIOCHEM BIOPH RES CO, V209, P111, DOI 10.1006/bbrc.1995.1477; ROTH S, 1991, DEVELOPMENT, V112, P371; SCHNEIDER DS, 1994, DEVELOPMENT, V120, P1243; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SMITH C, 1994, GENETICS, V136, P1355; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; SUN SC, 1991, EUR J BIOCHEM, V196, P247, DOI 10.1111/j.1432-1033.1991.tb15811.x; TATEI K, 1995, MOL CELL BIOL, V15, P3627; TRYSELIUS Y, 1992, EUR J BIOCHEM, V204, P395, DOI 10.1111/j.1432-1033.1992.tb16648.x; Vey A., 1986, P89; WASSERMAN SA, 1993, MOL BIOL CELL, V4, P767, DOI 10.1091/mbc.4.8.767; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6; WICKER C, 1990, J BIOL CHEM, V265, P22493	55	2745	2966	14	311	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1996	86	6					973	983		10.1016/S0092-8674(00)80172-5	http://dx.doi.org/10.1016/S0092-8674(00)80172-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VJ443	8808632	Bronze, Green Published			2022-12-24	WOS:A1996VJ44300015
J	Clegg, CH; Rulffes, JT; Wallace, PM; Haugen, HS				Clegg, CH; Rulffes, JT; Wallace, PM; Haugen, HS			Regulation of an extrathymic T-cell development pathway by oncostatin M	NATURE			English	Article							STEM-CELLS; EXPRESSION; CD4+	MOST Of the T lymphocytes that populate the immune system develop in the thymus before its involution during late adolescence, Therefore, subsequent losses in T cells caused by HIV infection(1), chemotherapy(2) or age related factors(3) can greatly diminish immune responses to new antigenic challenge, Here we report the discovery of a thymus-independent pathway of T-cell development that may provide help for T cell immunodeficiency, We show that expression of an oncostatin M transgene(4) in the early T lineage stimulates a dramatic accumulation of immature and mature T cells in lymph nodes, A functional thymus is not required for this effect as reconstitution of nu/nu mice with transgenic bone marrow stimulated a 500-fold increase in Thy-1(+) lymph node cells and restored immune responsiveness to allogeneic mouse melanoma cells, This lymphopoietic pathway is not unique to transgenic mice because administration of oncostatin M protein produced a similar response in non-transgenic mice, These results identify a new pathway of T-cell development and a potential treatment for T-cell immunodeficiency with oncostatin M.			Clegg, CH (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,3005 1ST AVE,SEATTLE,WA 98121, USA.							BERNAD A, 1994, IMMUNITY, V1, P725, DOI 10.1016/S1074-7613(94)80014-6; Bruce A. Gregory, 1992, Progress in Growth Factor Research, V4, P157, DOI 10.1016/0955-2235(92)90029-H; ESCARY JL, 1993, NATURE, V363, P361, DOI 10.1038/363361a0; FRANCESCHI C, 1995, IMMUNOL TODAY, V16, P12, DOI 10.1016/0167-5699(95)80064-6; GEANING DP, 1992, SCIENCE, V255, P1434; KSIELOW P, 1995, ADV IMMUNOL, V58, P87; LI YW, 1994, J IMMUNOL, V153, P421; MACKALL CL, 1995, NEW ENGL J MED, V332, P143, DOI 10.1056/NEJM199501193320303; MALIK N, 1995, MOL CELL BIOL, V15, P2349; ROCHA B, 1995, CURR OPIN IMMUNOL, V7, P235, DOI 10.1016/0952-7915(95)80008-5; ROEDERER M, 1995, NAT MED, V1, P621, DOI 10.1038/nm0795-621; SAINTRUF C, 1994, SCIENCE, V266, P1208, DOI 10.1126/science.7973703; SHEN MM, 1994, EMBO J, V13, P1375, DOI 10.1002/j.1460-2075.1994.tb06391.x; Wallace PM, 1995, ANN NY ACAD SCI, V762, P42; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x	16	90	90	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 21	1996	384	6606					261	263		10.1038/384261a0	http://dx.doi.org/10.1038/384261a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU381	8918875				2022-12-24	WOS:A1996VU38100050
J	Jarvis, LM; Davidson, F; Hanley, JP; Yap, PL; Ludlam, CA; Simmonds, P				Jarvis, LM; Davidson, F; Hanley, JP; Yap, PL; Ludlam, CA; Simmonds, P			Infection with hepatitis G virus among recipients of plasma products	LANCET			English	Article							C VIRUS; BLOOD-DONORS; FACTOR-VIII; HEMOPHILIACS; PREVALENCE; ORGANIZATION; GENOTYPES	Background Hepatitis G virus (HGV or GBV-C) is a newly discovered human flavivirus distantly related to hepatitis C Virus (HCV). Little information is available on its natural history or routes of transmission, although it can be transmitted parenterally. We investigated the prevalence of persistent infection of HGV and HCV in patients exposed to non-virus-inactivated pooled blood products associated with transmission of HCV. Methods RNA was extracted from the plasma of 112 patients with haemophilia and 57 with hypogammaglobulinaemia, as well as from 64 different batches of archived coagulation-factor concentrates and immunoglobulins. RNA was reverse transcribed and amplified with primers from the 5' non-coding region of HCV and HGV by a nested polymerase chain reaction (PCR): Viral RNA was quantified by titration of complementary DNA before amplification. Findings Among non-remunerated UK blood donors HGV infection (detected by PCR) was more common than HCV infection (four [3 . 2%] of 125 compared with 137 [0 . 076%] of 180 658 in southeast Scotland]. Testing of batches of factor VIII and factor IX concentrates prepared without viral inactivation procedures showed high frequencies of contamination with HGV (16 of 17 factor VIII batches positive; six of six factor IX batches positive), with no difference between remunerated and non-renumerated donors. However, among 95 haemophiliacs who had received non-virus-inactivated concentrates, 13 (14%) were positive for HGV compared with 79 (83%) who were positive for HCV. Two of 37 recipients of long-term immunoglobulin replacement therapy were positive for HGV. Virus inactivation of blood products substantially reduced or eliminated contamination by HGV RNA sequences. Interpretation Despite the extremely high level of HGV contamination of non-virus-inactivated blood products, their use was not associated with high rates of persistent infection in recipients. The infectivity of HGV in blood products may be lower than that of HCV, or the virus may be less able to establish persistent infection in humans. Whatever the case, the high prevalence of active HGV infection in the general population remains difficult to explain.	UNIV EDINBURGH, DEPT HAEMATOL, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND; EDINBURGH & SE SCOTLAND BLOOD TRANSFUS SERV, EDINBURGH, MIDLOTHIAN, SCOTLAND	University of Edinburgh	Jarvis, LM (corresponding author), UNIV EDINBURGH, DEPT MED MICROBIOL, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND.			Simmonds, Peter/0000-0002-7964-4700				CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; CRAWFORD RJ, 1994, TRANSFUSION MED, V4, P121, DOI 10.1111/j.1365-3148.1994.tb00252.x; DAVIDSON F, 1995, J GEN VIROL, V76, P1197, DOI 10.1099/0022-1317-76-5-1197; Feucht HH, 1996, LANCET, V347, P615, DOI 10.1016/S0140-6736(96)91309-4; FLETCHER ML, 1983, BRIT MED J, V287, P1754, DOI 10.1136/bmj.287.6407.1754; FOLLETT EAC, 1992, LANCET, V339, P928, DOI 10.1016/0140-6736(92)90964-5; JARVIS LM, 1994, J INFECT DIS, V170, P1018, DOI 10.1093/infdis/170.4.1018; Kao JH, 1996, LANCET, V347, P120, DOI 10.1016/S0140-6736(96)90244-5; Leary TP, 1996, J MED VIROL, V48, P60, DOI 10.1002/(SICI)1096-9071(199601)48:1&lt;60::AID-JMV10&gt;3.0.CO;2-A; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; Moaven LD, 1996, MED J AUSTRALIA, V165, P84, DOI 10.5694/j.1326-5377.1996.tb124854.x; MUERHOFF AS, 1995, J VIROL, V69, P5621, DOI 10.1128/JVI.69.9.5621-5630.1995; SIMMONDS P, 1990, LANCET, V336, P1469, DOI 10.1016/0140-6736(90)93179-S; SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564; TEDDER RS, 1991, BRIT J HAEMATOL, V79, P512, DOI 10.1111/j.1365-2141.1991.tb08064.x; WATSON HG, 1992, BRIT J HAEMATOL, V80, P514, DOI 10.1111/j.1365-2141.1992.tb04566.x; WEINER AJ, 1992, P NATL ACAD SCI USA, V89, P3468, DOI 10.1073/pnas.89.8.3468; YOSHIBA M, 1995, LANCET, V346, P1131, DOI 10.1016/S0140-6736(95)91802-7	18	227	229	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 16	1996	348	9038					1352	1355		10.1016/S0140-6736(96)04041-X	http://dx.doi.org/10.1016/S0140-6736(96)04041-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT332	8918279				2022-12-24	WOS:A1996VT33200012
J	Yel, L; Minegishi, Y; CoustanSmith, E; Buckley, RH; Trubel, H; Pachman, LM; Kitchingman, GR; Campana, D; Rohrer, J; Conley, ME				Yel, L; Minegishi, Y; CoustanSmith, E; Buckley, RH; Trubel, H; Pachman, LM; Kitchingman, GR; Campana, D; Rohrer, J; Conley, ME			Mutations in the mu heavy-chain gene in patients with agammaglobulinemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							X-LINKED AGAMMAGLOBULINEMIA; BRUTONS TYROSINE KINASE; SWITCH RECOMBINATION; B-LYMPHOCYTES; IMMUNOGLOBULIN; DNA; DEFICIENT; SEQUENCE; REGIONS; CELLS	Background Most patients with congenital hypogammaglobulinemia and absent B cells are males with X-linked agammaglobulinemia, which is caused by mutations in the gene for Bruton's tyrosine kinase (Btk); however, there are females with a similar disorder who do not have mutations in this gene. We studied two families with autosomal recessive defects in B-cell development and patients with presumed X-linked agammaglobulinemia who did not have mutations in Btk. Methods A series of candidate genes that encode proteins involved in B-cell signal-transduction pathways were analyzed by linkage studies and mutation screening. Results Four different mutations were identified in the mu heavy-chain gene on chromosome 14. In one family, there was a homozygous 75-to-100-kb deletion that included D-region genes, J-region genes, and the mu constant-region gene. In a second family, there was a homozygous base-pair substitution in the alternative splice site of the mu heavy-chain gene. This mutation would inhibit production of the membrane form of the mu chain and produce an amino acid substitution in the secreted form. In additions, a patient previously thought to have X-linked agammaglobulinemia was found to have an amino acid substitution on one chromosome at an invariant cysteine that is required for the intrachain disulfide bond and, on the other chromosome, a large deletion that included the immunoglobulin locus. Conclusions Defects in the mu heavy-chain gene are a cause of agammaglobulinemia in humans. This implies that an intact membrane-bound mu chain is essential for B-cell development. (C) 1996, Massachusetts Medical Society.	ST JUDE CHILDRENS RES HOSP, DEPT IMMUNOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT VIROL, MEMPHIS, TN 38105 USA; DUKE UNIV, SCH MED, DEPT PEDIAT, DURHAM, NC USA; UNIV MAINZ, DEPT PEDIAT, D-6500 MAINZ, GERMANY; NORTHWESTERN UNIV, SCH MED, DEPT PEDIAT, CHICAGO, IL 60611 USA; UNIV TENNESSEE, DEPT PEDIAT, MEMPHIS, TN USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; Duke University; Johannes Gutenberg University of Mainz; Northwestern University; University of Tennessee System; University of Tennessee Health Science Center			Buckley, Rebecca/AAB-1578-2019; Pachman, Lauren/AAZ-6061-2021	Pachman, Lauren/0000-0001-8117-574X	NATIONAL CANCER INSTITUTE [R01CA058297, P01CA020180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI025129, R01AI025129] Funding Source: NIH RePORTER; NCI NIH HHS [CA58297, P01 CA20180] Funding Source: Medline; NIAID NIH HHS [AI25129] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AOKI Y, 1994, P NATL ACAD SCI USA, V91, P10606, DOI 10.1073/pnas.91.22.10606; BEALE D, 1976, Q REV BIOPHYS, V9, P135, DOI 10.1017/S0033583500002390; BENGER JC, 1989, AM J HUM GENET, V45, P606; BENGER JC, 1991, GENOMICS, V9, P614, DOI 10.1016/0888-7543(91)90354-H; BORZILLO GV, 1987, J IMMUNOL, V139, P1326; BORZILLO GV, 1988, J IMMUNOL, V141, P3625; BRADLEY LAD, 1994, HUM MOL GENET, V3, P79, DOI 10.1093/hmg/3.1.79; BUBB MO, 1978, IMMUNOLOGY, V34, P449; Burrows P D, 1990, Semin Immunol, V2, P189; CAMPANA D, 1990, J IMMUNOL, V145, P1675; CARTER M, 1991, LEUKEMIA, V5, P668; CHEN JZ, 1993, INT IMMUNOL, V5, P647, DOI 10.1093/intimm/5.6.647; CONLEY ME, 1985, J IMMUNOL, V134, P3070; CONLEY ME, 1992, J CLIN IMMUNOL, V12, P139, DOI 10.1007/BF00918144; CONLEY ME, 1994, HUM MOL GENET, V3, P1751, DOI 10.1093/hmg/3.10.1751; DELAMORENA M, 1995, EUR J IMMUNOL, V25, P809, DOI 10.1002/eji.1830250327; DEWEERS M, 1994, J BIOL CHEM, V269, P23857; FRIEDLANDER RM, 1990, NUCLEIC ACIDS RES, V18, P4278, DOI 10.1093/nar/18.14.4278; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; HA HJ, 1994, J IMMUNOL, V152, P5749; HAGEMANN TL, 1994, HUM MOL GENET, V3, P1743, DOI 10.1093/hmg/3.10.1743; HOFFMAN T, 1977, CLIN IMMUNOL IMMUNOP, V7, P364, DOI 10.1016/0090-1229(77)90070-8; ICHIHARA Y, 1988, EMBO J, V7, P4141, DOI 10.1002/j.1460-2075.1988.tb03309.x; JIN H, 1995, HUM MOL GENET, V4, P693, DOI 10.1093/hmg/4.4.693; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KU G, 1994, IMMUNOGENETICS, V40, P300, DOI 10.1007/BF00189976; MCKINNEY RE, 1987, REV INFECT DIS, V9, P334; MELCHERS F, 1994, ANNU REV IMMUNOL, V12, P209, DOI 10.1146/annurev.immunol.12.1.209; MIGONE N, 1983, P NATL ACAD SCI-BIOL, V80, P467, DOI 10.1073/pnas.80.2.467; MILATOVICH A, 1994, MAMM GENOME, V5, P211, DOI 10.1007/BF00360547; NAGAOKA H, 1994, GENOMICS, V22, P189, DOI 10.1006/geno.1994.1360; PUTNAM FW, 1973, SCIENCE, V182, P287, DOI 10.1126/science.182.4109.287; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; Satterthwaite A, 1996, ANNU REV IMMUNOL, V14, P131, DOI 10.1146/annurev.immunol.14.1.131; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SMITH CIE, 1994, IMMUNOL REV, V138, P159, DOI 10.1111/j.1600-065X.1994.tb00851.x; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V364, P362, DOI 10.1038/364362a0; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VORECHOVSKY I, 1995, HUM MOL GENET, V4, P51, DOI 10.1093/hmg/4.1.51; WICKER LS, 1986, CURR TOP MICROBIOL, V124, P87	44	169	178	1	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 14	1996	335	20					1486	1493		10.1056/NEJM199611143352003	http://dx.doi.org/10.1056/NEJM199611143352003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT340	8890099				2022-12-24	WOS:A1996VT34000003
J	Starr, SE				Starr, SE			Novel mechanism of immunosuppression after measles	LANCET			English	Editorial Material							INTERLEUKIN-12				Starr, SE (corresponding author), UNIV PENN,CHILDRENS HOSP PHILADELPHIA,SCH MED,DEPT PEDIAT,PHILADELPHIA,PA 19104, USA.							AABY P, 1993, INT J EPIDEMIOL, V20, P156; CHEHIMI J, 1994, J EXP MED, V179, P1361, DOI 10.1084/jem.179.4.1361; GRIFFIN DE, 1994, J INFECT DIS S1, V170, P24; Hussey GD, 1996, J INFECT DIS, V173, P1320, DOI 10.1093/infdis/173.6.1320; Karp CL, 1996, SCIENCE, V273, P228, DOI 10.1126/science.273.5272.228; STARR S, 1964, NEW ENGL J MED, V270, P386, DOI 10.1056/NEJM196402202700802; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; von Pirquet C, 1908, DEUT MED WOCHENSCHR, V34, P1297	8	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 9	1996	348	9037					1257	1258		10.1016/S0140-6736(05)65753-4	http://dx.doi.org/10.1016/S0140-6736(05)65753-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR555	8909375	hybrid			2022-12-24	WOS:A1996VR55500005
J	Sanguinetti, MC; Curran, ME; Zou, A; Shen, J; Spector, PS; Atkinson, DL; Keating, MT				Sanguinetti, MC; Curran, ME; Zou, A; Shen, J; Spector, PS; Atkinson, DL; Keating, MT			Coassembly of K(v)LQT1 and minK (IsK) proteins to form cardiac I-Ks potassium channel	NATURE			English	Article							DEPENDENT OUTWARD CURRENT; PIG VENTRICULAR MYOCYTES; GUINEA-PIG; DELAYED RECTIFIER; K+; MUTATIONS; ARRHYTHMIA; BLOCK	THE slowly activating delayed-rectifier K+ current, I-Ks, modulates the repolarization or cardiac action potentials. The molecular structure of the I-Ks, channel is not known, but physiological data indicate that one component of the I-Ks channel is minK (refs 1-6), a 130-amino-acid protein with a single putative transmembrane domain(7). The size and structure of this protein is such that it is unlikely that minK alone forms functional channels(8,9). We have previously used positional cloning techniques to define a new putative K+-channel gene, KVLQT1(10). Mutations in this gene cause long-QT syndrome, an inherited disorder that increases the risk of sudden death from cardiac arrhythmias. Here se show that KVLQT1 encodes a K+ channel with biophysical properties unlike other known cardiac currents. We considered that K(v)LQT1 might coassemble with another subunit to form functional channels in cardiac myocytes. Coexpression of K(v)LQT1 with minK induced a current that was almost identical to cardiac I-Ks. Therefore, K(v)LQT1 is the subunit that coassembles with minK to form I-Ks channels and I-Ks dysfunction is a cause of cardiac arrhythmia.	UNIV UTAH,ECCLES PROGRAM HUMAN MOL BIOL & GENET,SALT LAKE CITY,UT 84112; UNIV UTAH,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84112; UNIV UTAH,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Sanguinetti, MC (corresponding author), UNIV UTAH,DEPT MED,DIV CARDIOL,SALT LAKE CITY,UT 84112, USA.		Sanguinetti, Michael/AAN-2615-2020					ATTALI B, 1993, NATURE, V365, P850, DOI 10.1038/365850a0; BALSER JR, 1990, J GEN PHYSIOL, V96, P835, DOI 10.1085/jgp.96.4.835; BALSER JR, 1991, CIRC RES, V69, P519, DOI 10.1161/01.RES.69.2.519; BUSCH AE, 1992, SCIENCE, V255, P1705, DOI 10.1126/science.1553557; CUI J, 1994, J GEN PHYSIOL, V104, P87, DOI 10.1085/jgp.104.1.87; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; GOLDSTEIN SAN, 1991, NEURON, V7, P403, DOI 10.1016/0896-6273(91)90292-8; HAUSDORFF SF, 1991, BIOCHEMISTRY-US, V30, P3341, DOI 10.1021/bi00227a025; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; LESAGE F, 1993, RECEPTOR CHANNEL, V1, P143; Li GR, 1996, CIRC RES, V78, P689, DOI 10.1161/01.RES.78.4.689; MATSUURA H, 1987, PFLUG ARCH EUR J PHY, V410, P596, DOI 10.1007/BF00581319; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; Sanguinetti MC, 1996, P NATL ACAD SCI USA, V93, P2208, DOI 10.1073/pnas.93.5.2208; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; Spector PS, 1996, J GEN PHYSIOL, V107, P611, DOI 10.1085/jgp.107.5.611; TAKUMI T, 1991, J BIOL CHEM, V266, P22192; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; Wang KW, 1996, NEURON, V16, P571, DOI 10.1016/S0896-6273(00)80076-8; WANG KW, 1995, NEURON, V14, P1303, DOI 10.1016/0896-6273(95)90277-5; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17	22	1409	1465	0	31	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1996	384	6604					80	83		10.1038/384080a0	http://dx.doi.org/10.1038/384080a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR219	8900283				2022-12-24	WOS:A1996VR21900059
J	Gallinari, P; Jiricny, J				Gallinari, P; Jiricny, J			A new class of uracil-DNA glycosylases related to human thymine-DNA glycosylase	NATURE			English	Article							ESCHERICHIA-COLI; NUCLEAR EXTRACTS; G.T MISPAIRS; HUMAN-CELLS; HELA-CELLS; INSECTS; DROSOPHILA; MUTATIONS; REPAIR; GENE	MISPAIRS in DNA of guanine with uracil and thymine can arise as a result of deamination of cytosine and 5-methylcytosine, respectively. In humans such mispairs are removed by thymine-DNA glycosylase (TDG)(1-3). By deleting the carboxy and amino termini of this enzyme we have identified a core region capable of processing G/U but not G/T mispairs. We have further identified two bacterial proteins with strong sequence homology to this core and shown that the homologue from Escherichia coli (dsUDG) can remove uracil from G/U mispairs. This enzyme is likely to act as a back-up to the highly efficient and abundant enzyme uracil-DNA glycosylase (UDG) which is found in most organisms. Pupating insects have been reported to lack UDG activity(4), but we have identified an enzyme similar to dsUDG in cell lines from three different insect species. These data imply the existence of a family of double-strand-specific uracil-DNA glycosylases which, although they are subservient to UDG in mast organisms, may constitute the first line of defence against the mutagenic effects of cytosine deamination in insects.	IST RIC BIOL MOL P ANGELETTI,I-00040 POMEZIA,ITALY	Merck & Company			Gallinari, Paola/ABE-8238-2021					AUSUBEL FM, 1995, CURR PROT MOL BIOL; Deutsch W. A., 1995, Insect Molecular Biology, V4, P1, DOI 10.1111/j.1365-2583.1995.tb00001.x; DUDLEY B, 1992, J BIOL CHEM, V267, P11964; DUNCAN BK, 1982, J BACTERIOL, V151, P750, DOI 10.1128/JB.151.2.750-755.1982; DUNCAN BK, 1985, J BACTERIOL, V164, P689, DOI 10.1128/JB.164.2.689-695.1985; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; MORGAN AR, 1989, J BIOL CHEM, V264, P9911; NEDDERMANN P, 1993, J BIOL CHEM, V268, P21218; NEDDERMANN P, 1994, P NATL ACAD SCI USA, V91, P1642, DOI 10.1073/pnas.91.5.1642; Neddermann P, 1996, J BIOL CHEM, V271, P12767, DOI 10.1074/jbc.271.22.12767; Sawa R., 1995, NATURE, V373, P487; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; TOMLIN NV, 1989, INT REV CYTOL, P125; VARSHNEY U, 1989, NUCLEIC ACIDS RES, V17, P813, DOI 10.1093/nar/17.2.813; WANG Z, 1989, J BIOL CHEM, V264, P1163; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; WIEBAUER K, 1989, NATURE, V339, P234, DOI 10.1038/339234a0	18	179	182	2	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 24	1996	383	6602					735	738		10.1038/383735a0	http://dx.doi.org/10.1038/383735a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN918	8878487				2022-12-24	WOS:A1996VN91800059
J	Gilbert, MJ; Riddell, SR; Plachter, B; Greenberg, PD				Gilbert, MJ; Riddell, SR; Plachter, B; Greenberg, PD			Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product	NATURE			English	Article							CYTOTOXIC T-LYMPHOCYTES; KINASE-ACTIVITY; INFECTED-CELLS; PROTEIN PP65; VIRUS; EXPRESSION; CHAINS; IDENTIFICATION; TRANSCRIPTION; MOLECULES	RECOGNITION of virus-infected cells by CD8(+) cytotoxic T lymphocytes requires that the viral proteins be processed into peptides, the derived peptides transported into the endoplasmic reticulum and inserted into the binding groove of a major histocompatability complex class I molecule, and the antigenic complex exported to the cell surface(1). However, viral pathogens can disrupt this process and interfere with immune recognition(1-4). These mechanisms may be vital to large viruses such as human cytomegalovirus (CMV), which causes persistent infection despite producing over 200 potentially antigenic proteins during the sequential immediate-early, early and late phases of viral gene expression(5,6). Products of CMV early-phase gene expression can globally block class I presentation(7-10) and prevent recognition of infected cells by cytotoxic T lymphocytes, but an essential viral transcription factor, the 72K principal immediate-early protein, is abundantly expressed before this blockade. However, only a few host CD8(+) cytotoxic T lymphocytes specific for immediate-early protein are present in seropositive individuals, and these lyse CMV-infected cells poorly(11). Here we demonstrate selective abrogation of immediate-early peptide presentation by a CMV matrix protein with associated kinase activity and suggest that modification of a viral protein can result in limiting access to the processing machinery and evasion of cytotoxic-T-cell recognition.	UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98104; UNIV WASHINGTON,DEPT IMMUNOL,SEATTLE,WA 98104; UNIV ERLANGEN NURNBERG,INST KLIN & MOL VIROL,D-91054 ERLANGEN,GERMANY	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Erlangen Nuremberg	Gilbert, MJ (corresponding author), FRED HUTCHINSON CANC RES CTR,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.							BEERSMA MFC, 1993, J IMMUNOL, V151, P4455; BRITT WJ, 1986, J VIROL, V59, P185, DOI 10.1128/JVI.59.1.185-188.1986; DEMARCHI JM, 1980, J VIROL, V35, P277, DOI 10.1128/JVI.35.2.277-286.1980; FALK K, 1993, IMMUNOGENETICS, V38, P161, DOI 10.1007/BF00190906; GAVIN MA, 1993, J IMMUNOL, V151, P3971; GILBERT MJ, 1993, J VIROL, V67, P3461, DOI 10.1128/JVI.67.6.3461-3469.1993; GOODING LR, 1992, CELL, V71, P5; JAHN G, 1987, J GEN VIROL, V68, P1327, DOI 10.1099/0022-1317-68-5-1327; JONES TR, 1995, J VIROL, V69, P4830, DOI 10.1128/JVI.69.8.4830-4841.1995; MACH M, 1989, J GEN VIROL, V70, P3117, DOI 10.1099/0022-1317-70-12-3117; MAUDSLEY DJ, 1991, IMMUNOL TODAY, V12, P429, DOI 10.1016/0167-5699(91)90013-J; MCLAUGHLINTAYLOR E, 1994, J MED VIROL, V43, P103, DOI 10.1002/jmv.1890430119; MURRAY N, 1992, CURR OPIN IMMUNOL, V4, P401, DOI 10.1016/S0952-7915(06)80030-0; PARKER KC, 1994, J IMMUNOL, V152, P163; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; RIDDELL SR, 1991, J IMMUNOL, V146, P2795; RUGER B, 1987, J VIROL, V61, P446; SCHMOLKE S, 1995, J VIROL, V69, P5959, DOI 10.1128/JVI.69.10.5959-5968.1995; SCHMOLKE S, 1995, J VIROL, V69, P1071, DOI 10.1128/JVI.69.2.1071-1078.1995; SOMOGYI T, 1990, VIROLOGY, V174, P276, DOI 10.1016/0042-6822(90)90075-3; STENBERG RM, 1990, J VIROL, V64, P1556, DOI 10.1128/JVI.64.4.1556-1565.1990; STINSKI MF, 1983, J VIROL, V46, P1; STINSKI MF, 1978, J VIROL, V26, P686, DOI 10.1128/JVI.26.3.686-701.1978; WARREN AP, 1994, J VIROL, V68, P2822, DOI 10.1128/JVI.68.5.2822-2829.1994; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; YORK IA, 1994, CELL, V77, P525, DOI 10.1016/0092-8674(94)90215-1	26	221	230	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 24	1996	383	6602					720	722		10.1038/383720a0	http://dx.doi.org/10.1038/383720a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN918	8878482				2022-12-24	WOS:A1996VN91800054
J	Mann, RS; AbuShaar, M				Mann, RS; AbuShaar, M			Nuclear import of the homeodomain protein Extradenticle in response to Wg and Dpp signalling	NATURE			English	Article							HOMEOTIC GENE-EXPRESSION; VISCERAL MESODERM; DROSOPHILA EMBRYOS; PATTERN-FORMATION; LIMB DEVELOPMENT; DISTAL-LESS; GERM LAYERS; MIDGUT; ULTRABITHORAX; WINGLESS	IN Drosophila, Decapentaplegic (Dpp)(1) and Wingless (Wg)(2) are two secreted signalling proteins of the transforming growth factor (TGF)-beta and Wnt families, respectively. Although both are often required during development, only a few downstream components of these signalling pathways have been described. Here we present evidence that in the embryonic midgut both signalling pathways control the subcellular localization of the homeodomain protein encoded by the extradenticle (exd) gene. Exd protein is predominantly nuclear in endoderm cells close to Dpp- and Wg-secreting cells of the, visceral mesoderm, but is in the cytoplasm in more distant endoderm cells. Both dpp and log are required for the nuclear localization of Exd in the endoderm.	COLUMBIA UNIV,COLL PHYS & SURG,INTEGRATED PROGRAM CELLULAR MOL & BIOPHYS STUDIES,NEW YORK,NY 10032	Columbia University	Mann, RS (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,DEPT BIOCHEM & MOL BIOPHYS,630 W 168TH ST,NEW YORK,NY 10032, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058575] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM058575] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIENZ M, 1988, NATURE, V333, P576, DOI 10.1038/333576a0; BRAND AH, 1993, DEVELOPMENT, V118, P401; Chan SK, 1996, P NATL ACAD SCI USA, V93, P5223, DOI 10.1073/pnas.93.11.5223; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHAN SK, 1996, EMBO J, V15, P2477; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; DIEDERICH RJ, 1989, GENE DEV, V3, P399, DOI 10.1101/gad.3.3.399; GELBART WM, 1989, DEVELOPMENT, V107, P65; GONZALEZCRESPO S, 1995, DEVELOPMENT, V121, P2117; GRILLI M, 1993, INT REV CYTOL, V143, P1; HOFFMANN FM, 1987, GENE DEV, V1, P615, DOI 10.1101/gad.1.6.615; HOPPLER S, 1995, EMBO J, V14, P5016, DOI 10.1002/j.1460-2075.1995.tb00184.x; HURSH DA, 1993, DEVELOPMENT, V117, P1211; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; LEE KJ, 1991, EMBO J, V10, P817, DOI 10.1002/j.1460-2075.1991.tb08014.x; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; Poulson D. F., 1950, BIOL DROSOPHILA; RAUSKOLB C, 1994, EMBO J, V13, P3561, DOI 10.1002/j.1460-2075.1994.tb06663.x; RAUSKOLB C, 1995, DEVELOPMENT, V121, P3663; RAUSKOLB C, 1993, CELL, V74, P1; REUTER R, 1990, DEVELOPMENT, V110, P1031; RUSHLOW C, 1992, BIOESSAYS, V14, P89, DOI 10.1002/bies.950140204; STAEHLINGHAMPTON K, 1994, DEV BIOL, V164, P502, DOI 10.1006/dbio.1994.1219; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; TEPASS U, 1994, DEVELOPMENT, V120, P579; TREMML G, 1989, EMBO J, V8, P2677, DOI 10.1002/j.1460-2075.1989.tb08408.x; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; XU T, 1993, DEVELOPMENT, V117, P1223	30	109	109	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1996	383	6601					630	633		10.1038/383630a0	http://dx.doi.org/10.1038/383630a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM755	8857540				2022-12-24	WOS:A1996VM75500056
J	Michelson, D; Stratakis, C; Hill, L; Reynolds, J; Galliven, E; Chrousos, G; Gold, P				Michelson, D; Stratakis, C; Hill, L; Reynolds, J; Galliven, E; Chrousos, G; Gold, P			Bone mineral density in women with depression	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORTICOTROPIN-RELEASING HORMONE; BIOCHEMICAL MANIFESTATIONS; THERAPEUTIC IMPLICATIONS; TYROSINE-HYDROXYLASE; CUSHINGS-SYNDROME; RAT-BRAIN; NEUROBIOLOGY; OSTEOPOROSIS; POLYMORPHISM; DISORDERS	Background Depression is associated with alterations in behavior and neuroendocrine systems that are risk factors for decreased bone mineral density. This study was undertaken to determine whether women with past or current major depression have demonstrable decreases in bone density. Methods We measured bone mineral density at the hip, spine, and radius in 24 women with past or current major depression and 24 normal women matched for age, body-mass index, menopausal status, and race, using dual-energy x-ray absorptiometry. We also evaluated cortisol and growth hormone secretion, bone metabolism, and vitamin D-receptor alleles. Results AS compared with the normal women, the mean (+/- SD) bone density in the women with past or current depression was 6.5 percent lower at the spine (1.00 +/- 0.15 vs. 1.07 +/- 0.09 g per square centimeter, P=0.02), 13.6 percent lower at the femoral neck (0.76 +/- 0.11 vs, 0.88 +/- 0.11 g per square centimeter, P<0.001), 13.6 percent lower at Ward's triangle (0.70 +/- 0.14 vs. 0.81 +/- 0.13 g per square centimeter, P<0.001), and 10.8 percent lower at the trochanter (0.66+/-0.11 vs. 0.74+/-0.08 g per square centimeter, P<0.001), In addition, women with past or current depression had higher urinary cortisol excretion (71 +/- 29 vs. 51 +/- 19 mu g per day [196 +/- 80 vs. 141 +/- 52 nmol per day], P=0.006), lower serum osteocalcin concentrations (P=0.04), and lower urinary excretion of deoxypyridinoline (P=0.02). Conclusions Past or current depression in women is associated with decreased bone mineral density (C) 1996, Massachusetts Medical Society.	NIMH,CLIN NEUROENDOCRINOL BRANCH,BETHESDA,MD 20892; NICHHD,DEV ENDOCRINOL BRANCH,BETHESDA,MD 20892; GEORGETOWN UNIV,CHILDRENS MED CTR,DIV GENET,WASHINGTON,DC 20007	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Georgetown University	Michelson, D (corresponding author), NIH,DEPT NUCL MED,WARREN G MAGNUSON CLIN CTR,ROOM 2D 46,MSC 1284,BETHESDA,MD 20892, USA.		Stratakis, Constantine/AAP-4745-2020					ABRAHAM G, 1995, BIOL PSYCHIAT, V38, P131, DOI 10.1016/0006-3223(95)00062-L; ALEKEL L, 1995, MED SCI SPORT EXER, V27, P1477; BRADY LS, 1992, BRAIN RES, V572, P117, DOI 10.1016/0006-8993(92)90459-M; BRADY LS, 1991, J CLIN INVEST, V87, P831, DOI 10.1172/JCI115086; FLEISS JL, 1971, BRIT J MATH STAT PSY, V24, P117, DOI 10.1111/j.2044-8317.1971.tb00454.x; GOLD PW, 1986, NEW ENGL J MED, V314, P1329, DOI 10.1056/NEJM198605223142101; GOLD PW, 1988, NEW ENGL J MED, V319, P348, DOI 10.1056/NEJM198808113190606; GOLD PW, 1988, NEW ENGL J MED, V319, P413, DOI 10.1056/NEJM198808183190706; Gold PW, 1988, NEW ENGL J MED, V319, P1428; HALBREICH U, 1995, PSYCHOSOM MED, V57, P485, DOI 10.1097/00006842-199509000-00011; HERMUS AR, 1995, J CLIN ENDOCR METAB, V80, P2859, DOI 10.1210/jc.80.10.2859; HERZOG W, 1993, J BONE MINER RES, V8, P597; HUSTMYER FG, 1994, J CLIN INVEST, V94, P2130, DOI 10.1172/JCI117568; JONES G, 1994, DRUG SAFETY, V10, P480, DOI 10.2165/00002018-199410060-00006; KEEN RW, 1995, LANCET, V345, P990, DOI 10.1016/S0140-6736(95)90740-8; Kelly TL., 1990, J BONE MIN RES, V5, pS249; KLEEREKOPPER M, 1995, J CLIN ENDOCR METAB, V80, P2856, DOI 10.1210/jc.80.10.2856; LEONG GM, 1995, 77 ANN M END SOC WAS, P438; MANNING PJ, 1992, CLIN ENDOCRINOL, V36, P229, DOI 10.1111/j.1365-2265.1992.tb01437.x; MAZESS RB, 1988, J BONE MINER RES, V3, P13; MELTON LJ, 1988, J CLIN EPIDEMIOL, V41, P985; MICHELSON D, 1995, 77 ANN M END SOC WAS, P484; MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0; NIELSEN HK, 1992, J CLIN ENDOCR METAB, V74, P1410, DOI 10.1210/jc.74.6.1410; ROBINS LN, 1984, ARCH GEN PSYCHIAT, V41, P949; SCHWEIGER U, 1994, AM J PSYCHIAT, V151, P1691; SPECTOR TD, 1995, BRIT MED J, V310, P1357, DOI 10.1136/bmj.310.6991.1357; VANDERWIEL HE, 1994, J BONE JOINT SURG AM, V76A, P230, DOI 10.2106/00004623-199402000-00009; Waller K, 1996, J CLIN ENDOCR METAB, V81, P663, DOI 10.1210/jc.81.2.663; ZELISSEN PMJ, 1994, ANN INTERN MED, V120, P207, DOI 10.7326/0003-4819-120-3-199402010-00005	30	354	364	1	17	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 17	1996	335	16					1176	1181		10.1056/NEJM199610173351602	http://dx.doi.org/10.1056/NEJM199610173351602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VN401	8815939				2022-12-24	WOS:A1996VN40100002
J	Basu, S; Senior, R; Dore, C; Lahiri, A				Basu, S; Senior, R; Dore, C; Lahiri, A			Value of thallium-201 imaging in detecting adverse cardiac events after myocardial infarction and thrombolysis: A follow up of 100 consecutive patients	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PROGNOSTIC VALUE; JEOPARDIZED MYOCARDIUM; RISK STRATIFICATION; SCINTIGRAPHY; TETROFOSMIN; ANGIOGRAPHY; THERAPY; TRIAL; SOON	Objective-To determine the prognostic role of thallium-201 imaging compared with that of exercise electrocardiography in patients with acute myocardial infarction treated by thrombolysis. Design-Patients who remained free of adverse cardiac events six weeks after myocardial infarction had stress and rest Tl-201 imaging and exercise electrocardiography and were followed up for 8-32 months. Adverse cardiac events (death, reinfarction, unstable angina, and congestive heart failure) were documented. Setting-Large district general hospital, Middlesex. Subjects-100 consecutive male and female patients who were stable six weeks after thrombolysis for myocardial infarction. Main outcome measures-Prediction of occurrence of adverse cardiac events after myocardial infarction by exercise cardiography and Tl-201 myocardial perfusion imaging. Results-Reversible ischaemia on Tl-201 imaging predicted adverse cardiac events in 33 out of 37 patients with such events during follow up (hazard ratio 8.1 (95% confidence interval 2.7 to 23.8), P<0.001). Exercise electrocardiography showed reversible ischaemia in 33 patients, of whom 13 had subsequent events, and failed to predict events in 24 patients (hazard ratio 1.1 (0.56 to 2.2), P = 0.8). Conclusion-Tl-201 imaging is a sensitive predictor of subsequent adverse cardiac events in patients who have received thrombolysis after acute myocardial infarction, whereas exercise electrocardiography fails to predict outcome.	NORTHWICK PK HOSP & CLIN RES CTR, DEPT CARDIAC RES, HARROW HA1 3UJ, MIDDX, ENGLAND; INST MED RES, HARROW HA1 3UJ, MIDDX, ENGLAND; HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, MED STAT UNIT, LONDON, ENGLAND	Imperial College London; MRC National Institute for Medical Research; Imperial College London			Dore, Caroline J/J-4716-2012	Dore, Caroline J/0000-0001-9796-4970				[Anonymous], 1987, Lancet, V2, P871; [Anonymous], 1988, LANCET, V2, P349; BASU S, 1993, BRIT HEART J, V69, P61; BROWN KA, 1990, AM J CARDIOL, V65, P160, DOI 10.1016/0002-9149(90)90078-F; DAVIDSON DM, 1980, CIRCULATION, V61, P236, DOI 10.1161/01.CIR.61.2.236; ELLESTAD MH, 1969, CIRCULATION, V39, P517, DOI 10.1161/01.CIR.39.4.517; FEIT F, 1990, J AM COLL CARDIOL, V16, P1529, DOI 10.1016/0735-1097(90)90295-Z; GIBSON RS, 1983, CIRCULATION, V68, P321, DOI 10.1161/01.CIR.68.2.321; GIBSON RS, 1981, AM J CARDIOL, V47, P1010, DOI 10.1016/0002-9149(81)90206-X; HUNG J, 1984, AM J CARDIOL, V53, P1221, DOI 10.1016/0002-9149(84)90068-7; JAIN A, 1990, AM J CARDIOL, V66, P551, DOI 10.1016/0002-9149(90)90480-O; JAIN D, 1990, AM J CARDIOL, V65, P154, DOI 10.1016/0002-9149(90)90077-E; LEPPO JA, 1984, NEW ENGL J MED, V310, P1014, DOI 10.1056/NEJM198404193101603; McMurray J., 1993, European Heart Journal, V14, P133; NORRIS RM, 1970, LANCET, V2, P485; PEEL AAF, 1962, BRIT HEART J, V24, P745; SCHELBERT HR, 1976, AM J CARDIOL, V38, P407, DOI 10.1016/0002-9149(76)90455-0; SENIOR R, 1995, BRIT HEART J, V74, P358; SENIOR R, 1995, J NUCL CARDIOL, V2, P296, DOI 10.1016/S1071-3581(05)80073-X; SIMOONS ML, 1989, J AM COLL CARDIOL, V14, P1609, DOI 10.1016/0735-1097(89)90003-X; SRIDHARA B, 1994, J NUCL CARDIOL, V1, P138, DOI 10.1007/BF02984085; STARLING MR, 1980, AM J CARDIOL, V46, P909, DOI 10.1016/0002-9149(80)90344-6; STEVENSON R, 1993, BRIT HEART J, V70, P415; THEROUX P, 1979, NEW ENGL J MED, V301, P341, DOI 10.1056/NEJM197908163010701; TILKEMEIER PL, 1990, AM J CARDIOL, V66, P1203, DOI 10.1016/0002-9149(90)91100-K; TURNER JD, 1980, CIRCULATION, V61, P729, DOI 10.1161/01.CIR.61.4.729; WELD FM, 1981, CIRCULATION, V64, P306, DOI 10.1161/01.CIR.64.2.306; ZARET BL, 1995, CIRCULATION, V91, P313, DOI 10.1161/01.CIR.91.2.313; 1993, LANCET, V339, P753	29	26	26	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 5	1996	313	7061					844	848						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL559	8870569				2022-12-24	WOS:A1996VL55900019
J	Sonke, GS; Beaglehole, R; Stewart, AW; Jackson, R; Stewart, FM				Sonke, GS; Beaglehole, R; Stewart, AW; Jackson, R; Stewart, FM			Sex differences in case fatality before and after admission to hospital after acute cardiac events: Analysis of community based coronary heart disease register	BRITISH MEDICAL JOURNAL			English	Article							ACUTE MYOCARDIAL-INFARCTION; MORTALITY; PROGNOSIS; COUNTRIES; GENDER; WOMEN	Objective-To determine whether the reported higher case fatality in hospital after an acute cardiac event in women can be explained by sex differences in mortality before admission and in baseline risk factors. Design-Analyses of data from a community based coronary heart disease register. Setting-Auckland region, New Zealand. Subjects-5106 patients aged 25-64 years with an acute cardiac event leading to coronary death or definite myocardial infarction within 28 days of onset, occurring between 1986 and 1992. Main outcome measures-Case fatality before admission, 28 day case fatality for patients in hospital, and total case fatality after an acute cardiac event. Results-Despite a more unfavourable risk profile women tended to have lower case fatality before admission than men (crude odds ratio 0.88; 95% confidence interval 0.75 to 1.02). Adjustment for age, Living arrangements, smoking, medical history, and treatment increased the effect of sex (0.72; 0.60 to 0.86). After admission to hospital, women had a higher case fatality than men (1.76; 1.43 to 2.17), but after adjustment for confounders this was reduced to 1.18 (0.89 to 1.58). Total case fatality 28 days after an acute cardiac event showed no significant difference between men and women (0.85; 0.70 to 1.02). Conclusions-The higher case fatality after an acute cardiac event in women admitted to hospital is largely explained by differences in Living status, history, and medical treatment and is balanced by a lower case fatality before admission.	UNIV AUCKLAND,FAC MED & HLTH SCI,DEPT COMMUNITY HLTH,AUCKLAND,NEW ZEALAND; AUCKLAND HOSP,DEPT MED,AUCKLAND,NEW ZEALAND	University of Auckland; Auckland City Hospital				Sonke, Gabe/0000-0001-8088-9628; Jackson, Rod/0000-0001-5914-6934				Brett Kate M., 1995, Annals of Epidemiology, V5, P25, DOI 10.1016/1047-2797(94)00037-T; CASE RB, 1992, JAMA-J AM MED ASSOC, V267, P515, DOI 10.1001/jama.267.4.515; DEMIROVIC J, 1995, AM J CARDIOL, V75, P1096, DOI 10.1016/S0002-9149(99)80737-1; JACKSON R, 1990, INT J EPIDEMIOL, V19, P279, DOI 10.1093/ije/19.2.279; KANNEL WB, 1984, NEW ENGL J MED, V311, P1144, DOI 10.1056/NEJM198411013111802; KARLSON BW, 1994, AM HEART J, V128, P477, DOI 10.1016/0002-8703(94)90620-3; LOWEL H, 1993, CIRCULATION, V88, P2524, DOI 10.1161/01.CIR.88.6.2524; MARRUGAT J, 1994, J CLIN EPIDEMIOL, V47, P111, DOI 10.1016/0895-4356(94)90016-7; Moser D K, 1993, Prog Cardiovasc Nurs, V8, P6; Prineas R., 1982, MINNESOTA CODE MANUA; *SAS I, 1994, SAS SOFTW REL 6 10; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; VACCARINO V, 1995, CIRCULATION, V91, P1861, DOI 10.1161/01.CIR.91.6.1861; WILKINSON P, 1994, BRIT MED J, V309, P566, DOI 10.1136/bmj.309.6954.566	14	70	72	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 5	1996	313	7061					853	855						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL559	8870571				2022-12-24	WOS:A1996VL55900021
J	Stumpf, G; Domdey, H				Stumpf, G; Domdey, H			Dependence of yeast pre-mRNA 3'-end processing on CFT1: A sequence homolog of the mammalian AAUAAA binding factor	SCIENCE			English	Article							POLYADENYLATION SPECIFICITY FACTOR; MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; POLY(A) POLYMERASE; CLEAVAGE; GENE; SITE; SUBUNIT; PROTEIN; IDENTIFICATION	3'-End formation of pre-mRNA in yeast and mammals follows a similar but distinct pathway. In Saccharomyces cerevisiae, the cleavage reaction can be reconstituted by two activities called cleavage factor I and II (CFI and CFII). A CFII component, designated CFT1 (cleavage factor two) was identified by its sequence similarity to the AAUAAA-binding subunit of the mammalian cleavage and polyadenylation specificity factor (CPSF), even though the AAUAAA signal sequence appears to play no rote in yeast pre-mRNA 3' processing. Depletion of a yeast whole-cell extract with antibodies to CFT1 protein abolished cleavage and polyadenylation of pre-mRNAs, Addition of CFII restored cleavage activity, but not polyadenylation. Polyadenylation required the further addition of poly(A) polymerase and polyadenylation factor I, suggesting a close but not necessarily direct association of these two factors with the CFT1 protein.	UNIV MUNICH,GENZENTRUM,INST BIOCHEM,D-81377 MUNICH,GERMANY	University of Munich								BIENROTH S, 1993, EMBO J, V12, P585, DOI 10.1002/j.1460-2075.1993.tb05690.x; BIENROTH S, 1991, J BIOL CHEM, V266, P19768; BILGER A, 1994, GENE DEV, V8, P1106, DOI 10.1101/gad.8.9.1106; BUTLER JS, 1988, SCIENCE, V242, P1270, DOI 10.1126/science.2848317; BUTLER JS, 1990, MOL CELL BIOL, V10, P2599, DOI 10.1128/MCB.10.6.2599; CHEN J, 1992, MOL CELL BIOL, V12, P3470, DOI 10.1128/MCB.12.8.3470; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; GILMARTIN GM, 1995, GENE DEV, V9, P72, DOI 10.1101/gad.9.1.72; GUO ZJ, 1995, MOL CELL BIOL, V15, P5983; HANI J, 1995, FEBS LETT, V365, P198, DOI 10.1016/0014-5793(95)00471-K; HEIDMANN S, 1994, MOL CELL BIOL, V14, P4633, DOI 10.1128/MCB.14.7.4633; HEIDMANN S, 1992, MOL CELL BIOL, V12, P4215, DOI 10.1128/MCB.12.9.4215; JENNY A, 1995, NUCLEIC ACIDS RES, V23, P2629, DOI 10.1093/nar/23.14.2629; KELLER W, 1995, CELL, V81, P829, DOI 10.1016/0092-8674(95)90001-2; KESSLER MM, 1995, BIOCHEMISTRY-US, V34, P1750, DOI 10.1021/bi00005a032; LINGNER J, 1991, NATURE, V354, P496, DOI 10.1038/354496a0; MINVIELLESEBASTIA L, 1991, MOL CELL BIOL, V11, P3075, DOI 10.1128/MCB.11.6.3075; MINVIELLESEBASTIA L, 1994, SCIENCE, V266, P1702, DOI 10.1126/science.7992054; MOREIRA A, 1995, EMBO J, V14, P3809, DOI 10.1002/j.1460-2075.1995.tb00050.x; MURTHY KGK, 1992, J BIOL CHEM, V267, P14804; MURTHY KGK, 1995, GENE DEV, V9, P2672, DOI 10.1101/gad.9.21.2672; PREKER PJ, 1995, CELL, V81, P379, DOI 10.1016/0092-8674(95)90391-7; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Stumpf G, 1996, MOL CELL BIOL, V16, P2204; TAKAGAKI Y, 1994, NATURE, V372, P471, DOI 10.1038/372471a0; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WAHLE E, 1995, BBA-GENE STRUCT EXPR, V1261, P183, DOI 10.1016/0167-4781(94)00248-2; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; ZHELKOVSKY AM, 1995, J BIOL CHEM, V270, P26715, DOI 10.1074/jbc.270.44.26715	29	42	43	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1996	274	5292					1517	1520		10.1126/science.274.5292.1517	http://dx.doi.org/10.1126/science.274.5292.1517			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929410				2022-12-24	WOS:A1996VV77500045
J	Jia, ZC; DeLuca, CI; Chao, HM; Davies, PL				Jia, ZC; DeLuca, CI; Chao, HM; Davies, PL			Structural basis for the binding of a globular antifreeze protein to ice	NATURE			English	Article							ADSORPTION; MECHANISM; PROGRAM	ANTIFREEZE proteins (AFPs) have the unique ability to adsorb to ice and inhibit its growth(1). Many organisms ranging from fish to bacteria use AFPs to retard freezing or lessen the damage incurred upon freezing and thawing(2-6). The ice-binding mechanism of the long linear alpha-helical type I AFPs has been attributed to their regularly spaced polar residues matching the ice lattice along a pyramidal plane(7,8). In contrast, it is not known how globular antifreeze proteins such as type III AFP that lack repeating ice-binding residues bind to ice. Here we report the 1.25 Angstrom crystal structure of recombinant type III AFP (QAE isoform(9)) from eel pout (Macrozoarces americanus), which reveals a remarkably hat amphipathic ice-binding site where five hydrogen-bonding atoms match two ranks of oxygens on the {10 (1) over bar 0} ice prism plane in the [0001] direction, giving high ice binding affinity and specificity. This binding site, substantiated by the structures and properties of several ice-binding site mutants, suggests that the AFP occupies a niche in the ice surface in which it covers the basal plane while binding to the prism face.			Jia, ZC (corresponding author), QUEENS UNIV,DEPT BIOCHEM,KINGSTON,ON K7L 3N6,CANADA.							[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CHAO H, 1993, PROTEIN SCI, V2, P1411, DOI 10.1002/pro.5560020906; CHAO H, 1994, PROTEIN SCI, V3, P1760, DOI 10.1002/pro.5560031016; CHAO H, 1994, THESIS QUEENS U; Cheng C.C., 1991, P1; DAVIES PL, 1990, FASEB J, V4, P2460, DOI 10.1096/fasebj.4.8.2185972; Duman J.G., 1991, P94; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Frishman D, 1995, PROTEINS, V23, P566, DOI 10.1002/prot.340230412; GRIFFITH M, 1992, PLANT PHYSIOL, V100, P593, DOI 10.1104/pp.100.2.593; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; JIA ZC, 1995, PROTEIN SCI, V4, P1236, DOI 10.1002/pro.5560040621; KALLUNGAL JP, 1975, THESIS SYRACUSE U; KNIGHT CA, 1991, BIOPHYS J, V59, P409, DOI 10.1016/S0006-3495(91)82234-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; RAYMOND JA, 1977, P NATL ACAD SCI USA, V74, P2589, DOI 10.1073/pnas.74.6.2589; Sheldrick G.M., 1986, SHELXS86 PROGRAM SOL; SICHERI F, 1995, NATURE, V375, P427, DOI 10.1038/375427a0; SONNICHSEN FD, 1993, SCIENCE, V259, P1154, DOI 10.1126/science.8438165; SUN XY, 1995, CAN J MICROBIOL, V41, P776, DOI 10.1139/m95-107; UMUTLA ME, 1992, BIOCHIM BIOPHYS ACTA, V1121, P199; WEN DY, 1992, BIOPHYS J, V63, P1659, DOI 10.1016/S0006-3495(92)81750-2	26	197	213	4	75	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 21	1996	384	6606					285	288		10.1038/384285a0	http://dx.doi.org/10.1038/384285a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU381	8918883				2022-12-24	WOS:A1996VU38100058
J	Fieschi, C; Toni, D; Pantano, P				Fieschi, C; Toni, D; Pantano, P			Are studies of early reperfusion after a stroke worthwhile?	LANCET			English	Editorial Material							ACUTE ISCHEMIC STROKE; EMISSION-COMPUTED-TOMOGRAPHY				Fieschi, C (corresponding author), UNIV ROMA LA SAPIENZA,DEPT NEUROL SCI,I-00185 ROME,ITALY.		Patrizia, Pantano/C-8214-2009; Toni, Danilo/K-3151-2016	Patrizia, Pantano/0000-0001-9659-8294; Toni, Danilo/0000-0003-2735-8427				BARID AE, 1996, J NEUROL NEUROSUR PS, V61, P26; GIUBILEI F, 1990, STROKE, V21, P895, DOI 10.1161/01.STR.21.6.895; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; HANSON SK, 1993, STROKE, V24, P1322, DOI 10.1161/01.STR.24.9.1322; OVERGAARD K, 1993, STROKE, V24, P1439, DOI 10.1161/01.STR.24.10.1439; TONI D, 1995, ARCH NEUROL-CHICAGO, V52, P670, DOI 10.1001/archneur.1995.00540310040014; Toni D, 1996, NEUROLOGY, V46, P341, DOI 10.1212/WNL.46.2.341; VONKUMMER R, 1994, AM J NEURORADIOL, V15, P9; WITYK RJ, 1994, STROKE, V25, P362, DOI 10.1161/01.STR.25.2.362	9	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 16	1996	348	9038					1327	1328		10.1016/S0140-6736(05)65405-0	http://dx.doi.org/10.1016/S0140-6736(05)65405-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT332	8918273				2022-12-24	WOS:A1996VT33200006
J	Frisch, M; Hjalgrim, H; Olsen, JH; Melbye, M				Frisch, M; Hjalgrim, H; Olsen, JH; Melbye, M			Risk for subsequent cancer after diagnosis of basal-cell carcinoma - A population-based, epidemiologic study	ANNALS OF INTERNAL MEDICINE			English	Article						carcinoma, basal-cell; melanoma; lymphoma, non-Hodgkin; testicular neoplasms; breast neoplasms	SALIVARY-GLAND CARCINOMA; NON-HODGKINS-LYMPHOMA; SKIN-CANCER; MALIGNANCIES	Background: Considerable debate is taking place over whether patients with basal-cell carcinoma and other skin neoplasms are at increased risk for internal cancer. Objective: To investigate risk for subsequent cancer in patients with basal-cell carcinoma. Design: Population-based cohort study. Setting: Denmark, from 1978 to 1991. Patients: 37 674 patients followed for a maximum of 14 years after a first diagnosis of basal-cell carcinoma. Measurements: The occurrence of subsequent cancer was compared with the expected cancer pattern (which was determined on the basis of national incidence data). Standardized incidence ratios (SIRs), ratios of actual to expected number of cases of cancer, yielded estimates of the relative risk. Results: During 190 945 patient-years of follow-up, 3663 new cases of cancer occurred where only 3245 were expected. As anticipated, malignant melanoma occurred frequently (SIR, 2.64 [95% CI, 2.21 to 3.13]), but patients were also at increased risk for noncutaneous cancer (SIR, 1.19 [CI, 1.13 to 1.24] for men and 1.09 [CI, 1.03 to 1.16] for women). The excess risk for noncutaneous cancer pertained to cancer of the lip (SIR, 2.07), salivary glands (SIR, 2.45), larynx (SIR, 1.41), lung (SIR, 1.40), breast (SIR, 1.13), and kidney (SIR, 1.30) and non-Hodgkin lymphoma (SIR, 1.36). Patients receiving a diagnosis of basal-cell carcinoma before 60 years of age (SIR, 1.26) had a statistically higher risk for developing new cancer (P < 0.01) than did those receiving the diagnosis at 60 years of age or older (SIR, 1.11). This applied to breast cancer (SIR, 1.37 in patients <60 years of age compared with 1.05 in those greater than or equal to 60 years of age), testicular cancer (SIR, 3.52 in patients <60 years of age compared with 0 seen and 1.96 expected in those greater than or equal to 60 years of age), and non-Hodgkin lymphoma (SIR, 2.50 in patients <60 years of age compared with 1.16 in those greater than or equal to 60 years of age). Conclusion: In addition to having an increased risk for new skin cancer, patients with basal-cell carcinoma have an increased risk for noncutaneous cancer at various sites. Increased risks for testicular cancer, breast cancer, and non-Hodgkin lymphoma should be kept in mind, particularly for patients in whom basal-cell carcinoma is diagnosed when they are at a young age.	DANISH CANC SOC, DIV CANC EPIDEMIOL, DK-2100 COPENHAGEN O, DENMARK	Danish Cancer Society	Frisch, M (corresponding author), STATENS SERUM INST, DANISH EPIDEMIOL SCI CTR, 5 ARTILLERIVEJ, DK-2300 COPENHAGEN S, DENMARK.		Frisch, Morten/E-9206-2016; Hjalgrim, Henrik/AAG-4973-2021	Frisch, Morten/0000-0002-3864-8860; Olsen, Jorgen Helge/0000-0001-9633-5662; melbye, mads/0000-0001-8264-6785				ADAMI J, 1995, BRIT MED J, V310, P1491, DOI 10.1136/bmj.310.6993.1491; BATSAKIS JG, 1981, CLIN OTOLARYNGOL, V6, P129, DOI 10.1111/j.1365-2273.1981.tb01799.x; Breslow N. E., 1987, STAT METHODS CANC RE, VII, P65; CARTWRIGHT R, 1994, LEUKEMIA LYMPHOMA, V14, P387, DOI 10.3109/10428199409049694; CHUTE CG, 1991, JAMA-J AM MED ASSOC, V266, P816, DOI 10.1001/jama.266.6.816; FRISCH M, 1994, AM J EPIDEMIOL, V140, P12, DOI 10.1093/oxfordjournals.aje.a117154; FRISCH M, 1995, AM J EPIDEMIOL, V141, P916, DOI 10.1093/oxfordjournals.aje.a117358; Hakulinen T, 1986, Acta Pathol Microbiol Immunol Scand Suppl, V288, P1; Hartge P, 1996, J NATL CANCER I, V88, P298, DOI 10.1093/jnci/88.5.298; Hunter David J., 1990, Annals of Epidemiology, V1, P13; KARAGAS MR, 1992, JAMA-J AM MED ASSOC, V267, P3305, DOI 10.1001/jama.267.24.3305; LINDELOF B, 1991, J AM ACAD DERMATOL, V25, P245, DOI 10.1016/0190-9622(91)70189-9; PRESTON DS, 1992, NEW ENGL J MED, V327, P1649, DOI 10.1056/NEJM199212033272307; SANDSTROM A, 1984, ACTA RADIOL ONCOL, V23, P227, DOI 10.3109/02841868409136016; SCOTTO J, 1982, CANCER EPIDEMIOL, P996; SPITZ MR, 1985, ANN OTO RHINOL LARYN, V94, P129, DOI 10.1177/000348948509400206; SPITZ MR, 1984, CANCER, V54, P1854, DOI 10.1002/1097-0142(19841101)54:9<1854::AID-CNCR2820540915>3.0.CO;2-1; Storm H H, 1985, Natl Cancer Inst Monogr, V68, P411; STORM HH, 1994, CANC INCIDENCE DENMA; STORM HH, 1991, CANC REGISTRATION PR, P220; TEPPO L, 1985, J NATL CANCER I, V75, P207; World Health Organization, 1976, INT CLASS DIS	22	106	107	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1996	125	10					815	+		10.7326/0003-4819-125-10-199611150-00005	http://dx.doi.org/10.7326/0003-4819-125-10-199611150-00005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU524	8928988				2022-12-24	WOS:A1996VU52400008
J	Zachariae, W; Shin, TH; Galova, M; Obermaier, B; Nasmyth, K				Zachariae, W; Shin, TH; Galova, M; Obermaier, B; Nasmyth, K			Identification of subunits of the anaphase-promoting complex of Saccharomyces cerevisiae	SCIENCE			English	Article							CELL-CYCLE CONTROL; ASPERGILLUS-NIDULANS; BUDDING YEAST; S-PHASE; MITOSIS; PROTEIN; GENE; DESTRUCTION; PROTEOLYSIS; TRANSITION	Entry into anaphase and proteolysis of B-type cyclins depend on a complex containing the tetratricopeptide repeat proteins Cdc16p, Cdc23p, and Cdc27p. This particle, called the anaphase-promoting complex (APC) or cyclosome, functions as a cell cycle-regulated ubiquitin-protein ligase. Two additional subunits of the budding yeast APC were identified: The largest subunit, encoded by the APC1 gene, is conserved between fungi and vertebrates and shows similarity to BIMEp from Aspergillus nidulans. A small heat-inducible subunit is encoded by the CDC26 gene. The yeast APC is a 36S particle that contains at least seven different proteins.	RES INST MOL PATHOL, A-1030 VIENNA, AUSTRIA; MEDIGENE GMBH, D-82152 MARTINSRIED, GERMANY	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)				Nasmyth, Kim/0000-0001-7030-4403				AKARI H, 1992, MOL GEN GENET, V231, P329; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; CIECHANOVER A, 1994, CELL, V79, P113; CIOSK R, UNPUB; CVRCKOVA F, 1993, EMBO J, V12, P5277, DOI 10.1002/j.1460-2075.1993.tb06223.x; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; ENGLE DB, 1990, J BIOL CHEM, V265, P16132; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; HIRANO T, 1988, J CELL BIOL, V106, P1171, DOI 10.1083/jcb.106.4.1171; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; JAMES SW, 1995, J CELL SCI, V108, P3485; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; MURRAY AW, 1989, NATURE, V339, P503; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; ODONNELL KL, 1991, J CELL SCI, V99, P711; OSMANI SA, 1988, CELL, V52, P241, DOI 10.1016/0092-8674(88)90513-2; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; Peters JM, 1996, SCIENCE, V274, P1199, DOI 10.1126/science.274.5290.1199; SAMEJIMA I, 1994, J CELL BIOL, V127, P1655, DOI 10.1083/jcb.127.6.1655; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHIN TJ, UNPUB; STARBORG M, 1994, J BIOL CHEM, V269, P24133; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; Zachariae W, 1996, MOL BIOL CELL, V7, P791, DOI 10.1091/mbc.7.5.791; ZACHARIAE W, UNPUB	32	235	238	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 15	1996	274	5290					1201	1204		10.1126/science.274.5290.1201	http://dx.doi.org/10.1126/science.274.5290.1201			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT335	8895471				2022-12-24	WOS:A1996VT33500057
J	Schobel, HP; Fischer, T; Heuszer, K; Geiger, H; Schmieder, RE				Schobel, HP; Fischer, T; Heuszer, K; Geiger, H; Schmieder, RE			Preeclampsia - A state of sympathetic overactivity	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PREGNANCY-INDUCED HYPERTENSION; NITRIC-OXIDE; HUMANS; NORADRENALINE; RESPONSES; NERVES	Background Preeclampsia is characterized by a marked increase in peripheral vascular resistance leading to an increase in blood pressure, but the triggering mechanisms are unclear. Methods To determine whether augmented sympathetic vasoconstrictor activity may be an important mechanism in mediating the increase in vasomotor tone, we measured postganglionic sympathetic-nerve activity in the blood vessels of skeletal muscle by means of intraneural microelectrodes in nine women with preeclampsia, eight normotensive pregnant women, six normotensive nonpregnant women, and seven nonpregnant women with hypertension, both at rest and during noninvasive cardiovascular-reflex testing (with the Valsalva maneuver and the cold presser test). Results The mean (+/-SE) rate of sympathetic nerve activity in the normotensive pregnant women (10+/-1 bursts per minute) was not significantly different from that in normotensive nonpregnant women (12+/-2 bursts per minute) or hypertensive nonpregnant women (15+/-3 bursts per minute). In contrast, the rate of sympathetic-nerve activity in the patients with preeclampsia (33+/-3 bursts per minute) was more than three times as high as that in the normotensive pregnant women (P<0.05) and more than twice as high as in the group of nonpregnant women with hypertension (P<0.05). Hemodynamic and sympathetic-nerve responses to both reflex tests did not differ significantly among the four groups. Six patients with preeclampsia were studied again after delivery; mean sympathetic-nerve activity at that time had decreased significantly from the value during pregnancy (from 36+/-4 to 13+/-2 bursts per minute, P<0.01), as had mean arterial pressure (from 118+/-3 to 96+/-1 mm Hg, P<0.01). Conclusions Preeclampsia is a state of sympathetic overactivity, which reverts to normal after delivery. Our data indicate that the increases in peripheral vascular resistance and blood pressure that characterize this disorder are mediated, at least in part, by a substantial increase in sympathetic vasoconstrictor activity. (C) 1996 Massachusetts Medical Society.	UNIV ERLANGEN NURNBERG,DEPT OBSTET & GYNECOL,D-91054 ERLANGEN,GERMANY	University of Erlangen Nuremberg	Schobel, HP (corresponding author), UNIV ERLANGEN NURNBERG,MED KLIN 4,DEPT INTERNAL MED,KRANKENHAUSSTR 12,D-91054 ERLANGEN,GERMANY.		Fischer, Thorsten/F-6341-2013	Fischer, Thorsten/0000-0002-9371-4672				BARTON JR, 1992, AM J OBSTET GYNECOL, V167, P931, DOI 10.1016/S0002-9378(12)80014-7; CAMERON IT, 1993, HYPERTENS PREGNANCY, V12, P85, DOI 10.3109/10641959309031055; CASTREN O, 1973, INT J GYNECOL OBSTET, V11, P236; CONRAD KP, 1993, FASEB J, V7, P566, DOI 10.1096/fasebj.7.6.7682524; CUNNINGHAM FG, 1992, NEW ENGL J MED, V326, P927; Cunningham FG, 1989, WILLIAMS OBSTET, V18th, P653; CURTIS NE, 1995, HYPERTENS PREGNANCY, V14, P339, DOI 10.3109/10641959509015680; DAVEY DA, 1986, CLIN EXP HYPERTENS B, V5, P97, DOI 10.3109/10641958609023478; DAVEY DA, 1981, BRIT J OBSTET GYNAEC, V88, P611, DOI 10.1111/j.1471-0528.1981.tb01217.x; DELIUS W, 1972, ACTA PHYSIOL SCAND, V84, P82, DOI 10.1111/j.1748-1716.1972.tb05158.x; EKHOLM EMK, 1994, HYPERTENS PREGNANCY, V13, P253, DOI 10.3109/10641959409072227; FOLKOW B, 1983, HYPERTENSION, V5, P399, DOI 10.1161/01.HYP.5.4.399; KAUNITZ AM, 1985, OBSTET GYNECOL, V65, P605; LEVIN AB, 1966, AM J CARDIOL, V18, P90, DOI 10.1016/0002-9149(66)90200-1; MARK AL, 1985, CIRC RES, V57, P461, DOI 10.1161/01.RES.57.3.461; NISELL H, 1985, AM J OBSTET GYNECOL, V152, P554, DOI 10.1016/0002-9378(85)90623-4; PASSLOER HJ, 1991, Z GEBURTSH PERINATOL, V195, P137; ROBERTS JM, 1993, LANCET, V342, P504; SCHOBEL HP, 1992, CIRC RES, V70, P172, DOI 10.1161/01.RES.70.1.172; SELIGMAN SP, 1994, AM J OBSTET GYNECOL, V171, P944, DOI 10.1016/S0002-9378(94)70064-8; TUNBRIDGE RDG, 1981, BRIT J OBSTET GYNAEC, V88, P105, DOI 10.1111/j.1471-0528.1981.tb00950.x; VALLBO AB, 1979, PHYSIOL REV, V59, P919, DOI 10.1152/physrev.1979.59.4.919; VICTOR RG, 1987, HYPERTENSION, V9, P429, DOI 10.1161/01.HYP.9.5.429; WEINER CP, 1994, P NATL ACAD SCI USA, V91, P5212, DOI 10.1073/pnas.91.11.5212; ZUSPAN FP, 1979, J REPROD MED, V23, P143	25	409	421	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 14	1996	335	20					1480	1485		10.1056/NEJM199611143352002	http://dx.doi.org/10.1056/NEJM199611143352002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT340	8890098				2022-12-24	WOS:A1996VT34000002
J	DeCock, KM; Binkin, NJ; Zuber, PLF; Tappero, JW; Castro, KG				DeCock, KM; Binkin, NJ; Zuber, PLF; Tappero, JW; Castro, KG			Research issues involving HIV-associated tuberculosis in resource-poor countries	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NEW-YORK-CITY; CALMETTE-GUERIN IMMUNIZATION; DIRECTLY OBSERVED THERAPY; PULMONARY TUBERCULOSIS; COTE-DIVOIRE; MYCOBACTERIUM-TUBERCULOSIS; INFECTED PATIENTS; ANTITUBERCULOSIS DRUGS; ACTIVE TUBERCULOSIS	Each year, there are an estimated 8 million new cases of tuberculosis (TB) and 3 million deaths due to TB, most of which occur in resource-poor countries. Tuberculosis incidence is increasing rapidly in countries with high rates of human immunodeficiency virus (HIV) infection, and despite the availability of effective interventions, many TB programs are failing to cope with the increased TB caseload. This report highlights gaps in current understanding of the interaction between TB and HIV that contribute to failure of optimal TB management and control; we focus on the diagnosis of TB, its epidemiology and transmission, preventive strategies, and programmatic issues in the integration of HIV and TB services. Research into how best to apply existing knowledge will be at least as important as searching for new knowledge, The global control of TB will also require increased resources, greater political commitment, and stronger international public health leadership.	CTR DIS CONTROL & PREVENT, NATL CTR HIV STD TB PREVENT, DIV TB ELIMINATION, ATLANTA, GA USA	Centers for Disease Control & Prevention - USA	DeCock, KM (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED, KEPPEL ST, LONDON WC1E 7HT, ENGLAND.		Castro, Kenneth G/P-1882-2018	Castro, Kenneth G/0000-0001-7964-6354				ABOUYA L, 1995, TUBERCLE LUNG DIS, V76, P436, DOI 10.1016/0962-8479(95)90011-X; ACKAH AN, 1995, LANCET, V345, P607, DOI 10.1016/S0140-6736(95)90519-7; AISU T, 1995, AIDS, V9, P267, DOI 10.1097/00002030-199509030-00008; ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; [Anonymous], 1991, Am Rev Respir Dis, V143, P700; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; [Anonymous], 1994, MMWR Recomm Rep, V43, P1; BARRY M, 1988, NEW ENGL J MED, V319, P1083, DOI 10.1056/NEJM198810203191609; BAYER R, 1995, LANCET, V345, P1545, DOI 10.1016/S0140-6736(95)91090-5; BESNARD M, 1993, PEDIATR INFECT DIS J, V12, P993, DOI 10.1097/00006454-199312000-00006; BRAUN MM, 1992, AIDS, V6, P1327, DOI 10.1097/00002030-199211000-00014; BRAUN MM, 1992, PEDIATR INFECT DIS J, V11, P220, DOI 10.1097/00006454-199203000-00010; BRINDLE RJ, 1993, AIDS, V7, P1469, DOI 10.1097/00002030-199311000-00010; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; Cantwell MF, 1996, TUBERCLE LUNG DIS, V77, P220, DOI 10.1016/S0962-8479(96)90004-0; CANTWELL MF, IN PRESS TUBER LUNG; CASTRO KG, 1993, INFECT CONT HOSP EP, V14, P65, DOI 10.2307/30147162; CHINTU C, 1993, PEDIATR INFECT DIS J, V12, P499, DOI 10.1097/00006454-199306000-00008; COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698; COLEBUNDERS RL, 1989, AM REV RESPIR DIS, V139, P1082, DOI 10.1164/ajrccm/139.5.1082; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DECOCK KM, 1995, LANCET, V346, P675, DOI 10.1016/S0140-6736(95)92284-9; DECOCK KM, 1994, JAMA-J AM MED ASSOC, V272, P481, DOI 10.1001/jama.272.6.481; DECOCK KM, 1991, BMJ-BRIT MED J, V302, P496, DOI 10.1136/bmj.302.6775.496; DECOCK KM, 1995, LANCET, V345, P873, DOI 10.1016/S0140-6736(95)90003-9; DECOCK KM, 1995, LANCET, V345, P833, DOI 10.1016/S0140-6736(95)92967-3; DIPERRI G, 1993, INFECT CONT HOSP EP, V14, P67, DOI 10.2307/30147163; DIPERRI G, 1989, LANCET, V2, P1502; ELLIOTT AM, 1995, T ROY SOC TROP MED H, V89, P78, DOI 10.1016/0035-9203(95)90668-1; ELLIOTT AM, 1993, TUBERCLE LUNG DIS, V74, P191, DOI 10.1016/0962-8479(93)90010-U; ENARSON DA, 1994, TUBERCULOSIS GUIDE L; FINE PEM, 1995, CLIN INFECT DIS, V20, P11, DOI 10.1093/clinids/20.1.11; FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; GANGADHARAM PRJ, 1994, TUBERCLE LUNG DIS, V75, P241, DOI 10.1016/0962-8479(94)90127-9; GEBRE N, 1995, T ROY SOC TROP MED H, V89, P191, DOI 10.1016/0035-9203(95)90491-3; GITHUI W, 1992, TUBERCLE LUNG DIS, V73, P203, DOI 10.1016/0962-8479(92)90087-Z; GREENBERG AE, 1995, AIDS, V9, P1251, DOI 10.1097/00002030-199511000-00006; GROSSET J, 1995, TUBERCLE LUNG DIS, V76, P183, DOI 10.1016/S0962-8479(05)80001-2; HAWKEN M, 1993, LANCET, V342, P332, DOI 10.1016/0140-6736(93)91474-Z; ISEMAN MD, 1993, NEW ENGL J MED, V328, P576, DOI 10.1056/NEJM199302253280811; JACOBS WR, 1993, SCIENCE, V260, P819, DOI 10.1126/science.8484123; KASSIM S, 1995, AIDS, V9, P1185, DOI 10.1097/00002030-199510000-00011; LALLEMANTLECOEUR S, 1991, AIDS, V5, P195, DOI 10.1097/00002030-199102000-00010; LANGE JMA, 1993, AIDS, V7, P1675, DOI 10.1097/00002030-199312000-00021; LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005; LUCAS SB, 1994, TUBERCLE LUNG DIS, V75, P301, DOI 10.1016/0962-8479(94)90137-6; LUCS SB, 1996, BRIT MED J, V312, P335; MARTIN DJ, 1995, J ACQ IMMUN DEF SYND, V8, P386; Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6; MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P663; NARAIN JP, 1992, TUBERCLE LUNG DIS, V73, P311, DOI 10.1016/0962-8479(92)90033-G; NUNN P, 1992, AM REV RESPIR DIS, V146, P849, DOI 10.1164/ajrccm/146.4.849; NUNN P, 1994, TUBERCLE LUNG DIS, V75, P163, DOI 10.1016/0962-8479(94)90001-9; NUNN P, 1991, LANCET, V337, P627; OBRIEN RJ, 1995, AIDS, V9, P665, DOI 10.1097/00002030-199507000-00001; OKWERA A, 1994, LANCET, V344, P1323, DOI 10.1016/S0140-6736(94)90693-9; PAPE JW, 1993, LANCET, V342, P268, DOI 10.1016/0140-6736(93)91817-6; PERRIENS JH, 1995, NEW ENGL J MED, V332, P779, DOI 10.1056/NEJM199503233321204; PERRIENS JH, 1991, AM REV RESPIR DIS, V144, P750, DOI 10.1164/ajrccm/144.4.750; POZNIAK AL, 1992, AIDS, V6, P809, DOI 10.1097/00002030-199208000-00007; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; RICKMAN TW, 1980, J CLIN MICROBIOL, V11, P618, DOI 10.1128/JCM.11.6.618-620.1980; RIEDER HL, 1995, TUBERCLE LUNG DIS, V76, P114, DOI 10.1016/0962-8479(95)90552-9; SACEANU CA, 1993, J CLIN MICROBIOL, V31, P2371, DOI 10.1128/JCM.31.9.2371-2374.1993; SASSANMOROKRO M, 1994, T ROY SOC TROP MED H, V88, P178, DOI 10.1016/0035-9203(94)90285-2; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; SMITH PJ, 1995, C GLOB LUNG HLTH 199; STANFORD JL, 1991, LANCET, V338, P557, DOI 10.1016/0140-6736(91)91113-9; SUMARTOJO E, 1993, AM REV RESPIR DIS, V147, P1311, DOI 10.1164/ajrccm/147.5.1311; VARELDZIS BP, 1993, WHO PUBLICATION; WEIS SE, 1994, NEW ENGL J MED, V330, P1179, DOI 10.1056/NEJM199404283301702; WILKINSON D, 1994, LANCET, V343, P647, DOI 10.1016/S0140-6736(94)92640-9; Wilkinson D, 1996, AM J PUBLIC HEALTH, V86, P1094, DOI 10.2105/AJPH.86.8_Pt_1.1094; World Bank, 1993, INV HLTH WORLD DEV R; World Health Organization, 1993, TREATM TUB GUID NAT; 1994, TUBER LUNG DIS, V75, P94; 1987, WKLY EPIDEMIOL REC, V62, P297; 1993, MMWR-MORBID MORTAL W, V42, P961	81	19	20	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	1996	276	18					1502	1507		10.1001/jama.276.18.1502	http://dx.doi.org/10.1001/jama.276.18.1502			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ774	8903262				2022-12-24	WOS:A1996VQ77400033
J	Rouse, DJ; Owen, J; Goldenberg, RL; Cliver, SP				Rouse, DJ; Owen, J; Goldenberg, RL; Cliver, SP			The effectiveness and costs of elective cesarean delivery for fetal macrosomia diagnosed by ultrasound	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SHOULDER DYSTOCIA; RISK-FACTORS; BIRTH TRAUMA; SONOGRAPHIC DIAGNOSIS; DIABETIC PREGNANCIES; TERM; MANAGEMENT; SECTION; WEIGHT; LABOR	Objective.-To quantitate the potential effectiveness and monetary costs of a policy of elective cesarean delivery for fetal macrosomia diagnosed by ultrasound. Design.-A decision analytic model was constructed to compare 3 policies: (1) management without ultrasound; (2) ultrasound and elective cesarean delivery for estimated fetal weight of 4000 g or more (4000-g policy); and (3) ultrasound and elective cesarean delivery for estimated fetal weight of 4500 g or more (4500-g policy). The impact of maternal diabetes was analyzed separately. Probability data used in the decision analytic model were summarized from the literature and supplemented with unpublished data from the Collaborative Trial of Preterm Birth Prevention. Costs were estimated from the literature, regional reimbursements, and clinical practice data. Main Outcome Measures.-Rates of shoulder dystocia and permanent brachial plexus injury, and both the number of additional cesarean births and monetary costs per permanent brachial plexus injury averted. Results.-In the baseline analysis for nondiabetic women, the ultrasound policies increased both the cesarean delivery rate and costs, while decreasing the rate of shoulder dystocia and brachial plexus injury. For each permanent brachial plexus injury prevented by the 4500-g policy, 3695 cesarean deliveries were performed at an additional cost of $8.7 million, vs 2345 cesarean deliveries and $4.9 million with the 4000-g policy. in the baseline analysis for diabetic women, with all 3 policies, rates of cesarean delivery, shoulder dystocia and brachial plexus injury, and total costs were higher than for nondiabetic women. However, more favorable ratios for both cesarean deliveries and cost per permanent injury avoided were observed: 443 deliveries and $930 000, respectively, with the 4500-g policy, and 489 deliveries and $880 000, respectively, with the 4000-g policy. Sensitivity analysis confirmed the general robustness of these findings. Conclusions.-For the 97% of pregnant women who are not diabetic, a policy of elective cesarean delivery for ultrasonographically diagnosed fetal macrosomia is medically and economically unsound. In pregnancies complicated by diabetes, such a policy appears to be more tenable, although the merits of such an approach are debatable.			Rouse, DJ (corresponding author), UNIV ALABAMA, DEPT OBSTET & GYNECOL, CTR OBSTET RES, DIV MATERNAL FETAL MED, 618 S 20TH 457 OHB, BIRMINGHAM, AL 35233 USA.				BHP HRSA HHS [DHHS 290-92-0055] Funding Source: Medline	BHP HRSA HHS		ACKER DB, 1988, OBSTET GYNECOL, V71, P389; ACKER DB, 1985, OBSTET GYNECOL, V66, P762; *AM COLL OBST GYN, 1991, FET MAT ASS PRIOR EL, P98; *AM COLL OBST GYN, 1991, AM COLL OBST GYN TEC, V159; BENEDETTI TJ, 1978, OBSTET GYNECOL, V52, P526; BENSON CB, 1987, AM J OBSTET GYNECOL, V156, P441, DOI 10.1016/0002-9378(87)90303-6; BOCHNER CJ, 1987, AM J OBSTET GYNECOL, V157, P703, DOI 10.1016/S0002-9378(87)80033-9; BOOME RS, 1988, J BONE JOINT SURG BR, V70, P571, DOI 10.1302/0301-620X.70B4.3403599; BOYD ME, 1983, OBSTET GYNECOL, V61, P715; BROWN KLB, 1984, CLIN PLAST SURG, V11, P181; CHERVENAK JL, 1989, AM J OBSTET GYNECOL, V161, P753, DOI 10.1016/0002-9378(89)90395-5; CLARKE SC, 1995, BIRTH-ISS PERINAT C, V22, P63, DOI 10.1111/j.1523-536X.1995.tb00561.x; COMBS CA, 1993, OBSTET GYNECOL, V81, P492; DELPAPA EH, 1991, OBSTET GYNECOL, V78, P340; DENNIS J, 1989, AM J OBSTET GYNECOL, V161, P213, DOI 10.1016/0002-9378(89)90269-X; DEPP R, 1993, AM J OBSTET GYNECOL, V169, P352; DETER RL, 1985, J CLIN ULTRASOUND, V13, P519, DOI 10.1002/1097-0096(199010)13:8<519::AID-JCU1870130802>3.0.CO;2-L; *DIV QUAL ASS, 1995, NAT PRACT DAT BANK R; FEE SC, 1990, AM J OBSTET GYNECOL, V162, P802, DOI 10.1016/0002-9378(90)91014-4; GILBERT A, 1991, CLIN ORTHOP RELAT R, P39; GOLDITCH IM, 1978, OBSTET GYNECOL, V52, P26; GONIK B, 1991, AM J PERINAT, V8, P31, DOI 10.1055/s-2007-999334; GORDON M, 1973, AM J OBSTET GYNECOL, V117, P51, DOI 10.1016/0002-9378(73)90727-8; GROSS SJ, 1987, AM J OBSTET GYNECOL, V156, P334, DOI 10.1016/0002-9378(87)90278-X; GROSS TL, 1987, AM J OBSTET GYNECOL, V156, P1408, DOI 10.1016/0002-9378(87)90008-1; HARDY AE, 1981, J BONE JOINT SURG BR, V63, P98, DOI 10.1302/0301-620X.63B1.7204481; *HLTH CAR CONS AM, 1995, PHYS FEE COD GUID, P508; JENNETT RJ, 1992, AM J OBSTET GYNECOL, V166, P1673, DOI 10.1016/0002-9378(92)91555-O; KELLER JD, 1991, AM J OBSTET GYNECOL, V165, P928, DOI 10.1016/0002-9378(91)90441-S; LANDON MB, 1991, OBSTET NORMAL PROBLE, P1215; LANGER O, 1991, AM J OBSTET GYNECOL, V165, P831, DOI 10.1016/0002-9378(91)90424-P; LEVINE AB, 1992, OBSTET GYNECOL, V79, P55; LEVINE MG, 1984, OBSTET GYNECOL, V63, P792; LEWIS DF, 1995, AM J OBSTET GYNECOL, V172, P1369, DOI 10.1016/0002-9378(95)90464-6; LIPSCOMB KR, 1995, OBSTET GYNECOL, V85, P558, DOI 10.1016/0029-7844(95)00005-C; MCFARLAND LV, 1986, OBSTET GYNECOL, V68, P784; MCLAREN RA, 1995, OBSTET GYNECOL, V85, P565, DOI 10.1016/0029-7844(94)00454-L; MINTZ MC, 1989, AM J PERINAT, V6, P240, DOI 10.1055/s-2007-999585; MODANLOU HD, 1980, OBSTET GYNECOL, V55, P420; MORRISON JC, 1992, SURG GYNECOL OBSTET, V175, P515; MORRISON JJ, 1995, BRIT J OBSTET GYNAEC, V102, P101, DOI 10.1111/j.1471-0528.1995.tb09060.x; MUSHINSKI M, 1994, AVERAGE CHARGES UNCO; NADAS S, 1992, EUR J PEDIATR SURG, V2, P165, DOI 10.1055/s-2008-1063431; NOCON JJ, 1993, AM J OBSTET GYNECOL, V168, P1732, DOI 10.1016/0002-9378(93)90684-B; PARKS DG, 1978, OBSTET GYNECOL, V52, P407; PARRISH KM, 1994, JAMA-J AM MED ASSOC, V271, P443, DOI 10.1001/jama.271.6.443; PEDERSEN JF, 1992, BRIT J OBSTET GYNAEC, V99, P475, DOI 10.1111/j.1471-0528.1992.tb13784.x; POLLACK RN, 1992, AM J OBSTET GYNECOL, V167, P7, DOI 10.1016/S0002-9378(11)91615-9; RANDOLPH AG, 1993, JAMA-J AM MED ASSOC, V270, P77, DOI 10.1001/jama.270.1.77; ROSSAVIK IK, 1993, SOUTHERN MED J, V86, P1129, DOI 10.1097/00007611-199310000-00010; SANDMIRE HF, 1988, INT J GYNECOL OBSTET, V26, P65, DOI 10.1016/0020-7292(88)90198-1; SANDMIRE HF, 1993, OBSTET GYNECOL, V82, P860; SARNO AP, 1991, MIL MED, V156, P55, DOI 10.1093/milmed/156.2.55; SPECHT EE, 1975, CLIN ORTHOP RELAT R, V110, P32; SPELLACY WN, 1985, OBSTET GYNECOL, V66, P158; TURNPENNY PD, 1993, BRIT J OBSTET GYNAEC, V100, P338, DOI 10.1111/j.1471-0528.1993.tb12976.x	56	275	282	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	1996	276	18					1480	1486		10.1001/jama.276.18.1480	http://dx.doi.org/10.1001/jama.276.18.1480			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ774	8903259				2022-12-24	WOS:A1996VQ77400030
J	Haase, AT; Henry, K; Zupancic, M; Sedgewick, G; Faust, RA; Melroe, H; Cavert, W; Gebhard, K; Staskus, K; Zhang, ZQ; Dailey, PJ; Balfour, HH; Erice, A; Perelson, AS				Haase, AT; Henry, K; Zupancic, M; Sedgewick, G; Faust, RA; Melroe, H; Cavert, W; Gebhard, K; Staskus, K; Zhang, ZQ; Dailey, PJ; Balfour, HH; Erice, A; Perelson, AS			Quantitative image analysis of HIV-1 infection in lymphoid tissue	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; FOLLICULAR DENDRITIC CELLS; INSITU HYBRIDIZATION; T-CELLS; REPLICATION; LATENCY; TYPE-1; RNA; LYMPHOCYTES; EXPRESSION	Tracking human immunodeficiency virus-type 1 (HIV-1) infection at the cellular level in tissue reservoirs provides opportunities to better understand the pathogenesis of infection and to rationally design and monitor therapy. A quantitative technique was developed to determine viral burden in two important cellular compartments in lymphoid tissues. Image analysis and in situ hybridization were combined to show that in the presymptomatic stages of infection there is a large, relatively stable pool of virions on the surfaces of follicular dendritic cells and a smaller pool of productively infected cells. Despite evidence of constraints on HIV-1 replication in the infected cell population in lymphoid tissues, estimates of the numbers of these cells and the virus they could produce are consistent with the quantities of virus that have been detected in the bloodstream. The cellular Sources of virus production and storage in lymphoid tissues can now be studied with this approach over the course of infection and treatment.	UNIV MINNESOTA,SCH MED,DEPT MED,MINNEAPOLIS,MN 55455; ST PAUL RAMSEY MED CTR,HIV PROGRAM,ST PAUL,MN 55101; UNIV MINNESOTA,SCH MED,DEPT CELL BIOL & NEUROANAT,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH MED,DEPT OTOLARYNGOL,MINNEAPOLIS,MN 55455; CHIRON CORP,EMERYVILLE,CA 94608; UNIV MINNESOTA,SCH MED,DEPT LAB MED & PATHOL,MINNEAPOLIS,MN 55455; LOS ALAMOS NATL LAB,LOS ALAMOS,NM 87545	University of Minnesota System; University of Minnesota Twin Cities; Saint Paul Ramsey Medical Center; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Novartis; University of Minnesota System; University of Minnesota Twin Cities; United States Department of Energy (DOE); Los Alamos National Laboratory	Haase, AT (corresponding author), UNIV MINNESOTA,SCH MED,DEPT MICROBIOL,MINNEAPOLIS,MN 55455, USA.		Perelson, Alan S/Z-1959-2019	Perelson, Alan S/0000-0002-2455-0002	NCRR NIH HHS [RR 06555] Funding Source: Medline; NIAID NIH HHS [AI 28246, AI 27661] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR006555] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027661, R37AI028246] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS M, 1994, P NATL ACAD SCI USA, V91, P3862, DOI 10.1073/pnas.91.9.3862; BAIER M, 1995, NATURE, V378, P563, DOI 10.1038/378563a0; BRINCHMANN JE, 1990, J IMMUNOL, V144, P2961; CAO YZ, 1995, AIDS RES HUM RETROV, V11, P353, DOI 10.1089/aid.1995.11.353; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; DEWAR RL, 1994, J INFECT DIS, V170, P1172, DOI 10.1093/infdis/170.5.1172; DUAN LX, 1994, VIROLOGY, V199, P474, DOI 10.1006/viro.1994.1148; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; Faust RA, 1996, OTOLARYNG HEAD NECK, V114, P593, DOI 10.1016/S0194-5998(96)70252-8; FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729; FOX CH, 1991, J INFECT DIS, V164, P1051, DOI 10.1093/infdis/164.6.1051; GARCIABLANCO MA, 1991, SCIENCE, V254, P815, DOI 10.1126/science.1658933; HAASE AT, 1982, VIROLOGY, V119, P399, DOI 10.1016/0042-6822(82)90099-X; Haase AT, 1987, IN SITU HYBRIDIZATIO, P197; Haynes BF, 1996, SCIENCE, V271, P324, DOI 10.1126/science.271.5247.324; HEATH SL, 1995, NATURE, V377, P740, DOI 10.1038/377740a0; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; LYDYARD P, 1989, IMMUNOLOGY; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; NUOVO GJ, 1994, AM J PATHOL, V144, P659; NUOVO GJ, 1994, AM J PATHOL, V144, P40; PACHL C, 1995, J ACQ IMMUN DEF SYND, V8, P446, DOI 10.1097/00042560-199504120-00003; PANTALEO G, 1991, P NATL ACAD SCI USA, V88, P9838, DOI 10.1073/pnas.88.21.9838; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PANTALEO G, 1995, ANNU REV IMMUNOL, V13, P487, DOI 10.1146/annurev.immunol.13.1.487; PATTERSON BK, 1993, SCIENCE, V260, P976, DOI 10.1126/science.8493534; PENG HR, 1995, VIROLOGY, V206, P16, DOI 10.1016/S0042-6822(95)80015-8; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7; ROGERS AW, 1979, TECHNIQUES AUTORADIO, P102; SCHMITZ J, 1994, J IMMUNOL, V153, P1352; SESHAMMA T, 1992, P NATL ACAD SCI USA, V89, P10663, DOI 10.1073/pnas.89.22.10663; SPIEGEL H, 1992, AM J PATHOL, V140, P15; TENNERRACZ K, 1988, AIDS, V2, P299, DOI 10.1097/00002030-198808000-00010; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WALKER CM, 1991, J VIROL, V65, P5921, DOI 10.1128/JVI.65.11.5921-5927.1991; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wolinsky SM, 1996, SCIENCE, V272, P537, DOI 10.1126/science.272.5261.537; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	39	497	503	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1996	274	5289					985	989		10.1126/science.274.5289.985	http://dx.doi.org/10.1126/science.274.5289.985			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR792	8875941				2022-12-24	WOS:A1996VR79200050
J	Ling, LH; EnriquezSarano, M; Seward, JB; Tajik, AJ; Schaff, HV; Bailey, KR; Frye, RL				Ling, LH; EnriquezSarano, M; Seward, JB; Tajik, AJ; Schaff, HV; Bailey, KR; Frye, RL			Clinical outcome of mitral regurgitation due to flail leaflet	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TWO-DIMENSIONAL ECHOCARDIOGRAPHY; VENTRICULAR EJECTION FRACTION; RUPTURED CHORDAE-TENDINEAE; NATURAL-HISTORY; VALVE REPLACEMENT; TREATED PATIENTS; PERFORMANCE; PREDICTION; VALIDATION; SURVIVAL	Background Mitral regurgitation due to flail leaflet is difficult to manage, because it is frequently asymptomatic yet carries a high risk of left ventricular dysfunction and because the natural history of the condition is poorly defined. Methods We obtained clinical follow-up data through 1994-1995 in 229 patients with isolated mitral regurgitation due to flail leaflet; this condition was first diagnosed by echocardiography between 1980 and 1989. Results The 86 patients who were treated medically had a mortality rate significantly higher than expected (6.3 percent yearly, P = 0.016 for the comparison with the expected rate in the U.S. population according to the 1990 census). independent determinants of mortality were an older age, the presence of symptoms, and a lower ejection fraction. Patients who were even transiently in New York Heart Association functional class III or IV had a high mortality rate (34 percent yearly), but the rate was also notable (4.1 percent yearly) among those in class I or ii. At 10 years, the mean (+/-SE) rates of heart failure, atrial fibrillation, and death or surgery were 63+/-8, 30+/-12, and 90+/-3 percent, respectively. In a multivariate analysis, surgical correction of mitral regurgitation (performed in 143 patients) was associated with a reduced mortality rate (hazard ratio, 0.29; 95 percent confidence interval, 0.15 to 0.56; P<0.001). Conclusions When treated medically, mitral regurgitation due to flail leaflet is associated with excess mortality and high morbidity. Surgery is almost unavoidable within 10 years after the diagnosis and appears to be associated with an improved prognosis; this finding suggests that surgery should be considered early in the course of the disease. (C)1996, Massachusetts Medical Society.	MAYO CLIN & MAYO FDN,DIV CARDIOVASC DIS & INTERNAL MED,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,CARDIOVASC SURG SECT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,BIOSTAT SECT,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic; Mayo Clinic				Schaff, Hartzell/0000-0003-0994-027X; Ling, Lieng H./0000-0001-6063-8530				ABBASI AS, 1980, CIRCULATION, V61, P143, DOI 10.1161/01.CIR.61.1.143; ACAR J, 1991, EUR HEART J, V12, P52, DOI 10.1093/eurheartj/12.suppl_B.52; BARLOW JB, 1987, PERSPECTIVES MITRAL, P113; BAXLEY WA, 1973, CIRCULATION, V48, P1288, DOI 10.1161/01.CIR.48.6.1288; BERGERON GA, 1986, AM J MED, V81, P333, DOI 10.1016/0002-9343(86)90273-1; BURWASH IG, 1992, AM J CARDIOL, V70, P774, DOI 10.1016/0002-9149(92)90558-G; CARABELLO BA, 1988, MOD CONC CARDIOV DIS, V57, P53; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; DELAHAYE JP, 1991, EUR HEART J, V12, P5, DOI 10.1093/eurheartj/12.suppl_B.5; DEPACE NL, 1983, AM J CARDIOL, V52, P789, DOI 10.1016/0002-9149(83)90416-2; ELLIS LB, 1969, AM HEART J, V78, P406, DOI 10.1016/0002-8703(69)90047-7; EMOND M, 1994, CIRCULATION, V90, P2645, DOI 10.1161/01.CIR.90.6.2645; ENRIQUEZSARANO M, 1995, CIRCULATION, V91, P1022, DOI 10.1161/01.CIR.91.4.1022; ENRIQUEZSARANO M, 1994, J AM COLL CARDIOL, V24, P1536, DOI 10.1016/0735-1097(94)90151-1; ENRIQUEZSARANO M, 1994, CIRCULATION, V90, P830, DOI 10.1161/01.CIR.90.2.830; ENRIQUEZSARANO M, 1994, J AM COLL CARDIOL, V23, P443, DOI 10.1016/0735-1097(94)90432-4; GALLOWAY AC, 1988, CIRCULATION, V78, P97; GEHL LG, 1982, AM J CARDIOL, V49, P33, DOI 10.1016/0002-9149(82)90274-0; GRENADIER E, 1985, EUR HEART J, V6, P1006, DOI 10.1093/oxfordjournals.eurheartj.a061803; HAMMERMEISTER KE, 1978, CIRCULATION, V57, P341, DOI 10.1161/01.CIR.57.2.341; HELMCKE F, 1987, CIRCULATION, V75, P175, DOI 10.1161/01.CIR.75.1.175; HOCHREITER C, 1986, CIRCULATION, V73, P900, DOI 10.1161/01.CIR.73.5.900; HORSTKOTTE D, 1983, Z KARDIOL, V72, P494; JHAVERI S, 1960, CIRCULATION, V22, P39, DOI 10.1161/01.CIR.22.1.39; KOLIBASH AJ, 1986, AM J CARDIOL, V58, P762, DOI 10.1016/0002-9149(86)90352-8; LUXEREAU P, 1991, EUR HEART J, V12, P2, DOI 10.1093/eurheartj/12.suppl_B.2; MINTZ GS, 1978, CIRCULATION, V57, P244, DOI 10.1161/01.CIR.57.2.244; MINTZ GS, 1980, AM J CARDIOL, V45, P253, DOI 10.1016/0002-9149(80)90643-8; MUNOZ S, 1975, AM J CARDIOL, V35, P234, DOI 10.1016/0002-9149(75)90007-7; OLIVEIRA DBG, 1983, BRIT HEART J, V50, P312; OLSON LJ, 1987, MAYO CLIN PROC, V62, P22, DOI 10.1016/S0025-6196(12)61522-5; PEARSON AC, 1990, J AM COLL CARDIOL, V16, P232, DOI 10.1016/0735-1097(90)90483-6; PHILLIPS HR, 1981, AM J CARDIOL, V48, P647, DOI 10.1016/0002-9149(81)90142-9; QUINONES MA, 1981, CIRCULATION, V64, P744, DOI 10.1161/01.CIR.64.4.744; RAMANATHAN KB, 1984, J AM COLL CARDIOL, V3, P1412, DOI 10.1016/S0735-1097(84)80279-X; RAPAPORT E, 1975, AM J CARDIOL, V35, P221, DOI 10.1016/0002-9149(75)90005-3; REICHEK N, 1982, CIRCULATION, V65, P99, DOI 10.1161/01.CIR.65.1.99; REN JF, 1985, AM HEART J, V109, P435, DOI 10.1016/0002-8703(85)90544-7; RICH S, 1982, AM HEART J, V104, P603, DOI 10.1016/0002-8703(82)90233-2; ROBERTS WC, 1966, CIRCULATION, V33, P58; ROSEN SE, 1994, AM J CARDIOL, V74, P374, DOI 10.1016/0002-9149(94)90406-5; ROZICH JD, 1992, CIRCULATION, V86, P1718, DOI 10.1161/01.CIR.86.6.1718; SANDERS CA, 1967, NEW ENGL J MED, V276, P943, DOI 10.1056/NEJM196704272761702; SANDERS CA, 1965, CIRCULATION, V31, P506, DOI 10.1161/01.CIR.31.4.506; SELZER A, 1972, MEDICINE, V51, P337, DOI 10.1097/00005792-197209000-00001; TAJIK AJ, 1978, MAYO CLIN PROC, V53, P271; VAZIRI SM, 1994, CIRCULATION, V89, P724, DOI 10.1161/01.CIR.89.2.724; WILSON MG, 1957, CIRCULATION, V16, P700, DOI 10.1161/01.CIR.16.5.700	48	444	453	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 7	1996	335	19					1417	1423		10.1056/NEJM199611073351902	http://dx.doi.org/10.1056/NEJM199611073351902			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT339	8875918	Bronze			2022-12-24	WOS:A1996VT33900002
J	Feinberg, MB				Feinberg, MB			Lessons from and about AIDS ...	LANCET			English	Editorial Material											Feinberg, MB (corresponding author), NIH,OFF AIDS RES,BETHESDA,MD 20892, USA.							Coates TJ, 1996, LANCET, V348, P1143, DOI 10.1016/S0140-6736(96)02307-0; DCRUZGROTE, 1996, LANCET, V348, P1071; Feinberg MB, 1996, LANCET, V348, P239, DOI 10.1016/S0140-6736(96)06231-9; Haynes BF, 1996, LANCET, V348, P933, DOI 10.1016/S0140-6736(96)09339-7; Kirby M, 1996, LANCET, V348, P1217, DOI 10.1016/S0140-6736(96)05468-2; Quinn TC, 1996, LANCET, V348, P99, DOI 10.1016/S0140-6736(96)01029-X	6	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 2	1996	348	9036					1188	1188		10.1016/S0140-6736(05)65479-7	http://dx.doi.org/10.1016/S0140-6736(05)65479-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ467	8898034				2022-12-24	WOS:A1996VQ46700007
J	Harper, PS				Harper, PS			Naming of syndromes and unethical activities: The case of Hallervorden and Spatz	LANCET			English	Editorial Material											Harper, PS (corresponding author), UNIV WALES COLL MED,INST MED GENET,HEATH PK,CARDIFF CF4 4XN,S GLAM,WALES.							ADAMS JH, 1992, GREENFIELDS NEUROPAT, P857; Beighton P., 1986, MAN SYNDROME; ELEJALDE BR, 1979, CLIN GENET, V16, P1; FIRKIN BG, 1987, DICT MED EPONYMS, P214; Hallervorden J, 1922, Z GESAMTE NEUROL PSY, V79, P254, DOI 10.1007/BF02878455; JABLONSKI S, 1991, JABLONSKIS DICT SYND; Leiber Bernfried, 1957, WORTERBUCH KLINISCHE; Muller-Hill B., 1988, MURDEROUS SCI; Peiffer J, 1991, BRAIN PATHOL, V1, P125, DOI 10.1111/j.1750-3639.1991.tb00649.x; Spatz H, 1966, Nervenarzt, V37, P477; VANBOGAERT L, 1967, J NEUROL SCI, V5, P190, DOI 10.1016/0022-510X(67)90018-4	11	48	48	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 2	1996	348	9036					1224	1225		10.1016/S0140-6736(96)05222-1	http://dx.doi.org/10.1016/S0140-6736(96)05222-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ467	8898043				2022-12-24	WOS:A1996VQ46700017
J	Jousilahti, P; Vartiainen, E; Tuomilehto, J; Puska, P				Jousilahti, P; Vartiainen, E; Tuomilehto, J; Puska, P			Twenty-year dynamics of serum cholesterol levels in the middle-aged population of eastern Finland	ANNALS OF INTERNAL MEDICINE			English	Article						cholesterol; Finland; middle age; dietary fats; cardiovascular diseases	CORONARY HEART-DISEASE; RISK-FACTORS; CARDIOVASCULAR-DISEASE; BLOOD-PRESSURE; NORTH KARELIA; LIPOPROTEINS; FRAMINGHAM; MORTALITY; PROJECT; ADULTS	Background: In cross-sectional analyses, serum cholesterol levels differ among different age groups. However, secular time trends in cholesterol levels can be seen across age groups in a population. A birth cohort analysis provides useful information on the combined effect of age and time on changes in serum cholesterol levels. Objective: To analyze the 20-year dynamics of serum total cholesterol levels in relation to age, sex, birth cohort, time period, mortality rate, and changes in the intake of saturated fats. Design: Cross-sectional measurements of serum total cholesterol levels in five independent population surveys done in 1972, 1977, 1982, 1987, and 1992. Setting: Kuopio and North Karelia provinces in eastern Finland. Patients: Random sample of 16 711 men and 17 542 women 25 to 64 years of age. Persons in the oldest birth cohort were born in 1913; persons in the youngest birth cohort were born in 1967. Measurements: Total serum cholesterol levels and daily intake of dietary fat. Results: Between 1972 and 1992, mean cholesterol levels decreased with time in each age group and for both sexes. According to the cross-sectional data, cholesterol levels increased with age and increased more steeply in women than in men. Contrary to these data, cholesterol levels in birth cohorts did not increase with age. Cholesterol levels did not change at all within birth cohorts of women and started to decrease after 45 years of age in birth cohorts of men. Cholesterol levels in the youngest birth cohorts (persons 25 to 29 years of age) entering the study each study year were markedly lower than levels in the same age group in the previous survey of risk factors. Daily intake of saturated fat decreased markedly between 1972 and 1992. Most of this decrease could be explained by change in intake of liquid dairy products and spreadable fats. In both sexes, changes in saturated fat intake were correlated with the time period, whereas the association with age was weak. Conclusions: In this Finnish population, total serum cholesterol levels are more closely associated with birth cohort than with age. Changes in dietary intake of saturated fat over time may account for changes in cholesterol levels. This finding suggests that community-based strategies for preventing cardiovascular disease can affect most of the population.			Jousilahti, P (corresponding author), NATL PUBL HLTH INST, DEPT EPIDEMIIOL & HLTH PROMOT, MANNERHEIMINTIE 166, FIN-00300 HELSINKI, FINLAND.							[Anonymous], COMMUNITY CONTROL CA; EHNHOLM C, 1982, NEW ENGL J MED, V307, P850, DOI 10.1056/NEJM198209303071403; FARQUHAR JW, 1990, JAMA-J AM MED ASSOC, V264, P359, DOI 10.1001/jama.264.3.359; FULWOOD R, 1986, DHHS PUBLICATION; GUTZWILLER F, 1985, PREV MED, V14, P482, DOI 10.1016/0091-7435(85)90008-8; HJORTLAND MC, 1976, AM J EPIDEMIOL, V103, P304, DOI 10.1093/oxfordjournals.aje.a112228; JOHNSON CL, 1993, JAMA-J AM MED ASSOC, V269, P3002, DOI 10.1001/jama.269.23.3002; KANNEL WB, 1971, ANN INTERN MED, V74, P1, DOI 10.7326/0003-4819-74-1-1; KEYS A, 1965, METABOLIS, V14, P776, DOI 10.1016/0026-0495(65)90004-1; KEYS A, 1970, CIRCULATION, V41, pI1; Kleemola P, 1994, 1992 DIETARY SURVEY; KOSKINEN EH, 1975, REPORT SOCIAL INSURA; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; MENOTTI A, 1993, EUR J EPIDEMIOL, V9, P527, DOI 10.1007/BF00209531; MIETTINEN TA, 1995, NEW ENGL J MED, V333, P1308, DOI 10.1056/NEJM199511163332002; NEATON JD, 1992, ARCH INTERN MED, V152, P56, DOI 10.1001/archinte.152.1.56; NEWMAN WP, 1986, NEW ENGL J MED, V314, P138, DOI 10.1056/NEJM198601163140302; NEWSCHAFFER CJ, 1992, AM J EPIDEMIOL, V136, P23, DOI 10.1093/oxfordjournals.aje.a116417; Nissinen A, 1988, Scand J Prim Health Care Suppl, V1, P49; OKAYAMA A, 1993, INT J EPIDEMIOL, V22, P1038, DOI 10.1093/ije/22.6.1038; Pietinen P, 1996, INT J OBESITY, V20, P114; PUSKA P, 1983, BRIT MED J, V287, P1840, DOI 10.1136/bmj.287.6408.1840; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; ROSSOUW JE, 1986, ATHEROSCLEROSIS, V7; SAS Institute Inc, 1990, SAS STAT US GUID VER, V4; STAMLER J, 1979, CIRCULATION, V60, P1575, DOI 10.1161/01.CIR.60.7.1575; Thelle Dag S., 1995, Current Opinion in Lipidology, V6, P25, DOI 10.1097/00041433-199502000-00006; Thom TJ, 1992, NIH PUBLICATION; UUSITALO U, 1990, FOOD NUTRIENT INTAKE; VARTIAINEN E, 1994, INT J EPIDEMIOL, V23, P495, DOI 10.1093/ije/23.3.495; VARTIAINEN E, 1994, BMJ-BRIT MED J, V309, P23, DOI 10.1136/bmj.309.6946.23; VIIKARI J, 1991, ANN MED, V23, P53, DOI 10.3109/07853899109147931; *WHO MONICA PROJ P, 1988, J CLIN EPIDEMIOL, V41, P105, DOI [DOI 10.1016/0895-4356(88)90084-4, 10.1016/0895-4356(88)90084-4]; 1991, WORLD HLTH STAT Q, V44, P48	34	32	32	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1996	125	9					713	+		10.7326/0003-4819-125-9-199611010-00002	http://dx.doi.org/10.7326/0003-4819-125-9-199611010-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ072	8929004				2022-12-24	WOS:A1996VQ07200002
J	NoirotGros, MF; Ehrlich, SD				NoirotGros, MF; Ehrlich, SD			Change of a catalytic reaction carried out by a DNA replication protein	SCIENCE			English	Article							ACTIVE-SITE TYROSINE; STRAND TRANSFER; TOPOISOMERASE; MUTAGENESIS; MECHANISM	The RepA protein of plasmid pC194 initiates and terminates rolling circle replication. At initiation, it forms a 5'-phosphotyrosyl DNA link, whereas at termination, a glutamate residue directs hydrolytic cleavage of the newly synthesized origin, and the resulting 5'-hydroxyl group undergoes transesterification with the phosphotyrosine link. The protein is thus released from DNA, and the termination is uncoupled from reinitiation of replication. Replacement of the glulamate with tyrosine in RepA altered this mechanism, so that termination occurred by two successive transesterifications and became coupled to reinitiation. This result suggests that various enzymes involved in DNA cleavage and rejoining may have similar mechanistic and evolutionary roots.	INRA,F-78352 JOUY EN JOSAS,FRANCE	INRAE; UDICE-French Research Universities; Universite Paris Saclay			Noirot-Gros, Marie-Françoise/AAY-1001-2021; Ehrlich, S./Y-2423-2019; noirot-gros, marie-francoise/C-5051-2011	Ehrlich, S./0000-0002-7563-4046; 				ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; GROS MF, 1989, EMBO J, V8, P2711, DOI 10.1002/j.1460-2075.1989.tb08412.x; HANAI R, 1993, J BIOL CHEM, V268, P23830; JO K, 1995, SCIENCE, V267, P1817, DOI 10.1126/science.7892605; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; NOIROTGROS MF, 1994, EMBO J, V13, P4412, DOI 10.1002/j.1460-2075.1994.tb06761.x; PARGELLIS CA, 1988, J BIOL CHEM, V263, P7678; RASOOLY A, 1993, SCIENCE, V262, P1048, DOI 10.1126/science.8235621; REED RR, 1984, COLD SPRING HARB SYM, V49, P245, DOI 10.1101/SQB.1984.049.01.028; ROTH MJ, 1984, J BIOL CHEM, V259, P556	12	22	23	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1996	274	5288					777	780		10.1126/science.274.5288.777	http://dx.doi.org/10.1126/science.274.5288.777			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ145	8864116				2022-12-24	WOS:A1996VQ14500041
J	Rucker, J; Samson, M; Doranz, BJ; Libert, F; Berson, JF; Yi, YJ; Smyth, RJ; Collman, RG; Broder, CC; Vassart, G; Doms, RW; Parmentier, M				Rucker, J; Samson, M; Doranz, BJ; Libert, F; Berson, JF; Yi, YJ; Smyth, RJ; Collman, RG; Broder, CC; Vassart, G; Doms, RW; Parmentier, M			Regions in beta-chemokine receptors CCR5 and CCR2b that determine HIV-1 cofactor specificity	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ENVELOPE GLYCOPROTEIN; CD4-MEDIATED FUSION; MOLECULAR-CLONING; INFECTION; TYPE-1; CELLS; IDENTIFICATION; PROGRESSION; EXPRESSION	Macrophage-tropic (M-tropic) HIV-1 strains use the beta-chemokine receptor CCR5, but not CCR2b, as a cofactor for membrane fusion and infection, while the dual-tropic strain 89.6 uses both. CCR5/2b chimeras and mutants were used to map regions of CCR5 important for cofactor function and specificity. M-tropic strains required either the amino-terminal domain or the first extracellular loop of CCR5. A CCR2b chimera containing the first 20 N-terminal residues of CCR5 supported M-tropic envelope protein fusion. Aminoterminal truncations of CCR5/CCR2b chimeras indicated that residues 2-5 are important for M-tropic viruses, while 89.6 is dependent on residues 6-9. The identification of multiple functionally important regions in CCR5, coupled with differences in how CCR5 is used by M- and dual-tropic viruses, suggests that interactions between HIV-1 and entry cofactors are conformationally complex.	UNIV PENN,DEPT MED,DIV PULM & CRIT CARE,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; FREE UNIV BRUSSELS,IRIBHN,B-1070 BRUSSELS,BELGIUM; FREE UNIV BRUSSELS,SERV GENET MED,B-1070 BRUSSELS,BELGIUM; UNIFORMED SERV UNIV HLTH SCI,DEPT IMMUNOL & MICROBIOL,BETHESDA,MD 20814	University of Pennsylvania; University of Pennsylvania; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Uniformed Services University of the Health Sciences - USA			Samson, Michel/F-8356-2013; Broder, Christopher/E-1169-2013	Parmentier, Marc/0000-0001-8081-4685	NIAID NIH HHS [AI-35383, AI-38225] Funding Source: Medline; NINDS NIH HHS [NS-27405] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035383, R01AI038225] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS027405, P01NS027405] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahuja SK, 1996, J BIOL CHEM, V271, P225, DOI 10.1074/jbc.271.1.225; ALEXANDER WA, 1992, J VIROL, V66, P2934, DOI 10.1128/JVI.66.5.2934-2942.1992; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; ASHORN PA, 1990, J VIROL, V64, P2149, DOI 10.1128/JVI.64.5.2149-2156.1990; ASJO B, 1986, LANCET, V2, P660; Berson JF, 1996, J VIROL, V70, P6288, DOI 10.1128/JVI.70.9.6288-6295.1996; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; BRODER CC, 1993, VIROLOGY, V193, P483, DOI 10.1006/viro.1993.1151; BRODER CC, 1995, P NATL ACAD SCI USA, V92, P9004, DOI 10.1073/pnas.92.19.9004; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CHESEBRO B, 1990, J VIROL, V64, P215, DOI 10.1128/JVI.64.1.215-221.1990; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COLLMAN R, 1992, J VIROL, V66, P7517, DOI 10.1128/JVI.66.12.7517-7521.1992; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DOMS RW, 1993, VIROLOGY, V193, P545, DOI 10.1006/viro.1993.1164; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; DRAGIC T, 1992, J VIROL, V66, P4794, DOI 10.1128/JVI.66.8.4794-4802.1992; Earl P, 1991, CURRENT PROTOCOLS MO; FEDERSPPIEL B, 1993, GENOMICS, V16, P707, DOI 10.1006/geno.1993.1251; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FRANCI C, 1995, J IMMUNOL, V154, P6511; Gong JH, 1996, J BIOL CHEM, V271, P10521, DOI 10.1074/jbc.271.18.10521; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; HORUK R, 1994, IMMUNOL TODAY, V15, P169, DOI 10.1016/0167-5699(94)90314-X; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; LustiNarasimhan M, 1996, J BIOL CHEM, V271, P3148, DOI 10.1074/jbc.271.6.3148; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; ROOS MTL, 1992, J INFECT DIS, V165, P427, DOI 10.1093/infdis/165.3.427; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SCHUITEMAKER H, 1991, J VIROL, V65, P356, DOI 10.1128/JVI.65.1.356-363.1991; TERSMETTE M, 1988, J VIROL, V62, P2026, DOI 10.1128/JVI.62.6.2026-2032.1988; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; Wells TNC, 1996, J LEUKOCYTE BIOL, V59, P53, DOI 10.1002/jlb.59.1.53; Zhao-Hai Lu, 1995, Journal of Biological Chemistry, V270, P26239	41	273	296	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 1	1996	87	3					437	446		10.1016/S0092-8674(00)81364-1	http://dx.doi.org/10.1016/S0092-8674(00)81364-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VQ466	8898197	hybrid			2022-12-24	WOS:A1996VQ46600010
J	Conconi, A; Smerdon, MJ; Howe, GA; Ryan, CA				Conconi, A; Smerdon, MJ; Howe, GA; Ryan, CA			The octadecanoid signalling pathway in plants mediates a response to ultraviolet radiation	NATURE			English	Article							PROTEINASE INHIBITOR-I; GENE-EXPRESSION; TOMATO LEAVES; VIRUS-INFECTION; B RADIATION; ACID; ACTIVATION; INDUCTION; DAMAGE; CELLS	MANY plant genes that respond to environmental and developmental changes are regulated by jasmonic acid, which is derived from linolenic acid via the octadecanoid pathway(1). Linolenic acid is an important fatty-acid constituent of membranes in most plant species and its intracellular levels increase in response to certain signals. Here we report that irradiation of tomato leaves with ultraviolet light induces the expression of several plant defensive genes that are normally activated through the octadecanoid pathway after wounding(2). The response to ultraviolet light is blocked by an inhibitor of the octadecanoid pathway and it does not occur in a tomato mutant defective in this pathway. The ultraviolet irradiation maximally induces the defence genes at levels where cyclobutane pyrimidine dimer formation, an indicator of DNA damage, is less than 0.2 dimers per gene. Our evidence indicates that this plant defence response to certain wavelengths of ultraviolet radiation requires the activation of the octadecanoid defence signalling pathway.	WASHINGTON STATE UNIV,INST BIOL CHEM,PULLMAN,WA 99164; WASHINGTON STATE UNIV,DEPT BIOCHEM & BIOPHYS,PULLMAN,WA 99164	Washington State University; Washington State University			Howe, Gregg A/N-1887-2014	Howe, Gregg A/0000-0002-9218-979X				BLACK HS, 1987, PHOTOCHEM PHOTOBIOL, V46, P213, DOI 10.1111/j.1751-1097.1987.tb04759.x; Bohr VA, 1988, DNA REPAIR LABORATOR, V3, P347; BOL JF, 1990, ANNU REV PHYTOPATHOL, V28, P113, DOI 10.1146/annurev.py.28.090190.000553; BREDERODE FT, 1991, PLANT MOL BIOL, V17, P1117, DOI 10.1007/BF00028729; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; COHEN D, 1993, PHOTOCHEM PHOTOBIOL, V57, P383, DOI 10.1111/j.1751-1097.1993.tb02306.x; FARMER EE, 1992, PLANT CELL, V4, P129, DOI 10.1105/tpc.4.2.129; GOLD WG, 1983, PHYSIOL PLANTARUM, V58, P435, DOI 10.1111/j.1399-3054.1983.tb04205.x; GORDON LK, 1982, RADIAT RES, V89, P99, DOI 10.2307/3575688; GRAHAM JS, 1986, PLANTA, V169, P399, DOI 10.1007/BF00392137; GRAHAM JS, 1985, J BIOL CHEM, V260, P6561; GREEN R, 1995, PLANT CELL, V7, P203, DOI 10.1105/tpc.7.2.203; HAWK JLM, 1983, J INVEST DERMATOL, V80, P496, DOI 10.1111/1523-1747.ep12535038; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HILDMANN T, 1992, PLANT CELL, V4, P1157, DOI 10.1105/tpc.4.9.1157; HOWE GA, IN PRESS PLANT CELL; JONES JS, 1991, NUCLEIC ACIDS RES, V19, P893, DOI 10.1093/nar/19.4.893; LEE JS, 1986, P NATL ACAD SCI USA, V83, P7277, DOI 10.1073/pnas.83.19.7277; MITCHELL DL, 1992, NUCLEIC ACIDS RES, V20, P225, DOI 10.1093/nar/20.2.225; MITCHELL DL, 1991, PHOTOCHEM PHOTOBIOL, V54, P741, DOI 10.1111/j.1751-1097.1991.tb02084.x; MURAD AO, 1995, J BIOL CHEM, V270, P3949, DOI 10.1074/jbc.270.8.3949; PENACORTES H, 1993, PLANTA, V191, P123, DOI 10.1007/BF00240903; QUAITE FE, 1992, NATURE, V358, P576, DOI 10.1038/358576a0; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; REINBOTHE S, 1994, PLANT CELL, V6, P1197, DOI 10.1105/tpc.6.9.1197; SCHALLER A, 1995, PLANT CELL, V7, P1893, DOI 10.1105/tpc.7.11.1893; SHENG YH, 1995, CURR EYE RES, V14, P341, DOI 10.3109/02713689508999931; STAPLETON AE, 1992, PLANT CELL, V4, P1353, DOI 10.1105/tpc.4.11.1353; Tyrrell RM, 1996, BIOESSAYS, V18, P139, DOI 10.1002/bies.950180210; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984	30	183	203	0	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 31	1996	383	6603					826	829		10.1038/383826a0	http://dx.doi.org/10.1038/383826a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ144	8893008				2022-12-24	WOS:A1996VQ14400064
J	Snowden, JA; Biggs, JC; Brooks, PM				Snowden, JA; Biggs, JC; Brooks, PM			Autologous blood stem cell transplantation for autoimmune diseases	LANCET			English	Editorial Material							BONE-MARROW TRANSPLANTATION; COLONY-STIMULATING FACTOR; RHEUMATOID-ARTHRITIS; ANTIBODY		ST VINCENTS HOSP,MED PROFESSORIAL UNIT,SYDNEY,NSW 2110,AUSTRALIA	St Vincents Hospital Sydney	Snowden, JA (corresponding author), ST VINCENTS HOSP,DEPT HAEMATOL,SYDNEY,NSW 2110,AUSTRALIA.			SNOWDEN, JOHN/0000-0001-6819-3476				ATKINSON K, 1995, AUST NZ J MED, V25, P483, DOI 10.1111/j.1445-5994.1995.tb01492.x; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; HAMILTON JA, 1995, BAILLIERE CLIN RHEUM, V9, P673; MARKENSON JA, 1991, SEMIN ARTHRITIS RHEU, V21, P4, DOI 10.1016/0049-0172(91)90046-3; MARMONT AM, 1994, STEM CELLS, V12, P125, DOI 10.1002/stem.5530120119; MIYAHARA H, 1993, CLIN IMMUNOL IMMUNOP, V69, P69, DOI 10.1006/clin.1993.1151; MKENDRY RJR, 1996, ARTHRITIS RHEUM, V39, P1246; Tyndall A, 1996, ANN RHEUM DIS, V55, P149, DOI 10.1136/ard.55.3.149; VIDARSSON B, 1995, AM J MED, V98, P589, DOI 10.1016/S0002-9343(99)80019-9; WILSKE KR, 1993, RHEUM DIS CLIN N AM, V19, P153	10	33	33	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 26	1996	348	9035					1112	1113		10.1016/S0140-6736(05)65267-1	http://dx.doi.org/10.1016/S0140-6736(05)65267-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP106	8888160				2022-12-24	WOS:A1996VP10600004
J	Bentley, DR				Bentley, DR			Genomic sequence information should be released immediately and freely in the public domain	SCIENCE			English	Editorial Material											Bentley, DR (corresponding author), SANGER CTR,WELLCOME TRUST GENOME CAMPUS,HINXTON HALL,CAMBRIDGE CB10 1SA,ENGLAND.							*BAT CTR HUM GEN R, 1996, POL AV PAT HUM GEN D; *BIOIND ASS, 1995, PENT HUM GEN; Marshall E, 1996, SCIENCE, V272, P188, DOI 10.1126/science.272.5259.188; MARSHALL E, 1995, SCIENCE, V267, P783, DOI 10.1126/science.7846520; *NAT SCI COUNC, 1988, MAPP SEQ HUM GEN; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; *WELLC TRUST, 1996, 1 INT STRAT M HUM GE; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; 1996, HUMAN GENOME NEWS, V7	9	42	47	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 25	1996	274	5287					533	534		10.1126/science.274.5287.533	http://dx.doi.org/10.1126/science.274.5287.533			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN919	8928006				2022-12-24	WOS:A1996VN91900034
J	Pruss, D; Bartholomew, B; Persinger, J; Hayes, J; Arents, G; Moudrianakis, EN; Wolffe, AP				Pruss, D; Bartholomew, B; Persinger, J; Hayes, J; Arents, G; Moudrianakis, EN; Wolffe, AP			An asymmetric model for the nucleosome: A binding site for linker histones inside the DNA gyres	SCIENCE			English	Article							POSITIONED NUCLEOSOMES; CHROMATIN STRUCTURE; CRYSTAL-STRUCTURE; GLOBULAR DOMAIN; MMTV PROMOTER; RNA GENE; TRANSCRIPTION; OCTAMER; CORE; H5	Histone-DNA contacts within a nucleosome influence the function of trans-acting factors and the molecular machines required to activate the transcription process, The internal architecture of a positioned nucleosome has now been probed with the use of photoactivatable cross-linking reagents to determine the placement of histones along the DNA molecule. A model for the nucleosome is proposed in which the winged-helix domain of the linker histone is asymmetrically located inside the gyres of DNA that also wrap around the core histones. This domain extends the path of the protein superhelix to one side of the core particle.	NICHHD,MOL EMBRYOL LAB,NIH,BETHESDA,MD 20892; SO ILLINOIS UNIV,SCH MED,DEPT MED BIOCHEM,CARBONDALE,IL 62901; UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642; JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Southern Illinois University System; Southern Illinois University; University of Rochester; Johns Hopkins University								ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; ARENTS G, 1995, P NATL ACAD SCI USA, V92, P11170, DOI 10.1073/pnas.92.24.11170; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BARTHOLOMEW B, 1993, MOL CELL BIOL, V13, P942, DOI 10.1128/MCB.13.2.942; BOULIKAS T, 1980, P NATL ACAD SCI-BIOL, V77, P127, DOI 10.1073/pnas.77.1.127; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P273, DOI 10.1093/nar/20.2.273; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; CARON F, 1981, J MOL BIOL, V146, P513, DOI 10.1016/0022-2836(81)90045-0; CLARK DJ, 1990, J MOL BIOL, V211, P883, DOI 10.1016/0022-2836(90)90081-V; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; EICKBUSH TH, 1978, BIOCHEMISTRY-US, V17, P4955, DOI 10.1021/bi00616a016; GRUNSTEIN M, 1995, J CELL SCI S, V19, P29; Hamiche A, 1996, J MOL BIOL, V257, P30, DOI 10.1006/jmbi.1996.0144; HAYES JJ, 1994, P NATL ACAD SCI USA, V91, P7817, DOI 10.1073/pnas.91.16.7817; HAYES JJ, 1990, P NATL ACAD SCI USA, V87, P7405, DOI 10.1073/pnas.87.19.7405; HAYES JJ, 1993, P NATL ACAD SCI USA, V90, P6415, DOI 10.1073/pnas.90.14.6415; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; KHOCHBIN S, 1994, EUR J BIOCHEM, V225, P501, DOI 10.1111/j.1432-1033.1994.00501.x; KORNBERG RD, 1974, SCIENCE, V184, P868, DOI 10.1126/science.184.4139.868; KORNBERG RD, 1974, SCIENCE, V184, P865, DOI 10.1126/science.184.4139.865; KRUGER W, 1995, GENE DEV, V9, P2770, DOI 10.1101/gad.9.22.2770; LENNARD AC, 1985, EMBO J, V4, P3455, DOI 10.1002/j.1460-2075.1985.tb04104.x; LI Q, 1995, MOL CELL BIOL, V15, P4375; MEERSSEMAN G, 1991, J MOL BIOL, V220, P89, DOI 10.1016/0022-2836(91)90383-H; Nightingale KP, 1996, J BIOL CHEM, V271, P7090, DOI 10.1074/jbc.271.12.7090; NOLL M, 1977, J MOL BIOL, V109, P393, DOI 10.1016/S0022-2836(77)80019-3; PENNINGS S, 1994, P NATL ACAD SCI USA, V91, P10275, DOI 10.1073/pnas.91.22.10275; PRUSS D, 1993, BIOCHEMISTRY-US, V32, P6810, DOI 10.1021/bi00078a002; PRUSS D, 1995, BIOESSAYS, V17, P161, DOI 10.1002/bies.950170211; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; RICHMOND TJ, 1993, COLD SPRING HARB SYM, V58, P265, DOI 10.1101/SQB.1993.058.01.031; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; SIMPSON RT, 1990, NATURE, V343, P387, DOI 10.1038/343387a0; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; URA K, 1995, EMBO J, V14, P3752, DOI 10.1002/j.1460-2075.1995.tb00045.x; van Holde K.E., 1988, CHROMATIN; YANEVA J, 1995, P NATL ACAD SCI USA, V92, P7060, DOI 10.1073/pnas.92.15.7060	41	156	160	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 25	1996	274	5287					614	617		10.1126/science.274.5287.614	http://dx.doi.org/10.1126/science.274.5287.614			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN919	8849453				2022-12-24	WOS:A1996VN91900051
J	Janowski, BA; Willy, PJ; Devi, TR; Falck, JR; Mangelsdorf, DJ				Janowski, BA; Willy, PJ; Devi, TR; Falck, JR; Mangelsdorf, DJ			An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha	NATURE			English	Article							THYROID-HORMONE RECEPTOR; 9-CIS RETINOIC ACID; HETERODIMER FORMATION; RESPONSE PATHWAY; CO-REPRESSOR; ERB-A; IDENTIFICATION; SUPERFAMILY; ACTIVATION; EXPRESSION	CHOLESTEROL and its oxysterol congeners are important constitutents of cell membranes and function as intermediates in several crucial biosynthetic pathways. These compounds autoregulate their metabolic fate by end-product repression and activation of downstream catabolism(1). Although end-product repression by oxysterols is relatively well understood(2), the mechanism by which these compounds act as positive transcription signalling molecules is unknown. Here we identify a specific group of endogenous oxysterols that activate transcription through the nuclear receptor LXR alpha. Transactivation of LXR alpha by oxysterols occurs at concentrations at which these compounds exist in vivo. The most potent activators also serve as intermediary substrates in the rate-limiting steps of three important metabolic pathways: steroid hormone biosynthesis, bile acid synthesis, and conversion of lanosterol to cholesterol. Our results demonstrate the existence of a nuclear receptor signalling pathway for oxysterols and suggest that LXR alpha may be important as a sensor of cholesterol metabolites.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT MOL GENET,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Mangelsdorf, David/0000-0002-4355-0796; Falck, John/0000-0002-9219-7845				BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BYSKOV AG, 1995, NATURE, V374, P559, DOI 10.1038/374559a0; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; DHAR AK, 1973, J NEUROCHEM, V21, P51, DOI 10.1111/j.1471-4159.1973.tb04224.x; DIXON R, 1970, BIOCHEM BIOPH RES CO, V40, P161, DOI 10.1016/0006-291X(70)91060-0; DOLLE RE, 1989, J AM CHEM SOC, V111, P278, DOI 10.1021/ja00183a042; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; HARMON MA, 1995, P NATL ACAD SCI USA, V92, P6157, DOI 10.1073/pnas.92.13.6157; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; IKEKAWA N, 1985, STEROLS BILE ACIDS, P199; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JAVITT NB, 1981, J BIOL CHEM, V256, P2644; KANDUTSCH AA, 1978, SCIENCE, V201, P498, DOI 10.1126/science.663671; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; LENG XH, 1993, J STEROID BIOCHEM, V46, P643, DOI 10.1016/0960-0760(93)90306-H; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MORISAKI M, 1977, CHEM PHARM BULL, V25, P2576; ONATE SA, 1995, SCIENCE, V270, P1354; RUSSELL DW, 1992, CARDIOVASC DRUG THER, V6, P103, DOI 10.1007/BF00054556; SONG C, 1994, P NATL ACAD SCI USA, V91, P10809, DOI 10.1073/pnas.91.23.10809; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F	31	1413	1468	2	61	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 24	1996	383	6602					728	731		10.1038/383728a0	http://dx.doi.org/10.1038/383728a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN918	8878485				2022-12-24	WOS:A1996VN91800057
J	Joutel, A; Corpechot, C; Ducros, A; Vahedi, K; Chabriat, H; Mouton, P; Alamowitch, S; Domenga, V; Cecillion, M; Marechal, E; Maciazek, J; Vayssiere, C; Cruaud, C; Cabanis, EA; Ruchoux, MM; Weissenbach, J; Bach, JF; Bousser, MG; TournierLasserve, E				Joutel, A; Corpechot, C; Ducros, A; Vahedi, K; Chabriat, H; Mouton, P; Alamowitch, S; Domenga, V; Cecillion, M; Marechal, E; Maciazek, J; Vayssiere, C; Cruaud, C; Cabanis, EA; Ruchoux, MM; Weissenbach, J; Bach, JF; Bousser, MG; TournierLasserve, E			Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia	NATURE			English	Article							ALZHEIMERS-DISEASE; GENE-PRODUCT; C-ELEGANS; DROSOPHILA; LEUKOENCEPHALOPATHY; RECEPTOR; REPEATS; LOCUS; PROTEINS; HOMOLOG	STROKE is the third leading cause of death, and vascular dementia the second cause of dementia after Alzheimer's disease. CADASIL (for cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) causes a type of stroke and dementia whose key features include recurrent subcortical ischaemic events and vascular dementia and which is associated with diffuse white-matter abnormalities on neuroimaging(1,2). Pathological examination reveals multiple small, deep cerebral infarcts, a leukoencephalopathy, and a non-atherosclerotic, non-amyloid angiopathy involving mainly the small cerebral arteries(3). Severe alterations of vascular smooth-muscle cells are evident on ultrastructural analysis(4). We have previously mapped the mutant gene to chromosome 19 (ref. 5). Here we report the characterization of the human Notch3 gene which we mapped to the CADASIL critical region. We have identified mutations in CADASIL patients that cause serious disruption of this gene, indicating that Notch3 could be the defective protein in CADASIL patients.	UNIV PARIS 05,INSERM,U25,F-75730 PARIS,FRANCE; HOP ST ANTOINE,SERV NEUROL,F-75012 PARIS,FRANCE; GENETHON,F-91000 EVRY,FRANCE; CHNO XV XX,F-75571 PARIS,FRANCE; CH&U LILLE,SERV NEUROPATHOL,F-59000 LILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; CHNO des Quinze-Vingts; UDICE-French Research Universities; Sorbonne Universite; Universite de Lille - ISITE; CHU Lille			Tournier-Lasserve, Elisabeth/N-7134-2017; Joutel, Anne/K-5601-2017; DUCROS, Anne/D-1899-2010; Chabriat, Hugues/G-5699-2010	Tournier-Lasserve, Elisabeth/0000-0002-3039-1677; Joutel, Anne/0000-0003-3963-3860; DUCROS, Anne/0000-0001-5560-5013; Cruaud, Corinne/0000-0002-4752-7278; Chabriat, Hugues/0000-0001-8436-6074; Dichgans, Martin/0000-0002-0654-387X				ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; ASHWORTH LK, 1995, NAT GENET, V11, P422, DOI 10.1038/ng1295-422; BAUDRIMONT M, 1993, STROKE, V24, P122, DOI 10.1161/01.STR.24.1.122; BELLANNECHANTELOT C, 1992, CELL, V70, P1059, DOI 10.1016/0092-8674(92)90254-A; BUROKER NE, 1987, HUM GENET, V76, P90; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; CHABRIAT H, 1995, LANCET, V346, P934, DOI 10.1016/S0140-6736(95)91557-5; Ducros A, 1996, AM J HUM GENET, V58, P171; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; HENDERSON ST, 1994, DEVELOPMENT, V120, P2913; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; KIDD S, 1989, GENE DEV, V3, P1113, DOI 10.1101/gad.3.8.1113; LARDELLI M, 1994, MECH DEVELOP, V46, P123, DOI 10.1016/0925-4773(94)90081-7; LARSSON C, 1994, GENOMICS, V24, P253, DOI 10.1006/geno.1994.1613; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; MELLO CC, 1994, CELL, V77, P95, DOI 10.1016/0092-8674(94)90238-0; MLODZIK M, 1990, GENE DEV, V4, P1848, DOI 10.1101/gad.4.11.1848; PARIMOO S, 1991, P NATL ACAD SCI USA, V88, P9623, DOI 10.1073/pnas.88.21.9623; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; ROMMENS JM, 1993, HUM MOL GENET, V2, P901, DOI 10.1093/hmg/2.7.901; RUCHOUX MM, 1995, NEUROPATHOL, V89, P500; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; TOURNIERLASSERVE E, 1991, STROKE, V22, P1297, DOI 10.1161/01.STR.22.10.1297; TOURNIERLASSERVE E, 1993, NAT GENET, V3, P256, DOI 10.1038/ng0393-256; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6	30	1513	1599	2	73	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 24	1996	383	6602					707	710		10.1038/383707a0	http://dx.doi.org/10.1038/383707a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN918	8878478				2022-12-24	WOS:A1996VN91800050
J	Koskinen, SVP; Martelin, TP; Valkonen, T				Koskinen, SVP; Martelin, TP; Valkonen, T			Socioeconomic differences in mortality among diabetic people in Finland: Five year follow up	BRITISH MEDICAL JOURNAL			English	Article							SOCIAL-CLASS; MELLITUS	Objective-To compare socioeconomic differences in mortality (by cause of death) among diabetic people with those in the rest of the population. Design-Five year follow up of mortality in the population of Finland, comparing people with diabetes and those without diabetes. Setting-Finland. Subjects-All residents of Finland aged 30 to 74 included in the 1980 census. Subjects were classified as diabetic (230 000 person years) or other (12 400 000 person years) according to whether they were exempted from charges for medication for diabetes, During 1981-5 there were 114 058 deaths, of which 11 215 were in people with diabetes. Main outcome measures-Age standardised mortality by sex, social class, and cause of death for the diabetic and non-diabetic populations. Results-No significant social class differences in mortality were found among women with diabetes. Among diabetic men there was a slight increasing trend in mortality from the upper white collar group to the unskilled blue collar workers but it was much less steep than that of non-diabetic men. Conclusions-Among people with diabetes in Finland the quality of treatment and compliance with treatment probably do not vary by socioeconomic status. Health education for diabetic people seems to be effective in all socioeconomic strata; in people from the lower strata this leads to greater changes because their health behaviour was originally less good.	UNIV HELSINKI,DEPT SOCIOL,POPULAT RES UNIT,FIN-00014 HELSINKI,FINLAND	University of Helsinki								AARVA P, 1995, J SOCIAL MED, V32, P103; Aitkin M., 1980, Applied Statistics, V29, P156, DOI 10.2307/2986301; AUVINEN A, 1995, AM J EPIDEMIOL, V142, P1089, DOI 10.1093/oxfordjournals.aje.a117562; Dahlgren G., 1992, POLICIES STRATEGIES; DORMAN JS, 1985, DIABETES CARE, V8, P54, DOI 10.2337/diacare.8.1.S54; HAKKINEN U, 1992, 20 NAT AG WELF HLTH; KESKIMAKI I, 1995, SOC SCI MED, V41, P425, DOI 10.1016/0277-9536(94)00339-U; KOSKENVUO M, 1981, J EPIDEMIOL COMMUN H, V35, P192, DOI 10.1136/jech.35.3.192; KOSKINEN S, 1994, SOC SCI MED, V38, P1385, DOI 10.1016/0277-9536(94)90276-3; LAAKSO M, 1991, AM J EPIDEMIOL, V133, P850, DOI 10.1093/oxfordjournals.aje.a115965; Matsushima M, 1996, DIABETOLOGIA, V39, P710; MOSS SE, 1994, ARCH INTERN MED, V154, P2473; NYMAN K, 1993, PUBLICATIONS SOCIA M, V88; PAYNE CD, 1985, GLIM SYSTEM RELEASE; PILL R, 1995, J EPIDEMIOL COMMUN H, V49, P28, DOI 10.1136/jech.49.1.28; PYORALA K, 1987, Diabetes Metabolism Reviews, V3, P463; RICHMOND RL, 1993, ADDICTION, V88, P1127, DOI 10.1111/j.1360-0443.1993.tb02132.x; TOWNSEND P, 1988, INEQUALITIES HLTH HL; Valkonen T, 1992, Int J Health Sci, V3, P157; VALKONEN T, 1990, SOCIOECONOMIC MORTAL; VALKONEN T, 1993, POPULATION, P1; 1993, NEW ENGL J MED, V329, P977; [No title captured]	23	47	47	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 19	1996	313	7063					975	978						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VN916	8892417	Green Published			2022-12-24	WOS:A1996VN91600021
J	Shaheen, SO; Aaby, P; Hall, AJ; Barker, DJP; Heyes, CB; Shiell, AW; Goudiaby, A				Shaheen, SO; Aaby, P; Hall, AJ; Barker, DJP; Heyes, CB; Shiell, AW; Goudiaby, A			Cell mediated immunity after measles in Guinea-Bissau: Historical cohort study	BRITISH MEDICAL JOURNAL			English	Article							T-LYMPHOCYTE SUBSETS; CHILD-MORTALITY; WEST-AFRICA; DELAYED-HYPERSENSITIVITY; BANGLADESHI CHILDREN; PERUVIAN CHILDREN; VACCINE EFFICACY; COMMUNITY; IMMUNIZATION; TRANSMISSION	Objective-To investigate whether children who have had measles have reduced general cell mediated immunity three years later compared with vaccinated children who have not had measles. Design-Historical cohort study. Setting-Bissau, Guinea-Bissau. Subjects-391 children aged 3-13 years who were living in Bissau during a measles epidemic in 1991 and still lived there. These included 131 primary cases and 139 secondary cases from the epidemic and 121 vaccinated controls with no history of measles. Main outcome measures-General cell mediated immunity assessed by measurement of delayed type hypersensitivity skin responses to seven recall antigens. Anergy was defined as a lack of response to all antigens. Results-82 out of 268 cases of measles (31%) were anergic compared with 20 of the 121 vaccinated controls (17%) (odds ratio adjusted for potential confounding variables 2.2 (95% confidence interval 1.2 to 4.0); P = 0.009), The prevalence of anergy was higher in secondary cases (33% (46/138)) than in primary cases (28% (36/130)), although this difference was not significant, Anergy was more common in the rainy season (unadjusted prevalence 31% (91/291)) than in the dry season (11% (11/98)) (adjusted odds ratio 4.8 (2.2 to 10.3)). This seasonal increase occurred predominantly in the cases of measles. Conclusions-Reduced general cell mediated immunity may contribute to the higher long term mortality in children who have had measles compared with recipients of standard measles vaccine and to the higher child mortality in the rainy season in west Africa.	UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND; STATENS SERUM INST,DANISH EPIDEMIOL SCI CTR,EPIDEMIOL RES UNIT,DK-2300 COPENHAGEN,DENMARK; UNIV LONDON LONDON SCH HYG & TROP MED,COMMUNICABLE DIS EPIDEMIOL UNIT,LONDON WC1E 7HT,ENGLAND; MINIST PUBL HLTH,BISSAU,GUINEA BISSAU	University of Southampton; Aarhus University; Statens Serum Institut; University of London; London School of Hygiene & Tropical Medicine				Aaby, Peter/0000-0001-8331-1389	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AABY P, 1993, BRIT MED J, V307, P1308, DOI 10.1136/bmj.307.6915.1308; AABY P, 1989, PEDIATR INFECT DIS J, V8, P197; AABY P, 1990, J INFECT DIS, V162, P1043, DOI 10.1093/infdis/162.5.1043; AABY P, 1995, BRIT MED J, V311, P481, DOI 10.1136/bmj.311.7003.481; Aaby P, 1996, AM J EPIDEMIOL, V143, P1035, DOI 10.1093/oxfordjournals.aje.a008667; AABY P, 1993, J PEDIATR-US, V122, P904, DOI 10.1016/S0022-3476(09)90015-4; Aaby P, 1996, PEDIATR INFECT DIS J, V15, P39, DOI 10.1097/00006454-199601000-00009; AABY P, 1985, MED HYPOTHESES, V18, P93, DOI 10.1016/0306-9877(85)90042-8; AABY P, 1988, REV INFECT DIS, V10, P474; AABY P, 1984, J INFECTION, V8, P13, DOI 10.1016/S0163-4453(84)93192-X; AKINWOLERE O A O, 1988, African Journal of Medicine and Medical Sciences, V17, P47; BAQUI AH, 1993, AM J EPIDEMIOL, V137, P355, DOI 10.1093/oxfordjournals.aje.a116682; BLACK RE, 1989, PEDIATR INFECT DIS J, V8, P210; CHANDRA RK, 1977, BIOL NEONATE, V31, P15; CORRIEL RN, 1985, AM J DIS CHILD, V139, P141, DOI 10.1001/archpedi.1985.02140040039022; FERGUSON AC, 1978, J PEDIATR-US, V93, P52, DOI 10.1016/S0022-3476(78)80599-X; FOULSEN AG, 1992, J ACQ IMMUN DEF SYND, V5, P25; GADNER MJ, 1989, STAT CONFIDENCE; GARENNE M, 1990, J INFECT DIS, V161, P1088, DOI 10.1093/infdis/161.6.1088; GORDIN FM, 1994, J INFECT DIS, V169, P893, DOI 10.1093/infdis/169.4.893; GREENWOOD BM, 1972, LANCET, V1, P169; HARLAND PSE, 1965, LANCET, V2, P719; HULL HF, 1983, LANCET, V1, P972; KAUFFMAN CA, 1976, INFECT IMMUN, V13, P78, DOI 10.1128/IAI.13.1.78-83.1976; KIPPS A, 1996, S AFR MED J, V40, P104; KNIKER WT, 1985, AM J DIS CHILD, V139, P840, DOI 10.1001/archpedi.1985.02140100102044; KNIKER WT, 1979, ANN ALLERGY, V43, P73; KOSTER FT, 1987, AM J CLIN NUTR, V46, P115, DOI 10.1093/ajcn/46.1.115; LEON ME, 1993, J INFECT DIS, V168, P1097, DOI 10.1093/infdis/168.5.1097; LISSE I, IN PRESS J PEDIAT; LISSE IM, 1994, T ROY SOC TROP MED H, V88, P709, DOI 10.1016/0035-9203(94)90242-9; LISSE IM, 1994, PEDIATR INFECT DIS J, V13, P109, DOI 10.1097/00006454-199402000-00006; MOLBAK K, 1992, T ROY SOC TROP MED H, V86, P216, DOI 10.1016/0035-9203(92)90580-6; PABST HF, 1989, LANCET, V1, P295, DOI 10.1016/S0140-6736(89)91307-X; POULSEN AG, 1989, LANCET, V1, P827, DOI 10.1016/S0140-6736(89)92281-2; POULSEN AG, 1993, J ACQ IMMUN DEF SYND, V6, P941; SALMERON G, 1983, AM J MED, V75, P19, DOI 10.1016/0002-9343(83)91266-4; SCHLESINGER JJ, 1977, LANCET, V2, P529; SEMBA RD, 1993, LANCET, V341, P5, DOI 10.1016/0140-6736(93)92478-C; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Smedman L, 1983, Ann Trop Paediatr, V3, P169; SMITH SM, 1987, J NUTR, V117, P857, DOI 10.1093/jn/117.5.857; SOKAL JE, 1975, NEW ENGL J MED, V293, P501, DOI 10.1056/NEJM197509042931013; TAMASHIRO VG, 1987, PEDIATR INFECT DIS J, V6, P451, DOI 10.1097/00006454-198705000-00007; von Pirquet C, 1908, DEUT MED WOCHENSCHR, V34, P1297; WHITTLE HC, 1973, ARCH DIS CHILD, V48, P753, DOI 10.1136/adc.48.10.753; 1994, LANCET, V344, P174	47	59	59	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 19	1996	313	7063					969	974						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN916	8892416	Green Published			2022-12-24	WOS:A1996VN91600020
J	Denissenko, MF; Pao, A; Tang, MS; Pfeifer, GP				Denissenko, MF; Pao, A; Tang, MS; Pfeifer, GP			Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53	SCIENCE			English	Article							DIPLOID HUMAN FIBROBLASTS; EXCISION REPAIR; DNA ADDUCTS; HPRT GENE; DAMAGE; STRAND; CLUES; CELLS	Cigarette smoke carcinogens such as benzo[a]pyrene are implicated in the development of lung cancer. The distribution of benzo[a]pyrene diol epoxide (BPDE) adducts along exons of the P53 gene in BPDE-treated HeLa cells and bronchial epithelial cells was mapped at nucleotide resolution. Strong and selective adduct formation occurred at guanine positions in codons 157, 248, and 273. These same positions are the major mutational hotspots in human lung cancers. Thus, targeted adduct formation rather than phenotypic selection appears to shape the P53 mutational spectrum in lung cancer. These results provide a direct etiological link between a defined chemical carcinogen and human cancer.	UNIV TEXAS, MD ANDERSON CANC CTR, SMITHVILLE, TX 78957 USA; BECKMAN RES INST CITY HOPE, DEPT BIOL, DUARTE, CA 91010 USA	University of Texas System; UTMD Anderson Cancer Center; City of Hope; Beckman Research Institute of City of Hope					NATIONAL CANCER INSTITUTE [R01CA065652] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003124] Funding Source: NIH RePORTER; NCI NIH HHS [CA65652] Funding Source: Medline; NIEHS NIH HHS [ES03124] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		CHEN RH, 1990, P NATL ACAD SCI USA, V87, P8680, DOI 10.1073/pnas.87.21.8680; CHEN RH, 1992, P NATL ACAD SCI USA, V89, P5413, DOI 10.1073/pnas.89.12.5413; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DENISSENKO MF, UNPUB; EISENSTADT E, 1982, P NATL ACAD SCI-BIOL, V79, P1945, DOI 10.1073/pnas.79.6.1945; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HECHT SS, 1993, J CELL BIOCHEM, P27; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; Levine AJ, 1995, ANN NY ACAD SCI, V768, P111, DOI 10.1111/j.1749-6632.1995.tb12115.x; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MAZUR M, 1988, SOMAT CELL MOLEC GEN, V14, P393, DOI 10.1007/BF01534647; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; PFEIFER GP, 1991, P NATL ACAD SCI USA, V88, P1374, DOI 10.1073/pnas.88.4.1374; PUISIEUX A, 1991, CANCER RES, V51, P6185; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; RUGGERI B, 1993, P NATL ACAD SCI USA, V90, P1013, DOI 10.1073/pnas.90.3.1013; SANCAR A, 1993, PHOTOCHEM PHOTOBIOL, V57, P905, DOI 10.1111/j.1751-1097.1993.tb09233.x; Singer B., 1983, MOL BIOL MUTAGENS CA; TANG MS, 1992, BIOCHEMISTRY-US, V31, P8429, DOI 10.1021/bi00151a006; TANG MS, 1996, TECHNOLOGIES DETECTI, P39; TOMALETTI S, 1993, ONCOGENE, V8, P2051; TORNALETTI S, 1995, ONCOGENE, V10, P1493; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; VANHOUTEN B, 1993, BIOESSAYS, V15, P51, DOI 10.1002/bies.950150108; VENKATACHALAM S, 1995, CARCINOGENESIS, V16, P2029, DOI 10.1093/carcin/16.9.2029	26	1368	1415	3	131	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 18	1996	274	5286					430	432		10.1126/science.274.5286.430	http://dx.doi.org/10.1126/science.274.5286.430			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN173	8832894				2022-12-24	WOS:A1996VN17300057
J	Hunter, CP; Kenyon, C				Hunter, CP; Kenyon, C			Spatial and temporal controls target pal-1 blastomere-specification activity to a single blastomere lineage in C-elegans embryos	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; DROSOPHILA BODY PATTERN; 3' UNTRANSLATED REGION; MESSENGER-RNA; HOMEOBOX GENE; TRANSLATIONAL REGULATION; CELLULAR INTERACTIONS; PROTEIN GRADIENT; MATERNAL GENES; CAUDAL GENE	The early asymmetric cleavages of Caenorhabditis elegans embryos produce blastomeres with distinct developmental potentials. Here, we show that the caudal-like homeodomain protein PAL-1 is required to specify the somatic identity of one posterior blastomere in the 4 cell embryo. We find that pal-1 activity is sequentially restricted to this blastomere. First, at the 4 cell stage, it is translated only in the two posterior blastomeres. Then, its function is restricted to one of these blastomeres. This second targeting step is dependent on the activities of the posteriorly localized SKN-1 and asymmetrically segregated PIE-1 proteins. We propose that the segregation of PIE-1, combined with the temporal decay of SKN-1, targets pal-1 activity to this posterior lineage, thus coupling the regulation of this conserved posterior patterning gene to asymmetric cell cleavages.			Hunter, CP (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037053] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-37053] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHRINGER J, 1991, NATURE, V349, P346, DOI 10.1038/349346a0; Ahringer J, 1996, GENE DEV, V10, P1120, DOI 10.1101/gad.10.9.1120; BLACKWELL TK, 1994, SCIENCE, V266, P621, DOI 10.1126/science.7939715; BORING L, 1993, MECH DEVELOP, V42, P97, DOI 10.1016/0925-4773(93)90102-4; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; BOWERMAN B, 1993, CELL, V74, P443, DOI 10.1016/0092-8674(93)80046-H; BRENNER S, 1974, GENETICS, V77, P71; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; DAVIDSON EH, 1990, DEVELOPMENT, V108, P365; Dubnau J, 1996, NATURE, V379, P694, DOI 10.1038/379694a0; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FRUMKIN A, 1991, DEVELOPMENT, V112, P207; GAMER LW, 1993, MECH DEVELOP, V43, P71, DOI 10.1016/0925-4773(93)90024-R; GOODWIN EB, 1993, CELL, V75, P329, DOI 10.1016/0092-8674(93)80074-O; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; HUTTER H, 1995, DEVELOPMENT, V121, P1559; HUTTER H, 1994, DEVELOPMENT, V120, P2051; JOLY JS, 1992, DIFFERENTIATION, V50, P75, DOI 10.1111/j.1432-0436.1992.tb00488.x; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; LIN RL, 1995, CELL, V83, P599, DOI 10.1016/0092-8674(95)90100-0; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MANGO SE, 1994, DEVELOPMENT, V120, P2305; MELLO CC, 1992, CELL, V70, P163, DOI 10.1016/0092-8674(92)90542-K; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Mello CC, 1996, NATURE, V382, P710, DOI 10.1038/382710a0; MELLO CC, 1994, CELL, V77, P95, DOI 10.1016/0092-8674(94)90238-0; MILLER DM, 1983, CELL, V34, P477, DOI 10.1016/0092-8674(83)90381-1; Miller DM, 1995, METHOD CELL BIOL, V48, P365; MLODZIK M, 1987, CELL, V48, P465, DOI 10.1016/0092-8674(87)90197-8; MLODZIK M, 1985, EMBO J, V4, P2961, DOI 10.1002/j.1460-2075.1985.tb04030.x; MOSKOWITZ IPG, 1994, DEVELOPMENT, V120, P3325; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; PULAK R, 1993, GENE DEV, V7, P1885, DOI 10.1101/gad.7.10.1885; RiveraPomar R, 1996, NATURE, V379, P746, DOI 10.1038/379746a0; SCHULZ C, 1995, DEVELOPMENT, V121, P1023; SCHULZ C, 1994, DEVELOPMENT, V120, P3043; Seydoux G, 1996, NATURE, V382, P713, DOI 10.1038/382713a0; Seydoux G, 1995, METHOD CELL BIOL, V48, P323; STJOHNSTON D, 1992, CELL, V68, P201; STROME S, 1982, P NATL ACAD SCI-BIOL, V79, P1558, DOI 10.1073/pnas.79.5.1558; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; SUBRAMANIAN V, 1995, CELL, V83, P641, DOI 10.1016/0092-8674(95)90104-3; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SURDEJ P, 1994, ANNU REV GENET, V28, P263; WARING DA, 1991, NATURE, V350, P712, DOI 10.1038/350712a0; WARING DA, 1990, CELL, V60, P123, DOI 10.1016/0092-8674(90)90722-Q; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WOOD WB, 1994, TRENDS GENET, V10, P49, DOI 10.1016/0168-9525(94)90148-1; XU X, 1994, DEVELOPMENT, V120, P277; YANDELL MD, 1994, P NATL ACAD SCI USA, V91, P1381, DOI 10.1073/pnas.91.4.1381	52	175	186	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1996	87	2					217	226		10.1016/S0092-8674(00)81340-9	http://dx.doi.org/10.1016/S0092-8674(00)81340-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VN403	8861906	Bronze			2022-12-24	WOS:A1996VN40300010
J	Rowles, A; Chong, JPJ; Brown, L; Howell, M; Evan, GI; Blow, JJ				Rowles, A; Chong, JPJ; Brown, L; Howell, M; Evan, GI; Blow, JJ			Interaction between the origin recognition complex and the replication licensing system in Xenopus	CELL			English	Article							CYCLIN-DEPENDENT KINASES; DNA-REPLICATION; CELL-CYCLE; EGG EXTRACTS; CHROMOSOMAL REPLICATION; NUCLEAR-ENVELOPE; PURIFIED DNA; YEAST; INITIATION; PROTEIN	The origin recognition complex (ORC) binds to origins of replication in budding yeast. We have cloned a Xenopus homolog of the largest ORC polypeptide (XORC1). Immunodepletion of XOrc1 from Xenopus egg extracts blocks the initiation of DNA replication. We have purified Xenopus ORC, consisting of a protein complex similar to yeast ORC. In Xenopus egg extracts, ORC associates with chromatin throughout G1 and S phases. RLF-M, a component of the replication licensing system, also associates with chromatin early in the cell cycle but dissociates during S phase. We show that the assembly of RLF-M onto chromatin is dependent on the presence of chromatin-bound ORC, leading to sequential assembly of initiation proteins onto replication origins during the cell cycle.	IMPERIAL CANC RES FUND, LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND	Cancer Research UK	Rowles, A (corresponding author), IMPERIAL CANC RES FUND, CLARE HALL LABS, S MIMMS EN6 3LD, HERTS, ENGLAND.		Chong, James/AAC-4957-2019; Blow, J. Julian/B-3977-2009	Blow, J. Julian/0000-0002-9524-5849; Chong, James/0000-0001-9447-7421; Howell, Michael/0000-0003-0912-0079				BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BLOW JJ, 1990, J CELL SCI, V95, P383; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BLOW JJ, 1993, J CELL BIOL, V122, P993, DOI 10.1083/jcb.122.5.993; BLOW JJ, 1987, EMBO J, V6, P1997, DOI 10.1002/j.1460-2075.1987.tb02463.x; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; CHEN YR, 1992, P NATL ACAD SCI USA, V89, P10459, DOI 10.1073/pnas.89.21.10459; CHEVALIER S, 1995, J CELL SCI, V108, P1831; Chong JPJ, 1996, TRENDS BIOCHEM SCI, V21, P102, DOI 10.1016/0968-0004(96)10013-X; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; CHOU J, 1994, P NATL ACAD SCI USA, V91, P5247, DOI 10.1073/pnas.91.12.5247; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DOLAN A, 1992, J GEN VIROL, V73, P971, DOI 10.1099/0022-1317-73-4-971; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; GIBSON SI, 1990, MOL CELL BIOL, V10, P5707, DOI 10.1128/MCB.10.11.5707; GOSSEN M, 1995, SCIENCE, V270, P1674, DOI 10.1126/science.270.5242.1674; HARLAND RM, 1980, CELL, V21, P761, DOI 10.1016/0092-8674(80)90439-0; Harlow E, 1988, ANTIBODIES LAB MANUA; HYRIEN O, 1995, SCIENCE, V270, P994, DOI 10.1126/science.270.5238.994; HYRIEN O, 1992, NUCLEIC ACIDS RES, V20, P1463, DOI 10.1093/nar/20.7.1463; HYRIEN O, 1993, EMBO J, V12, P4511, DOI 10.1002/j.1460-2075.1993.tb06140.x; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; KUBOTA Y, 1993, J CELL BIOL, V123, P1321, DOI 10.1083/jcb.123.6.1321; LASKEY RA, 1993, PHILOS T ROY SOC B, V339, P263, DOI 10.1098/rstb.1993.0024; Leatherwood J, 1996, NATURE, V379, P360, DOI 10.1038/379360a0; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MADINE MA, 1995, CURR BIOL, V5, P1270, DOI 10.1016/S0960-9822(95)00253-3; MAHBUBANI HM, 1992, NUCLEIC ACIDS RES, V20, P1457, DOI 10.1093/nar/20.7.1457; MAINE GT, 1984, GENETICS, V106, P365; MAITI AK, 1992, J MOL BIOL, V224, P545, DOI 10.1016/0022-2836(92)90543-S; MECHALI M, 1984, CELL, V38, P55, DOI 10.1016/0092-8674(84)90526-9; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; MuziFalconi M, 1995, P NATL ACAD SCI USA, V92, P12475, DOI 10.1073/pnas.92.26.12475; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; PHILPOTT A, 1991, CELL, V65, P569, DOI 10.1016/0092-8674(91)90089-H; ROWLEY A, 1994, BBA-GENE STRUCT EXPR, V1217, P239, DOI 10.1016/0167-4781(94)90283-6; Sambrook JFE, 1989, MOL CLONING LAB MANU; SINHA P, 1986, J MOL BIOL, V192, P805, DOI 10.1016/0022-2836(86)90030-6; Strausfeld UP, 1996, J CELL SCI, V109, P1555; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Takahara K, 1996, GENOMICS, V31, P119, DOI 10.1006/geno.1996.0018; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; YAN H, 1991, GENE DEV, V5, P944, DOI 10.1101/gad.5.6.944; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149	60	222	225	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 18	1996	87	2					287	296		10.1016/S0092-8674(00)81346-X	http://dx.doi.org/10.1016/S0092-8674(00)81346-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VN403	8861912	Bronze			2022-12-24	WOS:A1996VN40300016
J	Kamada, K; Horiuchi, T; Ohsumi, K; Shimamoto, N; Morikawa, K				Kamada, K; Horiuchi, T; Ohsumi, K; Shimamoto, N; Morikawa, K			Structure of a replication-terminator protein complexed with DNA	NATURE			English	Article							RIBOSOMAL-RNA GENES; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; CRYSTAL-STRUCTURE; ANTIGEN HELICASE; BINDING-PROTEIN; FORK MOVEMENT; SEQUENCE; INVITRO; IDENTIFICATION	The crystal structure of the Escherichia coli replication-terminator protein (Tus) bound to terminus-site (Ter) DNA has been determined at 2.7 Angstrom resolution. The Tus protein folds into a previously undescribed architecture divided into two domains by a central basic cleft. This cleft accommodates locally deformed B-form Ter DNA and makes extensive contacts with the major groove, mainly through two interdomain beta-strands. The unusual structural features of this complex may explain how the replication fork is halted in only one direction.	PROT ENGN RES INST,BIOMOL ENGN RES INST,SUITA,OSAKA 565,JAPAN; NATL INST GENET,MISHIMA,SHIZUOKA 411,JAPAN; GRAD UNIV ADV STUDIES,DEPT MOL BIOMECH,OKAZAKI,AICHI 444,JAPAN; NATL INST BASIC BIOL,OKAZAKI,AICHI 444,JAPAN; GRAD UNIV ADV STUDIES,DEPT GENET,MISHIMA,SHIZUOKA 411,JAPAN	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Graduate University for Advanced Studies - Japan; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Graduate University for Advanced Studies - Japan			Shimamoto, Nobuo/AAJ-4999-2020; Kamada, Katsuhiko/M-3666-2017	Shimamoto, Nobuo/0000-0001-7579-0084; Kamada, Katsuhiko/0000-0001-8523-3417				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BABCOCK MS, 1993, J BIOMOL STRUCT DYN, V11, P597, DOI 10.1080/07391102.1993.10508018; BAKER TA, 1995, CELL, V80, P521, DOI 10.1016/0092-8674(95)90504-9; BEDROSIAN CL, 1991, P NATL ACAD SCI USA, V88, P2618, DOI 10.1073/pnas.88.7.2618; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BUSSIERE DE, 1995, CELL, V80, P651; DUGGAN LJ, 1995, J BIOL CHEM, V270, P28049; FRANKS AH, 1995, MOL MICROBIOL, V17, P13, DOI 10.1111/j.1365-2958.1995.mmi_17010013.x; GOTTLIEB PA, 1992, J BIOL CHEM, V267, P7434; HERNANDEZ P, 1988, EMBO J, V7, P303, DOI 10.1002/j.1460-2075.1988.tb02813.x; HIASA H, 1992, J BIOL CHEM, V267, P11379; HIDAKA M, 1992, J BIOL CHEM, V267, P5361; HILL TM, 1992, ANNU REV MICROBIOL, V46, P603, DOI 10.1146/annurev.micro.46.1.603; HORIUCHI T, 1995, J BACTERIOL, V177, P783, DOI 10.1128/jb.177.3.783-791.1995; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kamada K, 1996, PROTEINS, V24, P402; KAUL S, 1994, P NATL ACAD SCI USA, V91, P11143, DOI 10.1073/pnas.91.23.11143; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; LEE EH, 1992, J BIOL CHEM, V267, P8778; LEE EH, 1989, P NATL ACAD SCI USA, V86, P9104, DOI 10.1073/pnas.86.23.9104; LITTLE RD, 1993, MOL CELL BIOL, V13, P6600, DOI 10.1128/MCB.13.10.6600; MARUYAMA M, 1983, J MOL BIOL, V167, P757, DOI 10.1016/S0022-2836(83)80109-0; NATARAJAN S, 1993, CELL, V72, P113, DOI 10.1016/0092-8674(93)90055-U; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; OLIS DL, 1985, NATURE, V313, P762; OTWINOWSKI Z, 1994, MACEDENZO MANUAL; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; SAKABE N, 1983, J APPL CRYSTALLOGR, V16, P542, DOI 10.1107/S0021889883010973; SISTA PR, 1991, GENE DEV, V5, P74, DOI 10.1101/gad.5.1.74; SKOLKOTAS A, 1994, J BIOL CHEM, V269, P20446; SKOLKOTAS A, 1995, J BIOL CHEM, V270, P30941; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; SWINDELLS MB, 1995, TRENDS BIOCHEM SCI, V20, P300, DOI 10.1016/S0968-0004(00)89055-6; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999; WEISS AS, 1984, J MOL BIOL, V179, P745, DOI 10.1016/0022-2836(84)90165-7; WIESENDANGER B, 1994, NUCLEIC ACIDS RES, V22, P5038, DOI 10.1093/nar/22.23.5038; YOUNG PA, 1994, J MOL BIOL, V240, P275, DOI 10.1006/jmbi.1994.1444	41	92	96	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1996	383	6601					598	603		10.1038/383598a0	http://dx.doi.org/10.1038/383598a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM755	8857533				2022-12-24	WOS:A1996VM75500045
J	Doyle, L				Doyle, L			Antenatal phenobarbitone and neonatal outcome	LANCET			English	Editorial Material											Doyle, L (corresponding author), ROYAL HOSP WOMEN,DEPT OBSTET & GYNAECOL,CARLTON,VIC 3053,AUSTRALIA.		Doyle, Lex/AAJ-5205-2021	Doyle, Lex/0000-0002-7667-7312				Horbar Jeffrey D., 1992, P562; MENT LR, 1994, PEDIATRICS, V93, P543; NELSON KB, 1995, PEDIATRICS, V95, P263; Shankaran S, 1996, PEDIATRICS, V97, P644; Shankaran S, 1996, PEDIATRICS, V97, P649; Shankaran Seetha, 1996, Pediatric Research, V39, p245A	6	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 12	1996	348	9033					975	976		10.1016/S0140-6736(05)64922-7	http://dx.doi.org/10.1016/S0140-6736(05)64922-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM027	8855850				2022-12-24	WOS:A1996VM02700006
J	Kelsey, MC; Kouloumas, GA; Lamport, PA; Davis, CL				Kelsey, MC; Kouloumas, GA; Lamport, PA; Davis, CL			Relation between general practitioners' prescribing of antibacterial drugs and their use of laboratory tests	BRITISH MEDICAL JOURNAL			English	Article									CAMDEN & ISLINGTON FAMILY HLTH SERV AUTHOR,LONDON NW1 TLJ,ENGLAND		Kelsey, MC (corresponding author), WHITTINGTON HOSP,DEPT MICROBIOL,LONDON N19 5NF,ENGLAND.							BUYS H, 1994, BRIT MED J, V308, P690, DOI 10.1136/bmj.308.6930.690; *JONT FORM COMM, 1994, BRIT NAT FORM, V23; POWELL HR, 1987, ARCH DIS CHILD, V62, P138, DOI 10.1136/adc.62.2.138; ROBERTS SJ, 1993, BRIT MED J, V307, P485, DOI 10.1136/bmj.307.6902.485; 1991, J R COLL PHYSICIANS, V25, P36	5	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 12	1996	313	7062					922	922						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM754	8876098				2022-12-24	WOS:A1996VM75400030
J	Brazas, R; Ganem, D				Brazas, R; Ganem, D			A cellular homolog of hepatitis delta antigen: Implications for viral replication and evolution	SCIENCE			English	Article							VIRUS-RNA; SELF-CLEAVAGE; NONRADIOACTIVE NORTHERN; NUCLEAR TRANSPORT; LEUCINE ZIPPER; GENOME; SEQUENCES; BINDING; CLONING; COMPLEX	Hepatitis delta virus (HDV) is a pathogenic human virus whose RNA genome and replication cycle resemble those of plant viroids. However, viroid genomes contain no open reading frames, whereas HDV RNA encodes a single protein, hepatitis delta antigen (HDAg), which is required for viral replication. A cellular gene whose product interacts with HDAg has now been identified, and this interaction was found to affect viral genomic replication in intact cells. DNA sequence analysis revealed that this protein, termed delta-interacting protein A (DIPA), is a cellular homolog of HDAg. These observations demonstrate that a host gene product can modulate HDV replication and suggest that HDV may have evolved from a primitive viroidlike RNA through capture of a cellular transcript.	UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; APTE AN, 1993, BIOTECHNIQUES, V15, P890; AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, V2; BRANCH AD, 1989, SCIENCE, V243, P649, DOI 10.1126/science.2492676; BRANCH AD, 1984, SCIENCE, V223, P450, DOI 10.1126/science.6197756; CHANG MF, 1992, J VIROL, V66, P6019, DOI 10.1128/JVI.66.10.6019-6027.1992; CHAO M, 1991, J VIROL, V65, P4057, DOI 10.1128/JVI.65.8.4057-4062.1991; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN PJ, 1992, J VIROL, V66, P2853, DOI 10.1128/JVI.66.5.2853-2859.1992; CHEN PJ, 1986, P NATL ACAD SCI USA, V83, P8774, DOI 10.1073/pnas.83.22.8774; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DESHAZER D, 1994, BIOTECHNIQUES, V17, P288; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; ENGLERBLUM G, 1993, ANAL BIOCHEM, V210, P235, DOI 10.1006/abio.1993.1189; FORSTER AC, 1987, CELL, V50, P9, DOI 10.1016/0092-8674(87)90657-X; FU TB, 1993, J VIROL, V67, P6965, DOI 10.1128/JVI.67.12.6965-6972.1993; GLENN JS, 1990, J VIROL, V64, P3104, DOI 10.1128/JVI.64.6.3104-3107.1990; Harlow E, 1988, ANTIBODIES LAB MANUA; HARPER JW, 1993, CELL, V75, P805; HWANG SB, 1992, VIROLOGY, V190, P413, DOI 10.1016/0042-6822(92)91227-L; KOS A, 1986, NATURE, V323, P558, DOI 10.1038/323558a0; KUO MYP, 1988, J VIROL, V62, P4439, DOI 10.1128/JVI.62.12.4439-4444.1988; KUO MYP, 1989, J VIROL, V63, P1945, DOI 10.1128/JVI.63.5.1945-1950.1989; LAZINSKI DW, 1993, J VIROL, V67, P2672, DOI 10.1128/JVI.67.5.2672-2680.1993; LEE CZ, 1993, J VIROL, V67, P2221, DOI 10.1128/JVI.67.4.2221-2227.1993; LIN JH, 1990, J VIROL, V64, P4051, DOI 10.1128/JVI.64.9.4051-4058.1990; LOW R, 1994, BIOTECHNIQUES, V17, P1026; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; Lupas A, 1996, METHOD ENZYMOL, V266, P513; MACNAUGHTON TB, 1991, VIROLOGY, V184, P387, DOI 10.1016/0042-6822(91)90855-6; MAKINO S, 1987, NATURE, V329, P343, DOI 10.1038/329343a0; POLO JM, 1995, J VIROL, V69, P4880, DOI 10.1128/JVI.69.8.4880-4887.1995; PRODY GA, 1986, SCIENCE, V231, P1577, DOI 10.1126/science.231.4745.1577; RIZZETTO M, 1983, HEPATOLOGY, V3, P729; RIZZETTO M, 1980, P NATL ACAD SCI-BIOL, V77, P6124, DOI 10.1073/pnas.77.10.6124; SHARMEEN L, 1988, J VIROL, V62, P2674, DOI 10.1128/JVI.62.8.2674-2679.1988; SHARMEEN L, 1989, J VIROL, V63, P1428, DOI 10.1128/JVI.63.3.1428-1430.1989; Smedile A, 1994, Prog Liver Dis, V12, P157; SYMONS RH, 1990, SEMIN VIROL, V1, P75; WANG KS, 1986, NATURE, V323, P508, DOI 10.1038/323508a0; WINSHIP PR, 1989, NUCLEIC ACIDS RES, V17, P1266, DOI 10.1093/nar/17.3.1266; WU HN, 1990, MOL CELL BIOL, V10, P5575, DOI 10.1128/MCB.10.10.5575; WU HN, 1989, SCIENCE, V243, P652, DOI 10.1126/science.2492677; XIA YP, 1992, J VIROL, V66, P6641, DOI 10.1128/JVI.66.11.6641-6648.1992; XIA YP, 1992, J VIROL, V66, P914, DOI 10.1128/JVI.66.2.914-921.1992	45	102	109	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 4	1996	274	5284					90	94		10.1126/science.274.5284.90	http://dx.doi.org/10.1126/science.274.5284.90			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VK748	8810253				2022-12-24	WOS:A1996VK74800053
J	Hsiao, K; Chapman, P; Nilsen, S; Eckman, C; Harigaya, Y; Younkin, S; Yang, FS; Cole, G				Hsiao, K; Chapman, P; Nilsen, S; Eckman, C; Harigaya, Y; Younkin, S; Yang, FS; Cole, G			Correlative memory deficits, A beta elevation, and amyloid plaques in transgenic mice	SCIENCE			English	Article							PRECURSOR PROTEIN GENE; FAMILIAL ALZHEIMERS-DISEASE; SENILE PLAQUES; MUTATION; ANTIBODIES; TERMINUS; PEPTIDE; BRAIN	Transgenic mice overexpressing the 695-amino acid isoform of human Alzheimer beta-amyloid (A beta) precursor protein containing a Lys(670) --> Asn, Met(671)--> Leu mutation had normal learning and memory in spatial reference and alternation tasks at 3 months of age but showed impairment by 9 to 10 months of age. A fivefold increase in A beta(1-40) and a 14-fold increase in A beta(1-42/43) accompanied the appearance of these behavioral deficits, Numerous A beta plaques that stained with Congo red dye were present in cortical and limbic structures of mice with elevated amounts of A beta. The correlative appearance of behavioral, biochemical, and pathological abnormalities reminiscent of Alzheimer's disease in these transgenic mice suggests new opportunities for exploring the pathophysiology and neurobiology of this disease.	UNIV WALES COLL CARDIFF,PHYSIOL UNIT,CARDIFF CF1 3US,S GLAM,WALES; MAYO CLIN JACKSONVILLE,JACKSONVILLE,FL 32224; VET ADM MED CTR,GRECC,SEPULVEDA,CA 91343; UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 91343; UNIV CALIF LOS ANGELES,DEPT NEUROL,LOS ANGELES,CA 91343	Cardiff University; Mayo Clinic; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Hsiao, K (corresponding author), UNIV MINNESOTA,DEPT NEUROL,UMHC BOX 295,420 DELAWARE ST,MINNEAPOLIS,MN 55455, USA.				NIA NIH HHS [AG06656, AG9009] Funding Source: Medline; NINDS NIH HHS [NS33249] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033249] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG006656, R01AG009009] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; DOUGLAS RJ, 1990, SPONTANEOUS ALTERNAT, P73; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; HIGGINS LS, 1994, ANN NEUROL, V35, P598, DOI 10.1002/ana.410350514; HSIAO KK, 1995, NEURON, V15, P1203, DOI 10.1016/0896-6273(95)90107-8; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; Kim K., 1988, NEUROSCI RES COMMUN, V2, P121; KIM KS, 1990, NEUROSCI RES COMMUN, V7, P113; KOO EH, 1990, NEURON, V2, P97; MAK K, 1994, BRAIN RES, V667, P138, DOI 10.1016/0006-8993(94)91725-6; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; MORAN PM, 1995, P NATL ACAD SCI USA, V92, P5341, DOI 10.1073/pnas.92.12.5341; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; PUCHTLER H, 1962, J HISTOCHEM CYTOCHEM, V10, P355, DOI 10.1177/10.3.355; SAIDO TC, 1994, J BIOL CHEM, V269, P15253; SAIDO TC, 1995, NEURON, V14, P457, DOI 10.1016/0896-6273(95)90301-1; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SCOTT MR, 1992, PROTEIN SCI, V1, P986, DOI 10.1002/pro.5560010804; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; YANG FS, 1994, NEUROREPORT, V5, P2117, DOI 10.1097/00001756-199410270-00032	28	3546	3797	4	379	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1996	274	5284					99	102		10.1126/science.274.5284.99	http://dx.doi.org/10.1126/science.274.5284.99			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VK748	8810256				2022-12-24	WOS:A1996VK74800056
J	Rep, M; vanDijl, JM; Suda, K; Schatz, G; Grivell, LA; Suzuki, CK				Rep, M; vanDijl, JM; Suda, K; Schatz, G; Grivell, LA; Suzuki, CK			Promotion of mitochondrial membrane complex assembly by a proteolytically inactive yeast Lon	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; PUTATIVE ATPASES; PROTEIN FAMILY; GENE; MEMBER; ENCODES; CHAPERONE; SEQUENCE; BINDING; OXIDASE	Afg3p and Rca1p are adenosine triphosphate (ATP)-dependent metalloproteases in yeast mitochondria. Cells lacking both proteins exhibit defects in respiration-dependent growth, degradation of mitochondrially synthesized proteins, and assembly of inner-membrane complexes. Defects in growth and protein assembly, but not in degradation, were suppressed by overproduction of yeast mitochondrial Lon, an ATP-dependent serine protease. Suppression by Lon was enhanced by inactivation of the proteolytic site and was prevented by mutation of the ATP-binding site. It is suggested that the mitochondrial proteases Lon, Afg3p, and Rca1p can also serve a chaperone-like function in the assembly of mitochondrial protein complexes.	UNIV BASEL,BIOZENTRUM,BIOCHEM ABT,CH-4056 BASEL,SWITZERLAND; UNIV AMSTERDAM,DEPT MOL CELL BIOL,MOL BIOL SECT,NL-1098 SM AMSTERDAM,NETHERLANDS	University of Basel; University of Amsterdam			van Dijl, Jan Maarten/G-1205-2013	Rep, Martijn/0000-0003-3608-6283				Altamura N, 1996, FEBS LETT, V382, P111, DOI 10.1016/0014-5793(96)00165-2; AMERIK AY, 1991, FEBS LETT, V287, P211, DOI 10.1016/0014-5793(91)80053-6; BONNEFOY N, 1994, J MOL BIOL, V239, P201, DOI 10.1006/jmbi.1994.1363; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; CRAIG EA, 1989, MOL CELL BIOL, V9, P3000, DOI 10.1128/MCB.9.7.3000; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Guelin E, 1996, FEBS LETT, V381, P42, DOI 10.1016/0014-5793(96)00074-9; GUELIN E, 1994, YEAST, V10, P1389, DOI 10.1002/yea.320101016; Langer T, 1995, METHOD ENZYMOL, V260, P495, DOI 10.1016/0076-6879(95)60161-9; LEONHARDT SA, 1993, MOL CELL BIOL, V13, P6304, DOI 10.1128/MCB.13.10.6304; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; MASON TL, 1973, J BIOL CHEM, V248, P1346; PAJIC A, 1994, FEBS LETT, V353, P201, DOI 10.1016/0014-5793(94)01046-3; PAUL MF, 1995, FEBS LETT, V373, P66, DOI 10.1016/0014-5793(95)00979-J; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; Rep M, 1996, FEBS LETT, V388, P185, DOI 10.1016/0014-5793(96)00543-1; Rep M, 1996, CURR GENET, V30, P206, DOI 10.1007/s002940050122; ROSPERT S, 1993, FEBS LETT, V335, P358, DOI 10.1016/0014-5793(93)80419-U; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SCHNALL R, 1994, YEAST, V10, P1141, DOI 10.1002/yea.320100903; SUZUKI CK, 1994, SCIENCE, V264, P891, DOI 10.1126/science.8178144; SUZUKI CK, 1994, SCIENCE, V264, P273, DOI 10.1126/science.8146662; TAUER R, 1994, FEBS LETT, V353, P197, DOI 10.1016/0014-5793(94)01045-5; TOMOYASU T, 1993, J BACTERIOL, V175, P1344, DOI 10.1128/JB.175.5.1344-1351.1993; TZAGOLOFF A, 1994, J BIOL CHEM, V269, P26144; VANDYCK L, 1994, J BIOL CHEM, V269, P238; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218	30	135	138	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1996	274	5284					103	106		10.1126/science.274.5284.103	http://dx.doi.org/10.1126/science.274.5284.103			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VK748	8810243	Green Submitted			2022-12-24	WOS:A1996VK74800057
J	Zerr, I; Bodemer, M; Otto, A; Poser, S; Windl, O; Kretzschmar, HA; Gefeller, O; Weber, T				Zerr, I; Bodemer, M; Otto, A; Poser, S; Windl, O; Kretzschmar, HA; Gefeller, O; Weber, T			Diagnosis of Creutzfeldt-Jakob disease by two-dimensional gel electrophoresis of cerebrospinal fluid	LANCET			English	Article							NEURON-SPECIFIC ENOLASE; EARLY STAGE; PROTEINS	Background The diagnosis of Creutzfeldt-Jakob disease (CJD) is based on clinical and electroencephalographic criteria which do not allow a reliable diagnosis to be made during life. Methods Serum and cerebrospinal fluid (CSF) samples were obtained after informed consent from relatives of suspected cases of CJD referred to the German CJD surveillance unit. CSF samples from 58 definite (neuropathologically verified), 46 probable, and 34 possible CJD cases, and from 44 patients without CJD were analysed by two-dimensional gel electrophoresis (2-DE). Two investigators blinded to clinical findings recorded the presence of two proteins, p130/131. The kappa value for the level of agreement between these investigators was calculated. Results obtained were compared with the determination of neuron-specific enolase (NSE) in CSF. NSE concentrations of more than 35 ng/mL were considered indicative of CJD. Findings p130/131 was detected in 81% of definite (47/58), 80% of probable (37/46), 68% of possible (23/34) CJD cases, and in none of the other 44 cases, NSE concentrations of more than 35 ng/mL were seen in 79% of definite (46/58), 80% of probable (37/46), 59% of possible (20/34) CJD cases, and 9% of other cases (4/43). The positive predictive value for 2-DE of CSF is 100% and the negative predictive value is 69%. The level of agreement for the detection of p130/131 by two evaluators in a subset of 141 2-DE gels was a kappa of 0.93 (95% Cl 0.86-0.99). Of 13 cases initially classified as possible and later reclassified as definite, ten cases were identified correctly by the 2-DE analysis, indicating a better diagnostic accuracy of this test compared with the current clinical classification. None of nine cases classified as other by neuropathology had p130/131 in 2-DE. Interpretation 2-DE for p130/131 is a specific test for the diagnosis of CJD. These data suggest including detection of p130/131 as a criterion for the diagnosis of probable CJD in addition to the currently accepted criteria of a rapidly progressive dementia of less than 2 years duration, typical neurological signs, and periodic sharp-wave complexes in the EEG.	MARIEN HOSP,NEUROL KLIN,D-22087 HAMBURG,GERMANY; UNIV GOTTINGEN,NEUROL KLIN & POLIKLIN,D-3400 GOTTINGEN,GERMANY; UNIV GOTTINGEN,INST NEUROPATHOL,D-3400 GOTTINGEN,GERMANY; UNIV GOTTINGEN,ABT MED STAT,D-3400 GOTTINGEN,GERMANY	St. Marien Hospital; University of Gottingen; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Gottingen; University of Gottingen			Otto, Markus/F-4304-2015; Gefeller, Olaf/W-9604-2019; Windl, Otto/C-6760-2011	Otto, Markus/0000-0003-4273-4267; Gefeller, Olaf/0000-0002-8985-7582; Weber, Thomas/0000-0002-3833-6197				ALPEROVITCH A, 1994, LANCET, V343, P918, DOI 10.1016/S0140-6736(94)90037-X; BLISARD KS, 1990, J NEUROL SCI, V99, P75, DOI 10.1016/0022-510X(90)90201-W; BLYTH CR, 1983, J AM STAT ASSOC, V78, P108, DOI 10.2307/2287116; BROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504; BUDKA H, 1995, BRAIN PATHOL, V5, P319, DOI 10.1111/j.1750-3639.1995.tb00609.x; Chazot G, 1996, LANCET, V347, P1181, DOI 10.1016/S0140-6736(96)90638-8; ESMONDE TFG, 1992, ANN NEUROL, V31, P230, DOI 10.1002/ana.410310218; Finkenstaedt M, 1996, RADIOLOGY, V199, P793, DOI 10.1148/radiology.199.3.8638007; HARRINGTON MG, 1986, NEW ENGL J MED, V315, P279, DOI 10.1056/NEJM198607313150502; HAYASHI R, 1992, ACTA NEUROL SCAND, V85, P161; Hsich G, 1996, NEW ENGL J MED, V335, P924, DOI 10.1056/NEJM199609263351303; JIMI T, 1992, CLIN CHIM ACTA, V211, P37, DOI 10.1016/0009-8981(92)90103-W; KOVANEN J, 1985, J COMPUT ASSIST TOMO, V9, P125, DOI 10.1097/00004728-198501000-00023; KRETZSCHMAR HA, 1996, IN PRESS ARCH NEUROL, V53; LEE LKH, 1996, LANCET, V348, P887; LEVY SR, 1986, J CLIN NEUROPHYSIOL, V3, P1, DOI 10.1097/00004691-198601000-00001; MASTERS CL, 1979, ANN NEUROL, V5, P177, DOI 10.1002/ana.410050212; MASULLO C, 1988, EUR J EPIDEMIOL, V4, P482, DOI 10.1007/BF00146403; MOKUNO K, 1983, J NEUROL SCI, V60, P443, DOI 10.1016/0022-510X(83)90155-7; PERRY RT, 1995, AM J MED GENET, V60, P12, DOI 10.1002/ajmg.1320600104; Steinhoff BJ, 1996, ARCH NEUROL-CHICAGO, V53, P162, DOI 10.1001/archneur.1996.00550020074017; TARTARO A, 1993, EUR J RADIOL, V17, P155, DOI 10.1016/0720-048X(93)90095-5; WAKAYAMA Y, 1987, KLIN WOCHENSCHR, V65, P798, DOI 10.1007/BF01743256; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; Windl O, 1996, HUM GENET, V98, P259, DOI 10.1007/s004390050204; YAMAMOTO K, 1992, ANN NEUROL, V32, P114, DOI 10.1002/ana.410320124; ZERR I, 1995, LANCET, V345, P1609, DOI 10.1016/S0140-6736(95)90118-3	27	92	96	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 28	1996	348	9031					846	849		10.1016/S0140-6736(96)08077-4	http://dx.doi.org/10.1016/S0140-6736(96)08077-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK037	8826809				2022-12-24	WOS:A1996VK03700009
J	Foulkes, WD; Brunet, JS; Sieh, W; Black, MJ; Shenouda, G; Narod, SA				Foulkes, WD; Brunet, JS; Sieh, W; Black, MJ; Shenouda, G; Narod, SA			Familial risks of squamous cell carcinoma of the head and neck: Retrospective case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							UPPER AERODIGESTIVE TRACT; 2ND PRIMARY TUMORS; LUNG-CANCER RISK; MUTAGEN SENSITIVITY; PHARYNGEAL CANCER; ESOPHAGEAL CANCER; MAJOR CANCERS; ORAL-CANCER; HISTORY; SMOKING	Objective-To determine the contribution of inheritance to the incidence of squamous cell carcinoma of the head and neck. Design-Historical cohort study. First degree relatives of cases with squamous cell carcinoma of the head and neck made up the exposed cohort and first degree relatives of spouses of cases made up the comparison unexposed cohort. Setting-Ear, nose, and throat clinic in a large metropolitan teaching hospital. Subjects-1429 first degree relatives of 242 index cases of squamous cell carcinoma of the head and neck; as controls, 934 first degree relatives of the spouses of 156 index cases. Main outcome measures-Relative risk of developing squamous cell carcinoma in first degree relatives of cases compared with risk in first degree relatives of spouses. Results-The adjusted relative risk for developing head and neck cancer if the index case had squamous cell carcinoma of the head and neck was 3.79 (95% confidence interval 1.11 to 13.0). There were no significantly increased risks associated with a family history of cancer at other sites. The adjusted relative risk for squamous cell carcinoma of the head and neck was 7.89 (1.50 to 41.6) in first degree relatives of patients with multiple primary head and neck tumours. Conclusions-These data suggest that genetic factors are important in the aetiology of head and neck cancer, in particular for patients with multiple primary cancers. Given the prolonged exposure of these subjects to carcinogens, these genetic factors may have a role in modifying carcinogen activity or in host resistance to carcinogens. Inherited factors may be important in persons with environmentally induced cancers.	MCGILL UNIV, SIR MORTIMER B DAVIS JEWISH GEN HOSP, MONTREAL, PQ H3T 1E2, CANADA	McGill University	Foulkes, WD (corresponding author), MCGILL UNIV, MONTREAL GEN HOSP,DEPT MED,DIV MED GENET, ROOM L10-116, 1650 CEDAR AVE, MONTREAL, PQ H3G 1A4, CANADA.		Foulkes, William D./AAR-9586-2021; Narod, Steven A/AAA-6112-2022	Foulkes, William D./0000-0001-7427-4651; 				AITKEN J, 1995, AM J EPIDEMIOL, V141, P863, DOI 10.1093/oxfordjournals.aje.a117522; BLOT WJ, 1988, CANCER RES, V48, P3282; BONDY ML, 1993, CANCER EPIDEM BIOMAR, V2, P103; BRAUN MM, 1994, LANCET, V344, P440, DOI 10.1016/S0140-6736(94)91770-1; Califano J, 1996, CANCER RES, V56, P2488; COPPER MP, 1995, ARCH OTOLARYNGOL, V121, P157; DAY GL, 1993, JNCI-J NATL CANCER I, V85, P465, DOI 10.1093/jnci/85.6.465; DAY GL, 1992, CANCER, V70, P14, DOI 10.1002/1097-0142(19920701)70:1<14::AID-CNCR2820700103>3.0.CO;2-S; ELWOOD JM, 1984, INT J CANCER, V34, P603, DOI 10.1002/ijc.2910340504; Foulkes WD, 1995, INT J CANCER, V63, P769, DOI 10.1002/ijc.2910630603; FRANCO EL, 1989, INT J CANCER, V43, P992, DOI 10.1002/ijc.2910430607; GHADIRIAN P, 1985, CANCER-AM CANCER SOC, V56, P2112, DOI 10.1002/1097-0142(19851015)56:8<2112::AID-CNCR2820560838>3.0.CO;2-3; GOLDGAR DE, 1994, J NATL CANCER I, V86, P1600, DOI 10.1093/jnci/86.21.1600; HERRMANN N, 1985, AM J EPIDEMIOL, V121, P937, DOI 10.1093/oxfordjournals.aje.a114064; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; LI JY, 1989, INT J CANCER, V43, P755, DOI 10.1002/ijc.2910430502; LONDON SJ, 1995, J NATL CANCER I, V87, P1246, DOI 10.1093/jnci/87.16.1246; LOVE RR, 1985, J CHRON DIS, V38, P289, DOI 10.1016/0021-9681(85)90074-8; MCLAUGHLIN JK, 1987, AM J EPIDEMIOL, V126, P144, DOI 10.1093/oxfordjournals.aje.a114647; MORITA M, 1994, INT J CANCER, V58, P207, DOI 10.1002/ijc.2910580211; OOI WL, 1986, J NATL CANCER I, V76, P217; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; PINTOS J, 1994, EPIDEMIOLOGY, V5, P583, DOI 10.1097/00001648-199411000-00005; SAMET JM, 1986, AM REV RESPIR DIS, V134, P466; SAS, 1988, SAS STAT US GUID REL; SELLERS TA, 1987, AM J EPIDEMIOL, V126, P237, DOI 10.1093/aje/126.2.237; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; SPITZ MR, 1994, J NATL CANCER I, V86, P1681, DOI 10.1093/jnci/86.22.1681; *STAT CAN, 1990 CANC CAN, P28; TOKUHATA GEORGE K., 1963, JOUR NATL CANCER INST, V30, P289; TRIZNA Z, 1992, OTOLARYNG CLIN N AM, V25, P1089; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; Wu AH, 1996, AM J EPIDEMIOL, V143, P535; WYNDER EL, 1957, CANCER, V10, P1300, DOI 10.1002/1097-0142(195711/12)10:6&lt;1300::AID-CNCR2820100628&gt;3.0.CO;2-2; WYNDER EL, 1977, CANCER RES, V37, P4608	37	105	105	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 21	1996	313	7059					716	721						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VJ441	8819440	Green Published			2022-12-24	WOS:A1996VJ44100021
J	Mitchell, DN				Mitchell, DN			Mycobacteria and sarcoidosis	LANCET			English	Editorial Material							CROHNS-DISEASE				Mitchell, DN (corresponding author), ROYAL BROMPTON HOSP,LONDON SW3 6NP,ENGLAND.							Almenoff PL, 1996, THORAX, V51, P530, DOI 10.1136/thx.51.5.530; BURNET FM, 1959, CLONAL SELECTION THE, P160; Graham D, 1988, SARCOIDOSIS OTHER GR, P161; GRONHAGENRISKA C, 1983, LANCET, V1, P1287; MANGIAPAN G, 1995, SARCOIDOSIS, V12, P20; MITCHELL DN, 1983, 9TH INT C SARC OTH G, P132; Moscovic E A, 1978, Pathol Annu, V13 Pt 2, P69; MOSS MT, 1992, GUT, V33, P1209, DOI 10.1136/gut.33.9.1209; RIOZ MP, 1995, J CLIN MICROBIOL, V3, P1389; SCADDING JG, 1971, 5TH INT C SARC PRAG, P89; Taub R N, 1974, Trans Assoc Am Physicians, V87, P219	11	24	24	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 21	1996	348	9030					768	769		10.1016/S0140-6736(05)65205-1	http://dx.doi.org/10.1016/S0140-6736(05)65205-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH989	8813979				2022-12-24	WOS:A1996VH98900005
J	Gaillard, PHL; Martini, EMD; Kaufman, PD; Stillman, B; Moustacchi, E; Almouzni, G				Gaillard, PHL; Martini, EMD; Kaufman, PD; Stillman, B; Moustacchi, E; Almouzni, G			Chromatin assembly coupled to DNA repair: A new role for chromatin assembly factor I	CELL			English	Article							NUCLEOTIDE EXCISION-REPAIR; XENOPUS-LAEVIS OOCYTES; HUMAN CELL-EXTRACTS; SIMIAN VIRUS-40 DNA; REPLICATION INVITRO; FREE SYSTEM; DROSOPHILA EMBRYOS; HISTONE COMPLEXES; BINDING-PROTEIN; TRANSCRIPTION	DNA repair in the eukaryotic cell disrupts local chromatin organization. To investigate whether the resetting of nucleosomal arrays can be linked to the repair process, we developed model systems, with both Xenopus egg extract and human cell extracts, to follow repair and chromatin assembly in parallel on circular DNA templates. Both systems were able to carry out nucleotide excision repair of DNA lesions. We observed that UV-dependent DNA synthesis occurs simultaneously with chromatin assembly, strongly indicating a mechanistic coupling between the two processes. A complementation assay established that chromatin assembly factor I (CAF1) is necessary for this repair-associated chromatin formation.	INST CURIE,RES SECT,UMR218 CNRS,F-75231 PARIS 05,FRANCE; INST CURIE,RES SECT,LRC 1 CEA,F-75231 PARIS 05,FRANCE; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CEA; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Cold Spring Harbor Laboratory	Gaillard, PHL (corresponding author), INST CURIE,RES SECT,UMR144 CNRS,26 RUE ULM,F-75231 PARIS 05,FRANCE.		gaillard, pierre-henri/AAC-6004-2020; Almouzni, Genevieve/ABG-1029-2021	gaillard, pierre-henri/0000-0003-0781-0826; Almouzni, Genevieve/0000-0001-5570-0723; Stillman, Bruce/0000-0002-9453-4091; Kaufman, Paul/0000-0003-3089-313X				ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; ALMOUZNI G, 1988, EMBO J, V7, P665, DOI 10.1002/j.1460-2075.1988.tb02861.x; ALMOUZNI G, 1993, EXP CELL RES, V205, P1, DOI 10.1006/excr.1993.1051; ALMOUZNI G, 1988, EMBO J, V7, P4355, DOI 10.1002/j.1460-2075.1988.tb03334.x; ALMOUZNI G, 1993, GENE DEV, V7, P2033, DOI 10.1101/gad.7.10.2033; ALMOUZNI G, 1991, MOL CELL BIOL, V11, P655, DOI 10.1128/MCB.11.2.655; BANERJEE S, 1990, MOL CELL BIOL, V10, P2863, DOI 10.1128/MCB.10.6.2863; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; BECKER PB, 1994, BIOESSAYS, V16, P541, DOI 10.1002/bies.950160807; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULGER M, 1995, P NATL ACAD SCI USA, V92, P11726, DOI 10.1073/pnas.92.25.11726; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; FRIEDBERG EC, 1995, DNA REPAIR; GERMOND JE, 1979, P NATL ACAD SCI USA, V76, P3779, DOI 10.1073/pnas.76.8.3779; GLIKIN GC, 1984, CELL, V37, P33, DOI 10.1016/0092-8674(84)90298-8; GRUSS C, 1990, EMBO J, V9, P2911, DOI 10.1002/j.1460-2075.1990.tb07482.x; GRUSS C, 1993, EMBO J, V12, P4533, DOI 10.1002/j.1460-2075.1993.tb06142.x; GURDON JB, 1986, METHOD CELL BIOL, V15, P270; ISHIMI Y, 1984, EUR J BIOCHEM, V142, P431, DOI 10.1111/j.1432-1033.1984.tb08305.x; ISHIMI Y, 1991, J BIOL CHEM, V266, P7025; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; Kamakaka RT, 1996, MOL CELL BIOL, V16, P810; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; KLEINSCHMIDT JA, 1990, EMBO J, V9, P1309, DOI 10.1002/j.1460-2075.1990.tb08240.x; KLEINSCHMIDT JA, 1985, J BIOL CHEM, V260, P1166; KORNBERG RD, 1995, CURR OPIN CELL BIOL, V7, P371, DOI 10.1016/0955-0674(95)80092-1; KORNBERG RD, 1992, ANNU REV CELL BIOL, V8, P563, DOI 10.1146/annurev.cellbio.8.1.563; KRUDE T, 1995, EXP CELL RES, V220, P304, DOI 10.1006/excr.1995.1320; KRUDE T, 1995, CURR BIOL, V5, P1232, DOI 10.1016/S0960-9822(95)00245-4; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; LASKEY RA, 1977, CELL, V10, P237, DOI 10.1016/0092-8674(77)90217-3; LASKEY RA, 1993, PHILOS T ROY SOC B, V339, P263, DOI 10.1098/rstb.1993.0024; LEGERSKI RJ, 1987, MOL CELL BIOL, V7, P4317, DOI 10.1128/MCB.7.12.4317; LI JJ, 1985, MOL CELL BIOL, V5, P12038; MATSUMOTO H, 1995, PHOTOCHEM PHOTOBIOL, V61, P459, DOI 10.1111/j.1751-1097.1995.tb02345.x; Moggs JG, 1996, J BIOL CHEM, V271, P7177, DOI 10.1074/jbc.271.12.7177; NELSON T, 1979, P NATL ACAD SCI USA, V76, P5510, DOI 10.1073/pnas.76.11.5510; NELSON T, 1981, BIOCHEMISTRY-US, V20, P2594, DOI 10.1021/bi00512a035; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, pU3559; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; RYOJI M, 1989, NUCLEIC ACIDS RES, V17, P10243, DOI 10.1093/nar/17.24.10243; SAXENA JK, 1990, NUCLEIC ACIDS RES, V18, P7425, DOI 10.1093/nar/18.24.7425; SEALY L, 1986, BIOCHEMISTRY-US, V25, P3064, DOI 10.1021/bi00358a049; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SMERDON M, 1992, DNA REPAIR MECH THEI; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; SMITH S, 1991, J BIOL CHEM, V266, P12041; SOGO JM, 1986, J MOL BIOL, V189, P189, DOI 10.1016/0022-2836(86)90390-6; STILLMAN B, 1986, CELL, V45, P555, DOI 10.1016/0092-8674(86)90287-4; SUGASAWA K, 1993, J BIOL CHEM, V268, P9098; SVOBODA DL, 1993, J BIOL CHEM, V268, P1931; SZYMKOWSKI DE, 1992, P NATL ACAD SCI USA, V89, P10772, DOI 10.1073/pnas.89.22.10772; TRAVERS AA, 1994, BIOESSAYS, V16, P657, DOI 10.1002/bies.950160911; TURNER BM, 1995, BIOESSAYS, V17, P1013, DOI 10.1002/bies.950171204; WANG ZG, 1991, J BIOL CHEM, V266, P22472; WEINBERG DH, 1989, P NATL ACAD SCI USA, V86, P9742, DOI 10.1073/pnas.86.24.9742; WOLFFE AP, 1994, CURR OPIN GENET DEV, V4, P245, DOI 10.1016/S0959-437X(05)80051-6; WOLFFE AP, 1994, DEV GENET, V15, P463, DOI 10.1002/dvg.1020150604; WOOD RD, 1993, COLD SPRING HARB SYM, V58, P625, DOI 10.1101/SQB.1993.058.01.069; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; Wood Richard D., 1995, Methods (Orlando), V7, P163, DOI 10.1006/meth.1995.1022	64	275	281	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1996	86	6					887	896		10.1016/S0092-8674(00)80164-6	http://dx.doi.org/10.1016/S0092-8674(00)80164-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VJ443	8808624	Bronze			2022-12-24	WOS:A1996VJ44300007
J	Liang, R; Yan, L; Loebach, J; Ge, M; Uozumi, Y; Sekanina, K; Horan, N; Gildersleeve, J; Thompson, C; Smith, A; Biswas, K; Still, WC; Kahne, D				Liang, R; Yan, L; Loebach, J; Ge, M; Uozumi, Y; Sekanina, K; Horan, N; Gildersleeve, J; Thompson, C; Smith, A; Biswas, K; Still, WC; Kahne, D			Parallel synthesis and screening of a solid phase carbohydrate library	SCIENCE			English	Article							SUPPORTED SOLUTION SYNTHESIS; INFLUENZA-VIRUS; CHEMICAL LIBRARIES; DRUG DISCOVERY; GENERAL-METHOD; OLIGOSACCHARIDES; GLYCOSYLATION; AGGLUTINATION; ERYTHROCYTES; RECOGNITION	A solid phase carbohydrate library was synthesized and screened against Bauhinia purpurea lectin. The library, which contains approximately 1300 di- and trisaccharides, was synthesized with chemical encoding on TentaGel resin so that each bead contained a single carbohydrate. Two ligands that bind more tightly to the lectin than Gal-beta-1,3-GalNAc (the known ligand) have been identified. The strategy outlined can be used to identify carbohydrate-based ligands for any receptor; however, because the derivatized beads mimic the polyvalent presentation of cell surface carbohydrates, the screen may prove especially valuable for discovering new compounds that bind to proteins participating in cell adhesion.	PRINCETON UNIV,DEPT CHEM,PRINCETON,NJ 08544; COLUMBIA UNIV,DEPT CHEM,NEW YORK,NY 10027	Princeton University; Columbia University			Gildersleeve, Jeffrey/N-3392-2014; Uozumi, Yasuhiro/A-7841-2016	Gildersleeve, Jeffrey/0000-0002-3744-6423; Uozumi, Yasuhiro/0000-0001-6805-3422				BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; DANISHEFSKY SJ, 1993, SCIENCE, V260, P1307, DOI 10.1126/science.8493573; DOUGLAS SP, 1995, J AM CHEM SOC, V117, P2116, DOI 10.1021/ja00112a035; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; Frechet J. M., 1980, POLYM SUPPORTED REAC, P407; FURKA A, 1991, INT J PEPT PROT RES, V37, P487, DOI 10.1111/j.1399-3011.1991.tb00765.x; GLICK GD, 1991, J AM CHEM SOC, V113, P4701, DOI 10.1021/ja00012a060; GORDON EM, 1994, J MED CHEM, V37, P1385, DOI 10.1021/jm00036a001; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; Hunt JA, 1996, J AM CHEM SOC, V118, P9998, DOI 10.1021/ja962128f; JANDA KD, 1994, P NATL ACAD SCI USA, V91, P10779, DOI 10.1073/pnas.91.23.10779; Kanie O, 1995, ANGEW CHEM INT EDIT, V34, P2720; Kiessling LL, 1996, CHEM BIOL, V3, P71, DOI 10.1016/S1074-5521(96)90280-X; KINGERYWOOD JE, 1992, J AM CHEM SOC, V114, P7303, DOI 10.1021/ja00044a057; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LEE YC, 1995, ACCOUNTS CHEM RES, V28, P321, DOI 10.1021/ar00056a001; Mortell KH, 1996, J AM CHEM SOC, V118, P2297, DOI 10.1021/ja953574q; NESTLER HP, 1994, J ORG CHEM, V59, P4723, DOI 10.1021/jo00096a008; OHLMEYER MHJ, 1993, P NATL ACAD SCI USA, V90, P10922, DOI 10.1073/pnas.90.23.10922; Osawa T, 1978, Methods Enzymol, V50, P367; Rademann J, 1996, TETRAHEDRON LETT, V37, P3989, DOI 10.1016/0040-4039(96)00763-0; ROY R, 1995, TETRAHEDRON LETT, V36, P4377, DOI 10.1016/0040-4039(95)00817-V; ROY R, 1988, CARBOHYD RES, V177, pC1, DOI 10.1016/0008-6215(88)85068-7; SCHNAAR RL, 1978, J BIOL CHEM, V253, P7940; SCHUSTER M, 1994, J AM CHEM SOC, V116, P1135, DOI 10.1021/ja00082a047; SHARON N, 1993, SCI AM, V268, P82, DOI 10.1038/scientificamerican0193-82; SPALTENSTEIN A, 1991, J AM CHEM SOC, V113, P686, DOI 10.1021/ja00002a053; SPEVAK W, 1993, J AM CHEM SOC, V115, P1146, DOI 10.1021/ja00056a047; Thompson LA, 1996, CHEM REV, V96, P555, DOI 10.1021/cr9402081; TOSHIMA K, 1993, CHEM REV, V93, P1503, DOI 10.1021/cr00020a006; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; VERDUYN R, 1993, RECL TRAV CHIM PAY B, V112, P464; WU AM, 1980, ARCH BIOCHEM BIOPHYS, V204, P622, DOI 10.1016/0003-9861(80)90074-0; YAN L, 1994, J AM CHEM SOC, V116, P6953, DOI 10.1021/ja00094a067	35	266	456	1	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1996	274	5292					1520	1522		10.1126/science.274.5292.1520	http://dx.doi.org/10.1126/science.274.5292.1520			3	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929411				2022-12-24	WOS:A1996VV77500046
J	Wilhelmi, LK; Preuss, D				Wilhelmi, LK; Preuss, D			Self-sterility in Arabidopsis due to defective pollen tube guidance	SCIENCE			English	Article							MOLECULAR MECHANISMS; GROWTH; INCOMPATIBILITY; GLYCOPROTEIN; PLANTS; GENE	In flowering plants, a series of cell-cell interactions govern the delivery of sperm to the ovules through precise guidance of pollen tubes. Two Arabidopsis genes, POP2 and POP3, were found that mediate pollen tube guidance and are critical for self-fertility in diploid reproductive cells. The pop2 and pop3 mutations exhibited genetic redundancy: Self-sterility occurred only when male and female tissues were defective in both genes. This phenotype resembles that found in many self-incompatible species.	UNIV CHICAGO, DEPT MOL GENET & CELL BIOL, CHICAGO, IL 60637 USA	University of Chicago								BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; CHEUNG AY, 1995, CELL, V82, P383, DOI 10.1016/0092-8674(95)90427-1; Dodds PN, 1996, CELL, V85, P141, DOI 10.1016/S0092-8674(00)81090-9; FOOTE HCC, 1994, P NATL ACAD SCI USA, V91, P2265, DOI 10.1073/pnas.91.6.2265; GOODMAN CS, 1994, CELL, V78, P353, DOI 10.1016/0092-8674(94)90413-8; HILL JP, 1987, AM J BOT, V74, P988, DOI 10.2307/2443938; HISCOCK SJ, 1995, PLANTA, V196, P367, DOI 10.1007/BF00201397; HULSKAMP M, 1995, PLANT CELL, V7, P57, DOI 10.1105/tpc.7.1.57; KANDASAMY MK, 1994, DEVELOPMENT, V120, P3405; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; LIPKE PN, 1992, MICROBIOL REV, V56, P180, DOI 10.1128/MMBR.56.1.180-194.1992; LORD EM, 1992, DEV BIOL, V153, P16, DOI 10.1016/0012-1606(92)90088-X; MASCARENHAS JP, 1993, PLANT CELL, V5, P1303, DOI 10.1105/tpc.5.10.1303; MO YY, 1992, P NATL ACAD SCI USA, V89, P7213, DOI 10.1073/pnas.89.15.7213; NASRALLAH JB, 1994, SCIENCE, V266, P1505, DOI 10.1126/science.266.5190.1505; NIYOGI KK, 1993, PLANT CELL, V5, P1011, DOI 10.1105/tpc.5.9.1011; PREUSS D, 1993, GENE DEV, V7, P974, DOI 10.1101/gad.7.6.974; PRUITT RE, 1994, ARABIDOPSIS, P467; SEAVEY SR, 1986, BOT REV, V52, P195, DOI 10.1007/BF02861001; TAYLOR LP, 1992, J HERED, V83, P11, DOI 10.1093/oxfordjournals.jhered.a111149	20	74	79	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 29	1996	274	5292					1535	1537		10.1126/science.274.5292.1535	http://dx.doi.org/10.1126/science.274.5292.1535			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929415				2022-12-24	WOS:A1996VV77500050
J	Slaper, H; Velders, GJM; Daniel, JS; deGruijl, FR; vanderLeun, JC				Slaper, H; Velders, GJM; Daniel, JS; deGruijl, FR; vanderLeun, JC			Estimates of ozone depletion and skin cancer incidence to examine the Vienna Convention achievements	NATURE			English	Article							ULTRAVIOLET; UV; RADIATION; RISK; INDUCTION; SUNLIGHT; CLOUDS	DEPLETION of the ozone layer has been observed on a global scale(1), and is probably related to halocarbon emissions, Ozone depletion increases the biologically harmful solar ultraviolet radiation reaching the surface of the Earth, which leads to a variety of adverse effects, including an increase in the incidence of skin cancer. The 1985 Vienna Convention provided the framework for international restrictions on the production of ozone-depleting substances, The consequences of such restrictions have not yet been assessed in terms of effects avoided. Here we present a new method of estimating future excess skin cancer risks which is used to compare effects of a 'no restrictions' scenario with two restrictive scenarios specified under the Vienna Convention: the Montreal Protocol, and the much stricter Copenhagen Amendments, The no-restrictions and Montreal Protocol scenarios produce a runaway increase in skin cancer incidence, up to a quadrupling and doubling, respectively, by the year 2100. The Copenhagen Amendments scenario leads to an ozone minimum around the year 2000, and a peak relative increase in incidence of skin cancer of almost 10% occurring 60 years later. These results demonstrate the importance of the international measures agreed upon under the Vienna Convention.	NATL INST PUBL HLTH & ENVIRONM,AIR RES LAB,NL-3720 BA BILTHOVEN,NETHERLANDS; NOAA,AERON LAB,BOULDER,CO 80303; UNIV UTRECHT,INST DERMATOL,NL-3508 GA UTRECHT,NETHERLANDS	Netherlands National Institute for Public Health & the Environment; National Oceanic Atmospheric Admin (NOAA) - USA; Utrecht University	Slaper, H (corresponding author), NATL INST PUBL HLTH & ENVIRONM,RADIAT RES LAB,POB 1,NL-3720 BA BILTHOVEN,NETHERLANDS.		Daniel, John S/D-9324-2011; Velders, Guus/H-1204-2013	Velders, Guus/0000-0002-6597-7088				*ALT FLUOR ENV ACC, 1993, PROD SAL ATM REL FLU; Berg RJW, 1996, P NATL ACAD SCI USA, V93, P274, DOI 10.1073/pnas.93.1.274; BORDEWIJK JA, 1995, GEOPHYS RES LETT, V22, P2151, DOI 10.1029/95GL01506; DANIEL JS, 1995, J GEOPHYS RES-ATMOS, V100, P1271, DOI 10.1029/94JD02516; DEGRUIJL FR, 1994, HEALTH PHYS, V67, P319, DOI 10.1097/00004032-199410000-00001; DEGRUIJL FR, 1993, CANCER RES, V53, P53; DEGRUIJL FR, 1995, BIOESSAYS, V17, P651, DOI 10.1002/bies.950170711; DEWINTER R, 1995, 722201005 RIVM; GALLAGHER RP, 1995, ARCH DERMATOL, V131, P157, DOI 10.1001/archderm.131.2.157; *HLTH COUNC NETH, 1994, UV RAD SUNL; HOLMAN CD, 1984, JNCI-J NATL CANCER I, V73, P75; KERR RA, 1995, SCIENCE, V270, P376; KRICKER A, 1994, NATURE, V368, P594, DOI 10.1038/368594b0; LONGSTRETH JD, 1987, UAEPA400187001D; LUBIN D, 1995, NATURE, V377, P710, DOI 10.1038/377710a0; MADRONICH S, 1993, NATURE, V366, P23, DOI 10.1038/366023a0; MCKENZIE RL, 1995, WMO REP, V37, pCH9; SCOTTO J, 1981, NIH PUBLICATION; SETLOW RB, 1993, P NATL ACAD SCI USA, V90, P6666, DOI 10.1073/pnas.90.14.6666; SLAPER H, 1995, GEOPHYS RES LETT, V22, P2721, DOI 10.1029/95GL02824; SLAPER H, 1986, PHOTODERMATOLOGY, V3, P271; SLAPER H, 1987, THESIS UTRECHT U; SLAPER H, 1992, 749202001 RIVM; VELDERS GJM, 1995, 722201006 RIVM; VITASA BC, 1990, CANCER, V65, P2611; World Meteorological Organization, 1992, 25 WMO; World Meteorological Organization, 1995, 37 WMO; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	28	178	182	1	42	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 21	1996	384	6606					256	258		10.1038/384256a0	http://dx.doi.org/10.1038/384256a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU381	8918873				2022-12-24	WOS:A1996VU38100048
J	Nashef, L; Brown, S				Nashef, L; Brown, S			Epilepsy and sudden death	LANCET			English	Editorial Material							UNEXPLAINED DEATH; UNEXPECTED DEATH; COHORT		NORWICH COMMUNITY HLTH PARTNERSHIP,NORWICH,NORFOLK,ENGLAND		Nashef, L (corresponding author), KENT & CANTERBURY HOSP,CANTERBURY,KENT,ENGLAND.							Coyle H P, 1994, Seizure, V3, P247, DOI 10.1016/S1059-1311(05)80171-2; JOHNSTON SC, 1995, ANN NEUROL, V37, P531, DOI 10.1002/ana.410370416; Lathers CM, 1990, EPILEPSY SUDDEN DEAT, V7; LEESTMA JE, 1989, ANN NEUROL, V26, P195, DOI 10.1002/ana.410260203; LIP GYH, 1992, J ROY SOC MED, V85, P609; Nashef L, 1996, J NEUROL NEUROSUR PS, V60, P297, DOI 10.1136/jnnp.60.3.297; NASHEF L, 1995, J NEUROL NEUROSUR PS, V58, P462, DOI 10.1136/jnnp.58.4.462; NASHEF L, 1995, EPILEPSIA, V36, P1187, DOI 10.1111/j.1528-1157.1995.tb01061.x; *OFF NAT STAT MON, 1996, DHW962, P6; TENNIS P, 1995, EPILEPSIA, V36, P29, DOI 10.1111/j.1528-1157.1995.tb01661.x	10	57	57	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 16	1996	348	9038					1324	1325		10.1016/S0140-6736(05)65402-5	http://dx.doi.org/10.1016/S0140-6736(05)65402-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT332	8918270				2022-12-24	WOS:A1996VT33200003
J	Castilla, LH; Wijmenga, C; Wang, Q; Stacy, T; Speck, NA; Eckhaus, M; MarinPadilla, M; Collins, FS; WynshawBoris, A; Liu, PP				Castilla, LH; Wijmenga, C; Wang, Q; Stacy, T; Speck, NA; Eckhaus, M; MarinPadilla, M; Collins, FS; WynshawBoris, A; Liu, PP			Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11	CELL			English	Article							ACUTE MYELOID-LEUKEMIA; CORE-BINDING-FACTOR; MYOSIN HEAVY-CHAIN; ACUTE LYMPHOBLASTIC-LEUKEMIA; RECEPTOR-DELTA-ENHANCER; TRANSCRIPTION FACTOR; ERYTHROID DEVELOPMENT; MICE LACKING; AML1 GENE; C-MYB	The fusion oncogene CBFB-MYH11 is generated by a chromosome 16 inversion in human acute myeloid leukemia subtype M4Eo. Mouse embryonic stem (ES) cells heterozygous for this oncogene were generated by inserting part of the human MYH11 cDNA into the mouse Cbfb gene through homologous recombination (knock-in). Chimeric mice were leukemia free, but the ES cells with the knocked-in Cbfb-MYH11 gene did not contribute to their hematopoietic tissues. Mouse embryos heterozygous for Cbfb-MYH11 lacked definitive hematopoiesis and developed multiple fatal hemorrhages around embryonic day 12.5. This phenotype is very similar to that resulting from homozygous deletions of either Cbfb or Cbfa2 (AML1), consistent with a dominant negative function of the Cbfb-MYH11 fusion oncogene. An impairment of primitive hematopoiesis was also observed, however, suggesting a possible additional function of Cbfb-MYH11.	NIH,NATL CTR HUMAN GENOME RES,LAB GENET DIS RES,BETHESDA,MD 20892; NIH,NATL CTR RES RESOURCES,VET RESOURCES PROGRAM,BETHESDA,MD 20892; DARTMOUTH COLL SCH MED,DEPT BIOCHEM,HANOVER,NH 03755; DARTMOUTH COLL SCH MED,DEPT PATHOL,HANOVER,NH 03755	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; Dartmouth College; Dartmouth College	Castilla, LH (corresponding author), NIH,NATL CTR HUMAN GENOME RES,LAB GENE TRANSFER,BETHESDA,MD 20892, USA.		Liu, Paul/A-7976-2012; Wijmenga, Cisca/D-2173-2009; Wijmenga, Cisca/AAE-7719-2019	Liu, Paul/0000-0002-6779-025X; Wijmenga, Cisca/0000-0002-5635-1614	NATIONAL CANCER INSTITUTE [R01CA058343] Funding Source: NIH RePORTER; NCI NIH HHS [CA58343] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAE SC, 1993, ONCOGENE, V8, P809; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CAMERON S, 1994, BLOOD, V83, P2851, DOI 10.1182/blood.V83.10.2851.2851; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; DIGGS LW, 1954, MORPHOLOGY BLOOD CEL; Eaves C, 1995, ATLAS HUMAN HEMATOPO; Frank R, 1995, ONCOGENE, V11, P2667; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; LEBEAU MM, 1983, NEW ENGL J MED, V309, P630, DOI 10.1056/NEJM198309153091103; LIU P, 1994, COLD SPRING HARB SYM, V59, P547, DOI 10.1101/SQB.1994.059.01.061; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; LIU PP, 1995, BLOOD, V85, P2289, DOI 10.1182/blood.V85.9.2289.bloodjournal8592289; MARLTON P, 1995, BLOOD, V85, P772, DOI 10.1182/blood.V85.3.772.bloodjournal853772; MATSUOKA R, 1993, AM J MED GENET, V46, P61, DOI 10.1002/ajmg.1320460110; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PROSSER HM, 1992, P NATL ACAD SCI USA, V89, P9934, DOI 10.1073/pnas.89.20.9934; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; TAKAHASHI A, 1995, BLOOD, V86, P607, DOI 10.1182/blood.V86.2.607.bloodjournal862607; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Wijmenga C, 1996, P NATL ACAD SCI USA, V93, P1630, DOI 10.1073/pnas.93.4.1630; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; ZAIMAN AL, 1995, J VIROL, V69, P2898, DOI 10.1128/JVI.69.5.2898-2906.1995; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	41	242	249	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1996	87	4					687	696		10.1016/S0092-8674(00)81388-4	http://dx.doi.org/10.1016/S0092-8674(00)81388-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VU035	8929537	hybrid			2022-12-24	WOS:A1996VU03500011
J	Hill, LN				Hill, LN			My not-so-near-death experience	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Hill, LN (corresponding author), AMER EMBASSY, APO, AP 96440 USA.								0	0	0	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1996	125	10					855	857		10.7326/0003-4819-125-10-199611150-00012	http://dx.doi.org/10.7326/0003-4819-125-10-199611150-00012			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU524	8928995				2022-12-24	WOS:A1996VU52400015
J	Mombaerts, P; Wang, F; Dulac, C; Chao, SK; Nemes, A; Mendelsohn, M; Edmondson, J; Axel, R				Mombaerts, P; Wang, F; Dulac, C; Chao, SK; Nemes, A; Mendelsohn, M; Edmondson, J; Axel, R			Visualizing an olfactory sensory map	CELL			English	Article							ODORANT RECEPTOR EXPRESSION; MITRAL TUFTED CELLS; NUCLEOTIDE-SEQUENCE; GENE-EXPRESSION; BULB; MOUSE; NEURONS; ORGANIZATION; EPITHELIUM; MOLECULES	We have developed a genetic approach to visualize axons from olfactory sensory neurons expressing a given odorant receptor, as they project to the olfactory bulb. Neurons expressing a specific receptor project to only two topographically fixed loci among the 1800 glomeruli in the mouse olfactory bulb. Our data provide direct support for a model in which a topographic map of receptor activation encodes odor quality in the olfactory bulb. Receptor swap experiments suggest that the olfactory receptor plays an instructive role in the guidance process but cannot be the sole determinant in the establishment of this map. This genetic approach may be more broadly applied to visualize the development and plasticity of projections in the mammalian nervous system.	COLUMBIA UNIV,COLL PHYS & SURG,HOWARD HUGHES MED INST,DEPT BIOCHEM & MOL BIOPHYS,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute; Columbia University				Dulac, Catherine/0000-0001-5024-5418; Axel, Richard/0000-0002-3141-4076	NCI NIH HHS [5 PO1 CA23767] Funding Source: Medline; NIMH NIH HHS [5 P50 MH 50733] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA023767] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH050733] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BENARIE N, 1994, HUM MOL GENET, V3, P229, DOI 10.1093/hmg/3.2.229; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Buck LB, 1996, ANNU REV NEUROSCI, V19, P517, DOI 10.1146/annurev.ne.19.030196.002505; BUIAKOVA OI, 1994, GENOMICS, V20, P452, DOI 10.1006/geno.1994.1200; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; CALLAHAN CA, 1994, P NATL ACAD SCI USA, V91, P5972, DOI 10.1073/pnas.91.13.5972; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; FARBMAN AI, 1980, DEV BIOL, V74, P205, DOI 10.1016/0012-1606(80)90062-7; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; HOESS RH, 1982, P NATL ACAD SCI-BIOL, V79, P3398, DOI 10.1073/pnas.79.11.3398; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; IMAMURA K, 1992, J NEUROPHYSIOL, V68, P1986, DOI 10.1152/jn.1992.68.6.1986; KATOH K, 1993, J NEUROPHYSIOL, V70, P2161, DOI 10.1152/jn.1993.70.5.2161; KAUER JS, 1987, BRAIN RES, V418, P255, DOI 10.1016/0006-8993(87)90093-X; KIM DG, 1992, MOL CELL BIOL, V12, P3636, DOI 10.1128/MCB.12.8.3636; LANCET D, 1982, P NATL ACAD SCI-BIOL, V79, P670, DOI 10.1073/pnas.79.2.670; LEVY NS, 1991, J STEROID BIOCHEM, V39, P633, DOI 10.1016/0960-0760(91)90262-4; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCKNIGHT SL, 1980, NUCLEIC ACIDS RES, V8, P5949, DOI 10.1093/nar/8.24.5949; Mombaerts P, 1996, CURR OPIN NEUROBIOL, V6, P481, DOI 10.1016/S0959-4388(96)80053-5; MORI K, 1992, J NEUROPHYSIOL, V67, P786, DOI 10.1152/jn.1992.67.3.786; MOUNTFORD PS, 1995, TRENDS GENET, V11, P179, DOI 10.1016/S0168-9525(00)89040-X; NGAI J, 1993, CELL, V72, P667, DOI 10.1016/0092-8674(93)90396-8; PARMENTIER M, 1992, NATURE, V355, P453, DOI 10.1038/355453a0; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; ROYET JP, 1988, J COMP NEUROL, V270, P559, DOI 10.1002/cne.902700409; SAUER B, 1990, New Biologist, V2, P441; SHEPHERD GM, 1994, NEURON, V13, P771, DOI 10.1016/0896-6273(94)90245-3; STEWART WB, 1979, J COMP NEUROL, V185, P715, DOI 10.1002/cne.901850407; STROTMANN J, 1995, EUR J NEUROSCI, V7, P492, DOI 10.1111/j.1460-9568.1995.tb00345.x; STROTMANN J, 1994, CELL TISSUE RES, V278, P11, DOI 10.1007/s004410050189; STROTMANN J, 1992, NEUROREPORT, V3, P1053, DOI 10.1097/00001756-199212000-00005; Sullivan SL, 1996, P NATL ACAD SCI USA, V93, P884, DOI 10.1073/pnas.93.2.884; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; Woolsey T.A., 1990, P461	41	1538	1560	9	133	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1996	87	4					675	686		10.1016/S0092-8674(00)81387-2	http://dx.doi.org/10.1016/S0092-8674(00)81387-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VU035	8929536	hybrid			2022-12-24	WOS:A1996VU03500010
J	Rikkert, MGMO; tenHave, HAMJ; Hoefnagels, WHL				Rikkert, MGMO; tenHave, HAMJ; Hoefnagels, WHL			Informed consent in biomedical studies on aging: Survey of four journals	BMJ-BRITISH MEDICAL JOURNAL			English	Article									UNIV NIJMEGEN, SCH MED SCI, DEPT ETH PHILOSOPHY & HIST MED, NIJMEGEN, NETHERLANDS	Radboud University Nijmegen	Rikkert, MGMO (corresponding author), UNIV NIJMEGEN HOSP, DEPT GERIATR MED, POB 9101, NL-6500 HB NIJMEGEN, NETHERLANDS.		Rikkert, Marcel Olde/D-9773-2012; Have, Henk ten/AAF-5188-2020					GARFIELD E, 1994, SCI J CITATION REPOR; HIGH DM, 1992, J AM GERIATR SOC, V40, P950, DOI 10.1111/j.1532-5415.1992.tb01995.x; LOCK S, 1991, BRIT MED J, V302, P338; TYMCHUK AJ, 1990, EDUC GERONTOL, V16, P245, DOI 10.1080/0380127900160302	4	39	40	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 2	1996	313	7065					1117	1117		10.1136/bmj.313.7065.1117	http://dx.doi.org/10.1136/bmj.313.7065.1117			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VR217	8916698	Green Published			2022-12-24	WOS:A1996VR21700023
J	Ireton, K; Payrastre, B; Chap, H; Ogawa, W; Sakaue, H; Kasuga, M; Cossart, P				Ireton, K; Payrastre, B; Chap, H; Ogawa, W; Sakaue, H; Kasuga, M; Cossart, P			A role for phosphoinositide 3-kinase in bacterial invasion	SCIENCE			English	Article							LISTERIA-MONOCYTOGENES; EPITHELIAL-CELLS; DYNAMIN BINDS; PROTEIN; KINASE; INTERNALIN; PLATELETS; ENTRY	Listeria monocytogenes is a bacterial pathogen that invades cultured nonphagocytic cells. inhibitors and a dominant negative mutation were used to demonstrate that efficient entry requires the phosphoinositide (PI) 9-kinase p85 alpha-p110. Infection with L. monocytogenes caused rapid increases in cellular amounts of PI(3,4)P-2 and PI(3,4,5)P-3, indicating that invading bacteria stimulated PI 3-kinase activity. This stimulation required the bacterial protein In1B, host cell tyrosine phosphorylation, and association of p85 alpha with one or more tyrosine-phosphorylated proteins. This role for PI 3-kinase in bacterial entry may have parallels in some endocytic events.	INST PASTEUR,UNITE INTERACT BACTERIES CELLULES,F-75724 PARIS 15,FRANCE; HOP PURPAN,INSERM,U326,F-31059 TOULOUSE,FRANCE; KOBE UNIV,SCH MED,DEPT INTERNAL MED 2,CHUO KU,KOBE 650,JAPAN	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Kobe University			Sakaue, Hiroshi/ABE-2337-2021; OGAWA, Wataru/AAQ-9586-2020	Sakaue, Hiroshi/0000-0002-2468-2363; , Bernard/0000-0002-8693-0190				ANDO A, 1994, EMBO J, V13, P3033, DOI 10.1002/j.1460-2075.1994.tb06602.x; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; DRAMSI S, 1995, MOL MICROBIOL, V16, P251, DOI 10.1111/j.1365-2958.1995.tb02297.x; Dramsi S, 1996, CURR TOP MICROBIOL, V209, P61; GAILLARD JL, 1991, CELL, V65, P1127, DOI 10.1016/0092-8674(91)90009-N; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; IRETON K, UNPUB; KASUGA M, UNPUB; Mengaud J, 1996, CELL, V84, P923, DOI 10.1016/S0092-8674(00)81070-3; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Shepherd PR, 1996, TRENDS CELL BIOL, V6, P92, DOI 10.1016/0962-8924(96)80998-6; TANG P, 1994, MOL BIOL CELL, V5, P455, DOI 10.1091/mbc.5.4.455; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VELGE P, 1994, MICROB PATHOGENESIS, V17, P37, DOI 10.1006/mpat.1994.1050; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241	19	281	288	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1996	274	5288					780	782		10.1126/science.274.5288.780	http://dx.doi.org/10.1126/science.274.5288.780			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ145	8864117				2022-12-24	WOS:A1996VQ14500042
J	Sidrauski, C; Cox, JS; Walter, P				Sidrauski, C; Cox, JS; Walter, P			tRNA ligase is required for regulated mRNA splicing in the unfolded protein response	CELL			English	Article							TRANSFER-RNA LIGASE; KAR2 BIP GENE; ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; TRANSMEMBRANE PROTEIN; RESIDENT PROTEINS; SHUTTLE VECTORS; MESSENGER-RNAS; YEAST; KINASE	The accumulation of unfolded proteins in the endoplasmic reticulum (ER) triggers an intracellular signaling pathway, the unfolded protein response (UPR), that leads to increased transcription of genes encoding ER-resident proteins. Transcriptional activation is mediated by a dedicated transcription factor, Hac1p, whose activity is controlled by regulated splicing of its mRNA. We have identified a mutation in tRNA ligase that disrupts the UPR in the yeast Saccharomyces cerevisiae. In this mutant, splicing of HAC1 mRNA, but not tRNA, is blocked. In contrast, HAC1 mRNA splicing is not impaired in cells that are blocked in spliceosome-mediated mRNA splicing. Furthermore, the splice junctions of HAC1 mRNA do not conform to the consensus sequences of other yeast pre-mRNAs. Our results suggest that the regulated splicing of HAC1 mRNA occurs by a novel pathway, involving tRNA ligase and bypassing the spliceosome.			Sidrauski, C (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.							APOSTOL BL, 1991, J BIOL CHEM, V266, P7445; APOSTOL BL, 1991, NUCLEIC ACIDS RES, V19, P1853, DOI 10.1093/nar/19.8.1853; BEH CT, 1995, P NATL ACAD SCI USA, V92, P9820, DOI 10.1073/pnas.92.21.9820; BORK P, 1993, FEBS LETT, V334, P149, DOI 10.1016/0014-5793(93)81701-Z; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CLARK MW, 1987, J CELL BIOL, V105, P1515, DOI 10.1083/jcb.105.4.1515; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Craven RA, 1996, EMBO J, V15, P2640, DOI 10.1002/j.1460-2075.1996.tb00624.x; DONG BH, 1995, J BIOL CHEM, V270, P4133, DOI 10.1074/jbc.270.8.4133; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GREER CL, 1983, CELL, V32, P537, DOI 10.1016/0092-8674(83)90473-7; HARDWICK KG, 1990, EMBO J, V9, P623, DOI 10.1002/j.1460-2075.1990.tb08154.x; JACKSON SP, 1988, MOL CELL BIOL, V8, P1067, DOI 10.1128/MCB.8.3.1067; KOHNO K, 1993, MOL CELL BIOL, V13, P877, DOI 10.1128/MCB.13.2.877; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KOSHLAND D, 1985, CELL, V40, P393, DOI 10.1016/0092-8674(85)90153-9; LEE MG, 1984, EMBO J, V3, P2825, DOI 10.1002/j.1460-2075.1984.tb02215.x; McMillan D. Randy, 1994, Current Opinion in Biotechnology, V5, P540, DOI 10.1016/0958-1669(94)90071-X; MORI K, 1992, EMBO J, V11, P2583, DOI 10.1002/j.1460-2075.1992.tb05323.x; MORI K, 1993, CELL, V74, P743; PEEBLES CL, 1983, CELL, V32, P525, DOI 10.1016/0092-8674(83)90472-5; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PHIZICKY EM, 1992, J BIOL CHEM, V267, P4577; PHIZICKY EM, 1986, J BIOL CHEM, V261, P2978; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; RYMOND BC, 1992, MOL CELLULAR BIOL YE, P143; Shamu Caroline E., 1994, Trends in Cell Biology, V4, P56, DOI 10.1016/0962-8924(94)90011-6; Shamu CE, 1996, EMBO J, V15, P3028, DOI 10.1002/j.1460-2075.1996.tb00666.x; SIKORSKI RS, 1989, GENETICS, V122, P19; Simos G, 1996, EMBO J, V15, P2270, DOI 10.1002/j.1460-2075.1996.tb00580.x; SWEET DJ, 1993, CURR BIOL, V3, P622, DOI 10.1016/0960-9822(93)90014-F; TEEM JL, 1983, MOL GEN GENET, V192, P101, DOI 10.1007/BF00327653; WARNER JR, 1991, METHOD ENZYMOL, V194, P423; WESTAWAY SK, 1988, J BIOL CHEM, V263, P3171; XU Q, 1990, BIOCHEMISTRY-US, V29, P6132, DOI 10.1021/bi00478a004; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D	37	337	350	1	14	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 1	1996	87	3					405	413		10.1016/S0092-8674(00)81361-6	http://dx.doi.org/10.1016/S0092-8674(00)81361-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VQ466	8898194	Bronze			2022-12-24	WOS:A1996VQ46600007
J	Doherty, JF; Moody, AH; Wright, SG				Doherty, JF; Moody, AH; Wright, SG			Lesson of the week - Katayama fever: An acute manifestation of schistosomiasis	BRITISH MEDICAL JOURNAL			English	Article									HOSP TROP DIS,LONDON NW1 0PE,ENGLAND	University College London Hospitals NHS Foundation Trust; University of London; London School of Hygiene & Tropical Medicine								COOK GC, 1988, LANCET, V1, P127; Davis A., 1996, Manson's tropical diseases., P1413; Day JH, 1996, BRIT MED J, V313, P268, DOI 10.1136/bmj.313.7052.268; HARRIES AD, 1987, J INFECTION, V14, P159, DOI 10.1016/S0163-4453(87)92002-0; MCLAREN ML, 1981, T ROY SOC TROP MED H, V75, P72, DOI 10.1016/0035-9203(81)90014-6; VAZQUEZ ML, 1987, NEUROLOGY, V37, P1561, DOI 10.1212/WNL.37.9.1561; 1985, NEW ENGL J MED, V312, P1376	7	64	64	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 26	1996	313	7064					1071	1072						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP742	8898604	Green Published			2022-12-24	WOS:A1996VP74200038
J	Zhang, K; Guo, B; Colarusso, P; Bernath, PF				Zhang, K; Guo, B; Colarusso, P; Bernath, PF			Far-infrared emission spectra of selected gas-phase PAHs: Spectroscopic fingerprints	SCIENCE			English	Article							AROMATIC HYDROCARBON CATIONS; MOLECULES; BANDS; TEMPERATURE; DUST; IDENTIFICATION; CORONENE; MATTER	The emission spectra of the gaseous polycyclic aromatic hydrocarbons (PAHs) naphthalene, chrysene, and pyrene were recorded in the far-infrared (far-IR) region. The vibrational bands that lie in the far IR are unique for each PAH molecule and allow discrimination among the three PAH molecules. The far-IR PAH spectra, therefore, may prove useful in the assignment of unidentified spectral features from astronomical objects.	UNIV ARIZONA, DEPT CHEM, TUCSON, AZ 85721 USA	University of Arizona	Zhang, K (corresponding author), UNIV WATERLOO, DEPT CHEM, CTR MOL BEAMS & LASER CHEM, OTTAWA, ON N2L 3G1, CANADA.		Bernath, Peter F/B-6567-2012	Bernath, Peter F/0000-0002-1255-396X				ALLAMANDOLA LJ, 1989, ASTROPHYS J SUPPL S, V71, P733, DOI 10.1086/191396; ALLAMANDOLA LJ, 1985, ASTROPHYS J, V290, pL25, DOI 10.1086/184435; BERNARD JP, 1989, ASTRON ASTROPHYS, V220, P245; Bernath PF, 1996, CHEM SOC REV, V25, P111, DOI 10.1039/cs9962500111; BERNATH PF, 1992, LECT NOTES PHYSICS, V407; BLANCO A, 1990, ASTROPHYS J, V364, P152, DOI 10.1086/169396; CLEMETT SJ, 1993, SCIENCE, V262, P721, DOI 10.1126/science.262.5134.721; Cook DJ, 1996, NATURE, V380, P227, DOI 10.1038/380227a0; DESERT FX, 1995, ASTRON ASTROPHYS, V303, P223; HAHN JH, 1988, SCIENCE, V239, P1523, DOI 10.1126/science.239.4847.1523; HUDGINS DM, 1995, J PHYS CHEM-US, V99, P8978, DOI 10.1021/j100022a007; HUDGINS DM, 1994, J PHYS CHEM-US, V98, P4243, DOI 10.1021/j100067a008; JOBLIN C, 1994, ASTRON ASTROPHYS, V281, P923; JOBLIN C, 1995, ASTRON ASTROPHYS, V299, P835; KURTZ J, 1992, ASTRON ASTROPHYS, V255, pL1; Langhoff SR, 1996, J PHYS CHEM-US, V100, P2819, DOI 10.1021/jp952074g; LEGER A, 1984, ASTRON ASTROPHYS, V137, pL5; Moutou C, 1996, ASTRON ASTROPHYS, V310, P297; MULLIE F, 1987, TOP CURR CHEM, V139, P83; PUGET JL, 1989, ANNU REV ASTRON ASTR, V27, P161; SALAMA F, 1994, J CHEM PHYS, V101, P10252, DOI 10.1063/1.467905; SCHLEMMER S, 1994, SCIENCE, V265, P1686, DOI 10.1126/science.11539830; SNOW TP, 1995, SCIENCE, V270, P1455, DOI 10.1126/science.270.5241.1455; SZCZEPANSKI J, 1993, ASTROPHYS J, V414, P646, DOI 10.1086/173110	24	44	44	2	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 25	1996	274	5287					582	583		10.1126/science.274.5287.582	http://dx.doi.org/10.1126/science.274.5287.582			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN919	8849443				2022-12-24	WOS:A1996VN91900041
J	Blazeby, JM; Cooper, MJ				Blazeby, JM; Cooper, MJ			Is site of necrosis in acute pancreatitis a predictor of outcome?	LANCET			English	Editorial Material							COMPUTED-TOMOGRAPHY; CT				Blazeby, JM (corresponding author), ROYAL DEVON & EXETER HOSP,DEPT SURG,EXETER EX2 5DW,DEVON,ENGLAND.							BALTHAZAR EJ, 1985, RADIOLOGY, V156, P767, DOI 10.1148/radiology.156.3.4023241; BALTHAZAR EJ, 1990, RADIOLOGY, V174, P331, DOI 10.1148/radiology.174.2.2296641; Kemppainen E, 1996, BRIT J SURG, V83, P924, DOI 10.1002/bjs.1800830713; LUCAROTTI ME, 1993, BRIT J SURG, V80, P1393, DOI 10.1002/bjs.1800801112; VESENTINI S, 1993, BRIT J SURG, V80, P755, DOI 10.1002/bjs.1800800633	5	3	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 19	1996	348	9034					1044	1044		10.1016/S0140-6736(05)64408-X	http://dx.doi.org/10.1016/S0140-6736(05)64408-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM886	8874449				2022-12-24	WOS:A1996VM88600002
J	Suhonen, JO; Peterson, DA; Ray, J; Gage, FH				Suhonen, JO; Peterson, DA; Ray, J; Gage, FH			Differentiation of adult hippocampus-derived progenitors into olfactory neurons in vivo	NATURE			English	Article							SUBVENTRICULAR ZONE; N-CAM; NERVOUS-SYSTEM; DENTATE GYRUS; CELLS; RAT; BRAIN; PRECURSORS; FOREBRAIN; ASTROCYTES	NEUROGENESIS continues throughout adulthood in discrete regions. Proliferative zones include the subependymal zone(1-4), from where progenitors migrate along the rostral migratory pathway to differentiate into neurons in the olfactory bulb(4), and the hippocampal subgranular zone, where they migrate and differentiate into granule neurons(5-7). Progenitors isolated from adult subependymal zone exhibit in vitro neurogenesis when stimulated with epidermals(8,9) or fibroblast growth factor(10). Cultured adult rat hippocampal progenitors (AHPs) grafted to adult rat hippocampus show site specific neuronal differentiation(11). Were we investigate determinants of multipotentiality in the adult central nervous system, by grafting AHPs into homotypic (hippocampus) or heterotypic (the rostral migratory pathway) neurogenic sites or a heterotypic, non-neurogenic site (the cerebellum). We found that grafts into neurogenic, but not non-neurogenic sites, showed neuronal differentiation. Furthermore, AHPs grafted in the rostral migratory pathway migrated into the olfactory bulb, differentiating into tyrosine-hydroxylase-positive neurons, a non-hippocampus phenotype. These results reveal that AHP populations can respond to persistent neuronal differentiation cues in the adult central nervous system.	SALK INST BIOL STUDIES, GENET LAB, LA JOLLA, CA 92037 USA	Salk Institute								ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; BAYER SA, 1982, EXP BRAIN RES, V46, P315; Campbell K, 1995, NEURON, V15, P1259, DOI 10.1016/0896-6273(95)90006-3; CELIO MR, 1990, NEUROSCIENCE, V35, P375, DOI 10.1016/0306-4522(90)90091-H; EDELMAN GM, 1981, J SUPRAMOL STR CELL, V16, P259, DOI 10.1002/jsscb.1981.380160306; FISHELL G, 1995, DEVELOPMENT, V121, P803; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.neuro.18.1.159; GAO WQ, 1993, SCIENCE, V260, P367, DOI 10.1126/science.8469990; HALASZ N, 1977, BRAIN RES, V126, P455, DOI 10.1016/0006-8993(77)90597-2; Hu HY, 1996, NEURON, V16, P735, DOI 10.1016/S0896-6273(00)80094-X; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; KEVERNE EB, 1995, CURR OPIN NEUROBIOL, V5, P482, DOI 10.1016/0959-4388(95)80009-3; LEVEY MS, 1991, J NEUROSCI, V11, P3556; LEVISON SW, 1993, NEURON, V10, P201, DOI 10.1016/0896-6273(93)90311-E; Lois C, 1996, SCIENCE, V271, P978, DOI 10.1126/science.271.5251.978; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; Menezes JRL, 1995, MOL CELL NEUROSCI, V6, P496, DOI 10.1006/mcne.1995.0002; MIRAGALL F, 1988, DEV BIOL, V129, P516, DOI 10.1016/0012-1606(88)90397-1; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; ORourke NA, 1996, NEURON, V16, P1061, DOI 10.1016/S0896-6273(00)80130-0; PALMER TD, 1995, MOL CELL NEUROSCI, V6, P474, DOI 10.1006/mcne.1995.1035; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; RICHARDS LJ, 1992, P NATL ACAD SCI USA, V89, P8591, DOI 10.1073/pnas.89.18.8591; ROUGON G, 1986, J CELL BIOL, V103, P2429, DOI 10.1083/jcb.103.6.2429; ROUSSELOT P, 1995, J COMP NEUROL, V351, P51, DOI 10.1002/cne.903510106; SEKI T, 1991, NEUROSCI RES, V12, P503, DOI 10.1016/S0168-0102(09)80003-5; VICARIOABEJON C, 1995, J NEUROSCI, V15, P6351	30	491	533	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 17	1996	383	6601					624	627		10.1038/383624a0	http://dx.doi.org/10.1038/383624a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM755	8857538				2022-12-24	WOS:A1996VM75500054
J	Coleman, TR; Carpenter, PB; Dunphy, WG				Coleman, TR; Carpenter, PB; Dunphy, WG			The Xenopus Cdc6 protein is essential for the initiation of a single round of DNA replication in cell-free extracts	CELL			English	Article							CYCLIN-DEPENDENT KINASES; EGG EXTRACTS; SACCHAROMYCES-CEREVISIAE; S-PHASE; FISSION YEAST; NEGATIVE REGULATION; LICENSING FACTOR; PURIFIED DNA; INVITRO; GENE	We have cloned a Xenopus Cdc6 homolog (Xcdc6) and characterized its role in DNA replication with Xenopus egg extracts. Immunodepletion of Xcdc6 abolishes chromosomal replication but not elongation on single-stranded DNA templates. Xcdc6 binds to chromatin at the beginning of interphase but disappears from chromatin upon initiation of replication. Immunodepletion studies indicate that binding of Xcdc6 to chromatin requires Xorc2, a component of the origin recognition complex. Moreover, Xmcm3 cannot bind to chromatin lacking Xcdc6, suggesting that Xorc2, Xcdc6, and Xmcm3 associate with the DNA sequentially. In postreplicative nuclei, Xcdc6 is associated with the nuclear envelope. These studies indicate that Xcdc6 is essential for initiation of replication in vertebrates and that interaction with the nuclear envelope may regulate its function.			Coleman, TR (corresponding author), CALTECH, HOWARD HUGHES MED INST, DIV BIOL 21676, PASADENA, CA 91125 USA.							ADACHI Y, 1992, J CELL BIOL, V119, P1, DOI 10.1083/jcb.119.1.1; ADACHI Y, 1994, EMBO J, V13, P4153, DOI 10.1002/j.1460-2075.1994.tb06733.x; BELL SP, 1995, CURR OPIN GENET DEV, V5, P162, DOI 10.1016/0959-437X(95)80003-4; BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; BENAVENTE R, 1985, CELL, V41, P177, DOI 10.1016/0092-8674(85)90072-8; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BROWN JA, 1991, MOL CELL BIOL, V11, P5301, DOI 10.1128/MCB.11.10.5301; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; Chong JPJ, 1996, TRENDS BIOCHEM SCI, V21, P102, DOI 10.1016/0968-0004(96)10013-X; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; COLEMAN TR, 1993, CELL, V72, P919, DOI 10.1016/0092-8674(93)90580-J; COVERLEY D, 1994, ANNU REV BIOCHEM, V63, P745, DOI 10.1146/annurev.bi.63.070194.003525; COX LS, 1991, CELL, V66, P271, DOI 10.1016/0092-8674(91)90617-8; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DEPAMPHILIS ML, 1993, ANNU REV BIOCHEM, V62, P29; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; Diffley JFX, 1995, YEAST, V11, P1651, DOI 10.1002/yea.320111608; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FANG F, 1993, J CELL SCI, V106, P983; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; Harlow E, 1988, ANTIBODIES LAB MANUA; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; Jallepalli PV, 1996, GENE DEV, V10, P541, DOI 10.1101/gad.10.5.541; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; KORNBLUTH S, 1992, MOL CELL BIOL, V12, P3216, DOI 10.1128/MCB.12.7.3216; KROHNE G, 1986, EXP CELL RES, V162, P1, DOI 10.1016/0014-4827(86)90421-0; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; KUMAGAI A, 1995, MOL BIOL CELL, V6, P199, DOI 10.1091/mbc.6.2.199; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LISZIEWICZ J, 1988, NUCLEIC ACIDS RES, V16, P11507, DOI 10.1093/nar/16.24.11507; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MADINE MA, 1995, CURR BIOL, V5, P1270, DOI 10.1016/S0960-9822(95)00253-3; MECHALI M, 1982, CELL, V30, P93, DOI 10.1016/0092-8674(82)90015-0; MILLS AD, 1989, J CELL SCI, V94, P471; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; MuziFalconi F, 1996, CURR BIOL, V6, P229, DOI 10.1016/S0960-9822(02)00464-5; MuziFalconi M, 1996, P NATL ACAD SCI USA, V93, P1566, DOI 10.1073/pnas.93.4.1566; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; TANG ZH, 1993, EMBO J, V12, P3427, DOI 10.1002/j.1460-2075.1993.tb06017.x; WANG TA, 1995, CURR OPIN CELL BIOL, V7, P414, DOI 10.1016/0955-0674(95)80098-0; YAN H, 1995, J CELL BIOL, V129, P1, DOI 10.1083/jcb.129.1.1; ZHOU C, 1989, J BIOL CHEM, V264, P9022	56	337	341	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 4	1996	87	1					53	63		10.1016/S0092-8674(00)81322-7	http://dx.doi.org/10.1016/S0092-8674(00)81322-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VL695	8858148	Bronze			2022-12-24	WOS:A1996VL69500008
J	Sheikh, SP; Zvyaga, TA; Lichtarge, O; Sakmar, TP; Bourne, HR				Sheikh, SP; Zvyaga, TA; Lichtarge, O; Sakmar, TP; Bourne, HR			Rhodopsin activation blocked by metal-ion-binding sites linking transmembrane helices C and F	NATURE			English	Article							TRANSDUCIN INTERACTION; PROJECTION STRUCTURE; METARHODOPSIN-II; BOVINE RHODOPSIN; PROTEIN; SPECIFICITY; MUTATIONS; RECEPTOR; CELLS; FORM	A LARGE superfamily of receptors containing seven transmembrane (TRI) helices transmits hormonal and sensory signals across the plasma membrane to heterotrimeric G proteins at the cytoplasmic face of the membrane. To investigate how G-protein-coupled receptors work at the molecular level, we have engineered metal-ion-binding sites between TM helices to restrain activation-induced conformational change in specific locations. In rhodopsin, the photoreceptor of retinal rod cells, we substituted histidine residues for natural amino acids at the cytoplasmic ends of the TM helices C and F. The resulting mutant proteins were able to activate the visual G protein transducin in the absence but not in the presence of metal ions. These results indicate that the TM helices C and F are in close proximity and suggest that movements of these helices relative to one another are required for transducin activation. Thus a change in the orientations of TRI helices C and F is likely to be a key element in the mechanism for coupling binding of ligands (or isomerization of retinal) to the activation of G-protein-coupled receptors.	UNIV CALIF SAN FRANCISCO,DEPT MOL & CELLULAR BIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,INST CARDIOVASC RES,SAN FRANCISCO,CA 94143; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,DEPT MOL BIOL & BIOCHEM,NEW YORK,NY 10021	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; Rockefeller University			Sakmar, Thomas P/D-1833-2015	Sakmar, Thomas P/0000-0002-2836-8953				BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BOURNE HR, 1990, NATURE, V363, P274; CHAKRABATI P, 1991, PROTEIN ENG, V4, P57; COHEN GB, 1992, BIOCHEMISTRY-US, V31, P12592, DOI 10.1021/bi00165a008; ELLING CE, 1995, NATURE, V374, P74, DOI 10.1038/374074a0; FAHMY K, 1995, BIOPHYS CHEM, V56, P171, DOI 10.1016/0301-4622(95)00030-2; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7229, DOI 10.1021/bi00079a020; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; FARRENS DL, IN PRESS SCIENCE; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FRANKE RR, 1992, J BIOL CHEM, V267, P9478; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; HIGAKI JN, 1992, TRENDS BIOCHEM SCI, V17, P100, DOI 10.1016/0968-0004(92)90245-5; KIBELBEK J, 1991, BIOCHEMISTRY-US, V30, P6761, DOI 10.1021/bi00241a019; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lin SW, 1996, BIOCHEMISTRY-US, V35, P11149, DOI 10.1021/bi960858u; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; MIN KC, 1993, J BIOL CHEM, V268, P9400; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; REGAN L, 1995, TRENDS BIOCHEM SCI, V20, P280, DOI 10.1016/S0968-0004(00)89044-1; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SCHERTLER GFX, 1995, P NATL ACAD SCI USA, V92, P11578, DOI 10.1073/pnas.92.25.11578; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WILLETT WS, 1995, BIOCHEMISTRY-US, V34, P2172, DOI 10.1021/bi00007a010; YOSHIZAWA T, 1963, NATURE, V197, P1279, DOI 10.1038/1971279a0; ZVYAGA TA, 1994, BIOCHEMISTRY-US, V33, P9753, DOI 10.1021/bi00198a046; ZVYAGA TA, 1993, J BIOL CHEM, V268, P4661	29	384	386	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 26	1996	383	6598					347	350		10.1038/383347a0	http://dx.doi.org/10.1038/383347a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VJ439	8848049				2022-12-24	WOS:A1996VJ43900048
J	Benson, J; Britten, N				Benson, J; Britten, N			Respecting the autonomy of cancer patients when talking with their families: Qualitative analysis of semistructured interviews with patients	BRITISH MEDICAL JOURNAL			English	Article							ETHICAL DECISION-MAKING; MEDICAL-ETHICS; GENERAL-PRACTITIONERS; CONFIDENTIALITY; PHYSICIANS; NETHERLANDS; RECORDS; ACCESS	Objectives-To discover cancer patients) views about disclosure of information to their family, their family's influence over the information given them, and their preferences for doctors' behaviour if they and their family disagree, as a complement to applied ethical theory. Design-Semistructured interviews followed by qualitative content analysis. Setting-Mainly urban British general practice. Subjects-30 patients in whom cancer, excluding basal and squamous cell skin carcinomas, was diagnosed 1-7 years earlier. Results-All subjects wished doctors to respect their views rather than those of their family, should they differ. With their consent, subjects favoured close family receiving information about their illness, all but one mentioning advantage to their family. Without such consent, six unconditionally favoured disclosure of information to their family while seven unconditionally opposed disclosure. Seventeen participants restricted their approval for such disclosure to specific circumstances. Only two participants approved of their family influencing the information that they received about their illness; all but seven wished to receive full information, the exceptions relating to information about bad prognosis. Conclusions-Subjects favoured openness with their family but most rejected unconditional disclosure of information without their consent and their family influencing what information they would be given. They valued respect for their autonomy more highly than beneficence and considered that their own needs took priority over those of their family.	UNITED MED & DENT SCH,DEPT GEN PRACTICE,LONDON SE11 6SP,ENGLAND	University of London; King's College London								BRITTEN N, 1991, J ROY SOC MED, V84, P284, DOI 10.1177/014107689108400513; CHRISTIE RJ, 1987, CAN MED ASSOC J, V137, P891; CHRISTIE RJ, 1989, J ROY COLL GEN PRACT, V39, P448; CHRISTIE RJ, 1983, J FAM PRACTICE, V16, P1133; DAYRINGER R, 1983, J FAM PRACTICE, V17, P267; DUNN JWM, 1983, J ROY COLL GEN PRACT, V33, P763; FISHER B, 1993, BRIT J GEN PRACT, V43, P52; Gillion R, 1995, J MED ETHICS, V21, P323, DOI 10.1136/jme.21.6.323; GILLON R, 1994, BRIT MED J, V309, P184, DOI 10.1136/bmj.309.6948.184; *GMC, 1995, CONF GUID GEN MED CO; HOFFMASTER B, 1992, SOC SCI MED, V35, P1421, DOI 10.1016/0277-9536(92)90045-R; HOFFMASTER B, 1994, SOC SCI MED, V39, P1155, DOI 10.1016/0277-9536(94)90348-4; Hoffmaster C B, 1992, Fam Med, V24, P433; Holm S, 1995, J MED ETHICS, V21, P332, DOI 10.1136/jme.21.6.332; LAKO CJ, 1990, J FAM PRACTICE, V31, P167; LAKO CJ, 1990, FAM PRACT, V7, P34, DOI 10.1093/fampra/7.1.34; LAKO CJ, 1991, SOC SCI MED, V32, P153, DOI 10.1016/0277-9536(91)90055-H; MAYS N, 1995, BRIT MED J, V311, P109, DOI 10.1136/bmj.311.6997.109; Ritchie J, 2002, ANAL QUALITATIVE DAT, P187; WEISS BD, 1982, JAMA-J AM MED ASSOC, V247, P2695, DOI 10.1001/jama.247.19.2695; 1984, HDB MED ETHICS; 1990, ACCESS HLTH RECORDS	22	68	68	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 21	1996	313	7059					729	731		10.1136/bmj.313.7059.729	http://dx.doi.org/10.1136/bmj.313.7059.729			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VJ441	8819445	Green Published			2022-12-24	WOS:A1996VJ44100026
J	Kuida, K; Zheng, TS; Na, SQ; Kuan, CY; Yang, D; Karasuyama, H; Rakic, P; Flavell, RA				Kuida, K; Zheng, TS; Na, SQ; Kuan, CY; Yang, D; Karasuyama, H; Rakic, P; Flavell, RA			Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice	NATURE			English	Article							PROGRAMMED CELL-DEATH; CHICK-EMBRYO; SPINAL-CORD; PHOSPHATIDYLSERINE; INHIBITION; MIGRATION; PROTEASE; ELEGANS	PROGRAMMED cell death (apoptosis) is a prominent feature of the development of the immune and nervous systems(1,2). The identification of the Caenorhabditis elegans cell death gene, ced-3, as a prototype of the interleukin-1 beta converting enzyme (ICE) protease family has led to extensive evidence implicating these enzymes in apoptosis(3,4). Among the ten or more members of the ICE protease family, CPP32/yama/apopain(5-7) exhibits the highest similarity to CED-3 in both sequence homolog and substrate specificity(8). To analyse its function in vivo, we generated CPP32-deficient mice by homologous recombination, These mice, horn at a frequency lower than expected by mendelian genetics, mere smaller than their Littermates and died at 1-3 weeks of age, Although their thymocytes retained normal susceptibility to various apoptotic stimuli, brain development in CPP32-deficient mice was profoundly affected, and discernible by embryonic day 12, resulting in a variety of hyperplasias and disorganized cell deployment, These supernumerary cells were postmitotic and terminally differentiated by the postnatal stage, Pyknotic clusters at sites of major morphogenetic change during normal brain development(9) were not observed in the mutant embryos, indicating decreased apoptosis in the absence of CPP32. Thus CPP32 is shown to play a critical role during morphogenetic cell death(9,10) in the mammalian brain.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,NEUROBIOL SECT,NEW HAVEN,CT 06510; TOKYO METROPOLITAN INST MED SCI,DEPT IMMUNOL,BUNKYO KU,TOKYO 113,JAPAN	Howard Hughes Medical Institute; Yale University; Yale University; Tokyo Metropolitan Institute of Medical Science			Karasuyama, Hajime/A-7966-2011	Karasuyama, Hajime/0000-0003-0689-0836				Chinnaiyan AM, 1996, CURR BIOL, V6, P555; COWAN WM, 1984, SCIENCE, V225, P1258, DOI 10.1126/science.6474175; Eksioglu YZ, 1996, NEURON, V16, P77, DOI 10.1016/S0896-6273(00)80025-2; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; HAMBURGER V, 1958, AM J ANAT, V102, P265; HOMMA S, 1994, J COMP NEUROL, V345, P377, DOI 10.1002/cne.903450305; HORVITZ HR, 1983, COLD SPRING HARB SYM, V48, P453, DOI 10.1101/SQB.1983.048.01.050; KALLEN B, 1955, J ANAT, V89, P153; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MIALE IL, 1961, EXP NEUROL, V4, P277, DOI 10.1016/0014-4886(61)90055-3; MILLER MW, 1988, BRAIN RES, V457, P44, DOI 10.1016/0006-8993(88)90055-8; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; Osborne BA, 1996, CURR OPIN IMMUNOL, V8, P245, DOI 10.1016/S0952-7915(96)80063-X; PITTMAN R, 1979, J COMP NEUROL, V187, P425, DOI 10.1002/cne.901870210; RAKIC P, 1968, J COMP NEUROL, V132, P45, DOI 10.1002/cne.901320103; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; SILVER J, 1973, J MORPHOL, V140, P159, DOI 10.1002/jmor.1051400204; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; Whyte M, 1996, TRENDS CELL BIOL, V6, P245, DOI 10.1016/0962-8924(96)20025-X; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073	30	1656	1687	2	66	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1996	384	6607					368	372		10.1038/384368a0	http://dx.doi.org/10.1038/384368a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV271	8934524				2022-12-24	WOS:A1996VV27100052
J	Petrov, DA; Lozovskaya, ER; Hartl, DL				Petrov, DA; Lozovskaya, ER; Hartl, DL			High intrinsic: Rate of DNA loss in Drosophila	NATURE			English	Article							TRANSPOSABLE ELEMENTS; PROCESSED PSEUDOGENES; SEQUENCE EVOLUTION; GENES; MECHANISM	PSEUDOGENES are common in mammals but virtually absent in Drosophila(1). All putative Drosophila pseudogenes show patterns of molecular evolution that are inconsistent with the lack of functional constraints(2-5). The absence of bona fide pseudogenes is not only puzzling it also hampers attempts to estimate rates and patterns of neutral DNA change. The estimation problem is especially acute in the case of deletions and insertions, which are likely to have large effects when they occur in functional genes and are therefore subject to strong purifying selection. We propose a solution to this problem by taking advantage of the propensity of retrotransposable elements, without long terminal repeats (non-LTR) to: create non-functional, 'dead-on-arrival' copies of themselves as a common by-product of their transpositional cycle(6-8). Phylogenetic analysis of a non-LTR element, Helena, demonstrates that copies lose DNA at an unusually high rate, suggesting that lack of pseudogenes in Drosophila is the product of rampant deletion of DNA in unconstrained regions, This finding has important implications for the study of genome evolution in general and the 'C-value paradox'(9) in particular.			Petrov, DA (corresponding author), HARVARD UNIV, DEPT ORGANISM & EVOLUTIONARY BIOL, 16 DIVINITY AVE, CAMBRIDGE, MA 02138 USA.			Petrov, Dmitri/0000-0002-3664-9130				BEBENEK K, 1993, REVERSE TRANSCRIPTAS; Bernard J., 1988, EUKARYOTE GENOME DEV, DOI [10.1007/978-94-011-5991-3, DOI 10.1007/978-94-011-5991-3]; CURRIE PD, 1994, GENETICS, V138, P353; deSouza SJ, 1996, GENES CELLS, V1, P493, DOI 10.1046/j.1365-2443.1996.d01-264.x; EICKBUSH DG, 1995, GENETICS, V139, P685; FINNEGAN DJ, 1989, MOBILE DNA, P503; GRAUR D, 1989, J MOL EVOL, V28, P279, DOI 10.1007/BF02103423; HUGHES AL, 1995, NATURE, V377, P391, DOI 10.1038/377391a0; JEFFS P, 1991, P ROY SOC B-BIOL SCI, V244, P151, DOI 10.1098/rspb.1991.0064; JONES CW, 1982, J MOL EVOL, V19, P87, DOI 10.1007/BF02100227; LEVINSON G, 1987, MOL BIOL EVOL, V4, P203; LONG MY, 1993, SCIENCE, V260, P91, DOI 10.1126/science.7682012; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; MADDISON WP, 1992, VERSION 3; MCCLURE M, 1993, REVERSE TRANSCRIPTAS; PETROV DA, 1995, P NATL ACAD SCI USA, V92, P8050, DOI 10.1073/pnas.92.17.8050; SHARP PM, 1989, J MOL EVOL, V28, P398, DOI 10.1007/BF02603075; SPRINGER MS, 1995, MOL BIOL EVOL, V12, P219; STRATHMANN M, 1991, P NATL ACAD SCI USA, V88, P1247, DOI 10.1073/pnas.88.4.1247; SULLIVAN DT, 1994, MOL BIOL EVOL, V11, P443; SWOFFORD DL, 1991, PAUP PHYLOGENETIC AN; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.bi.55.070186.003215; [No title captured]	23	295	300	2	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1996	384	6607					346	349		10.1038/384346a0	http://dx.doi.org/10.1038/384346a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV271	8934517				2022-12-24	WOS:A1996VV27100045
J	Bresee, JS; Mast, EE; Coleman, FJ; Baron, MJ; Schonberger, LB; Alter, MJ; Jonas, MM; Yu, MYW; Renzi, PM; Schneider, LC				Bresee, JS; Mast, EE; Coleman, FJ; Baron, MJ; Schonberger, LB; Alter, MJ; Jonas, MM; Yu, MYW; Renzi, PM; Schneider, LC			Hepatitis C virus infection associated with administration of intravenous immune globulin - A cohort study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NON-B-HEPATITIS; NON-A-HEPATITIS; POSTTRANSFUSION HEPATITIS; IMMUNOGLOBULIN; PLASMA; FRACTIONATION; TRANSMISSION; ANTIBODY; ASSAY	Objective.-To determine the risk of and risk factors for hepatitis C virus (HCV) infection among persons with immune deficiencies who had received intravenous immune globulin (IGIV) between March 1993 and February 1994. Design.-Retrospective cohort study. Setting.-An immunology program in a tertiary care hospital. Patients.-Of 341 persons who had received IGIV between March 1, 1993, and February 22, 1994, 278 (82%) were enrolled. The mean age for the enrolled persons was 9 years, and 99% had primary immune deficiencies. Main Outcome Measures.-Evidence of HCV infection by detection in sera of antibody to HCV and/or HCV RNA by reverse transcriptase polymerase chain reaction. Results.-Twenty-three (11%) of 210 persons who received the IGIV Gammagard (Baxter Healthcare Corporation, Deerfield, Ill) became infected compared with none of 52 persons who received exclusively other IGIV products (P=.01). In a multivariate analysis, HCV infection was associated only with Gammagard produced from plasma screened by second-generation (multiantigen) anti-HCV tests (P=.03). Hepatitis C virus RNA was detected in Gammagard, and the risk of transmission to recipients increased with increasing quantity of HCV RNA infused, from 0 for those who received no HCV RNA-positive lots to 29% for the quartile of patients receiving the greatest amount (P<.001). At least 9 different lots of Gammagard were required to account for all cases. Conclusion.-Gammagard was the only IGIV product implicated in the transmission of HCV. Infection was associated with higher quantities of HCV RNA in Gammagard produced from second-generation anti-HCV-screened plasma. Further studies are needed to determine reasons for the infectivity of Gammagard, and viral inactivation and removal steps are needed to ensure the safety of IGIV products.	CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV VIRAL & RICKETTSIAL DIS, HEPATITIS BRANCH, ATLANTA, GA 30333 USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA; CHILDRENS HOSP, DIV GASTROENTEROL, BOSTON, MA USA; US FDA, CTR BIOL EVALUAT & RES, DIV HEMATOL, BETHESDA, MD 20892 USA; CHILDRENS HOSP, DIV IMMUNOL, BOSTON, MA USA	Centers for Disease Control & Prevention - USA; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; US Food & Drug Administration (FDA); Harvard University; Boston Children's Hospital					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002172] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR 2172] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; BISWAS RM, 1994, TRANSFUSION, V34, P100, DOI 10.1046/j.1537-2995.1994.34294143934.x; BJORKANDER J, 1988, AM J MED, V84, P107, DOI 10.1016/0002-9343(88)90016-2; Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P505; Davis G L, 1993, Recent Results Cancer Res, V132, P213; FINLAYSON JS, 1990, LANCET, V335, P1274, DOI 10.1016/0140-6736(90)91335-8; LAI ME, 1993, J PEDIATR GASTR NUTR, V16, P458, DOI 10.1097/00005176-199305000-00020; LANE RS, 1983, LANCET, V2, P974; LEVER AML, 1984, LANCET, V2, P1062; LOK ASF, 1993, HEPATOLOGY, V18, P497, DOI 10.1002/hep.1840180305; MARCELLIN P, 1994, J INFECT DIS, V170, P433, DOI 10.1093/infdis/170.2.433; MARTIN P, 1989, GASTROENTEROLOGY, V97, P1559, DOI 10.1016/0016-5085(89)90405-8; OCHS HD, 1985, LANCET, V1, P404; VALLARI DS, 1992, J CLIN MICROBIOL, V30, P552, DOI 10.1128/JCM.30.3.552-556.1992; WEILAND O, 1986, LANCET, V1, P976; WILLIAMS PE, 1988, LANCET, V2, P501; YAP PL, 1994, J HEPATOL, V21, P455, DOI 10.1016/S0168-8278(05)80328-9; YEI S, 1992, TRANSFUSION, V32, P824, DOI 10.1046/j.1537-2995.1992.32993110753.x; YU MW, 1995, LANCET, V345, P1173, DOI 10.1016/S0140-6736(95)91002-6; YU MYW, 1994, TRANSFUSION, V34, P596, DOI 10.1046/j.1537-2995.1994.34794330014.x	20	80	81	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 20	1996	276	19					1563	1567		10.1001/jama.276.19.1563	http://dx.doi.org/10.1001/jama.276.19.1563			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT025	8918853				2022-12-24	WOS:A1996VT02500028
J	Fowke, KR; Nagelkerke, NJD; Kimani, J; Simonsen, JN; Anzala, AO; Bwayo, JJ; MacDonald, KS; Ngugi, EN; Plummer, FA				Fowke, KR; Nagelkerke, NJD; Kimani, J; Simonsen, JN; Anzala, AO; Bwayo, JJ; MacDonald, KS; Ngugi, EN; Plummer, FA			Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SEXUALLY-TRANSMITTED DISEASES; POLYMERASE CHAIN-REACTION; BLOOD MONONUCLEAR-CELLS; HOMOSEXUAL MEN; PERIPHERAL-BLOOD; TYPE-1 INFECTION; TRANSMISSION; AMPLIFICATION; RESPONSES	Background There is indirect evidence that HIV-1 exposure does not inevitably lead to persistent infection. Heterogeneity in susceptibility to infection could be due to protective immunity. The objective of this study was to find out whether in highly HIV-1-exposed populations some individuals are resistant to infection. Methods We did an observational cohort study of incident HIV-1 infection among 424 initially HIV-1-seronegative prostitutes in Nairobi, Kenya, between 1985 and 1994. 239 women seroconverted to HIV-1 during the study period. Exponential, Weibull, and mixture survival models were used to examine the effect of the duration of follow-up on incidence of HIV-1 infection. The influence of the duration of exposure to HIV-1 through prostitution on seroconversion risk was examined by Cox proportional hazards modelling, with control for other known or suspected risk factors for incident HIV-1 infection. HIV-1 PCR with env, nef, and vif gene primers was done on 43 persistently seronegative prostitutes who remained seronegative after 3 or more years of follow-up. Findings Modelling of the time to HIV-1 seroconversion showed that the incidence of HIV-1 seroconversion decreased with increasing duration of exposure, which indicates that there is heterogeneity in HIV-1. susceptibility or acquired immunity to HIV-1. Each weighted year of exposure through prostitution resulted in a 1.2-fold reduction in HIV-1 seroconversion risk (hazard ratio 0 . 83 [95% CI 0 . 79-0 . 88], p<0 . 0001). Analyses of epidemiological and laboratory data, show that persistent seronegativity is not explained by seronegative HIV-1 infection or by differences in risk factors for HIV-1 infection such as safer sexual behaviours or the incidence of other sexually transmitted infections. Interpretation We conclude that a small proportion of highly exposed individuals, who may have natural protective immunity to HIV-1, are resistant to HIV-1.	UNIV MANITOBA,DEPT MED MICROBIOL,WINNIPEG,MB R3E 0W3,CANADA; UNIV MANITOBA,DEPT MED,WINNIPEG,MB R3E 0W3,CANADA; UNIV NAIROBI,DEPT MED MICROBIOL,NAIROBI,KENYA; UNIV NAIROBI,DEPT COMMUNITY HLTH,NAIROBI,KENYA	University of Manitoba; University of Manitoba; University of Nairobi; University of Nairobi			MacDonald, Kelly S/L-3315-2019	Fowke, Keith/0000-0001-8227-6649				ANZALA OA, 1995, J INFECT DIS, V171, P686, DOI 10.1093/infdis/171.3.686; BARCELLINI W, 1995, AIDS, V9, P691, DOI 10.1097/00002030-199507000-00004; BORKOWSKY W, 1990, AIDS RES HUM RETROV, V6, P673, DOI 10.1089/aid.1990.6.673; BRUISTEN SM, 1992, J INFECT DIS, V166, P620, DOI 10.1093/infdis/166.3.620; CHEYNIER R, 1992, EUR J IMMUNOL, V22, P2211, DOI 10.1002/eji.1830220905; CLERICI M, 1992, J INFECT DIS, V165, P1012, DOI 10.1093/infdis/165.6.1012; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; DAWOOD MR, 1992, J CLIN MICROBIOL, V30, P2279, DOI 10.1128/JCM.30.9.2279-2283.1992; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Elandt-Johnson R C, 1980, SURVIVAL MODELS DATA; FISCHL MA, 1987, 2 INT C AIDS WASH DC; FOWKE K, 1990, 5 INT C AIDS AFR KIN; FOWKE KR, 1995, CAN J INFECT DIS, V6, pB8; IMAGAWA DT, 1989, NEW ENGL J MED, V320, P1458, DOI 10.1056/NEJM198906013202205; LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015; LANGLADEDEMOYEN P, 1994, J CLIN INVEST, V93, P1293, DOI 10.1172/JCI117085; LEVY JA, 1993, AIDS, V7, P1401, DOI 10.1097/00002030-199311000-00001; NGUGI EN, 1988, LANCET, V2, P887, DOI 10.1016/S0140-6736(88)92480-4; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; PAN LZ, 1991, J INFECT DIS, V164, P962, DOI 10.1093/infdis/164.5.962; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; RANKI A, 1989, AIDS, V3, P63, DOI 10.1097/00002030-198902000-00002; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; ROWLANDJONES SL, 1993, LANCET, V341, P860, DOI 10.1016/0140-6736(93)93063-7; SALK J, 1993, SCIENCE, V260, P1270, DOI 10.1126/science.8098553; SIMONSEN JN, 1988, NEW ENGL J MED, V319, P274, DOI 10.1056/NEJM198808043190504; SIMONSEN JN, 1990, AIDS, V4, P139, DOI 10.1097/00002030-199002000-00007; TRAVERS K, 1995, SCIENCE, V268, P1612, DOI 10.1126/science.7539936; WILLERFORD DM, 1993, J INFECT DIS, V167, P1414, DOI 10.1093/infdis/167.6.1414	31	357	363	1	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 16	1996	348	9038					1347	1351		10.1016/S0140-6736(95)12269-2	http://dx.doi.org/10.1016/S0140-6736(95)12269-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT332	8918278				2022-12-24	WOS:A1996VT33200011
J	Bugge, TH; Kombrinck, KW; Flick, MJ; Daugherty, CC; Danton, MJS; Degen, JL				Bugge, TH; Kombrinck, KW; Flick, MJ; Daugherty, CC; Danton, MJS; Degen, JL			Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency	CELL			English	Article							TUMOR-CELL INVASION; UROKINASE RECEPTOR; DEGRADATION PRODUCTS; ACTIVATOR; MOUSE; GROWTH; INHIBITION; EMBRYOGENESIS; DISSEMINATION; LOCALIZATION	Plasmin(ogen) is an extracellular serine protease implicated in the activation of latent growth factors and procollagenase, degradation of extracellular matrix components, and fibrin clearance. Plasminogen (Plg) deficiency in mice results in high mortality, wasting, spontaneous gastrointestinal ulceration, rectal prolapse, and severe thrombosis. Furthermore, Plg-deficient mice display delayed wound healing following skin injury, a defect partly related to impaired keratinocyte migration. We generated mice deficient in Pig and fibrinogen (Fib) and show that removal of fibrin(ogen) from the extracellular environment alleviates the diverse spontaneous pathologies previously associated with Pig deficiency and corrects healing times. Mice deficient in Pig and Fib are phenotypically indistinguishable from Fib-deficient mice. These data suggest that the fundamental and possibly only essential physiological role of Pig is fibronolysis.	RIGSHOSP,FINSEN LAB,DK-2100 COPENHAGEN 0,DENMARK; CHILDRENS HOSP RES FDN,DIV PATHOL,CINCINNATI,OH 45229	Rigshospitalet; University of Copenhagen; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Bugge, TH (corresponding author), CHILDRENS HOSP RES FDN,DIV DEV BIOL,CINCINNATI,OH 45229, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047826] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47826] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BODE VC, 1979, DEV BIOL, V73, P272, DOI 10.1016/0012-1606(79)90067-8; BRUNNER G, 1991, J CELL BIOL, V114, P1275, DOI 10.1083/jcb.114.6.1275; Bugge TH, 1996, P NATL ACAD SCI USA, V93, P5899, DOI 10.1073/pnas.93.12.5899; BUGGE TH, 1995, J BIOL CHEM, V270, P16886, DOI 10.1074/jbc.270.28.16886; BUGGE TH, 1995, GENE DEV, V9, P794, DOI 10.1101/gad.9.7.794; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CARMELIET P, 1993, J CLIN INVEST, V92, P2756, DOI 10.1172/JCI116893; Clark R. A. F., 1988, MOL CELLULAR BIOL WO; COLLEN D, 1994, MOL BASIS BLOOD DIS, P725; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; DANO K, 1994, FIBRINOLYSIS, V8, P189, DOI 10.1016/0268-9499(94)90717-X; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; Dewerchin M, 1996, J CLIN INVEST, V97, P870, DOI 10.1172/JCI118489; DONALDSON DJ, 1988, J INVEST DERMATOL, V90, P623, DOI 10.1111/1523-1747.ep12560762; DUMLER I, 1993, FEBS LETT, V322, P37, DOI 10.1016/0014-5793(93)81106-A; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Eitzman DT, 1996, J CLIN INVEST, V97, P232, DOI 10.1172/JCI118396; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; Gyetko MR, 1996, J CLIN INVEST, V97, P1818, DOI 10.1172/JCI118611; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; Leonardsson G, 1995, P NATL ACAD SCI USA, V92, P12446, DOI 10.1073/pnas.92.26.12446; MAROTTI KR, 1982, DEV BIOL, V90, P154, DOI 10.1016/0012-1606(82)90220-2; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MOSCATELLI D, 1988, BIOCHIM BIOPHYS ACTA, V948, P67, DOI 10.1016/0304-419X(88)90005-4; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; ODEKON LE, 1994, J CELL PHYSIOL, V158, P398, DOI 10.1002/jcp.1041580303; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OSSOWSKI L, 1991, CANCER RES, V51, P274; OSSOWSKI L, 1988, CELL, V52, P321, DOI 10.1016/S0092-8674(88)80025-4; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; OSSOWSKI L, 1991, J CELL BIOL, V115, P1107, DOI 10.1083/jcb.115.4.1107; PEPPER MS, 1987, J CELL BIOL, V105, P2435; PLOPLIS VA, 1995, CIRCULATION, V92, P2585, DOI 10.1161/01.CIR.92.9.2585; PLOW EF, 1986, J IMMUNOL, V137, P1910; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; ROBSON SC, 1993, BLOOD, V81, P3006; ROBSON SC, 1994, BRIT J HAEMATOL, V86, P322, DOI 10.1111/j.1365-2141.1994.tb04733.x; ROMER J, 1994, J INVEST DERMATOL, V102, P519, DOI 10.1111/1523-1747.ep12373187; Romer J, 1996, NAT MED, V2, P287, DOI 10.1038/nm0396-287; ROMER J, 1991, J INVEST DERMATOL, V97, P803, DOI 10.1111/1523-1747.ep12486833; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SAPPINO AP, 1989, J CELL BIOL, V109, P2471, DOI 10.1083/jcb.109.5.2471; SAPPINO AP, 1991, J CLIN INVEST, V87, P962, DOI 10.1172/JCI115104; SKOGEN WF, 1988, BLOOD, V71, P1475; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8; SUH TT, 1995, GENE DEV, V9, P2020, DOI 10.1101/gad.9.16.2020; THOMPSON WD, 1993, BLOOD COAGUL FIBRIN, V4, P113, DOI 10.1097/00001721-199304010-00019; TRUDEL M, 1994, BLOOD, V84, P3189; VALINSKY JE, 1981, CELL, V25, P471, DOI 10.1016/0092-8674(81)90065-9; VASSALLI JD, 1994, FIBRINOLYSIS, V8, P172, DOI 10.1016/0268-9499(94)90715-3; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; WALTZ DA, 1994, J BIOL CHEM, V269, P14746; WERB Z, 1977, NEW ENGL J MED, V296, P1017, DOI 10.1056/NEJM197705052961801	54	321	333	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1996	87	4					709	719		10.1016/S0092-8674(00)81390-2	http://dx.doi.org/10.1016/S0092-8674(00)81390-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VU035	8929539	Bronze			2022-12-24	WOS:A1996VU03500013
J	Polymeropoulos, MH; Higgins, JJ; Golbe, LI; Johnson, WG; Ide, SE; DiIorio, G; Sanges, G; Stenroos, ES; Pho, LT; Schaffer, AA; Lazzarini, AM; Nussbaum, RL; Duvoisin, RC				Polymeropoulos, MH; Higgins, JJ; Golbe, LI; Johnson, WG; Ide, SE; DiIorio, G; Sanges, G; Stenroos, ES; Pho, LT; Schaffer, AA; Lazzarini, AM; Nussbaum, RL; Duvoisin, RC			Mapping of a gene for Parkinson's disease to chromosome 4q21-q23	SCIENCE			English	Article							MITOCHONDRIAL-DNA; COMPLEX; LINKAGE; HUMANS; DEFECT	Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease, affecting approximately 1 percent of the population over age 50. Recent studies have confirmed significant familial aggregation of PD and a large number of large multicase families have been documented. Genetic markers on chromosome 4q21-q23 were found to be linked to the PD phenotype in a large kindred with autosomal dominant PD, with a Z(max) = 6.00 for marker D4S2380. This finding will facilitate identification of the gene and research on the pathogenesis of PD.	NINCDS,CLIN NEUROGENET UNIT,MED NEUROL BRANCH,NIH,BETHESDA,MD 20892; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,PISCATAWAY,NJ 08854; UNIV NAPLES 2,FAC MED,IST SCI NEUROL,NAPLES,ITALY	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); NIH National Institute of Neurological Disorders & Stroke (NINDS); Rutgers State University New Brunswick; Rutgers State University Medical Center; Universita della Campania Vanvitelli	Polymeropoulos, MH (corresponding author), NIH,LAB GENET DIS RES,NATL CTR HUMAN GENOME RES,BETHESDA,MD 20892, USA.		Schaffer, Alejandro A/F-2902-2012; Schaffer, Alejandro/N-1222-2019					ARMSTRONG M, 1992, LANCET, V339, P1017, DOI 10.1016/0140-6736(92)90537-D; BELL GI, 1981, P NATL ACAD SCI USA, V78, P5979; CARREROVALENZUELA R, 1995, NEUROLOGY, V45, P1760, DOI 10.1212/WNL.45.9.1760; COTTINGHAM RW, 1984, AM J HUM GENET, V54, P252; DAVIS GC, 1979, PSYCHIAT RES, V1, P249, DOI 10.1016/0165-1781(79)90006-4; DUVOISIN RC, 1995, ANN NEUROL, V38, P355, DOI 10.1002/ana.410380303; Duvoisin RC, 1996, ADV NEUROL, V69, P33; FORNO LS, 1986, ADV NEUROL, V45, P35; GASSER T, 1994, ANN NEUROL, V36, P387, DOI 10.1002/ana.410360310; GIBB WRG, 1988, J NEUROL NEUROSUR PS, V51, P745, DOI 10.1136/jnnp.51.6.745; GIBB WRG, 1986, BRAIN, V1110, P1131; GOLBE LI, 1990, ANN NEUROL, V27, P276, DOI 10.1002/ana.410270309; GOLBE LI, 1992, MOV DIS, V7, P24; GOLBE LI, IN PRESS ANN NEUROL; GONZALEZ FJ, 1988, NATURE, V331, P442, DOI 10.1038/331442a0; GOWERS WR, 1893, MANUAL DIS NERVOUS S, P6366; GUPTA SK, 1995, COMPUT BIOMED RES, V28, P116, DOI 10.1006/cbmr.1995.1009; GYAPAY JM, 1994, NAT GENET, V7, P262; IKEBE S, 1990, BIOCHEM BIOPH RES CO, V170, P1044, DOI 10.1016/0006-291X(90)90497-B; JAGER WAD, 1978, J NEUROL NEUROSUR PS, V23, P283; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; LATHROP GM, 1984, P NATL ACAD SCI USA, V81, P3442; LAZZARINI AM, 1994, NEUROLOGY, V44, P499, DOI 10.1212/WNL.44.3_Part_1.499; LESTIENNE P, 1990, J NEUROCHEM, V55, P1810, DOI 10.1111/j.1471-4159.1990.tb04973.x; LYNCH T, 1994, NEUROLOGY, V44, P1878, DOI 10.1212/WNL.44.10.1878; MJONES HENRY, 1949, ACTA PSYCHIAT ET NEUROL [COPENHAGEN], V54, P1; Parkinson J, 1817, ESSAY SHAKING PALSY; POLYMEROPOULOS M, UNPUB; SANDY MS, 1993, MOVEMENT DISORD, V8, P74, DOI 10.1002/mds.870080114; SCHAPIRA AHV, 1990, MOVEMENT DISORD, V5, P294, DOI 10.1002/mds.870050406; SMITH CAD, 1992, LANCET, V339, P1375, DOI 10.1016/0140-6736(92)91196-F; TSUNEOKA Y, 1993, J BIOCHEM, V114, P263, DOI 10.1093/oxfordjournals.jbchem.a124164; VYAS I, 1986, J NEUROCHEM, V46, P1501, DOI 10.1111/j.1471-4159.1986.tb01768.x; WAKABAYASHI K, 1988, ACTA NEUROPATHOL, V76, P217, DOI 10.1007/BF00687767	34	571	613	1	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1996	274	5290					1197	1199		10.1126/science.274.5290.1197	http://dx.doi.org/10.1126/science.274.5290.1197			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT335	8895469	Green Submitted			2022-12-24	WOS:A1996VT33500055
J	Dronkers, NF				Dronkers, NF			A new brain region for coordinating speech articulation	NATURE			English	Article							SOMATOSENSORY AREA; STROKE PATIENTS; CT SCAN; INSULA; LOCALIZATION; VARIABILITY; COMPONENT; LANGUAGE; APRAXIA; APHEMIA	HUMAN speech requires complex planning and coordination of mouth and tongue movements, Certain types of brain injury can lead to a condition known as apraxia of speech, in which patients are impaired in their ability to coordinate speech movements but their ability to perceive speech sounds, including their own errors, is unaffected(1-3). The brain regions involved in coordinating speech, however, remain largely unknown, In this study, brain lesions of 25 stroke patients with a disorder in the motor planning of articulatory movements were compared with lesions of 19 patients without such deficits. A robust double dissociation was found between these two groups. All patients,vith articulatory planning deficits had lesions that included a discrete region of the left precentral gyrus of the insula, a cortical area beneath the frontal and temporal lobes. This area was completely spared in all patients without these articulation deficits. Thus this area seems to be specialized for the motor planning of speech.	UNIV CALIF DAVIS,DEPT NEUROL,DAVIS,CA 95616; UNIV CALIF DAVIS,DEPT LINGUIST,DAVIS,CA 95616	University of California System; University of California Davis; University of California System; University of California Davis	Dronkers, NF (corresponding author), VA NO CALIF HLTH CARE SYST,150 MUIR RD 126S,MARTINEZ,CA 94553, USA.		Dronkers, Nina F/K-6312-2015					Augustine J R, 1985, Neurol Res, V7, P2; Blumstein S., 1991, ACQUIRED APHASIA, P151; BURTON H, 1993, SOMATOSENS MOT RES, V10, P297, DOI 10.3109/08990229309028839; CANIER M, 1990, AGRAMMATIC APHASIA C, P37; DAMASIO H, 1980, BRAIN, V103, P337, DOI 10.1093/brain/103.2.337; Darley FL, 1975, MOTOR SPEECH DISORDE; DEAMMOND SJ, 1976, STRUCTURE HUMAN BRAI; DRONKERS N, 1992, J CLIN EXPT NEUROPSY, V14, P52; FREY R T, 1987, Society for Neuroscience Abstracts, V13, P1266; HABIB M, 1995, NEUROPSYCHOLOGIA, V33, P327, DOI 10.1016/0028-3932(94)00108-2; HALPERN H, 1973, J SPEECH HEAR DISORD, V38, P162, DOI 10.1044/jshd.3802.162; JOHNS DF, 1970, J SPEECH HEAR RES, V13, P556, DOI 10.1044/jshr.1303.556; Kertesz A, 1984, APRAXIA SPEECH PHYSL, P73; Luria A.R., 1966, HIGHER CORTICAL FUNC, P3; MARIE P, 1906, SEM MED, V26, P241; Marquardt T. P., 1984, APRAXIA SPEECH PHYSL, P91; MAZZOCCHI F, 1979, CORTEX, V15, P627, DOI 10.1016/S0010-9452(79)80051-9; MESULAM MM, 1982, J COMP NEUROL, V212, P1, DOI 10.1002/cne.902120102; OJEMANN GA, 1978, BRAIN LANG, V6, P239, DOI 10.1016/0093-934X(78)90061-5; OPPENHEIMER SM, 1992, NEUROLOGY, V42, P1727, DOI 10.1212/WNL.42.9.1727; PAULESU E, 1993, NATURE, V362, P342, DOI 10.1038/362342a0; RUFF RL, 1981, NEUROLOGY, V31, P353, DOI 10.1212/WNL.31.3.353; SCHIFF HB, 1983, ARCH NEUROL-CHICAGO, V40, P720, DOI 10.1001/archneur.1983.04050110038005; SCHNEIDER RJ, 1993, BRAIN RES, V621, P116, DOI 10.1016/0006-8993(93)90305-7; Shankweiler D., 1966, CORTEX, V2, P277, DOI [10.1016/S0010-9452(66)80008-4, DOI 10.1016/S0010-9452(66)80008-4]; SQUARE PA, IN PRESS APRAXIA; Talairach J., 1988, COPLANAR STEREOTAXIC; TOGNOLA G, 1980, NEUROPSYCHOLOGIA, V18, P257, DOI 10.1016/0028-3932(80)90122-0; WERTZ RT, 1991, APRAXIA SPEECH DISOR	29	848	871	0	59	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 14	1996	384	6605					159	161		10.1038/384159a0	http://dx.doi.org/10.1038/384159a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	VT336	8906789				2022-12-24	WOS:A1996VT33600063
J	Takimoto, E; Ishida, J; Sugiyama, F; Horiguchi, H; Murakami, K; Fukamizu, A				Takimoto, E; Ishida, J; Sugiyama, F; Horiguchi, H; Murakami, K; Fukamizu, A			Hypertension induced in pregnant mice by placental renin and maternal angiotensinogen	SCIENCE			English	Article							HUMAN CHORIONIC-GONADOTROPIN; TRANSGENIC MICE; INACTIVE RENIN; BLOOD-PRESSURE; EXPRESSION; SYSTEM; GENES; PRORENIN; SEQUENCE; CDNA	Maternal hypertension is a common complication of pregnancy and its pathophysiology is poorly understood. This phenomenon was studied in an animal model by mating transgenic mice expressing components of the human renin-angiotensin system. When transgenic females expressing angiotensinogen were mated with transgenic males expressing renin, the pregnant females displayed a transient elevation of blood pressure in late pregnancy, due to secretion of placental human renin into the maternal circulation. Blood pressure returned to normal levels after delivery of the pup. Histopathologic examination revealed uniform enlargement of glomeruli associated with an increase in urinary protein excretion, myocardial hypertrophy, and necrosis and edema in the placenta. These mice may provide molecular insights into pregnancy-associated hypertension in humans.	UNIV TSUKUBA,INST APPL BIOCHEM,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,TSUKUBA ADV RES ALLIANCE,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,LAB ANIM RES CTR,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,INST BASIC MED SCI,TSUKUBA,IBARAKI 305,JAPAN	University of Tsukuba; University of Tsukuba; University of Tsukuba; University of Tsukuba			fukamizu, akiyoshi/J-5350-2012	fukamizu, akiyoshi/0000-0002-8786-6020				BRAR HS, 1987, AM J OBSTET GYNECOL, V157, P363, DOI 10.1016/S0002-9378(87)80173-4; FUKAMIZU A, 1993, ARZNEIMITTEL-FORSCH, V43-1, P222; FUKAMIZU A, 1993, J BIOL CHEM, V268, P11617; FUKAMIZU A, 1989, BIOCHEM BIOPH RES CO, V165, P826, DOI 10.1016/S0006-291X(89)80040-3; GRAVES SW, 1993, NAT GENET, V4, P7, DOI 10.1038/ng0593-7; HAGEMANN A, 1994, EXP CLIN ENDOCRINOL, V102, P252, DOI 10.1055/s-0029-1211289; HSUEH WA, 1982, J CLIN ENDOCR METAB, V54, P1010, DOI 10.1210/jcem-54-5-1010; IHARA Y, 1987, ENDOCRINOL JAPON, V34, P887; IMAI T, 1983, P NATL ACAD SCI-BIOL, V80, P7405, DOI 10.1073/pnas.80.24.7405; LENZ T, 1991, AM J PHYSIOL, V260, pE876, DOI 10.1152/ajpendo.1991.260.6.E876; LENZ T, 1989, J CLIN ENDOCR METAB, V69, P31, DOI 10.1210/jcem-69-1-31; LI Y, 1991, J HYPERTENS, V9, P1119; NADEN RP, 1981, J CLIN INVEST, V68, P468, DOI 10.1172/JCI110277; SEALEY JE, 1985, AM J OBSTET GYNECOL, V153, P514, DOI 10.1016/0002-9378(85)90464-8; SHAW KJ, 1989, J CLIN INVEST, V83, P2085, DOI 10.1172/JCI114121; SKINNER SL, 1993, RENIN ANGIOTENSIN SY; SYMONDS EM, 1968, NATURE, V217, P1152, DOI 10.1038/2171152a0; TAKAHASHI S, 1991, BIOCHEM BIOPH RES CO, V180, P1103, DOI 10.1016/S0006-291X(05)81180-5; TANIMOTO K, 1994, J BIOL CHEM, V269, P31334; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; WARD K, 1993, NAT GENET, V4, P59, DOI 10.1038/ng0593-59; WARD K, 1993, NAT GENET, V4, P114; WARREN AY, 1982, BRIT J OBSTET GYNAEC, V89, P628, DOI 10.1111/j.1471-0528.1982.tb04717.x; WILSON M, 1980, AM J MED, V68, P97, DOI 10.1016/0002-9343(80)90178-3	24	203	207	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1996	274	5289					995	998		10.1126/science.274.5289.995	http://dx.doi.org/10.1126/science.274.5289.995			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR792	8875944				2022-12-24	WOS:A1996VR79200053
J	Cravatt, BF; Giang, DK; Mayfield, SP; Boger, DL; Lerner, RA; Gilula, NB				Cravatt, BF; Giang, DK; Mayfield, SP; Boger, DL; Lerner, RA; Gilula, NB			Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides	NATURE			English	Article							CANNABINOID RECEPTOR; NUCLEOTIDE-SEQUENCE; ANANDAMIDE; PURIFICATION; AMIDASE; GENE; IDENTIFICATION; MEMBRANE; PROTEINS; KETONES	ENDOGENOUS neuromodulatory molecules are commonly coupled to specific metabolic enzymes to ensure rapid signal inactivation, Thus, acetylcholine is hydrolysed by acetylcholine esterase(1) and tryptamine neurotransmitters like serotonin are degraded by monoamine oxidases(2). Previously, we reported the structure and sleep-inducing properties of cis-9-octadecenamide, a lipid isolated from the cerebrospinal fluid of sleep-deprived cats(3). cis-9-Octadecenamide, or oleamide, has since been shown to affect serotonergic systems(4) and block gap-junction communication in glial cells (our unpublished results). We also identified a membrane-bound enzyme activity that hydrolyses oleamide to its inactive acid, oleic acid(3). We now report the mechanism-based isolation, cloning and expression of this enzyme activity, originally named oleamide hydrolase(5), from rat liver plasma membranes. We also show that oleamide hydrolase converts anandamide, a fatty-acid amide identified as the endogenous ligand for the cannabinoid receptor(6), to arachidonic acid, indicating that oleamide hydrolase may serve as the general inactivating enzyme for a growing family of bioactive signalling molecules, the fatty-acid amides(6-8). Therefore we will hereafter refer to oleamide hydrolase as fatty-acid amide hydrolase, in recognition of the plurality of fatty-acid amides that the enzyme can accept as substrates.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92307 USA; Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92307 USA	Scripps Research Institute; Scripps Research Institute					NIDA NIH HHS [R01 DA015648] Funding Source: Medline	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ABDELAAL YAI, 1986, SCIENCE, V233, P1073, DOI 10.1126/science.3738525; BOIVIN J, 1992, TETRAHEDRON LETT, V33, P1285, DOI 10.1016/S0040-4039(00)91602-2; CHANG TH, 1990, NUCLEIC ACIDS RES, V18, P7180, DOI 10.1093/nar/18.23.7180; CORRICK CM, 1987, GENE, V53, P63, DOI 10.1016/0378-1119(87)90093-X; CRAVATT BF, 1995, SCIENCE, V268, P1506, DOI 10.1126/science.7770779; Cravatt BF, 1996, J AM CHEM SOC, V118, P580, DOI 10.1021/ja9532345; DESARNAUD F, 1995, J BIOL CHEM, V270, P6030, DOI 10.1074/jbc.270.11.6030; DEUTSCH DG, 1993, BIOCHEM PHARMACOL, V46, P791, DOI 10.1016/0006-2952(93)90486-G; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; ETTINGER RA, 1995, ARCH BIOCHEM BIOPHYS, V316, P14, DOI 10.1006/abbi.1995.1003; FACCI L, 1995, P NATL ACAD SCI USA, V92, P3376, DOI 10.1073/pnas.92.8.3376; FALK MM, 1994, J CELL BIOL, V127, P343, DOI 10.1083/jcb.127.2.343; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FERNANDEZ J, 1994, ANAL BIOCHEM, V218, P112, DOI 10.1006/abio.1994.1148; HuidobroToro JP, 1996, P NATL ACAD SCI USA, V93, P8078, DOI 10.1073/pnas.93.15.8078; IMPERIALI B, 1986, BIOCHEMISTRY-US, V25, P3760, DOI 10.1021/bi00361a005; KLEE H, 1984, P NATL ACAD SCI-BIOL, V81, P1728, DOI 10.1073/pnas.81.6.1728; MACPHEEQUIGLEY K, 1985, J BIOL CHEM, V260, P2185; Maurelli S, 1995, FEBS LETT, V377, P82, DOI 10.1016/0014-5793(95)01311-3; MAYAUX JF, 1990, J BACTERIOL, V172, P6764, DOI 10.1128/jb.172.12.6764-6773.1990; Patterson JE, 1996, J AM CHEM SOC, V118, P5938, DOI 10.1021/ja954064z; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; SINGER TP, 1995, FASEB J, V9, P605, DOI 10.1096/fasebj.9.8.7768351; UEDA N, 1995, J BIOL CHEM, V270, P23823, DOI 10.1074/jbc.270.40.23823; WAKAMATSU K, 1990, BIOCHEM BIOPH RES CO, V168, P423, DOI 10.1016/0006-291X(90)92338-Z; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YAMADA T, 1985, P NATL ACAD SCI USA, V82, P6522, DOI 10.1073/pnas.82.19.6522	28	1658	1719	7	149	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 7	1996	384	6604					83	87		10.1038/384083a0	http://dx.doi.org/10.1038/384083a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	VR219	8900284				2022-12-24	WOS:A1996VR21900060
J	Jain, C; Belasco, JG				Jain, C; Belasco, JG			A structural model for the HIV-1 Rev-RRE complex deduced from altered-specificity rev variants isolated by a rapid genetic strategy	CELL			English	Article							HOMEODOMAIN-DNA INTERACTIONS; CRYSTAL-STRUCTURE; TRANS-ACTIVATOR; MESSENGER-RNA; RESPONSIVE ELEMENT; OPERATOR COMPLEX; ESCHERICHIA-COLI; BINDING-ELEMENT; TARGET SEQUENCE; CLONED GENES	A broadly applicable genetic strategy was developed for investigating RNA-protein interactions and applied to the HIV-1 Rev protein. By rapidly screening thousands of Rev-RNA interactions in Escherichia coli, we isolated Rev suppressor mutations that alleviated the deleterious effect of mutations in RRE stem-loop IIB, the high affinity RNA-binding site for Rev. All of these suppressor mutations map to a single arginine-deficient face of a Rev alpha-helix, and some alter the binding specificity of the protein, providing genetic evidence for direct contacts between specific Rev amino acids and RNA nucleotides in the RNA complex of Rev. The spatial constraints suggested by these data have enabled us to model the structure of this complex.			Jain, C (corresponding author), HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOL GENET,BOSTON,MA 02115, USA.		Jain, Chaitanya/ABA-4238-2021	Jain, Chaitanya/0000-0003-2429-0105				AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; Battiste JL, 1995, J BIOMOL NMR, V6, P375; BATTISTE JL, 1994, BIOCHEMISTRY-US, V33, P2741, DOI 10.1021/bi00176a001; BEAMER LJ, 1992, J MOL BIOL, V227, P177, DOI 10.1016/0022-2836(92)90690-L; BENTLEY RC, 1991, MOL CELL BIOL, V11, P1829, DOI 10.1128/MCB.11.4.1829; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CADWELL RC, 1992, PCR METH APPL, V2, P28; DUNBRACK RL, 1993, J MOL BIOL, V230, P543, DOI 10.1006/jmbi.1993.1170; GHOSH S, 1996, IN PRESS GENE; GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215; HEAPHY S, 1990, CELL, V60, P685, DOI 10.1016/0092-8674(90)90671-Z; HOPE TJ, 1990, J VIROL, V64, P5360, DOI 10.1128/JVI.64.11.5360-5366.1990; IWAI S, 1992, NUCLEIC ACIDS RES, V20, P6465, DOI 10.1093/nar/20.24.6465; JAIN C, 1993, MOL MICROBIOL, V9, P233, DOI 10.1111/j.1365-2958.1993.tb01686.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KJEMS J, 1992, EMBO J, V11, P1119, DOI 10.1002/j.1460-2075.1992.tb05152.x; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LECLERC F, 1994, NAT STRUCT BIOL, V1, P293, DOI 10.1038/nsb0594-293; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MANDELGUTFREUND Y, 1995, J MOL BIOL, V253, P370, DOI 10.1006/jmbi.1995.0559; MANN DA, 1994, J MOL BIOL, V241, P193, DOI 10.1006/jmbi.1994.1488; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Miller J.H., 1972, EXPT MOL GENETICS; PETERSON RD, 1994, BIOCHEMISTRY-US, V33, P5357, DOI 10.1021/bi00184a001; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; PUGLISI JD, 1995, SCIENCE, V270, P1200, DOI 10.1126/science.270.5239.1200; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0; STRIPECKE R, 1994, MOL CELL BIOL, V14, P5898, DOI 10.1128/MCB.14.9.5898; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAN RY, 1995, P NATL ACAD SCI USA, V92, P5282, DOI 10.1073/pnas.92.12.5282; TAN RY, 1993, CELL, V73, P1031, DOI 10.1016/0092-8674(93)90280-4; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; Ye XM, 1995, CHEM BIOL, V2, P827, DOI 10.1016/1074-5521(95)90089-6	42	84	87	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1996	87	1					115	125		10.1016/S0092-8674(00)81328-8	http://dx.doi.org/10.1016/S0092-8674(00)81328-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VL695	8858154	Bronze			2022-12-24	WOS:A1996VL69500014
J	Ma, QF; Kintner, C; Anderson, DJ				Ma, QF; Kintner, C; Anderson, DJ			Identification of neurogenin, a vertebrate neuronal determination gene	CELL			English	Article							PERIPHERAL NERVOUS-SYSTEM; CELL FATE SPECIFICATION; ACHAETE-SCUTE HOMOLOG-1; LOOP-HELIX PROTEIN; XENOPUS-EMBRYOS; NEURAL INDUCTION; PRONEURAL GENE; LATERAL INHIBITION; DROSOPHILA-HAIRY; ORGAN FORMATION	Several bHLH proteins are involved in vertebrate neurogenesis, but those controlling early stages of neuronal determination have not yet been identified. Here we describe a novel, NeuroD-related bHLH protein, NEUROGENIN, whose expression precedes that of NeuroD in both mouse and Xenopus. Expression of Xenopus NEUROGENIN-related-1 (X-NGNR-1) defines the three prospective territories of primary neurogenesis. Overexpression of X-NGNR-1 (or NEUROGENIN) induces ectopic neurogenesis and ectopic expression of XNeuroD mRNA. Endogenous X-ngnr-1 expression becomes restricted to subsets of cells by lateral inhibition, mediated by X-Delta-1 and X-Notch. The properties of X-NGNR-1 are thus analogous to those of the Drosophila proneural genes, suggesting that it functions as a vertebrate neuronal determination factor.	CALTECH,HOWARD HUGHES MED INST,PASADENA,CA 91125; SALK INST BIOL STUDIES,LA JOLLA,CA 92186	California Institute of Technology; Howard Hughes Medical Institute; Salk Institute	Ma, QF (corresponding author), CALTECH,DIV BIOL 21676,PASADENA,CA 91125, USA.							AKAZAWA C, 1992, J BIOL CHEM, V267, P21879; AKAZAWA C, 1995, J BIOL CHEM, V270, P8730, DOI 10.1074/jbc.270.15.8730; Amon A, 1996, CELL, V84, P651, DOI 10.1016/S0092-8674(00)81041-7; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; BARTHOLOMA A, 1994, MECH DEVELOP, V48, P217, DOI 10.1016/0925-4773(94)90061-2; BIRREN SJ, 1993, DEVELOPMENT, V119, P597; Bobola N, 1996, CELL, V84, P699, DOI 10.1016/S0092-8674(00)81048-X; BRAND M, 1993, DEVELOPMENT, V119, P1; CHITNIS A, 1995, NATURE, V375, P761, DOI 10.1038/375761a0; Chitnis A, 1996, DEVELOPMENT, V122, P2295; CHITNIS AB, 1995, MOL CELL NEUROSCI, V6, P311, DOI 10.1006/mcne.1995.1024; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; COFFMAN CR, 1993, CELL, V73, P659, DOI 10.1016/0092-8674(93)90247-N; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; DOMINGUEZ M, 1993, EMBO J, V12, P2049, DOI 10.1002/j.1460-2075.1993.tb05854.x; FERREIRO B, 1994, DEVELOPMENT, V120, P3649; FERREIRO B, 1992, MECH DEVELOP, V40, P25; GHYSEN A, 1993, GENE DEV, V7, P723, DOI 10.1101/gad.7.5.723; GUILLEMOT F, 1993, MECH DEVELOP, V42, P171, DOI 10.1016/0925-4773(93)90006-J; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; GURDON JB, 1987, DEVELOPMENT, V99, P285; HINZ U, 1994, CELL, V76, P77, DOI 10.1016/0092-8674(94)90174-0; ISHIBASHI M, 1993, EUR J BIOCHEM, V215, P645, DOI 10.1111/j.1432-1033.1993.tb18075.x; JAN YN, 1994, ANNU REV GENET, V28, P373, DOI 10.1146/annurev.ge.28.120194.002105; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JARMAN AP, 1993, DEVELOPMENT, V119, P19; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KOPAN R, 1994, DEVELOPMENT, V120, P2385; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Kume H, 1996, BIOCHEM BIOPH RES CO, V219, P526, DOI 10.1006/bbrc.1996.0267; KUNISCH M, 1994, P NATL ACAD SCI USA, V91, P10139, DOI 10.1073/pnas.91.21.10139; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; OSCHWALD R, 1991, International Journal of Developmental Biology, V35, P399; Ramon y Cajal S., 1897, HISTOLOGY NERVOUS SY, V1; SAITO T, 1995, MOL CELL NEUROSCI, V6, P280, DOI 10.1006/mcne.1995.1022; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SHIMIZU C, 1995, EUR J BIOCHEM, V229, P239, DOI 10.1111/j.1432-1033.1995.0239l.x; Sil A, 1996, CELL, V84, P711, DOI 10.1016/S0092-8674(00)81049-1; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; Sommer L, 1995, NEURON, V15, P1245, DOI 10.1016/0896-6273(95)90005-5; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; Wang YK, 1996, NATURE, V379, P823, DOI 10.1038/379823a0; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; ZIMMERMAN K, 1993, DEVELOPMENT, V119, P221	52	707	718	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1996	87	1					43	52		10.1016/S0092-8674(00)81321-5	http://dx.doi.org/10.1016/S0092-8674(00)81321-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VL695	8858147	Bronze			2022-12-24	WOS:A1996VL69500007
J	Stefansson, S; Lawrence, DA				Stefansson, S; Lawrence, DA			The serpin PAI-1 inhibits cell migration by blocking integrin alpha(v)beta(3) binding to vitronectin	NATURE			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; SMOOTH-MUSCLE CELLS; ENDOTHELIAL-CELLS; EXTRACELLULAR-MATRIX; RECEPTOR; DOMAIN; LOCALIZATION; PURIFICATION; MEMBRANE; FORMS	DURING wound healing, migrating cells increase expression of both the vitronectin receptor (VNR) integrins(1) and plasminogen activators(2,3). Here we report that vitronectin significantly enhances the migration of smooth muscle cells (SMCs), and that the specific VNR alpha(v) beta(3) is required for cell motility, We also show that the alpha(v) beta(3) attachment site on vitronectin overlaps with the binding site for plasminogen activator inhibitor (PAI)-1, and that the active conformation of PAI-I blocks SMC migration, This effect requires high-affinity binding to vitronectin, and is not dependent on the ability of PAI-1 to inhibit plasminogen activators. Formation of a complex between PAI-1 and plasminogen activators results in loss of PAI-1 affinity for vitronectin and restores cell migration. These data demonstrate a direct link between plasminogen activators and integrin-mediated cell migration, and show that PAI-1 can control cell-matrix interactions by regulating the accessibility of specific cell-attachment sites. This indicates that the localization of plasminogen activators at sites of focal contact does not initiate a proteolytic cascade leading to generalized matrix destruction, but instead is required to expose cryptic cell-attachment sites necessary for SMC migration.	AMER RED CROSS,JEROME H HOLLAND LAB,DEPT BIOCHEM,ROCKVILLE,MD 20855	American Red Cross				Lawrence, Daniel/0000-0003-3126-1935				BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BROWN SL, 1994, CARDIOVASC RES, V28, P1815, DOI 10.1093/cvr/28.12.1815; CARMELIET P, 1996, FIBRINOLYSIS, V10, P194; CIAMBRONE GJ, 1992, J BIOL CHEM, V267, P13617; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Clark RAF, 1996, AM J PATHOL, V148, P1407; CLYMAN RI, 1992, EXP CELL RES, V200, P272, DOI 10.1016/0014-4827(92)90173-6; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; ENRLICH HJ, 1990, J BIOL CHEM, V265, P13029; GRADAHLHANSEN J, 1988, J INVEST DERMATOL, V90, P790; HAAS TA, 1994, CURR OPIN CELL BIOL, V6, P656, DOI 10.1016/0955-0674(94)90091-4; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Jones JI, 1996, P NATL ACAD SCI USA, V93, P2482, DOI 10.1073/pnas.93.6.2482; KIM JP, 1994, J BIOL CHEM, V269, P26926; KVASSMAN JO, 1995, FIBRINOLYSIS, V9, P215, DOI 10.1016/S0268-9499(08)80062-8; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; LEVIN EG, 1987, J CELL BIOL, V105, P2543, DOI 10.1083/jcb.105.6.2543; MIMURO J, 1987, BLOOD, V70, P721; MORE RS, 1995, CARDIOVASC RES, V29, P22, DOI 10.1016/0008-6363(96)88541-5; NASKI MC, 1993, J BIOL CHEM, V268, P12367; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; PINTUCCI G, 1993, J LAB CLIN MED, V122, P69; SEIFFERT D, 1994, J BIOL CHEM, V269, P2659; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; SMITH JW, 1988, J BIOL CHEM, V263, P18726; Stefansson S, 1996, J BIOL CHEM, V271, P8215, DOI 10.1074/jbc.271.14.8215; VASSALLI JD, 1994, NATURE, V370, P14, DOI 10.1038/370014a0	30	591	601	1	32	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 3	1996	383	6599					441	443		10.1038/383441a0	http://dx.doi.org/10.1038/383441a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL463	8837777				2022-12-24	WOS:A1996VL46300063
J	Derbyshire, SWG; Furedi, A				Derbyshire, SWG; Furedi, A			For debate: Do fetuses feel pain? ''Fetal pain'' is a misnomer	BRITISH MEDICAL JOURNAL			English	Article									UNIV MANCHESTER,HOPE HOSP,CTR RHEUMAT DIS,SALFORD M6 8HD,LANCS,ENGLAND; BIRTH CONTROL TRUST,LONDON W1N 7RD,ENGLAND	University of Manchester				Derbyshire, Stuart/0000-0002-2766-3424				FITZGERALD M, 1994, TXB PAIN, P153; Fitzgerald M., 1995, FOETAL PAIN UPDATE C; GIANNAKOULOPOULOS X, 1994, LANCET, V344, P77, DOI 10.1016/S0140-6736(94)91279-3; LEVENTHAL H, 1984, ADV EXP SOC PSYCHOL, V17, P117, DOI 10.1016/S0065-2601(08)60119-7; MRZLJAK L, 1988, J COMP NEUROL, V271, P355, DOI 10.1002/cne.902710306; *OFF NAT STAT, 1995, SERIES AB, V21, P19	6	34	35	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1996	313	7060					795	795						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK566	8842074				2022-12-24	WOS:A1996VK56600026
J	Hole, DJ; Watt, GCM; DaveySmith, G; Hart, CL; Gillis, CR; Hawthorne, VM				Hole, DJ; Watt, GCM; DaveySmith, G; Hart, CL; Gillis, CR; Hawthorne, VM			Impaired lung function and mortality risk in men and women: Findings from the Renfrew and Paisley prospective population study	BRITISH MEDICAL JOURNAL			English	Article							FORCED EXPIRATORY VOLUME; CORONARY HEART-DISEASE; CARDIOVASCULAR-DISEASE; PULMONARY-FUNCTION; RESPIRATORY SYMPTOMS; PLASMA-CHOLESTEROL; CANCER; INTERVENTION; DEATH; BREATHLESSNESS	Objective-To assess the relation between forced expiratory volume in one second (FEV(1)) and subsequent mortality. Design-Prospective general population study. Setting-Renfrew and Paisley, Scotland. Subjects-7058 men and 8353 women aged 45-64 years at baseline screening in 1972-6. Main outcome measure-Mortality from all causes, ischaemic heart disease, cancer, lung and other cancers, stroke, respiratory disease, and other causes of death after 15 years of follow up. Results-2545 men and 1894 women died during the follow up period. Significant trends of increasing risk with diminishing FEV(1) are apparent for both sexes for all the causes of death examined after adjustment for age, cigarette smoking, diastolic blood pressure, cholesterol concentration, body mass index, and social class. The relative hazard ratios for all cause mortality for subjects in the lowest fifth of the FEV(1) distribution were 1.92 (95% confidence interval 1.68 to 2.20) for men and 1.89 (1.63 to 2.20) for women. Corresponding relative hazard ratios were 1.56 (1.26 to 1.92) and 1.88 (1.44 to 2.47) for ischaemic heart disease, 2.53 (1.69 to 3.79) and 4.37 (1.84 to 10.42) for lung cancer, and 1.66 (1.07 to 2.59) and 1.65 (1.09 to 2.49) for stroke. Reduced FEV(1) was also associated with an increased risk for each cause of death examined except cancer for lifelong nonsmokers. Conclusions-Impaired lung function is major clinical indicator of mortality risk in men and women for a wide range of diseases. The use of FEV(1) as part of any health assessment of middle aged patients should be considered. Smokers with reduced FEV(1) should form a priority group for targeted advice to stop smoking.	UNIV GLASGOW,DEPT GEN PRACTICE,GLASGOW,LANARK,SCOTLAND; UNIV BRISTOL,DEPT SOCIAL MED,BRISTOL,AVON,ENGLAND; UNIV MICHIGAN,SCH PUBL HLTH,DEPT EPIDEMIOL,ANN ARBOR,MI 48109	University of Glasgow; University of Bristol; University of Michigan System; University of Michigan	Hole, DJ (corresponding author), RUCHILL HOSP,W SCOTLAND CANC SURVEILLANCE UNIT,GLASGOW G20 9NB,LANARK,SCOTLAND.		Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314				ANTHONISEN NR, 1994, JAMA-J AM MED ASSOC, V272, P1497, DOI 10.1001/jama.272.19.1497; BROWNER WS, 1992, WESTERN J MED, V157, P534; COOK DG, 1988, EUR HEART J, V9, P1215, DOI 10.1093/oxfordjournals.eurheartj.a062432; COX DR, 1972, J R STAT SOC B, V34, P187; EBIKRYSTON KL, 1988, J CLIN EPIDEMIOL, V41, P251, DOI 10.1016/0895-4356(88)90129-1; EBIKRYSTON KL, 1989, INT J EPIDEMIOL, V18, P84, DOI 10.1093/ije/18.1.84; FARCHI G, 1987, AM J EPIDEMIOL, V126, P400, DOI 10.1093/oxfordjournals.aje.a114671; Fletcher CM, 1976, NATURAL HIST CHRONIC; GILLIS CR, 1988, J EPIDEMIOL COMMUN H, V42, P44, DOI 10.1136/jech.42.1.44; HAWTHORNE VM, 1974, BMJ-BRIT MED J, V3, P600, DOI 10.1136/bmj.3.5931.600; ISLES CG, 1989, BMJ-BRIT MED J, V298, P920, DOI 10.1136/bmj.298.6678.920; KANNELL WB, 1983, AM HEART J, V331, P315; KRZYZANOWSKI M, 1986, INT J EPIDEMIOL, V15, P56, DOI 10.1093/ije/15.1.56; KULLER LH, 1990, AM J EPIDEMIOL, V132, P265, DOI 10.1093/oxfordjournals.aje.a115656; KULLER LW, 1989, AM REV RESPIR DIS, V140, P576; PERSSON C, 1986, AM J EPIDEMIOL, V124, P942, DOI 10.1093/oxfordjournals.aje.a114483; PETO R, 1983, AM REV RESPIR DIS, V128, P491, DOI 10.1164/arrd.1983.128.3.491; ROSE G, 1986, BRIT MED J, V293, P306, DOI 10.1136/bmj.293.6542.306; SHAPER AG, 1989, BRIT MED J, V298, P1381, DOI 10.1136/bmj.298.6684.1381; SMITH GD, 1992, BRIT MED J, V305, P757, DOI 10.1136/bmj.305.6856.757; STRACHAN DP, 1991, BMJ-BRIT MED J, V302, P84, DOI 10.1136/bmj.302.6768.84; TOCKMAN MS, 1989, AM REV RESPIR DIS, V140, pS56, DOI 10.1164/ajrccm/140.3_Pt_2.S56; TOCKMAN MS, 1987, ANN INTERN MED, V106, P512, DOI 10.7326/0003-4819-106-4-512; VANDENEEDEN SK, 1992, EPIDEMIOLOGY, V3, P253, DOI 10.1097/00001648-199205000-00011; WELIN L, 1987, NEW ENGL J MED, V317, P521, DOI 10.1056/NEJM198708273170901; 1985, ACTA MED SCAND, V217, P241	26	693	708	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 21	1996	313	7059					711	715						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VJ441	8819439				2022-12-24	WOS:A1996VJ44100019
J	Yuzhakov, A; Turner, J; ODonnell, M				Yuzhakov, A; Turner, J; ODonnell, M			Replisome assembly reveals the basis for asymmetric function in leading and lagging strand replication	CELL			English	Article							DNA-POLYMERASE-III; ONE HOLOENZYME PARTICLE; CELL NUCLEAR ANTIGEN; ESCHERICHIA-COLI; SLIDING CLAMPS; ACCESSORY PROTEINS; PRIMED DNA; HELICASE; PRIMASE; BACTERIOPHAGE-T7	The E. coli replicase, DNA polymerase III holoenzyme, contains two polymerases for replication of duplex DNA. The DNA strands are antiparallel requiring different modes of replicating the two strands: one is continuous (leading) while the other is discontinuous (lagging). The two polymerases within holoenzyme are generally thought to have asymmetric functions for replication of these two strands. This report finds that the two polymerases have equal properties, both are capable of replicating the more difficult lagging strand. Asymmetric action is, however, imposed by the helicase that encircles the lagging strand. The helicase contact defines the leading polymerase constraining it to a subset of actions, while leaving the other to cycle on the lagging strand. The symmetric actions of the two polymerases free holoenzyme to assemble into the replisome in either orientation without concern for a correct match to one or the other strand.	CORNELL UNIV,COLL MED,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Cornell University; Howard Hughes Medical Institute	Yuzhakov, A (corresponding author), CORNELL UNIV,COLL MED,DEPT MICROBIOL,NEW YORK,NY 10021, USA.				NIGMS NIH HHS [GM 38839] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839, R37GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI K, 1979, P NATL ACAD SCI USA, V76, P4308, DOI 10.1073/pnas.76.9.4308; BUJALOWSKI W, 1995, BIOCHEMISTRY-US, V34, P8513, DOI 10.1021/bi00027a001; BURGERS PMJ, 1983, J BIOL CHEM, V258, P7669; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; DONG ZM, 1993, J BIOL CHEM, V268, P11758; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; HACKER KJ, 1994, J BIOL CHEM, V269, P24221; JOHANSON KO, 1984, J BIOL CHEM, V259, P4589; KELMAN Z, 1995, GENE, V166, P177, DOI 10.1016/0378-1119(95)00556-7; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kelman Z, 1995, METHOD ENZYMOL, V262, P430; Kim S, 1996, J BIOL CHEM, V271, P4315; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1992, DNA REPLICATION, P165; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; MAKI H, 1988, J BIOL CHEM, V263, P6570; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MOK M, 1987, J BIOL CHEM, V262, P16558; NAKAI H, 1986, J BIOL CHEM, V261, P5208; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4732; ROWEN L, 1978, J BIOL CHEM, V253, P758; SANMARTIN MC, 1995, J STRUCT BIOL, V114, P167, DOI 10.1006/jsbi.1995.1016; SELICK HE, 1987, DNA REPLICATION RECO, V47, P183; SINHA NK, 1980, J BIOL CHEM, V263, P6561; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; STUKENBERG PT, 1995, J BIOL CHEM, V270, P13384, DOI 10.1074/jbc.270.22.13384; TOUGU K, 1994, J BIOL CHEM, V269, P4675; TURNER J, 1994, METHOD ENZYMOL, V262, P442; WICKNER W, 1973, P NATL ACAD SCI USA, V70, P1764, DOI 10.1073/pnas.70.6.1764; WU CA, 1992, J BIOL CHEM; XIAO H, 1993, J BIOL CHEM, V268, P11773; Yao N, 1996, GENES CELLS, V1, P101, DOI 10.1046/j.1365-2443.1996.07007.x; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001; Yu X, 1996, J MOL BIOL, V259, P7, DOI 10.1006/jmbi.1996.0297	47	156	158	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1996	86	6					877	886		10.1016/S0092-8674(00)80163-4	http://dx.doi.org/10.1016/S0092-8674(00)80163-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VJ443	8808623	hybrid			2022-12-24	WOS:A1996VJ44300006
J	Grunewald, A; Lankheet, MJM				Grunewald, A; Lankheet, MJM			Orthogonal motion after-effect illusion predicted by a model of cortical motion processing	NATURE			English	Article							TRANSPARENT MOTION; AREA MT; PERCEPTION; DIRECTION; INTEGRATION; MOVEMENT; PATTERNS; ADAPTATION; COHERENCE; NEURONS	THE motion after-effect occurs after prolonged viewing of motion; a subsequent stationary scene is perceived as moving in the opposite direction(1,2). This illusion Is thought to arise because motion is represented by the differential activities of populations of cortical neurons toned to opposite directions; fatigue in one population leads to an imbalance that favours the opposite direction once the stimulus ceases(3). Following adaptation to multiple directions of motion, the after-effect is unidirectional(4-6), indicating that motion signals are integrated across all directions. Yet humans can perceive several directions of motion simultaneously(7-10). The question therefore arises as to how the visual system can perform both sharp segregation and global integration of motion signals, Here me show in computer simulations that this can occur if excitatory interactions between different directions are sharply tuned while inhibitory interactions are broadly tuned, Our model predicts that adaptation to simultaneous motion in opposite directions will lead to an orthogonal motion after-effect. This prediction was confirmed in psychophysical experiments, Thus, broadly tuned inhibitory interactions are likely to be important in the integration and segregation of motion signals. These interactions may occur in the cortical area MT, which contains motion-sensitive neurons with properties similar to those required by our model(11-14).	MAX PLANCK INST BIOL CYBERNET,D-72076 TUBINGEN,GERMANY; UNIV UTRECHT,DEPT COMPARAT PHYSIOL,NL-3584 CH UTRECHT,NETHERLANDS; UNIV UTRECHT,HELMHOLTZ INST,NL-3584 CH UTRECHT,NETHERLANDS	Max Planck Society; Utrecht University; Utrecht University	Grunewald, A (corresponding author), CALTECH,DIV BIOL,MAIL CODE 216-76,PASADENA,CA 91125, USA.							Addams J, 1834, LONDON EDINBURGH PHI, V5, P373, DOI [DOI 10.1080/14786443408648481, 10.1080/14786443408648481]; ADELSON EH, 1982, NATURE, V300, P523, DOI 10.1038/300523a0; ALBRIGHT TD, 1984, J NEUROPHYSIOL, V52, P1106, DOI 10.1152/jn.1984.52.6.1106; BRADDICK O, 1993, TRENDS NEUROSCI, V16, P263, DOI 10.1016/0166-2236(93)90179-P; BRADLEY DC, 1995, NATURE, V373, P609, DOI 10.1038/373609a0; CLARKE PGH, 1977, VISION RES, V17, P1243, DOI 10.1016/0042-6989(77)90164-X; GIASCHI D, 1993, J NEUROPHYSIOL, V70, P2024, DOI 10.1152/jn.1993.70.5.2024; GROSSBERG S, 1972, Mathematical Biosciences, V15, P253, DOI 10.1016/0025-5564(72)90038-7; GROSSBERG S, 1976, BIOL CYBERN, V23, P121, DOI 10.1007/BF00344744; Grunewald A, 1996, ADV NEUR IN, V8, P837; Heeger DJ, 1996, P NATL ACAD SCI USA, V93, P623, DOI 10.1073/pnas.93.2.623; HINS E, 1992, P NATL ACAD SCI USA, V89, P9025; Hiris E, 1996, VISUAL NEUROSCI, V13, P187, DOI 10.1017/S0952523800007227; HUBEL DH, 1968, J PHYSIOL-LONDON, V195, P215, DOI 10.1113/jphysiol.1968.sp008455; MATHER G, 1980, PERCEPTION, V9, P379, DOI 10.1068/p090379; MINGOLLA E, 1992, VISION RES, V32, P1015, DOI 10.1016/0042-6989(92)90003-2; MULLIGAN JB, 1993, VISION RES, V33, P2021, DOI 10.1016/0042-6989(93)90025-R; NAKAYAMA K, 1985, VISION RES, V25, P625, DOI 10.1016/0042-6989(85)90171-3; NEWSOME WT, 1989, NATURE, V341, P52, DOI 10.1038/341052a0; QIAN N, 1994, J NEUROSCI, V14, P7357; SNOWDEN RJ, 1991, J NEUROSCI, V11, P2768; STONER GR, 1990, NATURE, V344, P153, DOI 10.1038/344153a0; SUTHERLAND NS, 1961, Q J EXP PSYCHOL, V13, P222, DOI 10.1080/17470216108416498; TOOTELL RBH, 1995, NATURE, V375, P139, DOI 10.1038/375139a0; VANDOORN AJ, 1985, PERCEPTION, V14, P209, DOI 10.1068/p140209; VERSTRATEN FAJ, 1994, VISION RES, V34, P349, DOI 10.1016/0042-6989(94)90093-0; VERSTRATEN FAJ, 1994, VISION RES, V34, P1149, DOI 10.1016/0042-6989(94)90297-6; WATAMANIUK SNJ, 1989, VISION RES, V29, P47, DOI 10.1016/0042-6989(89)90173-9; Wohlgemuth A., 1911, AFTER EFFECT SEEN MO, V1	29	62	62	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1996	384	6607					358	360		10.1038/384358a0	http://dx.doi.org/10.1038/384358a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV271	8934521				2022-12-24	WOS:A1996VV27100049
J	Nelson, RG; Bennett, PH; Beck, GJ; Tan, M; Knowler, WC; Mitch, WE; Hirschman, GH; Myers, BD				Nelson, RG; Bennett, PH; Beck, GJ; Tan, M; Knowler, WC; Mitch, WE; Hirschman, GH; Myers, BD			Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OVERT NEPHROPATHY; ALBUMIN EXCRETION; NEPHROTIC HUMANS; PROTEINURIA; SELECTIVITY; PREVALENCE; DIET	Background Non-insulin-dependent diabetes mellitus (NIDDM) is a major cause of end-stage renal disease. However, the course and determinants of renal failure in this type of diabetes have not been clearly defined. Methods We studied glomerular function at intervals of 6 to 12 months for 4 years in 194 Pima Indians selected to represent different stages in the development and progression of diabetic renal disease. Initially, 31 subjects had normal glucose tolerance, 29 had impaired glucose tolerance, 30 had newly diagnosed diabetes, and 104 had had diabetes for five years or more; of these 104, 20 had normal albumin excretion, 50 had microalbuminuria, and 34 had macroalbuminuria. The glomerular filtration rate, renal plasma flow, urinary albumin excretion, and blood pressure were measured at each examination. Results Initially, the mean (+/-SE) glomerular filtration rate was 143+/-7 ml per minute in subjects with newly diagnosed diabetes, 155+/-7 ml per minute in those with microalbuminuria, and 124+/-7 ml per minute in those with macroalbuminuria; these values were 16 percent, 26 percent, and 1 percent higher, respectively, than in the subjects with normal glucose tolerance (123+/-4 ml per minute). During four years of follow-up, the glomerular filtration rate increased by 18 percent in the subjects who initially had newly diagnosed diabetes (P=0.008); the rate declined by 3 percent in those with microalbuminuria at base line (P=0.29) and by 35 percent in those with macroalbuminuria (P<0.001). Higher base-line blood pressure predicted increasing urinary albumin excretion (P=0.006), and higher base-line urinary albumin excretion predicted a decline in the glomerular filtration rate (P<0.001). The initial glomerular filtration rate did not predict worsening albuminuria. Conclusions The glomerular filtration rate is elevated at the onset of NIDDM and remains so while normal albumin excretion or microalbuminuria persists. it declines progressively after the development of macroalbuminuria. (C)1996, Massachusetts Medical Society.	CLEVELAND CLIN FDN,DEPT BIOSTAT & EPIDEMIOL,DIABET RENAL DIS STUDY DATA COORDINATING CTR,CLEVELAND,OH 44195; EMORY UNIV,SCH MED,DIV RENAL,ATLANTA,GA 30322; NIDDKD,DIV KIDNEY UROL & HEMATOL DIS,CHRON RENAL DIS PROGRAM,BETHESDA,MD; NIDDKD,PHOENIX EPIDEMIOL & CLIN RES BRANCH,PHOENIX,AZ; STANFORD UNIV,SCH MED,DIV NEPHROL,STANFORD,CA 94305	Cleveland Clinic Foundation; Emory University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Stanford University			Nelson, Robert G/B-1470-2012; Bennett, Peter/AAH-9605-2021		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [N01DK072291, N01DK062285] Funding Source: NIH RePORTER; NIDDK NIH HHS [N01-DK-7-2291, N01-DK-6-2285] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHANG RLS, 1975, BIOPHYS J, V15, P861, DOI 10.1016/S0006-3495(75)85862-0; COWIE CC, 1989, NEW ENGL J MED, V321, P1074, DOI 10.1056/NEJM198910193211603; DEEN WM, 1985, AM J PHYSIOL, V249, pF374, DOI 10.1152/ajprenal.1985.249.3.F374; DRUMOND MC, 1994, J CLIN INVEST, V94, P1187, DOI 10.1172/JCI117435; HOSTETTER TH, 1982, AM J MED, V72, P375, DOI 10.1016/0002-9343(82)90490-9; HOSTETTER TH, 1981, KIDNEY INT, V19, P410, DOI 10.1038/ki.1981.33; KNOWLER WC, 1978, AM J EPIDEMIOL, V108, P497, DOI 10.1093/oxfordjournals.aje.a112648; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; Maschio G, 1996, NEW ENGL J MED, V334, P939, DOI 10.1056/NEJM199604113341502; MAUER SM, 1984, J CLIN INVEST, V74, P1143, DOI 10.1172/JCI111523; MENARD L, 1980, CLIN CHEM, V26, P1598; MYERS BD, 1995, KIDNEY INT, V47, P1781, DOI 10.1038/ki.1995.246; NAKAMURA Y, 1988, DIABETES, V37, P1202, DOI 10.2337/diabetes.37.9.1202; NELSON RG, 1991, ARCH INTERN MED, V151, P1761, DOI 10.1001/archinte.151.9.1761; NELSON RG, 1995, DIABETES CARE, V18, P182, DOI 10.2337/diacare.18.2.182; NELSON RG, 1989, DIABETOLOGIA, V32, P870, DOI 10.1007/BF00297452; NELSON RG, 1988, DIABETOLOGIA, V31, P730, DOI 10.1007/BF00274774; NELSON RG, 1991, ACTA DIABETOL, V28, P143, DOI 10.1007/BF00579717; PAGTALUNAN ME, 1994, J AM SOC NEPHROL, V5, P381; PARVING HH, 1992, KIDNEY INT, V41, P758, DOI 10.1038/ki.1992.118; PETERSON JC, 1995, ANN INTERN MED, V123, P754, DOI 10.7326/0003-4819-123-10-199511150-00003; VASQUEZ B, 1984, DIABETOLOGIA, V26, P127, DOI 10.1007/BF00281119; World Health Organization, 1985, WHO TECH REP SER, V727, P7; [No title captured]	25	369	377	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 28	1996	335	22					1636	1642		10.1056/NEJM199611283352203	http://dx.doi.org/10.1056/NEJM199611283352203			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV936	8929360	Bronze			2022-12-24	WOS:A1996VV93600003
J	Joneson, T; McDonough, M; BarSagi, D; VanAelst, L				Joneson, T; McDonough, M; BarSagi, D; VanAelst, L			RAC regulation of actin polymerization and proliferation by a pathway distinct from Jun kinase	SCIENCE			English	Article							ACTIVATED PROTEIN-KINASES; BINDING; GTPASES; TRANSFORMATION; CDC42; RHOA; PHOSPHORYLATION; IDENTIFICATION; DOMAIN	The RAC guanine nucleotide binding proteins regulate multiple biological activities, including actin polymerization, activation of the Jun kinase (JNK) cascade, and cell proliferation. RAC effector loop mutants were identified that separate the ability of RAC to interact with different downstream effecters. One mutant of activated human RAC protein, RAC(V12H40) (with valine and histidine substituted at position 12 and 40, respectively), was defective in binding to PAK3, a Ste20-related p21-activated kinase (PAK), but bound to PORI, a RAG-binding protein. This mutant failed to stimulate PAK and JNK activity but still induced membrane ruffling and mediated transformation. A second mutant, RAC(V12L37) (with leucine substituted at position 37), which bound PAK but not PORI, induced JNK activation but was defective in inducing membrane ruffling and transformation, These results indicate that the effects of RAC on the JNK cascade and on actin polymerization and cell proliferation are mediated by distinct effector pathways that diverge at the level of RAC itself.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; SUNY STONY BROOK,DEPT MOL GENET & MICROBIOL,STONY BROOK,NY 11794	Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook				McDonough, Michele/0000-0002-3718-6465; Bar-Sagi, Dafna/0000-0003-2597-8948	NCI NIH HHS [CA55360] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055360, R37CA055360, R56CA055360] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P1; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; JONESON T, UNPUB; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; VANAELST L, 1994, COLD SPRING HARB SYM, V59, P181, DOI 10.1101/SQB.1994.059.01.022; VanAelst L, 1996, EMBO J, V15, P3778, DOI 10.1002/j.1460-2075.1996.tb00751.x; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHOU YH, 1991, NUCLEIC ACIDS RES, V19, P6052, DOI 10.1093/nar/19.21.6052	32	234	238	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 22	1996	274	5291					1374	1376		10.1126/science.274.5291.1374	http://dx.doi.org/10.1126/science.274.5291.1374			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU954	8910277				2022-12-24	WOS:A1996VU95400053
J	Pearce, KF; Haefner, HK; Sarwar, SF; Nolan, TE				Pearce, KF; Haefner, HK; Sarwar, SF; Nolan, TE			Cytopathological findings on vaginal Papanicolaou smears after hysterectomy for benign gynecologic disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INVASIVE-CARCINOMA; INSITU; CANCER; NEED	Background Periodic, routine Papanicolaou smears of cells from the vagina are commonly examined in women who have undergone a hysterectomy for benign gynecologic disease. The benefits of this method of screening are not known. Methods We analyzed Papanicolaou smears obtained from the vaginal apex (cuff) in 6265 women at Charity Hospital in New Orleans between January 1, 1992, and December 31, 1994. Of the 10,595 vaginal smears, an estimated 9610 were obtained during follow-up examinations of 5682 women who had undergone hysterectomy for benign gynecologic disease. Results Among these 9610 vaginal smears, 104, from 79 women, were abnormal. The abnormal smears were categorized according to the findings, as follows: atypical squamous cells of undetermined significance, 52 (0.5 percent of all smears); low-grade squamous intraepithelial lesion, 44 (0.5 percent); high-grade squamous intraepithelial lesion, 6 (0.1 percent); and squamous-cell carcinoma, 2 (0.02 per cent). In five women, biopsies revealed vaginal intraepithelial neoplasia type I or II; there were no biopsy proved cases of vaginal cancer. The probability of an abnormal Papanicolaou smear in this group of women was 1.1 percent, and the positive predictive value of the Papanicolaou test for detecting vaginal cancer was 0 percent (95 percent confidence interval, 0 to 33 percent). Conclusions The prevalence of abnormal findings on cytopathological examination of vaginal Papanicolaou smears after hysterectomy for benign gynecologic disease is extremely low. (C) 1996, Massachusetts Medical Society.	LOUISIANA STATE UNIV,MED CTR,DEPT OBSTET & GYNECOL,NEW ORLEANS,LA 70112; LOUISIANA STATE UNIV,MED CTR,DEPT INTERNAL MED,NEW ORLEANS,LA; LOUISIANA STATE UNIV,MED CTR,DEPT PATHOL,NEW ORLEANS,LA 70112; UNIV MICHIGAN,DEPT OBSTET & GYNECOL,ANN ARBOR,MI 48109	Louisiana State University System; Louisiana State University System; Louisiana State University System; University of Michigan System; University of Michigan								AHO M, 1991, CANCER, V68, P195, DOI 10.1002/1097-0142(19910701)68:1<195::AID-CNCR2820680135>3.0.CO;2-L; *AM COLL OBST GYN, 1993, ACOG TECHN B, V183; American Cancer Society, 1991, PAP TEST; BELL J, 1984, OBSTET GYNECOL, V64, P699; BRINTON LA, 1990, GYNECOL ONCOL, V38, P49, DOI 10.1016/0090-8258(90)90010-I; CHRISTOPHERSON WM, 1969, CANCER-AM CANCER SOC, V24, P64, DOI 10.1002/1097-0142(196907)24:1<64::AID-CNCR2820240108>3.0.CO;2-Y; CHRISTOPHERSON WM, 1976, CANCER, V38, P1357, DOI 10.1002/1097-0142(197609)38:3<1357::AID-CNCR2820380340>3.0.CO;2-A; CRAMER DW, 1974, AM J OBSTET GYNECOL, V118, P443, DOI 10.1016/S0002-9378(16)33683-3; DICKINSON L, 1972, MAYO CLIN PROC, V47, P545; Fetters MD, 1996, JAMA-J AM MED ASSOC, V275, P940, DOI 10.1001/jama.275.12.940; FOLTZ AM, 1978, MILBANK FUND Q, V56, P426, DOI 10.2307/3349572; FUNNELL JD, 1963, SURG GYNECOL OBSTET, V117, P15; GALLUP DG, 1975, OBSTET GYNECOL, V46, P334; GALLUP DG, 1987, OBSTET GYNECOL, V69, P782; HANKINS CA, 1994, CAN MED ASSOC J, V150, P681; HUMMER WK, 1970, AM J OBSTET GYNECOL, V108, P1109, DOI 10.1016/0002-9378(70)90461-8; JIMERSON G K, 1976, Gynecologic Oncology, V4, P328, DOI 10.1016/0090-8258(76)90040-8; JOHNSTON GA, 1983, SURG GYNECOL OBSTET, V156, P34; Kurman RJ, 1994, BETHESDA SYSTEM REPO; Kvale K M, 1994, Wis Med J, V93, P275; MCINDOE WA, 1969, ACTA CYTOL, V13, P158; MILLER J, 1987, POSTGRAD MED, V82, P205; MILLER JM, 1987, POSTGRAD MED, V82, P200, DOI 10.1080/00325481.1987.11699908; OLIVER JA, 1979, AM J OBSTET GYNECOL, V134, P133, DOI 10.1016/0002-9378(79)90876-7; PISCITELLI JT, 1995, AM J OBSTET GYNECOL, V173, P424, DOI 10.1016/0002-9378(95)90262-7; RUTLEDGE F, 1967, AM J OBSTET GYNECOL, V97, P635, DOI 10.1016/0002-9378(67)90451-6; SCHIFFER MA, 1972, SURG GYNECOL OBSTET, V134, P653; STUART GCE, 1981, AM J OBSTET GYNECOL, V139, P311, DOI 10.1016/0002-9378(81)90016-8	28	81	84	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 21	1996	335	21					1559	1562		10.1056/NEJM199611213352103	http://dx.doi.org/10.1056/NEJM199611213352103			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT341	8900088				2022-12-24	WOS:A1996VT34100003
J	Gray, GC; Coate, BD; Anderson, CM; Kang, HK; Berg, SW; Wignall, FS; Knoke, JD; BarrettConnor, E				Gray, GC; Coate, BD; Anderson, CM; Kang, HK; Berg, SW; Wignall, FS; Knoke, JD; BarrettConnor, E			The postwar hospitalization experience of US veterans of the Persian Gulf War	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNITED-STATES-ARMY; NAVY PERSONNEL; DESERT-STORM; RECRUITS; HEALTH	Background Since the Persian Gulf War ended in 1991, many veterans of that conflict have reported diverse, unexplained symptoms. To evaluate the health of Gulf War veterans, we studied their postwar hospitalization experience and compared it with that of other military personnel serving at the same time who did not go to the Persian Gulf. Methods Using a retrospective cohort approach and data from Department of Defense hospitals, we studied hospitalizations of 547,076 veterans of the Gulf War who were serving in the Army, Navy, Marine Corps, and Air Force and 618,335 other veterans from the same era who did not serve in the Persian Gulf. Using multivariate logistic-regression models, we analyzed risk factors for hospitalization both overall and in 14 broad diagnostic categories during three periods from August 1991 through September 1993 (a total of 45 comparisons). Results After the war, the overall odds ratio for hospitalization of the Gulf War veterans was not higher than that of the other veterans, even after adjustment for selection effects related to deployment. In 16 of the 42 comparisons involving specific diagnoses, the risk of hospitalization among Gulf War veterans differed significantly from that among other veterans. Among these 16 comparisons, Gulf War veterans were at higher risk in 5: neoplasms (largely benign) during 1991, diseases of the genitourinary system during 1991, diseases of the blood and blood-forming organs (mostly forms of anemia) during 1992, and mental disorders during both 1992 and 1993. The differences were not consistent over time and could be accounted for by deferred care, postwar pregnancies, and postwar stress. Conclusions During the two years after the Persian Gulf War, there was no excess of unexplained hospitalization among Americans who remained on active duty after serving in that conflict. (C) 1996, Massachusetts Medical Society.	DEPT VET AFFAIRS,ENVIRONM EPIDEMIOL SERV,WASHINGTON,DC; USN,CTR ENVIRONM HLTH,NORFOLK,VA; NAVAL MED RES UNIT 2,JAKARTA,INDONESIA; UNIV CALIF SAN DIEGO,SCH MED,DEPT FAMILY & PREVENT MED,LA JOLLA,CA 92093	United States Department of Defense; United States Navy; Naval Medical Research Center (NMRC); US Naval Medical Research Unit-2 (NAMRU-2); University of California System; University of California San Diego	Gray, GC (corresponding author), USN,HLTH RES CTR,DIV CLIN EPIDEMIOL,EMERGING ILLNESS RES TEAM,POB 85122,SAN DIEGO,CA 92186, USA.		Gray, Gregory C./ABF-1298-2020	Gray, Gregory/0000-0002-4628-5908				[Anonymous], 1995, Arch Intern Med, V155, P262; ARDAY DR, 1989, AM J PUBLIC HEALTH, V79, P471, DOI 10.2105/AJPH.79.4.471; BEST F, 1995, MED GULF WAR; BROWN D, 1994, WASHINGTON POST 0724; *C RES SERV, 1992, IR KUW CRIS CHRON EV; *COMM REV HLTH CON, 1995, HLTH CONS SERV PERS; COMSTOCK GW, 1974, AM REV RESPIR DIS, V110, P572; COTTON P, 1992, JAMA-J AM MED ASSOC, V268, P2619, DOI 10.1001/jama.268.19.2619; COWLEY G, 1994, NEWSWEEK        1024, P56; *DEF SCI BOARD, 1994, REP DEF SCI BOARD TA; DEFRAITES RF, 1992, INVESTIGATION SUSPEC; *DEP DEF, 1996, COMPR CLIN EV PROGR; *DHHS, 1989, DHHS PUBL; FLANDERS L, 1995, NATION          0123, P94; FRANCE D, 1994, REDBOOK          SEP, V114, P148; FUMENTO M, 1995, AM SPECTATOR     MAY, P28; GARLAND FC, 1990, AM J EPIDEMIOL, V132, P293, DOI 10.1093/oxfordjournals.aje.a115658; GRAY GC, 1990, PEDIATRICS, V86, P867; GRAY GC, 1994, AM J EPIDEMIOL, V139, P793, DOI 10.1093/oxfordjournals.aje.a117076; HELMKAMP JC, 1994, J OCCUP ENVIRON MED, V36, P609; HELMKAMP JC, 1992, MIL MED, V157, pA7, DOI 10.1093/milmed/157.3.A7; HOBFOLL SE, 1991, AM PSYCHOL, V146, P848; HOIBERG A, 1980, J OCCUP ENVIRON MED, V22, P685, DOI 10.1097/00043764-198010000-00017; Hosmer D., 1989, APPL LOGISTIC REGRES, P82; HYAMS KC, 1995, CLIN INFECT DIS, V20, P1497, DOI 10.1093/clinids/20.6.1497; JEHL D, 1995, NY TIMES        0307, pA14; Kang HK, 1996, NEW ENGL J MED, V335, P1498, DOI 10.1056/NEJM199611143352006; KANG HK, 1995, HLTH SURVEILLANCE PE; MILNER UB, 1994, JAMA-J AM MED ASSOC, V271, P1661; *NAT I HLTH TECHN, 1994, JAMA-J AM MED ASSOC, V272, P391; NELSON S, 1995, NAVY TIMES      0704, P10; NELSON S, 1995, ARMY TIMES      0619; *OFF ASS SECR DEF, 1991, OCC CONV MAN ENL OFF; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P144; STRETCH RH, 1995, MIL MED, V160, P131, DOI 10.1093/milmed/160.3.131; SUTKER PB, 1994, J TRAUMA STRESS, V71, P159; TIPPIT S, 1994, LADIES HOME J    JUN, V100, P148; Writer JV, 1996, JAMA-J AM MED ASSOC, V275, P118, DOI 10.1001/jama.275.2.118; 1995, MMWR-MORBID MORTAL W, V44, P443; 1991, FED REGISTER, V156, P2663; 1995, PERSIAN GULF REV, P5	41	137	139	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 14	1996	335	20					1505	1513		10.1056/NEJM199611143352007	http://dx.doi.org/10.1056/NEJM199611143352007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VT340	8890103				2022-12-24	WOS:A1996VT34000007
J	Marigo, V; Davey, RA; Zuo, Y; Cunningham, JM; Tabin, CJ				Marigo, V; Davey, RA; Zuo, Y; Cunningham, JM; Tabin, CJ			Biochemical evidence that Patched is the Hedgehog receptor	NATURE			English	Article							TERMINAL CLEAVAGE PRODUCT; SONIC-HEDGEHOG; DROSOPHILA SEGMENT; GENE ENCODES; POLARITY; PROTEIN; INDUCTION; LOCALIZATION; EMBRYOS; SOMITE	THE protein Sonic hedgehog (Shh) is essential for a variety of patterning events during development. It is the signal from the notochord that induces ventral cell fate in the neural tube and somites(1,2), and is the polarizing signal for patterning of the anterior-posterior axis of the developing limb bud(3). Because of these and other inductive functions of Shh, it is important to understand how the Hedgehog (Hh) signal is received by the target cells. Here we describe binding studies using labelled Shh that strongly suggest that the Hh receptor is encoded by patched (ptc), a gene first identified in genetic screens in Drosophila(4).	HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute			Marigo, Valeria/B-7947-2015	Marigo, Valeria/0000-0002-4428-2084; Davey, Robert/0000-0001-9168-2892	Telethon [TGM06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; Bitgood MJ, 1996, CURR BIOL, V6, P298, DOI 10.1016/S0960-9822(02)00480-3; BUMCROT DA, 1995, CURR BIOL, V5, P612, DOI 10.1016/S0960-9822(95)00123-0; CAPDEVILA J, 1994, DEVELOPMENT, V120, P987; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; FORBES AJ, 1993, DEVELOPMENT, P115; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; HALL TMT, 1995, NATURE, V378, P212, DOI 10.1038/378212a0; HIDALGO A, 1990, DEVELOPMENT, V110, P291; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; HOOPER JE, 1994, NATURE, V372, P461, DOI 10.1038/372461a0; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; LOPEZMARTINEZ A, 1995, CURR BIOL, V5, P791, DOI 10.1016/S0960-9822(95)00156-4; Lumsden A, 1995, CURR BIOL, V5, P1347, DOI 10.1016/S0960-9822(95)00266-1; Marigo V, 1996, DEVELOPMENT, V122, P1225; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; MUNSTERBERG AE, 1995, GENE DEV, V9, P2911, DOI 10.1101/gad.9.23.2911; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NIKAIDO H, 1992, SCIENCE, V258, P936, DOI 10.1126/science.1279804; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; OPRESKO LK, 1990, J CELL BIOL, V111, P1661, DOI 10.1083/jcb.111.4.1661; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; TAYLOR AM, 1993, MECH DEVELOP, V42, P89, DOI 10.1016/0925-4773(93)90101-3; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0	29	700	731	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 14	1996	384	6605					176	179		10.1038/384176a0	http://dx.doi.org/10.1038/384176a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT336	8906794				2022-12-24	WOS:A1996VT33600068
J	Winter, GB				Winter, GB			What about the ethics?	BRITISH MEDICAL JOURNAL			English	Editorial Material							CARIES											DODDSSMITH I, 1992, DOCTORS PATIENTS LAW, P157; ISOKANGAS P, 1991, CARIES RES, V25, P444, DOI 10.1159/000261408; KANDELMAN D, 1988, CARIES RES, V22, P55, DOI 10.1159/000261084; Makinen KK, 1995, J DENT RES, V74, P1904, DOI 10.1177/00220345950740121501; RUGGGUNN AJ, 1993, DENT CARIES NONSUGAR, P272; Scheinin A., 1975, ACTA ODONTOL SCAND, V33, P1	6	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1996	313	7066					1183	1184		10.1136/bmj.313.7066.1183	http://dx.doi.org/10.1136/bmj.313.7066.1183			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR907	8916750	Green Published			2022-12-24	WOS:A1996VR90700023
J	Herxheimer, A				Herxheimer, A			Euthanasia and palliative care: A pseudoconflict?	LANCET			English	Editorial Material																		*HOUS LORDS, 1994, REP SEL COMM MED ETH, V1; World Health Organization, 1996, CANC PAIN REL	2	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 2	1996	348	9036					1187	1188		10.1016/S0140-6736(05)65478-5	http://dx.doi.org/10.1016/S0140-6736(05)65478-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ467	8898033				2022-12-24	WOS:A1996VQ46700006
J	Nicholson, KG; Kent, J; Hammersley, V; Cancio, E				Nicholson, KG; Kent, J; Hammersley, V; Cancio, E			Risk factors for lower respiratory complications of rhinovirus infections in elderly people living in the community: Prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INFLUENZA IMMUNIZATION; ILLNESS; SUSCEPTIBILITY; FREQUENCY; TECUMSEH; ASTHMA; ADULTS; NASAL; COLDS	Objective-To assess the role of rhinoviruses in elderly people living in the community. Design-Prospective community based surveillance of elderly people, without intervention. Subjects were telephoned weekly to identify symptomatic upper respiratory tract infections. Symptoms and impact of illnesses were monitored, and specimens were collected for diagnostic serology and human rhinovirus polymerase chain reaction. Setting-Leicestershire, England. Subjects-533 subjects aged 60 to 90. Main outcome measures-Symptoms, restriction of activity, medical consultations, and antibiotic use during 96 rhinovirus infections. Adjusted odds ratios for lower respiratory syndromes with respect to smoking and health status. Results-A viral cause was established in 211 (43%) of 497 respiratory illnesses; rhinoviruses were identified in 121 (24%) and as single pathogens in 107. The median duration of the first or only rhinovirus infection in the 96 people with 107 rhinovirus infections was 16 days; 18 of the 96 patients were confined to bed and 25 were unable to cope with routine household activities. Overall, 60 patients with rhinovirus infections had lower respiratory tract syndromes; 41 patients consulted their doctor, 31 of them (76%) receiving antibiotics. One patient died. Logistic regression analysis showed that chronic medical conditions increased the estimated probability of lower respiratory rhinovirus illness by 40% (95% confidence interval 17% to 68%) and smoking by 47% (14% to 90%). There were almost six times as many symptomatic rhinovirus infections as influenza A and B infections. Conclusions-Rhinoviruses are an important cause of debility and lower respiratory illness among elderly people in the community. Chronic ill health and smoking increase the likelihood of lower respiratory complications from such infections. The overall burden of rhinovirus infections in elderly people may approach that of influenza.			Nicholson, KG (corresponding author), UNIV LEICESTER, SCH MED, DEPT MICROBIOL & IMMUNOL, LEICESTER LE1 9HN, LEICS, ENGLAND.							[Anonymous], IMM INF DIS; AROLA M, 1988, J PEDIATR-US, V113, P693, DOI 10.1016/S0022-3476(88)80380-9; BLAIR HT, 1976, AM REV RESPIR DIS, V114, P95; BUSSE WW, 1989, CLIN EXP ALLERGY, V19, P1, DOI 10.1111/j.1365-2222.1989.tb02336.x; CATE TR, 1973, AM REV RESPIR DIS, V108, P858; COHEN S, 1993, AM J PUBLIC HEALTH, V83, P1277, DOI 10.2105/AJPH.83.9.1277; CRAIGHEAD JE, 1969, NEW ENGL J MED, V281, P1403, DOI 10.1056/NEJM196912182812506; DALESSIO DJ, 1976, J INFECT DIS, V133, P28, DOI 10.1093/infdis/133.1.28; DOUGLAS RG, 1966, AM REV RESPIR DIS, V94, P159; EADIE MB, 1966, BMJ-BRIT MED J, V2, P671, DOI 10.1136/bmj.2.5515.671; EVANS FO, 1975, NEW ENGL J MED, V293, P735, DOI 10.1056/NEJM197510092931502; FLEMING DM, 1993, EUR J EPIDEMIOL, V9, P571, DOI 10.1007/BF00211429; FORSYTH BR, 1963, NEW ENGL J MED, V269, P602, DOI 10.1056/NEJM196309192691203; FRIDY WW, 1974, ANN INTERN MED, V80, P150, DOI 10.7326/0003-4819-80-2-150; GEORGE RB, 1969, ANN INTERN MED, V71, P1073, DOI 10.7326/0003-4819-71-6-1073; GOINGS SAJ, 1989, AM REV RESPIR DIS, V139, P1075, DOI 10.1164/ajrccm/139.5.1075; GWALTNEY JM, 1967, J AMER MED ASSOC, V202, P494, DOI 10.1001/jama.202.6.494; HALPERIN SA, 1983, AM REV RESPIR DIS, V128, P806; HAMRE D, 1961, BRIT MED J, V2, P1382, DOI 10.1136/bmj.2.5264.1382; HOBSON D, 1960, BRIT MED J, V2, P1414, DOI 10.1136/bmj.2.5210.1414; HORN MEC, 1975, J HYG-CAMBRIDGE, V74, P157, DOI 10.1017/S0022172400024220; IRELAND DC, 1993, J MED VIROL, V40, P96, DOI 10.1002/jmv.1890400204; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; MONTO AS, 1993, EPIDEMIOL INFECT, V110, P145, DOI 10.1017/S0950268800050779; MONTO AS, 1971, AM J EPIDEMIOL, V94, P280, DOI 10.1093/oxfordjournals.aje.a121321; MONTO AS, 1987, J INFECT DIS, V156, P43, DOI 10.1093/infdis/156.1.43; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Nicholson KG, 1996, EPIDEMIOL INFECT, V116, P51, DOI 10.1017/S0950268800058957; NICHOLSON KG, 1990, EPIDEMIOL INFECT, V105, P609, DOI 10.1017/S0950268800048251; NICHOLSON KG, 1995, VACCINE, V13, P365, DOI 10.1016/0264-410X(95)98258-C; Office of Health Economics, 1989, COMP HLTH STAT; REILLY CM, 1962, ANN INTERN MED, V57, P515, DOI 10.7326/0003-4819-57-4-515; STENHOUSE AC, 1967, BMJ-BRIT MED J, V3, P461, DOI 10.1136/bmj.3.5563.461; STOTT EJ, 1968, J MED MICROBIOL, V1, P109, DOI 10.1099/00222615-1-1-109; WALD TG, 1995, ANN INTERN MED, V123, P588, DOI 10.7326/0003-4819-123-8-199510150-00004; WINTHER B, 1984, ACTA OTO-LARYNGOL, V98, P315, DOI 10.3109/00016488409107569	36	108	113	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 2	1996	313	7065					1119	1123		10.1136/bmj.313.7065.1119	http://dx.doi.org/10.1136/bmj.313.7065.1119			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR217	8916700	Green Published			2022-12-24	WOS:A1996VR21700025
J	Chen, Y; Struhl, G				Chen, Y; Struhl, G			Dual roles for patched in sequestering and transducing hedgehog	CELL			English	Article							PROTEIN-KINASE-A; TERMINAL CLEAVAGE PRODUCT; TGF-BETA FAMILY; SIGNAL-TRANSDUCTION; DROSOPHILA EMBRYO; WINGLESS TRANSCRIPTION; GENETIC MOSAICS; SONIC HEDGEHOG; IMAGINAL DISKS; BODY PATTERN	Secreted proteins of the Hedgehog (Hh) family have diverse organizing roles in animal development. Recently, a serpentine protein Smoothened (Smo) has been proposed as a Hh receptor. Here, we present evidence that implicates another multiple-pass transmembrane protein, Patched (Ptc), in Hh reception and suggests a novel signal transduction mechanism in which Hh binds to Ptc, or a Ptc-Smo complex, and thereby induces Smo activity. Our results also show that Ptc limits the range of Hh action; we provide evidence that high levels of Ptc induced by Hh serve to sequester any free Hh and therefore create a barrier to its further movement.			Chen, Y (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,DEPT GENET & DEV,NEW YORK,NY 10032, USA.							Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; CASANOVA J, 1995, GENE DEV, V9, P2539, DOI 10.1101/gad.9.20.2539; CASANOVA J, 1993, NATURE, V362, P152, DOI 10.1038/362152a0; CHOU TB, 1992, GENETICS, V131, P643; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; HOOPER JE, 1994, NATURE, V372, P461, DOI 10.1038/372461a0; Ingham PW, 1991, CURR OPIN GENET DEV, V1, P261, DOI 10.1016/S0959-437X(05)80080-2; INGHAM PW, 1994, CURR BIOL, V4, P347, DOI 10.1016/S0960-9822(00)00076-2; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; INGHAM PW, 1993, DEVELOPMENT, V117, P283; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; Johnson RL, 1995, DEVELOPMENT, V121, P4161; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; Marigo V, 1996, DEVELOPMENT, V122, P1225; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; MOTZNY CK, 1995, MECH DEVELOP, V52, P137, DOI 10.1016/0925-4773(95)00397-J; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; Perrimon N, 1996, CELL, V86, P513, DOI 10.1016/S0092-8674(00)80124-5; PHILLIPS RG, 1990, DEVELOPMENT, V110, P105; POSAKONY LG, 1991, MECH DEVELOP, V33, P69; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1995, CURR OPIN NEUROBIOL, V6, P33; SPRENGER F, 1992, CELL, V71, P987, DOI 10.1016/0092-8674(92)90394-R; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; VANDENHEUVEL M, 1993, DEVELOPMENT, P105; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0; VINCENT JP, 1994, DEV BIOL, V164, P328, DOI 10.1006/dbio.1994.1203; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; XU T, 1993, DEVELOPMENT, V117, P1223; ZECCA M, 1995, DEVELOPMENT, V121, P2265	51	729	770	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 1	1996	87	3					553	563		10.1016/S0092-8674(00)81374-4	http://dx.doi.org/10.1016/S0092-8674(00)81374-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VQ466	8898207	hybrid			2022-12-24	WOS:A1996VQ46600020
J	Montgomery, RI; Warner, MS; Lum, BJ; Spear, PG				Montgomery, RI; Warner, MS; Lum, BJ; Spear, PG			Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family	CELL			English	Article							NECROSIS-FACTOR RECEPTOR; GROWTH-FACTOR RECEPTOR; GLYCOPROTEIN-D; HEPARAN-SULFATE; SYN PHENOTYPE; STRAIN KOS; TYPE-1; INFECTION; SEQUENCES; REPLICATION	We identified and cloned a cellular mediator of herpes simplex virus (HSV) entry. Hamster and swine cells resistant to viral entry became susceptible upon expression of a human cDNA encoding this protein, designated HVEM (for herpesvirus entry mediator). HVEM was shown to mediate the entry of several wild-type HSV strains of both serotypes. Anti-HVEM antibodies and a soluble hybrid protein containing the HVEM ectodomain inhibited HVEM-dependent infection but not virus binding to cells. Mutations in the HSV envelope glycoprotein go significantly reduced HVEM-mediated entry. The contribution of HVEM to HSV entry into human cells was demonstrable in activated T cells. HVEM, the first identified mediator of HSV entry, is a new member of the TNF/NGF receptor family.			Montgomery, RI (corresponding author), NORTHWESTERN UNIV, SCH MED, DEPT MICROBIOL IMMUNOL, 303 E CHICAGO AVE, CHICAGO, IL 60611 USA.			Warner, Morgyn/0000-0002-4053-1610				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; ARMITAGE RJ, 1994, CURR OPIN IMMUNOL, V6, P407, DOI 10.1016/0952-7915(94)90119-8; BANFIELD BW, 1995, J VIROL, V69, P3290, DOI 10.1128/JVI.69.6.3290-3298.1995; BATTERSON W, 1983, J VIROL, V46, P371, DOI 10.1128/JVI.46.2.371-377.1983; BODDINGIUS J, 1987, J CUTAN PATHOL, V14, P165, DOI 10.1111/j.1600-0560.1987.tb00492.x; BRUNETTI CR, 1995, J VIROL, V69, P3517, DOI 10.1128/JVI.69.6.3517-3528.1995; CAL WH, 1988, J VIROL, V62, P2596, DOI 10.1128/JVI.62.8.2596-2604.1988; CAMPADELLIFIUME G, 1988, J VIROL, V62, P159, DOI 10.1128/JVI.62.1.159-167.1988; CAMPBELL MEM, 1984, J MOL BIOL, V180, P1, DOI 10.1016/0022-2836(84)90427-3; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COREY L, 1986, NEW ENGL J MED, V314, P686, DOI 10.1056/NEJM198603133141105; COREY L, 1986, NEW ENGL J MED, V314, P749, DOI 10.1056/NEJM198603203141205; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DEAN HJ, 1994, VIROLOGY, V199, P67, DOI 10.1006/viro.1994.1098; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; EJERCITO PM, 1968, J GEN VIROL, V2, P357, DOI 10.1099/0022-1317-2-3-357; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FORRESTER A, 1992, J VIROL, V66, P341, DOI 10.1128/JVI.66.1.341-348.1992; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HIGHLANDER SL, 1987, J VIROL, V61, P3356, DOI 10.1128/JVI.61.11.3356-3364.1987; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOGGAN MD, 1959, AM J HYG, V70, P208, DOI 10.1093/oxfordjournals.aje.a120071; HUANG AS, 1964, P SOC EXP BIOL MED, V116, P863, DOI 10.3181/00379727-116-29392; JOHNSON RM, 1989, J VIROL, V63, P819, DOI 10.1128/JVI.63.2.819-827.1989; KANER RJ, 1990, SCIENCE, V248, P1410, DOI 10.1126/science.2162560; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KLUPP BG, 1994, J VIROL, V68, P3868, DOI 10.1128/JVI.68.6.3868-3878.1994; LIGAS MW, 1988, J VIROL, V62, P1486, DOI 10.1128/JVI.62.5.1486-1494.1988; LITTLE SP, 1981, VIROLOGY, V112, P686, DOI 10.1016/0042-6822(81)90314-7; MADDON PJ, 1988, CELL, V54, P865, DOI 10.1016/S0092-8674(88)91241-X; MANESS LM, 1994, NEUROSCI BIOBEHAV R, V18, P143, DOI 10.1016/0149-7634(94)90043-4; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; MIRDA DP, 1992, J VIROL, V66, P448, DOI 10.1128/JVI.66.1.448-457.1992; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; MUNK K., 1963, ARCH GES VIRUSFORSCH, V13, P529, DOI 10.1007/BF01267795; PELTON BK, 1977, IMMUNOLOGY, V32, P803; POGUEGEILE KL, 1987, VIROLOGY, V157, P67, DOI 10.1016/0042-6822(87)90314-X; RABIZADEH S, 1994, DEV NEUROSCI-BASEL, V16, P207, DOI 10.1159/000112108; RINALDO CR, 1978, J IMMUNOL, V120, P130; ROOP C, 1993, J VIROL, V67, P2285, DOI 10.1128/JVI.67.4.2285-2297.1993; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SARMIENTO M, 1979, J VIROL, V29, P1149, DOI 10.1128/JVI.29.3.1149-1158.1979; SHIEH MT, 1991, SCIENCE, V253, P208, DOI 10.1126/science.1649495; SHIEH MT, 1992, J CELL BIOL, V116, P1273, DOI 10.1083/jcb.116.5.1273; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SPEAR PG, 1993, SEMIN VIROL, V4, P167, DOI 10.1006/smvy.1993.1012; SUBRAMANIAN G, 1994, J VIROL, V68, P5667, DOI 10.1128/JVI.68.9.5667-5676.1994; TEUTE H, 1983, INTERVIROLOGY, V20, P32, DOI 10.1159/000149371; WEISE K, 1987, J GEN VIROL, V68, P1909, DOI 10.1099/0022-1317-68-7-1909; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WITTELS M, 1991, VIRUS RES, V18, P271, DOI 10.1016/0168-1702(91)90024-P	54	964	1060	0	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 1	1996	87	3					427	436		10.1016/S0092-8674(00)81363-X	http://dx.doi.org/10.1016/S0092-8674(00)81363-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VQ466	8898196	Bronze			2022-12-24	WOS:A1996VQ46600009
J	Kiechl, S; Willeit, J; Poewe, W; Egger, G; Oberhollenzer, F; Muggeo, M; Bonora, E				Kiechl, S; Willeit, J; Poewe, W; Egger, G; Oberhollenzer, F; Muggeo, M; Bonora, E			Insulin sensitivity and regular alcohol consumption: Large, prospective, cross sectional population study (Bruneck study)	BRITISH MEDICAL JOURNAL			English	Article							SYNDROME SYNDROME-X; CAROTID ATHEROSCLEROSIS; HEALTHY POPULATION; GLUCOSE-TOLERANCE; RISK-FACTORS; RESISTANCE; ETHANOL; RAT; HYPERINSULINEMIA; METABOLISM	Objectives-To assess the relation between regular alcohol consumption and insulin sensitivity, and to estimate the importance of insulin in the association of alcohol with multiple vascular risk factors and cardiovascular disease. Design-Prospective and cross sectional study of a large randomly selected population sample. Setting-Part of the Bruneck study 1990-5 (Bolzano province, Italy). Subjects-820 healthy non-diabetic women and men aged 40-79 years. Main outcome measure-Concentrations of fasting and post-glucose insulin, cholesterol, apolipoproteins, triglycerides, Lp(a) lipoprotein, glucose, fibrinogen, and antithrombin III; blood pressure; insulin resistance estimated by the homeostasis model assessment. Results-Fasting insulin concentrations in those who did not drink alcohol and subjects reporting low (1-50 g/day), moderate (51-99 g/day), and heavy (greater than or equal to 100 g/day) alcohol intake were 12.4, 10.0, 8.7, and 7.1 mU/l (P<0.001). Likewise, post-glucose insulin concentrations and estimates for insulin resistance assessed by the homeostasis model assessment decreased significantly with increasing amounts of regular alcohol consumption. These trends were independent of sex, body mass index, physical activity, cigarette smoking, medication, and diet (P<0.001). Regular alcohol intake predicted multiple changes in vascular risk factors over a five year period including increased concentrations of high density lipoprotein cholesterol and apolipoprotein A I; higher blood pressure; and decreased concentration of antithrombin III. These associations were in part attributable to the decrease in insulin concentrations observed among alcohol consumers. Conclusions-Low to moderate amounts of alcohol, when taken on a regular basis, improve insulin sensitivity. Insulin is a potential intermediate component in the association between alcohol consumption and vascular risk factors (metabolic syndrome).	BRUNECK HOSP, DEPT INTERNAL MED, I-39031 BRUNICO, ITALY; OSPED CIVILE, DEPT ENDOCRINOL & METAB, I-37126 VERONA, ITALY		Kiechl, S (corresponding author), UNIV INNSBRUCK, DEPT NEUROL, ANICHST 35, A-6020 INNSBRUCK, AUSTRIA.		Bonora, Enzo/AAA-5300-2022	BONORA, Enzo/0000-0003-1074-5164				ALANKO T, 1984, RES ADV ALCOHOL DRUG; AVOGARO A, 1993, DIABETES METAB REV, V9, P129, DOI 10.1002/dmr.5610090205; BERGMAN RN, 1985, ENDOCR REV, V6, P45, DOI 10.1210/edrv-6-1-45; BODEN G, 1993, DIABETES, V42, P28, DOI 10.2337/diabetes.42.1.28; CASEY CA, 1992, BIOCHIM BIOPHYS ACTA, V1134, P96, DOI 10.1016/0167-4889(92)90032-7; FACCHINI F, 1994, DIABETES CARE, V17, P115, DOI 10.2337/diacare.17.2.115; FAWCETT J, 1993, AM J PHYSIOL, V264, pE420, DOI 10.1152/ajpendo.1993.264.3.E420; FONTBONNE A, 1991, DIABETOLOGIA, V34, P356, DOI 10.1007/BF00405009; HAFFNER SM, 1992, DIABETES, V41, P715, DOI 10.2337/diabetes.41.6.715; HAFFNER SM, 1994, ARTERIOSCLER THROMB, V14, P1430, DOI 10.1161/01.ATV.14.9.1430; HALES CN, 1963, BIOCHEM J, V88, P137, DOI 10.1042/bj0880137; HILL MA, 1987, BMDP USERS GUIDE; KIECHL S, 1994, STROKE, V25, P1593, DOI 10.1161/01.STR.25.8.1593; KIECHL S, 1994, NEUROEPIDEMIOLOGY, V13, P314, DOI 10.1159/000110397; LAAKSO M, 1993, AM J EPIDEMIOL, V137, P959, DOI 10.1093/oxfordjournals.aje.a116768; LAAKSO M, 1991, ARTERIOSCLER THROMB, V11, P1068, DOI 10.1161/01.ATV.11.4.1068; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; MANOLIO TA, 1990, ARTERIOSCLEROSIS, V10, P430, DOI 10.1161/01.ATV.10.3.430; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; MAYER EJ, 1993, CIRCULATION, V88, P2190, DOI 10.1161/01.CIR.88.5.2190; METZ R, 1969, DIABETES, V18, P517, DOI 10.2337/diab.18.8.517; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; NORUSIS MJ, 1990, USERS GUIDE SPSS X V; PANDIT MK, 1993, ANN INTERN MED, V118, P529, DOI 10.7326/0003-4819-118-7-199304010-00008; PATEL DG, 1979, METABOLISM, V28, P85, DOI 10.1016/0026-0495(79)90173-2; PYORALA K, 1985, ACTA MED SCAND, P38; RAZAY G, 1992, BRIT MED J, V304, P80, DOI 10.1136/bmj.304.6819.80; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; RUSSELL JC, 1989, ARTERIOSCLEROSIS, V9, P122, DOI 10.1161/01.ATV.9.1.122; SEVAK L, 1994, AM J CLIN NUTR, V59, P1069, DOI 10.1093/ajcn/59.5.1069; SINGH SP, 1988, ALCOHOL CLIN EXP RES, V12, P727, DOI 10.1111/j.1530-0277.1988.tb01335.x; TIENGO A, 1981, DIABETES, V30, P705, DOI 10.2337/diabetes.30.9.705; Welborn T A, 1979, Diabetes Care, V2, P154, DOI 10.2337/diacare.2.2.154; *WHO, 1985, WHO TECH REP SER, V727; WILLEIT J, 1993, ARTERIOSCLER THROMB, V13, P661, DOI 10.1161/01.ATV.13.5.661; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086	36	265	270	0	10	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 26	1996	313	7064					1040	1044						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP742	8898593				2022-12-24	WOS:A1996VP74200022
J	Verkasalo, PK; Pukkala, E; Kaprio, J; Heikkila, KV; Koskenvuo, M				Verkasalo, PK; Pukkala, E; Kaprio, J; Heikkila, KV; Koskenvuo, M			Magnetic fields of high voltage power Lines and risk of cancer in Finnish adults: Nationwide cohort study	BRITISH MEDICAL JOURNAL			English	Article							ELECTRIC UTILITY WORKERS; BREAST-CANCER; ELECTROMAGNETIC-FIELDS; TELECOMMUNICATIONS INDUSTRY; TRANSMISSION EQUIPMENT; OCCUPATIONAL EXPOSURE; MALIGNANT-MELANOMA; BRAIN CANCER; MORTALITY; LEUKEMIA	Objective-To investigate the risk of cancer in association with magnetic fields in Finnish adults Living close to high voltage power lines. Design-Nationwide cohort study. Subjects-383 700 people who Lived during 1970-89 within 500 metres of overhead power lines of 110-400 kV in a magnetic field calculated to be greater than or equal to 0.01 mu T. Study subjects were identified by record linkages of nationwide registers. Main outcome measures-Numbers of observed and expected cases of cancer, standardised incidence ratios, and incidence rate ratios adjusted for sex, age, calendar year, and social class-for example, by continuous cumulative exposure per 1 mu T year-with 95% confidence intervals from multiplicative models for all cancers combined and 21 selected types. Results-Altogether 8415 cases of cancer were observed (standardised incidence ratio 0.98; 95% confidence interval 0.96 to 1.00) in adults. All incidence rate ratios for both sexes combined were non-significant and between 0.91 and 1.11. Significant excesses were observed in multiple myeloma in men (incidence rate ratio 1.22) and in colon cancer in women (1.16). Conclusions-Typical residential magnetic fields generated by high voltage power lines do not seem to be related to the risk of overall cancer in adults. The previously suggested associations between extremely low frequency magnetic fields and tumours of the nervous system, lymphoma, and leukaemia in adults and breast cancer in women were not confirmed.	FINNISH CANC REGISTRY,INST STAT & EPIDEMIOL CANC RES,FIN-00170 HELSINKI,FINLAND; UNIV TURKU,DEPT PUBL HLTH,FIN-20520 TURKU,FINLAND	Finnish Cancer Registry; University of Turku	Verkasalo, PK (corresponding author), UNIV HELSINKI,DEPT PUBL HLTH,POB 41,FIN-00014 HELSINKI,FINLAND.		Kaprio, Jaakko/A-1820-2008; Heikkilä, Kauko/E-5578-2019	Kaprio, Jaakko/0000-0002-3716-2455; Heikkilä, Kauko/0000-0002-9256-8028				COLEMAN MP, 1989, BRIT J CANCER, V60, P793, DOI 10.1038/bjc.1989.362; DEGUIRE L, 1988, BRIT J IND MED, V45, P824; FEYCHTING M, 1994, EPIDEMIOLOGY, V5, P501; FEYCHTING M, 1993, AM J EPIDEMIOL, V138, P467, DOI 10.1093/oxfordjournals.aje.a116881; FLODERUS B, 1993, CANCER CAUSE CONTROL, V4, P465, DOI 10.1007/BF00050866; GUENEL P, 1993, BRIT J IND MED, V50, P758; Gurney JG, 1996, AM J EPIDEMIOL, V143, P120; LOOMIS DP, 1994, J NATL CANCER I, V86, P921, DOI 10.1093/jnci/86.12.921; MCDOWALL ME, 1986, BRIT J CANCER, V53, P271, DOI 10.1038/bjc.1986.45; OLIN R, 1985, BRIT J IND MED, V42, P211; OLSEN JH, 1993, BRIT MED J, V307, P891, DOI 10.1136/bmj.307.6909.891; PHILLIPS JL, 1986, CANCER RES, V46, P239; PrestonMartin S, 1996, AM J EPIDEMIOL, V143, P105; PRESTONMARTIN S, 1988, BIOELECTROMAGNETICS, V9, P207, DOI 10.1002/bem.2250090302; Pukkala E, 1992, GEOGRAPHICAL ENV EPI, P125; Pukkala E, 1995, CONTRIBUTIONS EPIDEM, V7; ROCKLEY PF, 1994, INT J DERMATOL, V33, P398, DOI 10.1111/j.1365-4362.1994.tb04038.x; SAHL JD, 1993, EPIDEMIOLOGY, V4, P104, DOI 10.1097/00001648-199303000-00005; SAVITZ DA, 1995, AM J EPIDEMIOL, V141, P123, DOI 10.1093/oxfordjournals.aje.a117400; SAVITZ DA, 1994, BIOL EFFECTS ELECTRI, V2, P233; SCHREIBER GH, 1993, INT J EPIDEMIOL, V22, P9, DOI 10.1093/ije/22.1.9; SEVERSON RK, 1988, AM J EPIDEMIOL, V128, P10, DOI 10.1093/oxfordjournals.aje.a114932; SORAHAN T, 1985, BRIT J IND MED, V42, P546; STEVENS RG, 1993, ENVIRON HEALTH PERSP, V101, P93, DOI 10.2307/3431665; STEVENS RG, 1987, AM J EPIDEMIOL, V125, P556, DOI 10.1093/oxfordjournals.aje.a114569; TEPPO L, 1994, ACTA ONCOL, V33, P365, DOI 10.3109/02841869409098430; THERIAULT G, 1994, AM J EPIDEMIOL, V139, P550, DOI 10.1093/oxfordjournals.aje.a117046; TYNES T, 1994, SCAND J WORK ENV HEA, V20, P339, DOI 10.5271/sjweh.1388; TYNES T, 1992, AM J EPIDEMIOL, V136, P81, DOI 10.1093/oxfordjournals.aje.a116423; VAGERO D, 1985, BRIT J IND MED, V42, P191; VAGERO D, 1983, BRIT J IND MED, V40, P188; Valjus J, 1995, BIOELECTROMAGNETICS, V16, P365, DOI 10.1002/bem.2250160604; VENA JE, 1994, AM J EPIDEMIOL, V140, P974, DOI 10.1093/oxfordjournals.aje.a117204; VENA JE, 1991, AM J EPIDEMIOL, V134, P180, DOI 10.1093/oxfordjournals.aje.a116070; VERKASALO P, 1994, BRIT MED J, V308, P1162; VERKASALO PK, 1993, BRIT MED J, V307, P895, DOI 10.1136/bmj.307.6909.895; VERREAULT R, 1990, AM J EPIDEMIOL, V131, P759, DOI 10.1093/oxfordjournals.aje.a115565; WERTHEIMER N, 1979, AM J EPIDEMIOL, V109, P273, DOI 10.1093/oxfordjournals.aje.a112681; WERTHEIMER N, 1982, INT J EPIDEMIOL, V11, P345, DOI 10.1093/ije/11.4.345; WERTHEIMER N, 1987, ANN NY ACAD SCI, V502, P43, DOI 10.1111/j.1749-6632.1987.tb37645.x; WHITEMAN D, 1994, CANCER CAUSE CONTROL, V5, P564, DOI 10.1007/BF01831385; YOUNGSON JHAM, 1991, BRIT J CANCER, V63, P977, DOI 10.1038/bjc.1991.214	42	72	74	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 26	1996	313	7064					1047	1051						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP742	8898595	Green Published			2022-12-24	WOS:A1996VP74200025
J	Cavaille, J; Nicoloso, M; Bachellerie, JP				Cavaille, J; Nicoloso, M; Bachellerie, JP			Targeted ribose methylation of RNA in vivo directed by tailored antisense RNA guides	NATURE			English	Article							NUCLEOLIN GENE; MESSENGER-RNA; NUCLEAR-RNA; YEAST; LOCALIZATION; SEQUENCES; DUPLEXES; MOUSE	EUKARYOTIC ribosomal RNAs are post-transcriptionally modified by methylation at the ribose sugar of specific nucleotides(1). This takes place in the nucleolus and involves a family of small nucleolar RNAs (snoRNAs) with long regions (10-21 nucleotides) complementary to rRNA sequences spanning the methylation site(2-4)-a complementary snoRNA is required for methylation at a specific site(5). Here we show that altering the sequence of the snoRNA is sufficient to change the specificity of methylation. Mammalian cells transfected with a snoRNA engineered to be complementary to an arbitrary rRNA sequence direct the methylation of the predicted nucleotide in that sequence. We have further identified structural features, both of the guide and substrate RNA, required for methylation and have used these to design an exogenous transcript, devoid of rRNA sequence, that is site-specifically methylated when co-expressed with an appropriate guide snoRNA. Endogenous non-ribosomal RNA can thus be targeted, possibly providing a highly selective tool for the alteration of gene expression at the post-transcriptional level.	UNIV TOULOUSE 3, CNRS, LAB BIOL MOL EUCARYOTE, F-31062 TOULOUSE, FRANCE	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)			cavaille, jerome/AAM-8047-2020	CAVAILLE, Jerome/0000-0003-2833-6836				Bachellerie JP, 1995, BIOCHEM CELL BIOL, V73, P835, DOI 10.1139/o95-091; BACHELLERIE JP, 1995, TRENDS BIOCHEM SCI, V20, P261, DOI 10.1016/S0968-0004(00)89039-8; BARDWELL VJ, 1991, CELL, V65, P125, DOI 10.1016/0092-8674(91)90414-T; BOND VC, 1993, MOL CELL BIOL, V13, P3221, DOI 10.1128/MCB.13.6.3221; BOURBON HM, 1990, GENE, V88, P187, DOI 10.1016/0378-1119(90)90031-L; BRANCH AD, 1989, METHOD ENZYMOL, V180, P130; CAAILLE J, 1996, BIOCHIMIE, V78, P443; CABOCHE M, 1977, EUR J BIOCHEM, V74, P19, DOI 10.1111/j.1432-1033.1977.tb11362.x; Caffarelli E, 1996, EMBO J, V15, P1121, DOI 10.1002/j.1460-2075.1996.tb00450.x; CATTANEO R, 1994, CURR BIOL, V4, P134, DOI 10.1016/S0960-9822(94)00030-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; HADJIOLOVA KV, 1994, MOL CELL BIOL, V14, P4044, DOI 10.1128/MCB.14.6.4044; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Maden B E, 1990, Prog Nucleic Acid Res Mol Biol, V39, P241, DOI 10.1016/S0079-6603(08)60629-7; MADEN BEH, 1974, J MOL BIOL, V88, P133, DOI 10.1016/0022-2836(74)90299-X; MADEN BEH, 1995, BIOCHIMIE, V77, P22, DOI 10.1016/0300-9084(96)88100-4; MAXWELL ES, 1995, ANNU REV BIOCHEM, V64, P897, DOI 10.1146/annurev.bi.64.070195.004341; MILLER KS, 1984, J MOL BIOL, V177, P343, DOI 10.1016/0022-2836(84)90461-3; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; NICOLOSO M, 1994, MOL CELL BIOL, V14, P5766, DOI 10.1128/MCB.14.9.5766; Nicoloso M, 1996, J MOL BIOL, V260, P178, DOI 10.1006/jmbi.1996.0391; PERRY RP, 1970, J CELL PHYSIOL, V76, P127, DOI 10.1002/jcp.1040760202; REIMER G, 1987, ARTHRITIS RHEUM, V30, P793, DOI 10.1002/art.1780300709; SCHNEITER R, 1995, MOL BIOL CELL, V6, P357, DOI 10.1091/mbc.6.4.357; STEITZ JA, 1995, SCIENCE, V270, P1626, DOI 10.1126/science.270.5242.1626; TOLLERVEY D, 1987, EMBO J, V6, P4169, DOI 10.1002/j.1460-2075.1987.tb02763.x; TOLLERVEY D, 1993, CELL, V72, P443, DOI 10.1016/0092-8674(93)90120-F; Tycowski KT, 1996, NATURE, V379, P464, DOI 10.1038/379464a0; WARNER JR, 1966, J MOL BIOL, V19, P383, DOI 10.1016/S0022-2836(66)80012-8	30	275	307	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 24	1996	383	6602					732	735		10.1038/383732a0	http://dx.doi.org/10.1038/383732a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN918	8878486				2022-12-24	WOS:A1996VN91800058
J	Lange, RA; Hillis, LD				Lange, RA; Hillis, LD			Thrombolysis - The preferred treatment	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; PRIMARY ANGIOPLASTY; IMMEDIATE ANGIOPLASTY; CORONARY ANGIOPLASTY; THERAPY; REPERFUSION				Lange, RA (corresponding author), UNIV TEXAS, SW MED CTR, RM CS7102, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.		Lange, Richard/AAM-9594-2021					APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; BERGER PB, 1994, AM J CARDIOL, V73, P231, DOI 10.1016/0002-9149(94)90225-9; BRODIE BR, 1995, BRIT HEART J, V73, P411; CRAGG DR, 1991, ANN INTERN MED, V115, P173, DOI 10.7326/0003-4819-115-3-173; Every NR, 1996, NEW ENGL J MED, V335, P1253, DOI 10.1056/NEJM199610243351701; Fibrinolytic Therapy Trialists' (FTT) Collaborative Group, 1994, LANCET, V343, P311; GIBBONS RJ, 1993, NEW ENGL J MED, V328, P685, DOI 10.1056/NEJM199303113281003; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; MULLER DWM, 1990, ANN INTERN MED, V113, P949, DOI 10.7326/0003-4819-113-12-949; OKEEFE JH, 1993, AM J CARDIOL, V72, pG107, DOI 10.1016/0002-9149(93)90115-S; Ribeiro EE, 1993, J AM COLL CARDIOL, V22, P376, DOI 10.1016/0735-1097(93)90040-8; STONE GW, 1995, J AM COLL CARDIOL, V25, P370, DOI 10.1016/0735-1097(94)00367-Y; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002	14	60	60	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 24	1996	335	17					1311	1312						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN594	8857013				2022-12-24	WOS:A1996VN59400010
J	Moore, JK; Haber, JE				Moore, JK; Haber, JE			Capture of retrotransposon DNA at the sites of chromosomal double-strand breaks	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; REVERSE TRANSCRIPTION; NUCLEOTIDE-SEQUENCE; TY ELEMENT; YEAST; RECOMBINATION; MECHANISMS; EVOLUTION; REPAIR; RNA	NON-HOMOLOGOUS repair of broken chromosomes in Saccharomyces cerevisiae san be studied at a defined location by expressing the site-specific HO endonuclease that cuts the mating-type (MAT) locus. When homologous recombination is prevented, most double-strand breaks are repaired by non-homologous end-joinings similar to those observed in mammalian cells. About 1% of non-homologous repair events were exceptional, having 'captured' approximately 100 base pairs of DNA within the HO cleavage site. In each case, the insertion came from yeast's retrotransposon Ty1 element. Four of the five contained the R-U5 region, which is the first part of Ty1 messenger RNA to be converted to complementary DNA. The capture of cDNA fragments at fhe sites of double-strand breaks may account for the way that pseudogenes and long and short interspersed sequences (LINES and SINES) have been inserted at many locations in the mammalian genome.	BRANDEIS UNIV,ROSENSTIEL CTR,WALTHAM,MA 02254; BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254	Brandeis University; Brandeis University			Wilson, Matthew H/K-3193-2013	Haber, James/0000-0002-1878-0610				BOEKE JD, 1988, SCIENCE, V239, P280, DOI 10.1126/science.2827308; BOEKE JD, 1989, ANNU REV MICROBIOL, V43, P403, DOI 10.1146/annurev.micro.43.1.403; BRITTEN RJ, 1988, P NATL ACAD SCI USA, V85, P4770, DOI 10.1073/pnas.85.13.4770; CHAPMAN KB, 1992, P NATL ACAD SCI USA, V89, P3236, DOI 10.1073/pnas.89.8.3236; CLARE J, 1985, P NATL ACAD SCI USA, V82, P2829, DOI 10.1073/pnas.82.9.2829; CONNOLLY B, 1988, MOL CELL BIOL, V8, P2342, DOI 10.1128/MCB.8.6.2342; DERR LK, 1991, CELL, V67, P355, DOI 10.1016/0092-8674(91)90187-4; ERREDE B, 1986, MOL CELL BIOL, V6, P1334, DOI 10.1128/MCB.6.4.1334; HABER JE, 1995, BIOESSAYS, V17, P609, DOI 10.1002/bies.950170707; HAUBER J, 1985, NUCLEIC ACIDS RES, V13, P2745, DOI 10.1093/nar/13.8.2745; JENSEN RE, 1984, COLD SPRING HARB SYM, V49, P97, DOI 10.1101/SQB.1984.049.01.013; KRAMER KM, 1994, MOL CELL BIOL, V14, P1293, DOI 10.1128/MCB.14.2.1293; MEZARD C, 1994, MOL CELL BIOL, V14, P1278, DOI 10.1128/MCB.14.2.1278; Moore JK, 1996, MOL CELL BIOL, V16, P2164, DOI 10.1128/mcb.16.5.2164; MULLER F, 1991, MOL GEN GENET, V226, P145, DOI 10.1007/BF00273598; NICKOLOFF JA, 1989, J MOL BIOL, V207, P527, DOI 10.1016/0022-2836(89)90462-2; PFEIFFER P, 1994, MOL CELL BIOL, V14, P888, DOI 10.1128/MCB.14.2.888; Roth D., 1988, GENETIC RECOMBINATIO, P621; SHEN MR, 1991, J MOL EVOL, V33, P311; TENG SC, 1986, NATURE, V383, P641; VOYTAS DF, 1993, TRENDS GENET, V9, P421, DOI 10.1016/0168-9525(93)90105-Q; Yang J, 1996, NATURE, V381, P332, DOI 10.1038/381332a0	22	200	207	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1996	383	6601					644	646		10.1038/383644a0	http://dx.doi.org/10.1038/383644a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM755	8857544				2022-12-24	WOS:A1996VM75500060
J	Sanson, B; White, P; Vincent, JP				Sanson, B; White, P; Vincent, JP			Uncoupling cadherin-based adhesion from wingless signalling in Drosophila	NATURE			English	Article							POLARITY GENE ARMADILLO; CELL-ADHESION; CYTOPLASMIC DOMAIN; BETA-CATENIN; PROTEIN; COMPLEX; INDUCTION; MOLECULE; HOMOLOG; REGION	THE Wnt genes encode secreted glycoproteins used in intercellular communication at multiple steps during development. Signalling by Wingless, the Drosophila Wnt-1 homologue, requires the activity of Armadillo(1,2), the homologue of vertebrate beta-catenin(3), which is a component of the cadherin/catenin complex at adherens junctions(4,5). The genetic link between wingless and armadillo suggests that cell fate specification and cell-cell adhesion might be controlled concurrently. For instance, in one extreme view, Wingless could specify cell fate entirely by modulating cell adhesion. Alternatively, it might signal independently of adherens junctions. To distinguish between these alternatives, we have expressed two polypeptides that have opposite effects on cadherin-dependent adhesion: full-length Drosophila E-cadherin and a dominant-negative truncated form. We found that overexpression of either construct mimics wingless phenotypes, thereby uncoupling changes in adhesion from signalling effects. We demonstrate that both constructs titrate Armadillo from a 'signalling' pool which is functionally distinct from the junctional pool.	MRC,MOL BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology				Sanson, Benedicte/0000-0002-2782-4195				Aberle H, 1996, J BIOL CHEM, V271, P1520, DOI 10.1074/jbc.271.3.1520; ABERLE H, 1994, J CELL SCI, V107, P3655; ARIAS AM, 1988, DEVELOPMENT, V103, P157; BENJUMEA FD, 1995, DEVELOPMENT, V121, P4215; BRAND AH, 1993, DEVELOPMENT, V118, P401; COUSO JP, 1994, DEVELOPMENT, V120, P621; DTNARDO S, 1988, NATURE, V332, P604; Fagotto F, 1996, J CELL BIOL, V132, P1105, DOI 10.1083/jcb.132.6.1105; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; Grawe F, 1996, DEVELOPMENT, V122, P951; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; HINCK L, 1994, TRENDS BIOCHEM SCI, V19, P538, DOI 10.1016/0968-0004(94)90057-4; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; NOORDEMEER J, 1994, NATURE, V387, P80; ODA H, 1994, DEV BIOL, V165, P716, DOI 10.1006/dbio.1994.1287; ODA H, 1993, J CELL BIOL, V121, P1133, DOI 10.1083/jcb.121.5.1133; Orsulic S, 1996, J CELL BIOL, V134, P1283, DOI 10.1083/jcb.134.5.1283; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1993, J CELL SCI, V105, P993; PEIFER M, 1993, DEVELOPMENT, V118, P1191; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; SHARMA RP, 1976, DEV BIOL, V48, P461, DOI 10.1016/0012-1606(76)90108-1; Stappert J, 1993, Curr Opin Neurobiol, V3, P60, DOI 10.1016/0959-4388(93)90036-X; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; Tepass U, 1996, GENE DEV, V10, P672, DOI 10.1101/gad.10.6.672; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; Uemura T, 1996, GENE DEV, V10, P659, DOI 10.1101/gad.10.6.659	30	313	316	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1996	383	6601					627	630		10.1038/383627a0	http://dx.doi.org/10.1038/383627a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM755	8857539				2022-12-24	WOS:A1996VM75500055
J	Tan, KH; Kilby, MD; Whittle, MJ; Beattie, BR; Booth, IW; Botting, BJ				Tan, KH; Kilby, MD; Whittle, MJ; Beattie, BR; Booth, IW; Botting, BJ			Congenital anterior abdominal wall defects in England and Wales 1987-93: Retrospective analysis of OPCS data	BRITISH MEDICAL JOURNAL			English	Article							OMPHALOMESENTERIC ARTERY; RISK-FACTORS; GASTROSCHISIS; MALFORMATIONS; OMPHALOCELE; NOTIFICATION; INTERRUPTION; MANAGEMENT; PREGNANCY	Objective-Analysis of incidence and characteristics of congenital abdominal wall defects, with special reference to the differences between the incidence of gastroschisis and exomphalos (omphalocele). Design-Retrospective analysis using data from the Office of Population Censuses and Surveys (recoded to differentiate exomphalos and gastroschisis) and the National Congenital Malformation Notification Scheme. Setting-England and Wales, 1987 to 1993. Results-1043 congenital anterior abdominal wall defects were notified within the seven year study period. Of these, 539 were classified as gastroschisis, 448 as exomphalos, 19 as ''prune belly syndrome,'' and 37 as ''unclassified'' Gastroschisis doubled in incidence from 0.65 in 1987 to 1.35 per 10 000 total births in 1991, with little further change; the incidence of exomphalos decreased from 1.13 to 0.77 per 10 000 births. The overall incidence of notified congenital abdominal wall defects was 2.15 per 10 000 total births. Gastroschisis was associated with a lower overall maternal age than exomphalos and with a significantly lower proportion of additional reported congenital malformations (5.0%) than in the cohort with exomphalos (27.4%) (odds ratio 0.14, 95% confidence interval 0.09 to 0.22; P<0.001). The sex ratio of the two cohorts was the same. The incidence of gastroschisis and exomphalos was higher in the northern regions of England than in the south east of the country. Conclusions-The national congenital malformation notification system showed an increasing trend in the incidence of fetuses born with gastroschisis and a progressive decreasing incidence of exomphalos in England and Wales between 1987 and 1993. Although the reasons for this are likely to be multifactorial, a true differential change seems likely. The observed increase in incidence Of gastroschisis relative to exomphalos and the differentiation in maternal age have implications for resource management within the NHS and warrant further epidemiological monitoring. Regional differences may be due to a dietary or environmental factor, which requires further study.	UNIV BIRMINGHAM,ACAD DEPT OBSTET,DIV FETAL MED,BIRMINGHAM B15 2TG,W MIDLANDS,ENGLAND; UNIV WALES COLL CARDIFF,DEPT FETAL MED,CARDIFF CF4 4XN,S GLAM,WALES; UNIV BIRMINGHAM,INST CHILD HLTH,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; OFF NATL STAT,LONDON WC2B 6JP,ENGLAND	University of Birmingham; Cardiff University; University of Birmingham			FRCPI, Mark D Kilby MB BS DSc MD FRCOG/AAW-9704-2020	FRCPI, Mark D Kilby MB BS DSc MD FRCOG/0000-0001-9987-4223; Tan, Kok Hian/0000-0003-1945-0266				BAIRD PA, 1981, AM J HUM GENET, V33, P470; BALLANTYNE TW, 1904, MANUAL ANTENATAL PAT; BILL AH, 1969, PEDIAT SURG, P885; BIRCH D, 1986, SCHOOLGIRL PREGNANCI; *CAL DEP HLTH SERV, 1994, CAL BIRTH DEF MON PR; CALZOLARI E, 1993, TERATOLOGY, V48, P47; DOYLE PE, 1990, J EPIDEMIOL COMMUNIT, V45, P43; DUTTON SJ, 1991, J EPIDEMIOL COMMUN H, V45, P294, DOI 10.1136/jech.45.4.294; FRISANCHO AR, 1983, AM J CLIN NUTR, V38, P739, DOI 10.1093/ajcn/38.5.739; GIERUP J, 1979, Z KINDERCHIR, V28, P39; GOLDBAUM G, 1990, TERATOLOGY, V42, P397, DOI 10.1002/tera.1420420408; HEMMINKI K, 1982, J EPIDEMIOL COMMUN H, V36, P289, DOI 10.1136/jech.36.4.289; HOLLABAUGH RS, 1977, J PEDIATR SURG, V8, P263; HOYME HE, 1983, SEMIN PERINATOL, V7, P294; HOYME HE, 1981, J PEDIATR-US, V98, P228, DOI 10.1016/S0022-3476(81)80640-3; KIRK EP, 1983, AM J OBSTET GYNECOL, V146, P512, DOI 10.1016/0002-9378(83)90791-3; KNOX EG, 1984, J EPIDEMIOL COMMUN H, V38, P296, DOI 10.1136/jech.38.4.296; LAMBERT P, 1976, POPULATION TRENDS, V4, P4; LINDHAM S, 1981, ACTA PAEDIATR SCAND, V70, P55, DOI 10.1111/j.1651-2227.1981.tb07173.x; MARTINEZFRIAS ML, 1984, TERATOLOGY, V29, P377, DOI 10.1002/tera.1420290308; MAYER T, 1980, ANN SURG, V192, P783, DOI 10.1097/00000658-198012000-00015; MCALLISTER F, 1978, NEONATAL SURG, P308; MOORE TC, 1977, SURGERY, V82, P561; MOORE TC, 1963, ANN SURG, V158, P263, DOI 10.1097/00000658-196308000-00017; MOORE TC, 1953, SURGERY, V33, P112; MORROW RJ, 1993, PRENATAL DIAG, V13, P111, DOI 10.1002/pd.1970130205; *OFF POP CENS SURV, 1993, MORT STAT PER IN DH3, P9; *OFF POP CENS SURV, 1994, AB STAT NOT 1987 AB; *OFF POP CENS SURV, 1990, CONG MALF STAT 1 MB3; PARE A, 1634, WORKS FAMOUS CHIRURG, V24, P59; PAYNE JN, 1992, PUBLIC HEALTH, V106, P437, DOI 10.1016/S0033-3506(05)80458-5; RICHMAN PP, 1969, NEONATAL SURG, P245; ROEPER PJ, 1987, TERATOLOGY, V35, P203, DOI 10.1002/tera.1420350206; SWERDLOW AJ, 1988, J EPIDEMIOL COMMUN H, V42, P8, DOI 10.1136/jech.42.1.8; TORFS CP, 1994, TERATOLOGY, V50, P44, DOI 10.1002/tera.1420500107; WHITTLE MJ, 1989, PRENATAL DIAGNOSIS O, P65; 1991, LANCET, V338, P131	37	135	137	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 12	1996	313	7062					903	906						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM754	8876090				2022-12-24	WOS:A1996VM75400021
J	Nightingale, SL				Nightingale, SL			Plan for distribution of prescription drug information for patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1996, JAMA-J AM MED ASSOC, V276, P935; 1996, RED REG, V61, P43769; 1995, JAMA-J AM MED ASSOC, V274, P1109	3	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1996	276	14					1128	1128						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL332	8827954				2022-12-24	WOS:A1996VL33200004
J	Claret, FX; Hibi, M; Dhut, S; Toda, T; Karin, M				Claret, FX; Hibi, M; Dhut, S; Toda, T; Karin, M			A new group of conserved coactivators that increase the specificity of AP-1 transcription factors	NATURE			English	Article							DNA-BINDING SPECIFICITY; PROTEIN-KINASE; MDR1 GENE; YEAST; JUN; FOS; TRANSFORMATION; EXTRADENTICLE; ACTIVATION; EXPRESSION	THE Jun proteins are nuclear proteins that combine with Fos proteins to form a gene-regulatory protein, AP-1. They have highly conserved DNA-binding and dimerization domains, resulting in almost identical sequence-recognition properties(1-3). Nevertheless, there are many indications that each Jun protein activates a distinct and only partially overlapping set of AP-1 target genes(4-6). Using the more variable activation domain of c-Jun as a bait, we identified a protein, JAB1, that interacts with c-Jun and JunD, but not with JunB or v-Jun. As a result, JAB1 selectively potentiates transactivation by only c-Jun or JunD, In vitro, JAB1 specifically stabilizes complexes of c-Jun or JunD with AP-1 sites and does not affect binding of either JunB or v-Jun. The amino-terminal half of JAB1 is very similar to the amino terminal region of Pad1 from fission yeast, which was identified genetically as a coactivator of a subset of AP-1 target genes(7). JAB1 and Pad1 are also functionally interchangeable. They define a new group of coactivators that increase the specificity of target gene activation by AP-1 proteins.	UNIV CALIF SAN DIEGO, SCH MED, DEPT PHARMACOL, PROGRAM BIOMED SCI, LA JOLLA, CA 92093 USA; IMPERIAL CANC RES FUND, LAB CELL REGULAT, LONDON WC2A 3PX, ENGLAND	University of California System; University of California San Diego; Cancer Research UK			Claret, Francois X/R-2104-2016; Hibi, Masahiko/I-6215-2014	Claret, Francois X/0000-0003-4629-6495; Hibi, Masahiko/0000-0002-9142-4444				ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bartel P. L., 1993, CELLULAR INTERACTION, P153; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; Claret FX, 1996, MOL CELL BIOL, V16, P219; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Johnson R, 1996, MOL CELL BIOL, V16, P4504; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Kumada K, 1996, MOL GEN GENET, V250, P59, DOI 10.1007/s004380050051; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NAKABEPPU Y, 1989, EMBO J, V8, P3833, DOI 10.1002/j.1460-2075.1989.tb08561.x; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; SHIMANUKI M, 1995, J CELL SCI, V108, P569; SMEAL T, 1994, EMBO J, V13, P6006, DOI 10.1002/j.1460-2075.1994.tb06946.x; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; UCHIUMI T, 1993, FEBS LETT, V326, P11, DOI 10.1016/0014-5793(93)81750-T; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	30	402	424	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 3	1996	383	6599					453	457		10.1038/383453a0	http://dx.doi.org/10.1038/383453a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL463	8837781				2022-12-24	WOS:A1996VL46300067
J	AdamKlages, S; Adam, D; Wiegmann, K; Struve, S; Kolanus, W; SchneiderMergener, J; Kronke, M				AdamKlages, S; Adam, D; Wiegmann, K; Struve, S; Kolanus, W; SchneiderMergener, J; Kronke, M			FAN, a novel WD-repeat protein, couples the p55 TNF-receptor to neutral sphingomyelinase	CELL			English	Article							TUMOR-NECROSIS-FACTOR; CELL-FREE SYSTEM; PHOSPHOLIPASE-C; DEATH DOMAIN; FACTOR-ALPHA; KAPPA-B; MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; FAS/APO-1 CD95; BETA-SUBUNIT	The initiation of intracellular signaling events through the 55 kDa tumor necrosis factor-receptor (TNF-R55) appears to depend on protein intermediates that interact with specific cytoplasmic domains of TNF-R55. By combined use of the yeast interaction trap system and a peptide scanning library, the novel WD-repeat protein FAN has been identified, which specifically binds to a cytoplasmic nine amino acid binding motif of TNF-R55. This region has been previously recognized as a distinct functional domain that is both required and sufficient for the activation of neutral sphingomyelinase (N-SMase). Overexpression of full-length FAN enhanced N-SMase activity in TNF-treated cells, while truncated mutants of FAN produced dominant negative effects. The data suggest that FAN regulates ceramide production by N-SMase, which is a crucial step in TNF signaling.	UNIV MUNICH,GENZENTRUM,MOL BIOL LAB,D-81375 MUNICH,GERMANY; UNIV KLINIKUM CHARITE,INST MED IMMUNOL,D-10117 BERLIN,GERMANY	University of Munich; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	AdamKlages, S (corresponding author), CHRISTIAN ALBRECHTS UNIV KIEL,INST IMMUNOL,D-24105 KIEL,GERMANY.		Adam, Dieter/E-9763-2010; Adam-Klages, Sabine/E-9761-2010	Adam, Dieter/0000-0002-5668-5032; 				Adam D, 1996, J BIOL CHEM, V271, P14617, DOI 10.1074/jbc.271.24.14617; BARBARA JAJ, 1994, EMBO J, V13, P843, DOI 10.1002/j.1460-2075.1994.tb06327.x; Bazzoni F, 1995, J INFLAMM, V45, P221; BELKA K, 1995, EMBO J, V14, P1156; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BOLDIN MP, 1995, FEBS LETT, V367, P39, DOI 10.1016/0014-5793(95)00534-G; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; CLARK MA, 1991, P NATL ACAD SCI USA, V88, P5418, DOI 10.1073/pnas.88.12.5418; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; FEUCHTER AE, 1992, GENOMICS, V13, P1237, DOI 10.1016/0888-7543(92)90041-P; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; GEHR G, 1992, J IMMUNOL, V149, P911; GOEDDEL DV, 1986, COLD SPRING HARB SYM, V51, P597, DOI 10.1101/SQB.1986.051.01.072; GRELL M, 1994, J IMMUNOL, V153, P1963; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kramer Achim, 1994, Methods (Orlando), V6, P388, DOI 10.1006/meth.1994.1039; Kronke M, 1992, Immunol Ser, V56, P189; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LIU J, 1994, J BIOL CHEM, V269, P3047; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MACHLEIDT T, 1994, J BIOL CHEM, V269, P13760; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MURAKAWA K, 1994, GENOMICS, V23, P379, DOI 10.1006/geno.1994.1514; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; PUSHKAREVA M, 1995, IMMUNOL TODAY, V16, P294, DOI 10.1016/0167-5699(95)80184-7; REDDY SAG, 1994, J BIOL CHEM, V269, P25369; REINEKE U, 1996, IN PRESS MOL DIVERSI; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; ROTHE J, 1992, IMMUNOL RES, V11, P81, DOI 10.1007/BF02918612; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SONG HY, 1995, J BIOL CHEM, V270, P3574, DOI 10.1074/jbc.270.8.3574; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; VIETOR I, 1993, J BIOL CHEM, V268, P18994; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; WEIHERGRABER O, 1996, FEBS LETT, V379, P122; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0	63	337	349	1	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1996	86	6					937	947		10.1016/S0092-8674(00)80169-5	http://dx.doi.org/10.1016/S0092-8674(00)80169-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VJ443	8808629	Bronze			2022-12-24	WOS:A1996VJ44300012
J	Peters, LL; Shivdasani, RA; Liu, SC; Hanspal, M; John, KM; Gonzalez, JM; Brugnara, C; Gwynn, B; Mohandas, N; Alper, SL; Orkin, SH; Lux, SE				Peters, LL; Shivdasani, RA; Liu, SC; Hanspal, M; John, KM; Gonzalez, JM; Brugnara, C; Gwynn, B; Mohandas, N; Alper, SL; Orkin, SH; Lux, SE			Anion exchanger 1 (band 3) is required to prevent erythrocyte membrane surface loss but not to form the membrane skeleton	CELL			English	Article							REFLECT SPECTRIN DEFICIENCIES; RED-BLOOD-CELL; HEREDITARY SPHEROCYTOSIS; CYTOPLASMIC DOMAIN; HEMOLYTIC-ANEMIA; PROTEIN BAND-3; KIDNEY BAND-3; BETA-SPECTRIN; GENE FAMILY; ANKYRIN	The red blood cell (RBC) membrane protein AE1 provides high affinity binding sites for the membrane skeleton, a structure critical to RBC integrity. AE1 biosynthesis is postulated to be required for terminal erythropoiesis and membrane skeleton assembly. We used targeted mutagenesis to assess AE1 function in vivo. RBCs lacking AE1 spontaneously shed membrane vesicles and tubules, leading to severe spherocytosis and hemolysis, but the levels of the major skeleton components, the synthesis of spectrin in mutant erythroblasts, and skeletal architecture are normal or nearly normal. The results indicate that AE1 does not regulate RBC membrane skeleton assembly in vivo but is essential for membrane stability. We postulate that stabilization is achieved through AE1-lipid interactions and that loss of these interactions is a key pathogenic event in hereditary spherocytosis.	CHILDRENS HOSP, DEPT MED, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA; DANA FARBER CANC INST, DEPT PEDIAT ONCOL, BOSTON, MA 02115 USA; ST ELIZABETHS MED CTR, DEPT BIOMED RES, BOSTON, MA 02115 USA; CHILDRENS HOSP, DEPT LAB MED, BOSTON, MA 02115 USA; UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, BERKELEY, CA 94720 USA; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DEPT MED, MOL MED UNIT, BOSTON, MA 02115 USA; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DEPT MED, RENAL UNIT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; CHILDRENS HOSP, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; St. Elizabeth's Medical Center; Harvard University; Boston Children's Hospital; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute	Peters, LL (corresponding author), JACKSON LAB, 600 MAIN ST, BAR HARBOR, ME 04609 USA.		Brugnara, Carlo/A-8041-2010	Brugnara, Carlo/0000-0001-8192-8713; Peters, Luanne/0000-0002-0784-0534	NHLBI NIH HHS [HL37462, R01 HL055321, HL32262] Funding Source: Medline; NIDDK NIH HHS [DK34083] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL032262, P01HL037462, R01HL055321] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034083, R01DK034083] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPER SL, 1989, P NATL ACAD SCI USA, V86, P5429, DOI 10.1073/pnas.86.14.5429; ALPER SL, 1994, CELL PHYSIOL BIOCHEM, V4, P265, DOI 10.1159/000154730; BENNETT V, 1979, J BIOL CHEM, V254, P2533; BENNETT V, 1980, J BIOL CHEM, V255, P6424; BROSIUS FC, 1989, J BIOL CHEM, V264, P7784; CHASIS JA, 1988, J CLIN INVEST, V82, P617, DOI 10.1172/JCI113640; CHASIS JA, 1992, BLOOD, V80, P1869; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK MR, 1983, BLOOD, V61, P899, DOI 10.1182/blood.V61.5.899.899; COHEN AM, 1986, BLOOD, V68, P920; COX JV, 1987, J CELL BIOL, V105, P1405, DOI 10.1083/jcb.105.3.1405; DING Y, 1994, J BIOL CHEM, V269, P32201; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; GILLIGAN DM, 1993, SEMIN HEMATOL, V30, P74; GROVES JD, 1994, J MEMBRANE BIOL, V140, P81; HANSPAL M, 1991, J BIOL CHEM, V266, P15626; HANSPAL M, 1987, J CELL BIOL, V105, P1417, DOI 10.1083/jcb.105.3.1417; HANSPAL M, 1992, EUR J CELL BIOL, V58, P313; HANSPAL M, 1992, BLOOD, V80, P530; Inaba M, 1996, J CLIN INVEST, V97, P1804, DOI 10.1172/JCI118610; JAROLIM P, 1995, BLOOD, V85, P634, DOI 10.1182/blood.V85.3.634.bloodjournal853634; JONS T, 1992, EMBO J, V11, P2863, DOI 10.1002/j.1460-2075.1992.tb05354.x; KAY MMB, 1990, P NATL ACAD SCI USA, V87, P5734, DOI 10.1073/pnas.87.15.5734; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KOPITO RR, 1987, J BIOL CHEM, V262, P8035; KORSGREN C, 1988, J BIOL CHEM, V263, P10212; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARIDES E, 1987, CELL, V51, P345, DOI 10.1016/0092-8674(87)90631-3; LEHNERT ME, 1988, J CELL BIOL, V107, P413, DOI 10.1083/jcb.107.2.413; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIU SC, 1987, J CELL BIOL, V104, P527, DOI 10.1083/jcb.104.3.527; LIU SC, 1990, BLOOD, V76, P198; LIU SC, 1994, BLOOD, V84, pA362; LOMBARDO CR, 1994, J BIOL CHEM, V269, P29212; Lux SE, 1995, BLOOD PRINCIPLES PRA, P1701; MAKSYMIW R, 1987, BIOCHEMISTRY-US, V26, P2983, DOI 10.1021/bi00385a005; NEHLS V, 1993, AM J PATHOL, V142, P1565; ORTWEIN R, 1994, BBA-BIOMEMBRANES, V1191, P317, DOI 10.1016/0005-2736(94)90182-1; PETERS LL, 1993, BLOOD, V81, P2144; PETERS LL, 1993, SEMIN HEMATOL, V30, P85; PETERS LL, 1992, BLOOD, V80, P2122; PETERS LL, 1992, P NATL ACAD SCI USA, V89, P5749, DOI 10.1073/pnas.89.13.5749; PETERS LL, 1995, J CELL BIOL, V130, P313, DOI 10.1083/jcb.130.2.313; REID ME, 1990, BLOOD, V75, P2229; REINHART WH, 1994, BRIT J HAEMATOL, V86, P147, DOI 10.1111/j.1365-2141.1994.tb03266.x; Robertson E. J., 1987, TERATOCARCINOMAS EMB; RYBICKI AC, 1988, J CLIN INVEST, V81, P893, DOI 10.1172/JCI113400; SAVVIDES P, 1993, BLOOD, V82, P2953; SCHOFIELD AE, 1992, NATURE, V355, P836, DOI 10.1038/355836a0; SHEETZ MP, 1980, NATURE, V285, P510, DOI 10.1038/285510a0; THOMAS HA, 1989, AM J PHYSIOL, V257, pC537, DOI 10.1152/ajpcell.1989.257.3.C537; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VONDENHOF A, 1994, BIOCHEMISTRY-US, V33, P4517, DOI 10.1021/bi00181a011; WANG CC, 1995, J BIOL CHEM, V270, P17892, DOI 10.1074/jbc.270.30.17892; WAUGH RE, 1988, J CLIN INVEST, V81, P133, DOI 10.1172/JCI113284; WILLARDSON BM, 1989, J BIOL CHEM, V264, P15893; WOODS CM, 1986, J CELL BIOL, V103, P1789, DOI 10.1083/jcb.103.5.1789; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	58	208	209	1	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	1996	86	6					917	927		10.1016/S0092-8674(00)80167-1	http://dx.doi.org/10.1016/S0092-8674(00)80167-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VJ443	8808627	Bronze			2022-12-24	WOS:A1996VJ44300010
J	Shibata, D; Reale, MA; Lavin, P; Silverman, M; Fearon, ER; Steele, G; Jessup, JM; Loda, M; Summerhayes, IC				Shibata, D; Reale, MA; Lavin, P; Silverman, M; Fearon, ER; Steele, G; Jessup, JM; Loda, M; Summerhayes, IC			The DCC protein and prognosis in colorectal cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUPPRESSOR GENE DCC; FLUOROURACIL PLUS LEVAMISOLE; FREQUENT LOSS; ADJUVANT THERAPY; COLON-CANCER; CHROMOSOME 18Q; CARCINOMA GENE; ALLELIC LOSS; EXPRESSION; HETEROZYGOSITY	Background Allelic loss of chromosome 18q predicts a poor outcome in patients with stage II colorectal cancer. Although the specific gene inactivated by this allelic loss has not been elucidated, the DCC (deleted in colorectal cancer) gene is a candidate. We investigated whether the expression of the DCC protein in tumor cells is a prognostic marker in colorectal carcinoma. Methods The expression of DCC was evaluated immunohistochemically in 132 paraffin-embedded samples from patients with curatively resected stage II or III colorectal carcinomas. The Cox proportional-hazards model was used to adjust for covariates including age, sex, tumor site, degree of tumor differentiation, and use of adjuvant therapy. Results The expression of DCC was a strong positive predictive factor for survival in both stage II and stage III colorectal carcinomas. In patients with stage II disease whose tumors expressed DCC, the five-year survival rate was 94.3 percent, whereas in patients with DCC-negative tumors, the survival rate was 61.6 percent (P<0.001). In patients with stage III disease, the respective survival rates were 59.3 percent and 33.2 percent (P = 0.03). Conclusions DCC is a prognostic marker in patients with stage II or stage III colorectal cancer. In stage II colorectal carcinomas, the absence of DCC identifies a subgroup of patients with lesions that behave like stage III cancers. These findings may thus have therapeutic implications in this group of (C) 1996, Massachusetts Medical Society.	HARVARD UNIV, NEW ENGLAND DEACONESS HOSP,SCH MED,DEPT SURG, LAB CANC BIOL, BOSTON, MA 02215 USA; HARVARD UNIV, NEW ENGLAND DEACONESS HOSP, SCH MED, DEPT PATHOL, BOSTON, MA 02215 USA; YALE UNIV, SCH MED, SECT MED ONCOL, NEW HAVEN, CT USA; BOSTON BIOSTAT RES FDN, FRAMINGHAM, MA USA; LAHEY HITCHCOCK MED CTR, DEPT PATHOL, BURLINGTON, MA USA; UNIV MICHIGAN, MED CTR, DEPT INTERNAL MED, DIV MED & MOL GENET, ANN ARBOR, MI 48109 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Yale University; Lahey Hospital & Medical Center; University of Michigan System; University of Michigan					NCI NIH HHS [CA-44704] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA044704] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1984, NEW ENGL J MED, V310, P737; BRABANT G, 1993, CANCER RES, V53, P4987; BREWSTER SF, 1994, J UROLOGY, V151, P1073, DOI 10.1016/S0022-5347(17)35186-8; BREWSTER SF, 1994, BRIT J CANCER, V70, P697, DOI 10.1038/bjc.1994.376; BROWN RW, 1995, MODERN PATHOL, V8, P515; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; CHUONG CM, 1994, DEV BIOL, V164, P383, DOI 10.1006/dbio.1994.1208; Cordon-Cardo C, 1994, Important Adv Oncol, P71; COX DR, 1972, J R STAT SOC B, V34, P187; ENOMOTO T, 1995, BRIT J CANCER, V71, P462, DOI 10.1038/bjc.1995.94; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FISHER B, 1988, JNCI-J NATL CANCER I, V80, P21, DOI 10.1093/jnci/80.1.21; FROGGATT NJ, 1995, J CANCER RES CLIN, V121, P7, DOI 10.1007/BF01202723; GAO X, 1993, CANCER RES, V53, P2723; GIMA T, 1994, INT J CANCER, V57, P480, DOI 10.1002/ijc.2910570407; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; HOHNE MW, 1992, CANCER RES, V52, P2616; IACOPETTA B, 1994, EUR J CANCER, V30A, P664, DOI 10.1016/0959-8049(94)90541-X; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KASHIWABA M, 1995, VIRCHOWS ARCH, V426, P441; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KLINGELHUTZ AJ, 1995, ONCOGENE, V10, P1581; KODNER IJ, 1994, PRINCIPLES SURG, P1191; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; LAWLOR KG, 1992, CELL GROWTH DIFFER, V3, P609; LUMADUE JA, 1995, SURG CLIN N AM, V75, P845, DOI 10.1016/S0039-6109(16)46731-9; MIYAKE K, 1994, LEUKEMIA LYMPHOMA, V16, P13, DOI 10.3109/10428199409114135; MIYAKE K, 1993, BLOOD, V82, P927; MIYAKE S, 1994, CANCER RES, V54, P3007; MOERTEL CG, 1995, J CLIN ONCOL, V13, P2936, DOI 10.1200/JCO.1995.13.12.2936; MOERTEL CG, 1994, NEW ENGL J MED, V330, P1136; MOERTEL CG, 1995, ANN INTERN MED, V122, P321, DOI 10.7326/0003-4819-122-5-199503010-00001; MURTY VVVS, 1994, ONCOGENE, V9, P3227; NARAYANAN R, 1992, ONCOGENE, V7, P553; OCONNELL MJ, 1992, CANCER-AM CANCER SOC, V70, P1732, DOI 10.1002/1097-0142(19920915)70:4+<1732::AID-CNCR2820701614>3.0.CO;2-#; PIERCEALL WE, 1994, J CELL BIOL, V124, P1017, DOI 10.1083/jcb.124.6.1017; REALE MA, 1994, CANCER RES, V54, P4493; SCHECK AC, 1993, CANCER RES, V53, P5605; Shibata David, 1995, Surgical Forum, V46, P526; TURLEY H, 1995, CANCER RES, V55, P5628; UCHINO S, 1992, CANCER RES, V52, P3099; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WOLMARK N, 1993, J CLIN ONCOL, V11, P1879, DOI 10.1200/JCO.1993.11.10.1879	46	238	247	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 5	1996	335	23					1727	1732		10.1056/NEJM199612053352303	http://dx.doi.org/10.1056/NEJM199612053352303			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VW795	8929264				2022-12-24	WOS:A1996VW79500003
J	Mena, M; Ambrose, BA; Meeley, RB; Briggs, SP; Yanofsky, MF; Schmidt, RJ				Mena, M; Ambrose, BA; Meeley, RB; Briggs, SP; Yanofsky, MF; Schmidt, RJ			Diversification of C-function activity in maize flower development	SCIENCE			English	Article							FLORAL HOMEOTIC GENES; ZEA-MAYS; ARABIDOPSIS; SEPARATION	The Arabidopsis gene AGAMOUS is required for male and female reproductive organ development and for floral determinacy. Reverse genetics allowed the isolation of a transposon-induced mutation in ZAG1, the maize homolog of AGAMOUS. ZAG1 mutants exhibited a loss of determinacy, but the identity of reproductive organs was largely unaffected. This suggested a redundancy in maize sex organ specification that led to the identification and cloning of a second AGAMOUS homolog, ZMM2, that has a pattern of expression distinct from that of ZAG1. C-function organ identity in maize (as defined by the A, B, C model of floral organ development) may therefore be orchestrated by two closely related genes, ZAG1 and ZMM2, with overlapping but nonidentical activities.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR MOL GENET, LA JOLLA, CA 92093 USA; PIONEER HI BRED INT INC, DEPT BIOTECHNOL RES, JOHNSTON, IA 50131 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; DuPont; Pioneer Hi-Bred International, Inc.			Mena, Montaña/AAB-1153-2019	Mena, Montaña/0000-0001-7521-1644				BENSEN RJ, 1995, PLANT CELL, V7, P75, DOI 10.1105/tpc.7.1.75; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; BRADLEY D, 1993, CELL, V72, P85, DOI 10.1016/0092-8674(93)90052-R; CHENG PC, 1983, AM J BOT, V70, P450, DOI 10.2307/2443252; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; Davies B, 1994, Results Probl Cell Differ, V20, P235; GOODMAN MM, 1980, GENETICS, V96, P697; HELENTJARIS T, 1989, GENETICS, V118, P6442; KIESSELBACH TA, 1949, U NEBR AGR EXP STN R, V161; MA H, 1994, GENE DEV, V8, P745, DOI 10.1101/gad.8.7.745; MANDEL A, UNPUB; Mena M, 1995, PLANT J, V8, P845, DOI 10.1046/j.1365-313X.1995.8060845.x; MIZUKAMI Y, 1995, PLANT MOL BIOL, V28, P767, DOI 10.1007/BF00042064; Riechmann JL, 1996, P NATL ACAD SCI USA, V93, P4793, DOI 10.1073/pnas.93.10.4793; SCHMIDT RJ, 1993, PLANT CELL, V5, P729, DOI 10.1105/tpc.5.7.729; SIEBURTH LE, 1995, PLANT CELL, V7, P1249, DOI 10.1105/tpc.7.8.1249; THEISSEN G, 1995, GENE, V156, P155, DOI 10.1016/0378-1119(95)00020-7; WEIGEL D, 1994, CELL, V78, P203, DOI 10.1016/0092-8674(94)90291-7; WENDEL JF, 1986, THEOR APPL GENET, V72, P178, DOI 10.1007/BF00266990; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0; YANOFSKY MF, 1995, ANNU REV PLANT PHYS, V46, P167, DOI 10.1146/annurev.pp.46.060195.001123	22	240	258	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 29	1996	274	5292					1537	1540		10.1126/science.274.5292.1537	http://dx.doi.org/10.1126/science.274.5292.1537			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929416				2022-12-24	WOS:A1996VV77500051
J	Nozette, S; Lichtenberg, CL; Spudis, P; Bonner, R; Ort, W; Malaret, E; Robinson, M; Shoemaker, EM				Nozette, S; Lichtenberg, CL; Spudis, P; Bonner, R; Ort, W; Malaret, E; Robinson, M; Shoemaker, EM			The Clementine bistatic radar experiment	SCIENCE			English	Article							OUTER PLANET SATELLITES; GREENLAND ICE-SHEET; COHERENT-BACKSCATTER; MOON; MERCURY; STABILITY; MODEL; POLARIZATION; GANYMEDE; CRATERS	During the Clementine 1 mission, a bistatic radar experiment measured the magnitude and polarization of the radar echo versus bistatic angle, beta, for selected lunar areas. Observations of the lunar south pole yield a same-sense polarization enhancement around beta = 0. Analysis shows that the observed enhancement is localized to the permanently shadowed regions of the lunar south pole. Radar observations of periodically solar-illuminated lunar surfaces, including the north pole, yielded no such enhancement. A probable explanation for these differences is the presence of low-loss volume scatterers, such as water ice, in the permanently shadowed region at the south pole.	USN,RES LAB,WASHINGTON,DC 20375; LUNAR & PLANETARY INST,HOUSTON,TX 77058; PROTASIS INC,ALEXANDRIA,VA 22314; APPL COHERENT TECHNOL,HERNDON,VA 22070; US GEOL SURVEY,FLAGSTAFF,AZ 86001	United States Department of Defense; United States Navy; Naval Research Laboratory; United States Department of the Interior; United States Geological Survey	Nozette, S (corresponding author), USAF,PHILLIPS LAB,SPACE EXPT DIRECTORATE,711 N FAYETTE ST,ALEXANDRIA,VA 22314, USA.							ARNOLD JR, 1979, J GEOPHYS RES, V84, P5659, DOI 10.1029/JB084iB10p05659; BUTLER BJ, 1993, J GEOPHYS RES-PLANET, V98, P15003, DOI 10.1029/93JE01581; CAMPBELL DB, 1978, ICARUS, V34, P254, DOI 10.1016/0019-1035(78)90166-5; ESCHLEMAN VR, 1986, SCIENCE, V234, P587, DOI 10.1126/science.234.4776.587; Eternad S., 1987, PHYS REV LETT, V59, P1420; Evans J.V., 1968, RADAR ASTRONOMY; GOLDSTEIN RM, 1980, SCIENCE, V207, P179, DOI 10.1126/science.207.4427.179; GORODNICHEV EE, 1990, PHYS LETT A, V144, P48, DOI 10.1016/0375-9601(90)90047-R; HAPKE B, 1990, ICARUS, V88, P407, DOI 10.1016/0019-1035(90)90091-M; HAPKE B, 1991, NATURE, V352, P46, DOI 10.1038/352046a0; HARMON JK, 1994, NATURE, V369, P213, DOI 10.1038/369213a0; INGERSOLL AP, 1992, ICARUS, V100, P40, DOI 10.1016/0019-1035(92)90016-Z; MISHCHENKO MI, 1992, ASTROPHYS SPACE SCI, V194, P327, DOI 10.1007/BF00644001; MISHCHENKO MI, 1992, J OPT SOC AM A, V9, P978, DOI 10.1364/JOSAA.9.000978; MISHCHENKO MI, 1992, EARTH MOON PLANETS, V58, P127, DOI 10.1007/BF00054650; MUHLEMAN DO, 1991, SCIENCE, V253, P1508, DOI 10.1126/science.253.5027.1508; NOZETTE S, 1994, SCIENCE, V266, P1835, DOI 10.1126/science.266.5192.1835; OSTRO SJ, 1990, ICARUS, V85, P335, DOI 10.1016/0019-1035(90)90121-O; OSTRO SJ, 1982, SATELLITES JUPITER; PAIGE DA, 1992, SCIENCE, V258, P643, DOI 10.1126/science.258.5082.643; PETERS KJ, 1992, PHYS REV B, V46, P801, DOI 10.1103/PhysRevB.46.801; RIGNOT E, 1995, J GEOPHYS RES-PLANET, V100, P9389, DOI 10.1029/95JE00485; RIGNOT EJ, 1993, SCIENCE, V261, P1710, DOI 10.1126/science.261.5129.1710; SALVAIL JR, 1994, ICARUS, V111, P441, DOI 10.1006/icar.1994.1155; SHOEMAKER EM, 1994, SCIENCE, V266, P1851, DOI 10.1126/science.266.5192.1851; SIMPSON RA, 1993, IEEE T GEOSCI REMOTE, V31, P465, DOI 10.1109/36.214923; SLADE MA, 1992, SCIENCE, V258, P635, DOI 10.1126/science.258.5082.635; Spudis P.D., 1993, GEOLOGY MULTIRING IM; SPUDIS PD, 1994, SCIENCE, V266, P1848, DOI 10.1126/science.266.5192.1848; SPUDIS PD, 1995, LUNAR PLANET SCI, V26, P1339; STACY NJS, 1993, THESIS CORNELL U; Tsang L., 1985, THEORY MICROWAVE REM; WATSON K, 1961, J GEOPHYS RES, V66, P3033, DOI 10.1029/JZ066i009p03033; ZUBER MT, 1994, SCIENCE, V266, P1839, DOI 10.1126/science.266.5192.1839	34	254	275	3	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1996	274	5292					1495	1498		10.1126/science.274.5292.1495	http://dx.doi.org/10.1126/science.274.5292.1495			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929403	Green Submitted			2022-12-24	WOS:A1996VV77500038
J	Hahne, M; Rimoldi, D; Schroter, M; Romero, P; Schreier, M; French, LE; Schneider, P; Bornand, T; Fontana, A; Lienard, D; Cerottini, JC; Tschopp, J				Hahne, M; Rimoldi, D; Schroter, M; Romero, P; Schreier, M; French, LE; Schneider, P; Bornand, T; Fontana, A; Lienard, D; Cerottini, JC; Tschopp, J			Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape	SCIENCE			English	Article							HUMAN FAS LIGAND; T-LYMPHOCYTES; CD95 LIGAND; ANTIGENS; MICE; IDENTIFICATION; CYTOTOXICITY; MECHANISMS; INHIBITOR; PERFORIN	Malignant melanoma accounts for most of the increasing mortality from skin cancer. Melanoma cells were found to express Fas (also called Apo-1 or CD95) ligand (Fast). In metastatic lesions, Fas-expressing T cell infiltrates were proximal to FasL(+) tumor cells. In vitro, apoptosis of Fas-sensitive target cells occurred upon incubation with melanoma tumor cells; and in vivo, injection of FasL(+) mouse melanoma cells in mice led to rapid tumor formation. In contrast, tumorigenesis was delayed in Fas-deficient lpr mutant mice in which immune effector Cells cannot be killed by Fast. Thus, Fast may contribute to the immune privilege of tumors.	UNIV LAUSANNE,INST BIOCHEM,CH-1066 EPALINGES,SWITZERLAND; UNIV LAUSANNE,LUDWIG INST CANC RES,CH-1066 EPALINGES,SWITZERLAND; UNIV GENEVA,SCH MED,DEPT DERMATOL,CH-1211 GENEVA 4,SWITZERLAND; UNIV ZURICH HOSP,DEPT INTERNAL MED,CH-8044 ZURICH,SWITZERLAND; CHU VAUDOIS,CTR PLURIDISCIPLINAIRE ONCOL,CH-1011 LAUSANNE,SWITZERLAND	University of Lausanne; Ludwig Institute for Cancer Research; University of Lausanne; University of Geneva; University of Zurich; University Zurich Hospital; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)			French, Lars/AAL-5977-2020; Romero, Pedro/S-6015-2017	French, Lars/0000-0002-4629-1486; Romero, Pedro/0000-0002-9688-2882; Schneider, Pascal/0000-0003-0677-9409				BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.immunol.12.1.337; Braun MY, 1996, J EXP MED, V183, P657, DOI 10.1084/jem.183.2.657; Carrel S, 1996, INT J CANCER, V67, P417, DOI 10.1002/(SICI)1097-0215(19960729)67:3<417::AID-IJC17>3.0.CO;2-4; FERRONE S, 1995, IMMUNOL TODAY, V16, P487, DOI 10.1016/0167-5699(95)80033-6; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; FRENCH LE, 1996, J CELL BIOL, P335; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; HAHN S, 1995, EUR J IMMUNOL, V25, P2679, DOI 10.1002/eji.1830250942; HAHNE M, 1995, INT IMMUNOL, V7, P1381, DOI 10.1093/intimm/7.9.1381; HAHNE M, UNPUB; HERIN M, 1987, INT J CANCER, V39, P390, DOI 10.1002/ijc.2910390320; HUBER D, 1992, J IMMUNOL, V148, P277; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; KLEIN G, 1993, CURR OPIN IMMUNOL, V5, P687, DOI 10.1016/0952-7915(93)90122-9; Lau HT, 1996, SCIENCE, V273, P109, DOI 10.1126/science.273.5271.109; Lowin B, 1996, INT IMMUNOL, V8, P57, DOI 10.1093/intimm/8.1.57; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; MARIANI SM, 1995, EUR J IMMUNOL, V25, P2303, DOI 10.1002/eji.1830250828; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; Mukherji Bijay, 1995, Current Opinion in Oncology, V7, P175, DOI 10.1097/00001622-199503000-00014; MUUL LM, 1987, J IMMUNOL, V138, P989; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; RENSINGEHL A, 1995, EUR J IMMUNOL, V25, P2253, DOI 10.1002/eji.1830250821; ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; VANPEL A, 1995, IMMUNOL REV, V145, P229, DOI 10.1111/j.1600-065X.1995.tb00084.x; Zier K, 1996, IMMUNOL TODAY, V17, P39, DOI 10.1016/0167-5699(96)80567-6	34	1136	1226	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 22	1996	274	5291					1363	1366		10.1126/science.274.5291.1363	http://dx.doi.org/10.1126/science.274.5291.1363			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU954	8910274				2022-12-24	WOS:A1996VU95400050
J	Weidner, KM; DiCesare, S; Sachs, M; Brinkmann, V; Behrens, J; Birchmeier, W				Weidner, KM; DiCesare, S; Sachs, M; Brinkmann, V; Behrens, J; Birchmeier, W			Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis	NATURE			English	Article							HEPATOCYTE GROWTH-FACTOR; SCATTER FACTOR; MOTILITY; SIGNALS; INSULIN; CELLS	THE proteins Gab1 and the related DOS (for 'daughter of sevenless') each bind to substrates of tyrosine kinases like Grb2 or Corkscrew, and act in signalling pathways downstream of tyrosine kinase receptors(1-3). Here we show that Gab1 interacts directly with the c-met-encoded receptor tyrosine kinase but not ,vith a number of other tyrosine kinases from different subfamilies. A newly identified proline-rich domain of Gab1 is responsible for the binding of this protein to the tyrosine-phosphorylated bidentate docking site(4,5) in c-Met. Expression of Gab1 in epithelial cells is sufficient to induce the c-Met-specific activities(6-9), including branching morphogenesis. Thus we have discovered a new phosphotyrosine interaction domain in Gab1 and shown that Gab1 is the substrate of the c-Met receptor tyrosine kinase that mediates epithelial morphogenesis.	MAX DELBRUCK CTR MOL MED,D-13125 BERLIN,GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine			Brinkmann, Volker/A-6015-2009					Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BRINKMANN V, 1995, J CELL BIOL, V131, P215; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Miller J.H., 1972, EXPT MOL GENETICS; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; Sachs M, 1996, J CELL BIOL, V133, P1095, DOI 10.1083/jcb.133.5.1095; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0; ZHU H, 1994, J BIOL CHEM, V269, P29943	25	489	501	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 14	1996	384	6605					173	176		10.1038/384173a0	http://dx.doi.org/10.1038/384173a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT336	8906793				2022-12-24	WOS:A1996VT33600067
J	Kakimoto, T				Kakimoto, T			CKI1, a histidine kinase homolog implicated in cytokinin signal transduction	SCIENCE			English	Article							2-COMPONENT REGULATORS; ADAPTIVE RESPONSES; GENE; TRANSFORMATION; PROTEIN; FAMILY; YEAST; ETR1	Although cytokinin plays a central role in plant development, little is known about cytokinin signal transduction. Five Arabidopsis thaliana mutants that exhibit typical cytokinin responses, including rapid cell division and shoot formation in tissue culture in the absence of exogenous cytokinin, were isolated by activation transferred DNA tagging. A gene, CKI1, which was tagged in four of the five mutants and induced typical cytokinin responses after introduction and overexpression in plants, was cloned. CKI1 encodes a protein similar to the two-component regulators. These results suggest that CKI1 is involved in cytokinin signal transduction, possibly as a cytokinin receptor.			Kakimoto, T (corresponding author), OSAKA UNIV,GRAD SCH SCI,DEPT BIOL,TOYONAKA,OSAKA 560,JAPAN.							AKAMA K, 1992, PLANT CELL REP, V12, P7, DOI 10.1007/BF00232413; BINNS AN, 1994, ANNU REV PLANT PHYS, V45, P173, DOI 10.1146/annurev.pp.45.060194.001133; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; HAYASHI H, 1992, SCIENCE, V258, P1350, DOI 10.1126/science.1455228; HORGAN R, 1984, ADV PLANT PHYSL, P53; HRABAK EM, 1992, J BACTERIOL, V174, P3011, DOI 10.1128/JB.174.9.3011-3020.1992; HUA J, 1995, SCIENCE, V269, P1712, DOI 10.1126/science.7569898; KONCZ C, 1994, PLANT MOL BIOL MANUA; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; Meyerowitz E. M., 1992, Methods in Arabidopsis research., P100; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; NAGASAWA S, 1992, MOL MICROBIOL, V6, P799, DOI 10.1111/j.1365-2958.1992.tb01530.x; OLA IM, 1993, SCIENCE, V262, P566; PERKINSON JS, 1992, ANNU REV GENET, V26, P71; ROGERS SG, 1987, METHOD ENZYMOL, V153, P253; SCHALLER GE, 1995, SCIENCE, V270, P1809, DOI 10.1126/science.270.5243.1809; SKOOG F, 1957, Symp Soc Exp Biol, V11, P118; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; Wang N, 1996, EMBO J, V15, P3890, DOI 10.1002/j.1460-2075.1996.tb00763.x; WILKINSON JQ, 1995, SCIENCE, V270, P1807, DOI 10.1126/science.270.5243.1807	20	474	541	3	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1996	274	5289					982	985		10.1126/science.274.5289.982	http://dx.doi.org/10.1126/science.274.5289.982			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR792	8875940				2022-12-24	WOS:A1996VR79200049
J	Beg, AA; Baltimore, D				Beg, AA; Baltimore, D			An essential role for NF-kappa B in preventing TNF-alpha-induced cell death	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; MANGANOUS SUPEROXIDE-DISMUTASE; DNA-BINDING SUBUNIT; REL; INHIBITION; EXPRESSION; CLONING; IMMUNOSUPPRESSION; GLUCOCORTICOIDS; STIMULATION	Studies on mice deficient in nuclear factor kappa B (NF-kappa B) subunits have shown that this transcription factor is important for lymphocyte responses to antigens and cylokine-inducible gene expression. In particular, the RelA (p65) subunit is required for induction of tumor necrosis factor-alpha (TNF-alpha)-dependent genes. Treatment of RelA-deficient (RelA(-/-)) mouse fibroblasts and macrophages with TNF-alpha resulted in a significant reduction in viability, whereas RelA(+/+) cells were unaffected. Cytotoxicity to both cell types was mediated by TNF receptor 1. Reintroduction of RelA into RelA(-/-) fibroblasts resulted in enhanced survival, demonstrating that the presence of RelA is required for protection from TNF-alpha. These results have implications for the treatment of inflammatory and proliferative diseases.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)								AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BEG AA, UNPUB; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; COICO R, 1994, CURRENT PROTOCOLS IM; GAMBLE JR, 1985, P NATL ACAD SCI USA, V82, P8667, DOI 10.1073/pnas.82.24.8667; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; HAVELL EA, 1988, J EXP MED, V167, P1067, DOI 10.1084/jem.167.3.1067; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KLEBANOFF SJ, 1986, J IMMUNOL, V136, P4220; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OHSAWA T, 1989, DEV BIOL, V135, P459, DOI 10.1016/0012-1606(89)90194-2; OPLPARI AW, 1992, J BIOL CHEM, V267, P12424; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6	31	2781	2891	3	167	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1996	274	5288					782	784		10.1126/science.274.5288.782	http://dx.doi.org/10.1126/science.274.5288.782			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ145	8864118				2022-12-24	WOS:A1996VQ14500043
J	Maina, F; Casagranda, F; Audero, E; Simeone, A; Comoglio, PM; Klein, R; Ponzetto, C				Maina, F; Casagranda, F; Audero, E; Simeone, A; Comoglio, PM; Klein, R; Ponzetto, C			Uncoupling of Grb2 from the Met receptor in vivo reveals complex roles in muscle development	CELL			English	Article							HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; EPITHELIAL-CELLS; TYROSINE KINASE; PROTOONCOGENE; MOTILITY; GENE; MICE; IDENTIFICATION; TRANSFORMATION	Hepatocyte growth factor (HGF) and its receptor, the Met tyrosine kinase, are determinants of placenta, liver, and muscle development. Here, we show that Met function in vivo requires signaling via two carboxyterminal tyrosines. Mutation of both residues in the mouse genome caused embryonal death, with placenta, liver, and limb muscle defects, mimicking the phenotype of met null mutants. In contrast, disrupting the consensus for Grb2 binding allowed development to proceed to term without affecting placenta and liver but caused a striking reduction in limb muscle coupled to a generalized deficit of secondary fibers. These data show that the requirements for Met signaling vary depending on the tissue and reveal a novel role for HGF/Met in late myogenesis.	UNIV TURIN, DEPT BIOMED SCI & ONCOL, I-10126 TURIN, ITALY; EUROPEAN MOL BIOL LAB, D-69117 HEIDELBERG, GERMANY; INT INST GENET & BIOPHYS, I-80125 NAPLES, ITALY; INST CANC RES, I-10060 CANDIOLO, TORINO, ITALY	University of Turin; European Molecular Biology Laboratory (EMBL); Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)			Maina, Flavio/J-9962-2019; Simeone, Antonio/ABG-5269-2020; Klein, Ruediger/C-6147-2008	Maina, Flavio/0000-0001-6100-4695; Simeone, Antonio/0000-0003-2693-9836; Klein, Ruediger/0000-0002-3109-0163; Audero, Enrica/0000-0002-6138-244X; ponzetto, antonio/0000-0002-1551-3664; Comoglio, Paolo/0000-0002-7056-5328	Telethon [805] Funding Source: Medline	Telethon(Fondazione Telethon)		ALLEN RE, 1995, J CELL PHYSIOL, V165, P307, DOI 10.1002/jcp.1041650211; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHAN AML, 1988, ONCOGENE, V2, P593; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HANKS M, 1995, SCIENCE, V269, P679, DOI 10.1126/science.7624797; Haramis AG, 1995, DEVELOPMENT, V121, P4237; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HOGAN B, 1994, MANIPULATING MOUSE E, P325; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; LYONS GE, 1992, SEM DEV BIOL, V3, P243; Matsumoto K, 1993, EXS, V65, P225; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; ORDAHL CP, 1992, DEVELOPMENT, V114, P339; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Sambrook JFE, 1989, MOL CLONING LAB MANU; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; TAKEBAYASHI T, 1995, J CELL BIOL, V129, P1411, DOI 10.1083/jcb.129.5.1411; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Wachtler F., 1992, SEMIN DEV BIOL, V3, P217; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU H, 1994, J BIOL CHEM, V269, P29943	46	261	277	1	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 1	1996	87	3					531	542		10.1016/S0092-8674(00)81372-0	http://dx.doi.org/10.1016/S0092-8674(00)81372-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VQ466	8898205	Bronze			2022-12-24	WOS:A1996VQ46600018
J	Hedges, REM; Jiang, ZX; Ramsey, CB; Cowey, A; Roberts, JDB; Somogyi, P				Hedges, REM; Jiang, ZX; Ramsey, CB; Cowey, A; Roberts, JDB; Somogyi, P			Imaging of radiocarbon labelled tracer molecules in neural tissue using accelerator mass spectrometry	NATURE			English	Article							GAMMA-AMINOBUTYRIC ACID; STRIATE CORTEX; VISUAL-CORTEX; GOLGI IMPREGNATION; NEURONS; H-3-GABA; MONKEY; CONNECTIONS; ANTISERA; SYSTEM	AUTORADIOGRAPHY is widely and successfully used to image the distribution of radiolabelled tracer molecules in biological samples. The method is, however, limited in resolution and sensitivity, especially for C-14. Here we describe a new method for imaging C-14-labelled tracers in sections of biological tissue. A highly focused beam of gallium ions bombards the tissue, which is eroded (sputtered) into constituent atoms, molecules and secondary ions. The C-14 ions are detected in the secondary beam by the most sensitive method available, namely accelerator mass spectrometry(1). The specimen is scanned pixel by pixel (1 x 2 mu m), generating an image in a manner analogous to scanning electron microscopy. The method can thus be regarded as a specialized form of scanning secondary ion mass spectrometry (SIMS), referred to here as SIAMS (ref. 2). We have used SIAMS to localize the neurotransmitter gamma-aminobutyric acid (GABA) in thin sections of cerebral cortex, and show that it can generate C-14 images that are much improved on C-14 autoradiography. A scan takes 10-20 min and reveals individual axons, neurons and glial cells at high sensitivity. In principle, the resolution could be increased by up to tenfold, and the method could be extended to some other nuclides.	DEPT EXPT PSYCHOL,OXFORD OX1 3UD,ENGLAND; MRC,ANAT NEUROPHARMACOL UNIT,DEPT PHARMACOL,OXFORD OX1 3TH,ENGLAND		Hedges, REM (corresponding author), RES LAB ARCHAEOL,RAIOCARBON ACCELERATOR UNIT,6 KEBLE RD,OXFORD OX1 3QJ,ENGLAND.		Ramsey, Christopher Bronk/A-3277-2012; Ramsey, Christopher Bronk/AAQ-2227-2021	Ramsey, Christopher Bronk/0000-0002-8641-9309; Ramsey, Christopher Bronk/0000-0002-8641-9309				BAKER JRJ, 1989, MICROSCOPY HDB, V18; CUENOD M, 1983, METHODS CHEM NEUROAN, P365; DUNCAN GE, 1990, METHODS NEUROSCIENCE, V3, P50; FREEMAN SPH, 1993, NUCL INSTRUM METH B, V93, P231; HEDGES REM, 1987, PHILOS T R SOC A, V323, P57, DOI 10.1098/rsta.1987.0072; HERTZ L, 1979, PROG NEUROBIOL, V13, P277, DOI 10.1016/0301-0082(79)90018-2; HODGSON AJ, 1985, J HISTOCHEM CYTOCHEM, V33, P229, DOI 10.1177/33.3.3973378; HOLDFELT T, 1972, EXP BRAIN RES, V14, P354; JIANG ZX, IN PRESS NUCL INST B; KISVARDAY ZF, 1987, J COMP NEUROL, V260, P1, DOI 10.1002/cne.902600102; LITHERLAND AE, 1987, PHILOS T R SOC A, V323, P5, DOI 10.1098/rsta.1987.0069; Martin D.L., 1976, GABA NERVOUS SYSTEM, P347; SOMOGYI P, 1985, J HISTOCHEM CYTOCHEM, V33, P240, DOI 10.1177/33.3.2579123; SOMOGYI P, 1983, P NATL ACAD SCI-BIOL, V80, P2385, DOI 10.1073/pnas.80.8.2385; SOMOGYI P, 1984, EXP BRAIN RES, V53, P295; SOMOGYI P, 1984, EXP BRAIN RES, V54, P45; SOMOGYI P, 1983, NEUROSCIENCE, V10, P261, DOI 10.1016/0306-4522(83)90133-1; SOMOGYI P, 1981, NATURE, V294, P761, DOI 10.1038/294761a0	18	8	8	1	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 31	1996	383	6603					823	826		10.1038/383823a0	http://dx.doi.org/10.1038/383823a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ144	8893007				2022-12-24	WOS:A1996VQ14400063
J	Morris, JS; Frith, CD; Perrett, DI; Rowland, D; Young, AW; Calder, AJ; Dolan, RJ				Morris, JS; Frith, CD; Perrett, DI; Rowland, D; Young, AW; Calder, AJ; Dolan, RJ			A differential neural response in the human amygdala to fearful and happy facial expressions	NATURE			English	Article							RHESUS-MONKEY; CONNECTIONS; IDENTITY; EMOTION; MULATTA; BRAIN	THE amygdala is thought to play a crucial role in emotional and social behaviour(1). Animal studies implicate the amygdala in both fear conditioning(2) and face perception(3). In humans, lesions of the amygdala can lead to selective deficits in the recognition of fearful facial expressions(4,5) and impaired fear conditioning(6,7), and direct electrical stimulation evokes fearful emotional responses(8). Here we report direct in vivo evidence of a differential neural response in the human amygdala to facial expressions of fear and happiness, Positron-emission tomography (PET) measures of neural activity were acquired while subjects viewed photographs of fearful or happy faces, varying systematically in emotional intensity, The neuronal response in the left amygdala was significantly greater to fearful as opposed to happy expressions, Furthermore, this response showed a significant interaction with the intensity of emotion (increasing with increasing fearfulness, decreasing with increasing happiness). The findings provide direct evidence that the human amygdala is engaged in processing the emotional salience of faces, with a specificity of response to fearful facial expressions.	WELLCOME DEPT COGNIT NEUROL, LONDON WC1N 3BG, ENGLAND; UNIV ST ANDREWS, SCH PSYCHOL, ST ANDREWS KY16 9JU, FIFE, SCOTLAND; MRC, APPL PSYCHOL UNIT, CAMBRIDGE CBE 2EF, ENGLAND; ROYAL FREE HOSP, LONDON NW3 2DF, ENGLAND; UCL HOSP, SCH MED, LONDON NW3 2DF, ENGLAND	University of London; University College London; University of St Andrews; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London; UCL Medical School			Morris, John/B-9190-2013; Young, Andy/G-2189-2011; Frith, Chris D/A-2171-2009; anand, amit/A-7222-2009; Tudusciuc, Oana/C-1339-2011	Young, Andy/0000-0002-1202-6297; Frith, Chris D/0000-0002-8665-0690; Dolan, Ray/0000-0001-9356-761X; Perrett, David/0000-0002-6025-0939	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADOLPHS R, 1995, J NEUROSCI, V15, P5879; ADOLPHS R, 1994, NATURE, V372, P669, DOI 10.1038/372669a0; AGGLETON JP, 1980, BRAIN RES, V190, P347, DOI 10.1016/0006-8993(80)90279-6; BECHARA A, 1995, SCIENCE, V269, P1115, DOI 10.1126/science.7652558; Calder AJ, 1996, COGNITIVE NEUROPSYCH, V13, P699, DOI 10.1080/026432996381890; Darwin C., 1965, EXPRESSION EMOTIONS; Ekman P., 1982, EMOTION HUMAN FACE; Ekman P., 1976, PICTURES FACIAL AFFE; Friston K.J., 1994, HUMAN BRAIN MAPPING, V2, P211, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; Friston KJ, 1995, HUM BRAIN MAPP, V3, P165, DOI 10.1002/hbm.460030303; GEORGE MS, 1993, J NEUROPSYCH CLIN N, V5, P384; HALGREN E, 1978, BRAIN, V101, P83, DOI 10.1093/brain/101.1.83; HALGREN E, 1992, AMYGDALA NEUROBIOLOG, P190; Hamann SB, 1996, NATURE, V379, P497, DOI 10.1038/379497a0; HERZOG AG, 1976, BRAIN RES, V115, P57, DOI 10.1016/0006-8993(76)90822-2; IWAI E, 1987, J COMP NEUROL, V261, P362, DOI 10.1002/cne.902610304; Ketter TA, 1996, ARCH GEN PSYCHIAT, V53, P59; KING AS, 1979, EXP NEUROL, V66, P88; KLING A S, 1992, P353; Kluver H, 1939, ARCH NEURO PSYCHIATR, V42, P979; LABAR KS, 1995, J NEUROSCI, V15, P6846; LEDOUX JE, 1990, J NEUROSCI, V10, P1062; LEDOUX JE, 1993, BEHAV BRAIN RES, V58, P69, DOI 10.1016/0166-4328(93)90091-4; PERRETT DI, 1994, NATURE, V368, P239, DOI 10.1038/368239a0; PERRETT DI, 1989, J EXP BIOL, V146, P87; PERRETT DI, 1984, HUM NEUROBIOL, V3, P197; ROLLS E T, 1992, P143; Sergent J., 1994, VIS COGN, V1, P349, DOI [10.1080/13506289408402305, DOI 10.1080/13506289408402305]; WEISKRANTZ L, 1956, J COMP PHYSIOL PSYCH, V49, P381, DOI 10.1037/h0088009; WORSLEY KJ, IN PRESS HUM BRAIN M	30	1455	1474	1	198	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 31	1996	383	6603					812	815		10.1038/383812a0	http://dx.doi.org/10.1038/383812a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ144	8893004	Green Submitted			2022-12-24	WOS:A1996VQ14400060
J	Grodstein, F; Stampfer, MJ; Goldhaber, SZ; Manson, JE; Colditz, GA; Speizer, FE; Willett, WC; Hennekens, CH				Grodstein, F; Stampfer, MJ; Goldhaber, SZ; Manson, JE; Colditz, GA; Speizer, FE; Willett, WC; Hennekens, CH			Prospective study of exogenous hormones and risk of pulmonary embolism in women	LANCET			English	Article							ESTROGEN REPLACEMENT THERAPY; ORAL-CONTRACEPTIVES; THROMBOEMBOLIC DISEASE; VENOUS THROMBOEMBOLISM; MENOPAUSAL WOMEN; PROGESTAGEN; COAGULATION; THROMBOSIS; SAFETY; DEATH	Background Current use of oral contraceptives (OCs) is a well-recognised risk factor for venous thrombosis and consequent pulmonary embolism (PE). Little is known about residual effects of past OC use. Furthermore, few epidemiological studies have assessed the relation between postmenopausal use of hormones and thrombotic disease. Methods in this prospective study information was obtained through questionnaires sent every 2 years (1976-92) to 112 593 women aged 30-55 in 1976, We excluded women with previously diagnosed cardiovascular disease or cancer in 1976 and at the beginning of each subsequent 2-year follow-up period. Findings From self-reports and medical records, we documented 123 cases of primary PE (no identified antecedent cancer, trauma, surgery, or immobilisation). Current users of postmenopausal hormones had an increased risk of primary PE (relative risk adjusted for multiple risk factors 2 . 1 [95% CI 1 . 2-3 . 8]). However, past use showed no relation to PE (1 . 3[0 . 7-2 . 4]). In current users of OCs the risk of primary PE was about twice that in non-users (2 . 2[0 . 8-5 . 9]), but this finding was based on only five cases who were current OC users. Users of OCs in the past had no increase in risk of PE (0 . 8[0 . 5-1 . 2]). These relations were consistent irrespective of cigarette-smoking status. Interpretation Primary PE was uncommon in this cohort. The risk was increased by current though not past use of postmenopausal hormones or OCs.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV PREVENT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Grodstein, F (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,CHANNING LAB,181 LONGWOOD AVE,BOSTON,MA 02115, USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA 40935] Funding Source: Medline; NHLBI NIH HHS [HL 24074, HL 34594] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040935] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1974, N Engl J Med, V290, P15; [Anonymous], 1995, LANCET, V346, P1575; BLOEMENKAMP KWM, 1995, LANCET, V346, P1593, DOI 10.1016/S0140-6736(95)91929-5; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P319, DOI 10.1093/aje/126.2.319; DEVOR M, 1992, AM J MED, V92, P275, DOI 10.1016/0002-9343(92)90077-O; GERSTMAN BB, 1991, AM J EPIDEMIOL, V133, P32, DOI 10.1093/oxfordjournals.aje.a115799; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; INMAN WHW, 1970, BMJ-BRIT MED J, V2, P203, DOI 10.1136/bmj.2.5703.203; JICK H, 1995, LANCET, V346, P1589, DOI 10.1016/S0140-6736(95)91928-7; KOSTER T, 1995, J INTERN MED, V238, P31, DOI 10.1111/j.1365-2796.1995.tb00896.x; LIDEGAARD O, 1993, BRIT MED J, V306, P956, DOI 10.1136/bmj.306.6883.956; LOBO RA, 1992, AM J MED, V92, P283, DOI 10.1016/0002-9343(92)90078-P; MEADE TW, 1988, AM J OBSTET GYNECOL, V158, P1646, DOI 10.1016/0002-9378(88)90203-7; MEADE TW, 1980, BRIT MED J, V280, P1157, DOI 10.1136/bmj.280.6224.1157; MELIS GB, 1988, MATURITAS S1, V10, P131; NACHTIGALL LE, 1979, OBSTET GYNECOL, V54, P74, DOI 10.1097/00006250-197907000-00017; NOTELOVITZ M, 1983, OBSTET GYNECOL, V62, P596; NOTELOVITZ M, 1984, OBSTET GYNECOL, V63, P621; PETTITI DB, 1979, JAMA-J AM MED ASSOC, V242, P1150; POLLER L, 1977, BRIT MED J, V1, P935, DOI 10.1136/bmj.1.6066.935; QUINN DA, 1992, JAMA-J AM MED ASSOC, V268, P1689, DOI 10.1001/jama.268.13.1689; REALINI JP, 1985, AM J OBSTET GYNECOL, V152, P729, DOI 10.1016/S0002-9378(85)80001-6; ROSENBERG L, 1985, JAMA-J AM MED ASSOC, V253, P2965, DOI 10.1001/jama.253.20.2965; *ROYAL COLL GEN PR, 1974, OR CONTR HLTH; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STAMPFER MJ, 1993, CARDIOVASCULAR HLTH, P175; STAMPFER MJ, 1992, CIRCULATION, V86, P1; STANGEL JJ, 1977, OBSTET GYNECOL, V49, P314; VESSEY MP, 1968, BMJ-BRIT MED J, V2, P199, DOI 10.1136/bmj.2.5599.199; 1995, JAMA-J AM MED ASSOC, V273, P199; 1995, LANCET, V346, P1582	32	447	457	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 12	1996	348	9033					983	987		10.1016/S0140-6736(96)07308-4	http://dx.doi.org/10.1016/S0140-6736(96)07308-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM027	8855854				2022-12-24	WOS:A1996VM02700010
J	Lefebvre, O; Chenard, MP; Masson, R; Linares, J; Dierich, A; LeMeur, M; Wendling, C; Tomasetto, C; Chambon, P; Rio, MC				Lefebvre, O; Chenard, MP; Masson, R; Linares, J; Dierich, A; LeMeur, M; Wendling, C; Tomasetto, C; Chambon, P; Rio, MC			Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein	SCIENCE			English	Article							PANCREATIC SPASMOLYTIC POLYPEPTIDE; TUMOR-SUPPRESSOR GENES; HUMAN-BREAST-CANCER; P-DOMAIN; EXPRESSION; STOMACH; FAMILY; CARCINOMA; PEPTIDES; HSP	To determine the function of the pS2 trefoil protein, which is normally expressed in the gastric mucosa, the mouse pS2 (mpS2) gene was inactivated, The antral and pyloric gastric mucosa of mpS2-null mice was dysfunctional and exhibited severe hyperplasia and dysplasia. All homozygous mutant mice developed antropyloric adenoma, and 30 percent developed multifocal intraepithelial or intramucosal carcinomas. The small intestine was characterized by enlarged villi and an abnormal infiltrate of lymphoid cells. These results indicate that mpS2 is essential for normal differentiation of the antral and pyloric gastric mucosa and may function as a gastric-specific tumor suppressor gene.	UNIV STRASBOURG 1,COLL FRANCE,CNRS,INSERM,INST GENET & BIOL MOL & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE; CHU HAUTEPIERRE,SERV ANAT PATHOL GEN,F-67098 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg			Tomasetto, Catherine Laure/J-2783-2014; Lefebvre, Olivier/S-6436-2019; Lefebvre, Olivier/I-2388-2016; Chenard, Marie-Pierre/O-2373-2016	Tomasetto, Catherine Laure/0000-0002-1811-5848; Lefebvre, Olivier/0000-0001-9130-9174; Lefebvre, Olivier/0000-0001-9130-9174; 				CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DE A, 1994, P NATL ACAD SCI USA, V91, P1084, DOI 10.1073/pnas.91.3.1084; GAJHEDE M, 1993, STRUCTURE, V1, P253, DOI 10.1016/0969-2126(93)90014-8; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; HAGGITT RC, 1994, HUM PATHOL, V25, P982, DOI 10.1016/0046-8177(94)90057-4; HENRY JA, 1991, BRIT J CANCER, V64, P677, DOI 10.1038/bjc.1991.380; HOFFMANN W, 1993, TRENDS BIOCHEM SCI, V18, P239, DOI 10.1016/0968-0004(93)90170-R; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; LEFEBVRE O, 1993, J CELL BIOL, V122, P191, DOI 10.1083/jcb.122.1.191; LEFEBVRE O, UNPUB; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUQMANI Y, 1989, INT J CANCER, V44, P806, DOI 10.1002/ijc.2910440510; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; PANJA A, 1994, J EXP MED, V179, P943, DOI 10.1084/jem.179.3.943; Playford RJ, 1996, P NATL ACAD SCI USA, V93, P2137, DOI 10.1073/pnas.93.5.2137; PONCE MR, 1992, NUCLEIC ACIDS RES, V20, P623, DOI 10.1093/nar/20.3.623; RIDDELL RH, 1983, HUM PATHOL, V14, P931, DOI 10.1016/S0046-8177(83)80175-0; RIO MC, 1991, GASTROENTEROLOGY, V100, P375, DOI 10.1016/0016-5085(91)90205-Y; RIO MC, 1988, SCIENCE, V241, P705, DOI 10.1126/science.3041593; RIO MC, 1990, CANCER CELL-MON REV, V2, P269; RIO MC, 1988, CR ACAD SCI III-VIE, V307, P825; ROCHA B, 1995, CURR OPIN IMMUNOL, V7, P235, DOI 10.1016/0952-7915(95)80008-5; ROSAI J, 1996, ACKERMANS SURG PATHO, V8, P632; SUEMORI S, 1991, P NATL ACAD SCI USA, V88, P11017, DOI 10.1073/pnas.88.24.11017; THEISINGER B, 1991, EUR J CANCER, V27, P770, DOI 10.1016/0277-5379(91)90186-H; THIM L, 1994, DIGESTION, V55, P353, DOI 10.1159/000201165; TOMASETTO C, 1990, EMBO J, V9, P407, DOI 10.1002/j.1460-2075.1990.tb08125.x; TOMASETTO C, 1992, GENOMICS, V13, P1328, DOI 10.1016/0888-7543(92)90059-2; TOMITA M, 1995, BIOCHEM J, V311, P293, DOI 10.1042/bj3110293; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WELTER C, 1992, LAB INVEST, V66, P187; WRIGHT NA, 1990, J PATHOL, V162, P279, DOI 10.1002/path.1711620402	35	434	459	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1996	274	5285					259	262		10.1126/science.274.5285.259	http://dx.doi.org/10.1126/science.274.5285.259			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM671	8824193				2022-12-24	WOS:A1996VM67100047
J	Malhotra, A; Severinova, E; Darst, SA				Malhotra, A; Severinova, E; Darst, SA			Crystal structure of a sigma(70) subunit fragment from E-coli RNA polymerase	CELL			English	Article							TRANSCRIPTION INITIATION-FACTOR; SINGLE-STRANDED REGIONS; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; 3-DIMENSIONAL STRUCTURE; SIGMA-70 SUBUNIT; AMINO-ACIDS; ANOMALOUS DIFFRACTION; PROMOTER RECOGNITION; GENETIC-EVIDENCE	The 2.6 Angstrom crystal structure of a fragment of the sigma(70) promoter specificity subunit of E. coli RNA polymerase is described. Residues involved in core RNA polymerase binding lie on one face of the structure. On the opposite face, aligned along one helix, are exposed residues that interact with the -10 consensus promoter element (the Pribnow box), including four aromatic residues involved in promoter melting. The structure suggests one way in which DNA interactions may be inhibited in the absence of RNA polymerase and provides a framework for the interpretation of a large number of genetic and biochemical analyses.			Malhotra, A (corresponding author), ROCKEFELLER UNIV, 1230 YORK AVE, NEW YORK, NY 10021 USA.		Malhotra, Arun/Z-5140-2019; Malhotra, Arun/A-3916-2008	Malhotra, Arun/0000-0001-6656-7841; Malhotra, Arun/0000-0001-6656-7841				AHEARN JM, 1987, J BIOL CHEM, V262, P10695; AIYAR SE, 1994, BIOCHEMISTRY-US, V33, P11501, DOI 10.1021/bi00204a012; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; AMOUYAL M, 1987, J MOL BIOL, V195, P795, DOI 10.1016/0022-2836(87)90485-2; BIGGS J, 1985, CELL, V42, P611, DOI 10.1016/0092-8674(85)90118-7; Brunger A.T., 1992, X PLOR VERSION 3 1 M; BUCKLE M, 1989, BIOCHEMISTRY-US, V28, P4388, DOI 10.1021/bi00436a040; BUCKLE M, 1991, NUCLEIC ACIDS RES, V19, P833, DOI 10.1093/nar/19.4.833; BURGESS RR, 1969, NATURE, V221, P43, DOI 10.1038/221043a0; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHAN B, 1990, FEBS LETT, V267, P46, DOI 10.1016/0014-5793(90)80284-P; CHRISTIE GE, 1995, GENE, V162, P161, DOI 10.1016/0378-1119(95)00333-2; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; DANIELS D, 1990, P NATL ACAD SCI USA, V87, P8075, DOI 10.1073/pnas.87.20.8075; DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; DEHASETH PL, 1995, MOL MICROBIOL, V16, P817, DOI 10.1111/j.1365-2958.1995.tb02309.x; DOMBROSKI AJ, 1993, GENE DEV, V7, P2446, DOI 10.1101/gad.7.12a.2446; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; Gross C., 1992, BACTERIAL SIGMA FACT; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HARLEY CB, 1987, NUCLEIC ACIDS RES, V15, P2343, DOI 10.1093/nar/15.5.2343; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HILTON MD, 1985, J BIOL CHEM, V260, P8121; HINKLE DC, 1972, J MOL BIOL, V70, P157, DOI 10.1016/0022-2836(72)90531-1; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; JANG SH, 1991, J BIOL CHEM, V266, P22671; JONES CH, 1992, P NATL ACAD SCI USA, V89, P1958, DOI 10.1073/pnas.89.5.1958; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUANG YL, 1995, BIOCHEMISTRY-US, V34, P8465, DOI 10.1021/bi00026a030; JUANG YL, 1994, J MOL BIOL, V235, P1470, DOI 10.1006/jmbi.1994.1102; KENNEY TJ, 1989, P NATL ACAD SCI USA, V86, P9109, DOI 10.1073/pnas.86.23.9109; KIRKEGAARD K, 1983, P NATL ACAD SCI-BIOL, V80, P2544, DOI 10.1073/pnas.80.9.2544; LESLEY SA, 1991, J BIOL CHEM, V266, P2632; LESLEY SA, 1989, BIOCHEMISTRY-US, V28, P7728, DOI 10.1021/bi00445a031; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; LOSICK R, 1981, CELL, V25, P582, DOI 10.1016/0092-8674(81)90164-1; MCCRACKEN S, 1991, SCIENCE, V253, P900, DOI 10.1126/science.1652156; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; OHKUMA Y, 1991, NATURE, V354, P398, DOI 10.1038/354398a0; PARK CS, 1980, NUCLEIC ACIDS RES, V8, P5895, DOI 10.1093/nar/8.23.5895; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; RONG JC, 1994, J BACTERIOL, V176, P5218, DOI 10.1128/JB.176.17.5218-5224.1994; SCHULTZ P, 1993, EMBO J, V12, P2601, DOI 10.1002/j.1460-2075.1993.tb05920.x; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; SHELDRICK GM, 1991, P CCP4 STUDY WEEKEND, P23; SHULER MF, 1995, J BACTERIOL, V177, P3687, DOI 10.1128/jb.177.13.3687-3694.1995; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; SIMPSON RB, 1979, CELL, V18, P277, DOI 10.1016/0092-8674(79)90047-3; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; SPASSKY A, 1988, EMBO J, V7, P1871, DOI 10.1002/j.1460-2075.1988.tb03020.x; STRAGIER P, 1985, FEBS LETT, V187, P11, DOI 10.1016/0014-5793(85)81203-5; SUMIMOTO H, 1991, NATURE, V354, P401, DOI 10.1038/354401a0; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; TATTI KM, 1991, J BACTERIOL, V173, P7828, DOI 10.1128/jb.173.24.7828-7833.1991; TINTUT Y, 1995, J BACTERIOL, V177, P5818, DOI 10.1128/jb.177.20.5818-5825.1995; TRAVERS AA, 1969, NATURE, V222, P537, DOI 10.1038/222537a0; TRAVERS AA, 1990, CELL, V60, P177, DOI 10.1016/0092-8674(90)90729-X; WALDBURGER C, 1990, J MOL BIOL, V215, P267, DOI 10.1016/S0022-2836(05)80345-6; WONG CN, 1994, J MOL BIOL, V236, P81, DOI 10.1006/jmbi.1994.1120; YONG K, 1990, ACTA CRYSTALLOGR A, V46, P41; ZUBER P, 1989, J MOL BIOL, V206, P605, DOI 10.1016/0022-2836(89)90569-X	73	266	272	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 4	1996	87	1					127	136		10.1016/S0092-8674(00)81329-X	http://dx.doi.org/10.1016/S0092-8674(00)81329-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VL695	8858155	Bronze			2022-12-24	WOS:A1996VL69500015
J	Middleton, RE; Pheasant, DJ; Miller, C				Middleton, RE; Pheasant, DJ; Miller, C			Homodimeric architecture of a CIC-type chloride ion channel	NATURE			English	Article							DOMINANT MYOTONIA-CONGENITA; TORPEDO ELECTROPLAX; ACETYLCHOLINE-RECEPTOR; THOMSEN	THE recent discovery of the ClC-family of anion-conducting channel proteins(1-3) has led to an appreciation of the central roles played by chloride ion channels in cellular functions, such as electrical behaviour of muscle(4-7) and nerve(8) and epithelial solute transport(9). Little is known, however, about molecular architecture or sequence-function relationships in these membrane proteins, In the single case of ClC-0, a voltage-gated 'muscle-type' chloride channel, the functional complex is known to be a homo-oligomer of a polypeptide of M(r) similar to 90,000, with no associated 'helper' subunits(10). The subunit stoichiometry of ClC-type channels is controversial, however, with either dimeric or tetrameric association suggested by different indirect experiments(10,11). Before a coherent molecular view of this new class of ion channels can emerge, the fundamental question of subunit composition must first be settled, We have examined hybrid ClC-0 channels constructed from functionally tagged subunits, and report here that ClC-0 is a homodimer containing two chloride-conduction pores.	BRANDEIS UNIV,HOWARD HUGHES MED INST,GRAD DEPT BIOCHEM,WALTHAM,MA 02254	Brandeis University; Howard Hughes Medical Institute								ACKERMAN MJ, 1993, TRENDS CARDIOVAS MED, V3, P23, DOI 10.1016/1050-1738(93)90024-Z; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; BAUER CK, 1991, P NATL ACAD SCI USA, V88, P11052, DOI 10.1073/pnas.88.24.11052; COOPER E, 1991, NATURE, V350, P235, DOI 10.1038/350235a0; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; GEORGE AL, 1993, NAT GENET, V3, P305, DOI 10.1038/ng0493-305; HANKE W, 1983, J GEN PHYSIOL, V82, P25, DOI 10.1085/jgp.82.1.25; Hille B., 1992, IONIC CHANNELS EXCIT; JENTSCH TJ, 1995, J PHYSIOL-LONDON, V482P, pS19; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; Liu DT, 1996, NEURON, V16, P983, DOI 10.1016/S0896-6273(00)80121-X; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; MACKINNON R, 1995, NEURON, V14, P889, DOI 10.1016/0896-6273(95)90327-5; MAYER ML, 1985, J PHYSIOL-LONDON, V364, P217, DOI 10.1113/jphysiol.1985.sp015740; MIDDLETON RE, 1994, BIOCHEMISTRY-US, V33, P13189, DOI 10.1021/bi00249a005; MILLER C, 1984, P NATL ACAD SCI-BIOL, V81, P2772, DOI 10.1073/pnas.81.9.2772; MILLER C, 1982, PHILOS T ROY SOC B, V299, P401, DOI 10.1098/rstb.1982.0140; MILLER C, 1990, CHLORIDE CHANNELS AND CARRIERS IN NERVE, MUSCLE, AND GLIAL CELLS, P383; MINDELL JA, 1994, P NATL ACAD SCI USA, V91, P5272, DOI 10.1073/pnas.91.12.5272; PALADE PT, 1977, J GEN PHYSIOL, V69, P879, DOI 10.1085/jgp.69.6.879; PUSCH M, 1994, PHYSIOL REV, V74, P813, DOI 10.1152/physrev.1994.74.4.813; PUSCH M, 1995, NATURE, V373, P527, DOI 10.1038/373527a0; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013; STEINMEYER K, 1994, EMBO J, V13, P737, DOI 10.1002/j.1460-2075.1994.tb06315.x; STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0; WEISS MS, 1992, J MOL BIOL, V227, P493, DOI 10.1016/0022-2836(92)90903-W	26	219	222	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 26	1996	383	6598					337	340		10.1038/383337a0	http://dx.doi.org/10.1038/383337a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VJ439	8848046				2022-12-24	WOS:A1996VJ43900045
J	Craig, AD; Reiman, EM; Evans, A; Bushnell, MC				Craig, AD; Reiman, EM; Evans, A; Bushnell, MC			Functional imaging of an illusion of pain	NATURE			English	Article							COLD; VIBRATION; PRIMATE; NEURONS; CORTEX; BLOCK; INPUT	TOUCHING warm and cool bars that are spatially interlaced produces a painful burning sensation resembling that caused by intense, noxious cold. We demonstrated previously that this thermal grill illusion can be explained as an unmasking phenomenon that reveals the central inhibition of pain by thermosensory integration(1). In order to localize this unmasking in the human brain, we have used positron emission tomography (PET) to compare the cortical activation patterns evoked by the thermal grill and by cool, warm, noxious cold and noxious heat stimuli. The thermal grill illusion produces activation in the anterior cingulate cortex, whereas its component warm and cool stimuli do not. This area is also activated bq noxious heat or cold. Thus, increased activity in the anterior cingulate cortex appears to be selectively associated with the perception of thermal pain. Disruption of thermosensory and pain integration may account for the central pain syndrome that can occur after stroke damage.	GOOD SAMARITAN REG MED CTR, POSITRON EMISS TOMOG CTR, PHOENIX, AZ 85006 USA; UNIV ARIZONA, DEPT PSYCHIAT, TUCSON, AZ 85721 USA; MCGILL UNIV, MONTREAL NEUROL INST, MCCONNELL BRAIN IMAGING CTR, POSITRON IMAGING LABS, MONTREAL, PQ H3A 2B4, CANADA; UNIV MONTREAL, CTR RECH SCI NEUROL, MONTREAL, PQ H3C 3J7, CANADA; UNIV MONTREAL, FAC MED DENT, DEPT STOMATOL, MONTREAL, PQ H3C 3J7, CANADA	University of Arizona; McGill University; Universite de Montreal; Universite de Montreal	Craig, AD (corresponding author), BARROW NEUROL INST, DIV NEUROBIOL, 350 W THOMAS RD, PHOENIX, AZ 85013 USA.							BINI G, 1984, PAIN, V18, P239, DOI 10.1016/0304-3959(84)90819-4; BOGOUSSLAVSKY J, 1988, NEUROLOGY, V38, P837, DOI 10.1212/WNL.38.6.837; BOIVIE J, 1989, PAIN, V37, P173, DOI 10.1016/0304-3959(89)90128-0; BOIVIE J, 1991, SYMP PAIN R, P65; Bushnell M. C., 1995, Society for Neuroscience Abstracts, V21, P1637; Casey KL, 1996, J NEUROPHYSIOL, V76, P571, DOI 10.1152/jn.1996.76.1.571; COGHILL RC, 1994, J NEUROSCI, V14, P4095; Craig A. D., 1995, Society for Neuroscience Abstracts, V21, P1165; Craig A. D, 1996, SOMESTHESIS NEUROBIO, P27; CRAIG AD, 1994, NATURE, V372, P770, DOI 10.1038/372770a0; CRAIG AD, 1994, SCIENCE, V265, P252, DOI 10.1126/science.8023144; CRAIG AD, 1991, EXP BRAIN RES, V85, P470; CRAIG AD, 1996, SOC NEUR ABSTR, V22, P11; EVANS AC, 1991, J CEREBR BLOOD F MET, V11, pA69, DOI 10.1038/jcbfm.1991.40; FRUHSTORFER H, 1984, PAIN, V20, P355, DOI 10.1016/0304-3959(84)90112-X; Head H, 1911, BRAIN, V34, P102, DOI 10.1093/brain/34.2-3.102; JONES AKP, 1991, P ROY SOC B-BIOL SCI, V244, P39, DOI 10.1098/rspb.1991.0048; KENSHALO DR, 1982, PAIN, V12, P141, DOI 10.1016/0304-3959(82)90190-7; LAMOTTE RH, 1982, BRAIN RES, V244, P279, DOI 10.1016/0006-8993(82)90086-5; OCHOA JL, 1994, BRAIN, V117, P185, DOI 10.1093/brain/117.1.185; OSGOOD PF, 1990, BRAIN RES, V507, P11, DOI 10.1016/0006-8993(90)90514-C; RELMAN EM, 1996, NEW ENGL J MED, V334, P752; SCHMAHMANN JD, 1992, ARCH NEUROL-CHICAGO, V49, P1032, DOI 10.1001/archneur.1992.00530340048017; SIKES RW, 1992, J NEUROPHYSIOL, V68, P1720, DOI 10.1152/jn.1992.68.5.1720; Talairach J., 1988, COPLANAR STEREOTAXIC; TALBOT JD, 1991, SCIENCE, V251, P1355, DOI 10.1126/science.2003220; VANHOESEN GW, 1996, NEUROBIOLOGY CINGULA, P249; WAHREN LK, 1989, PAIN, V38, P313, DOI 10.1016/0304-3959(89)90218-2; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; YARNITSKY D, 1990, BRAIN, V113, P893, DOI 10.1093/brain/113.4.893	30	410	422	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 21	1996	384	6606					258	260		10.1038/384258a0	http://dx.doi.org/10.1038/384258a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU381	8918874				2022-12-24	WOS:A1996VU38100049
J	Yamashita, YM; Nakaseko, Y; Samejima, I; Kumada, K; Yamada, H; Michaelson, D; Yanagida, M				Yamashita, YM; Nakaseko, Y; Samejima, I; Kumada, K; Yamada, H; Michaelson, D; Yanagida, M			20S cyclosome complex formation and proteolytic activity inhibited by the cAMP/PKA pathway	NATURE			English	Article							FISSION YEAST; GENE; UBIQUITIN; PROTEIN; MITOSIS; SPINDLE; ASPERGILLUS; REGULATOR; ANAPHASE; MUTATION	THE 20S cyclosome complex (also known as the anaphase-promoting complex) has ubiquitin ligase activity and is required for mitotic cyclin destruction(1-3) and sister chromatid separation(4,5). The formation and activation of the 20S cyclosome complex is regulated by an unknown mechanism. Here we show that Cut4 (ref. 6) is an essential component of the cyclosome in fission yeast. Cut4 shares sequence similarity with BimE, a protein that regulates mitosis in Aspergillus nidulans(7-9). Mutations in cut4 result In hypersensitivity to cyclic AMP and to stress-inducing heavy metals, inhibition of the onset of anaphase, disruption of the 20S complex, and inhibition of mitotic cyclin ubiquitination, These phenotypes are fully suppressed by cAMP phosphodiesterase and the protein kinase A (PKA) regulatory subunit and weakly suppressed by Sti1 (an activator of the Hsp70 and Hsp90 chaperones(10,11)), Suppression correlates with the amount of 20S complex, indicating that cyclosome formation and activation is inhibited by the cAMP/PKA pathway.	KYOTO UNIV,GRAD SCH SCI,DEPT BIOPHYS,SAKYO KU,KYOTO 606,JAPAN	Kyoto University				Yamada, Hiroshi/0000-0002-0536-5581; Yamashita, Yukiko/0000-0001-5541-0216				CHANG HCJ, 1994, J BIOL CHEM, V269, P24983; DEVOTI J, 1991, EMBO J, V10, P3759, DOI 10.1002/j.1460-2075.1991.tb04945.x; ENGLE DB, 1990, J BIOL CHEM, V265, P16132; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; Grieco D, 1996, SCIENCE, V271, P1718, DOI 10.1126/science.271.5256.1718; Harlow E, 1988, ANTIBODIES LAB MANUA; HIRANO T, 1988, J CELL BIOL, V106, P1171, DOI 10.1083/jcb.106.4.1171; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; ISHII T, IN PRESS EMBO J; JAMES SW, 1995, J CELL SCI, V108, P3495; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; MACNEIL SA, 1993, CELL CYCLE PRACTICAL, P93; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MIZUKAMI T, 1993, CELL, V73, P121, DOI 10.1016/0092-8674(93)90165-M; MOCHIZUKI N, 1992, MOL GEN GENET, V233, P17, DOI 10.1007/BF00587556; OSMANI SA, 1988, CELL, V52, P241, DOI 10.1016/0092-8674(88)90513-2; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SAMEJIMA I, 1994, J CELL BIOL, V127, P1665; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; STARBORG M, 1994, J BIOL CHEM, V269, P24133; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4	26	140	144	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 21	1996	384	6606					276	279		10.1038/384276a0	http://dx.doi.org/10.1038/384276a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU381	8918880				2022-12-24	WOS:A1996VU38100055
J	Orth, B; Frei, R; Itin, PH; Rinaldi, MG; Speck, B; Gratwohl, A; Widmer, AF				Orth, B; Frei, R; Itin, PH; Rinaldi, MG; Speck, B; Gratwohl, A; Widmer, AF			Outbreak of invasive mycoses caused by Paecilomyces lilacinus from a contaminated skin lotion	ANNALS OF INTERNAL MEDICINE			English	Article						Paecilomyces lilacinus; mycoses; immunocompromised host; opportunistic infections	BONE-MARROW TRANSPLANTATION; SOLID-ORGAN TRANSPLANTATION; SPECIES INFECTIONS; FUNGAL INFECTION; PATIENT; NEUTROPENIA; CELLULITIS; CANCER	Background: Invasive mycoses are an important cause of illness and death in immunocompromised patients. Infections with molds other than aspergilli have been increasingly seen in patients with hematologic cancers, but epidemics of these infections have not yet been reported. Objective: To describe an outbreak of invasive mycoses with Paecilomyces lilacinus in severely neutropenic patients. Design: An outbreak investigation. Setting: The hematology-oncology isolation and bone marrow transplantation unit of the University Hospital, Basel, Switzerland. Patients: 25 consecutive patients admitted between 17 August 1993 (the date of the first manifestation of P. lilacinus infection) and 31 October 1993 (when the unit was closed). Measurements: Clinical and microbiological data, including histologic findings; cultures from several patient sites; and environmental examinations of potential airborne, parenteral, enteric, and horizontal routes of transmission. Infections were defined by the isolation of P. lilacinus from clinically evident skin eruptions. Results: 12 of the 25 patients (48%) were infected or colonized. Nine patients (36%), including all bone marrow transplant recipients, had documented invasive P. lilacinus infections. All 9 infected patients had papular, pustular, or necrotic skin eruptions. Two patients with severe graft-versus-host disease died with refractory fungal disease; 1 also had microbiologically documented endophthalmitis and kidney infiltrates. Seven affected patients no longer had P. lilacinus after recovery of bone marrow function. The organism was resistant in vitro to amphotericin B, itraconazole, and fluconazole. Patients did not respond clinically to these agents. The outbreak was ultimately traced to a contaminated, commercially available, pharmaceutically prepared skin lotion. The outbreak ended after the skin lotion was recalled and has not recurred after a follow-up period of 2 years. Conclusion: Contaminated skin lotion is a potential cause of opportunistic fungal infections in immunocompromised hosts. Paecilomyces lilacinus is a common saprophytic mold that can cause, by direct cutaneous inoculation, invasive infections associated with illness and death.	UNIV BASEL HOSP, DIV CLIN EPIDEMIOL, CH-4031 BASEL, SWITZERLAND; UNIV BASEL HOSP, DEPT LAB MED, BACTERIOL LAB, CH-4031 BASEL, SWITZERLAND; UNIV BASEL HOSP, DEPT DERMATOL, CH-4031 BASEL, SWITZERLAND; UNIV BASEL HOSP, DIV HEMATOL, CH-4031 BASEL, SWITZERLAND; UNIV BASEL HOSP, DIV CLIN EPIDEMIOL, CH-4031 BASEL, SWITZERLAND; UNIV TEXAS, HLTH SCI CTR, SAN ANTONIO, TX 78284 USA	University of Basel; University of Basel; University of Basel; University of Basel; University of Basel; University of Texas System; University of Texas Health San Antonio								ABDELHAFEZ AII, 1990, J BASIC MICROB, V30, P3; ANAISSIE E, 1992, CLIN INFECT DIS, V14, pS43, DOI 10.1093/clinids/14.Supplement_1.S43; BENEDICT LM, 1992, CLIN INFECT DIS, V15, P17, DOI 10.1093/clinids/15.1.17; Bernacer M., 1992, Medical Microbiology Letters, V1, P207; BODEY GP, 1993, CLIN INFECT DIS, V17, P705, DOI 10.1093/clinids/17.4.705; CASTRO LGM, 1990, J MED VET MYCOL, V28, P15; DOEBBELING BN, 1988, ANN INTERN MED, V109, P394, DOI 10.7326/0003-4819-109-5-394; ESPINELINGROFF A, 1995, ANTIMICROB AGENTS CH, V39, P314, DOI 10.1128/AAC.39.2.314; GORDON MA, 1984, SABOURAUDIA, V22, P109; JADE KB, 1986, ARCH DERMATOL, V122, P1169, DOI 10.1001/archderm.122.10.1169; Merz William G., 1995, P709; MORSE LJ, 1967, NEW ENGL J MED, V277, P472, DOI 10.1056/NEJM196708312770906; NELSON PE, 1994, CLIN MICROBIOL REV, V7, P479, DOI 10.1128/CMR.7.4.479-504.1994; OPAL SM, 1986, J INFECT DIS, V153, P634, DOI 10.1093/infdis/153.3.634; PANDEY A, 1990, MYCOSES, V33, P116, DOI 10.1111/myc.1990.33.3.116; PASSWEG J, 1994, SCHWEIZ MED WSCHR, V124, P62; PAYA CV, 1993, CLIN INFECT DIS, V16, P677, DOI 10.1093/clind/16.5.677; PETERSEN FB, 1992, BONE MARROW TRANSPL, V10, P83; PETTIT TH, 1980, ARCH OPHTHALMOL-CHIC, V98, P1025, DOI 10.1001/archopht.1980.01020031015002; PIZZO PA, 1993, NEW ENGL J MED, V328, P1323; RAPER KB, 1949, MANUAL PENICILLIA, P284; RILEY DK, 1994, AM J MED, V97, P509, DOI 10.1016/0002-9343(94)90345-X; SACHS MK, 1990, ARCH INTERN MED, V150, P1907, DOI 10.1001/archinte.150.9.1907; SHTAYEH MSA, 1996, MYCOPATHOLOGIA, V106, P95; SPECK B, 1992, TRANSPLANT P, V24, P88; SUPPARATPINYO K, 1992, CLIN INFECT DIS, V14, P871, DOI 10.1093/clinids/14.4.871; TAKAYASU S, 1977, ARCH DERMATOL, V113, P1687, DOI 10.1001/archderm.113.12.1687; TAN TQ, 1992, J CLIN MICROBIOL, V30, P2479, DOI 10.1128/JCM.30.9.2479-2483.1992; VARTIVARIAN SE, 1993, CLIN INFECT DIS, V17, pS487, DOI 10.1093/clinids/17.Supplement_2.S487; VOLNA F, 1990, Ceskoslovenska Epidemiologie Mikrobiologie Imunologie, V39, P315; WILLIAMSON PR, 1992, CLIN INFECT DIS, V14, P1023, DOI 10.1093/clinids/14.5.1023; WINGARD JR, 1991, NEW ENGL J MED, V325, P1274, DOI 10.1056/NEJM199110313251803; ZIMMERLI W, 1991, BLOOD, V77, P393	33	83	90	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1996	125	10					799	+		10.7326/0003-4819-125-10-199611150-00003	http://dx.doi.org/10.7326/0003-4819-125-10-199611150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU524	8928986				2022-12-24	WOS:A1996VU52400006
J	Rubin, SC; Benjamin, I; Behbakht, K; Takahashi, H; Morgan, MA; LiVolsi, VA; Berchuck, A; Muto, MG; Garber, JE; Weber, BL; Lynch, HT; Boyd, J				Rubin, SC; Benjamin, I; Behbakht, K; Takahashi, H; Morgan, MA; LiVolsi, VA; Berchuck, A; Muto, MG; Garber, JE; Weber, BL; Lynch, HT; Boyd, J			Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FAMILIES; BREAST; GENE; MANAGEMENT	Background We tested the hypothesis that ovarian cancers associated with germ-line mutations of BRCA1 have distinct clinical and pathological features as compared with sporadic ovarian cancers. Methods We reviewed clinical and pathological data on patients with primary epithelial ovarian cancer found to have germ-fine mutations of BRCA1. Survival among patients with advanced-stage cancer and such mutations was compared with that in control patients matched for age and stage, grade, and histologic subtype of the tumors. A combination of single-strand conformation and sequencing analyses was used to examine the 22 coding exons and intronic splice-donor and splice-acceptor regions of BRCA1 for mutations in pathological specimens. Alternatively, some patients were known to be obligate carriers of the mutant BRCA1 gene because of their parental relationships with documented mutant-gene carriers. Results We identified 53 patients with germ-line mutations of BRCA1. The average age at diagnosis was 48 years (range, 28 to 78). Histologic examination in 43 of the 53 patients showed serous adenocarcinoma. Thirty-seven tumors were of grade 3, 11 were of grade 2, 2 were of grade 1, and 3 were of low malignant potential. In 38 patients, the tumors were of stage III; 9 patients (including those with tumors of low malignant potential) had stage I disease, 5 had stage IV, and 1 had stage II. As of June 1996, with a median follow-up among survivors of 71 months from diagnosis, 20 patients had died of ovarian cancer, 27 had no evidence of the disease, 4 were alive with the disease, and 2 had died of other diseases. Actuarial median survival for the 43 patients with advanced-stage disease was 77 months, as compared with 29 months for the matched controls (P<0.001). Conclusions As compared with sporadic ovarian cancers, cancers associated with BRCA1 mutations appear to have a significantly more favorable clinical course. (C)1996, Massachusetts Medical Society.	UNIV PENN, MED CTR, DEPT LAB MED & PATHOL, DIV ANAT PATHOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, MED CTR, DIV HEMATOL & ONCOL, DEPT MED, PHILADELPHIA, PA 19104 USA; BRIGHAM & WOMENS HOSP, DEPT OBSTET & GYNECOL, DIV GYNECOL ONCOL, BOSTON, MA 02115 USA; DANA FARBER CANC INST, DIV CANC EPIDEMIOL & CONTROL, BOSTON, MA 02115 USA; CREIGHTON UNIV, SCH MED, DEPT PREVENT MED & PUBL HLTH, OMAHA, NE USA	University of Pennsylvania; University of Pennsylvania; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Creighton University	Rubin, SC (corresponding author), UNIV PENN, MED CTR, DEPT OBSTET & GYNECOL, DIV GYNECOL ONCOL, 3400 SPRUCE ST, PHILADELPHIA, PA 19104 USA.		Rubin, Stephen/U-8535-2019	Rubin, Stephen/0000-0003-3688-5333; Behbakht, Kian/0000-0003-4793-9958; Boyd, Jeff/0000-0002-3517-7637				BENJAMIN I, 1990, GYNECOL ONCOL, V38, P431, DOI 10.1016/0090-8258(90)90086-Z; BULLER RE, 1993, GYNECOL ONCOL, V51, P160, DOI 10.1006/gyno.1993.1265; EASTON DF, 1993, AM J HUM GENET, V52, P678; EISENKOP SM, 1992, GYNECOL ONCOL, V47, P203, DOI 10.1016/0090-8258(92)90107-T; Eisinger F, 1996, CANCER RES, V56, P471; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LYNCH HT, 1993, OVARIAN CANCER, P189; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W; McGuire WP, 1996, NEW ENGL J MED, V334, P1, DOI 10.1056/NEJM199601043340101; Merajver SD, 1995, CLIN CANCER RES, V1, P539; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MILLER BA, NIH PUBLICATION; Ozols RF, 1992, PRINCIPLES PRACTICE, P731; PIVER MS, 1993, CANCER-AM CANCER SOC, V71, P582; PORTER DE, 1994, BRIT J SURG, V81, P1512, DOI 10.1002/bjs.1800811038; Sankila R, 1996, GASTROENTEROLOGY, V110, P682, DOI 10.1053/gast.1996.v110.pm8608876; STEICHENGERSDORF E, 1994, AM J HUM GENET, V55, P870; TAKAHASHI H, 1995, CANCER RES, V55, P2998; THIGPEN T, 1993, CANCER-AM CANCER SOC, V71, P606	20	361	371	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 7	1996	335	19					1413	1416		10.1056/NEJM199611073351901	http://dx.doi.org/10.1056/NEJM199611073351901			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT339	8875917	Bronze			2022-12-24	WOS:A1996VT33900001
J	Alonso, JM; Usrey, WM; Reid, RC				Alonso, JM; Usrey, WM; Reid, RC			Precisely correlated firing in cells of the lateral geniculate nucleus	NATURE			English	Article							CROSS-CORRELATION ANALYSIS; CAT STRIATE CORTEX; RETINAL GANGLION-CELLS; VISUAL-CORTEX; GENICULOCORTICAL AFFERENTS; ORIENTATION SELECTIVITY; ACTION-POTENTIALS; RECEPTIVE-FIELDS; CIRCUITS; NEURONS	SIMPLE cells within layer IV of the cat primary visual cortex are selective for lines of a specific orientation, It has been proposed that their receptive-field properties are established by the pattern of connections that they receive from the lateral geniculate nucleus (LGN) of the thalamus(1-5). Thalamic inputs, however, represent only a small proportion of the synapses made onto simple cells(6-8), and others have argued that corticocortical connections are likely to be important in shaping simple-cell response properties(9,11). Here we describe a mechanism that might be involved in selectively strengthening the effect of thalamic inputs, We show that neighbouring geniculate neurons with overlapping receptive fields of the same type (on-centre or off-centre) often fire spikes that are synchronized to within 1 millisecond, Moreover, these neurons often project to a common cortical target neuron where synchronous spikes are more effective in evoking a postsynaptic response. We propose that precisely correlated firing within a group of geniculate neurons could serve to reinforce the thalamic input to cortical simple cells.			Alonso, JM (corresponding author), ROCKEFELLER UNIV, NEUROBIOL LAB, NEW YORK, NY 10021 USA.							AHMED B, 1994, J COMP NEUROL, V341, P39, DOI 10.1002/cne.903410105; CHAPMAN B, 1991, J NEUROSCI, V11, P1347; CLELAND BG, 1971, NATURE-NEW BIOL, V231, P191, DOI 10.1038/newbio231191a0; Dan Yang, 1996, Society for Neuroscience Abstracts, V22, P1703; DOUGLAS RJ, 1995, SCIENCE, V269, P981, DOI 10.1126/science.7638624; ECKHORN R, 1993, J NEUROSCI METH, V49, P175, DOI 10.1016/0165-0270(93)90121-7; Ferster D, 1996, NATURE, V380, P249, DOI 10.1038/380249a0; HAMOS JE, 1987, J COMP NEUROL, V259, P165, DOI 10.1002/cne.902590202; HIRSCH JA, 1995, NATURE, V378, P612, DOI 10.1038/378612a0; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; JAGADEESH B, 1993, SCIENCE, V262, P1901, DOI 10.1126/science.8266083; JONES JP, 1987, J NEUROPHYSIOL, V58, P1233, DOI 10.1152/jn.1987.58.6.1233; LEVAY S, 1976, BRAIN RES, V113, P1, DOI 10.1016/0006-8993(76)90002-0; MASTRONARDE DN, 1989, TRENDS NEUROSCI, V12, P75, DOI 10.1016/0166-2236(89)90140-9; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; MEISTER M, 1995, SCIENCE, V270, P1207, DOI 10.1126/science.270.5239.1207; Neuenschwander S, 1996, NATURE, V379, P728, DOI 10.1038/379728a0; PERKEL DH, 1967, BIOPHYS J, V7, P419, DOI 10.1016/S0006-3495(67)86597-4; PETERS A, 1993, CEREB CORTEX, V3, P69, DOI 10.1093/cercor/3.1.69; REID RC, 1995, NATURE, V378, P281, DOI 10.1038/378281a0; RODIECK RW, 1967, J NEUROPHYSIOL, V30, P1043, DOI 10.1152/jn.1967.30.5.1043; SILLITO AM, 1994, NATURE, V369, P479, DOI 10.1038/369479a0; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.ne.18.030195.003011; SOMERS DC, 1995, J NEUROSCI, V15, P5448; STEVENS JK, 1976, J NEUROPHYSIOL, V39, P239, DOI 10.1152/jn.1976.39.2.239; Stratford KJ, 1996, NATURE, V382, P258, DOI 10.1038/382258a0; Sutter E.E., 1987, ADV METHODS PHYSIOLO, V1, P303; TANAKA K, 1983, J NEUROPHYSIOL, V49, P1303, DOI 10.1152/jn.1983.49.6.1303; TOYAMA K, 1981, J NEUROPHYSIOL, V46, P191, DOI 10.1152/jn.1981.46.2.191; TSO DY, 1986, J NEUROSCI, V6, P1160	30	358	362	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 31	1996	383	6603					815	819		10.1038/383815a0	http://dx.doi.org/10.1038/383815a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ144	8893005				2022-12-24	WOS:A1996VQ14400061
J	dCruzGrote, D				dCruzGrote, D			Prevention of HIV infection in developing countries	LANCET			English	Article								The HIV/AIDS epidemic continues to spread rapidly in developing countries. Heterosexual transmission accounts for almost three-quarters of infections. Current strategies have been effective in the prevention of HIV spread within certain groups but they have had limited impact on the general spread of the epidemic. There is a need to complement these strategies with approaches that will influence the social and environmental determinants of risk to enable those vulnerable to infection to protect themselves.										ANKRAH ME, 1994, AIDS AFRICA, P553; ARMSTRONG S, 1993, WORLDAIDS        MAY; BALDO M, 1993, AM MED ASS MED BRIEF; BALDO M, 1995, 6 C AD HLTH YOUTH HL; BANG R, 1994, LISTENING WOMEN TALK; BELL RA, 1990, AIDS EDUC PREV, V2, P71; BRABIN L, 1995, LANCET, V345, P300, DOI 10.1016/S0140-6736(95)90281-3; Carballo Manuel, 1994, P497; CHANDRAMOULI V, 1993, 7 INT C AIDS AFR DEC; CHOI KH, 1994, AIDS, V8, P1371, DOI 10.1097/00002030-199410000-00003; DECOSAS J, 1995, EUR C TROP MED HAMB; Fontanet A, 1994, Health Transit Rev, V4 Suppl, P11; FRANSEN L, 1991, HLTH POLICY PLANN, V6, P48; GBILLAH P, 1995, EFFECTIVE APPROACHES; *GERM FDN INT DEV, 1993, INT C POP OCT 1993; GUPTA GR, 1995, 3 USAID HIV AIDS PRE; GUPTA GR, 1993, ICRW POLICY SERIES, V1; HEISE LL, 1995, SOC SCI MED, V40, P931, DOI 10.1016/0277-9536(94)00165-P; JANA S, 1995, EFFECTIVE APPROACH P; *KIT SAFAIDS, 1995, FAC CHALL HIV AIDS S; KLOUDA T, 1995, J INT DEV, V7, P457; LENTON C, 1993, ESTABLISHMENT NATL N; LISKEN LS, 1989, POPULATION REPORTS 8, V8; MERSON MH, 1993, 9TH INT C AIDS BERL; MWIZARUBI BK, 1994, FOCUSING INTERVENTIO, V2, P109; *NAT AIDS CONTR PR, 1994, COUNTR SCEN UPD; OPPONG C, 1993, SOCIOECONOMIC ASPECT; PACHAURI S, 1995, LISTENING WOMEN TALK, P184; PACHAURI S, 1994, LISTENING WOMEN TALK; PIOT P, 1994, SEX TRANSM DIS S2, V21, P7; RADIKA R, 1993, SEXUAL BEHAV NETWORK, P175; Reid Elizabeth, 1992, P657; ROSA D, 1993, EFFECTIVE APPROACHES; SCHOPPER D, 1990, SOC SCI MED, V30, P1265, DOI 10.1016/0277-9536(90)90306-D; SCHULER SR, 1994, STUD FAMILY PLANN, V25, P65, DOI 10.2307/2138085; TAWIL O, 1995, AIDS, V9, P1299, DOI 10.1097/00002030-199512000-00001; *WHO, 1993, GLOB PROGR AIDS EFF; WILSON D, 1994, NARESA MONOGRAPH, V2, P83; *WOM DEV DIV WORLD, 1989, 269 WPS WOM DEV DIV; 1992, 8 INT C AIDS 3 STD W; 1995, GLOBAL PROGRAMME AID; 1995, PAN AFR C YOUTH DEV	42	43	44	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 19	1996	348	9034					1071	1074		10.1016/S0140-6736(95)11031-3	http://dx.doi.org/10.1016/S0140-6736(95)11031-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VM886	8874461				2022-12-24	WOS:A1996VM88600014
J	Rafferty, JB; Sedelnikova, SE; Hargreaves, D; Artymiuk, PJ; Baker, PJ; Sharples, GJ; Mahdi, AA; Lloyd, RG; Rice, DW				Rafferty, JB; Sedelnikova, SE; Hargreaves, D; Artymiuk, PJ; Baker, PJ; Sharples, GJ; Mahdi, AA; Lloyd, RG; Rice, DW			Crystal structure of DNA recombination protein RuvA and a model for its binding to the Holliday junction	SCIENCE			English	Article							ESCHERICHIA-COLI; BRANCH MIGRATION; HOMOLOGOUS RECOMBINATION; HELICASE ACTIVITY; HEXAMERIC RINGS; POLYMERASE-BETA; GENE-PRODUCT; RECG PROTEIN; IN-VITRO; RESOLUTION	The Escherichia coli DNA binding protein RuvA acts in concert with the helicase RuvB to drive branch migration of Holliday intermediates during recombination and DNA repair. The atomic structure of RuvA was determined at a resolution of 1.9 angstroms. Four monomers of RuvA are related by fourfold symmetry in a manner reminiscent of a four-petaled flower. The four DNA duplex arms of a Holliday junction can be modeled in a square planar configuration and docked into grooves on the concave surface of the protein around a central pin that may facilitate strand separation during the migration reaction. The model presented reveals how a RuvAB-junction complex may also accommodate the resolvase RuvC.	UNIV SHEFFIELD, KREBS INST, DEPT MOL BIOL & BIOTECHNOL, SHEFFIELD S10 2TN, S YORKSHIRE, ENGLAND; UNIV NOTTINGHAM, QUEENS MED CTR, DEPT GENET, NOTTINGHAM NG7 2UH, ENGLAND	University of Sheffield; University of Nottingham			Sharples, Gary/B-8638-2016	Sharples, Gary/0000-0003-2495-0062; Baker, Patrick/0000-0003-1995-5643; Rafferty, John/0000-0003-1183-7474	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; ARNOTT S, 1969, ACTA CRYSTALL B-STRU, VB 25, P2192, DOI 10.1107/S0567740869005450; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BENNETT RJ, 1995, P NATL ACAD SCI USA, V92, P5635, DOI 10.1073/pnas.92.12.5635; BENNETT RJ, 1995, J MOL BIOL, V252, P213, DOI 10.1006/jmbi.1995.0489; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; CONNOLLY B, 1991, P NATL ACAD SCI USA, V88, P6063, DOI 10.1073/pnas.88.14.6063; DAVIES JF, 1994, CELL, V76, P1123, DOI 10.1016/0092-8674(94)90388-3; Doherty AJ, 1996, NUCLEIC ACIDS RES, V24, P2488, DOI 10.1093/nar/24.13.2488; DUCKETT DR, 1990, EMBO J, V9, P583, DOI 10.1002/j.1460-2075.1990.tb08146.x; DUCKETT DR, 1988, CELL, V55, P79, DOI 10.1016/0092-8674(88)90011-6; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; DUNDERDALE HJ, 1994, J BIOL CHEM, V269, P5187; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GRINDLEY HM, 1993, J MOL BIOL, V229, P707, DOI 10.1006/jmbi.1993.1074; HAMLIN R, 1985, METHOD ENZYMOL, V114, P416; HIOM K, 1995, CELL, V80, P787, DOI 10.1016/0092-8674(95)90357-7; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; HYDE H, 1994, J BIOL CHEM, V269, P5202; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; IWASAKI H, 1992, GENE DEV, V6, P2214, DOI 10.1101/gad.6.11.2214; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Leslie A. G. W., 1992, JOINT CCP4 ESF EAMCB, P26; LLOYD RG, 1993, EMBO J, V12, P17, DOI 10.1002/j.1460-2075.1993.tb05627.x; LLOYD RG, 1993, NUCLEIC ACIDS RES, V21, P1719, DOI 10.1093/nar/21.8.1719; LLOYD RG, IN PRESS CELLULAR MO; LOLL PJ, 1989, PROTEINS, V5, P183, DOI 10.1002/prot.340050302; MAESHIMA K, 1995, GENE, V160, P195, DOI 10.1016/0378-1119(95)00148-Y; Mahdi AA, 1996, J MOL BIOL, V257, P561, DOI 10.1006/jmbi.1996.0185; MANDAL TN, 1993, J BACTERIOL, V175, P4325, DOI 10.1128/JB.175.14.4325-4334.1993; MITCHELL AH, 1994, J MOL BIOL, V243, P208, DOI 10.1006/jmbi.1994.1648; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Palmer T. A., UNPUB; PANYUTIN IG, 1994, P NATL ACAD SCI USA, V91, P2021, DOI 10.1073/pnas.91.6.2021; PANYUTIN IG, 1995, EMBO J, V14, P1819, DOI 10.1002/j.1460-2075.1995.tb07170.x; PARSONS CA, 1995, NATURE, V374, P375, DOI 10.1038/374375a0; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; SEDELNIKOVA SE, IN PRESS ACTA CRYS D; SHAH R, 1994, CELL, V79, P853, DOI 10.1016/0092-8674(94)90074-4; SHARPLES GJ, 1990, MOL GEN GENET, V221, P219, DOI 10.1007/BF00261724; SHARPLES GJ, 1994, EMBO J, V13, P6133, DOI 10.1002/j.1460-2075.1994.tb06960.x; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; STAHL FW, 1994, GENETICS, V138, P241; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TSANEVA IR, 1992, MOL GEN GENET, V235, P1, DOI 10.1007/BF00286175; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; TSANEVA IR, 1994, J BIOL CHEM, V269, P26552; TSANEVA IR, 1993, P NATL ACAD SCI USA, V90, P1315, DOI 10.1073/pnas.90.4.1315; West SC, 1996, J BACTERIOL, V178, P1237, DOI 10.1128/jb.178.5.1237-1241.1996; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; WHITBY M, UNPUB; WHITBY MC, 1994, EMBO J, V13, P5220, DOI 10.1002/j.1460-2075.1994.tb06853.x; White MF, 1996, J MOL BIOL, V257, P330, DOI 10.1006/jmbi.1996.0166; XUONG NH, 1985, J APPL CRYSTALLOGR, V18, P342, DOI 10.1107/S0021889885010433; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	71	150	151	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 18	1996	274	5286					415	421		10.1126/science.274.5286.415	http://dx.doi.org/10.1126/science.274.5286.415			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN173	8832889				2022-12-24	WOS:A1996VN17300052
J	Roseman, AM; Chen, SX; White, H; Braig, K; Saibil, HR				Roseman, AM; Chen, SX; White, H; Braig, K; Saibil, HR			The chaperonin ATPase cycle: Mechanism of allosteric switching and movements of substrate-binding domains in GroEL	CELL			English	Article							CRYOELECTRON MICROSCOPY; PROTEIN SUBSTRATE; ESCHERICHIA-COLI; COOPERATIVITY; RESOLUTION; HYDROLYSIS; RELEASE; RECONSTITUTION; POLYPEPTIDE; NUCLEOTIDES	Chaperonin-assisted protein folding proceeds through cycles of ATP binding and hydrolysis by the large chaperonin GroEL, which undergoes major allosteric rearrangements. Interaction between the two back-to-back seven-membered rings of GroEL plays an important role in regulating binding and release of folding substrates and of the small chaperonin GroES. Using cryo-electron microscopy, we have obtained three-dimensional reconstructions to 30 Angstrom resolution for GroEL and GroEL-GroES complexes in the presence of ADP, ATP, and the nonhydrolyzable ATP analog, AMP-PNP. Nucleotide binding to the equatorial domains of GroEL causes large rotations of the apical domains, containing the GroES and substrate protein-binding sites. We propose a mechanism for allosteric switching and describe conformational changes that may be involved in critical steps of folding for substrates encapsulated by GroES.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Yale University	Roseman, AM (corresponding author), UNIV LONDON BIRKBECK COLL,DEPT CRYSTALLOG,MALET ST,LONDON WC1E 7HX,ENGLAND.		Roseman, Alan/AAE-6689-2019	Roseman, Alan/0000-0002-4783-2619	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aharoni A, 1996, J MOL BIOL, V258, P732, DOI 10.1006/jmbi.1996.0282; Azem A, 1995, P NATL ACAD SCI USA, V92, P12021, DOI 10.1073/pnas.92.26.12021; Baker TS, 1996, J STRUCT BIOL, V116, P120, DOI 10.1006/jsbi.1996.0020; BOCHKAREVA ES, 1994, J BIOL CHEM, V269, P23869; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1995, NAT STRUCT BIOL, V2, P1083, DOI 10.1038/nsb1295-1083; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOROVITS BM, 1995, J BIOL CHEM, V270, P28551, DOI 10.1074/jbc.270.48.28551; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KOVALENKO O, 1994, BIOCHEMISTRY-US, V33, P14974, DOI 10.1021/bi00254a004; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LLORCA O, 1994, FEBS LETT, V345, P181, DOI 10.1016/0014-5793(94)00432-3; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; MILLIGAN RA, 1987, J CELL BIOL, V105, P29, DOI 10.1083/jcb.105.1.29; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; PENCZEK PA, 1994, ULTRAMICROSCOPY, V53, P251, DOI 10.1016/0304-3991(94)90038-8; RADERMACHER M, 1994, ULTRAMICROSCOPY, V53, P121, DOI 10.1016/0304-3991(94)90003-5; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHATZ M, 1995, J STRUCT BIOL, V114, P28, DOI 10.1006/jsbi.1995.1003; STANIFORTH RA, 1994, BIOCHEM J, V300, P651, DOI 10.1042/bj3000651; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; YIFRACH O, 1994, J MOL BIOL, V243, P397, DOI 10.1006/jmbi.1994.1667; YIFRACH O, 1995, BIOCHEMISTRY-US, V34, P5303, DOI 10.1021/bi00016a001; Yifrach O, 1996, J MOL BIOL, V255, P356, DOI 10.1006/jmbi.1996.0028	41	345	347	0	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1996	87	2					241	251		10.1016/S0092-8674(00)81342-2	http://dx.doi.org/10.1016/S0092-8674(00)81342-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VN403	8861908	hybrid			2022-12-24	WOS:A1996VN40300012
J	Seddon, JM; Willett, WC; Speizer, FE; Hankinson, SE				Seddon, JM; Willett, WC; Speizer, FE; Hankinson, SE			A prospective study of cigarette smoking and age-related macular degeneration in women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VITAMIN-C; PLASMA; RISK; SMOKERS; HEART; EYE	Objective.-To evaluate the relationship between cigarette smoking acid incidence of age-related macular degeneration (AMD) among women. Design.-Prospective cohort study with 12 years of follow-up (1980 to 1992), in which information on smoking habits was updated every 2 years. Setting.-Eleven states throughout the United States. Participants.-A total of 31 843 registered nurses enrolled in the Nurses' Health Study who were aged 50 to 59 years in 1980 and did not report a diagnosis of cancer or AMD at the beginning of the study. Additional women entered the analytic cohort as they reached 50 years of age. Main Outcome Measure.-Incidence of AMD with visual loss. Results.-During 556 338 person-years of follow-up, 215 women were newly diagnosed as having AMD. After adjusting for other risk factors for AMD, women who currently smoked 25 or more cigarettes per day had a relative risk (RR) of AMD of 2.4 (95% confidence interval [CI], 1.4-4.0) compared with women who never smoked. Past smokers of this amount also had a 2-fold increased risk (RR=2.0; 95% CI, 1.2-3.4) relative to never smokers. Compared with current smokers, little reduction in risk was suggested even after quitting smoking for 15 or more years. Risk of AMD also increased with an increasing number of pack-years smoked (P for trend <.001); among women who smoked for 65 or more pack-years, the risk was 2.4 times the risk of never smokers (95% CI, 1.5-3.8). Analyses of dry and exudative types of AMD and other alternative definitions of AMD revealed similar results, Conclusions.-Cigarette smoking is an independent and avoidable risk factor for AMD among women. Because AMD is the most common cause of severe visual impairment among the elderly and treatment is not available or is ineffective for most patients, reducing the risk of this disease is another important reason to avoid smoking.	BRIGHAM & WOMENS HOSP,DEPT MED,CHANNING LAB,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT OPHTHALMOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Seddon, JM (corresponding author), MASSACHUSETTS EYE & EAR INFIRM,DEPT OPHTHALMOL,EPIDEMIOL UNIT,243 CHARLES ST,BOSTON,MA 02114, USA.				NCI NIH HHS [CA 40356] Funding Source: Medline; NEI NIH HHS [EY 09611] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY009611] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BETMAN J, 1958, ARCH OPHTHALMOL-CHIC, V59, P481; BLACKMAN BC, 1984, ANN NY ACAD SCI, V435, P385, DOI 10.1111/j.1749-6632.1984.tb13828.x; CHOW CK, 1986, J AM COLL NUTR, V5, P305; COX DR, 1972, J R STAT SOC B, V34, P187; GREENLAND S, 1984, STAT MED, V3, P131, DOI 10.1002/sim.4780030206; HANKINSON SE, 1992, JAMA-J AM MED ASSOC, V268, P994, DOI 10.1001/jama.268.8.994; Hosmer D.W., 2004, APPL LOGISTIC REGRES, VSecond; HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629; KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429; KLEIN R, 1992, OPHTHALMOLOGY, V99, P933; KLEIN R, 1993, AM J EPIDEMIOL, V137, P191; *NAT ADV EY COUNC, 1993, NAT I HLTH PUBL; SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413; STRYKER WS, 1988, AM J EPIDEMIOL, V127, P283, DOI 10.1093/oxfordjournals.aje.a114804; U.S. Department of Health and Human Services, 1990, US DEP HLTH HUM SERV; *US DEP HHS, 1983, HLTH CONS SMOK CARD; WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038; WILLETT W, 1983, AM HEART J, V105, P417, DOI 10.1016/0002-8703(83)90358-7; WILLETT WC, 1987, NEW ENGL J MED, V317, P1303, DOI 10.1056/NEJM198711193172102; WILLETT WC, 1987, NEW ENGL J MED, V316, P22, DOI 10.1056/NEJM198701013160105; Willett WC, 1996, JAMA-J AM MED ASSOC, V275, P458, DOI 10.1001/jama.275.6.458; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; 1992, ARCH OPHTHALMOL-CHIC, V110, P1701; 1993, ARCH OPHTHALMOL-CHIC, V111, P104; 1986, ARCH OPHTHALMOL-CHIC, V104, P503	25	377	383	0	33	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1996	276	14					1141	1146		10.1001/jama.276.14.1141	http://dx.doi.org/10.1001/jama.276.14.1141			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL332	8827966				2022-12-24	WOS:A1996VL33200023
J	Donoghue, J; Tylee, A; Wildgust, H				Donoghue, J; Tylee, A; Wildgust, H			Cross sectional database analysis of antidepressant prescribing in general practice in the United Kingdom, 1993-5	BRITISH MEDICAL JOURNAL			English	Article									ST GEORGE HOSP,SCH MED,ROYAL COLL GEN PRACTITIONERS,UNIT MENTAL HLTH EDUC,LONDON SW17 0RE,ENGLAND; LILLY IND,BASINGSTOKE RG21 2SY,HANTS,ENGLAND	St Georges University London	Donoghue, J (corresponding author), CLATTERBRIDGE HOSP,WIRRAL HOSP NHS TRUST,DEPT PHARM,PSYCHIAT SERV,WIRRAL L63 4JY,MERSEYSIDE,ENGLAND.		Tylee, Andre T/D-8468-2010					ALI IM, 1994, THESIS U WALES; ISACSSON G, 1994, BRIT MED J, V308, P506, DOI 10.1136/bmj.308.6927.506; KERR MP, 1994, BRIT J GEN PRACT, V44, P275; PAYKEL ES, 1992, BRIT MED J, V305, P1198, DOI 10.1136/bmj.305.6863.1198; TURTON P, 1995, ED GEN PRACT, V6, P226	5	71	71	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 5	1996	313	7061					861	862						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL559	8870576				2022-12-24	WOS:A1996VL55900027
J	Irvine, WM; BockeleeMorvan, D; Lis, DC; Matthews, HE; Biver, N; Crovisier, J; Davies, JK; Dent, WRF; Gautier, D; Godfrey, PD; Keene, J; Lovell, AJ; Owen, TC; Phillips, TG; Rauer, H; Schloerb, FP; Senay, M; Young, K				Irvine, WM; BockeleeMorvan, D; Lis, DC; Matthews, HE; Biver, N; Crovisier, J; Davies, JK; Dent, WRF; Gautier, D; Godfrey, PD; Keene, J; Lovell, AJ; Owen, TC; Phillips, TG; Rauer, H; Schloerb, FP; Senay, M; Young, K			Spectroscopic evidence for interstellar ices in comet Hyakutake	NATURE			English	Article							ABSORPTION FEATURES; ABUNDANCE RATIO; HNC; HCN; CHEMISTRY; MOLECULES; CLOUDS; WATER	VOLATILE compounds in comets are the most pristine materials surviving from the time of formation of the Solar System, and thus potentially provide information about conditions that prevailed in the primitive solar nebula(1-3). Moreover, comets may have supplied a substantial fraction of the volatiles on the terrestrial planets, perhaps including organic compounds that played a role in the origin of life on Earth(4-6), Here we report the detection of hydrogen isocyanide (HNC) in comet Hyakutake. The abundance of HNC relative to hydrogen cyanide (HCN) is very similar to that observed in quiescent interstellar molecular clouds, and quite different from the equilibrium ratio expected in the outermost solar nebula, where comets are thought to form. Such a departure from equilibrium has long been considered a hallmark of gas-phase chemical processing in the interstellar medium(7), suggesting that interstellar gases have been incorporated into the comet's nucleus, perhaps as ices frozen onto interstellar grains. If this interpretation is correct, our results should provide constraints on the temperature of the solar nebula, and the subsequent chemical processes that occurred in the region where comets formed.	OBSERV PARIS, F-92195 MEUDON, FRANCE; MONASH UNIV, DEPT CHEM, CLAYTON, VIC 3168, AUSTRALIA; UNIV HAWAII, INST ASTRON, HONOLULU, HI 96822 USA; CALTECH, DOWN LAB PHYS 32047, PASADENA, CA 91125 USA; NATL RES COUNCIL CANADA, HERZBERG INST ASTROPHYS, OTTAWA, ON K1A 0R6, CANADA; JOINT ASTRON CTR, HILO, HI 96720 USA	UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; Monash University; University of Hawaii System; California Institute of Technology; National Research Council Canada	Irvine, WM (corresponding author), UNIV MASSACHUSETTS, FIVE COLL RADIO ASTRON OBSERV, 619 LGRC, AMHERST, MA 01003 USA.			Lis, Dariusz/0000-0002-0500-4700				Bergin EA, 1996, ASTROPHYS J, V460, P343, DOI 10.1086/176974; BERNSTEIN MP, 1995, ASTROPHYS J, V454, P327, DOI 10.1086/176485; BOCKELEEMORVAN D, 1984, ASTRON ASTROPHYS, V141, P411; BROWN PD, 1988, MON NOT R ASTRON SOC, V231, P409, DOI 10.1093/mnras/231.2.409; BROWN RD, 1977, NATURE, V270, P39, DOI 10.1038/270039a0; BROWN RD, 1989, ASTROPHYS J, V347, P855, DOI 10.1086/168175; CRONIN JR, 1993, NATO ADV SCI INST SE, V416, P209; CROVISIER J, 1984, ASTRON ASTROPHYS, V130, P361; CROVISIER J, 1987, ASTRON ASTROPHYS SUP, V68, P223; CROVISIER J, 1994, IAU SYMP, P313; DEISEMME AH, 1991, FRONTEIRS LIFE, P105; DESFORETS GP, 1990, MON NOT R ASTRON SOC, V244, P668; EBERHARDT P, 1995, ASTRON ASTROPHYS, V302, P301; Fegley B.J., 1989, FORMATION EVOLUTION, P171; GOLDSMITH PF, 1986, ASTROPHYS J, V310, P383, DOI 10.1086/164692; GOLDSMITH PF, 1981, ASTROPHYS J, V249, P524, DOI 10.1086/159312; GREENBERG JM, 1994, IAU SYMP, P327; GREENBERG JM, 1993, NATO ADV SCI INST SE, V416, P195; GREENBERG JM, 1992, ADV SPACE RES-SERIES, V12, P169; HERZBERG G, 1966, ELECT SPECTRA ELECT, P494; Huebner W. F., 1991, COMETS POST HALLEY E, V2, P907; Irvine W. M., 1987, INTERSTELLAR PROCESS, V134, P561; IRVINE WM, 1985, PROTOSTARS PLANETS, V2, P579; Irvine WM, 1989, ORIGIN EVOLUTION PLA, P3; LACY JH, 1984, ASTROPHYS J, V276, P533, DOI 10.1086/161642; LARSON HP, 1985, ASTROPHYS J, V299, P873, DOI 10.1086/163754; LIS D, 1996, 6362 IAU; MATTHEWS HE, 1996, 6353 IAU; MILLIGAN DE, 1967, J CHEM PHYS, V47, P278, DOI 10.1063/1.1711859; Mumma M. J., 1993, PROTOSTARS PLANETS, P1177; MUMMA MJ, 1996, 6366 IAU; OWEN T, 1995, ICARUS, V116, P215, DOI 10.1006/icar.1995.1122; SCHILKE P, 1992, ASTRON ASTROPHYS, V256, P595; SWADE DA, 1987, COMETARY RADIO ASTRO, P79; Watson W. D., 1980, International Astronomical Union Symposium. No.87. Interstellar Molecules, P341	35	109	110	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 3	1996	383	6599					418	420		10.1038/383418a0	http://dx.doi.org/10.1038/383418a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL463	8837771				2022-12-24	WOS:A1996VL46300055
J	Lala, DS; Mukherjee, R; Schulman, IG; Koch, SSC; Dardashti, LJ; Nadzan, AM; Croston, GE; Evans, RM; Heyman, RA				Lala, DS; Mukherjee, R; Schulman, IG; Koch, SSC; Dardashti, LJ; Nadzan, AM; Croston, GE; Evans, RM; Heyman, RA			Activation of specific RXR heterodimers by an antagonist of RXR homodimers	NATURE			English	Article							9-CIS RETINOIC ACID; NUCLEAR HORMONE RECEPTORS; LIGAND-BINDING DOMAIN; CO-REPRESSOR; X RECEPTOR; RESPONSE PATHWAYS; CRYSTAL-STRUCTURE; TRANSACTIVATION; ALPHA; RAR	RETINOID X receptor (RXR) plays a central role in the regulation a of many intracellular receptor signalling pathways(1) and can mediate ligand-dependent transcription, acting as a homodimer or as a heterodimer(1-6). Here we identify an antagonist towards RXR homodimers which also functions as an agonist when RXR is paired as a heterodimer to specific partners, including peroxisome proliferator-activated receptor and retinoic acid receptor. This dimer-selective ligand confers differential interactions on the transcription machinery: the antagonist promotes association with TAF110) (TATA-binding protein (TBP)-associated factor 110) and the co-repressor SMRT(7), but not with TBP, and these properties are distinct from pure RXR agonists. This unique class of RXR ligands will provide a means to control distinct target genes at the level of transcription and allow the development of retinoids with a new pharmacological action.	LIGAND PHARMACEUT INC, DEPT RETINOID RES, SAN DIEGO, CA 92121 USA; LIGAND PHARMACEUT INC, DEPT CARDIOVASC RES, SAN DIEGO, CA 92121 USA; LIGAND PHARMACEUT INC, DEPT RETINOID CHEM, SAN DIEGO, CA 92121 USA; LIGAND PHARMACEUT INC, DEPT NEW LEADS, SAN DIEGO, CA 92121 USA; SALK INST BIOL STUDIES, LA JOLLA, CA 92037 USA	Ligand Pharmaceuticals; Ligand Pharmaceuticals; Ligand Pharmaceuticals; Ligand Pharmaceuticals; Salk Institute			Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965				ALLEGRETTO EA, 1993, J BIOL CHEM, V268, P26625; BOEHM MF, 1995, J MED CHEM, V38, P3146, DOI 10.1021/jm00016a018; BOEHM MF, 1994, J MED CHEM, V37, P408, DOI 10.1021/jm00029a013; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; DANIELIAN PS, 1993, MOL ENDOCRINOL, V7, P232, DOI 10.1210/me.7.2.232; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Koch SSC, 1996, J MED CHEM, V39, P3229, DOI 10.1021/jm960311d; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LANOTTE M, 1991, BLOOD, V77, P1080; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MEYER ME, 1990, EMBO J, V9, P3923, DOI 10.1002/j.1460-2075.1990.tb07613.x; MUKHERJEE R, 1994, J STEROID BIOCHEM, V51, P157, DOI 10.1016/0960-0760(94)90089-2; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGPAL S, 1995, J BIOL CHEM, V270, P923, DOI 10.1074/jbc.270.2.923; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; ROY DY, 1995, MOL CELL BIOL, V15, P6481; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033	30	150	153	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 3	1996	383	6599					450	453		10.1038/383450a0	http://dx.doi.org/10.1038/383450a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL463	8837780				2022-12-24	WOS:A1996VL46300066
J	Zook, HA; Grun, E; Baguhl, M; Hamilton, DP; Linkert, G; Liou, JC; Forsyth, R; Phillips, JL				Zook, HA; Grun, E; Baguhl, M; Hamilton, DP; Linkert, G; Liou, JC; Forsyth, R; Phillips, JL			Solar wind magnetic field bending of Jovian dust trajectories	SCIENCE			English	Article							JUPITER; EJECTION; GALILEO	From September 1991 to October 1992, the cosmic dust detector on the Ulysses spacecraft recorded 11 short bursts, or streams, of dust. These dust grains emanated from the jovian system, and their trajectories were strongly affected by solar wind magnetic field forces. Analyses of the on-board measurements of these fields, and of stream approach directions, show that stream-associated dust grain masses are of the order of 10(-18) gram and dust grain velocities exceed 200 kilometers per second. These masses and velocities are, respectively, about 10(3) times less massive and 5 to 10 times faster than earlier reported.	MAX PLANCK INST KERNPHYS,D-69029 HEIDELBERG,GERMANY; UNIV MARYLAND,DEPT ASTRON,COLLEGE PK,MD 20742; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,BLACKETT LAB,LONDON SW7 2BZ,ENGLAND; LOS ALAMOS NATL LAB,LOS ALAMOS,NM 87545	Max Planck Society; University System of Maryland; University of Maryland College Park; Imperial College London; United States Department of Energy (DOE); Los Alamos National Laboratory	Zook, HA (corresponding author), NASA,LYNDON B JOHNSON SPACE CTR,HOUSTON,TX 77058, USA.							BAGUHI M, 1994, PLANET SPACE SCI, V41, P1085; BALOGH A, 1993, GEOPHYS RES LETT, V20, P2331, DOI 10.1029/93GL02621; BARNE SJ, 1993, GEOPHYS RES LETT, V20, P2323; GOLLER JR, 1989, PLANET SPACE SCI, V37, P1197, DOI 10.1016/0032-0633(89)90014-7; GRUN E, 1995, PLANET SPACE SCI, V43, P971, DOI 10.1016/0032-0633(94)00233-H; GRUN E, 1993, NATURE, V362, P428, DOI 10.1038/362428a0; GRUN E, 1995, PLANET SPACE SCI, V43, P941, DOI 10.1016/0032-0633(94)00232-G; GRUN E, 1992, SCIENCE, V257, P1550, DOI 10.1126/science.11538054; Grun E, 1996, SCIENCE, V274, P399, DOI 10.1126/science.274.5286.399; Grun E, 1996, NATURE, V381, P395, DOI 10.1038/381395a0; HAMILTON DP, 1993, NATURE, V364, P695, DOI 10.1038/364695a0; HORANYI M, 1993, NATURE, V363, P144, DOI 10.1038/363144a0; MARIANI F, 1990, PHYSICS INNER HELIOS, P99; ZOOK HA, 1996, P 150 C INT ASTR UN, V104, P23	14	75	75	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1996	274	5292					1501	1503		10.1126/science.274.5292.1501	http://dx.doi.org/10.1126/science.274.5292.1501			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929405				2022-12-24	WOS:A1996VV77500040
J	Schnipper, HH				Schnipper, HH			Through the looking glass	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 20	1996	276	19					1535	1536						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT025	8918836				2022-12-24	WOS:A1996VT02500001
J	Rosette, C; Karin, M				Rosette, C; Karin, M			Ultraviolet light and osmotic stress: Activation of the JNK cascade through multiple growth factor and cytokine receptors	SCIENCE			English	Article							SIGNAL-TRANSDUCTION PATHWAY; C-JUN; PROTEIN-KINASES; UV; PHOSPHORYLATION; BINDING; DOMAIN; GENE; FOS; EXPRESSION	Exposure of mammalian cells to ultraviolet (UV) light or high osmolarity strongly activates the c-Jun amino-terminal protein kinase (JNK) cascade, causing induction of many target genes. Exposure to UV light or osmotic shock induced clustering and internalization of cell surface receptors for epidermal growth factor (EGF), tumor necrosis factor (TNF), and interleukin-1 (IL-1), Activation of the EGF and TNF receptors was also detected biochemically. Whereas activation of each receptor alone resulted in modest activation of JNK, coadministration of EGF, IL-1, and TNF resulted in a strong synergistic response equal to that caused by exposure to osmotic shock or UV light. Inhibition of clustering or receptor down-regulation attenuated both the osmotic shock and UV responses. Physical stresses may perturb the cell surface or alter receptor conformation, thereby subverting signaling pathways normally used by growth factors and cytokines.	UNIV CALIF SAN DIEGO,SCH MED,DEPT PHARMACOL,PROGRAM BIOMED SCI,LA JOLLA,CA 92093	University of California System; University of California San Diego								ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; BUSCHER M, 1988, ONCOGENE, V3, P301; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; FISHER GJ, 1995, NATURE, V379, P353; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GORDEN P, 1978, P NATL ACAD SCI USA, V75, P5025, DOI 10.1073/pnas.75.10.5025; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KOCH A, 1990, J EXP MED, V172, P1609; Krutmann J., 1995, J INVEST DERMATOL, V105, P675; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Shapiro L, 1995, P NATL ACAD SCI USA, V92, P12230, DOI 10.1073/pnas.92.26.12230; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x	37	919	946	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1996	274	5290					1194	1197		10.1126/science.274.5290.1194	http://dx.doi.org/10.1126/science.274.5290.1194			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT335	8895468				2022-12-24	WOS:A1996VT33500054
J	Wary, KK; Mainiero, F; Isakoff, SJ; Marcantonio, EE; Giancotti, FG				Wary, KK; Mainiero, F; Isakoff, SJ; Marcantonio, EE; Giancotti, FG			The adaptor protein Shc couples a class of integrins to the control of cell cycle progression	CELL			English	Article							HUMAN-ENDOTHELIAL CELLS; FOCAL ADHESION KINASE; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAIN; MEMBRANE DOMAINS; DIFFERENTIATION; FIBRONECTIN; EXPRESSION; RECEPTOR; CAVEOLIN	We provide evidence that a class of integrins combines with the adaptor She and thereby with Grb2. Coimmunoprecipitation and mutagenesis experiments indicate that the recruitment of She is specified by the extracellular or transmembrane domain of integrin cu subunit and suggest that this process is mediated by caveolin. Mutagenesis and dominant-negative inhibition studies reveal that She is necessary and sufficient for activation of the MAP kinase pathway in response to integrin ligation. Mitogens and She-activating integrins cooperate to promote transcription from the Fos serum response element and transit through G1. In contrast, adhesion mediated by integrins not linked to She results in cell cycle arrest and apoptosis even in presence of mitogens. These findings indicate that the association of specific integrins with She regulates cell survival and cell cycle progression.	NYU,SCH MED,DEPT PATHOL,NEW YORK,NY 10016; NYU,SCH MED,KAPLAN CANC CTR,NEW YORK,NY 10016; NYU,SCH MED,SACKLER INST GRAD BIOMED SCI,NEW YORK,NY 10016; COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032	New York University; New York University; New York University; Columbia University			Isakoff, Steven/ABE-3566-2020	Wary, Kishore/0000-0001-8851-8565; Mainiero, Fabrizio/0000-0002-7136-9839	NCI NIH HHS [CA-16087, CA-58976] Funding Source: Medline; NIGMS NIH HHS [GM-44585] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058976, P30CA016087, R37CA058976] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044585] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUER JS, 1993, J CELL BIOL, V122, P209, DOI 10.1083/jcb.122.1.209; BRIESEWITZ R, 1993, MOL BIOL CELL, V4, P593, DOI 10.1091/mbc.4.6.593; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CONFORTI G, 1989, BLOOD, V73, P1576; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIANCOTTI FG, 1994, METHOD ENZYMOL, V245, P297; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GIANCOTTI FG, 1994, BBA-REV CANCER, V1198, P47, DOI 10.1016/0304-419X(94)90005-1; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1996, IN PRESS DEV BIOL; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; KEM A, 1994, J BIOL CHEM, V269, P22811; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; MAINIERO F, 1995, EMBO J, V14, P4470, DOI 10.1002/j.1460-2075.1995.tb00126.x; MASTICK CC, 1995, J CELL BIOL, V129, P1523, DOI 10.1083/jcb.129.6.1523; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Pullan S, 1996, J CELL SCI, V109, P631; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SALCINI AE, 1994, ONCOGENE, V9, P2827; Sastry SK, 1996, J CELL BIOL, V133, P169, DOI 10.1083/jcb.133.1.169; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHLAEPFER DD, 1994, NATURE, V372, P786; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SPINARDI L, 1995, J CELL BIOL, V129, P473, DOI 10.1083/jcb.129.2.473; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; VONDERMARK K, 1989, DIFFERENTIATION, V40, P150, DOI 10.1111/j.1432-0436.1989.tb00823.x; Vuori K, 1996, MOL CELL BIOL, V16, P2606; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	48	633	642	1	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1996	87	4					733	743		10.1016/S0092-8674(00)81392-6	http://dx.doi.org/10.1016/S0092-8674(00)81392-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VU035	8929541	hybrid			2022-12-24	WOS:A1996VU03500015
J	Stein, CE; Fall, CHD; Kumaran, K; Osmond, C; Cox, V; Barker, DJP				Stein, CE; Fall, CHD; Kumaran, K; Osmond, C; Cox, V; Barker, DJP			Fetal growth and coronary heart disease in South India	LANCET			English	Article							CARDIOVASCULAR-DISEASE; RURAL-POPULATION; ADULT LIFE; PREVALENCE; THINNESS; BIRTH; DEATH	Background Coronary heart disease is predicted to become the commonest cause of death in India within 15 years, People from India living overseas already have high rates of the disease that are not explained by known coronary risk factors. Small size at birth is a newly described risk factor for coronary heart disease, but associations between size at birth and the disease have not been examined in India. Methods We studied 517 men and women who were born between 1934 and 1954 in a mission hospital in Mysore, South India, and who still lived near to the hospital. We related the prevalence of coronary heart disease, defined by standard criteria, to their birth size. Findings 25 (9%) men and 27 (11%) women had coronary heart disease. Low birthweight, short birth length, and small head circumference at birth were associated with a raised prevalence of the disease. Prevalence fell from 11% in people whose birthweights were 55 lb (2.5 kg) or less to 3% in those whose birthweights were more than 7 lb (3.1 kg), p for trend = 0.09. The trends were stronger and statistically significant among people aged 45 years and over (p = 0.03 for birthweight, 0.04 for length, and 0.02 for head circumference), High rates of disease were also found in those whose mothers had a low body weight during pregnancy. The highest prevalence of the disease (20%) was in people who weighed 5.5 lb (2.5 kg) or less at birth and whose mothers weighed less than 100 lb (45 kg) in pregnancy. These associations were largely independent of known coronary risk factors. Interpretation In India, as in the UK, coronary heart disease is associated with small size al birth, suggesting that its pathogenesis is influenced by events in utero, The association with low maternal bodyweight is further evidence that the disease originates through fetal undernutrition, Prevention of the rising epidemic of the disease in India may require improvements in the nutrition and health of young women.	SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND; HOLDSWORTH MEM HOSP,MYSORE,KARNATAKA,INDIA	University of Southampton				Osmond, Clive/0000-0002-9054-4655	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; CHADHA SL, 1990, INDIAN J MED RES-B, V92, P424; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; EDWARDS JR, 1995, AM J EPIDEMIOL, V141, pS78; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GAIRDNER D, 1971, ARCH DIS CHILD, V46, P783, DOI 10.1136/adc.46.250.783; GUPTA R, 1994, BRIT MED J, V309, P1332, DOI 10.1136/bmj.309.6965.1332; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; Hales CN, 1996, BIOCHEM SOC T, V24, P341, DOI 10.1042/bst0240341; Kuppuswamy B., 1962, MANUAL SOCIOECONOMIC; KUTTY VR, 1993, INT J CARDIOL, V39, P59; LANGLEY SC, 1994, CLIN SCI, V86, P217, DOI 10.1042/cs0860217; LAW CM, 1993, J EPIDEMIOL COMMUN H, V47, P255, DOI 10.1136/jech.47.4.255; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; MANN M, 1990, INDIAN PEDIATR, V27, P43; MCKEIGUE PM, 1988, BRIT MED J, V297, P903, DOI 10.1136/bmj.297.6653.903; *OFF POP CENS SURV, 1990, DIST NUTR SURV BRIT; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; Prineas R., 1982, MINNESOTA CODE MANUA; REID DD, 1974, LANCET, V1, P469; Rose G, 1968, CARDIOVASCULAR SURVE; SARVOTHAM SG, 1968, CIRCULATION, V37, P939, DOI 10.1161/01.CIR.37.6.939; SNOECK A, 1990, BIOL NEONATE, V57, P107, DOI 10.1159/000243170	25	401	410	0	19	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 9	1996	348	9037					1269	1273		10.1016/S0140-6736(96)04547-3	http://dx.doi.org/10.1016/S0140-6736(96)04547-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR555	8909379				2022-12-24	WOS:A1996VR55500009
J	Chinnaiyan, AM; ORourke, K; Yu, GL; Lyons, RH; Garg, M; Duan, DR; Xing, L; Gentz, R; Ni, J; Dixit, VM				Chinnaiyan, AM; ORourke, K; Yu, GL; Lyons, RH; Garg, M; Duan, DR; Xing, L; Gentz, R; Ni, J; Dixit, VM			Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95	SCIENCE			English	Article							CELL-DEATH; FAS ANTIGEN; APOPTOSIS; PROTEIN; INTERACTS; FAMILY	Tumor necrosis factor receptor-1 (TNFR-1) and CD95 (also called Fas or APO-I) are cytokine receptors that engage the apoptosis pathway through a region of intracellular homology, designated the ''death domain.'' Another death domain-containing member of the TNFR family, death receptor 3 (DR3), was identified and was shown to induce both apoptosis and activation of nuclear factor kappa B. Expression of DR3 appears to be restricted to tissues enriched in lymphocytes. DR3 signal transduction is mediated by a complex of intracellular signaling molecules including TRADD, TRAF2, FADD, and FLICE. Thus, DR3 likely plays a role in regulating lymphocyte homeostasis.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; HUMAN GENOME SCI INC,ROCKVILLE,MD 20850; UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; GlaxoSmithKline; Human Genome Sciences Inc; University of Michigan System; University of Michigan			dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007863] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-07863] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MD, 1995, NATURE, V377, P3; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CHINNAIYAN AM, UNPUB; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GOLSTEIN P, 1995, CELL, V81, P185, DOI 10.1016/0092-8674(95)90327-5; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; ITOH N, 1993, J BIOL CHEM, V268, P10932; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8	31	514	589	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1996	274	5289					990	992		10.1126/science.274.5289.990	http://dx.doi.org/10.1126/science.274.5289.990			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR792	8875942				2022-12-24	WOS:A1996VR79200051
J	Farrens, DL; Altenbach, C; Yang, K; Hubbell, WL; Khorana, HG				Farrens, DL; Altenbach, C; Yang, K; Hubbell, WL; Khorana, HG			Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin	SCIENCE			English	Article							BOVINE RHODOPSIN; STRUCTURAL-CHANGES; AMINO-ACIDS; BACTERIORHODOPSIN; TRANSDUCIN; FLUORESCENCE; ARRANGEMENT; PHOTOCYCLE; MEMBRANE; RECEPTOR	Conformational changes are thought to underlie the activation of heterotrimeric GTP-binding protein (G protein)-coupled receptors. Such changes in rhodopsin were explored by construction of double cysteine mutants, each containing one cysteine at the cytoplasmic end of helix C and one cysteine at various positions in the cytoplasmic end of helix F. Magnetic dipolar interactions between spin labels attached to these residues revealed their proximity, and changes in their interaction upon rhodopsin light activation suggested a rigid body movement of helices relative to one another. Disulfide crosslinking of the helices prevented activation of transducin, which suggests the importance of this movement for activation of rhodopsin.	UNIV CALIF LOS ANGELES,JULES STEIN EYE INST,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,DEPT CHEM,LOS ANGELES,CA 90095; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; MIT,DEPT CHEM,CAMBRIDGE,MA 02139	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)					NEI NIH HHS [EY05216, EY06465] Funding Source: Medline; NIGMS NIH HHS [GM28289] Funding Source: Medline; NATIONAL EYE INSTITUTE [R37EY005216, R01EY005216, F32EY006465] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028289, R01GM028289] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; ALTENBACH C, IN PRESS BIOCHEMISTR; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BETH AH, 1984, J BIOL CHEM, V259, P9717; CAREAGA CL, 1992, J MOL BIOL, V226, P1219, DOI 10.1016/0022-2836(92)91063-U; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DRATZ EA, 1983, TRENDS BIOCHEM SCI, V8, P128, DOI 10.1016/0968-0004(83)90235-9; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7229, DOI 10.1021/bi00079a020; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; FARRENS DL, 1995, J BIOL CHEM, V270, P5073, DOI 10.1074/jbc.270.10.5073; FARRENS DL, UNPUB; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; Hubbell Wayne L., 1995, Biophysical Journal, V68, pA21; Kamikubo H, 1996, P NATL ACAD SCI USA, V93, P1386, DOI 10.1073/pnas.93.4.1386; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KOBASHI K, 1968, BIOCHIM BIOPHYS ACTA, V158, P239, DOI 10.1016/0304-4165(68)90136-0; NAKANISHI K, 1995, BIOPHYS CHEM, V56, P13, DOI 10.1016/0301-4622(95)00010-U; NAKAYAMA TA, 1990, J BIOL CHEM, V265, P15762; NAKAYAMA TA, 1991, J BIOL CHEM, V266, P4269; NAKAYAMA TA, 1989, THESIS MIT; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PAPPIN DJC, 1984, BIOCHEM J, V217, P605, DOI 10.1042/bj2170605; PHILLIPS WJ, 1988, J BIOL CHEM, V263, P15498; RABENSTEIN MD, 1995, P NATL ACAD SCI USA, V92, P8239, DOI 10.1073/pnas.92.18.8239; RESEK JF, 1993, BIOCHEMISTRY-US, V32, P12025, DOI 10.1021/bi00096a012; RIDGE KD, 1995, BIOCHEMISTRY-US, V34, P8804, DOI 10.1021/bi00027a032; SHEIKH S, IN PRESS NATURE; SHI W, 1995, J BIOL CHEM, V270, P2112, DOI 10.1074/jbc.270.5.2112; STEINHOFF HJ, 1994, SCIENCE, V266, P105, DOI 10.1126/science.7939627; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SUBRAMANIAM S, 1993, EMBO J, V12, P1; Thurmond Robin L., 1995, Biophysical Journal, V68, pA385; UNGER VM, 1995, BIOPHYS J, V68, P1776, DOI 10.1016/S0006-3495(95)80354-1; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; Yang K, 1996, BIOCHEMISTRY-US, V35, P12464, DOI 10.1021/bi960848t; YANG K, IN PRESS BIOCHEMISTR	38	1074	1090	2	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1996	274	5288					768	770		10.1126/science.274.5288.768	http://dx.doi.org/10.1126/science.274.5288.768			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ145	8864113				2022-12-24	WOS:A1996VQ14500038
J	Zhu, ZW; Thiele, DJ				Zhu, ZW; Thiele, DJ			A specialized nucleosome modulates transcription factor access to a C-glabrata metal responsive promoter	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; CHROMATIN STRUCTURE; MICROCOCCAL NUCLEASE; GENE-EXPRESSION; CORE PARTICLE; DNA; MECHANISM; ELEMENTS; OXYGEN; SITES	The ability of DNA binding transcription factors to access cis-acting promoter elements is critical for transcriptional responses. We demonstrate that rapid transcriptional autoactivation by the Amt1 Cu metalloregulatory transcription factor from the opportunistic pathogenic yeast Candida glabrata is dependent on rapid metal-induced DNA binding to a single metal response element (MRE). In vivo footprinting and chromatin-mapping experiments demonstrate that the MRE and a homopolymeric (dA . dT) element adjacent to the MRE are packaged into a positioned nucleosome that exhibits homopolymeric (dA . dT)-dependent localized distortion. This distortion is critical for rapid Amt1 binding to the MRE, for Cu-dependent AMT1 gene transcription, and for C. glabrata cells to mount a rapid transcriptional response to Cu for normal metal detoxification. The AMT1 promoter represents a novel class of specialized nucleosomal structures that links rapid transcriptional responses to the biology of metal homeostasis.			Zhu, ZW (corresponding author), UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041840, F32GM017067] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41840, F32 GM17067] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BERNARDI F, 1991, YEAST, V7, P547, DOI 10.1002/yea.320070603; COMPANY M, 1988, MOL CELL BIOL, V8, P2545, DOI 10.1128/MCB.8.6.2545; Dickerson RE, 1996, J MOL BIOL, V256, P108, DOI 10.1006/jmbi.1996.0071; FASCHER KD, 1990, EMBO J, V9, P2523, DOI 10.1002/j.1460-2075.1990.tb07432.x; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GANTER B, 1993, J MOL BIOL, V234, P975, DOI 10.1006/jmbi.1993.1652; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HAYES JJ, 1991, BIOCHEMISTRY-US, V30, P8434, DOI 10.1021/bi00098a022; HAYES JJ, 1992, BIOESSAYS, V14, P597, DOI 10.1002/bies.950140905; IYER V, 1995, EMBO J, V14, P2570, DOI 10.1002/j.1460-2075.1995.tb07255.x; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; Koch KA, 1996, MOL CELL BIOL, V16, P724; KORNBERG RD, 1995, CURR OPIN CELL BIOL, V7, P371, DOI 10.1016/0955-0674(95)80092-1; LEE HJ, 1995, J BIOL CHEM, V270, P17541, DOI 10.1074/jbc.270.29.17196; LEWIN B, 1994, CELL, V79, P397, DOI 10.1016/0092-8674(94)90249-6; LU Q, 1995, EMBO J, V14, P4738, DOI 10.1002/j.1460-2075.1995.tb00155.x; MCGHEE JD, 1983, CELL, V32, P1205, DOI 10.1016/0092-8674(83)90303-3; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; NOLL M, 1977, J MOL BIOL, V109, P393, DOI 10.1016/S0022-2836(77)80019-3; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PEREZORTIN JE, 1987, NUCLEIC ACIDS RES, V15, P6937; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; POLACH KJ, 1995, J MOL BIOL, V254, P130, DOI 10.1006/jmbi.1995.0606; PUHL HL, 1991, J MOL BIOL, V222, P1149, DOI 10.1016/0022-2836(91)90598-Z; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; SABOVA L, 1993, EUR J BIOCHEM, V213, P547, DOI 10.1111/j.1432-1033.1993.tb17793.x; SHOPLAND LS, 1995, GENE DEV, V9, P2756, DOI 10.1101/gad.9.22.2756; SIMPSON RT, 1983, P NATL ACAD SCI-BIOL, V80, P51, DOI 10.1073/pnas.80.1.51; STRAUSS EC, 1992, MOL CELL BIOL, V12, P2135, DOI 10.1128/MCB.12.5.2135; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; WALLRATH LL, 1994, BIOESSAYS, V16, P165, DOI 10.1002/bies.950160306; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cb.11.110195.002301; ZHOU PB, 1993, GENE DEV, V7, P1824, DOI 10.1101/gad.7.9.1824; ZHOU PB, 1992, MOL CELL BIOL, V12, P3766, DOI 10.1128/MCB.12.9.3766; ZHU ZW, 1995, GENETIC RESPONSE TO METALS, P379; ZITOMER RS, 1992, MICROBIOL REV, V56, P1	46	83	84	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 1	1996	87	3					459	470		10.1016/S0092-8674(00)81366-5	http://dx.doi.org/10.1016/S0092-8674(00)81366-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VQ466	8898199	Bronze			2022-12-24	WOS:A1996VQ46600012
J	Love, SM; Barsky, SH				Love, SM; Barsky, SH			Breast-duct endoscopy to study stages of cancerous breast disease	LANCET			English	Article							NIPPLE DISCHARGE	Background In breast-cancer research, we lack reproducible non-invasive access to breast tissue. Breast cancer is thought to start in the lining of the milk duct or lobule. We have had no direct access to this area other than in tissue removed surgically or by fine-needle aspiration. Our objective was to explore an intraductal approach to studying breast cancer and precancerous changes by duct cannulation and endoscopy. Methods In this pilot study, women in a university hospital were asked to participate. Nine patients with previously diagnosed ductal carcinoma-in-situ (DCIS) or invasive breast cancer who were about to undergo mastectomy under general anaesthesia agreed. After the patient was asleep but before the operation, we spent 15 minutes cannulating their ducts, obtaining washings, and attempting endoscopy. The ducts that had been cannulated were marked by instillation of dye or other materials, the nipple was sutured shut, and the mastectomy proceeded as planned. The mastectomy specimen underwent extensive histopathological examination. Findings We were successful in intraductal cannulation and endoscopy in seven of the nine patients, In five of the nine, we obtained epithelial cells in the washings. In one the cells were consistent with proliferative disease, in three there was atypical epithelium, and in one there was frank DCIS. With several different contrast materials injected into separate duct orifices, DCIS was confined to a single duct system. Interpretation We found that the intraductal approach is feasible for the study of the early changes of breast cancer. Technical difficulties include identification of the breast-duct orifices, determining the distensibility of the duct, and developing a reliable technique to obtain washings.	UNIV CALIF LOS ANGELES,DEPT SURG,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT PATHOL & LAB MED,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NCI NIH HHS [CA01351, CA40225] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040225] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		FABIAN C, 1993, P AM ASSOC CANC RES, V34, pA1556; LVOE SM, 1992, 15 ANN SAN ANT BREAS; MAKITA M, 1991, BREAST CANCER RES TR, V18, P179, DOI 10.1007/BF01990034; OHTAKE T, 1995, CANCER, V76, P32, DOI 10.1002/1097-0142(19950701)76:1<32::AID-CNCR2820760106>3.0.CO;2-R; OKAZAKI A, 1991, JPN J CLIN ONCOL, V21, P188; Sartorius OW, 1977, BREAST CARCINOMA, P281; WRENSCH MR, 1991, AM J EPIDEMIOL, V135, P130	7	67	90	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 12	1996	348	9033					997	999		10.1016/S0140-6736(96)04145-1	http://dx.doi.org/10.1016/S0140-6736(96)04145-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM027	8855857				2022-12-24	WOS:A1996VM02700013
J	Smith, GD; Phillips, AN				Smith, GD; Phillips, AN			Passive smoking and health: Should we believe Philip Morris's ''experts''?	BRITISH MEDICAL JOURNAL			English	Article							ENVIRONMENTAL TOBACCO-SMOKE; LUNG-CANCER; CORRELATED EXPOSURES; CIGARETTE-SMOKE; RISK; EPIDEMIOLOGY; INHALATION; BIAS		UNIV LONDON,ROYAL FREE HOSP,SCH MED,DEPT PRIMARY CARE & POPULAT SCI,LONDON NW3 2PF,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Smith, GD (corresponding author), UNIV BRISTOL,DEPT SOCIAL MED,BRISTOL BS8 2PR,AVON,ENGLAND.		Phillips, Andrew N/B-4427-2008; Davey Smith, George/A-7407-2013	Phillips, Andrew N/0000-0003-2384-4807; Davey Smith, George/0000-0002-1407-8314				BERO LA, 1994, JAMA-J AM MED ASSOC, V272, P133, DOI 10.1001/jama.272.2.133; Blair PS, 1996, BRIT MED J, V313, P195, DOI 10.1136/bmj.313.7051.195; Boffetta P, 1996, LANCET, V348, P410, DOI 10.1016/S0140-6736(05)65031-3; BORLAND R, 1990, AM J PUBLIC HEALTH, V80, P178, DOI 10.2105/AJPH.80.2.178; CHAPMAN S, 1990, INT J HLTH SERV, V20, P117; Charlton A, 1996, BRIT MED BULL, V52, P90, DOI 10.1093/oxfordjournals.bmb.a011535; Ciruzzi M., 1996, European Heart Journal, V17, P309; COOPER G, 1996, INDEPENDENT     0828, P3; EGGER M, 1995, BMJ-BRIT MED J, V310, P752, DOI 10.1136/bmj.310.6982.752; *EUR WORK GRP, 1996, ENV TOB SMOK LUNG CA; FRANKEL S, 1991, BRIT J GEN PRACT, V41, P428; Glantz S.A., 1996, CIGARETTE PAPERS; GLANTZ SA, 1995, JAMA-J AM MED ASSOC, V273, P1047, DOI 10.1001/jama.273.13.1047; HECHT SS, 1993, NEW ENGL J MED, V329, P1543, DOI 10.1056/NEJM199311183292105; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; HOLE DJ, 1989, BRIT MED J, V299, P423, DOI 10.1136/bmj.299.6696.423; Howard G, 1996, BRIT MED BULL, V52, P143, DOI 10.1093/oxfordjournals.bmb.a011522; KULLER LH, 1991, PREV MED, V20, P638, DOI 10.1016/0091-7435(91)90060-H; Law MR, 1996, BRIT MED BULL, V52, P22, DOI 10.1093/oxfordjournals.bmb.a011528; Lee PN, 1996, STAT MED, V15, P581, DOI 10.1002/(SICI)1097-0258(19960330)15:6<581::AID-SIM182>3.0.CO;2-B; LEE PN, 1995, INT ARCH OCC ENV HEA, V67, P287, DOI 10.1007/BF00385642; LEE PN, 1987, HUM TOXICOL, V6, P517, DOI 10.1177/096032718700600612; LEE PN, 1992, ENV TOBACCO SMOKE MO; LEMARCHAND L, 1991, CANCER CAUSE CONTROL, V2, P11, DOI 10.1007/BF00052356; *OFF HLTH ENV ASS, 1992, RESP HLTH EFF PASS S; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; PENN A, 1993, CIRCULATION, V88, P1820, DOI 10.1161/01.CIR.88.4.1820; PENN A, 1994, CIRCULATION, V90, P1363, DOI 10.1161/01.CIR.90.3.1363; PHILLIPS AN, 1992, STAT MED, V11, P953, DOI 10.1002/sim.4780110712; PHILLIPS AN, 1991, J CLIN EPIDEMIOL, V44, P1223, DOI 10.1016/0895-4356(91)90155-3; Proctor RN, 1995, CANC WARS POLITICS S; RICHMOND C, 1996, OBSERVER        0818, P2; SMITH GD, 1992, BRIT MED J, V305, P757, DOI 10.1136/bmj.305.6856.757; Smith GD, 1996, BMJ-BRIT MED J, V312, P1659, DOI 10.1136/bmj.312.7047.1659; SMITH GD, 1992, LANCET, V340, P709; Smith GD, 1996, BRIT MED J, V312, P1479, DOI 10.1136/bmj.312.7044.1479c; STRACHAN DP, 1989, BRIT MED J, V298, P1549, DOI 10.1136/bmj.298.6687.1549; TRICHOPOULOS D, 1992, JAMA-J AM MED ASSOC, V268, P1697, DOI 10.1001/jama.268.13.1697; WOLFF S, 1989, SCIENCE, V245, P575, DOI 10.1126/science.2762808; WOLFF S, 1989, SCIENCE, V245, P621; 1994, NEW ENGL J MED, V330, P1029	41	26	26	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 12	1996	313	7062					929	933						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM754	8876102				2022-12-24	WOS:A1996VM75400034
J	Dikic, I; Tokiwa, G; Lev, S; Courtneidge, SA; Schlessinger, J				Dikic, I; Tokiwa, G; Lev, S; Courtneidge, SA; Schlessinger, J			A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP kinase activation	NATURE			English	Article							TYROSINE-KINASE; SIGNALING PATHWAY; BINDING; DOMAIN	THE mechanisms by which mitogenic G-protein-coupled receptors activate the MAP kinase signalling pathway are poorly understood. Candidate protein tyrosine kinases that link G-protein-coupled receptors with MAP kinase include Src family kinases(1), the epidermal growth factor receptor(2), Lyn and Syk(3). Here we show that lysophosphatidic acid (LPA) and bradykinin induce tyrosine phosphorylation of Pyk2 and complex formation between Pyk2 and activated Src. Moreover, tyrosine phosphorylation of Pyk2 Leads to binding of the SH2 domain of Src to tyrosine 402 of Pyk2 and activation of Src. Transient overexpression of a dominant interfering mutant of Pyk2 or the protein tyrosine kinase Csk reduces LPA- or bradykinin-induced activation of MAP kinase. LPA- or bradykinin-induced MAP kinase activation was also inhibited by overexpression of dominant interfering mutants of Grb2 and Sos. We propose that Pyk2 acts with Src to link G(i)- and G(q)-coupled receptors with Grb2 and Sos to activate the MAP kinase signalling pathway in PC12 cells.	NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016; SUGEN INC,REDWOOD CITY,CA 94063	New York University			Dikic, Ivan/O-4650-2015; Lev, Sima/AAP-7880-2020	Dikic, Ivan/0000-0001-8156-9511; Lev, Sima/0000-0002-2108-3330				Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CHEN YH, 1994, J BIOL CHEM, V269, P27372; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; GISHIZKY ML, 1995, P NATL ACAD SCI USA, V92, P10889, DOI 10.1073/pnas.92.24.10889; JALINK K, 1993, CELL GROWTH DIFFER, V4, P247; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LIU XQ, 1993, ONCOGENE, V8, P1119; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; Simonson MS, 1996, J BIOL CHEM, V271, P77, DOI 10.1074/jbc.271.1.77; SONGYANG Z, 1993, CELL, V72, P76; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Xie YM, 1995, J BIOL CHEM, V270, P30717, DOI 10.1074/jbc.270.51.30717	18	868	891	0	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1996	383	6600					547	550		10.1038/383547a0	http://dx.doi.org/10.1038/383547a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL755	8849729				2022-12-24	WOS:A1996VL75500056
J	Wilcox, MH				Wilcox, MH			Cleaning up Clostridium difficile infection	LANCET			English	Editorial Material							DIARRHEA		GEN INFIRM,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND	Leeds General Infirmary	Wilcox, MH (corresponding author), UNIV LEEDS,DEPT MICROBIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND.							ANAND A, 1994, AM J GASTROENTEROL, V89, P519; BORRIELLO SP, 1986, J MED MICROBIOL, V21, P299, DOI 10.1099/00222615-21-4-299; *DEP HLTH PUBL HLT, 1994, CLOSTR DIFF INF PREV; Djuretic T, 1996, Commun Dis Rep CDR Rev, V6, pR107; IMPALLOMENI M, 1995, BRIT MED J, V311, P1345, DOI 10.1136/bmj.311.7016.1345; MCFARLAND LV, 1989, NEW ENGL J MED, V320, P204, DOI 10.1056/NEJM198901263200402; PALLARES R, 1993, INFECT CONT HOSP EP, V14, P376, DOI 10.2307/30148319; *PARL OFF SCI TECH, 1994, DIS FIGHT BACK; Samore MH, 1996, AM J MED, V100, P32, DOI 10.1016/S0002-9343(96)90008-X; Wilcox MH, 1996, J HOSP INFECT, V34, P23, DOI 10.1016/S0195-6701(96)90122-X	10	42	43	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 21	1996	348	9030					767	768		10.1016/S0140-6736(05)65204-X	http://dx.doi.org/10.1016/S0140-6736(05)65204-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH989	8813978				2022-12-24	WOS:A1996VH98900004
J	Posas, F; WurglerMurphy, SM; Maeda, T; Witten, EA; Thai, TC; Saito, H				Posas, F; WurglerMurphy, SM; Maeda, T; Witten, EA; Thai, TC; Saito, H			Yeast HOG1 MAP kinase cascade is regulated by a multistep phosphorelay mechanism in the SLN1-YPD1-SSK1 ''two-component'' osmosensor	CELL			English	Article							SIGNAL-TRANSDUCTION PATHWAY; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; 2-COMPONENT REGULATORS; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; BACTERIAL CHEMOTAXIS; RESPONSE PATHWAY; MAMMALIAN-CELLS; GENE	An osmosensing mechanism in the budding yeast (Saccharomyces cerevisiae) involves both a two-component signal transducer (Sln1p, Ypd1p and Ssk1p) and a MAP kinase cascade (Ssk2p/Ssk22p, Pbs2p, and Hog1p). The transmembrane protein Sln1p contains an extracellular sensor domain and cytoplasmic histidine kinase and receiver domains, whereas the cytoplasmic protein Ssk1p contains a receiver domain. Ypd1p binds to both Sln1p and Ssk1p and mediates the multistep phosphotransfer reaction (phosphorelay). This phosphorelay system is initiated by the autophosphorylation of Sln1p at His576. This phosphate is then sequentially transferred to Sln1p-Asp1144, then to Ypd1p-His64, and finally to Ssk1p-Asp554. We propose that the multistep phosphorelay mechanism is a universal signal transduction apparatus utilized both in prokaryotes and eukaryotes.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOL PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	Posas, F (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV TUMOR IMMUNOL, 44 BINNEY ST, BOSTON, MA 02115 USA.		Saito, Haruo/AAF-6113-2019; Posas, Francesc/K-1364-2013	Saito, Haruo/0000-0001-7891-1689; Posas, Francesc/0000-0002-4164-7076	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050909, F32GM016154] Funding Source: NIH RePORTER; NIGMS NIH HHS [F32 GM16154, R01 GM50909] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; Alex LA, 1996, P NATL ACAD SCI USA, V93, P3416, DOI 10.1073/pnas.93.8.3416; BOGUSLAWSKI G, 1992, J GEN MICROBIOL, V138, P2425, DOI 10.1099/00221287-138-11-2425; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; BROWN JL, 1993, J BACTERIOL, V175, P6908, DOI 10.1128/jb.175.21.6908-6915.1993; BROWN JL, 1994, EMBO J, V13, P5186, DOI 10.1002/j.1460-2075.1994.tb06849.x; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FUJITAKI JM, 1984, METHOD ENZYMOL, V107, P23; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GEGNER JA, 1991, P NATL ACAD SCI USA, V88, P750, DOI 10.1073/pnas.88.3.750; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HARPER JW, 1993, CELL, V75, P805; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HIRAYAMA T, 1995, MOL GEN GENET, V249, P127, DOI 10.1007/BF00290358; HUA J, 1995, SCIENCE, V269, P1712, DOI 10.1126/science.7569898; IGO MM, 1989, GENE DEV, V3, P1725, DOI 10.1101/gad.3.11.1725; ISHIGE K, 1994, EMBO J, V13, P5195, DOI 10.1002/j.1460-2075.1994.tb06850.x; IUCHI S, 1993, J BIOL CHEM, V268, P23972; KEENER J, 1988, P NATL ACAD SCI USA, V85, P4976, DOI 10.1073/pnas.85.14.4976; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KIM YH, 1993, J BIOL CHEM, V268, P18513; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; MAEDA T, 1993, MOL CELL BIOL, V13, P5408, DOI 10.1128/MCB.13.9.5408; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; MAGER WH, 1993, MOL MICROBIOL, V10, P253, DOI 10.1111/j.1365-2958.1993.tb01951.x; MORGAN BA, 1995, EMBO J, V14, P5679, DOI 10.1002/j.1460-2075.1995.tb00255.x; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; NINFA EG, 1993, J BACTERIOL, V175, P7024, DOI 10.1128/jb.175.21.7024-7032.1993; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PEREGO M, 1994, CELL, V79, P1047, DOI 10.1016/0092-8674(94)90035-3; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; SIKORSKI RS, 1989, GENETICS, V122, P19; STOCK JB, 1991, ANNU REV BIOPHYS BIO, V20, P109, DOI 10.1146/annurev.bb.20.060191.000545; TRACH KA, 1993, MOL MICROBIOL, V8, P69, DOI 10.1111/j.1365-2958.1993.tb01204.x; Tsuzuki M, 1995, MOL MICROBIOL, V18, P953, DOI 10.1111/j.1365-2958.1995.18050953.x; Uhl MA, 1996, EMBO J, V15, P1028, DOI 10.1002/j.1460-2075.1996.tb00440.x; VARELA JCS, 1995, MOL CELL BIOL, V15, P6232; WANNER BL, 1992, J BACTERIOL, V174, P2053, DOI 10.1128/JB.174.7.2053-2058.1992; WARNER JR, 1991, METHOD ENZYMOL, V194, P423; WILKINSON JQ, 1995, SCIENCE, V270, P1807, DOI 10.1126/science.270.5243.1807; YANG Y, 1991, P NATL ACAD SCI USA, V88, P11057, DOI 10.1073/pnas.88.24.11057; YOCUM RR, 1984, MOL CELL BIOL, V4, P1985, DOI 10.1128/MCB.4.10.1985; [No title captured]	52	725	757	0	37	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	1996	86	6					865	875		10.1016/S0092-8674(00)80162-2	http://dx.doi.org/10.1016/S0092-8674(00)80162-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VJ443	8808622	Bronze			2022-12-24	WOS:A1996VJ44300005
J	Tamura, T; Tamura, N; Cejka, Z; Hegerl, R; Lottspeich, F; Baumeister, W				Tamura, T; Tamura, N; Cejka, Z; Hegerl, R; Lottspeich, F; Baumeister, W			Tricorn protease - The core of a modular proteolytic system	SCIENCE			English	Article							MULTICATALYTIC PROTEINASE; THERMOPLASMA-ACIDOPHILUM; PROJECTION DIRECTIONS; CRYSTAL-STRUCTURE; 20S PROTEASOME; RNA-POLYMERASE; EXPRESSION; GENES; ARCHAEBACTERIA; COMPLEX	Large macromolecular assemblies have evolved as a means of compartmentalizing reactions in organisms lacking membrane-bounded compartments. A tricorn-shaped protease was isolated from the archaeon Thermoplasma and was shown to form a multisubunit proteolytic complex. The 120-kilodalton monomer assembled to form a hexameric toroid that could assemble further into a capsid structure. Tricorn protease appeared to act as the core of a proteolytic system; when it interacted with several smaller proteins, it displayed multicatalytic activities.	MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY	Max Planck Society			Tamura, Tomohiro/M-4732-2018	Tamura, Tomohiro/0000-0003-2409-6556				ALFANDARI D, 1994, PCR METH APPL, V4, P46; BAUMEISTER W, 1988, FEBS LETT, V241, P239, DOI 10.1016/0014-5793(88)81069-X; BRINKMANN U, 1989, GENE, V85, P109, DOI 10.1016/0378-1119(89)90470-8; CHRISTIANSEN C, 1975, INT J SYST BACTERIOL, V25, P99, DOI 10.1099/00207713-25-2-99; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; FARROW NA, 1992, J OPT SOC AM A, V9, P1749, DOI 10.1364/JOSAA.9.001749; Jentsch S, 1996, SCIENCE, V271, P955, DOI 10.1126/science.271.5251.955; JOSHUATOR L, 1995, SCIENCE, V269, P945, DOI 10.1126/science.7638617; KEILER KC, 1995, J BIOL CHEM, V270, P28864, DOI 10.1074/jbc.270.48.28864; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; LIOU GIH, 1991, PROG CLIN BIOL RES, V362, P115; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUPAS A, 1993, ENZYME PROTEIN, V47, P252, DOI 10.1159/000468684; LUPAS A, 1994, TRENDS BIOCHEM SCI, V19, P533, DOI 10.1016/0968-0004(94)90054-X; MAUPINFURLOW JA, 1995, J BIOL CHEM, V270, P28617, DOI 10.1074/jbc.270.48.28617; Ochman H., 1990, PCR PROTOCOLS GUIDE, P219; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; PUHLER G, 1992, EMBO J, V11, P1607, DOI 10.1002/j.1460-2075.1992.tb05206.x; RIVETT AJ, 1993, BIOCHEM J, V291, P1; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAMURA T, 1995, CURR BIOL, V5, P766, DOI 10.1016/S0960-9822(95)00153-9; TAMURA T, IN PRESS FEBS LETT; TAMURA T, UNPUB; TANAKA K, 1992, NEW BIOL, V4, P173; VANHEEL M, 1987, ULTRAMICROSCOPY, V21, P111, DOI 10.1016/0304-3991(87)90078-7; WENZEL T, 1995, NAT STRUCT BIOL, V2, P199, DOI 10.1038/nsb0395-199; ZILLIG W, 1988, EUR J BIOCHEM, V173, P473, DOI 10.1111/j.1432-1033.1988.tb14023.x	31	92	94	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 22	1996	274	5291					1385	1389		10.1126/science.274.5291.1385	http://dx.doi.org/10.1126/science.274.5291.1385			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU954	8910281				2022-12-24	WOS:A1996VU95400057
J	Sabatini, BL; Regehr, WG				Sabatini, BL; Regehr, WG			Timing of neurotransmission at fast synapses in the mammalian brain	NATURE			English	Article							SQUID GIANT SYNAPSE; PRESYNAPTIC TERMINALS; CALCIUM TRANSIENTS; SENSORY NEURONS; PARALLEL FIBERS; TRANSMISSION; CURRENTS; FURA-2; RAT; EXOCYTOSIS	UNDERSTANDING the factors controlling synaptic delays has broad implications. On a systems level, the speed of synaptic transmission limits the communication rate between neurons and strongly influences local circuit dynamics(1,2). On a molecular level, the delay from presynaptic calcium entry to postsynaptic responses constrains the molecular mechanism of vesicle fusion(3). Previously it has not been possible to elucidate the determinants of synaptic delays in the mammalian central nervous system, where presynaptic terminals are small and difficult to study. We have developed a new approach to study timing at rat cerebellar synapses: we used optical techniques to measure voltage and calcium current simultaneously from presynaptic boutons while monitoring postsynaptic currents electrically(4-6). Here we report that the classic view that vesicle release is driven by calcium entry during action-potential repolarization(7) holds for these synapses at room temperature, but not at physiological temperatures, where postsynaptic responses commence just 150 mu s after the start of the presynaptic action potential. This brisk communication is a consequence of rapid calcium channel kinetics, which allow significant calcium entry during the upstroke of the presynaptic action potential, and extremely fast calcium-driven vesicle fusion, which lags behind calcium influx by 60 mu s.	HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School								APPENTENG K, 1989, J PHYSIOL-LONDON, V417, P91, DOI 10.1113/jphysiol.1989.sp017792; Atluri PP, 1996, J NEUROSCI, V16, P5661; AUGUSTINE GJ, 1985, J PHYSIOL-LONDON, V367, P163, DOI 10.1113/jphysiol.1985.sp015819; BARBOUR B, 1994, NEURON, V12, P1331, DOI 10.1016/0896-6273(94)90448-0; DELBONO O, 1993, J PHYSIOL-LONDON, V463, P689, DOI 10.1113/jphysiol.1993.sp019617; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; HODGKIN AL, 1949, J PHYSIOL-LONDON, V109, P240, DOI 10.1113/jphysiol.1949.sp004388; HOPFIELD JJ, 1995, NATURE, V376, P33, DOI 10.1038/376033a0; Kandel E.R., 1991, PRINC NEUROSCI; KAO JPY, 1988, BIOPHYS J, V53, P635, DOI 10.1016/S0006-3495(88)83142-4; KOCSIS JD, 1983, J PHYSIOL-LONDON, V334, P225, DOI 10.1113/jphysiol.1983.sp014491; KONNERTH A, 1987, J PHYSIOL-LONDON, V393, P681, DOI 10.1113/jphysiol.1987.sp016848; LLINAS R, 1982, P NATL ACAD SCI-BIOL, V79, P2415, DOI 10.1073/pnas.79.7.2415; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; LOEW LM, 1985, BIOPHYS J, V47, P71, DOI 10.1016/S0006-3495(85)83878-9; MCALLISTERWILLIAMS RH, 1995, NEUROPHARMACOLOGY, V34, P1479, DOI 10.1016/0028-3908(95)00130-X; NEHER E, 1995, NEUROPHARMACOLOGY, V34, P1423, DOI 10.1016/0028-3908(95)00144-U; NOBILE M, 1990, PFLUG ARCH EUR J PHY, V415, P658, DOI 10.1007/BF02584002; OERTEL D, 1983, J NEUROSCI, V3, P2043; Palay S. L., 1974, CEREBELLAR CORTEX CY; PFRIEGER FW, 1992, J NEUROSCI, V12, P4347; REGEHR WG, 1991, J NEUROSCI METH, V37, P111, DOI 10.1016/0165-0270(91)90121-F; REGEHR WG, 1995, BIOPHYS J, V68, P2156, DOI 10.1016/S0006-3495(95)80398-X; SABATINI BL, 1995, NEUROPHARMACOLOGY, V34, P1453, DOI 10.1016/0028-3908(95)00129-T; SCHWEIZER FE, 1995, NEURON, V14, P689, DOI 10.1016/0896-6273(95)90213-9; Stratford KJ, 1996, NATURE, V382, P258, DOI 10.1038/382258a0; TAYLOR WR, 1988, J PHYSIOL-LONDON, V407, P405, DOI 10.1113/jphysiol.1988.sp017423; Wheeler DB, 1996, J NEUROSCI, V16, P2226; Zhao MD, 1996, BIOPHYS J, V70, P896, DOI 10.1016/S0006-3495(96)79633-9	30	289	297	0	24	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 14	1996	384	6605					170	172		10.1038/384170a0	http://dx.doi.org/10.1038/384170a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT336	8906792				2022-12-24	WOS:A1996VT33600066
J	Lindberg, FP; Bullard, DC; Caver, TE; Gresham, HD; Beaudet, AL; Brown, EJ				Lindberg, FP; Bullard, DC; Caver, TE; Gresham, HD; Beaudet, AL; Brown, EJ			Decreased resistance to bacterial infection and granulocyte defects in IAP-deficient mice	SCIENCE			English	Article							INTEGRIN-ASSOCIATED PROTEIN; CHRONIC GRANULOMATOUS-DISEASE; LEUKOCYTE RESPONSE INTEGRIN; GROWTH-FACTOR-BETA; LIGAND-BINDING; NEUTROPHILS; MODEL; CD47; PROTOONCOGENE; PHAGOCYTOSIS	Granulocyte [polymorphonuclear leucocyte (PMN)] migration to sites of infection and subsequent activation is essential for host defense. Gene-targeted mice deficient for integrin-associated protein (IAP, also termed CD47) succumbed to Escherichia coli peritonitis at inoccula survived by heterozygous littermates. In vivo, they had an early defect in PMN accumulation at the site of infection. In vitro, IAP(-/-) PMNs were deficient in beta(3) integrin-dependent ligand binding, activation oi an oxidative burst, and Fc receptor-mediated phagocytosis. Thus, IAP plays a key role in host defense by participating both in PMN migration in response to bacterial infection and in PMN activation at extravascular sites.	WASHINGTON UNIV, SCH MED, DEPT MOL MICROBIOL, ST LOUIS, MO 63110 USA; BAYLOR COLL MED, DEPT MOL & HUMAN GENET, HOUSTON, TX 77030 USA; UNIV MISSOURI, SCH MED, DEPT MOL MICROBIOL & IMMUNOL, COLUMBIA, MO 65212 USA; HARRY S TRUMAN VET AFFAIRS MED CTR, RES SERV, COLUMBIA, MO 65201 USA; BAYLOR COLL MED, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA	Washington University (WUSTL); Baylor College of Medicine; University of Missouri System; University of Missouri Columbia; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harry S. Truman Memorial Veterans' Hospital; Baylor College of Medicine; Howard Hughes Medical Institute	Lindberg, FP (corresponding author), WASHINGTON UNIV, SCH MED, DEPT INFECT DIS, ST LOUIS, MO 63110 USA.				NIAID NIH HHS [AI32177] Funding Source: Medline; NIGMS NIH HHS [GM38330, GM15483] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032177, R37AI032177] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038330] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; BROWN EJ, 1993, BLOOD CELL BIOCH, V5, P279; BULLARD DC, 1995, J CLIN INVEST, V95, P1782, DOI 10.1172/JCI117856; COOPER D, 1995, P NATL ACAD SCI USA, V92, P3978, DOI 10.1073/pnas.92.9.3978; CROSS AS, 1989, J EXP MED, V169, P2021, DOI 10.1084/jem.169.6.2021; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; GRESHAM HD, 1992, J BIOL CHEM, V267, P13895; GRESHAM HD, 1991, J IMMUNOL, V146, P3911; GRESHAM HD, 1991, J CLIN INVEST, V88, P588, DOI 10.1172/JCI115343; GRESHAM HD, 1989, J CELL BIOL, V108, P1935, DOI 10.1083/jcb.108.5.1935; GRIFFIN JA, 1979, J EXP MED, V150, P653, DOI 10.1084/jem.150.3.653; JACKSON SH, 1995, J EXP MED, V182, P751, DOI 10.1084/jem.182.3.751; KUEHN MR, 1987, NATURE, V326, P295, DOI 10.1038/326295a0; LINDBERG FP, 1994, J BIOL CHEM, V269, P1567; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; LINDBERG FP, UNPUB; LOWRANCE JH, 1994, J EXP MED, V180, P1693, DOI 10.1084/jem.180.5.1693; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; Parkos CA, 1996, J CELL BIOL, V132, P437, DOI 10.1083/jcb.132.3.437; POLLOCK JD, 1995, NAT GENET, V9, P202, DOI 10.1038/ng0295-202; REINHOLD MI, 1995, J CELL SCI, V108, P3419; SARMAN G, 1995, J INFECT DIS, V172, P1001, DOI 10.1093/infdis/172.4.1001; SLIGH JE, 1993, P NATL ACAD SCI USA, V90, P8529, DOI 10.1073/pnas.90.18.8529; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; ZHOU MJ, 1993, J EXP MED, V178, P1165, DOI 10.1084/jem.178.4.1165	27	289	304	2	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 1	1996	274	5288					795	798		10.1126/science.274.5288.795	http://dx.doi.org/10.1126/science.274.5288.795			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ145	8864123				2022-12-24	WOS:A1996VQ14500048
J	Wang, CY; Mayo, MW; Baldwin, AS				Wang, CY; Mayo, MW; Baldwin, AS			TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-kappa B	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; UBIQUITIN-PROTEASOME PATHWAY; GLUCOCORTICOID RECEPTOR; ALPHA PROTEOLYSIS; ACTIVATION; PHOSPHORYLATION; RADIATION; MECHANISM; CERAMIDE; CELLS	Many cells are resistant to stimuli that can induce apoptosis, but the mechanisms involved are not fully understood. The activation of the transcription factor nuclear factor-kappa B (NF-kappa B) by tumor necrosis factor (TNF), ionizing radiation, or daunorubicin (a cancer chemotherapeutic compound), was found to protect from cell killing. Inhibition of NF-kappa B nuclear translocation enhanced apoptotic killing by these reagents but not by apoptotic stimuli that do not activate NF-kappa B. These results provide a mechanism of cellular resistance to killing by some apoptotic reagents, offer insight into a new role for NF-kappa B, and have potential for improvement of the efficacy of cancer therapies.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CURRICULUM GENET & MOL BIOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH DENT,DEPT ENDODONT,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL CANCER INSTITUTE [F32CA069790] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035098, R37AI035098] Funding Source: NIH RePORTER; NCI NIH HHS [1F32-CA69790-01] Funding Source: Medline; NIAID NIH HHS [AI35098] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BESSHO R, 1994, BIOCHEM PHARMACOL, V48, P1883, DOI 10.1016/0006-2952(94)90586-X; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; DEVITA VT, 1987, CANCER RES, V47, P5810; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRIMM S, 1996, J CELL BIOL, V134, P1; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HOLTMANN H, 1988, IMMUNOBIOLOGY, V177, P7, DOI 10.1016/S0171-2985(88)80087-1; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SCHARTZMAN RA, 1993, ENDOCR REV, V14, P133; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SINGH SP, 1990, MOL CELL BIOL, V10, P5279, DOI 10.1128/MCB.10.10.5279; SLATER A, 1995, BIOCHEM J, V312, P844; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang C.-W., UNPUB; WU M, 1996, EMBO J, V15, P4662	49	2434	2554	2	121	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1996	274	5288					784	787		10.1126/science.274.5288.784	http://dx.doi.org/10.1126/science.274.5288.784			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ145	8864119	Green Submitted			2022-12-24	WOS:A1996VQ14500044
J	Duff, K; Eckman, C; Zehr, C; Yu, X; Prada, CM; Pereztur, J; Hutton, M; Buee, L; Harigaya, Y; Yager, D; Morgan, D; Gordon, MN; Holcomb, L; Refolo, L; Zenk, B; Hardy, J; Younkin, S				Duff, K; Eckman, C; Zehr, C; Yu, X; Prada, CM; Pereztur, J; Hutton, M; Buee, L; Harigaya, Y; Yager, D; Morgan, D; Gordon, MN; Holcomb, L; Refolo, L; Zenk, B; Hardy, J; Younkin, S			Increased amyloid-beta 42(43) in brains of mice expressing mutant presenilin 1	NATURE			English	Article							FAMILIAL ALZHEIMERS-DISEASE; AMYLOID PRECURSOR PROTEIN; MISSENSE MUTATIONS; TRANSGENIC MICE; A-BETA; GENE; A-BETA-42(43)	MUTATIONS in the genes encoding amyloid-beta precursor protein (APP)(1), presenilin 1 (PS1)(2) and presenilin 2 (PS2)(3,4) are known to cause early-onset, autosomal dominant Alzheimer's disease. Studies of plasma and fibroblasts from subjects with these mutations have established that they all alter amyloid beta-protein (beta APP) processing, which normally leads to the secretion of amyloid-beta protein (relative molecular mass 4,000; M(r) 4K; similar to 90% A beta 1-40, similar to 10% A beta 1-42(43)), so that the extracellular concentration of A beta 42(43) is increased(5). This increase in A beta 42(43) is believed to be the critical change that initiates Alzheimer's disease pathogenesis because A beta 42(43) is deposited early and selectively in the senile plaques that are observed in the brains of patients with all forms of the disease. To establish that the presenilin mutations increase the amount of A beta 42(43) in the brain and to test whether presenilin mutations act as true (gain of function) dominants, we have now constructed mice expressing wild-type and mutant presenilin genes. Analysis of these mice showed that overexpression of mutant, but not wild-type, PS1 selectively increases brain A beta 42(43). These results indicate that the presenilin mutations probably cause Alzheimer's disease through a gain of deleterious function that increases the amount of A beta 42(43) in the brain.	MAYO CLIN JACKSONVILLE,JACKSONVILLE,FL 32224; UNIV S FLORIDA,SUNCOAST ALZHEIMERS DIS LABS,TAMPA,FL 33612; INSERM,U422,F-50945 LILLE,FRANCE; UNIV S FLORIDA,ALZHEIMERS RES LAB,DEPT PHARMACOL,TAMPA,FL 33613	Mayo Clinic; State University System of Florida; University of South Florida; Institut National de la Sante et de la Recherche Medicale (Inserm); State University System of Florida; University of South Florida			Morgan, David G/J-5989-2012; Hardy, John/C-2451-2009; BUEE, Luc/B-3126-2010; Perez-Tur, Jordi/A-2143-2010; Gordon, Marcia N. N/K-2420-2012	Hardy, John/0000-0002-3122-0423; BUEE, Luc/0000-0002-6261-4230; Perez-Tur, Jordi/0000-0002-9111-1712; Gordon, Marcia N. N/0000-0002-4051-9283; Duff, Karen/0000-0002-6177-868X				BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; HALTIA M, 1994, ANN NEUROL, V36, P362, DOI 10.1002/ana.410360307; HSIAO K, IN PRESS SCIENCE; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LHERNAULT SW, 1992, J CELL BIOL, V119, P55, DOI 10.1083/jcb.119.1.55; ODAKA N, 1995, BIOCHEMISTRY-US, V34, P10272; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; SASAHARA M, 1991, CELL, V64, P217, DOI 10.1016/0092-8674(91)90223-L; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SUZUKI N, 1994, AM J PATHOL, V145, P452; SUZUKI N, 1994, SCIENCE, V264, P1335; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; XU HX, 1995, J BIOL CHEM, V270, P23243, DOI 10.1074/jbc.270.40.23243; 1995, NAT GENET, V11, P219	21	1282	1358	0	51	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 24	1996	383	6602					710	713		10.1038/383710a0	http://dx.doi.org/10.1038/383710a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN918	8878479				2022-12-24	WOS:A1996VN91800051
J	Grines, CL				Grines, CL			Primary angioplasty - The strategy of choice	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; INTRAVENOUS STREPTOKINASE; IMMEDIATE ANGIOPLASTY; THROMBOLYSIS				Grines, CL (corresponding author), WILLIAM BEAUMONT HOSP, DIV CARDIOL, 3601 W 13 MILE RD, ROYAL OAK, MI 48073 USA.							[Anonymous], 1994, Circulation, V90, P1631; BRODIE B, 1995, J AM COLL CARDIOL, V25, pA5; BRODIE BR, 1994, CIRCULATION, V90, P156, DOI 10.1161/01.CIR.90.1.156; CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142; ELLIS S, 1996, AM COLL CARD SCI SES; GIBBONS RJ, 1993, NEW ENGL J MED, V328, P685, DOI 10.1056/NEJM199303113281003; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; MEIJER A, 1993, CIRCULATION, V87, P1524, DOI 10.1161/01.CIR.87.5.1524; MICHELS KB, 1995, CIRCULATION, V91, P476, DOI 10.1161/01.CIR.91.2.476; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002	12	70	74	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 24	1996	335	17					1313	1316						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN594	8857014				2022-12-24	WOS:A1996VN59400011
J	Love, RA; Parge, HE; Wickersham, JA; Hostomsky, Z; Habuka, N; Moomaw, EW; Adachi, T; Hostomska, Z				Love, RA; Parge, HE; Wickersham, JA; Hostomsky, Z; Habuka, N; Moomaw, EW; Adachi, T; Hostomska, Z			The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site	CELL			English	Article							GLUTATHIONE-S-TRANSFERASE; SERINE PROTEINASE; HUMAN RHINOVIRUS; HYDROGEN-BOND; NON-A; PROTEASE; POLYPROTEIN; CLEAVAGE; ORGANIZATION; RESOLUTION	During replication of hepatitis C virus (HCV), the final steps of polyprotein processing are performed by a viral proteinase located in the N-terminal one-third of nonstructural protein 3. The structure of NS3 proteinase from HCV BK strain was determined by X-ray crystallography at 2.4 Angstrom resolution. NS3P folds as a trypsinlike proteinase with two beta barrels and a catalytic triad of His-57, Asp-81, Ser-139. The structure has a substrate-binding site consistent with the cleavage specificity of the enzyme. Novel features include a structural zinc-binding site and a long N-terminus that interacts with neighboring molecules by binding to a hydrophobic surface patch.	AGOURON PHARMACEUT INC,SAN DIEGO,CA 92121; JAPAN TOBACCO INC,CENT PHARMACEUT RES INST,TAKATSUKI,OSAKA 569,JAPAN; UNIV TSUKUBA,CTR TSUKUBA ADV RES ALLIANCE,TSUKUBA,IBARAKI 305,JAPAN	Pfizer; Japan Tobacco Inc.; University of Tsukuba				Moomaw, Ellen/0000-0002-2341-1676				ALLAIRE M, 1994, NATURE, V369, P72, DOI 10.1038/369072a0; BARTENSCHLAGER R, 1995, J VIROL, V69, P198, DOI 10.1128/JVI.69.1.198-205.1995; BARTENSCHLAGER R, 1994, J VIROL, V68, P5045, DOI 10.1128/JVI.68.8.5045-5055.1994; BAZAN JF, 1988, P NATL ACAD SCI USA, V85, P7872, DOI 10.1073/pnas.85.21.7872; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHOI HK, 1991, NATURE, V354, P37, DOI 10.1038/354037a0; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DSOUZA EDA, 1995, J GEN VIROL, V76, P1729, DOI 10.1099/0022-1317-76-7-1729; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FAILLA C, 1994, J VIROL, V68, P3753, DOI 10.1128/JVI.68.6.3753-3760.1994; FUJINAGA M, 1985, J MOL BIOL, V183, P479; FUREY W, 1990, ACA M SUMM, V73; GRAKOUI A, 1993, J VIROL, V67, P2832, DOI 10.1128/JVI.67.5.2832-2843.1993; HAN DS, 1995, J GEN VIROL, V76, P985, DOI 10.1099/0022-1317-76-4-985; HIJIKATA M, 1993, J VIROL, V67, P4665, DOI 10.1128/JVI.67.8.4665-4675.1993; HOUGHTON M, 1996, FIELDS VIROLOGY, P1035; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; Koch JO, 1996, VIROLOGY, V221, P54, DOI 10.1006/viro.1996.0352; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEVITT M, 1988, J MOL BIOL, V201, P751, DOI 10.1016/0022-2836(88)90471-8; LIN C, 1994, J VIROL, V68, P8147, DOI 10.1128/JVI.68.12.8147-8157.1994; LIN C, 1995, P NATL ACAD SCI USA, V92, P7622, DOI 10.1073/pnas.92.17.7622; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; LIU SX, 1993, J AM CHEM SOC, V115, P7910, DOI 10.1021/ja00070a060; MATTHEWS DA, 1994, CELL, V77, P761, DOI 10.1016/0092-8674(94)90059-0; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MEYER E, 1988, ACTA CRYSTALLOGR B, V44, P26, DOI 10.1107/S0108768187007559; MILLER RH, 1990, P NATL ACAD SCI USA, V87, P2057, DOI 10.1073/pnas.87.6.2057; OTWINOWSKI Z, 1996, METHOD ENZYMOL, V276, P307; PIZZI E, 1994, P NATL ACAD SCI USA, V91, P888, DOI 10.1073/pnas.91.3.888; READ RJ, 1986, PROTEINASE INHIBITOR, P301; Schwabe JWR, 1994, STRUCT BIOL, V1, P345; SIMMONDS P, 1994, J GEN VIROL, V75, P1053, DOI 10.1099/0022-1317-75-5-1053; SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564; SOMMERGRUBER W, 1994, VIROLOGY, V204, P815, DOI 10.1006/viro.1994.1599; Steinkuhler C, 1996, J BIOL CHEM, V271, P6367, DOI 10.1074/jbc.271.11.6367; SUZICH JA, 1993, J VIROL, V67, P6152, DOI 10.1128/JVI.67.10.6152-6158.1993; TAKAMIZAWA A, 1991, J VIROL, V65, P1105, DOI 10.1128/JVI.65.3.1105-1113.1991; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VANDOORN LJ, 1994, J MED VIROL, V43, P345, DOI 10.1002/jmv.1890430406; VOSS T, 1995, PROTEIN SCI, V4, P2526, DOI 10.1002/pro.5560041209; WANG BC, 1985, METHOD ENZYMOL, V115, P90; YU SYF, 1992, VIROLOGY, V186, P725, DOI 10.1016/0042-6822(92)90039-R	51	466	495	0	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1996	87	2					331	342		10.1016/S0092-8674(00)81350-1	http://dx.doi.org/10.1016/S0092-8674(00)81350-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VN403	8861916	Bronze			2022-12-24	WOS:A1996VN40300020
J	Rathmell, JC; Townsend, SE; Xu, JCC; Flavell, RA; Goodnow, CC				Rathmell, JC; Townsend, SE; Xu, JCC; Flavell, RA; Goodnow, CC			Expansion or elimination of B cells in vivo: Dual roles for CD40- and Fas (CD95)-ligands modulated by the B cell antigen receptor	CELL			English	Article							X-LINKED IMMUNODEFICIENCY; PRESENT SELF ANTIGEN; HUMAN T-LYMPHOCYTES; HYPER-IGM SYNDROME; LYMPHOPROLIFERATIVE SYNDROME; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; CROSS-LINKING; UP-REGULATION; LIGAND	Signals from CD4(+) T cells induce two opposite fates in B cells: clonal proliferation of B cells that bind specifically to foreign antigens and clonal deletion of equivalent B cells that bind self-antigens. This B cell fate decision is determined by the concerted action of two surface proteins on activated T cells, CD40- and Fas-ligands (CD40L and Fast), whose effects are switched by signals from the B cell antigen receptor (BCR). Foreign antigens that stimulate the BCR acutely cause CD40L and Fast to promote clonal proliferation. CD40L and Fast trigger deletion, however, when the BCRs become desensitized by chronic stimulation with self-antigens or when BCRs have not bound an antigen. The need for both Fas and CD40L to correctly regulate self-reactive B cell fate may explain the severe autoantibody disorders in Fas- or CD40L-deficient children.	STANFORD UNIV,HOWARD HUGHES MED INST,DEPT IMMUNOL & MICROBIOL,STANFORD,CA 94305; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Yale University			Goodnow, Christopher C/V-8108-2018	Goodnow, Christopher C/0000-0001-5296-6155	NIAID NIH HHS [P01 AI19512, P01 AI36535] Funding Source: Medline; NIAMS NIH HHS [P60 AR20610] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI036535, P01AI019512] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020610] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABREUMARTIN MT, 1995, J IMMUNOL, V155, P4147; ACKERMAN BD, 1964, PEDIATRICS, V34, P211; ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; ALDERSON MR, 1993, J EXP MED, V178, P2231, DOI 10.1084/jem.178.6.2231; ALLEN PM, 1987, NATURE, V327, P713, DOI 10.1038/327713a0; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; BACHMANN MF, 1993, SCIENCE, V262, P1448, DOI 10.1126/science.8248784; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CHOI MSK, 1995, EUR J IMMUNOL, V25, P1352, DOI 10.1002/eji.1830250533; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; COOKE MP, 1994, J EXP MED, V179, P425, DOI 10.1084/jem.179.2.425; Cyster JG, 1995, IMMUNITY, V3, P691, DOI 10.1016/1074-7613(95)90059-4; CYSTER JG, 1994, NATURE, V371, P389, DOI 10.1038/371389a0; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; ERIKSON J, 1991, NATURE, V349, P331, DOI 10.1038/349331a0; ERIS JM, 1994, P NATL ACAD SCI USA, V91, P4392, DOI 10.1073/pnas.91.10.4392; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; Foy TM, 1996, ANNU REV IMMUNOL, V14, P591, DOI 10.1146/annurev.immunol.14.1.591; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Fulcher DA, 1996, J EXP MED, V183, P2313, DOI 10.1084/jem.183.5.2313; FUNAKOSHI S, 1994, BLOOD, V83, P2787, DOI 10.1182/blood.V83.10.2787.2787; GARRONE P, 1995, J EXP MED, V182, P1265, DOI 10.1084/jem.182.5.1265; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; Goodnow CC, 1996, P NATL ACAD SCI USA, V93, P2264, DOI 10.1073/pnas.93.6.2264; GOODNOW CC, 1990, SCIENCE, V248, P1373, DOI 10.1126/science.2356469; HINZ CF, 1963, NEW ENGL J MED, V269, P1329, DOI 10.1056/NEJM196312192692501; HO WY, 1994, J EXP MED, V179, P1539, DOI 10.1084/jem.179.5.1539; HOLLENBAUGH D, 1994, J CLIN INVEST, V94, P616, DOI 10.1172/JCI117377; INUI S, 1990, EUR J IMMUNOL, V20, P1747, DOI 10.1002/eji.1830200819; JACOBSON BA, 1995, IMMUNITY, V3, P509, DOI 10.1016/1074-7613(95)90179-5; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KANOST D, 1994, EUR J IMMUNOL, V24, P1186, DOI 10.1002/eji.1830240527; KLAUS SJ, 1994, J IMMUNOL, V152, P5643; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; KRAMMER PH, 1994, IMMUNOL REV, V142, P175, DOI 10.1111/j.1600-065X.1994.tb00889.x; KUPFER H, 1994, J EXP MED, V179, P1507, DOI 10.1084/jem.179.5.1507; Lagresle C, 1996, J EXP MED, V183, P1377, DOI 10.1084/jem.183.4.1377; Lens SMA, 1996, J IMMUNOL, V156, P507; LENSCHOW DJ, 1994, J IMMUNOL, V153, P1990; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LIU YJ, 1995, IMMUNITY, V2, P239, DOI 10.1016/1074-7613(95)90048-9; MERINO R, 1995, J IMMUNOL, V155, P3830; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NELSON CA, 1994, NATURE, V371, P250, DOI 10.1038/371250a0; OKAMOTO M, 1992, J EXP MED, V175, P71, DOI 10.1084/jem.175.1.71; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; PARKER DC, 1993, ANNU REV IMMUNOL, V11, P331, DOI 10.1146/annurev.immunol.11.1.331; PUI CH, 1980, J PEDIATR-US, V97, P754, DOI 10.1016/S0022-3476(80)80258-7; RAMESH N, 1993, INT IMMUNOL, V5, P769, DOI 10.1093/intimm/5.7.769; RATHMELL JC, 1994, J IMMUNOL, V153, P2831; RATHMELL JC, 1995, NATURE, V376, P181, DOI 10.1038/376181a0; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; ROSEN FS, 1966, NEW ENGL J MED, V275, P769, DOI 10.1056/NEJM196610062751407; ROTHSTEIN TL, 1995, NATURE, V374, P163, DOI 10.1038/374163a0; RUST S, 1993, NUCLEIC ACIDS RES, V21, P3623, DOI 10.1093/nar/21.16.3623; SANTOSARGUMEDO L, 1994, CELL IMMUNOL, V156, P272, DOI 10.1006/cimm.1994.1174; SCHATTNER EJ, 1995, J EXP MED, V182, P1557, DOI 10.1084/jem.182.5.1557; STUBER E, 1995, IMMUNITY, V2, P507, DOI 10.1016/1074-7613(95)90031-4; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; VALENTINE MA, 1992, EUR J IMMUNOL, V22, P3141, DOI 10.1002/eji.1830221217; VIGNAUX F, 1995, J EXP MED, V181, P781, DOI 10.1084/jem.181.2.781; Wang JY, 1996, EUR J IMMUNOL, V26, P92, DOI 10.1002/eji.1830260114; WANG ZH, 1995, J IMMUNOL, V155, P3722; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6	69	352	357	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1996	87	2					319	329		10.1016/S0092-8674(00)81349-5	http://dx.doi.org/10.1016/S0092-8674(00)81349-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VN403	8861915	Bronze			2022-12-24	WOS:A1996VN40300019
J	Ferreira, PA; Nakayama, TA; Pak, WL; Travis, GH				Ferreira, PA; Nakayama, TA; Pak, WL; Travis, GH			Cyclophilin-related protein RanBP2 acts as chaperone for red/green opsin	NATURE			English	Article							CYCLOSPORINE-A BINDING; BOVINE RHODOPSIN; HOMOLOG NINAA; ACTIVE-SITE; DROSOPHILA; MEMBRANE; INTERACT; RAN/TC4; ENCODES; RETINA	CYCLOPHILINS are ubiquitous and abundant proteins that exhibit peptidyl prolyl cis-trans isomerization (PPlase) activity in vitro(1,2). Their functions in vivo, however, are not well understood. Two new retinal cyclophilin isoforms, types I and II, are highly expressed in cone photoreceptors of the vertebrate retina(3). Type-II cyclophilin is identical to RanBP2, a large protein that binds the GTPase Ran(4,5). Here we report that two contiguous domains in RanBP(2), Ran binding domain 4 (RBD4) and cyclophilin, act in concert as a chaperone for the opsin molecule of the red/green-sensitive visual pigment of a dichromatic vertebrate. In Drosophila, the cyclophilin NinaA(6,7) is expressed in all photoreceptors(8) and is required for the expression of only a subset of opsins(8,9). The molecular basis of these photoreceptor class-specific effects and the functions of NinaA and other cyclophilins in vivo remain unclear(10). Unlike NinaA, which forms a stable complex with opsin from retinular cells R1-6(11) we find that the cyclophilin domain of RanBP2 does not bind opsin directly; rather, it augments and stabilizes the interaction between red/green (R/G) opsin and the RBD4 domain. This involves a cyclophilin-mediated modification of R/G opsin, possibly involving proline isomerization. The RBD4-cyclophilin supradomain of RanBP2, therefore, is a form of vertebrate chaperone of defined substrate specificity, which may be involved in the processing and/or transport of long-wavelength opsin in cone photoreceptor cells.	UNIV TEXAS,SW MED CTR,PROGRAM NEUROSCI,DALLAS,TX 75235; UNIV CONNECTICUT,CTR HLTH,DEPT BIOSTRUCT & FUNCT,FARMINGTON,CT 06030; PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Connecticut; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Ferreira, PA (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PSYCHIAT,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.		Ferreira, Paulo/A-3893-2008; Travis, Gabriel Harvey/AIF-1062-2022; Ferreira, Paulo A/S-4209-2016	Travis, Gabriel Harvey/0000-0003-4020-9493; Ferreira, Paulo A/0000-0003-4585-1717				BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; BERGSMA DJ, 1991, J BIOL CHEM, V266, P23204; FERREIRA PA, 1995, J BIOL CHEM, V270, P23179, DOI 10.1074/jbc.270.39.23179; Ferreira PA, 1995, DEGENERATIVE DISEASES OF THE RETINA, P263; FISHER G, 1989, NATURE, V337, P476; KALLEN J, 1992, FEBS LETT, V300, P286, DOI 10.1016/0014-5793(92)80865-E; KAMPS KMP, 1982, BIOCHIM BIOPHYS ACTA, V687, P296, DOI 10.1016/0005-2736(82)90558-2; KE HM, 1993, P NATL ACAD SCI USA, V90, P3324, DOI 10.1073/pnas.90.8.3324; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; LARRIVEE DC, 1981, J GEN PHYSIOL, V78, P521, DOI 10.1085/jgp.78.5.521; Meindl A, 1996, NAT GENET, V13, P35, DOI 10.1038/ng0596-35; MOLDAY RS, 1987, J CELL BIOL, V105, P2598; NAKAYAMA TA, 1991, J BIOL CHEM, V266, P4269; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; PAK WL, 1995, INVEST OPHTH VIS SCI, V36, P2340; REN MD, 1995, MOL CELL BIOL, V15, P2117; Roepman R, 1996, HUM MOL GENET, V5, P1035, DOI 10.1093/hmg/5.7.1035; Roepman R, 1996, HUM MOL GENET, V5, P827, DOI 10.1093/hmg/5.6.827; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; SCHNEUWLY S, 1989, P NATL ACAD SCI USA, V86, P5390, DOI 10.1073/pnas.86.14.5390; SHIEH BH, 1989, NATURE, V338, P67, DOI 10.1038/338067a0; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; STEPHENSON RS, 1983, BIOL PHOTORECEPTION, P447; TRAVIS GH, 1991, NEURON, V6, P61, DOI 10.1016/0896-6273(91)90122-G; WALTER AE, 1986, INVEST OPHTH VIS SCI, V27, P1609; WANG YS, 1992, NEURON, V9, P429, DOI 10.1016/0896-6273(92)90181-C; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0; ZYDOWSKY LD, 1992, PROTEIN SCI, V1, P1092, DOI 10.1002/pro.5560010903	30	188	191	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1996	383	6601					637	640		10.1038/383637a0	http://dx.doi.org/10.1038/383637a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM755	8857542				2022-12-24	WOS:A1996VM75500058
J	Williams, TN; Maitland, K; Bennett, S; Ganczakowski, M; Peto, TEA; Newbold, CI; Bowden, DK; Weatherall, DJ; Clegg, JB				Williams, TN; Maitland, K; Bennett, S; Ganczakowski, M; Peto, TEA; Newbold, CI; Bowden, DK; Weatherall, DJ; Clegg, JB			High incidence of malaria in alpha-thalassaemic children	NATURE			English	Article							PLASMODIUM-FALCIPARUM; NATURAL-SELECTION; BETA-THALASSEMIA; RED-CELLS; DEFICIENCY; SUSCEPTIBILITY; ERYTHROCYTES; HEMOGLOBIN; GENETICS; ANTIGENS	THE alpha(+)-thalassaemias are the commonest known human genetic disorders, affecting up to 80 per cent of some populations(1). Although there is good evidence from both epidemiological(2,3) and clinical(4) studies that these gene frequencies reflect selection by, and protection from, malaria, the mechanism is unknown. We have studied the epidemiology of malaria in childhood on the southwestern Pacific island of Espiritu Santo in Vanuatu and here we report that, paradoxically, both the incidence of uncomplicated malaria and the prevalence of splenomegaly, an index of malaria infection, are significantly higher in young children with alpha(+)-thalassnemia than in normal children. Furthermore, this effect is most marked in the youngest children and for the nonlethal parasite Plasmodium vivax. The alpha(+)-thalassaemias may have been selected for their ability beneficially to increase susceptibility to P. vivax, which, by acting as a natural vaccine in this community, induces limited cross-species protection against subsequent severe P. falciparum malaria.	UNIV LONDON LONDON SCH HYG & TROP MED,TROP HLTH EPIDEMIOL UNIT,LONDON WC1E 7HT,ENGLAND; MONASH UNIV,DEPT ANAT,CLAYTON,VIC 3168,AUSTRALIA	University of London; London School of Hygiene & Tropical Medicine; Monash University	Williams, TN (corresponding author), JOHN RADCLIFFE HOSP,INST MOL MED,OXFORD OX3 9DU,ENGLAND.			Maitland, Kathryn/0000-0002-0007-0645; Newbold, Chris/0000-0002-9274-3789	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLEN SJ, 1993, T ROY SOC TROP MED H, V87, P282, DOI 10.1016/0035-9203(93)90129-E; BALFOUR M. C., 1935, American Journal of Tropical Medicine, V15, P301; BATE CAW, 1992, INFECT IMMUN, V60, P1241, DOI 10.1128/IAI.60.3.1241-1243.1992; BOWDEN DK, 1985, LANCET, V2, P1025; Djaparidze P. S., 1942, Medical Parasitology and Parasitic Diseases Moscow, V11, P3; EARLE W. C., 1939, Puerto Rico Journal of Public Health and Tropical Medicine, V15, P3; FLINT J, 1986, NATURE, V321, P744, DOI 10.1038/321744a0; FLINT J, 1993, BAILLIERE CLIN HAEM, V6, P215, DOI 10.1016/S0950-3536(05)80071-X; GANCZAKOWSKI M, 1995, BRIT J HAEMATOL, V89, P485, DOI 10.1111/j.1365-2141.1995.tb08353.x; GENTON B, 1995, NATURE, V378, P564, DOI 10.1038/378564a0; GILLES HM, 1993, ESSENTIAL MALARIOLOG, P134; GUNEWARDENA DM, 1994, MEM I O CRUZ, V89, P61; HIGGS DR, 1989, BLOOD, V73, P1081; HILL AVS, 1992, BAILLIERE CLIN HAEM, V5, P209, DOI 10.1016/S0950-3536(11)80042-9; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; LUZZI GA, 1990, BRIT J HAEMATOL, V74, P519, DOI 10.1111/j.1365-2141.1990.tb06344.x; LUZZI GA, 1991, J EXP MED, V173, P785, DOI 10.1084/jem.173.4.785; MAITLAND K, IN PRESS T R SOC TRO; Old J. M, 1983, METHODS HAEMATOLOGY, P74; OPPENHEIMER SJ, 1987, T ROY SOC TROP MED H, V81, P322, DOI 10.1016/0035-9203(87)90253-7; PASVOL G, 1977, NATURE, V270, P171, DOI 10.1038/270171a0; PASVOL G, 1980, BRIT J HAEMATOL, V45, P285, DOI 10.1111/j.1365-2141.1980.tb07148.x; RUWENDE C, 1995, NATURE, V376, P246, DOI 10.1038/376246a0; WEATHERALL DJ, 1987, ANN TROP MED PARASIT, V81, P539, DOI 10.1080/00034983.1987.11812155; WEATHERALL DJ, 1981, THALASSAEMIA SYNDROM, P212; WILLCOX M, 1983, ANN TROP MED PARASIT, V77, P335, DOI 10.1080/00034983.1983.11811722; YATES SNR, 1995, THESIS U OXFORD	27	196	202	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1996	383	6600					522	525		10.1038/383522a0	http://dx.doi.org/10.1038/383522a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL755	8849722				2022-12-24	WOS:A1996VL75500049
J	Christen, WG; Glynn, RJ; Manson, JE; Ajani, UA; Buring, JE				Christen, WG; Glynn, RJ; Manson, JE; Ajani, UA; Buring, JE			A prospective study of cigarette smoking and risk of age-related macular degeneration in men	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SMOKERS; PLASMA; ANTIOXIDANTS; MACULOPATHY; THROMBOSIS; EYE	Objective.-To examine the association between cigarette smoking and the incide Design.-Prospective cohort study with average person-years of follow-up for AMD of 12.2 years. Participants.-A total of 21 157 US male physicians participating in the Physicians' Health Study who did not have a diagnosis of AMD at baseline, were followed for at least 7 years, and had known levels of baseline smoking. Based on information reported at baseline, 11% were current smokers, 39% were past smokers, and 50% were never smokers. Main Outcome Measure.-Incident AMD, defined as a self-report that was confirmed by medical record review, first diagnosed after randomization, and responsible for vision loss to 20/30 or worse. Results.-A total of 268 incident cases of AMD with vision loss were confirmed. In multivariate analysis, current smokers of 20 or more cigarettes per day, compared with never smokers, had an increased risk of AMD (relative risk [RR], 2.46; 95% confidence interval [CI], 1.60-3.79). Past smokers had a modest elevation in risk of AMD (RR, 1.30; 95% CI, 0.99-1.70). For current smokers of fewer than 20 cigarettes per day, there was a nonsignificant 26% increased risk of AMD (RR, 1.26; 95% CI, 0.61-2.59). Conclusions.-These prospective data provide support for the hypothesis that cigarette smoking increases the risk of developing AMD.	BRIGHAM & WOMENS HOSP, DEPT MED, DIV PREVENT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, CHANNING LAB, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT AMBULATORY CARE & PREVENT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health					NEI NIH HHS [EY03355, EY06633] Funding Source: Medline; NHLBI NIH HHS [HL34595] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552; BOLTONSMITH C, 1991, BRIT J NUTR, V65, P337, DOI 10.1079/BJN19910094; BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5; CHOW CK, 1986, J AM COLL NUTR, V5, P305; CHRISTEN WG, 1992, JAMA-J AM MED ASSOC, V268, P989; CHURCH DF, 1985, ENVIRON HEALTH PERSP, V64, P111, DOI 10.2307/3430003; CRAIG WY, 1989, BMJ-BRIT MED J, V298, P784, DOI 10.1136/bmj.298.6676.784; DUTHIE GG, 1991, AM J CLIN NUTR, V53, pS1061, DOI 10.1093/ajcn/53.4.1061S; FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912; FOULDS WS, 1990, EYE, V4, P243, DOI 10.1038/eye.1990.35; FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8; GOTTSCH JD, 1990, INVEST OPHTH VIS SCI, V31, P1674; HAWKINS RI, 1972, NATURE, V236, P450, DOI 10.1038/236450a0; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629; KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429; KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; LEHR HA, 1993, FREE RADICAL BIO MED, V14, P573, DOI 10.1016/0891-5849(93)90138-K; LEVINE PH, 1973, CIRCULATION, V48, P619, DOI 10.1161/01.CIR.48.3.619; MALTZMAN BA, 1979, ANN OPHTHALMOL, V11, P1197; MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007; MORROW JD, 1995, NEW ENGL J MED, V332, P1198, DOI 10.1056/NEJM199505043321804; *NAT ADV EYE COUNC, NIH PUBL; *NAT CTR HLTH STAT, 1993, HLTH US 1992; NORDENBERG D, 1990, JAMA-J AM MED ASSOC, V264, P1556, DOI 10.1001/jama.264.12.1556; OGSTON D, 1970, ATHEROSCLEROSIS, V11, P349, DOI 10.1016/0021-9150(70)90073-0; PAETKAU ME, 1978, CAN J OPHTHALMOL, V13, P67; SEDDON J, 1995, AM J EPIDEMIOL, V141, pS34; STRYKER WS, 1988, AM J EPIDEMIOL, V127, P283, DOI 10.1093/oxfordjournals.aje.a114804; WEST S, 1994, ARCH OPHTHALMOL-CHIC, V112, P222, DOI 10.1001/archopht.1994.01090140098031; WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038; YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701; YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1145/1165387.275645; [No title captured]	35	226	231	0	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1996	276	14					1147	1151		10.1001/jama.276.14.1147	http://dx.doi.org/10.1001/jama.276.14.1147			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL332	8827967				2022-12-24	WOS:A1996VL33200024
J	Gorlich, D; Kraft, R; Kostka, S; Vogel, F; Hartmann, E; Laskey, RA; Mattaj, IW; Izaurralde, E				Gorlich, D; Kraft, R; Kostka, S; Vogel, F; Hartmann, E; Laskey, RA; Mattaj, IW; Izaurralde, E			Importin provides a link between nuclear protein and U snRNA export	CELL			English	Article							CAP-BINDING PROTEIN; MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; ACTIVATING PROTEIN; HNRNP A1; SPECIFICALLY INTERACTS; REV PROTEIN; TRANSPORT; IDENTIFICATION; YEAST	Importin-alpha mediates nuclear protein import by binding nuclear localization signals and importin-beta. We find approximately 30% of SRP1p, the yeast importin-alpha, in a nuclear complex with the Saccharomyces cerevisiae nuclear cap-binding protein complex (CBC). Similarly, a large fraction of Xenopus CBC is associated with importin-alpha in the nucleus. CBC promotes nuclear export of capped U snRNAs and shuttles between nucleus and cytoplasm. The CBC-importin-alpha complex binds specifically to capped RNA, suggesting that CBC might shuttle while bound to importin-alpha. Strikingly, importin-beta binding displaces the RNA from the CBC-importin-alpha complex. Thus, the commitment of CBC for nuclear reentry triggers the release of the export substrate into the cytoplasm. We provide evidence for a mechanism that ensures that importin-mediated RNA release is a specifically cytoplasmic event.	WELLCOME CRC INST,CAMBRIDGE CB2 1QR,ENGLAND; UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 1QR,ENGLAND; EUROPEAN MOL BIOL LAB,D-69117 HEIDELBERG,GERMANY; MAX DELBRUCK ZENTRUM MOL MED,D-13122 BERLIN,GERMANY	University of Cambridge; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Max Delbruck Center for Molecular Medicine	Gorlich, D (corresponding author), UNIV HEIDELBERG,ZENTRUM MOL BIOL,D-69120 HEIDELBERG,GERMANY.		Izaurralde, Elisa/G-3239-2012; Gorlich, Dirk/B-8296-2017	Mattaj, Iain/0000-0002-5537-8284; Izaurralde, Elisa/0000-0001-7365-2649; Gorlich, Dirk/0000-0002-4343-5210	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AMBERG DC, 1993, EMBO J, V12, P233, DOI 10.1002/j.1460-2075.1993.tb05649.x; ATKINSON NS, 1985, MOL CELL BIOL, V5, P907, DOI 10.1128/MCB.5.5.907; BELANGER KD, 1994, J CELL BIOL, V126, P619, DOI 10.1083/jcb.126.3.619; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BISCHOFF FR, 1995, P NATL ACAD SCI USA, V92, P1749, DOI 10.1073/pnas.92.5.1749; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; CHENG Y, 1995, SCIENCE, V267, P1807, DOI 10.1126/science.7534442; Colot HV, 1996, GENE DEV, V10, P1699, DOI 10.1101/gad.10.13.1699; CORBETT AH, 1995, J CELL BIOL, V130, P1017, DOI 10.1083/jcb.130.5.1017; CUOMO CA, 1994, P NATL ACAD SCI USA, V91, P6156, DOI 10.1073/pnas.91.13.6156; DAVIS LI, 1995, ANNU REV BIOCHEM, V64, P865, DOI 10.1146/annurev.bi.64.070195.004245; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; FABRE E, 1994, CURR OPIN CELL BIOL, V6, P335, DOI 10.1016/0955-0674(94)90023-X; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; FORRESTER W, 1992, GENE DEV, V6, P1914, DOI 10.1101/gad.6.10.1914; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; GORLICH D, 1996, IN PRESS EMBO J; HOPPER AK, 1990, J CELL BIOL, V111, P309, DOI 10.1083/jcb.111.2.309; Iovine MK, 1995, J CELL BIOL, V131, P1699, DOI 10.1083/jcb.131.6.1699; Izaurralde E, 1992, Semin Cell Biol, V3, P279, DOI 10.1016/1043-4682(92)90029-U; IZAURRALDE E, 1995, CELL, V81, P153, DOI 10.1016/0092-8674(95)90323-2; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; IZAURRALDE E, 1995, NATURE, V376, P709, DOI 10.1038/376709a0; IZAURRALDE E, 1996, IN PRESS COLD SPRING; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; KADOWAKI T, 1992, IN PRESS P NATL ACAD; KAERGEL E, 1996, YEAST, V12, P333; KATAOKA N, 1994, NUCLEIC ACIDS RES, V22, P3861, DOI 10.1093/nar/22.19.3861; KATAOKA N, 1995, NUCLEIC ACIDS RES, V23, P3638, DOI 10.1093/nar/23.18.3638; Koepp DM, 1996, J CELL BIOL, V133, P1163, DOI 10.1083/jcb.133.6.1163; Lewis JD, 1996, GENE DEV, V10, P1683, DOI 10.1101/gad.10.13.1683; LEWIS JD, 1996, IN PRESS NUCL ACIDS; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MELCHIOR F, 1993, MOL BIOL CELL, V4, P569, DOI 10.1091/mbc.4.6.569; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; MICHAEL WM, 1995, CELL, V83, P415; MOORE MS, 1994, TRENDS BIOCHEM SCI, V19, P211, DOI 10.1016/0968-0004(94)90024-8; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; PERKINS A, 1989, J ACQ IMMUN DEF SYND, V2, P256; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; SCHLENSTEDT G, 1995, EMBO J, V14, P5367, DOI 10.1002/j.1460-2075.1995.tb00221.x; SHATKIN AJ, 1985, CELL, V40, P223, DOI 10.1016/0092-8674(85)90132-1; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7; TACHIBANA T, 1994, J BIOL CHEM, V269, P24542; TERNS MP, 1992, NUCLEIC ACIDS RES, V21, P4569; UEMURA H, 1992, J BACTERIOL, V174, P5526, DOI 10.1128/JB.174.17.5526-5532.1992; Visa N, 1996, J CELL BIOL, V133, P5, DOI 10.1083/jcb.133.1.5; WEIGHARDT F, 1995, J CELL SCI, V108, P545; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640	70	166	167	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1996	87	1					21	32		10.1016/S0092-8674(00)81319-7	http://dx.doi.org/10.1016/S0092-8674(00)81319-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VL695	8858145	Bronze			2022-12-24	WOS:A1996VL69500005
J	Schwarz, K; Gauss, GH; Ludwig, L; Pannicke, U; Li, Z; Lindner, D; Friedrich, W; Seger, RA; HansenHagge, TE; Desiderio, S; Lieber, MR; Bartram, CR				Schwarz, K; Gauss, GH; Ludwig, L; Pannicke, U; Li, Z; Lindner, D; Friedrich, W; Seger, RA; HansenHagge, TE; Desiderio, S; Lieber, MR; Bartram, CR			RAG mutations in human B cell-negative SCID	SCIENCE			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; BARE LYMPHOCYTE SYNDROME; RECEPTOR GAMMA-CHAIN; CLASS-II DEFICIENCY; V(D)J RECOMBINATION; INTERLEUKIN-2; GENES; PROTEINS; SIGNAL; DEFECT	Patients with human severe combined immunodeficiency (SCID) can be divided into those with B lymphocytes (B+ SCID) and those without (B- SCID). Although several genetic causes are known for B+ SCID, the etiology of B- SCID has not been defined. Six of 14 B- SCID patients tested were found to carry a mutation of the recombinase activating gene 1 (RAG-1), RAG-2, or both. This mutation resulted in a functional inability to form antigen receptors through genetic recombination and links a defect in one of the site-specific recombination systems to a human disease.	UNIV ULM,MOL BIOL SECT,D-89070 ULM,GERMANY; UNIV ULM,DEPT PEDIAT 2,D-89070 ULM,GERMANY; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; JOHNS HOPKINS UNIV,SCH MED,DEPT MOL BIOL & GENET,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205; UNIV ZURICH,CHILDRENS HOSP,ZURICH,SWITZERLAND	Ulm University; Ulm University; Washington University (WUSTL); Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; University Children's Hospital Zurich; University of Zurich			Pannicke, Ulrich/D-7348-2014	Lieber, Michael/0000-0003-3700-6345; Lieber, Michael/0000-0001-8809-0909				ABE T, 1994, J IMMUNOL, V152, P5504; AMAIZ VA, 1992, NEW ENGL J MED, V327, P529; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHATILA T, 1990, P NATL ACAD SCI USA, V87, P10033, DOI 10.1073/pnas.87.24.10033; CUOMO CA, 1994, NUCLEIC ACIDS RES, V22, P1810, DOI 10.1093/nar/22.10.1810; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; FISCHER A, 1992, Immunodeficiency Reviews, V3, P83; GAUSS GH, 1993, MOL CELL BIOL, V13, P3900, DOI 10.1128/MCB.13.7.3900; Gauss GH, 1996, MOL CELL BIOL, V16, P258; Hirschhorn R., 1993, PEDIATR RES, V33, P35; ICHIKARA Y, 1992, IMMUNOL LETT, V33, P272; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; MARKERT M L, 1991, Immunodeficiency Reviews, V3, P45; MATTHEWS DJ, 1995, BLOOD, V85, P38, DOI 10.1182/blood.V85.1.38.bloodjournal85138; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; SADOFSKY MJ, 1994, NUCLEIC ACIDS RES, V22, P1805, DOI 10.1093/nar/22.10.1805; SADOFSKY MJ, 1993, NUCLEIC ACIDS RES, V21, P5644, DOI 10.1093/nar/21.24.5644; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHWARZ K, 1991, J EXP MED, V174, P1039, DOI 10.1084/jem.174.5.1039; SCHWARZ K, UNPUB; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SILVER DP, 1993, P NATL ACAD SCI USA, V90, P6100, DOI 10.1073/pnas.90.13.6100; SOUDAIS C, 1993, NAT GENET, V3, P77, DOI 10.1038/ng0193-77; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1995, GENE DEV, V9, P1021, DOI 10.1101/gad.9.9.1021; WEINBERG K, 1990, NEW ENGL J MED, V322, P1718, DOI 10.1056/NEJM199006143222406	32	377	391	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1996	274	5284					97	99		10.1126/science.274.5284.97	http://dx.doi.org/10.1126/science.274.5284.97			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VK748	8810255				2022-12-24	WOS:A1996VK74800055
J	Heymann, TD; Chopra, K; Nunn, E; Coulter, L; Westaby, D; MurrayLyon, IM				Heymann, TD; Chopra, K; Nunn, E; Coulter, L; Westaby, D; MurrayLyon, IM			Bowel preparation at home: Prospective study of adverse effects in elderly people	BRITISH MEDICAL JOURNAL			English	Article									CHELSEA & WESTMINSTER HOSP,DEPT GASTROENTEROL,LONDON SW10 9NH,ENGLAND; CHARING CROSS HOSP,LONDON W6 8RF,ENGLAND	Imperial College London; Imperial College London								BORKJE B, 1991, SCAND J GASTROENTERO, V26, P162, DOI 10.3109/00365529109025026; *BRIT MED ASS, 1995, 27 BMA RPS, P48; GURWITZ JH, 1992, AM J MED, V92, P41, DOI 10.1016/0002-9343(92)90013-2; MARSHALL JB, 1993, ALIMENT PHARM THERAP, V7, P679	4	27	27	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 21	1996	313	7059					727	728						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VJ441	8819444				2022-12-24	WOS:A1996VJ44100025
J	Grouard, G; Durand, I; Filgueira, L; Banchereau, J; Liu, YJ				Grouard, G; Durand, I; Filgueira, L; Banchereau, J; Liu, YJ			Dendritic cells capable of stimulating T cells in germinal centres	NATURE			English	Article							AIDS-RELATED LYMPHADENOPATHY; VIRUS-LIKE PARTICLES; RETICULUM CELLS; LYMPHOID-TISSUE; HUMAN BLOOD; B-CELLS; CENTERS; ANTIGEN; INFECTION; LYMPHOCYTES	THE B cells within the germinal centres of lymphoid organs undergo affinity maturation of their antigen receptors, a critical event for antibody memory(1-3). Follicular dendritic cells within the germinal centres retain immune complexes(4-6) that select the developing B cells for which they have a higher affinity(7). We have now identified a subset of CD4(+)CD11c(+)CD3(-) dendritic cells in the germinal centres. These are strong antigen-presenting cells for T cells, but do not co-stimulate CD40-activated B cells, These dendritic cells probably stimulate germinal centre T cells and aid the complicated processes that are required for the generation of memory B cells.	SCHERING PLOUGH CORP,LAB IMMUNOL RES,F-69571 DARDILLY,FRANCE; UNIV ZURICH IRCHEL,DIV CELL BIOL,INST ANAT,CH-8057 ZURICH,SWITZERLAND	Merck & Company; Schering Plough Corporation; University of Zurich			Filgueira, Luis/B-6492-2008	Filgueira, Luis/0000-0002-2266-6650				ARMSTRONG JA, 1984, LANCET, V2, P370; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913; CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0; CHEN LL, 1978, J CELL BIOL, V77, P148, DOI 10.1083/jcb.77.1.148; CLARK EA, 1994, J IMMUNOL, V153, P2951; Frankel SS, 1996, SCIENCE, V272, P115, DOI 10.1126/science.272.5258.115; FULLER KA, 1993, J IMMUNOL, V151, P4505; GORCZYCA W, 1993, LEUKEMIA, V7, P659; GROUARD G, 1995, J IMMUNOL, V155, P3345; INABA K, 1992, J EXP MED, V175, P1157, DOI 10.1084/jem.175.5.1157; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; KIM HS, 1994, J IMMUNOL, V153, P2951; KNAPP W, 1989, LEUCOCYTE TYPING, V4, P183; KOSCO MH, 1988, J IMMUNOL, V140, P354; KUPPERS R, 1993, EMBO J, V12, P4955, DOI 10.1002/j.1460-2075.1993.tb06189.x; LAUSE DB, 1981, CELL TISSUE RES, V218, P557; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LIU YJ, IN PRESS J EXP MED; MACKAY CR, 1993, ADV IMMUNOL, V53, P217, DOI 10.1016/S0065-2776(08)60501-5; NAIEM M, 1983, J CLIN PATHOL, V36, P167, DOI 10.1136/jcp.36.2.167; NOSSAL GJV, 1968, J EXP MED, V127, P277, DOI 10.1084/jem.127.2.277; ODOHERTY U, 1994, IMMUNOLOGY, V82, P487; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PARWARESCH MR, 1983, J IMMUNOL, V131, P2719; POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SCHIEVER F, 1989, J EXP MED, V169, P2043; TENNERRACZ K, 1985, LANCET, V1, P105; TEW JG, 1989, IMMUNOL TODAY, V10, P229, DOI 10.1016/0167-5699(89)90258-2	32	233	240	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1996	384	6607					364	367		10.1038/384364a0	http://dx.doi.org/10.1038/384364a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV271	8934523				2022-12-24	WOS:A1996VV27100051
J	Bischoff, JR; Kim, DH; Williams, A; Heise, C; Horn, S; Muna, M; Ng, L; Nye, JA; SampsonJohannes, A; Fattaey, A; McCormick, F				Bischoff, JR; Kim, DH; Williams, A; Heise, C; Horn, S; Muna, M; Ng, L; Nye, JA; SampsonJohannes, A; Fattaey, A; McCormick, F			An adenovirus mutant that replicates selectively in p53-deficient human tumor cells	SCIENCE			English	Article							5 DNA; P53; TRANSFORMATION; GENES; LINES; EXPRESSION; PROTEINS	The human adenovirus E1B gene encodes a 55-kilodalton protein that inactivates the cellular tumor suppressor protein p53, Here it is shown that a mutant adenovirus that does not express this viral protein can replicate in and lyse p53-deficient human tumor cells but not cells with functional p53. Ectopic expression of the 55-kilodalton E1B protein in the latter cells rendered them sensitive to infection with the mutant virus. Injection of the mutant virus into p53-deficient human cervical carcinomas grown in nude mice caused a significant reduction in tumor size and caused complete regression of 60 percent of the tumors. These data raise the possibility that mutant adenoviruses can be used to treat certain human tumors.	ONYX PHARMACEUT,RICHMOND,CA 94806									BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; BISCHOFF JL, UNPUB; BOULANGER PA, 1991, BIOCHEM J, V275, P281, DOI 10.1042/bj2750281; CROOK T, 1991, ONCOGENE, V6, P873; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; DYSON N, 1992, CANCER SURV, V12, P161; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; KIM D, UNPUB; Kovach JS, 1996, P NATL ACAD SCI USA, V93, P1093, DOI 10.1073/pnas.93.3.1093; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; Righetti SC, 1996, CANCER RES, V56, P689; RUGGERI B, 1992, ONCOGENE, V7, P1503; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; VAN MEIR EG, 1994, CANCER RES, V54, P649; VANDEREB AJ, 1977, GENE, V2, P115, DOI 10.1016/0378-1119(77)90012-9; VANDYKE TA, 1994, SEMIN CANCER BIOL, V5, P47; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; WHITE E, 1994, APOPTOSIS, V2, P111; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	24	1423	1569	1	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1996	274	5286					373	376		10.1126/science.274.5286.373	http://dx.doi.org/10.1126/science.274.5286.373			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN173	8832876				2022-12-24	WOS:A1996VN17300039
J	Kemp, TJ; Siebers, RW; Fishwick, D; OGrady, GB; Fitzharris, P; Crane, J				Kemp, TJ; Siebers, RW; Fishwick, D; OGrady, GB; Fitzharris, P; Crane, J			House dust mite allergen in pillows	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ASTHMA		WELLINGTON SCH MED, DEPT MED, WELLINGTON ASTHMA RES GRP, WELLINGTON, NEW ZEALAND	University of Otago			Siebers, Robert/A-4102-2009	Siebers, Robert/0000-0002-6359-3144; Fishwick, David/0000-0001-5941-090X				LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; STONE L, 1996, IN PRESS AUST NZ J M; STRACHAN DP, 1995, BRIT MED J, V311, P1053, DOI 10.1136/bmj.311.7012.1053	4	60	61	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 12	1996	313	7062					916	916						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM754	8876094	Green Published			2022-12-24	WOS:A1996VM75400025
J	Chen, RH; Waters, JC; Salmon, ED; Murray, AW				Chen, RH; Waters, JC; Salmon, ED; Murray, AW			Association of spindle assembly checkpoint component XMAD2 with unattached kinetochores	SCIENCE			English	Article							BUDDING YEAST; EXTRACTS	The spindle assembly checkpoint delays anaphase until all chromosomes are attached to a mitotic spindle. The mad (mitotic arrest-deficient) and bub (budding uninhibited by benzimidazole) mutants of budding yeast rack this checkpoint and fail to arrest the cell cycle when microtubules are depolymerized. A frog homolog of MAD2 (XMAD2) was isolated and found to play an essential role in the spindle assembly checkpoint in frog egg extracts. XMAD2 protein associated with unattached kinetochores in prometaphase and in nocodazole-treated cells and disappeared from kinetochores at metaphase in untreated cells, suggesting that XMAD2 plays a role in the activation of the checkpoint by unattached kinetochores. This study furthers understanding of the mechanism of cell cycle checkpoints in metazoa and provides a marker for studying the role of the spindle assembly checkpoint in the genetic instability of tumors.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599	University of California System; University of California San Francisco; University of North Carolina; University of North Carolina Chapel Hill			Chen, Rey-Huei/AAA-5087-2021	Chen, Rey-Huei/0000-0002-6006-2137				BRENNER S, 1981, J CELL BIOL, V91, P95, DOI 10.1083/jcb.91.1.95; Chen R., UNPUB; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CYERT MS, 1988, DEV BIOL, V129, P209, DOI 10.1016/0012-1606(88)90175-3; GORBSKY GJ, 1993, J CELL BIOL, V122, P1311, DOI 10.1083/jcb.122.6.1311; HARDWICK KG, 1995, J CELL BIOL, V131, P709, DOI 10.1083/jcb.131.3.709; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; MURRAY A, 1994, CURR OPIN CELL BIOL, V6, P872, DOI 10.1016/0955-0674(94)90059-0; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; NICKLAS RB, 1995, J CELL BIOL, V130, P929, DOI 10.1083/jcb.130.4.929; Rieder C.L., 1990, International Review of Cytology, V122, P153, DOI 10.1016/S0074-7696(08)61208-5; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; ROBERTS BT, 1994, MOL CELL BIOL, V14, P8282, DOI 10.1128/MCB.14.12.8282; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; Wells WAE, 1996, J CELL BIOL, V133, P75, DOI 10.1083/jcb.133.1.75	22	377	390	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1996	274	5285					242	246		10.1126/science.274.5285.242	http://dx.doi.org/10.1126/science.274.5285.242			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM671	8824188				2022-12-24	WOS:A1996VM67100042
J	Goodman, OB; Krupnick, JG; Santini, F; Gurevich, VV; Penn, RB; Gagnon, AW; Keen, JH; Benovic, JL				Goodman, OB; Krupnick, JG; Santini, F; Gurevich, VV; Penn, RB; Gagnon, AW; Keen, JH; Benovic, JL			beta-arrestin acts as a clathrin adaptor in endocytosis of the beta(2)-adrenergic receptor	NATURE			English	Article							PLASMA-MEMBRANE; COATED VESICLES; PROTEIN; SEQUESTRATION; RESENSITIZATION; PHOSPHORYLATION; DISSOCIATION; MECHANISM; KINASES; SUBUNIT	THE ability of a system to regulate its responsiveness in the presence of a continuous stimulus, often termed desensitization, has been extensively characterized for the beta(2)-adrenergic receptor (beta(2)AR). beta(2)AR signalling is rapidly attenuated through receptor phosphorylation and subsequent binding of the protein beta-arrestin(1,2). Ultimately the receptor undergoes internalization(3,4), and although the molecular mechanism is unclear, receptor phosphorylation and beta-arrestin binding have been implicated in this process(5,6). Here we report that beta-arrestin and arrestin-3, but not visual arrestin, promote beta(2)AR internalization and bind with high affinity directly and stoichiometrically to clathrin, the major structural protein of coated pits, Moreover, beta-arrestin/arrestin chimaeras that are defective in either beta(2)AR or clathrin binding show a reduced ability to promote beta(2)AR endocytosis. Immunofluorescence microscopy of intact cells indicates an agonist-dependent colocalization of the beta(2)AR and beta-arrestin with clathrin, These results show that beta-arrestin functions as an adaptor in the receptor-mediated endocytosis pathway, and suggest a general mechanism for regulating the trafficking of G-protein-coupled receptors.	THOMAS JEFFERSON UNIV,KIMMEL CANC INST,DEPT BIOCHEM & MOL PHARMACOL,PHILADELPHIA,PA 19107	Jefferson University			Gurevich, Vsevolod/A-3236-2008	Gurevich, Vsevolod/0000-0002-3950-5351; Goodman, Oscar/0000-0002-0882-3621				Diviani D, 1996, J BIOL CHEM, V271, P5049; DUA HS, 1992, CURR EYE RES, V11, P107, DOI 10.3109/02713689208999519; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; GOODMAN OB, 1995, J BIOL CHEM, V270, P2376; GUERVICH VV, 1995, J BIOL CHEM, V270, P720; GUREVICH VV, 1992, J BIOL CHEM, V267, P21919; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; KEEN JH, 1981, J BIOL CHEM, V256, P2538; LAHSE MJ, 1990, SCIENCE, V248, P1547; NESTEROV A, 1995, P NATL ACAD SCI USA, V92, P8719, DOI 10.1073/pnas.92.19.8719; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PEARSE BMF, 1981, ANNU REV BIOCHEM, V50, P85, DOI 10.1146/annurev.bi.50.070181.000505; PEELER JS, 1993, J CELL BIOL, V120, P47, DOI 10.1083/jcb.120.1.47; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; Santini F, 1996, J CELL BIOL, V132, P1025, DOI 10.1083/jcb.132.6.1025; SCHMID SL, 1985, J BIOL CHEM, V260, P44; SCHRODER S, 1991, J BIOL CHEM, V266, P7910; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975, DOI 10.1073/pnas.84.20.6975; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; Sorkin A, 1996, J BIOL CHEM, V271, P13377, DOI 10.1074/jbc.271.23.13377; STERNEMARR R, 1993, J BIOL CHEM, V268, P15640; SterneMarr R, 1995, VITAM HORM, V51, P193, DOI 10.1016/S0083-6729(08)61039-0; VONZASTROW M, 1994, J BIOL CHEM, V269, P18448; YU SS, 1993, J BIOL CHEM, V268, P337	28	1098	1117	1	42	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 3	1996	383	6599					447	450		10.1038/383447a0	http://dx.doi.org/10.1038/383447a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL463	8837779				2022-12-24	WOS:A1996VL46300065
J	Carballo, M; Simic, S; Zeric, D				Carballo, M; Simic, S; Zeric, D			Health in countries torn by conflict: Lessons from Sarajevo	LANCET			English	Editorial Material									INT CTR MIGRAT & HLTH, SARAJEVO, BOSNIA & HERCEG; KOSEVO CLIN, DEPT OBSTET & GYNAECOL, SARAJEVO, BOSNIA & HERCEG		Carballo, M (corresponding author), INT CTR MIGRAT & HLTH, CH-1206 GENEVA, SWITZERLAND.							FerroLuzzi A, 1995, WHO TECH REP SER, V854, P1; FILIPOVICHADZIO.A, 1996, HLTH SOCIAL CONSEQUE; *INT CTR MIGR HLTH, 1995, 1995 ICMH TECHN WORK; *REP COMM HLTH SOC, 1995, B SOC HLTH CONS AGGR, P179; SIMIC S, 1996, HLTH SOCIAL CONSEQUE; SMAJKIC A, 1996, HLTH SOCIAL CONSEQUE	6	20	20	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 28	1996	348	9031					872	874		10.1016/S0140-6736(96)05386-X	http://dx.doi.org/10.1016/S0140-6736(96)05386-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK037	8826816				2022-12-24	WOS:A1996VK03700016
J	Peters, JM; King, RW; Hoog, C; Kirschner, MW				Peters, JM; King, RW; Hoog, C; Kirschner, MW			Identification of BIME as a subunit of the anaphase-promoting complex	SCIENCE			English	Article							NIMA PROTEIN-KINASE; ASPERGILLUS-NIDULANS; CELL-CYCLE; UBIQUITIN LIGASE; BUDDING YEAST; MITOSIS; TRANSITION; GENE; DESTRUCTION; CHECKPOINT	The initiation of anaphase and exit from mitosis require the activation of a proteolytic system that ubiquitinates and degrades cyclin B. The regulated component of this system is a large ubiquitin ligase complex, termed the anaphase-promoting complex (APC) or cyclosome. Purified Xenopus laevis APC was found to be composed of eight major subunits, at least four of which became phosphorylated in mitosis. In addition to CDC27, CDC16, and CDC23, APC contained a homolog of Aspergillus nidulans BIME, a protein essential for anaphase. Because mutation of bimE can bypass the interphase arrest induced by either nimA mutation or unreplicated DNA, it appears that ubiquitination catalyzed by APC may also negatively regulate entry into mitosis.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; KAROLINSKA INST,MED NOBEL INST,DEPT CELL & MOL BIOL,S-17177 STOCKHOLM,SWEDEN	Harvard University; Harvard Medical School; Karolinska Institutet								Aristarkhov A, 1996, P NATL ACAD SCI USA, V93, P4294, DOI 10.1073/pnas.93.9.4294; DESHAIES R, 1995, CURR OPIN CELL BIOL, V7, P781, DOI 10.1016/0955-0674(95)80061-1; ENGLE DB, 1990, J BIOL CHEM, V265, P16132; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GORLICH D, 1990, J CELL BIOL, V111, P2283, DOI 10.1083/jcb.111.6.2283; Heichman KA, 1996, CELL, V85, P39, DOI 10.1016/S0092-8674(00)81080-6; HIRANO T, 1988, J CELL BIOL, V106, P1171, DOI 10.1083/jcb.106.4.1171; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; JAMES SW, 1995, J CELL SCI, V108, P3485; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; LAHAVBARATZ S, 1995, P NATL ACAD SCI USA, V92, P9303, DOI 10.1073/pnas.92.20.9303; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORRIS NR, 1976, EXP CELL RES, V98, P204, DOI 10.1016/0014-4827(76)90480-8; ODONNELL KL, 1991, J CELL SCI, V99, P711; OSMANI AH, 1991, EMBO J, V10, P2669, DOI 10.1002/j.1460-2075.1991.tb07810.x; OSMANI SA, 1988, CELL, V52, P241, DOI 10.1016/0092-8674(88)90513-2; PETERS JM, 1996, P NATL ACAD SCI USA, V93, P2670; PU RT, 1995, EMBO J, V14, P995, DOI 10.1002/j.1460-2075.1995.tb07080.x; SAMEJIMA I, 1994, J CELL BIOL, V127, P1655, DOI 10.1083/jcb.127.6.1655; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; STARBORG M, 1994, J BIOL CHEM, V269, P24133; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; TUGENDREICH S, 1993, P NATL ACAD SCI USA, V90, P10031, DOI 10.1073/pnas.90.21.10031; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85; Yu HT, 1996, CURR BIOL, V6, P455, DOI 10.1016/S0960-9822(02)00513-4; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201	33	177	180	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1996	274	5290					1199	1201		10.1126/science.274.5290.1199	http://dx.doi.org/10.1126/science.274.5290.1199			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT335	8895470				2022-12-24	WOS:A1996VT33500056
J	Dart, RC; Stark, Y; Fulton, B; KoziolMcLain, J; Lowenstein, SR				Dart, RC; Stark, Y; Fulton, B; KoziolMcLain, J; Lowenstein, SR			Insufficient stocking of poisoning antidotes in hospital pharmacies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIGITALIS	Objective.-To determine whether antidotes for poisoning and overdose are available in hospitals that provide emergency department care. Design.-Written survey of hospital pharmacy directors, each of whom reported the amount currently in stock of 8 different antidotes: antivenin (Crotalidae) polyvalent, cyanide kit, deferoxamine mesylate, digoxin immune Fab, ethanol, naloxone hydrochloride, pralidoxime chloride, and pyridoxine hydrochloride. Participants.-Pharmacy directors of all hospitals with emergency departments in Colorado, Montana, and Nevada. Main Outcome Measures.-Proportions of hospitals with insufficient stocking of each antidote, defined as complete lack of the antidote or an amount inadequate to initiate treatment of 1 seriously poisoned 70-kg patient. Results.-Questionnaires were mailed to 137 hospital pharmacy directors and 108 (79%) responded. Only 1 (0.9%) of the 108 hospitals stacked all 8 antidotes in adequate amounts. The rate of insufficient stocking for individual antidotes ranged from 2% (for naloxone) to 98% (for digoxin immune Fab). In a multiple regression analysis, smaller hospital size and lack of a formal review of antidote stocking were independent predictors of the number of antidotes stocked insufficiently. Conclusions.-Insufficient stocking of antidotes is a widespread problem in Colorado, Montana, and Nevada. Although these states are served by a certified regional poison center, potentially lifesaving antidotes are frequently not available when and where they might be needed to treat a single poisoned patient.	UNIV COLORADO,COLORADO EMERGENCY MED RES CTR,DENVER,CO 80202	University of Colorado System; University of Colorado Denver	Dart, RC (corresponding author), DENVER DEPT HLTH & HOSP,ROCKY MT POISON & DRUG CTR,8802 E 9TH AVE,DENVER,CO 80220, USA.			Koziol-McLain, Jane/0000-0003-3453-023X; Dart, Richard/0000-0001-5989-9354				*AM ASS POIS CONTR, 1991, CRIT CERT REG POIS C; *AM HOSP ASS, 1993, AM HOSP ASS GUID HLT, pA78; ANTMAN EM, 1990, CIRCULATION, V81, P1744, DOI 10.1161/01.CIR.81.6.1744; BISMUTH C, 1973, CLIN TOXICOL, V6, P153, DOI 10.3109/15563657308990513; CHYKA PA, 1994, AM J HOSP PHARM, V51, P1346, DOI 10.1093/ajhp/51.10.1346; COE C, 1994, UPDATE JOINT HOSPITA, P26; DART RC, 1991, VET HUM TOXICOL, V33, P267; HOWLAND MA, 1986, NEW ENGL J MED, V314, P927; HOWLAND MA, 1994, GOLDFRANKS TOXICOLOG, P636; *JOINT COMM ACCR H, 1992, ACCR MAN HOSP, V1, P111; KANATANI M S, 1992, Veterinary and Human Toxicology, V34, P319; LITOVITZ TL, 1994, AM J EMERG MED, V12, P546, DOI 10.1016/0735-6757(94)90276-3; *MED EC CO, 1995, DRUG TOP REDB; *MED EC CO, 1996, PHYS DESK REF, P1092; ROBERTS JR, 1994, GOLDFRANKS TOXICOLOG, P1313; RUMACK BH, 1996, POISINDEX SYSTEM, P87; WEISMAN RS, 1994, GOLDFRANKS TOXICOLOG, P784	17	77	82	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	1996	276	18					1508	1510		10.1001/jama.276.18.1508	http://dx.doi.org/10.1001/jama.276.18.1508			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ774	8903263				2022-12-24	WOS:A1996VQ77400034
J	Wu, Q; Krainer, AR				Wu, Q; Krainer, AR			U1-mediated exon definition interactions between AT-AC and GT-AG introns	SCIENCE			English	Article							PRE-MESSENGER-RNA; SMALL NUCLEAR RIBONUCLEOPROTEINS; SPLICE-SITE SELECTION; CARTILAGE MATRIX PROTEIN; SODIUM-CHANNEL GENE; GENOMIC STRUCTURE; LAST NUCLEOTIDES; U1 SNRNP; INVITRO; BINDING	A minor class of metazoan introns has well-conserved splice sites with 5'-AU-AC-3' boundaries, compared to the 5'-GU-AG-3' boundaries and degenerate splice sites of conventional introns. Splicing of the AT-AC intron 2 of a sodium channel (SCN4A) precursor messenger RNA in vitro did not require inhibition of conventional splicing and required adenosine triphosphate, magnesium, and U12 small nuclear RNA (snRNA). When exon 3 was followed by the 5' splice site from the downstream conventional intron, splicing of intron 2 was greatly stimulated. This effect was U1 snRNA-dependent, unlike the basal AT-AC splicing reaction. Therefore, U1-mediated exon definition interactions can coordinate the activities of major and minor spliceosomes.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory			Wu, Qiang/A-6751-2009	Wu, Qiang/0000-0003-3841-3591; Krainer, Adrian/0000-0001-9024-9501	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042699] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42699] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baserga S., 1993, RNA WORLD, P359; BERGET SM, 1986, CELL, V46, P691, DOI 10.1016/0092-8674(86)90344-2; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; BLACK DL, 1989, MOL CELL BIOL, V9, P3350, DOI 10.1128/MCB.9.8.3350; BLACK DL, 1985, CELL, V42, P737, DOI 10.1016/0092-8674(85)90270-3; BLACK DL, 1986, CELL, V46, P697, DOI 10.1016/0092-8674(86)90345-4; CHANFREAU G, 1994, NUCLEIC ACIDS RES, V22, P1981, DOI 10.1093/nar/22.11.1981; CHIARA MD, 1995, NATURE, V375, P510, DOI 10.1038/375510a0; Deirdre A, 1995, EMBO J, V14, P3236; GEORGE AL, 1993, GENOMICS, V15, P598, DOI 10.1006/geno.1993.1113; GONTAREK RR, 1993, GENE DEV, V7, P1926, DOI 10.1101/gad.7.10.1926; GRABOWSKI PJ, 1984, CELL, V37, P415, DOI 10.1016/0092-8674(84)90372-6; HALL SL, 1994, J MOL BIOL, V239, P357, DOI 10.1006/jmbi.1994.1377; Hall SL, 1996, SCIENCE, V271, P1716, DOI 10.1126/science.271.5256.1716; HOFFMAN BE, 1992, GENE DEV, V6, P2554, DOI 10.1101/gad.6.12b.2554; Hogan K, 1996, GENOMICS, V31, P392, DOI 10.1006/geno.1996.0066; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; JENKINS RN, 1990, J BIOL CHEM, V265, P19624; KISS I, 1989, J BIOL CHEM, V264, P8126; Kohrman DC, 1996, J BIOL CHEM, V271, P17576, DOI 10.1074/jbc.271.29.17576; KRAINER AR, 1985, CELL, V42, P725, DOI 10.1016/0092-8674(85)90269-7; KRAMER A, 1984, CELL, V38, P299, DOI 10.1016/0092-8674(84)90551-8; KRAWCZAK M, 1992, HUM GENET, V90, P41; KREIVI JP, 1991, NUCLEIC ACIDS RES, V19, P6956, DOI 10.1093/nar/19.24.6956; KUO HC, 1991, SCIENCE, V251, P1045, DOI 10.1126/science.1825520; LARSON RG, 1990, CANCER COMMUN, V2, P63, DOI 10.3727/095535490820874704; Lutz CS, 1996, GENE DEV, V10, P325, DOI 10.1101/gad.10.3.325; MADHANI HD, 1994, ANNU REV GENET, V28, P1; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MCCLATCHEY AI, 1992, HUM MOL GENET, V1, P521; MONTZKA KA, 1988, P NATL ACAD SCI USA, V85, P8885, DOI 10.1073/pnas.85.23.8885; Moore M., 1993, RNA WORLD, P303; NAKAI K, 1994, GENE, V141, P171, DOI 10.1016/0378-1119(94)90567-3; NILSEN TW, 1994, CELL, V78, P1, DOI 10.1016/0092-8674(94)90563-0; NIWA M, 1991, GENE DEV, V5, P2086, DOI 10.1101/gad.5.11.2086; OHNO M, 1987, P NATL ACAD SCI USA, V84, P5187, DOI 10.1073/pnas.84.15.5187; OHSHIMA J, 1995, GENOMICS, V28, P585, DOI 10.1006/geno.1995.1194; PARKER R, 1993, NATURE, V361, P660, DOI 10.1038/361660a0; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; SERAPHIN B, 1988, EMBO J, V7, P1533; SHUMYATSKY GP, 1990, NUCLEIC ACIDS RES, V18, P6347, DOI 10.1093/nar/18.21.6347; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; SOLDATOV NM, 1994, GENOMICS, V22, P77, DOI 10.1006/geno.1994.1347; STAKNIS D, 1994, MOL CELL BIOL, V14, P7670, DOI 10.1128/MCB.14.11.7670; Tarn WY, 1996, CELL, V84, P801, DOI 10.1016/S0092-8674(00)81057-0; Wang Q, 1996, GENOMICS, V34, P9, DOI 10.1006/geno.1996.0236; WASSARMAN DA, 1991, MOL CELL BIOL, V11, P3432, DOI 10.1128/MCB.11.7.3432; WASSARMAN KM, 1992, MOL CELL BIOL, V12, P1276, DOI 10.1128/MCB.12.3.1276; WASSARMAN KM, 1993, GENE DEV, V7, P647, DOI 10.1101/gad.7.4.647; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; YAMADA Y, 1995, GENOMICS, V27, P312, DOI 10.1006/geno.1995.1048; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4	54	73	75	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1996	274	5289					1005	1008		10.1126/science.274.5289.1005	http://dx.doi.org/10.1126/science.274.5289.1005			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR792	8875927				2022-12-24	WOS:A1996VR79200056
J	Kustov, AA; Robinson, DL				Kustov, AA; Robinson, DL			Shared neural control of attentional shifts and eye movements	NATURE			English	Article							MONKEY SUPERIOR COLLICULUS; VISUAL-ATTENTION; STIMULATION; MACAQUES; CELLS; LOCALIZATION; SACCADES	WE are able to move visual attention away from the direction of gaze, fixating on one object while attending to something else at a different location. Within the region of peripheral vision, It has been widely assumed that the attentional neural systems are separate from the motor systems, but some studies challenge this idea(1-5). It has now been suggested that the attentional system is part of the premotor processing in the brain(6). This model proposes that attentional processes evolved as part of the motor systems, with isolated attentional shifts representing an artificial separation of a natural linkage, Here we test how attentional shifts might be linked to the preparations for making saccadic eye movements. We studied the superior colliculus in monkeys as they shifted their attention during different tasks, and found that each attentional shift is associated with eye-movement preparation.	NEI,SENSORIMOTOR RES LAB,SECT VISUAL BEHAV,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)								Andersen R A, 1989, Rev Oculomot Res, V3, P315; BOWMAN EM, 1993, J NEUROPHYSIOL, V70, P431, DOI 10.1152/jn.1993.70.1.431; BUSHNELL MC, 1981, J NEUROPHYSIOL, V46, P755, DOI 10.1152/jn.1981.46.4.755; CORBETTA M, 1991, J NEUROSCI, V11, P2383; COWIE RJ, 1994, J NEUROPHYSIOL, V72, P2648, DOI 10.1152/jn.1994.72.6.2648; DORRIS MC, 1995, NEUR ABSTR, V21, P1193; James W., 1890, PRINCIPLES PSYCHOL; KOWLER E, 1995, VISION RES, V35, P1897, DOI 10.1016/0042-6989(94)00279-U; KUSTOV AA, 1995, J NEUROPHYSIOL, V73, P1724, DOI 10.1152/jn.1995.73.4.1724; KUYPERS HENRICUS G. J. M., 1967, BRAIN RES, V4, P151, DOI 10.1016/0006-8993(67)90004-2; MAYS LE, 1987, J NEUROPHYSIOL, V58, P300; MOHLER CW, 1976, J NEUROPHYSIOL, V39, P722, DOI 10.1152/jn.1976.39.4.722; MUNOZ DP, 1995, J NEUROPHYSIOL, V73, P2313, DOI 10.1152/jn.1995.73.6.2313; POSNER MI, 1988, SCIENCE, V240, P1627, DOI 10.1126/science.3289116; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; POSNER MI, 1982, PHILOS T ROY SOC B, V298, P187, DOI 10.1098/rstb.1982.0081; RIZZOLATTI G, 1994, ATTENTION PERFORM, V15, P231; RIZZOLATTI G, 1983, ADV VERTEBRATE NEURO; ROBINSON DA, 1972, VISION RES, V12, P1795, DOI 10.1016/0042-6989(72)90070-3; ROBINSON DL, 1995, J NEUROPHYSIOL, V74, P713, DOI 10.1152/jn.1995.74.2.713; SCHILLER PH, 1972, J NEUROPHYSIOL, V35, P915, DOI 10.1152/jn.1972.35.6.915; SHELIGA BM, 1994, EXP BRAIN RES, V98, P507; SPARKS DL, 1983, J NEUROPHYSIOL, V49, P45, DOI 10.1152/jn.1983.49.1.45; WRIGHT RD, 1994, CAN J EXP PSYCHOL, V48, P151, DOI 10.1037/1196-1961.48.2.151; WURTZ RH, 1972, J NEUROPHYSIOL, V35, P575, DOI 10.1152/jn.1972.35.4.575	25	482	488	0	33	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1996	384	6604					74	77		10.1038/384074a0	http://dx.doi.org/10.1038/384074a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR219	8900281	Green Published			2022-12-24	WOS:A1996VR21900057
J	OKeefe, TL; Williams, GT; Davies, SL; Neuberger, MS				OKeefe, TL; Williams, GT; Davies, SL; Neuberger, MS			Hyperresponsive B cells in CD22-Deficient mice	SCIENCE			English	Article							PROTEIN TYROSINE PHOSPHORYLATION; ANTIGEN RECEPTOR; LYMPHOCYTES-B; MONOCLONAL-ANTIBODY; PHOSPHATASE 1C; STEM-CELLS; CD22; ACTIVATION; IMMUNOGLOBULIN; STIMULATION	CD22 is a surface glycoprotein of B lymphocytes that is rapidly phosphorylated on cytoplasmic tyrosines after antigen receptor cross-linking. Splenic B cells from mice with a disrupted CD22 gene were found to be hyperresponsive lo receptor signaling: Heightened calcium fluxes and cell proliferation were obtained at lower ligand concentrations. The mice gave an augmented immune response, had an expanded peritoneal B-1 cell population, and contained increased serum titers of autoantibody. Thus, CD22 is a negative regulator of antigen receptor signaling whose onset of expression at the mature B cell stage may serve to raise the antigen concentration threshold required for B cell triggering.	MRC,MOL BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology				Davies, Sarah/0000-0001-9853-3929				Benatar T, 1996, J EXP MED, V183, P329, DOI 10.1084/jem.183.1.329; Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.immunol.12.1.457; CAMPBELL MA, 1995, EUR J IMMUNOL, V25, P1573, DOI 10.1002/eji.1830250616; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CHAOUCHI N, 1995, J IMMUNOL, V154, P3096; Cyster JG, 1996, NATURE, V381, P325, DOI 10.1038/381325a0; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; DORKEN B, 1986, J IMMUNOL, V136, P4470; ERIKSON LD, 1996, INT IMMUNOL, V8, P1121; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GOODNOW CC, 1989, NATURE, V342, P385, DOI 10.1038/342385a0; JULIUS MH, 1984, EUR J IMMUNOL, V14, P753, DOI 10.1002/eji.1830140816; KLIX N, UNPUB; LAW CL, 1994, IMMUNOL TODAY, V15, P442, DOI 10.1016/0167-5699(94)90275-5; Law CL, 1996, J EXP MED, V183, P547, DOI 10.1084/jem.183.2.547; LEPRINCE C, 1993, P NATL ACAD SCI USA, V90, P3236, DOI 10.1073/pnas.90.8.3236; MOHAN C, 1995, J IMMUNOL, V154, P1470; OKEEFE TL, UNPUB; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; PEAKER CJG, 1993, EUR J IMMUNOL, V23, P1358, DOI 10.1002/eji.1830230626; PEZZUTTO A, 1988, J IMMUNOL, V140, P1791; PEZZUTTO A, 1987, J IMMUNOL, V138, P98; POWELL LD, 1993, J BIOL CHEM, V268, P7019; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; SCHULTE RJ, 1992, SCIENCE, V258, P1001, DOI 10.1126/science.1279802; SHULTZ LD, 1976, J IMMUNOL, V116, P936; SIDMAN CL, 1986, SCIENCE, V232, P1423, DOI 10.1126/science.3487115; SMITH AJH, 1995, NAT GENET, V9, P376, DOI 10.1038/ng0495-376; SYMINGTON FW, 1982, IMMUNOGENETICS, V16, P381, DOI 10.1007/BF00372098; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Tuscano J, 1996, BLOOD, V87, P4723, DOI 10.1182/blood.V87.11.4723.bloodjournal87114723; Tuscano JM, 1996, EUR J IMMUNOL, V26, P1246, DOI 10.1002/eji.1830260610; WELLS SM, 1994, J IMMUNOL, V153, P5503; WILLIAMS GT, 1994, P NATL ACAD SCI USA, V91, P474, DOI 10.1073/pnas.91.2.474	36	445	452	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1996	274	5288					798	801		10.1126/science.274.5288.798	http://dx.doi.org/10.1126/science.274.5288.798			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ145	8864124				2022-12-24	WOS:A1996VQ14500049
J	Schuler, GD; Boguski, MS; Hudson, TJ; Hui, L; Ma, J; Castle, AB; Wu, X; Silva, J; Nusbaum, HC; Birren, BB; Slonim, DK; Rozen, S; Stein, LD; Page, D; Lander, ES; Stewart, EA; Aggarwal, A; Bajorek, E; Brady, S; Chu, A; Fang, N; Hadley, D; Harris, M; Hussain, S; Maratukulam, A; Perkins, S; Piercy, M; Qin, F; Reif, T; Sanders, C; She, X; Sun, WL; Tabar, P; Voyticky, S; Mader, C; McKusick, KB; Fan, JB; Cowles, S; Quackenbush, J; Vollrath, D; Myers, RM; Cox, DR; Butler, A; Clee, C; Dibling, T; East, C; Edwards, C; Garrett, C; Green, L; Harrison, P; Hicks, A; Holloway, E; Ranby, S; MacGilvery, A; Mungall, A; Peck, A; Wilmer, T; Soderlund, C; Rice, K; Dunham, I; Bentley, D; Deloukas, P; Gyapay, G; Chiannilkulchai, N; Fizames, C; Bentolila, S; Duprat, S; VegaCzarny, N; Muselet, D; Drouot, N; Morissette, J; Weissenbach, J; Morissette, J; James, MR; White, RE; Thangarajah, T; LouisDitSully, C; Day, PJR; Goodfellow, PN; Schmitt, K; Walter, NAR; Berry, R; Iorio, KR; Sikela, JM; Polymeropoulos, MH; Torres, R; Ide, SE; Dehejia, A; Houlgatte, R; Auffray, C; Adams, MD; Phillips, C; Brandon, R; Sandusky, M; Venter, JC; Seki, N; Nagase, T; Ishikawa, K; Nomura, N; RodriguezTome, P; Matise, TC; Lee, WY; Swanson, KA; Hudson, JR				Schuler, GD; Boguski, MS; Hudson, TJ; Hui, L; Ma, J; Castle, AB; Wu, X; Silva, J; Nusbaum, HC; Birren, BB; Slonim, DK; Rozen, S; Stein, LD; Page, D; Lander, ES; Stewart, EA; Aggarwal, A; Bajorek, E; Brady, S; Chu, A; Fang, N; Hadley, D; Harris, M; Hussain, S; Maratukulam, A; Perkins, S; Piercy, M; Qin, F; Reif, T; Sanders, C; She, X; Sun, WL; Tabar, P; Voyticky, S; Mader, C; McKusick, KB; Fan, JB; Cowles, S; Quackenbush, J; Vollrath, D; Myers, RM; Cox, DR; Butler, A; Clee, C; Dibling, T; East, C; Edwards, C; Garrett, C; Green, L; Harrison, P; Hicks, A; Holloway, E; Ranby, S; MacGilvery, A; Mungall, A; Peck, A; Wilmer, T; Soderlund, C; Rice, K; Dunham, I; Bentley, D; Deloukas, P; Gyapay, G; Chiannilkulchai, N; Fizames, C; Bentolila, S; Duprat, S; VegaCzarny, N; Muselet, D; Drouot, N; Morissette, J; Weissenbach, J; Morissette, J; James, MR; White, RE; Thangarajah, T; LouisDitSully, C; Day, PJR; Goodfellow, PN; Schmitt, K; Walter, NAR; Berry, R; Iorio, KR; Sikela, JM; Polymeropoulos, MH; Torres, R; Ide, SE; Dehejia, A; Houlgatte, R; Auffray, C; Adams, MD; Phillips, C; Brandon, R; Sandusky, M; Venter, JC; Seki, N; Nagase, T; Ishikawa, K; Nomura, N; RodriguezTome, P; Matise, TC; Lee, WY; Swanson, KA; Hudson, JR			Genome maps .7. The human transcript map	SCIENCE			English	Article									WHITEHEAD INST,CTR GENOME RES,CAMBRIDGE,MA 02142; STANFORD HUMAN GENOME CTR,STANFORD,CA; SANGER CTR,CAMBRIDGE,ENGLAND; CNRS,GENETHON,EVRY,FRANCE; CHU LAVAL,CTR RECH,LAVAL,PQ,CANADA; WELLCOME TRUST CTR HUMAN GENET,OXFORD,ENGLAND; UNIV CAMBRIDGE,CAMBRIDGE CB2 1TN,ENGLAND; UNIV COLORADO,HLTH SCI CTR,DENVER,CO; NIH,NATL CTR HUMAN GENOME RES,BETHESDA,MD 20892; CNRS,GENEXPRESS,VILLEJUIF,FRANCE; INST GENOM RES,ROCKVILLE,MD; KAZUSA DNA RES INST,KISARAZU,JAPAN; EUROPEAN MOL BIOL LAB OUTSTN,EUROPEAN BIOINFORMAT INST,CAMBRIDGE,ENGLAND; ROCKEFELLER UNIV,NEW YORK,NY; RES GENET,HUNTSVILLE,AL	Massachusetts Institute of Technology (MIT); Whitehead Institute; Stanford University; Wellcome Trust Sanger Institute; Centre National de la Recherche Scientifique (CNRS); Laval University; University of Oxford; Wellcome Centre for Human Genetics; University of Cambridge; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Centre National de la Recherche Scientifique (CNRS); J. Craig Venter Institute; Kazusa DNA Research Institute; European Molecular Biology Laboratory (EMBL); Rockefeller University	Schuler, GD (corresponding author), NATL LIB MED,NATL CTR BIOTECHNOL INFORMAT,BETHESDA,MD 20894, USA.		Houlgatte, Remi/P-3020-2017; Mungall, Andrew J./U-7067-2018; Deloukas, Panos/B-2922-2013; Rozen, Steven G./J-5939-2013	Mungall, Andrew J./0000-0002-0905-2742; Deloukas, Panos/0000-0001-9251-070X; Rozen, Steven G./0000-0002-4288-0056; Slonim, Donna/0000-0003-3357-437X				RES GENETICS RESOURC, V3, P1	1	32	32	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 25	1996	274	5287					547	558						12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN919	8928009				2022-12-24	WOS:A1996VN91900039
J	Kai, J				Kai, J			What worries parents when their preschool children are acutely ill, and why: A qualitative study	BRITISH MEDICAL JOURNAL			English	Article							FEVER PHOBIA; CONSULT; CARE	Objective-To identify and explore parents' concerns when young children become acutely ill. Design-Qualitative study making use of semistructured one to one and group interviews with parents of preschool children. Setting-Disadvantaged inner city community. Subjects-95 parents of preschool children. Results-Fever, cough, and the possibility of meningitis were parents' primary concerns when their children became acutely ill. Parents' concerns reflected lay beliefs, their interpretation of medical knowledge, and their fears that their child might die or be permanently harmed. Parents worried about failing to recognise a serious problem. Concerns were expressed within the context of keenly felt pressure, emphasising parents' responsibility to protect their child from harm. They were grounded in two linked factors: parents' sense of personal control when faced with illness in their child and the perceived threat posed by an illness. Conclusions-Better understanding of parents' concerns may promote effective communication between health professionals and parents. Modification of parents' personal control and perceived threat using appropriate information and education that acknowledge and address their concerns may be a means of empowering parents.			Kai, J (corresponding author), UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT PRIMARY HLTH CARE,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND.			Kai, Joe/0000-0001-9040-9384				BOGDAN RC, 1982, AQUALITATIVE RES ED; CAMPION PD, 1984, BRIT MED J, V288, P1426, DOI 10.1136/bmj.288.6428.1426; CORNFORD CS, 1993, FAM PRACT, V10, P193, DOI 10.1093/fampra/10.2.193; Cunningham-Burley Sarah, 1990, READINGS MED SOCIOLO, P85; *DEP HLTH, 1994, KNOW MEN SEPT; Glaser B. G., 1978, AWARENESS DYING; HALLAM L, 1994, BRIT MED J, V308, P249, DOI 10.1136/bmj.308.6923.249; Helman C., 1986, CULTURE HLTH ILLNESS; HURWITZ B, 1995, BRIT MED J, V311, P824, DOI 10.1136/bmj.311.7009.824; Kai J, 1996, BRIT MED J, V313, P987; KLUGER NJ, 1991, FEVER BASIC MECH MAN; KRAMER MS, 1985, PEDIATRICS, V75, P1110; Kreuger R, 1988, FOCUS GROUPS PRACTIC; MAYALL B, 1986, KEEPING CHILDREN HLT; MAYS N, 1995, BRIT MED J, V311, P109, DOI 10.1136/bmj.311.6997.109; MCCORMICK A, 1995, MORBIDITY STAT GEN P; *MEN RES, 1994, WHAT DO YOU SUSP MEN; Paterson E., 1982, STUDIES DEPRIVATION, V5; SCHMITT BD, 1980, AM J DIS CHILD, V134, P176, DOI 10.1001/archpedi.1980.02130140050015; Spencer N, 1996, ARCH DIS CHILD, V74, P50, DOI 10.1136/adc.74.1.50; SPENCER NJ, 1984, PROGR CHILD HLTH, P100; STEPHENSON T, 1994, MAT CHILD HLTH, V19, P128; Strauss AL, 1990, BASICS QUALITATIVE G; WIIKIN D, 1987, ANATOMY URBAN GEN PR; WYKE S, 1990, BRIT J GEN PRACT, V40, P226	25	173	180	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 19	1996	313	7063					983	986						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN916	8892420				2022-12-24	WOS:A1996VN91600026
J	Gertler, FB; Niebuhr, K; Reinhard, M; Wehland, J; Soriano, P				Gertler, FB; Niebuhr, K; Reinhard, M; Wehland, J; Soriano, P			Mena, a relative of VASP and Drosophila enabled, is implicated in the control of microfilament dynamics	CELL			English	Article							ABL TYROSINE KINASE; VASODILATOR-STIMULATED PHOSPHOPROTEIN; ACTIN-BASED MOTILITY; RICH FOCAL ADHESION; LISTERIA-MONOCYTOGENES; HUMAN-PLATELETS; PROTEIN VASP; C-ABL; GROWTH CONES; BINDING-SITE	Drosophila Enabled is required for proper formation of axonal structures and is genetically implicated in signaling pathways mediated by Drosophila Abl. We have identified two murine proteins, Mena and Evl, that are highly related to Enabled as well as VASP (Vasodilator-Stimulated Phosphoprotein). A conserved domain targets Mena to localized proteins containing a specific proline-rich motif. The association of Mena with the surface of the intracellular pathogen Listeria monocytogenes and the G-actin binding protein profilin suggests that this molecule may participate in bacterial movement by facilitating actin polymerization. Expression of neural-enriched isoforms of Mena in fibroblasts induces the formation of abnormal F-actin-rich outgrowths, supporting a role for this protein in microfilament assembly and cell motility.	GESELL BIOTECHNOL FORSCH MBH, D-38124 BRAUNSCHWEIG, GERMANY; UNIV WURZBURG, MED KLIN, D-97080 WURZBURG, GERMANY	Gesellschaft fur Biotechnologische Forschung mbH; University of Wurzburg	Gertler, FB (corresponding author), FRED HUTCHINSON CANC RES CTR, DEPT MOL MED, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA.		Reinhard, Martin/A-1006-2008; Soriano, Philippe M/E-5797-2015	Reinhard, Martin/0000-0002-7833-6175; Soriano, Philippe M/0000-0002-0427-926X				BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BIXBY JL, 1993, J NEUROSCI, V13, P3421; BUTT E, 1994, J BIOL CHEM, V269, P14509; CAO LG, 1992, J CELL BIOL, V117, P1023, DOI 10.1083/jcb.117.5.1023; CHAKRABORTY T, 1995, EMBO J, V14, P1314, DOI 10.1002/j.1460-2075.1995.tb07117.x; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOMANN E, 1992, EMBO J, V11, P1981, DOI 10.1002/j.1460-2075.1992.tb05252.x; FAIVRE SC, 1993, S SOC EXP BIOL, V47, P317; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FORSCHER P, 1992, NATURE, V357, P515, DOI 10.1038/357515a0; FRIEDERICH E, 1995, EMBO J, V14, P2731, DOI 10.1002/j.1460-2075.1995.tb07274.x; GEIGER B, 1980, P NATL ACAD SCI-BIOL, V77, P4127, DOI 10.1073/pnas.77.7.4127; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GERTLER FB, 1990, SCIENCE, V248, P857, DOI 10.1126/science.2188361; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; HAFFNER C, 1995, EMBO J, V14, P19, DOI 10.1002/j.1460-2075.1995.tb06971.x; HALBRUGGE M, 1989, EUR J BIOCHEM, V185, P41, DOI 10.1111/j.1432-1033.1989.tb15079.x; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; IGARASHI M, 1990, EUR J BIOCHEM, V193, P551, DOI 10.1111/j.1432-1033.1990.tb19371.x; JANMEY PA, 1991, METHOD ENZYMOL, V196, P92; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; KOCKS C, 1993, J CELL SCI, V105, P699; Lasa I, 1996, TRENDS CELL BIOL, V6, P109, DOI 10.1016/0962-8924(96)81001-4; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; MAHER PA, 1985, P NATL ACAD SCI USA, V82, P6576, DOI 10.1073/pnas.82.19.6576; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MARCHAND JB, 1995, J CELL BIOL, V130, P331, DOI 10.1083/jcb.130.2.331; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NIEBUHR K, 1993, INFECT IMMUN, V61, P2793, DOI 10.1128/IAI.61.7.2793-2802.1993; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; PERELROIZEN I, 1994, BIOCHEMISTRY-US, V33, P8472, DOI 10.1021/bi00194a011; PISTOR S, 1995, CURR BIOL, V5, P517, DOI 10.1016/S0960-9822(95)00104-7; POLLARD TD, 1995, CURR BIOL, V5, P837, DOI 10.1016/S0960-9822(95)00167-9; REINHARD M, 1995, P NATL ACAD SCI USA, V92, P7956, DOI 10.1073/pnas.92.17.7956; REINHARD M, 1992, EMBO J, V11, P2063, DOI 10.1002/j.1460-2075.1992.tb05264.x; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SOUTHWICK FS, 1994, P NATL ACAD SCI USA, V91, P5168, DOI 10.1073/pnas.91.11.5168; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Theriot JA, 1995, ANNU REV CELL DEV BI, V11, P213, DOI 10.1146/annurev.cb.11.110195.001241; THERIOT JA, 1993, CELL, V75, P835, DOI 10.1016/0092-8674(93)90527-W; THERIOT JA, 1994, CELL, V76, P505, DOI 10.1016/0092-8674(94)90114-7; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; VanTroys M, 1996, EMBO J, V15, P201, DOI 10.1002/j.1460-2075.1996.tb00350.x; WENG ZG, 1993, J BIOL CHEM, V268, P14956; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	55	554	573	0	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 18	1996	87	2					227	239		10.1016/S0092-8674(00)81341-0	http://dx.doi.org/10.1016/S0092-8674(00)81341-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VN403	8861907	Bronze			2022-12-24	WOS:A1996VN40300011
J	Mallat, Z; Tedgui, A; Fontaliran, F; Frank, R; Durigon, M; Fontaine, G				Mallat, Z; Tedgui, A; Fontaliran, F; Frank, R; Durigon, M; Fontaine, G			Evidence of apoptosis in arrhythmogenic right ventricular dysplasia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CELL-DEATH; CARDIOMYOPATHY; IDENTIFICATION	Background Arrhythmogenic right ventricular dysplasia, a disorder that may lead to severe ventricular arrhythmias and sudden death, is characterized by the progressive replacement of myocardial cells by fat and fibrous tissue. We examined whether the loss of myocardial cells in this disease could result from cell death by apoptosis (programmed cell death). Methods Specimens obtained at autopsy from the right ventricular myocardium of eight patients with arrhythmogenic right Ventricular dysplasia and four age-matched normal subjects were analyzed. To identify individual cells undergoing apoptosis, we performed in situ end-labeling of fragmented DNA on paraffin sections using biotinylated deoxyuridine triphosphate and the enzyme terminal deoxynucleotidyl transferase, We also examined the level of expression of CPP-32, a cysteine protease required for apoptotic cell death in mammalian cells, using immunohistochemical techniques. Results Apoptosis was detected in the right ventricular myocardium of six of the eight patients with arrhythmogenic right ventricular dysplasia and was absent in the controls, High levels of expression of CPP-32 were associated with positive in situ end-labeling of fragmented DNA. Conclusions These results indicate that apoptotic myocardial cell death occurs in arrhythmogenic right ventricular dysplasia and may contribute to the loss of myocardial cells in this disorder. (C) 1996, Massachusetts Medical Society.	HOP LARIBOISIERE,INSERM,U141,F-75475 PARIS,FRANCE; HOP RAY POINCARE,SERV ANAT & CYTOL PATHOL,GARCHES,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP	Mallat, Z (corresponding author), HOP JEAN ROSTAND,CTR RYTHMOL & STIMULAT CARDIAQUE,39 RUE JEAN LE GALLEU,F-94200 IVRY,FRANCE.		Mallat, Ziad/D-4041-2012	Mallat, Ziad/0000-0003-0443-7878				CARSON DA, 1993, LANCET, V341, P1251, DOI 10.1016/0140-6736(93)91154-E; CHENG W, 1995, J CLIN INVEST, V96, P2247, DOI 10.1172/JCI118280; FONTAINE G, 1995, HEART VESSELS, V10, P227, DOI 10.1007/BF01744901; FONTALIRAN F, 1991, ARCH MAL COEUR VAISS, V84, P33; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOLD R, 1994, LAB INVEST, V71, P219; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; Gottlieb RA, 1996, J CLIN INVEST, V97, P2391, DOI 10.1172/JCI118683; James TN, 1996, CIRCULATION, V93, P1588, DOI 10.1161/01.CIR.93.8.1588; JAMES TN, 1994, CIRCULATION, V90, P556, DOI 10.1161/01.CIR.90.1.556; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KERR JFR, 1994, CELL BIOL LAB HDB, V1, P319; MARCUS FI, 1982, CIRCULATION, V65, P384, DOI 10.1161/01.CIR.65.2.384; MCKENNA WJ, 1994, BRIT HEART J, V71, P215; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Sharov VG, 1996, AM J PATHOL, V148, P141; THIENE G, 1988, NEW ENGL J MED, V318, P129, DOI 10.1056/NEJM198801213180301; Walker N I, 1988, Methods Achiev Exp Pathol, V13, P18; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; Wyllie A H, 1980, Int Rev Cytol, V68, P251	20	336	355	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 17	1996	335	16					1190	1196		10.1056/NEJM199610173351604	http://dx.doi.org/10.1056/NEJM199610173351604			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN401	8815941	Bronze			2022-12-24	WOS:A1996VN40100004
J	Preston, H; Wright, TL				Preston, H; Wright, TL			Interferon therapy for hepatitis C	LANCET			English	Editorial Material							NON-B-HEPATITIS; NON-A		UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94121 USA	University of California System; University of California San Francisco	Preston, H (corresponding author), DEPT VET AFFAIRS MED CTR, GASTROENTEROL SECT, SAN FRANCISCO, CA 94121 USA.							DAVIS GL, 1994, J HEPATOL, V21, P1, DOI 10.1016/S0168-8278(94)80128-2; Pawlotsky JM, 1996, J INFECT DIS, V174, P1, DOI 10.1093/infdis/174.1.1; POYNARD T, 1995, NEW ENGL J MED, V332, P1457, DOI 10.1056/NEJM199506013322201; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; Sherlock S, 1995, J HEPATOL, V23, P3; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202	6	9	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 12	1996	348	9033					973	974		10.1016/S0140-6736(05)64920-3	http://dx.doi.org/10.1016/S0140-6736(05)64920-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM027	8855848				2022-12-24	WOS:A1996VM02700004
J	Nightingale, SL				Nightingale, SL			Treatment to protect against poison ivy approved	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1996	276	14					1128	1128						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL332	8827954				2022-12-24	WOS:A1996VL33200006
J	Sakai, S; Miyauchi, T; Kobayashi, M; Yamaguchi, I; Goto, K; Sugishita, Y				Sakai, S; Miyauchi, T; Kobayashi, M; Yamaguchi, I; Goto, K; Sugishita, Y			Inhibition of myocardial endothelin pathway improves long-term survival in heart failure	NATURE			English	Article							PULMONARY-HYPERTENSION; INFARCTION; RATS; LOCALIZATION; RECEPTOR; POTENT	OCCLUSION Of the diseased coronary artery in humans causes acute myocardial infarction, survivors of which have a high risk for the development of chronic heart failure(1). Cardiac myocytes and vascular endothelial cells produce endothelin-1 (refs 2-4), which increases the contractility of cardiac muscle and of vascular smooth muscle cells(2,3,5). Endothelin-1 also exerts long-term effects such as myocardial hypertrophy, and causes cellular injury in cardiac myocytes(3,5-7). Production of endothelin-l is markedly increased in the myocardium of rats with heart failure, and acute application of an endothelin-receptor antagonist decreases myocardial contractility in such rats, indicating that myocardial endothelin-1 may help to support contractility of the failing heart(8). But we report here that the upregulated myocardial endothelin system may contribute to the progression of chronic heart failure, because long-term treatment with an endothelin-receptor antagonist greatly improved the survival of rats with chronic heart failure, This beneficial effect was accompanied by significant amelioration of left ventricular dysfunction and prevention of ventricular remodelling, in which there is usually an increase in the ventricular mass and cavity enlargement of the ventricle.	UNIV TSUKUBA,INST CLIN MED,DEPT INTERNAL MED,DIV CARDIOVASC,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,INST BASIC MED SCI,DEPT PHARMACOL,TSUKUBA,IBARAKI 305,JAPAN; BANYU PHARMACEUT CO LTD,TSUKUBA RES INST,TSUKUBA,IBARAKI 30033,JAPAN	University of Tsukuba; University of Tsukuba; Merck & Company; Novartis								GOTO K, 1995, NATURE, V375, P539, DOI 10.1038/375539a0; IHARA M, 1992, LIFE SCI, V50, P247, DOI 10.1016/0024-3205(92)90331-I; ISHIKAWA S, 1995, J THORAC CARDIOV SUR, V110, P271, DOI 10.1016/S0022-5223(05)80036-4; KATZ AM, 1986, CIRCULATION, V73, P184; KOBAYASHI M, 1995, ACTA HISTOCHEM CYTOC, V28, P129, DOI 10.1267/ahc.28.129; KOWSKI W, 1995, LANCET, V346, P732; Melillo G, 1996, CIRCULATION, V93, P1447, DOI 10.1161/01.CIR.93.7.1447; MIYAUCHI T, 1993, CIRC RES, V73, P887, DOI 10.1161/01.RES.73.5.887; MIYAUCHI T, 1989, LANCET, V2, P53, DOI 10.1016/S0140-6736(89)90303-6; MOLENAAR P, 1993, CIRC RES, V72, P526, DOI 10.1161/01.RES.72.3.526; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; PFEFFER JM, 1995, ANNU REV PHYSIOL, V57, P805, DOI 10.1146/annurev.ph.57.030195.004105; PFEFFER MA, 1979, CIRC RES, V44, P503, DOI 10.1161/01.RES.44.4.503; PFEFFER MA, 1995, ANNU REV MED, V46, P455, DOI 10.1146/annurev.med.46.1.455; PRASAD MR, 1991, BIOCHEM BIOPH RES CO, V174, P952, DOI 10.1016/0006-291X(91)91511-A; RUBANYI GM, 1994, PHARMACOL REV, V46, P325; Sakai S, 1996, CIRCULATION, V93, P1214, DOI 10.1161/01.CIR.93.6.1214; STEWART DJ, 1992, CIRCULATION, V85, P510, DOI 10.1161/01.CIR.85.2.510; SUZUKI T, 1993, BIOCHEM BIOPH RES CO, V191, P823, DOI 10.1006/bbrc.1993.1291; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YORIKANE R, 1993, FEBS LETT, V332, P31, DOI 10.1016/0014-5793(93)80476-B; YORIKANE R, 1990, JPN J PHARMACOL, V53, P259, DOI 10.1254/jjp.53.259	22	528	537	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1996	384	6607					353	355		10.1038/384353a0	http://dx.doi.org/10.1038/384353a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV271	8934519				2022-12-24	WOS:A1996VV27100047
J	Tajbakhsh, S; Rocancourt, D; Buckingham, M				Tajbakhsh, S; Rocancourt, D; Buckingham, M			Muscle progenitor cells failing to respond to positional cues adopt non-myogenic fates in myf-5 null mice	NATURE			English	Article							SKELETAL-MUSCLE; REGULATORY GENE; MOUSE; DIFFERENTIATION; INACTIVATION; PROTEIN; EMBRYO; MYOD; LIMB	MICE that have mutations in both myogenic transcription factors Myf-5 and MyoD totally lack skeletal muscle fibres and their precursor myoblasts(1), whereas with either mutation alone, muscle is present(2,3). Skeletal muscle in the vertebrate body is derived from epithelial somites that respond to environmental signals to form the dorsal epithelial dermomyotome (dermis, muscle) and ventral mesenchymal sclerotome (axial skeleton, ribs)(4,5). The first muscle, the myotome, forms centrally in the somite, when only myf-5 is programming myogenesis. By targeting the nlacZ reporter gene into the myf-5 locus, we demonstrate that beta-galactosidase(+) muscle progenitor cells are present in the dermomyotome of myf-5 null embryos, and that they undergo a normal epithelial-mesenchymal transition; however, they migrate aberrantly. Dorsally, they accumulate under the ectoderm and express a non-muscle dermal marker, Dermo-1, Ventrally, beta-galactosidase(+) cells also fail to localize correctly, express a cartilage marker scleraxis, and are subsequently found in ribs, Therefore Myf-5 protein is necessary for cells to respond correctly to positional cues in the embryo and to adopt their myogenic fate, In its absence, muscle progenitors, having activated myf-5, remain multipotent and differentiate into other semitic derivatives according to their local environment.			Tajbakhsh, S (corresponding author), INST PASTEUR,DEPT MOL BIOL,CNRS,URA 1947,UNITE GENET MOL DEV,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE.							BOBER E, 1994, DEVELOPMENT, V120, P3073; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; CHRIST B, 1995, ANAT EMBRYOL, V191, P381, DOI 10.1007/BF00304424; COSSU G, 1995, P NATL ACAD SCI USA, V92, P2254, DOI 10.1073/pnas.92.6.2254; Cossu G, 1996, TRENDS GENET, V12, P218, DOI 10.1016/0168-9525(96)10025-1; CSERJESI P, 1995, DEVELOPMENT, V121, P1099; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; GODSAVE SF, 1991, DEVELOPMENT, V111, P523; Grass S, 1996, DEVELOPMENT, V122, P141; GURDON JB, 1988, NATURE, V336, P772, DOI 10.1038/336772a0; Hay ED, 1993, CURR OPIN CELL BIOL, V5, P1029, DOI 10.1016/0955-0674(93)90088-8; LI L, 1995, DEV BIOL, V172, P280, DOI 10.1006/dbio.1995.0023; MAGIN TM, 1992, NUCLEIC ACIDS RES, V20, P3795, DOI 10.1093/nar/20.14.3795; OTT MO, 1991, DEVELOPMENT, V111, P1097; Pownall ME, 1996, DEVELOPMENT, V122, P1475; RONG PM, 1992, DEVELOPMENT, V115, P657; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; Tajbakhsh S, 1995, DEVELOPMENT, V121, P4077; Tajbakhsh S, 1996, DEV DYNAM, V206, P291, DOI 10.1002/(SICI)1097-0177(199607)206:3<291::AID-AJA6>3.0.CO;2-D; TAJBAKHSH S, 1994, P NATL ACAD SCI USA, V91, P747, DOI 10.1073/pnas.91.2.747; TAJBAKHSH S, 1995, TRENDS GENET, V11, P42, DOI 10.1016/S0168-9525(00)88994-5; TOSNEY KW, 1994, DEV BIOL, V163, P389, DOI 10.1006/dbio.1994.1157; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918; Yang XM, 1996, DEVELOPMENT, V122, P2163	27	242	249	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 21	1996	384	6606					266	270		10.1038/384266a0	http://dx.doi.org/10.1038/384266a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU381	8918877				2022-12-24	WOS:A1996VU38100052
J	Stone, DM; Hynes, M; Armanini, M; Swanson, TA; Gu, QM; Johnson, RL; Scott, MP; Pennica, D; Goddard, A; Phillips, H; Noll, M; Hooper, JE; deSauvage, F; Rosenthal, A				Stone, DM; Hynes, M; Armanini, M; Swanson, TA; Gu, QM; Johnson, RL; Scott, MP; Pennica, D; Goddard, A; Phillips, H; Noll, M; Hooper, JE; deSauvage, F; Rosenthal, A			The tumour-suppressor gene patched encodes a candidate receptor for Sonic hedgehog	NATURE			English	Article							TERMINAL CLEAVAGE PRODUCT; MOTOR-NEURON INDUCTION; FLOOR PLATE; POLARIZING ACTIVITY; DROSOPHILA SEGMENT; LARVAL CUTICLE; FEEDBACK LOOP; ZYGOTIC LOCI; PROTEIN; PATTERN	The protein Sonic hedgehog (Shh) controls patterning and growth during vertebrate development. Here we demonstrate that it binds Patched (vPtc), which has been identified as a tumour-suppressor protein in basal cell carcinoma, with high affinity. We show that Ptc can form a physical complex with a newly cloned vertebrate homologue of the Drosophila protein Smoothened (vSmo), and that vSmo is coexpressed with vPtc in many tissues but does not bind Shh directly. These findings, combined with available genetic evidence from Drosophila, support the hypothesis that Ptc is a receptor for Shh, and that vSmo could be a signalling component that is linked to Ptc.	GENENTECH INC,DEPT NEUROSCI,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT MOL ONCOL,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT MOL BIOL,S SAN FRANCISCO,CA 94080; STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT DEV BIOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,STANFORD,CA 94305; UNIV ZURICH,INST MOL BIOL,DIV 2,CH-8057 ZURICH,SWITZERLAND; UNIV COLORADO,HLTH SCI CTR,DEPT CELLULAR & STRUCT BIOL,DENVER,CO 80262	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University; University of Zurich; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver				Hynes, Mary/0000-0001-6623-6727				Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bitgood MJ, 1996, CURR BIOL, V6, P298, DOI 10.1016/S0960-9822(02)00480-3; CHAN SDH, 1992, J BIOL CHEM, V267, P25202; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Currie PD, 1996, NATURE, V382, P452, DOI 10.1038/382452a0; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; EKKER SC, 1995, CURR BIOL, V5, P944, DOI 10.1016/S0960-9822(95)00185-0; Ericson J, 1995, INT J DEV BIOL, V39, P809; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; HIDALGO A, 1990, DEVELOPMENT, V110, P291; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; HYNES M, 1995, CELL, V80, P95, DOI 10.1016/0092-8674(95)90454-9; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; JOHNSON RL, 1994, CELL, V79, P1165, DOI 10.1016/0092-8674(94)90008-6; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; Marigo V, 1996, DEVELOPMENT, V122, P1225; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROBERTS DJ, 1995, DEVELOPMENT, V121, P3163; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V	39	927	987	0	45	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 14	1996	384	6605					129	134		10.1038/384129a0	http://dx.doi.org/10.1038/384129a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT336	8906787				2022-12-24	WOS:A1996VT33600055
J	Hoffman, C; Rice, D; Sung, HY				Hoffman, C; Rice, D; Sung, HY			Persons with chronic conditions - Their prevalence and costs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LONG-TERM-CARE; UNITED-STATES; HEALTH; IMPACT	Objectives.-To determine (1) the number and proportion of Americans living with chronic conditions, and (2) the magnitude of their costs, including direct costs (annual personal health expenditures) and indirect costs to society (lost productivity due to chronic conditions and premature death). Design.-Analysis of the 1987 National Medical Expenditure Survey for prevalence and direct health care costs; indirect costs based on the 1990 National Health Interview Survey and Vital Statistics of the United States. Setting.-US population. Participants.-For the estimate of prevalence and direct costs, the National Medical Expenditure Survey sample of persons who reported health conditions associated with (1) use of health services or supplies or (2) periods of disability. Interventions.-None. Main Outcome Measures.-The number of persons with chronic conditions, their annual direct health care costs, and indirect costs from lost productivity and premature deaths. Results.-In 1987, 90 million Americans were living with chronic conditions, 39 million of whom were living with more than 1 chronic condition. Over 45% of noninstitutionalized Americans have 1 or more chronic conditions and their direct health care costs account for three fourths of US health care expenditures. Total costs projected to 1990 for people with chronic conditions amounted to $659 billion-$425 billion for direct health care costs and $234 billion in indirect costs. Conclusions.-The prevalence and costs of chronic conditions as a whole have rarely been estimated. Because the number of persons with limitations due to chronic conditions is more regularly reported in the literature, the total prevalence of chronic conditions has perhaps been minimized. The majority of persons with chronic conditions are not disabled, nor are they elderly. Chronic conditions affect all ages. Because persons with chronic conditions have greater health needs at any age, their costs are disproportionately high.	UNIV CALIF SAN FRANCISCO, INST HLTH & AGING, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco								BAUMOL WJ, 1968, AM ECON REV, V58, P788; COOPER BS, 1976, SOC SECUR BULL, V39, P21; DAY JC, 1993, CURRENT POPULATI P25, V1104; DOUGLASS J, 1990, J FORENSIC EC, V4, P25, DOI DOI 10.5085/0898-5510-4.1.25; EDWARDS WS, 1989, US DHHS PUBLICATION; GRAMLICH EDWARD M., 1990, GUIDE BENEFIT COST A, V2d; Haddix A, 1996, PREVENTION EFFECTIVE; HING E, 1989, VITAL HLTH STAT 13, V13; *HLTH CAR FIN ADM, 1995, MED PROF; *HLTH CAR FIN ADM, 1995, HLTH CAR FIN REV S S, V20, P368; HODGSON TA, 1982, MILBANK FUND Q, V60, P429, DOI 10.2307/3349801; Johnson AE, 1993, J ECON SOC MEAS, V19, P199; LETSCH SW, 1991, HLTH CARE FINANC REV, V14, P1; MANTON KG, 1993, J GERONTOL, V48, pS153, DOI 10.1093/geronj/48.4.S153; *NAT CTR HLTH STAT, 1995, PUBL PHS; *NAT CTR HLTH STAT, 1994, US DEP HHS PUBL, V2; *NAT CTR HLTH STAT, 1988, VIT HLTH STAT 10, V10; *NAT CTR HLTH STAT, 1993, VIT STAT US MORT, V2; NEWACHECK PW, 1994, J PEDIATR-US, V124, P40, DOI 10.1016/S0022-3476(94)70252-7; OLSEN JA, 1993, J HEALTH ECON, V12, P39, DOI 10.1016/0167-6296(93)90039-H; Pihlbland C. T., 1937, NATL HLTH SURVEY PRE; Rice D P, 1985, Health Care Financ Rev, V7, P61; Rice D P, 1980, World Health Stat Q, V33, P56; Rice D.P., 1966, HLTH EC SERIES, V6; RICE DP, 1991, PUBLIC HLTH REP, V106, P281; SCITOVSKY AA, 1987, PUBLIC HEALTH REP, V102, P5; SHORT PF, 1995, JAMA-J AM MED ASSOC, V274, P1302; STRAUSS A, 1987, SOCIETY, V25, P33, DOI 10.1007/BF02695394; SYDENSTRICKER E, 1933, RECENT TRENDS US, pCH2; TRUPIN L, 1995, MED EXPENDITURES PEO, P6; *US BUR CENS, 1992, CP1 CENS POP; *US BUR CENS, 1995, 1995 STAT ABSTR US; *US BUR CENS, 1990, CURR POP REP P25, V1045; *US BUR CENS, 1992, CURR POP REP P60, V180; *US BUR LAB STAT, 1991, EMPL EARN; *US DEP HHS, 1987, PUBL US DAT TAP DO 3; VERBRUGGE LM, 1995, AM J PUBLIC HEALTH, V85, P173, DOI 10.2105/AJPH.85.2.173; WEISSERT WG, 1988, MILBANK Q, V66, P309, DOI 10.2307/3350034	38	678	680	1	28	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	1996	276	18					1473	1479		10.1001/jama.276.18.1473	http://dx.doi.org/10.1001/jama.276.18.1473			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VQ774	8903258				2022-12-24	WOS:A1996VQ77400029
J	Roldan, CA; Shively, BK; Crawford, MH				Roldan, CA; Shively, BK; Crawford, MH			An echocardiographic study of valvular heart disease associated with systemic lupus erythematosus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONBACTERIAL THROMBOTIC ENDOCARDITIS; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; CARDIAC ABNORMALITIES; COMPLEMENT ACTIVATION; VALVE DISEASE; ANTIBODIES; PREVALENCE; SEVERITY; STROKE	Background Valvular heart disease is the most important cardiac manifestation of systemic lupus erythematosus. We performed a study to determine the relation of valvular disease to other clinical features of lupus, whether or not the valve disease progresses, and the associated morbidity and mortality. Methods We performed transesophageal echo-cardiography and rheumatologic evaluations in 69 patients with systemic lupus erythematosus. The echocardiographic findings were compared with those in 56 healthy volunteers. Fifty-eight patients (84 percent) had second evaluations a mean (+/-SD) period of 29+/-13 months later. The patients and controls were followed for 57 months. Results Valvular abnormalities were common on the initial and the follow-up echocardiograms (in 61 and 53 percent of the patients, respectively). Valvular thickening was the predominant finding initially and on follow-up (in 51 and 52 percent of the patients, respectively), followed by vegetations (in 43 and 34 percent), valvular regurgitation (in 25 and 28 percent), and stenosis (in 4 and 3 percent). Valvular abnormalities frequently resolved, appeared for the first time, or persisted but changed in appearance or size between the two studies. Mild or moderate valvular regurgitation did not progress to become severe, and new stenoses did not develop. Neither the presence of valvular disease nor changes in the echocardiographic findings were temporally related to the duration, activity, or severity of lupus or to its treatment. The combined incidence of stroke, peripheral embolism, heart failure, infective endocarditis, and the need for valve replacement was 22 percent in the patients with valvular disease, but only 8 percent in those without it. A total of seven patients died during follow-up, in most cases as a result of valvular disease. Valvular abnormalities and complications were uncommon in the controls (occurring in 9 and 2 percent, respectively). Conclusions Valvular heart disease is common in patients with systemic lupus erythematosus, frequently changes over time, appears to be temporally unrelated to other clinical features of lupus, and is associated with substantial morbidity and mortality. (C)1996, Massachusetts Medical Society.	UNIV NEW MEXICO,CTR HLTH SCI,ALBUQUERQUE,NM 87131	University of New Mexico	Roldan, CA (corresponding author), VET AFFAIRS MED CTR,DIV CARDIOL,5B-111,2100 RIDGECREST DR SE,ALBUQUERQUE,NM 87108, USA.							BELMONT HM, 1986, ARTHRITIS RHEUM, V29, P1085, DOI 10.1002/art.1780290905; BIDANI AK, 1980, AM J MED, V69, P849, DOI 10.1016/S0002-9343(80)80010-6; BLANCHARD DG, 1992, CHEST, V102, P954, DOI 10.1378/chest.102.3.954; BULKLEY BH, 1975, AM J MED, V58, P243, DOI 10.1016/0002-9343(75)90575-6; CASTELLO R, 1992, J AM COLL CARDIOL, V19, P1516, DOI 10.1016/0735-1097(92)90612-Q; CURRIE PJ, 1985, CIRCULATION, V71, P1162, DOI 10.1161/01.CIR.71.6.1162; CYT SOFTW, 1995, STATX 3 WIND US MAN; DAJEE H, 1983, J THORAC CARDIOV SUR, V85, P718; DEPPISCH LM, 1976, AM HEART J, V92, P723, DOI 10.1016/S0002-8703(76)80008-7; DEVINSKY O, 1988, ANN NEUROL, V23, P380, DOI 10.1002/ana.410230411; ESTES D, 1971, MEDICINE, V50, P85, DOI 10.1097/00005792-197103000-00001; Fleiss JL., 1981, STAT METHODS RATES P, V2, P22; FUTRELL N, 1989, STROKE, V20, P583, DOI 10.1161/01.STR.20.5.583; GALVE E, 1988, NEW ENGL J MED, V319, P817, DOI 10.1056/NEJM198809293191302; GORELICK PB, 1985, ARCH NEUROL-CHICAGO, V42, P813, DOI 10.1001/archneur.1985.04210090081022; HAY E, 1993, ANN RHEUM DIS, V52, P169, DOI 10.1136/ard.52.3.169; HELLMANN DB, 1987, MEDICINE, V66, P341, DOI 10.1097/00005792-198709000-00002; Hojnik M, 1996, CIRCULATION, V93, P1579, DOI 10.1161/01.CIR.93.8.1579; KATZ JD, 1993, LUPUS, V2, P119, DOI 10.1177/096120339300200210; KHAMASHTA MA, 1990, LANCET, V335, P1541, DOI 10.1016/0140-6736(90)91373-I; Klemperer P, 1941, ARCH PATHOL, V32, P569; LEHMAN TJA, 1983, J RHEUMATOL, V10, P655; LEUNG WH, 1990, INT J CARDIOL, V27, P367, DOI 10.1016/0167-5273(90)90294-F; LIANG MH, 1988, ARTHRITIS RHEUM, V31, P817, DOI 10.1002/art.1780310701; Libman E, 1924, ARCH INTERN MED, V33, P701, DOI 10.1001/archinte.1924.00110300044002; LOPEZ JA, 1987, AM J CARDIOL, V59, P478, DOI 10.1016/0002-9149(87)90961-1; NIHOYANNOPOULOS P, 1990, CIRCULATION, V82, P369, DOI 10.1161/01.CIR.82.2.369; NIVED O, 1985, Q J MED, V55, P271; ONG ML, 1992, INT J CARDIOL, V34, P69, DOI 10.1016/0167-5273(92)90084-G; PERRY GJ, 1987, J AM COLL CARDIOL, V9, P952, DOI 10.1016/S0735-1097(87)80254-1; PILIERO P, 1990, SEMIN ARTHRITIS RHEU, V20, P185, DOI 10.1016/0049-0172(90)90059-O; PORCEL JM, 1995, CLIN IMMUNOL IMMUNOP, V74, P283, DOI 10.1006/clin.1995.1040; ROLDAN CA, 1992, J AM COLL CARDIOL, V20, P1127, DOI 10.1016/0735-1097(92)90368-W; SAS Institute, 1990, SAS STAT US GUID VER; SEWARD JB, 1988, MAYO CLIN PROC, V63, P649, DOI 10.1016/S0025-6196(12)65529-3; STURFELT G, 1992, MEDICINE, V71, P216, DOI 10.1097/00005792-199207000-00004; UROWITZ MB, 1984, J RHEUMATOL, V11, P783; WEI JY, 1992, NEW ENGL J MED, V327, P1735, DOI 10.1056/NEJM199212103272408	38	210	223	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 7	1996	335	19					1424	1430		10.1056/NEJM199611073351903	http://dx.doi.org/10.1056/NEJM199611073351903			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT339	8875919				2022-12-24	WOS:A1996VT33900003
J	Julian, DG				Julian, DG			If I woke with central chest pain	LANCET			English	Article							TRIALS; INFARCTION											ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1986, Lancet, V2, P57; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; *BET BLOCK POOL PR, 1988, J HYPERTENS       S4, V9, P8; COHEN M, 1994, CIRCULATION, V89, P81, DOI 10.1161/01.CIR.89.1.81; COLLINS R, 1995, LANCET, V345, P669; DEVITA C, 1994, LANCET, V343, P1115; HUNT D, 1992, LANCET, V339, P753; LEIZOROVICZ A, 1988, EUR HEART J, V9, P8; MICHELS KB, 1995, CIRCULATION, V91, P476, DOI 10.1161/01.CIR.91.2.476; PEDERSEN TR, 1994, LANCET, V344, P1383; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; VANDEWERF F, 1990, LANCET, V336, P71; WALSH JT, 1995, BRIT HEART J, V73, P470; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1; YUSUF S, 1993, J HYPERTENS, V11, pS61	16	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV	1996	348			1			S29	S31		10.1016/S0140-6736(96)98010-1	http://dx.doi.org/10.1016/S0140-6736(96)98010-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU008	8918527				2022-12-24	WOS:A1996VU00800011
J	Yang, YF; Cole, MD				Yang, YF; Cole, MD			Visual acuity testing in schools: What needs to be done	BRITISH MEDICAL JOURNAL			English	Article									TORBAY HOSP,DEPT OPHTHALMOL,TORQUAY TQ2 7AA,DEVON,ENGLAND									BLACKHURST DW, 1989, RETINA-J RET VIT DIS, V9, P163, DOI 10.1097/00006982-198909030-00001; *BRIT STAND I, 1968, 42741968 BS BRIT STA; EVANSJONES G, 1994, JOINT WORK PART OPHT; INGRAM RM, 1989, BRIT MED J, V298, P935, DOI 10.1136/bmj.298.6678.935	4	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 26	1996	313	7064					1053	1053						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP742	8898598				2022-12-24	WOS:A1996VP74200028
J	Lapham, CK; Ouyang, J; Chandrasekhar, B; Nguyen, NY; Dimitrov, DS; Golding, H				Lapham, CK; Ouyang, J; Chandrasekhar, B; Nguyen, NY; Dimitrov, DS; Golding, H			Evidence for cell-surface association between fusin and the CD4-gp120 complex in human cell lines	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ENVELOPE GLYCOPROTEIN; T-CELL; CD4; COMPONENT(S); MACROPHAGES; MODULATION; TROPISM	Accessory cell-surface molecules involved in the entry of human immunodeficiency virus-type 1 into cells have recently been identified and shown to belong to the family of chemokine receptors, Treatment of human cell lines with soluble monomeric gp120 at 37 degrees C induced an association between the surface CD4-gp120 complex and a 45-kilodalton protein, which can be down-modulated by the phorbol ester phorbol 12-myristate 13-acetate. The three proteins were coprecipitated from the cell membranes with antibodies to CD4 or to gp120, The 45-kilodalton protein comigrated with fusin on sodium dodecyl sulfate gels and reacted with rabbit antisera to fusin in protein immunoblots, No 45-kilodalton protein could be coprecipitated from similarly treated nonhuman cells, However, infection of 3T3.CD4.401 cells with vaccinia-fusin recombinant virus (vCBYF1), followed by gp120 treatment, resulted in coprecipitation of fusin and CD4.401 molecules from their membranes. Together these data provide evidence for physical association between fusin and the CD4-gp120 complex on cell membranes.	NCI, MEMBRANE STRUCT & FUNCT SECT, BETHESDA, MD 20892 USA; US FDA, CTR BIOL EVALUAT & RES, FACIL BIOTECHNOL RESOURCES, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA)	Lapham, CK (corresponding author), US FDA, CTR BIOL EVALUAT & RES,DIV VIRAL PROD,BLDG 29B, ROOM 3G21,HFM 454, 8800 ROCKVILLE PIKE, BETHESDA, MD 20892 USA.							Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; ASHORN PA, 1990, J VIROL, V64, P2149, DOI 10.1128/JVI.64.5.2149-2156.1990; ASJO B, 1986, LANCET, V2, P660; Berson JF, 1996, J VIROL, V70, P6288, DOI 10.1128/JVI.70.9.6288-6295.1996; BRODER CC, 1993, VIROLOGY, V193, P483, DOI 10.1006/viro.1993.1151; BRODER CC, 1995, P NATL ACAD SCI USA, V92, P9004, DOI 10.1073/pnas.92.19.9004; CHENGMAYER C, 1990, J VIROL, V64, P4390, DOI 10.1128/JVI.64.9.4390-4398.1990; CHESEBRO B, 1991, J VIROL, V65, P5782, DOI 10.1128/JVI.65.11.5782-5789.1991; CHOE H, 1996, SCIENCE, V272, P1149; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dimitrov DS, 1996, NAT MED, V2, P640, DOI 10.1038/nm0696-640; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GOLDING H, 1995, J VIROL, V69, P6140, DOI 10.1128/JVI.69.10.6140-6148.1995; GOLDING H, 1994, J VIROL, V68, P1962, DOI 10.1128/JVI.68.3.1962-1969.1994; HORUK R, 1994, IMMUNOL TODAY, V15, P169, DOI 10.1016/0167-5699(94)90314-X; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409	17	341	351	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 25	1996	274	5287					602	605		10.1126/science.274.5287.602	http://dx.doi.org/10.1126/science.274.5287.602			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN919	8849450				2022-12-24	WOS:A1996VN91900048
J	Collinge, J; Sidle, KCL; Meads, J; Ironside, J; Hill, AF				Collinge, J; Sidle, KCL; Meads, J; Ironside, J; Hill, AF			Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD	NATURE			English	Article							CREUTZFELDT-JAKOB-DISEASE; TRANSMISSIBLE MINK ENCEPHALOPATHY; BOVINE SPONGIFORM ENCEPHALOPATHY; MICE EXPRESSING HUMAN; SCRAPIE; PROTEIN; PRP; REPLICATION; PROPAGATION; MEDICINE	Strains of transmissible spongiform encephalopathies are distinguished by differing physicochemical properties of PrPSc, the disease-related isoform of prion protein, which can be maintained on transmission to transgenic mice. 'New variant' Creutzfeldt-Jakob disease (CJD) has strain characteristics distinct from other types of CJD and which resemble those of BSE transmitted to mice, domestic cat and macaque, consistent with BSE being the source of this new disease. Strain characteristics revealed here suggest that the prion protein may itself encode disease phenotype.	WESTERN GEN HOSP, NATL CJD SURVEILLANCE UNIT, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND; ST MARYS HOSP, DEPT NEUROL, LONDON W2 1NY, ENGLAND	University of Edinburgh; Imperial College London	Collinge, J (corresponding author), ST MARYS, IMPERIAL COLL SCH MED, DEPT BIOCHEM & MOL GENET, NEUROGENET UNIT, LONDON W2 1PG, ENGLAND.		Hill, Andrew F./GZL-4124-2022; Hill, Andrew F./AAH-2854-2020; Hill, Andrew F/B-4527-2009	Hill, Andrew F./0000-0001-5581-2354; Hill, Andrew F/0000-0001-5581-2354; Ironside, James/0000-0001-5869-2108	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAKER HF, 1991, LANCET, V337, P1286, DOI 10.1016/0140-6736(91)92953-Y; BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; BESSEN RA, 1992, J VIROL, V66, P2096, DOI 10.1128/JVI.66.4.2096-2101.1992; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; BROWN P, 1994, NEUROLOGY, V44, P291, DOI 10.1212/WNL.44.2.291; BROWN P, 1992, LANCET, V340, P24, DOI 10.1016/0140-6736(92)92431-E; BRUCE M, 1994, PHILOS T R SOC B, V343, P405, DOI 10.1098/rstb.1994.0036; BRUCE ME, 1992, HUMAN ANIMALS, P497; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CARLSON GA, 1986, CELL, V46, P503, DOI 10.1016/0092-8674(86)90875-5; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; COLLINGE J, 1995, NATURE, V378, P779, DOI 10.1038/378779a0; Collinge J, 1996, LANCET, V348, P56, DOI 10.1016/S0140-6736(05)64378-4; HARAGUCHI T, 1989, ARCH BIOCHEM BIOPHYS, V274, P1, DOI 10.1016/0003-9861(89)90409-8; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KIMBERLIN RH, 1988, J GEN VIROL, V69, P2953, DOI 10.1099/0022-1317-69-12-2953; KIMBERLIN RH, 1989, VIRUS RES, V12, P201, DOI 10.1016/0168-1702(89)90039-7; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPLANCHE JL, 1994, NEUROLOGY, V44, P2347, DOI 10.1212/WNL.44.12.2347; Lasmezas CI, 1996, NATURE, V381, P743, DOI 10.1038/381743a0; MARSH RF, 1975, J INFECT DIS, V131, P104, DOI 10.1093/infdis/131.2.104; Page G, 1996, NATURE, V382, P381, DOI 10.1038/382381b0; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; Palmer MS, 1996, HUM MUTAT, V7, P280, DOI 10.1002/(SICI)1098-1004(1996)7:3<280::AID-HUMU17>3.0.CO;2-Z; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Parchi P, 1996, ANN NEUROL, V39, P767, DOI 10.1002/ana.410390613; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Schreuder BEC, 1996, NATURE, V381, P563, DOI 10.1038/381563a0; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; TELLING GC, 1994, P NATL ACAD SCI USA, V91, P9936, DOI 10.1073/pnas.91.21.9936; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEISSMANN C, 1991, NATURE, V349, P569, DOI 10.1038/349569a0; WELLER RO, 1989, PSYCHOL MED, V19, P1, DOI 10.1017/S0033291700010965; WELLS GAH, 1995, BRAIN PATHOL, V5, P91, DOI 10.1111/j.1750-3639.1995.tb00580.x; WHITTINGTON MA, 1995, NAT GENET, V9, P197, DOI 10.1038/ng0295-197; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; Windl O, 1996, HUM GENET, V98, P259, DOI 10.1007/s004390050204; WYATT JM, 1991, VET REC, V129, P233, DOI 10.1136/vr.129.11.233	42	1465	1490	1	114	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 24	1996	383	6602					685	690		10.1038/383685a0	http://dx.doi.org/10.1038/383685a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN918	8878476				2022-12-24	WOS:A1996VN91800044
J	Williams, DJ; Mauk, BH; McEntire, RE; Roelof, EC; Armstrong, TP; Wilken, B; Roederer, JG; Krimigis, SM; Fritz, TA; Lanzerotti, LJ				Williams, DJ; Mauk, BH; McEntire, RE; Roelof, EC; Armstrong, TP; Wilken, B; Roederer, JG; Krimigis, SM; Fritz, TA; Lanzerotti, LJ			Electron beams and ion composition measured at Io and in its torus	SCIENCE			English	Article							JOVIAN MAGNETOSPHERE; PLASMA TORUS; HOT PLASMA; JUPITER	Intense, magnetic field-aligned, bidirectional, energetic (>15 kiloelectron volts) electron beams were discovered by the Galileo energetic particles detector during the flyby of Io. These beams can carry sufficient energy flux into Jupiter's atmosphere to produce a visible aurora at the footprint of the magnetic flux tube connecting Io to Jupiter. Composition measurements through the torus showed that the spatial distributions of protons, oxygen, and sulfur are different, with sulfur being the dominant energetic (>similar to 10 kiloelectron volts per nucleon) ion at closest approach.	UNIV KANSAS,DEPT PHYS & ASTRON,LAWRENCE,KS 66045; MAX PLANCK INST AERON,D-37189 KATLENBURG DUHM,GERMANY; UNIV ALASKA,INST GEOPHYS,FAIRBANKS,AK 99775; BOSTON UNIV,CTR SPACE PHYS,BOSTON,MA 02215; LUCENT TECHNOL,MURRAY HILL,NJ 07974	University of Kansas; Max Planck Society; University of Alaska System; University of Alaska Fairbanks; Boston University; Alcatel-Lucent; Lucent Technologies	Williams, DJ (corresponding author), JOHNS HOPKINS UNIV,APPL PHYS LAB,JOHNS HOPKINS RD,LAUREL,MD 20723, USA.		Krimigis, Stamatios/G-4591-2019; Roelof, Edmond/G-6654-2019; Mauk, Barry H/E-8420-2017	Krimigis, Stamatios/0000-0003-2781-2386; Roelof, Edmond/0000-0002-2270-0652; Mauk, Barry H/0000-0001-9789-3797; Roederer, Juan/0000-0002-8042-5150				ARMSTRONG TP, 1981, J GEOPHYS RES-SPACE, V86, P8343, DOI 10.1029/JA086iA10p08343; BAGENAL F, 1983, J GEOPHYS RES-SPACE, V88, P3013, DOI 10.1029/JA088iA04p03013; CARR TD, 1983, PHYSICS JOVIAN MAGNE, P266; Clarke JT, 1996, SCIENCE, V274, P404, DOI 10.1126/science.274.5286.404; CONNERNEY JEP, 1993, SCIENCE, V262, P1035, DOI 10.1126/science.262.5136.1035; FILLIUS RW, 1974, J GEOPHYS RES, V79, P3589, DOI 10.1029/JA079i025p03589; GOERTZ CK, 1980, J GEOPHYS RES-SPACE, V85, P2949, DOI 10.1029/JA085iA06p02949; GOLDREICH P, 1969, ASTROPHYS J, V156, P59, DOI 10.1086/149947; GOLDSTEIN ML, 1983, PHYSICS JOVIAN MAGNE, P317; GURNETT DA, 1972, ASTROPHYS J, V175, P525, DOI 10.1086/151576; Kivelson MG, 1996, SCIENCE, V273, P337, DOI 10.1126/science.273.5273.337; KLUMPAR DM, 1988, GEOPHYS RES LETT, V15, P1295, DOI 10.1029/GL015i011p01295; KRIMIGIS SM, 1981, J GEOPHYS RES-SPACE, V86, P8227, DOI 10.1029/JA086iA10p08227; LANZEROTTI LJ, 1992, SCIENCE, V257, P1518, DOI 10.1126/science.257.5076.1518; NEUBAUER FM, 1980, J GEOPHYS RES-SPACE, V85, P1171, DOI 10.1029/JA085iA03p01171; Prange R, 1996, NATURE, V379, P323, DOI 10.1038/379323a0; SHAWHAN SD, 1976, J GEOPHYS RES-SPACE, V81, P3373, DOI 10.1029/JA081i019p03373; SMITH RA, 1978, J GEOPHYS RES-SPACE, V83, P2617, DOI 10.1029/JA083iA06p02617; WILLIAMS DJ, 1992, SPACE SCI REV, V60, P385, DOI 10.1007/BF00216863	19	92	92	2	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1996	274	5286					401	403		10.1126/science.274.5286.401	http://dx.doi.org/10.1126/science.274.5286.401			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN173	8832885				2022-12-24	WOS:A1996VN17300048
J	Durr, A; Cossee, M; Agid, Y; Campuzano, V; Mignard, C; Penet, C; Mandel, JL; Brice, A; Koenig, M				Durr, A; Cossee, M; Agid, Y; Campuzano, V; Mignard, C; Penet, C; Mandel, JL; Brice, A; Koenig, M			Clinical and genetic abnormalities in patients with Friedreich's ataxia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RETAINED TENDON REFLEXES; ONSET CEREBELLAR-ATAXIA; DISEASE; CARDIOMYOPATHY; MUTATION; FEATURES; PROTEIN; LOCUS	Background Friedreich's ataxia, the most common inherited ataxia, is associated with a mutation that consists of an unstable expansion of GAA repeats in the first intron of the frataxin gene on chromosome 9, which encodes a protein of unknown function. Methods We studied 187 patients with autosomal recessive ataxia, determined the size of the GAA expansions, and analyzed the clinical manifestations in relation to the number of GAA repeats and the duration of disease. Results One hundred forty of the 187 patients, with ages at onset ranging from 2 to 51 years, were homozygous for a GAA expansion that had 120 to 1700 repeats of the trinucleotides. About one quarter of the patients, despite being homozygous, had atypical Friedreich's ataxia; they were older at presentation and had intact tendon reflexes. Larger GAA expansions correlated with earlier age at onset and shorter times to loss of ambulation. The size of the GAA expansions (and particularly that of the smaller of each pair) was associated with the frequency of cardiomyopathy and loss of reflexes in the upper limbs. The GAA repeats were unstable during transmission. Conclusions The clinical spectrum of Friedreich's ataxia is broader than previously recognized, and the direct molecular test for the GAA expansion on chromosome 9 is useful for diagnosis, determination of prognosis, and genetic counseling. (C) 1996, Massachusetts Medical Society.	HOP LA PITIE SALPETRIERE, INSERM, U289, F-75651 PARIS 13, FRANCE; HOP LA PITIE SALPETRIERE, FEDERAT NEUROL, F-75651 PARIS 13, FRANCE; INST GENET & BIOL MOL & CELLULAIRE, STRASBOURG, FRANCE; CTR HOSP GEN ST PIERRE, ST PIERRE, Reunion, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm)			CAMPUZANO, VICTORIA/K-7883-2019; brice, alexis/AAE-8275-2019; Campuzano, Victoria/ABG-7429-2020; Brice, Alexis/A-2170-2009; Campuzano, V/G-1826-2014	brice, alexis/0000-0002-0941-3990; Campuzano, Victoria/0000-0001-8128-2641; Campuzano, V/0000-0001-8128-2641				Ashley CT, 1995, ANNU REV GENET, V29, P703, DOI 10.1146/annurev.ge.29.120195.003415; BENHAMIDA C, 1993, NAT GENET, V5, P195, DOI 10.1038/ng1093-195; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; CHAMBERLAIN S, 1988, NATURE, V334, P248, DOI 10.1038/334248a0; DEMICHELE G, 1994, J NEUROL NEUROSUR PS, V57, P977, DOI 10.1136/jnnp.57.8.977; DEMICHELE G, 1989, J NEUROL NEUROSUR PS, V52, P1398, DOI 10.1136/jnnp.52.12.1398; DEVYS D, 1993, NAT GENET, V4, P335, DOI 10.1038/ng0893-335; Durr A, 1996, CURR OPIN NEUROL, V9, P290; FILLA A, 1990, J NEUROL NEUROSUR PS, V53, P667, DOI 10.1136/jnnp.53.8.667; HANAUER A, 1990, AM J HUM GENET, V46, P133; HARDING AE, 1981, BRAIN, V104, P589, DOI 10.1093/brain/104.3.589; HARDING AE, 1981, J NEUROL NEUROSUR PS, V44, P503, DOI 10.1136/jnnp.44.6.503; KLOCKGETHER T, 1991, BRAIN, V114, P1559, DOI 10.1093/brain/114.4.1559; KLOCKGETHER T, 1993, ARCH NEUROL-CHICAGO, V50, P803, DOI 10.1001/archneur.1993.00540080014006; Klockgether T, 1996, NEUROLOGY, V46, P118, DOI 10.1212/WNL.46.1.118; MORVAN D, 1992, EUR HEART J, V13, P1393, DOI 10.1093/oxfordjournals.eurheartj.a060072; PALAU F, 1995, ANN NEUROL, V37, P359, DOI 10.1002/ana.410370312; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; ROSS CA, 1995, NEURON, V15, P493, DOI 10.1016/0896-6273(95)90138-8; TROTTIER Y, 1995, NAT GENET, V10, P104, DOI 10.1038/ng0595-104	20	747	763	0	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 17	1996	335	16					1169	1175		10.1056/NEJM199610173351601	http://dx.doi.org/10.1056/NEJM199610173351601			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN401	8815938				2022-12-24	WOS:A1996VN40100001
J	Lazard, T; Retel, O; Guidet, B; Maury, E; Valleron, AJ; Offenstadt, G				Lazard, T; Retel, O; Guidet, B; Maury, E; Valleron, AJ; Offenstadt, G			AIDS in a medical intensive care unit - Immediate prognosis and long-term survival	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PNEUMOCYSTIS-CARINII PNEUMONIA; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; RESPIRATORY-FAILURE; MECHANICAL VENTILATION; ADMISSION; INFECTION; MORTALITY; OUTCOMES; COUNT	Objective.-To help physicians decide whether to admit patients with acquired immunodeficiency syndrome (AIDS) to the medical intensive care unit (MICU). Design.-Case series study of AIDS patients admitted to the MICU between October 1990 and October 1992 and followed up until April 1993 (median follow-up, 1 year). Setting.-The MICU in a 970-bed teaching hospital in Paris, France. Patients.-A total of 120 consecutive AIDS patients with acute respiratory failure (50%), central nervous system dysfunction (22.5%), pneumothorax (12.5%), shock (10.8%), or miscellaneous conditions (4.2%), A fetal of 86 patients were discharged alive from the MICU. Main Outcome Measures.-Predictive factors for mortality during and after MICU stay. Results.-Multivariate analysis identified 3 factors predicting poor MICU outcome: Simplified Acute Physiology Score I (SAPS I) above 10 (relative risk [RR], 6.1, 95% confidence interval [CI]: 1.5-26.6), time between AIDS diagnosis and MICU admission more than 1 year(RR, 6.0; 95% CI, 2.1-17.5), serum albumin level less than 30 g/L (RR, 4.9; 95% CI, 1.3-18.2). The CD4 cell count, beta(2)-microglobulinemia, and previous opportunistic infections had no influence on MICU mortality. After MICU discharge, survival rates were 86% al 1 week, 82% at 1 month, 53% at 6 months, and 39% at 1 year, The Karnofsky scale score and the number of previous opportunistic infections were simultaneously associated with post-MICU outcome. Predictive factors for MICU survival did not influence post-MICU survival. Conclusion.-The MICU mortality was related to immediate severity (assessed within 48 hours of admission) and the time between AIDS diagnosis and MICU admission. Long-term survival after MICU discharge depended only on the severity of AIDS. We conclude that AIDS patients should be admitted to the MICU on the same basis as other patients.	HOP ST ANTOINE,UNITE BIOSTAT & INFORMAT MED,F-75571 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite	Lazard, T (corresponding author), HOP ST ANTOINE,SERV REANIMAT POLYVALENTE,184 RUE FAUBOURG ST ANTOINE,F-75012 PARIS,FRANCE.							BEDOS JP, 1995, JAMA-J AM MED ASSOC, V273, P35, DOI 10.1001/jama.273.1.35; DEAM R, 1988, ANAESTHESIA, V43, P150; DEPALO VA, 1995, CHEST, V107, P506, DOI 10.1378/chest.107.2.506; EFFEREN LS, 1989, AM J MED, V87, P401, DOI 10.1016/S0002-9343(89)80821-6; ELSADR W, 1988, AM REV RESPIR DIS, V137, P1264, DOI 10.1164/ajrccm/137.6.1264; FRIEDMAN Y, 1990, CRIT CARE MED, V18, P346, DOI 10.1097/00003246-199003000-00027; FRIEDMAN Y, 1991, JAMA-J AM MED ASSOC, V266, P89, DOI 10.1001/jama.266.1.89; HAWLEY PH, 1994, CHEST, V106, P1456, DOI 10.1378/chest.106.5.1456; HOOVER DR, 1993, NEW ENGL J MED, V329, P1922, DOI 10.1056/NEJM199312233292604; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEGALL JR, 1984, CRIT CARE MED, V12, P975; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; MILLS GD, 1993, AIDS, V7, P1383, DOI 10.1097/00002030-199310000-00013; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; ROGERS PL, 1989, CRIT CARE MED, V17, P113, DOI 10.1097/00003246-198902000-00001; ROSEN MJ, 1993, CRIT CARE CLIN, V9, P107, DOI 10.1016/S0749-0704(18)30210-0; ROSEN MJ, 1986, J INTENSIVE CARE MED, V1, P55; SCHEIN RMH, 1986, CRIT CARE MED, V14, P1026, DOI 10.1097/00003246-198612000-00006; SMITH RL, 1989, CHEST, V96, P857, DOI 10.1378/chest.96.4.857; STAIKOWSKY F, 1993, CHEST, V104, P756, DOI 10.1378/chest.104.3.756; TEASDALE G, 1974, LANCET, V2, P81; TUCKER KJ, 1992, WESTERN J MED, V157, P637; WACHTER RM, 1991, AM REV RESPIR DIS, V143, P251, DOI 10.1164/ajrccm/143.2.251; WACHTER RM, 1995, JAMA-J AM MED ASSOC, V273, P230, DOI 10.1001/jama.273.3.230; WACHTER RM, 1986, AM REV RESPIR DIS, V134, P891, DOI 10.1164/arrd.1986.134.5.891; WACHTER RM, 1992, JAMA-J AM MED ASSOC, V267, P541, DOI 10.1001/jama.267.4.541; YARCHOAN R, 1991, ANN INTERN MED, V115, P184, DOI 10.7326/0003-4819-115-3-184; 1986, REANIM SOINS INTENSI, V2, P219; 1987, MMWR-MORBID MORTAL W, V36, pS1; 1993, B EPIDEMIOL HEBDOMAD, V7, P25	30	27	28	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	1996	276	15					1240	1245		10.1001/jama.276.15.1240	http://dx.doi.org/10.1001/jama.276.15.1240			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL691	8849752				2022-12-24	WOS:A1996VL69100033
J	Anderson, RM; Garnett, GP				Anderson, RM; Garnett, GP			Low-efficacy HIV vaccines: Potential for community-based intervention programmes	LANCET			English	Article							DEVELOPING-COUNTRIES; SPREAD; TRANSMISSION; POPULATIONS; INFECTION; IMPACT; TRIALS; RATES; AGE	To combat the spread of HIV, progress on vaccine development is eagerly awaited. Haynes in this series has described the progress made so far with various vaccine types. This article describes how mathematical modelling techniques can be used to predict the likely impact of low-efficacy vaccines in community transmission of the virus. The answers are often not what one would predict by intuition alone, and they have great bearing on the likely success of such vaccination strategies.			Anderson, RM (corresponding author), UNIV OXFORD, DEPT ZOOL, CTR EPIDEMIOL INFECT DIS, S PARKS RD, OXFORD OX1 3PS, ENGLAND.		Garnett, Geoffrey P/A-9312-2008	Anderson, Roy/0000-0002-9528-3175				ANDERSON R M, 1991; ANDERSON RM, 1991, NATURE, V350, P356, DOI 10.1038/350356a0; ANDERSON RM, 1995, P ROY SOC B-BIOL SCI, V261, P147, DOI 10.1098/rspb.1995.0129; Bloom BR, 1996, SCIENCE, V272, P1888, DOI 10.1126/science.272.5270.1888; BLOWER SM, 1994, SCIENCE, V265, P1451, DOI 10.1126/science.8073289; GARNETT GP, 1993, PHILOS T R SOC B, V342, P137, DOI 10.1098/rstb.1993.0143; GARNETT GP, 1995, J ACQ IMMUN DEF SYND, V9, P500; GARNETT GP, 1994, IMA J MATH APPL MED, V11, P161; Gregson S, 1994, Health Transit Rev, V4 Suppl, P65; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; HALLORAN ME, 1991, AM J EPIDEMIOL, V133, P323, DOI 10.1093/oxfordjournals.aje.a115884; HALLORAN ME, 1994, STAT MED, V13, P357, DOI 10.1002/sim.4780130404; JACKSON DJ, 1995, AIDS, V9, P1279, DOI 10.1097/00002030-199511000-00010; MCLEAN AR, 1993, P ROY SOC B-BIOL SCI, V253, P9, DOI 10.1098/rspb.1993.0075; MOORE J, 1994, NATURE, V372, P313, DOI 10.1038/372313a0; MULDER D, 1995, BRIT MED J, V311, P833, DOI 10.1136/bmj.311.7009.833; PARKER G, IN PRESS IMAJ MATH A; RIDA WN, 1994, STAT MED, V13, P2155, DOI 10.1002/sim.4780131922; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59	19	70	70	2	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 12	1996	348	9033					1010	1013		10.1016/S0140-6736(96)07100-0	http://dx.doi.org/10.1016/S0140-6736(96)07100-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM027	8855867				2022-12-24	WOS:A1996VM02700023
J	Ramos, R; Kennedy, KI; Visness, CM				Ramos, R; Kennedy, KI; Visness, CM			Effectiveness of lactational amenorrhoea in prevention of pregnancy in Manila, the Philippines: Non-comparative prospective trial	BRITISH MEDICAL JOURNAL			English	Article							CONTRACEPTIVE FAILURE	Objective-To determine the contraceptive efficacy of the lactational amenorrhoea method. Design-Non-comparative prospective trial. Setting-Urban Manila, the Philippines. Subjects-485 lower income, educated women with extensive experience of breast feeding. Intervention-Women were offered all available contraceptives for use after birth. Those who chose the lactational amenorrhoea method were taught the method, screened for the study, and followed for 12 months to determine the risk of pregnancy when the method was used. Main outcome measures-Life table pregnancy rates during correct and incorrect use of the method, censored monthly in the event of sexual abstinence or the use of another contraceptive method. Results-The lactational amenorrhoea method was 99% effective when used correctly (that is, during lactational amenorrhoea and full or nearly full breast feeding for up to six months). At 12 months the effectiveness during amenorrhoea dropped to 97%. Conclusions-The lactational amenorrhoea method provided as much protection from pregnancy as non-breast feeding women experience with non-medicated intrauterine devices and barrier methods. The contraceptive effect of lactation cannot be attributed to lactational or postpartum abstinence.	JOSE FABELLA MEM HOSP,COMPREHENS FAMILY PLANNING CTR,MANILA,PHILIPPINES; FAMILY HLTH INT,RES TRIANGLE PK,NC 27709									COX DR, 1984, ANAL SURVIVAL DATA, P2; Francis B., 1993, GLIM SYSTEM RELEASE; KAZI A, 1995, FERTIL STERIL, V64, P717, DOI 10.1016/S0015-0282(16)57845-5; KENNEDY KI, 1989, CONTRACEPTION, V39, P477, DOI 10.1016/0010-7824(89)90103-0; LABBOK M, 1994, GUIDELINES BREASFEED; MOGGIA AV, 1991, CONTRACEPTION, V44, P31, DOI 10.1016/0010-7824(91)90104-N; PEREZ A, 1992, LANCET, V339, P968, DOI 10.1016/0140-6736(92)91538-J; ROLLAND R, 1976, BIBLIO REPROD, V8, P1; ROLLAND R, 1976, BIBLIO REPROD, V8, P93; *SAS I, 1991, SAS STAT REL 6 07; SIMPSONHEBERT M, 1981, STUD FAMILY PLANN, V12, P125, DOI 10.2307/1965593; TRUSSELL J, 1987, STUD FAMILY PLANN, V18, P237, DOI 10.2307/1966856; TRUSSELL J, 1991, STAT MED, V10, P201, DOI 10.1002/sim.4780100206; VANGINNE.JK, 1974, STUD FAMILY PLANN, V5, P201, DOI 10.2307/1965371; 1988, LANCET, V2, P1204	15	34	34	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 12	1996	313	7062					909	912						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM754	8876092	Green Published			2022-12-24	WOS:A1996VM75400023
J	Schnitzer, JE; Oh, P; McIntosh, DP				Schnitzer, JE; Oh, P; McIntosh, DP			Role of GTP hydrolysis in fission of caveolae directly from plasma membranes	SCIENCE			English	Article							GPI-ANCHORED PROTEINS; FROG MESENTERIC CAPILLARIES; TRANS-GOLGI-NETWORK; CELL-SURFACE; 3-DIMENSIONAL ORGANIZATION; VESICULAR TRANSPORT; MEDIATED TRANSPORT; ENDOTHELIAL-CELLS; MODIFIED ALBUMINS; VESICLES	Caveolae are specialized invaginated cell surface microdomains of undefined function. A cell-free system that reconstituted fission of caveolae from lung endothelial plasma membranes was developed. Addition of cytosol and the hydrolysis of guanosine triphosphate (GTP) induced caveolar fission. The budded caveolae were isolated as vesicles rich in caveolin and the sialoglycolipid G(M1) but not glycosylphosphatidylinositol (GPI)-anchored proteins. These vesicles contained the molecular machinery for endocytosis and transcytosis. In permeabilized endothelial cells, GTP stimulated, whereas GTP gamma S prevented, caveolar budding and endocytosis of the cholera toxin B chain to endosomes. Thus, caveolae may bud to form discrete carrier vesicles that participate in membrane trafficking.			Schnitzer, JE (corresponding author), HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT PATHOL,RES N,99 BROOKLINE AVE,BOSTON,MA 02215, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052766, R29HL043278] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52766, HL43278] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BUNDGAARD M, 1983, FED PROC, V42, P2425; BUNDGAARD M, 1979, P NATL ACAD SCI USA, V76, P6439, DOI 10.1073/pnas.76.12.6439; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; FRA AM, 1994, J BIOL CHEM, V269, P30745; FROKJAERJENSEN J, 1991, J ELECTRON MICR TECH, V19, P291, DOI 10.1002/jemt.1060190305; FROKJAERJENSEN J, 1980, J ULTRA MOL STRUCT R, V73, P9, DOI 10.1016/0022-5320(80)90111-2; FROKJAERJENSEN J, 1988, CELL TISSUE RES, V254, P17; GHITESCU L, 1992, J CELL BIOL, V117, P745, DOI 10.1083/jcb.117.4.745; GHITESCU L, 1986, J CELL BIOL, V102, P1304, DOI 10.1083/jcb.102.4.1304; GOLDBERG RI, 1987, J CELL PHYSIOL, V133, P203, DOI 10.1002/jcp.1041330202; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; HUET C, 1980, CELL, V21, P429, DOI 10.1016/0092-8674(80)90479-1; KING GL, 1985, SCIENCE, V227, P1583, DOI 10.1126/science.3883490; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; MAHOLTA V, 1989, CELL, V58, P329; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; MILICI AJ, 1987, J CELL BIOL, V105, P2603, DOI 10.1083/jcb.105.6.2603; MONTESANO R, 1982, NATURE, V296, P651, DOI 10.1038/296651a0; PALADE GE, 1968, J CELL BIOL, V37, P633, DOI 10.1083/jcb.37.3.633; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; PREDESCU D, 1994, P NATL ACAD SCI USA, V91, P3014, DOI 10.1073/pnas.91.8.3014; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; SCHNITZER JE, 1993, J BIOL CHEM, V268, P7562; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; SCHNITZER JE, 1992, J BIOL CHEM, V267, P24544; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; SCHNITZER JE, 1995, AM J PHYSIOL-HEART C, V268, pH48, DOI 10.1152/ajpheart.1995.268.1.H48; SCHNITZER JE, 1994, J BIOL CHEM, V269, P6072; SCHNITZER JE, 1994, BIOCHEM BIOPH RES CO, V199, P11, DOI 10.1006/bbrc.1994.1185; SCHNITZER JE, 1992, AM J PHYSIOL, V263, pH1872, DOI 10.1152/ajpheart.1992.263.6.H1872; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; SCHNITZER JE, 1996, AM J PHYSIOL, V270, P416; SCHNITZER JE, 1993, TRENDS CARDIOVAS MED, V3, P1024; SCHNITZER JE, UNPUB; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; SEVERS NJ, 1988, J CELL SCI, V90, P341; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMART EJ, 1994, J CELL BIOL, V124, P307, DOI 10.1083/jcb.124.3.307; TOOZE SA, 1990, NATURE, V347, P207, DOI 10.1038/347207a0; TRAN D, 1987, P NATL ACAD SCI USA, V84, P7957, DOI 10.1073/pnas.84.22.7957; Van Deurs Bo, 1993, Trends in Cell Biology, V3, P249	48	202	205	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1996	274	5285					239	242		10.1126/science.274.5285.239	http://dx.doi.org/10.1126/science.274.5285.239			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM671	8824187				2022-12-24	WOS:A1996VM67100041
J	Ericson, J; Morton, S; Kawakami, A; Roelink, H; Jessell, TM				Ericson, J; Morton, S; Kawakami, A; Roelink, H; Jessell, TM			Two critical periods of Sonic Hedgehog signaling required for the specification of motor neuron identify	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; MIDBRAIN DOPAMINERGIC-NEURONS; FLOOR PLATE DIFFERENTIATION; TERMINAL CLEAVAGE PRODUCT; CELL PATTERN; POLARIZING ACTIVITY; FROG EMBRYOS; SPINAL-CORD; INDUCTION; EXPRESSION	Antibodies that block Sonic Hedgehog (SHH) signaling have been used to show that SHH activity is required for the induction of floor plate differentiation by the notochord and independently for the induction of motor neurons by both the notochord and midline neural eels. Motor neuron generation depends on two critical periods of SHH signaling: an early period during which naive neural plate cells are converted into ventralized progenitors and a late period that extends well into S phase of the final progenitor cell division, during which SHH drives the differentiation of ventralized progenitors into motor neurons. The ambient SHH concentration during the late period determines whether ventralized progenitors differentiate into motor neurons or interneurons, thus defining the pattern of neuronal cell types generated in the neural tube.	NAGOYA UNIV, DIV BIOL SCI, NAGOYA, AICHI, JAPAN; UNIV WASHINGTON, DEPT BIOL STRUCT, SEATTLE, WA 98195 USA	Nagoya University; University of Washington; University of Washington Seattle	Ericson, J (corresponding author), COLUMBIA UNIV, CTR NEUROBIOL & BEHAV, HOWARD HUGHES MED INST, DEPT BIOCHEM & MOL BIOPHYS, NEW YORK, NY 10032 USA.		Kawakami, Atsushi/D-3785-2019	Kawakami, Atsushi/0000-0001-9461-6372; Ericson, Johan/0000-0002-8019-7127; Roelink, Henk/0000-0002-5260-3634				ALTABA AR, 1995, DEV BIOL, V170, P299; ALTABA ARI, 1993, P NATL ACAD SCI USA, V90, P8268, DOI 10.1073/pnas.90.17.8268; ALTABA ARI, 1995, MOL CELL NEUROSCI, V6, P106, DOI 10.1006/mcne.1995.1011; Bitgood MJ, 1996, CURR BIOL, V6, P298, DOI 10.1016/S0960-9822(02)00480-3; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; EKKER SC, 1995, CURR BIOL, V5, P944, DOI 10.1016/S0960-9822(95)00185-0; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; ERICSON J, 1995, CELL, V81, P747, DOI 10.1016/0092-8674(95)90536-7; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; GOULDING MD, 1993, DEVELOPMENT, V117, P1001; GURDON JB, 1987, DEVELOPMENT, V99, P285; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HATTA K, 1992, NEURON, V9, P629, DOI 10.1016/0896-6273(92)90027-B; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; HYNES M, 1995, CELL, V80, P95, DOI 10.1016/0092-8674(95)90454-9; HYNES M, 1995, NEURON, V15, P35, DOI 10.1016/0896-6273(95)90062-4; JESSELL TM, 1992, HARVEY LECT, V86, P87; JOSTES B, 1990, MECH DEVELOP, V33, P27, DOI 10.1016/0925-4773(90)90132-6; KIMMEL CB, 1994, DEVELOPMENT, V120, P265; KORZH V, 1993, DEVELOPMENT, V118, P417; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LANGMAN J, 1966, J COMP NEUROL, V127, P399, DOI 10.1002/cne.901270308; LEBER SM, 1990, J NEUROSCI, V10, P2451; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; Marigo V, 1996, P NATL ACAD SCI USA, V93, P9346, DOI 10.1073/pnas.93.18.9346; MARTI E, 1995, DEVELOPMENT, V121, P2537; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; MCCONNELL SK, 1991, SCIENCE, V254, P282, DOI 10.1126/science.1925583; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; PLACZEK M, 1993, DEVELOPMENT, V117, P205; PLACZEK M, 1995, CURR OPIN GENET DEV, V5, P499, DOI 10.1016/0959-437X(95)90055-L; PLACZEK M, 1991, DEVELOPMENT, P105; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; SASAKI H, 1994, CELL, V76, P103, DOI 10.1016/0092-8674(94)90176-7; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; TANABE Y, 1995, CURR BIOL, V5, P651, DOI 10.1016/S0960-9822(95)00130-8; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; Tremblay P, 1996, DEVELOPMENT, V122, P2555; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; WICKHAM TJ, 1992, BIOTECHNOL PROGR, V8, P391, DOI 10.1021/bp00017a003; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; ZECCA M, 1995, DEVELOPMENT, V121, P2265	52	735	766	0	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 15	1996	87	4					661	673		10.1016/S0092-8674(00)81386-0	http://dx.doi.org/10.1016/S0092-8674(00)81386-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VU035	8929535	hybrid			2022-12-24	WOS:A1996VU03500009
J	Kuzin, B; Roberts, I; Peunova, N; Enikolopov, G				Kuzin, B; Roberts, I; Peunova, N; Enikolopov, G			Nitric oxide regulates cell proliferation during Drosophila development	CELL			English	Article							NEURONAL NADPH DIAPHORASE; RIBONUCLEOTIDE REDUCTASE; NERVOUS-SYSTEM; SYNTHASE; EXPRESSION; PROTEIN; GROWTH; DEATH; TRANSIENT; CYCLE	Cell division and subsequent programmed cell death in imaginal discs of Drosophila larvae determine the final size of organs and structures of the adult fly. We show here that nitric oxide (NO) is involved in controlling the size of body structures during Drosophila development. We have found that NO synthase (NOS) is expressed at high levels in developing imaginal discs. Inhibition of NOS in larvae causes hypertrophy of organs and their segments in adult flies, whereas ectopic expression of NOS in larvae has the opposite effect. Blocking apoptosis in eye imaginal discs unmasks surplus cell proliferation and results in an increase in the number of ommatidia and component cells of individual ommatidia. These results argue that NO acts as an antiproliferative agent during Drosophila development, controlling the balance between cell proliferation and cell differentiation.	UNIV CAMBRIDGE, DEPT GENET, CAMBRIDGE, ENGLAND; RUSSIAN ACAD SCI, NK KOLTSOV DEV BIOL INST, MOSCOW 117808, RUSSIA	University of Cambridge; Russian Academy of Sciences	Kuzin, B (corresponding author), COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA.		Enikolopov, Grigori/P-5731-2019; Enikolopov, Grigori N/B-7771-2009	Enikolopov, Grigori/0000-0001-8178-8917; Enikolopov, Grigori N/0000-0001-8178-8917; Kuzin, Boris/0000-0001-9951-1553				BAKER NE, 1992, DEV BIOL, V150, P381, DOI 10.1016/0012-1606(92)90250-K; BLOTTNER D, 1995, HISTOCHEM J, V27, P785; BREDT DS, 1994, NEURON, V13, P301, DOI 10.1016/0896-6273(94)90348-4; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRYANT PJ, 1984, Q REV BIOL, V59, P387, DOI 10.1086/414040; BRYANT PJ, 1990, J CELL SCI, P169; BUCHKOVICH KJ, 1994, MOL BIOL CELL, V5, P1225, DOI 10.1091/mbc.5.11.1225; Cohen Stephen M., 1993, P747; COLLINOSDOBY P, 1995, J CELL BIOCHEM, V57, P399, DOI 10.1002/jcb.240570305; CRAMER KS, 1995, J COMP NEUROL, V353, P306, DOI 10.1002/cne.903530211; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; DECKER KF, 1995, J GASTROEN HEPATOL, V10, pS12, DOI 10.1111/j.1440-1746.1995.tb01789.x; ELLIS MC, 1993, DEVELOPMENT, V119, P855; FAIN MJ, 1982, DEV BIOL, V92, P247, DOI 10.1016/0012-1606(82)90169-5; Forstermann U, 1995, Adv Pharmacol, V34, P171; Fristrom D, 1993, DEV DROSOPHILA MELAN, P843; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3547, DOI 10.1073/pnas.87.9.3547; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; GRAVES BJ, 1982, DEV BIOL, V93, P104, DOI 10.1016/0012-1606(82)90243-3; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; HAY BA, 1994, DEVELOPMENT, V120, P2121; HOPE BT, 1991, P NATL ACAD SCI USA, V88, P2811, DOI 10.1073/pnas.88.7.2811; HORTELANO S, 1995, HEPATOLOGY, V21, P776; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; LEPOIVRE M, 1990, J BIOL CHEM, V265, P14143; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; MISRA S, 1990, CELL, V62, P269, DOI 10.1016/0092-8674(90)90365-L; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MULLER U, 1994, EUR J NEUROSCI, V6, P1362, DOI 10.1111/j.1460-9568.1994.tb00327.x; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; PEUNOVA N, 1995, NATURE, V375, P68, DOI 10.1038/375068a0; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; REGULSKI M, 1995, P NATL ACAD SCI USA, V92, P9072, DOI 10.1073/pnas.92.20.9072; ROSKAMS AJ, 1994, NEURON, V13, P289; SCHUBIGER M, 1987, DEV BIOL, V123, P145, DOI 10.1016/0012-1606(87)90436-2; Shaul P W, 1995, Adv Pediatr, V42, P367; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SPRADLING AC, 1986, DROSOPHILA PRACTICAL, P60; Thummel CS, 1992, DROS INF SERV, V71, P150; Wang Y, 1995, Adv Pharmacol, V34, P71; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WETTS R, 1995, DEV DYNAM, V202, P215, DOI 10.1002/aja.1002020302; WOLFF T, 1991, DEVELOPMENT, V113, P825; Wolff Tanya, 1993, P1277	51	220	229	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 15	1996	87	4					639	649		10.1016/S0092-8674(00)81384-7	http://dx.doi.org/10.1016/S0092-8674(00)81384-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VU035	8929533	Bronze			2022-12-24	WOS:A1996VU03500007
J	Ross, JDC; Sutherland, S; Coia, J				Ross, JDC; Sutherland, S; Coia, J			Genital Chlamydia trachomatis infections in primary care	BRITISH MEDICAL JOURNAL			English	Article									UNIV EDINBURGH,DEPT MED MICROBIOL,EDINBURGH,MIDLOTHIAN,SCOTLAND; WESTERN GEN HOSP,DEPT MED MICROBIOL,EDINBURGH,MIDLOTHIAN,SCOTLAND	University of Edinburgh; University of Edinburgh			Coia, John/AAP-5379-2020	Coia, John/0000-0002-4966-8453; Ross, Jonathan/0000-0002-4193-6919				MARDH PA, 1977, NEW ENGL J MED, V296, P1377, DOI 10.1056/NEJM197706162962403; REES E, 1980, AM J OBSTET GYNECOL, V138, P1042, DOI 10.1016/0002-9378(80)91105-9; WHITE D, 1991, BR J GEN PRACT, V41, P234	3	30	30	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1996	313	7066					1192	1193		10.1136/bmj.313.7066.1192a	http://dx.doi.org/10.1136/bmj.313.7066.1192a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR907	8916755	Green Published			2022-12-24	WOS:A1996VR90700028
J	Kai, J				Kai, J			Parents' difficulties and information needs in coping with acute illness in preschool children: A qualitative study	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; MINOR ILLNESS; BABY-CHECK; MOTHERS; BABIES	Objectives-To identify and explore difficulties parents experience with acute illness in young children and the information they seek to help them. Design-Qualitative study using semistructured one to one and group interviews with parents of preschool children. Setting-Disadvantaged inner city community, Subjects-95 parents of preschool children. Results-Parents felt disempowered when dealing with acute illness in their children because of difficulties making sense of the illness. Central to parents' difficulties were their experiences of inadequate information sharing by their general practitioners and variations in their doctors) decisions and behaviour. Disparity between parents' beliefs and expectations about illness and treatment and professionals' behaviour further frustrated parents' attempts to understand illness. Parents expressed a need for a range of accessible and specific information to support them through their negotiation of children's illness. Conclusions-Communication with parents requires greater recognition of parents) difficulties. Professionals have considerable potential to empower parents by sharing more information and skills. Such information should be consistent and address parents' concerns, beliefs, and expressed needs if this potential is to be realised.			Kai, J (corresponding author), UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT PRIMARY HLTH CARE,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND.			Kai, Joe/0000-0001-9040-9384				ANDERSON JE, 1980, BRIT MED J, V281, P924, DOI 10.1136/bmj.281.6245.924; BENSON P, 1988, J ROY COLL GEN PRACT, V38, P539; BLAXTER M, 1982, MTOHERS DAUGHTERS 3; Bloor MJ C., 1975, SOCIOLOGY MEDICAL PR, V1st ed, P271; Cunningham-Burley Sarah, 1990, READINGS MED SOCIOLO, P85; FIELD P, 1985, NURSING RES APPL QUA, P91; IRVINE S, 1991, BRIT J GEN PRACT, V41, P371; KAI J, 1993, BRIT MED J, V307, P660, DOI 10.1136/bmj.307.6905.660; KAI J, 1994, FAM PRACT, V11, P245, DOI 10.1093/fampra/11.3.245; Kai J, 1996, BRIT MED J, V313, P983; MARSH GN, 1995, BRIT MED J, V310, P778, DOI 10.1136/bmj.310.6982.778; MAYALL B, 1986, KEEPING CHILDREN HLT; MORRELL DC, 1980, BRIT MED J, V280, P769, DOI 10.1136/bmj.280.6216.769; MORRISON JM, 1991, BRIT MED J, V303, P1111, DOI 10.1136/bmj.303.6810.1111; Pike L A, 1980, J R Coll Gen Pract, V30, P517; Ruel A, 1981, J R Coll Gen Pract, V31, P496; Strauss A. L., 1990, GROUNDED THEORY PROC; THORNTON AJ, 1991, ARCH DIS CHILD, V66, P106, DOI 10.1136/adc.66.1.106; USHERWOOD TP, 1991, BRIT J GEN PRACT, V41, P58; WILKIN D, 1987, ANATOMY URBAN GEN P, P136	20	149	152	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 19	1996	313	7063					987	990						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN916	8892421				2022-12-24	WOS:A1996VN91600027
J	Julia, V; Rassoulzadegan, M; Glaichenhaus, N				Julia, V; Rassoulzadegan, M; Glaichenhaus, N			Resistance to Leishmania major induced by tolerance to a single antigen	SCIENCE			English	Article							CD4(+) T-CELLS; INTERFERON-GAMMA; MURINE LEISHMANIASIS; CUTANEOUS LEISHMANIASIS; TRANSGENIC MICE; TH2 CLONES; EXPRESSION; INTERLEUKIN-4; LYMPHOCYTES; INFECTION	In mice, susceptibility to Leishmania major is associated with the early expansion of T helper 2 cells (T(H)2) cells, but nothing is known of the specificity of these cells. A previously identified antigen, Leishmania homolog of receptors for activated C kinase (LACK), was found to be the focus of this initial response. Mice made tolerant to LACK by the transgenic expression of the antigen in the thymus exhibited both a diminished T(H)2 response and a healing phenotype. Thus, T cells that are activated early and are reactive to a single antigen play a pivotal role in directing the immune response to the entire parasite.	CNRS, INST PHARMACOL MOL & CELLULAIRE, F-06560 VALBONNE, FRANCE; FAC SCI, INSERM, U273, F-06108 NICE 2, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur			Rassoulzadegan, Minoo/O-7939-2016					ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; BENDELAC A, 1994, SCIENCE, V263, P1774, DOI 10.1126/science.7907820; BENDELAC A, 1995, SCIENCE, V268, P863, DOI 10.1126/science.7538697; CAMPOSNETO A, 1995, J EXP MED, V182, P1423, DOI 10.1084/jem.182.5.1423; Carrera L, 1996, J EXP MED, V183, P515, DOI 10.1084/jem.183.2.515; CHANG TL, 1990, J IMMUNOL, V145, P2803; CONSTANT S, 1995, J EXP MED, V182, P1591, DOI 10.1084/jem.182.5.1591; GAJEWSKI TF, 1991, J IMMUNOL, V146, P1750; Guler ML, 1996, SCIENCE, V271, P984, DOI 10.1126/science.271.5251.984; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; HEINZEL FP, 1991, P NATL ACAD SCI USA, V88, P7011, DOI 10.1073/pnas.88.16.7011; HOSKEN NA, 1995, J EXP MED, V182, P1579, DOI 10.1084/jem.182.5.1579; KUMAR V, 1995, P NATL ACAD SCI USA, V92, P9510, DOI 10.1073/pnas.92.21.9510; Liblau RS, 1996, P NATL ACAD SCI USA, V93, P3031, DOI 10.1073/pnas.93.7.3031; MORRIS L, 1993, INT IMMUNOL, V5, P761, DOI 10.1093/intimm/5.7.761; MORRIS L, 1992, J IMMUNOL, V149, P2715; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; MOUGNEAU E, 1995, SCIENCE, V268, P563, DOI 10.1126/science.7725103; MOWAT AM, 1987, IMMUNOL TODAY, V8, P93, DOI 10.1016/0167-5699(87)90853-X; REINER S, COMMUNICATION; REINER SL, 1994, J EXP MED, V179, P447, DOI 10.1084/jem.179.2.447; REINER SL, 1993, SCIENCE, V259, P1457, DOI 10.1126/science.8451641; ROBERTS M, 1993, EUR J IMMUNOGENET, V20, P349, DOI 10.1111/j.1744-313X.1993.tb00154.x; SADICK MD, 1987, J IMMUNOL, V139, P1303; SADICK MD, 1990, J EXP MED, V171, P115, DOI 10.1084/jem.171.1.115; SCOTT P, 1987, J IMMUNOL, V139, P3118; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SHANKAR AH, 1995, J EXP MED, V181, P845, DOI 10.1084/jem.181.3.845; SOARES LRB, 1994, INT IMMUNOL, V6, P785, DOI 10.1093/intimm/6.5.785; URBAN JL, 1988, CELL, V54, P577, DOI 10.1016/0092-8674(88)90079-7; VANEWIJK W, 1988, CELL, V53, P357, DOI 10.1016/0092-8674(88)90156-0; WEINER HL, 1994, ANNU REV IMMUNOL, V12, P809, DOI 10.1146/annurev.immunol.12.1.809	33	193	204	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 18	1996	274	5286					421	423		10.1126/science.274.5286.421	http://dx.doi.org/10.1126/science.274.5286.421			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN173	8832890				2022-12-24	WOS:A1996VN17300053
J	Spanopoulou, E; Zaitseva, F; Wang, FH; Santagata, S; Baltimore, D; Panayotou, G				Spanopoulou, E; Zaitseva, F; Wang, FH; Santagata, S; Baltimore, D; Panayotou, G			The homeodomain region of Rag-1 reveals the parallel mechanisms of bacterial and V(D)J recombination	CELL			English	Article							STRAND BREAK REPAIR; SITE-SPECIFIC RECOMBINATION; DNA-BINDING DOMAIN; IMMUNE-SYSTEM; HIN RECOMBINASE; CAENORHABDITIS-ELEGANS; RAG-1-DEFICIENT MICE; JOINING SIGNALS; TC1 TRANSPOSASE; SEQUENCE	The V(D)J recombinase subunits Rag-1 and Rag-2 mediate assembly of antigen receptor gene segments. We studied the mechanisms of DNA recognition by Rag-1/Rag-2 using surface plasmon resonance. The critical step for signal recognition is binding of Rag-1 to the nonamer. This is achieved by a region of Rag-1 homologous to the DNA-binding domain of the Hin family of bacterial invertases and to homeodomain proteins. Strikingly, the Hin homeodomain can functionally substitute for the Rag-1 homologous region. Rag-1 also interacts with the heptamer but with low affinity. Rag-2 shows no direct binding to DNA. Once the Rag-1/Rag-2 complex is engaged on the DNA, subsequent cleavage is directed by the heptamer sequence. This order of events remarkably parallels mechanisms that mediate transposition in bacteria and nematodes.	MIT,CAMBRIDGE,MA 02139; LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND	Massachusetts Institute of Technology (MIT); Ludwig Institute for Cancer Research	Spanopoulou, E (corresponding author), MT SINAI SCH MED,RUTTENBERG CANC CTR,NEW YORK,NY 10029, USA.		Santagata, Sandro/A-7714-2009	Santagata, Sandro/0000-0002-7528-9668				AFFOLTER M, 1991, CELL, V64, P879, DOI 10.1016/0092-8674(91)90311-L; BARTL S, 1994, P NATL ACAD SCI USA, V91, P10769, DOI 10.1073/pnas.91.23.10769; Bogue M, 1996, CURR OPIN IMMUNOL, V8, P175, DOI 10.1016/S0952-7915(96)80055-0; BONDESON K, 1993, ANAL BIOCHEM, V214, P245, DOI 10.1006/abio.1993.1484; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; CRAIG NL, 1988, ANNU REV GENET, V22, P77; CUOMO CA, 1994, NUCLEIC ACIDS RES, V22, P1810, DOI 10.1093/nar/22.10.1810; DERBYSHIRE KM, 1992, EMBO J, V11, P3449, DOI 10.1002/j.1460-2075.1992.tb05424.x; DREYFUS DH, 1992, MOL IMMUNOL, V29, P807, DOI 10.1016/0161-5890(92)90191-Y; Eastman QM, 1996, NATURE, V380, P85, DOI 10.1038/380085a0; FENG JA, 1994, SCIENCE, V263, P348, DOI 10.1126/science.8278807; FISHER RJ, 1994, PROTEIN SCI, V3, P257; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.bi.63.070194.002415; HANSEN JD, 1995, IMMUNOGENETICS, V42, P188, DOI 10.1007/BF00191224; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; HUGHES KT, 1992, EMBO J, V11, P2695, DOI 10.1002/j.1460-2075.1992.tb05335.x; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; JONSSON U, 1991, BIOTECHNIQUES, V11, P520; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; LIEBER MR, 1991, FASEB J, V5, P2934, DOI 10.1096/fasebj.5.14.1752360; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PANAYOTOU G, 1993, CURR BIOL, V3, P913, DOI 10.1016/0960-9822(93)90236-H; PERGOLA F, 1993, MOL CELL BIOL, V13, P3464, DOI 10.1128/MCB.13.6.3464; RAMSDEN DA, 1994, NUCLEIC ACIDS RES, V22, P1785, DOI 10.1093/nar/22.10.1785; Ramsden DA, 1996, EMBO J, V15, P3197, DOI 10.1002/j.1460-2075.1996.tb00682.x; Rathbun G.A., 1987, P85; Roman CAJ, 1996, P NATL ACAD SCI USA, V93, P2333, DOI 10.1073/pnas.93.6.2333; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; SADOFSKY MJ, 1995, GENE DEV, V9, P2193, DOI 10.1101/gad.9.17.2193; SADOFSKY MJ, 1994, NUCLEIC ACIDS RES, V22, P1805, DOI 10.1093/nar/22.10.1805; SADOFSKY MJ, 1993, NUCLEIC ACIDS RES, V21, P5644, DOI 10.1093/nar/21.24.5644; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SILVER DP, 1993, P NATL ACAD SCI USA, V90, P6100, DOI 10.1073/pnas.90.13.6100; Spanopoulou E, 1995, IMMUNITY, V3, P715, DOI 10.1016/1074-7613(95)90061-6; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; Spanopoulou E, 1996, Int Rev Immunol, V13, P257, DOI 10.3109/08830189609061752; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; THOMPSON CB, 1995, IMMUNITY, V3, P531, DOI 10.1016/1074-7613(95)90124-8; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; vanGent DC, 1996, CELL, V85, P107, DOI 10.1016/S0092-8674(00)81086-7; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592; VANGENT DC, 1995, CELL, V81, P825; VOS JC, 1993, GENE DEV, V7, P1244, DOI 10.1101/gad.7.7a.1244; VOS JC, 1994, EMBO J, V13, P6125, DOI 10.1002/j.1460-2075.1994.tb06959.x; WHITE R, 1994, CURR BIOL, V4, P48, DOI 10.1016/S0960-9822(00)00010-5; XU WG, 1995, CELL, V80, P639, DOI 10.1016/0092-8674(95)90518-9; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	56	187	189	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1996	87	2					263	276		10.1016/S0092-8674(00)81344-6	http://dx.doi.org/10.1016/S0092-8674(00)81344-6			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VN403	8861910	Bronze			2022-12-24	WOS:A1996VN40300014
J	Brooke, TY; Tokunaga, AT; Weaver, HA; Crovisier, J; BockeleeMorvan, D; Crisp, D				Brooke, TY; Tokunaga, AT; Weaver, HA; Crovisier, J; BockeleeMorvan, D; Crisp, D			Detection of acetylene in the infrared spectrum of comet Hyakutake	NATURE			English	Article							CHEMICAL-MODELS; MOLECULES; FLUORESCENCE; ATMOSPHERES; RESOLUTION; HALLEY; GAS	COMETS are rich in volatile materials, of which roughly 80% (by number) are mater molecules(1). Considerable progress(2-4) being made in identifying the other volatile species, the abundances of which should enable us to determine whether comets formed primarily from ice-covered interstellar grains(5), or from material that was chemically processed in the early solar nebula(6,7). Here we report the detection of acetylene (C2H2,) in the infrared spectrum of comet C/1996 B2 (Hyakutake). The estimated abundance is 0.3-0.9%, relative to water, which is comparable to the predicted solid-phase abundance in cold interstellar clouds. This suggests that the volatiles in comet Hyakotake may have come from ice-covered interstellar grains, rather than material processed in the accretion disk out of which the Solar System formed.	UNIV HAWAII, INST ASTRON, HONOLULU, HI 96822 USA; JOHNS HOPKINS UNIV, DEPT PHYS & ASTRON, BALTIMORE, MD 21218 USA; OBSERV PARIS, F-92195 MEUDON, FRANCE	University of Hawaii System; Johns Hopkins University; UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris	Brooke, TY (corresponding author), CALTECH, JET PROP LAB, 4800 OAK GROVE DR, M-S 169-237, PASADENA, CA 91109 USA.		Crisp, David/F-6642-2017; Weaver, Harold A/D-9188-2016	Crisp, David/0000-0002-4573-9998; Weaver, Harold A/0000-0003-0951-7762; Tokunaga, Alan/0000-0001-8136-9704				BOCKELEEMORVAN D, 1989, ASTRON ASTROPHYS, V216, P278; BOCKELEEMORVAN D, 1991, NATURE, V350, P318, DOI 10.1038/350318a0; CARR JS, 1995, ASTROPHYS J, V450, P667, DOI 10.1086/176174; CROVISIER J, 1989, ASTRON ASTROPHYS, V213, P459; CROVISIER J, 1983, ASTRON ASTROPHYS, V126, P170; CROVISIER J, 1987, ASTRON ASTROPHYS SUP, V68, P223; Fegley B.J., 1989, FORMATION EVOLUTION, P171; Greenberg J., 1982, COMETS, P131; GREENE TP, 1993, P SOC PHOTO-OPT INS, V1946, P313, DOI 10.1117/12.158684; HASEGAWA TI, 1993, MON NOT R ASTRON SOC, V263, P589, DOI 10.1093/mnras/263.3.589; Herzberg G., 1945, INFRARED RAMAN SPECT, V2; HUEBNER WF, 1992, ASTROPHYS SPACE SCI, V195, P1, DOI 10.1007/BF00644558; JACKSON WM, 1976, J PHOTOCHEM, V5, P107, DOI 10.1016/0047-2670(76)85014-9; KRANKOWSKY D, 1986, NATURE, V321, P326, DOI 10.1038/321326a0; LUNINE JI, 1989, FORMATION EVOLUTION, P213; MATTHEWS HE, 1996, 6353 IAU; Meadows VS, 1996, J GEOPHYS RES-PLANET, V101, P4595, DOI 10.1029/95JE03567; Mumma M. J., 1993, PROTOSTARS PLANETS, P1177; Mumma MJ, 1996, SCIENCE, V272, P1310, DOI 10.1126/science.272.5266.1310; ODELL CR, 1988, ASTROPHYS J, V334, P476, DOI 10.1086/166852; PRINN RG, 1981, ASTROPHYS J, V249, P308, DOI 10.1086/159289; SCHLEICHER D, 1996, 6344 IAU; SCHLEICHER DG, 1988, ASTROPHYS J, V331, P1058, DOI 10.1086/166622; STRAZZULLA G, 1991, ASTROPHYS SPACE SC L, V167, P243; TOKUNAGA AT, 1990, P SOC PHOTO-OPT INS, V1235, P131, DOI 10.1117/12.19082; VANDERAUWERA J, 1993, J MOL SPECTROSC, V157, P337, DOI 10.1006/jmsp.1993.1027; WEAVER HA, 1984, ASTROPHYS J, V276, P782, DOI 10.1086/161664; WOOTTEN A, 1996, INT C AST COM MET 39; YAMAMOTO T, 1991, ASTROPHYS SPACE SC L, V167, P361	29	127	127	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 17	1996	383	6601					606	608		10.1038/383606a0	http://dx.doi.org/10.1038/383606a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM755	8857534				2022-12-24	WOS:A1996VM75500047
J	Bruno, G; CavalloPerin, P; Bargero, G; Borra, M; DErrico, N; Pagano, G				Bruno, G; CavalloPerin, P; Bargero, G; Borra, M; DErrico, N; Pagano, G			Association of fibrinogen with glycemic control and albumin excretion rate in patients with non-insulin-dependent diabetes mellitus	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY HEART-DISEASE; RISK FACTOR; MICROALBUMINURIA; NIDDM	Background: The high prevalence of classic cardiac risk factors in patients with non-insulin-dependent diabetes mellitus does not explain the increased cardiovascular-related morbidity and mortality in these patients. Fibrinogen may have a role in this excess risk. Objective: To evaluate the following in patients with non-insulin-dependent diabetes mellitus: 1) the distribution of plasma fibrinogen levels and the prevalence of hyperfibrinogenemia and 2) the association of fibrinogen level with hemoglobin A(1c) value and albumin excretion rate. Design: Cross-sectional study of a population-based cohort. Setting: Rural area in northern Italy. Patients: 1574 patients with non-insulin-dependent diabetes mellitus who represented 81% of the initial cohort of 1967 patients. Measurements: Albumin excretion rate was measured in urine samples obtained during an overnight collection. Venous blood samples were collected while patients fasted. Results: Fibrinogen levels were available for 1525 of the 1574 patients who were examined (669 men and 856 women). The mean age (+/- SD) was 67.3 +/- 10.3 years for men and 70.7 +/- 10.7 years for women. The mean plasma fibrinogen level (+/- SD) was 3.6 +/- 0.9 g/L; levels slightly differed between men and women. In 50.3% of patients, plasma fibrinogen level exceeded 3.5 g/L. In men, fibrinogen level increased with age (P < 0.001). In both men and women, fibrinogen level adjusted for age and sex was significantly and linearly related to hemoglobin A(1c) value (P < 0.001) and albumin excretion rate (P < 0.001). In a multiple regression analysis, hemoglobin A(1c) value (b = 0.06; P < 0.001) and albumin excretion rate (b = 0.09; P = 0.005) were associated with fibrinogen level independent of other cardiovascular risk factors (sex, age, hypertensive status, total cholesterol level, smoking habit, and body mass index). Conclusions: Patients with non-insulin-dependent diabetes mellitus had a high prevalence of hyperfibrinogenemia. Fibrinogen level was independently associated with hemoglobin A(1c) value and albumin excretion rate, which suggests that fibrinogen may be involved in the increased cardiovascular risk of patients with diabetes mellitus.	OSPED SANTO SPIRITO, SERV DIABETOL, I-15033 CASALE MONFERRATO, ALESSANDRIA, ITALY		Bruno, G (corresponding author), UNIV TURIN, DIPARTIMENTO MED INTERNA, CORSO DOGLIOTTI 14, I-10126 TURIN, ITALY.		Bruno, Graziella/E-9673-2012	BRUNO, Graziella/0000-0002-3011-8304				BRUNO G, 1994, DIABETES CARE, V17, P548, DOI 10.2337/diacare.17.6.548; BRUNO G, 1992, DIABETOLOGIA, V35, P851, DOI 10.1007/BF00399931; Bruno G, 1996, DIABETES CARE, V19, P43, DOI 10.2337/diacare.19.1.43; CERIELLO A, 1995, NUTR METAB CARDIOVAS, V5, P237; CERIELLO A, 1994, DIABETES, V43, P430, DOI 10.2337/diabetes.43.3.430; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; COLLIER A, 1992, DIABETES, V41, P909, DOI 10.2337/diabetes.41.8.909; DEFEO P, 1991, J CLIN INVEST, V88, P833, DOI 10.1172/JCI115384; ERNST E, 1993, ANN INTERN MED, V118, P956, DOI 10.7326/0003-4819-118-12-199306150-00008; GANDA OP, 1992, DIABETES CARE, V15, P1245, DOI 10.2337/diacare.15.10.1245; HEINRICH J, 1994, ARTERIOSCLER THROMB, V14, P54, DOI 10.1161/01.ATV.14.1.54; KANNEL WB, 1990, AM HEART J, V120, P672, DOI 10.1016/0002-8703(90)90026-T; KNOBL P, 1993, DIABETOLOGIA, V36, P1045, DOI 10.1007/BF02374497; LEE AJ, 1993, BRIT HEART J, V69, P338; MATTOCK MB, 1988, DIABETOLOGIA, V31, P82, DOI 10.1007/BF00395552; NEIL A, 1993, DIABETES CARE, V16, P996, DOI 10.2337/diacare.16.7.996; PAGANO G, 1994, DIABETIC MED, V11, P475, DOI 10.1111/j.1464-5491.1994.tb00309.x; SCHMITZ A, 1990, DIABETIC MED, V7, P521, DOI 10.1111/j.1464-5491.1990.tb01435.x; SCHWARTZ CJ, 1988, SEMIN THROMB HEMOST, V14, P189, DOI 10.1055/s-2007-1002775; THOMPSON SG, 1995, NEW ENGL J MED, V332, P635, DOI 10.1056/NEJM199503093321003	20	62	62	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1996	125	8					653	657		10.7326/0003-4819-125-8-199610150-00005	http://dx.doi.org/10.7326/0003-4819-125-8-199610150-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM889	8849150				2022-12-24	WOS:A1996VM88900007
J	Novack, DH				Novack, DH			The bet	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Novack, DH (corresponding author), MED COLL PENN & HAHNEMANN UNIV, SCH MED, 2900 QUEEN LANE, PHILADELPHIA, PA 19129 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1996	125	8					692	693		10.7326/0003-4819-125-8-199610150-00012	http://dx.doi.org/10.7326/0003-4819-125-8-199610150-00012			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM889	8849157				2022-12-24	WOS:A1996VM88900014
J	Garcia, KC; Degano, M; Stanfield, RL; Brunmark, A; Jackson, MR; Peterson, PA; Teyton, L; Wilson, IA				Garcia, KC; Degano, M; Stanfield, RL; Brunmark, A; Jackson, MR; Peterson, PA; Teyton, L; Wilson, IA			An alpha beta T cell receptor structure at 2.5 angstrom and its orientation in the TCR-MHC complex	SCIENCE			English	Review							DROSOPHILA-MELANOGASTER CELLS; INFLUENZA-VIRUS NEURAMINIDASE; ANTIBODY-ANTIGEN COMPLEXES; TOXIC LYMPHOCYTES-T; 3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURE; CRYSTALLOGRAPHIC REFINEMENT; HYPERVARIABLE REGIONS; IMMUNE RECOGNITION; PROTEIN-STRUCTURE	The central event in the cellular immune response to invading microorganisms is the specific recognition of foreign peptides bound to major histocompatibility complex (MHC) molecules by the alpha beta T cell receptor (TCR). The x-ray structure of the complete extracellular fragment of a glycosylated alpha beta TCR was determined at 2.5 angstroms, and its orientation bound to a class I MHC-peptide (pMHC) complex was elucidated from crystals of the TCR-pMHC complex. The TCR resembles an antibody in the variable V alpha and V beta domains but deviates in the constant C alpha domain and in the interdomain pairing of C alpha with C beta. Four of seven possible asparagine-linked glycosylation sites have ordered carbohydrate moieties, one of which lies in the C alpha-C beta interface. The TCR combining site is relatively flat except for a deep hydrophobic cavity between the hypervariable CDR3s (complementarity-determining regions) of the alpha and beta chains. The 2C TCR covers the class I MHC H-2K(b) binding groove so that the V alpha CDRs 1 and 2 are positioned over the amino-terminal region of the bound dEV8 peptide, the V beta chain CDRs 1 and 2 are over the carboxyl-terminal region of the peptide, and the V alpha and V beta CDR3s straddle the peptide between the helices around the central position of the peptide.	Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, SKAGGS INST CHEM BIOL, LA JOLLA, CA 92037 USA; RW JOHNSON PHARMACEUT RES INST LA JOLLA, SAN DIEGO, CA 92121 USA	Scripps Research Institute; Scripps Research Institute			Stanfield, Robyn/AAH-3190-2019; Degano, Massimo/K-4669-2018	Degano, Massimo/0000-0002-0787-1883	NATIONAL CANCER INSTITUTE [R01CA058896] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA58896] Funding Source: Medline; PHS HHS [T32-A107244] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABERGEL C, 1991, EUR J IMMUNOL, V21, P3021, DOI 10.1002/eji.1830211218; AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; Bentley GA, 1996, ANNU REV IMMUNOL, V14, P563, DOI 10.1146/annurev.immunol.14.1.563; BENTLEY GA, 1995, SCIENCE, V267, P1984, DOI 10.1126/science.7701320; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BHAT TN, 1986, PROT STRUCT FUNC GEN, V1, P74; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CASPARBAUGUIL S, 1994, SCAND J IMMUNOL, V40, P323, DOI 10.1111/j.1365-3083.1994.tb03469.x; CHANG HC, 1994, P NATL ACAD SCI USA, V91, P11408, DOI 10.1073/pnas.91.24.11408; CHIEN Y, 1984, NATURE, V312, P31, DOI 10.1038/312031a0; CHITARRA V, 1993, P NATL ACAD SCI USA, V90, P7711, DOI 10.1073/pnas.90.16.7711; CHOI YW, 1990, NATURE, V346, P471, DOI 10.1038/346471a0; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; CHOTHIA C, 1988, EMBO J, V7, P3745, DOI 10.1002/j.1460-2075.1988.tb03258.x; CHUNG S, 1994, P NATL ACAD SCI USA, V91, P12654, DOI 10.1073/pnas.91.26.12654; CLAVERIE JM, 1989, IMMUNOL TODAY, V10, P10, DOI 10.1016/0167-5699(89)90058-3; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; COLMAN PM, 1988, ADV IMMUNOL, V43, P99; COLMAN PM, 1987, NATURE, V326, P358, DOI 10.1038/326358a0; COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; CONNOLLY ML, 1993, J MOL GRAPH MODEL, V11, P139, DOI 10.1016/0263-7855(93)87010-3; CORR M, 1994, SCIENCE, V265, P946, DOI 10.1126/science.8052850; CYGLER M, 1991, SCIENCE, V253, P442, DOI 10.1126/science.1713710; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DOHERTY PC, 1976, TRANSPLANT REV, V29, P89; ENGEL I, 1988, CELL, V54, P473, DOI 10.1016/0092-8674(88)90068-2; ENGEL I, 1992, SCIENCE, V256, P1318, DOI 10.1126/science.1598575; EPP O, 1974, EUR J BIOCHEM, V45, P513, DOI 10.1111/j.1432-1033.1974.tb03576.x; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FIELDS BA, 1995, SCIENCE, V270, P1821, DOI 10.1126/science.270.5243.1821; FRASER MJ, 1989, IN VITRO CELL DEV B, V25, P225; FREMONT DH, 1995, P NATL ACAD SCI USA, V92, P2479, DOI 10.1073/pnas.92.7.2479; FREMONT DH, COMMUNICATION; FUREY WJ, 1990, AM CRYST ASS 40 ANN; FUREY WJ, 1994, ACTA CRYSTALLOGR D, V50, P760; GARCIA KC, UNPUB; GEISLER C, 1992, J IMMUNOL, V148, P3469; GREGOIRE C, 1991, P NATL ACAD SCI USA, V88, P8077, DOI 10.1073/pnas.88.18.8077; HE XM, 1992, P NATL ACAD SCI USA, V89, P7154, DOI 10.1073/pnas.89.15.7154; HEDRICK SM, 1984, NATURE, V308, P153, DOI 10.1038/308153a0; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; HERON JN, 1991, PROT STRUCT FUNC GEN, V11, P159; HILYARD KL, 1994, P NATL ACAD SCI USA, V91, P9057, DOI 10.1073/pnas.91.19.9057; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOO WFS, 1992, P NATL ACAD SCI USA, V89, P4759, DOI 10.1073/pnas.89.10.4759; JACKSON MR, 1992, P NATL ACAD SCI USA, V89, P12117, DOI 10.1073/pnas.89.24.12117; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORGENSEN JL, 1992, NATURE, V355, P224, DOI 10.1038/355224a0; Kabat EA, 1991, SEQUENCES PROTEINS I; KATAYAMA CD, 1995, EMBO J, V14, P927, DOI 10.1002/j.1460-2075.1995.tb07074.x; KATZ DH, 1973, J EXP MED, V137, P1405, DOI 10.1084/jem.137.6.1405; KEARSE KP, 1994, EMBO J, V13, P4504, DOI 10.1002/j.1460-2075.1994.tb06772.x; KERSH GJ, IN PRESS J EXP MED; KRANZ DM, 1984, P NATL ACAD SCI-BIOL, V81, P7922, DOI 10.1073/pnas.81.24.7922; KRONENBERG M, 1986, ANNU REV IMMUNOL, V4, P529, DOI 10.1146/annurev.iy.04.040186.002525; KURODA K, 1990, VIROLOGY, V174, P418, DOI 10.1016/0042-6822(90)90095-9; KURUCZ I, 1995, IMMUNITY, V2, P281, DOI 10.1016/1074-7613(95)90052-7; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESCAR J, 1994, PROTEIN SCI, V3, P788; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MALBY RL, 1994, STRUCTURE, V2, P733, DOI 10.1016/S0969-2126(00)00074-5; MARQUART M, 1980, J MOL BIOL, V141, P369, DOI 10.1016/0022-2836(80)90252-1; MATSUMURA M, 1992, J BIOL CHEM, V267, P23589; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NOVOTNY J, 1991, P NATL ACAD SCI USA, V88, P8646, DOI 10.1073/pnas.88.19.8646; NOVOTNY J, 1986, P NATL ACAD SCI USA, V83, P742, DOI 10.1073/pnas.83.3.742; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; PATTEN P, 1984, NATURE, V312, P40, DOI 10.1038/312040a0; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; ROSSMANN MG, 1975, J BIOL CHEM, V250, P7525; SAITO H, 1984, NATURE, V312, P36, DOI 10.1038/312036a0; SantAngelo DB, 1996, IMMUNITY, V4, P367, DOI 10.1016/S1074-7613(00)80250-2; SCHIFFER M, 1992, IMMUNOGENETICS, V35, P224, DOI 10.1007/BF00166827; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; SHEVACH EM, 1973, J EXP MED, V138, P1213, DOI 10.1084/jem.138.5.1213; STAERZ UD, 1985, J IMMUNOL, V134, P3994; STANFIELD RL, 1993, STRUCTURE, V1, P83, DOI 10.1016/0969-2126(93)90024-B; STRONG RK, 1994, J IMMUNOL, V153, P4111; SYKULEV Y, 1994, IMMUNITY, V1, P15, DOI 10.1016/1074-7613(94)90005-1; Tallquist MD, 1996, J EXP MED, V184, P1017, DOI 10.1084/jem.184.3.1017; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; UPSON C, 1989, IEEE COMPUT GRAPH, V9, P30, DOI 10.1109/38.31462; WARD ES, 1991, SCAND J IMMUNOL, V34, P215, DOI 10.1111/j.1365-3083.1991.tb01539.x; WEBER S, 1992, NATURE, V356, P793, DOI 10.1038/356793a0; WILSON IA, 1991, METHOD ENZYMOL, V203, P153; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4; WILSON IA, 1991, CIBA F SYMP, V5, P139; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0; ZEMEL R, 1994, MOL IMMUNOL, V31, P127, DOI 10.1016/0161-5890(94)90085-X	104	1034	1049	1	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 11	1996	274	5285					209	219		10.1126/science.274.5285.209	http://dx.doi.org/10.1126/science.274.5285.209			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM671	8824178				2022-12-24	WOS:A1996VM67100032
J	Tanaka, S; Amling, M; Neff, L; Peyman, A; Uhlmann, E; Levy, JB; Baron, R				Tanaka, S; Amling, M; Neff, L; Peyman, A; Uhlmann, E; Levy, JB; Baron, R			c-Cbl is downstream of c-Src in a signalling pathway necessary for bone resorption	NATURE			English	Article							TYROSINE KINASE; PROTEIN PRODUCT; SH3 DOMAIN; PROTOONCOGENE; PHOSPHORYLATION; OSTEOCLASTS; STIMULATION; RECEPTOR; MICE; OSTEOPETROSIS	THE primacy defect in mice lacking the c-src gene is osteopetrosis, a deficiency in bone resorption by osteoclasts(1). Osteoclasts express high levels of the c-Src protein(2,3) and the defect responsible for the osteopetrotic phenotype of the c-src-deficient (src(-)) mouse is fell-autonomous and occurs in mature osteoclasts(4,5). However, the specific signalling pathways that require c-Src expression for normal osteoclast activity have not been elucidated. We report here that the proto-oncogene product c-Cbl is tyrosine-phosphorylated in a Src-dependent manner in osteoclasts, where the two proteins colocalize on some vesicular structures. In vitro bone resorption by osteoclast-like cells (OCLs) is inhibited by both c-src and c-cbl antisense oligonucleotides, Furthermore, tryosine phosphorylation of c-Cbl and the localization of c-Cbl-containing structures to the peripheral cytoskeleton are impaired in resorption-deficient c-src(-) OCLs, as well as in wild-type OCLs that have been treated with c-src antisense oligonucleotides. These results indicate that c-Cbl may act downstream of c-Src in a signalling pathway that is required for bone resorption.	YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT ORTHOPED, NEW HAVEN, CT 06510 USA; HOECHST AG, CENT PHARMA RES, D-65926 FRANKFURT, GERMANY	Yale University; Yale University; Sanofi-Aventis			Tanaka, Sakae/Y-3061-2019	Tanaka, Sakae/0000-0001-9210-9414				AKATSU T, 1992, J BONE MINER RES, V7, P1297; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BARON R, 1988, J CELL BIOL, V106, P1863, DOI 10.1083/jcb.106.6.1863; BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210; BLAKE TJ, 1991, ONCOGENE, V6, P653; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; HORNE WC, 1992, J CELL BIOL, V119, P1003, DOI 10.1083/jcb.119.4.1003; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Peyman A, 1996, BIOL CHEM H-S, V377, P67; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; TANAKA S, 1992, FEBS LETT, V313, P85, DOI 10.1016/0014-5793(92)81190-W; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509	21	245	250	0	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 10	1996	383	6600					528	531		10.1038/383528a0	http://dx.doi.org/10.1038/383528a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL755	8849724				2022-12-24	WOS:A1996VL75500051
J	Nightingale, SL				Nightingale, SL			Symposium on deadly diseases and people of color: Are clinical trials an option?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1996	276	14					1128	1128						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL332	8827954				2022-12-24	WOS:A1996VL33200005
J	deLima, J; LloydThomas, AR; Howard, RF; Summer, E; Quinn, TM				deLima, J; LloydThomas, AR; Howard, RF; Summer, E; Quinn, TM			Infant and neonatal pain: Anaesthetists' perceptions and prescribing patterns	BRITISH MEDICAL JOURNAL			English	Article									GREAT ORMOND ST HOSP CHILDREN NHS TRUST,DEPT ANAESTHESIA,LONDON WC1N 3JH,ENGLAND	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust				Howard, Richard/0000-0001-9271-0074				AYNSLEYGREEN A, 1995, STRESS PAIN INFANCY; AYNSLEYGREEN A, 1995, STRESS PAIN INFANCY, P449; BEYER JE, 1983, PAIN, V17, P71, DOI 10.1016/0304-3959(83)90129-X; LLOYDTHOMAS AR, 1994, PAEDIATRIC ANAESTHES, V4, P3; PURCELLJONES G, 1988, PAIN, V33, P181, DOI 10.1016/0304-3959(88)90089-9	5	58	60	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1996	313	7060					787	787						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK566	8842071				2022-12-24	WOS:A1996VK56600023
J	Chen, P; Hochstrasser, M				Chen, P; Hochstrasser, M			Autocatalytic subunit processing couples active site formation in the 20S proteasome to completion of assembly	CELL			English	Article							PROTEIN-DEGRADATION; IN-VIVO; UBIQUITIN; ACIDOPHILUM; COMPLEXES; DIMER; CELL	The eukaryotic 20S proteasome is responsible for the degradation of many cellular proteins, but how it is assembled and how its distinct active sites are formed are not understood. Like other proteasome subunits, the yeast Doa3 protein is synthesized in precursor form. We show that the N-terminal propeptide is required for Doa3 incorporation into the proteasome and, remarkably, that the propeptide functions in trans, suggesting it serves a chaperone-like function in proteasome biogenesis. Propeptide processing is not required for proteasome assembly but is needed for maturation of a specific subset of active sites. The likely nucleophile for these sites is provided by the N-terminal threonine of mature Doa3. Additional data indicate that precursor processing is autocatalytic and requires association of the two halves of the proteasome particle, thereby preventing formation of proteolytic sites until the central hydrolytic chamber has been sealed off from the rest of the cell.			Chen, P (corresponding author), UNIV CHICAGO,DEPT BIOCHEM & MOL BIOL,CHICAGO,IL 60637, USA.			Hochstrasser, Mark/0000-0002-1131-5484	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046904] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07183, GM46904] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F, 1989, MOL REPROD DEV, V1, P146; Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CHEN P, 1995, EMBO J, V14, P2620, DOI 10.1002/j.1460-2075.1995.tb07260.x; DEMARINI DJ, 1995, MOL CELL BIOL, V15, P6311; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FRENTZEL S, 1994, J MOL BIOL, V236, P975, DOI 10.1016/0022-2836(94)90003-5; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; Hochstrasser M, 1995, COLD SPRING HARB SYM, V60, P503, DOI 10.1101/SQB.1995.060.01.054; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; KOPP F, 1995, J MOL BIOL, V248, P264; KOPP F, 1993, J MOL BIOL, V229, P14, DOI 10.1006/jmbi.1993.1003; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; YANG Y, 1995, J BIOL CHEM, V270, P27687, DOI 10.1074/jbc.270.46.27687; ZWICKL P, 1994, NAT STRUCT BIOL, V1, P765, DOI 10.1038/nsb1194-765	20	307	312	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1996	86	6					961	972		10.1016/S0092-8674(00)80171-3	http://dx.doi.org/10.1016/S0092-8674(00)80171-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VJ443	8808631	Bronze			2022-12-24	WOS:A1996VJ44300014
J	Horsburgh, BC; Kollmus, H; Hauser, H; Coen, DM				Horsburgh, BC; Kollmus, H; Hauser, H; Coen, DM			Translational recoding induced by G-rich mRNA sequences that form unusual structures	CELL			English	Article							ORNITHINE DECARBOXYLASE ANTIZYME; IMMUNODEFICIENCY-VIRUS TYPE-1; PROGRAMMED FRAMESHIFT SITE; RESISTANT HERPES-SIMPLEX; THYMIDINE KINASE; TRANSFER-RNA; DNA-POLYMERASE; TELOMERIC DNA; QUARTET STRUCTURES; EXPRESSION	We investigated a herpesvirus mutant that contains a single base insertion in its thymidine kinase (tk) gene yet expresses low levels of TK via a net + 1 translational recoding event. Within this mutant gene, we defined a G-rich signal that is sufficient to induce recoding. Unlike other translational recoding events, downstream RNA structures or termination codons did not stimulate recoding, and paused ribosomes were not detected. Mutational analysis indicated that specific tRNAs or codon-anticodon slippage were unlikely to account for recoding. Rather, recoding efficiency correlated with the G-richness of the signal and its ability to form unusual structures. These findings identify a mechanism of translational recoding with unique features and potential implications for clinical drug resistance and other biological systems.	GESELL BIOTECHNOL FORSCH MBH,GENET EUKARYOTES,D-38124 BRAUNSCHWEIG,GERMANY	Gesellschaft fur Biotechnologische Forschung mbH	Horsburgh, BC (corresponding author), HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026126] Funding Source: NIH RePORTER; NIAID NIH HHS [AI26126, R01 AI026126] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABOULELA F, 1995, J MOL BIOL, V253, P313, DOI 10.1006/jmbi.1995.0555; ATKINS JF, 1990, CELL, V62, P413, DOI 10.1016/0092-8674(90)90007-2; BALAGURUMOORTHY P, 1992, NUCLEIC ACIDS RES, V20, P4061, DOI 10.1093/nar/20.15.4061; BATTISTE JL, 1994, BIOCHEMISTRY-US, V33, P2741, DOI 10.1021/bi00176a001; BELCOURT MF, 1990, CELL, V62, P339, DOI 10.1016/0092-8674(90)90371-K; BENHAR I, 1993, CELL, V72, P121, DOI 10.1016/0092-8674(93)90056-V; BRIERLEY I, 1992, J MOL BIOL, V227, P463, DOI 10.1016/0022-2836(92)90901-U; BROWN DG, 1995, NAT STRUCT BIOL, V2, P876, DOI 10.1038/nsb1095-876; COEN DM, 1980, P NATL ACAD SCI-BIOL, V77, P2265, DOI 10.1073/pnas.77.4.2265; COEN DM, 1989, P NATL ACAD SCI USA, V86, P4735; CURRAN JF, 1993, NUCLEIC ACIDS RES, V21, P1837, DOI 10.1093/nar/21.8.1837; DIGARD P, 1993, J VIROL, V67, P398, DOI 10.1128/JVI.67.1.398-406.1993; EFSTATHIOU S, 1989, J GEN VIROL, V70, P869, DOI 10.1099/0022-1317-70-4-869; ENGLUND JA, 1990, ANN INTERN MED, V112, P416, DOI 10.7326/0003-4819-76-3-112-6-416; FARABAUGH PJ, 1993, CELL, V74, P93, DOI 10.1016/0092-8674(93)90297-4; Farabaugh PJ, 1996, MICROBIOL REV, V60, P103, DOI 10.1128/MMBR.60.1.103-134.1996; FYFE JA, 1978, J BIOL CHEM, V253, P8721; GESTELAND RF, 1992, SCIENCE, V257, P1640, DOI 10.1126/science.1529352; GROSJEAN HJ, 1978, P NATL ACAD SCI USA, V75, P610, DOI 10.1073/pnas.75.2.610; GUPTA RC, 1980, BIOCHEMISTRY-US, V19, P1699, DOI 10.1021/bi00549a028; Haas J, 1996, CURR BIOL, V6, P315, DOI 10.1016/S0960-9822(02)00482-7; HERBST KL, 1994, P NATL ACAD SCI USA, V91, P12525, DOI 10.1073/pnas.91.26.12525; HIRSCH MS, 1989, NEW ENGL J MED, V320, P313, DOI 10.1056/NEJM198902023200510; HWANG CBC, 1994, P NATL ACAD SCI USA, V91, P5461, DOI 10.1073/pnas.91.12.5461; HWANG CBC, 1995, GENE, V152, P191, DOI 10.1016/0378-1119(94)00712-2; JACKS T, 1988, CELL, V55, P447, DOI 10.1016/0092-8674(88)90031-1; JACOBSON JG, 1993, J VIROL, V67, P6903, DOI 10.1128/JVI.67.11.6903-6908.1993; KALNIK MW, 1989, J BIOL CHEM, V264, P3702; KIT S, 1987, ANTIMICROB AGENTS CH, V31, P1483, DOI 10.1128/AAC.31.10.1483; KOLLMUS H, 1994, J VIROL, V68, P6087, DOI 10.1128/JVI.68.9.6087-6091.1994; KURLAND CG, 1992, ANNU REV GENET, V26, P29, DOI 10.1146/annurev.ge.26.120192.000333; LARSEN B, 1994, J BACTERIOL, V176, P6842, DOI 10.1128/JB.176.22.6842-6851.1994; LEBOWITZ JH, 1991, GENE, V103, P119, DOI 10.1016/0378-1119(91)90402-W; LINDSLEY D, 1993, P NATL ACAD SCI USA, V90, P5469, DOI 10.1073/pnas.90.12.5469; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; PANDE S, 1995, MOL CELL BIOL, V15, P298, DOI 10.1128/MCB.15.1.298; REIL H, 1993, J VIROL, V67, P5579, DOI 10.1128/JVI.67.9.5579-5584.1993; ROM E, 1994, P NATL ACAD SCI USA, V91, P3959, DOI 10.1073/pnas.91.9.3959; SACKS SL, 1989, ANN INTERN MED, V111, P893, DOI 10.7326/0003-4819-111-11-893; SCHENBORN E, 1993, PROMEGA NOTES, V41, P11; SMITH FW, 1992, NATURE, V356, P164, DOI 10.1038/356164a0; SOMOGYI P, 1993, MOL CELL BIOL, V13, P6931, DOI 10.1128/MCB.13.11.6931; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; TU CL, 1992, P NATL ACAD SCI USA, V89, P8636, DOI 10.1073/pnas.89.18.8636; VIMALADITHAN A, 1994, MOL CELL BIOL, V14, P8107, DOI 10.1128/MCB.14.12.8107; Weiss R B, 1990, Prog Nucleic Acid Res Mol Biol, V39, P159, DOI 10.1016/S0079-6603(08)60626-1; WEISS RB, 1987, COLD SPRING HARB SYM, V52, P687, DOI 10.1101/SQB.1987.052.01.078; WILLIAMSON JR, 1994, ANNU REV BIOPH BIOM, V23, P703, DOI 10.1146/annurev.bb.23.060194.003415; ZIMMERMAN SB, 1975, J MOL BIOL, V92, P181, DOI 10.1016/0022-2836(75)90222-3	49	57	59	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1996	86	6					949	959		10.1016/S0092-8674(00)80170-1	http://dx.doi.org/10.1016/S0092-8674(00)80170-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VJ443	8808630	Green Published, Bronze			2022-12-24	WOS:A1996VJ44300013
J	Gallant, P; Shiio, Y; Cheng, PF; Parkhurst, SM; Eisenman, RN				Gallant, P; Shiio, Y; Cheng, PF; Parkhurst, SM; Eisenman, RN			Myc and max homologs in Drosophila	SCIENCE			English	Article							C-MYC; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; NEOPLASTIC-CELLS; N-MYC; PROTEIN; GENE; DIMERIZATION; FAMILY; ONCOPROTEIN	The proteins encoded by the myc proto-oncogene family are involved in cell proliferation, apoptosis, differentiation, and neoplasia. Myc acts through dimerization with Max to bind DNA and activate transcription. Homologs of the myc and mau genes were cloned from the fruit fly Drosophila melanogaster and their protein products (dMyc and dMax) were shown to heterodimerize, recognize the same DNA sequence as their vertebrate homologs, and activate transcription. The dMyc protein is likely encoded by the Drosophila gene diminutive (dm), a mutation in which results in small body size and female sterility caused by degeneration of the ovaries. These findings indicate a potential role for Myc in germ cell development and set the stage for genetic analysis of Myc and Max.	FRED HUTCHINSON CANC RES CTR, DIV BASIC SCI, SEATTLE, WA 98104 USA	Fred Hutchinson Cancer Center					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047852] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA47138] Funding Source: Medline; NIGMS NIH HHS [R01GM47852] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; ATCHLEY WR, 1995, P NATL ACAD SCI USA, V92, P10217, DOI 10.1073/pnas.92.22.10217; AUSUBEL FM, 1995, CURRENT PROTOCOLS S, V29; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; DANG CV, 1992, P NATL ACAD SCI USA, V89, P599, DOI 10.1073/pnas.89.2.599; DANG CV, 1991, BIOCHIM BIOPHYS ACTA, V1072, P103, DOI 10.1016/0304-419X(91)90009-A; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALLANT P, UNPUB; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KOSKINEN PJ, 1994, CELL GROWTH DIFFER, V5, P313; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAHERTY CD, UNPUB; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MAGRATH I, 1990, ADV CANCER RES, V55, P134; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARLOR RL, 1986, MOL CELL BIOL, V6, P1129, DOI 10.1128/MCB.6.4.1129; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MODOLELL J, 1983, P NATL ACAD SCI-BIOL, V80, P1678, DOI 10.1073/pnas.80.6.1678; MOENS CB, 1992, GENE DEV, V6, P691, DOI 10.1101/gad.6.5.691; MOZER B, 1985, MOL CELL BIOL, V5, P885, DOI 10.1128/MCB.5.4.885; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; PARKHURST SM, 1985, CELL, V41, P429, DOI 10.1016/S0092-8674(85)80016-7; PRENDERGAST GC, 1992, TRENDS GENET, V8, P91, DOI 10.1016/0168-9525(92)90196-B; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SAWAI S, 1993, DEVELOPMENT, V117, P1445; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041	48	145	151	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 29	1996	274	5292					1523	1527		10.1126/science.274.5292.1523	http://dx.doi.org/10.1126/science.274.5292.1523			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929412				2022-12-24	WOS:A1996VV77500047
J	Subramanya, HS; Bird, LE; Brannigan, JA; Wigley, DB				Subramanya, HS; Bird, LE; Brannigan, JA; Wigley, DB			Crystal structure of a DExx box DNA helicase	NATURE			English	Article							REPLICATION PROTEIN PRIA; COLI REP HELICASE; ESCHERICHIA-COLI; RNA HELICASE; BINDING; OVEREXPRESSION; DIMERIZATION; COMPONENT; MUTATIONS; PRIMOSOME	THERE are a wide variety of helicases that unwind helical DNA(1) and RNA substrates(2). The twelve helicases that have been identified in Escherichia coli(1) play a role in almost all cellular processes involving nucleic acids, We have solved the crystal structure of a monomeric form of a DNA helicase from Bacillus stearothermophilus, alone and in a complex with ADP, at 2.5 and 2.9 Angstrom resolution, respectively, The enzyme comprises two domains with a deep cleft running between them, The ATP-binding site, which is situated at the bottom of this cleft, is formed by motifs that are conserved across the superfamily of related helicases, Unexpected structural homology with the DNA recombination protein, RecA, suggests how ATP binding and hydrolysis may drive conformational changes of the enzyme during catalysis, and implies that there is a common mechanism for all helicases.	UNIV OXFORD,MOL BIOPHYS LAB,OXFORD OX1 3QU,ENGLAND; UNIV YORK,DEPT CHEM,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of Oxford; University of York - UK				Bird, Louise/0000-0002-9846-5716	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BROSH RM, 1995, J BACTERIOL, V177, P5612, DOI 10.1128/jb.177.19.5612-5621.1995; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BUJALOWSKI W, 1993, BIOCHEMISTRY-US, V32, P5888, DOI 10.1021/bi00073a023; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; CRUTE JJ, 1988, NUCLEIC ACIDS RES, V16, P6585, DOI 10.1093/nar/16.14.6585; Egelman EH, 1996, STRUCTURE, V4, P759, DOI 10.1016/S0969-2126(96)00081-0; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; GROSS CH, 1995, J VIROL, V69, P4727, DOI 10.1128/JVI.69.8.4727-4736.1995; Hingorani MM, 1996, BIOCHEMISTRY-US, V35, P2218, DOI 10.1021/bi9521497; IORDANESCU S, 1993, MOL GEN GENET, V241, P185, DOI 10.1007/BF00280216; LEE MS, 1987, P NATL ACAD SCI USA, V84, P8345, DOI 10.1073/pnas.84.23.8345; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MIWA Y, 1995, J MOL BIOL, V254, P815, DOI 10.1006/jmbi.1995.0658; OPPERMAN T, 1994, J BACTERIOL, V176, P6033; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; RUNYON GT, 1993, BIOCHEMISTRY-US, V32, P602, DOI 10.1021/bi00053a028; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; STASIAK A, 1988, J MOL BIOL, V202, P659, DOI 10.1016/0022-2836(88)90293-8; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WASHBURN BK, 1993, J BACTERIOL, V175, P341, DOI 10.1128/JB.175.2.341-350.1993; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; Yu X, 1995, BIOPHYS J, V69, P2728, DOI 10.1016/S0006-3495(95)80144-X; ZAVITZ KH, 1993, J BIOL CHEM, V268, P4337; ZAVITZ KH, 1992, J BIOL CHEM, V267, P6933; ZHU L, 1988, VIROLOGY, V166, P366, DOI 10.1016/0042-6822(88)90507-7	30	382	385	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1996	384	6607					379	383		10.1038/384379a0	http://dx.doi.org/10.1038/384379a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV271	8934527				2022-12-24	WOS:A1996VV27100055
J	LeClerc, JE; Li, BG; Payne, WL; Cebula, TA				LeClerc, JE; Li, BG; Payne, WL; Cebula, TA			High mutation frequencies among Escherichia coli and Salmonella pathogens	SCIENCE			English	Article							MISMATCH-REPAIR; HEMORRHAGIC COLITIS; SINGLE ORGANISM; STRAINS; TYPHIMURIUM; GENE; DNA; IDENTIFICATION; RECOMBINATION; AMPLIFICATION	Here it is reported that the incidence of mutators among isolates of pathogenic Escherichia coli and Salmonella enterica is high (over 1 percent). These findings counter the theory, founded on studies with laboratory-attenuated strains, that suggests mutators are rare among bacterial populations. Defects in methyl-directed mismatch repair underlie all mutator phenotypes described here. Of nine independently derived hypermutable strains, seven contained a defective mutS allele. Because these mutant alleles increase the mutation rate and enhance recombination among diverse species, these studies may help explain both the rapid emergence of antibiotic resistance and the penetrance of virulence genes within the prokaryotic community.	US FDA,MOL BIOL BRANCH,CTR FOOD SAFETY & APPL NUTR HFS235,WASHINGTON,DC 20204	US Food & Drug Administration (FDA)								Barinaga M, 1996, SCIENCE, V272, P1261, DOI 10.1126/science.272.5266.1261; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; Boyd EF, 1996, APPL ENVIRON MICROB, V62, P804, DOI 10.1128/AEM.62.3.804-808.1996; CHAO L, 1983, EVOLUTION, V37, P125, DOI 10.1111/j.1558-5646.1983.tb05521.x; CHENG S, 1994, P NATL ACAD SCI USA, V91, P5695, DOI 10.1073/pnas.91.12.5695; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; COX EC, 1995, BIOESSAYS, V17, P747, DOI 10.1002/bies.950170902; DRAKE JW, 1991, P NATL ACAD SCI USA, V88, P7160, DOI 10.1073/pnas.88.16.7160; FENG C, 1996, J BACTERIOL, V178, P2388; GIBSON TC, 1970, SCIENCE, V169, P686, DOI 10.1126/science.169.3946.686; GROSS MD, 1981, MUTAT RES, V91, P107, DOI 10.1016/0165-7992(81)90081-6; HARTL DL, 1989, PRINCIPLES POPULATIO, P198; HAYES W, 1968, GENETICS BACTERIA TH, P190; HENGGEARONIS R, 1993, CELL, V72, P165, DOI 10.1016/0092-8674(93)90655-A; JYSSUM K., 1960, ACTA PATHOL ET MICROBIOL SCAND, V48, P113; KUPCHELLA E, 1994, ENVIRON MOL MUTAGEN, V23, P81, DOI 10.1002/em.2850230202; LEIGH EG, 1970, AM NAT, V104, P301, DOI 10.1086/282663; MATIC I, 1995, CELL, V80, P507, DOI 10.1016/0092-8674(95)90501-4; MILLS DM, 1995, MOL MICROBIOL, V15, P749, DOI 10.1111/j.1365-2958.1995.tb02382.x; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MOXON ER, 1978, P NATL ACAD SCI USA, V75, P1534, DOI 10.1073/pnas.75.3.1534; OCHMAN H, 1984, J BACTERIOL, V157, P690, DOI 10.1128/JB.157.2.690-693.1984; ORBACH MJ, 1982, J BACTERIOL, V149, P985, DOI 10.1128/JB.149.3.985-994.1982; PANG PP, 1985, J BACTERIOL, V163, P1007, DOI 10.1128/JB.163.3.1007-1015.1985; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; RILEY LW, 1983, NEW ENGL J MED, V308, P681, DOI 10.1056/NEJM198303243081203; RILEY LW, 1995, MMWR-MORBID MORTAL W, V44, P157; RUBIN LG, 1987, REV INFECT DIS, V9, P488; SNIEGOWSKI PD, COMMUNICATION; STLOUIS ME, 1988, JAMA-J AM MED ASSOC, V259, P2103, DOI 10.1001/jama.259.14.2103; TAUCHERSCHOLZ G, 1983, EUR J BIOCHEM, V137, P573, DOI 10.1111/j.1432-1033.1983.tb07864.x; TROBNER W, 1984, MOL GEN GENET, V198, P177, DOI 10.1007/BF00328720; WHITTAM TS, 1993, INFECT IMMUN, V61, P1619, DOI 10.1128/IAI.61.5.1619-1629.1993	33	668	689	1	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1996	274	5290					1208	1211		10.1126/science.274.5290.1208	http://dx.doi.org/10.1126/science.274.5290.1208			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT335	8895473				2022-12-24	WOS:A1996VT33500059
J	MacLeod, K; Laurent, G				MacLeod, K; Laurent, G			Distinct mechanisms for synchronization and temporal patterning of odor-encoding neural assemblies	SCIENCE			English	Article							OLFACTORY-BULB; SYNAPTIC INHIBITION; NEURONAL-ACTIVITY; CHLORIDE CHANNEL; PIRIFORM CORTEX; NERVOUS-SYSTEM; MANDUCA-SEXTA; NITRIC-OXIDE; OSCILLATIONS; INTERNEURONS	Stimulus-evoked oscillatory synchronization of neural assemblies and temporal patterns of neuronal activity have been observed in many sensory systems, such as the visual and auditory cortices of mammals or the olfactory system of insects. In the locust olfactory system, single odor puffs cause the immediate formation of odor-specific neural assemblies, defined both by their transient synchronized firing and their progressive transformation over the course of a response. The application of an antagonist of ionotropic gamma-aminobutyric acid (GABA) receptors to the first olfactory relay neuropil selectively blocked the fast inhibitory synapse between local and projection neurons. This manipulation abolished the synchronization of the odor-coding neural ensembles but did not affect each neuron's temporal response patterns to odors, even when these patterns contained periods of inhibition. Fast GABA-mediated inhibition, therefore, appears to underlie neuronal synchronization but not response tuning in this olfactory system. The selective desynchronization of stimulus-evoked oscillating neural assemblies in vivo is now possible, enabling direct functional tests of their significance for sensation and perception.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA	California Institute of Technology			Laurent, Gilles/A-4583-2012; MacLeod, Katrina/F-4595-2015	Laurent, Gilles/0000-0002-2296-114X; MacLeod, Katrina/0000-0003-0632-1158				Adrian ED, 1942, J PHYSIOL-LONDON, V100, P459, DOI 10.1113/jphysiol.1942.sp003955; BACON JP, 1977, BRAIN RES, V138, P359, DOI 10.1016/0006-8993(77)90753-3; Boeckh J, 1990, CHEMOSENSORY INFORM, P201, DOI [10.1007/978-3-642-75127-1_13, DOI 10.1007/978-3-642-75127-1_13]; BUSH P, 1996, COMPUT NEUROSCI, V3, P91; CHAPUT M, 1980, J PHYSIOL-PARIS, V76, P551; CHRISTENSEN TA, 1993, J COMP PHYSIOL A, V173, P385, DOI 10.1007/BF00193512; CINELLI AR, 1995, J NEUROPHYSIOL, V73, P2053, DOI 10.1152/jn.1995.73.5.2053; CLAIBORNE BJ, 1984, J NEUROSCI, V4, P708; COBB SR, 1995, NATURE, V378, P75, DOI 10.1038/378075a0; ENGEL AK, 1992, TRENDS NEUROSCI, V15, P218, DOI 10.1016/0166-2236(92)90039-B; FREEMAN WJ, 1968, J NEUROPHYSIOL, V31, P349, DOI 10.1152/jn.1968.31.3.349; FREEMAN WJ, 1961, SCIENCE, V133, P2058, DOI 10.1126/science.133.3470.2058; FREEMAN WJ, OLFACTION MODEL SYST, P225; GELPERIN A, 1994, NATURE, V369, P61, DOI 10.1038/369061a0; Gray C M, 1994, J Comput Neurosci, V1, P11, DOI 10.1007/BF00962716; HARDIE RC, 1989, NATURE, V339, P704, DOI 10.1038/339704a0; HILDEBRAND JG, 1995, P NATL ACAD SCI USA, V92, P67, DOI 10.1073/pnas.92.1.67; JAHR CE, 1982, J PHYSIOL-LONDON, V326, P213, DOI 10.1113/jphysiol.1982.sp014187; Jefferys JGR, 1996, TRENDS NEUROSCI, V19, P202, DOI 10.1016/S0166-2236(96)10023-0; KETCHUM KL, 1993, J NEUROSCI, V13, P3980; LAURENT G, 1994, J NEUROSCI, V14, P2993; LAURENT G, 1994, SCIENCE, V265, P1872, DOI 10.1126/science.265.5180.1872; Laurent G, 1996, J NEUROSCI, V16, P3837; Laurent G, 1996, NEURON, V16, P473, DOI 10.1016/S0896-6273(00)80066-5; LAURENT G, IN PRESS TRENDS NEUR; Leitch B, 1996, J COMP NEUROL, V372, P487; LYTTON WW, 1991, J NEUROPHYSIOL, V66, P1059, DOI 10.1152/jn.1991.66.3.1059; MACLEOD K, UNPUB; MCCLINTOCK TS, 1989, P NATL ACAD SCI USA, V86, P8137, DOI 10.1073/pnas.86.20.8137; MEREDITH M, 1986, J NEUROPHYSIOL, V56, P572, DOI 10.1152/jn.1986.56.3.572; MORI K, 1995, PROG NEUROBIOL, V45, P585, DOI 10.1016/0301-0082(94)00058-P; MULLER U, 1993, NATURWISSENSCHAFTEN, V80, P524, DOI 10.1007/BF01140811; RALL W, 1966, EXP NEUROL, V14, P44, DOI 10.1016/0014-4886(66)90023-9; SATOU M, 1990, PROG NEUROBIOL, V34, P115, DOI 10.1016/0301-0082(90)90004-Z; SHEPHERD GM, 1994, NEURON, V13, P771, DOI 10.1016/0896-6273(94)90245-3; SHURMANN FW, 1974, EXP BRAIN RES, V19, P406; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.ne.18.030195.003011; WALDROP B, 1987, J COMP PHYSIOL A, V161, P23, DOI 10.1007/BF00609452; WEHR M, IN PRESS NATURE; WHITTINGTON MA, 1995, NATURE, V373, P612, DOI 10.1038/373612a0; WILSON M, 1992, J NEUROPHYSIOL, V67, P981, DOI 10.1152/jn.1992.67.4.981; YOKOI M, 1995, P NATL ACAD SCI USA, V92, P3371, DOI 10.1073/pnas.92.8.3371	42	279	280	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 8	1996	274	5289					976	979		10.1126/science.274.5289.976	http://dx.doi.org/10.1126/science.274.5289.976			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR792	8875938				2022-12-24	WOS:A1996VR79200047
J	VanAntwerp, DJ; Martin, SJ; Kafri, T; Green, DR; Verma, IM				VanAntwerp, DJ; Martin, SJ; Kafri, T; Green, DR; Verma, IM			Suppression of TNF-alpha-induced apoptosis by NF-kappa B	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; SIGNAL-INDUCED PHOSPHORYLATION; ACTIVATION; EXPRESSION; PHOSPHATIDYLSERINE; IMMUNOSUPPRESSION; GLUCOCORTICOIDS; TRANSCRIPTION; PROTEOLYSIS; INHIBITION	Tumor necrosis factor alpha (TNF-alpha) signaling gives rise to a number of events, including activation of transcription factor NF-kappa B and programmed cell death (apoptosis). Previous studies of TNF-alpha signaling have suggested that these two events occur independently. The sensitivity and kinetics of TNF-alpha-induced apoptosis are shown to be enhanced in a number of cell types expressing a dominant-negative I kappa B alpha (I kappa B alpha M). These findings suggest that a negative feedback mechanism results from TNF-alpha signaling in which NF-kappa B activation suppresses the signals for cell death.	SALK INST BIOL STUDIES,GENET LAB,LA JOLLA,CA 92037; UNIV CALIF SAN DIEGO,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093; LA JOLLA INST ALLERGY & IMMUNOL,SAN DIEGO,CA 92121	Salk Institute; University of California System; University of California San Diego; La Jolla Institute for Immunology			Green, Douglas R/N-8083-2018	Green, Douglas R/0000-0002-7332-1417	NIGMS NIH HHS [GM52735] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM052735, R01GM052735] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CAULEY K, 1994, P NATL ACAD SCI USA, V91, P390, DOI 10.1073/pnas.91.1.390; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Lin RT, 1996, MOL CELL BIOL, V16, P1401; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER AD, 1989, BIOTECHNIQUES, V7, P984; MILLER AD, 1989, BIOTECHNIQUES, V7, P989; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; PALMER TD, 1991, P NATL ACAD SCI USA, V88, P1330, DOI 10.1073/pnas.88.4.1330; Ponton A, 1996, J BIOL CHEM, V271, P8991, DOI 10.1074/jbc.271.15.8991; RUBIN BY, 1988, CANCER RES, V48, P6006; SATAKE H, 1995, BIOCHEM BIOPH RES CO, V216, P568, DOI 10.1006/bbrc.1995.2660; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; THIAGARAJAN P, 1990, J BIOL CHEM, V265, P17420; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VANANTWERP D, UNPUB	30	1619	1649	0	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1996	274	5288					787	789		10.1126/science.274.5288.787	http://dx.doi.org/10.1126/science.274.5288.787			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ145	8864120				2022-12-24	WOS:A1996VQ14500045
J	Timmerman, LA; Clipstone, NA; Ho, SN; Northrop, JP; Crabtree, GR				Timmerman, LA; Clipstone, NA; Ho, SN; Northrop, JP; Crabtree, GR			Rapid shuttling of NF-AT in discrimination of Ca2+ signals and immunosuppression	NATURE			English	Article							CAPACITATIVE CALCIUM-ENTRY; T-CELL ACTIVATION; CYCLOSPORINE-A; NUCLEAR FACTOR; NERVOUS-SYSTEM; GENE FAMILY; LYMPHOCYTES; CALCINEURIN; RECEPTOR; PROTEINS	CELLS need to distinguish between transient Ca2+ signals that induce events such as muscle contraction, secretion, adhesion and synaptic transmission, and sustained Ca2+ signals that are involved in cell proliferation and differentiation, The latter class of events is blocked in lymphocytes by the immunosuppressive drugs cyclosporin A and FK506, which inhibit calcineurin, a Ca2+-activated serine/threonine phosphatase necessary for the nuclear import of NF-AT transcription factors(1-4). Here we report that sustained high concentrations of Ca2+, but not transient pulses, are required to maintain NF-AT transcription factors in the nucleus, where they participate in Ca2+-dependent induction of genes required for lymphocyte activation and proliferation, Furthermore, overexpression and constitutive nuclear localization of NF-AT, but not Jun, Fos, NF-kappa B, Oct or Ets family members, renders the interleukin-2 enhancer in Jurkat T lymphocytes resistant to FK506 and cyclosporin A, Thus a primary effect of these immunosuppressive reagents is to control the subcellular localization of the NF-AT family of transcription factors.	STANFORD UNIV,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT PATHOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305; STANFORD UNIV,PROGRAM IMMUNOL,STANFORD,CA 94305	Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University; Stanford University			Agena, Fabiana A/C-5819-2015	Agena, Fabiana A/0000-0002-4526-4857				CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FANGER CM, 1995, J CELL BIOL, V131, P655, DOI 10.1083/jcb.131.3.655; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; HO AM, 1994, J BIOL CHEM, V269, P28181; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; Ho SN, 1996, NATURE, V382, P822, DOI 10.1038/382822a0; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; JAIN JN, 1993, J IMMUNOL, V151, P837; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MCKNIGHT SL, 1992, TRANSCRIPTIONAL REGU, V1; MCKNIGHT SL, 1992, TRANSCRIPTIONAL REGU, V2; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NOWELL PC, 1960, CANCER RES, V20, P462; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; SANDER B, 1993, J IMMUNOL METHODS, V166, P201, DOI 10.1016/0022-1759(93)90361-A; SERAFINI AT, 1995, IMMUNITY, V3, P239, DOI 10.1016/1074-7613(95)90093-4; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TSIEN RY, 1982, NATURE, V295, P68, DOI 10.1038/295068a0; TURNER CA, 1994, CELL, V77, P297, DOI 10.1016/0092-8674(94)90321-2; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WEISS A, 1987, J IMMUNOL, V138, P2169; WHITNEY RB, 1972, J CELL PHYSIOL, V80, P329, DOI 10.1002/jcp.1040800303	31	457	475	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 31	1996	383	6603					837	840		10.1038/383837a0	http://dx.doi.org/10.1038/383837a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ144	8893011				2022-12-24	WOS:A1996VQ14400067
J	CasacciaBonnefil, P; Carter, BD; Dobrowsky, RT; Chao, MV				CasacciaBonnefil, P; Carter, BD; Dobrowsky, RT; Chao, MV			Death of oligodendrocytes mediated by the interaction of nerve growth factor with its receptor p75	NATURE			English	Article							AFFINITY NEUROTROPHIN RECEPTOR; NGF RECEPTOR; CELL-DEATH; CERAMIDE; BINDING; COEXPRESSION; APOPTOSIS; SURVIVAL; EXPRESS; DOMAIN	MEMBERS of the nerve growth factor (NGF) family promote the survival of neurons during development(1). NGF specifically activates the receptor trkA, initiating a signal transduction cascade which ultimately blocks cell death. Here we show that NGF can have the opposite effect, inducing the death of mature oligodendrocytes cultured from postnatal rat cerebral cortex. This effect was highly specific, because NGF had no effect on oligodendrocyte precursors and astrocytes. Other neurotrophins such as brain-derived neurotrophin factor (BDNF) and neurotrophin-3 (NT-3) did not induce cell death. NGF binding to mature oligodendrocytes expressing the p75 neurotrophin receptor, but not trkA, resulted in a sustained increase of intracellular ceramide and c-Jun amino-terminal kinase (JNK) activity, which are thought to participate in a signal transduction pathway leading to cell death. Taken together, these results indicate that NGF has the ability to promote cell death in specific cell types through a ligand-dependent signalling mechanism involving the p75 neurotrophin receptor.	CORNELL UNIV,COLL MED,DEPT CELL BIOL & ANAT,DIV HEMATOL ONCOL,NEW YORK,NY 10021; UNIV KANSAS,DEPT PHARMACOL & TOXICOL,LAWRENCE,KS 66045	Cornell University; University of Kansas				Chao, Moses/0000-0002-6969-3744				ALTHAUS HH, 1992, NEUROSCI LETT, V135, P219, DOI 10.1016/0304-3940(92)90440-I; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BARRETT GL, 1994, P NATL ACAD SCI USA, V91, P6501, DOI 10.1073/pnas.91.14.6501; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CasacciaBonnefil P, 1996, J NEUROSCI RES, V43, P382, DOI 10.1002/(SICI)1097-4547(19960201)43:3<382::AID-JNR13>3.0.CO;2-7; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; CLARY DO, 1994, MOL BIOL CELL, V5, P549, DOI 10.1091/mbc.5.5.549; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DOBROWSKY RT, 1995, J BIOL CHEM, V270, P22135, DOI 10.1074/jbc.270.38.22135; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HUBER LJ, 1995, DEV BIOL, V167, P227, DOI 10.1006/dbio.1995.1019; ITOH N, 1993, J BIOL CHEM, V268, P10932; JUNIER MP, 1994, MOL BRAIN RES, V24, P247, DOI 10.1016/0169-328X(94)90138-4; KUMAR S, 1993, MOL BRAIN RES, V17, P163, DOI 10.1016/0169-328X(93)90086-5; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; RODRIGUEZTEBAR A, 1992, EMBO J, V11, P917, DOI 10.1002/j.1460-2075.1992.tb05130.x; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	30	664	687	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 24	1996	383	6602					716	719		10.1038/383716a0	http://dx.doi.org/10.1038/383716a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN918	8878481				2022-12-24	WOS:A1996VN91800053
J	Frank, LA; Paterson, WR; Ackerson, KL; Vasyliunas, VM; Coroniti, FV; Bolton, SJ				Frank, LA; Paterson, WR; Ackerson, KL; Vasyliunas, VM; Coroniti, FV; Bolton, SJ			Plasma observations at Io with the Galileo spacecraft	SCIENCE			English	Article							ATMOSPHERE	Plasma measurements made during the flyby of Io on 7 December 1995 with the Galileo spacecraft plasma analyzers reveal that the spacecraft unexpectedly passed directly through the ionosphere of Io. The ionosphere is identified by a dense plasma that is at rest with respect to Io. This plasma is cool relative to those encountered outside the ionosphere. The composition of the ionospheric plasmas includes O++, O+ and S++, S+, and SO2+ ions. The plasma conditions at Io appear to account for the decrease in the magnetic field, without the need to assume that Io has a magnetized interior.	MAX PLANCK INST AERON,D-3411 KATLENBURG DUHM,GERMANY; UNIV CALIF LOS ANGELES,DEPT PHYS & ASTRON,LOS ANGELES,CA 90095; CALTECH,JET PROP LAB,PASADENA,CA 91109	Max Planck Society; University of California System; University of California Los Angeles; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Frank, LA (corresponding author), UNIV IOWA,DEPT PHYS & ASTRON,IOWA CITY,IA 52242, USA.		Bolton, Scott/M-4392-2019; Paterson, William/F-5684-2012	bolton, scott/0000-0002-9115-0789				BALLESTER GE, 1994, ICARUS, V111, P2, DOI 10.1006/icar.1994.1129; BANKS PM, 1973, AERONOMY A, P217; BIGG EK, 1964, NATURE, V203, P1008, DOI 10.1038/2031008a0; Brown R. A., 1974, EXPLORATION PLANETAR, P527; DESSLER AJ, 1979, ASTROPHYS J, V227, P664, DOI 10.1086/156777; FRANK LA, 1992, SPACE SCI REV, V60, P283, DOI 10.1007/BF00216858; GOLDREICH P, 1969, ASTROPHYS J, V156, P59, DOI 10.1086/149947; GURNETT DA, 1972, ASTROPHYS J, V175, P525, DOI 10.1086/151576; Kivelson MG, 1996, SCIENCE, V273, P337, DOI 10.1126/science.273.5273.337; KUPO I, 1976, ASTROPHYS J, V205, pL51, DOI 10.1086/182088; MORABITO LA, 1979, SCIENCE, V204, P972, DOI 10.1126/science.204.4396.972; NESS NF, 1979, SCIENCE, V204, P982, DOI 10.1126/science.204.4396.982; NEUBAUER FM, 1980, J GEOPHYS RES-SPACE, V85, P1171, DOI 10.1029/JA085iA03p01171; PIDDINGTON JH, 1968, NATURE, V217, P935, DOI 10.1038/217935a0; SCHNEIDER NM, 1991, ASTROPHYS J, V368, P298, DOI 10.1086/169694; SOUTHWOOD DJ, 1980, J GEOPHYS RES-SPACE, V85, P5959, DOI 10.1029/JA085iA11p05959; STROBEL DF, 1994, ICARUS, V111, P18, DOI 10.1006/icar.1994.1130; WILSON JK, 1994, ICARUS, V111, P31, DOI 10.1006/icar.1994.1131	18	175	177	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1996	274	5286					394	395		10.1126/science.274.5286.394	http://dx.doi.org/10.1126/science.274.5286.394			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN173	8832882				2022-12-24	WOS:A1996VN17300045
J	Wu, XH; Haber, JE				Wu, XH; Haber, JE			A 700 bp cis-acting region controls mating-type dependent recombination along the entire left arm of yeast chromosome III	CELL			English	Article							LOCUS-CONTROL REGION; SACCHAROMYCES-CEREVISIAE; X-CHROMOSOME; DOSAGE COMPENSATION; DONOR PREFERENCE; GENE; INTERCONVERSION; DIRECTIONALITY; REPRESSION; BETA	Homothallic switching of the mating-type MATa gene in Saccharomyces cerevisiae results from replacement by gene conversion of MAT-Ya DNA with Ya sequences copied from one of two unexpressed donors. MATa preferentially recombines with HML alpha, located near the left end of chromosome III, but can use HMR alpha, near the right chromosome end. MATa donor preference depends on a 700 bp orientation-independent cis-acting recombination enhancer, located 17 kb proximal to HML. Deletion of this element markedly reduces MATa's use of a donor inserted at any of four different locations along the leftmost 92 kb of chromosome III. This enhancer is sufficient for donor activation, since it stimulates use of the ''wrong'' donor, when it is inserted 7 kb proximal to HMR.	BRANDEIS UNIV,ROSENSTIEL CTR,WALTHAM,MA 02254; BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254	Brandeis University; Brandeis University				Haber, James/0000-0002-1878-0610	NIGMS NIH HHS [GM20056] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020056, R37GM020056] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALADJEM MI, 1995, SCIENCE, V270, P815, DOI 10.1126/science.270.5237.815; BONE JR, 1994, GENE DEV, V8, P96, DOI 10.1101/gad.8.1.96; BROWN CJ, 1991, NATURE, V349, P82, DOI 10.1038/349082a0; CAPONE M, 1993, EMBO J, V12, P4335, DOI 10.1002/j.1460-2075.1993.tb06118.x; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; GERRING SL, 1990, EMBO J, V9, P4347, DOI 10.1002/j.1460-2075.1990.tb07884.x; HABER JE, 1992, TRENDS GENET, V8, P446, DOI 10.1016/0168-9525(92)90329-3; HABER JE, 1974, GENETICS, V78, P843; HERSCHBACH BM, 1994, NATURE, V370, P309, DOI 10.1038/370309a0; HICKS JB, 1977, GENETICS, V85, P373; JENSEN RE, 1984, COLD SPRING HARB SYM, V49, P97, DOI 10.1101/SQB.1984.049.01.013; KIM CG, 1992, GENE DEV, V6, P928, DOI 10.1101/gad.6.6.928; KLAR AJS, 1982, CELL, V28, P551, DOI 10.1016/0092-8674(82)90210-0; KOSTRIKEN R, 1983, CELL, V35, P167, DOI 10.1016/0092-8674(83)90219-2; LIRAS P, 1978, GENETICS, V88, P651; LOO S, 1994, SCIENCE, V264, P1768, DOI 10.1126/science.8209257; NICKOLOFF JA, 1989, J MOL BIOL, V207, P527, DOI 10.1016/0022-2836(89)90462-2; ORRWEAVER TL, 1983, METHOD ENZYMOL, V101, P228; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SMITH DL, 1994, EMBO J, V13, P2378, DOI 10.1002/j.1460-2075.1994.tb06521.x; STRATHERN JN, 1979, CELL, V17, P371, DOI 10.1016/0092-8674(79)90163-6; STRATHERN JN, 1989, GENETIC RECOMBINATIO, P445; SUGAWARA N, 1995, NATURE, V373, P84, DOI 10.1038/373084a0; THOMPSON JS, 1994, MOL CELL BIOL, V14, P446, DOI 10.1128/MCB.14.1.446; VERHAGE R, 1994, MOL CELL BIOL, V14, P6135, DOI 10.1128/MCB.14.9.6135; WEILER KS, 1992, GENETICS, V132, P929; WEILER KS, 1995, GENETICS, V139, P1495; WU XH, 1995, GENE DEV, V9, P1922, DOI 10.1101/gad.9.15.1922; Wu XH, 1996, MOL CELL BIOL, V16, P657	31	85	86	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1996	87	2					277	285		10.1016/S0092-8674(00)81345-8	http://dx.doi.org/10.1016/S0092-8674(00)81345-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VN403	8861911	Bronze			2022-12-24	WOS:A1996VN40300015
J	Behar, O; Golden, JA; Mashimo, H; Schoen, FJ; Fishman, MC				Behar, O; Golden, JA; Mashimo, H; Schoen, FJ; Fishman, MC			Semaphorin III Is needed for normal patterning and growth of nerves, bones and heart	NATURE			English	Article							SPINAL-CORD; CONE GUIDANCE; GENE; FAMILY; EXPRESSION; COLLAPSIN; MEMBER	THE expression patterns of the recently discovered family of semaphorin genes suggests that they have widespread roles in embryonic development(1-9). Some seem to guide neuronal growth cones, but otherwise their functions are unknown(2,10-12). Semaphorin III is a membrane-associated secreted protein with a developmentally dynamic pattern of expression, including particular domains of the nervous system, the borders of developing bones, and the heart(6,7). In vitro, semaphorin III causes growth-cone collapse, and repels cutaneous sensory axons from the ventral spinal cord(2,11). Mutants in the Drosophila gene semaII, which encodes a related semaphorin, die after eclosion, but no responsible abnormality is evident(3). We have generated mice mutant in the semaIII gene by homologous recombination. Here we show that in the mutants, some sensory axons project into inappropriate regions of the spinal cord where semaIII is normally expressed. The cerebral cortex of hymozygous mutant mice shows a paucity of neuropil and abnormally oriented neuronal processes, especially of the large pyramidal neurons. Certain embryonic bones and cartilaginous structures develop abnormally, with vertebral fusions and partial rib duplications. The few mice that survive more than a few days postnatally manifest pronounced and selective hypertrophy of the right ventricle of the heart and dilation of the right atrium. Thus, semaphorin III might serve as a signal that restrains growth in several developing organs.	MASSACHUSETTS GEN HOSP EAST,CARDIOVASC RES CTR,CHARLESTOWN,MA 02129; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School			Behar, Oded/AAH-8806-2019	Behar, Oded/0000-0001-6913-2827; Golden, Jeffrey/0000-0001-9933-5502				BEHAR O, 1994, ENDOCRINOLOGY, V134, P475, DOI 10.1210/en.134.1.475; DODD J, 1995, CELL, V81, P471, DOI 10.1016/0092-8674(95)90066-7; GIBSON SJ, 1984, J NEUROSCI, V4, P3101, DOI 10.1523/jneurosci.04-12-03101.1984; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; INAGAKI S, 1995, FEBS LETT, V370, P269, DOI 10.1016/0014-5793(95)00850-9; KOLODKIN AL, 1992, NEURON, V9, P831, DOI 10.1016/0896-6273(92)90237-8; Kolodkin AL, 1996, TRENDS CELL BIOL, V6, P15, DOI 10.1016/0962-8924(96)81033-6; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, COLD SPRING HARB SYM, V58, P297, DOI 10.1101/SQB.1993.058.01.035; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; LUO YL, 1995, NEURON, V14, P1131, DOI 10.1016/0896-6273(95)90261-9; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; LYONS GE, 1994, TRENDS CARDIOVAS MED, V4, P70, DOI 10.1016/1050-1738(94)90012-4; MATTHES DJ, 1995, CELL, V81, P631, DOI 10.1016/0092-8674(95)90084-5; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; MISCHEL PS, 1995, J NEUROPATH EXP NEUR, V54, P137, DOI 10.1097/00005072-199503000-00001; PUSCHEL AW, 1995, NEURON, V14, P941, DOI 10.1016/0896-6273(95)90332-1; Shepherd I, 1996, DEV BIOL, V173, P185, DOI 10.1006/dbio.1996.0016; WRIGHT DE, 1995, J COMP NEUROL, V361, P321, DOI 10.1002/cne.903610209; Xiang RH, 1996, GENOMICS, V32, P39, DOI 10.1006/geno.1996.0074; ZHANG W, 1995, GENE DEV, V9, P1388, DOI 10.1101/gad.9.11.1388	22	500	512	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1996	383	6600					525	528		10.1038/383525a0	http://dx.doi.org/10.1038/383525a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL755	8849723				2022-12-24	WOS:A1996VL75500050
J	Pearce, SHS; Williamson, C; Kifor, O; Bai, M; Coulthard, MG; Davies, M; LewisBarned, N; McCredie, D; Powell, H; KendallTaylor, P; Brown, EM; Thakker, RV				Pearce, SHS; Williamson, C; Kifor, O; Bai, M; Coulthard, MG; Davies, M; LewisBarned, N; McCredie, D; Powell, H; KendallTaylor, P; Brown, EM; Thakker, RV			A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AUTOSOMAL-DOMINANT HYPOPARATHYROIDISM; EXTRACELLULAR CA2+-SENSING RECEPTOR; NEONATAL SEVERE HYPERPARATHYROIDISM; BENIGN HYPOCALCIURIC HYPERCALCEMIA; PARATHYROID-HORMONE GENE; CHILDREN; LINKAGE; CLONING; LOCUS; CELLS	Background The calcium-sensing receptor regulates the secretion of parathyroid hormone in response to changes in extracellular calcium concentrations, and mutations that result in a loss of function of the receptor are associated with familiar hypocalciuric hypercalcemia. Mutations involving a gain of function have been associated with hypocalcemia in two kindreds. We examined the possibility that the latter type of mutation may result in a phenotype of familial hypocalcemia with hypercalciuria. Methods We studied six kindreds given a diagnosis of autosomal dominant hypoparathyroidism on the basis of their hypocalcemia and normal serum parathyroid hormone concentrations, a combination that suggested a defect of the calcium-sensing receptor. The hypocalcemia was associated with hypercalciuria, and treatment with vitamin D resulted in increased hypercalciuria, nephrocalcinosis, and renal impairment. Mutations in the calcium-sensing-receptor gene were identified by DNA-sequence analysis and expressed in human embryonic kidney cells (HEK-293). Results Five heterozygous missense mutations (Asn118Lys, Phe128Leu, Thr151Met, Glu191Lys, and Phe612Ser) were detected in the extracellular domain of the calcium-sensing-receptor gene and shown to cosegregate with the disease. Analysis of the functional expression of three of the mutant receptors in HEK-293 cells demonstrated shifts in the dose-response curves so that the extracellular calcium concentrations needed to produce half-maximal increases in total inositol phosphate in the cells were significantly (P = 0.02 to P < 0.001) lower than those required for the wild-type receptor. Conclusions Gain-of-function mutations in the calcium-sensing receptor are associated with a familial syndrome of hypocalcemia with hypercalciuria that needs to be distinguished from hypoparathyroidism.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,MRC,CLIN SCI CTR,MOL ENDOCRINOL GRP,LONDON W12 0NN,ENGLAND; BRIGHAM & WOMENS HOSP,DIV ENDOCRINE HYPERTENS,BOSTON,MA 02115; ROYAL VICTORIA INFIRM,PEDIAT UNIT,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND; ROYAL VICTORIA INFIRM,ENDOCRINE UNIT,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND; MANCHESTER ROYAL INFIRM,DEPT MED,MANCHESTER M13 9WL,LANCS,ENGLAND; UNIV OTAGO,DEPT MED,DUNEDIN,NEW ZEALAND; ROYAL CHILDRENS HOSP,MELBOURNE,VIC,AUSTRALIA	Imperial College London; Harvard University; Brigham & Women's Hospital; Newcastle University - UK; Newcastle University - UK; University of Manchester; University of Otago; Royal Children's Hospital Melbourne			Pearce, Simon/AAB-3692-2019	Pearce, Simon/0000-0001-8384-8063; Williamson, Catherine/0000-0002-6226-7611; Thakker, Rajesh/0000-0002-1438-3220	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048330, R01DK044588, R01DK041415] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44588, DK48330, DK41415] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AALTONEN J, 1994, NAT GENET, V8, P83, DOI 10.1038/ng0994-83; AHN TG, 1986, MEDICINE, V65, P73, DOI 10.1097/00005792-198603000-00001; AIDA K, 1995, J CLIN ENDOCR METAB, V80, P2594, DOI 10.1210/jc.80.9.2594; ARNOLD A, 1990, J CLIN INVEST, V86, P1084, DOI 10.1172/JCI114811; ATTIE MF, 1983, J CLIN INVEST, V72, P667, DOI 10.1172/JCI111016; BILOUS RW, 1992, NEW ENGL J MED, V327, P1069, DOI 10.1056/NEJM199210083271506; BROWN E, 1987, FEBS LETT, V218, P113, DOI 10.1016/0014-5793(87)81029-3; BROWN EM, 1995, NEW ENGL J MED, V333, P234, DOI 10.1056/NEJM199507273330407; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; BROWN EM, 1995, AM J KIDNEY DIS, V25, P506, DOI 10.1016/0272-6386(95)90118-3; CAREY AH, 1992, AM J HUM GENET, V51, P964; CHOU YHW, 1995, AM J HUM GENET, V56, P1075; DAVIES M, 1984, ACTA ENDOCRINOL-COP, V106, P499, DOI 10.1530/acta.0.1060499; FINEGOLD DN, 1994, PEDIATR RES, V36, P414, DOI 10.1203/00006450-199409000-00024; GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919; GHAZALI S, 1974, ARCH DIS CHILD, V49, P97, DOI 10.1136/adc.49.2.97; Heath H, 1996, J CLIN ENDOCR METAB, V81, P1312, DOI 10.1210/jcem.81.4.8636323; HEATH H, 1993, AM J HUM GENET, V53, P193; HUNTER AGW, 1981, J MED GENET, V18, P431, DOI 10.1136/jmg.18.6.431; JANICIC N, 1995, AM J HUM GENET, V56, P880; KIFOR O, 1992, J BONE MINER RES, V7, P1327; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MARKOWITZ ME, 1982, J CLIN ENDOCR METAB, V55, P727, DOI 10.1210/jcem-55-4-727; MARX SJ, 1981, J CLIN ENDOCR METAB, V52, P736, DOI 10.1210/jcem-52-4-736; MOORE ES, 1978, J PEDIATR-US, V92, P906, DOI 10.1016/S0022-3476(78)80358-8; Nussbaum Samuel R., 1994, P157; NUSSBAUM SR, 1987, CLIN CHEM, V33, P1364; PARKINSON DB, 1992, NAT GENET, V1, P149, DOI 10.1038/ng0592-149; PARKINSON DB, 1993, HUM GENET, V91, P281; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; Pearce SHS, 1995, J CLIN INVEST, V96, P2683, DOI 10.1172/JCI118335; Perry Y. M., 1994, American Journal of Human Genetics, V55, pA17; POLLAK MR, 1994, NAT GENET, V8, P303, DOI 10.1038/ng1194-303; POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092-8674(93)90617-Y; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; Thakker Rajesh V., 1994, P765; THAKKER RV, 1990, J CLIN INVEST, V86, P40, DOI 10.1172/JCI114712; THAKKER RV, 1989, NEW ENGL J MED, V321, P218, DOI 10.1056/NEJM198907273210403; THAKKER RV, 1986, BONE MINER, V1, P137; TRUMP D, 1995, HUM GENET, V96, P183, DOI 10.1007/BF00207376	41	404	417	1	25	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 10	1996	335	15					1115	1122		10.1056/NEJM199610103351505	http://dx.doi.org/10.1056/NEJM199610103351505			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN399	8813042	Bronze			2022-12-24	WOS:A1996VN39900005
J	Gray, CM; McCormick, DA				Gray, CM; McCormick, DA			Chattering cells: Superficial pyramidal neurons contributing to the generation of synchronous oscillations in the visual cortex	SCIENCE			English	Article							RECEPTIVE-FIELD PROPERTIES; CAT; ELECTROPHYSIOLOGY; RAT; FACILITATION; HIPPOCAMPUS; MORPHOLOGY; INVITRO; SLICES	In response to visual stimulation, a subset of neurons in the striate and prestriate cortex displays synchronous rhythmic firing in the gamma frequency band (20 to 70 hertz). This finding has raised two fundamental questions: What is the functional significance of synchronous gamma-band activity and how is it generated? This report addresses the second of these two questions. By means of intracellular recording and staining of single cells in the cat striate cortex in vivo, a biophysically distinct class of pyramidal neuron termed ''chattering cells'' is described. These neurons are located in the superficial layers of the cortex, intrinsically generate 20- to 70-hertz repetitive burst firing in response to suprathreshold depolarizing current injection, and exhibit pronounced oscillations in membrane potential during visual stimulation that are largely absent during periods of spontaneous activity. These properties suggest that chattering cells may make a substantial intracortical contribution to the generation of synchronous cortical oscillations and thus participate in the recruitment of large populations of cells into synchronously firing assemblies.	YALE UNIV,SCH MED,NEUROBIOL SECT,NEW HAVEN,CT 06510	Yale University	Gray, CM (corresponding author), UNIV CALIF DAVIS,CTR NEUROSCI,SECT NEUROBIOL PHYSIOL & BEHAV,DAVIS,CA 95616, USA.		McCormick, David A/J-2649-2015; Kobelt, Liza/F-5926-2011	McCormick, David A/0000-0002-9803-8335; 				BRAGIN A, 1995, J NEUROSCI, V15, P47; BRINGUIER V, 1992, NEUROREPORT, V3, P1065, DOI 10.1097/00001756-199212000-00008; CALVIN WH, 1975, BRAIN RES, V83, P498, DOI 10.1016/0006-8993(75)90843-4; CONNORS BW, 1982, J NEUROPHYSIOL, V48, P1302, DOI 10.1152/jn.1982.48.6.1302; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; ENGEL AK, 1990, EUR J NEUROSCI, V2, P588, DOI 10.1111/j.1460-9568.1990.tb00449.x; FRIEDMANHILL SR, 1995, SOC NEUR ABSTR, V21; FRIEN A, 1994, NEUROREPORT, V5, P2273, DOI 10.1097/00001756-199411000-00017; GHOSE GM, 1992, J NEUROPHYSIOL, V68, P1558, DOI 10.1152/jn.1992.68.5.1558; GILBERT CD, 1977, J PHYSIOL-LONDON, V268, P391, DOI 10.1113/jphysiol.1977.sp011863; GILBERT CD, 1983, J NEUROSCI, V3, P1116; Gray C. M., 1987, SOC NEUR ABSTR, V13, P4043; GRAY CM, 1990, EUR J NEUROSCI, V2, P607, DOI 10.1111/j.1460-9568.1990.tb00450.x; GRAY CM, 1989, P NATL ACAD SCI USA, V86, P1698, DOI 10.1073/pnas.86.5.1698; GRAY CM, 1993, SOC NEUR ABSTR, V19; GRAY CM, 1995, SOC NEUR ABSTR, V21; HAMMOND P, 1985, NEUROSCIENCE, V15, P639, DOI 10.1016/0306-4522(85)90065-X; HUBEL DH, 1965, J NEUROPHYSIOL, V28, P229, DOI 10.1152/jn.1965.28.2.229; JAGADEESH B, 1992, SCIENCE, V257, P552, DOI 10.1126/science.1636094; KANG YN, 1994, J NEUROPHYSIOL, V72, P578, DOI 10.1152/jn.1994.72.2.578; Koenig Peter, 1995, Proceedings of the National Academy of Sciences of the United States of America, V92, P290; LARKMAN A, 1990, J NEUROSCI, V10, P1407; LAUFER M, 1967, VISION RES, V7, P215, DOI 10.1016/0042-6989(67)90086-7; Livingstone MS, 1996, J NEUROPHYSIOL, V75, P2467, DOI 10.1152/jn.1996.75.6.2467; LLINAS RR, 1991, P NATL ACAD SCI USA, V88, P897, DOI 10.1073/pnas.88.3.897; MARTIN KAC, 1984, J PHYSIOL-LONDON, V353, P463, DOI 10.1113/jphysiol.1984.sp015347; MASON A, 1990, J NEUROSCI, V10, P1415; MCCORMICK DA, 1985, J NEUROPHYSIOL, V54, P782, DOI 10.1152/jn.1985.54.4.782; MCCORMICK DA, 1995, SOC NEUR ABSTR, V21; MCCORMICK DA, 1993, SOC NEUR ABSTR, V19; MCCORMICK DA, IN PRESS SOC NEUR AB; MILES R, 1986, J PHYSIOL-LONDON, V373, P397, DOI 10.1113/jphysiol.1986.sp016055; MILNER P, 1985, BER BUNSEN PHYS CHEM, V89, P703; MILNER PM, 1974, PSYCHOL REV, V81, P521, DOI 10.1037/h0037149; Munk MHJ, 1996, SCIENCE, V272, P271, DOI 10.1126/science.272.5259.271; Neuenschwander S, 1996, NATURE, V379, P728, DOI 10.1038/379728a0; NUNEZ A, 1993, J NEUROPHYSIOL, V70, P418, DOI 10.1152/jn.1993.70.1.418; PALMER LA, 1974, BRAIN RES, V67, P27, DOI 10.1016/0006-8993(74)90295-9; SINGER W, 1993, ANNU REV PHYSIOL, V55, P349, DOI 10.1146/annurev.physiol.55.1.349; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.ne.18.030195.003011; Steriade M, 1996, J NEUROSCI, V16, P392, DOI 10.1523/jneurosci.16-01-00392.1996; STEVENS CF, 1995, NEURON, V14, P795, DOI 10.1016/0896-6273(95)90223-6; THOMSON AM, 1993, NEUROSCIENCE, V54, P347, DOI 10.1016/0306-4522(93)90257-G; Traub RD, 1996, J PHYSIOL-LONDON, V493, P471, DOI 10.1113/jphysiol.1996.sp021397; *U CA YAL U I AN C, 1991, NIH PUBL; VONDERMALSBURG C, 1986, BIOL CYBERN, V54, P29, DOI 10.1007/BF00337113; VONDERMALSBURG C, 1981, INTERNAL REPORT MAX; WHITTINGTON MA, 1995, NATURE, V373, P612, DOI 10.1038/373612a0	48	620	636	3	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1996	274	5284					109	113		10.1126/science.274.5284.109	http://dx.doi.org/10.1126/science.274.5284.109			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VK748	8810245				2022-12-24	WOS:A1996VK74800059
J	Ludewig, U; Pusch, M; Jentsch, TJ				Ludewig, U; Pusch, M; Jentsch, TJ			Two physically distinct pores in the dimeric CIC-0 chloride channel	NATURE			English	Article							TORPEDO ELECTROPLAX; VOLTAGE; MUTATIONS; DOMINANT; MYOTONIA	THE Torpedo chloride channel ClC-0 (ref, 1) is the prototype of a large family of chloride channels that have roles in transepithelial transport(2) and in regulating electrical excitability(3-6) and cell volume(7). ClC-0 opens in bursts with two identical conductance levels of similar to 8 pS (refs 8-10), Hyperpolarization slowly increases the probability of bursts ('slow gating'), and depolarization increases channel opening within bursts ('fast gating'). Replacing serine 123 by threonine changes rectification, ion selectivity and gating, but retains the typical bursting behaviour with two identical independent albeit reduced, conductance states (similar to 1.5 pS), Coexpression with wild-type ClC-0, either as covalently linked concatamers or as independent proteins, leads to bursting channels with two different pores. Our experiments strongly suggest that conductance, ion selectivity and 'fast' gating are determined only by the single subunit forming a single pore, independent from the attached pore; in contrast, 'slow' gating is a function of both subunits. Thus ClC-0 is a homodimer with two largely independent pores.	UNIV HAMBURG,CTR MOL NEUROBIOL HAMBURG ZMNH,D-20246 HAMBURG,GERMANY	University of Hamburg				Jentsch, Thomas/0000-0002-3509-2553; Pusch, Michael/0000-0002-8644-8847				BAUER CK, 1991, P NATL ACAD SCI USA, V88, P11052, DOI 10.1073/pnas.88.24.11052; Brandt S, 1995, FEBS LETT, V377, P15, DOI 10.1016/0014-5793(95)01298-2; FUJITA N, 1994, NUCLEIC ACIDS RES, V22, P1637, DOI 10.1093/nar/22.9.1637; GREENE JR, 1993, MOL GEN GENET, V241, P542, DOI 10.1007/BF00279896; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; MIDDLETON RE, 1994, BIOCHEMISTRY-US, V33, P13189, DOI 10.1021/bi00249a005; MILLER C, 1984, P NATL ACAD SCI-BIOL, V81, P2772, DOI 10.1073/pnas.81.9.2772; MILLER C, 1982, PHILOS T ROY SOC B, V299, P401, DOI 10.1098/rstb.1982.0140; PUSCH M, 1995, NATURE, V373, P527, DOI 10.1038/373527a0; Pusch M, 1995, NEURON, V15, P1455, DOI 10.1016/0896-6273(95)90023-3; STEINMEYER K, 1994, EMBO J, V13, P737, DOI 10.1002/j.1460-2075.1994.tb06315.x; STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0	16	235	238	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 26	1996	383	6598					340	343		10.1038/383340a0	http://dx.doi.org/10.1038/383340a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VJ439	8848047				2022-12-24	WOS:A1996VJ43900046
J	Jenny, A; MinvielleSebastia, L; Preker, PJ; Keller, W				Jenny, A; MinvielleSebastia, L; Preker, PJ; Keller, W			Sequence similarity between the 73-kilodalton protein of mammalian CPSF and a subunit of yeast polyadenylation factor I	SCIENCE			English	Article							PRE-MESSENGER-RNA; SPECIFICITY FACTOR; POLY(A) POLYMERASE; CLEAVAGE; 3'-END; CLONING; PURIFICATION; GENE	The 3' ends of most eukaryotic messenger RNAs are generated by endonucleolytic cleavage and polyadenylation. In mammals, the cleavage and polyadenylation specificity factor (CPSF) plays a central role in both steps of the processing reaction. Here, the cloning of the 73-kilodalton subunit of CPSF is reported. Sequence analyses revealed that a yeast protein (Ysh1) was highly similar to the 73-kD polypeptide. Ysh1 constitutes a new subunit of polyadenylation factor I (PFI), which has a role in yeast pre-mRNA 3'-end formation. This finding was unexpected because in contrast to CPSF, PFI is only required for the polyadenylation reaction. These results contribute to the understanding of how 3'-end processing factors may have evolved.	UNIV BASEL,BIOZENTRUM,DEPT CELL BIOL,CH-4056 BASEL,SWITZERLAND	University of Basel			Minvielle-Sebastia, Lionel/M-7154-2014					ANSARI A, 1995, EMBO J, V14, P4001, DOI 10.1002/j.1460-2075.1995.tb00071.x; BARABINO SML, UNPUB; BIENROTH S, 1993, EMBO J, V12, P585, DOI 10.1002/j.1460-2075.1993.tb05690.x; BIENROTH S, 1991, J BIOL CHEM, V266, P19768; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CHANFREAU G, COMMUNICATION; CHANFREAU G, UNPUB; CHEN J, 1992, MOL CELL BIOL, V12, P3470, DOI 10.1128/MCB.12.8.3470; COHEN SN, 1995, CELL, V80, P829, DOI 10.1016/0092-8674(95)90284-8; GUO ZJ, 1995, MOL CELL BIOL, V15, P5983; Harlow E, 1988, ANTIBODIES LAB MANUA; JENNY A, 1994, MOL CELL BIOL, V14, P8183, DOI 10.1128/MCB.14.12.8183; JENNY A, 1995, NUCLEIC ACIDS RES, V23, P2629, DOI 10.1093/nar/23.14.2629; JENNY A, UNPUB; LINGNER J, 1991, NATURE, V354, P496, DOI 10.1038/354496a0; MANLEY JL, 1995, CURR OPIN GENET DEV, V5, P222, DOI 10.1016/0959-437X(95)80012-3; MINVIELLESEBASTIA L, 1994, SCIENCE, V266, P1702, DOI 10.1126/science.7992054; MURTHY KGK, 1992, J BIOL CHEM, V267, P14804; MURTHY KGK, 1995, GENE DEV, V9, P2672, DOI 10.1101/gad.9.21.2672; Noble SM, 1996, GENETICS, V143, P67; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; PARK EC, 1992, P NATL ACAD SCI USA, V89, P1249, DOI 10.1073/pnas.89.4.1249; PREKER PJ, 1995, CELL, V81, P379, DOI 10.1016/0092-8674(95)90391-7; PREKER PJ, UNPUB; Ruegsegger U, 1996, J BIOL CHEM, V271, P6107; Sambrook J., 1989, MOL CLONING; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; TAKAGAKI Y, 1994, NATURE, V372, P471, DOI 10.1038/372471a0; VARSHAVSKY A, 1996, COLD SPRING HARB SYM, V60, P461; Wahle E, 1996, TRENDS BIOCHEM SCI, V21, P247, DOI 10.1016/S0968-0004(96)10030-X; WAHLE E, 1991, CELL, V66, P759, DOI 10.1016/0092-8674(91)90119-J	31	94	98	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1996	274	5292					1514	1517		10.1126/science.274.5292.1514	http://dx.doi.org/10.1126/science.274.5292.1514			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929409				2022-12-24	WOS:A1996VV77500044
J	Eng, C; Clayton, D; Schuffenecker, I; Lenoir, G; Cote, G; Gagel, RF; vanAmstel, HKP; Lips, CJM; Nishisho, I; Takai, SI; Marsh, DJ; Robinson, BG; FrankRaue, K; Raue, F; Xue, FY; Noll, WW; Romei, C; Pacini, F; Fink, M; Niederle, B; Zedenius, J; Nordenskjold, M; Komminoth, P; Hendy, GN; Gharib, H; Thibodeau, SN; Lacroix, A; Frilling, A; Ponder, BAJ; Mulligan, LM				Eng, C; Clayton, D; Schuffenecker, I; Lenoir, G; Cote, G; Gagel, RF; vanAmstel, HKP; Lips, CJM; Nishisho, I; Takai, SI; Marsh, DJ; Robinson, BG; FrankRaue, K; Raue, F; Xue, FY; Noll, WW; Romei, C; Pacini, F; Fink, M; Niederle, B; Zedenius, J; Nordenskjold, M; Komminoth, P; Hendy, GN; Gharib, H; Thibodeau, SN; Lacroix, A; Frilling, A; Ponder, BAJ; Mulligan, LM			The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2 - International RET mutation consortium analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDULLARY-THYROID CARCINOMA; TYROSINE KINASE DOMAIN; MEN 2A; PROTOONCOGENE MUTATIONS; HIRSCHSPRUNG DISEASE; POINT MUTATION; FMTC; FAMILIES	Objective.-Multiple endocrine neoplasia type 2 (MEN 2) is an autosomal dominant disorder. The 3 recognized subtypes include MEN 2A, characterized by medullary thyroid carcinoma (MTC), pheochromocytoma (pheo), and hyperparathyroidism (HPT); MEN 2B, by MTC, pheo, and characteristic stigmata; and familial MTC (FMTC), by the presence of MTC only. The purpose of this study was to establish the relationship between specific mutations and the presence of certain disease features in MEN 2 which could help in clinical decision making. Design.-Correlative survey study of 477 MEN 2 families. Setting.-Eighteen tertiary referral centers worldwide. Patients.-A total of 477 independent MEN 2 families. Main Outcome Measures.-Association between the position and type of germline mutation in the RET proto-oncogene and the presence or absence of MTC, pheo, HPT, and/or other features in a family. Results.-There is a statistically significant association between the presence of any mutation at a specific position (codon 634) and the presence of pheo and HPT. The presence of a specific mutation, CGC at codon 634, has yet to be associated with FMTC, Conversely, mutations at codons 768 and 804 are thus far seen only with FMTC, while codon 918 mutation is MEN 2B-specific. Rare families with both MEN 2 and Hirschsprung disease were found to have MEN 2-specific codon mutations. Patients with Hirschsprung disease presenting with such mutations should be monitored for the possible development of MEN 2 tumors. Conclusions.-This consortium analysis suggests that genotype-phenotype correlations do exist and, if made reliably absolute, could prove useful in the future in clinical management with respect to screening, surveillance, and prophylaxis, as well as provide insight into the genetic effects of particular mutations.	QUEENS UNIV,DEPT PAEDIAT,KINGSTON,ON K7L 3N6,CANADA; UNIV CAMBRIDGE,CANC RES CAMPAIGN,HUMAN CANC GENET RES GRP,CAMBRIDGE CB2 1TN,ENGLAND; UNIV CAMBRIDGE,INST PUBL HLTH,MRC,BIOSTAT UNIT,CAMBRIDGE CB2 1TN,ENGLAND; INT AGCY RES CANC,F-69372 LYON,FRANCE; UNIV TEXAS,MD ANDERSON CANC CTR,HOUSTON,TX; UNIV UTRECHT,DEPT INTERNAL MED,UTRECHT,NETHERLANDS; UNIV UTRECHT,CLIN GENET CTR,UTRECHT,NETHERLANDS; OSAKA UNIV,SCH MED,DEPT MED GENET,OSAKA,JAPAN; UNIV SYDNEY,ROYAL N SHORE HOSP,KOLLING INST MED RES,MOL GENET UNIT,ST LEONARDS,NSW 2065,AUSTRALIA; UNIV HEIDELBERG,DEPT INTERNAL MED 1,HEIDELBERG,GERMANY; DARTMOUTH HITCHCOCK MED CTR,DEPT PATHOL,LEBANON,NH 03766; UNIV PISA,INST ENDOCRINOL,PISA,ITALY; UNIV VIENNA,DEPT SURG,A-1010 VIENNA,AUSTRIA; KAROLINSKA HOSP,DEPT MOL MED,S-10401 STOCKHOLM,SWEDEN; KAROLINSKA HOSP,DEPT SURG,S-10401 STOCKHOLM,SWEDEN; KAROLINSKA HOSP,DEPT CLIN GENET,S-10401 STOCKHOLM,SWEDEN; UNIV ZURICH,DEPT PATHOL,CH-8006 ZURICH,SWITZERLAND; ROYAL VICTORIA HOSP,CALCIUM RES LAB,MONTREAL,PQ H3A 1A1,CANADA; MAYO CLIN,DIV ENDOCRINOL,ROCHESTER,MN; HOP HOTEL DIEU,CTR RECH,MONTREAL,PQ,CANADA; UNIV HAMBURG,DEPT SURG,HAMBURG,GERMANY; QUEENS UNIV,DEPT PATHOL,KINGSTON,ON K7L 3N6,CANADA; QUEENS UNIV,DEPT PAEDIAT,KINGSTON,ON,CANADA	Queens University - Canada; CRUK Cambridge Institute; University of Cambridge; MRC Biostatistics Unit; University of Cambridge; World Health Organization; International Agency for Research on Cancer (IARC); University of Texas System; UTMD Anderson Cancer Center; Utrecht University; Utrecht University; Osaka University; Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research; Ruprecht Karls University Heidelberg; Dartmouth College; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Pisa; University of Vienna; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; University of Zurich; McGill University; Royal Victoria Hospital; Mayo Clinic; Universite de Montreal; University of Hamburg; Queens University - Canada; Queens University - Canada	Eng, C (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT MED,DIV CANC EPIDEMIOL & CONTROL,44 BINNEY ST,BOSTON,MA 02115, USA.		Marsh, Deborah J/I-1491-2014; Lacroix, Andre/AAI-5645-2020; Raue, Friedhelm/ABD-6150-2021	Marsh, Deborah J/0000-0001-5899-4931; Raue, Friedhelm/0000-0002-7700-1648; Niederle, Bruno/0000-0001-8107-4068; Nordenskjold, Magnus/0000-0002-4974-425X; Eng, Charis/0000-0002-3693-5145				ANGRIST M, 1995, HUM MOL GENET, V4, P821, DOI 10.1093/hmg/4.5.821; ATTIE T, 1995, HUM MOL GENET, V4, P1381, DOI 10.1093/hmg/4.8.1381; BOLINO A, 1995, ONCOGENE, V10, P2415; BORST MJ, 1995, SURGERY, V117, P386, DOI 10.1016/S0039-6060(05)80057-1; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; ENG C, 1995, CLIN ENDOCRINOL, V43, P123, DOI 10.1111/j.1365-2265.1995.tb01903.x; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, 1995, ONCOGENE, V10, P509; ENG C, IN PRESS HUM MUTAT; FARNDON JR, 1986, BRIT J SURG, V73, P278, DOI 10.1002/bjs.1800730411; FRILLING A, 1992, H FORD HOSP MED J, V40, P233; GAGEL RF, 1989, ANN INTERN MED, V111, P802, DOI 10.7326/0003-4819-111-10-802; GARDNER E, 1994, HUM MOL GENET, V3, P1771, DOI 10.1093/hmg/3.10.1771; Hofstra R. M. W., 1994, American Journal of Human Genetics, V55, pA60; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; KOMMINOTH P, 1995, CANCER, V76, P479; Komminoth P, 1996, J CLIN ENDOCR METAB, V81, P2041, DOI 10.1210/jc.81.6.2041; LIPS CJM, 1994, NEW ENGL J MED, V331, P828, DOI 10.1056/NEJM199409293311302; Marsh DJ, 1996, CLIN ENDOCRINOL, V44, P213, DOI 10.1046/j.1365-2265.1996.505292.x; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, HUM MOL GENET, V3, P2163, DOI 10.1093/hmg/3.12.2163; MULLIGAN LM, 1995, J INTERN MED, V238, P343, DOI 10.1111/j.1365-2796.1995.tb01208.x; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; Noorani HZ, 1996, AM J HUM GENET, V59, P301; Okamoto E, 1967, J PEDIATR SURG, V2, P437; Pausova Z, 1996, J CLIN ENDOCR METAB, V81, P2711, DOI 10.1210/jc.81.7.2711; PONDER BAJ, 1988, Q J MED, V67, P299; Reynolds Lucinda F., 1995, Current Opinion in Pediatrics, V7, P702; SCHIMKE RN, 1984, ANNU REV MED, V35, P25, DOI 10.1146/annurev.me.35.020184.000325; SCHIMKE RN, 1968, NEW ENGL J MED, V279, P1, DOI 10.1056/NEJM196807042790101; SCHUFFENECKER I, 1994, HUM MOL GENET, V3, P1939, DOI 10.1093/hmg/3.11.1939; THAKKER RV, 1988, CLIN ENDOCRINOL META, V28, P1031; VERDY M, 1982, J PEDIATR GASTR NUTR, V1, P603, DOI 10.1097/00005176-198212000-00027; ZEDENIUS J, 1995, J CLIN ENDOCR METAB, V80, P3088, DOI 10.1210/jc.80.10.3088	35	855	884	0	21	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 20	1996	276	19					1575	1579		10.1001/jama.276.19.1575	http://dx.doi.org/10.1001/jama.276.19.1575			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT025	8918855				2022-12-24	WOS:A1996VT02500030
J	Walker, MC; Li, LM; Sander, JWAS				Walker, MC; Li, LM; Sander, JWAS			Long term use of lamotrigine and vigabatrin in in severe refractory epilepsy: Audit of outcome	BRITISH MEDICAL JOURNAL			English	Article									NATL SOC EPILEPSY,CHALFONT ST PETER SL9 0RJ,BUCKINGHAMSHIRE,ENGLAND				li, li/AAT-2097-2020; Li, Li/AEM-3636-2022; li, li/GPX-3938-2022; Walker, Matthew C/C-1577-2008; LI, LI QING/GRR-8855-2022; Sander, Josemir W/C-1576-2008; Li, Li/C-4916-2013	Walker, Matthew C/0000-0002-0812-0352; Sander, Josemir W/0000-0001-6041-9661; Li, Li/0000-0001-6062-4649	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		KLENERMAN P, 1993, J NEUROL NEUROSUR PS, V56, P149, DOI 10.1136/jnnp.56.2.149; NASHEF L, 1995, J NEUROL NEUROSUR PS, V58, P462, DOI 10.1136/jnnp.58.4.462; SANDER JWAS, 1990, EPILEPSY RES, V7, P226, DOI 10.1016/0920-1211(90)90019-R; SANDER JWAS, 1990, J NEUROL NEUROSUR PS, V53, P1008, DOI 10.1136/jnnp.53.11.1008; Walker MC, 1996, NEUROLOGY, V46, P912, DOI 10.1212/WNL.46.4.912	5	36	36	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1996	313	7066					1184	1185		10.1136/bmj.313.7066.1184	http://dx.doi.org/10.1136/bmj.313.7066.1184			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR907	8916751	Green Published			2022-12-24	WOS:A1996VR90700024
J	Jaffrey, SR; Snyder, SH				Jaffrey, SR; Snyder, SH			PIN: An associated protein inhibitor of neuronal nitric oxide synthase	SCIENCE			English	Article							CIS-TRANS ISOMERASE; BINDING PROTEIN; BRAIN; PURIFICATION; CLONING; ENZYME; TETRAHYDROBIOPTERIN; CYCLOPHILIN; APOPTOSIS; DOMAINS	The neurotransmitter functions of nitric oxide are dependent on dynamic regulation of its biosynthetic enzyme, neuronal nitric oxide synthase (nNOS), By means of a yeast two-hybrid screen, a 10-kilodalton protein was identified that physically interacts with and inhibits the activity of nNOS. This inhibitor, designated PIN, appears to be one of the most conserved proteins in nature, showing 92 percent amino acid identity with the nematode and rat homologs,Binding of PIN destabilizes the nNOS dimer, a conformation necessary for activity. These results suggest that PIN may regulate numerous biological processes through its effects on nitric oxide synthase activity.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOL SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT & BEHAV SCI,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University				Jaffrey, Samie/0000-0003-3615-6958	NIDA NIH HHS [DA00074] Funding Source: Medline; NIGMS NIH HHS [GM-07309] Funding Source: Medline	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1995, P NATL ACAD SCI USA, V92, P6753, DOI 10.1073/pnas.92.15.6753; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Dick T, 1996, MOL CELL BIOL, V16, P1966; DINERMAN JL, 1994, NEUROPHARMACOLOGY, V33, P1245, DOI 10.1016/0028-3908(94)90023-X; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; HEVEI JM, 1991, J BIOL CHEM, V266, P289; Jaffrey SR, 1995, ANNU REV CELL DEV BI, V11, P417; JAFFREY SR, UNPUB; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KING SM, 1995, J BIOL CHEM, V270, P11445, DOI 10.1074/jbc.270.19.11445; KLATT P, 1994, J BIOL CHEM, V269, P13861; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SIEKIERKA JJ, 1990, J BIOL CHEM, V265, P21011; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; WANG T, 1995, NATURE, V374, P262, DOI 10.1038/374262a0; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	35	411	448	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1996	274	5288					774	777		10.1126/science.274.5288.774	http://dx.doi.org/10.1126/science.274.5288.774			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ145	8864115				2022-12-24	WOS:A1996VQ14500040
J	Neitz, J; Neitz, M; Kainz, PM				Neitz, J; Neitz, M; Kainz, PM			Visual pigment gene structure and the severity of color vision defects	SCIENCE			English	Article							MOLECULAR-GENETICS; HUMAN RED; GREEN; POLYMORPHISM; CONE; DISCRIMINATION; PHOTOPIGMENT	Rearrangements of the visual pigment genes are associated with defective color vision and with differences between types of red-green color blindness. Among individuals within the most common category of defective color vision, deuteranomaly, there is a large variation in the severity of color vision loss. An examination of specific photopigment gene sites responsible for tuning photopigment absorption spectra revealed differences that predict these variations in the color defect. The results indicate that the severity of the defect in deuteranomalous color vision depends on the degree of similarity among the residual photopigments that serve vision in the color-anomalous eye.	MED COLL WISCONSIN,DEPT OPHTHALMOL,MILWAUKEE,WI 53226	Medical College of Wisconsin	Neitz, J (corresponding author), MED COLL WISCONSIN,DEPT CELLULAR BIOL & ANAT,8701 WATERTOWN PLANK RD,MILWAUKEE,WI 53226, USA.			Neitz, Maureen/0000-0002-5404-3343	NEI NIH HHS [EY09620, EY01931, EY09303] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009620, R01EY009303, P30EY001931] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALPERN M, 1977, J PHYSIOL-LONDON, V266, P647, DOI 10.1113/jphysiol.1977.sp011786; ASENJO AB, 1994, NEURON, V12, P1131, DOI 10.1016/0896-6273(94)90320-4; CHAN T, 1992, J BIOL CHEM, V267, P9478; DEEB SS, 1992, AM J HUM GENET, V51, P687; DEMARCO P, 1992, J OPT SOC AM A, V9, P1465, DOI 10.1364/JOSAA.9.001465; JAMESON D, 1956, J OPT SOC AM, V46, P1075, DOI 10.1364/JOSA.46.001075; MERBS SL, 1992, SCIENCE, V258, P464, DOI 10.1126/science.1411542; NAGY AL, 1982, J OPT SOC AM, V72, P571, DOI 10.1364/JOSA.72.000571; NATHANS J, 1986, SCIENCE, V232, P203, DOI 10.1126/science.3485310; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NEITZ J, 1989, NATURE, V342, P679, DOI 10.1038/342679a0; NEITZ J, 1990, VISION RES, V30, P621, DOI 10.1016/0042-6989(90)90073-T; NEITZ J, 1986, NATURE, V323, P623, DOI 10.1038/323623a0; NEITZ J, 1994, MOL GENETICS INHERIT; NEITZ M, 1995, VISION RES, V35, P2095, DOI 10.1016/0042-6989(94)00306-8; NEITZ M, 1995, VISION RES, V35, P2395, DOI 10.1016/0042-6989(95)00008-9; NEITZ M, 1991, SCIENCE, V252, P971, DOI 10.1126/science.1903559; NEITZ M, 1995, SCIENCE, V267, P1013, DOI 10.1126/science.7863325; PIANTANIDA T, 1976, AM J OPTOM PHYS OPT, V53, P647; POKORNY J, 1982, COLOR RES APPL, V7, P159, DOI 10.1002/col.5080070222; POKORNY J, 1977, J OPT SOC AM, V67, P1196, DOI 10.1364/JOSA.67.001196; POKORNY J, 1987, FRONTIERS VISUAL SCI, P150; REGAN BC, 1994, VISION RES, V34, P1279, DOI 10.1016/0042-6989(94)90203-8; WANG YS, 1992, NEURON, V9, P429, DOI 10.1016/0896-6273(92)90181-C; WILLIAMS AJ, 1992, EMBO J, V11, P2039, DOI 10.1002/j.1460-2075.1992.tb05261.x; WINDERICKX J, 1992, P NATL ACAD SCI USA, V89, P9710, DOI 10.1073/pnas.89.20.9710	26	81	84	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1996	274	5288					801	804		10.1126/science.274.5288.801	http://dx.doi.org/10.1126/science.274.5288.801			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ145	8864125				2022-12-24	WOS:A1996VQ14500050
J	Ophoff, RA; Terwindt, GM; Vergouwe, MN; vanEijk, R; Oefner, PJ; Hoffman, SMG; Lamerdin, JE; Mohrenweiser, HW; Bulman, DE; Ferrari, M; Haan, J; Lindhout, D; vanOmmen, GJB; Hofker, MH; Ferrari, MD; Frants, RR				Ophoff, RA; Terwindt, GM; Vergouwe, MN; vanEijk, R; Oefner, PJ; Hoffman, SMG; Lamerdin, JE; Mohrenweiser, HW; Bulman, DE; Ferrari, M; Haan, J; Lindhout, D; vanOmmen, GJB; Hofker, MH; Ferrari, MD; Frants, RR			Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4	CELL			English	Article							HYPOKALEMIC PERIODIC PARALYSIS; CALCIUM-CHANNEL; POINT MUTATIONS; SKELETAL-MUSCLE; SEROTONIN; BRAIN; MAPS; DNA; HETEROGENEITY; MAGNESIUM	Genes for familial hemiplegic migraine (FHM) and episodic ataxia type-2 (EA-2) have been mapped to chromosome 19p13. We characterized a brain-specific P/Q-type Ca2+ channel alpha 1-subunit gene, CACNL1A4, covering 300 kb with 47 exons. Sequencing of all exons and their surroundings revealed polymorphic variations, including a (CA)(n)-repeat (D19S1150), a (CAG)(n)-repeat in the 3'-UTR, and different types of deleterious mutations in FHM and EA-2. In FHM, we found four different missense mutations in conserved functional domains. One mutation has occurred on two different haplotypes in unrelated FHM families. In EA-2, we found two mutations disrupting the reading frame. Thus, FHM and EA-2 can be considered as allelic channelopathies. A similar etiology may be involved in common types of migraine.	LEIDEN UNIV HOSP, DEPT NEUROL, NL-2333 AL LEIDEN, NETHERLANDS; STANFORD UNIV, DEPT GENET, STANFORD, CA 94305 USA; LAWRENCE LIVERMORE NATL LAB, BBRP, LIVERMORE, CA 94550 USA; LONDON HLTH SCI CTR, DEPT CLIN NEUROL SCI, LONDON, ON N6A 5A5, CANADA; IRCCS S RAFFAELE, CLIN MOL BIOL LAB, I-20132 MILAN, ITALY; ERASMUS UNIV ROTTERDAM, MGC, DEPT CLIN GENET, NL-3000 DR ROTTERDAM, NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Stanford University; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; London Health Sciences Centre; Erasmus University Rotterdam	Ophoff, RA (corresponding author), LEIDEN UNIV, MGC, DEPT HUMAN GENET, SYLVIUS LAB, WASSENAARSEWEG 72, NL-2333 AL LEIDEN, NETHERLANDS.		Lindhout, Dick/AAH-5765-2019; Hoffman, Susan/K-1995-2019; Ferrari, Michel D./ABE-3758-2021; Ferrari, Maurizio/D-9107-2013	Ferrari, Michel D./0000-0001-9691-9449; Lindhout, Dick/0000-0001-9580-624X				ALTURA B M, 1985, Magnesium, V4, P169; BROWNE DL, 1994, NAT GENET, V8, P136, DOI 10.1038/ng1094-136; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; Cannon SC, 1996, TRENDS NEUROSCI, V19, P3, DOI 10.1016/0166-2236(96)81859-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CODIGNOLA A, 1993, J BIOL CHEM, V268, P26240; DEWAARD M, 1996, ION CHANNELS, V4; Diriong S, 1995, GENOMICS, V30, P605, DOI 10.1006/geno.1995.1284; Elliott MA, 1996, ANN NEUROL, V39, P100, DOI 10.1002/ana.410390115; FERRARI MD, 1993, CEPHALALGIA, V13, P151, DOI 10.1046/j.1468-2982.1993.1303151.x; FERRARI MD, 1989, NEUROLOGY, V39, P1239, DOI 10.1212/WNL.39.9.1239; FERRARI MD, 1995, EUR J NEUROL, V2, P5, DOI 10.1111/j.1468-1331.1995.tb00087.x; GRIGGS RC, 1995, ANN NEUROL, V37, P285, DOI 10.1002/ana.410370302; GUY HR, 1996, ION CHANNELS, V4; HAAN J, 1996, ADV HEADACHE; HAYWARDLESTER A, 1996, GENE QUANTIFICATION; HUBER CG, 1995, ANAL CHEM, V67, P578, DOI 10.1021/ac00099a015; HUDSON AJ, 1995, BRAIN, V118, P547, DOI 10.1093/brain/118.2.547; JOUTEL A, 1994, AM J HUM GENET, V55, P1166; JOUTEL A, 1993, NAT GENET, V5, P40, DOI 10.1038/ng0993-40; JURKATROTT K, 1994, HUM MOL GENET, V3, P1415, DOI 10.1093/hmg/3.8.1415; KRAMER PL, 1995, AM J HUM GENET, V57, P182; LAURITZEN M, 1996, SCI MED, V3, P32; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MARGOLIS RL, 1995, SOMAT CELL MOLEC GEN, V21, P279, DOI 10.1007/BF02255782; MAY A, 1995, HUM GENET, V96, P604, DOI 10.1007/BF00197420; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; MOSKOWITZ MA, 1992, TRENDS PHARMACOL SCI, V13, P307, DOI 10.1016/0165-6147(92)90097-P; Oefner P. J., 1995, American Journal of Human Genetics, V57, pA266; OPHOFF RA, 1994, GENOMICS, V22, P21, DOI 10.1006/geno.1994.1340; OPHOFF RA, 1996, IN PRESS EUR J HUM G; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; Peikert A, 1996, CEPHALALGIA, V16, P257, DOI 10.1046/j.1468-2982.1996.1604257.x; PTACEK LJ, 1991, CELL, V67, P1021; PTACEK LJ, 1994, CELL, V77, P863; RAMADAN NM, 1989, HEADACHE, V29, P416, DOI 10.1111/j.1526-4610.1989.hed2907416.x; RAVNIKGLAVAC M, 1994, HUM MOL GENET, V3, P801, DOI 10.1093/hmg/3.5.801; RUSSELL MB, 1995, INT J EPIDEMIOL, V24, P612, DOI 10.1093/ije/24.3.612; RUSSELL MB, 1995, BRIT MED J, V311, P541, DOI 10.1136/bmj.311.7004.541; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; STEA A, 1995, LIGAND VOLTAGE GATED, P113; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TEH BT, 1995, AM J HUM GENET, V56, P1443; Terwindt GM, 1996, CEPHALALGIA, V16, P153, DOI 10.1046/j.1468-2982.1996.1603153.x; VONBREDERLOW B, 1995, HUM MOL GENET, V4, P279, DOI 10.1093/hmg/4.2.279; ZHANG A, 1992, BIOCHIM BIOPHYS ACTA, V1134, P25, DOI 10.1016/0167-4889(92)90024-6; 1988, CEPHALALGIA, V8, P19	49	1791	1848	1	203	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 1	1996	87	3					543	552		10.1016/S0092-8674(00)81373-2	http://dx.doi.org/10.1016/S0092-8674(00)81373-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VQ466	8898206	Green Published, Bronze			2022-12-24	WOS:A1996VQ46600019
J	Gaiano, N; Amsterdam, A; Kawakami, K; Allende, M; Becker, T; Hopkins, N				Gaiano, N; Amsterdam, A; Kawakami, K; Allende, M; Becker, T; Hopkins, N			Insertional mutagenesis and rapid cloning of essential genes In zebrafish	NATURE			English	Article							DROSOPHILA GENOME; MUTATION; VECTOR; CELLS; MICE	LARGE-SCALE chemical mutagenesis screens in zebrafish have led to the isolation of thousands of lethal mutations in genes that are essential for embryonic development(1,2). However, the cloning of these mutated genes is difficult at present as it requires positional cloning methods, In Drosophila, chemical mutagenesis screens were complemented with P-element insertional mutagenesis which facilitated the cloning of many genes that had been identified by chemical lesions(3,4). To facilitate the cloning of vertebrate genes that are important during embryogenesis, we have developed an insertional mutagenesis strategy in zebrafish using a retroviral vector, Here, in a pilot screen of 217 proviral insertions, we obtained three insertional mutants with embryonic lethal phenotypes, and identified two of the disrupted genes, One of these, no arches, is essential for normal pharyngeal arch development, and is homologous to the recently characterized Drosophila zinc-finger gene, clipper, which encodes a novel type of ribonuclease(5). As it is easy to generate tens to hundreds of thousands of proviral transgenes in zebrafish(6), it should now be possible to use this screening method to mutate and then rapidly clone a large number of genes affecting vertebrate developmental and cellular processes.	MIT,CTR CANC RES,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)			Becker, Thomas S/A-3125-2012; Allende, Miguel L/C-5167-2008; Kawakami, Koichi/AAF-1380-2019	Allende, Miguel L/0000-0002-2783-2152; 				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAI C, IN PRESS MOL CELL BI; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; CHEN J, 1994, METH MOL G, V4, P123; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; DINGERKUS G, 1977, STAIN TECHNOL, V52, P229, DOI 10.3109/10520297709116780; Driever W, 1996, DEVELOPMENT, V123, P37; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Gaiano N, 1996, P NATL ACAD SCI USA, V93, P7777, DOI 10.1073/pnas.93.15.7777; Haffter P, 1996, DEVELOPMENT, V123, P1; HOPKINS N, 1993, P NATL ACAD SCI USA, V90, P8759, DOI 10.1073/pnas.90.19.8759; LIN S, 1994, SCIENCE, V265, P666, DOI 10.1126/science.8036514; MEISLER MH, 1992, TRENDS GENET, V8, P341, DOI 10.1016/0168-9525(92)90278-C; SCHILLING TF, 1994, DEVELOPMENT, V120, P483; SUMMERS MF, 1991, J CELL BIOCHEM, V45, P41, DOI 10.1002/jcb.240450110; Westerfield M, 1993, ZEBRAFISH BOOK	17	200	211	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 31	1996	383	6603					829	832		10.1038/383829a0	http://dx.doi.org/10.1038/383829a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ144	8893009				2022-12-24	WOS:A1996VQ14400065
J	Dyck, PJ				Dyck, PJ			Nerve growth factor and diabetic neuropathy	LANCET			English	Editorial Material											Dyck, PJ (corresponding author), MAYO CLIN,DEPT NEUROL,ROCHESTER,MN 55905, USA.							Anand P, 1996, NAT MED, V2, P703, DOI 10.1038/nm0696-703; APFEL SC, 1994, BRAIN RES, V634, P7, DOI 10.1016/0006-8993(94)90252-6; Dyck Peter James, 1993, Neurology, V43, P1050; HELLWEG R, 1991, NEUROSCI LETT, V125, P1, DOI 10.1016/0304-3940(91)90114-9; LEWIN GR, 1993, TRENDS NEUROSCI, V16, P353, DOI 10.1016/0166-2236(93)90092-Z; Thomas P.K., 1993, PERIPHERAL NEUROPATH, V3rd ed., P1219; 1995, ANN INTERN MED, V122, P561; 1995, ANN NEUROL, V38, P869	8	24	24	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 19	1996	348	9034					1044	1045		10.1016/S0140-6736(05)64409-1	http://dx.doi.org/10.1016/S0140-6736(05)64409-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM886	8874450				2022-12-24	WOS:A1996VM88600003
J	Taylor, R				Taylor, R			Insulin resistance: Circumventing nature's blocks	LANCET			English	Editorial Material							RECEPTOR GENE; MUTANT ALLELES; SUBUNIT				Taylor, R (corresponding author), SCH MED,HUMAN METAB RES CTR,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND.			Taylor, Roy/0000-0001-6273-0170				ALMIND K, 1993, LANCET, V342, P828, DOI 10.1016/0140-6736(93)92694-O; HANSEN L, 1995, HUM MOL GENET, V4, P1313, DOI 10.1093/hmg/4.8.1313; KADOWAKI T, 1990, J CLIN INVEST, V86, P254, DOI 10.1172/JCI114693; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KROOK A, 1994, DIABETES, V43, P357, DOI 10.2337/diabetes.43.3.357; Krook A, 1996, LANCET, V347, P1586, DOI 10.1016/S0140-6736(96)91076-4; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; TAYLOR R, 1991, CLIN ENDOCRINOL, V34, P159, DOI 10.1111/j.1365-2265.1991.tb00287.x; TAYLOR R, 1987, BIOCHEM J, V242, P123, DOI 10.1042/bj2420123; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407	11	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 19	1996	348	9034					1045	1046		10.1016/S0140-6736(05)64410-8	http://dx.doi.org/10.1016/S0140-6736(05)64410-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM886	8874451				2022-12-24	WOS:A1996VM88600004
J	Difilippantonio, MJ; McMahan, CJ; Eastman, QM; Spanopoulou, E; Schatz, DG				Difilippantonio, MJ; McMahan, CJ; Eastman, QM; Spanopoulou, E; Schatz, DG			RAG1 mediates signal sequence recognition and recruitment of RAG2 in V(D)J recombination	CELL			English	Article							GENE-EXPRESSION; IMMUNE-SYSTEM; MICE; TRANSPOSASE; SPECIFICITY; DEFINITION; EVOLUTION; ELEMENTS; INSIGHTS; BINDING	Recent studies have demonstrated that DNA cleavage during V(D)J recombination is mediated by the RAG-1 and RAG2 proteins. These proteins must therefore bind to the recombination signals, but the specific binding interaction has been difficult to study in vitro. Here, we use an in vivo one-hybrid DNA binding assay to demonstrate that RAG1, in the absence of RAG2, can mediate signal recognition via the nonamer, with the heptamer acting to enhance its binding. A region of RAG1 with sequence similarity to bacterial invertases is essential for DNA binding. Localization of RAG2 to the signal is dependent upon the presence of RAG1 and is substantially more efficient with a 12 bp spacer signal than with a 23 bp spacer signal.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,DEPT MOL BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520; MT SINAI SCH MED,RUTTENBERG CANC CTR,NEW YORK,NY 10021	Howard Hughes Medical Institute; Yale University; Yale University; Yale University; Icahn School of Medicine at Mount Sinai			Difilippantonio, Michael/AAF-2839-2021; Schatz, David/A-6748-2013	Difilippantonio, Michael/0000-0002-4676-7034; Schatz, David/0000-0002-5669-1176	NIAID NIH HHS [T32-AI07019, AI32524] Funding Source: Medline; NICHD NIH HHS [T32-HD70194] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007019, R01AI032524] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKAMATSU Y, 1994, J IMMUNOL, V153, P4520; CUOMO CA, 1994, P NATL ACAD SCI USA, V91, P6156, DOI 10.1073/pnas.91.13.6156; CUOMO CA, 1994, NUCLEIC ACIDS RES, V22, P1810, DOI 10.1093/nar/22.10.1810; DERBYSHIRE KM, 1992, EMBO J, V11, P3449, DOI 10.1002/j.1460-2075.1992.tb05424.x; DREYFUS DH, 1992, MOL IMMUNOL, V29, P807, DOI 10.1016/0161-5890(92)90191-Y; Eastman QM, 1996, NATURE, V380, P85, DOI 10.1038/380085a0; FENG JA, 1994, SCIENCE, V263, P348, DOI 10.1126/science.8278807; GAUSS GH, 1993, MOL CELL BIOL, V13, P3900, DOI 10.1128/MCB.13.7.3900; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HANSEN JD, 1995, IMMUNOGENETICS, V42, P188, DOI 10.1007/BF00191224; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; HUISMAN O, 1989, EMBO J, V8, P2101, DOI 10.1002/j.1460-2075.1989.tb03619.x; LEU TMJ, 1995, MOL CELL BIOL, V15, P5657; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RAMSDEN DA, 1994, NUCLEIC ACIDS RES, V22, P1785, DOI 10.1093/nar/22.10.1785; Rathbun G.A., 1987, P85; Rodgers KK, 1996, J MOL BIOL, V260, P70, DOI 10.1006/jmbi.1996.0382; Roman CAJ, 1996, P NATL ACAD SCI USA, V93, P2333, DOI 10.1073/pnas.93.6.2333; SADOFSKY MJ, 1995, GENE DEV, V9, P2193, DOI 10.1101/gad.9.17.2193; SADOFSKY MJ, 1994, NUCLEIC ACIDS RES, V22, P1805, DOI 10.1093/nar/22.10.1805; SADOFSKY MJ, 1993, NUCLEIC ACIDS RES, V22, P550; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; SILVER DP, 1993, P NATL ACAD SCI USA, V90, P6100, DOI 10.1073/pnas.90.13.6100; SIMON M, 1980, SCIENCE, V209, P1370, DOI 10.1126/science.6251543; Spanopoulou E, 1995, IMMUNITY, V3, P715, DOI 10.1016/1074-7613(95)90061-6; THOMPSON CB, 1995, IMMUNITY, V3, P531, DOI 10.1016/1074-7613(95)90124-8; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; vanGent DC, 1996, CELL, V85, P107, DOI 10.1016/S0092-8674(00)81086-7; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592; VOS JC, 1994, EMBO J, V13, P6125, DOI 10.1002/j.1460-2075.1994.tb06959.x	38	167	173	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1996	87	2					253	262		10.1016/S0092-8674(00)81343-4	http://dx.doi.org/10.1016/S0092-8674(00)81343-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VN403	8861909	hybrid			2022-12-24	WOS:A1996VN40300013
J	PablosMendez, A; Sterling, TR; Frieden, TR				PablosMendez, A; Sterling, TR; Frieden, TR			The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NEW-YORK-CITY; MULTIDRUG-RESISTANT TUBERCULOSIS; HIV-INFECTED PATIENTS; PULMONARY TUBERCULOSIS; UNITED-STATES; EPIDEMIOLOGY; THERAPY; DIAGNOSIS; SURVIVAL	Objective.-To analyze the factors associated with survival in patients with pulmonary and extrapulmonary tuberculosis in New York City. Design.-Observational study of a citywide cohort of tuberculosis cases. Setting.-New York City, April 1991, before the strengthening of its control program. Patients.-All 229 newly diagnosed cases of tuberculosis documented by culture in April 1991. Most patients (74%) were male, and the median age was 37 years (range, 1-89 years). In all, 89% belonged to minority groups. Human immunodeficiency virus (HIV) infection was present in 50% and multidrug resistance in 7% of the cases. Twenty-one patients (9%) were not treated. Main Outcome Measures.-Follow-up information was collected through the New York City tuberculosis registry; death from any cause was verified through the National Death Index. Results.-Cumulative all-cause mortality by October 1994 was 44%; the median survival for those who died was 6.3 months (range, 0 days to 3 years). The most important baseline predictors of mortality, adjusted for baseline clinical and demographic factors, were acquired immunodeficiency syndrome (AIDS) (91% vs 11% in HIV-seronegative patients; Cox relative risk [RR], 7.8; 95% confidence interval [CI], 2.1-29.1), multidrug resistance (87% vs 39% in pansensitive cases; adjusted RR, 5.8; 95% CI, 2.3-14.5), and lack of treatment (81% vs 40%; adjusted RR, 3.1; 95% CI, 1.0-9.7). Also, 11 of 13 HIV-infected patients who started treatment after a 1-month delay died. Among 173 patients surviving the recommended treatment period, those who completed therapy (66%) had a lower subsequent mortality (20% vs 37%; RR, 0.5; 95% CI, 0.3-0.9). Conclusions.-Mortality from tuberculosis was high, even among patients without multidrug resistance who were not known to be infected with HIV. Most HIV-seropositive patients with delayed therapy died. Multidrug resistance predicted higher mortality, and treatment completion was associated with improved subsequent patient survival.	NEW YORK CITY DEPT HLTH, BUR TB CONTROL, NEW YORK, NY 10013 USA; KEESLER MED CTR, KEESLER AFB, MS USA; CTR DIS CONTROL & PREVENT, ATLANTA, GA 30341 USA	New York City Department of Health & Mental Hygiene; Centers for Disease Control & Prevention - USA	PablosMendez, A (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, DIV GEN MED, 622 W 168TH ST, PH-9E-105, NEW YORK, NY 10032 USA.							ACKAH AN, 1995, LANCET, V345, P607, DOI 10.1016/S0140-6736(95)90519-7; ALWOOD K, 1994, AIDS, V8, P1103, DOI 10.1097/00002030-199408000-00010; BARNES PF, 1993, ANN INTERN MED, V119, P400, DOI 10.7326/0003-4819-119-5-199309010-00009; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; BLOCH AB, 1989, CLIN CHEST MED, V10, P297; BLOCH AB, 1994, JAMA-J AM MED ASSOC, V271, P665, DOI 10.1001/jama.271.9.665; BRAUN MM, 1993, JAMA-J AM MED ASSOC, V269, P2865, DOI 10.1001/jama.269.22.2865; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; *BUR TUB CONTR, 1995, INF SUMM 1994; CANTWELL MF, 1994, JAMA-J AM MED ASSOC, V272, P535, DOI 10.1001/jama.272.7.535; Centers for Disease Control and Prevention (CDC), 1993, MMWR Morb Mortal Wkly Rep, V42, P961; CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; CHAULK CP, 1995, JAMA-J AM MED ASSOC, V274, P945, DOI 10.1001/jama.274.12.945; COX DR, 1972, J R STAT SOC B, V34, P187; *CTR DIS CONTR, 1989, US DEPT HLTH HUM SER; *CTR DIS CONTR, 1986, US DEPT HLTH HUM SER; *CTR DIS CONTR, 1990, US DEPT HLTH HUM SER; DEAN AG, 1994, EPI INFO VERSION 6; DRUCKER E, 1994, LANCET, V343, P1482, DOI 10.1016/S0140-6736(94)92588-7; FISCHL MA, 1992, ANN INTERN MED, V117, P184, DOI 10.7326/0003-4819-117-3-184; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; ISEMAN MD, 1993, NEW ENGL J MED, V328, P576, DOI 10.1056/NEJM199302253280811; Jereb J A, 1991, MMWR CDC Surveill Summ, V40, P23; MATHUR P, 1994, ARCH INTERN MED, V154, P306, DOI 10.1001/archinte.154.3.306; MENDELSON MH, 1990, MT SINAI J MED, V57, P221; MITCHISON DA, 1986, AM REV RESPIR DIS, V133, P423; NARAIN R, 1974, B WORLD HEALTH ORGAN, V51, P273; NEVILLE K, 1994, CHEST, V105, P45, DOI 10.1378/chest.105.1.45; Norusis M J, 1993, SPSS WINDOWS ADV STA; NUNN P, 1992, AM REV RESPIR DIS, V146, P849, DOI 10.1164/ajrccm/146.4.849; *NY CIT DEPT HLTH, 1981, TUB NEW YORK CIT 199; PERRIENS JH, 1995, NEW ENGL J MED, V332, P779, DOI 10.1056/NEJM199503233321204; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; RIEDER HL, 1991, CHEST, V100, P678, DOI 10.1378/chest.100.3.678; Shirai T, 1990, Kekkaku, V65, P397; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STONEBURNER R, 1992, ARCH INTERN MED, V152, P2033, DOI 10.1001/archinte.152.10.2033; TELZAK EE, 1995, NEW ENGL J MED, V333, P907, DOI 10.1056/NEJM199510053331404; WASHKO RM, 1992, P 43 ANN EP INT SERV; *WHO TUB PROGR, 1994, WHO PUBL	43	189	195	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	1996	276	15					1223	1228		10.1001/jama.276.15.1223	http://dx.doi.org/10.1001/jama.276.15.1223			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL691	8849749				2022-12-24	WOS:A1996VL69100030
J	Konig, M; Zimmer, AM; Steiner, H; Holmes, PV; Crawley, JN; Brownstein, MJ; Zimmer, A				Konig, M; Zimmer, AM; Steiner, H; Holmes, PV; Crawley, JN; Brownstein, MJ; Zimmer, A			Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin	NATURE			English	Article							INDUCED ANALGESIA; RATS; MORPHINE; BEHAVIOR; AMYGDALA; BRAIN; FEAR; EXPRESSION; MECHANISMS; SYSTEMS	ENKEPHALINS are endogenous opioid peptides that are derived from a pre-proenkephalin precursor protein(1,2). They are thought to be vital in regulating many physiological functions, including pain perception and analgesia, responses to stress, aggression and dominance (3-5). Here we have used a genetic approach to study the role of the mammalian opioid system. We disrupted the preproenkephalin gene using homologous recombination in embryonic stem cells to generate enkephalin-deficient mice. Mutant enk(-/-) animals are healthy, fertile, and care for their offspring, but display significant behavioural abnormalities. Mice with the enk(-/-) genotype are more anxious and males display increased offensive aggressiveness. Mutant animals show marked differences from controls in supraspinal, but not in spinal, responses to painful stimuli. Unexpectedly, enk(-/-) mice exhibit normal stress-induced analgesia. Our results show that enkephalins modulate responses to painful stimuli. Thus, genetic factors may contribute significantly to the experience of pain.	NIMH,DEV BIOL UNIT,CELL BIOL LAB,BETHESDA,MD 20892; NIMH,NEUROANAT SECT,NEUROPHYSIOL LAB,BETHESDA,MD 20892; NIMH,SECT BEHAV NEUROPHARMACOL,EXPT THERAPEUT BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)			Brownstein, Michael/B-8609-2009; Zimmer, Andreas/B-8357-2009					ARCHER J, 1973, ANIM BEHAV, V21, P205, DOI 10.1016/S0003-3472(73)80065-X; CHEN C, 1994, SCIENCE, V266, P291, DOI 10.1126/science.7939668; CHOZICK BS, 1985, INT J NEUROSCI, V26, P197, DOI 10.3109/00207458508985617; COMB M, 1983, DNA-J MOLEC CELL BIO, V2, P213, DOI 10.1089/dna.1983.2.213; DAVIS M, 1992, ANNU REV NEUROSCI, V15, P353, DOI 10.1146/annurev.neuro.15.1.353; DIAZ JL, 1990, BEHAV BRAIN RES, V39, P275, DOI 10.1016/0166-4328(90)90033-B; FANSELOW MS, 1984, BEHAV NEUROSCI, V98, P79, DOI 10.1037/0735-7044.98.1.79; FILE SE, 1979, PHARMACOL BIOCHEM BE, V11, P313, DOI 10.1016/0091-3057(79)90141-2; FLINT J, 1995, SCIENCE, V269, P1432, DOI 10.1126/science.7660127; Gerlai R, 1996, TRENDS NEUROSCI, V19, P177, DOI 10.1016/S0166-2236(96)20020-7; GIRAUD P, 1981, NEUROPEPTIDES, V1, P237, DOI 10.1016/0143-4179(81)90002-0; GOOD AJ, 1995, BEHAV NEUROSCI, V109, P631, DOI 10.1037/0735-7044.109.4.631; KRUK MR, 1991, NEUROSCI BIOBEHAV R, V15, P527, DOI 10.1016/S0149-7634(05)80144-7; LIPP J, 1991, CLIN NEUROPHARMACOL, V14, P131, DOI 10.1097/00002826-199104000-00003; MANSOUR A, 1995, TRENDS NEUROSCI, V18, P22, DOI 10.1016/0166-2236(95)93946-U; MAREK P, 1992, BRAIN RES, V578, P197, DOI 10.1016/0006-8993(92)90248-8; MENENDEZ L, 1993, BRAIN RES, V611, P264, DOI 10.1016/0006-8993(93)90512-L; NIEUWENHUYS R, 1985, CHEMOARCHITECTURE BR, P1; PASTERNAK GW, 1993, CLIN NEUROPHARMACOL, V16, P1, DOI 10.1097/00002826-199302000-00001; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; RODGERS RJ, 1979, PHARMACOL BIOCHEM BE, V11, P505, DOI 10.1016/0091-3057(79)90033-9; ROSENFELD JP, 1994, NEUROSCI BIOBEHAV R, V18, P403, DOI 10.1016/0149-7634(94)90053-1; Rubinstein M, 1996, P NATL ACAD SCI USA, V93, P3995, DOI 10.1073/pnas.93.9.3995; SHEPHERD JK, 1994, PSYCHOPHARMACOLOGY, V116, P56, DOI 10.1007/BF02244871; SIEGEL A, 1995, REV NEUROSCIENCE, V6, P47; TREIT D, 1989, PHARM BIOCH BEHAV, V31, P959; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WALKER JM, 1981, EUR J PHARMACOL, V69, P71, DOI 10.1016/0014-2999(81)90603-8; WALSH RN, 1976, PSYCHOL BULL, V83, P482, DOI 10.1037/0033-2909.83.3.482; YAMADA K, 1995, BEHAV BRAIN RES, V67, P133, DOI 10.1016/0166-4328(94)00150-E	30	364	365	1	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1996	383	6600					535	538		10.1038/383535a0	http://dx.doi.org/10.1038/383535a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL755	8849726				2022-12-24	WOS:A1996VL75500053
J	Geballe, TR; Oka, T				Geballe, TR; Oka, T			Detection af H-3(+) in interstellar space	NATURE			English	Article							INFRARED-SPECTRUM; H-3+; CLOUDS; GAS; MOLECULES; FEATURES; SEARCH; LINES; CO	THE H-3(+) ion is widely believed to play an important role in interstellar chemistry, by initiating the chains of reactions that lead to the production of many of the complex molecular species observed in the interstellar medium(1-5). The presence of H-3(+) in the interstellar medium was first suggested(6) in 1961, and its infrared spectrum was measured(7) in the laboratory in 1980. But attempts(8-11) to detect it in interstellar space have hitherto proved unsuccessful, Here we report the detection of H-3(+) absorption in the spectra of two molecular clouds. Ali-hough the present results do not permit an accurate determination of the H-3(+) abundances, these ions appear nevertheless to be present in sufficient quantities to drive much of the chemistry in molecular clouds, It should soon be possible to obtain more accurate measurements, and thus better quantify the role of ion-neutral reactions in the chemical evolution of molecular clouds.	UNIV CHICAGO, DEPT CHEM, DEPT ASTRON & ASTROPHYS, CHICAGO, IL 60637 USA; UNIV CHICAGO, ENRICO FERMI INST, CHICAGO, IL 60637 USA	University of Chicago; University of Chicago	Geballe, TR (corresponding author), JOINT ASTRON CTR, UNIV PK, HILO, HI 96720 USA.							AMANO T, 1988, ASTROPHYS J, V329, pL121, DOI 10.1086/185190; ANICICH VG, 1986, ASTROPHYS J SUPPL S, V62, P553, DOI 10.1086/191151; BLACK JH, 1990, ASTROPHYS J, V358, P459, DOI 10.1086/168999; DALGARNO A, 1976, REP PROG PHYS, V39, P573, DOI 10.1088/0034-4885/39/6/002; DROSSART P, 1989, NATURE, V340, P539, DOI 10.1038/340539a0; GEBALLE TR, 1993, ASTROPHYS J, V408, pL109, DOI 10.1086/186843; GEBALLE TR, 1989, ASTROPHYS J, V342, P855, DOI 10.1086/167641; GEBALLE TR, 1985, ASTRON ASTROPHYS, V146, pL6; HERBST E, 1973, ASTROPHYS J, V185, P505, DOI 10.1086/152436; Lee HH, 1996, ASTRON ASTROPHYS SUP, V119, P111, DOI 10.1051/aas:1996232; LEPP S, 1987, ASTROPHYS J, V321, P383, DOI 10.1086/165636; MAILLARD JP, 1995, SPECTROCHIM ACTA A, V51, P1105, DOI 10.1016/0584-8539(94)00014-3; MARTIN DW, 1961, ASTROPHYS J, V134, P1012, DOI 10.1086/147232; MILLER S, 1992, NATURE, V355, P420, DOI 10.1038/355420a0; MILLER S, 1994, CAN J PHYS, V72, P760, DOI 10.1139/p94-100; MITCHELL GF, 1990, ASTROPHYS J, V363, P554, DOI 10.1086/169365; OKA T, 1981, PHILOS T R SOC A, V303, P543, DOI 10.1098/rsta.1981.0223; OKA T, 1980, PHYS REV LETT, V45, P531, DOI 10.1103/PhysRevLett.45.531; Schutte WA, 1996, ASTRON ASTROPHYS, V309, P633; SPITZER L, 1975, ANNU REV ASTRON ASTR, V13, P133, DOI 10.1146/annurev.aa.13.090175.001025; SUZUKI H, 1979, PROG THEOR PHYS, V62, P936, DOI 10.1143/PTP.62.936; TIELENS AGGM, 1991, ASTROPHYS J, V381, P181, DOI 10.1086/170640; TRAFTON LM, 1993, ASTROPHYS J, V405, P761, DOI 10.1086/172404; WATSON WD, 1973, ASTROPHYS J, V183, pL17, DOI 10.1086/181242; WATSON WD, 1976, REV MOD PHYS, V48, P513, DOI 10.1103/RevModPhys.48.513	25	301	304	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 28	1996	384	6607					334	335		10.1038/384334a0	http://dx.doi.org/10.1038/384334a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV271	8934516				2022-12-24	WOS:A1996VV27100040
J	Sornson, MW; Wu, W; Dasen, JS; Flynn, SE; Norman, DJ; OConnell, SM; Gukovsky, I; Carriere, C; Ryan, AK; Miller, AP; Zuo, L; Gleiberman, AS; Andersen, B; Beamer, WG; Rosenfeld, MG				Sornson, MW; Wu, W; Dasen, JS; Flynn, SE; Norman, DJ; OConnell, SM; Gukovsky, I; Carriere, C; Ryan, AK; Miller, AP; Zuo, L; Gleiberman, AS; Andersen, B; Beamer, WG; Rosenfeld, MG			Pituitary lineage determination by the Prophet of Pit-1 homeodomain factor defective in Ames dwarfism	NATURE			English	Article							GENE; EXPRESSION; MICE; DNA; DROSOPHILA; MUTATION; ARISTALESS; FRAGMENTS; SEQUENCE; CONTAINS	The gene apparently responsible for a heritable form of murine pituitary-dependent dwarfism (Ames dwarf, df) has been positionally cloned, identifying a novel, tissue-specific, paired-like homeodomain transcription factor, termed Prophet of Pit-1 (Prop-1). The df phenotype results from an apparent failure of initial determination of the Pit-1 lineage required for production of growth hormone, prolactin or thyroid-stimulating hormone, resulting in dysmorphogenesis and failure to activate Pit-1 gene expression. These results imply that a cascade of tissue-specific regulators is responsible for the determination and differentiation of specific cell lineages in pituitary organogenesis.	UNIV CALIF SAN DIEGO,DEPT & SCH MED,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT & SCH MED,BIOL GRAD PROGRAM,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT & SCH MED,BIOMED SCI GRAD PROGRAM,LA JOLLA,CA 92093; SEQUANA THERAPEUT INC,LA JOLLA,CA 92037; JACKSON LAB,BAR HARBOR,ME 04609	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Jackson Laboratory				gleiberman, anatoli/0000-0001-8491-0826				Andersen B, 1995, DEV BIOL, V172, P495, DOI 10.1006/dbio.1995.8040; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; BARTKE A, 1965, MOUSE NEWSLETT, V32, P52; BAUMGARTNER S, 1987, GENE DEV, V1, P1247, DOI 10.1101/gad.1.10.1247; BUCKWALTER MS, 1991, GENOMICS, V10, P515, DOI 10.1016/0888-7543(91)90430-M; BUM TC, 1995, GENE, V161, P183; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; CAMPER SA, 1990, GENOMICS, V8, P586, DOI 10.1016/0888-7543(90)90050-5; CATRON KM, 1995, MOL CELL BIOL, V15, P861; COULY G, 1988, DEVELOPMENT, V103, P101; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; Gage PJ, 1996, DEVELOPMENT, V122, P151; GODFREY P, 1993, NAT GENET, V4, P227, DOI 10.1038/ng0793-227; HEARNE CM, 1991, MAMM GENOME, V1, P273, DOI 10.1007/BF00352339; HEMESZ E, 1996, DEVELOPMENT, V122, P41; KAPPEN C, 1993, GENOMICS, V18, P54, DOI 10.1006/geno.1993.1426; KENDALL SK, 1995, GENE DEV, V9, P2007, DOI 10.1101/gad.9.16.2007; KEYNES R, 1994, ANNU REV NEUROSCI, V17, P109, DOI 10.1146/annurev.ne.17.030194.000545; Lamonerie T, 1996, GENE DEV, V10, P1284, DOI 10.1101/gad.10.10.1284; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; LEW D, 1993, GENE DEV, V7, P683, DOI 10.1101/gad.7.4.683; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LIN SC, 1993, NATURE, V364, P208, DOI 10.1038/364208a0; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; LISITSYN NA, 1994, NAT GENET, V6, P57, DOI 10.1038/ng0194-57; MORGAN JG, 1992, NUCLEIC ACIDS RES, V20, P5173, DOI 10.1093/nar/20.19.5173; Oliver G, 1995, DEVELOPMENT, V121, P4045; PARIMOO S, 1991, P NATL ACAD SCI USA, V88, P9623, DOI 10.1073/pnas.88.21.9623; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; RUBENSTEIN JLR, 1994, SCIENCE, V266, P578, DOI 10.1126/science.7939711; Schaible R., 1961, Genetics, V46, P896; SCHNEITZ K, 1993, GENE DEV, V7, P114, DOI 10.1101/gad.7.1.114; Schonemann MD, 1995, GENE DEV, V9, P3122, DOI 10.1101/gad.9.24.3122; SEIDAH NG, 1994, DNA CELL BIOL, V13, P1163, DOI 10.1089/dna.1994.13.1163; Sheng HZ, 1996, SCIENCE, V272, P1004, DOI 10.1126/science.272.5264.1004; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; SIMEONE A, 1993, EMBO J, V12, P2735, DOI 10.1002/j.1460-2075.1993.tb05935.x; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; SZETO DP, 1996, P NATL ACAD SCI USA, V15, P7706; THOMAS PQ, 1995, J BIOL CHEM, V270, P3869, DOI 10.1074/jbc.270.8.3869; VOSS JW, 1992, CELL, V70, P527, DOI 10.1016/0092-8674(92)90422-9; WATANABE YG, 1982, CELL TISSUE RES, V227, P257, DOI 10.1007/BF00210884; WIJNHOLDS J, 1995, DEV BIOL, V171, P73, DOI 10.1006/dbio.1995.1261; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; WOLOSHIN P, 1995, CELL, V82, P611, DOI 10.1016/0092-8674(95)90033-0	48	560	573	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1996	384	6607					327	333		10.1038/384327a0	http://dx.doi.org/10.1038/384327a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV271	8934515				2022-12-24	WOS:A1996VV27100039
J	Hanein, D; Matlack, KES; Jungnickel, B; Plath, K; Kalies, KU; Miller, KR; Rapoport, TA; Akey, CW				Hanein, D; Matlack, KES; Jungnickel, B; Plath, K; Kalies, KU; Miller, KR; Rapoport, TA; Akey, CW			Oligomeric rings of the Sec61p complex induced by ligands required for protein translocation	CELL			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; SECRETORY PROTEINS; CONDUCTING CHANNEL; ER-MEMBRANE; YEAST; INSERTION; COMPONENTS; RIBOSOMES; POLYPEPTIDES; TRANSPORT	The heterotrimeric Sec61p complex is a major component of the protein-conducting channel of the endoplasmic reticulum (ER) membrane, associating with either ribosomes or the Sec62/63 complex to perform co- and posttranslational transport, respectively. We show by electron microscopy that purified mammalian and yeast Sec61p complexes in detergent form cylindrical oligomers with a diameter of similar to 85 Angstrom and a central pore of similar to 20 Angstrom. Each oligomer contains 3-4 heterotrimers. Similar ring structures are seen in reconstituted proteoliposomes and native membranes. Oligomer formation by the reconstituted Sec61p complex is stimulated by its association with ribosomes or the Sec62/63p complex. We propose that these cylindrical oligomers represent protein-conducting channels of the ER, formed by ligands specific for co- and posttranslational transport.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; MAX DELBRUCK CTR MOL MED,D-13122 BERLIN,GERMANY; BROWN UNIV,DIV BIOL & MED,PROVIDENCE,RI 02912	Harvard University; Harvard Medical School; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Brown University	Hanein, D (corresponding author), BOSTON UNIV,SCH MED,DEPT BIOPHYS,BOSTON,MA 02218, USA.			Plath, Kathrin/0000-0001-7796-3372; Akey, Christopher/0000-0002-3059-3121				AKEY CW, 1995, J MOL BIOL, V248, P273, DOI 10.1016/S0022-2836(95)80050-6; Belin D, 1996, EMBO J, V15, P468, DOI 10.1002/j.1460-2075.1996.tb00379.x; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; DESHAIES RJ, 1995, P NATL ACAD SCI USA, V92, P1182, DOI 10.1073/pnas.92.4.1182; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; Finke K, 1996, EMBO J, V15, P1482, DOI 10.1002/j.1460-2075.1996.tb00492.x; FRANK J, 1988, J MICROSC-OXFORD, V150, P99, DOI 10.1111/j.1365-2818.1988.tb04602.x; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; GIDDINGS TH, 1980, J CELL BIOL, V85, P147, DOI 10.1083/jcb.85.1.147; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; HIGH S, 1993, J CELL BIOL, V121, P743, DOI 10.1083/jcb.121.4.743; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; KELLARIS KV, 1991, J CELL BIOL, V114, P21, DOI 10.1083/jcb.114.1.21; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; MUSCH A, 1992, CELL, V69, P343, DOI 10.1016/0092-8674(92)90414-8; NICCHITTA CV, 1995, J CELL BIOL, V129, P957, DOI 10.1083/jcb.129.4.957; OJAKIAN GK, 1977, J CELL BIOL, V72, P530, DOI 10.1083/jcb.72.3.530; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; RAPOPORT TA, 1985, FEBS LETT, V187, P1, DOI 10.1016/0014-5793(85)81202-3; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SINGER SJ, 1987, P NATL ACAD SCI USA, V84, P1960, DOI 10.1073/pnas.84.7.1960; STRAMBIODECASTILLIA C, 1995, J CELL BIOL, V131, P19, DOI 10.1083/jcb.131.1.19; WALL JS, 1986, ANNU REV BIOPHYS BIO, V15, P355; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; [No title captured]	38	275	280	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1996	87	4					721	732		10.1016/S0092-8674(00)81391-4	http://dx.doi.org/10.1016/S0092-8674(00)81391-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VU035	8929540	hybrid			2022-12-24	WOS:A1996VU03500014
J	Mason, D; Kerry, S; Oakeshott, P				Mason, D; Kerry, S; Oakeshott, P			Postal survey of management of cervical Chlamydia trachomatis infection in English and Welsh general practices	BRITISH MEDICAL JOURNAL			English	Article									ST GEORGE HOSP,SCH MED,DEPT GEN PRACTICE & PRIMARY CARE,LONDON SW17 0RE,ENGLAND	St Georges University London				Oakeshott, Pippa/0000-0003-2568-8211				*BRIT MED ASS ROYA, 1995, BRIT NAT FORM, P236; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; OWEN PA, 1991, BRIT J GEN PRACT, V41, P279; SOUTHGATE LJ, 1983, BRIT MED J, V287, P879, DOI 10.1136/bmj.287.6396.879; TAYLORROBINSON D, 1994, BMJ-BRIT MED J, V308, P150, DOI 10.1136/bmj.308.6922.150	5	22	22	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1996	313	7066					1193	1194		10.1136/bmj.313.7066.1193	http://dx.doi.org/10.1136/bmj.313.7066.1193			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR907	8916756	Green Published			2022-12-24	WOS:A1996VR90700029
J	Rous, E; Coppel, A; Haworth, J; Noyce, S				Rous, E; Coppel, A; Haworth, J; Noyce, S			A purchaser experience of managing new expensive drugs: Interferon beta	BRITISH MEDICAL JOURNAL			English	Article							CYSTIC-FIBROSIS	Interferon beta is a new and expensive drug for treating multiple sclerosis. One published trial has shown that it reduces the exacerbation rate in patients who have relapsing-remitting disease without important disability. This paper describes the development of a strategy for purchasing the drug in one region of England before its licensing. Purchasers felt unable to decline funding for this marginally effective drug and thereby undertake explicit rationing. To ensure prescribing was within the guidelines, a vast communication network had to be sustained with managers, general practitioners, neurologists, the Multiple Sclerosis Society, and professional advisers in all the purchasing authorities. The workload involved was considerable. The dilemma of rationing in a public service with a high political profile is demonstrated.	E LANCASHIRE HLTH COMMISS,NELSON,LANCS,ENGLAND; SEFTON HLTH,LIVERPOOL L22 0QB,MERSEYSIDE,ENGLAND		Rous, E (corresponding author), STOCKPORT HLTH AUTHOR,SPRINGWOOD HOUSE,STOCKPORT SK7 5BY,ENGLAND.							DAVIES LM, 1990, PSYCHIATRIC B, V14, P522; ELBORN JS, 1991, THORAX, V46, P881, DOI 10.1136/thx.46.12.881; FUCHS HJ, 1994, NEW ENGL J MED, V331, P637, DOI 10.1056/NEJM199409083311003; MCDONALD WI, 1995, BRIT MED J, V310, P345, DOI 10.1136/bmj.310.6976.345; MELTZER HY, 1993, AM J PSYCHIAT, V150, P1630; The IFNb Multiple Sclerosis Study Group, 1993, NEUROLOGY, V43, P655; WALLEY T, 1995, BRIT MED J, V311, P796, DOI 10.1136/bmj.311.7008.796	7	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1996	313	7066					1195	1196		10.1136/bmj.313.7066.1195	http://dx.doi.org/10.1136/bmj.313.7066.1195			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR907	8916757	Green Published			2022-12-24	WOS:A1996VR90700030
J	Verrees, M				Verrees, M			Touch me	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	1996	276	16					1285	1286		10.1001/jama.276.16.1285	http://dx.doi.org/10.1001/jama.276.16.1285			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM825	8861971				2022-12-24	WOS:A1996VM82500002
J	Picarelli, A; Maiuri, L; Frate, A; Greco, M; Auricchio, S; Londei, M				Picarelli, A; Maiuri, L; Frate, A; Greco, M; Auricchio, S; Londei, M			Production of antiendomysial antibodies after in-vitro gliadin challenge of small intestine biopsy samples from patients with coeliac disease	LANCET			English	Article							CELIAC-DISEASE; MARKERS; CELLS	Background Diagnosis of many immune-mediated diseases is helped by detection of antibodies directed against the pathogenetic (self or foreign) antigen. In coeliac disease (CD), we have a situation in which antiendomysial antibodies (EMA), which are not specific for the pathogenetic antigen, reach a specificity and sensitivity of detection of CD approaching 100%, whereas detection of antibodies against gliadin (AGA), the pathogenetic antigen, is far less specific and sensitive in diagnosis. No direct evidence of a relation between gluten/gliadin challenge and EMA production exists. We tried to establish whether the small intestine of CD patients is the site of EMA production and whether gliadin challenge could induce their release. Methods Small intestine biopsy samples from treated (23) and untreated (16) CD patients and controls (18) were cultured in vitro for 24-48 h in the presence of gliadin, another alimentary antigen, or medium. EMA and AGA were detected in the supernatants of these organ culture biopsy samples by ELISA and immunofluorescence technique, respectively. Findings No EMA were found in the culture supernatants of biopsy samples of 18 controls, whereas they were detected in the culture supernatants of all 16 untreated CD patients irrespective of gliadin challenge. Conversely, EMA were not detected in supernatants of biopsy samples cultured in medium only from 23 treated CD patients, but were detected in 17 of the 23 biopsy samples challenged with gliadin. Interpretation Our results suggest that a more complex pathogenetic mechanism than normally accepted is involved in CD, Furthermore, our findings raise the possibility that EMA, or the antigen recognised by them, are involved directly in the pathogenesis of CD.	KENNEDY INST,LONDON W6 8LW,ENGLAND; UNIV ROMA LA SAPIENZA,CATTEDRA GASTROENTEROL,MED CLIN 2,ROME,ITALY; CHILDRENS HOSP PAUSILIPON,NAPLES,ITALY; UNIV NAPLES FEDERICO II,DEPT PEDIAT,NAPLES,ITALY	University of Oxford; Sapienza University Rome; University of Naples Federico II			Picarelli, Antonio/L-3229-2019	Picarelli, Antonio/0000-0002-6104-8193				CORRAO G, 1994, GUT, V35, P771, DOI 10.1136/gut.35.6.771; FERREIRA M, 1992, GUT, V33, P1633, DOI 10.1136/gut.33.12.1633; FRANCO A, 1994, CLIN IMMUNOL IMMUNOP, V71, P75, DOI 10.1006/clin.1994.1054; LUNDIN KEA, 1993, J EXP MED, V178, P187, DOI 10.1084/jem.178.1.187; Maiuri L, 1996, GASTROENTEROLOGY, V110, P1368, DOI 10.1053/gast.1996.v110.pm8613040; MAKI M, 1991, LANCET, V338, P724, DOI 10.1016/0140-6736(91)91445-Z; MAKI M, 1991, LANCET, V338, P1350, DOI 10.1016/0140-6736(91)92234-S; MARSH MN, 1992, GASTROENTEROLOGY, V102, P330, DOI 10.1016/0016-5085(92)91819-P; MARTTINEN A, 1993, PEDIATR RES, V34, P420, DOI 10.1203/00006450-199310000-00007; OFARRELLY C, 1983, BRIT MED J, V286, P2007, DOI 10.1136/bmj.286.6383.2007; QUARATINO S, 1995, P NATL ACAD SCI USA, V92, P10398, DOI 10.1073/pnas.92.22.10398; Quaratino S, 1996, J EXP MED, V183, P349, DOI 10.1084/jem.183.2.349; TRONCONE R, 1991, J PEDIATR GASTR NUTR, V12, P150, DOI 10.1097/00005176-199102000-00002; VOLTA U, 1985, GUT, V26, P667, DOI 10.1136/gut.26.7.667	14	130	130	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 19	1996	348	9034					1065	1067		10.1016/S0140-6736(96)03060-7	http://dx.doi.org/10.1016/S0140-6736(96)03060-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM886	8874458				2022-12-24	WOS:A1996VM88600011
J	Kim, JL; Morgenstern, KA; Lin, C; Fox, T; Dwyer, MD; Landro, JA; Chambers, SP; Markland, W; Lepre, CA; OMalley, ET; Harbeson, SL; Rice, CM; Murcko, MA; Caron, PR; Thomson, JA				Kim, JL; Morgenstern, KA; Lin, C; Fox, T; Dwyer, MD; Landro, JA; Chambers, SP; Markland, W; Lepre, CA; OMalley, ET; Harbeson, SL; Rice, CM; Murcko, MA; Caron, PR; Thomson, JA			Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide	CELL			English	Article							YELLOW-FEVER VIRUS; NON-B-HEPATITIS; PUTATIVE NONSTRUCTURAL PROTEINS; SERINE-TYPE PROTEINASE; NON-A; VIRAL REPLICATION; TERMINAL DOMAIN; HEPATOCELLULAR-CARCINOMA; INTERFERON THERAPY; SEQUENCE-ANALYSIS	An estimated 1% of the global human population is infected by hepatitis C viruses (HCVs), and there are no broadly effective treatments for the debilitating progression of chronic hepatitis C. A serine protease located within the HCV NS3 protein processes the viral polyprotein at four specific sites and is considered essential for replication. Thus, it emerges as an attractive target for drug design. We report here the 2.5 Angstrom resolution X-ray crystal structure of the NS3 protease domain complexed with a synthetic NS4A activator peptide. The protease has a chymotrypsin-like fold and features a tetrahedrally coordinated metal ion distal to the active site. The NS4A peptide intercalates within a beta sheet of the enzyme core.	WASHINGTON UNIV, SCH MED, DEPT MOL MICROBIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)	Kim, JL (corresponding author), VERTEX PHARMACEUT INC, 130 WAVERLY ST, CAMBRIDGE, MA 02139 USA.							ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER MJ, 1994, GASTROENTEROL CLIN N, V23, P437; APPEL W, 1986, CLIN BIOCHEM, V19, P317, DOI 10.1016/S0009-9120(86)80002-9; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTENSCHLAGER R, 1993, J VIROL, V67, P3835, DOI 10.1128/JVI.67.7.3835-3844.1993; BARTENSCHLAGER R, 1995, J VIROL, V69, P7519, DOI 10.1128/JVI.69.12.7519-7528.1995; BAZAN JF, 1989, VIROLOGY, V171, P637, DOI 10.1016/0042-6822(89)90639-9; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; Brunger A. T., 1993, XPLOR SYSTEM XRAY CR; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BUKH J, 1993, P NATL ACAD SCI USA, V90, P8234, DOI 10.1073/pnas.90.17.8234; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHAMBERS TJ, 1993, J VIROL, V67, P6797, DOI 10.1128/JVI.67.11.6797-6807.1993; CHAMBERS TJ, 1995, J VIROL, V69, P1600, DOI 10.1128/JVI.69.3.1600-1605.1995; CHAMBERS TJ, 1990, P NATL ACAD SCI USA, V87, P8898, DOI 10.1073/pnas.87.22.8898; CHAMBERS TJ, 1989, VIROLOGY, V169, P100, DOI 10.1016/0042-6822(89)90045-7; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; Ding JZ, 1996, EMBO J, V15, P1778, DOI 10.1002/j.1460-2075.1996.tb00526.x; ECKART MR, 1993, BIOCHEM BIOPH RES CO, V192, P399, DOI 10.1006/bbrc.1993.1429; EDWARDS PD, 1994, MED RES REV, V14, P127, DOI 10.1002/med.2610140202; FAILLA C, 1995, J VIROL, V69, P1769, DOI 10.1128/JVI.69.3.1769-1777.1995; FAILLA C, 1994, J VIROL, V68, P3753, DOI 10.1128/JVI.68.6.3753-3760.1994; Failla CM, 1996, FOLD DES, V1, P35, DOI 10.1016/S1359-0278(96)00010-7; FALGOUT B, 1993, J VIROL, V67, P2034, DOI 10.1128/JVI.67.4.2034-2042.1993; Francki RIB, 1991, ARCH VIROL         S, V2, P223; FUJINAGA M, 1985, J MOL BIOL, V184, P479, DOI 10.1016/0022-2836(85)90296-7; FUREY W, 1996, IN PRESS METH ENZYMO; GOMEZ JE, 1977, BIOCHIM BIOPHYS ACTA, V495, P177, DOI 10.1016/0005-2795(77)90252-5; GRAKOUI A, 1993, J VIROL, V67, P2832, DOI 10.1128/JVI.67.5.2832-2843.1993; GRAKOUI A, 1993, P NATL ACAD SCI USA, V90, P10583, DOI 10.1073/pnas.90.22.10583; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; HAHM B, 1995, J VIROL, V69, P2534, DOI 10.1128/JVI.69.4.2534-2539.1995; HIJIKATA M, 1993, P NATL ACAD SCI USA, V90, P10773, DOI 10.1073/pnas.90.22.10773; HIJIKATA M, 1993, J VIROL, V67, P4665, DOI 10.1128/JVI.67.8.4665-4675.1993; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; IWARSON S, 1994, FEMS MICROBIOL REV, V14, P201, DOI 10.1111/j.1574-6976.1994.tb00089.x; JANSSEN HLA, 1994, J HEPATOL, V21, P241, DOI 10.1016/S0168-8278(05)80402-7; JIN L, 1995, ARCH BIOCHEM BIOPHYS, V323, P47, DOI 10.1006/abbi.1995.0008; KANAI A, 1995, FEBS LETT, V376, P221, DOI 10.1016/0014-5793(95)01283-X; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; KEW MC, 1994, FEMS MICROBIOL REV, V14, P211, DOI 10.1111/j.1574-6976.1994.tb00091.x; KIM DW, 1995, BIOCHEM BIOPH RES CO, V215, P160, DOI 10.1006/bbrc.1995.2447; Koch JO, 1996, VIROLOGY, V221, P54, DOI 10.1006/viro.1996.0352; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LI YY, 1995, J BIOL CHEM, V270, P25127, DOI 10.1074/jbc.270.42.25127; LIN C, 1994, J VIROL, V68, P5063, DOI 10.1128/JVI.68.8.5063-5073.1994; LIN C, 1995, J VIROL, V69, P4373, DOI 10.1128/JVI.69.7.4373-4380.1995; LIN C, 1994, J VIROL, V68, P8147, DOI 10.1128/JVI.68.12.8147-8157.1994; LIN C, 1995, P NATL ACAD SCI USA, V92, P7622, DOI 10.1073/pnas.92.17.7622; MANABE S, 1994, VIROLOGY, V198, P636, DOI 10.1006/viro.1994.1075; Mangel WF, 1996, J BIOL CHEM, V271, P536, DOI 10.1074/jbc.271.1.536; MILLER RH, 1990, P NATL ACAD SCI USA, V87, P2057, DOI 10.1073/pnas.87.6.2057; MIZUSHIMA H, 1994, J VIROL, V68, P2731, DOI 10.1128/JVI.68.4.2731-2734.1994; NESTOROWICZ A, 1994, VIROLOGY, V199, P114, DOI 10.1006/viro.1994.1103; PIZZI E, 1994, P NATL ACAD SCI USA, V91, P888, DOI 10.1073/pnas.91.3.888; PURCELL RH, 1994, FEMS MICROBIOL REV, V14, P181, DOI 10.1111/j.1574-6976.1994.tb00087.x; RENAULT PF, 1989, SEMIN LIVER DIS, V9, P273, DOI 10.1055/s-2008-1040523; ROST B, 1995, PROTEIN SCI, V4, P521; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SATOH S, 1995, J VIROL, V69, P4255, DOI 10.1128/JVI.69.7.4255-4260.1995; Shimizu Y, 1996, J VIROL, V70, P127, DOI 10.1128/JVI.70.1.127-132.1996; Simmonds Peter, 1994, V61, P12; SOMMERGRUBER W, 1994, VIROLOGY, V204, P815, DOI 10.1006/viro.1994.1599; SUZICH JA, 1993, J VIROL, V67, P6152, DOI 10.1128/JVI.67.10.6152-6158.1993; TAKAMIZAWA A, 1991, J VIROL, V65, P1105, DOI 10.1128/JVI.65.3.1105-1113.1991; TANJI Y, 1995, J VIROL, V69, P3980, DOI 10.1128/JVI.69.7.3980-3986.1995; TANJI Y, 1995, J VIROL, V69, P1575, DOI 10.1128/JVI.69.3.1575-1581.1995; TOMEI L, 1993, J VIROL, V67, P4017, DOI 10.1128/JVI.67.7.4017-4026.1993; Tomei L, 1996, J GEN VIROL, V77, P1065, DOI 10.1099/0022-1317-77-5-1065; TONG L, 1993, J MOL BIOL, V230, P228, DOI 10.1006/jmbi.1993.1139; TSAI DE, 1992, P NATL ACAD SCI USA, V89, P8864, DOI 10.1073/pnas.89.19.8864; Van Der Poel C. L., 1994, V61, P137; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEBSTER A, 1993, CELL, V72, P97, DOI 10.1016/0092-8674(93)90053-S; WEILAND O, 1994, FEMS MICROBIOL REV, V14, P279, DOI 10.1016/0168-6445(94)90044-2; YU SYF, 1992, VIROLOGY, V186, P725, DOI 10.1016/0042-6822(92)90039-R; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158	79	632	681	0	32	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 18	1996	87	2					343	355		10.1016/S0092-8674(00)81351-3	http://dx.doi.org/10.1016/S0092-8674(00)81351-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VN403	8861917	Bronze			2022-12-24	WOS:A1996VN40300021
J	Webb, E; Ashton, CH; Kelly, P; Kamali, F				Webb, E; Ashton, CH; Kelly, P; Kamali, F			Alcohol and drug use in UK university students	LANCET			English	Article							MEDICAL-STUDENTS; COLLEGE-STUDENTS; PROBLEM DRINKING; YOUNG ADULTHOOD; CONSUMPTION; PERSONALITY; ADOLESCENCE; PATTERNS; SAMPLE	Background Alcohol and illicit drug use are increasing among school children and young adults in the UK. Such increases have also been noted among university students and there is a need for a large survey across different universities and faculties. We report such a survey. Methods information about drinking, use of cannabis and other illicit drugs, other lifestyle variables, and subjective ratings of anxiety and depression was obtained by questionnaire in a cross-faculty sample of 3075 second-year university students (1610 men, 1447 women, 18 sex not stated) from ten UK universities. The questionnaire was personally administered during scheduled lecture hours and almost ail the students participated. The sample reflected the interfaculty and sex distribution and the proportion of non-white students at UK universities. Findings 11% of the students were non-drinkers, Among drinkers, 61% of the men and 48% of the women exceeded ''sensible'' limits of 14 units per week for women and 21 for men. Hazardous drinking (greater than or equal to 36 units per week for women, greater than or equal to 51 for men) was reported by 15% of the drinkers, Binge drinking was declared by 28% of drinkers. 60% of the men and 55% of the women reported having used cannabis once or twice and 20% of the sample reported regular cannabis use (weekly or more often). Experience with other illicit drugs was reported by 33% of the sample, most commonly LSD (lysergic acid diethylamide), amphetamines, Ecstasy (methylenedioxymethamphetamine), and amyl/butyl nitrate which had each been used by 13-18% of students. 34% of these had used several drugs, Drug use had started at school in 46% of the sample; 13% began after entering university. The overwhelming reason given for taking alcohol or drugs was pleasure, Subjective ratings of anxiety on the hospital anxiety depression scale were high, and sleep difficulties were common, but neither related to alcohol or drug use. Interpretation There is a need far better education about alcohol, drugs, and general health in universities. Such education should include all faculties. It remains unclear whether university students' lifestyles are carried over into later life.	UNIV NEWCASTLE UPON TYNE,DEPT PHARMACOL SCI,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,DEPT PSYCHIAT,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,DEPT MED STAT,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK								ANDREASSON S, 1993, AM J PUBLIC HEALTH, V83, P845, DOI 10.2105/AJPH.83.6.845; ASHTON CH, 1995, MED EDUC, V29, P187, DOI 10.1111/j.1365-2923.1995.tb02828.x; BALDING J, 1994, YOUNG PEOPLE 1993; BROWN C, 1991, COLL STUDENT J, V25, P451; Calman K, 1995, Health Trends, V27, P71; COGGANS N, 1991, BRIT J ADDICT, V86, P1099; COLLIER DJ, 1989, BRIT MED J, V299, P19, DOI 10.1136/bmj.299.6690.19; *DEP HLTH, 1995, SENS DRINK REP INT; Department of Health, 1992, HLTH NAT STRAT HLTH; DONOVAN JE, 1983, J STUD ALCOHOL, V44, P109, DOI 10.15288/jsa.1983.44.109; Edwards G, 1996, BRIT MED J, V312, P1, DOI 10.1136/bmj.312.7022.1; FILE SE, 1994, J PSYCHOPHARMACOL, V8, P22, DOI 10.1177/026988119400800104; FIRTH J, 1986, BRIT MED J, V292, P1177, DOI 10.1136/bmj.292.6529.1177; Ghodse A H, 1994, Health Trends, V26, P85; Gold M. S, 1991, COMPREHENSIVE HDB AL, P353; GOLDING JF, 1983, PERS INDIV DIFFER, V4, P703, DOI 10.1016/0191-8869(83)90129-0; GOLDING JF, 1987, PSYCHOL HEALTH, V1, P287; Hall W, 1994, NATL DRUG STRATEGY M, V25; HAMMER T, 1990, J ADOLESCENCE, V13, P129, DOI 10.1016/0140-1971(90)90003-P; *HLTH ED AUTH, 1992, THATS LIM GUID SENS; *HM STAT OFF, 1995, ED STAT UK; JACKSON R, 1995, LANCET, V346, P716, DOI 10.1016/S0140-6736(95)91496-X; KLEIN H, 1994, J YOUTH ADOLESCENCE, V23, P251, DOI 10.1007/BF01537448; Marmot M, 1995, LANCET, V346, P1643, DOI 10.1016/S0140-6736(95)92833-2; MENDELSON JH, 1987, PSYCHOPHARMACOLOGY 3, P1565; MOORE L, 1994, HEALTH EDUC RES, V9, P497, DOI 10.1093/her/9.4.497; Nahas GG, 1984, MARIHUANA SCI MED, P109; PAFFENBARGER RS, 1994, MED SCI SPORT EXER, V26, P857; Plant M., 1992, RISK TAKERS ALCOHOL; POLS R, 1991, IS THERE SAFE LEVEL; RITSON EB, 1990, BRIT MED J, V30, P134; WEST R, 1990, BRIT J ADDICT, V85, P479; WRIGHT JD, 1995, BRIT MED J, V310, P20, DOI 10.1136/bmj.310.6971.20; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; 1995, J R COLL PHYS LOND, V29, P470; 1995, J R COLL PHYS LOND, V29, P266	36	288	300	0	96	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 5	1996	348	9032					922	925		10.1016/S0140-6736(96)03410-1	http://dx.doi.org/10.1016/S0140-6736(96)03410-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VL097	8843811				2022-12-24	WOS:A1996VL09700011
J	Colgan, DF; Murthy, KGK; Prives, C; Manley, JL				Colgan, DF; Murthy, KGK; Prives, C; Manley, JL			Cell-cycle related regulation poly(A) polymerase by phosphorylation	NATURE			English	Article							XENOPUS-LAEVIS OOCYTES; MESSENGER-RNA; DEPENDENT KINASES; MATURATION; EXPRESSION; CLEAVAGE	THE poly(A) tail found on almost all eukaryotic messenger RNAs(1,2) is important in enhancing translation initiation and determining mRNA stability(3,4). Control of poly(A)-tail synthesis thus has the potential to be a key regulatory step in gene expression and is indeed known to be important during early development in many organisms(5). To study a possible basis for such regulation, we examined phosphorylation of poly(A) polymerase (PAP) by p34(cdc2)/cyclin B (maturation/mitosis-promoting factor, MPF). We show here that PAP can be phosphorylated in vivo and in vitro by MPF. Consistent with this, PAP becomes hyperphosphorylated both during meiotic maturation of Xenopus laevis oocytes and in HeLa cells arrested at M phase, times in the cell-cycle when MPF is known to be active(6,7). We show further that hyperphosphorylation by MPF dramatically reduces the activity of purified PAP, and that PAP isolated from mitotic HeLa cells is similarly inhibited by hyperphosphorylation. This repression probably contributes to the well established reductions in poly(A)(+) RNA and/or protein synthesis known to occur in M-phase cells(8-15).	COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA	Columbia University				Manley, James/0000-0002-8341-1459				BALLANTYNE S, 1995, RNA, V1, P64; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BIENROTH S, 1991, J BIOL CHEM, V266, P19768; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; DAMBROUGH C, 1979, DEV BIOL, V71, P323; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; FAN H, 1970, J MOL BIOL, V50, P655, DOI 10.1016/0022-2836(70)90091-4; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; KANKI JP, 1991, DEV BIOL, V146, P198, DOI 10.1016/0012-1606(91)90460-K; KELLER W, 1995, CELL, V81, P829, DOI 10.1016/0092-8674(95)90001-2; KOBAYASHI H, 1991, COLD SH Q B, V56, P437; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MANLEY JL, 1995, CURR OPIN GENET DEV, V5, P222, DOI 10.1016/0959-437X(95)80012-3; Martin G, 1996, EMBO J, V15, P2593, DOI 10.1002/j.1460-2075.1996.tb00617.x; MURTHY KGK, 1992, J BIOL CHEM, V267, P14804; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PAWLOWSKI PJ, 1974, DEV BIOL, V40, P71, DOI 10.1016/0012-1606(74)90108-0; PRIVES C, 1991, METHOD CELL BIOL, V36, P185; RAABE T, 1994, MOL CELL BIOL, V14, P2946, DOI 10.1128/MCB.14.5.2946; RAABE T, 1991, NATURE, V353, P229, DOI 10.1038/353229a0; SAGATA N, 1980, DEV BIOL, V77, P431, DOI 10.1016/0012-1606(80)90486-8; SLATER DW, 1972, NATURE, V240, P333, DOI 10.1038/240333a0; STEWARD DL, 1968, SCIENCE, V161, P791, DOI 10.1126/science.161.3843.791; THURESSON AC, 1994, P NATL ACAD SCI USA, V91, P979, DOI 10.1073/pnas.91.3.979; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; WAHLE E, 1991, EMBO J, V10, P4251, DOI 10.1002/j.1460-2075.1991.tb05003.x; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WICKENS M, 1992, SEM DEV BIOL, V3, P399; WILT FH, 1977, CELL, V11, P673, DOI 10.1016/0092-8674(77)90084-8; Zhao WQ, 1996, MOL CELL BIOL, V16, P2378	30	133	135	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 21	1996	384	6606					282	285		10.1038/384282a0	http://dx.doi.org/10.1038/384282a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU381	8918882				2022-12-24	WOS:A1996VU38100057
J	Cui, JS; OShea, KS; Purkayastha, A; Saunders, TL; Ginsburg, D				Cui, JS; OShea, KS; Purkayastha, A; Saunders, TL; Ginsburg, D			Fatal haemorrhage and incomplete block to embryogenesis in mice locking coagulation factor V	NATURE			English	Article							ACTIVATED PROTEIN-C; WARFARIN EMBRYOPATHY; TARGETED DISRUPTION; HEMOPHILIA-A; MECHANISM; PROTHROMBINASE; DEFICIENCY; RESISTANCE; THROMBOSIS; PHENOTYPE	COAGULATION factor V is a critical cofactor for the activation of prothrombin to thrombin, the penultimate step in the generation of a fibrin blood clot(1,2). Genetic deficiency of factor V results in a congenital bleeding disorder (parahaemophilia)(3), whereas inheritance of a mutation rendering factor V resistant to inactivation is an important risk factor for thrombosis(4,5). We report here that approximately half of homozygous embryos deficient in factor V (F upsilon(-/-)), which have been generated by gene targeting, die at embryonic day (E) 9-10, possibly as a result of an abnormality in the yolk-sac vasculature. The remaining F upsilon(-/-) mice progress normally to term, but die from massive haemorrhage within 2 hours or birth. Considered together with the milder phenotypes generally associated with deficiencies of other clotting factors(6,7), our findings demonstrate the primary role of the common coagulation pathway and the absolute requirement for functional factor V for prothrombinase activity. They also provide direct evidence for the existence of other critical haemostatic functions for thrombin in addition to fibrin clot formation, and identify a previously unrecognized role for the coagulation system in early mammalian development.	UNIV MICHIGAN,SCH MED,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT HUMAN GENET,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT ANAT & CELL BIOL,ANN ARBOR,MI 48109	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan				Saunders, Thom/0000-0003-2015-101X				BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BI L, 1995, NAT GENET, V10, P119, DOI 10.1038/ng0595-119; Bugge TH, 1996, P NATL ACAD SCI USA, V93, P6258, DOI 10.1073/pnas.93.13.6258; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; FLIER JS, 1992, NEW ENGL J MED, V326, P800; FRANCO B, 1995, CELL, V81, P15, DOI 10.1016/0092-8674(95)90367-4; GALANAKIS DK, 1992, HEMATOL ONCOL CLIN N, V6, P1171, DOI 10.1016/S0889-8588(18)30303-4; HAN YM, 1993, J ASSIST REPROD GEN, V10, P151, DOI 10.1007/BF01207739; HANSON SR, 1988, P NATL ACAD SCI USA, V85, P3184, DOI 10.1073/pnas.85.9.3184; HIRSH J, 1991, NEW ENGL J MED, V324, P1865; HOYER LW, 1994, NEW ENGL J MED, V330, P38, DOI 10.1056/NEJM199401063300108; Kaufman M.H., 1992, ATLAS MOUSE DEV; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; PAULI RM, 1987, AM J HUM GENET, V41, P566; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; SOIFER SJ, 1994, AM J PATHOL, V144, P60; SUH TT, 1995, GENE DEV, V9, P2020, DOI 10.1101/gad.9.16.2020; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; TRACY PB, 1987, HUM PATHOL, V18, P162, DOI 10.1016/S0046-8177(87)80334-9; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Zheng XX, 1995, P NATL ACAD SCI USA, V92, P12426, DOI 10.1073/pnas.92.26.12426	25	206	209	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1996	384	6604					66	68		10.1038/384066a0	http://dx.doi.org/10.1038/384066a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR219	8900278	Green Published			2022-12-24	WOS:A1996VR21900054
J	Rulifson, EJ; Micchelli, CA; Axelrod, JD; Perrimon, N; Blair, SS				Rulifson, EJ; Micchelli, CA; Axelrod, JD; Perrimon, N; Blair, SS			wingless refines its own expression domain on the Drosophila wing margin	NATURE			English	Article							SPLIT COMPLEX GENES; SIGNALING PATHWAY; PROTEIN; POLARITY; NOTCH; BOUNDARY; ZESTE-WHITE-3; NEUROGENESIS; SUPPRESSOR; ACTIVATION	THE imaginal discs of Drosophila, which give rise to the adult appendages, are patterned during a period of intense cell proliferation. The specification of differing regions occurs in some cases by subdividing the disc epithelium into lineage compartments(1). However, in most cases precise boundaries are formed between different cell types without early compartmentalization(2). One such boundary occurs between the wingless (wg)-expressing cells of the wing margin and the adjacent proneural cells, which give rise to margin sensory bristles. Here we show that this boundary arises in part by a mechanism of 'self-refinement', by which wingless protein (Wg) represses wg expression in adjacent cells. Cells unable to receive the Wg signal do not resolve the boundary between wg-expressing and proneural cells.	UNIV WISCONSIN,DEPT ZOOL,MADISON,WI 53706; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115; UNIV WISCONSIN,PROGRAM NEUROSCI,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; University of Wisconsin System; University of Wisconsin Madison				Perrimon, Norbert/0000-0001-7542-472X				Axelrod JD, 1996, SCIENCE, V271, P1826, DOI 10.1126/science.271.5257.1826; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; BALLYCUIF L, 1995, MECH DEVELOP, V53, P23, DOI 10.1016/0925-4773(95)00421-1; BLAIR SS, 1994, DEV BIOL, V162, P229, DOI 10.1006/dbio.1994.1081; BLAIR SS, 1995, BIOESSAYS, V17, P299, DOI 10.1002/bies.950170406; BLAIR SS, 1992, DEV BIOL, V152, P263, DOI 10.1016/0012-1606(92)90134-3; Couso JP, 1995, CURR BIOL, V5, P1437, DOI 10.1016/S0960-9822(95)00281-8; COUSO JP, 1994, DEVELOPMENT, V120, P621; deCelis JF, 1996, DEVELOPMENT, V122, P359; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; DIAZBENJUMEA FJ, 1989, GENOME, V31, P612; Doherty D, 1996, GENE DEV, V10, P421, DOI 10.1101/gad.10.4.421; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HING HK, 1994, MECH DEVELOP, V47, P261, DOI 10.1016/0925-4773(94)90044-2; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; LECOURTOIS M, 1995, GENE DEV, V9, P2598, DOI 10.1101/gad.9.21.2598; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; PANGANIBAN G, 1994, CURR BIOL, V4, P671, DOI 10.1016/S0960-9822(00)00151-2; PEIFER M, 1994, DEVELOPMENT, V120, P369; PERRIMON N, 1989, DEV BIOL, V135, P287, DOI 10.1016/0012-1606(89)90180-2; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; RULIFSON EJ, 1995, DEVELOPMENT, V121, P2813; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; SIMPSON P, 1988, DEVELOPMENT, V103, P391; THEISEN H, 1994, DEVELOPMENT, V120, P347; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087	30	101	101	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1996	384	6604					72	74		10.1038/384072a0	http://dx.doi.org/10.1038/384072a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR219	8900280				2022-12-24	WOS:A1996VR21900056
J	Kirby, M				Kirby, M			Human rights and the HIV paradox	LANCET			English	Article								Faced with the grave challenge to public health posed by HIV infection, governments are obliged to ''do something''. One response, which often finds favour with the general public, is to enact laws that criminalise the activities of certain target groups. However, such laws maginalise individuals in these groups and have very little impact on containment of the epidemic. It is far better to introduce measures that protect the rights of people most at risk of infection and thereby encourage and sustain behaviour modification.	INT COMMISS JURISTS,GENEVA,SWITZERLAND		Kirby, M (corresponding author), HIGH COURT AUSTRALIA,POB E435 QUEEN VICTORIA TERRACE,CANBERRA,ACT 2600,AUSTRALIA.								0	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 2	1996	348	9036					1217	1218		10.1016/S0140-6736(96)05468-2	http://dx.doi.org/10.1016/S0140-6736(96)05468-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VQ467	8898041				2022-12-24	WOS:A1996VQ46700015
J	Lagna, G; Hata, A; HemmatiBrivanlou, A; Massague, J				Lagna, G; Hata, A; HemmatiBrivanlou, A; Massague, J			Partnership between DPC4 and SMAD proteins in TGF-beta signalling pathways	NATURE			English	Article							MESODERM INDUCTION; ACTIVIN-A; XENOPUS; RECEPTOR; EMBRYOS; HOMOLOG; INDUCER	THE TGF-beta/activin/BMP superfamily of growth factors signals through heteromeric receptor complexes of type I and type II serine/threonine kinase receptors(1) The signal originated by TGF-beta-like molecules appears to be transduced by a set of evolutionarily conserved proteins known as SMADs, which upon activation directly translocate to the nucleus where they may activate transcription(2), Five SMAD proteins have so far been characterized in vertebrates(1), These factors are related to the mediator of decapentaplegic (dpp) signalling, mothers against dpp (Mad), in Drosophila(3) and to the Sma genes from Caenorhabditis elegans(4). Smad1 and Smad2 have been shown to mimic the effects of BMP and activin, respectively, both in Xenopus and in mammalian cells(2,5-9), whereas Smad3 (a close homologue of Smad2) and the related protein DPC4, a tumour-suppressor gene product(10), mediate TGF-beta actions(11). We report here that DPC4 is essential for the function of Smad1 and Smad2 in pathways that signal mesoderm induction and patterning in Xenopus embryos, as well as antimitogenic and transcriptional responses in breast epithelial cells, DPC4 associates with Smad1 in response to BMP and with Smad2 in response to activin or TGF-beta. DPC4 is therefore a regulated partner of SMADs that function in different signalling pathways of the TGF-beta family.	MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,MOL EMBRYOL LAB,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Rockefeller University				Massague, Joan/0000-0001-9324-8408				ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; Attisano L, 1996, MOL CELL BIOL, V16, P1066; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Gawantka V, 1995, EMBO J, V14, P6268, DOI 10.1002/j.1460-2075.1995.tb00317.x; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Harland RM, 1991, METHODS CELL BIOL; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; LIU F, 1995, MOL CELL BIOL, V15, P3479; LIU F, 1996, NATURE, V381, P622; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; Schutte M, 1996, CANCER RES, V56, P2527; SEKELSKY JJ, 1995, GENETICS, V139, P1347; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SOKOL S, 1990, SCIENCE, V249, P561, DOI 10.1126/science.2382134; TENDIJKE P, 1993, ONCOGENE, V8, P2879; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	29	792	835	0	26	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 31	1996	383	6603					832	836		10.1038/383832a0	http://dx.doi.org/10.1038/383832a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ144	8893010				2022-12-24	WOS:A1996VQ14400066
J	Uusitalo, U; Feskens, EJM; Tuomilehto, J; Dowse, G; Haw, U; Fareed, D; Hemraj, F; Gareeboo, H; Alberti, KGMM; Zimmet, P				Uusitalo, U; Feskens, EJM; Tuomilehto, J; Dowse, G; Haw, U; Fareed, D; Hemraj, F; Gareeboo, H; Alberti, KGMM; Zimmet, P			Fall in total cholesterol concentration over five years in association with changes in fatty acid composition of cooking oil in Mauritius: Cross sectional survey	BRITISH MEDICAL JOURNAL			English	Article							LOW-DENSITY-LIPOPROTEIN; PREVALENCE; POPULATION; DISEASE; LIPIDS	Objective-To determine the extent to which reducing the saturated fatty acid composition of a ubiquitously used cooking oil influenced changes in cholesterol concentration in the population during a five year intervention programme in Mauritius. Design-Cross sectional surveys in 1987 and 1992 determined mean total cholesterol concentrations in the population. A random sample of respondents in the 1992 survey completed a nutrition questionnaire that included questions on diet in the previous 24 hours. Setting-Mauritius. Intervention-In 1987 the government of Mauritius changed the composition of the commonly used cooking oil from being mostly palm oil (high in saturated fatty acids) to being wholly soya bean oil (high in unsaturated fatty acids). Subjects-5080 and 5162 subjects in 1987 and 1992 cross sectional surveys, 2059 subjects aged 30-64 years were randomly selected from the respondents of the 1992 survey to take part in the nutrition survey Main outcome measures-Fatty acid composition of phospholipids in pooled serum samples from men and women from the two surveys; measured and predicted change in serum cholesterol concentration. Results-From 1987 to 1992 total cholesterol concentrations fell significantly by 0.79 mmol/l (P<0.001) in men and 0.82 mmol/l (P<0.001) in women. The estimated intake of saturated fatty acids decreased by 3.5% of energy intake in men and by 3.6% in women, and the intake of polyunsaturated fatty acids increased by 5.5% and 5.6% of energy intake, respectively. These changes were reflected in changes in the fatty acid composition of serum phospholipids, and according to Keys' formula these changes explained much of the decrease in serum cholesterol concentrations (predicted decrease of 0.38 mmol/l in men and by 0.40 mmol/l in women). Conclusion-Dietary changes that entailed a reduction in the saturated fat content of a ubiquitous cooking oil explained most of the observed decrease in serum cholesterol concentration over five years in the population of Mauritius.	NATL PUBL HLTH INST,DIABET & GENET EPIDEMIOL UNIT,DEPT EPIDEMIOL & HLTH PROMOT,FIN-00300 HELSINKI,FINLAND; NATL INST PUBL HLTH & ENVIRONM,DEPT CHRON DIS & ENVIRONM EPIDEMIOL,NL-3720 BA BILTHOVEN,NETHERLANDS; INT DIABET INST,MELBOURNE,VIC,AUSTRALIA; MINIST HLTH,PORT LOUIS,MAURITIUS; WHO,PORT LOUIS,MAURITIUS; UNIV NEWCASTLE UPON TYNE,HUMAN DIABET & METAB RES CTR,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND	Finland National Institute for Health & Welfare; Netherlands National Institute for Public Health & the Environment; World Health Organization; Newcastle University - UK			Zimmet, Paul/O-8486-2019; Feskens, Edith JM/A-3757-2012; Feskens, Edith/ABI-1446-2020	Zimmet, Paul/0000-0003-0627-0776; Feskens, Edith/0000-0001-5819-2488; Uusitalo, Ulla/0000-0001-9132-7727	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025446] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 25446] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERNS M, 1990, EUR J CLIN NUTR, V12, P911; BONANOME A, 1988, NEW ENGL J MED, V318, P1244, DOI 10.1056/NEJM198805123181905; DENKE MA, 1992, AM J CLIN NUTR, V56, P895, DOI 10.1093/ajcn/56.5.895; DOWSE GK, 1990, DIABETES, V39, P390, DOI 10.2337/diabetes.39.3.390; DOWSE GK, 1995, BRIT MED J, V311, P1255, DOI 10.1136/bmj.311.7015.1255; GAREEBOO H, 1988, HLTH LIFESTYLE MAURI; Houwelingen A. C. V., 1992, Early Human Development, V31, P97, DOI 10.1016/0378-3782(92)90038-I; KEYS A, 1965, METABOLIS, V14, P776, DOI 10.1016/0026-0495(65)90004-1; LAVECCHIA C, 1993, SOZ PRAVENTIV MED, V38, pS3, DOI 10.1007/BF02026086; LI N, 1991, J HYPERTENS, V9, P859; MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911; NG TKW, 1991, AM J CLIN NUTR, V53, pS1015, DOI 10.1093/ajcn/53.4.1015S; REAVEN P, 1993, J CLIN INVEST, V91, P668, DOI 10.1172/JCI116247; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; TUOMILEHTO J, 1993, J INTERN MED, V233, P187, DOI 10.1111/j.1365-2796.1993.tb00672.x; WILLETT W, 1990, NUT EPIDEMIOLOGY	16	74	76	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 26	1996	313	7064					1044	1046						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP742	8898594	Green Published			2022-12-24	WOS:A1996VP74200023
J	Watt, GCM; Britton, A; Gilmour, WH; Moore, MR; Murray, GD; Robertson, SJ; Womersley, J				Watt, GCM; Britton, A; Gilmour, WH; Moore, MR; Murray, GD; Robertson, SJ; Womersley, J			Is lead in tap water still a public health problem? An observational study in Glasgow	BRITISH MEDICAL JOURNAL			English	Article							BLOOD LEAD; CHILDREN; EDINBURGH; EXPOSURE; ABILITY	Objective-To assess the relation between tap water lead and maternal blood lead concentrations and assess the exposure of infants to lead in tap water in a water supply area subjected to maximal water treatment to reduce plumbosolvency. Design-Postal questionnaire survey and collection of kettle water from a representative sample of mothers; blood and further water samples were collected in a random sample of households and households with raised water lead concentrations. Setting-Loch Katrine water supply area, Glasgow. Subjects-1812 mothers with a live infant born between October 1991 and September 1992. Blood lead concentrations were measured in 342 mothers. Main outcome measures-Mean geometric blood lead concentrations and the prevalence of raised tap water lead concentrations. Results-17% of households had water lead concentrations of 10 mu g/l (48.3 nmol/l) or more in 1993 compared with 49% of households in 1981. Tap water lead remained the main correlate of raised maternal blood lead concentrations and accounted for 62% and 76% of cases of maternal blood lead concentrations above 5 and 10 mu g/dl (0.24 and 0.48 mu mol/l) respectively. The geometric mean maternal blood lead concentration was 3.65 mu g/dl (0.18 mu mol/l) in a random sample of mothers and 3.16 mu g/dl (0.15 mu mol/l) in mothers whose tap water lead concentrations were consistently below 2 mu g/l (9.7 nmol/l). No mother in the study had a blood lead concentration above 25 mu g/dl (1.21 mu mol/l). An estimated 13% of infants were exposed via bottle feeds to tap water lead concentrations exceeding the World Health Organisation's guideline of 10 mu g/l (48.3 nmol/l). Conclusions-Tap water lead and maternal blood lead concentrations in the Loch Katrine water supply area have fallen substantially since the early 1980s. Maternal blood lead concentrations are well within limits currently considered safe for human health. Tap water lead is still a public health problem in relation to the lead exposure of bottle fed infants.	W SCOTLAND WATER AUTHOR,GLASGOW G22 6NU,LANARK,SCOTLAND; GREATER GLASGOW HLTH BOARD,GLASGOW G2 4JT,LANARK,SCOTLAND		Watt, GCM (corresponding author), UNIV GLASGOW,WOODSIDE HLTH CTR,DEPT GEN PRACTICE,GLASGOW G20 7LR,LANARK,SCOTLAND.		Moore, Michael R/C-4163-2012	Moore, Michael R/0000-0002-7012-9534; Murray, Gordon/0000-0001-9866-4734				Centers for Disease Control, 1991, PREV LEAD POIS YOUNG; *CIT GLASG DISTR C, 1994, 1992 93 CGDC ENV HLT; *COMM EUR UN, 1995, 80778EEC COMM EUR UN; Delves HT, 1996, BRIT MED J, V313, P883; *DEP ENV, 1983, 18 DEP ENV POLL; *DEP ENV MIN AGR F, 1982, GLASG DUPL DIET STUD; FORWELL GD, 1989, ANN REPORT DIRECTOR, P59; FULTON M, 1987, LANCET, V1, P1221; HALLS DJ, 1984, ANALYST, V109, P1081, DOI 10.1039/an9840901081; LACEY RF, 1985, SCI TOTAL ENVIRON, V41, P235, DOI 10.1016/0048-9697(85)90144-5; MACDONALD C, 1994, ENV HLTH, V102, P165; MCINTOSH L, 1992, STRATHCLYDE WATER SE; MILLSTONE E, 1995, J ROY SOC HEALTH, V115, P347, DOI 10.1177/146642409511500603; MOORE MR, 1985, ENVIRON RES, V38, P67, DOI 10.1016/0013-9351(85)90073-8; MOORE MR, 1982, SCOTT MED J, V26, P354; MOORE MR, 1979, CLIN CHIM ACTA, V95, P113; MOORE MR, 1982, SCOTT MED J, V27, P112; NEEDLEMAN HL, 1990, JAMA-J AM MED ASSOC, V263, P673, DOI 10.1001/jama.263.5.673; POCOCK SJ, 1994, BRIT MED J, V309, P1189, DOI 10.1136/bmj.309.6963.1189; QUINN MJ, 1990, FOOD ADDIT CONTAM, V7, P387, DOI 10.1080/02652039009373904; RAAB GM, 1990, BRIT J DEV PSYCHOL, V8, P101, DOI 10.1111/j.2044-835X.1990.tb00826.x; Richards W., 1980, J I WATER ENG SCI, p[34, 315]; SCHWARTZ J, 1991, ARCH ENVIRON HEALTH, V46, P300, DOI 10.1080/00039896.1991.9934391; *STAND COMM AN, 1986, LEAD CADM FRESH WAT; STOEPPLER M, 1978, ANALYST, V103, P714, DOI 10.1039/an9780300714; Tong SL, 1996, BRIT MED J, V312, P1569, DOI 10.1136/bmj.312.7046.1569; *WHO, 1995, LEAD HLTH LOC HLTH A; *WHO, 1993, GUID DRINK WAT QUAL, V1; WROATH AS, 1995, 295 UK WAT IND RES	29	33	33	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 19	1996	313	7063					979	981						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN916	8892418	Green Published			2022-12-24	WOS:A1996VN91600023
J	Wevrick, R; Francke, U				Wevrick, R; Francke, U			Diagnostic test for the Prader-Willi syndrome by SNRPN expression in blood	LANCET			English	Article							MOLECULAR DIAGNOSIS; ANGELMAN SYNDROMES; CRITICAL REGION; GENE	Background Prader-Willi syndrome (PWS) is caused by alterations of the paternally derived chromosome 15 or by maternal uniparental disomy. The gene for the small nuclear ribonucleoprotein polypeptide N (SNRPN) is expressed only from the paternally derived chromosome 15, due to epigenetic imprinting. The SNRPN gene is not expressed in any patients with PWS regardless of the underlying cytogenetic or molecular causes. Methods To develop a rapid molecular diagnostic assay for PWS, we tested the expression of the SNRPN gene and a control gene in 9 patients with PWS and 40 control individuals by PCR analysis of reverse transcribed mRNA from blood leucocytes. We then tested 11 blood samples from patients with suspected PWS. Findings SNRPN expression could readily be detected in blood leucocytes by PCR analysis in all control samples but not in samples from known PWS patients. Four suspected plus were negative for SNRPN expression were found to have chromosome 15 rearrangements, while the diagnosis of PWS was excluded in the remaining seven with normal SNRPN expression based on clinical, molecular, and cytogenetic findings. Interpretation The SNRPN-expression test is rapid and reliable in the molecular diagnosis of Prader-Willi syndrome.	STANFORD UNIV,MED CTR,DEPT PAEDIAT,STANFORD,CA 94305; STANFORD UNIV,MED CTR,DEPT GENET,STANFORD,CA 94305	Stanford University; Stanford University	Wevrick, R (corresponding author), STANFORD UNIV,MED CTR,HOWARD HUGHES MED INST,STANFORD,CA 94305, USA.			Wevrick, Rachel/0000-0002-3343-5794				DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; DITTRICH B, 1992, HUM GENET, V90, P313; GLENN CC, 1993, HUM MOL GENET, V2, P2001, DOI 10.1093/hmg/2.12.2001; HOLM VA, 1993, PEDIATRICS, V91, P398; KNOLL JHM, 1993, AM J MED GENET, V46, P2, DOI 10.1002/ajmg.1320460103; MUTIRANGURA A, 1993, HUM MOL GENET, V2, P143, DOI 10.1093/hmg/2.2.143; NAKAO M, 1994, HUM MOL GENET, V3, P309, DOI 10.1093/hmg/3.2.309; OZCELIK T, 1992, NAT GENET, V2, P265, DOI 10.1038/ng1292-265; ROBINSON WP, 1991, AM J HUM GENET, V49, P1219; SUTCLIFFE JS, 1994, NAT GENET, V8, P52, DOI 10.1038/ng0994-52; 1996, AM J HUM GENET, V58, P1085	11	27	27	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 19	1996	348	9034					1068	1069		10.1016/S0140-6736(96)04342-5	http://dx.doi.org/10.1016/S0140-6736(96)04342-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM886	8874459				2022-12-24	WOS:A1996VM88600012
J	Carlson, R; Smythe, W; Baines, K; Barbinis, E; Becker, K; Burns, R; Calcutt, S; Calvin, W; Clark, R; Danielson, G; Davies, A; Drossart, P; Encrenaz, T; Fanale, F; Granahan, J; Hansen, G; Herrera, P; Hibbitts, C; Hui, J; Irwin, P; Johnson, T; Kamp, L; Kieffer, H; Leader, F; Lellouch, E; LopesGautier, R; Matson, D; McCord, T; Mehlman, R; Ocampo, A; Orton, G; RoosSerote, M; Segura, M; Shirley, J; Soderblom, L; Stevenson, A; Taylor, F; Torson, J; Weir, A; Weissman, P				Carlson, R; Smythe, W; Baines, K; Barbinis, E; Becker, K; Burns, R; Calcutt, S; Calvin, W; Clark, R; Danielson, G; Davies, A; Drossart, P; Encrenaz, T; Fanale, F; Granahan, J; Hansen, G; Herrera, P; Hibbitts, C; Hui, J; Irwin, P; Johnson, T; Kamp, L; Kieffer, H; Leader, F; Lellouch, E; LopesGautier, R; Matson, D; McCord, T; Mehlman, R; Ocampo, A; Orton, G; RoosSerote, M; Segura, M; Shirley, J; Soderblom, L; Stevenson, A; Taylor, F; Torson, J; Weir, A; Weissman, P			Near-infrared spectroscopy and spectral mapping of Jupiter and the Galilean satellites: Results from Galileo's initial orbit	SCIENCE			English	Article							MU-M; 5-MU-M; WATER; BELT	The Near Infrared Mapping Spectrometer performed spectral studies of Jupiter and the Galilean satellites during the June 1996 perijove pass of the Galileo spacecraft. Spectra for a 5-micrometer hot spot on Jupiter are consistent with the absence of a significant water cloud above 8 bars and with a depletion of water compared lo that predicted for solar composition, corroborating results from the Galileo probe. Great Red Spot (GRS) spectral images show that parts of this feature extend upward to 240 millibars, although considerable altitude-dependent structure is found within it. A ring of dense clouds surrounds the GRS and is lower than it by 3 to 7 kilometers. Spectra of Callisto and Ganymede reveal a feature at 4.25 micrometers, attributed to the presence of hydrated minerals or possibly carbon dioxide on their surfaces. Spectra of Europa's high latitudes imply that fine-grained water frost overlies larger grains. Several active volcanic regions were found on lo, with temperatures of 420 to 620 kelvin and projected areas of 5 to 70 square kilometers.	UNIV CALIF LOS ANGELES,INST GEOPHYS & PLANETARY PHYS,LOS ANGELES,CA 90095; UNIV OXFORD,DEPT ATMOSPHER OCEAN & PLANETARY SCI,OXFORD OX1 3PU,ENGLAND; US GEOL SURVEY,FLAGSTAFF,AZ 86001; CALTECH,DIV GEOL & PLANETARY SCI,PASADENA,CA 91125; US GEOL SURVEY,DENVER,CO 80225; OBSERV PARIS,F-92150 MEUDON,FRANCE; UNIV HAWAII,HAWAII INST GEOPHYS & PLANETOL,HONOLULU,HI 96822	University of California System; University of California Los Angeles; University of Oxford; United States Department of the Interior; United States Geological Survey; California Institute of Technology; United States Department of the Interior; United States Geological Survey; UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; University of Hawaii System	Carlson, R (corresponding author), CALTECH,JET PROP LAB,4800 OAK GROVE DR,PASADENA,CA 91109, USA.		Orton, Glenn/AAD-9862-2020; Hibbitts, Charles/B-7787-2016; Shirley, James/AAR-1264-2020; Lopes, Rosaly M.C./D-1608-2016; Drossart, Pierre/H-8670-2013; Davies, Ashley/S-5588-2018	Hibbitts, Charles/0000-0001-9089-4391; Lopes, Rosaly M.C./0000-0002-7928-3167; Irwin, Patrick Gerard Joseph/0000-0002-6772-384X; Calcutt, Simon/0000-0002-0102-3170; Davies, Ashley/0000-0003-1747-8142; Taylor, Fred/0000-0002-0675-9769				ATREYA S, 1996, COMMUNICATION; Atreya S., COMMUNICATION; BAINES KH, 1990, ICARUS, V85, P65, DOI 10.1016/0019-1035(90)90104-H; BAINES KH, 1993, J GEOPHYS RES-PLANET, V98, P5517, DOI 10.1029/92JE02808; BORYSOW J, 1985, ASTROPHYS J, V296, P644, DOI 10.1086/163482; CALVIN WM, 1995, J GEOPHYS RES-PLANET, V100, P19041, DOI 10.1029/94JE03349; CARLSON R, 1990, SPACE SCI REV, V60, P457; CLARK RN, 1990, J GEOPHYS RES-SOLID, V95, P12653, DOI 10.1029/JB095iB08p12653; CLARK RN, 1981, J GEOPHYS RES, V86, P3087, DOI 10.1029/JB086iB04p03087; DROSSART P, 1982, ICARUS, V52, P483, DOI 10.1016/0019-1035(82)90008-2; IRWIN P, IN PRESS ADV SPACE S; KARKOSCHKA E, 1992, ICARUS, V97, P161, DOI 10.1016/0019-1035(92)90125-Q; KLEINER I, 1996, 14 INT C HIGH RES MO; KUNDE V, 1982, ASTROPHYS J, V263, P443, DOI 10.1086/160516; LELLOUCH E, 1989, ICARUS, V77, P457, DOI 10.1016/0019-1035(89)90099-7; Niemann HB, 1996, SCIENCE, V272, P846, DOI 10.1126/science.272.5263.846; Orton G, 1996, SCIENCE, V272, P839, DOI 10.1126/science.272.5263.839; Ragent B, 1996, SCIENCE, V272, P854, DOI 10.1126/science.272.5263.854; Seiff A, 1996, SCIENCE, V272, P844, DOI 10.1126/science.272.5263.844; SEIFF A, COMMUNICATION; Spencer JR, 1996, ANNU REV EARTH PL SC, V24, P125, DOI 10.1146/annurev.earth.24.1.125; TOMASKO MG, 1978, ICARUS, V33, P558, DOI 10.1016/0019-1035(78)90191-4; WEIDENSCHILING SJ, 1973, ICARUS, V20, P45; Young RE, 1996, SCIENCE, V272, P837, DOI 10.1126/science.272.5263.837; [No title captured]	25	127	127	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1996	274	5286					385	388		10.1126/science.274.5286.385	http://dx.doi.org/10.1126/science.274.5286.385			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN173	8832878				2022-12-24	WOS:A1996VN17300041
J	Pilote, L; Miller, DP; Califf, RM; Rao, JS; Weaver, WD; Topol, EJ				Pilote, L; Miller, DP; Califf, RM; Rao, JS; Weaver, WD; Topol, EJ			Determinants of the use of coronary angiography and revascularization after thrombolysis for acute myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLASMINOGEN-ACTIVATOR; CARDIAC-CATHETERIZATION; CARDIOGENIC-SHOCK; RANDOMIZED TRIAL; SURGICAL THERAPY; ARTERY SURGERY; HOLDING GUSTO; ANGIOPLASTY; SURVIVAL; MORTALITY	Background Clinical trials and practice guidelines have identified clinical criteria for the use of coronary angiography and revascularization procedures after thrombolysis for acute myocardial infarction. The effect of these criteria on clinical practice has not been extensively evaluated. Methods We used classification-and-regression-tree (CART) and logistic-regression models to study the patients in the first Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries trial, to identify the variables that best predicted the use of angiography and revascularization procedures after thrombolysis. Results Among the 21,772 U.S. patients in the trial, 71 percent underwent coronary angiography before discharge from the hospital. Of these, 58 percent underwent revascularization (73 percent receiving angioplasty). The CART model for the use of angiography showed that age was the Variable most predictive of angiography; only 53 percent of patients at least 73 years of age underwent angiography, as compared with 76 percent of those under 73. Among the older patients, age was again the most predictive factor; among the younger patients, the availability of angioplasty was a more important predictor (67 percent of patients in hospitals without angioplasty facilities underwent angiography, as compared with 33 percent in hospitals with such facilities). The next most important variable was recurrent ischemia, which was more predictive at hospitals without an gioplasty facilities than at those with them. Both statistical models identified coronary anatomy as the most important predictor of the use and type of revascularization. Conclusions More patients treated with thrombolysis underwent angiography and revascularization before discharge than might be expected. Younger age and the availability of the procedures appeared to be the major determinants of the use of coronary angiography, whereas coronary anatomy largely determined the use and type of revascularization. This process appeared to select low-risk patients for intervention rather than those at higher risk, who would be the most likely to benefit. (C) 1996, Massachusetts Medical Society.	CLEVELAND CLIN FDN, CLEVELAND, OH 44195 USA; MONTREAL GEN HOSP, MONTREAL, PQ H3G 1A4, CANADA; DUKE UNIV, DURHAM, NC USA; UNIV WASHINGTON, SEATTLE, WA 98195 USA	Cleveland Clinic Foundation; McGill University; Duke University; University of Washington; University of Washington Seattle				Pilote, Louise/0000-0002-6159-0628; Topol, Eric/0000-0002-1478-4729; Miller, Dave/0000-0003-2947-152X				ALDERMAN EL, 1990, CIRCULATION, V82, P1629, DOI 10.1161/01.CIR.82.5.1629; *AM HOSP ASS, 1993, AM HOSP ASS GUID HLT; BARBASH GI, 1990, AM J CARDIOL, V66, P538, DOI 10.1016/0002-9149(90)90478-J; BLUSTEIN J, 1993, JAMA-J AM MED ASSOC, V270, P344, DOI 10.1001/jama.270.3.344; Breiman L, 1983, CLASSIFICATION REGRE; CALIFF RM, 1989, JAMA-J AM MED ASSOC, V261, P2077, DOI 10.1001/jama.261.14.2077; CALIFF RM, 1991, CIRCULATION, V83, P1543, DOI 10.1161/01.CIR.83.5.1543; CHAMBERS JM, 1993, STAT MODELS S, P414; DETRE KM, 1984, AM J CARDIOL, V53, P444, DOI 10.1016/0002-9149(84)90010-9; EMOND M, 1994, CIRCULATION, V90, P2645, DOI 10.1161/01.CIR.90.6.2645; EVERY NR, 1993, NEW ENGL J MED, V329, P546, DOI 10.1056/NEJM199308193290807; Ferguson JJ, 1996, CIRCULATION, V93, P843, DOI 10.1161/01.CIR.93.5.843; Granger Christopher B., 1996, Journal of the American College of Cardiology, V27, p181A; Gunnar R M, 1990, Circulation, V82, P664; HENNING H, 1979, CIRCULATION, V59, P1124, DOI 10.1161/01.CIR.59.6.1124; HOLMES DR, 1995, J AM COLL CARDIOL, V26, P668, DOI 10.1016/0735-1097(95)00215-P; KIRKLIN JW, 1991, J AM COLL CARDIOL, V17, P543; KNATTERUD G, 1988, JAMA-J AM MED ASSOC, V260, P2849; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; LEE KL, 1994, ANN INTERN MED, V120, P876, DOI 10.7326/0003-4819-120-10-199405150-00009; LEE L, 1988, CIRCULATION, V78, P1345, DOI 10.1161/01.CIR.78.6.1345; MEYER J, 1982, AM HEART J, V103, P132, DOI 10.1016/0002-8703(82)90540-3; MICHELS KB, 1995, CIRCULATION, V91, P476, DOI 10.1161/01.CIR.91.2.476; PILOTE L, 1995, NEW ENGL J MED, V333, P565, DOI 10.1056/NEJM199508313330907; PRYOR DB, 1993, ANN INTERN MED, V118, P81, DOI 10.7326/0003-4819-118-2-199301150-00001; RIDKER PM, 1994, ANN INTERN MED, V120, P882, DOI 10.7326/0003-4819-120-10-199405150-00010; ROGERS WJ, 1990, CIRCULATION, V81, P1457, DOI 10.1161/01.CIR.81.5.1457; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; SIMOONS ML, 1988, LANCET, V1, P199; SPERTUS JA, 1995, ARCH INTERN MED, V155, P2309, DOI 10.1001/archinte.155.21.2309; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; TOPOL EJ, 1991, ANN INTERN MED, V114, P877, DOI 10.7326/0003-4819-114-10-877; TOPOL EJ, 1987, NEW ENGL J MED, V317, P581, DOI 10.1056/NEJM198709033171001; VANDEWERF F, 1990, LANCET, V336, P71; YUSUF, 1994, LANCET, V344, P1446; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1; 1987, CIRCULATION, V76, pA963	37	151	153	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 17	1996	335	16					1198	1205		10.1056/NEJM199610173351606	http://dx.doi.org/10.1056/NEJM199610173351606			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN401	8815943				2022-12-24	WOS:A1996VN40100006
J	Harrison, JF; Fewell, JH; Roberts, SP; Hall, HG				Harrison, JF; Fewell, JH; Roberts, SP; Hall, HG			Achievement of thermal stability by varying metabolic heat production in flying honeybees	SCIENCE			English	Article							BODY-TEMPERATURE REGULATION; APIS-MELLIFERA; FLIGHT; THERMOREGULATION; MECHANISMS; AFRICAN; BEES	Thermoregulation of the thorax allows endothermic insects to achieve power outputs during flight that are among the highest in the animal kingdom. Flying endothermic insects, including the honeybee Apis mellifera, are believed to thermoregulate almost exclusively by varying heat loss. Here it is shown that a rise in air temperature from 20 degrees to 40 degrees C causes large decreases in metabolic heat production and wing-beat frequency in honeybees during hovering, agitated, or loaded flight. Thus, variation in heat production may be the primary mechanism for achieving thermal stability in flying honeybees, and this mechanism may occur commonly in endothermic insects.	UNIV FLORIDA,DEPT ENTOMOL & NEMATOL,GAINESVILLE,FL 32611	State University System of Florida; University of Florida	Harrison, JF (corresponding author), ARIZONA STATE UNIV,DEPT ZOOL,TEMPE,AZ 85287, USA.							Casey T.M., 1989, P257; CASEY TM, 1988, ADV INSECT PHYSL, V20, P120; COELHO JR, 1991, PHYSIOL ZOOL, V64, P823, DOI 10.1086/physzool.64.3.30158209; COOPER PD, 1985, J EXP BIOL, V114, P1; DICKINSON MH, 1995, SCIENCE, V268, P87, DOI 10.1126/science.7701346; ELLINGTON CP, 1984, PHILOS T ROY SOC B, V305, P1, DOI 10.1098/rstb.1984.0049; Harrison JF, 1996, FUNCT ECOL, V10, P81, DOI 10.2307/2390265; HARRISON JF, 1993, NATURE, V363, P258, DOI 10.1038/363258a0; HEINRICH B, 1980, J EXP BIOL, V85, P73; HEINRICH B, 1980, J EXP BIOL, V85, P61; HEINRICH B, 1979, J EXP BIOL, V80, P217; HEINRICH B, 1994, AM SCI, V82, P164; HEINRICH B, 1992, HOT BLOODED INSECTS; MAY ML, 1995, J EXP BIOL, V198, P2385; ROBERTS SP, 1994, AM ZOOL, V34, P142; SCHUCHMANN KL, 1979, IBIS, V121, P85, DOI 10.1111/j.1474-919X.1979.tb05018.x; Spangler Hayward G., 1992, BeeScience, V2, P181; SPANGLER HG, 1991, J KANSAS ENTOMOL SOC, V64, P107	18	56	56	3	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1996	274	5284					88	90		10.1126/science.274.5284.88	http://dx.doi.org/10.1126/science.274.5284.88			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VK748	8810252				2022-12-24	WOS:A1996VK74800052
J	Madireddi, MT; Coyne, RS; Smothers, JF; Mickey, KM; Yao, MC; Allis, CD				Madireddi, MT; Coyne, RS; Smothers, JF; Mickey, KM; Yao, MC; Allis, CD			Pdd1p, a novel chromodomain-containing protein, links heterochromatin assembly and DNA elimination in Tetrahymena	CELL			English	Article							POSITION-EFFECT VARIEGATION; STYLONYCHIA-MYTILUS; CHROMOSOME ELIMINATION; THERMOPHILA; CHROMATIN; DOMAIN; REARRANGEMENTS; IDENTIFICATION; SEQUENCES; GENE	During Tetrahymena conjugation, programmed DNA degradation occurs in two separate nuclei. Thousands of germline-specific deletion elements are removed from the genome of the developing somatic macronucleus, and the old parental macronucleus is degraded by an apoptotic mechanism. An abundant polypeptide, Pdd1p (formerly p65), localizes to both of these nuclei at the time of DNA degradation. Here we report that, in developing macronuclei, Pdd1p localizes to electron-dense, heterochromatic structures that contain germline-specific deletion elements. Pdd1p also associates with parental macronuclei during terminal stages of apoptosis. Sequencing of the PDD1 gene reveals it to be a member of the chromodomain family, suggesting a molecular link between heterochromatin assembly and programmed DNA degradation.	UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627; FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,SEATTLE,WA 98104; FRED HUTCHINSON CANC RES CTR,PROGRAM MOL & CELLULAR BIOL,SEATTLE,WA 98104	University of Rochester; Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026210, R01GM053512, F32GM016129, R37GM053512] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26210, GM16129, GM53512] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASLAND R, 1995, NUCLEIC ACIDS RES, V23, P3168; ALLIS CD, 1986, J BIOL CHEM, V261, P1941; AMMERMANN D, 1971, CHROMOSOMA, V33, P209, DOI 10.1007/BF00285634; AMMERMANN D, 1974, CHROMOSOMA, V45, P401, DOI 10.1007/BF00283386; AUSTERBERRY CF, 1984, P NATL ACAD SCI-BIOL, V81, P7383, DOI 10.1073/pnas.81.23.7383; BALDWIN GS, 1983, NATURE, V301, P435, DOI 10.1038/301435a0; BARNARD R, 1994, BIOTECHNIQUES, V16, P251; BAROICH A, 1992, NUCLEIC ACIDS RES, V20, P2013; BEERMANN S, 1977, CHROMOSOMA, V60, P297, DOI 10.1007/BF00292858; BORST P, 1987, SCIENCE, V235, P658, DOI 10.1126/science.3544215; Boveri T., 1887, ANAT ANZEIGER, V22, P685; BRUNK CF, 1990, NUCLEIC ACIDS RES, V18, P323, DOI 10.1093/nar/18.2.323; CALLAHAN RC, 1984, CELL, V36, P441, DOI 10.1016/0092-8674(84)90237-X; Chalker DL, 1996, MOL CELL BIOL, V16, P3658; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COYNE RS, 1996, IN PRESS ANN REV GEN, V30; Cross GAM, 1996, BIOESSAYS, V18, P283, DOI 10.1002/bies.950180406; DAVIS MC, 1992, DEV BIOL, V154, P419, DOI 10.1016/0012-1606(92)90080-Z; Dernburg AF, 1996, CELL, V86, P135, DOI 10.1016/S0092-8674(00)80084-7; EISSENBERG JC, 1994, J BIOL CHEM, V269, P1; Elgin SCR, 1996, CURR OPIN GENET DEV, V6, P193, DOI 10.1016/S0959-437X(96)80050-5; FRELS JS, 1996, MOL BIOL CELL, V5, P755; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GODAY C, 1984, SCIENCE, V224, P411, DOI 10.1126/science.224.4647.411; GODISKA R, 1990, CELL, V61, P1237, DOI 10.1016/0092-8674(90)90688-B; GODISKA R, 1993, GENE DEV, V7, P2357, DOI 10.1101/gad.7.12a.2357; GUTTMAN SD, 1980, CELL, V22, P299, DOI 10.1016/0092-8674(80)90177-4; HENIKOFF S, 1990, TRENDS GENET, V6, P422, DOI 10.1016/0168-9525(90)90304-O; HENIKOFF S, 1994, GENETICS, V138, P1; HENNIG W, 1988, GERM LINE SOMA DIFFE, P176; KARPEN GH, 1994, CURR OPIN GENET DEV, V4, P281, DOI 10.1016/S0959-437X(05)80055-3; Karpen GH, 1996, SCIENCE, V273, P118, DOI 10.1126/science.273.5271.118; KLAR AJS, 1993, CURR OPIN GENET DEV, V3, P745, DOI 10.1016/S0959-437X(05)80093-0; Klobutcher LA, 1991, CURR OPIN GENET DEV, V1, P397, DOI 10.1016/S0959-437X(05)80306-5; KOONIN EV, 1995, NUCLEIC ACIDS RES, V23, P4229, DOI 10.1093/nar/23.21.4229; KUBOTA S, 1993, CHROMOSOMA, V102, P163, DOI 10.1007/BF00387731; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBER MR, 1992, CELL, V70, P873, DOI 10.1016/0092-8674(92)90237-7; LOHE AR, 1995, CURR OPIN GENET DEV, V5, P746, DOI 10.1016/0959-437X(95)80007-R; Madireddi Malavi T., 1995, Seminars in Developmental Biology, V6, P305, DOI 10.1016/S1044-5781(06)80072-1; MADIREDDI MT, 1994, DEV BIOL, V165, P418, DOI 10.1006/dbio.1994.1264; MARTINDALE DW, 1982, EXP CELL RES, V140, P227, DOI 10.1016/0014-4827(82)90172-0; MARTINDALE DW, 1989, J PROTOZOOL, V36, P29; MARTINDALE DW, 1983, MOL CELL BIOL, V3, P1857, DOI 10.1128/MCB.3.10.1857; MESSMER S, 1992, GENE DEV, V6, P1241, DOI 10.1101/gad.6.7.1241; MEYER GF, 1980, CHROMOSOMA, V77, P285, DOI 10.1007/BF00286054; Mpoke S, 1996, EXP CELL RES, V225, P357, DOI 10.1006/excr.1996.0186; Muller F, 1996, BIOESSAYS, V18, P133, DOI 10.1002/bies.950180209; NAKAI Y, 1991, CYTOGENET CELL GENET, V56, P196, DOI 10.1159/000133087; NAKAI Y, 1995, CHROMOSOME RES, V3, P321, DOI 10.1007/BF00713071; NEIL JC, 1981, NATURE, V291, P675, DOI 10.1038/291675a0; OCHMAN H, 1988, GENETICS, V120, P621; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; PLATERO JS, 1995, EMBO J, V14, P3977, DOI 10.1002/j.1460-2075.1995.tb00069.x; PRESCOTT DM, 1994, MICROBIOL REV, V58, P233, DOI 10.1128/MMBR.58.2.233-267.1994; SINGH PB, 1991, NUCLEIC ACIDS RES, V19, P789, DOI 10.1093/nar/19.4.789; SPRADLING A, 1980, P NATL ACAD SCI USA, V17, P1096; SPRADLING AC, 1993, COLD SPRING HARB SYM, V58, P585, DOI 10.1101/SQB.1993.058.01.065; SPRADLING AC, 1993, EVOLUTIONARY CONSERV, V4, P39; StanhopeBaker P, 1996, CELL, V85, P887, DOI 10.1016/S0092-8674(00)81272-6; TOBLER H, 1988, GERM LINE SOMA DIFFE, P1; TRIGLIA T, 1988, NUCLEIC ACIDS RES, V16, P81; Weiler KS, 1995, ANNU REV GENET, V29, P577, DOI 10.1146/annurev.ge.29.120195.003045; WEISKEBENNER A, 1985, DIFFERENTIATION, V28, P225, DOI 10.1111/j.1432-0436.1985.tb00829.x; WENKERT D, 1984, J CELL BIOL, V98, P2107, DOI 10.1083/jcb.98.6.2107; WOLFFE AP, 1994, DEV GENET, V15, P463, DOI 10.1002/dvg.1020150604; YAO M, 1974, CHROMOSOMA, V48, P1; YAO MC, 1982, J CELL BIOL, V92, P783, DOI 10.1083/jcb.92.3.783; Yao MC, 1996, TRENDS GENET, V12, P26, DOI 10.1016/0168-9525(96)81385-0; YAO MC, 1984, CELL, V36, P433, DOI 10.1016/0092-8674(84)90236-8; YOKOYAMA RW, 1982, NUCLEIC ACIDS RES, V12, P6103	71	138	145	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1996	87	1					75	84		10.1016/S0092-8674(00)81324-0	http://dx.doi.org/10.1016/S0092-8674(00)81324-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VL695	8858150	hybrid			2022-12-24	WOS:A1996VL69500010
J	Verreault, A; Kaufman, PD; Kobayashi, R; Stillman, B				Verreault, A; Kaufman, PD; Kobayashi, R; Stillman, B			Nucleosome assembly by a complex of CAF-1 and acetylated histones H3/H4	CELL			English	Article							DNA-REPLICATION INVITRO; NEWLY SYNTHESIZED HISTONES; NEGATIVE REGULATOR; CHROMATIN; PROTEINS; TRANSCRIPTION; YEAST; CELLS; RAS; H4	Chromatin assembly factor 1 (CAF-1) assembles nucleosomes in a replication-dependent manner. The small subunit of CAF-1 (p48) is a member of a highly conserved subfamily of WD-repeat proteins. There are at least two members of this subfamily in both human (p46 and p48) and yeast cells (Hat2p, a subunit of the B-type H4 acetyltransferase, and Msi1p). Human p48 can bind to histone H4 in the absence of CAF-1 p150 and p60. p48, also a known subunit of a histone deacetylase, copurifies with a chromatin assembly complex (CAC), which contains the three subunits of CAF-1 (p150, p60, p48) and H3 and H4, and promotes DNA replication-dependent chromatin assembly. CAC histone H4 exhibits a novel pattern of lysine acetylation that overlaps with, but is distinct from, that reported for newly synthesized H4 isolated from nascent chromatin. Our data suggest that CAC is a key intermediate of the de novo nucleosome assembly pathway and that the p48 subunit participates in other aspects of histone metabolism.			Verreault, A (corresponding author), COLD SPRING HARBOR LAB,POB 100,COLD SPRING HARBOR,NY 11724, USA.			Stillman, Bruce/0000-0002-9453-4091; Kaufman, Paul/0000-0003-3089-313X	NCI NIH HHS [CA13106] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANERJEE S, 1991, NUCLEIC ACIDS RES, V19, P5999, DOI 10.1093/nar/19.21.5999; BARRATT MJ, 1994, P NATL ACAD SCI USA, V91, P4781, DOI 10.1073/pnas.91.11.4781; DAVIE JR, 1982, ANAL BIOCHEM, V120, P276, DOI 10.1016/0003-2697(82)90348-7; DELCUVE GP, 1992, ANAL BIOCHEM, V200, P339, DOI 10.1016/0003-2697(92)90475-M; Harlow E, 1988, ANTIBODIES LAB MANUA; ISHIMI Y, 1991, J BIOL CHEM, V266, P16141; JACKSON V, 1976, J MOL BIOL, V104, P471, DOI 10.1016/0022-2836(76)90282-5; JACKSON V, 1990, BIOCHEMISTRY-US, V29, P719, DOI 10.1021/bi00455a019; Kaufman PD, 1996, CURR OPIN CELL BIOL, V8, P369, DOI 10.1016/S0955-0674(96)80012-3; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; KLEFF S, 1995, J BIOL CHEM, V270, P24674, DOI 10.1074/jbc.270.42.24674; KRUDE T, 1995, EXP CELL RES, V220, P304, DOI 10.1006/excr.1995.1320; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LANFORD RE, 1988, VIROLOGY, V167, P72, DOI 10.1016/0042-6822(88)90055-4; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LIN R, 1989, J CELL BIOL, V108, P1577, DOI 10.1083/jcb.108.5.1577; Ling XF, 1996, GENE DEV, V10, P686, DOI 10.1101/gad.10.6.686; LUCCHINI R, 1995, NATURE, V374, P276, DOI 10.1038/374276a0; MORGAN BA, 1991, MOL CELL BIOL, V11, P4111, DOI 10.1128/MCB.11.8.4111; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NEER EJ, 1996, CELL, V84, P176; NOLL M, 1977, J MOL BIOL, V109, P303; PERRY CA, 1991, EXP CELL RES, V196, P337, DOI 10.1016/0014-4827(91)90269-Z; PERRY CA, 1993, BIOCHEMISTRY-US, V32, P13605, DOI 10.1021/bi00212a028; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; QIAN YW, 1995, J BIOL CHEM, V270, P25507, DOI 10.1074/jbc.270.43.25507; RUGGIERI R, 1989, P NATL ACAD SCI USA, V86, P8778, DOI 10.1073/pnas.86.22.8778; RUIZCARRILLO A, 1975, SCIENCE, V190, P117, DOI 10.1126/science.1166303; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SIMANIS V, 1985, VIROLOGY, V144, P80; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; SOGO JM, 1986, J MOL BIOL, V189, P189, DOI 10.1016/0022-2836(86)90390-6; STILLMAN B, 1986, CELL, V45, P555, DOI 10.1016/0092-8674(86)90287-4; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Thomas J O, 1978, Methods Cell Biol, V18, P429; TURNER BM, 1989, EUR J BIOCHEM, V179, P131, DOI 10.1111/j.1432-1033.1989.tb14530.x; TYLER JK, 1996, IN PRESS MOL CELL BI; Wolffe A., 1995, CHROMATIN STRUCTURE; WORCEL A, 1978, CELL, V15, P969, DOI 10.1016/0092-8674(78)90280-5	44	518	526	1	21	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1996	87	1					95	104		10.1016/S0092-8674(00)81326-4	http://dx.doi.org/10.1016/S0092-8674(00)81326-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VL695	8858152	Bronze			2022-12-24	WOS:A1996VL69500012
J	Angus, DC; LindeZwirble, WT; Sirio, CA; Rotondi, AJ; Chelluri, L; Newbold, RC; Lave, JR; Pinsky, MR				Angus, DC; LindeZwirble, WT; Sirio, CA; Rotondi, AJ; Chelluri, L; Newbold, RC; Lave, JR; Pinsky, MR			The effect of managed care on ICU length of stay - Implications for Medicare	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; IMPROVING INTENSIVE-CARE; UNITED-STATES; TRADITIONAL INSURANCE; INCEPTION COHORT; MORTALITY; SEVERITY; OUTCOMES; COSTS; PERFORMANCE	Objective.-To determine whether insurance status (managed care vs traditional commercial and Medicare) influences resource consumption (as measured by length of stay [LOS]) in the intensive care unit (ICU). Design.-Retrospective analysis of the 1992 Massachusetts state hospital discharge database, using prospectively developed and validated risk-stratification models. Setting.-All nonfederal hospitals in Massachusetts. Subjects.-Of all adult hospitalizations where an ICU stay was incurred (n=104 270), we selected those covered by 1 of 4 payer groups (n=88 050): (1) commercial fee-for-service (patients aged <65 years); (2) commercial managed care (patients aged <65 years); (3) traditional Medicare (patients aged greater than or equal to 65 years); and (4) Medicare-sponsored managed care (patients aged greater than or equal to 65 years). Main Outcome Measure.-Mean ICU LOS. Analysis.-The ICU LOS regression models were constructed using split-halves validation to adjust for differences in age, sex, severity of illness, diagnosis, discharge status, and payer. Separate models were constructed for those younger than 65 years and those aged 65 years or older. Robustness of the models was explored using goodness of fit and correlation. The effect of payer on hospital mortality was also explored using logistic regression. Observed minus predicted mean ICU LOS and mortality rates were correlated with managed care penetration at the hospital level. Results.-The ICU LOS models performed well (R(2)=0.84 and R(L)(2), [likelihood ratio statistic]=0.92 for the development set, and R(2)=0.83 and R(L)(2)=0.89 for the validation set). Significant covariables affecting LOS included age, severity of principal illness, comorbidity, reason for admission, and discharge status (P<.001 for each). Among the cohort younger than 65 years (n=27 805), although unadjusted mean ICU LOS was shorter (2.9 vs 3.43 days; P<.05) for those covered by managed care organizations, payer status had no independent effect on ICU LOS (P=.48). Among those older than 65 years, there was neither a difference in unadjusted ICU LOS (3.94 vs 3.88 days; P greater than or equal to.05) nor an independent effect of payer on ICU LOS (P=.35). Unadjusted mortality was lower among managed care patients (3.9% vs 5.1% in patients aged < 65 years [P<.05] and 8.7% vs 12.1% in patients aged greater than or equal to 65 years [P<.05]). Age, severity of principal diagnosis, comorbidity, and reason for admission significantly influenced mortality (P<.001), After controlling for these factors with the mortality model (R(L)(2)=0.92 and 0.89, C statistic [12 df]=8.45 and 17.58, and P=.75 and .13 [where a large P reflects good agreement] for the development and validation sets, respectively), payer continued to have a small but significant effect on mortality (odds ratios ranging from 1.67 at 0.1% probability of death to 1.11 at 30% probability of death). Managed care penetration among the commercially insured varied across hospitals (n=82) from 0% to 68%. There was no correlation between managed care penetration and either ICU LOS (R(2)=0.04; P=.09) or mortality (R(2)=0.0; P=.88). Conclusions.-Though patients covered under managed care consume fewer ICU resources, this appears to be primarily attributable to a difference in patient-related factors. Thus, as managed care case mix changes in the future to include sicker and older patients, the initial advantages of reduced resource consumption may diminish.	UNIV PITTSBURGH, GRAD SCH PUBL HLTH, PITTSBURGH, PA 15213 USA; HLTH PROC MANAGEMENT INC, DOYLESTOWN, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Angus, DC (corresponding author), UNIV PITTSBURGH, MED CTR, DEPT ANESTHESIOL & CRIT CARE MED, DIV CRIT CARE MED, PITTSBURGH, PA 15213 USA.		Angus, Derek C/E-9671-2012					*AG HLTH CAR POL R, 1992, COST FIN ISS HLTH CA, P93; ANGUS DC, 1995, AM J RESP CRIT CARE, V151, pA492; ANGUS DC, 1994, P ASS HLTH SERV RES, P7; ANGUS DC, 1995, CHEST, V108, pS105; ARNOULD RJ, 1984, INQUIRY-J HEALTH CAR, V21, P243; BECK M, 1995, NEWSWEEK        0918, P42; BRADBURY RC, 1991, INQUIRY-J HEALTH CAR, V28, P87; BRAVEMAN P, 1994, NEW ENGL J MED, V331, P444, DOI 10.1056/NEJM199408183310706; CARLISLE DM, 1992, AM J PUBLIC HEALTH, V82, P1626, DOI 10.2105/AJPH.82.12.1626; CLERMONT G, 1995, P INT C HLTH POL RES; CLERMONT G, 1996, CRIT CARE MED S1, V24, pA52; DALEY J, 1994, RISK ADJUSTMENT MEAS, P239; DOWD BE, 1986, MED CARE, V24, P694, DOI 10.1097/00005650-198608000-00005; FETTER RB, 1981, NEW ICD 9 CM DIAGN R; GONNELLA JS, 1984, JAMA-J AM MED ASSOC, V251, P637; HALPERN NA, 1994, CRIT CARE MED, V22, P2001; HANLEY JA, 1988, RADIOLOGY, V168, P568, DOI 10.1148/radiology.168.2.3393683; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HILBE J, 1995, XPLORE INTERACTIVE S, P195; HILBE JM, 1994, AM STAT, V48, P255, DOI 10.2307/2684732; IEZZONI L, 1994, P ASS HLTH SERV RES, P21; Iezzoni L I, 1994, Am J Med Qual, V9, P43, DOI 10.1177/0885713X9400900202; IEZZONI LI, 1995, ANN INTERN MED, V123, P763, DOI 10.7326/0003-4819-123-10-199511150-00004; IEZZONI LI, 1992, MED CARE, V30, P347, DOI 10.1097/00005650-199204000-00005; IEZZONI LI, 1990, JAMA-J AM MED ASSOC, V264, P1426, DOI 10.1001/jama.264.11.1426; IEZZONI LI, 1994, RISK ADJUSTMENT MEAS, P119; JACOBS P, 1990, CRIT CARE MED, V18, P1282, DOI 10.1097/00003246-199011000-00020; JOHNSON AN, 1989, INQUIRY-J HEALTH CAR, V26, P388; KNAUS WA, 1982, LANCET, V2, P642; KNAUS WA, 1993, ANN INTERN MED, V118, P753, DOI 10.7326/0003-4819-118-10-199305150-00001; LAVE JR, 1994, MED CARE, V32, pJS77; LEMESHOW S, 1993, JAMA-J AM MED ASSOC, V270, P2478, DOI 10.1001/jama.270.20.2478; LINDEZWIRBLE WT, 1995, P 155 ANN JOINT STAT; LUFT HS, 1981, HLTH MAINTENANCE ORG; *MA ASS HMOS, 1996, HMO ENR MASS RES 199, P1; MAKLAN CW, 1994, MED CARE, V32, pJS13; MARTIN DP, 1989, AM J PUBLIC HEALTH, V79, P1628, DOI 10.2105/AJPH.79.12.1628; MCCLELLAN M, 1994, JAMA-J AM MED ASSOC, V272, P859, DOI 10.1001/jama.272.11.859; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; MILLER RH, 1994, JAMA-J AM MED ASSOC, V271, P1512, DOI 10.1001/jama.271.19.1512; MITCHELL JB, 1994, MED CARE, V32, pJS38; NAESSENS JM, 1992, MAYO CLIN PROC, V67, P1140, DOI 10.1016/S0025-6196(12)61143-4; RAPOPORT J, 1992, ARCH INTERN MED, V152, P2207, DOI 10.1001/archinte.152.11.2207; RAPOPORT J, 1994, CRIT CARE MED, V22, P1385, DOI 10.1097/00003246-199409000-00006; RAPOPORT J, 1990, MED CARE, V28, P338, DOI 10.1097/00005650-199004000-00005; RAPOPORT J, 1995, CRIT CARE MED, V23, P1336, DOI 10.1097/00003246-199508000-00006; SHORTELL SM, 1994, MED CARE, V32, P508, DOI 10.1097/00005650-199405000-00009; SIRIO CA, 1992, CRIT CARE MED, V20, P1207, DOI 10.1097/00003246-199209000-00006; SPRAGGINS EE, 1995, NEWSWEEK        0619, P55; *STAT FL AG HLTH C, 1994, 1994 PAT DAT TAP; *STAT MD, 1993, NONC VERS MAR STAT I; STERN RS, 1989, ARCH INTERN MED, V149, P1185, DOI 10.1001/archinte.149.5.1185; *SYST INC, 1983, DIS STAG CLIN BAS AP; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; *US DEP HHS, 1988, INT CLASS DIS 9 REV; Wagner D P, 1989, Am Rev Respir Dis, V140, pS14; WENNBERG JE, 1987, JAMA-J AM MED ASSOC, V257, P933, DOI 10.1001/jama.257.7.933; YELIN EH, 1986, MED CARE, V24, P236, DOI 10.1097/00005650-198603000-00006; ZIMMERMAN JE, 1993, CRIT CARE MED, V21, P1432, DOI 10.1097/00003246-199310000-00009; ZIMMERMAN JE, 1994, CRIT CARE MED, V22, P1373, DOI 10.1097/00003246-199409000-00005; ZIMMERMAN JE, 1988, CRIT CARE MED, V16, P318, DOI 10.1097/00003246-198804000-00003; ZIMMERMAN JE, 1993, CRIT CARE MED, V21, P1443, DOI 10.1097/00003246-199310000-00010; ZINNER MJ, 1995, ARCH SURG-CHICAGO, V130, P937; 1995, P INT C HLTH POL RES; 1986, ICU COST BENEFIT ANA, P101; 1994, FED REGISTER, V59, P1951; 1995, HLTH CARE FINANC R S, P24	67	92	93	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1996	276	13					1075	1082		10.1001/jama.276.13.1075	http://dx.doi.org/10.1001/jama.276.13.1075			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VK035	8847771				2022-12-24	WOS:A1996VK03500030
J	Crouse, JR				Crouse, JR			Heart of the matter in cerebral arterial sclerosis	LANCET			English	Editorial Material							STROKE				Crouse, JR (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT MED,WINSTON SALEM,NC 27157, USA.							Blankenhorn DH, 1961, AM J MED SCI, V242, P41; CHAMBERS BR, 1986, NEW ENGL J MED, V315, P860, DOI 10.1056/NEJM198610023151404; Friedlander AH, 1996, BRIT DENT J, V181, P23, DOI 10.1038/sj.bdj.4809143; MOORE WS, 1995, CIRCULATION, V91, P566, DOI 10.1161/01.CIR.91.2.566; Reinmuller R, 1987, DYNAMIC CARDIOVASCUL, V1, P139; SACCO RL, 1989, ANN NEUROL, V25, P382, DOI 10.1002/ana.410250410; SIRNA S, 1990, STROKE, V21, P14, DOI 10.1161/01.STR.21.1.14; Wexler L, 1996, CIRCULATION, V94, P1175, DOI 10.1161/01.CIR.94.5.1175	8	12	12	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 21	1996	348	9030					766	766		10.1016/S0140-6736(05)65202-6	http://dx.doi.org/10.1016/S0140-6736(05)65202-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH989	8813976				2022-12-24	WOS:A1996VH98900002
J	Grilli, M; Pizzi, M; Memo, M; Spano, P				Grilli, M; Pizzi, M; Memo, M; Spano, P			Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappa B activation	SCIENCE			English	Article							CEREBELLAR GRANULE CELLS; GLUTAMATE; NEUROTOXICITY; NEURONS; DEPENDENCE; CULTURES	Aspirin (acetylsalicylic acid) is a commonly prescribed drug with a wide pharmacological spectrum. At concentrations compatible with amounts in plasma during chronic antiinflammatory therapy, acetylsalicylic acid and its metabolite sodium salicylate were found to be protective against neurotoxicity elicited by the excitatory amino acid glutamate in rat primary neuronal cultures and hippocampal slices. The site of action of the drugs appeared to be downstream of glutamate receptors and to involve specific inhibition of glutamate-mediated induction of nuclear factor kappa B. These results may contribute to the emerging theme of anti-inflammatory drugs and neurodegeneration.			Grilli, M (corresponding author), UNIV BRESCIA,SCH MED,DEPT BIOMED SCI & BIOTECHNOL,I-25123 BRESCIA,ITALY.		grilli, mariagrazia/ABF-1542-2020; Spano, Pier Franco F/J-9944-2016; Pizzi, Marina/C-1452-2011; Memo, Maurizio/C-2555-2011; Memo, Maurizio/AAK-7197-2020; Spano, Pier Franco A/E-7621-2010; Pizzi, Marina/K-2064-2016	grilli, mariagrazia/0000-0001-9165-5827; Spano, Pier Franco F/0000-0002-9906-0964; MEMO, Maurizio/0000-0002-7543-0289; Pizzi, Marina/0000-0002-4857-5204				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Barger SW, 1996, MOL BRAIN RES, V40, P116; CHOI DW, 1987, J NEUROSCI, V7, P369; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; FAMAEY JP, 1992, THERAPEUTIC APPL NSA; FAVARON M, 1988, P NATL ACAD SCI USA, V85, P7351, DOI 10.1073/pnas.85.19.7351; GALLO V, 1982, P NATL ACAD SCI-BIOL, V79, P7919, DOI 10.1073/pnas.79.24.7919; GARTHWAITE G, 1989, NEUROSCI LETT, V97, P316, DOI 10.1016/0304-3940(89)90617-4; GRILLI M, 1995, J BIOL CHEM, V270, P26774, DOI 10.1074/jbc.270.45.26774; Grilli M, 1996, J BIOL CHEM, V271, P15002, DOI 10.1074/jbc.271.25.15002; GRILLI M, 1993, INT REV CYTOL, V143, P1; GRILLI M, UNPUB; GUERRINI L, 1995, P NATL ACAD SCI USA, V92, P9077, DOI 10.1073/pnas.92.20.9077; Hardman J.G., 1996, GOODMAN GILSMANS PHA, P617; JONES KH, 1985, J HISTOCHEM CYTOCHEM, V33, P77, DOI 10.1177/33.1.2578146; KALTSCHMIDT C, 1993, MECH DEVELOP, V43, P135, DOI 10.1016/0925-4773(93)90031-R; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; KALTSCHMIDT C, 1995, P NATL ACAD SCI USA, V92, P9618, DOI 10.1073/pnas.92.21.9618; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; Memo M, 1995, INT REV PSYCHIATR, V7, P339, DOI 10.3109/09540269509022986; PIZZI M, 1993, J NEUROCHEM, V61, P683; Pizzi M, 1996, MOL PHARMACOL, V49, P586; Rainsford K.D., 1984, ASPIRIN SALICYLATES; WEISMANN G, 1991, SCI AM, V84, P264	28	708	743	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 22	1996	274	5291					1383	1385		10.1126/science.274.5291.1383	http://dx.doi.org/10.1126/science.274.5291.1383			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU954	8910280				2022-12-24	WOS:A1996VU95400056
J	Balbach, J; Forge, V; Lau, WS; vanNuland, NAJ; Brew, K; Dobson, CM				Balbach, J; Forge, V; Lau, WS; vanNuland, NAJ; Brew, K; Dobson, CM			Protein folding monitored at individual residues during a two-dimensional NMR experiment	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; MOLTEN GLOBULE STATE; ALPHA-LACTALBUMIN; STOPPED-FLOW; SPECTROSCOPY; EXCHANGE; LYSOZYME; INTERMEDIATE; EQUILIBRIUM; RATES	An approach is described to monitor directly at the level of individual residues the formation of structure during protein folding. A two-dimensional heteronuclear nuclear magnetic resonance (NMR) spectrum was recorded after the rapid initiation of the refolding of a protein labeled with nitrogen-15. The intensities and line shapes of the cross peaks in the spectrum reflected the kinetic time course of the folding events that occurred during the spectral accumulation. The method was used to demonstrate the cooperative nature of the acquisition of the native main chain fold of apo bovine alpha-lactalbumin. The general approach, however, should be applicable to the investigation of a wide range of chemical reactions.	UNIV OXFORD,OXFORD CTR MOL SCI,NEW CHEM LAB,OXFORD OX1 3QT,ENGLAND; UNIV MIAMI,SCH MED,DEPT BIOCHEM & MOL BIOL,MIAMI,FL 33101	University of Oxford; University of Miami			Brew, Keith/A-6746-2009; Brew, Keith/W-1643-2019	Brew, Keith/0000-0003-1306-1032; 				ALEXANDRESCU AT, 1993, BIOCHEMISTRY-US, V32, P5681; Arai M, 1996, FOLD DES, V1, P275, DOI 10.1016/S1359-0278(96)00041-7; BALBACH J, 1995, NAT STRUCT BIOL, V2, P865, DOI 10.1038/nsb1095-865; BALDWIN RL, 1993, CURR OPIN STRUC BIOL, V3, P84, DOI 10.1016/0959-440X(93)90206-Z; BAUM J, 1989, BIOCHEMISTRY-US, V28, P7, DOI 10.1021/bi00427a002; BAX A, 1994, CURR OPIN STRUC BIOL, V4, P738, DOI 10.1016/S0959-440X(94)90173-2; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BODENHAUSEN G, 1982, J AM CHEM SOC, V104, P1304, DOI 10.1021/ja00369a027; CHEN BL, 1989, BIOCHEMISTRY-US, V28, P691, DOI 10.1021/bi00428a042; Dill KA, 1996, CURR OPIN STRUC BIOL, V6, P1, DOI 10.1016/S0959-440X(96)80087-X; DOBSON CM, 1984, BIOCHEMISTRY-US, V23, P4267, DOI 10.1021/bi00314a001; Dobson CM., 1992, CURR OPIN STRUC BIOL, V2, P6; Engelhard M, 1996, FOLD DES, V1, pR31, DOI 10.1016/S1359-0278(96)00016-8; ENGLANDER SW, 1992, ANNU REV BIOPH BIOM, V21, P243, DOI 10.1146/annurev.bb.21.060192.001331; ERNST RR, 1987, PRINCIPLES NUCLEAR M, pCH9; EVANS PA, 1994, CURR OPIN STRUC BIOL, V4, P100, DOI 10.1016/S0959-440X(94)90066-3; FINK AL, 1995, ANNU REV BIOPH BIOM, V24, P495, DOI 10.1146/annurev.bb.24.060195.002431; FRIEDEN C, 1993, PROTEIN SCI, V2, P2007, DOI 10.1002/pro.5560021202; GROBLER JA, 1994, J BIOL CHEM, V269, P5106; HOELTZLI SD, 1995, P NATL ACAD SCI USA, V92, P9318, DOI 10.1073/pnas.92.20.9318; HUANG GS, 1995, P NATL ACAD SCI USA, V92, P6878, DOI 10.1073/pnas.92.15.6878; IKEGUCHI M, 1986, BIOCHEMISTRY-US, V25, P6965, DOI 10.1021/bi00370a034; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KIEFHABER T, 1995, NATURE, V375, P513, DOI 10.1038/375513a0; KIM PS, 1990, ANNU REV BIOCHEM, V59, P63; KUHNE RO, 1979, J MAGN RESON, V35, P39, DOI 10.1016/0022-2364(79)90077-5; KUMAR A, 1981, J AM CHEM SOC, V103, P3654, DOI 10.1021/ja00403a008; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; Kuwajima K, 1996, FASEB J, V10, P102, DOI 10.1096/fasebj.10.1.8566530; KUWAJIMA K, 1985, BIOCHEMISTRY-US, V24, P894; Liu XY, 1996, BIOCHEMISTRY-US, V35, P4306, DOI 10.1021/bi952270d; MATTHEWS CR, 1993, ANNU REV BIOCHEM, V62, P653, DOI 10.1146/annurev.bi.62.070193.003253; Miranker AD, 1996, CURR OPIN STRUC BIOL, V6, P31, DOI 10.1016/S0959-440X(96)80092-3; MUCKE M, 1994, BIOCHEMISTRY-US, V33, P14608; OLSEN HB, 1993, J AM CHEM SOC, V115, P1456, DOI 10.1021/ja00057a033; PTITSYN OB, 1995, CURR OPIN STRUC BIOL, V5, P74, DOI 10.1016/0959-440X(95)80011-O; SCHLEUCHER J, 1994, J BIOMOL NMR, V4, P301; SERRANO L, 1994, CURR OPIN STRUC BIOL, V4, P107, DOI 10.1016/S0959-440X(94)90067-1; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; SUGAI S, 1994, ADV BIOPHYS, V30, P37, DOI 10.1016/0065-227X(94)90010-8; WU LC, 1995, NAT STRUCT BIOL, V2, P281, DOI 10.1038/nsb0495-281; [No title captured]	42	128	128	2	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1996	274	5290					1161	1163		10.1126/science.274.5290.1161	http://dx.doi.org/10.1126/science.274.5290.1161			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT335	8895458				2022-12-24	WOS:A1996VT33500044
J	Morgan, CL; Donnelly, PD; Lester, CA; Assar, DH				Morgan, CL; Donnelly, PD; Lester, CA; Assar, DH			Effectiveness of the BBC's 999 training roadshows on cardiopulmonary resuscitation: Video performance of cohort of unforewarned participants at home six months afterwards	BRITISH MEDICAL JOURNAL			English	Article							CARDIAC-ARREST; CPR SKILLS; RETENTION; SURVIVAL; IMPACT	Objective-To examine the competence of a cohort trained in cardiopulmonary resuscitation by the BBC's 999 training roadshows. Design-Descriptive cohort study applying an innovative testing procedure to a nationwide systematic sample. The test sample received an unsolicited home visit and without warning were required to perform cardiopulmonary resuscitation on a manikin while being videoed. The videos were then analysed for effectiveness and safety using the new test. Setting-Nine cities and surrounding areas in the United Kingdom, Subjects-280 people aged between 11 and 72. Results-Thirty three (12%) trainees were able to perform effective cardiopulmonary resuscitation, but of these 14 (5%) performed one or more elements in a way that was deemed to be potentially injurious, Thus only 19 (7%) trainees were able at six months to provide safe cardiopulmonary resuscitation, In addition, large numbers of subjects failed to shout for help, effectively assess the status of the patient, or alert an ambulance, Significantly better performances were recorded by those under 45 years old (31 (14%) v 2 (4%) gave effective performances respectively, P<0.05), those who had attended a subsequent cardiopulmonary resuscitation course (8 (40%) v 25 (10%) gave effective performances respectively, P<0.0001), and those confident in their initial ability (26 (20%) v 7 (6%) gave effective performances respectively, P<0.005). Females were significantly less likely than males to perform procedures in a harmful way (117 (62%) v 10 (12%) performed safely respectively, P<0.005). Conclusion-Television is an effective means of generating large training cohorts, Volunteers will cooperate with unsolicited testing in their home, such testing being a realistic simulation of the stress and lack of forewarning that would surround a real event, Under such conditions the performance of cardiopulmonary resuscitation was disappointing. However, retraining greatly improves performance.	UNIV WALES COLL CARDIFF,COLL MED,CTR APPL PUBL HLTH MED,CARDIFF F1 8UL,S GLAM,WALES	Cardiff University								ASSAR D, 1995, SHOULD S GLAMORGAN H, P41; BASKETT PJF, 1985, ANAESTHAESIA, V37, P74; BERDEN HJJM, 1993, BRIT MED J, V306, P1576, DOI 10.1136/bmj.306.6892.1576; COBB LA, 1982, ANN NY ACAD SCI, V382, P330, DOI 10.1111/j.1749-6632.1982.tb55228.x; COBB LA, 1980, ANNU REV MED, V31, P453, DOI 10.1146/annurev.me.31.020180.002321; CUMMINS RO, 1985, BRIT MED J, V291, P1401, DOI 10.1136/bmj.291.6506.1401; CUMMINS RO, 1985, JAMA-J AM MED ASSOC, V253, P2408, DOI 10.1001/jama.253.16.2408; CUMMINS RO, 1991, CIRCULATION, V83, P1833; DAVID J, 1993, BRIT MED J, V306, P1578, DOI 10.1136/bmj.306.6892.1578; DELIERE DM, 1980, EMT J, V4, P57; FOSSEL M, 1983, J MED EDUC, V58, P568; GALLAGHER EJ, 1995, JAMA-J AM MED ASSOC, V274, P1922, DOI 10.1001/jama.274.24.1922; GASS DA, 1983, CAN MED ASSOC J, V128, P550; GOMBESKI WR, 1982, AM J PUBLIC HEALTH, V72, P849, DOI 10.2105/AJPH.72.8.849; HEARNE TR, 1988, PACING CLIN ELECTROP, V2, P1968; Hughes R J, 1988, Health Educ J, V47, P53, DOI 10.1177/001789698804700205; JONES J, 1994, AM J EMERG MED, V12, P687, DOI 10.1016/0735-6757(94)90042-6; KALMTHOUT P, 1985, BRIT HEART J, V53, P562; KAYE W, 1991, RESUSCITATION, V21, P67, DOI 10.1016/0300-9572(91)90080-I; KORTTILA K, 1979, ACTA ANAESTH SCAND, V23, P235, DOI 10.1111/j.1399-6576.1979.tb01445.x; KOWALSKI R, 1984, ANN EMERG MED, V13, P1016, DOI 10.1016/S0196-0644(84)80061-X; LITWIN PE, 1987, ANN EMERG MED, V16, P787, DOI 10.1016/S0196-0644(87)80576-0; MARTIN WJ, 1983, AM J PUBLIC HEALTH, V73, P1310, DOI 10.2105/AJPH.73.11.1310; MCKENNA SP, 1985, J OCCUP PSYCHOL, V58, P109, DOI 10.1111/j.2044-8325.1985.tb00186.x; MOSER DK, 1992, HEART LUNG, V21, P372; WEAVER FJ, 1979, JAMA-J AM MED ASSOC, V241, P901, DOI 10.1001/jama.241.9.901; WESTON CFM, 1994, J ROY COLL PHYS LOND, V28, P402; WIK L, 1994, RESUSCITATION, V28, P195, DOI 10.1016/0300-9572(94)90064-7; 1992, RESUSCITATION, V24, P103	29	53	53	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 12	1996	313	7062					912	916						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM754	8876093				2022-12-24	WOS:A1996VM75400024
J	Chaturvedi, N; Jarrett, J; Morrish, N; Keen, H; Fuller, JH				Chaturvedi, N; Jarrett, J; Morrish, N; Keen, H; Fuller, JH			Differences in mortality and morbidity in African Caribbean and European people with non-insulin dependent diabetes mellitus: Results of 20 year follow up of a London cohort of a multinational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							STAGE RENAL-DISEASE; BLOOD-PRESSURE; VASCULAR-DISEASE; RISK-FACTORS; CARDIOVASCULAR-DISEASE; RACIAL-DIFFERENCES; BLACK; WHITE; TRANSPLANTATION; INDIVIDUALS	Objective-To examine differences in morbidity and mortality due to non-insulin dependent diabetes in African Caribbeans and Europeans. Design-Cohort study of patients with noninsulin dependent diabetes drawn from diabetes clinics in London, Baseline investigations were performed in 1975-7; follow up continued until 1995. Patients-150 Europeans and 77 African Caribbeans with non-insulin dependent diabetes. Main outcome measures-All cause and cardiovascular mortality; prevalence of microvascular and macrovascular complications. Results-Duration of diabetes was shorter in African Caribbeans, particularly women, African Caribbeans were more likely than the Europeans to have been given a diagnosis after the onset of symptoms and less likely to be taking insulin, Mean cholesterol concentration was lower in African Caribbeans, but blood pressure and body mass index were not different in the two ethnic groups, Prevalence of microvascular and macrovascular complications was insignificantly lower in African Caribbeans than in Europeans. 59 Europeans and 16 African Caribbeans had died by the end of follow up, The risk ratio for all cause mortality was 0.41 (95% confidence interval 0.23 to 0.73) (P=0.002) for African Caribbeans v Europeans, This was attenuated to 0.59 (0.32 to 1.10) (P=0.1) after adjustment for sex, smoking, proteinuria, and body mass index. Further adjustment for systolic blood pressure, cholesterol concentration, age, duration of diabetes, and treatment made little difference to the risk ratio, Unadjusted risk ratios for cardiovascular and ischaemic heart disease were 0.33 (0.15 to 0.70) (P=0.004) and 0.37 (0.16 to 0.85) (P=0.02) respectively. Conclusions-African Caribbeans with noninsulin dependent diabetes maintain a low risk of heart disease, Management priorities for diabetes developed in one ethnic group may not necessarily be applicable to ether groups.	BEDFORD HOSP, S WING, BEDFORD MK42 9DJ, ENGLAND; GUYS HOSP, METAB MED UNIT, LONDON SE1 9RT, ENGLAND	Guy's & St Thomas' NHS Foundation Trust	Chaturvedi, N (corresponding author), UCL, DEPT EPIDEMIOL & PUBL HLTH, MORTIMER ST, LONDON WC1E 6BT, ENGLAND.							[Anonymous], 1985, DIABETOLOGIA, V28, P615, DOI [10.1007/BF00290267, DOI 10.1007/BF00290267]; ASHCROFT MT, 1970, B WORLD HEALTH ORGAN, V42, P205; AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; BANERJI MA, 1991, AM J MED, V91, P51, DOI 10.1016/0002-9343(91)90073-7; BINDMAN AB, 1995, JAMA-J AM MED ASSOC, V274, P305, DOI 10.1001/jama.274.4.305; Blackburn H, 1969, J Electrocardiol, V2, P305; CHATURVEDI N, 1993, HYPERTENSION, V22, P90, DOI 10.1161/01.HYP.22.1.90; Chaturvedi N, 1996, J EPIDEMIOL COMMUN H, V50, P137, DOI 10.1136/jech.50.2.137; CHATURVEDI N, 1994, DIABETOLOGIA, V37, P765, DOI 10.1007/s001250050177; CHATURVEDI N, 1994, J EPIDEMIOL COMMUN H, V48, P107, DOI 10.1136/jech.48.2.107; Collett D, 1994, MODELLING SURVIVAL D, P149; Collett D, 1994, MODELLING SURVIVAL D, P53; COWIE CC, 1994, DIABETES CARE, V17, P681, DOI 10.2337/diacare.17.7.681; COWIE CC, 1994, CIRCULATION, V90, P1185, DOI 10.1161/01.CIR.90.3.1185; CRUICKSHANK JK, 1987, DIABETES CARE, V10, P170, DOI 10.2337/diacare.10.2.170; Destefano Frank, 1993, Ethnicity and Disease, V3, P145; *EP RES, 1991, EGRET EP GRAPH EST T; FALASE AO, 1973, TROP GEOGR MED, V25, P147; FULLER JH, 1983, DIABETOLOGIA, V24, P336; GAYLIN DS, 1993, JAMA-J AM MED ASSOC, V269, P603, DOI 10.1001/jama.269.5.603; HARRIS EL, 1993, DIABETES CARE, V16, P748, DOI 10.2337/diacare.16.5.748; HARRIS MI, 1990, DIABETES METAB REV, V6, P71, DOI 10.1002/dmr.5610060202; KANNEL WB, 1979, JAMA-J AM MED ASSOC, V241, P2035, DOI 10.1001/jama.241.19.2035; KJELLSTRAND CM, 1988, ARCH INTERN MED, V148, P1305; KLEINMAN JC, 1988, AM J EPIDEMIOL, V128, P389, DOI 10.1093/oxfordjournals.aje.a114979; LARSSON B, 1984, BRIT MED J, V288, P1401, DOI 10.1136/bmj.288.6428.1401; MEYER LC, 1994, DIABETIC MED, V11, P670; MIALL WE, 1972, B WORLD HEALTH ORGAN, V46, P429; MORRISH NJ, 1990, DIABETOLOGIA, V33, P538, DOI 10.1007/BF00404141; MORRISH NJ, 1991, DIABETOLOGIA, V34, P584, DOI 10.1007/BF00400278; MOST RS, 1983, DIABETES CARE, V6, P87, DOI 10.2337/diacare.6.1.87; *OFF POP CENS SURV, 1990, MORT GEOGR REV MI DS, V9; PACY PJ, 1987, DIABETES RES CLIN EX, V4, P187; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; *SAS I, 1988, SAS US GUID; SELBY JV, 1995, DIABETES CARE, V18, P509, DOI 10.2337/diacare.18.4.509; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; Summerson J H, 1996, Ethn Health, V1, P9; TYROLER HA, 1984, AM HEART J, V108, P738, DOI 10.1016/0002-8703(84)90667-7; WHITE IR, 1994, STAT MED, V13, P1635, DOI 10.1002/sim.4780131604; YOUNG EW, 1994, KIDNEY INT, V45, P907, DOI 10.1038/ki.1994.120	41	67	67	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 5	1996	313	7061					848	852						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL559	8870570				2022-12-24	WOS:A1996VL55900020
J	MacDonald, TM; McMahan, AD; Reid, IC; Fenton, GW; McDevitt, DG				MacDonald, TM; McMahan, AD; Reid, IC; Fenton, GW; McDevitt, DG			Antidepressant drug use in primary care: A record linkage study in Tayside, Scotland	BRITISH MEDICAL JOURNAL			English	Article									UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT PSYCHIAT,DUNDEE DD1 9SY,SCOTLAND	University of Dundee	MacDonald, TM (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT CLIN PHARMACOL,MED MONITORING UNIT,DUNDEE DD1 9SY,SCOTLAND.		Reid, Ian C/B-8326-2008; McMahon, Alex D/C-4304-2008	MacDonald, Thomas/0000-0001-5189-6669				BEARDON PHG, 1993, BRIT MED J, V307, P846, DOI 10.1136/bmj.307.6908.846; *CLIN RES AUD GROU, 1993, DEPR ILLN CRIT REV C; Donoghue J. M., 1996, British Journal of Psychiatry, V168, P164, DOI 10.1192/bjp.168.2.164; Evans J. M. M., 1995, Pharmaceutical Medicine (London), V9, P177; PAYKEL ES, 1992, BRIT MED J, V305, P1198, DOI 10.1136/bmj.305.6863.1198	5	68	68	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 5	1996	313	7061					860	861						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL559	8870575				2022-12-24	WOS:A1996VL55900026
J	Fainzilber, M; Smit, AB; Syed, NI; Wildering, WC; Hermann, PM; vanderSchors, RC; Jimenez, C; Li, KW; vanMinnen, J; Bulloch, AGM; Ibanez, CF; Geraerts, WPM				Fainzilber, M; Smit, AB; Syed, NI; Wildering, WC; Hermann, PM; vanderSchors, RC; Jimenez, C; Li, KW; vanMinnen, J; Bulloch, AGM; Ibanez, CF; Geraerts, WPM			CRNF, a molluscan neurotrophic factor that interacts with the p75 neurotrophin receptor	SCIENCE			English	Article							NERVE GROWTH-FACTOR; LYMNAEA-STAGNALIS; NEURONS; EVOLUTIONARY; EXPRESSION; FAMILY; SNAIL; NGF	A 13.1-kilodalton protein, cysteine-rich neurotrophic factor (CRNF), was purified from the mollusk Lymnaea stagnalis by use of a binding assay on the p75 neurotrophin receptor. CRNF bound to p75 with nanomolar affinity but was not similar in sequence to neurotrophins or any other known gene product. CRNF messenger RNA expression was highest in adult foot subepithelial cells; in the central nervous system, expression was regulated by lesion. The factor evoked neurite outgrowth and modulated calcium currents in pedal motor neurons. Thus, CRNF may be involved in target-derived trophic support for motor neurons and could represent the prototype of another family of p75 ligands.	VRIJE UNIV AMSTERDAM,INST NEUROSCI,GRAD SCH NEUROSCI,NL-1081 HV AMSTERDAM,NETHERLANDS; UNIV CALGARY,NEUROSCI RES GRP,CALGARY,AB T2N 4N1,CANADA	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); Vrije Universiteit Amsterdam; University of Calgary	Fainzilber, M (corresponding author), KAROLINSKA INST,MOL NEUROBIOL LAB,DEPT NEUROSCI,BERZELIUS LABS BLDG,DOKTORSRINGEN 12A,S-17177 STOCKHOLM,SWEDEN.		Smit, August B/E-8410-2011	Fainzilber, Mike/0000-0001-8173-8557				BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BARBACID M, 1994, J NEUROBIOL, V25, P1373; BARDE YA, 1994, J NEUROBIOL, V25, P1329, DOI 10.1002/neu.480251102; Bothwell M, 1996, SCIENCE, V272, P506, DOI 10.1126/science.272.5261.506; BULLOCH AGM, UNPUB; COHENCORY S, 1995, NATURE, V378, P192, DOI 10.1038/378192a0; Fisher Robert J., 1994, Current Opinion in Biotechnology, V5, P389, DOI 10.1016/0958-1669(94)90047-7; GOODMAN CS, 1994, CELL, V78, P353, DOI 10.1016/0092-8674(94)90413-8; Goodman CS, 1996, ANNU REV NEUROSCI, V19, P341, DOI 10.1146/annurev.ne.19.030196.002013; GOTZ R, 1992, J NEUROCHEM, V59, P432, DOI 10.1111/j.1471-4159.1992.tb09389.x; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; IBANEZ CF, 1995, LIFE DEATH NERVOUS S; JACKSON AR, 1995, CELL TISSUE RES, V281, P507, DOI 10.1007/s004410050446; JIMENEZ CR, 1994, J NEUROCHEM, V62, P404; Kang HJ, 1996, SCIENCE, V273, P1402, DOI 10.1126/science.273.5280.1402; KORSCHING S, 1993, J NEUROSCI, V13, P2739; MAROIS R, 1990, J NEUROBIOL, V21, P1053, DOI 10.1002/neu.480210710; RIDGWAY RL, 1991, J NEUROBIOL, V22, P377, DOI 10.1002/neu.480220406; RYDEN M, 1995, EMBO J, V14, P1979, DOI 10.1002/j.1460-2075.1995.tb07190.x; SYED NI, 1989, COMP BIOCHEM PHYS A, V93, P633, DOI 10.1016/0300-9629(89)90024-8; SYED NI, 1992, NEURON, V8, P767, DOI 10.1016/0896-6273(92)90097-W; SYED NI, 1990, SCIENCE, V250, P282, DOI 10.1126/science.2218532; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; TRUPP M, 1995, J CELL BIOL, V130, P137, DOI 10.1083/jcb.130.1.137; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; Wildering WC, 1995, J NEUROPHYSIOL, V74, P2778, DOI 10.1152/jn.1995.74.6.2778	26	71	72	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1996	274	5292					1540	1543		10.1126/science.274.5292.1540	http://dx.doi.org/10.1126/science.274.5292.1540			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929417				2022-12-24	WOS:A1996VV77500052
J	Liu, ZG; Baskaran, R; LeaChou, ET; Wood, LD; Chen, Y; Karin, M; Wang, JYJ				Liu, ZG; Baskaran, R; LeaChou, ET; Wood, LD; Chen, Y; Karin, M; Wang, JYJ			Three distinct signalling responses by murine fibroblasts to genotoxic stress	NATURE			English	Article							ABL TYROSINE KINASE; ACTIVATED PROTEIN-KINASES; C-ABL; CELL-CYCLE; TRANSCRIPTIONAL ACTIVATION; P53-DEPENDENT APOPTOSIS; PHOSPHORYLATION; DOMAIN; TRANSDUCTION; AGENTS	GENOTOXIC stress triggers signalling pathways that mediate either the protection or killing of affected cells, Whereas induction of p53 involves events in the cell nucleus(1), the activation of transcription factors AP-1 and NF-kappa B by ultraviolet radiation is mediated through membrane-associated signalling proteins, ruling out a nuclear signal(2-6), An early event in AP-1 induction by ultraviolet radiation is activation of Jun kinases (JNKs)(3,7), which mediate the induction of the immediate-early genes c-jun and c-fos(7-13). The JNKs have also been proposed to mediate the apoptopic response to genotoxins(14). The non-receptor tyrosine kinase c-Abl is also activated by genotoxic stress(15,16), To understand the relationship between these events, we compared the activation of p53, JNK and c-Abl by several DNA-damaging agents in murine fibroblasts. We found that whereas p53 was induced by every genotoxic stimulus tested, c-Abl was activated by most stimuli except ultraviolet irradiation and JNK was strongly stimulated only by ultraviolet light and the alkylating agent methyl methanesulphonate. Activation of JNK by this alkylating agent was normal in c-Abl-null cells but was reduced in c-Src-null cells, Unlike p53 induction, c-Abl activation occurs in the S phase of the cell cycle and does not affect cell proliferation, These findings show that signals generated by genotoxins are transduced by multiple, independent pathways. Only p53 appears to be a universal sensor of genotoxic stress.	UNIV CALIF SAN DIEGO,SCH MED,DEPT PHARMACOL,PROGRAM BIOMED SCI,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR GENET MOL,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego			Wood, Laura/ABF-1531-2020		NATIONAL CANCER INSTITUTE [R01CA043054] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA043054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baskaran R, 1996, MOL CELL BIOL, V16, P3361; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KHARBANDA S, 1995, J BIOL CHEM, V270, P30178; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; Renshaw MW, 1996, CURR BIOL, V6, P76, DOI 10.1016/S0960-9822(02)00424-4; ROSETTE CL, IN PRESS SCIENCE; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	30	340	344	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 21	1996	384	6606					273	276		10.1038/384273a0	http://dx.doi.org/10.1038/384273a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU381	8918879				2022-12-24	WOS:A1996VU38100054
J	Zheng, B; Han, SH; Zhu, Q; Goldsby, R; Kelsoe, G				Zheng, B; Han, SH; Zhu, Q; Goldsby, R; Kelsoe, G			Alternative pathways for the selection of antigen-specific peripheral T cells	NATURE			English	Article							GERMINAL-CENTERS; IN-VIVO; B-CELLS; RECEPTOR; DEATH; APOPTOSIS; ANTIBODIES; IMMUNITY; INVIVO; NUR77	IN the thymus, maturing lymphocytes receive activation signals mediated by the T-cell antigen receptor (TCR) that either promote clonal survival (positive selection) or induce apoptosis (negative selection), This balance between life and death is mirrored by the sensitivity of cortical thymocytes to apoptotic death induced by antibodies against the CD3 component of the TCR signal-transduction complex, bacterial superantigens that bind to the TCR beta-chain, and corticosteroids(1-3). In contrast, mature peripheral T cells are positively activated by anti-CD3 antibody or superantigens and are resistant to steroid-induced death(4,5). Here we show that in splenic germinal centres, T cells regain thymocyte-like sensitivity to TCR- and steroid-induced apoptosis and undergo antigen-driven positive and negative selection, T-cell responses elsewhere in the spleen are unaccompanied by programmed cell death, Our observations define a new differentiation pathway for peripheral T cells and suggest that germinal centres induce a lymphocyte phenotype necessary for the maintenance of self-tolerance.	UNIV MARYLAND, SCH MED, DEPT MICROBIOL & IMMUNOL, BALTIMORE, MD 21201 USA; AMHERST COLL, DEPT BIOL, AMHERST, MA 01002 USA	University System of Maryland; University of Maryland Baltimore; Amherst College			Goldsby, Robert/O-8363-2019					COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; FINK PJ, 1986, NATURE, V321, P219, DOI 10.1038/321219a0; FULLER KA, 1993, J IMMUNOL, V151, P4505; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GUBRANSONJUDGE A, 1996, EUR J IMMUNOL, V26, P1830; HEDRICK SM, 1988, ADV IMMUNOL, V43, P193; HEDRICK SM, 1988, SCIENCE, V239, P1541, DOI 10.1126/science.2832942; JACOB J, 1993, J EXP MED, V178, P1293, DOI 10.1084/jem.178.4.1293; JAMESON SC, 1991, J IMMUNOL, V147, P3185; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; Kelsoe G, 1996, IMMUNITY, V4, P107, DOI 10.1016/S1074-7613(00)80675-5; KELSOE G, 1993, CURR OPIN IMMUNOL, V5, P418, DOI 10.1016/0952-7915(93)90062-W; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; MCHEYZERWILLIAMS MG, 1993, J EXP MED, V178, P295, DOI 10.1084/jem.178.1.295; MCHEYZERWILLIAMS MG, 1995, SCIENCE, V268, P106, DOI 10.1126/science.7535476; MERCEP M, 1989, SCIENCE, V246, P1162, DOI 10.1126/science.2531464; PUTLEN AM, 1988, NATURE, V335, P796; ROCK EP, 1994, J EXP MED, V179, P323, DOI 10.1084/jem.179.1.323; ROTHENBERG EV, 1992, ADV IMMUNOL, V51, P85, DOI 10.1016/S0065-2776(08)60487-3; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SURTH CD, 1994, NATURE, V372, P100; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; WINOTO A, 1986, NATURE, V324, P679, DOI 10.1038/324679a0; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; WYLIE AH, 1989, NATURE, V284, P555; Zheng B, 1996, J EXP MED, V184, P1083, DOI 10.1084/jem.184.3.1083; ZHENG B, 1994, NATURE, V372, P556, DOI 10.1038/372556a0	29	77	84	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 21	1996	384	6606					263	266		10.1038/384263a0	http://dx.doi.org/10.1038/384263a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU381	8918876				2022-12-24	WOS:A1996VU38100051
J	Cornuz, J; Pearson, SD; Creager, MA; Cook, EF; Goldman, L				Cornuz, J; Pearson, SD; Creager, MA; Cook, EF; Goldman, L			Importance of findings on the initial evaluation for cancer in patients with symptomatic idiopathic deep venous thrombosis	ANNALS OF INTERNAL MEDICINE			English	Article						thrombophlebitis; ultrasonography, Doppler duplex; comorbidity; neoplasms; physical examination	VEIN THROMBOSIS; OCCULT CANCER; DIAGNOSIS	Background: The relation between thrombosis and cancer is well documented, but the clinical evaluation appropriate for detecting underlying cancer in patients with deep venous thrombosis remains unknown. Objectives: To 1) determine the appropriate initial evaluation for cancer in patients with idiopathic deep venous thrombosis and 2) estimate the incidence of subsequently diagnosed cancer in patients who were not found to have cancer when deep venous thrombosis was diagnosed. Design: Retrospective cohort study. Setting: Urban, tertiary care teaching hospital. Patients: 986 consecutive patients (637 women and 349 men; mean age +/- SD, 53 +/- 17 years) who had no risk factors for venous disease and had venous ultrasonography because idiopathic deep venous thrombosis was suspected. Measurements: Initial clinical evaluation was assessed by using chart review. The incidence of cancer at a median of 34 months after diagnosis of deep venous thrombosis was obtained through hospital chart review (38%), computerized record extraction (54%), mailed questionnaires (6%), telephone interviews (1%), or a death registry (1%). Results: Deep venous thrombosis was diagnosed in 142 patients (14%); 136 of the 142 were hospitalized. Cancer was diagnosed in 16 of these 136 patients (12%) during the index hospitalization. All 16 of these patients had one or more abnormalities on at least one of the four components of the clinical examination: history, physical examination, basic laboratory testing, or chest radiography. The probability of detecting cancer increased as the number of findings suggestive of cancer on the four components of the clinical evaluation increased. Cancer was diagnosed in none of the 56 patients with deep venous thrombosis who did not have findings on the clinical evaluation. The probability of cancer-free survival during follow-up (median, 34 months) was similar in patients with (3 of 122 [2.5%]) and without (23 of 844 [2.7%]) deep venous thrombosis and in the age- and sex-matched U.S. population. Conclusions: A clinical evaluation that includes a comprehensive medical history, physical examination, routine laboratory testing, and chest radiography seems to be appropriate for detecting cancer in these patients. Additional testing should be guided by any abnormalities detected by this clinical evaluation.	HARVARD COMMUNITY HLTH PLAN, DEPT AMBULATORY CARE & PREVENT, BOSTON, MA 02215 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DIV GEN MED, CLIN EPIDEMIOL SECT, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DIV CARDIOVASC, VASC DIAGNOST LAB, BOSTON, MA 02115 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of California System; University of California San Francisco	Cornuz, J (corresponding author), UNIV LAUSANNE HOSP, DEPT INTERNAL MED, BUGNON AVE, CH-1011 LAUSANNE, SWITZERLAND.				NHLBI NIH HHS [HL02663] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADERKA D, 1986, CANCER, V57, P1846, DOI 10.1002/1097-0142(19860501)57:9<1846::AID-CNCR2820570925>3.0.CO;2-3; ANLYAN WG, 1956, JAMA-J AM MED ASSOC, V161, P964, DOI 10.1001/jama.1956.62970100002009a; Bounameaux H, 1988, Vasa Suppl, V25, P1; CORNUZ J, 1995, RADIOLOGY, V197, P434; *EARL DET BRANC, 1987, WORK GUID EARL CANC; Feinstein AR, 1985, CLIN EPIDEMIOLOGY AR, P39; GOLDBERG RJ, 1987, ARCH INTERN MED, V147, P251, DOI 10.1001/archinte.147.2.251; GRIFFIN MR, 1987, ARCH INTERN MED, V147, P1907, DOI 10.1001/archinte.147.11.1907; HIRSCH DR, 1993, PREVENTION VENOUS TH, P485; LEVINE M, 1990, SEMIN ONCOL, V17, P160; Miller A B, 1993, J Public Health Policy, V14, P403, DOI 10.2307/3342875; MILLER AB, 1993, CANCER PRINCIPLES PR, P564; MONREAL M, 1991, CANCER, V67, P541, DOI 10.1002/1097-0142(19910115)67:2<541::AID-CNCR2820670237>3.0.CO;2-J; NORDSTROM M, 1994, BRIT MED J, V308, P891, DOI 10.1136/bmj.308.6933.891; OCONNOR NTJ, 1984, POSTGRAD MED J, V60, P275, DOI 10.1136/pgmj.60.702.275; POLAK JF, 1991, CHEST, V99, pS165, DOI 10.1378/chest.99.4.165S; PRANDONI P, 1992, NEW ENGL J MED, V327, P1128, DOI 10.1056/NEJM199210153271604; PRINS MH, 1994, ARCH INTERN MED, V154, P1310, DOI 10.1001/archinte.154.12.1310; RICKLES FR, 1983, BLOOD, V62, P14; RIES LAG, 1994, NIH PUB; ROSE SC, 1990, RADIOLOGY, V175, P639, DOI 10.1148/radiology.175.3.2188293; ROSNER B, 1990, FUNDAMENTALS BIOSTAT, P458; SILVERSTEIN RL, 1992, NEW ENGL J MED, V327, P1163, DOI 10.1056/NEJM199210153271611; SIMONS GR, 1995, AM J MED, V99, P43, DOI 10.1016/S0002-9343(99)80103-X; SOX HC, 1994, NEW ENGL J MED, V330, P1589, DOI 10.1056/NEJM199406023302208; YUCEL EK, 1991, RADIOLOGY, V179, P443, DOI 10.1148/radiology.179.2.2014289	26	113	123	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1996	125	10					785	+		10.7326/0003-4819-125-10-199611150-00001	http://dx.doi.org/10.7326/0003-4819-125-10-199611150-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU524	8928984				2022-12-24	WOS:A1996VU52400004
J	Freeman, M				Freeman, M			Reiterative use of the EGF receptor triggers differentiation of all cell types in the Drosophila eye	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; PROTEIN TYROSINE KINASE; DORSAL-VENTRAL AXIS; FAINT-LITTLE-BALL; SIGNAL TRANSDUCTION; MAP KINASE; PC12 CELLS; PHOTORECEPTOR CELLS; IMAGINAL DISKS; FATE DECISIONS	The Drosophila eye has contributed much to our knowledge of cell differentiation. This understanding has primarily come from the study of the R7 photoreceptor; much less is known about the development of the other classes of photoreceptor or the nonneuronal cone or pigment cells. I have used a dominant-negative form of the Drosophila epidermal growth factor receptor (DER) to show that this receptor tyrosine kinase (RTK) is required for the differentiation of all these cell types, and I have also shown that DER is sufficient to trigger their development. DER is even required in R7, where it can replace Sevenless, another RTK. These results broaden our view of eye development to include the whole ommatidium and suggest that reiterative activation of DER is critical for triggering the differentiation of all cell types.			Freeman, M (corresponding author), MRC,MOL BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.			Freeman, Matthew/0000-0003-0410-5451				AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BAKER NE, 1992, DEV BIOL, V150, P381, DOI 10.1016/0012-1606(92)90250-K; BAKER NE, 1989, NATURE, V340, P150, DOI 10.1038/340150a0; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BAUMANN P, 1993, DEVELOPMENT, V119, P65; BOWTELL DDL, 1989, P NATL ACAD SCI USA, V86, P6245, DOI 10.1073/pnas.86.16.6245; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CAGAN RL, 1989, DEV BIOL, V136, P346, DOI 10.1016/0012-1606(89)90261-3; CLIFFORD RJ, 1989, GENETICS, V123, P771; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P569; DICKSON B, 1992, GENE DEV, V6, P2327, DOI 10.1101/gad.6.12a.2327; ELLIS MC, 1993, DEVELOPMENT, V119, P855; FISCHER JA, 1988, NATURE, V332, P853, DOI 10.1038/332853a0; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; FREEMAN M, 1994, DEVELOPMENT, V120, P2297; FREEMAN M, 1992, DEVELOPMENT, V116, P335; FREEMAN M, 1994, MECH DEVELOP, V48, P25, DOI 10.1016/0925-4773(94)90003-5; FREEMAN M, 1992, CELL, V69, P963, DOI 10.1016/0092-8674(92)90615-J; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; Golembo M, 1996, DEVELOPMENT, V122, P223; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HAY BA, 1994, DEVELOPMENT, V120, P2121; HEBERLEIN U, 1993, DEV BIOL, V160, P51, DOI 10.1006/dbio.1993.1285; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; JARMAN AP, 1994, NATURE, V369, P398, DOI 10.1038/369398a0; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KOLODKIN AL, 1994, DEVELOPMENT, V120, P1731; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; LAWRENCE PA, 1979, DEV BIOL, V71, P142, DOI 10.1016/0012-1606(79)90088-5; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; RAZ E, 1993, GENE DEV, V7, P1937, DOI 10.1101/gad.7.10.1937; RAZ E, 1992, DEVELOPMENT, V114, P113; REICHMANFRIED M, 1994, GENE DEV, V8, P428, DOI 10.1101/gad.8.4.428; ROGGE R, 1992, P NATL ACAD SCI USA, V89, P5271, DOI 10.1073/pnas.89.12.5271; RUOHOLABAKER H, 1993, CELL, V73, P953, DOI 10.1016/0092-8674(93)90273-S; RUTLEDGE BJ, 1992, GENE DEV, V6, P1503, DOI 10.1101/gad.6.8.1503; SAWAMOTO K, 1994, DEV BIOL, V164, P267, DOI 10.1006/dbio.1994.1197; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHWEITZER R, 1995, NATURE, V376, P699, DOI 10.1038/376699a0; SCHWEITZER R, 1995, GENE DEV, V9, P1518, DOI 10.1101/gad.9.12.1518; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SIMPSON P, 1990, DEVELOPMENT, V109, P509; SPRENGER F, 1992, CELL, V71, P987, DOI 10.1016/0092-8674(92)90394-R; STURTEVANT MA, 1994, DEVELOPMENT, V120, P2593; STURTEVANT MA, 1993, GENE DEV, V7, P961, DOI 10.1101/gad.7.6.961; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; TIO M, 1994, MECH DEVELOP, V48, P13, DOI 10.1016/0925-4773(94)90002-7; TOMLINSON A, 1988, DEVELOPMENT, V104, P183; TOMLINSON A, 1986, SCIENCE, V231, P400, DOI 10.1126/science.231.4736.400; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; UENO H, 1992, J BIOL CHEM, V267, P1470; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VANVACTOR DL, 1991, CELL, V67, P1145, DOI 10.1016/0092-8674(91)90291-6; VASSIN H, 1987, EMBO J, V6, P3433; WASSARMAN DA, 1995, CURR OPIN GENET DEV, V5, P44, DOI 10.1016/S0959-437X(95)90052-7; WOLFF T, 1991, DEVELOPMENT, V113, P825; XU T, 1993, DEVELOPMENT, V117, P1223; ZAK NB, 1992, DEV BIOL, V149, P448, DOI 10.1016/0012-1606(92)90299-V; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	68	678	684	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1996	87	4					651	660		10.1016/S0092-8674(00)81385-9	http://dx.doi.org/10.1016/S0092-8674(00)81385-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VU035	8929534	Bronze			2022-12-24	WOS:A1996VU03500008
J	Devchand, PR; Keller, H; Peters, JM; Vazquez, M; Gonzalez, FJ; Wahli, W				Devchand, PR; Keller, H; Peters, JM; Vazquez, M; Gonzalez, FJ; Wahli, W			The PPAR alpha-leukotriene B-4 pathway to inflammation control	NATURE			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; RETINOID-X RECEPTOR; PEROXISOME PROLIFERATOR; FATTY-ACIDS; CDNA CLONING; HETERODIMER FORMATION; TARGETED DISRUPTION; BETA-OXIDATION; EXPRESSION; GAMMA	Inflammation is a local immune response to 'foreign' molecules, infection and injury. Leukotriene B-4, a potent chemotactic agent that initiates, coordinates, sustains and amplifies the inflammatory response, is shown to be an activating ligand for the transcription factor PPAR alpha. Because PPAR alpha regulates the oxidative degradation of fatty acids and their derivatives, like this lipid mediator, a feedback mechanism is proposed that controls the duration of an inflammatory response and the clearance of leukotriene B-4 in the liver. Thus PPAR alpha offers a new route to the development of anti- or pro-inflammatory reagents.	UNIV LAUSANNE, INST BIOL ANIM, CH-1015 LAUSANNE, SWITZERLAND; NCI, MOL CARCINOGENESIS LAB, NIH, BETHESDA, MD 20892 USA	University of Lausanne; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Vázquez-Carrera, Manuel/H-2612-2015; Wahli, Walter/B-1398-2009; Peters, Jeffrey/D-8847-2011; Wahli, Walter/I-3194-2019	Vázquez-Carrera, Manuel/0000-0001-7138-8207; Wahli, Walter/0000-0002-5966-9089; Peters, Jeffrey/0000-0003-2782-2998				AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; APERLO C, 1995, GENE, V162, P297, DOI 10.1016/0378-1119(95)00196-D; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; CARLSON RP, 1985, AGENTS ACTIONS, V17, P197, DOI 10.1007/BF01966592; CHEN F, 1993, BIOCHEM BIOPH RES CO, V196, P671, DOI 10.1006/bbrc.1993.2302; CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; COUVE AO, 1992, EXP CELL RES, V202, P541, DOI 10.1016/0014-4827(92)90109-L; DESVERGNE B, 1995, INDUCIBLE GENE EXPRE, V1, P142; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; FORDHUTCHINSON AW, 1990, CRIT REV IMMUNOL, V10, P1; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GAD SC, 1986, TOXICOL APPL PHARM, V84, P93, DOI 10.1016/0041-008X(86)90419-9; GOTTLICHER M, 1993, BIOCHEM PHARMACOL, V46, P2177, DOI 10.1016/0006-2952(93)90607-X; Greene M. E., 1995, Gene Expression, V4, P281; HARPER TW, 1986, J BIOL CHEM, V261, P5414; Hertz R, 1996, EUR J BIOCHEM, V235, P242, DOI 10.1111/j.1432-1033.1996.00242.x; HUSSAIN H, 1994, AM J PHYSIOL, V266, pC243, DOI 10.1152/ajpcell.1994.266.1.C243; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JEDLITSCHKY G, 1991, J BIOL CHEM, V266, P24763; JEDLITSCHKY G, 1993, ADV ENZYME REGUL, V33, P181; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KIKUTA Y, 1993, J BIOL CHEM, V268, P9376; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KREY G, 1993, J STEROID BIOCHEM, V47, P65, DOI 10.1016/0960-0760(93)90058-5; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lemberger T, 1996, J BIOL CHEM, V271, P1764, DOI 10.1074/jbc.271.3.1764; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; MILLER AM, 1993, PROSTAG LEUKOTR ESS, V49, P561, DOI 10.1016/0952-3278(93)90161-O; OPAS EE, 1985, J INVEST DERMATOL, V84, P253, DOI 10.1111/1523-1747.ep12265320; Peters JM, 1996, MOL PHARMACOL, V50, P67; ROLAPLESZCZYNSKI M, 1991, ADV EXP MED BIOL, V314, P205; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; SERHAN CN, 1982, J BIOL CHEM, V257, P4746; SHER T, 1993, BIOCHEMISTRY-US, V32, P5598, DOI 10.1021/bi00072a015; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; TAYLOR BM, 1985, BIOCHEM PHARMACOL, V34, P3495, DOI 10.1016/0006-2952(85)90723-3; VONSCHACKY C, 1993, BIOCHIM BIOPHYS ACTA, V1166, P20, DOI 10.1016/0005-2760(93)90278-H; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	43	1106	1130	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 7	1996	384	6604					39	43		10.1038/384039a0	http://dx.doi.org/10.1038/384039a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR219	8900274				2022-12-24	WOS:A1996VR21900046
J	Matthes, HWD; Maldonado, R; Simonin, F; Valverde, O; Slowe, S; Kitchen, I; Befort, K; Dierich, A; LeMeur, M; Dolle, P; Tzavara, E; Hanoune, J; Roques, BP; Kieffer, BL				Matthes, HWD; Maldonado, R; Simonin, F; Valverde, O; Slowe, S; Kitchen, I; Befort, K; Dierich, A; LeMeur, M; Dolle, P; Tzavara, E; Hanoune, J; Roques, BP; Kieffer, BL			Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene	NATURE			English	Article							PEPTIDES; PHARMACOLOGY; MECHANISMS; ACTIVATION; DEPENDENCE; OPIATES; ABUSE; DRUGS; RATS	DESPITE tremendous efforts in the search for safe, efficacious and non-addictive opioids for pain treatment, morphine remains the most valuable painkiller in contemporary medicine. Opioids exert their pharmacological actions through three opioid-receptor classes(1,2), mu, delta and kappa, whose genes have been cloned(3). Genetic approaches are now available to delineate the contribution of each receptor in opioid function in vivo. Here we disrupt the mu-opioid-receptor gene in mice by homologous recombination and find that there are no overt behavioural abnormalities or major compensatory changes within the opioid system in these animals. Investigation of the behavioural effects of morphine reveals that a lack of mu receptors abolishes the analgesic effect of morphine, as well as place-preference activity and physical dependence. We observed no behavioural responses related to delta- or kappa-receptor activation with morphine, although these receptors are present and bind opioid ligands. We conclude that the mu-opioid-receptor gene product is the molecular target of morphine in vivo and that it is a mandatory component of the opioid system for morphine action.	UNIV STRASBOURG 1,ESBS,CNRS,UPR 9050,F-67400 ILLKIRCH GRAFFENS,FRANCE; UNIV PARIS 05,CNRS,URA D1500,INSERM,U266,DEPT PHARMACOCHIM MOL & STRUCT,F-75270 PARIS,FRANCE; UNIV SURREY,SCH BIOL SCI,RECEPTORS & CELLULAR REGULAT RES GRP,GUILDFORD GU2 5XH,SURREY,ENGLAND; INST GENET & BIOL MOL & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE; HOP HENRI MONDOR,INSERM,U99,UNITE RECH,F-94010 CRETEIL,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Surrey; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)			Valverde, Olga/D-8654-2012; Maldonado, Rafael/F-5657-2014; Dolle, Pascal/A-8037-2010	Valverde, Olga/0000-0003-2264-7852; Maldonado, Rafael/0000-0002-4359-8773; Dolle, Pascal/0000-0002-9294-9090				BAAMONDE A, 1991, J PHARMACOL EXP THER, V257, P767; BROWNSTEIN MJ, 1993, P NATL ACAD SCI USA, V90, P5391, DOI 10.1073/pnas.90.12.5391; COWAN A, 1988, J PHARMACOL EXP THER, V246, P950; COWAN A, 1993, HDB EXPT PHARM, V104, P393; DECIMO D, 1995, GENE PROBES PRACTICA, V2, P183; DICHIARA G, 1992, TRENDS PHARMACOL SCI, V13, P185; DICKENSON AH, 1991, BRIT MED BULL, V47, P690, DOI 10.1093/oxfordjournals.bmb.a072501; GACEL G, 1988, J MED CHEM, V31, P374, DOI 10.1021/jm00397a019; GOLDSTEIN A, 1989, MOL PHARMACOL, V36, P265; HANOUNE J, 1977, J BIOL CHEM, V252, P2039; ILIEN B, 1988, BIOCHEM PHARMACOL, V37, P3843, DOI 10.1016/0006-2952(88)90065-2; KATZ RJ, 1979, PHARMACOL BIOCHEM BE, V11, P231, DOI 10.1016/0091-3057(79)90019-4; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; KITCHEN I, 1995, J PHARMACOL EXP THER, V275, P1595; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; Maldonado R, 1996, SCIENCE, V273, P657, DOI 10.1126/science.273.5275.657; MALDONADO R, 1992, NEUROPHARMACOLOGY, V31, P1231, DOI 10.1016/0028-3908(92)90051-P; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; PASTERNAK GW, 1993, CLIN NEUROPHARMACOL, V16, P1, DOI 10.1097/00002826-199302000-00001; ROQUES BP, 1993, PHARMACOL REV, V45, P87; ROSSIER J, 1982, NATURE, V298, P221, DOI 10.1038/298221a0; SCHMIDT C, 1991, EUR J PHARMACOL, V192, P253, DOI 10.1016/0014-2999(91)90050-Z; SHIPPENBERG TS, 1987, BRAIN RES, V436, P234, DOI 10.1016/0006-8993(87)91667-2; TERWILLIGER RZ, 1991, BRAIN RES, V548, P100, DOI 10.1016/0006-8993(91)91111-D; TRAYNOR JR, 1993, TRENDS PHARMACOL SCI, V14, P84, DOI 10.1016/0165-6147(93)90068-U; Valverde O, 1996, PSYCHOPHARMACOLOGY, V123, P119, DOI 10.1007/BF02246168; WEI ET, 1981, J PHARMACOL EXP THER, V216, P12	29	1325	1380	3	159	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 31	1996	383	6603					819	823		10.1038/383819a0	http://dx.doi.org/10.1038/383819a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ144	8893006				2022-12-24	WOS:A1996VQ14400062
J	Strang, JIG				Strang, JIG			Tracing patients in rural Africa	LANCET			English	Editorial Material							PREDNISOLONE; TRIAL		CECILIA MAKLWANE HOSP, DEPT MED, MDANTSANE, EASTERN CAPE, SOUTH AFRICA									GELFAND M, 1957, SICK AFRICAN, P494; STRANG JIG, 1988, LANCET, V2, P759; STRANG JIG, 1987, LANCET, V2, P1418	3	2	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 19	1996	348	9034					1083	1084		10.1016/S0140-6736(96)05130-6	http://dx.doi.org/10.1016/S0140-6736(96)05130-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM886	8874464				2022-12-24	WOS:A1996VM88600017
J	Gulbis, JM; Kelman, Z; Hurwitz, J; ODonnell, M; Kuriyan, J				Gulbis, JM; Kelman, Z; Hurwitz, J; ODonnell, M; Kuriyan, J			Structure of the C-terminal region of p21(WAF1/CIP1) complexed with human PCNA	CELL			English	Article							CELL NUCLEAR ANTIGEN; DEPENDENT KINASE INHIBITOR; NUCLEOTIDE EXCISION-REPAIR; DNA-REPLICATION; POTENTIAL MEDIATOR; BINDING DOMAINS; CYCLIN; PROTEIN; CLONING; CDK	The crystal structure of the human DNA polymerase delta processivity factor PCNA (proliferating cell nuclear antigen) complexed with a 22 residue peptide derived from the C-terminus of the cell-cycle checkpoint protein p21(WAF1/CIP1) has been determined at 2.6 Angstrom resolution. p21 binds to PCNA in a 1:1 stoichiometry with an extensive array of interactions that include the formation of a beta sheet with the interdomain connector loop of PCNA. An intact trimeric ring is maintained in the structure of the p21-PCNA complex, with a central hole available for DNA interaction. The ability of p21 to inhibit the action of PCNA is therefore likely to be due to its masking of elements on PCNA that are required for the binding of other components of the polymerase assembly.	ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021; CORNELL UNIV MED COLL,DEPT MICROBIOL,NEW YORK,NY 10021; CORNELL UNIV MED COLL,HOWARD HUGHES MED INST,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,NEW YORK,NY 10021	Howard Hughes Medical Institute; Rockefeller University; Cornell University; Cornell University; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Gulbis, JM (corresponding author), ROCKEFELLER UNIV,LAB MOL BIOPHYS,NEW YORK,NY 10021, USA.			O'Donnell, Michael/0000-0001-9002-4214	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038839, R01GM038839] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 38839, GM 38559, GM 45547] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAUER GA, 1990, NUCLEIC ACIDS RES, V18, P261, DOI 10.1093/nar/18.2.261; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; CHEN IT, 1995, ONCOGENE, V11, P1931; Chen JJ, 1996, NUCLEIC ACIDS RES, V24, P1727, DOI 10.1093/nar/24.9.1727; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FUKUDA K, 1995, J BIOL CHEM, V270, P22527, DOI 10.1074/jbc.270.38.22527; GOUBIN F, 1995, ONCOGENE, V10, P2281; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALL PA, 1995, ONCOGENE, V10, P2427; HARPER JW, 1993, CELL, V75, P805; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KELMAN Z, 1995, NUCLEIC ACIDS RES, V23, P3613, DOI 10.1093/nar/23.18.3613; KELMAN Z, 1996, THESIS CORNELL U MED; KLEWEGT GJ, 1994, P CCP4 STUD WEEK, P59; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MATSUOKA S, 1994, J BIOL CHEM, V269, P11030; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; REDINBO MR, 1993, ACTA CRYSTALLOGR D, V49, P375, DOI 10.1107/S090744499300294X; ROBBINS J, 1991, CELL, V64, P616; ROOS G, 1996, IN PRESS EXP CELL RE; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SU JY, 1995, P NATL ACAD SCI USA, V92, P10187, DOI 10.1073/pnas.92.22.10187; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	47	640	658	1	26	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1996	87	2					297	306		10.1016/S0092-8674(00)81347-1	http://dx.doi.org/10.1016/S0092-8674(00)81347-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VN403	8861913	hybrid			2022-12-24	WOS:A1996VN40300017
J	KeinoMasu, K; Masu, M; Hinck, L; Leonardo, ED; Chan, SSY; Culotti, JG; TessierLavigne, M				KeinoMasu, K; Masu, M; Hinck, L; Leonardo, ED; Chan, SSY; Culotti, JG; TessierLavigne, M			Deleted in Colorectal Cancer (DCC) encodes a netrin receptor	CELL			English	Article							CELL-ADHESION MOLECULE; PIONEER AXON MIGRATIONS; C-ELEGANS; IMMUNOGLOBULIN SUPERFAMILY; COMMISSURAL AXONS; NERVOUS-SYSTEM; SPINAL-CORD; MOUSE-BRAIN; GUIDES CELL; FLOOR PLATE	The guidance of developing axons in the nervous system is mediated partly by diffusible chemoattractants secreted by axonal target cells. Netrins are chemoattractants for commissural axons in the vertebrate spinal cord, but the mechanisms through which they produce their effects are unknown. We show that Deleted in Colorectal Cancer (DCC), a transmembrane protein of the immunoglobulin superfamily, is expressed on spinal commissural axons and possesses netrin-1-binding activity. Moreover, an antibody to DCC selectively blocks the netrin-1-dependent outgrowth of commissural axons in vitro. These results indicate that DCC is a receptor or a component of a receptor that mediates the effects of netrin-1 on commissural axons, and they complement genetic evidence for interactions between DCC and netrin homologs in C. elegans and Drosophila.	NATL DEF MED COLL,DEPT PHYSIOL,TOKOROZAWA,SAITAMA 359,JAPAN; MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO,ON M5G 1X5,CANADA; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT ANAT,PROGRAM NEUROSCI,SAN FRANCISCO,CA 94143	National Defense Medical College - Japan; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Howard Hughes Medical Institute; University of California System; University of California San Francisco	KeinoMasu, K (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT ANAT,PROGRAM CELL & DEV BIOL,SAN FRANCISCO,CA 94143, USA.		Leonardo, Eduardo/AAH-1525-2020; Culotti, Joseph/G-6467-2013	Leonardo, Eduardo/0000-0001-7426-0217; Hinck, Lindsay/0000-0002-4009-3913; Culotti, Joseph/0000-0001-6325-4612				ALTMAN J, 1984, ADV ANAT EMBRYOL CEL, V85, P1; BRUMMENDORF T, 1994, PROTEIN PROFILE CELL, V1, P1001; CHO KR, 1995, CURR OPIN GENET DEV, V5, P72, DOI 10.1016/S0959-437X(95)90056-X; CHUONG CM, 1994, DEV BIOL, V164, P383, DOI 10.1006/dbio.1994.1208; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; Cooper HM, 1995, ONCOGENE, V11, P2243; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; EASTER SS, 1993, J NEUROSCI, V13, P285; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; Goodman CS, 1996, ANNU REV NEUROSCI, V19, P341, DOI 10.1146/annurev.ne.19.030196.002013; GRUMET M, 1993, CELL ADHES COMMUN, V1, P177, DOI 10.3109/15419069309095693; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; Harris R, 1996, NEURON, V17, P217, DOI 10.1016/S0896-6273(00)80154-3; HEDGECOCK EM, 1990, NEURON, V2, P61; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KEYNES R, 1995, CELL, V83, P161, DOI 10.1016/0092-8674(95)90157-4; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; Mitchell KJ, 1996, NEURON, V17, P203, DOI 10.1016/S0896-6273(00)80153-1; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; NORENBERG U, 1992, NEURON, V8, P849, DOI 10.1016/0896-6273(92)90199-N; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; PESHEVA P, 1993, NEURON, V10, P69, DOI 10.1016/0896-6273(93)90243-K; PFAFF M, 1994, EUR J BIOCHEM, V225, P975, DOI 10.1111/j.1432-1033.1994.0975b.x; PIERCEALL WE, 1994, DEV BIOL, V166, P654, DOI 10.1006/dbio.1994.1345; PLACZEK M, 1990, DEVELOPMENT, V110, P19; REALE MA, 1994, CANCER RES, V54, P4493; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SHIMAMURA K, 1994, DEVELOPMENT, V120, P2225; SHIRASAKI R, 1995, NEURON, V14, P961, DOI 10.1016/0896-6273(95)90334-8; SKARNES WC, 1995, P NATL ACAD SCI USA, V92, P6592, DOI 10.1073/pnas.92.14.6592; TAIRA E, 1994, NEURON, V12, P861, DOI 10.1016/0896-6273(94)90338-7; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; VIELMETTER J, 1994, J CELL BIOL, V127, P2009, DOI 10.1083/jcb.127.6.2009; Wadsworth WG, 1996, NEURON, V16, P35, DOI 10.1016/S0896-6273(00)80021-5; ZISCH AH, 1992, J CELL BIOL, V119, P203, DOI 10.1083/jcb.119.1.203	39	828	856	0	41	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1996	87	2					175	185		10.1016/S0092-8674(00)81336-7	http://dx.doi.org/10.1016/S0092-8674(00)81336-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VN403	8861902	Bronze			2022-12-24	WOS:A1996VN40300006
J	Derbyshire, SWG; Furedi, A				Derbyshire, SWG; Furedi, A			For debate - Do fetuses feel pain? ''Fetal pain'' is a misnomer	BRITISH MEDICAL JOURNAL			English	Article									UNIV MANCHESTER,HOPE HOSP,CTR RHEUMAT DIS,SALFORD M6 8HD,LANCS,ENGLAND; BIRTH CONTROL TRUST,LONDON W1N 7RD,ENGLAND	University of Manchester				Derbyshire, Stuart/0000-0002-2766-3424				FITZGERALD M, 1994, TXB PAIN, P153; Fitzgerald M., 1995, FOETAL PAIN UPDATE C; GIANNAKOULOPOULOS X, 1994, LANCET, V344, P77, DOI 10.1016/S0140-6736(94)91279-3; LEVENTHAL H, 1984, ADV EXP SOC PSYCHOL, V17, P117, DOI 10.1016/S0065-2601(08)60119-7; MRZLJAK L, 1988, J COMP NEUROL, V271, P355, DOI 10.1002/cne.902710306; *OFF NAT STAT HMSO, 1995, ABORT STAT, P19	6	34	35	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1996	313	7060					795	795						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK566	8842074				2022-12-24	WOS:A1996VK56600027
J	Szawarski, Z				Szawarski, Z			For debate - Do fetuses feel pain? Probably no pain in the absence of ''self''	BRITISH MEDICAL JOURNAL			English	Article											Szawarski, Z (corresponding author), UNIV WALES SWANSEA,CTR PHILOSOPHY & HLTH CARE,SWANSEA SA2 8PP,W GLAM,WALES.							Butler Nance Cunningham, 1989, Bioethics, V3, P181, DOI 10.1111/j.1467-8519.1989.tb00339.x; Campbell Neil, 1989, Bioethics, V3, P200, DOI 10.1111/j.1467-8519.1989.tb00340.x; DENNETT DC, 1993, CONSCIOUSNESS EXPLAI, P431; Nagel Thomas, 1979, MORTAL QUESTIONS, P165; Searle J., 1992, REDISCOVERY MIND BRA, P151	5	7	7	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1996	313	7060					796	797						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK566	8842076				2022-12-24	WOS:A1996VK56600028
J	Smith, TJ; Chase, ES; Schmidt, TJ; Olson, NH; Baker, TS				Smith, TJ; Chase, ES; Schmidt, TJ; Olson, NH; Baker, TS			Neutralizing antibody to human rhinovirus 14 penetrates the receptor-binding canyon	NATURE			English	Article							COMMON COLD VIRUS; CONFORMATIONAL-CHANGES; FAB FRAGMENTS; ATTACHMENT; COMPLEX; VIRION; SITE	THE three-dimensional structure of intact human rhinovirus 14 (HRV-14) complexed with Fab fragments (Fab17-IA) from a strongly neutralizing antibody that binds bivalently to the virion(1,2) has been determined to 4.0 Angstrom resolution by a combination of X-ray crystallography and cryo-electron microscopy. In contradiction to the most commonly held model of antibody-mediated neutralization, Fab17-IA does not induce a conformational change in the HRV-14 capsid. Instead, the paratope of the antibody undergoes a large conformational change to accommodate the epitope. Unlike any previously described antibody-antigen structure, the conserved framework region of the antibody makes extensive contact with the viral surface. Fab17-IA penetrates deep within the canyon in which the cellular receptor for HRV-14 binds(3,4). Hence, it is unlikely that viral quaternary structure evolves merely to evade immune recognition, Instead, the shape and position of the receptor-binding region on a virus probably dictates receptor binding and subsequent uncoating events and has little or no influence on concealing the virus from the immune system.			Smith, TJ (corresponding author), PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907, USA.		Smith, Thomas J/K-9086-2013	Smith, Thomas J/0000-0003-3528-6793; , Timothy/0000-0001-6543-8968	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033050] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM033050] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHARYA R, 1989, NATURE, V337, P709, DOI 10.1038/337709a0; ARNOLD E, 1984, J MOL BIOL, V177, P417, DOI 10.1016/0022-2836(84)90293-6; BIZEBARD T, 1995, NATURE, V376, P92, DOI 10.1038/376092a0; BRUNGER AT, 1992, X PLOR VERSION 3 1 U; COLONNO RJ, 1989, J VIROL, V63, P36, DOI 10.1128/JVI.63.1.36-42.1989; Harber J, 1995, VIROLOGY, V214, P559, DOI 10.1006/viro.1995.0067; HOOVERLITTY H, 1993, J VIROL, V67, P390, DOI 10.1128/JVI.67.1.390-397.1993; LEE WM, 1991, THESIS U WISCONSIN U; LIU HS, 1994, J MOL BIOL, V240, P127, DOI 10.1006/jmbi.1994.1427; LUO M, 1987, SCIENCE, V235, P182, DOI 10.1126/science.3026048; MCCULLOUGH KC, 1992, J VIROL, V66, P1835, DOI 10.1128/JVI.66.4.1835-1840.1992; MOSSER AG, 1989, MOL ASPECTS PICORNAV, P00155; OLIVEIRA MA, 1993, STRUCTURE, V1, P51, DOI 10.1016/0969-2126(93)90008-5; OLSON NH, 1993, P NATL ACAD SCI USA, V90, P507, DOI 10.1073/pnas.90.2.507; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; ROSSMANN MG, 1992, J APPL CRYSTALLOGR, V25, P166, DOI 10.1107/S002188989101141X; ROSSMANN MG, 1989, J BIOL CHEM, V264, P14587; ROSSMANN MG, 1985, NATURE, V317, P145, DOI 10.1038/317145a0; SHERIFF S, 1993, IMMUNOMETHODS, V3, P191; SMITH TJ, 1993, P NATL ACAD SCI USA, V90, P7015, DOI 10.1073/pnas.90.15.7015; SMITH TJ, 1993, J VIROL, V67, P1148, DOI 10.1128/JVI.67.3.1148-1158.1993; SMITH TJ, 1995, P NATL ACAD SCI USA, V92, P10648, DOI 10.1073/pnas.92.23.10648; SMITH TJ, 1986, SCIENCE, V233, P1286, DOI 10.1126/science.3018924; STANFIELD RL, 1994, TRENDS BIOTECHNOL, V12, P275, DOI 10.1016/0167-7799(94)90139-2; Tomlinson IM, 1996, J MOL BIOL, V256, P813, DOI 10.1006/jmbi.1996.0127; TONG L, 1990, ACTA CRYSTALLOGR A, V46, P783, DOI 10.1107/S0108767390005530; VERDAGUER N, 1995, EMBO J, V14, P1690, DOI 10.1002/j.1460-2075.1995.tb07158.x; WANG KS, 1991, VIROLOGY, V181, P694, DOI 10.1016/0042-6822(91)90903-O; WIEN MW, 1995, NAT STRUCT BIOL, V2, P232, DOI 10.1038/nsb0395-232	29	137	140	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 26	1996	383	6598					350	354		10.1038/383350a0	http://dx.doi.org/10.1038/383350a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VJ439	8848050	Green Submitted, Green Accepted			2022-12-24	WOS:A1996VJ43900049
J	Medvinsky, A; Dzierzak, E				Medvinsky, A; Dzierzak, E			Definitive hematopoiesis is autonomously initiated by the AGM region	CELL			English	Article							FETAL LIVER HEMATOPOIESIS; PRIMORDIAL GERM-CELLS; EMBRYONIC YOLK-SAC; STEM-CELLS; MOUSE EMBRYO; IN-VITRO; PARAAORTIC SPLANCHNOPLEURA; ONTOGENY; PRECURSORS; MIGRATION	The adult hematopoietic system of mammals is a dynamic hierarchy of cells with the hematopoietic stem cell at its foundation. During embryonic development, the source and expansion potential of this cell remain unclear. Two sites of hematopoietic activity, the yolk sac and aorta-gonad-mesonephros (AGM) region, function in mouse ontogeny at the pre-liver stage of hematopoiesis. However, cellular interchange between these tissues obscures the embryonic site of hematopoietic stem cell generation. Here we present the results of a novel in vitro organ culture system demonstrating that, at day 10 in gestation, hematopoietic stem cells initiate autonomously and exclusively within the AGM region. Furthermore, we provide evidence for the in vitro expansion of hematopoietic stem cells within the AGM region. These results strongly suggest that the AGM region is the source of the definitive adult hematopoietic system, which subsequently colonizes the liver.			Medvinsky, A (corresponding author), NATL INST MED RES,THE RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CUMANO A, 1993, P NATL ACAD SCI USA, V90, P6429, DOI 10.1073/pnas.90.14.6429; DETRICH HW, 1995, P NATL ACAD SCI USA, V92, P10713, DOI 10.1073/pnas.92.23.10713; Dieterlen-Lievre F, 1993, SEMIN DEV BIOL, V4, P325; DIETERLENLIEVRE F, 1975, J EMBRYOL EXP MORPH, V33, P607; DZIERZAK E, 1995, TRENDS GENET, V11, P359, DOI 10.1016/S0168-9525(00)89107-6; FLEISCHMAN RA, 1982, CELL, V30, P351, DOI 10.1016/0092-8674(82)90233-1; GODIN I, 1995, P NATL ACAD SCI USA, V92, P773, DOI 10.1073/pnas.92.3.773; GODIN IE, 1993, NATURE, V364, P67, DOI 10.1038/364067a0; HARRISON DE, 1987, BLOOD, V69, P1021; HARRISON DE, 1979, BLOOD, V54, P1152; HUANG H, 1993, P NATL ACAD SCI USA, V90, P10110, DOI 10.1073/pnas.90.21.10110; JENKINSON EJ, 1982, EUR J IMMUNOL, V12, P583, DOI 10.1002/eji.1830120710; JOHNSON GR, 1985, EXP HEMATOL, V13, P200; JOHNSON GR, 1975, NATURE, V258, P726, DOI 10.1038/258726a0; JORDAN CT, 1990, GENE DEV, V4, P220, DOI 10.1101/gad.4.2.220; JORDAN CT, 1990, CELL, V61, P953, DOI 10.1016/0092-8674(90)90061-I; KAU CL, 1983, J IMMUNOL, V131, P2262; KAUFMAN MH, 1992, ATLAS MOUSE DEV, P465; KINOSHITA K, 1995, DEVELOPMENT, V121, P1581; Kratochwil K., 1983, P99; LASSILA O, 1978, NATURE, V272, P353, DOI 10.1038/272353a0; LIU CP, 1991, DEVELOPMENT, V113, P1315; MAENO M, 1985, DEV BIOL, V110, P503, DOI 10.1016/0012-1606(85)90108-3; MARTIN C, 1978, CELL DIFFER DEV, V7, P115, DOI 10.1016/0045-6039(78)90012-X; MATSUI Y, 1992, CELL, V70, P841, DOI 10.1016/0092-8674(92)90317-6; MEDVINSKY A, 1993, SEMIN DEV BIOL, V4, P333; Medvinsky AL, 1996, BLOOD, V87, P557, DOI 10.1182/blood.V87.2.557.bloodjournal872557; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; MORRISON SJ, 1995, P NATL ACAD SCI USA, V92, P10302, DOI 10.1073/pnas.92.22.10302; MULLER AM, 1993, DEVELOPMENT, V118, P1343; MULLER AM, 1994, IMMUNITY, V1, P291, DOI 10.1016/1074-7613(94)90081-7; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; PALACIOS R, 1993, P NATL ACAD SCI USA, V90, P6581, DOI 10.1073/pnas.90.14.6581; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; PERAH G, 1977, J CELL PHYSIOL, V91, P193, DOI 10.1002/jcp.1040910205; RICH IN, 1995, BLOOD, V86, P463, DOI 10.1182/blood.V86.2.463.bloodjournal862463; RUSSELL ELIZABETH S., 1966, P351; SAMOYLINA NL, 1990, SOV J DEVEL BIOL, V21, P127; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SERRA R, 1995, DEVELOPMENT, V121, P3057; SONODA T, 1983, DEV BIOL, V97, P89, DOI 10.1016/0012-1606(83)90066-0; SYMANN M, 1978, EXP HEMATOL, V6, P749; TICKLE C, 1994, ANNU REV CELL BIOL, V10, P121; TOLES JF, 1989, P NATL ACAD SCI USA, V86, P7456, DOI 10.1073/pnas.86.19.7456; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TURPEN JB, 1982, DEV BIOL, V89, P138, DOI 10.1016/0012-1606(82)90302-5; TURPEN JB, 1981, DEV BIOL, V85, P99, DOI 10.1016/0012-1606(81)90239-6; Weissman I, 1978, DIFFERENTIATION NORM, V5, P33; WONG PMC, 1986, P NATL ACAD SCI USA, V83, P3851, DOI 10.1073/pnas.83.11.3851	50	1089	1114	2	37	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1996	86	6					897	906		10.1016/S0092-8674(00)80165-8	http://dx.doi.org/10.1016/S0092-8674(00)80165-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VJ443	8808625	Green Published, Bronze			2022-12-24	WOS:A1996VJ44300008
J	Agulnick, AD; Taira, M; Breen, JJ; Tanaka, T; Dawid, IB; Westphal, H				Agulnick, AD; Taira, M; Breen, JJ; Tanaka, T; Dawid, IB; Westphal, H			Interactions of the LIM-domain-binding factor Ldb1 with LIM homeodomain proteins	NATURE			English	Article							GENE; ORGANIZER; MUSCLE; XENOPUS; XLIM-1; ZYXIN	THE LIM homeodomain (LIM-HD) proteins, which contain two tandem LIM domains followed by a homeodomain, are critical transcriptional regulators of embryonic development(1-5). The LIM domain is a conserved cysteine-rich zinc-binding motif found in LIM-HD and LMO (rhombotin or Ttg) proteins, cytoskeletal components, LIM kinases and other proteins(1). LIM domains are protein-protein interaction motifs(1), can binding of LIM-HD proteins to DNA(6,7) and can negatively regulate LIM-HD protein function(8). How LIM domains exert these regulatory effects is not known. We have now isolated a new LIM-domain-binding factor, LdB1, on the basis of tis ability to interact with the LIM-HD protein Lhx1 (Lim1)(9). High-affinity binding by Ldb1 requires paired LIM domains and is restricted to the related subgroup of LIM domains found in LIM-HD and LMO proteins. The highly conserved Xenopus Lbd protein XLbd1, interacts with Xlim-1, the Xenopus orthologue of Lhx1. When injected into Xenopus embryos, XLbd1 (or Lbd1) can synergize with Xlim-1 in the formation of partial secondary axes and in activation of the genes encoding goosecoid (gsc), chordin, NCAM and XCG7, demonstrating a functional as well as a physical interaction between the two proteins.	NICHHD,GENET MOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Agulnick, AD (corresponding author), NICHHD,LAB MAMMALIAN GENES & DEV,NIH,BETHESDA,MD 20892, USA.							ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; FUJII T, 1994, DEV DYNAM, V199, P73, DOI 10.1002/aja.1001990108; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; HARPER JW, 1993, CELL, V75, P805; Karavanov AA, 1996, INT J DEV BIOL, V40, P453; KINTNER CR, 1984, NATURE, V308, P67, DOI 10.1038/308067a0; NUNOUE K, 1995, ONCOGENE, V11, P701; Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SANCHEZGARCIA I, 1993, EMBO J, V12, P4243, DOI 10.1002/j.1460-2075.1993.tb06108.x; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; Sheng HZ, 1996, SCIENCE, V272, P1004, DOI 10.1126/science.272.5264.1004; TAIRA M, 1995, TRENDS GENET, V11, P431, DOI 10.1016/S0168-9525(00)89139-8; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; TAIRA M, 1994, NATURE, V372, P677, DOI 10.1038/372677a0; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239; ZHADANOV AB, 1995, DEV DYNAM, V202, P354, DOI 10.1002/aja.1002020405	23	284	295	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 21	1996	384	6606					270	272		10.1038/384270a0	http://dx.doi.org/10.1038/384270a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU381	8918878				2022-12-24	WOS:A1996VU38100053
J	Li, YM; Milne, JC; Madison, LL; Kolter, R; Walsh, CT				Li, YM; Milne, JC; Madison, LL; Kolter, R; Walsh, CT			From peptide precursors to oxazole and thiazole-containing peptide antibiotics: Microcin B17 synthase	SCIENCE			English	Article							ESCHERICHIA-COLI; DNA GYRASE; BACKBONE MODIFICATIONS; RECOGNITION SITE; INHIBITOR; PROTEIN; SEQUENCE; CARBOXYLATION; PURIFICATION; MATURATION	Esherichia coli microcin B17 is a posttranslationally modified peptide that inhibits bacterial DNA gyrase. it contains four oxazole and four thiazole rings and is representative of a broad class of pharmaceutically important natural products with five-membered heterocycles derived from peptide precursors. An in vitro assay was developed to detect heterocycle formation, and an enzyme complex, microcin B17 synthase, was purified and found to contain three proteins, McbB, McbC, and McbD, that convert 14 residues into the eight mono- and bisheterocyclic moieties in vitro that confer antibiotic activity on mature microcin B17. These enzymatic reactions alter the peptide backbone connectivity, The propeptide region of premicrocin is the major recognition determinant for binding and downstream heterocycle formation by microcin B17 synthase, A general pathway for the enzymatic biosynthesis of these heterocycles is formulated.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOL PHARMACOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOL GENET, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School					NIAID NIH HHS [5T32AI07410-03] Funding Source: Medline; NIGMS NIH HHS [GM20011, 5T32GM07306-19] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007410] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007306, R01GM020011, R37GM020011] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARDWELL JCA, 1987, P NATL ACAD SCI USA, V84, P5177, DOI 10.1073/pnas.84.15.5177; BARDWELL JCA, 1988, J BACTERIOL, V170, P2977, DOI 10.1128/jb.170.7.2977-2983.1988; BARRY AL, 1995, ANTIMICROB AGENTS CH, V39, P238, DOI 10.1128/AAC.39.1.238; BAYER A, 1993, ANGEW CHEM INT EDIT, V32, P1336, DOI 10.1002/anie.199313361; BAYER A, 1995, EUR J BIOCHEM, V234, P414, DOI 10.1111/j.1432-1033.1995.414_b.x; BENSON TE, 1993, BIOCHEMISTRY-US, V32, P2024, DOI 10.1021/bi00059a019; Bergmeyer H., 1974, METHODS ENZYMATIC AN, V1, P457; Chen T., UNPUB; CLARKE ND, 1994, P NATL ACAD SCI USA, V91, P11084, DOI 10.1073/pnas.91.23.11084; COOPER AA, 1993, EMBO J, V12, P2575, DOI 10.1002/j.1460-2075.1993.tb05913.x; COOPER AA, 1995, TRENDS BIOCHEM SCI, V20, P351, DOI 10.1016/S0968-0004(00)89075-1; DAVAGNINO J, 1986, Proteins Structure Function and Genetics, V1, P230, DOI 10.1002/prot.340010305; DAVIS EO, 1992, CELL, V71, P201, DOI 10.1016/0092-8674(92)90349-H; FLOSS HG, 1989, ANGEW CHEM INT EDIT, V28, P146, DOI 10.1002/anie.198901461; FREEMAN C, 1995, DIAGN MICR INFEC DIS, V21, P47, DOI 10.1016/0732-8893(94)00113-B; GARRIDO MD, 1988, EMBO J, V7, P1853, DOI 10.1002/j.1460-2075.1988.tb03018.x; GENILLOUD O, 1989, J BACTERIOL, V171, P1126, DOI 10.1128/jb.171.2.1126-1135.1989; GILSON L, 1987, J BACTERIOL, V169, P2466, DOI 10.1128/jb.169.6.2466-2470.1987; HODGES RA, 1992, NUCLEIC ACIDS RES, V20, P6153, DOI 10.1093/nar/20.23.6153; HUBBARD BR, 1989, J BIOL CHEM, V264, P14145; IRELAND CM, 1982, J ORG CHEM, V47, P1807, DOI 10.1021/jo00349a002; JANSEN R, 1992, LIEBIGS ANN CHEM, P357; JORGENSEN MJ, 1987, CELL, V48, P185, DOI 10.1016/0092-8674(87)90422-3; JURKIEWICZ E, 1992, ANTIVIR CHEM CHEMOTH, V3, P189, DOI 10.1177/095632029200300401; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LEWIS JR, 1995, NAT PROD REP, V12, P135, DOI 10.1039/np9951200135; LI Y, UNPUB; MADISON LL, IN PRESS MOL MICROBI; MANDERVILLE RA, 1994, J AM CHEM SOC, V116, P10851, DOI 10.1021/ja00102a087; MILLAN JLS, 1985, J BACTERIOL, V163, P1016; MILLAN JLS, 1985, J BACTERIOL, V163, P275, DOI 10.1128/JB.163.1.275-281.1985; PASCAL RA, 1983, BIOCHEMISTRY-US, V22, P171, DOI 10.1021/bi00270a025; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; RUZICKA FJ, 1977, J BIOL CHEM, V252, P8440; SCARPULLA RC, 1978, J BIOL CHEM, V253, P5997; SHI Y, 1994, P NATL ACAD SCI USA, V91, P2767, DOI 10.1073/pnas.91.7.2767; Siegers K, 1996, J BIOL CHEM, V271, P12294, DOI 10.1074/jbc.271.21.12294; TAKITA T, 1972, J ANTIBIOT, V25, P197, DOI 10.7164/antibiotics.25.197; VIZAN JL, 1991, EMBO J, V10, P467, DOI 10.1002/j.1460-2075.1991.tb07969.x; WILLIAMS AB, 1993, CANCER LETT, V71, P97, DOI 10.1016/0304-3835(93)90103-G; WU W, 1994, J AM CHEM SOC, V116, P10843, DOI 10.1021/ja00102a083; XU MQ, 1993, CELL, V75, P1371, DOI 10.1016/0092-8674(93)90623-X; XU MQ, 1994, EMBO J, V13, P5517, DOI 10.1002/j.1460-2075.1994.tb06888.x; YORGEY P, 1993, MOL MICROBIOL, V9, P897, DOI 10.1111/j.1365-2958.1993.tb01747.x; YORGEY P, 1994, P NATL ACAD SCI USA, V91, P4519, DOI 10.1073/pnas.91.10.4519; ZWICKL P, 1994, NAT STRUCT BIOL, V1, P765, DOI 10.1038/nsb1194-765	46	246	252	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 15	1996	274	5290					1188	1193		10.1126/science.274.5290.1188	http://dx.doi.org/10.1126/science.274.5290.1188			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT335	8895467				2022-12-24	WOS:A1996VT33500053
J	Wehr, M; Laurent, G				Wehr, M; Laurent, G			Odour encoding by temporal sequences of firing in oscillating neural assemblies	NATURE			English	Article							NEURONAL-ACTIVITY; BEHAVING MONKEYS; OLFACTORY-BULB; CORTEX; RECOGNITION; PATTERN; RABBIT; CODE; CAT	STIMULUS-EVOKED oscillatory synchronization of activity has been observed in many neural systems, including the cerebral cortex of mammals and the brain of insects(1-8). The possible functions of such rhythmic synchronization in neural coding, however, remain largely speculative(9-13). In the locust, odours evoke activity in dynamic (evolving) ensembles of transiently synchronized neurons(8,14,15). We report here that the active neurons composing these ensembles change in a stimulus-specific manner and with a high degree of reliability on a cycle-by-cycle basis during an odour response. Hence, information about an odour is contained not only in the neural assembly active at each oscillation cycle, but also in the precise temporal sequence in which these assemblies are updated during an odour response. Neural coding with oscillations thus allows combinatorial representations in time as well as in space.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology			Laurent, Gilles/A-4583-2012	Laurent, Gilles/0000-0002-2296-114X				ABELES M, 1993, J NEUROPHYSIOL, V70, P1629, DOI 10.1152/jn.1993.70.4.1629; Adrian ED, 1942, J PHYSIOL-LONDON, V100, P459, DOI 10.1113/jphysiol.1942.sp003955; BIALEK W, 1991, SCIENCE, V252, P1854, DOI 10.1126/science.2063199; BRESSLER SL, 1980, ELECTROEN CLIN NEURO, V50, P19, DOI 10.1016/0013-4694(80)90319-3; Brillinger D.R., 1981, TIME SERIES; CINELLI AR, 1995, J NEUROPHYSIOL, V73, P2053, DOI 10.1152/jn.1995.73.5.2053; FREEMAN WJ, 1960, J NEUROPHYSIOL, V23, P111, DOI 10.1152/jn.1960.23.2.111; GELPERIN A, 1990, NATURE, V345, P437, DOI 10.1038/345437a0; Gray C M, 1994, J Comput Neurosci, V1, P11, DOI 10.1007/BF00962716; GRAY CM, 1988, EXP BRAIN RES, V69, P378; GRAY CM, 1989, P NATL ACAD SCI USA, V86, P1698, DOI 10.1073/pnas.86.5.1698; HOPFIELD JJ, 1995, NATURE, V376, P33, DOI 10.1038/376033a0; HOPPEL E, 1986, NATURWISSENSCHAFTEN, V73, P267; HUBEL DH, 1965, J NEUROPHYSIOL, V28, P229, DOI 10.1152/jn.1965.28.2.229; LAURENT G, 1994, J NEUROSCI, V14, P2993; LAURENT G, 1994, SCIENCE, V265, P1872, DOI 10.1126/science.265.5180.1872; Laurent G, 1996, J NEUROSCI, V16, P3837; LAURENT G, IN PRESS TRENDS NEUR; MAINEN ZF, 1995, SCIENCE, V268, P1503, DOI 10.1126/science.7770778; MIDDLEBROOKS JC, 1994, SCIENCE, V264, P842, DOI 10.1126/science.8171339; MILNER PM, 1974, PSYCHOL REV, V81, P521, DOI 10.1037/h0037149; MURTHY VN, 1992, P NATL ACAD SCI USA, V89, P5670, DOI 10.1073/pnas.89.12.5670; PAULIN MG, 1992, BIOL CYBERN, V66, P525, DOI 10.1007/BF00204117; SHEPHERD GM, 1994, NEURON, V13, P771, DOI 10.1016/0896-6273(94)90245-3; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.ne.18.030195.003011; SINGER W, 1990, CONCEPTS NEUROSCI, V1, P1; SMITH BH, 1989, ETHOLOGY, V82, P68; VONDERMALSBURG C, 1986, BIOL CYBERN, V54, P29, DOI 10.1007/BF00337113; VONDERMALSBURG C, 1981, CORRELATION THEORY B, P81	29	371	377	2	29	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 14	1996	384	6605					162	166		10.1038/384162a0	http://dx.doi.org/10.1038/384162a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT336	8906790				2022-12-24	WOS:A1996VT33600064
J	Ambrosone, CB; Freudenheim, JL; Graham, S; Marshall, JR; Vena, JE; Brasure, JR; Michalek, AM; Laughlin, R; Nemoto, T; Gillenwater, KA; Harrington, AM; Shields, PG				Ambrosone, CB; Freudenheim, JL; Graham, S; Marshall, JR; Vena, JE; Brasure, JR; Michalek, AM; Laughlin, R; Nemoto, T; Gillenwater, KA; Harrington, AM; Shields, PG			Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RAT MAMMARY-GLAND; METABOLIC-ACTIVATION; ALCOHOL-CONSUMPTION; COLORECTAL-CANCER; BLADDER-CANCER; ACETYLATOR POLYMORPHISM; EPITHELIAL-CELLS; DNA ADDUCTS; PHENOTYPE; WOMEN	Objective.-To determine if N-acetyltransferase 2 (NAT2) polymorphisms result in decreased capacity to detoxify carcinogenic aromatic amines in cigarette smoke, thus making some women who smoke more susceptible to breast cancer. Design.-Case-control study with genetic analyses, DNA analyses were performed for 3 polymorphisms accounting for 90% to 95% of the slow acetylation phenotype among whites. Setting and Participants.-White women with incident primary breast cancer (n=304) and community controls (n=327). Results.-Neither smoking nor NAT2 status was independently associated with breast cancer risk. There were no clear patterns of increased risk associated with smoking by NAT2 status among premenopausal women. In postmenopausal women, NAT2 strongly modified the association of smoking with risk. For slow acetylators, current smoking and smoking in the distant past increased breast cancer risk in a dose-dependent manner (odds ratios [95% confidence intervals] for the highest quartile of cigarettes smoked 2 and 20 years previously, 4.4 [1.3-14.8] and 3.9 [1.4-10.8], respectively). Among rapid acetylators, smoking was not associated with increased breast cancer risk. Conclusions.-Our results suggest that smoking may be an important risk factor for breast cancer among postmenopausal women who are slow acetylators, demonstrate heterogeneity in response to carcinogenic exposures, and may explain previous inconsistent findings for cigarette smoking as a breast cancer risk factor.	SUNY BUFFALO,DEPT SOCIAL & PREVENT MED,BUFFALO,NY 14260; SUNY BUFFALO,DEPT SURG,BUFFALO,NY 14260; NCI,HUMAN CARCINOGENESIS LAB,BETHESDA,MD 20892	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ambrosone, CB (corresponding author), NATL CTR TOXICOL RES,DIV MOL EPIDEMIOL,3900 NCTR RD,JEFFERSON,AR 72079, USA.		Shields, Peter G/I-1644-2012	Freudenheim, Jo/0000-0002-9301-0499	NCI NIH HHS [CA-11535, CA-01633, CA-62995] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA062995, P01CA011535, R01CA062995, K04CA001633] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMI HO, 1988, BRIT J CANCER, V58, P832, DOI 10.1038/bjc.1988.320; ALLABEN WT, 1982, CARCINOGENESIS, V3, P233, DOI 10.1093/carcin/3.3.233; ALLABEN WT, 1983, CARCINOGENESIS, V4, P1067, DOI 10.1093/carcin/4.8.1067; AMBROSONE CB, 1995, CANCER RES, V55, P3483; BARON JA, 1984, AM J EPIDEMIOL, V119, P9, DOI 10.1093/oxfordjournals.aje.a113730; BARON JA, 1986, J NATL CANCER I, V77, P677, DOI 10.1093/jnci/77.3.677; BEGG CB, 1994, CANCER EPIDEM BIOMAR, V3, P173; BELL DA, 1993, CARCINOGENESIS, V14, P1689, DOI 10.1093/carcin/14.8.1689; BLUM M, 1991, P NATL ACAD SCI USA, V99, P523; BRINTON LA, 1986, AM J EPIDEMIOL, V123, P614, DOI 10.1093/oxfordjournals.aje.a114281; BROWNSON RC, 1988, ARCH INTERN MED, V148, P140, DOI 10.1001/archinte.148.1.140; BULOVSKAYA LN, 1978, ONCOLOGY, V35, P185, DOI 10.1159/000225282; CARTWRIGHT RA, 1984, GENETIC VARIABILITY, P359; CHU SY, 1990, AM J EPIDEMIOL, V131, P244, DOI 10.1093/oxfordjournals.aje.a115494; COLDITZ GA, 1995, CANCER EPIDEM BIOMAR, V4, P67; Debiec-Rychter M., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P133; DEVITA VT, 1989, CANCER PRINCIPLES PR; DOLL R, 1980, BRIT MED J, V280, P967, DOI 10.1136/bmj.280.6219.967; ELDRIDGE SR, 1992, CANCER RES, V52, P5617; ELLARD GA, 1976, CLIN PHARMACOL THER, V19, P610; Evans D A, 1986, Prog Clin Biol Res, V214, P209; EWARTZ M, 1990, CANCER CAUSE CONTROL, V1, P31; FIELD NA, 1992, INT J EPIDEMIOL, V21, P842, DOI 10.1093/ije/21.5.842; GRAHAM S, 1991, AM J EPIDEMIOL, V134, P552, DOI 10.1093/oxfordjournals.aje.a116129; HANSSEN HP, 1985, EUR UROL, V11, P263; HARRIS HW, 1958, AM REV TUBERC PULM, V78, P944; HEIN DW, 1988, BIOCHIM BIOPHYS ACTA, V948, P37, DOI 10.1016/0304-419X(88)90004-2; HIATT RA, 1986, JNCI-J NATL CANCER I, V76, P833; HIATT RA, 1988, CANCER RES, V48, P2284; HIRVONEN A, 1994, CARCINOGENESIS, V15, P813, DOI 10.1093/carcin/15.5.813; ILETT KF, 1987, CANCER RES, V47, P1466; *INT AG RES CANC, 1972, MON EV CARC RISK C 1, P74; Josephy PD, 1996, MUTAGENESIS, V11, P3, DOI 10.1093/mutage/11.1.3; KADLUBAR FF, 1992, ENVIRON HEALTH PERSP, V98, P69, DOI 10.2307/3431249; KARIM AKMB, 1981, J MED GENET, V18, P325, DOI 10.1136/jmg.18.5.325; KAUFMAN DW, 1980, AM J PUBLIC HEALTH, V70, P420, DOI 10.2105/AJPH.70.4.420; KING CM, 1979, CANCER RES, V39, P3369; LADERO JM, 1987, ONCOLOGY, V44, P341, DOI 10.1159/000226508; LANG NP, 1994, CANCER EPIDEM BIOMAR, V3, P675; LANG NP, 1986, ARCH SURG-CHICAGO, V121, P1259, DOI 10.1001/archsurg.121.11.1259; LESKO SM, 1985, NEW ENGL J MED, V313, P593, DOI 10.1056/NEJM198509053131001; Li DH, 1996, CANCER RES, V56, P287; LIN HJ, 1993, AM J HUM GENET, V52, P827; LONDON SJ, 1989, JNCI-J NATL CANCER I, V81, P1625, DOI 10.1093/jnci/81.21.1625; MEARA J, 1989, BRIT J CANCER, V60, P70, DOI 10.1038/bjc.1989.222; MINCHIN RF, 1993, MUTAT RES, V290, P35, DOI 10.1016/0027-5107(93)90030-J; MOMMSEN S, 1983, CARCINOGENESIS, V4, P335, DOI 10.1093/carcin/4.3.335; Morabia A, 1996, AM J EPIDEMIOL, V143, P918, DOI 10.1093/oxfordjournals.aje.a008835; NAKACHI K, 1991, CANCER RES, V51, P5177; OCONNELL DL, 1987, J NATL CANCER I, V78, P229; PALMER JR, 1991, AM J EPIDEMIOL, V134, P1; PERERA FP, 1995, CANCER EPIDEM BIOMAR, V4, P233; PETRAKIS NL, 1978, SCIENCE, V199, P303, DOI 10.1126/science.619458; PETRAKIS NL, 1980, CANCER RES, V40, P188; PHILIP PA, 1987, EUR J CANCER CLIN ON, V23, P1701, DOI 10.1016/0277-5379(87)90453-6; PIERGORSCH WW, 1994, STAT MED, V13, P153; RISCH A, 1995, HUM MOL GENET, V4, P231, DOI 10.1093/hmg/4.2.231; ROHAN TE, 1989, AM J EPIDEMIOL, V129, P36, DOI 10.1093/oxfordjournals.aje.a115122; ROSENBERG L, 1984, NEW ENGL J MED, V310, P92, DOI 10.1056/NEJM198401123100205; ROSS RK, 1988, DIAGNOSIS MANAGEMENT, P23; Sadrieh N, 1996, CANCER RES, V56, P2683; SALBER EJ, 1969, JNCI-J NATL CANCER I, V43, P1013; SARDAS S, 1990, INT J CANCER, V46, P1138, DOI 10.1002/ijc.2910460633; SCHATZKIN A, 1989, J NATL CANCER I, V81, P31, DOI 10.1093/jnci/81.1.31; SCHECTER MT, 1980, AM J EPIDEMIOL, V130, P213; SHIRAI T, 1981, CANCER RES, V41, P4346; STOCKWELL HG, 1987, AM J OBSTET GYNECOL, V157, P35, DOI 10.1016/S0002-9378(87)80341-1; SWAMINATHAN S, 1994, CARCINOGENESIS, V15, P611, DOI 10.1093/carcin/15.4.611; Taylor J. A., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P282; TONELLI QJ, 1979, CANCER RES, V39, P1784; VATSIS KP, 1995, PHARMACOGENETICS, V5, P1, DOI 10.1097/00008571-199502000-00001; VATTEN LJ, 1990, EUR J CANCER, V26, P830, DOI 10.1016/0277-5379(90)90164-O; VESSEY M, 1983, BRIT J CANCER, V47, P455, DOI 10.1038/bjc.1983.74; VINEIS P, 1994, NATURE, V369, P154, DOI 10.1038/369154a0; VINEIS P, 1990, CANCER RES, V50, P3002; WANG CY, 1988, CANCER RES, V48, P4227; YU MC, 1994, J NATL CANCER I, V86, P712, DOI 10.1093/jnci/86.9.712	77	289	293	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	1996	276	18					1494	1501		10.1001/jama.276.18.1494	http://dx.doi.org/10.1001/jama.276.18.1494			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ774	8903261				2022-12-24	WOS:A1996VQ77400032
J	Dahlquist, G; Bennich, SS; Kallen, B				Dahlquist, G; Bennich, SS; Kallen, B			Intrauterine growth pattern and risk of childhood onset insulin dependent (type I) diabetes: Population based case-control study	BRITISH MEDICAL JOURNAL			English	Article							MEDICAL BIRTH REGISTRY; MELLITUS; WEIGHT; LIFE; AGE	Objective-To investigate whether prenatal growth affects the risk of development of childhood onset insulin dependent (type I) diabetes mellitus. Design-Population based case-control study. Setting-Data from a nationwide childhood diabetes case register were linked with data from the nationwide Swedish Medical Birth Registry. Subjects-Data from a total of 4584 diabetic children born after 1973 and diagnosed with diabetes from 1978 to 1992 were studied. For each child with insulin dependent diabetes three control children were randomly selected from among all infants born in the same year and at the same hospital as the proband. Main outcome measures-Birth, weight, gestation, maternal age and parity, number of previous spontaneous abortions, and sex specific birth weight by gestational week expressed as multiples of the standard deviation (SD). Results-There was a clear trend in the odds ratio for childhood onset diabetes according to SD of birth weight. The odds ratio (95% confidence interval) for small for gestational age after stratification for maternal age, parity, smoking habits, and maternal diabetes was 0.81 (0.65 to 0.99) and for large for gestational age after similar stratification was 1.20 (1.02 to 1.42). Conclusions-Intrauterine conditions that affect prenatal growth seem also to affect the risk of development of childhood diabetes in the way previously described for postnatal growth: a poor growth decreases and an excess growth increases the risk. The mechanism for this association is unclear.	UMEA UNIV,DEPT EPIDEMIOL & PUBL HLTH,S-90185 UMEA,SWEDEN; UNIV UPPSALA,DEPT INTERNAL MED,UPPSALA,SWEDEN; LUND UNIV,TORNBLAD INST,LUND,SWEDEN	Umea University; Uppsala University; Lund University	Dahlquist, G (corresponding author), UMEA UNIV,DEPT PAEDIAT,S-90185 UMEA,SWEDEN.							ANDERSSON DKG, 1991, DIABETIC MED, V8, P428, DOI 10.1111/j.1464-5491.1991.tb01626.x; BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; BLOM L, 1992, DIABETOLOGIA, V35, P528, DOI 10.1007/BF00400480; BLOM L, 1989, DIABETOLOGIA, V32, P7; Breslow N., 1980, SCI PUBLICATIONS INT, V32; CNATTINGIUS S, 1990, SCAND J SOC MED, V18, P143, DOI 10.1177/140349489001800209; DAHLQUIST G, 1991, ACTA PAEDIATR SCAND, V80, P583, DOI 10.1111/j.1651-2227.1991.tb11914.x; DAHLQUIST G, 1992, DIABETOLOGIA, V35, P671, DOI 10.1007/BF00400261; DAHLQUIST G, 1982, ACTA PAEDIATR SCAND, V71, P7, DOI 10.1111/j.1651-2227.1982.tb09364.x; DAHLQUIST G, 1994, INT J EPIDEMIOL, V23, P1239; DORNER G, 1985, EXP CLIN ENDOCRINOL, V85, P1; JOHANSSON C, 1994, DIABETOLOGIA, V37, P91; KALLEN B, 1995, EUR J EPIDEMIOL, V11, P601, DOI 10.1007/BF01719316; KARVONEN M, 1993, DIABETOLOGIA, V36, P883, DOI 10.1007/BF02374468; MANTEL N, 1963, JNCI-J NATL CANCER I, V32, P719; NYSTROM L, 1990, INT J EPIDEMIOL, V19, P141, DOI 10.1093/ije/19.1.141; SOTHHILL JF, 1983, PAEDIAT IMMUNOLOGY	17	106	107	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1996	313	7066					1174	1177		10.1136/bmj.313.7066.1174	http://dx.doi.org/10.1136/bmj.313.7066.1174			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR907	8916747	Green Published			2022-12-24	WOS:A1996VR90700020
J	Wu, GY; Malinow, R; Cline, HT				Wu, GY; Malinow, R; Cline, HT			Maturation of a central glutamatergic synapse	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; LONG-TERM POTENTIATION; HIPPOCAMPAL SLICE NEURONS; NMDA RECEPTORS; VISUAL-CORTEX; TRANSMISSION; LTP; EXPRESSION; PLASTICITY; COMPONENT	Whole-cell recordings from optic tectal neurons in Xenopus tadpoles were used to study the maturation of a glutamatergic synapse. The first glutamatergic transmission is mediated only by N-methyl-D-aspartate (NMDA) receptors and is silent at resting potentials. More mature synapses acquire transmission by alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors. This maturational program is mimicked by postsynaptic expression of constitutively active calcium-calmodulin-dependent protein kinase II (CaMKII). Newly formed synapses may be silent unless sufficient depolarization is provided by coincident activity that could activate postsynaptic CaMKII, resulting in the appearance of AMPA responses.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory								ALLEN C, 1994, P NATL ACAD SCI USA, V91, P10380, DOI 10.1073/pnas.91.22.10380; BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; CARMIGNOTO G, 1992, SCIENCE, V258, P1007, DOI 10.1126/science.1279803; CHERUBINI E, 1991, TRENDS NEUROSCI, V14, P515, DOI 10.1016/0166-2236(91)90003-D; CLINE HT, 1991, TRENDS NEUROSCI, V14, P104, DOI 10.1016/0166-2236(91)90071-2; CRAIR MC, 1995, NATURE, V375, P325, DOI 10.1038/375325a0; Durand GM, 1996, NATURE, V381, P71, DOI 10.1038/381071a0; EDMONDS B, 1995, ANNU REV PHYSIOL, V57, P495; FOX K, 1989, J NEUROSCI, V9, P2443; Glazewski S, 1996, SCIENCE, V272, P421, DOI 10.1126/science.272.5260.421; GOSHIMA Y, 1993, J NEUROSCI, V13, P559; GRIFFITH LC, 1993, NEURON, V10, P501, DOI 10.1016/0896-6273(93)90337-Q; HESTRIN S, 1990, COLD SH Q B, V55, P87; HESTRIN S, 1992, NATURE, V357, P686, DOI 10.1038/357686a0; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; Katz B., 1969, SHERRINGTON LECT; KELLY PT, 1984, P NATL ACAD SCI-BIOL, V81, P945, DOI 10.1073/pnas.81.3.945; KENNEDY MB, 1983, J NEUROSCI, V3, P818; KULLMANN DM, 1994, NEURON, V12, P1111, DOI 10.1016/0896-6273(94)90318-2; KULLMANN DM, 1995, NEURON, V15, P997, DOI 10.1016/0896-6273(95)90089-6; LAZAR G, 1973, J ANAT, V116, P347; LIAO D, IN PRESS LEARN MEM; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; MALINOW R, 1991, SCIENCE, V252, P722, DOI 10.1126/science.1850871; OTMAKHOV N, 1993, NEURON, V10, P1101, DOI 10.1016/0896-6273(93)90058-Y; PERKEL DJ, 1993, J PHYSIOL-LONDON, V471, P481, DOI 10.1113/jphysiol.1993.sp019911; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; RASTAAD M, 1995, EUR J NEUROSCI, V7, P1882; SCHOLZ WK, 1988, J NEUROSCI, V8, P1039; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; WANG JH, 1995, NEURON, V15, P443, DOI 10.1016/0896-6273(95)90048-9; WU GY, 1995, NEURON, V14, P681, DOI 10.1016/0896-6273(95)90211-2; Zou DJ, 1996, NEURON, V16, P529, DOI 10.1016/S0896-6273(00)80072-0	35	450	455	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1996	274	5289					972	976		10.1126/science.274.5289.972	http://dx.doi.org/10.1126/science.274.5289.972			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR792	8875937				2022-12-24	WOS:A1996VR79200046
J	Bowie, C				Bowie, C			Tetanus toxoid for adults - Too much of a good thing	LANCET			English	Editorial Material														Bowie, Cam/0000-0002-6956-3691				BALESTRA DJ, 1993, J GEN INTERN MED, V8, P405, DOI 10.1007/BF02599616; GEORGEN PJ, 1995, NEW ENGL J MED, V332, P761; HEATH TC, 1969, MED J AUSTRALIA, V164, P593; Prevots Rebecca, 1992, Morbidity and Mortality Weekly Report, V41, P1; *UK HLTH DEP, 1996, IMM INF DIS; 1993, CDR WEEKLY, V3, P73	6	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 2	1996	348	9036					1185	1186		10.1016/S0140-6736(05)65476-1	http://dx.doi.org/10.1016/S0140-6736(05)65476-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ467	8898031				2022-12-24	WOS:A1996VQ46700004
J	Shelley, M; Croft, P; Chapman, S; Pantin, C				Shelley, M; Croft, P; Chapman, S; Pantin, C			As the ratio of inhaled corticosteroid to bronchodilator a good indicator of the quality of asthma prescribing? Cross sectional study linking prescribing data to data on admissions	BRITISH MEDICAL JOURNAL			English	Article							POVERTY	Objective-To investigate the ratio of inhaled corticosteroid to bronchodilator as a measure of the quality of asthma prescribing by general practitioners. Design-Ecological cross sectional study linking general practitioner asthma prescribing with hospital admission data and a measure of deprivation. Subject-11 family health services authorities in the West Midlands region and 99 general practices North Staffordshire. Main outcome measures-Hospital admission rates for asthma; the ratio of inhaled corticosteroid to bronchodilator; and Townsend deprivation scores. Results-No overall significant correlation was found between admission rates for asthma and corticosteroid:bronchodilator ratios for family health services authorities (Spearman's r(s) = -0.109, P = 0.750) or general practices (r(s) = -0.084, P = 0.407). In deprived family health services authority areas and general practices an inverse non-significant correlation existed between admission rates for asthma and corticosteroid:bronchodilator ratios (r(s) = -0.300, P = 0.624; r(s) = -0.218, P = 0.136). In contrast, in more affluent areas and general practices a positive non-significant correlation existed between admission rates and corticosteroid:bronchodilator ratios (r(s) = 0.371, P = 0.468; r(s) = 0.038, P = 0.792). Conclusion-Although the corticosteroid:bronchodilator ratio may be a valid indicator of the quality of prescribing for individual patients with asthma, caution should be applied in interpreting aggregated ratios, Differences in the severity of asthma or the prevalence of chronic obstructive pulmonary disease may explain inconsistent associations between admission rates for asthma and corticosteroid:bronchodilator ratios in family health services authorities and general practices with different deprivation scares.	UNIV KEELE,DEPT MED MANAGEMENT,KEELE ST5 5BG,STAFFS,ENGLAND	Keele University	Shelley, M (corresponding author), KEELE UNIV,N STAFFORDSHIRE MED INST,POSTGRAD MED SCH,IND & COMMUNITY HLTH RES CTR,STOKE ON TRENT ST4 7NY,STAFFS,ENGLAND.							Andersen H. R., 1994, Logical Foundations of Computer Science. Third International Symposium, LFCS '94 Proceedings, P8; *AUD COMM, 1994, PRESCR IMPR MOR RAT, P26; BOGLE SM, 1994, BRIT MED J, V308, P637, DOI 10.1136/bmj.308.6929.637; *BRIT THOR SOC, 1993, THORAX, V48, pS1; *CAMD ISL FAM HLTH, 1995, HLTH NEEDS ASS YOUR; ERNST P, 1995, AM J RESP CRIT CARE, V152, P570, DOI 10.1164/ajrccm.152.2.7633709; GORDON D, 1995, PEOPLE PLACES, V2; GOTTLIEB DJ, 1995, CHEST, V108, P28, DOI 10.1378/chest.108.1.28; Griffiths C, 1996, BRIT MED J, V312, P481, DOI 10.1136/bmj.312.7029.481; HALFON N, 1993, PEDIATRICS, V91, P56; Kleinschmidt I, 1995, J EPIDEMIOL COMMUN H, V49, pS72, DOI 10.1136/jech.49.Suppl_2.S72; LITTLEJOHNS P, 1993, RESP MED, V87, P139, DOI 10.1016/0954-6111(93)90142-M; SCRIVENER G, 1995, BRIT MED J, V311, P163, DOI 10.1136/bmj.311.6998.163; Townsend PP., 1988, HLTH DEPRIVATION INE; *W MIDL REG HLTH A, 1992, PARTN HLTH REP REG D, P16; *WHO COLL CTR DRUG, 1993, AN THER CHEM ATC CLA, P102	16	46	47	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 2	1996	313	7065					1124	1126		10.1136/bmj.313.7065.1124	http://dx.doi.org/10.1136/bmj.313.7065.1124			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR217	8916701	Green Published			2022-12-24	WOS:A1996VR21700027
J	Petri, M; Roubenoff, R; Dallal, GE; Nadeau, MR; Selhub, J; Rosenberg, IR				Petri, M; Roubenoff, R; Dallal, GE; Nadeau, MR; Selhub, J; Rosenberg, IR			Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus	LANCET			English	Article							MYOCARDIAL-INFARCTION; VASCULAR-DISEASE; HOMOCYST(E)INE; POPULATION; GROWTH; STROKE; ASSAY	Background The aim of this study was to asses whether plasma homocysteine is a risk factor for stroke and other thrombotic events in patients with systemic lupus erythematosus (SLE)-a condition known to be associated with premature atherothrombotic complications. Methods in this prospective study, we investigated the association between homocysteine and risk of stroke and thrombotic events in 337 SLE patients in the Hopkins Lupus Cohort Study, with follow-up of 1619 person-years (mean 4 . 8 [SD 1 . 7] years), Each patient had four follow-up assessments per year to obtain information about established risk factors for thrombosis and coronary artery disease. The prospectively defined endpoints were occurrence of stroke and arterial or venous thrombotic events between 1987 and 1995. Blood samples were taken at study entry from fasting patients. Plasma homocysteine, folate, vitamin B12, and pyridoxal 5'-phosphate (PLP) concentrations were measured. Raised homocysteine concentrations were defined as more than 14 . 1 mu mol/L. Findings 93% of the study population were women, 54% African American, and 45% white. The mean age of participants was 34 . 9 (SD 11 . 7) years. During follow-up there were 29 cases of stroke and 31 arterial thrombotic events. Raised homocysteine concentrations were found in 51 (15%) SLE patients. The log-transformed total homocysteine concentrations correlated with serum folate (r=0 . 31, p=0 . 0001). In univariate analyses, raised homocysteine concentrations were significantly associated with stroke (odds ratio 2 . 24 [95% CI 1 . 22-4 . 13], p=0 . 01) and arterial thrombotic events (3 . 74 [1 . 96-7 . 13], p=0 . 0001). After adjustment for established risk factors, total plasma homocysteine concentrations remained an independent risk factor for stroke (2 . 44 [1 . 04-5 . 75], p=0 . 04) and arterial thromboses (3 . 49 [0 . 97-12 . 54], p=0 . 05). Interpretation Homocysteine is a potentially modifiable, independent risk factor for stroke and thrombotic events in patients with SLE.	TUFTS UNIV,USDA,JEAN MAYER HUMAN NUTR RES CTR AGING,BOSTON,MA 02111; JOHNS HOPKINS MED INST,DEPT MED,DIV MOL & CLIN RHEUMATOL,BALTIMORE,MD 21205; TUFTS UNIV NEW ENGLAND MED CTR,DEPT MED,TUPPER RES INST,BOSTON,MA 02111; TUFTS UNIV,SCH MED,BOSTON,MA 02111	Tufts University; United States Department of Agriculture (USDA); Johns Hopkins University; Johns Hopkins Medicine; Tufts Medical Center; Tufts University				Roubenoff, Ronenn/0000-0002-3959-3179	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL047080] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002120] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00722] Funding Source: Medline; NHLBI NIH HHS [HL 47080] Funding Source: Medline; NIDDK NIH HHS [DK 02120] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI A, 1987, J CHROMATOGR-BIOMED, V422, P43, DOI 10.1016/0378-4347(87)80438-3; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; BROWN JH, 1988, BRIT MED J, V296, P1505, DOI 10.1136/bmj.296.6635.1505; BULKLEY BH, 1975, AM J MED, V58, P243, DOI 10.1016/0002-9343(75)90575-6; CAMP VM, 1983, CLIN CHEM, V29, P642; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; CUMMING RG, 1989, MED J AUSTRALIA, V150, P551, DOI 10.5694/j.1326-5377.1989.tb136692.x; DENHEIJER M, 1995, LANCET, V345, P882, DOI 10.1016/S0140-6736(95)90008-X; HARPER AE, 1970, PHYSIOL REV, V50, P428, DOI 10.1152/physrev.1970.50.3.428; KATTWINKEL N, 1992, ANN INTERN MED, V116, P974, DOI 10.7326/0003-4819-116-12-974; LINDER MC, 1991, NUTR BIOCH METABOLIS, P127; PERRY IJ, 1995, LANCET, V346, P1395, DOI 10.1016/S0140-6736(95)92407-8; PETRI M, 1991, J RHEUMATOL, V18, P1823; PETRI M, 1992, AM J MED, V93, P513, DOI 10.1016/0002-9343(92)90578-Y; PETRI M, 1987, ANN INTERN MED, V106, P624; RODGERS GM, 1986, J CLIN INVEST, V77, P1909, DOI 10.1172/JCI112519; ROUBENOFF R, 1990, ANN INTERN MED, V113, P501, DOI 10.7326/0003-4819-113-7-501; RUSSELL RM, 1993, AM J CLIN NUTR, V58, P4, DOI 10.1093/ajcn/58.1.4; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; TAMURA T, 1990, CLIN CHEM, V36, P1993; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; UELAND PM, 1989, ATHEROSCLEROTIC CARD, P182; VERHOEF P, 1994, STROKE, V25, P1924, DOI 10.1161/01.STR.25.10.1924; [No title captured]; 1979, DIABETES, V28, P1039	28	341	351	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 26	1996	348	9035					1120	1124		10.1016/S0140-6736(96)03032-2	http://dx.doi.org/10.1016/S0140-6736(96)03032-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP106	8888164	hybrid			2022-12-24	WOS:A1996VP10600008
J	Hopton, J; Hogg, R; McKee, I				Hopton, J; Hogg, R; McKee, I			Patients' accounts of calling the doctor out of hours: Qualitative study in one general practice	BRITISH MEDICAL JOURNAL			English	Article							NIGHT VISITING RATES; NORMAL WORKING HOURS; CARE; ORGANIZATION; SERVICES; DEMAND	Objective-To investigate patients' accounts of calling the doctor out of hours, Design-Qualitative analysis of semi-structured interviews with two groups of patients who called their doctors out of hours from one general practice. Subjects-23 people who had called the doctor on their behalf or on behalf of another adult and 23 people who had called on behalf of a child between 6 pm and 8 am on a week day (omitting the weekend from 6 pm on Friday to 8 am on Monday). Results-Although respondents described symptoms as the main reason for the call, they also described a range of other factors that led to the call, including their feelings, concerns about specific illnesses, their responsibility for others, and their previous attempts to manage the problem themselves. They also described past experiences with health services that were important in explaining the current out of hours call or explaining their general approach to using services. Conclusions-The pursuit of a model of out of hours care based on medical necessity that neglects the psychosocial context of illness may not be appropriate. The importance of previous experiences of health services and contacts with health professionals in explaining current service use requires wider acknowledgement by health professionals across sectors. Separate educational programmes to encourage patients to use out of hours services more appropriately that neglect these issues may be too simplistic.	WESTERHAILES HLTH CTR,EDINBURGH EH14 2SS,MIDLOTHIAN,SCOTLAND		Hopton, J (corresponding author), UNIV EDINBURGH,DEPT GEN PRACTICE,EDINBURGH EH8 9DX,MIDLOTHIAN,SCOTLAND.							ARMSTRONG D, 1979, SOC SCI MED-MED SOC, VA13, P1, DOI 10.1016/0271-7123(79)90002-6; BUXTON MJ, 1977, BRIT MED J, V1, P827, DOI 10.1136/bmj.1.6064.827; CARTISLE RD, 1993, BRIT MED J, V306, P1383; COWIE B, 1976, SOC SCI MED, V10, P87, DOI 10.1016/0037-7856(76)90059-7; CUBITT T, 1983, BRIT MED J, V287, P28, DOI 10.1136/bmj.287.6384.28; Cunningham-Burley Sarah, 1990, READINGS MED SOCIOLO, P85; CUNNINGHAMBURLEY S, 1987, BMJ-BRIT MED J, V295, P700, DOI 10.1136/bmj.295.6600.700; DONABEDIAN A, 1973, ASPECTS MED CARE ADM; HALLAM L, 1994, BRIT MED J, V308, P249, DOI 10.1136/bmj.308.6923.249; HALLAM L, 1994, BRIT MED J, V309, P1621, DOI 10.1136/bmj.309.6969.1621; HOPTON JL, 1995, BRIT MED J, V310, P1369, DOI 10.1136/bmj.310.6991.1369; LIVINGSTONE AE, 1984, BRIT MED J, V289, P474; Lofland J., 1996, ANAL SOCIAL SETTINGS; MAIN JA, 1989, BRIT MED J, V299, P627, DOI 10.1136/bmj.299.6699.627-b; MAJEED FA, 1995, BRIT J GEN PRACT, V45, P531; MORGAN M, 1985, SOCIOLOGICAL APPROAC, P76; MORRISON JM, 1991, BRIT MED J, V303, P1111, DOI 10.1136/bmj.303.6810.1111; PITTS J, 1990, BRIT MED J, V300, P1113, DOI 10.1136/bmj.300.6732.1113; Robinson D., 1973, PATIENTS PRACTITIONE; SALISBURY C, 1993, BRIT MED J, V306, P762, DOI 10.1136/bmj.306.6880.762; Stott N C, 1979, J R Coll Gen Pract, V29, P201; Strauss A., 1990, BASICS QUALITATIVE R; TELLES JL, 1981, SOC SCI MED A, V13, P243; USHERWOOD TP, 1985, J ROY COLL GEN PRACT, V35, P395; WILLIAMS G, 1984, SOCIOL HEALTH ILL, V6, P175, DOI 10.1111/1467-9566.ep10778250; ZOLA IK, 1973, SOC SCI MED, V7, P677, DOI 10.1016/0037-7856(73)90002-4	26	24	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 19	1996	313	7063					991	994						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN916	8892422				2022-12-24	WOS:A1996VN91600028
J	Nugent, CI; Hughes, TR; Lue, NF; Lundblad, V				Nugent, CI; Hughes, TR; Lue, NF; Lundblad, V			Cdc13p: A single-strand telomeric DNA binding protein with a dual role in yeast telomere maintenance	SCIENCE			English	Article							OXYTRICHA MACRONUCLEAR DNA; SACCHAROMYCES-CEREVISIAE; RNA COMPONENT; SENESCENCE; CELLS; VARIABILITY; THERMOPHILA; CHECKPOINT; MUTANTS; REPEAT	The CDC13 gene has previously been implicated in the maintenance of telomere integrity in Saccharomyces cerevisiae, With the use of two classes of mutations, here it is shown that CDC13 has two discrete roles at the telomere. The cdc13-2(est) mutation perturbs a function required in vivo for telomerase regulation but not in vitro for enzyme activity, whereas cdc13-1(ts) defines a separate essential role at the telomere. In vitro, purified Cdc13p binds to single-strand yeast telomeric DNA. Therefore, Cdc13p is a telomere-binding protein required to protect the telomere and mediate access of telomerase to the chromosomal terminus.	BAYLOR COLL MED,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030; BAYLOR COLL MED,CELL & MOL BIOL PROGRAM,HOUSTON,TX 77030; CORNELL UNIV,COLL MED,DEPT MICROBIOL,NEW YORK,NY 10021	Baylor College of Medicine; Baylor College of Medicine; Cornell University			Lue, Neal/AAO-6759-2020	Lue, Neal/0000-0001-9700-6895				ALLSHIRE RC, 1988, NATURE, V332, P656, DOI 10.1038/332656a0; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; CARDENAS ME, 1993, GENE DEV, V7, P883, DOI 10.1101/gad.7.5.883; COHN M, 1995, SCIENCE, V269, P396, DOI 10.1126/science.7618104; COOKE HJ, 1986, COLD SPRING HARB SYM, V51, P213, DOI 10.1101/SQB.1986.051.01.026; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; GRAY JT, 1991, CELL, V67, P807, DOI 10.1016/0092-8674(91)90075-A; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARTWELL LH, 1985, GENETICS, V110, P381; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HIYAMA K, 1995, J IMMUNOL, V155, P3711; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LENDVAY T, IN PRESS GENETICS; LOUIS EJ, 1990, GENETICS, V124, P533; LUE NF, 1995, J BIOL CHEM, V270, P21453, DOI 10.1074/jbc.270.37.21453; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; PRICE CM, 1987, GENE DEV, V1, P783, DOI 10.1101/gad.1.8.783; ROSS LL, UNPUB; SHENG H, 1995, MOL CELL BIOL, V15, P1144; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; VIRTAPEARLMAN V, UNPUB; Wellinger RJ, 1996, CELL, V85, P423, DOI 10.1016/S0092-8674(00)81120-4; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; Wright WE, 1996, EMBO J, V15, P1734, DOI 10.1002/j.1460-2075.1996.tb00519.x; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZENTGRAF H, 1995, NUCLEIC ACIDS RES, V23, P3347, DOI 10.1093/nar/23.16.3347	32	512	525	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1996	274	5285					249	252		10.1126/science.274.5285.249	http://dx.doi.org/10.1126/science.274.5285.249			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM671	8824190				2022-12-24	WOS:A1996VM67100044
J	Tereskerz, PM; Pearson, RD; Jagger, J				Tereskerz, PM; Pearson, RD; Jagger, J			Occupational exposure to blood among medical students	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							NEEDLESTICK INJURIES; RATES; RISK				Tereskerz, PM (corresponding author), UNIV VIRGINIA,HLTH SCI CTR,DEPT NEUROSURG,BOX 407,CHARLOTTESVILLE,VA 22908, USA.							*ACCR LIAIS COMM M, 1995, FUNCT STRUCT MED SCH, P17; BAIG EF, 1994, J FLA BAR, V68, P75; CHINA HP, 1993, ANN ACAD MED SINGAP, V22, P338; CHOUDHURY RP, 1992, J HOSP INFECT, V22, P143, DOI 10.1016/0195-6701(92)90098-7; DEVRIES B, 1994, MED J AUSTRALIA, V160, P398; DORGAN CA, 1995, STAT RECORD HLTH MED, P596; GLANTZ LH, 1992, MILBANK Q, V70, P43, DOI 10.2307/3350085; GOMPERTZ S, 1990, J SOC OCCUP MED, V40, P19; JAGGER J, 1988, NEW ENGL J MED, V319, P284, DOI 10.1056/NEJM198808043190506; JAGGER J, 1991, INFECT CONT HOSP EP, V12, P211, DOI 10.2307/30146993; KIRKPATRICK BL, 1993, J HOSP INFECT, V23, P315, DOI 10.1016/0195-6701(93)90149-T; KOENIG S, 1995, AM J INFECT CONTROL, V23, P40, DOI 10.1016/0196-6553(95)90007-1; ONEILL TM, 1992, ARCH INTERN MED, V152, P1451, DOI 10.1001/archinte.152.7.1451; RESNIC FS, 1995, ARCH INTERN MED, V155, P75, DOI 10.1001/archinte.155.1.75; STOTKA JL, 1991, INFECT CONT HOSP EP, V12, P583; TERESKERZ P, 1995, ADV EXPOSURE PREV, V1, P10; TERESKERZ PM, 1995, ADV EXPOSURE PREV, V2, P7; TESCH B, 1993, ACAD MED, V68, P87, DOI 10.1097/00001888-199301000-00014; VERGILIO JA, 1993, ARCH SURG-CHICAGO, V128, P36; WATERMAN J, 1994, J HOSP INFECT, V26, P149, DOI 10.1016/0195-6701(94)90058-2; 1989, MMWR-MORBID MORTAL W, V38, P746; 1995, MMWR-MORBID MORTAL W, V44, P929; 1996, MMWR-MORBID MORTAL W, V45, P468; 1996, INFECT CONT HOSP EP, V17, P476; 1989, MMWR-MORBID MORTAL W, V38, P1; 1991, MMWR-MORBID MORTAL W, V40, P1	26	37	42	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 10	1996	335	15					1150	1153		10.1056/NEJM199610103351512	http://dx.doi.org/10.1056/NEJM199610103351512			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN399	8813049				2022-12-24	WOS:A1996VN39900012
J	Felsenfeld, DP; Choquet, D; Sheetz, MP				Felsenfeld, DP; Choquet, D; Sheetz, MP			Ligand binding regulates the directed movement of beta 1 integrins on fibroblasts	NATURE			English	Article							LOCOMOTING CELLS; FIBRONECTIN; ASSOCIATIONS; EXPRESSION; CONTACTS; SUBUNIT	To enable cells to crawl, adhesion receptors such as integrins most bind to extracellular molecules and simultaneously interact with force-generating components of the cytoskeleton(1,2). We show here that the binding of extracellular ligand in living cells induces the attachment of beta 1 integrins to the retrograde-snoring cytoskeleton, Unliganded integrins are not associated with the rearward-moving cytoskeleton: gold particles attached to beta 1 integrin by a monoclonal antibody diffuse inn the membrane, However, addition of soluble RGD peptide (single-letter amino-acid code) or the use of fibronectin-coated gold particles causes the attachment of integrins to the rearward-moving cytoskeleton. Deletion of the beta 1 cytoplasmic tail blocks cytoskeletal attachment. The directed movement of integrins in response to ligand indicates that ligand binding is the critical step in regulating organized receptor movement on the cell surface and the migration of adherent cells.	DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA	Duke University			Choquet, Daniel/K-7893-2018; Choquet, Daniel/GOJ-8825-2022; Choquet, Daniel/E-4203-2013	Choquet, Daniel/0000-0003-4726-9763; Choquet, Daniel/0000-0003-4726-9763; 				BUCK CA, 1987, J CELL SCI, P231; DUBAND JL, 1988, J CELL BIOL, V107, P1385, DOI 10.1083/jcb.107.4.1385; GEHLSEN KR, 1988, J CELL BIOL, V106, P925, DOI 10.1083/jcb.106.3.925; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; KUCIK DF, 1989, NATURE, V340, P315, DOI 10.1038/340315a0; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MUELLER SC, 1989, J CELL BIOL, V109, P3455, DOI 10.1083/jcb.109.6.3455; Qian H, 1991, BIOPHYS J, V60, P910, DOI 10.1016/S0006-3495(91)82125-7; REGEN CM, 1992, J CELL BIOL, V119, P1347, DOI 10.1083/jcb.119.5.1347; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SCHMIDT CE, 1993, J CELL BIOL, V123, P977, DOI 10.1083/jcb.123.4.977; SCHNAPP BJ, 1988, CELL MOTIL CYTOSKEL, V10, P47, DOI 10.1002/cm.970100109; SHEETZ MP, 1989, NATURE, V340, P284, DOI 10.1038/340284a0; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853	22	196	197	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 3	1996	383	6599					438	440		10.1038/383438a0	http://dx.doi.org/10.1038/383438a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL463	8837776				2022-12-24	WOS:A1996VL46300062
J	Kaiser, RI; Ochsenfeld, C; HeadGordon, M; Lee, YT; Suits, AG				Kaiser, RI; Ochsenfeld, C; HeadGordon, M; Lee, YT; Suits, AG			A combined experimental and theoretical study on the formation of interstellar C3H isomers	SCIENCE			English	Article							NEUTRAL-NEUTRAL REACTIONS; GAUSSIAN-BASIS SETS; ATOMIC CARBON; MOLECULES; CLOUDS; CHEMISTRY; IRC+10216; ENVELOPE; RATES; BEAM	The reaction of ground-state carbon atoms with acetylene was studied under single-collision conditions in crossed beam experiments to investigate the chemical dynamics of forming cyclic and linear C3H isomers (c-C3H and l-C3H, respectively) in interstellar environments via an atom-neutral reaction. Combined state-of-the-art ab initio calculations and experimental identification of the carbon-hydrogen exchange channel to both isomers classify this reaction as an important alternative to ion-molecule encounters to synthesize C3H radicals in the interstellar medium. These findings strongly correlate with astronomical observations and explain a higher [c-C3H]/[l-C3H] ratio in the dark cloud TMC-1 than in the carbon star IRC+10216.	UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, DIV CHEM SCI, BERKELEY, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Kaiser, RI (corresponding author), UNIV CALIF BERKELEY, DEPT CHEM, BERKELEY, CA 94720 USA.		Ochsenfeld, Christian/E-8021-2015; Head-Gordon, Martin/AAR-4028-2020; Lee, Yuan-Tseh/F-7914-2012	Ochsenfeld, Christian/0000-0002-4189-6558; 				[Anonymous], 1991, MODERN MOL PHOTOCHEM; BETTENS RPA, 1995, ASTROPHYS J, V443, P664, DOI 10.1086/175558; CLARY DC, 1994, ASTROPHYS J, V422, P416, DOI 10.1086/173737; CLARY DC, 1993, J CHEM SOC FARADAY T, V89, P2185, DOI 10.1039/ft9938902185; DUNNING TH, 1989, J CHEM PHYS, V90, P1007, DOI 10.1063/1.456153; ENTENNMANN EA, 1986, THESIS HARVARD U; HERBST E, 1994, MON NOT R ASTRON SOC, V268, P335, DOI 10.1093/mnras/268.2.335; HERBST E, 1990, ASTRON ASTROPHYS, V233, P177; HERBST E, 1973, ASTROPHYS J, V185, P505, DOI 10.1086/152436; HERBST E, 1984, ASTROPHYS J, V285, P618, DOI 10.1086/162538; HERBST E, 1976, CHEM PHYS LETT, V42, P54, DOI 10.1016/0009-2614(76)80550-7; KAISER RI, 1995, J CHEM PHYS, V103, P10395, DOI 10.1063/1.469877; Kaiser RI, 1996, J CHEM PHYS, V105, P8705, DOI 10.1063/1.472652; Kaiser RI, 1995, REV SCI INSTRUM, V66, P5405, DOI 10.1063/1.1146061; Kanada M, 1996, J CHEM PHYS, V104, P2192, DOI 10.1063/1.471811; KEENE J, 1993, ASTROPHYS J, V415, pL131, DOI 10.1086/187050; LEE YT, 1969, REV SCI INSTRUM, V40, P1402, DOI 10.1063/1.1683809; LEE YT, 1987, SCIENCE, V236, P793, DOI 10.1126/science.236.4803.793; LEVINE RD, 1987, MOL REACTION DYNAMIC; LIAO Q, 1995, ASTROPHYS J, V444, P694, DOI 10.1086/175642; MILLAR TJ, 1994, ASTRON ASTROPHYS, V288, P561; MILLER WB, 1967, DISCUSS FARADAY SOC, P108, DOI 10.1039/df9674400108; MILLER WB, 1967, DISCUSS FARADAY SOC, V44, P291; RAGHAVACHARI K, 1989, CHEM PHYS LETT, V157, P479, DOI 10.1016/S0009-2614(89)87395-6; ROBINSON MS, 1995, J AM CHEM SOC, V117, P6766, DOI 10.1021/ja00130a017; SCHAFER A, 1992, J CHEM PHYS, V97, P2571, DOI 10.1063/1.463096; Seburg R. A., 1995, ANGEW CHEM, V107, P2198, DOI DOI 10.1002/ANGE.19951071826; SMITH D, 1992, CHEM REV, V92, P1580; STANTON JF, 1995, CHEM PHYS LETT, V237, P20, DOI 10.1016/0009-2614(95)00270-E; STANTON JF, 1992, INT J QUANTUM CHEM, P879; WATTS JD, 1992, CHEM PHYS LETT, V200, P1, DOI 10.1016/0009-2614(92)87036-O; WINNEWISSER G, 1987, TOP CURR CHEM, P121	32	153	153	2	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 29	1996	274	5292					1508	1511		10.1126/science.274.5292.1508	http://dx.doi.org/10.1126/science.274.5292.1508			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929407				2022-12-24	WOS:A1996VV77500042
J	Parada, CA; Roeder, RG				Parada, CA; Roeder, RG			Enhanced processivity of RNA polymerase II triggered by Tat-induced phosphorylation of its carboxy-terminal domain	NATURE			English	Article							TRANSCRIPTION FACTOR TFIIH; BASAL TRANSCRIPTION; ELONGATION; KINASE; INITIATION; BINDING; COMPLEX; VP16	THE protein Tat is encoded by the HIV-1 genome and is essential for viral replication because of its activation of viral transcription. Tat enhances the ability of RNA polymerase II (Pol II) to move long distances down the DNA through a poorly understood mechanism that involves its binding the to the 5' end of the nascent HIV-1 transcript(1-5), It has been suggested(6-10) that the stimulation of transcript elongation by conventional DNA-binding activators may involve phosphorylation of the carboxy-terminal domain (CTD) of Pol II by the transcription factor TFIIH11-13 through the associated CAK kinase(14-16). Here we show that Tat-enhanced HIV-1 transcription in vitro requires both TFIIH and the CTD of Pol II, In addition, Tat, through its activation domain, both interacts with a functional TFIIH-containing complex and stimulates phosphorylation of a CTD-containing substrate by the TFIIH kinase. Under conditions that jointly restrict transcriptional elongation(5,17) and TFIIH-mediated CTD phosphorylation, Tat stimulates both these activities. Furthermore, RNA synthesis is required for Tat to stimulate phosphorylation of the CTD when it is part of an initiation complex, as expected from Tat's interaction with viral transcripts(1). Thus, stimulation of Pol II elongation by Tat may involve direct effects on TFIIH-mediated CTD phosphorylation.	ROCKEFELLER UNIV,BIOCHEM & MOL BIOL LAB,NEW YORK,NY 10021	Rockefeller University								BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; Blair WS, 1996, EMBO J, V15, P1658, DOI 10.1002/j.1460-2075.1996.tb00511.x; Blau J, 1996, MOL CELL BIOL, V16, P2044; Dvir A, 1996, J BIOL CHEM, V271, P7245, DOI 10.1074/jbc.271.13.7245; FEINBERG MB, 1991, P NATL ACAD SCI USA, V88, P4045, DOI 10.1073/pnas.88.9.4045; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; Herrmann CH, 1996, NUCLEIC ACIDS RES, V24, P501, DOI 10.1093/nar/24.3.501; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; Jiang Y, 1996, MOL CELL BIOL, V16, P1614; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; KATO H, 1992, GENE DEV, V6, P655, DOI 10.1101/gad.6.4.655; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MADORE SJ, 1993, J VIROL, V67, P3703, DOI 10.1128/JVI.67.7.3703-3711.1993; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; OHKUMA Y, 1994, NATURE, V368, P160, DOI 10.1038/368160a0; OHKUMA Y, 1995, MOL CELL BIOL, V15, P4856; PARADA CA, 1995, J BIOL CHEM, V270, P2274, DOI 10.1074/jbc.270.5.2274; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; TILEY LS, 1992, GENE DEV, V6, P2077, DOI 10.1101/gad.6.11.2077; Wu-Baer Foon, 1996, Journal of Biological Chemistry, V271, P4201, DOI 10.1074/jbc.271.8.4201; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; Yang XZ, 1996, J VIROL, V70, P4576, DOI 10.1128/JVI.70.7.4576-4584.1996; YANKULOV K, 1995, J BIOL CHEM, V270, P23922, DOI 10.1074/jbc.270.41.23922; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2; ZHOU QA, 1995, EMBO J, V14, P321, DOI 10.1002/j.1460-2075.1995.tb07006.x	30	237	240	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1996	384	6607					375	378		10.1038/384375a0	http://dx.doi.org/10.1038/384375a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV271	8934526				2022-12-24	WOS:A1996VV27100054
J	van der Maas, PJ; vanderWal, G; Haverkate, I; deGraaff, CLM; Kester, JGC; OnwuteakaPhilipsen, BD; vanderHeide, A; Bosma, JM; Willems, DL				van der Maas, PJ; vanderWal, G; Haverkate, I; deGraaff, CLM; Kester, JGC; OnwuteakaPhilipsen, BD; vanderHeide, A; Bosma, JM; Willems, DL			Euthanasia, physician-assisted suicide, and other medical practices involving the end of life in the Netherlands, 1990-1995	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ATTITUDES	Background In 1991 a new procedure for reporting physician-assisted deaths was introduced in the Netherlands that led to a tripling in the number of reported cases. In 1995, as part of an evaluation of this procedure, a nationwide study of euthanasia and other medical practices concerning the end of life was begun that was identical to a study conducted in 1990. Methods We conducted two studies, the first involving interviews with 405 physicians (general practitioners, nursing home physicians, and clinical specialists) and the second involving questionnaires mailed to the physicians attending 6060 deaths that were identified from death certificates. The response rates were 89 percent and 77 percent, respectively. Results Among the deaths studied, 2.3 percent of those in the interview study and 2.4 percent of those in the death-certificate study were estimated to have resulted from euthanasia, and 0.4 percent and 0.2 percent, respectively, resulted from physician-assisted suicide. In 0.7 percent of cases, life was ended without the explicit, concurrent request of the patient. Pain and symptoms were alleviated with doses of opioids that may have shortened life in 14.7 to 19.1 percent of cases, and decisions to withhold or withdraw life-prolonging treatment were made in 20.2 percent. Euthanasia seems to have increased in incidence since 1990, and the ending of life without the patient's explicit request seems to have decreased slightly. For each type of medical decision except those in which life-prolonging treatment was withheld or withdrawn, cancer was the most frequently reported diagnosis. Conclusions Since the notification procedure was introduced, end-of-life decision making in the Netherlands has changed only slightly, in an anticipated direction. Close monitoring of such decisions is possible, and we found no signs of an unacceptable increase in the number of decisions or of less careful decision making. (C)1996, Massachusetts Medical Society.	VRIJE UNIV AMSTERDAM, INST RES EXTRAMURAL MED, AMSTERDAM, NETHERLANDS; STAT NETHERLANDS, VOORBURG, NETHERLANDS	Vrije Universiteit Amsterdam	van der Maas, PJ (corresponding author), ERASMUS UNIV ROTTERDAM, DEPT PUBL HLTH, POB 1738, NL-3000 DR ROTTERDAM, NETHERLANDS.							BLACK AL, 1996, JAMA-J AM MED ASSOC, V275, P919; Bokhove J., 1996, BALANS REKENONDERWIJ; Cochran W. G., 1963, SAMPLING TECHNIQUES, DOI [10.1002/bimj.19650070312, DOI 10.1002/BIMJ.19650070312]; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Folker AP, 1996, BIOETHICS, V10, P233, DOI 10.1111/j.1467-8519.1996.tb00122.x; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; PIJNENBORG L, 1993, LANCET, V341, P1196, DOI 10.1016/0140-6736(93)91014-D; *ROYAL DUTCH MED A, 1995, POS PAP EUTH; STEVENS CA, 1994, J MED ETHICS, V20, P41, DOI 10.1136/jme.20.1.41; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; VANDERMAAS PJ, 1992, HLTH POLICY, V22; vanderWal G, 1996, NEW ENGL J MED, V335, P1706; VANDERWAL G, 1994, BRIT MED J, V308, P1346, DOI 10.1136/bmj.308.6940.1346; WARD BJ, 1994, BRIT MED J, V308, P1332, DOI 10.1136/bmj.308.6940.1332	14	386	386	2	60	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 28	1996	335	22					1699	1705		10.1056/NEJM199611283352227	http://dx.doi.org/10.1056/NEJM199611283352227			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VV936	8929370	Green Published, Bronze			2022-12-24	WOS:A1996VV93600034
J	Tyson, JE; Younes, N; Verter, J; Wright, LL				Tyson, JE; Younes, N; Verter, J; Wright, LL			Viability, morbidity, and resource use among newborns of 501- to 800-g birth weight	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIAGNOSIS-RELATED GROUPS; NEONATAL INTENSIVE-CARE; EXTREMELY PREMATURE; GESTATIONAL-AGE; INFANTS BORN; MORTALITY; OUTCOMES; SEVERITY; CHILDREN; NETWORK	Objectives.-To assess risk factors affecting viability and analyze the effects of mechanical ventilation (MV) on neonatal outcome and resource use among extremely premature infants. Design.-Inception cohort study. Setting.-Neonatal intensive care units of the 12-center National Institute of Child Health and Human Development Neonatal Research Network. Participants.-A total of 1126 infants with a birth weight of 501 to 800 g born in network centers between January 1, 1994, and December 31, 1995. Main Outcome Measures.-Observed survival; maximum estimated survival (assuming the same survival among infants who died without MV as among infants in the same risk category who received MV); observed and maximum estimated survival without severe brain injury (either interventricular echodensity with ventricular dilation or parenchymal echodensity); hospital stay; resource investment. Results.-Overall mortality was 43%; mortality in infants without MV was 93%, A total of 15% of ail the infants died without MV. Females, small-for-gestational-age infants, and infants whose mothers received antenatal steroids had an advantage in survival with MV equivalent to an increase in birth weight of 90 g, 57 g, and 67 g, respectively, The corresponding advantage of these infants in survival without severe brain injury was 107 g, 97 g, and 64 g, respectively, Females in the lowest birth-weight group were more likely to die without MV than were larger males with a similar estimated likelihood of survival with MV. Mean hospital stay was 115 days for the survivors, values much greater than the 17.9-day standard for 501- to 800-g survivors under the diagnosis related group system. Resource investment was considerable (127 hospital days per survivor and 148 days per survivor without severe brain injury), but, like outcome, varied markedly between risk categories. Had MV been used for all infants who died, we estimate a substantial increase in resource use and a maximum of 8 additional survivors (no more than 6 without severe brain injury per 100 infants with a birth weight of 501 to 800 g. Conclusions.-Although recommendations to initiate or forgo MV for extremely premature infants have often focused on 1 factor(birth weight or gestational age), multiple factors should be considered. Other factors being equal, our analyses support use of MV for females at a minimum birth weight approximately 100 g lower than that for males. The current diagnosis related group reimbursement system can be expected to compromise resources for 501- to 800-g infants who would benefit from MV. Such care entails considerable resource use, although the cost per life-year gained is likely to be considerably less than that for many adults given intensive care. Our findings can be used to facilitate more appropriate treatment decisions, determine adequate resources, and better inform the debate about the benefits and burdens of intensive care for extremely premature newborns.	GEORGE WASHINGTON UNIV, CTR BIOSTAT, WASHINGTON, DC USA; NICHHD, BETHESDA, MD 20892 USA; CASE WESTERN RESERVE UNIV, CLEVELAND, OH 44106 USA; UNIV CINCINNATI, CINCINNATI, OH USA; EMORY UNIV, ATLANTA, GA 30322 USA; INDIANA UNIV, SCH MED, INDIANAPOLIS, IN USA; UNIV NEW MEXICO, ALBUQUERQUE, NM 87131 USA; STANFORD UNIV, STANFORD, CA 94305 USA; WAYNE STATE UNIV, DETROIT, MI USA; BROWN UNIV, WOMEN & INFANTS HOSP, PROVIDENCE, RI USA; YALE UNIV, NEW HAVEN, CT USA	George Washington University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Case Western Reserve University; University System of Ohio; University of Cincinnati; Emory University; Indiana University System; Indiana University-Purdue University Indianapolis; University of New Mexico; Stanford University; Wayne State University; Brown University; Women & Infants Hospital Rhode Island; Yale University	Tyson, JE (corresponding author), UNIV TEXAS, SW MED CTR, DEPT PEDIAT, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.				NICHD NIH HHS [2U01 HD 19897, 1U10 HD 21373] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U10HD021373] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD019897] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALLEN AC, 1994, CAN MED ASSOC J, V151, P547; ALLEN MC, 1993, NEW ENGL J MED, V329, P1597, DOI 10.1056/NEJM199311253292201; ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; ARBUCKLE TE, 1989, CAN MED ASSOC J, V140, P157; ARRAS JD, 1987, CONT ISSUES FETAL NE, V3, P151; AVERY GB, 1987, CLIN PERINATOL, V14, P361, DOI 10.1016/S0095-5108(18)30770-X; BALLARD JL, 1979, J PEDIATR-US, V95, P769, DOI 10.1016/S0022-3476(79)80734-9; BALLARD JL, 1991, J PEDIATR-US, V119, P417, DOI 10.1016/S0022-3476(05)82056-6; BAQUET D, 1995, NY TIMES        0305, P1; BERKI SE, 1987, PEDIATRICS, V79, P874; BOYLE MH, 1983, NEW ENGL J MED, V308, P1330, DOI 10.1056/NEJM198306023082206; BREGMAN J, 1992, CLIN PERINATOL, V19, P673, DOI 10.1016/S0095-5108(18)30451-2; BUCHANAN N, 1987, MED J AUSTRALIA, V147, P184, DOI 10.5694/j.1326-5377.1987.tb133354.x; COHEN IL, 1993, JAMA-J AM MED ASSOC, V269, P1025, DOI 10.1001/jama.269.8.1025; *COMM FET NEWB AM, 1995, PEDIATRICS, V5, P974; *COMM FET NEWB AM, 1971, STAND REC HOSP CAR N; CONSTANTINE NA, 1987, J PEDIATR-US, V110, P921, DOI 10.1016/S0022-3476(87)80416-X; Donovan EF, 1996, PEDIATR RES, V39, P1220; DOYLE LW, 1989, AM J DIS CHILD, V143, P223, DOI 10.1001/archpedi.1989.02150140117032; FANAROFF AA, 1995, AM J OBSTET GYNECOL, V173, P1423, DOI 10.1016/0002-9378(95)90628-2; Frader JE, 1996, PEDIATRICS, V98, P149; HACK M, 1991, PEDIATRICS, V87, P587; HACK M, 1994, NEW ENGL J MED, V331, P753, DOI 10.1056/NEJM199409223311201; HACK M, 1993, NEW ENGL J MED, V329, P1649, DOI 10.1056/NEJM199311253292210; HANLEY JA, 1982, DIAGN RADIOL, V149, P29; HARRISON H, 1993, PEDIATRICS, V92, P643; HORBAR JD, 1995, FUTURE CHILD, V5, P139, DOI 10.2307/1602512; HORBAR JD, 1993, CRIT CARE MED, V21, P12, DOI 10.1097/00003246-199301000-00008; IMERSHEIN AW, 1992, PEDIATRICS, V89, P56; JONES R, 1995, PEDIATRICS, V96, P897; KRAMER MS, 1988, JAMA-J AM MED ASSOC, V260, P3306, DOI 10.1001/jama.260.22.3306; KRAYBILL EN, 1988, J PEDIATR-US, V113, P327, DOI 10.1016/S0022-3476(88)80273-7; LICHTIG LK, 1989, PEDIATRICS, V84, P49; MILNER RDG, 1974, J OBSTET GYN BR COMM, V81, P956; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; PHIBBS CS, 1986, PEDIATRICS, V78, P829; POLAND RL, 1985, PEDIATRICS, V76, P104; QUINN MW, 1993, LANCET, V342, P324, DOI 10.1016/0140-6736(93)91472-X; RICHARDSON DK, 1993, PEDIATRICS, V91, P969; RUARK JE, 1988, NEW ENGL J MED, V318, P25, DOI 10.1056/NEJM198801073180106; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P117; SAIGAL S, 1994, J PEDIATR-US, V125, P418, DOI 10.1016/S0022-3476(05)83289-5; Saigal S, 1996, JAMA-J AM MED ASSOC, V276, P453, DOI 10.1001/jama.276.6.453; SCHAPIRA DV, 1993, JAMA-J AM MED ASSOC, V269, P783, DOI 10.1001/jama.269.6.783; SCHWARTZ LS, 1991, GEN HOSP PSYCHIAT, V13, P19, DOI 10.1016/0163-8343(91)90005-H; SIMON NP, 1994, CLIN PERINATOL, V21, P411, DOI 10.1016/S0095-5108(18)30353-1; SINCLAIR JC, 1995, PAEDIATR PERINAT EP, V9, P373, DOI 10.1111/j.1365-3016.1995.tb00157.x; STRONG C, 1987, CONT ISSUES FETAL NE, V3, P187; TARNOWMORDI W, 1990, BRIT MED J, V300, P1611, DOI 10.1136/bmj.300.6740.1611; TORRANCE GW, 1982, OPER RES, V30, P1043, DOI 10.1287/opre.30.6.1043; TYSON J, 1995, FUTURE CHILD, V5, P197, DOI 10.2307/1602515; TYSON J, 1992, Pediatric Research, V31, p26A; VOLPE J, 1995, NEUROLOGY NEWBORN, P427; WATTS JK, 1995, PAEDIATR PERINAT EP, V9, P375; YOUNG EWD, 1990, AM J DIS CHILD, V144, P549, DOI 10.1001/archpedi.1990.02150290043023; 1991, FED REG         0830, V56, P43292; [No title captured]; 1995, PAEDIATR PERINAT EP, V9, P370	58	116	117	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	1996	276	20					1645	1651		10.1001/jama.276.20.1645	http://dx.doi.org/10.1001/jama.276.20.1645			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VU209	8922450				2022-12-24	WOS:A1996VU20900031
J	Katz, DA; Griffith, JL; Beshansky, JR; Selker, HP				Katz, DA; Griffith, JL; Beshansky, JR; Selker, HP			The use of empiric clinical data in the evaluation of practice guidelines for unstable angina	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; ACUTE CARDIAC ISCHEMIA; CORONARY-CARE-UNIT; MEDICAL-PRACTICE GUIDELINES; PREDICTIVE INSTRUMENT; CHEST PAIN; PROSPECTIVE MULTICENTER; HEART-DISEASE; EMERGENCY; PECTORIS	Objective.-To determine the applicability to emergency department (ED) clinical practice of a nationally disseminated practice guideline on the disposition of patients with a diagnosis of unstable angina, and to determine the potential impact of the guideline on hospital admissions and demand for intensive care beds. Design.-Application of guideline criteria for ED disposition decisions to a validation sample derived from a prospective clinical trial. Setting.-Five hospitals, including 2 urban general teaching hospitals, 2 urban tertiary care university hospitals, and 1 suburban university-affiliated community hospital. Patients.-A consecutive sample of 457 patients who presented with symptoms suggestive of acute cardiac ischemia and who had ''unstable angina'' or ''rule out unstable angina'' diagnosed by ED physicians. Greater than 90% of eligible patients were enrolled in the clinical trial, follow-up data sufficient for assignment of a definitive diagnosis were obtained for 99% of subjects. Main outcome Measures.-Acute myocardial infarction and unstable angina, based on blind review of initial and follow-up clinical data, including cardiac enzyme levels and electrocardiograms. After completion of the trial, without knowledge of final diagnosis or outcome, the investigators classified patients into risk groups specified by the unstable angina guideline. Results.-Of subjects with an ED diagnosis of unstable angina, only 6% (n=28) met the guideline's criteria corresponding to low risk for adverse events and were therefore suitable for discharge directly to home. Fifty-four percent (n=247) mel the intermediate-risk criteria; 40% (n=182) met the high-risk criteria and were identified as requiring admission to an intensive care unit. Actual ED disposition differed from guideline recommendations in 2 major areas: only 4% (1/28) of low-risk patients were discharged to home with outpatient follow-up, and only 40% (72/182) of high-risk patients were admitted to an intensive care unit. Conclusions.-Although the guideline was intended to reduce hospitalization by identifying a low-risk group, the small size of this group among ED patients suggests that little reduction in hospitalization can be expected. Indeed, the guideline may increase demand for the limited number of intensive care beds to accommodate patients with unstable angina considered high-risk but currently placed elsewhere. These results emphasize the need to use empiric data from target clinical settings to assess the likely actual impact of guidelines on clinical care prior to national dissemination.	TUFTS UNIV, NEW ENGLAND MED CTR,SCH MED,DEPT MED, DIV CLIN DECIS MAKING, BOSTON, MA 02111 USA; TUFTS UNIV, NEW ENGLAND MED CTR,SCH MED,DEPT MED, DIV CLIN CARE RES, BOSTON, MA 02111 USA	Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University				Katz, David/0000-0001-5348-6532	AHRQ HHS [R01-HS07360] Funding Source: Medline; NLM NIH HHS [LM7092] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS007360] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [T15LM007092] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		ATKINS J, 1995, AM J EMERG MED, V13, P188; AUDET AM, 1990, ANN INTERN MED, V113, P709, DOI 10.7326/0003-4819-113-9-709; BERTINI G, 1991, Journal of Emergency Medicine, V9, P57, DOI 10.1016/0736-4679(91)90589-8; BRAUNWALD E, 1994, CLIN PRACTICE GUIDEL, V10; CALIFF RM, 1988, J AM COLL CARDIOL, V11, P20, DOI 10.1016/0735-1097(88)90160-X; CALVIN JE, 1995, JAMA-J AM MED ASSOC, V273, P136; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; CANNON CP, 1995, AM J CARDIOL, V75, P977, DOI 10.1016/S0002-9149(99)80707-3; CANTRILL S, 1992, EMERG MED CLIN N AM, V8, P507; COHEN M, 1991, AM J CARDIOL, V67, P1368, DOI 10.1016/0002-9149(91)90467-Y; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; Field MJ., 1992, GUIDELINES CLIN PRAC; FUCHS R, 1981, JAMA-J AM MED ASSOC, V246, P2037, DOI 10.1001/jama.246.18.2037; GILLUM RF, 1984, AM HEART J, V108, P150, DOI 10.1016/0002-8703(84)90558-1; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; GRAVES E, 1993, NATL CTR HLTH STAT S, V13; GRIJSEELS EWM, 1995, EUR HEART J, V16, P325; JAYES RL, 1992, J GEN INTERN MED, V7, P387, DOI 10.1007/BF02599153; KARCZ A, 1990, ANN EMERG MED, V19, P865, DOI 10.1016/S0196-0644(05)81559-8; KARLSON BW, 1993, CLIN CARDIOL, V16, P397, DOI 10.1002/clc.4960160506; MCCARTHY BD, 1990, J GEN INTERN MED, V5, P365, DOI 10.1007/BF02600409; MCDONALD C, 1994, CLIN PRACTICE GUIDEL, P71; MCNUTT RA, 1988, MED DECIS MAKING, V8, P90, DOI 10.1177/0272989X8800800204; NATTEL S, 1980, CAN MED ASSOC J, V122, P180; PEARSON SD, 1994, J GEN INTERN MED, V9, P241, DOI 10.1007/BF02599648; POZEN MW, 1984, NEW ENGL J MED, V310, P1273, DOI 10.1056/NEJM198405173102001; RIZIK DG, 1995, AM J CARDIOL, V75, P993, DOI 10.1016/S0002-9149(99)80710-3; SARASIN FP, 1994, J GEN INTERN MED, V9, P187, DOI 10.1007/BF02600122; SAS, 2021, SAS PROC KAPP COEFF; Selker H. P., 1995, Journal of Investigative Medicine, V43, p497A; SELKER HP, 1987, JAMA-J AM MED ASSOC, V257, P1181, DOI 10.1001/jama.257.9.1181; SELKER HP, 1991, MED CARE, V29, P610, DOI 10.1097/00005650-199107000-00002; SELKER HP, 1993, AM J CARDIOL, V71, P339, DOI 10.1016/0002-9149(93)90802-J; VANDERDOES E, 1976, HEART B, V7, P91; WHITE LD, 1990, J AM COLL CARDIOL, V16, P304, DOI 10.1016/0735-1097(90)90577-C	35	60	62	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 20	1996	276	19					1568	1574						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT025	8918854				2022-12-24	WOS:A1996VT02500029
J	Cohen, B; Novick, D; Rubinstein, M				Cohen, B; Novick, D; Rubinstein, M			Modulation of insulin activities by leptin	SCIENCE			English	Article							NECROSIS-FACTOR-ALPHA; RECEPTOR SUBSTRATE-1; TYROSINE PHOSPHORYLATION; OBESE GENE; PHOSPHATIDYLINOSITOL 3'-KINASE; SIGNALING SYSTEM; BODY-WEIGHT; OB PROTEIN; IRS-1; MOUSE	Leptin mediates its effects on food intake through the hypothalamic form of its receptor OB-R. Variants of OB-R are found in other tissues, but their function is unknown. Here, an OB-R variant was found in human hepatic cells. Exposure of these cells to leptin, at concentrations comparable with those present in obese individuals, caused attenuation of several insulin-induced activities, including tyrosine phosphorylation of the insulin receptor substrate-1 (IRS-1), association of the adapter molecule growth factor receptor-bound protein 2 with IRS-1, and down-regulation of gluconeogenesis. In contrast, leptin increased the activity of IRS-1-associated phosphatidylinositol 3-kinase. These in vitro studies raise the possibility that leptin modulates insulin activities in obese individuals.	WEIZMANN INST SCI,DEPT MOL GENET,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								ANDO A, 1994, EMBO J, V13, P3033, DOI 10.1002/j.1460-2075.1994.tb06602.x; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; Cioffi JA, 1996, NAT MED, V2, P585, DOI 10.1038/nm0596-585; COHEN B, 1995, MOL CELL BIOL, V15, P4208; Collins S, 1996, NATURE, V380, P677, DOI 10.1038/380677a0; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; FELBER JP, 1995, METABOLISM, V44, P4, DOI 10.1016/0026-0495(95)90201-5; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1994, J CLIN INVEST, V94, P1543, DOI 10.1172/JCI117495; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; KOSAKI A, 1995, J BIOL CHEM, V270, P20816, DOI 10.1074/jbc.270.35.20816; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; LONNQVIST F, 1995, NAT MED, V1, P950, DOI 10.1038/nm0995-950; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; PERNIS A, 1995, P NATL ACAD SCI USA, V92, P7971, DOI 10.1073/pnas.92.17.7971; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; WEIGLE DS, 1995, J CLIN INVEST, V96, P2065, DOI 10.1172/JCI118254; WHITE MF, 1994, J BIOL CHEM, V269, P1; XING LP, 1993, MOL ENDOCRINOL, V7, P1484, DOI 10.1210/me.7.11.1484; YIN TG, 1995, J BIOL CHEM, V270, P20497, DOI 10.1074/jbc.270.35.20497; YIN TG, 1994, J BIOL CHEM, V269, P26614; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	41	608	636	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1996	274	5290					1185	1188		10.1126/science.274.5290.1185	http://dx.doi.org/10.1126/science.274.5290.1185			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT335	8895466				2022-12-24	WOS:A1996VT33500052
J	Dickson, RM; Norris, DJ; Tzeng, YL; Moerner, WE				Dickson, RM; Norris, DJ; Tzeng, YL; Moerner, WE			Three-dimensional imaging of single molecules solvated in pores of poly(acrylamide) gels	SCIENCE			English	Article							FIELD OPTICAL MICROSCOPY; FLUORESCENCE MICROSCOPY; ELECTROPHORESIS; SPECTROSCOPY	Individual fluorescent molecules and individual singly labeled proteins were observed in the water-filled pores oi poly(acrylamide) gels by tar-field microscopy. Brownian motion was markedly reduced by the gel framework, thus enabling extended study of single fluorophores in aqueous environments. A highly axially dependent laser field was used both to excite the fluorophores and to image the molecules in three dimensions. Single molecules were followed as they moved within and through the porous gel structure. In contrast to dry polymeric hosts, these water-based gels may form a useful medium for single-molecule studies of biological systems in vitro.	UNIV CALIF SAN DIEGO, DEPT CHEM & BIOCHEM, LA JOLLA, CA 92093 USA; SCRIPPS RES INST, LA JOLLA, CA 92037 USA	University of California System; University of California San Diego; Scripps Research Institute			Moerner, William E/C-3260-2008; Norris, David J/F-4022-2010	Moerner, William E/0000-0002-2830-209X; Norris, David J/0000-0002-3765-0678				AMBROSE WP, 1994, SCIENCE, V265, P364, DOI 10.1126/science.265.5170.364; AXELROD D, 1989, FLUORESCENCE MICRO B, P399; BERNE BJ, 1990, DYNAMIC LIGHT SCATTE, P143; BETZIG E, 1993, SCIENCE, V262, P1422, DOI 10.1126/science.262.5138.1422; DABAN JR, 1991, ANAL BIOCHEM, V199, P162, DOI 10.1016/0003-2697(91)90084-7; EIGEN M, 1994, P NATL ACAD SCI USA, V91, P5740, DOI 10.1073/pnas.91.13.5740; Fawcett J. S., 1966, SEP SCI, V1, P9; FEINSTEI.A, 1965, NATURE, V205, P147, DOI 10.1038/205147a0; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; GUTTLER F, 1994, CHEM PHYS LETT, V217, P393, DOI 10.1016/0009-2614(94)87003-9; Ha T, 1996, P NATL ACAD SCI USA, V93, P6264, DOI 10.1073/pnas.93.13.6264; HAAB BB, 1995, ANAL CHEM, V67, P3253, DOI 10.1021/ac00114a023; JACKSON JD, 1975, CLASSICAL ELECTRODYN, P283; Jasny J, 1996, REV SCI INSTRUM, V67, P1425, DOI 10.1063/1.1146868; Macklin JJ, 1996, SCIENCE, V272, P255, DOI 10.1126/science.272.5259.255; MEIXNER AJ, 1995, OPT ENG, V34, P2324, DOI 10.1117/12.200620; MOERNER WE, 1989, PHYS REV LETT, V62, P2535, DOI 10.1103/PhysRevLett.62.2535; MOERNER WE, 1994, SCIENCE, V265, P46, DOI 10.1126/science.265.5168.46; NIE SM, 1994, SCIENCE, V266, P1018, DOI 10.1126/science.7973650; OGSTON AG, 1958, T FARADAY SOC, V54, P1754, DOI 10.1039/tf9585401754; ORRIT M, 1990, PHYS REV LETT, V65, P2716, DOI 10.1103/PhysRevLett.65.2716; RODBARD D, 1976, METHODS PROTEIN SEPA, V2, P145; Schmidt T, 1996, P NATL ACAD SCI USA, V93, P2926, DOI 10.1073/pnas.93.7.2926; SHERA EB, 1990, CHEM PHYS LETT, V174, P553, DOI 10.1016/0009-2614(90)85485-U; Shi Q., 1990, GEL ELECTROPHORESIS; Trautman JK, 1996, CHEM PHYS, V205, P221, DOI 10.1016/0301-0104(95)00391-6; TRAUTMAN JK, 1994, NATURE, V369, P40, DOI 10.1038/369040a0; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; WILKERSON CW, 1993, APPL PHYS LETT, V62, P2030, DOI 10.1063/1.109495; XIE XS, 1994, SCIENCE, V265, P361, DOI 10.1126/science.265.5170.361; ZIMM BH, 1993, MACROMOLECULES, V26, P226, DOI 10.1021/ma00053a035	31	324	343	5	72	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1996	274	5289					966	969		10.1126/science.274.5289.966	http://dx.doi.org/10.1126/science.274.5289.966			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR792	8875935				2022-12-24	WOS:A1996VR79200044
J	Matteucci, MD; Wagner, RW				Matteucci, MD; Wagner, RW			In pursuit of antisense	NATURE			English	Article							ADHESION MOLECULE-1 EXPRESSION; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; THERAPEUTIC AGENTS; GENE INHIBITION; NUCLEIC-ACIDS; OLIGODEOXYNUCLEOTIDES; RNA; BINDING; OLIGODEOXYRIBONUCLEOTIDE; PHARMACOKINETICS				Matteucci, MD (corresponding author), GILEAD SCI INC,353 LAKESIDE DR,FOSTER CITY,CA 94404, USA.							AGRAWAL S, 1995, CLIN PHARMACOKINET, V28, P7, DOI 10.2165/00003088-199528010-00002; ALTMANN KH, IN PRESS CHIMIA; BENNETT CF, 1994, J IMMUNOL, V152, P3530; BERGAN R, 1993, NUCLEIC ACIDS RES, V21, P3567, DOI 10.1093/nar/21.15.3567; BONHAM MA, 1995, NUCLEIC ACIDS RES, V23, P1197, DOI 10.1093/nar/23.7.1197; CHAVANY C, 1995, MOL PHARMACOL, V48, P738; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; CHRISTOFFERSEN RE, 1995, J MED CHEM, V38, P2023, DOI 10.1021/jm00012a001; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DEAN NM, 1994, J BIOL CHEM, V269, P16416; DEMESMAEKER A, 1995, ACCOUNTS CHEM RES, V28, P366, DOI 10.1021/ar00057a002; DEMPCY RO, 1995, P NATL ACAD SCI USA, V92, P6097, DOI 10.1073/pnas.92.13.6097; FLANAGAN WM, IN PRESS NATURE BIOT; FLANAGAN WM, IN PRESS MOL CELL BI; GALBRAITH WM, 1994, ANTISENSE RES DEV, V4, P201, DOI 10.1089/ard.1994.4.201; GHOSH MK, 1993, NUCLEIC ACIDS RES, V21, P5761, DOI 10.1093/nar/21.24.5761; GILES RV, 1995, NUCLEIC ACIDS RES, V23, P954, DOI 10.1093/nar/23.6.954; GLAZER V, 1996, GENET ENG NEWS, V16, P16; GLAZER V, 1996, GENET ENG NEWS, V16, P21; GLAZER V, 1996, GENET ENG NEWS, V16, P17; GLAZER V, 1996, GENET ENG NEWS, V16, P1; Gryaznov S, 1996, NUCLEIC ACIDS RES, V24, P1508, DOI 10.1093/nar/24.8.1508; GRYAZNOV S, 1994, J AM CHEM SOC, V116, P3143, DOI 10.1021/ja00086a062; GUERRIERTAKADA C, 1995, P NATL ACAD SCI USA, V92, P11115, DOI 10.1073/pnas.92.24.11115; GUVAKOVA MA, 1995, J BIOL CHEM, V270, P2620, DOI 10.1074/jbc.270.6.2620; HANVEY JC, 1992, SCIENCE, V258, P1481, DOI 10.1126/science.1279811; HERTL M, 1995, J INVEST DERMATOL, V104, P813, DOI 10.1111/1523-1747.ep12607006; HYRUP B, IN PRESS BIOORG BIOM; James William, 1995, Current Opinion in Biotechnology, V6, P44, DOI 10.1016/0958-1669(95)80008-5; Knudsen H, 1996, NUCLEIC ACIDS RES, V24, P494, DOI 10.1093/nar/24.3.494; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; KRIEG AM, IN PRESS LAB CLIN ME; Lewis JG, 1996, P NATL ACAD SCI USA, V93, P3176, DOI 10.1073/pnas.93.8.3176; LIN KY, 1995, J AM CHEM SOC, V117, P3873, DOI 10.1021/ja00118a026; MAITRA RK, 1995, J BIOL CHEM, V270, P15071, DOI 10.1074/jbc.270.25.15071; MALTESE JY, 1995, NUCLEIC ACIDS RES, V23, P1146, DOI 10.1093/nar/23.7.1146; Matthews M. C., 1996, PERSPECT DRUG DISCOV, P1; MOLLEGAARD NE, 1994, P NATL ACAD SCI USA, V91, P3892, DOI 10.1073/pnas.91.9.3892; Monia BP, 1996, NAT MED, V2, P668, DOI 10.1038/nm0696-668; MONIA BP, 1993, J BIOL CHEM, V268, P14514; Morvan F, 1996, J AM CHEM SOC, V118, P255, DOI 10.1021/ja9533959; MOULDS C, 1995, BIOCHEMISTRY-US, V34, P5044, DOI 10.1021/bi00015a015; SRINIVASAN SK, 1995, J CLIN LAB ANAL, V9, P129, DOI 10.1002/jcla.1860090210; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; STEIN CA, 1994, ANTISENSE RES DEV, V4, P67, DOI 10.1089/ard.1994.4.67; STEIN CA, 1995, NAT MED, V1, P1119, DOI 10.1038/nm1195-1119; VANAERSCHOT A, 1995, ANGEW CHEM INT EDIT, V34, P1338; VAUGHN JP, 1995, P NATL ACAD SCI USA, V92, P8338, DOI 10.1073/pnas.92.18.8338; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WAGNER RW, 1993, SCIENCE, V260, P1510, DOI 10.1126/science.7684856; WAGNER RW, 1996, NATURE BIOTECHNOL, V14, P838; ZHANG RW, 1995, CLIN PHARMACOL THER, V58, P44, DOI 10.1016/0009-9236(95)90071-3; Zhao QY, 1996, BIOCHEM PHARMACOL, V51, P173, DOI 10.1016/0006-2952(95)02177-9	53	103	113	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1996	384	6604		S			20	22						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR392	8895596				2022-12-24	WOS:A1996VR39200007
J	Shohat, T; Green, MS; Merom, D; Gill, ON; Reisfeld, A; Matas, A; Blau, D; Gal, N; Slater, PE				Shohat, T; Green, MS; Merom, D; Gill, ON; Reisfeld, A; Matas, A; Blau, D; Gal, N; Slater, PE			International epidemiological and microbiological study of outbreak of Salmonella agona infection from a ready to eat savoury snack .2. Israel	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objectives-To explain an increase in the incidence of salmonellosis caused by Salmonella agona in Israel between October 1994 and January 1995 in the light of an outbreak of S agona phage type 15 infection in England and Wales caused by consumption of a ready to eat savoury snack produced in Israel. Design-Epidemiology of S agona in 1994-5 was analysed and two consecutive, case-control studies of 32 and 26 case-control pairs were performed. Phage typing and molecular methods were used to characterise strains of S agona isolated from cases and samples of the snack in Israel and England and Wales. Results-The increase in the incidence of S agona between October 1994 and January 1995 was countrywide. Cases of infection with group B salmonella increased from 60% to 80% in children under 5 years old. In both case-control studies, cases consumed more of the snack than did controls (4.25 v 2.94 packets per week in the first study (P=0.086) and 4.04 v 2.37 packets per week in the second study (P=0.034)). When the two studies were combined there was a significant dose-response relation for the number of packets consumed weekly. Compared with consumption of less than two packets, the odds ratio was 1.43 for between two and six packets and 3.37 for seven or more packets (chi(2) for trend=5.27, P=0.02) S agona phage type 15 was isolated from a packet of the snack sold in Israel, and the strain was identical with those isolated from packets and cases in Israel and England and Wales. Conclusions-This outbreak of S agona was caused by the contamination of a snack produced in Israel. Even under modern operating conditions, large, widespread international outbreaks of foodborne disease can occur. The success of this investigation resulted from excellent international collaboration between public health authorities.	PUBL HLTH LAB SERV, CTR COMMUNICABLE DIS SURVEILLANCE, LONDON NW9 5EQ, ENGLAND	Public Health England	Shohat, T (corresponding author), SCHNEIDER CHILDRENS MED CTR ISRAEL, ISRAEL CTR DIS CONTROL, ISRAEL MINIST HLTH, POB 559, IL-49202 PETAH TIQWA, ISRAEL.		Merom, Dafna/AAW-5357-2021	Merom, Dafna/0000-0001-6459-8628; Green, Manfred S./0000-0002-9753-5612				CHALKER RB, 1988, REV INFECT DIS, V10, P111; CLARK GM, 1973, LANCET, V2, P490; Killalea D, 1996, BMJ-BRIT MED J, V313, P1105, DOI 10.1136/bmj.313.7065.1105; *NAT SALM CTR, 1968, SALM FIND ISR ANN RE; Threlfall EJ, 1996, EMERG INFECT DIS, V2, P130, DOI 10.3201/eid0202.960209; 1972, BRIT MED J, V4, P559; 1995, COMMUN DIS REP CDR W, V5, P29	7	58	59	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 2	1996	313	7065					1107	1109		10.1136/bmj.313.7065.1107	http://dx.doi.org/10.1136/bmj.313.7065.1107			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR217	8916694	Green Published			2022-12-24	WOS:A1996VR21700019
J	Waern, M; Beskow, J; Runeson, B; Skoog, I				Waern, M; Beskow, J; Runeson, B; Skoog, I			High rate of antidepressant treatment in elderly people who commit suicide	BRITISH MEDICAL JOURNAL			English	Article									UNIV STOCKHOLM,KAROLINSKA INST,CTR SUICIDE RES & PREVENT,STOCKHOLM,SWEDEN	Karolinska Institutet; Stockholm University	Waern, M (corresponding author), SAHLGRENS UNIV HOSP,INST CLIN NEUROSCI,SECT PSYCHIAT,S-41345 GOTHENBURG,SWEDEN.			Runeson, Bo/0000-0003-4122-4636				CATTELL H, 1995, BRIT J PSYCHIAT, V166, P451, DOI 10.1192/bjp.166.4.451; CLARK DC, 1993, SUICIDAL BEHAV STATE; CONWELL Y, 1991, NEW ENGL J MED, V325, P1100, DOI 10.1056/NEJM199110103251511; Conwell Y, 1995, Int Psychogeriatr, V7, P149, DOI 10.1017/S1041610295001943; ISACSSON G, 1994, BRIT MED J, V308, P71	5	25	25	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 2	1996	313	7065					1118	1118		10.1136/bmj.313.7065.1118	http://dx.doi.org/10.1136/bmj.313.7065.1118			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR217	8916699	Green Published			2022-12-24	WOS:A1996VR21700024
J	Pazmany, L; Mandelboim, O; ValesGomez, M; Davis, DM; Reyburn, HT; Strominger, JL				Pazmany, L; Mandelboim, O; ValesGomez, M; Davis, DM; Reyburn, HT; Strominger, JL			Protection from natural killer cell-mediated lysis by HLA-G expression on target cells	SCIENCE			English	Article							LARGE GRANULAR LYMPHOCYTES; CLASS-I MOLECULE; NK CELLS; TROPHOBLAST; ANTIGEN; CLONES; RECOGNITION; RECEPTORS; LINE; RESISTANCE	The outermost layer of the human placenta is devoid of classical class I human leukocyte antigens (HLA-A, HLA-B, and HLA-C) and class II proteins (HLA-DR, HLA-DQ, and HLA-DP). Although this prevents recognition by maternal T lymphocytes, the lack of class I molecules leaves these cells susceptible to attack by natural killer (NK) cells. However, trophoblast cells directly in contact with the maternal tissues express the class I molecule HLA-G, which may be involved in protecting the trophoblast from recognition by NK cells. Here evidence is provided that expression of HLA-G is sufficient to protect otherwise susceptible target cells from lysis by activated NK1 and NK2 cell lines and clones that are specific for distinct groups of HLA-C alleles. The receptors on NK cells that recognize HLA-G are also identified.			Pazmany, L (corresponding author), HARVARD UNIV,DEPT MOL & CELL BIOL,7 DIVIN AVE,CAMBRIDGE,MA 02138, USA.		Valés-Gómez, Mar/F-5351-2012; Vales-Gomez, Mar/ABG-7808-2020; Reyburn, Hugh T/B-4338-2009	Valés-Gómez, Mar/0000-0001-7424-3206; Vales-Gomez, Mar/0000-0001-7424-3206; Reyburn, Hugh T/0000-0003-2855-1595; Davis, Daniel/0000-0002-9182-291X; Mandelboim, Ofer/0000-0002-9354-1855	NATIONAL CANCER INSTITUTE [R35CA047554] Funding Source: NIH RePORTER; NCI NIH HHS [CA-47554] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CELLA M, 1994, J EXP MED, V180, P1235, DOI 10.1084/jem.180.4.1235; CHUMBLEY G, 1994, CELL IMMUNOL, V155, P312, DOI 10.1006/cimm.1994.1125; COLBERN GT, 1994, AM J OBSTET GYNECOL, V170, P1244, DOI 10.1016/S0002-9378(94)70134-2; COLONNA M, 1992, P NATL ACAD SCI USA, V89, P7983, DOI 10.1073/pnas.89.17.7983; COLONNA M, 1995, SCIENCE, V268, P405, DOI 10.1126/science.7716543; COLONNA M, 1993, P NATL ACAD SCI USA, V90, P12000, DOI 10.1073/pnas.90.24.12000; DANDREA A, 1995, J IMMUNOL, V155, P2306; DENIZ G, 1994, J IMMUNOL, V152, P4255; ELLIS SA, 1986, IMMUNOLOGY, V59, P595; ELLIS SA, 1990, J IMMUNOL, V144, P731; FAULK WP, 1976, NATURE, V262, P799, DOI 10.1038/262799a0; GERAGHTY DE, 1987, P NATL ACAD SCI USA, V84, P9145, DOI 10.1073/pnas.84.24.9145; GONG JH, 1994, LEUKEMIA, V8, P652; KING A, 1989, HUM IMMUNOL, V24, P195, DOI 10.1016/0198-8859(89)90060-8; King A, 1996, J IMMUNOL, V156, P2068; KING A, 1991, IMMUNOL TODAY, V12, P432, DOI 10.1016/0167-5699(91)90014-K; KOVATS S, 1990, SCIENCE, V248, P220, DOI 10.1126/science.2326636; LANIER LL, 1995, J IMMUNOL, V154, P3320; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; MANDELBOIM O, 1986, J EXP MED, V184, P913; MELERO I, 1994, J IMMUNOL, V152, P1662; MORALES P, 1993, IMMUNOGENETICS, V38, P323; MORETTA A, 1993, J EXP MED, V178, P597, DOI 10.1084/jem.178.2.597; NATUK RJ, 1987, J IMMUNOL, V138, P877; PAZMANY L, UNPUB; REDMAN CWG, 1984, IMMUNOLOGY, V52, P457; REYNBURN HT, UNPUB; SCHMIDT CM, 1993, CRIT REV IMMUNOL, V13, P207; STARKEY PM, 1988, IMMUNOLOGY, V65, P129; STEWART I, 1984, J ANAT, V139, P627; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; VANDERVEN K, 1994, J IMMUNOL, V153, P5628; VITALE M, 1995, P NATL ACAD SCI USA, V92, P3536, DOI 10.1073/pnas.92.8.3536; WAGTMANN N, 1995, IMMUNITY, V2, P439, DOI 10.1016/1074-7613(95)90025-X; Wagtmann N, 1995, IMMUNITY, V3, P801, DOI 10.1016/1074-7613(95)90069-1	35	311	331	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1996	274	5288					792	795		10.1126/science.274.5288.792	http://dx.doi.org/10.1126/science.274.5288.792			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ145	8864122				2022-12-24	WOS:A1996VQ14500047
J	Tanaka, E; Alter, HJ; Nakatsuji, Y; Shih, JWK; Kim, JP; Matsumoto, A; Kobayashi, M; Kiyosawa, K				Tanaka, E; Alter, HJ; Nakatsuji, Y; Shih, JWK; Kim, JP; Matsumoto, A; Kobayashi, M; Kiyosawa, K			Effect of hepatitis G virus infection on chronic hepatitis C	ANNALS OF INTERNAL MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; NON-B-HEPATITIS; NON-A; ANTIBODY; THERAPY; RNA; GENOTYPES	Objective: To clarify the effect of hepatitis G virus (HGV) infection on chronic hepatitis C. Design: Retrospective study. Setting: University hospital in Matsumoto, Japan. Patients: 189 randomly selected patients with histologically proven chronic hepatitis C, including 101 patients receiving interferon-alpha. Measurements: Serum levels of HGV RNA were measured by reverse-transcription polymerase chain reaction. Clinical features, including liver histologic findings, hepatitis C virus (HCV) markers, and response of HCV to interferon-alpha were compared between HGV RNA-positive and HGV RNA-negative patients. Results: 21 of 189 (11%) patients with chronic hepatitis C were positive for HCV RNA. On average, patients with HGV RNA were younger than those without HCV RNA (mean age +/- SD, 46.6 +/- 13.0 years and 51.7 +/- 10.7 years, respectively); other demographic and clinical features were similar. The HCV genotype and HCV RNA level were distributed similarly between patients with and those without HCV infection. Ten of 101 patients with chronic hepatitis C who received interferon-alpha were positive for HCV RNA. The rate of sustained HCV response to intepferon-alpha: in patients with HGV infection (30%) was similar to that in patients without HGV infection (36%). The HGV RNA level decreased during therapy in all 9 patients in whom this value was measured. However, only 2 of these patients had a sustained HGV response after discontinuation of therapy. Conclusions: Patients who only had HCV infection did not differ from patients with HCV and HGV co-infection in clinical presentation, HCV RNA level, or response of HCV to interferon-alpha therapy. Thus, HCV infection had no apparent influence on the clinical or virologic course of HCV, infection. Hepatitis G virus was uniformly sensitive to interferon-alpha therapy, but only a few patients had a sustained virologic response.	NIH, DEPT TRANSFUS MED, BETHESDA, MD 20852 USA; SHINSHU UNIV, SCH MED, DEPT INTERNAL MED 2, MATSUMOTO, NAGANO 390, JAPAN; GENELABS TECHNOL INC, REDWOOD CITY, CA 94063 USA	National Institutes of Health (NIH) - USA; Shinshu University								ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER HJ, 1995, J VIRAL HEPATITIS, V2, P121, DOI 10.1111/j.1365-2893.1995.tb00017.x; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629; FONG TL, 1991, HEPATOLOGY, V14, P64, DOI 10.1002/hep.1840140111; Jeffers L. J., 1995, Hepatology, V22, p182A, DOI 10.1016/0270-9139(95)94452-4; KAKLAMANI E, 1991, JAMA-J AM MED ASSOC, V265, P1974, DOI 10.1001/jama.265.15.1974; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LAU JYN, 1993, LANCET, V341, P1501, DOI 10.1016/0140-6736(93)90635-T; MATSUMOTO A, 1994, DIGEST DIS SCI, V39, P1273, DOI 10.1007/BF02093793; NAKATSUJI Y, IN PRESS J VIRAL HEP; OINNEN J, 1996, SCIENCE, V271, P505; OKAMOTO H, 1992, J GEN VIROL, V73, P673, DOI 10.1099/0022-1317-73-3-673; PONTISSO P, 1993, GASTROENTEROLOGY, V105, P1529, DOI 10.1016/0016-5085(93)90161-5; SHINDO M, 1991, ANN INTERN MED, V115, P700, DOI 10.7326/0003-4819-115-9-700; SIMMONDS P, 1994, HEPATOLOGY, V19, P1321, DOI 10.1016/0270-9139(94)90887-7; Tanaka E, 1996, HEPATOLOGY, V23, P1330, DOI 10.1002/hep.510230606; TANAKA E, 1991, J MED VIROL, V33, P117, DOI 10.1002/jmv.1890330210; YOSHIOKA K, 1992, HEPATOLOGY, V16, P293, DOI 10.1002/hep.1840160203	18	175	176	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1996	125	9					740	743		10.7326/0003-4819-125-9-199611010-00007	http://dx.doi.org/10.7326/0003-4819-125-9-199611010-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ072	8929008				2022-12-24	WOS:A1996VQ07200006
J	Chen, X; Rubock, MJ; Whitman, M				Chen, X; Rubock, MJ; Whitman, M			A transcriptional partner for MAD proteins in TGF-beta signalling	NATURE			English	Article							MESODERM INDUCTION; XENOPUS EMBRYOS; TRUNCATED ACTIVIN; AXIAL MESODERM; FAMILY; IDENTIFICATION; RECEPTORS; MEMBER; RESPONSES; INDUCERS	The transforming-growth-factor-beta (TGF-beta) superfamily is critical for establishing mesoderm during early embryogenesis in Xenopus. The transcriptional activation of Mix.2, an immediate-early response gene specific to activin-like members of the TGF-beta superfamily, is associated with the rapid appearance of a site-specific DNA-binding activity that recognizes a fifty-basepair regulatory element known as ARE in the Mix.2 promoter. Cloning of the site-specific DNA-binding component of this activity revealed it to be a new winged-helix transcription factor and a direct target for signalling by the TGF-beta superfamily. XMAD2, a recently identified TGF-beta signal transducer, forms a complex with the transcription factor in an activin-dependent fashion to generate an activated ARE-binding complex. A model is proposed to explain how TGF-beta superfamily signals might regulate the expression of specific genes in the early embryo.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School								ARORA K, 1995, CELL, V81, P781, DOI 10.1016/0092-8674(95)90539-1; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; BOLCE ME, 1992, DEVELOPMENT, V115, P681; Conlon FL, 1996, SEMIN CELL DEV BIOL, V7, P95, DOI 10.1006/scdb.1996.0014; DALE L, 1992, DEVELOPMENT, V115, P573; DAWID IB, 1994, J BIOL CHEM, V269, P6259; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GRIEDER NC, 1995, CELL, V81, P791, DOI 10.1016/0092-8674(95)90540-5; Grunz H, 1996, INT J DEV BIOL, V40, P279; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; Henry GL, 1996, DEVELOPMENT, V122, P1007; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; HUANG HC, 1995, EMBO J, V14, P5965, DOI 10.1002/j.1460-2075.1995.tb00285.x; Jones CM, 1996, DEVELOPMENT, V122, P1545; JONES CM, 1992, DEVELOPMENT, V115, P639; JONES CM, 1995, DEVELOPMENT, V121, P3651; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; KOSTER M, 1991, MECH DEVELOP, V33, P191, DOI 10.1016/0925-4773(91)90027-4; Lechleider RJ, 1996, J BIOL CHEM, V271, P17617, DOI 10.1074/jbc.271.30.17617; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MASSAGUE J, 1992, CELL, V69, P167; Mead PE, 1996, NATURE, V382, P357, DOI 10.1038/382357a0; MIURA N, 1993, FEBS LETT, V326, P171, DOI 10.1016/0014-5793(93)81785-X; Newfeld SJ, 1996, DEVELOPMENT, V122, P2099; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; QIAN XB, 1995, NUCLEIC ACIDS RES, V23, P1184, DOI 10.1093/nar/23.7.1184; Roberts AB, 1990, PEPTIDE GROWTH FACTO, P419; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; SCHULTEMERKER S, 1994, EMBO J, V13, P3533, DOI 10.1002/j.1460-2075.1994.tb06660.x; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH WC, 1995, CELL, V82, P37, DOI 10.1016/0092-8674(95)90050-0; Ten Dijke Peter, 1994, Progress in Growth Factor Research, V5, P55, DOI 10.1016/0955-2235(94)90017-5; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; Vize PD, 1996, DEV BIOL, V177, P226, DOI 10.1006/dbio.1996.0158; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; Watabe T, 1995, GENE DEV, V9, P3038, DOI 10.1101/gad.9.24.3038; WELGEL D, 1990, CELL, V63, P455; WHITMAN M, 1989, SCIENCE, V244, P803, DOI 10.1126/science.2658054; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	52	621	652	1	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 24	1996	383	6602					691	696		10.1038/383691a0	http://dx.doi.org/10.1038/383691a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN918	8878477				2022-12-24	WOS:A1996VN91800045
J	Kolodziej, PA; Timpe, LC; Mitchell, KJ; Fried, SR; Goodman, CS; Jan, LY; Jan, YN				Kolodziej, PA; Timpe, LC; Mitchell, KJ; Fried, SR; Goodman, CS; Jan, LY; Jan, YN			frazzled Encodes a Drosophila member of the DCC immunoglobulin subfamily and is required for CNS and motor axon guidance	CELL			English	Article							C-ELEGANS; COLORECTAL-CANCER; GENE-PRODUCT; CELL; OUTGROWTH; PROTEIN; UNC-6; DIFFERENTIATION; EXPRESSION; MIGRATIONS	We have identified a Drosophila member of the deleted in colorectal cancer (DCC) gene family. The frazzled gene encodes transmembrane proteins that contain four immunoglobulin C2 type domains, six fibronectin type III repeats, and a cytoplasmic domain of 278 amino acids. Like vertebrate members of the DCC family, Frazzled is expressed on axons in the embryonic central nervous system and on motor axons in the periphery. Frazzled is also expressed on epidermis and gut epithelium. Null mutants in frazzled are defective in axon guidance in the central nervous system and in motor axon guidance and targeting in the periphery. The phenotypes strongly resemble those of a deletion of the two Drosophila Netrin genes. We have rescued the frazzled CNS and motor axon defects by expressing Frazzled specifically in neurons; expression in target tissues does not rescue the phenotype. These data, together with vertebrate studies showing binding of DCC to netrin, suggest that Frazzled may function in vivo as a receptor or component of a receptor mediating Netrin-dependent axon guidance.	UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT BIOCHEM, SAN FRANCISCO, CA 94143 USA; VANDERBILT UNIV, MED CTR, HOWARD HUGHES MED INST, DEPT CELL BIOL, NASHVILLE, TN 37232 USA; UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, DIV NEUROBIOL, DEPT MOL & CELL BIOL, BERKELEY, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; Vanderbilt University; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Kolodziej, PA (corresponding author), UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT PHYSIOL, 3RD & PARNASSUS AVE, SAN FRANCISCO, CA 94143 USA.			Mitchell, Kevin/0000-0002-3433-4530; Jan, Yuh Nung/0000-0003-1367-6299; Jan, Lily/0000-0003-3938-8498				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BRAND AH, 1993, DEVELOPMENT, V118, P401; CHUONG CM, 1994, DEV BIOL, V164, P383, DOI 10.1006/dbio.1994.1208; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; Goodman CS, 1996, ANNU REV NEUROSCI, V19, P341, DOI 10.1146/annurev.ne.19.030196.002013; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; Harris R, 1996, NEURON, V17, P217, DOI 10.1016/S0896-6273(00)80154-3; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; Higgins D G, 1994, Methods Mol Biol, V25, P307; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KOLODZIEJ PA, 1995, NEURON, V15, P273, DOI 10.1016/0896-6273(95)90033-0; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Mitchell KJ, 1996, NEURON, V17, P203, DOI 10.1016/S0896-6273(00)80153-1; PATTHY L, 1990, CELL, V61, P13, DOI 10.1016/0092-8674(90)90208-V; PIERCEALL WE, 1994, J CELL BIOL, V124, P1017, DOI 10.1083/jcb.124.6.1017; PIROTTA V, 1986, DROSOPHILA PRACTICAL, P83; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; TESSIERLAVIGNE M, 1994, CURR OPIN GENET DEV, V4, P596, DOI 10.1016/0959-437X(94)90078-H; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; VIELMETTER J, 1994, J CELL BIOL, V127, P2009, DOI 10.1083/jcb.127.6.2009; Wadsworth WG, 1996, NEURON, V16, P35, DOI 10.1016/S0896-6273(00)80021-5; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	27	378	383	0	12	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 18	1996	87	2					197	204		10.1016/S0092-8674(00)81338-0	http://dx.doi.org/10.1016/S0092-8674(00)81338-0			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VN403	8861904	Bronze			2022-12-24	WOS:A1996VN40300008
J	Cassel, CK; Vladeck, BC				Cassel, CK; Vladeck, BC			ICD-9 code for palliative or terminal care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									US HLTH CARE FINANCING ADM,WASHINGTON,DC 20201		Cassel, CK (corresponding author), MT SINAI MED CTR,NEW YORK,NY 10029, USA.							Christakis NA, 1996, NEW ENGL J MED, V335, P172, DOI 10.1056/NEJM199607183350306; *NAT CTR HLTH STAT, 1991, VIT STAT US, V2; 1996, FED REGISTER, V61, P27451; 1996, FED REGISTER, V61, P27542; 1995, JAMA-J AM MED ASSOC, V274, P1591	5	58	58	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 17	1996	335	16					1232	1234		10.1056/NEJM199610173351612	http://dx.doi.org/10.1056/NEJM199610173351612			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN401	8815949				2022-12-24	WOS:A1996VN40100012
J	Frieden, TR; Sherman, LF; Maw, KL; Fujiwara, PI; Crawford, JT; Nivin, B; Sharp, V; Hewlett, D; Brudney, K; Alland, D; Kreiswirth, BN				Frieden, TR; Sherman, LF; Maw, KL; Fujiwara, PI; Crawford, JT; Nivin, B; Sharp, V; Hewlett, D; Brudney, K; Alland, D; Kreiswirth, BN			A multi-institutional outbreak of highly drug-resistant tuberculosis - Epidemiology and clinical outcomes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE WORKERS; HUMAN-IMMUNODEFICIENCY-VIRUS; NEW-YORK-CITY; MYCOBACTERIUM-TUBERCULOSIS; HIV-INFECTION; NOSOCOMIAL TRANSMISSION; RISK	Objective.-To investigate a multi-institutional outbreak of highly resistant tuberculosis and evaluate patient outcome. Design.-Epidemiologic investigation of every tuberculosis case reported in New York City. Setting.-Patients cared for at all public and nonpublic institutions from January 1, 1990, to August 1, 1993 (43 months). Patients.-We reviewed medical and public health records and conducted clinical, epidemiologic, drug susceptibility, and restriction fragment length polymorphism (RFLP) analyses. A case was defined as tuberculosis in a patient with an isolate resistant to isoniazid, rifampin, ethambutol hydrochloride, and streptomycin (and rifabutin, if sensitivity testing included it), and, if RFLP testing was done, a pattern identical to or closely related to strain W. Main Outcome Measures.-Patient survival and the conversion of sputum cultures from positive to negative. Results.-Of the 357 patients who met the case definition, 267 had identical or nearly identical RFLP patterns; isolates from the other 90 patients were not available for RFLP testing. Among these 267 patients, 86% were human immunodeficiency virus (HIV)-infected, 7% were HIV-negative, and 7% had unknown HIV status. All-cause mortality was 83%. Epidemiologic linkages were identified for 70% of patients, of whom 96% likely had nosocomially acquired disease at 11 hospitals. Survival was prolonged among patients who recieved medications to which their isolate was susceptible, especially capreomycin sulfate, and among patients with a CD4(+) T-lymphocyte count greater than 0.200x10(9)/L (200/mu L). Treatment with isoniazid and a fluoroquinolone antibiotic was also independently associated with longer survival. Conclusions.-This outbreak accounted for nearly one fourth of the cases of multidrug-resistant tuberculosis in the United States during a 43-month period. Most patients had nosocomially acquired disease, were infected with HIV, and unless promptly and appropriately treated, died rapidly. With appropriate directly observed treatment, especially combinations including an injectable medication, even severely immunocompromised patients had culture conversion and prolonged, tuberculosis-free survival.	CTR DIS CONTROL & PREVENT,DIV TB ELIMINAT,ATLANTA,GA; NATL CTR INFECT DIS,DIV AIDS STD & TB LAB RES,ATLANTA,GA; ST CLARES HOSP,NEW YORK,NY; LINCOLN MED & MENTAL HLTH CTR,BRONX,NY 10451; COLUMBIA PRESBYTERIAN MED CTR,NEW YORK,NY 10032; ALBERT EINSTEIN COLL MED,HOWARD HUGHES MED INST,BRONX,NY 10467; PUBL HLTH RES INST,NEW YORK,NY	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Columbia University; NewYork-Presbyterian Hospital; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine	Frieden, TR (corresponding author), NEW YORK CITY DEPT HLTH,BUR TB CONTROL,125 WORTH ST,BOX 74,NEW YORK,NY 10013, USA.							ALFALLA C, 1992, 32 INT C ANT AG CHEM; AUSINA V, 1995, EUR J CLIN MICROBIOL, V14, P105, DOI 10.1007/BF02111867; AZMEH W, 1993, 33 INT C ANT AG CHEM; Bifani PJ, 1996, JAMA-J AM MED ASSOC, V275, P452, DOI 10.1001/jama.275.6.452; BLOCH AB, 1994, JAMA-J AM MED ASSOC, V271, P665, DOI 10.1001/jama.271.9.665; CAVE MD, 1991, MOL CELL PROBE, V5, P73, DOI 10.1016/0890-8508(91)90040-Q; *CDC, 1991, MMWR-MORBID MORTAL W, V40, P585; COHN ML, 1954, AM REV TUBERC PULM, V70, P641; COMSTOCK GW, 1974, AM J EPIDEMIOL, V99, P131, DOI 10.1093/oxfordjournals.aje.a121593; CORONADO VG, 1993, J INFECT DIS, V168, P1052, DOI 10.1093/infdis/168.4.1052; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; Dean A., 1995, EPI INFO VERSION 6 0; FISCHL MA, 1992, ANN INTERN MED, V117, P184, DOI 10.7326/0003-4819-117-3-184; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; FRIEDMAN CR, 1995, AM J RESP CRIT CARE, V152, P355, DOI 10.1164/ajrccm.152.1.7599845; Goble M, 1986, Semin Respir Infect, V1, P220; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P2051, DOI 10.1128/JCM.28.9.2051-2058.1990; HEWLETT D, 1995, JAMA-J AM MED ASSOC, V273, P916, DOI 10.1001/jama.273.12.916; HORN DL, 1995, INFECT DIS CLIN PRAC, V4, P219, DOI 10.1097/00019048-199505000-00018; ISEMAN MD, 1993, NEW ENGL J MED, V329, P784, DOI 10.1056/NEJM199309093291108; MALONEY SA, 1995, ANN INTERN MED, V122, P90, DOI 10.7326/0003-4819-122-2-199501150-00002; MITCHISON DA, 1971, POSTGRAD MED J, V47, P737, DOI 10.1136/pgmj.47.553.737; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; PLIKAYTIS BB, 1994, J CLIN MICROBIOL, V32, P1542, DOI 10.1128/JCM.32.6.1542-1546.1994; SALOMON N, 1995, CLIN INFECT DIS, V21, P1245, DOI 10.1093/clinids/21.5.1245; *SAS I INC, 1993, SAS STAT SOFTW SYNT; SATHYAKUMAR C, 1995, 95 GEN M AM SOC MICR; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; TELZAK EE, 1995, NEW ENGL J MED, V333, P907, DOI 10.1056/NEJM199510053331404; TURETT GS, 1995, CLIN INFECT DIS, V21, P1238, DOI 10.1093/clinids/21.5.1238; VALWAY S, 1993, 33 INT C ANT AG CHEM; VALWAY SE, 1994, J INFECT DIS, V170, P151, DOI 10.1093/infdis/170.1.151; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; VILLARINO M E, 1992, Morbidity and Mortality Weekly Report, V41, P59; WENGER PN, 1995, LANCET, V345, P235, DOI 10.1016/S0140-6736(95)90228-7; 1989, MMWR-MORBID MORTAL W, V38, P313; 1995, ANN INTERN MED, V122, P90; 1994, MMWR-MORBID MORTAL W, V43, P1; 1989, MMWR-MORBID MORTAL W, V38, P325	40	309	318	0	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	1996	276	15					1229	1235		10.1001/jama.276.15.1229	http://dx.doi.org/10.1001/jama.276.15.1229			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL691	8849750				2022-12-24	WOS:A1996VL69100031
J	Dong, JW; Albertini, DF; Nishimori, K; Kumar, TR; Lu, NF; Matzuk, MM				Dong, JW; Albertini, DF; Nishimori, K; Kumar, TR; Lu, NF; Matzuk, MM			Growth differentiation factor-9 is required during early ovarian folliculogenesis	NATURE			English	Article							FACTOR-BETA SUPERFAMILY; PRIMORDIAL GERM-CELLS; MOUSE OOCYTES; FUNCTIONAL-ANALYSIS; MICE DEFICIENT; GENE; EXPRESSION; CULTURE; PATTERN; PROLIFERATION	GROWTH factors synthesized by ovarian somatic cells directly affect oocyte growth and function(1-6), but it is unclear whether oocyte-secreted factors(6-9) play a reciprocal role in modulating somatic cell functions in vivo. During the functional analysis of members of the transforming growth factor-beta superfamily in mouse development(10-15), we have uncovered a new family member, growth differentiation factor-9 (GDF-9), which is required for ovarian folliculogenesis. GDF-9 messenger RNA is synthesized only in the oocyte from the primary one-layer follicle stage until after ovulation(16,17). Here we analyse ovaries from GDF-9-deficient female mice and demonstrate that primordial and primary one-layer follicles can be formed, but there is a block in follicular development beyond the primary one-layer follicle stage which leads to complete infertility. Oocyte growth and zona pellucida formation proceed normally, but other aspects of oocyte differentiation are compromised. Thus, GDF-9 is the first oocyte-derived growth factor required for somatic cell function in vivo.	BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030; TUFTS UNIV,SCH MED,DEPT ANAT & CELLULAR BIOL,BOSTON,MA 02111	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Tufts University			Albertini, David/AAD-3856-2021	Albertini, David/0000-0001-6536-2828				ALBERTINI DF, 1992, MUTAT RES, V296, P57, DOI 10.1016/0165-1110(92)90032-5; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; Eppig John J., 1994, Seminars in Developmental Biology, V5, P51, DOI 10.1006/sedb.1994.1007; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; Hakuno N, 1996, ENDOCRINOLOGY, V137, P1938, DOI 10.1210/en.137.5.1938; HAMILTON SA, 1995, BIOL REPROD, V53, P890, DOI 10.1095/biolreprod53.4.890; HAMOUDI M, BIOTECHNIQUES, V7, P331; INCERTI B, 1994, BBA-MOL CELL RES, V1222, P125, DOI 10.1016/0167-4889(94)90034-5; MANOVA K, 1993, DEV BIOL, V157, P85, DOI 10.1006/dbio.1993.1114; MANOVA K, 1990, DEVELOPMENT, V110, P1057; MATSUI Y, 1991, NATURE, V353, P750, DOI 10.1038/353750a0; MATTSON BA, 1990, MOL REPROD DEV, V25, P374, DOI 10.1002/mrd.1080250411; MATZUK MM, 1995, NATURE, V374, P354, DOI 10.1038/374354a0; MATZUK MM, 1995, NATURE, V374, P360, DOI 10.1038/374360a0; MATZUK MM, 1995, NATURE, V374, P356, DOI 10.1038/374356a0; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; MATZUK MM, 1995, TRENDS ENDOCRIN MET, V6, P120, DOI 10.1016/1043-2760(95)00032-D; MCGRATH SA, 1995, MOL ENDOCRINOL, V9, P131, DOI 10.1210/me.9.1.131; MCPHERRON AC, 1993, J BIOL CHEM, V268, P3444; PEDERSEN T, 1968, J REPROD FERTIL, V17, P555, DOI 10.1530/jrf.0.0170555; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; VANDERHYDEN BC, 1992, BIOL REPROD, V46, P1196, DOI 10.1095/biolreprod46.6.1196; VANDERHYDEN BC, 1990, DEV BIOL, V140, P307, DOI 10.1016/0012-1606(90)90081-S; VASSALLI A, 1994, GENE DEV, V8, P414, DOI 10.1101/gad.8.4.414; Wassarman Paul M., 1994, P79; WICKRAMASINGHE D, 1991, DEV BIOL, V143, P162, DOI 10.1016/0012-1606(91)90063-9	27	976	1072	1	83	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1996	383	6600					531	535		10.1038/383531a0	http://dx.doi.org/10.1038/383531a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL755	8849725				2022-12-24	WOS:A1996VL75500052
J	Robinson, JC				Robinson, JC			Decline in hospital utilization and cost inflation under managed care in California	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMPETITION; CONTAINMENT; CAPITATION; SERVICES; MARKET	Objective.-To measure the impact of health maintenance organizations (HMOs) on hospital capacity, utilization, and expenditures between 1983 and 1993. Design.-Multivariate regression analysis. Setting.-Private nonprofit and for-profit hospitals in California with 25 or more beds. Patients.-Patient discharge abstract data were used to measure growth of HMO penetration of local hospital markets. Interventions.-None. Main Outcome Measures.-Hospital closures, changes in bed capacity, changes in acute care admissions and length of stay, psychiatric inpatient days, subacute inpatient days, inpatient and outpatient surgical procedures, ambulatory patient visits, and hospital expenditures. Results.-Between 1983 and 1993 hospital expenditures grew 44% less rapidly in markets with high HMO penetration than in markets with low HMO penetration. Of this, 28% was due to reductions in the volume and mix of services, 6% was due to reductions in bed capacity, and 10% was due to changes in the intensity of services provided. Health maintenance organizations accelerated the substitution of outpatient for inpatient surgery, the shift from acute to subacute inpatient days, and the reduction of psychiatric hospitalization. Conclusion.-Managed care is shifting the acute care hospital from the center toward the periphery of the health care system.			Robinson, JC (corresponding author), UNIV CALIF BERKELEY, SCH PUBL HLTH, BERKELEY, CA 94720 USA.							*AM HOSP ASS, 1994, HOSP STAT AHA PROF A; BERGTHOLD L, 1984, J HEALTH POLIT POLIC, V9, P203, DOI 10.1215/03616878-9-2-203; Coulam R F, 1991, Health Care Financ Rev Annu Suppl, P45; DOW MM, 1994, MANAGED CARE DIGEST; *GOV COMM, 1993, GRAND ALL VERT INT S; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; Helbing C, 1992, Health Care Financ Rev Annu Suppl, P55; JOSKOW PL, 1980, BELL J ECON, V11, P421, DOI 10.2307/3003372; KERR EA, 1995, ANN INTERN MED, V123, P500, DOI 10.7326/0003-4819-123-7-199510010-00004; LUFT HS, 1986, INQUIRY-J HEALTH CAR, V23, P83; LUFT HS, 1978, NEW ENGL J MED, V298, P1336, DOI 10.1056/NEJM197806152982404; MANNING WG, 1984, NEW ENGL J MED, V310, P1505, DOI 10.1056/NEJM198406073102305; MELNICK GA, 1988, JAMA-J AM MED ASSOC, V260, P2669, DOI 10.1001/jama.260.18.2669; MILLER RH, 1994, JAMA-J AM MED ASSOC, V271, P1512, DOI 10.1001/jama.271.19.1512; Robinson JC, 1996, J LAW ECON, V39, P357, DOI 10.1086/467352; ROBINSON JC, 1987, NEW ENGL J MED, V317, P85, DOI 10.1056/NEJM198707093170205; ROBINSON JC, 1994, MILBANK Q, V72, P259, DOI 10.2307/3350296; ROBINSON JC, 1995, NEW ENGL J MED, V333, P1684, DOI 10.1056/NEJM199512213332506; ROBINSON JC, 1987, JAMA-J AM MED ASSOC, V257, P3241, DOI 10.1001/jama.257.23.3241; Robinson JC, 1996, HEALTH AFFAIR, V15, P7, DOI 10.1377/hlthaff.15.1.7; ROBINSON JC, 1991, JAMA-J AM MED ASSOC, V266, P2719, DOI 10.1001/jama.266.19.2719; ROBINSON JC, 1988, JAMA-J AM MED ASSOC, V260, P2676, DOI 10.1001/jama.260.18.2676; Rosenberg Charles E., 1987, CARE STRANGERS RISE; SCHWARTZ WB, 1991, NEW ENGL J MED, V324, P1037, DOI 10.1056/NEJM199104113241506; Starr P, 1982, SOCIAL TRANSFORMATIO; Stevens Rosemary, 1989, SICKNESS WEALTH AM H	26	104	104	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1996	276	13					1060	1064		10.1001/jama.276.13.1060	http://dx.doi.org/10.1001/jama.276.13.1060			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VK035	8847768	Green Submitted			2022-12-24	WOS:A1996VK03500027
J	Ivanov, PC; Rosenblum, MG; Peng, CK; Mietus, J; Havlin, S; Stanley, HE; Goldberger, AL				Ivanov, PC; Rosenblum, MG; Peng, CK; Mietus, J; Havlin, S; Stanley, HE; Goldberger, AL			Scaling behaviour of heartbeat intervals obtained by wavelet-based time-series analysis	NATURE			English	Article								BIOLOGICAL time-series analysis is used to identify hidden dynamical patterns which could yield important insights into underlying physiological mechanisms, Such analysis is complicated by the fact that biological signals are typically both highly irregular and non-stationary, that is, their statistical character changes slowly or intermittently as a result of variations in background influences(1-3). Previous statistical analyses of heart beat dynamics(4-6) have identified long-range correlations and power-law scaling in the normal heartbeat, but not the phase interactions between the different frequency components of the signal, Here we introduce a new approach, based on the wavelet transform and an analytic signal approach, which can characterize non-stationary behaviour and elucidate such phase interactions, We find that, when suitably rescaled, the distributions of the variations in the beat-to-beat intervals for all healthy subjects are described by a single function stable over a Hide range of timescales. However, a similar scaling function does not exist for a group with cardiopulmonary instability caused by sleep apnoea. We attribute the functional form of the scaling observed in the healthy subjects to underlying nonlinear dynamics, which seem to be essential to normal heart function, The approach introduced here should be useful in the analysis of other nonstationary biological signals.	BOSTON UNIV,DEPT PHYS,BOSTON,MA 02215; HARVARD UNIV,BETH ISRAEL HOSP,DIV CARDIOVASC,SCH MED,BOSTON,MA 02215; BAR ILAN UNIV,DEPT PHYS,IL-52900 RAMAT GAN,ISRAEL; BAR ILAN UNIV,GONDA GOLDSCHMIED CTR,IL-52900 RAMAT GAN,ISRAEL	Boston University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Bar Ilan University; Bar Ilan University	Ivanov, PC (corresponding author), BOSTON UNIV,CTR POLYMER STUDIES,BOSTON,MA 02215, USA.		Peng, Chung-Kang/E-1489-2011; Peng, Chung-Kang/N-1308-2019; Ivanov, Plamen Ch./E-8004-2012; Havlin, Shlomo/ABF-1527-2020	Peng, Chung-Kang/0000-0003-3666-9833; Peng, Chung-Kang/0000-0003-3666-9833; Ivanov, Plamen Ch./0000-0001-7629-762X; 				AGHILI AA, 1995, PHYS REV LETT, V74, P1254, DOI 10.1103/PhysRevLett.74.1254; AKSELROD S, 1981, SCIENCE, V213, P220, DOI 10.1126/science.6166045; ARNEODO A, 1995, PHYS REV LETT, V74, P3293, DOI 10.1103/PhysRevLett.74.3293; Barabasi A.-L., 1995, FRACTAL CONCEPTS SUR; BASSINGTHWAIGHT.JB, 1994, FRACTAL PHYSL; BOX GEP, 1994, TIME SERIES ANAL; DAUBECHIES I, 1988, COMMUN PUR APPL MATH, V41, P909, DOI 10.1002/cpa.3160410705; Gabor D., 1946, J I ELECT ENG LOND, V93, P429, DOI DOI 10.1049/JI-3-2.1946.0074; GERSTEIN GL, 1964, BIOPHYS J, V4, P41, DOI 10.1016/S0006-3495(64)86768-0; GROSSMANN A, 1985, MATH PHYSICS LECT RE; GUILLEMINAULT C, 1984, LANCET, V1, P126; KERTESZ J, 1994, FRACTALS SCI; KITNEY R, 1982, Automedica (London), V4, P141; LIEBOVITCH LS, 1989, BIOPHYS J, V55, P373, DOI 10.1016/S0006-3495(89)82815-2; LIPSITZ LA, 1995, BRIT HEART J, V74, P340; *MIT BIH DAT DISTR, 1992, MIT BIH POL DAT CD R; MUZY JF, 1994, INT J BIFURCAT CHAOS, V4, P245, DOI 10.1142/S0218127494000204; PANTER D, 1965, MODULATION NOISE SPE; PENG CK, 1995, CHAOS, V5, P82, DOI 10.1063/1.166141; SHLESINGER MF, 1987, ANN NY ACAD SCI, V504, P214, DOI 10.1111/j.1749-6632.1987.tb48734.x; Stauffer D., 1996, NEWTON MANDELBROT PR; Stratonovich R. L., 1981, TOPICS THEORY RANDOM, VI; Vainshtein L. A., 1983, SEPARATION FREQUENCI	23	434	448	4	62	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 26	1996	383	6598					323	327		10.1038/383323a0	http://dx.doi.org/10.1038/383323a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VJ439	8848043				2022-12-24	WOS:A1996VJ43900040
J	Murphy, R; Wente, SR				Murphy, R; Wente, SR			An RNA-export mediator with an essential nuclear export signal	NATURE			English	Article							HIV-1 REV PROTEIN; SACCHAROMYCES-CEREVISIAE; BINDING; YEAST; IDENTIFICATION; INTERACTS; CYTOPLASM; SEQUENCE; DOMAIN; IMPORT	THE Rev protein of human immunodeficiency virus type 1 (HIV-1) mediates the translocation of viral messenger RNAs from the nucleus to the cytoplasm. In yeast, Rev can mediate the nuclear export of Rev response element containing RNAs(1). The export of Rev itself proceeds through the nuclear pore complex and requires a nuclear export signal (NES)(2,3) and interaction with a cellular cofactor, the protein Rip1 (refs 1, 4, 5). Endogenous RNA export mediators that interact with Rip1 and harbour NESs are thought to exist(6,7) but have yet to be identified, Here we report the characterization of a new and essential yeast protein, Gle1, which contains an NES and has a relative molecular mass of 62,000. Mutation of the NES in Gle1 prevents export of polyadenylated RNA from the nucleus. Gle1 interacts with Rip1 and the nucleo-porin Nup100 and is localized predominantly at nuclear pore complexes. These properties indicate that Gle1 is an RNA-export factor and that Rev may mediate viral RNA export by mimicking the function of Gle1.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL)								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; BOHNLEIN E, 1991, J VIROL, V65, P7051; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fridell RA, 1996, P NATL ACAD SCI USA, V93, P2936, DOI 10.1073/pnas.93.7.2936; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; Hardy CFJ, 1996, MOL CELL BIOL, V16, P1832; HENRIQUEZ R, 1990, J BIOL CHEM, V265, P2209; Iovine MK, 1995, J CELL BIOL, V131, P1699, DOI 10.1083/jcb.131.6.1699; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; SCHNEITER R, 1995, MOL BIOL CELL, V6, P357, DOI 10.1091/mbc.6.4.357; SHULGA N, IN PRESS J CELL BIOL; STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WENTE SR, 1994, J CELL BIOL, V125, P955, DOI 10.1083/jcb.125.5.955; WENTE SR, 1992, J CELL BIOL, V119, P705, DOI 10.1083/jcb.119.4.705; YANG X, 1992, SCIENCE, V257, P68; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640; ZAPP ML, 1991, P NATL ACAD SCI USA, V88, P7734, DOI 10.1073/pnas.88.17.7734; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0	29	203	210	1	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 26	1996	383	6598					357	360		10.1038/383357a0	http://dx.doi.org/10.1038/383357a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VJ439	8848052				2022-12-24	WOS:A1996VJ43900051
J	Ploeckinger, B; Dantendorfer, K; Ulm, M; Baischer, W; Derfler, K; Musalek, M; Dadak, C				Ploeckinger, B; Dantendorfer, K; Ulm, M; Baischer, W; Derfler, K; Musalek, M; Dadak, C			Rapid decrease of serum cholesterol concentration and postpartum depression	BRITISH MEDICAL JOURNAL			English	Article									UNIV VIENNA,DEPT PSYCHIAT,A-1010 VIENNA,AUSTRIA; UNIV VIENNA,DEPT INTERNAL MED,VIENNA,AUSTRIA	University of Vienna; University of Vienna	Ploeckinger, B (corresponding author), UNIV VIENNA,DEPT OBSTET & GYNECOL,KLIN FRAUENHEILKUNDE,WAHRINGER GURTEL 18-20,A-1090 VIENNA,AUSTRIA.			Derfler, Kurt/0000-0003-2062-7620				ENGELBERG H, 1992, LANCET, V339, P727, DOI 10.1016/0140-6736(92)90609-7; FOWKES FGR, 1992, LANCET, V340, P995, DOI 10.1016/0140-6736(92)93009-C; HARRIS B, 1994, BRIT MED J, V308, P949, DOI 10.1136/bmj.308.6934.949; KAPLAN JR, 1991, PSYCHOSOM MED, V53, P634, DOI 10.1097/00006842-199111000-00005; SMITH GD, 1992, JAMA-J AM MED ASSOC, V267, P70, DOI 10.1001/jama.267.1.70	5	38	38	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 14	1996	313	7058					664	664						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH165	8845727				2022-12-24	WOS:A1996VH16500022
J	Samuelsson, O; Pennert, K; Andersson, O; Berglund, G; Hedner, T; Persson, B; Wedel, H; Wilhelmsen, L				Samuelsson, O; Pennert, K; Andersson, O; Berglund, G; Hedner, T; Persson, B; Wedel, H; Wilhelmsen, L			Diabetes mellitus and raised serum triglyceride concentration in treated hypertension - Are they of prognostic importance? Observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY-HEART-DISEASE; CARDIOVASCULAR RISK-FACTORS; IMPAIRED GLUCOSE-TOLERANCE; ANTIHYPERTENSIVE DRUGS; INSULIN RESISTANCE; BLOOD-PRESSURE; MEN; PATHOGENESIS; MANAGEMENT; MORTALITY	Objective-To analyse whether metabolic changes during longterm treatment with antihypertensive drugs are associated with an increased risk of coronary heart disease. Design-Observational study. Setting-Gothenburg, Sweden. Subjects-686 middle aged hypertensive men, recruited after screening of a random population sample, and followed for 15 years during treatment with predominantly beta adrenoceptor blockers or thiazide diuretics, or both. Coronary heart disease and diabetes mellitus were registered at yearly patient examinations. Entry characteristics, as well as within study serum concentrations of cholesterol and triglycerides and the development of diabetes mellitus, were related to the incidence of coronary heart disease in a time dependent Cox's regression analysis. Main outcome variable-Coronary heart disease morbidity. Results-Diabetes mellitus, raised serum cholesterol and triglyceride concentrations present at the beginning of the study were all significantly predictive of coronary heart disease in univariate analysis. The relative risk of diabetes mellitus and of a 1 mmol/l increase in the cholesterol and triglyceride concentrations was 2.12 (95% confidence interval 1.11 to 4.07), 1.21 (1.05 to 1.39), and 1.21 (1.03 to 1.43) respectively. However, when the within study metabolic variables were analysed, only the serum cholesterol concentration was significantly and independently associated with coronary heart disease (relative risk 1.07 (1.02 to 1.13)). Although the triglyceride concentrations increased slightly during the follow up, the within study serum triglyceride concentrations were not associated with the incidence of coronary heart disease (1.04 (0.96 to 1.10)). New diabetes mellitus-that is, onset during follow up-was not significantly associated with an increased risk for coronary heart disease (1.48 (0.37 to 6.00)). Conclusions-Metabolic disturbances such as diabetes mellitus and hyperlipidaemia presenting before the start of antihypertensive treatment have a prognostic impact in middle aged, treated hypertensive men. Moreover, while within study cholesterol concentration was an independent predictor of coronary heart disease, drug related diabetes mellitus and raised serum triglyceride concentrations that are associated with treatment do not seem to have any major impact on the coronary heart disease prognosis in this category of patients.	SAHLGRENS UNIV HOSP, DEPT MED, ANGIOL SECT, GOTHENBURG, SWEDEN; SAHLGRENS UNIV HOSP, DEPT CLIN PHARMACOL, GOTHENBURG, SWEDEN; CLIN DATA CARE AB, LUND, SWEDEN; LUND UNIV, MALMO GEN HOSP, DEPT MED, S-21401 MALMO, SWEDEN; NORDIC SCH PUBL HLTH, DEPT EPIDEMIOL & BIOSTAT, GOTHENBURG, SWEDEN; OSTRA HOSP, DEPT MED, S-41685 GOTHENBURG, SWEDEN	Sahlgrenska University Hospital; Sahlgrenska University Hospital; Lund University; Sahlgrenska University Hospital	Samuelsson, O (corresponding author), SAHLGRENS UNIV HOSP, DEPT MED, NEPHROL SECT, S-41345 GOTHENBURG, SWEDEN.							ALTMAN DG, 1994, STAT MED, V13, P301, DOI 10.1002/sim.4780130402; [Anonymous], 1985, J Hypertens, V3, P379; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1980, LANCET, V1, P1261; [Anonymous], 1993, Blood Press, V2, P312; AUSTIN MA, 1991, ARTERIOSCLER THROMB, V11, P2, DOI 10.1161/01.ATV.11.1.2; BENGTSSON C, 1984, BMJ-BRIT MED J, V289, P1495, DOI 10.1136/bmj.289.6457.1495; BRENNAN PJ, 1988, BRIT HEART J, V59, P364; COLLINS P, 1992, EUR HEART J, V13, P560, DOI 10.1093/oxfordjournals.eurheartj.a060214; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COX DR, 1972, J R STAT SOC B, V34, P187; DAHLOF B, 1993, BLOOD PRESSURE, V2, P137; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; ELLIOTT WJ, 1995, AM J MED, V99, P261, DOI 10.1016/S0002-9343(99)80158-2; FORD CE, 1988, JAMA-J AM MED ASSOC, V259, P2113; FRAYN KN, 1992, CLIN SCI, V82, P1, DOI 10.1042/cs0820001; FREIS ED, 1995, ANN INTERN MED, V122, P223, DOI 10.7326/0003-4819-122-3-199502010-00011; FULLER JH, 1980, LANCET, V1, P1373; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; HAFFNER SM, 1993, J CLIN ENDOCR METAB, V76, P541, DOI 10.1210/jc.76.3.541; HANSSON L, 1990, J HYPERTENS, V8, P985; HARPER R, 1994, BRIT MED J, V309, P226, DOI 10.1136/bmj.309.6949.226; JACOBY RM, 1992, J AM COLL CARDIOL, V20, P736, DOI 10.1016/0735-1097(92)90033-J; JARRETT RJ, 1992, LANCET, V340, P469, DOI 10.1016/0140-6736(92)91781-3; Julius S, 1992, Blood Press, V1, P9, DOI 10.3109/08037059209065119; KANNEL WB, 1979, JAMA-J AM MED ASSOC, V241, P2035, DOI 10.1001/jama.241.19.2035; KANNEL WB, 1989, J CARDIOVASC PHARM, V13, pS4, DOI 10.1097/00005344-198900131-00003; KJELSBERG MO, 1990, JAMA-J AM MED ASSOC, V263, P1795; KJELSBERG MO, 1986, PREV MED, V15, P254; LITHELL HOL, 1991, DIABETES CARE, V14, P203, DOI 10.2337/diacare.14.3.203; MORALES PA, 1993, DIABETES, V42, P154, DOI 10.2337/diabetes.42.1.154; MOSER M, 1993, CLEV CLIN J MED, V60, P27; NILSSON P, 1993, J INTERN MED, V233, P239, DOI 10.1111/j.1365-2796.1993.tb00982.x; NORTHCOTE RJ, 1991, J HYPERTENS, V9, pS21, DOI 10.1097/00004872-199112007-00006; POLLARE T, 1989, THESIS UPPSALA U UPP; REAVEN GM, 1993, J CLIN ENDOCR METAB, V76, P537, DOI 10.1210/jc.76.3.537; REAVEN GM, 1991, DIABETES CARE, V14, P33, DOI 10.2337/diacare.14.4.33; RESNICK LM, 1993, AM J HYPERTENS, V6, pS123, DOI 10.1093/ajh/6.4S.123S; ROSE G, 1982, BRIT MED J, V284, P1600, DOI 10.1136/bmj.284.6329.1600; ROSENGREN A, 1989, BRIT MED J, V299, P1127, DOI 10.1136/bmj.299.6708.1127; ROSMAN J, 1990, Journal of Drug Development, V3, P129; SAMUELSSON O, 1985, ACTA MED SCAND, P1; SAS Institute, 1991, SAS STAT SOFTW PHREG; SCHWARTZ CJ, 1992, DIABETES CARE, V15, P1156, DOI 10.2337/diacare.15.9.1156; SEVER P, 1993, BMJ-BRIT MED J, V306, P983, DOI 10.1136/bmj.306.6883.983; SKARFORS ET, 1989, BRIT MED J, V298, P1147, DOI 10.1136/bmj.298.6681.1147; SKARFORS ET, 1991, BRIT MED J, V303, P755, DOI 10.1136/bmj.303.6805.755; SOWERS JR, 1991, AM HEART J, V122, P932, DOI 10.1016/0002-8703(91)90814-X; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; STANDLEY PR, 1993, AM J KIDNEY DIS, V21, P39; WEBER MA, 1993, ARCH INTERN MED, V153, P149, DOI 10.1001/archinte.153.2.149; WEINBERGER MH, 1986, AM J MED, V80, P64, DOI 10.1016/0002-9343(86)90162-2; WHO Expert Committee on Diabetes Mellitus, 1980, WHO TECHN REP SER, V646; WILHELMSEN L, 1972, Preventive Medicine, V1, P153, DOI 10.1016/0091-7435(72)90082-5; WINGARD DL, 1995, DIABETES CARE, V18, P1299, DOI 10.2337/diacare.18.9.1299; Wolfe RA, 1996, AM J KIDNEY DIS, V27, P124, DOI 10.1016/S0272-6386(96)90039-6; YUDKIN JS, 1991, BMJ-BRIT MED J, V303, P730, DOI 10.1136/bmj.303.6805.730; 1993, BLOOD PRESSURE, V2, P86; 1986, LANCET, V2, P1075; 1995, J INTERN MED S737, V238, P1	60	32	32	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 14	1996	313	7058					660	663						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH165	8811759				2022-12-24	WOS:A1996VH16500021
J	Shuker, SB; Hajduk, PJ; Meadows, RP; Fesik, SW				Shuker, SB; Hajduk, PJ; Meadows, RP; Fesik, SW			Discovering high-affinity ligands for proteins: SAR by NMR	SCIENCE			English	Article							ATOMIC-STRUCTURE; DRUG DESIGN; BINDING; COMPLEX; SPECTROSCOPY; FKBP-FK506; INHIBITORS; PROGRAM; FK506	A nuclear magnetic resonance (NMR)-based method is described in which small organic molecules that bind to proximal subsites of a protein are identified, optimized, and linked together to produce high-affinity ligands. The approach is called ''SAR by NMR'' because structure-activity relationships (SAR) are obtained from NMR. With this technique, compounds with nanomolar affinities for the FK506 binding protein were rapidly discovered by tethering two ligands with micromolar affinities. The method reduces the amount of chemical synthesis and time required for the discovery of high-affinity ligands and appears particularly useful in target-directed drug research.	ABBOTT LABS,DIV PHARMACEUT DISCOVERY,ABBOTT PK,IL 60064	Abbott Laboratories								Allen KN, 1996, J PHYS CHEM-US, V100, P2605, DOI 10.1021/jp952516o; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BOHM HJ, 1992, J COMPUT AID MOL DES, V6, P61, DOI 10.1007/BF00124387; BRUNGER AT, 1992, XPLOR 3 1 MANUAL; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; ECKER DJ, 1995, BIO-TECHNOL, V13, P351, DOI 10.1038/nbt0495-351; EISEN MB, 1994, PROTEINS, V19, P199, DOI 10.1002/prot.340190305; GALLOP MA, 1994, J MED CHEM, V37, P1233, DOI 10.1021/jm00035a001; HAUSKE JR, 1992, J MED CHEM, V35, P4284, DOI 10.1021/jm00101a005; HOLT DA, 1993, J AM CHEM SOC, V115, P9925, DOI 10.1021/ja00075a008; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MEADOWS RP, 1993, BIOCHEMISTRY-US, V32, P754, DOI 10.1021/bi00054a004; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; ROTSTEIN SH, 1993, J MED CHEM, V36, P1700, DOI 10.1021/jm00064a003; VANDUYNE GD, 1991, J AM CHEM SOC, V113, P7433, DOI 10.1021/ja00019a057; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; VERLINDE CLMJ, 1992, J COMPUT AID MOL DES, V6, P131, DOI 10.1007/BF00129424; WANG GT, 1994, BIOORG MED CHEM LETT, V4, P1161, DOI 10.1016/S0960-894X(01)80248-1; WERNER S, Patent No. 17356	22	1638	1813	12	328	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1996	274	5292					1531	1534		10.1126/science.274.5292.1531	http://dx.doi.org/10.1126/science.274.5292.1531			4	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929414				2022-12-24	WOS:A1996VV77500049
J	Schieber, RA; BrancheDorsey, CM; Ryan, GW; Rutherford, GW; Stevens, JA; ONeil, J				Schieber, RA; BrancheDorsey, CM; Ryan, GW; Rutherford, GW; Stevens, JA; ONeil, J			Risk factors for injuries from in-line skating and the effectiveness of safety gear	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background Of the estimated 22.5 million people participating in in-line skating in the United States in 1995, about 100,000 were sufficiently injured to require emergency department care. We investigated the effectiveness of wrist guards, elbow pads, knee pads, and helmets in preventing skating injuries. Methods We used data from the 91 hospital emergency departments participating in the National Electronic Injury Surveillance System, a national probability sample of randomly selected hospitals with 24-hour emergency departments. Injured in-line skaters who sought medical attention between December 1992 and July 1993 were interviewed by telephone. We conducted a case-control study of skaters who injured their wrists, elbows, knees, or heads as compared with skaters with injuries to other parts of their bodies. Results Of 206 eligible injured subjects, 161 (78 percent) were interviewed. Wrist injuries were the most common (32 percent); 25 percent of all injuries were wrist fractures. Seven percent of injured skaters wore all the types of safety gear; 46 percent wore none. Forty-five percent wore knee pads, 33 percent wrist guards, 28 percent elbow pads, and 20 percent helmets. The odds ratio for wrist injury, adjusted for age and sex, for those who did not wear wrist guards, as compared with those who did, was 10.4 (95 percent confidence interval, 2.9 to 36.9). The odds ratio for elbow injury, adjusted for the number of lessons skaters had had and whether or not they performed trick skating, was 9.5 (95 percent confidence interval, 2.6 to 34.4) for those who did not wear elbow pads. Nonuse of knee pads was associated with a nonsignificant increase in the risk of knee injury (crude odds ratio, 2.2; 95 percent confidence interval, 0.7 to 7.2). The effectiveness of helmets could not be assessed. Conclusions Wrist guards and elbow pads are effective in protecting in-line skaters against injuries. (C)1996, Massachusetts Medical Society.	CONSUMER PROD SAFETY COMMISS,DIRECTORATE EPIDEMIOL & HLTH SCI,WASHINGTON,DC		Schieber, RA (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INJURY PREVENT & CONTROL,MAILSTOP K-63,4770 BUFORD HWY,NE,ATLANTA,GA 30341, USA.							Agresti A., 1990, CATEGORICAL DATA ANA, pXV; *AM SPORTS DAT, 1996, AM SPORTS AN SUMM RE; CALLE SC, 1994, AM J PUBLIC HEALTH, V84, P675, DOI 10.2105/AJPH.84.4.675; *CONS PROD SAF COM, 1991, SAF COMM WARNS HAZ I; *CONS PROD SAF COM, 1992, NEISS SAMPL DES IMPL; FRANKEL LR, 1982, DEFINITION RESPONSE; HELLER D, 1993, HAZARD, V10, P11; *INT INL SKAT ASS, 1992, GUID EST INL SKAT TR; *NAT EL INJ SURV S, 1996, CONS PROD SAF COMM; SACKS JJ, 1991, JAMA-J AM MED ASSOC, V266, P3016, DOI 10.1001/jama.266.21.3016; SCHIEBER RA, 1994, JAMA-J AM MED ASSOC, V271, P1856, DOI 10.1001/jama.271.23.1856; Schlesselman JJ, 1982, CASE CONTROL STUDIES; Shah BV, 1996, SUDAAN USERS MANUAL; *SHUG RES, 1992, INL SKAT FOC GROUP S; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; ULLIS K, 1979, NEW ENGL J MED, V301, P1350; 1995, MMWR-MORBID MORTAL W, V44, P1	17	117	118	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 28	1996	335	22					1630	1635		10.1056/NEJM199611283352202	http://dx.doi.org/10.1056/NEJM199611283352202			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV936	8929359	Bronze			2022-12-24	WOS:A1996VV93600002
J	Blondel, M; Mann, C				Blondel, M; Mann, C			G2 cyclins are required for the degradation of G1 cyclins in yeast	NATURE			English	Article							UBIQUITIN-CONJUGATING ENZYME; B-TYPE CYCLINS; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; PROTEIN-KINASE; BUDDING YEAST; S-PHASE; PROTEOLYSIS; INHIBITOR; TURNOVER	PROGRESSION Of the eukaryotic cell cycle is controlled by cyclin-dependent kinases (CDKs)(1). Cdc28, the budding yeast homologue of Cdc2 (Cdk1), is required for both the G1/S and G2/M transitions of the cell cycle(2), The functional specificity of the Cdc28 kinase is determined by its association with G1 or G2 cyclins. Alternation of cell cycle phases is thus mainly due to mechanisms that ensure that one cyclin family succeeds another, Here we show that the G2 cyclins Clb1, Clb2, Clb3 and Clb4 are required for the proteolysis of the G1 cyclins Cln1 and Cln2, providing a mechanism for coupling synthesis of G2 cyclins with the disappearance of G1 cyclins. Our data indicate that this pathway involves the Ubc9 ubiquitin-conjugating enzyme(3). The Cdc34 ubiquitin-conjugating activity(4) may function redundantly with Ubc9, or it may only be involved in Cln1,2 turnover through its role in promoting the degradation of Sic1, a specific inhibitor of Cdc28-Clb complexes(5).	CEA SACLAY,SERV BIOCHIM & GENET MOL,F-91191 GIF SUR YVETTE,FRANCE	CEA; UDICE-French Research Universities; Universite Paris Saclay			Blondel, Marc/AAJ-9049-2020	Blondel, Marc/0000-0003-4897-2995; Mann, Carl/0000-0001-7212-1512				AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BARRAL Y, 1995, GENE DEV, V9, P399, DOI 10.1101/gad.9.4.399; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; FITCH I, 1992, MOL BIOL CELL, V3, P805, DOI 10.1091/mbc.3.7.805; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GRANDIN N, 1993, MOL CELL BIOL, V13, P2113, DOI 10.1128/MCB.13.4.2113; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; Koch C, 1996, GENE DEV, V10, P129, DOI 10.1101/gad.10.2.129; KUHNE C, 1993, EMBO J, V12, P3437, DOI 10.1002/j.1460-2075.1993.tb06018.x; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; NASMYTH K, 1991, CELL, V66, P995, DOI 10.1016/0092-8674(91)90444-4; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NUGROHO TT, 1994, MOL CELL BIOL, V14, P3320, DOI 10.1128/MCB.14.5.3320; RICHARDSON H, 1992, GENE DEV, V6, P2021, DOI 10.1101/gad.6.11.2021; SALAMA SR, 1994, MOL CELL BIOL, V14, P7953, DOI 10.1128/MCB.14.12.7953; Schneider BL, 1996, SCIENCE, V272, P560, DOI 10.1126/science.272.5261.560; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Tyers M, 1996, P NATL ACAD SCI USA, V93, P7772, DOI 10.1073/pnas.93.15.7772; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; YAGLOM J, 1995, MOL CELL BIOL, V15, P731	29	35	37	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 21	1996	384	6606					279	282		10.1038/384279a0	http://dx.doi.org/10.1038/384279a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU381	8918881				2022-12-24	WOS:A1996VU38100056
J	Modan, B				Modan, B			Carrying a genetic passport for ovarian	LANCET			English	Editorial Material							RISK				Modan, B (corresponding author), TEL AVIV UNIV,STANLEY STEYER INST,CHAIM SHEBA MED CTR,IL-52621 TEL HASHOMER,ISRAEL.							COLLINS F, 1996, J CLIN ONCOL, V14, P1730; JOHNSON BB, 1995, RISK ANAL, V15, P485, DOI 10.1111/j.1539-6924.1995.tb00341.x; MODAN B, 1984, PUBLIC HEALTH REP, V99, P228; Roa BB, 1996, NAT GENET, V14, P185, DOI 10.1038/ng1096-185; Rubin SC, 1996, NEW ENGL J MED, V335, P1413, DOI 10.1056/NEJM199611073351901; SLOVIC P, 1986, RISK ANAL, V6, P403, DOI 10.1111/j.1539-6924.1986.tb00953.x; 1996, J CLIN ONCOL, V14, P1730	7	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 16	1996	348	9038					1328	1328		10.1016/S0140-6736(05)65406-2	http://dx.doi.org/10.1016/S0140-6736(05)65406-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VT332	8918274				2022-12-24	WOS:A1996VT33200007
J	Swalla, BJ; Jeffery, WR				Swalla, BJ; Jeffery, WR			Requirement of the Manx gene for expression of chordate features in a tailless ascidian larva	SCIENCE			English	Article							ANURAL DEVELOPMENT; INTERSPECIFIC HYBRIDIZATION; ANTISENSE OLIGONUCLEOTIDES; MARINE-INVERTEBRATES; EVOLUTIONARY CHANGE; ALTERNATE MODES; MESSENGER-RNA; SHORT-GERM; EMBRYO; MUSCLE	An evolutionary change in development was studied in two closely related ascidian species, one exhibiting a conventional tadpole larva and the other a modified tailless larva. Interspecific hybridization restores chordate features to the tailless larva. The zinc finger gene Manx is expressed in cells that generate chordate features in the tailed species but is down-regulated in the tailless species. Manx expression is restored in hybrid embryos. Antisense oligodeoxynucleotide treatment inhibited Manx expression and chordate features in hybrid embryos, which suggests that Manx is required for development of the chordate larval phenotype in ascidians.	CNRS,BIOL STN,ROSCOFF,FRANCE; UNIV CALIF BODEGA,MARINE LAB,BODEGA BAY,CA 94923; UNIV CALIF DAVIS,SECT MOL & CELLULAR BIOL,DAVIS,CA 95616	Centre National de la Recherche Scientifique (CNRS); University of California System; University of California Davis	Swalla, BJ (corresponding author), VANDERBILT UNIV,DEPT BIOL,NASHVILLE,TN 37235, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD013970] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-13970] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AUGUSTINE K, 1993, DEV GENET, V14, P500, DOI 10.1002/dvg.1020140611; BATES WR, 1993, MICROSC RES TECHNIQ, V26, P285, DOI 10.1002/jemt.1070260404; Berrill NJ, 1931, PHILOS T R SOC LON B, V219, P281, DOI 10.1098/rstb.1931.0006; DELACAZEDUTHIER.FJ, 1874, ARCH ZOOL EXP GEN, V3, P119; Elinson R.P., 1990, Seminars in Developmental Biology, V1, P263; ERICKSON RP, 1993, DEV GENET, V14, P251, DOI 10.1002/dvg.1020140402; HADFIELD KA, 1995, J MOL EVOL, V40, P413, DOI 10.1007/BF00164028; HALL BK, 1984, BIOL REV, V59, P89, DOI 10.1111/j.1469-185X.1984.tb00402.x; HENRY JQ, 1994, DEV GENET, V15, P64, DOI 10.1002/dvg.1020150108; Jagersten G, 1972, EVOLUTION METAZOAN L; Jeffery W.R., 1990, Seminars in Developmental Biology, V1, P253; JEFFERY WR, 1992, BIOESSAYS, V14, P219, DOI 10.1002/bies.950140404; JEFFERY WR, 1994, J MAR BIOL ASSOC UK, V74, P35, DOI 10.1017/S0025315400035645; JEFFERY WR, 1993, ROUX ARCH DEV BIOL, V202, P103, DOI 10.1007/BF00636535; JEFFERY WR, 1992, DEV BIOL, V153, P194, DOI 10.1016/0012-1606(92)90105-P; JEFFERY WR, 1991, DEV BIOL, V145, P328, DOI 10.1016/0012-1606(91)90131-L; KARNOVSKY MJ, 1964, J HISTOCHEM CYTOCHEM, V12, P219, DOI 10.1177/12.3.219; KATZ MJ, 1983, BIOL BULL-US, V164, P1, DOI 10.2307/1541186; Kusakabe T, 1996, DEV BIOL, V174, P379, DOI 10.1006/dbio.1996.0082; LALLIER T, 1993, SCIENCE, V259, P692, DOI 10.1126/science.8430321; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MEEDEL TH, 1983, P NATL ACAD SCI-BIOL, V80, P4761, DOI 10.1073/pnas.80.15.4761; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; NISHIDA H, 1992, ROUX ARCH DEV BIOL, V201, P81, DOI 10.1007/BF00420418; NISHIDA H, 1992, DEVELOPMENT, V116, P521; NISHIDA H, 1991, DEVELOPMENT, V112, P389; NISHIDA H, 1989, DEV BIOL, V132, P355, DOI 10.1016/0012-1606(89)90232-7; PARIA BC, 1992, P NATL ACAD SCI USA, V89, P10051, DOI 10.1073/pnas.89.21.10051; PATEL NH, 1994, NATURE, V367, P429, DOI 10.1038/367429a0; PERRY HE, 1983, CELL DIFFER DEV, V13, P233, DOI 10.1016/0045-6039(83)90094-5; RAFF RA, 1992, BIOESSAYS, V14, P211, DOI 10.1002/bies.950140403; REVERBERI G., 1960, ACTA EMBRYOL MORPHOL EXPTL, V3, P296; Satoh N., 1994, DEV BIOL ASCIDIANS; SCOTT MP, 1994, CELL, V79, P1121, DOI 10.1016/0092-8674(94)90001-9; SOMMER RJ, 1994, DEV GENET, V15, P32, DOI 10.1002/dvg.1020150105; SOMMER RJ, 1992, P NATL ACAD SCI USA, V89, P10782, DOI 10.1073/pnas.89.22.10782; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; STRATHMANN RR, 1978, EVOLUTION, V32, P894, DOI 10.1111/j.1558-5646.1978.tb04642.x; SWALLA BJ, 1991, DEVELOPMENT, V111, P425; SWALLA BJ, 1990, DEV BIOL, V142, P319, DOI 10.1016/0012-1606(90)90353-K; SWALLA BJ, 1993, DEVELOPMENT, V119, P307; SWALLA BM, UNPUB; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WHITTAKER JR, 1979, BIOL BULL-US, V156, P393, DOI 10.2307/1540926; WRAY GA, 1991, TRENDS ECOL EVOL, V6, P45, DOI 10.1016/0169-5347(91)90121-D; YOUNG CM, 1988, BIOL BULL, V174, P39, DOI 10.2307/1541757	46	103	104	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1996	274	5290					1205	1208		10.1126/science.274.5290.1205	http://dx.doi.org/10.1126/science.274.5290.1205			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT335	8895472				2022-12-24	WOS:A1996VT33500058
J	Martyn, CN; Barker, DJP; Osmond, C				Martyn, CN; Barker, DJP; Osmond, C			Mothers' pelvic size, fetal growth, and death from stroke and coronary heart disease in men in the UK	LANCET			English	Article							ADULT LIFE; CARDIOVASCULAR-DISEASE; FACTOR-VII; FIBRINOGEN; NUTRITION; MORTALITY; THINNESS; ENGLAND; BIRTH; WALES	Background People who have a low birthweight show increased death rates from coronary heart disease and a higher prevalence for its risk factors. These findings have led to the hypothesis that the disease is programmed in fetal life. The aim of this study was to explore whether risk of stroke in adult life was linked to impaired fetal growth. Methods We ascertained deaths from stroke and coronary heart disease in 13249 men in two cohorts from Hertfordshire and Sheffield, UK. We related death rates from these diseases to body size at birth, weight at 1 year, and to measurements of the mothers' pelvises. Findings Death rates from both stroke and coronary heart disease tended to be highest in men whose birthweight had been low. Standardised mortality ratios (SMRs) far stroke felt by 12% (95% CI 1-22) and for coronary heart disease by 10% (6-14) between each of five groupings of increasing birthweight (less than or equal to 5 5 lb, 5.6-6.5 lb, 6.6-7.5 lb, 7.6-8.5 lb, and > 8.5 lb). Mortality from stroke was most strongly associated with low birthweight in relation to head size. and low placental weight in relation to head size. These patterns of growth occurred in offspring of mothers with flat bony pelvises. The SMR in sans of these women was 184 (67-396) compared with 104 (78-138) in the remainder of the cohort. In contrast, mortality from coronary heart disease was associated with small head circumference, thinness or shortness al birth and an altered ratio of placental weight to birthweight. Interpretation Stroke may originate in poor nutrition during the mother's childhood, which deforms the bony pelvis and subsequently impairs her ability to sustain the growth of the placenta and fetus in late pregnancy. Coronary heart disease, on the other hand, seems to originate in adaptations made by the fetus to inadequate delivery of nutrients when it occurs for reasons other than failure of placental growth.			Martyn, CN (corresponding author), UNIV SOUTHAMPTON, SOUTHAMPTON GEN HOSP, MRC, ENVIRONM EPIDEMIOL UNIT, SOUTHAMPTON SO16 6YD, HANTS, ENGLAND.			Osmond, Clive/0000-0002-9054-4655				BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1992, BMJ-BRIT MED J, V304, P148, DOI 10.1136/bmj.304.6820.148; BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; BARKER DJP, 1987, BMJ-BRIT MED J, V295, P83, DOI 10.1136/bmj.295.6590.83; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; BARKER DJP, 1986, LANCET, V1, P1077; BERKELEY C, 1941, PICTORICAL MIDWIERY; BERNARD R M, 1952, Edinb Med J, V59, P1; CAMPBELL JM, 1924, 25 PUBL HLTH MED SUB; CAMPBELL JM, 1932, 68 PUBL HLTH MED SUB; *ENC BRITT INC, 1984, ENC BRITT; Greulich WW, 1939, J AMER MED ASSOC, V112, P485, DOI 10.1001/jama.1939.02800060001001; Law CM, 1996, J HYPERTENS, V14, P935; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; MARTYN CN, 1995, BRIT J HAEMATOL, V89, P142, DOI 10.1111/j.1365-2141.1995.tb08920.x; MARTYN CN, 1995, BRIT HEART J, V73, P116; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; Mellanby E, 1933, LANCET, V2, P1131; NICHOLSON C, 1945, J ANAT, V79, P131; NICHOLSON C, 1946, LANCET, V251, P192; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; PHILLIPS DIW, 1994, DIABETOLOGIA, V37, P150, DOI 10.1007/s001250050086; RICHEDWARDS J, 1995, AM J EPIDEMIOL, V141, pS78; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804	25	285	291	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 9	1996	348	9037					1264	1268		10.1016/S0140-6736(96)04257-2	http://dx.doi.org/10.1016/S0140-6736(96)04257-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR555	8909378				2022-12-24	WOS:A1996VR55500008
J	Phillips, DM				Phillips, DM			Klebsiella pneumoniae	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Phillips, DM (corresponding author), POPULAT COUNCIL,1230 YORK AVE,NEW YORK,NY 10021, USA.								0	2	2	1	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 7	1996	335	19					1437	1437		10.1056/NEJM199611073351905	http://dx.doi.org/10.1056/NEJM199611073351905			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT339	8875921				2022-12-24	WOS:A1996VT33900005
J	Killalea, D; Ward, LR; Roberts, D; deLouvois, J; Sufi, F; Stuart, JM; Wall, PG; Susman, M; Schwieger, M; Sanderson, PJ; Fisher, IST; Mead, PS; Gill, ON; Bartlett, CLR; Rowe, B				Killalea, D; Ward, LR; Roberts, D; deLouvois, J; Sufi, F; Stuart, JM; Wall, PG; Susman, M; Schwieger, M; Sanderson, PJ; Fisher, IST; Mead, PS; Gill, ON; Bartlett, CLR; Rowe, B			International epidemiological and microbiological study of outbreak of Salmonella agona infection from a ready to eat savoury snack .1. England and Wales and the United States	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objectives-To identify the source of an international outbreak of food poisoning due to Salmonella agona phage type 15 and to measure how long the underlying cause persisted. Design-Case-control study of 16 primary household cases and 32 controls of similar age and dietary habit. Packets of the implicated foodstuff manufactured on a range of days were examined for salmonella. All isolates of the epidemic phage type were further characterised by pulsed field gel electrophoresis. Results-27 cases were identified, of which 26 were in children. The case-control study showed a strong association between infection with S agona phage type 15 and consumption of a peanut flavoured ready to eat kosher savoury snack imported from Israel. S agona phage type 15 was isolated from samples of this snack. The combined food sampling results from the United Kingdom, Canada, the United States, and Israel showed that contaminated snacks were manufactured on at least seven separate dates during a four month period between October 1994 and February 1995. Voluntary recalls of the product successfully interrupted transmission. Conclusions-Rapid international exchanges of information led to the identification of the source of a major outbreak of S agona in Israel and of associated cases in North America. The outbreak showed the value of the Salm-Net surveillance system and its links outside Europe, both for increasing case ascertainment and for improving the information on the duration of the fault at the manufacturing plant.	PUBL HLTH LAB SERV, CTR COMMUNICABLE DIS SURVEILLANCE, LONDON NW9 5EQ, ENGLAND; PUBL HLTH LAB SERV, CENT PUBL HLTH LAB, LONDON NW9 5HT, ENGLAND; PUBL HLTH LAB SERV, LAB ENTER PATHOGENS, SALMONELLA REFERENCE LAB, LONDON NW9 5EQ, ENGLAND; PUBL HLTH LAB SERV, FOOD HYG LAB, LONDON NW9 5EQ, ENGLAND; PUBL HLTH LAB SERV, STAT UNIT, LONDON NW9 5EQ, ENGLAND; COLINDALE HOSP, BARNET DIST HLTH AUTHOR, LONDON NW9 5HG, ENGLAND	Public Health England; Public Health England; Public Health England; Public Health England; Public Health England								AITKEN M, 1990, STAT MODELLING GLIM; *BRIT STAND I, 1993, 5763 BSI; Fisher I. S. T., 1994, PHLS Microbiology Digest, V11, P181; FROST JA, 1995, EMERG INFECT DIS, V1, P26, DOI 10.3201/eid0101.950105; Joseph C A, 1991, CDR (Lond Engl Rev), V1, pR16; Shohat T, 1996, BMJ-BRIT MED J, V313, P1107, DOI 10.1136/bmj.313.7065.1107; Threlfall EJ, 1996, EMERG INFECT DIS, V2, P130, DOI 10.3201/eid0202.960209	7	116	119	1	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 2	1996	313	7065					1105	1107		10.1136/bmj.313.7065.1105	http://dx.doi.org/10.1136/bmj.313.7065.1105			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR217	8916693	Green Published			2022-12-24	WOS:A1996VR21700018
J	Mangiarini, L; Sathasivam, K; Seller, M; Cozens, B; Harper, A; Hetherington, C; Lawton, M; Trottier, Y; Lehrach, H; Davies, SW; Bates, GP				Mangiarini, L; Sathasivam, K; Seller, M; Cozens, B; Harper, A; Hetherington, C; Lawton, M; Trottier, Y; Lehrach, H; Davies, SW; Bates, GP			Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice	CELL			English	Article							SPINOCEREBELLAR ATAXIA TYPE-1; PALLIDOLUYSIAN ATROPHY DRPLA; HUNTINGTONS-DISEASE; PROTEIN; BRAIN; EXPANSION; EXPRESSION; TISSUES	Huntington's disease (HD) is one of an increasing number of neurodegenerative disorders caused by a CAG/ polyglutamine repeat expansion. Mice have been generated that are transgenic for the 5' end of the human HD gene carrying (CAG)(115)-(CAG)(150) repeat expansions. In three lines, the transgene is ubiquitously expressed at both mRNA and protein level. Transgenic mice exhibit a progressive neurological phenotype that exhibits many of the features of HD, including choreiform-like movements, involuntary stereotypic movements, tremor, and epileptic seizures, as well as nonmovement disorder components. This transgenic model will greatly assist in an eventual understanding of the molecular pathology of HD and may open the way to the testing of intervention strategies.	UMDS,TRANSGEN UNIT,RAYNE INST,LONDON SE1 7EH,ENGLAND; UNIV OXFORD,JOHN RADCLIFFE HOSP,BIOMED SERV,OXFORD OX3 9DU,ENGLAND; UMDS,GUYS HOSP,BIOL SERV DIV,LONDON SE1 9RT,ENGLAND; UNIV STRASBOURG 1,INSERM,CNRS,INST GENET & BIOL MOL & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE; MAX PLANCK INST MOL GENET,D-14195 BERLIN,GERMANY; UNIV LONDON UNIV COLL,DEPT ANAT & DEV BIOL,LONDON WC1E 6BT,ENGLAND	University of London; King's College London; University of Oxford; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Max Planck Society; University of London; University College London	Mangiarini, L (corresponding author), UMDS,GUYS HOSP,DIV MED & MOL GENET,LONDON SE1 9RT,ENGLAND.		Trottier, Yvon/H-8852-2016; Bates, Gillian P/E-1146-2012; Longo, Kenneth A/A-5631-2010	Bates, Gillian P/0000-0002-4041-6305; Trottier, Yvon/0000-0001-7230-4810				BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; DELAMONTE SM, 1988, J NEUROPATH EXP NEUR, V47, P516, DOI 10.1097/00005072-198809000-00003; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; Durr A, 1996, ANN NEUROL, V39, P490, DOI 10.1002/ana.410390411; HARPER PS, 1991, J NEUROPATH EXP NEUR, V54, P105; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; JOU YS, 1995, HUM MOL GENET, V4, P465, DOI 10.1093/hmg/4.3.465; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; KENNEDY WR, 1968, NEUROLOGY, V18, P671, DOI 10.1212/WNL.18.7.671; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LAUDER I. M., 1954, Veterinary Record, V66, P607; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; LYON MF, 1990, GENETIC VARIANTS STR; MONACO AP, 1985, NATURE, V316, P842, DOI 10.1038/316842a0; MYERS RH, 1991, J NEUROPATH EXP NEUR, V50, P729, DOI 10.1097/00005072-199111000-00005; MYERS RH, 1988, NEUROLOGY, V38, P341, DOI 10.1212/WNL.38.3.341; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; SANBERG PR, 1981, MED J AUSTRALIA, V1, P407, DOI 10.5694/j.1326-5377.1981.tb135681.x; SERVADIO A, 1995, NAT GENET, V10, P94, DOI 10.1038/ng0595-94; Sidman Richard L., 1971, ATLAS MOUSE BRAIN SP; STRONG TV, 1993, NAT GENET, V5, P259, DOI 10.1038/ng1193-259; TAKAHASHI H, 1988, NEUROLOGY, V38, P1065, DOI 10.1212/WNL.38.7.1065; TELENIUS H, 1993, HUM MOL GENET, V2, P1535, DOI 10.1093/hmg/2.10.1535; TROTTIER Y, 1995, NAT GENET, V10, P104, DOI 10.1038/ng0595-104; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; WHEELER JS, 1985, BRIT J UROL, V57, P63, DOI 10.1111/j.1464-410X.1985.tb08987.x; YAZAWA I, 1995, NAT GENET, V10, P99, DOI 10.1038/ng0595-99; ZOGHBI HY, 1993, CURRENT NEUROLOGY, P87; 1993, CELL, V72, P971	31	2440	2529	4	110	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 1	1996	87	3					493	506		10.1016/S0092-8674(00)81369-0	http://dx.doi.org/10.1016/S0092-8674(00)81369-0			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VQ466	8898202	Bronze			2022-12-24	WOS:A1996VQ46600015
J	Eastman, N				Eastman, N			Inquiry into homicides by psychiatric patients: Systematic audit should replace mandatory inquiries	BRITISH MEDICAL JOURNAL			English	Article								Inquiries into homicides committed by psychiatric patients are currently mandatory under Department of Health guidance. They are often broadly defined in their terms of reference and almost always address not only the cause of the incident but also professional skill, practice, and culpability. Concurrent pursuit of both purposes is unlikely to maximise ''learning from experience.'' Also, since inquiries can set their own thresholds for culpability, doctors can potentially be judged to a higher standard than would be required by the General Medical Council or negligence law. Lack of strict legal process increases the inherent potential unfairness to doctors. Investigation of cause and culpability should be separated and inquiries restricted to the former. There should also be a standing secretariat for inquiries to set terms of reference and to collate and distribute findings of inquiries. Widespread mandatory systematic audit of professional practice and service efficiency concerning risk assessment and management should largely replace costly ad hoc mandatory inquiries after homicides.			Eastman, N (corresponding author), ST GEORGE HOSP,SCH MED,SECT FORENS PSYCHIAT,CRANMER TERRACE,LONDON SW17 0RE,ENGLAND.							BLOMCOOPER L, 1993, CURRENT LEGAL PROBLE; CARSON D, 1996, INQUIRIES HOMICIDE; CLOTHIER C, 1996, INQUIRIES HOMICIDE; *DEP HLTH, 1994, HSG9427 NHS DOH; Department of Health and Social Security (DoHSS), 1974, REP COMM INQ CAR SUP; EASTMAN N, 1996, INQUIRIES HOMICIDE; House A, 1996, BRIT MED J, V312, P135; MARTIN J, 1984, HOSP TROUBLE; PEAY J, 1996, INQUIRIES HOMOCIDE; Reder P, 1996, INQUIRIES HOMICIDE; Ritchie J., 1994, REPORT INQUIRY CARE; *ROYAL COLL PSYCH, 1996, REP CONF INQ HOM SUI; Sheppard D, 1995, LEARNING LESSONS MEN; THOROLD O, 1996, INQUIRIES HOMOCIDE; VINESTOCK MD, 1996, ADV PSYCHIAT TREATME, V2, P3	15	22	22	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 26	1996	313	7064					1069	1071						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP742	8898603				2022-12-24	WOS:A1996VP74200037
J	ONeill, D				ONeill, D			Dementia and driving: Screening, assessment, and advice	LANCET			English	Editorial Material							ALZHEIMERS-DISEASE; ELDERLY DRIVERS; CRASHES				ONeill, D (corresponding author), MEATH HOSP,CTR MOBIL ENHANCEMENT,DUBLIN 8,IRELAND.		O'Neill, Desmond/D-1486-2013	O'Neill, Desmond/0000-0002-5542-9897				BAHRO M, 1995, INT J GERIATR PSYCH, V10, P871, DOI 10.1002/gps.930101010; Bedard M., 1996, Journal of the American Geriatrics Society, V44, pS9; CARR D, 1991, J AM GERIATR SOC, V39, P1132, DOI 10.1111/j.1532-5415.1991.tb02882.x; DRACHMAN DA, 1993, NEUROLOGY, V43, P2448, DOI 10.1212/WNL.43.12.2448; HakamiesBlomqvist L, 1996, J AM GERIATR SOC, V44, P650, DOI 10.1111/j.1532-5415.1996.tb01826.x; HUNT L, 1993, J AM GERIATR SOC, V41, P747, DOI 10.1111/j.1532-5415.1993.tb07465.x; JOHANSSON K, 1994, AGEING DRIVING, P85; LEVY DT, 1995, JAMA-J AM MED ASSOC, V274, P1026, DOI 10.1001/jama.274.13.1026; MITCHELL RK, 1995, INT J GERIATR PSYCH, V10, P865, DOI 10.1002/gps.930101009; ONEILL D, 1992, LANCET, V339, P41, DOI 10.1016/0140-6736(92)90155-V; Trobe JD, 1996, ARCH NEUROL-CHICAGO, V53, P411, DOI 10.1001/archneur.1996.00550050033021	11	7	7	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 26	1996	348	9035					1114	1114		10.1016/S0140-6736(05)65269-5	http://dx.doi.org/10.1016/S0140-6736(05)65269-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VP106	8888162				2022-12-24	WOS:A1996VP10600006
J	Stick, SM; Burton, PR; Gurrin, L; Sly, PD; LeSouef, PN				Stick, SM; Burton, PR; Gurrin, L; Sly, PD; LeSouef, PN			Effects of maternal smoking during pregnancy and a family history of asthma on respiratory function in newborn infants	LANCET			English	Article							PULMONARY-FUNCTION; PARENTAL SMOKING; LUNG-FUNCTION; CHILDREN; OBSTRUCTION; EXPOSURE; NICOTINE; ILLNESS; LIFE	Introduction Infants of mothers who smoke have reduced respiratory function and are more likely to develop wheezing, Little evidence is available on the effect of inutero cigarette-smoke exposure as opposed to postnatal exposure to environmental tobacco smoke, We used a previously validated non-invasive method to measure the time to peak tidal expiratory flow (tPTEF) as a proportion of expiratory time (tE) in newborn infants soon after birth to examine the effects of a family history of asthma and in-utero cigarette-smoke exposure on the infants' respiratory function. Methods We collected respiratory-function data from 500 healthy infants of mothers taking part in the Western Australia Pregnancy Cohort Study, During behaviourally defined quiet sleep, measurements were obtained a median of 58 h (range 26-159) after the infants were born, We used uncalibrated inductance plethysmography. The uncalibrated volume signal was differentiated to flow and used to calculate respiratory rate, total inspiratory time, tE, and tPTEF, Mothers answered questionnaires on demographic, medical, and pregnancy characteristics, including smoking history. Serum cotinine measurements were available to validate self-reported smoking history in a subset of mothers (238). Results Data suitable for analysis were obtained from 461 infants. In multivariate regression analysis, lower values of tPTEF/tE were independently associated with respiratory rate (beta coefficient per 10 breaths/min 0.018 [SE 0.005], p<0.01), age (beta coefficient per 10 h -0.008 [0.003], p<0.01), maternal smoking during pregnancy (>10 cigarettes daily; beta coefficient -0.049 [0.022], p<0.05), maternal hypertension during pregnancy (-0.037 [0.015], p<0.02), and a family history of asthma (-0.028 [0.014], p<0.05). Conclusions In-utero smoke exposure, a family history of asthma, and maternal hypertension during pregnancy are associated with reduced respiratory function after birth. We speculate that these factors adversely affect lung development in utero.	CHILDRENS HOSP,MED CTR,INST CHILD HLTH RES,DIV CLIN SCI,PERTH,WA,AUSTRALIA; CHILDRENS HOSP,MED CTR,INST CHILD HLTH RES,DIV BIOSTAT,PERTH,WA,AUSTRALIA	Telethon Kids Institute; University of Western Australia; Telethon Kids Institute; University of Western Australia	Stick, SM (corresponding author), PRINCESS MARGARET HOSP CHILDREN,DEPT RESP MED,GPO BOX D184,PERTH,WA 6001,AUSTRALIA.		Study, Raine/K-4517-2013; Stick, Stephen/O-5683-2014; Stick, Stephen/AAA-5945-2021; Le Souef, Peter N/H-5256-2014; Sly, Peter D/F-1486-2010; Stick, Stephen/GZG-7584-2022; Burton, Paul R/H-7527-2016	Stick, Stephen/0000-0002-5386-8482; Sly, Peter D/0000-0001-6305-2201; Gurrin, Lyle/0000-0001-7052-1969; Le Souef, Peter/0000-0003-0930-1654				BASSI JA, 1984, PEDIATR RES, V18, P127, DOI 10.1203/00006450-198402000-00002; BROWN RW, 1995, PEDIATR PULM, V19, P23, DOI 10.1002/ppul.1950190105; CHEN MF, 1987, PEDIATR PULM, V3, P51, DOI 10.1002/ppul.1950030113; COLLINS MH, 1985, PEDIATR RES, V19, P408, DOI 10.1203/00006450-198519040-00018; CUTRERA R, 1991, PEDIATR PULM, V10, P6, DOI 10.1002/ppul.1950100103; ELLIS E, 1993, AM REV RESPIR DIS, V148, pA222; FOUCARD T, 1984, ACTA PAEDIATR SCAND, V73, P577, DOI 10.1111/j.1651-2227.1984.tb09977.x; HANRAHAN JP, 1992, AM REV RESPIR DIS, V145, P1129, DOI 10.1164/ajrccm/145.5.1129; MARITZ GS, 1988, BIOL NEONATE, V53, P163; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1988, NEW ENGL J MED, V319, P1112, DOI 10.1056/NEJM198810273191702; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; MILICEMILI J, 1976, CHEST, V70, P131, DOI 10.1378/chest.70.1.131; MORRIS MJ, 1981, THORAX, V36, P135, DOI 10.1136/thx.36.2.135; PARK ES, 1986, ARCH DIS CHILD, V61, P642, DOI 10.1136/adc.61.7.642; Seddon PC, 1996, AM J RESP CRIT CARE, V153, P1248, DOI 10.1164/ajrccm.153.4.8616549; SHERRILL DL, 1992, AM REV RESPIR DIS, V145, P1136, DOI 10.1164/ajrccm/145.5.1136; STICK SM, 1992, PEDIATR PULM, V14, P187, DOI 10.1002/ppul.1950140308; TAGER IB, 1983, NEW ENGL J MED, V309, P699, DOI 10.1056/NEJM198309223091204; TAYLOR B, 1987, ARCH DIS CHILD, V62, P786, DOI 10.1136/adc.62.8.786; VANVUNAKIS H, 1987, ENV CARCINOGENS METH, V9; WALL MA, 1988, AM J PUBLIC HEALTH, V78, P699, DOI 10.2105/AJPH.78.6.699; WANG NS, 1984, J PATHOL, V144, P89, DOI 10.1002/path.1711440204; WRIGHT AL, 1991, J PEDIATR-US, V118, P207, DOI 10.1016/S0022-3476(05)80484-6; YOUNG S, 1991, NEW ENGL J MED, V325, P747; YOUNG S, 1994, J PEDIATR-US, V124, P681, DOI 10.1016/S0022-3476(05)81355-1; YOUNG S, 1991, NEW ENGL J MED, V324, P1168, DOI 10.1056/NEJM199104253241704; 1984, EUR J RESPIR DIS S, V132, P1	28	316	329	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 19	1996	348	9034					1060	1064		10.1016/S0140-6736(96)04446-7	http://dx.doi.org/10.1016/S0140-6736(96)04446-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM886	8874457				2022-12-24	WOS:A1996VM88600010
J	Porter, JA; Young, KE; Beachy, PA				Porter, JA; Young, KE; Beachy, PA			Cholesterol modification of hedgehog signaling proteins in animal development	SCIENCE			English	Article							LEMLI-OPITZ SYNDROME; CELL-CELL COMMUNICATION; SONIC-HEDGEHOG; POLARITY GENE; AUTOPROTEOLYTIC CLEAVAGE; XENOPUS-LAEVIS; DROSOPHILA; EXPRESSION; INDUCTION; HOMOLOG	Hedgehog (Hh) proteins comprise a family of secreted signaling molecules essential for patterning a variety of structures in animal embryogenesis. During biosynthesis, Hh undergoes an autocleavage reaction, mediated by its carboxyl-terminal domain, that produces a lipid-modified amino-terminal fragment responsible for all known Hh signaling activity. Here it is reported that cholesterol is the lipophilic moiety covalently attached to the amino-terminal signaling domain during autoprocessing and that the carboxyl-terminal domain acts as an intramolecular cholesterol transferase. This use of cholesterol to modify embryonic signaling proteins may account for some of the effects of perturbed cholesterol biosynthesis on animal development.	JOHNS HOPKINS UNIV,SCH MED,DEPT MOL BIOL & GENET,HOWARD HUGHES MED INST,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Johns Hopkins University								Alberts B., 1994, MOL BIOL CELL; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; Bitgood MJ, 1996, CURR BIOL, V6, P298, DOI 10.1016/S0960-9822(02)00480-3; BROWN MS, 1992, CELL, V71, P187, DOI 10.1016/0092-8674(92)90346-E; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CHANG DT, 1994, DEVELOPMENT, V120, P3339; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Christie W.W., 2003, LIPID ANAL; COHEN BI, 1975, STEROIDS, V25, P365, DOI 10.1016/0039-128X(75)90093-8; DEALMEIDA MLC, 1983, NATURE, V302, P349, DOI 10.1038/302349a0; Dupont J., 1982, CHOLESTEROL SYSTEMS; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; EKKER SC, 1995, DEVELOPMENT, V121, P2337; EKKER SC, 1995, CURR BIOL, V5, P944, DOI 10.1016/S0960-9822(95)00185-0; ERICSON J, 1995, CELL, V81, P747, DOI 10.1016/0092-8674(95)90536-7; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; Field M. C., 1992, LIPID MODIFICATION P, P155; Forbes AJ, 1996, DEVELOPMENT, V122, P1125; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; GIBBONS GF, 1982, BIOCH CHOLESTEROL; HABERLAND ME, 1973, P NATL ACAD SCI USA, V70, P2313, DOI 10.1073/pnas.70.8.2313; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; HYNES M, 1995, NEURON, V15, P35, DOI 10.1016/0896-6273(95)90062-4; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; JOHNSON RL, 1994, CELL, V79, P1165, DOI 10.1016/0092-8674(94)90008-6; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LAI CJ, 1995, DEVELOPMENT, V121, P2349; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LOWRY RR, 1968, J LIPID RES, V9, P397; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MACDONALD R, 1995, DEVELOPMENT, V121, P3267; MOHLER J, 1992, DEVELOPMENT, V115, P957; MOHLER J, 1988, GENETICS, V120, P1061; Moore DD, 1995, GLOB MOB SURV; Morrison R.T., 1973, ORGANIC CHEM, V3rd; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; OPITZ JM, 1994, AM J MED GENET, V50, P344, DOI 10.1002/ajmg.1320500408; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; PORTER JW, UNPUB; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RODRIGUEZ RJ, 1985, METHOD ENZYMOL, V111, P37; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; ROUX C, 1979, TERATOLOGY, V19, P39, DOI 10.1002/tera.1420190107; ROUX C, 1966, CR SOC BIOL, V160, P1353; ROUX C, 1979, TERATOLOGY, V19, P35, DOI 10.1002/tera.1420190106; ROUX C, 1995, 23 ANN C EUR TER SOC; ROUX CHARLES, 1964, ARCH FRANC PEDIAT, V21, P451; Salen G, 1996, J LIPID RES, V37, P1169; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SILBERKANG M, 1983, J BIOL CHEM, V258, P8503; SVOBODA JA, 1995, LIPIDS, V30, P263, DOI 10.1007/BF02537831; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TASHIRO S, 1993, GENE, V124, P183; TINT GS, 1994, NEW ENGL J MED, V330, P107, DOI 10.1056/NEJM199401133300205; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; WALSH JP, 1992, METHOD ENZYMOL, V209, P153; XU GR, 1995, GASTROENTEROLOGY, V109, P1301, DOI 10.1016/0016-5085(95)90592-8; YEAGLE PL, 1985, BIOCHIM BIOPHYS ACTA, V822, P267, DOI 10.1016/0304-4157(85)90011-5	63	1062	1106	1	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1996	274	5285					255	259		10.1126/science.274.5285.255	http://dx.doi.org/10.1126/science.274.5285.255			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM671	8824192				2022-12-24	WOS:A1996VM67100046
J	Nightingale, SL				Nightingale, SL			Final regulations to reduce children's use of tobacco issued	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1995, JAMA-J AM MED ASSOC, V274, P1109	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1996	276	14					1128	1128						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL332	8827954				2022-12-24	WOS:A1996VL33200007
J	Altman, JD; Moss, PAH; Goulder, PJR; Barouch, DH; McHeyzerWilliams, MG; Bell, JI; McMichael, AJ; Davis, MM				Altman, JD; Moss, PAH; Goulder, PJR; Barouch, DH; McHeyzerWilliams, MG; Bell, JI; McMichael, AJ; Davis, MM			Phenotypic analysis of antigen-specific T lymphocytes	SCIENCE			English	Article							MEMORY B-CELLS; PERIPHERAL-BLOOD; ESCHERICHIA-COLI; IMMUNE-RESPONSE; HIGH-FREQUENCY; IN-VIVO; VIRUS; KINETICS; HIV-1; COMPLEXES	Identification and characterization of antigen-specific T lymphocytes during the course of an immune response is tedious and indirect. To address this problem, the peptide-major histocompatability complex (MHC) ligand for a given population of T cells was multimerized to make soluble peptide-MHC tetramers. Tetramers of human lymphocyte antigen A2 that were complexed with two different human immunodeficiency virus (HIV)-derived peptides or with a peptide derived from influenza A matrix protein bound to peptide-specific cytotoxic T cells in vitro and to T cells from the blood of HIV-infected individuals. In general, tetramer binding correlated well with cytotoxicity assays, This approach should be useful in the analysis of T cells specific for infectious agents, tumors, and autoantigens.	STANFORD UNIV,BECKMAN CTR,DEPT MICROBIOL & IMMUNOL,HOWARD HUGHES MED INST,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT IMMUNOL & MICROBIOL,STANFORD,CA 94305; JOHN RADCLIFFE HOSP,INST MOL MED,OXFORD OX3 9DU,ENGLAND	Howard Hughes Medical Institute; Stanford University; Stanford University; University of Oxford			Barouch, Dan/Y-3918-2019	Davis, Mark/0000-0001-6868-657X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BRUNO L, 1995, IMMUNITY, V2, P37, DOI 10.1016/1074-7613(95)90077-2; CARMICHAEL A, 1993, J EXP MED, V177, P249, DOI 10.1084/jem.177.2.249; CORR M, 1994, SCIENCE, V265, P946, DOI 10.1126/science.8052850; Doherty PC, 1996, IMMUNOL REV, V150, P23, DOI 10.1111/j.1600-065X.1996.tb00694.x; EWING C, 1995, VIROLOGY, V210, P179, DOI 10.1006/viro.1995.1329; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; GOTCH FM, 1990, INT IMMUNOL, V2, P707, DOI 10.1093/intimm/2.8.707; HAYAKAWA K, 1987, P NATL ACAD SCI USA, V84, P1379, DOI 10.1073/pnas.84.5.1379; HOFFENBACH A, 1989, J IMMUNOL, V142, P452; HOLTER W, 1985, CELL IMMUNOL, V90, P322, DOI 10.1016/0008-8749(85)90197-2; HOU S, 1993, J IMMUNOL, V150, P5494; JOHNSON RP, 1991, J IMMUNOL, V147, P1512; JULIUS MH, 1972, P NATL ACAD SCI USA, V69, P1934, DOI 10.1073/pnas.69.7.1934; KO HS, 1979, J EXP MED, V150, P246, DOI 10.1084/jem.150.2.246; KOUP RA, 1991, J EXP MED, V174, P1593, DOI 10.1084/jem.174.6.1593; LEHNER PJ, 1995, J EXP MED, V181, P79, DOI 10.1084/jem.181.1.79; MACDONALD HR, 1993, J EXP MED, V177, P1487, DOI 10.1084/jem.177.5.1487; MATSUI K, 1994, P NATL ACAD SCI USA, V91, P12862, DOI 10.1073/pnas.91.26.12862; MCHEYZERWILLIAMS MG, 1991, NATURE, V350, P502, DOI 10.1038/350502a0; MCHEYZERWILLIAMS MG, 1995, SCIENCE, V268, P106, DOI 10.1126/science.7535476; MOSS PAH, 1995, P NATL ACAD SCI USA, V92, P5773, DOI 10.1073/pnas.92.13.5773; NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0; PANTALEO G, 1990, J IMMUNOL, V144, P1696; PARISH CR, 1993, J IMMUNOL, V150, P4833; REINER SL, 1993, SCIENCE, V259, P1457, DOI 10.1126/science.8451641; ROEDERER M, IN PRESS HDB EXPT IM, V4; SCHATZ PJ, 1993, BIO-TECHNOL, V11, P1138, DOI 10.1038/nbt1093-1138; Selin LK, 1996, J EXP MED, V183, P2489, DOI 10.1084/jem.183.6.2489; SYKULEV Y, 1994, IMMUNITY, V1, P15, DOI 10.1016/1074-7613(94)90005-1; TRIPP RA, 1995, J IMMUNOL, V154, P5870; TSOMIDES TJ, 1991, P NATL ACAD SCI USA, V88, P11276, DOI 10.1073/pnas.88.24.11276; WALKER BD, 1988, SCIENCE, V240, P64, DOI 10.1126/science.2451288; WALKER PR, 1995, J IMMUNOL, V155, P3443; Zimmermann C, 1996, J EXP MED, V183, P1367, DOI 10.1084/jem.183.4.1367	34	2964	3353	4	195	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1996	274	5284					94	96		10.1126/science.274.5284.94	http://dx.doi.org/10.1126/science.274.5284.94			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VK748	8810254				2022-12-24	WOS:A1996VK74800054
J	Wang, XT; Culotta, VC; Klee, CB				Wang, XT; Culotta, VC; Klee, CB			Superoxide dismutase protects calcineurin from inactivation	NATURE			English	Article							PHOSPHOPROTEIN PHOSPHATASE; SACCHAROMYCES-CEREVISIAE; ACTIVE-SITE; KINASE; IDENTIFICATION; ADAPTATION; COMPLEXES; GENE	CALCINEURIN is the only protein phosphatase known to be under the control of Ca2+ and calmodulin(1,2). It is targeted by immuno-suppressive drugs and has a critical role in T-cell activation(3,4). It is specifically inhibited by immunosuppressant immunophilin complexes, which enabled its function in regulating a wide range of cellular responses to Ca2+-mobilizing signals(5,6) to be identified. Calcineurin in situ is 10-20 times more active than in the purified form and is subject to a time- and Ca2+/calmodulin-dependent reversible inactivation that is facilitated by small, heat-stable molecules(7). Here we identify a factor that prevents the inactivation of calcineurin be vitro and in vivo as the enzyme superoxide dismutase, which indicates that inactivation may be the result of oxidative damage to the Fe-Zn active centre of calcineurin. The redox state of iron provides a mechanism to regulate calcineurin activity by desensitizing the enzyme and coupling Ca2+-dependent protein dephosphorylation to the redox state of the cell. The protection of calcineurin against inactivation by superoxide dismutase constitutes a new physiological role for this enzyme which enables the Ca2+-dependent regulation of cellular processes to be modulated by the redox potential.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DIV TOXICOL SCI,BALTIMORE,MD 21205	Johns Hopkins University	Wang, XT (corresponding author), NCI,BIOCHEM LAB,NIH,BETHESDA,MD 20892, USA.							BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; BLUMENTHAL DK, 1986, J BIOL CHEM, V261, P8140; BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3187, DOI 10.1073/pnas.82.10.3187; CARRICO RJ, 1969, J BIOL CHEM, V244, P6087; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; DELABAR JM, 1987, EUR J BIOCHEM, V166, P181, DOI 10.1111/j.1432-1033.1987.tb13500.x; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; FRIDOVICH I, 1986, ADV ENZYMOL RAMB, V58, P61; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; HIRATA D, 1995, MOL GEN GENET, V249, P257, DOI 10.1007/BF00290525; HUBBARD MJ, 1991, MOL NEUROBIOL, P135; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; KINCAID RL, 1991, ADV PROT PHOSPHATASE, V6, P73; KING MM, 1984, J BIOL CHEM, V259, P8847; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; LIU XF, 1992, J BIOL CHEM, V267, P18298; MARTIN BL, 1986, J BIOL CHEM, V261, P4545; MENDOZA I, 1994, J BIOL CHEM, V269, P8792; PATERSON D, 1994, MOL GENET MED, V4, P79; Qin K. -F., 1995, FASEB J, V9, pA1347; Rouault TA, 1996, TRENDS BIOCHEM SCI, V21, P174, DOI 10.1016/0968-0004(96)10024-4; SEMMER PM, 1995, FEBS LETT, V374, P237; STRATER N, 1995, SCIENCE, V268, P1489, DOI 10.1126/science.7770774; WANG H, 1991, BIOCHEMISTRY-US, V30, P3019, DOI 10.1021/bi00226a006; YU L, 1995, J AM CHEM SOC, V117, P10147, DOI 10.1021/ja00145a040	30	233	243	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 3	1996	383	6599					434	437		10.1038/383434a0	http://dx.doi.org/10.1038/383434a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL463	8837775				2022-12-24	WOS:A1996VL46300061
J	Roberts, I; Power, C				Roberts, I; Power, C			Does the decline in child injury mortality vary by social class? A comparison of class specific mortality in 1981 and 1991	BRITISH MEDICAL JOURNAL			English	Article								Objective-To examine whether the decline in child injury death rates between 1981 and 1991 varied by social class. Design-Comparison of class specific child injury death rates for 1979, 1980, 1982, and 1983, with those for the four years 1989-92. Setting-England and Wales. Subjects-Children aged 0-15 years. Main outcome measures-Death rates from injury and poisoning. Results-Death rates from injury and poisoning have fallen for children in all social classes, The decline for children in social classes IV and V (21% and 2% respectively), however, is smaller than that for children in social classes I and II (32% and 37%). As a result of the differential decline in injury death rates, socioeconomic mortality differentials have increased. In the four years 1979-80 and 1982-83 the injury death rate for children in social class V was 3.5 times that of children in social class I. For the four years 1989-92 the injury death rate for children in social class V was 5.0 times that of children in social class I. Poisson regression modelling showed that the trend in the decline in death rates across the social classes was unlikely to have arisen by chance alone. Conclusions-Socioeconomic inequalities in child injury death rates have increased. If these gradients persist, the Health of the Nation's target is likely to be met for children in the non-manual social classes but not for those in the manual social classes.			Roberts, I (corresponding author), UNIV LONDON,INST CHILD HLTH,CHILD HLTH MONITORING UNIT,LONDON WC1N 1EH,ENGLAND.							Benzeval M, 1995, TACKLING INEQUALITIE; Bradshaw J., 1991, 6 DEP SOC SEC; *DEP HLTH, 1995, VAR HLTH WHAT CAN DE; *DEP HLTH, 1995, 2 DEP HLTH; Department of Health, 1992, HLTH NAT STRAT HLTH; EVANS L, 1992, AM J PUBLIC HEALTH, V82, P1105, DOI 10.2105/AJPH.82.8.1105; HASKEY J, 1993, POPULATION TRENDS, V72, P34; HASKEY J, 1994, POPULATION TRENDS, V78, P5; *HOM OFF, 1994, HOUS FIR ENGL WAL IN; JUDGE K, 1993, BRIT MED J, V306, P677, DOI 10.1136/bmj.306.6879.677; MARE RD, 1982, AM J PUBLIC HEALTH, V72, P539, DOI 10.2105/AJPH.72.6.539; MCLOONE P, 1994, BRIT MED J, V309, P1465, DOI 10.1136/bmj.309.6967.1465; PAUL CL, 1992, J PAEDIATR CHILD H, V28, P22, DOI 10.1111/j.1440-1754.1992.tb02612.x; PHILLIMORE P, 1994, BRIT MED J, V309, P57; *US BUR CENS, 1988, 1979 1980 CENS POP; *US CENS POP, 1991, CENS POP, V3; WILKINSON RG, 1994, UNFAIR SHARES EFFECT; WOODROFFE C, 1993, CHILDREN TEENAGERS H	18	172	176	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1996	313	7060					784	786						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK566	8842070				2022-12-24	WOS:A1996VK56600022
J	Stumpflen, I; Stumpflen, A; Wimmer, M; Bernaschek, G				Stumpflen, I; Stumpflen, A; Wimmer, M; Bernaschek, G			Effect of detailed fetal echocardiography as part of routine prenatal ultrasonographic screening on detection of congenital heart disease	LANCET			English	Article							LOW-RISK; DOPPLER ECHOCARDIOGRAPHY; SONOGRAPHIC DIAGNOSIS; 4-CHAMBER VIEW; HUMAN-FETUS; POPULATION; MALFORMATIONS; ACCURACY; DEFECTS; BIRTHS	Background Cardiac abnormalities are frequently not detected by routine ultrasound screening examinations. Although detailed fetal echocardiography is more sensitive in detection of congenital heart disease, it is used only for high-risk cases. The main aim of this study was to assess the prenatal detection of congenital heart disease by detailed fetal echocardiography in an unselected, consecutive group of pregnant women. Methods Between Jan 1, 1993, and Sept 30, 1994, all women who attended our antenatal-care unit were routinely offered a detailed fetal echocardiography examination at 18-28 weeks' gestation. 3085 consecutive women were screened: 2181 were screening cases with no known risk factor for congenital heart disease; 540 had maternal risk factors for congenital heart disease, such as a family history or coexisting maternal disease; 364 had sonographically detected abnormalities. The examination included the four-chamber view, outflow-tract scan, and colour-flow mapping; doppler and M-mode investigations were also done when appropriate. Findings 46 cases of congenital heart disease were detected prenatally by echocardiography-15 in the group with no risk factors, three in the group with maternal risk factors, and 28 in the group with sonographic abnormalities. Postnatal assessments found six further cases of congenital heart disease that had not been detected prenatally, but these were all minor cases. There were no false-positive diagnoses (sensitivity 85.5%, specificity 100%). The incidence of congenital heart disease in screening cases with no risk factors and in those with maternal risk factors was low (6.9% per 1000, 5.6 per 1000) and similar to the expected overall incidence of 8.0 per 1000 livebirths in the general population. In the group with sonographic abnormalities congenital heart disease was found significantly more often (79.9 per 1000). Interpretation inclusion of detailed fetal echocardiography as a screening examination has a substantial effect on detection of congenital heart disease since a major proportion of prenatally detectable cases occur in a low-risk population.	UNIV VIENNA,SCH MED,DEPT PRENATAL DIAG & THERAPY,A-1097 VIENNA,AUSTRIA; UNIV VIENNA,SCH MED,DEPT INTERNAL MED 2,A-1097 VIENNA,AUSTRIA; UNIV VIENNA,SCH MED,DEPT PAEDIAT CARDIOL,A-1097 VIENNA,AUSTRIA	University of Vienna; University of Vienna; University of Vienna								ACHIRON R, 1992, BRIT MED J, V304, P671, DOI 10.1136/bmj.304.6828.671; ACHIRON R, 1994, J ULTRAS MED, V13, P783; ALLAN L, 1994, ULTRASOUND OBST GYN, V4, P441, DOI 10.1046/j.1469-0705.1994.04060441.x; Allan L D, 1986, MANUAL FETAL ECHOCAR; ALLAN LD, 1980, BRIT HEART J, V44, P444; ALLAN LD, 1986, BRIT MED J, V292, P1717, DOI 10.1136/bmj.292.6537.1717; ALLAN LD, 1986, AM J CARDIOL, V58, P334, DOI 10.1016/0002-9149(86)90072-X; ALLAN LD, 1985, BRIT HEART J, V54, P523; BROMLEY B, 1992, AM J OBSTET GYNECOL, V166, P1473, DOI 10.1016/0002-9378(92)91622-H; COPEL JA, 1987, AM J OBSTET GYNECOL, V157, P648, DOI 10.1016/S0002-9378(87)80022-4; COPEL JA, 1991, OBSTET GYNECOL, V78, P1; DALTON ME, 1993, NEW ENGL J MED, V328, P114; DEVORE GR, 1987, AM J OBSTET GYNECOL, V156, P1054, DOI 10.1016/0002-9378(87)90110-4; DEVORE GR, 1994, ULTRASOUND OBST GYN, V6, P463; FERENCZ C, 1987, TERATOLOGY, V35, P367, DOI 10.1002/tera.1420350311; GEMBRUCH U, 1991, J PERINAT MED, V19, P27, DOI 10.1515/jpme.1991.19.1-2.27; GEMBRUCH U, 1989, PRENATAL DIAG, V9, P535, DOI 10.1002/pd.1970090802; GEMBRUCH U, 1990, OBSTET GYNECOL, V75, P496; GREENWOOD RD, 1975, PEDIATRICS, V55, P485; HOFFMAN JIE, 1978, AM J CARDIOL, V42, P641, DOI 10.1016/0002-9149(78)90635-5; KLEINMAN CS, 1980, PEDIATRICS, V65, P1059; MITCHELL SC, 1971, CIRCULATION, V43, P323, DOI 10.1161/01.CIR.43.3.323; OTT WJ, 1995, AM J OBSTET GYNECOL, V172, P1741, DOI 10.1016/0002-9378(95)91406-4; REED KL, 1986, CIRCULATION, V73, P41, DOI 10.1161/01.CIR.73.1.41; REED KL, 1988, FETAL ECHOCARDIOGRAP; ROTTEM S, 1989, LANCET, V1, P444; SAARIKEMPPAINEN A, 1990, LANCET, V336, P387, DOI 10.1016/0140-6736(90)91941-3; SAHN DJ, 1980, CIRCULATION, V62, P588, DOI 10.1161/01.CIR.62.3.588; SANDOR GGS, 1986, OBSTET GYNECOL, V67, P358; TEGNANDER E, 1995, ULTRASOUND OBST GYN, V5, P372, DOI 10.1046/j.1469-0705.1995.05060372.x; TODROS T, 1992, J MATERN-FETAL INVES, V2, P157; WIGTON TR, 1993, OBSTET GYNECOL, V82, P219	32	210	226	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 28	1996	348	9031					854	857		10.1016/S0140-6736(96)04069-X	http://dx.doi.org/10.1016/S0140-6736(96)04069-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK037	8826811				2022-12-24	WOS:A1996VK03700011
J	Booth, H; Pollitt, C; Jessen, EC; Hendrick, DJ; Cant, AJ				Booth, H; Pollitt, C; Jessen, EC; Hendrick, DJ; Cant, AJ			When is referral of Heaf test positive schoolchildren worth while? Prospective study	BRITISH MEDICAL JOURNAL			English	Article							BCG		NEWCASTLE GEN HOSP,DEPT PAEDIAT INFECTR DIS,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND; NEWCASTLE GEN HOSP,DEPT RESP MED,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND	Newcastle General Hospital; Newcastle General Hospital								[Anonymous], 1978, Tubercle, V59, P245; CAPEWELL S, 1986, BRIT J DIS CHEST, V80, P254, DOI 10.1016/0007-0971(86)90061-6; Hollyoak V, 1992, Commun Dis Rep CDR Rev, V2, pR67; JOSEPH CA, 1992, BRIT MED J, V305, P495, DOI 10.1136/bmj.305.6852.495; 1994, THORAX, V49, P1193	5	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 21	1996	313	7059					726	727						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VJ441	8819443				2022-12-24	WOS:A1996VJ44100024
J	Zureik, M; Courbon, D; Ducimetiere, P				Zureik, M; Courbon, D; Ducimetiere, P			Serum cholesterol concentration and death from suicide in men: Paris prospective study I	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PARASUICIDE; PREVENTION	Objective-To investigate whether low serum cholesterol concentration or changing serum cholesterol concentration is associated with risk of suicide in men. Design-Cohort study with annual repeat measurements of serum cholesterol concentration (for up to four years). Setting-Paris, France. Subjects-6393 working men, aged 43-52 in 1967-72, who had at least three measurements of serum cholesterol concentration. Main outcome measures-Individual change over time in serum cholesterol concentration (estimated using within person linear regression method); death hom suicide during average of 17 years) follow up after last examination. Results-32 men committed suicide during follow up. After adjustment for age and other factors, relative risk of suicide for men with low average serum cholesterol concentration (<4.78 mmol/l) compared with those with average serum cholesterol concentration of 4.78-6.21 mmol/l was 3.16 (95% confidence interval 1.38 to 7.22, P = 0.007). Men whose serum cholesterol concentration decreased by more than 0.13 mmol/l a year had multivariate adjusted relative risk of 2.17 (0.97 to 4.84, P = 0.056) compared with those whose cholesterol remained stable (change of less than or equal to 0.13 mmol/l a year). Conclusion-Both low serum cholesterol concentration and declining cholesterol concentration were associated with increased risk of death from suicide in men. Although there is some evidence in favour of a concomitant rather than a causal effect for interpreting these associations, long term surveillance of subjects included in trials of lipid lowering treatments seems warranted.			Zureik, M (corresponding author), HOP BROUSSAIS, NATL INST HLTH & MED RES, INSERM, U258, 96 RUE DIDOT, F-75014 PARIS, FRANCE.		Zureik, Mahmoud/F-7855-2018	Zureik, Mahmoud/0000-0002-8393-4217				ENGELBERG H, 1992, LANCET, V339, P727, DOI 10.1016/0140-6736(92)90609-7; GALLERANI M, 1995, BMJ-BRIT MED J, V310, P1632, DOI 10.1136/bmj.310.6995.1632; LAW MR, 1995, BMJ-BRIT MED J, V311, P807, DOI 10.1136/bmj.311.7008.807a; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; Lecomte D, 1995, Encephale, V21, P41; MAGNI G, 1988, NEUROPSYCHOBIOLOGY, V20, P126, DOI 10.1159/000118485; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; PEDERSEN TR, 1994, LANCET, V344, P1383; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Steegmans PHA, 1996, BRIT MED J, V312, P221, DOI 10.1136/bmj.312.7025.221; STEEGMANS PHA, 1995, CARDIOVASC RISK FACT, V5, P267	11	128	130	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 14	1996	313	7058					649	651						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH165	8811757	Green Published			2022-12-24	WOS:A1996VH16500018
J	Fourmy, D; Recht, MI; Blanchard, SC; Puglisi, JD				Fourmy, D; Recht, MI; Blanchard, SC; Puglisi, JD			Structure of the A site of Escherichia coli 16S ribosomal RNA complexed with an aminoglycoside antibiotic	SCIENCE			English	Article							NMR-SPECTROSCOPY; NOE CONTACTS; A-SITE; RESONANCE; H-1; RESISTANCE; ASSIGNMENT; RIBOZYME; BINDING; PROTONS	Aminoglycoside antibiotics that bind to 30S ribosomal A-site RNA cause misreading of the genetic code and inhibit translocation. The aminoglycoside antibiotic paromomycin binds specifically to an RNA oligonucleotide that contains the 30S subunit A site, and the solution structure of the RNA-paromomycin complex was determined by nuclear magnetic resonance spectroscopy. The antibiotic binds in the major groove of the model A-site RNA within a pocket created by an A-A base pair and a single bulged adenine. Specific interactions occur between aminoglycoside chemical groups important for antibiotic activity and conserved nucleotides in the RNA. The structure explains binding of diverse aminoglycosides to the ribosome, their specific activity against prokaryotic organisms, and various resistance mechanisms, and provides insight into ribosome function.	UNIV CALIF SANTA CRUZ,CTR MOL BIOL RNA,DEPT CHEM & BIOCHEM,SANTA CRUZ,CA 95064; UNIV CALIF SANTA CRUZ,CTR MOL BIOL RNA,DEPT BIOL,SANTA CRUZ,CA 95064	University of California System; University of California Santa Cruz; University of California System; University of California Santa Cruz			fourmy, dominique/J-4766-2014; Blanchard, Scott C./A-5804-2009	fourmy, dominique/0000-0002-2170-3536; Blanchard, Scott C./0000-0003-2717-9365	NIGMS NIH HHS [GM51266-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051266] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAIN FHT, 1995, J MOL BIOL, V250, P333, DOI 10.1006/jmbi.1995.0381; BAEYENS KJ, 1995, NAT STRUCT BIOL, V2, P56, DOI 10.1038/nsb0195-56; BEAUCLERK AAD, 1987, J MOL BIOL, V193, P661, DOI 10.1016/0022-2836(87)90349-4; BENVENISTE R, 1973, ANTIMICROB AGENTS CH, V4, P402, DOI 10.1128/AAC.4.4.402; Blanchard S., UNPUB; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P8172, DOI 10.1021/bi00487a027; DAVIES J, 1968, J BIOL CHEM, V243, P3312; DESTASIO EA, 1989, EMBO J, V8, P1213, DOI 10.1002/j.1460-2075.1989.tb03494.x; DESTASIO EA, 1990, J MOL BIOL, V212, P127, DOI 10.1016/0022-2836(90)90309-A; Dirheimer G., 1995, P93; EDELMANN P, 1977, CELL, V10, P131, DOI 10.1016/0092-8674(77)90147-7; FOURMY D, UNPUB; Gale E.F., 1981, MOL BASIS ANTIBIOTIC, Vsecond; GROSJEAN HJ, 1978, P NATL ACAD SCI USA, V75, P610, DOI 10.1073/pnas.75.2.610; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; KARIMI R, 1994, EUR J BIOCHEM, V226, P355, DOI 10.1111/j.1432-1033.1994.tb20059.x; LEE W, 1994, FEBS LETT, V350, P87, DOI 10.1016/0014-5793(94)00740-3; MARINO JP, 1994, J AM CHEM SOC, V116, P6472, DOI 10.1021/ja00093a073; MARINO JP, 1994, J AM CHEM SOC, V116, P2205, DOI 10.1021/ja00084a095; MOAZED D, 1990, J MOL BIOL, V211, P135, DOI 10.1016/0022-2836(90)90016-F; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; MUELLER L, 1995, J AM CHEM SOC, V117, P11043, DOI 10.1021/ja00150a001; NINIO J, 1975, BIOCHIMIE, V57, P587, DOI 10.1016/S0300-9084(75)80139-8; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; OTTING G, 1990, Q REV BIOPHYS, V23, P39, DOI 10.1017/S0033583500005412; PATAPOV AP, 1995, J BIOL CHEM, V270, P17680; Puglisi JD, 1995, METHOD ENZYMOL, V261, P323; PUROHIT P, 1994, NATURE, V370, P659, DOI 10.1038/370659a0; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; Recht MI, 1996, J MOL BIOL, V262, P421, DOI 10.1006/jmbi.1996.0526; REID DG, 1987, J BIOL CHEM, V262, P7967; Rodnina MV, 1996, J BIOL CHEM, V271, P646, DOI 10.1074/jbc.271.2.646; SANTORO J, 1992, J MAGN RESON, V97, P202, DOI 10.1016/0022-2364(92)90250-B; SHAW KJ, 1993, MICROBIOL REV, V57, P138, DOI 10.1128/MMBR.57.1.138-163.1993; Simorre JP, 1996, J AM CHEM SOC, V118, P5316, DOI 10.1021/ja954208+; SMALLCOMBE SH, 1993, J AM CHEM SOC, V115, P4776, DOI 10.1021/ja00064a043; WILHELM JM, 1978, BIOCHEMISTRY-US, V17, P1143, DOI 10.1021/bi00600a001; WOODCOCK J, 1991, EMBO J, V10, P3099, DOI 10.1002/j.1460-2075.1991.tb07863.x; YOSHIZAWA S, UNPUB; ZIMMERMANN RA, 1990, RIBOSOME, P331	41	691	724	3	66	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 22	1996	274	5291					1367	1371		10.1126/science.274.5291.1367	http://dx.doi.org/10.1126/science.274.5291.1367			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU954	8910275				2022-12-24	WOS:A1996VU95400051
J	Smith, JR; Freije, D; Carpten, JD; Gronberg, H; Xu, JF; Isaacs, SD; Brownstein, MJ; Bova, GS; Guo, H; Bujnovszky, P; Nusskern, DR; Damber, JE; Bergh, A; Emanuelsson, M; Kallioniemi, OP; WalkerDaniels, J; BaileyWilson, JE; Beaty, TH; Meyers, DA; Walsh, PC; Collins, FS; Trent, JM; Isaacs, WB				Smith, JR; Freije, D; Carpten, JD; Gronberg, H; Xu, JF; Isaacs, SD; Brownstein, MJ; Bova, GS; Guo, H; Bujnovszky, P; Nusskern, DR; Damber, JE; Bergh, A; Emanuelsson, M; Kallioniemi, OP; WalkerDaniels, J; BaileyWilson, JE; Beaty, TH; Meyers, DA; Walsh, PC; Collins, FS; Trent, JM; Isaacs, WB			Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search	SCIENCE			English	Article							INHERITANCE	Despite its high prevalence, very little is known regarding genetic predisposition to prostate cancer. A genome-wide scan performed in 66 high-risk prostate cancer families has provided evidence of linkage to the long arm of chromosome 1 (1q24-25). Analysis of an additional set of 25 North American and Swedish families with markers in this region resulted in significant evidence of linkage in the combined set of 91 families. The data provide strong evidence of a major prostate cancer susceptibility locus on chromosome 1.	NIH,NATL CTR HUMAN GENOME RES,BETHESDA,MD 20892; JOHNS HOPKINS UNIV,SCH MED,JAMES BUCHANAN BRADY UROL INST,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; NIMH,NIH,BETHESDA,MD 20892; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD; UNIV MICHIGAN,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UMEA UNIV,DEPT PATHOL,S-90187 UMEA,SWEDEN; UMEA UNIV,DEPT UROL,UMEA,SWEDEN	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Johns Hopkins University; University of Michigan System; University of Michigan; Umea University; Umea University			Smith, Jeff/C-3484-2012; Kallioniemi, Olli P/H-5111-2011; Brownstein, Michael/B-8609-2009	Kallioniemi, Olli P/0000-0002-3231-0332; Smith, Jeffrey/0000-0001-8424-910X; Bova, George/0000-0003-1639-3104; Bailey-Wilson, Joan/0000-0002-9153-2920	NATIONAL CANCER INSTITUTE [P50CA058236] Funding Source: NIH RePORTER; NCI NIH HHS [CA58236] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRAWLEY OW, 1996, COMPREHENSIVE TXB GE, P565; Brownstein MJ, 1996, BIOTECHNIQUES, V20, P1004, DOI 10.2144/96206st01; Cannon L., 1982, CANCER SURV, V1, P47; Cannon-Albright L. A., 1994, American Journal of Human Genetics, V55, pA147; CARTER BS, 1992, P NATL ACAD SCI USA, V89, P3367, DOI 10.1073/pnas.89.8.3367; CARTER BS, 1993, J UROLOGY, V150, P797, DOI 10.1016/S0022-5347(17)35617-3; Cher ML, 1996, CANCER RES, V56, P3091; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; Freije Diha, 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P670; ISAACS WB, 1995, GENETICS CANC 2 LOOK, P357; KOSARY CL, 1995, NIH PUB; KRUGLYAK L, 1995, AM J HUM GENET, V57, P439; LANDER ES, 1987, P NATL ACAD SCI USA, V84, P2363, DOI 10.1073/pnas.84.8.2363; OCONNELL JR, 1995, NAT GENET, V11, P402, DOI 10.1038/ng1295-402; OTT J, 1985, ANAL HUMAN GENETIC L, P200; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; STEINBERG GD, 1990, PROSTATE, V17, P337, DOI 10.1002/pros.2990170409; VANDENBERG C, 1995, CLIN CANCER RES, V1, P11; VISAKORPI T, 1995, CANCER RES, V55, P342	19	596	611	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 22	1996	274	5291					1371	1374		10.1126/science.274.5291.1371	http://dx.doi.org/10.1126/science.274.5291.1371			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU954	8910276	Green Submitted			2022-12-24	WOS:A1996VU95400052
J	Wagner, JM; McKinney, WP; Carpenter, JL				Wagner, JM; McKinney, WP; Carpenter, JL			Does this patient have appendicitis?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE ABDOMINAL-PAIN; RIGHT LOWER QUADRANT; PHYSICAL-EXAMINATION; ACUTE ABDOMEN; DECISION-MAKING; SCORING SYSTEM; DIAGNOSTIC-ACCURACY; PRACTICAL SCORE; HISTORY-TAKING; APPENDECTOMY	Appendicitis is a common cause of abdominal pain for which prompt diagnosis is rewarded by a marked decrease in morbidity and mortality. The history and physical examination are at least as accurate as any laboratory modality in diagnosing or excluding appendicitis. Those signs and symptoms most helpful in diagnosing or excluding appendicitis are reviewed. The presence of a positive psoas sign, fever, or migratory pain to the right lower quadrant suggests an increased likelihood of appendicitis. Conversely, the presence of vomiting before pain makes appendicitis unlikely. The lack of the classic migration of pain, right lower quadrant pain, guarding, or fever makes appendicitis less likely, This article reviews the literature evaluating the operating characteristics of the most useful elements of the history and physical examination for the diagnosis of appendicitis.			Wagner, JM (corresponding author), UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.			Wagner, James/0000-0001-9903-6588				ADAMS ID, 1986, BRIT MED J, V293, P800, DOI 10.1136/bmj.293.6550.800; ADDISS DG, 1990, AM J EPIDEMIOL, V132, P910, DOI 10.1093/oxfordjournals.aje.a115734; ALVARADO A, 1986, ANN EMERG MED, V15, P557, DOI 10.1016/S0196-0644(86)80993-3; ANTEBY SO, 1975, ANN SURG, V181, P484, DOI 10.1097/00000658-197504000-00022; AVORN J, 1991, ARCH INTERN MED, V151, P694, DOI 10.1001/archinte.151.4.694; BALSANO N, 1990, Emergency Medicine Clinics of North America, V8, P399; BARR D, 1991, WORLD J SURG, V15, P526, DOI 10.1007/BF01675654; BERRY J, 1984, ANN SURG, V200, P567, DOI 10.1097/00000658-198411000-00002; BJERKE K, 1986, GUT, V27, P667, DOI 10.1136/gut.27.6.667; BOND GR, 1990, ANN EMERG MED, V19, P1014; BONGARD F, 1985, AM J SURG, V150, P90, DOI 10.1016/0002-9610(85)90015-7; BRAZAITIS MP, 1993, MED CLIN N AM, V77, P939; BREWER RJ, 1976, AM J SURG, V131, P219, DOI 10.1016/0002-9610(76)90101-X; Britt H, 1994, Aust Fam Physician, V23, P375; BUGLIOSI TF, 1990, ANN EMERG MED, V19, P1383, DOI 10.1016/S0196-0644(05)82602-2; BUSCHARD K, 1973, ACTA CHIR SCAND, V139, P293; CHANG FC, 1973, AM J SURG, V126, P752, DOI 10.1016/S0002-9610(73)80063-7; CHRISTIAN F, 1992, ANN ROY COLL SURG, V74, P281; DAVIES AH, 1991, BRIT J SURG, V78, P1178, DOI 10.1002/bjs.1800781010; DEDOMBAL FT, 1993, POSTGRAD MED J, V69, pS94; DEDOMBAL FT, 1991, DIAGNOSIS ACUTE ABDO, V2, P1; DIXON JM, 1991, BRIT MED J, V302, P386, DOI 10.1136/bmj.302.6773.386; DOMBAL FTD, 1974, BRIT MED J, V1, P376, DOI 10.1136/bmj.1.5904.376; ESKELINEN M, 1995, SCAND J GASTROENTERO, V30, P349, DOI 10.3109/00365529509093289; ESKELINEN M, 1994, INT J BIOMED COMPUT, V36, P239, DOI 10.1016/0020-7101(94)90059-0; FENYO G, 1982, AM J SURG, V143, P751, DOI 10.1016/0002-9610(82)90052-6; FENYO G, 1974, ACTA CHIR SCAND, V140, P396; FENYO G, 1987, ACTA CHIR SCAND, V153, P545; FRANZ MG, 1995, AM SURGEON, V61, P40; GAMAL R, 1990, AM J SURG, V159, P589, DOI 10.1016/S0002-9610(06)80073-5; HAMPTON JR, 1975, BRIT MED J, V2, P486, DOI 10.1136/bmj.2.5969.486; HENNINGTON MH, 1991, ANN SURG, V214, P61; HOUGHTON A, 1988, GASTROINTEST ENDOSC, V34, P489, DOI 10.1016/S0016-5107(88)71451-0; HOWIE JGR, 1966, LANCET, V2, P1334; IRVIN TT, 1989, BRIT J SURG, V76, P1121, DOI 10.1002/bjs.1800761105; IZBICKI JR, 1992, EUR J SURG, V158, P227; Jerman R P, 1969, Br J Clin Pract, V23, P466; JESS P, 1981, AM J SURG, V141, P232, DOI 10.1016/0002-9610(81)90164-1; JOHN H, 1993, WORLD J SURG, V17, P243, DOI 10.1007/BF01658936; JOHNSON JE, 1986, ARCH INTERN MED, V146, P937, DOI 10.1001/archinte.146.5.937; JONES PF, 1990, BRIT J SURG, V77, P365, DOI 10.1002/bjs.1800770404; KANG WM, 1989, SURGERY, V167, P187; KOLLIAS J, 1994, AUST NZ J SURG, V64, P830, DOI 10.1111/j.1445-2197.1994.tb04558.x; LAVELLE SM, 1990, INT J BIOMED COMPUT, V26, P203, DOI 10.1016/0020-7101(90)90043-T; LEWIS FR, 1975, ARCH SURG-CHICAGO, V110, P677; LIDDINGTON MI, 1991, BRIT J SURG, V78, P795, DOI 10.1002/bjs.1800780710; LIM HK, 1992, AM J ROENTGENOL, V159, P539, DOI 10.2214/ajr.159.3.1503019; LIN J, 1990, AM J MED, V89, P377, DOI 10.1016/0002-9343(90)90353-F; LOPEZNAVIDAD A, 1990, REV INFECT DIS, V12, P297; MAXWELL JM, 1991, AM SURGEON, V57, P282; MITTELPUNKT A, 1966, SURGERY, V60, P971; MORGAN DL, 1995, ANN EMERG MED, V25, P140; NADLER S, 1990, DIGEST DIS SCI, V35, P603, DOI 10.1007/BF01540408; NARDONE DA, 1988, SOUTH MED J, V81, P770, DOI 10.1097/00007611-198806000-00019; NAUTA RJ, 1986, AM J SURG, V151, P746, DOI 10.1016/0002-9610(86)90057-7; NEUTRA RR, 1978, MED CARE, V16, P956, DOI 10.1097/00005650-197811000-00006; OHMANN C, 1995, EUR J SURG, V161, P273; ORIENT JM, 1985, MED DECIS MAKING, V5, P77, DOI 10.1177/0272989X8500500116; OWENS BJ, 1978, ANN SURG, V187, P392, DOI 10.1097/00000658-197804000-00008; PELTOKALLIO P, 1970, ARCH SURG-CHICAGO, V100, P140; PETERSON MC, 1992, WESTERN J MED, V156, P163; POOLE GV, 1990, SOUTH MED J, V83, P771, DOI 10.1097/00007611-199007000-00013; PUTNAM TC, 1990, SURG GYNECOL OBSTET, V170, P527; PUYLAERT JBCM, 1987, NEW ENGL J MED, V317, P666, DOI 10.1056/NEJM198709103171103; RAMIREZ JM, 1994, BRIT J SURG, V81, P680, DOI 10.1002/bjs.1800810516; SACKETT KL, 1991, CLIN EPIDEMIOLOGY BA, V2, P173; SARFATI MR, 1993, AM J SURG, V166, P660, DOI 10.1016/S0002-9610(05)80675-0; SCHROCK TR, 1996, GASTROINTESTINAL DIS, P1339; SCHRODER DM, 1993, AM SURGEON, V59, P541; SCHWARTZ SI, 1987, NEW ENGL J MED, V317, P703, DOI 10.1056/NEJM198709103171109; SHEN GK, 1991, ARCH SURG-CHICAGO, V126, P569; SILEN W, 1987, COPES EARLY DIAGNOSI, V17, P1; SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P763, DOI 10.1016/0895-4356(91)90128-V; STANILAND JR, 1972, BMJ-BRIT MED J, V3, P393, DOI 10.1136/bmj.3.5823.393; TAOUREL P, 1992, GASTROINTEST RADIOL, V17, P287, DOI 10.1007/BF01888571; TEICHER I, 1983, ANN SURG, V198, P753, DOI 10.1097/00000658-198312000-00014; TODD BS, 1993, MED INFORM, V18, P255, DOI 10.3109/14639239309025314; WADE DS, 1993, ARCH SURG-CHICAGO, V128, P1039; Wasson J H, 1981, Med Decis Making, V1, P215, DOI 10.1177/0272989X8100100302; WHITE JJ, 1975, AM SURGEON, V41, P793; WHITWORTH CM, 1988, SURG GYNECOL OBSTET, V167, P187; WIENER S, 1976, JAMA-J AM MED ASSOC, V236, P852, DOI 10.1001/jama.236.7.852; WILSON DH, 1977, BRIT J SURG, V64, P250, DOI 10.1002/bjs.1800640407	83	188	192	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 20	1996	276	19					1589	1594		10.1001/jama.276.19.1589	http://dx.doi.org/10.1001/jama.276.19.1589			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT025	8918857				2022-12-24	WOS:A1996VT02500032
J	Vinetz, JM; Glass, GE; Flexner, CE; Mueller, P; Kaslow, DC				Vinetz, JM; Glass, GE; Flexner, CE; Mueller, P; Kaslow, DC			Sporadic urban leptospirosis	ANNALS OF INTERNAL MEDICINE			English	Article						Leptospira interrogans; leptospirosis; urban population; rats; polymerase chain reaction	RISK-FACTORS; ROCHALIMAEA	Background: Surprisingly, many inner-city residents have antibodies to Leptospira interrogans. The manner in which these persons acquire this organism in the absence of recognized occupational, recreational, or epidemic risk factors is not known. Objective: To study the epidemiology of patients with leptospirosis who acquired L. interrogans in inner-city Baltimore, Maryland. Design: Epidemiologic investigation. Setting: Inner-city university hospital. Patients: Three inner-city residents who developed leptospirosis. Measurements: Trapping rats in alleys where the patients may have acquired L. interrogans; polymerase chain reaction (PCR) analysis of patient serum and cerebrospinal fluid specimens and rat tissues to determine the presence of leptospiral DNA; and serologic testing of serum from patients and rats by microagglutination assay to confirm L. interrogans infection. Results: Three patients developed leptospirosis after probable percutaneous exposure to rat (Rattus norvegicus) urine in Baltimore alleys. A PCR assay detected L. interrogans DNA in samples of body fluid obtained from the first two patients at presentation (one in cerebrospinal fluid, the other in serum). Results of PCR done on serum drawn from the third patient after antibiotic therapy began were negative. A microagglutination test showed that all patients had high levels of antibodies to the L. interrogans serogroup Icterohaemorrhagiae. In 19 of 21 rats that were trapped in the alleys where the patients had sustained lacerations before illness developed, kidney or brain tissues were positive by PCR for the presence of L. interrogans. Conclusions: A population was discovered to be at risk for acquiring L. interrogans: urban residents who are sporadically exposed to rat urine in the inner city. Inner-city rats often carry L. interrogans. Polymerase chain reaction can quickly establish the diagnosis of leptospirosis and is useful for epidemiologic study. An endemic substrate for the transmission of the organism is present in inner-city Baltimore. Leptospirosis may become increasingly recognized in deteriorating inner cities in which rat populations are expanding.	JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT MOL MICROBIOL & IMMUNOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD 21287 USA; NIH, BETHESDA, MD 20892 USA	Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA	Vinetz, JM (corresponding author), NIAID, PARASIT DIS LAB, 9000 ROCKVILLE PIKE, BLDG 4, ROOM 126, BETHESDA, MD 20892 USA.			Vinetz, Joseph/0000-0001-8344-2004				BABUDIERI B, 1958, ANN NY ACAD SCI, V70, P393, DOI 10.1111/j.1749-6632.1958.tb35398.x; CACCIAPUOTI B, 1994, EUR J EPIDEMIOL, V10, P173, DOI 10.1007/BF01730367; CHILDS JE, 1992, AM J PUBLIC HEALTH, V82, P597, DOI 10.2105/AJPH.82.4.597; COLE JR, 1973, APPL MICROBIOL, V25, P976, DOI 10.1128/AEM.25.6.976-980.1973; DEMERS RY, 1983, J FAM PRACTICE, V17, P1007; DRANCOURT M, 1995, NEW ENGL J MED, V332, P419, DOI 10.1056/NEJM199502163320702; EDWARDS GA, 1964, MEDICINE, V39, P117; FARR RW, 1995, CLIN INFECT DIS, V21, P1, DOI 10.1093/clinids/21.1.1; FEIGIN RD, 1973, ANN INTERN MED, V79, P777, DOI 10.7326/0003-4819-79-6-777; GRAVEKAMP C, 1993, J GEN MICROBIOL, V139, P1691, DOI 10.1099/00221287-139-8-1691; HEATH CW, 1965, NEW ENGL J MED, V273, P857, DOI 10.1056/NEJM196510142731606; MERIEN F, 1995, J INFECT DIS, V172, P281, DOI 10.1093/infdis/172.1.281; MORSE SS, 1995, EMERG INFECT DIS, V1, P7, DOI 10.3201/eid0101.950102; RELMAN DA, 1995, NEW ENGL J MED, V332, P463, DOI 10.1056/NEJM199502163320710; SASAKI DM, 1993, AM J TROP MED HYG, V48, P35, DOI 10.4269/ajtmh.1993.48.35; SPACH DH, 1995, NEW ENGL J MED, V332, P424, DOI 10.1056/NEJM199502163320703; STARR L, 1992, BIOTECHNIQUES, V13, P612; TORTEN M, 1994, HDB ZOONOSES A, P245; Zaki SR, 1996, LANCET, V347, P535, DOI 10.1016/S0140-6736(96)91167-8; 1972, MMWR-MORBID MORTAL W, V21, P401; 1994, MMWR-MORBID MORTAL W, V42, P36; 1995, MMWR-MORBID MORTAL W, V44, P841	22	170	175	0	23	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1996	125	10					794	+		10.7326/0003-4819-125-10-199611150-00002	http://dx.doi.org/10.7326/0003-4819-125-10-199611150-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU524	8928985				2022-12-24	WOS:A1996VU52400005
J	Trkola, A; Dragic, T; Arthos, J; Binley, JM; Olson, WC; Allaway, GP; ChengMayer, C; Robinson, J; Maddon, PJ; Moore, JP				Trkola, A; Dragic, T; Arthos, J; Binley, JM; Olson, WC; Allaway, GP; ChengMayer, C; Robinson, J; Maddon, PJ; Moore, JP			CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5	NATURE			English	Article							MONOCLONAL-ANTIBODIES; VIRUS; EXPRESSION; GP120	THE beta-chemokine receptor CCR-5 is an essential co-factor for fusion of HIV-1 strains of the non-syncytium-inducing (NSI) phenotype with CD4(+) T-cells(1-5). The primary binding site for human immunodeficiency virus (HIV)-1 is the CD4 molecule, and the interaction is mediated by the viral surface glycoprotein gp120 (refs 6, 7). The mechanism of CCR-5 function during HIV entry has not been defined, but we have shown previously that its beta-chemokine ligands prevent HIV-1 from fusing with the cell(1). We therefore investigated whether CCR-5 acts as a second binding site for HIV-1 simultaneously with or subsequent to the interaction between gp120 and CD4, We used a competition assay based on gp120 inhibition of the binding of the CCR-5 ligand, macrophage inflammatory protein (MIP)-1 beta, to its receptor on activated CD4(+) T cells or CCR-5-positive CD4(-) cells. We conclude that CD4 binding, although not absolutely necessary for the gp120-CCR-5 interaction, greatly increases its efficiency, Neutralizing monoclonal antibodies against several sites on gp120, including the V3 loop and CD4-induced epitopes, inhibited the interaction of gp120 with CCR-5, without affecting gp120-CD4 binding, Interference with HIV-1 binding to one or both of its receptors (CD4 and CCR-5) may be an important mechanism of virus neutralization.	ROCKEFELLER UNIV,AARON DIAMOND AIDS RES CTR,NEW YORK,NY 10016; NIAID,IMMUNOREGULAT LAB,NIH,BETHESDA,MD 20892; PROGEN PHARMACEUT INC,TARRYTOWN,NY 10591; TULANE UNIV,MED CTR,DEPT PEDIAT,NEW ORLEANS,LA 70112	Rockefeller University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Tulane University			Trkola, Alexandra/K-2115-2012	Trkola, Alexandra/0000-0003-1013-876X				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; ALLAWAY GP, 1995, AIDS RES HUM RETROV, V11, P533, DOI 10.1089/aid.1995.11.533; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DORANZ B, 1996, J CELL, V86, P1149; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; HEALEY D, 1990, J EXP MED, V172, P1233, DOI 10.1084/jem.172.4.1233; LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Loetscher P, 1996, J EXP MED, V184, P569, DOI 10.1084/jem.184.2.569; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Moore J P, 1995, AIDS, V9 Suppl A, pS117; Moore JP, 1996, J VIROL, V70, P1863, DOI 10.1128/JVI.70.3.1863-1872.1996; MOORE JP, 1994, J VIROL, V68, P469, DOI 10.1128/JVI.68.1.469-484.1994; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; Weissenhorn W, 1996, EMBO J, V15, P1507, DOI 10.1002/j.1460-2075.1996.tb00494.x; Wells TNC, 1996, J LEUKOCYTE BIOL, V59, P53, DOI 10.1002/jlb.59.1.53	20	968	1031	0	48	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 14	1996	384	6605					184	187		10.1038/384184a0	http://dx.doi.org/10.1038/384184a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT336	8906796				2022-12-24	WOS:A1996VT33600070
J	Cetron, MS; Chitsulo, L; Sullivan, JJ; Pilcher, J; Wilson, M; Noh, J; Tsang, VC; Hightower, AW; Addiss, DG				Cetron, MS; Chitsulo, L; Sullivan, JJ; Pilcher, J; Wilson, M; Noh, J; Tsang, VC; Hightower, AW; Addiss, DG			Schistosomiasis in Lake Malawi	LANCET			English	Article							ADULT MICROSOMAL ANTIGENS; SEROLOGIC REAGENT; FAST-ELISA; MANSONI; HAEMATOBIUM; COMPONENTS; MAMA	Background In 1992 two US Peace Corps volunteers (PCVs) developed central nervous system schistosomiasis due to infection with Schistosoma haematobium following recreational water exposure at Cape Maclear on Lake Malawi, an African lake considered by many to be free of schistosomiasis, To determine the transmission potential and risk for aquiring schistosomiasis in Lake Malawi, a cross-sectional survey of resident expatriates and visitors to Malawi was done during March and April, 1993. Methods A volunteer cohort of expatriates and visitors representing a cross-section of Malawi's foriegn population answered detailed questions about freshwater contact and provided blood specimens to determine the seroprevalence of S haematobium and S mansoni by ELISA and immunoblot analyses, A survey for Vector snails was conducted along Lake Malawi's southwestern shore. Findings The study population of 955 included 305 US citizens and 650 non-US foreign nationals. 303 of the study population had seroiogical evidence of current or past schistosome infection. Seroprevalence was 32% (141/440) among expatriates whose freshwater exposure was limited to Lake Malawi; S haematobium antibodies were found in 135 of 141 (96%) seropositive specimens. Risk of seropositivity increased with the number of freshwater exposures at Lake Malawi resorts. Although many resort areas in the southwestern lake region posed a significant risk, Cape Maclear was the location most strongly associated with seropositivity (OR 2.9, 95% CI 1.6-5.1). Methods Schistosome-infected Bulinus globosus, the snail vector of Objectives S haematobium in Malawi. were found at Cape Maclear and other locations along the lakeshore. Interpretation S haematobium infection is highly prevalent among expatriates and tourists in Malawi, Recreational water contact at popular resorts on Lake Malawi is the most likely source of infection. Transmission of schistosomiasis is occurring in Lake Malawi, a previously under-recognised site of transmission.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV PARASIT DIS,ATLANTA,GA	Centers for Disease Control & Prevention - USA								BLANCHARD TJ, 1993, LANCET, V341, P959, DOI 10.1016/0140-6736(93)91249-L; BLUNT SB, 1993, LANCET, V341, P557, DOI 10.1016/0140-6736(93)90317-A; *CDC, 1993, MMWR-MORBID MORTAL W, V42, P565; CROWTHER G, 1992, AFRICA SHOESTRING, P581; EULDERINK F, 1994, AM J DERMATOPATH, V16, P434, DOI 10.1097/00000372-199408000-00015; EVANS AC, 1975, MALAWI INVESTIGATION, P2; GOLDSMITH PC, 1993, BMJ-BRIT MED J, V307, P556, DOI 10.1136/bmj.307.6903.556; HANCOCK K, 1986, J IMMUNOL METHODS, V92, P167, DOI 10.1016/0022-1759(86)90162-6; HARRIES AD, 1986, LANCET, V1, P86; MCKAYE KR, 1986, EXP BIOL, V45, P279; POLLNER JH, 1994, CLIN INFECT DIS, V18, P354, DOI 10.1093/clinids/18.3.354; PUGH RNH, 1993, BRIT MED J, V307, P1354, DOI 10.1136/bmj.307.6915.1354-b; RUSSELL JM, 1993, BRIT MED J, V307, P937, DOI 10.1136/bmj.307.6909.937; SCRIMGEOUR EM, 1985, BRAIN, V108, P1023, DOI 10.1093/brain/108.4.1023; STAUFFER JR, IN PRESS BIOSCIENCE; TEESDALE CH, 1985, TROPENMED PARASITOL, V36, P1; TSANG VCW, 1984, J IMMUNOL, V132, P2607; TSANG VCW, 1983, J IMMUNOL, V130, P1366; TSANG VCW, 1983, J IMMUNOL, V130, P1359; TSANG VCW, 1991, CLIN LAB MED, V11, P1029, DOI 10.1016/S0272-2712(18)30533-X; WHITWORTH JAG, 1993, BRIT MED J, V307, P936, DOI 10.1136/bmj.307.6909.936-c	21	83	84	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 9	1996	348	9037					1274	1278		10.1016/S0140-6736(96)01511-5	http://dx.doi.org/10.1016/S0140-6736(96)01511-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR555	8909380				2022-12-24	WOS:A1996VR55500010
J	Onishi, HR; Pelak, BA; Gerckens, LS; Silver, LL; Kahan, FM; Chen, MH; Patchett, AA; Galloway, SM; Hyland, SA; Anderson, MS; Raetz, CRH				Onishi, HR; Pelak, BA; Gerckens, LS; Silver, LL; Kahan, FM; Chen, MH; Patchett, AA; Galloway, SM; Hyland, SA; Anderson, MS; Raetz, CRH			Antibacterial agents that inhibit lipid A biosynthesis	SCIENCE			English	Article							ESCHERICHIA-COLI; ENDOTOXIN BIOSYNTHESIS; 1ST STEP; RESISTANCE; ACYLTRANSFERASE; ANTIBIOTICS; RELEASE; GENE	Lipid A constitutes the outer monolayer of the outer membrane of Gram-negative bacteria and is essential for bacterial growth. Synthetic antibacterials were identified that inhibit the second enzyme (a unique deacetylase) of lipid A biosynthesis. The inhibitors are chiral hydroxamic acids bearing certain hydrophobic aromatic moieties. They may bind to a metal in the active site of the deacetylase. The most potent analog (with an inhibition constant of about 50 nM) displayed a minimal inhibitory concentration of about 1 microgram per milliliter against Escherichia coli, caused three logs of bacterial killing in 4 hours, and cured mice infected with a lethal intraperitoneal dose of E. coli.	MERCK RES LABS,DEPT MICROBIOL,RAHWAY,NJ 07065; MERCK RES LABS,DEPT MED CHEM,RAHWAY,NJ 07065; MERCK RES LABS,DEPT BIOCHEM,RAHWAY,NJ 07065	Merck & Company; Merck & Company; Merck & Company			Silver, Lynn L/A-7789-2009	Silver, Lynn L/0000-0002-8416-0487				ANDERSON MS, 1993, J BIOL CHEM, V268, P19858; BEALL B, 1987, J BACTERIOL, V169, P5408, DOI 10.1128/jb.169.12.5408-5415.1987; DAVIES J, 1994, SCIENCE, V264, P375, DOI 10.1126/science.8153624; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; GOLDMAN R, 1987, NATURE, V329, P162, DOI 10.1038/329162a0; GRUNDSTROM T, 1980, J BACTERIOL, V144, P884; HAMMOND SM, 1987, NATURE, V327, P730, DOI 10.1038/327730a0; JACKMAN JA, UNPUB; JACKSON JJ, 1992, J INFECT DIS, V165, P1033, DOI 10.1093/infdis/165.6.1033; KELLY TM, 1993, J BIOL CHEM, V268, P19866; KNUDSEN LF, 1947, J AM STAT ASSOC, V42, P282, DOI 10.2307/2280657; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; PRINS JM, 1994, ANTIMICROB AGENTS CH, V38, P1211, DOI 10.1128/AAC.38.6.1211; Raetz C. R. H., 1996, ESCHERICHIA COLI SAL, V1, P1035; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; Rich D. H., 1990, COMPREHENSIVE MED CH, V2, P391; SPRATT BG, 1994, SCIENCE, V264, P388, DOI 10.1126/science.8153626; STAMMER CH, 1957, J AM CHEM SOC, V79, P3236, DOI 10.1021/ja01569a065; VUORIO R, 1992, ANTIMICROB AGENTS CH, V37, P354; Williamson J. J., UNPUB; WILLIAMSON JM, 1991, J BACTERIOL, V173, P3591, DOI 10.1128/jb.173.11.3591-3596.1991; Young K, 1995, J BIOL CHEM, V270, P30384, DOI 10.1074/jbc.270.51.30384; YOUNG K, 1991, J BACTERIOL, V173, P3609, DOI 10.1128/JB.173.12.3609-3614.1991	23	342	360	1	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1996	274	5289					980	982		10.1126/science.274.5289.980	http://dx.doi.org/10.1126/science.274.5289.980			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR792	8875939				2022-12-24	WOS:A1996VR79200048
J	Kellermann, AL; Rivara, FP; Lee, RK; Banton, JG; Cummings, P; Hackman, BB; Somes, G				Kellermann, AL; Rivara, FP; Lee, RK; Banton, JG; Cummings, P; Hackman, BB; Somes, G			Injuries due to firearms in three cities	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNITED-STATES; DEATHS; COSTS; HOSPITALIZATION; EPIDEMIOLOGY; FATALITIES; CALIFORNIA; VIOLENCE; GUNSHOT; WOUNDS	Background To describe the incidence and outcome of injuries due to firearms, we conducted a population-based study of fatal and nonfatal gunshot wounds in three cities: Memphis, Tennessee; Seattle, Washington; and Galveston, Texas. Methods Records of the police, medical examiners, ambulance crews, and hospital emergency departments and hospital admissions were monitored to identify all injuries caused by firearms that were severe enough to prompt emergency medical treatment. These records were linked to generate a complete picture of each event. Census data were used to calculate rates of injury for various population groups. Results A total of 1915 cases of injury due to firearms were identified between November 16, 1992, and May 15, 1994. The crude rate of firearm injury per 100,000 person-years was 222.6 in Memphis, 143.6 in Galveston, and 54.1 in Seattle. Approximately 88 percent of the injuries were incurred during confirmed or probable assaults; 7 percent were sustained in the course of suicide or attempted suicide; unintentional injuries accounted for 4 percent of the cases. Handguns were used in 88 percent of the cases in which the type of weapon was recorded. Five percent of the 1677 victims who were brought to a hospital emergency department could not be resuscitated; 53 percent were hospitalized, and 42 percent were treated and released. Ninety-seven percent of the deaths occurred within 24 hours of the injury. Emergency department and inpatient charges exceeded $16.5 million. Conclusions Injuries due to firearms, most involving handguns, are a major cause of morbidity and mortality in U.S. urban areas. The incidence varies greatly from city to city. (C)1996, Massachusetts Medical Society.	UNIV WASHINGTON,HARBORVIEW INJURY PREVENT & RES CTR,SEATTLE,WA 98195; UNIV TEXAS,MED BRANCH,GALVESTON,TX 77550; UNIV TENNESSEE,DEPT PREVENT MED,MEMPHIS,TN	University of Washington; University of Washington Seattle; University of Texas System; University of Texas Medical Branch Galveston; University of Tennessee System; University of Tennessee Health Science Center	Kellermann, AL (corresponding author), EMORY UNIV,ROLLINS SCH PUBL HLTH,CTR INJURY CONTROL,1518 CLIFTON RD,NE,ATLANTA,GA 30322, USA.				PHS HHS [CCR-407419] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALEXANDER GR, 1985, AM J PUBLIC HEALTH, V75, P165, DOI 10.2105/AJPH.75.2.165; ANNEST JL, 1995, JAMA-J AM MED ASSOC, V273, P1749, DOI 10.1001/jama.273.22.1749; Ash P, 1996, JAMA-J AM MED ASSOC, V275, P1754, DOI 10.1001/jama.275.22.1754; Blumstein A, 1995, J CRIM LAW CRIM, V86, P10, DOI 10.2307/1143998; Cook PJ, 1996, JAMA-J AM MED ASSOC, V275, P1765, DOI 10.1001/jama.275.22.1765; *FED BUR INV, 1993, UN CRIM REP CRIM US; FINGERHUT LA, 1993, ADV DATA VITAL HLTH, V231; JAGGER J, 1986, JAMA-J AM MED ASSOC, V255, P3143, DOI 10.1001/jama.255.22.3143; KECK NJ, 1988, AM J DIS CHILD, V142, P623, DOI 10.1001/archpedi.1988.02150060057029; KELLERMANN AL, 1994, AM J PUBLIC HEALTH, V84, P541, DOI 10.2105/AJPH.84.4.541; KELLERMANN AL, 1986, NEW ENGL J MED, V314, P1557, DOI 10.1056/NEJM198606123142406; KELLERMANN AL, 1993, HEALTH AFFAIR, V12, P142, DOI 10.1377/hlthaff.12.4.142; KELLERMANN AL, 1991, ANNU REV PUBL HEALTH, V12, P17; KIZER KW, 1995, JAMA-J AM MED ASSOC, V273, P1768, DOI 10.1001/jama.273.22.1768; Lee R K, 1991, Tex Med, V87, P78; LEE RK, 1991, AM J EPIDEMIOL, V134, P511, DOI 10.1093/oxfordjournals.aje.a116123; MARKUSH RE, 1984, AM J PUBLIC HEALTH, V74, P123, DOI 10.2105/AJPH.74.2.123; MARTIN MJ, 1988, JAMA-J AM MED ASSOC, V260, P3048, DOI 10.1001/jama.260.20.3048; MERCY JA, 1988, NEW ENGL J MED, V319, P1283, DOI 10.1056/NEJM198811103191911; MOCK C, 1994, J TRAUMA, V36, P516, DOI 10.1097/00005373-199404000-00010; MORROW PL, 1986, AM J PUBLIC HEALTH, V76, P1120, DOI 10.2105/AJPH.76.9.1120; *NAT COMM INJ PREV, 1989, INJ PREV M CHALL, P261; OZONOFF VV, 1994, AM J PUBLIC HEALTH, V84, P2024; PAYNE JE, 1993, J TRAUMA, V34, P276, DOI 10.1097/00005373-199302000-00018; Reiss A., 1993, UNDERSTANDING PREVEN; Rice DP, 1989, COST INJURY US REPOR; ROTH JA, NCJ PUBLICATION; Sadowski LS, 1996, JAMA-J AM MED ASSOC, V275, P1762, DOI 10.1001/jama.275.22.1762; *US BUR CENS, 1992, CPH149 US BUR CENS; *US BUR CENS, 1990, CPH145 US BUR CENS; *US BUR CENS, 1990, CPH144 US BUR CENS; *WEAP REL INJ SURV, 1995, 2500 SHOT STABB VIOL; WINTEMUTE GJ, 1987, WESTERN J MED, V146, P374; WINTEMUTE GJ, 1992, J TRAUMA, V33, P556, DOI 10.1097/00005373-199210000-00011; WINTEMUTE GJ, 1987, J TRAUMA, V27, P532, DOI 10.1097/00005373-198705000-00013; Wintemute GJ, 1996, JAMA-J AM MED ASSOC, V275, P1749, DOI 10.1001/jama.275.22.1749; WINTEMUTE GJ, 1987, JAMA-J AM MED ASSOC, V257, P3107, DOI 10.1001/jama.257.22.3107; ZAWITZ MW, NCJ PUBLICATION; ZWERLING C, 1993, AM J PREV MED, V9, P21, DOI 10.1016/S0749-3797(18)30674-3; 1995, MMWR-MORBID MORTAL W, V44, P160; 1987, MMWR-MORBID MORTAL W, V36, P634; 1995, MMWR-MORBID MORTAL W, V44, P169; 1985, MMWR-MORBID MORTAL W, V34, P353	43	86	87	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 7	1996	335	19					1438	1444		10.1056/NEJM199611073351906	http://dx.doi.org/10.1056/NEJM199611073351906			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VT339	8875922				2022-12-24	WOS:A1996VT33900006
J	Verdine, GL				Verdine, GL			The combinatorial chemistry of nature	NATURE			English	Article							MODULAR POLYKETIDE SYNTHASE; POLYMERASE CHAIN-REACTION; RECOMBINANT PROTEINS; BIOSYNTHESIS; OVERPRODUCTION; RAPAMYCIN; PRODUCTS; COMPLEX; DOMAIN				Verdine, GL (corresponding author), HARVARD UNIV,DEPT CHEM & CHEM BIOL,CAMBRIDGE,MA 02138, USA.							ARNOLD FH, 1991, BIO-TECHNOL, V9, P151, DOI 10.1038/nbt0291-151; Blundell TL, 1996, NATURE, V384, P23; Broach JR, 1996, NATURE, V384, P14; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CHEN JK, 1993, J AM CHEM SOC, V115, P12591, DOI 10.1021/ja00079a051; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Corey E. J., 1989, LOGIC CHEM SYNTHESIS; CORTES J, 1995, SCIENCE, V268, P1487, DOI 10.1126/science.7770773; DONADIO S, 1993, P NATL ACAD SCI USA, V90, P7119, DOI 10.1073/pnas.90.15.7119; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; FANTEANY G, 1995, SCIENCE, V268, P726; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; Hogan JC, 1996, NATURE, V384, P17; HOPWOOD DA, 1985, NATURE, V314, P642, DOI 10.1038/314642a0; KAO CM, 1994, J AM CHEM SOC, V116, P11612, DOI 10.1021/ja00104a069; LEE JC, 1995, CHEM BIOL, V2, P721, DOI 10.1016/1074-5521(95)90100-0; LIU J, 1991, CELL, V66, P1; MACFERRIN KD, 1993, METHOD ENZYMOL, V217, P79; MACFERRIN KD, 1990, P NATL ACAD SCI USA, V87, P1937, DOI 10.1073/pnas.87.5.1937; MCDANIEL R, 1995, NATURE, V375, P549, DOI 10.1038/375549a0; Nicolaou K. C., 1995, CLASSICS TOTAL SYNTH; Roessner C A, 1994, Chem Biol, V1, P119; SCHWECKE T, 1995, P NATL ACAD SCI USA, V92, P7839, DOI 10.1073/pnas.92.17.7839; SMITH MC, 1988, J BIOL CHEM, V263, P7211; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; TSOI CJ, 1995, CHEM BIOL, V2, P355; VAGELOS PR, 1991, SCIENCE, V252, P1080, DOI 10.1126/science.252.5009.1080; WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551	28	105	114	1	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1996	384	6604		S			11	13						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR392	8895593				2022-12-24	WOS:A1996VR39200004
J	Benhamou, Y; Katlama, C; Lunel, F; Coutellier, A; Dohin, E; Hamm, N; Tubiana, R; Herson, S; Poynard, T; Opolon, P				Benhamou, Y; Katlama, C; Lunel, F; Coutellier, A; Dohin, E; Hamm, N; Tubiana, R; Herson, S; Poynard, T; Opolon, P			Effects of lamivudine on replication of hepatitis B virus in HIV-infected men	ANNALS OF INTERNAL MEDICINE			English	Article						hepatitis B; human immunodeficiency; virus infections; lamivudine; virus replication; comorbidity	HUMAN-IMMUNODEFICIENCY-VIRUS; CHRONIC ACTIVE HEPATITIS; ALPHA-INTERFERON; SURVIVAL; CARRIERS; EFFICACY; INVITRO; THERAPY; TRIAL	Background: Therapy for hepatitis B virus (HBV) infection is still unsatisfactory, particularly in patients who are co-infected with the human immunodeficiency virus (HIV). Lamivudine, a retroviral inhibitor, has been shown to have activity against HBV replication in vitro, in animal models, and in studies of immunocompetent persons. Objective: To assess the efficacy of lamivudine in inhibiting HBV replication during a 12-month period in patients with both HBV and HIV infection. Design: Prospective, open study. Setting: University hospital. Patients: 40 consecutive patients (39 men and 1 woman) infected with both HIV and HBV. All had progressive HIV disease; were refractory to or unable to tolerate therapies other than lamivudine; and received lamivudine, 600 mg/d or 600 mg/d followed by 300 mg/d, as therapy for HIV disease. Measurements: Serum concentrations of HBV DNA were assessed every 2 months by using molecular hybridization. Polymerase chain reaction (PCR) for HBV DNA was done at baseline and was done at months 2, 6, and 12 only if the HBV DNA concentration was less than 5 pg/mL. Results: Two groups were retrospectively identified at baseline: patients with high HBV replication (serum HBV DNA concentrations >5 pg/mL) (n = 30) and patients with low HBV replication (serum HBV DNA concentrations <5 pg/mL) (n = 10). After 12 months of treatment, 26 of 27 patients (96.3% [95% Cl, 81% to 99.9%]) who had had high HBV replication at baseline had serum HBV DNA concentrations less than 5 pg/mL. However, PCR could still detect HBV DNA in serum in 11.5% (Cl, 2% to 30%) of these patients. Among patients who had had low HBV replication at baseline, the results of PCR for serum HBV DNA became negative in the 6 patients who had had a positive result on PCR at baseline. No serious adverse events occurred during treatment. Conclusion: Although this study was not a randomized, blinded trial, it suggests that lamivudine is active against HBV replication in men infected with both HBV and HIV.	GRP HOSP PITIE SALPETRIERE, SERV MALAD INFECT, F-75651 PARIS 13, FRANCE; HOP LA PITIE SALPETRIERE, VIROL LAB, F-75651 PARIS 13, FRANCE; HOP LA PITIE SALPETRIERE, SERV MED INTERNE, F-75651 PARIS 13, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Benhamou, Y (corresponding author), GRP HOSP PITIE SALPETRIERE, SERV HEPATOGASTROENTEROL, 47 BLVD HOP, F-75651 PARIS 13, FRANCE.		françoise, lunel/B-7273-2015; Poynard, Thierry/C-1355-2010	françoise, lunel/0000-0002-1856-0300; Poynard, Thierry/0000-0002-3726-7230; Poynard, Thierry/0000-0002-2050-640X				[Anonymous], 1992, MMWR Recomm Rep, V41, P1; ANTINORI S, 1993, J HEPATOL, V18, P255, DOI 10.1016/S0168-8278(05)80254-5; ASHMAN C, 1994, 6 INT S VIR HEP MADR, P65; BROOK MG, 1989, HEPATOLOGY, V10, P761, DOI 10.1002/hep.1840100502; BROOK MG, 1988, VIRAL HEPATITIS LIVE, P906; CHANG CN, 1992, J BIOL CHEM, V267, P22414; CHOSSEGROS P, 1993, GASTROENTEROLOGY, V104, pA888; COATES JAV, 1992, ANTIMICROB AGENTS CH, V36, P202, DOI 10.1128/AAC.36.1.202; DEJONGH FE, 1992, GASTROENTEROLOGY, V103, P1630, DOI 10.1016/0016-5085(92)91188-A; DIANZANI F, 1993, GUT, V34, pS74, DOI 10.1136/gut.34.2_Suppl.S74; DIENSTAG JL, 1995, NEW ENGL J MED, V333, P1657, DOI 10.1056/NEJM199512213332501; DOONG SL, 1991, P NATL ACAD SCI USA, V88, P8495, DOI 10.1073/pnas.88.19.8495; FRIED MW, 1992, HEPATOLOGY, V20, pA209; GARCIA F, 1995, J CLIN MICROBIOL, V33, P413, DOI 10.1128/JCM.33.2.413-415.1995; KANE MA, 1993, GUT, V34, pS10, DOI 10.1136/gut.34.2_Suppl.S10; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; KROGSGAARD K, 1987, HEPATOLOGY, V7, P37, DOI 10.1002/hep.1840070109; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; MARCELLIN P, 1989, HEPATOLOGY, V10, P328, DOI 10.1002/hep.1840100313; MARCELLIN P, 1989, NEW ENGL J MED, V321, P1758; MCDONALD JA, 1987, HEPATOLOGY, V7, P719, DOI 10.1002/hep.1840070417; MCKENZIE R, 1995, NEW ENGL J MED, V333, P1099, DOI 10.1056/NEJM199510263331702; MONNO L, 1988, VIRAL HEPATITIS LIVE, P205; PERRILLO RP, 1986, ANN INTERN MED, V105, P382, DOI 10.7326/0003-4819-105-3-382; RUSTGI VK, 1984, ANN INTERN MED, V101, P795, DOI 10.7326/0003-4819-101-6-795; Taylor PE, 1988, VIRAL HEPATITIS LIVE, P198; TYRRELL DL, 1993, CLIN INVEST MED S4, V16, P877; VANLEEUWEN R, 1995, J INFECT DIS, V171, P1166, DOI 10.1093/infdis/171.5.1166; WEISSBERG JI, 1984, ANN INTERN MED, V101, P613, DOI 10.7326/0003-4819-101-5-613; WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011; WONG DKH, 1995, GASTROENTEROLOGY, V108, P165, DOI 10.1016/0016-5085(95)90021-7	31	135	137	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1996	125	9					705	+		10.7326/0003-4819-125-9-199611010-00001	http://dx.doi.org/10.7326/0003-4819-125-9-199611010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ072	8929003				2022-12-24	WOS:A1996VQ07200001
J	Stocklin, E; Wissler, M; Gouilleux, F; Groner, B				Stocklin, E; Wissler, M; Gouilleux, F; Groner, B			Functional interactions between Stat5 and the glucocorticoid receptor	NATURE			English	Article							COLONY-STIMULATING FACTOR; MAMMARY EPITHELIAL-CELLS; TRANSCRIPTION FACTOR; BETA-CASEIN; RESPONSIVE EXPRESSION; NUCLEAR FACTOR; DNA-BINDING; TUMOR VIRUS; PROLACTIN; GENE	SIGNAL transduction pathways enable extracellular signals to activate latent transcription factors in the cytoplasm of cells. Dimerization, nuclear localization and binding to specific DNA sequences result in the induction of gene transcription by these proteins. These events are necessary for the functioning of the JAK/STAT pathway and of the glucocorticoid-receptor pathway. In the former, the protein Stat5, which is a member of a family of signal transducers and activators of transcription, is activated by cytokines, hormones and growth factors(1-7). These polypeptide ligands bind at the outside of the cell to specific transmembrane receptors and activate intracellular Janus protein tyrosine kinases (JAKs) to tyrosine-phosphorylate STAT proteins; interaction with the SH2 domain of the dimerization partner then confers the ability to bind to DNA at the STAT-response element and induce transcription(8-10). In the glucocorticoid-receptor pathway, the receptor interacts with its steroid hormone ligand in the cytoplasm, undergoes an allosteric change that enables the hormone receptor complex to bind to specific DNA-response elements (glucocorticoid response elements, or GRE) and modulate transcription(11,12). Although these pathways appear to he unrelated, we show here that the glucocorticoid receptor can act as a transcriptional co-activator for Stat5 and enhance Stat5-dependent transcription. Stat5 forms a complex with the glucocorticoid receptor which binds to DNA independently of the GRE. This complex formation between Stat5 and the glucocorticoid receptor diminishes the glucocorticoid response of a GRE-containing promoter.	TUMOR BIOL CTR,INST EXPT CANC RES,D-79106 FREIBURG,GERMANY					Gouilleux, Fabrice/0000-0001-6047-1718				AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Cato ACB, 1996, BIOESSAYS, V18, P371, DOI 10.1002/bies.950180507; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DOPPLER W, 1989, P NATL ACAD SCI USA, V86, P104, DOI 10.1073/pnas.86.1.104; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; GOUILLEUX F, 1995, ENDOCRINOLOGY, V136, P5700, DOI 10.1210/en.136.12.5700; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GRONER B, 1994, MOL CELL ENDOCRINOL, V100, P109, DOI 10.1016/0303-7207(94)90288-7; GRONER B, 1995, CURR OPIN GENET DEV, V5, P587, DOI 10.1016/0959-437X(95)80027-1; HOCK W, 1990, J BIOL CHEM, V265, P5403; HYNES N, 1983, P NATL ACAD SCI-BIOL, V80, P3637, DOI 10.1073/pnas.80.12.3637; HYNES NE, 1981, P NATL ACAD SCI-BIOL, V78, P2038, DOI 10.1073/pnas.78.4.2038; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; IVASHKIV LB, 1995, IMMUNITY, V3, P1, DOI 10.1016/1074-7613(95)90152-3; LAVOIE HA, 1995, P SOC EXP BIOL MED, V209, P257; LEBRUN JJ, 1995, P NATL ACAD SCI USA, V92, P4031, DOI 10.1073/pnas.92.9.4031; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; SCHMITT-NEY M, 1992, P NATL ACAD SCI USA, V89, P3130, DOI 10.1073/pnas.89.7.3130; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; TEURICH S, 1995, CHEM SENSES, V20, P251, DOI 10.1093/chemse/20.2.251; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WELLE T, 1993, J STEROID BIOCH MOL, V47, P75; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x	30	536	541	3	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 24	1996	383	6602					726	728		10.1038/383726a0	http://dx.doi.org/10.1038/383726a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN918	8878484	Green Submitted			2022-12-24	WOS:A1996VN91800056
J	Zimmet, P; Hodge, A; Nicolson, M; Staten, M; deCourten, M; Moore, J; Morawiecki, A; Lubina, J; Collier, G; Alberti, G; Dowse, G				Zimmet, P; Hodge, A; Nicolson, M; Staten, M; deCourten, M; Moore, J; Morawiecki, A; Lubina, J; Collier, G; Alberti, G; Dowse, G			Serum leptin concentration, obesity, and insulin resistance in Western Samoans: Cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							GENE-EXPRESSION; ADIPOSE-TISSUE; MESSENGER-RNA; OB GENE; PREVALENCE; POPULATION; INCREASE; CLONING; PRODUCT; PERIOD	Objective-To measure serum leptin concentrations in the Polynesian population of Western Samoa and to examine epidemiological associations of leptin with anthropometric, demographic, behavioural, and metabolic factors in this population with a high prevalence of obesity and non-insulin dependent diabetes mellitus. Design-Cross sectional study, leptin concentration being measured in a subgroup of a population based sample. Subjects-240 Polynesian men and women aged 28-74 years were selected to cover the full range of age, body mass index, and glucose tolerance, Main outcome measurements-Serum leptin, insulin, and glucose concentrations; anthropometric measures; physical activity; and area of residence. Results-Leptin concentrations were correlated with body mass index (r = 0.80 in men, 0.79 in women) and waist circumference (r = 0.82 in men, 0.78 in women) but less so with waist to hip ratio, At any body mass index, leptin concentration was higher in women than men (geometric mean adjusted for body mass index 15.3 v 3.6 pg/l, P < 0.001). Leptin concentration also correlated with fasting insulin concentration (r = 0.63 in men, 0.64 in women) and insulin concentration 2 hours after a glucose load (r = 0.58 in men, 0.52 in women). These associations remained significant after controlling for body mass index; effects of physical activity and of rural or urban living on leptin concentration were eliminated after adjusting for obesity, except values remained high in urban men. 78% of variance in leptin was explained by a model including fasting insulin concentration, sex, body mass index, and a body mass index by sex interaction term. Similar results were obtained if waist circumference replaced body mass index. Conclusions-The strong relation of leptin with obesity is consistent with leptin production being proportional to mass of adipose tissue. The relation with insulin independent of body mass index suggests a possible role for leptin in insulin resistance or hyperinsulinaemia.	AMGEN INC,CLIN RES,THOUSAND OAKS,CA 91320; AMGEN INC,BIOSTAT,THOUSAND OAKS,CA 91320; DEAKIN UNIV,GEELONG,VIC 3220,AUSTRALIA; UNIV NEWCASTLE UPON TYNE,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND	Amgen; Amgen; Deakin University; Newcastle University - UK	Zimmet, P (corresponding author), INT DIABET INST,CAULFIELD,VIC 3162,AUSTRALIA.		de Courten, Maximilian P. J./AAH-5104-2020; Zimmet, Paul/O-8486-2019; de Courten, Maximilian/B-3300-2012	Zimmet, Paul/0000-0003-0627-0776; de Courten, Maximilian/0000-0001-9997-9359; Hodge, Allison/0000-0001-5464-2197	NIDDK NIH HHS [DK-25446] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025446] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bouchard C, 1993, Obes Res, V1, P133; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; COLEMAN DL, 1973, DIABETOLOGIA, V9, P294, DOI 10.1007/BF01221857; COLLIER GR, IN PRESS DIABETOLOGI; COLLINS VR, 1994, DIABETES CARE, V17, P288, DOI 10.2337/diacare.17.4.288; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2986, DOI 10.1172/JCI118007; CUSIN I, 1995, DIABETES, V44, P1467, DOI 10.2337/diabetes.44.12.1467; FREDERICH RC, 1995, NAT MED, V1, P311; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HAMILTON BS, 1995, NAT MED, V1, P953, DOI 10.1038/nm0995-953; HODGE AM, 1994, INT J OBESITY, V18, P419; LONNQVIST F, 1995, NAT MED, V1, P950, DOI 10.1038/nm0995-950; MACDOUGALD OA, 1995, P NATL ACAD SCI USA, V92, P9034, DOI 10.1073/pnas.92.20.9034; Maffei M, 1996, DIABETES, V45, P679, DOI 10.2337/diabetes.45.5.679; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; NORUSIS M, 1990, SPSS PC 4 0 IBM PC X; OGAWA Y, 1995, J CLIN INVEST, V96, P1647, DOI 10.1172/JCI118204; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Rosenbaum M, 1996, J CLIN ENDOCR METAB, V81, P3424, DOI 10.1210/jc.81.9.3424; SALADIN R, 1995, NATURE, V377, P527, DOI 10.1038/377527a0; Schwartz MW, 1996, DIABETES, V45, P531, DOI 10.2337/diabetes.45.4.531; SOELDNER JS, 1965, DIABETES, V14, P771, DOI 10.2337/diab.14.12.771; TARTAGLIA LA, 1995, CELL, V85, P1265; WEIGLE DS, 1995, J CLIN INVEST, V96, P2065, DOI 10.1172/JCI118254; *WHO STUD GROUP, 1985, WHO TECH REP SER, V727; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; ZIMMET P, 1981, DIABETES, V30, P45, DOI 10.2337/diabetes.30.1.45	28	206	208	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 19	1996	313	7063					965	969						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN916	8892415	Green Published			2022-12-24	WOS:A1996VN91600019
J	Garrard, TL; Stone, EC; Murphy, N				Garrard, TL; Stone, EC; Murphy, N			Effects of absorption by Io on composition of energetic heavy ions	SCIENCE			English	Article								The Galileo heavy ion counter is sensitive to ions with atomic numbers Z greater than or equal to 6 and energies greater than similar to 6 MeV per nucleon, During Galileo's passage through Jupiter's inner magnetosphere, the observed composition of these heavy ions was consistent with the presence of singly ionized iogenic. O, Na, and S and highly ionized solar C, O, and Ne. The solar component is absorbed more strongly by Io because its gyroradius is smaller than Io's diameter.	CALTECH,JET PROP LAB,PASADENA,CA 91109	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Garrard, TL (corresponding author), CALTECH,SPACE RADIAT LAB,PASADENA,CA 91125, USA.							GARRARD TL, 1992, SPACE SCI REV, V60, P305, DOI 10.1007/BF00216859; GEHRELS N, 1981, J GEOPHYS RES-SPACE, V86, P8906, DOI 10.1029/JA086iA11p08906; GEHRELS N, 1983, J GEOPHYS RES-SPACE, V88, P5537, DOI 10.1029/JA088iA07p05537; KRIMIGIS SM, 1979, SCIENCE, V204, P998, DOI 10.1126/science.204.4396.998; KRIMIGIS SM, 1979, SCIENCE, V206, P977, DOI 10.1126/science.206.4421.977; Luhn A., 1984, ADV SPACE RES, V4, P161, DOI DOI 10.1016/0273-1177(84)90307-7; PARANICAS C, 1994, J GEOPHYS RES-SPACE, V99, P19433, DOI 10.1029/94JA01573; VOGT RE, 1979, SCIENCE, V204, P1003, DOI 10.1126/science.204.4396.1003; VOGT RE, 1979, SCIENCE, V206, P984, DOI 10.1126/science.206.4421.984; [No title captured]	10	14	14	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1996	274	5286					393	394		10.1126/science.274.5286.393	http://dx.doi.org/10.1126/science.274.5286.393			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN173	8832881				2022-12-24	WOS:A1996VN17300044
J	Narula, J; Haider, N; Virmani, R; DiSalvo, TG; Kolodgie, FD; Hajjar, RJ; Schmidt, U; Semigran, MJ; Dec, GW; Khaw, BA				Narula, J; Haider, N; Virmani, R; DiSalvo, TG; Kolodgie, FD; Hajjar, RJ; Schmidt, U; Semigran, MJ; Dec, GW; Khaw, BA			Apoptosis in myocytes in end-stage heart failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROGRAMMED CELL-DEATH; PRESSURE-OVERLOAD; DNA FRAGMENTATION; IMMATURE THYMOCYTES; HYPERTROPHY; EXPRESSION; PROTEIN; IDENTIFICATION; CARDIOMYOCYTES; PROTOONCOGENE	Background Heart failure can result from a variety of causes, including ischemic, hypertensive, toxic, and inflammatory heart disease. However, the cellular mechanisms responsible for the progressive deterioration of myocardial function observed in heart failure remain unclear and may result from apoptosis (programmed cell death). Methods We examined seven explanted hearts obtained during cardiac transplantation for evidence of apoptosis, All seven patients had severe chronic heart failure: four had idiopathic dilated cardiomyopathy, and three had ischemic cardiomyopathy, DNA fragmentation (an indicator of apoptosis) was identified histochemically by in situ end-labeling as well as by agarose-gel electrophoresis of end-labeled DNA. Myocardial tissues obtained from four patients who had had a myocardial infarction one to two days previously were used as positive controls, and heart tissues obtained from Sour persons who died in motor vehicle accidents were used as negative controls for the end-labeling studies. Results Hearts from all four patients with idiopathic dilated cardiomyopathy and from one of the three patients with ischemic cardiomyopathy had histochemical evidence of DNA fragmentation, All four myocardial samples from patients with dilated cardiomyopathy also demonstrated DNA laddering, a characteristic of apoptosis, whereas this was not seen in any of the samples from patients with ischemic cardiomyopathy. Histologic evidence of apoptosis was also observed in the central necrotic zone of acute myocardial infarcts, but not in myocardium remote from the infarcted zone. Rare isolated apoptotic myocytes were seen in the myocardium from the four persons who died in motor vehicle accidents. Conclusions Loss of myocytes due to apoptosis occurs in patients with end-stage cardiomyopathy and may contribute to progressive myocardial dysfunction. (C) 1996, Massachusetts Medical Society.	NORTHEASTERN UNIV, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; ARMED FORCES INST PATHOL, WASHINGTON, DC 20306 USA	Northeastern University; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; United States Department of Defense								ARENDS MJ, 1990, AM J PATHOL, V136, P593; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; BING OHL, 1994, J MOL CELL CARDIOL, V26, P943, DOI 10.1006/jmcc.1994.1115; BRAUNWALD E, 1992, HEART DISEASE TXB CA, P393; BURSCH W, 1990, BIOCHEM CELL BIOL, V68, P1071, DOI 10.1139/o90-160; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; CONNOR J, 1988, PROSTATE, V13, P119, DOI 10.1002/pros.2990130204; DEC GW, 1992, J NUCL MED, V33, P477; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; GWATHMEY JK, 1985, CIRC RES, V57, P836, DOI 10.1161/01.RES.57.6.836; HER E, 1991, J CLIN INVEST, V88, P1982, DOI 10.1172/JCI115524; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; ITOH G, 1995, AM J PATHOL, V146, P1325; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; KATZ AM, 1994, ANN INTERN MED, V121, P363, DOI 10.7326/0003-4819-121-5-199409010-00009; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; MARCUS ML, 1981, AM J PHYSIOL, V241, pH358, DOI 10.1152/ajpheart.1981.241.3.H358; MARTIKAINEN P, 1991, CANCER RES, V51, P4693; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MCCONKEY DJ, 1990, J BIOL CHEM, V265, P3009; MURGIA M, 1992, J BIOL CHEM, V267, P10939; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; ROSL F, 1992, NUCLEIC ACIDS RES, V20, P5243, DOI 10.1093/nar/20.19.5243; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SANDFORD NL, 1984, PATHOLOGY, V16, P406, DOI 10.3109/00313028409084731; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; SEARLE J, 1982, PATHOL ANNU, V17, P229; TAKAHASHI T, 1992, J CLIN INVEST, V89, P939, DOI 10.1172/JCI115675; TANAKA M, 1994, CIRC RES, V75, P426, DOI 10.1161/01.RES.75.3.426; UCKER DS, 1991, NEW BIOL, V3, P103; WIJSMAN JH, 1993, J HISTOCHEM CYTOCHEM, V41, P7, DOI 10.1177/41.1.7678025; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; [No title captured]	40	1132	1183	0	36	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 17	1996	335	16					1182	1189		10.1056/NEJM199610173351603	http://dx.doi.org/10.1056/NEJM199610173351603			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN401	8815940				2022-12-24	WOS:A1996VN40100003
J	Byrne, GJ; McCarthy, MJ; Silverman, SH				Byrne, GJ; McCarthy, MJ; Silverman, SH			Improving uptake of prophylaxis for venous thromboembolism in general surgical patients using prospective audit	BRITISH MEDICAL JOURNAL			English	Article									KIDDERMINSTER HOSP,DEPT SURG,KIDDERMINSTER,W MIDLANDS,ENGLAND; CITY HOSP,DEPT SURG,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND	University of Birmingham				Byrne, Ged/0000-0002-8194-7540				Bahal V, 1993, J R Coll Surg Edinb, V38, P33; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; LINDBLAD B, 1991, BRIT MED J, V302, P709, DOI 10.1136/bmj.302.6778.709; SCURR JH, 1988, SWISS MED, V10, P77; VANEK VW, 1991, CURR SURG, V48, P539	5	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 12	1996	313	7062					917	917						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM754	8876095				2022-12-24	WOS:A1996VM75400026
J	Li, Y; Benezra, R				Li, Y; Benezra, R			Identification of a human mitotic checkpoint gene: hsMAD2	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; MITOSIS; ANAPHASE; PROTEIN; CELLS; KINETOCHORES; NOCODAZOLE; ONSET	In Saccharomyces cerevisiae, MAD2 is required for mitotic arrest if the spindle assembly is perturbed. The human homolog of MAD2 was isolated and shown to be a necessary component of the mitotic checkpoint in HeLa cells by antibody electroporation experiments. Human, or Homo sapiens, MAD2 (hsMAD2) was localized at the kinetochore after chromosome condensation but was no longer observed at the kinetochore in metaphase, suggesting that MAD2 might monitor the completeness of the spindle-kinetochore attachment. Finally, T47D, a human breast tumor cell line that is sensitive to taxol and nocodazole, had reduced MAD2 expression and failed to arrest in mitosis after nocodazole treatment. Thus, defects in the mitotic checkpoint may contribute to the sensitivity of certain tumors to mitotic spindle inhibitors.	MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center					NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA-08748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER RE, 1990, MOL CELL BIOL, V10, P2458, DOI 10.1128/MCB.10.6.2458; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CAMPBELL MS, 1995, J CELL BIOL, V129, P1195, DOI 10.1083/jcb.129.5.1195; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; DELLARCO VL, 1985, ANEUPLOIDY ETIOLOGY; EARNSHAW WC, 1994, BIOESSAYS, V16, P639, DOI 10.1002/bies.950160908; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GOH PY, 1993, J CELL BIOL, V121, P503, DOI 10.1083/jcb.121.3.503; GORBSKY GJ, 1995, TRENDS CELL BIOL, V5, P143, DOI 10.1016/S0962-8924(00)88968-0; Harlow E, 1988, ANTIBODIES LAB MANUA; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; JORDAN MA, 1992, J CELL SCI, V102, P401; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; LI Y, UNPUB; MELLOR J, 1990, EMBO J, V9, P4017, DOI 10.1002/j.1460-2075.1990.tb07623.x; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NICKLAS RB, 1995, J CELL BIOL, V130, P929, DOI 10.1083/jcb.130.4.929; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; WANG YC, 1995, MOL CELL BIOL, V15, P6838	25	522	549	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1996	274	5285					246	248		10.1126/science.274.5285.246	http://dx.doi.org/10.1126/science.274.5285.246			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM671	8824189				2022-12-24	WOS:A1996VM67100043
J	Bradford, WZ; Martin, JN; Reingold, AL; Schecter, GF; Hopewell, PC; Small, PM				Bradford, WZ; Martin, JN; Reingold, AL; Schecter, GF; Hopewell, PC; Small, PM			The changing epidemiology of acquired drug-resistant tuberculosis in San Francisco, USA	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NEW-YORK-CITY; MYCOBACTERIUM-TUBERCULOSIS; MALABSORPTION; RIFAMPIN	Background The increasing incidence of tuberculosis caused by drug-resistant Mycobacterium tuberculosis is thought in part to reflect inadequate implementation of standard tuberculosis control measures. However, in San Francisco, USA, which has an effective tuberculosis control programme, we have recently observed an increase in cases of acquired drug-resistance. Methods To explore further this observation, we analysed the secular trend of acquired drug-resistance and conducted a population-based case-control study oi all reported tuberculosis cases In the city of San Francisco between 1985 and 1994. Findings We identified 14 patients with tuberculosis caused by fully susceptible M tuberculosis who subsequently developed drug-resistance. Of these acquired drug-resistance cases, two occurred between 1985 and 1989, whereas 12 occurred between 1990 and 1994 (p=0.028); In the case-contra[ study, AIDS 20.2, 95% CI 1.12-363.6), nan;compliance with therapy (19.7, 1.66-234.4), and gastrointestinal symptoms (11.5, 1.23-107.0) were independently associated with acquired drug-resistance; Between 1990 and 1994, one in 16 tuberculosis patients with AIDS and either gastrointestinal symptoms or non-compliance developed acquired drug-resistance. Interpretation The substantial increase in acquired drug-resistance in San Francisco seems to bera product of the increasing prevalence: of HIV/M tuberculosis coinfection. Our data suggest that the interface of the HIV and tuberculosis epidemics fosters acquired drug-resistance, and that traditional tuberculosis control measures may not be sufficient in communities with high rates of HIV infection.	SAN FRANCISCO GEN HOSP,MED SERV,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143; FRANCES J CURRY NATL TB CTR,SAN FRANCISCO,CA; UNIV CALIF BERKELEY,SCH PUBL HLTH,DIV PUBL HLTH BIOL & EPIDEMIOL,BERKELEY,CA 94720; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,CTR AIDS PREVENT STUDIES,SAN FRANCISCO,CA 94143; DEPT PUBL HLTH,SAN FRANCISCO,CA; STANFORD UNIV,SCH MED,DEPT MED,PALO ALTO,CA 94304	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California Berkeley; University of California System; University of California San Francisco; Stanford University					NIAID NIH HHS [AI34238, AI01137] Funding Source: Medline; NIMH NIH HHS [T32 MH-19105] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034238] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH019105] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BLOCH AB, 1994, JAMA-J AM MED ASSOC, V271, P665, DOI 10.1001/jama.271.9.665; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; DAVID HL, 1970, APPL MICROBIOL, V20, P810, DOI 10.1128/AEM.20.5.810-814.1970; DYLEWSKI J, 1990, J INFECT DIS, V162, P778, DOI 10.1093/infdis/162.3.778; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; GOLLAPUDI S, 1994, BIOCHEM BIOPH RES CO, V199, P1181, DOI 10.1006/bbrc.1994.1355; GREENLAND S, 1982, AM J EPIDEMIOL, V116, P547, DOI 10.1093/oxfordjournals.aje.a113439; HACEK D, 1992, CLIN MICROBIOLOGY PR; LUFTEY M, 1996, AM J RESP CRIT CARE, V153, P837; MAHMOUDI A, 1993, JAMA-J AM MED ASSOC, V270, P65, DOI 10.1001/jama.270.1.65; MITCHISON DA, 1984, BRIT MED BULL, V40, P84, DOI 10.1093/oxfordjournals.bmb.a071952; NOLAN CM, 1995, AM J RESP CRIT CARE, V152, P1067, DOI 10.1164/ajrccm.152.3.7663785; PATEL KB, 1995, NEW ENGL J MED, V332, P336, DOI 10.1056/NEJM199502023320518; PELOQUIN CA, 1993, NEW ENGL J MED, V329, P1122, DOI 10.1056/NEJM199310073291513; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; *RETR PHYS DESK RE, 1992, MED EC DAT, P802; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; 1994, AM J RESP CRIT CARE, V149, P1359	19	83	84	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 5	1996	348	9032					928	931		10.1016/S0140-6736(96)03027-9	http://dx.doi.org/10.1016/S0140-6736(96)03027-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL097	8843813				2022-12-24	WOS:A1996VL09700013
J	Parthun, MR; Widom, J; Gottschling, DE				Parthun, MR; Widom, J; Gottschling, DE			The major cytoplasmic histone acetyltransferase in yeast: Links to chromatin replication and histone metabolism	CELL			English	Article							NEWLY SYNTHESIZED HISTONES; SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; NEGATIVE REGULATOR; ACETYLATION SITES; H4; PROTEINS; TETRAHYMENA; VECTORS; DOMAINS	We have isolated the predominant cytoplasmic histone acetyltransferase activity from Saccharomyces cerevisiae. This enzyme acetylates the lysine at residue 12 of free histone H4 but does not modify histone H4 when packaged in chromatin. The activity contains two proteins, Hat1p and Hat2p. Hat1p is the catalytic subunit of the histone acetyltransferase and has an intrinsic substrate specificity that modifies lysine in the recognition sequence GXG (K) under bar XG. The specificity of the enzyme in the yeast cytoplasm is restricted relative to recombinant Hat1p suggesting that it is negatively regulated in vivo. Hat2p, which is required for high affinity binding of the acetyltransferase to histone H4, is highly related to Rbap48, which is a subunit of the chromatin assembly factor, CAF-1, and copurifies with the human histone deacetylase HD1. We propose that the Hat2p/Rbap48 family serve as escorts of histone metabolism enzymes to facilitate their interaction with histone H4.	NORTHWESTERN UNIV,DEPT BIOCHEM MOL BIOL & CELL BIOL,EVANSTON,IL 60208	Northwestern University	Parthun, MR (corresponding author), FRED HUTCHINSON CANC RES CTR,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043893, R01GM050932] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50932, GM43893] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P329; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; BROTHERTON TW, 1981, NUCLEIC ACIDS RES, V9, P5061, DOI 10.1093/nar/9.19.5061; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; CHICOINE LG, 1986, J BIOL CHEM, V261, P1071; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; FENG HP, 1993, BIOCHEMISTRY-US, V32, P7824, DOI 10.1021/bi00081a030; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; GEORGAKOPOULOS T, 1995, MOL GEN GENET, V246, P723, DOI 10.1007/BF00290718; Harlow E, 1988, ANTIBODIES LAB MANUA; HENIKOFF S, 1987, GENETICS, V117, P711; HORIUCHI J, 1995, MOL CELL BIOL, V15, P1203; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; KLEFF S, 1995, J BIOL CHEM, V270, P24674, DOI 10.1074/jbc.270.42.24674; KRUDE T, 1995, CURR BIOL, V5, P1232, DOI 10.1016/S0960-9822(95)00245-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Ling XF, 1996, GENE DEV, V10, P686, DOI 10.1101/gad.10.6.686; LOPEZRODAS G, 1989, J BIOL CHEM, V264, P19028; LOWARY PT, 1989, P NATL ACAD SCI USA, V86, P8266, DOI 10.1073/pnas.86.21.8266; Means G.E., 1971, CHEM MODIFICATION PR; MORGAN BA, 1991, MOL CELL BIOL, V11, P4111, DOI 10.1128/MCB.11.8.4111; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; PERRY CA, 1993, BIOCHEMISTRY-US, V32, P13605, DOI 10.1021/bi00212a028; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; QIAN YW, 1995, J BIOL CHEM, V270, P25507, DOI 10.1074/jbc.270.43.25507; RUIZCARRILLO A, 1975, SCIENCE, V190, P117, DOI 10.1126/science.1166303; SIKORSKI RS, 1989, GENETICS, V122, P19; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P306; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; SOBEL RE, 1994, J BIOL CHEM, V269, P18576; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; SOGO JM, 1986, J MOL BIOL, V189, P189, DOI 10.1016/0022-2836(86)90390-6; STILLMAN B, 1986, CELL, V45, P555, DOI 10.1016/0092-8674(86)90287-4; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; van Holde KE., 1989, SPRINGER SERIES MOL; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; White T.J., 1990, PCR PROTOCOLS GUIDE, P315; WIDOM J, 1986, J MOL BIOL, V190, P411, DOI 10.1016/0022-2836(86)90012-4; WILLIAMS KR, 1995, TECH PROT CHEM, V6, P143, DOI 10.1016/S1080-8914(06)80020-7; WORCEL A, 1978, CELL, V15, P969, DOI 10.1016/0092-8674(78)90280-5; WU RS, 1981, CELL, V27, P321, DOI 10.1016/0092-8674(81)90415-3	46	365	374	2	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1996	87	1					85	94		10.1016/S0092-8674(00)81325-2	http://dx.doi.org/10.1016/S0092-8674(00)81325-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VL695	8858151	Bronze			2022-12-24	WOS:A1996VL69500011
J	Doxiadis, IIN; Smits, JMA; Schreuder, GMT; Persijn, GG; vanHouwelingen, HC; vanRood, JJ; Claas, FHJ				Doxiadis, IIN; Smits, JMA; Schreuder, GMT; Persijn, GG; vanHouwelingen, HC; vanRood, JJ; Claas, FHJ			Association between specific HLA combinations and probability of kidney allograft loss: The taboo concept	LANCET			English	Article							RENAL-TRANSPLANTATION; GRAFT-SURVIVAL; DR MISMATCHES; RECIPIENTS; ANTIGENS; HLA-DRW6; MARKER	Background HLA matching improves the outcome of cadaveric renal transplantation. However, many allografts function well even in the presence of one or more HLA mismatches, which raises the question of whether some mismatches are better recognised by the recipient's immune system than others. We aimed to identify mismatched HLA donor-recipient combinations that were associated with increased graft loss. Methods We selected 2877 first, unrelated renal transplants with a single HLA A, B, or DR mismatch, undertaken between 1982 and 1992, from the Eurotransplant database. To enhance statistical power the analysis was restricted to mismatches of an HLA antigen that occurred in 100 or more donors. 1342 transplants met this criterion and were grouped into a definition set (n=873) and a validation set (n=469). In the definition set, we studied further only those recipient HLA antigens that occurred in at least 30 cases within each donor antigen mismatch subset. By a Cox proportional hazards model, donor-recipient combinations that led to significantly higher graft loss than in the whole group were defined. Such combinations were classified as taboo; the remaining combinations were classified as indifferent. Findings 106 individual recipient antigens were found al least 30 times with a corresponding donor mismatch in the definition set; 11 of the 106 had a significant effect on graft survival. Seven combinations were classified as taboo. Taboo combinations, confirmed as such in the validation set, were associated with graft survival of 81% at one year and 50% at 5 years, significantly lower than the rates in the group with indifferent combinations (89% and 69%; p=0.04) or among 1190 recipients with no mismatches (89% and 72%; p=0.03). The findings were substantiated by a multivariate analysis that included the effect of patient immunisation, cold ischaemia time, age, and sex. Interpretation Mismatched donor antigens are differentially recognised depending on the HLA phenotype of the recipient. The findings may have important clinical consequences for graft survival after transplantation.	UNIV LEIDEN HOSP,BLOOD BANK,NL-2333 AA LEIDEN,NETHERLANDS; EUROTRANSPLANT FDN,LEIDEN,NETHERLANDS; LEIDEN UNIV,DEPT MED STAT,NL-2300 RA LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University - Excl LUMC	Doxiadis, IIN (corresponding author), UNIV LEIDEN HOSP,DEPT IMMUNOHAEMATOL,NL-2333 AA LEIDEN,NETHERLANDS.		van houwelingen, hans c/C-1872-2008; Doxiadis, ilias/AAH-9875-2020	van houwelingen, hans c/0000-0002-0494-4637; 				ALAMARTINE E, 1992, TRANSPL P, V24, P2461; BUSSON M, 1979, TRANSPLANTATION, V28, P313, DOI 10.1097/00007890-197910000-00009; COHEN B, 1994, EUROTRANSPLKANT ANN; COOK DJ, 1987, TRANSPLANT P, V19, P675; DOBBE CME, 1990, TRANSPLANTATION, V50, P446, DOI 10.1097/00007890-199009000-00017; DYER PA, 1985, TRANSPLANT P, V17, P2248; FORSBERG B, 1992, TRANSPLANT P, V24, P2463; GJERTSON DW, 1991, NEW ENGL J MED, V324, P1032, DOI 10.1056/NEJM199104113241505; GOULMY E, 1992, TRANSPLANTATION, V53, P1381, DOI 10.1097/00007890-199206000-00046; HENDRIKS GFJ, 1983, LANCET, V2, P187; KREISLER JM, 1988, TRANSPLANTATION, V45, P1071, DOI 10.1097/00007890-198806000-00014; MARUYA E, 1994, CLIN TRANSPLANTS 199, P511; OPELZ G, 1977, TRANSPLANTATION, V24, P106, DOI 10.1097/00007890-197708000-00003; OPELZ G, 1988, LANCET, V2, P61; OPELZ G, 1985, HISTOCOMPATIBILITY T, P342; POHANKA E, 1983, LANCET, V2, P402; SOULILLOU JP, 1983, NEW ENGL J MED, V308, P969; TAKEMOTO S, 1994, HUM IMMUNOL S1, V40, P17; VANROOD JJ, 1967, HISTOCOMPATIBILITY T, P451; VANROOD JJ, 1994, CLIN TRANSPLANTS 199, P285; VEREERSTRAETEN P, 1989, CLIN TRANSPLANT, V3, P54; VEREERSTRAETEN P, 1995, TRANSPLANTATION, V60, P253, DOI 10.1097/00007890-199508000-00008; VEREERSTRAETEN P, 1987, TRANSPLANT P, V19, P364	23	94	95	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 28	1996	348	9031					850	853		10.1016/S0140-6736(96)02296-9	http://dx.doi.org/10.1016/S0140-6736(96)02296-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK037	8826810				2022-12-24	WOS:A1996VK03700010
J	Key, TJA; Thorogood, M; Appleby, PN; Burr, ML				Key, TJA; Thorogood, M; Appleby, PN; Burr, ML			Dietary habits and mortality in 11000 vegetarians and health conscious people: Results of a 17 year follow up	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC-HEART-DISEASE; 7TH-DAY ADVENTISTS; BREAST-CANCER; RISK; ASSOCIATION; CONSUMPTION; POPULATION; VEGETABLES; STROKE; CHOLESTEROL	Objective-To investigate the association of dietary habits with mortality in a cohort of vegetarians and other health conscious people. Design-Observational study. Setting-United Kingdom. Subjects-4336 men and 6435 women recruited through health food shops, vegetarian societies, and magazines. Main outcome measures-Mortality ratios for vegetarianism and for daily versus less than daily consumption of wholemeal bread, bran cereals, nuts or dried fruit, fresh fruit, and raw salad in relation to all cause mortality and mortality fi om ischaemic heart disease, cerebrovascular disease, all malignant neoplasms, lung cancer, colorectal cancer, and breast cancer. Results-2064 (19%) subjects smoked, 4627 (43%) were vegetarian, 6699 (62%) ate wholemeal bread daily, 2948 (27%) ate bran cereals daily, 4091 (38%) ate nuts or dried fruit daily, 8304 (77%) ate fresh fruit daily, and 4105 (38%) ate raw salad daily. After a mean of 16.8 years follow up there were 1343 deaths before age 80. Overall the cohort had a mortality about half that of the general population. Within the cohort, daily consumption of fresh fruit was associated with significantly reduced mortality from ischaemic heart disease (rate ratio adjusted for smoking 0.76 (95% confidence interval 0.60 to 0.97)), cerebrovascular disease (0.68 (0.47 to 0.98)), and for all causes combined (0.79 (0.70 to 0.90)). Conclusions-In this cohort of health conscious individuals, daily consumption of fresh fruit is associated with a reduced mortality from ischaemic heart disease, cerebrovascular disease, and all causes combined.	LONDON SCH HYG & TROP MED, DEPT PUBL HLTH & POLICY, LONDON WC1E 6HT, ENGLAND; UNIV WALES COLL CARDIFF, COLL MED, CTR APPL PUBL HLTH MED, CARDIFF CF1 3NW, S GLAM, WALES	University of London; London School of Hygiene & Tropical Medicine; Cardiff University	Key, TJA (corresponding author), RADCLIFFE INFIRM, IMPERIAL CANC RES FUND, CANC EPIDEMIOL UNIT, OXFORD OX2 6HE, ENGLAND.							ACHESON RM, 1983, LANCET, V1, P1191; BLOCK G, 1992, NUTR CANCER, V18, P1, DOI 10.1080/01635589209514201; BURKITT DP, 1973, BMJ-BRIT MED J, V1, P274, DOI 10.1136/bmj.1.5848.274; BURR ML, 1988, AM J CLIN NUTR, V48, P830, DOI 10.1093/ajcn/48.3.830; BURR ML, 1981, J HUM NUTR, V35, P437; BURR ML, 1982, AM J CLIN NUTR, V36, P873, DOI 10.1093/ajcn/36.5.873; CHANGCLAUDE J, 1992, EPIDEMIOLOGY, V3, P395, DOI 10.1097/00001648-199209000-00003; ENSTROM JE, 1992, EPIDEMIOLOGY, V3, P194, DOI 10.1097/00001648-199205000-00003; GALE CR, 1995, BRIT MED J, V310, P1563, DOI 10.1136/bmj.310.6994.1563; Gaziano J. Michael, 1995, Annals of Epidemiology, V5, P255, DOI 10.1016/1047-2797(94)00090-G; GILLMAN MW, 1995, JAMA-J AM MED ASSOC, V273, P1113, DOI 10.1001/jama.273.14.1113; GRAMENZI A, 1990, BMJ-BRIT MED J, V300, P771, DOI 10.1136/bmj.300.6727.771; HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; KAHN HA, 1984, AM J EPIDEMIOL, V119, P775, DOI 10.1093/oxfordjournals.aje.a113798; KHAW KT, 1987, NEW ENGL J MED, V316, P235, DOI 10.1056/NEJM198701293160502; KNEKT P, 1994, AM J EPIDEMIOL, V139, P1180, DOI 10.1093/oxfordjournals.aje.a116964; LAW MR, 1994, BMJ-BRIT MED J, V308, P363, DOI 10.1136/bmj.308.6925.363; MILLS P, 1989, CANCER-AM CANCER SOC, V64, P582, DOI 10.1002/1097-0142(19890801)64:3&lt;582::AID-CNCR2820640304&gt;3.0.CO;2-V; MILLS PK, 1988, AM J EPIDEMIOL, V127, P440, DOI 10.1093/oxfordjournals.aje.a114821; Pandey DK, 1995, AM J EPIDEMIOL, V142, P1269, DOI 10.1093/oxfordjournals.aje.a117594; PHILLIPS RL, 1980, JNCI-J NATL CANCER I, V65, P1097; POTTER JD, 1995, EUR J CANCER, V31A, P1033, DOI 10.1016/0959-8049(95)00125-3; RAO DN, 1994, BRIT J CANCER, V70, P129, DOI 10.1038/bjc.1994.261; SNOWDON DA, 1984, PREV MED, V13, P490, DOI 10.1016/0091-7435(84)90017-3; THOROGOOD M, 1994, BMJ-BRIT MED J, V308, P1667, DOI 10.1136/bmj.308.6945.1667; White A, 1993, HLTH SURVEY ENGLAND; World Health Organization, 1967, INT CLASS DIS; World Health Organization, 1977, INT CLASS DIS	28	220	223	1	71	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 28	1996	313	7060					775	779						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK566	8842068	Green Published			2022-12-24	WOS:A1996VK56600020
J	Chapman, S				Chapman, S			Letter from Washington DC - Guns don't die. People do	BRITISH MEDICAL JOURNAL			English	Editorial Material											Chapman, S (corresponding author), UNIV SYDNEY,WESTMEAD HOSP,DEPT PUBL HLTH & COMMUNITY MED,WESTMEAD,NSW 2145,AUSTRALIA.							ANNEST JL, 1995, JAMA-J AM MED ASSOC, V273, P1749, DOI 10.1001/jama.273.22.1749; FINGERHUT L, 1994, 242 ADV DAT VIT HLTH; Kleck G., 1991, POINT BLANK GUNS VIO; PIERRE RE, 1996, WASHINGTON POST 0820, pB3; SUGARMANN J, 1996, NUMBER GUN DEALERS P; *VIOL POL CTR, 1992, MOR GUN DEAL GAS STA; 1994, MMWR-MORBID MORTAL W, V43, P37	7	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 21	1996	313	7059					739	740						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VJ441	8819448				2022-12-24	WOS:A1996VJ44100031
J	Meredith, C; Symonds, P; Webster, L; Lamont, D; Pyper, E; Gillis, CR; Fallowfield, L				Meredith, C; Symonds, P; Webster, L; Lamont, D; Pyper, E; Gillis, CR; Fallowfield, L			Information needs of cancer patients in west Scotland: Cross sectional survey of patients' views	BMJ-BRITISH MEDICAL JOURNAL			English	Article							EARLY BREAST-CANCER; PREFERENCES; DIAGNOSIS; TALKING	Objective-To assess the needs of patients with cancer for information about their condition. Design-Cross sectional survey of patients' views by means of semistructured interview with questionnaire. Setting-A regional cancer centre and two university hospitals in west Scotland. Subjects-250 (93%) of 269 cancer patients invited to participate in study who were selected by age, sex, socioeconomic status, and tumour site to be representative of cancer patients in west Scotland. Main outcome measures-Patients' need to know whether they had cancer, the medical name of their illness, progress through treatment, how treatment works, side effects, chances of cure, and treatment options. Results-79% (95% confidence interval 73% to 84%) of patients wanted as much information as possible, and 96% (93% to 98%) had a need or an absolute need to know if they had cancer. Most patients also wanted to know the chance of cure (91% (87% to 94%)) and about side effects of treatment (94% (90% to 97%)). When the replies were cross tabulated with patients' age, sex, deprivation score, and type of treatment there was a linear trend for patients from more affluent areas to want more information and those from deprived areas to want less. There was a strong preference for diagnosis of cancer to be given by a hospital doctor (60% (53% to 66%). Conclusion-Almost all patients wanted to know their diagnosis, and most wanted to know about prognosis, treatment options, and side effects.	WESTERN INFIRM & ASSOCIATED HOSP, BEATSON ONCOL CTR, GLASGOW G11 6NT, LANARK, SCOTLAND; GLASGOW CALEDONIAN UNIV, FAC HLTH, GLASGOW G13 1PP, LANARK, SCOTLAND; RUCHILL HOSP, W SCOTLAND CANC SURVEILLANCE UNIT, GLASGOW G20 9NB, LANARK, SCOTLAND; UCL, SCH MED, DEPT ONCOL, CRC COMMUN & COUNSELLING RES CTR, LONDON W1P 7PL, ENGLAND	Beatson Oncology Centre; Glasgow Caledonian University; University of Glasgow; University of London; University College London; UCL Medical School				Fallowfield, Lesley/0000-0003-0577-4518				*AUD COMM, 1993, 12 NHS AUD COMM; Carstairs V., 1991, DEPRIVATION HLTH SCO; CASSILETH BR, 1980, ANN INTERN MED, V92, P832, DOI 10.7326/0003-4819-92-6-832; FALLOWFIELD L, 1994, LANCET, V344, P1576, DOI 10.1016/S0140-6736(94)90386-7; FALLOWFIELD LJ, 1986, BMJ-BRIT MED J, V293, P1331, DOI 10.1136/bmj.293.6558.1331; FALLOWFIELD LJ, 1990, BRIT MED J, V301, P575, DOI 10.1136/bmj.301.6752.575; FLETCHER C, 1980, BRIT MED J, V281, P994, DOI 10.1136/bmj.281.6246.994; HOLLAND JC, 1987, CANCER INVEST, V5, P151, DOI 10.3109/07357908709018468; JONES SJ, 1981, BRIT MED J, V2, P291; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; SLEVIN ML, 1987, BRIT J HOSP MED, V38, P56; THOMSEN OO, 1993, LANCET, V341, P473, DOI 10.1016/0140-6736(93)90218-6; WILKES E, 1984, PALLIATIVE CARE MANA, P9	13	390	397	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 21	1996	313	7059					724	726						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VJ441	8819442				2022-12-24	WOS:A1996VJ44100023
J	Sacchini, V				Sacchini, V			Multicentricity end recurrence of breast cancer	LANCET			English	Editorial Material							SURGERY				Sacchini, V (corresponding author), EUROPEAN INST ONCOL,BREAST DEPT,I-20141 MILAN,ITALY.							FOWBLE B, 1990, INT J RADIAT ONCOL, V19, P833, DOI 10.1016/0360-3016(90)90002-2; FUKUTOMI T, 1993, SURG TODAY, V23, P402, DOI 10.1007/BF00309497; HOLLAND R, 1990, J CLIN ONCOL, V8, P113, DOI 10.1200/JCO.1990.8.1.113; HOLLAND R, 1985, CANCER, V56, P979, DOI 10.1002/1097-0142(19850901)56:5<979::AID-CNCR2820560502>3.0.CO;2-N; VAIDYA JS, 1996, BRIT J CANCER, V73, P820; VERONESI U, 1995, J NATL CANCER I, V87, P19, DOI 10.1093/jnci/87.1.19; VERONESI U, 1996, BREAST J, V2, P100	7	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 9	1996	348	9037					1256	1257		10.1016/S0140-6736(05)65752-2	http://dx.doi.org/10.1016/S0140-6736(05)65752-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR555	8909374				2022-12-24	WOS:A1996VR55500004
J	Kourtis, AP; Ibegbu, C; Nahmias, AJ; Lee, FK; Clark, WS; Sawyer, MK; Nesheim, S				Kourtis, AP; Ibegbu, C; Nahmias, AJ; Lee, FK; Clark, WS; Sawyer, MK; Nesheim, S			Early progression of disease in HIV-infected infants with thymus dysfunction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; B-CELLS; THYMOCYTE DEPLETION; SEROPOSITIVE WOMEN; T-CELLS; IN-VIVO; CHILDREN; SUBPOPULATIONS; ADULTS; MICE	Background Infants with congenital thymic deficiency (the DiGeorge syndrome) have immunodeficiency and a characteristic pattern of low CD4+ and CD8+ T-lymphocyte counts and low CD5+ B-lymphocyte counts. Because the thymus is essential for the generation of CD4+ cells, we sought evidence of thymus dysfunction in infants infected perinatally with the human immunodeficiency virus (HIV). Methods We studied the immunophenotypes of 59 infants with maternally transmitted HIV, 5 infants with the DiGeorge syndrome, and 168 infants exposed to HIV but not infected. The criteria for a presumed thymic defect were reductions in both the CD4+ and CD8+ T-cell subgroups during the first six months of life that were confirmed in a subgroup of infants by low counts of CD4+CD45RA+ and CD4+CD45RO+ T cells and CD5+ B cells. Results Of the 59 HIV-infected infants, 17 had immunophenotypes similar to those of infants with the DiGeorge syndrome. The risks of the acquired immunodeficiency syndrome (AIDS) by the ages of 12 and 24 months were, respectively, 75 percent and 92 percent in these 17 infants, as compared with 14 and 34 percent in the other 42 infants (P<0.001). Nine of the HIV-infected infants with the DiGeorge-like immunophenotype (53 percent) died within six months of the progression to AIDS, as compared with only three of the other infants (7 percent, P=0.006). Conclusions In some infants infected perinatally with HIV, a pattern of lymphocyte depletion develops that resembles the pattern in congenital thymic deficiency. Since HIV disease progresses rapidly in such infants, they may be candidates for early antiviral therapy and attempts at immune reconstitution. (C)1996, Massachusetts Medical Society.	EMORY UNIV, DEPT PEDIAT, DIV INFECT DIS EPIDEMIOL & IMMUNOL, ATLANTA, GA 30303 USA	Emory University				Kourtis, Athena/0000-0003-1585-1310	NIAID NIH HHS [R01-AI32456, R01-AI39081] Funding Source: Medline; PHS HHS [U64-CCU404456-06] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039081, R01AI032456] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BASTIAN J, 1989, J PEDIATR-US, V115, P391, DOI 10.1016/S0022-3476(89)80837-6; BROSSARD Y, 1995, AIDS, V9, P359, DOI 10.1097/00002030-199509040-00007; CALABRO ML, 1995, AIDS RES HUM RETROV, V11, P11, DOI 10.1089/aid.1995.11.11; DeRossi A, 1996, J CLIN INVEST, V97, P323, DOI 10.1172/JCI118419; FREDERICK T, 1994, PEDIATR INFECT DIS J, V13, P1091, DOI 10.1097/00006454-199412000-00004; GREENBERG F, 1984, J PEDIATR, V115, P412; IBEGBU C, 1994, CLIN IMMUNOL IMMUNOP, V71, P27, DOI 10.1006/clin.1994.1047; IBEGBU C, 1992, ANN NY ACAD SCI, V651, P572; INABA M, 1995, EUR J IMMUNOL, V25, P1244, DOI 10.1002/eji.1830250517; ISAACSON PG, 1987, LANCET, V2, P1488; JOSHI VV, 1985, ARCH PATHOL LAB MED, V109, P142; KOLLMANN TR, 1995, J IMMUNOL, V154, P907; LANGSTON C, 1995, J INFECT DIS, V172, P1451, DOI 10.1093/infdis/172.6.1451; LEE FK, 1991, J CLIN IMMUNOL, V11, P213, DOI 10.1007/BF00917427; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; LI SL, 1995, J ACQ IMMUN DEF SYND, V9, P1; LIDINJANSSON G, 1994, PEDIATRICS, V94, P815; MACKALL CL, 1995, NEW ENGL J MED, V332, P143, DOI 10.1056/NEJM199501193320303; MARGOLICK JB, 1995, NAT MED, V1, P674, DOI 10.1038/nm0795-674; Mayaux MJ, 1996, JAMA-J AM MED ASSOC, V275, P606, DOI 10.1001/jama.275.8.606; NAHMIAS AJ, 1995, 1995 INT S CLIN IMM; NANGO K, 1991, CELL IMMUNOL, V133, P109, DOI 10.1016/0008-8749(91)90183-C; NESHEIM S, 1992, PEDIATR INFECT DIS J, V11, P635; Oxtoby MJ, 1994, PEDIATRIC AIDS CHALL, P3; Papaevangelou V, 1996, J INFECT DIS, V173, P574, DOI 10.1093/infdis/173.3.574; PAPIERNIK M, 1992, PEDIATRICS, V89, P297; ROSENZWEIG M, 1993, AIDS, V7, P1601, DOI 10.1097/00002030-199312000-00009; SCHNITTMAN SM, 1990, P NATL ACAD SCI USA, V87, P7727, DOI 10.1073/pnas.87.19.7727; SPITS H, 1995, BLOOD, V85, P2654, DOI 10.1182/blood.V85.10.2654.bloodjournal85102654; STANLEY SK, 1993, J EXP MED, V178, P1151, DOI 10.1084/jem.178.4.1151; SU L, 1995, IMMUNITY, V2, P25, DOI 10.1016/1074-7613(95)90076-4; TOVO PA, 1992, LANCET, V339, P1249, DOI 10.1016/0140-6736(92)91592-V; UITTENBOGAART C, 1995, INT C IMM SOC SAN FR; US Public Health Service, 1994, MMWR-MORBID MORTAL W, V43, P1; VALENTIN H, 1994, J VIROL, V68, P3041, DOI 10.1128/JVI.68.5.3041-3050.1994; 1995, MMWR-MORBID MORTAL W, V44, P1; 1994, MMWR-MORBID MORTAL W, V43, P1	37	154	155	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 7	1996	335	19					1431	1436		10.1056/NEJM199611073351904	http://dx.doi.org/10.1056/NEJM199611073351904			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT339	8875920				2022-12-24	WOS:A1996VT33900004
J	Beaglehole, R				Beaglehole, R			Garlic for flavour, not cardioprotection	LANCET			English	Editorial Material							METAANALYSIS; LIPIDS				Beaglehole, R (corresponding author), UNIV AUCKLAND,FAC MED & HLTH SCI,AUCKLAND 1,NEW ZEALAND.							JAIN AK, 1993, AM J MED, V94, P632, DOI 10.1016/0002-9343(93)90216-C; MINDELL E, 1994, GARLIC MIRACLE NUTR; Neil HAW, 1996, J ROY COLL PHYS LOND, V30, P329; SILAGY CA, 1994, J ROY COLL PHYS LOND, V28, P39; SILAGY CAS, 1994, J HYPERTENS, V12, P463; SIMONS LA, 1995, ATHEROSCLEROSIS, V113, P219, DOI 10.1016/0021-9150(94)05449-S; WARSHAFSKY S, 1993, ANN INTERN MED, V119, P599, DOI 10.7326/0003-4819-119-7_Part_1-199310010-00009	7	16	19	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 2	1996	348	9036					1186	1187		10.1016/S0140-6736(05)65477-3	http://dx.doi.org/10.1016/S0140-6736(05)65477-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ467	8898032				2022-12-24	WOS:A1996VQ46700005
J	Cox, JS; Walter, P				Cox, JS; Walter, P			A novel mechanism for regulating activity of a transcription factor that controls the unfolded protein response	CELL			English	Article							KAR2 BIP GENE; ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; TRANSMEMBRANE PROTEIN; SHUTTLE VECTORS; YEAST; DEGRADATION; UBIQUITIN; KINASE; INDUCTION	Cells respond to an accumulation of unfolded proteins in the endoplasmic reticulum (ER) by increasing transcription of genes encoding ER-resident proteins. The information is transmitted from the ER lumen to the nucleus by an intracellular signaling pathway, the unfolded protein response (UPR). We have identified a basic-leucine zipper transcription factor, Hac1p, that is required for the UPR and binds to the UPR element in the promoter of UPR-regulated genes. Surprisingly, Hac1p is found in UPR-activated cells only, and its level is controlled by regulated splicing of its mRNA. Splicing replaces the C-terminal tail of Hac1p with a different peptide that renders Hac1p more resistant to an otherwise extremely rapid ubiquitin-dependent degradation. We propose that the complex regulation of Hac1p expression serves to provide multiple levels at which the UPR can be controlled.			Cox, JS (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.		Longo, Kenneth A/A-5631-2010					BAIRN SB, 1985, MOL CELL BIOL, V5, P1839; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; EIBLE R, 1992, BIOTECHNIQUES, V13, P18; EINERHAND AWC, 1993, EUR J BIOCHEM, V214, P323, DOI 10.1111/j.1432-1033.1993.tb17927.x; ENGEBRECHT J, 1991, CELL, V66, P1257, DOI 10.1016/0092-8674(91)90047-3; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Harlow E, 1988, ANTIBODIES LAB MANUA; HE F, 1993, P NATL ACAD SCI USA, V90, P7034, DOI 10.1073/pnas.90.15.7034; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; KOHNO K, 1993, MOL CELL BIOL, V13, P877, DOI 10.1128/MCB.13.2.877; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; McMillan D. Randy, 1994, Current Opinion in Biotechnology, V5, P540, DOI 10.1016/0958-1669(94)90071-X; MORI K, 1992, EMBO J, V11, P2583, DOI 10.1002/j.1460-2075.1992.tb05323.x; MORI K, 1993, CELL, V74, P743; NIKAWA JI, 1992, MOL MICROBIOL, V6, P1441, DOI 10.1111/j.1365-2958.1992.tb00864.x; NOJIMA H, 1994, NUCLEIC ACIDS RES, V22, P5279, DOI 10.1093/nar/22.24.5279; Nunnari J, 1996, CELL, V84, P389, DOI 10.1016/S0092-8674(00)81283-0; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; Shamu Caroline E., 1994, Trends in Cell Biology, V4, P56, DOI 10.1016/0962-8924(94)90011-6; Shamu CE, 1996, EMBO J, V15, P3028, DOI 10.1002/j.1460-2075.1996.tb00666.x; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; STRATHERN JN, 1991, METHOD ENZYMOL, V194, P319; SWEET DJ, 1993, CURR BIOL, V3, P622, DOI 10.1016/0960-9822(93)90014-F	35	762	796	2	58	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 1	1996	87	3					391	404		10.1016/S0092-8674(00)81360-4	http://dx.doi.org/10.1016/S0092-8674(00)81360-4			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VQ466	8898193	Bronze			2022-12-24	WOS:A1996VQ46600006
J	Malashkevich, VN; Kammerer, RA; Efimov, VP; Schulthess, T; Engel, J				Malashkevich, VN; Kammerer, RA; Efimov, VP; Schulthess, T; Engel, J			The crystal structure of a five-stranded coiled coil in COMP: A prototype ion channel?	SCIENCE			English	Article							OLIGOMERIC MATRIX PROTEIN; CARTILAGE; PHOSPHOLAMBAN; THROMBOSPONDIN-4; RESIDUES; PROGRAM; DOMAIN	Oligomerization by the formation of alpha-helical bundles is common in many proteins. The crystal structure of a parallel pentameric coiled coil, constituting the oligomerization domain in the cartilage oligomeric matrix protein (COMP), was determined at 2.05 angstroms resolution. The same structure probably occurs in two other extracellular matrix proteins, thrombospondins 3 and 4. Complementary hydrophobic interactions and conserved disulfide bridges between the or helices result in a thermostable structure with unusual properties. The long hydrophobic axial pore is filled with water molecules but can also accommodate small apolar groups. An ''ion trap'' is formed inside the pore by a ring of conserved glutamines, which binds chloride and probably other monatomic anions. The oligomerization domain of COMP has marked similarities with proposed models of the pentameric transmembrane ion channels in phospholamban and the acetylcholine receptor.	UNIV BASEL,BIOZENTRUM,DEPT BIOPHYS CHEM,CH-4056 BASEL,SWITZERLAND	University of Basel	Malashkevich, VN (corresponding author), UNIV BASEL,BIOZENTRUM,DEPT BIOL STRUCT,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND.			Kammerer, Richard/0000-0003-4570-5197				ADAMS PD, 1995, NAT STRUCT BIOL, V2, P154, DOI 10.1038/nsb0295-154; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; ARKIN IT, 1995, J MOL BIOL, V248, P824, DOI 10.1006/jmbi.1995.0263; ARKIN IT, 1994, EMBO J, V13, P4757, DOI 10.1002/j.1460-2075.1994.tb06801.x; ATKINS PW, 1994, PHYSICAL CHEM; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P685, DOI 10.1107/S0365110X53001952; DICESARE PE, 1994, EUR J BIOCHEM, V223, P927, DOI 10.1111/j.1432-1033.1994.tb19070.x; EFIMOV VP, 1994, FEBS LETT, V341, P54, DOI 10.1016/0014-5793(94)80239-4; Efimov VP, 1996, PROTEINS, V24, P259, DOI 10.1002/(SICI)1097-0134(199602)24:2<259::AID-PROT13>3.0.CO;2-M; Fass D, 1996, NAT STRUCT BIOL, V3, P465, DOI 10.1038/nsb0596-465; HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HAUSER N, 1995, FEBS LETT, V368, P307, DOI 10.1016/0014-5793(95)00675-Y; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kajava AV, 1996, PROTEINS, V24, P218, DOI 10.1002/(SICI)1097-0134(199602)24:2<218::AID-PROT8>3.3.CO;2-I; KAMMERER R, UNPUB; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LABARCA C, 1995, NATURE, V376, P514, DOI 10.1038/376514a0; LAWLER J, 1995, J BIOL CHEM, V270, P2809, DOI 10.1074/jbc.270.6.2809; Leslie AGW, 1994, MOSFLM USERS GUIDE; LESTER HA, 1992, ANNU REV BIOPH BIOM, V21, P267, DOI 10.1146/annurev.bb.21.060192.001411; MORGELIN M, 1992, J BIOL CHEM, V267, P6137; NEWTON G, 1994, GENOMICS, V24, P435, DOI 10.1006/geno.1994.1649; QABAR A, 1995, J BIOL CHEM, V270, P12725, DOI 10.1074/jbc.270.21.12725; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TSCHOPP J, 1980, FEBS LETT, V112, P152, DOI 10.1016/0014-5793(80)80168-2; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0	31	263	280	2	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1996	274	5288					761	765		10.1126/science.274.5288.761	http://dx.doi.org/10.1126/science.274.5288.761			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ145	8864111				2022-12-24	WOS:A1996VQ14500036
J	SanMiguel, P; Tikhonov, A; Jin, YK; Motchoulskaia, N; Zakharov, D; MelakeBerhan, A; Springer, PS; Edwards, KJ; Lee, M; Avramova, Z; Bennetzen, JL				SanMiguel, P; Tikhonov, A; Jin, YK; Motchoulskaia, N; Zakharov, D; MelakeBerhan, A; Springer, PS; Edwards, KJ; Lee, M; Avramova, Z; Bennetzen, JL			Nested retrotransposons in the intergenic regions of the maize genome	SCIENCE			English	Article							ZEA-MAYS; TRANSPOSABLE ELEMENTS; REPETITIVE SEQUENCES; GENES; DNA; FAMILY; ORGANIZATION; RETROELEMENTS; EVOLUTION; PLANTS	The relative organization of genes and repetitive DNAs in complex eukaryotic genomes is not well understood. Diagnostic sequencing indicated that a 280-kilobase region containing the maize Adh1-F and u22 genes is composed primarily of retrotransposons inserted within each other. Ten retroelement families were discovered, with reiteration frequencies ranging from 10 to 30,000 copies per haploid genome, These retrotransposons accounted for more than 60 percent of the Adh1-F region and at least 50 percent of the nuclear DNA of maize. These elements were largely intact and are dispersed throughout the gene-containing regions of the maize genome.	PURDUE UNIV, DEPT BIOL SCI, W LAFAYETTE, IN 47907 USA; UNIV BRISTOL, LONG ASHTON RES STN, BRISTOL BS18 9AF, AVON, ENGLAND	Purdue University System; Purdue University; Purdue University West Lafayette Campus; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of Bristol			SanMiguel, Phillip J/I-2196-2015; Tikhonov, Alexander/I-1453-2012	SanMiguel, Phillip J/0000-0002-3742-9527; Tikhonov, Alexander/0000-0003-3808-9701				ABLER ML, 1993, PLANT MOL BIOL, V22, P1031, DOI 10.1007/BF00028975; ALLEN RL, 1993, PLANT J, V3, P261, DOI 10.1046/j.1365-313X.1993.t01-14-00999.x; Arumuganathan K., 1991, PLANT MOL BIOL REP, V9, P208, DOI [10.1007/BF02672069, DOI 10.1007/BF02672069]; AVRAMOVA Z, 1995, PLANT CELL, V7, P1667, DOI 10.1105/tpc.7.10.1667; AVRAMOVA Z, IN PRESS PLANT J; Bennetzen JL, 1996, TRENDS MICROBIOL, V4, P347, DOI 10.1016/0966-842X(96)10042-1; BENNETZEN JL, 1994, GENOME, V37, P565, DOI 10.1139/g94-081; CRESSE AD, 1995, GENETICS, V140, P315; DEININGER PL, 1993, EVOL BIOL, V27, P157; Edwards KJ, 1996, GENOME, V39, P811, DOI 10.1139/g96-102; FLAVELL RB, 1974, BIOCHEM GENET, V12, P257, DOI 10.1007/BF00485947; GATTI M, 1992, ANNU REV GENET, V26, P239, DOI 10.1146/annurev.ge.26.120192.001323; GRANDBASTIEN MA, 1992, TRENDS GENET, V8, P103, DOI 10.1016/0168-9525(92)90198-D; GUPTA M, 1984, EMBO J, V3, P133, DOI 10.1002/j.1460-2075.1984.tb01773.x; HAKE S, 1980, CHROMOSOMA, V79, P251, DOI 10.1007/BF00327318; HU WM, 1995, MOL GEN GENET, V248, P471, DOI 10.1007/BF02191647; KERSANACH R, 1994, NATURE, V367, P387, DOI 10.1038/367387a0; KIRIHARA JA, 1988, GENE, V71, P359, DOI 10.1016/0378-1119(88)90053-4; KRIZ AL, 1987, MOL GEN GENET, V207, P90, DOI 10.1007/BF00331495; LEVIN HL, 1995, MOL CELL BIOL, V15, P3310; MONTOLIU L, 1990, PLANT MOL BIOL, V14, P1, DOI 10.1007/BF00015650; QUAYLE TJA, 1989, GENE, V80, P249, DOI 10.1016/0378-1119(89)90289-8; SANMIGUEL P, UNPUB; SMIT AFA, 1993, NUCLEIC ACIDS RES, V21, P1863, DOI 10.1093/nar/21.8.1863; SMIT AFA, 1995, J MOL BIOL, V246, P401, DOI 10.1006/jmbi.1994.0095; SPRINGER PS, 1994, P NATL ACAD SCI USA, V91, P863, DOI 10.1073/pnas.91.3.863; Turcich MP, 1996, SEX PLANT REPROD, V9, P65, DOI 10.1007/BF02153053; WESSLER SR, 1995, CURR OPIN GENET DEV, V5, P814, DOI 10.1016/0959-437X(95)80016-X	29	1076	1146	1	76	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 1	1996	274	5288					765	768		10.1126/science.274.5288.765	http://dx.doi.org/10.1126/science.274.5288.765			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ145	8864112				2022-12-24	WOS:A1996VQ14500037
J	Luo, D; Carpenter, R; Vincent, C; Copsey, L; Coen, E				Luo, D; Carpenter, R; Vincent, C; Copsey, L; Coen, E			Origin of floral asymmetry in Antirrhinum	NATURE			English	Article							FLOWER DEVELOPMENT; HOMEOTIC GENES; MAJUS; TRANSPOSON; ELEMENT	Dorsoventral asymmetry in flowers is thought to have evolved many times from a radially symmetrical ancestral condition. The first gene controlling floral asymmetry, cycloidea in Antirrhinum, has been isolated. The cycloidea gene is expressed at a very early stage in dorsal regions of floral meristems, where it affects growth rate and primordium initiation. Expression continues through to later stages in dorsal primordia to affect the asymmetry, size and cell types of petals and stamens.	JOHN INNES CTR PLANT SCI RES,DEPT GENET,NORWICH NR4 7UH,NORFOLK,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center								BONAS U, 1984, EMBO J, V3, P1015, DOI 10.1002/j.1460-2075.1984.tb01921.x; BRADLEY D, 1993, CELL, V72, P85, DOI 10.1016/0092-8674(93)90052-R; Carpenter R, 1995, PLANT CELL, V7, P2001, DOI 10.1105/tpc.7.12.2001; CARPENTER R, 1990, GENE DEV, V4, P1483, DOI 10.1101/gad.4.9.1483; CARPENTER R, 1987, MOL GEN GENET, V207, P82, DOI 10.1007/BF00331494; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; COEN ES, 1991, ANNU REV PLANT PHYS, V42, P241, DOI 10.1146/annurev.pp.42.060191.001325; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; COEN ES, 1994, DEVELOPMENT, P107; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Hammer K., 1990, Kulturpflanze, V38, P91; KREBBERS E, 1987, MOL GEN GENET, V209, P499, DOI 10.1007/BF00331156; KUCKUCK H, 1930, Z IND ABST VER, V56, P51; LINNAEUS C, 1749, THESIS UPPSALA; LUO D, 1991, PLANT J, V1, P59, DOI 10.1111/j.1365-313X.1991.00059.x; Running MP, 1996, DEVELOPMENT, V122, P1261; SIMON R, 1994, CELL, V78, P99, DOI 10.1016/0092-8674(94)90576-2; SOMER H, 1988, PLANT TRANSPOSABLE E, P227; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x; STUBBE H, 1966, GENETIK ZYTOLOGIE AN; Tucker SC, 1984, CONT PROBLEMS PLANT, P351; Vincent CA, 1995, CURR BIOL, V5, P1449, DOI 10.1016/S0960-9822(95)00282-X; WEIGEL D, 1994, CELL, V78, P203, DOI 10.1016/0092-8674(94)90291-7	23	551	637	10	122	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 31	1996	383	6603					794	799		10.1038/383794a0	http://dx.doi.org/10.1038/383794a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ144	8893002				2022-12-24	WOS:A1996VQ14400054
J	Gardina, PJ; Manson, MD				Gardina, PJ; Manson, MD			Attractant signaling by an aspartate chemoreceptor dimer with a single cytoplasmic domain	SCIENCE			English	Article							DIRECTED CROSS-LINKING; LIGAND-BINDING DOMAIN; ESCHERICHIA-COLI; RECEPTOR; CHEMOTAXIS; DIMERIZATION; TRANSDUCTION; CELL	Signal transduction across cell membranes often involves interactions among identical receptor subunits, but the contribution of individual subunits is not well understood. The chemoreceptors of enteric bacteria med late attractant responses by interrupting a phosphotransfer circuit initiated at receptor complexes with the protein kinase CheA. The aspartate receptor (Tar) is a homodimer, and oligomerized cytoplasmic domains stimulate CheA activity much more than monomers do in vitro. Intragenic complementation was used to show in Escherichia coli that heterodimers containing one full-length acid one truncated Tar subunit mediated responses to aspartate in the presence of full-length Tar homodimers that could not bind aspartate. Thus, a Tar dimer containing only one cytoplasmic domain can initiate an attractant (inhibitory) signal, although it may not be able to stimulate kinase activity of CheA.	TEXAS A&M UNIV,DEPT BIOL,COLLEGE STN,TX 77840	Texas A&M University System; Texas A&M University College Station					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039736] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39736] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIEMANN HP, 1994, BIOCHEMISTRY-US, V33, P629, DOI 10.1021/bi00169a002; BOURRET R, UNPUB; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; Cochran AG, 1996, SCIENCE, V271, P1113, DOI 10.1126/science.271.5252.1113; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DANIELSON MA, 1994, BIOCHEMISTRY-US, V33, P6100, DOI 10.1021/bi00186a009; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; GARDINA P, 1992, J BACTERIOL, V174, P528; GARDINA P, UNPUB; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; KRIKOS A, 1983, CELL, V33, P615, DOI 10.1016/0092-8674(83)90442-7; LEE GF, 1995, P NATL ACAD SCI USA, V92, P3391, DOI 10.1073/pnas.92.8.3391; LEE L, 1990, J BACTERIOL, V172, P377, DOI 10.1128/JB.172.1.377-382.1990; MADDOCK JR, 1993, SCIENCE, V259, P1717; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MILLIGAN DL, 1991, SCIENCE, V254, P1651, DOI 10.1126/science.1661030; OOSAWA K, 1988, J BACTERIOL, V170, P1326; PARKINSON JS, 1978, J BACTERIOL, V135, P45, DOI 10.1128/JB.135.1.45-53.1978; STOCK JB, 1996, CELLULAR MOL BIOL, P1103; Tatsuno I, 1996, SCIENCE, V274, P423, DOI 10.1126/science.274.5286.423; WOLFE AJ, 1994, J BACTERIOL, V176, P483; YANG Y, 1993, J MOL BIOL, V232, P493, DOI 10.1006/jmbi.1993.1405; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035	25	81	81	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1996	274	5286					425	426		10.1126/science.274.5286.425	http://dx.doi.org/10.1126/science.274.5286.425			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN173	8832892				2022-12-24	WOS:A1996VN17300055
J	Clower, DM; Hoffman, JM; Votaw, JR; Faber, TL; Woods, RP; Alexander, GE				Clower, DM; Hoffman, JM; Votaw, JR; Faber, TL; Woods, RP; Alexander, GE			Role of posterior parietal cortex in the recalibration of visually guided reaching	NATURE			English	Article							POSITRON EMISSION TOMOGRAPHY; AUTOMATED ALGORITHM; FUNCTIONAL-ANATOMY; ATTENTION; PET; MOVEMENTS; MECHANISMS; AREAS	VISUALLY guided reaching requires complex neural transformations to link visual and proprioceptive inputs with appropriate motor outputs(1,2). Despite the complexity of these transformations, hand-eye coordination in humans is remarkably flexible, as demonstrated by the ease with which reaching can be adapted to distortions in visual feedback. If subjects attempt to reach to visual targets while searing displacing prisms, they initially misreach in the direction of, visual displacement. Given feedback about their reaching errors, however, they quickly adapt to the visual distortion. This is shown by the gradual resumption of accurate reaching while the prisms remain in place, and by the immediate onset of reaching errors in the opposite direction after the prisms have been removed. Despite an abundance of psychophysical data on adaptation to prisms, the functional localization of this form of sensorimotor adaptation is uncertain, Here we use positron emission tomography (PET) to localize changes in regional cerebral blood flow (rCBF) in subjects who performed a prism-adaptation task as well as a task that controlled for the sensory, motor and cognitive conditions of the adaptation experiment. Difference images that reflected the net effects of the adaptation process showed selective activation of posterior parietal cortex contralateral to the reaching limb.	EMORY UNIV,SCH MED,DEPT NEUROL,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT RADIOL,ATLANTA,GA 30322; UNIV CALIF LOS ANGELES,SCH MED,DIV BRAIN MAPPING,LOS ANGELES,CA 90095	Emory University; Emory University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								BAILY JS, 1972, Q J EXP PSYCHOL, V24, P8, DOI 10.1080/14640747208400261; BECKETT PA, 1980, J EXP PSYCHOL HUMAN, V6, P433, DOI 10.1037/0096-1523.6.3.433; BONDA E, 1995, P NATL ACAD SCI USA, V92, P11180, DOI 10.1073/pnas.92.24.11180; CHOE CS, 1974, J EXP PSYCHOL, V102, P1076, DOI 10.1037/h0036325; COLBY CL, 1993, J NEUROPHYSIOL, V69, P902, DOI 10.1152/jn.1993.69.3.902; CORBETTA M, 1995, SCIENCE, V270, P802, DOI 10.1126/science.270.5237.802; CORBETTA M, 1993, J NEUROSCI, V13, P1202; DEIBER MP, 1991, EXP BRAIN RES, V84, P393; EIDELBERG D, 1984, ARCH NEUROL-CHICAGO, V41, P843, DOI 10.1001/archneur.1984.04050190049013; Friston K J, 1994, Hum Brain Mapp, V1, P210, DOI 10.1002/hbm.460010306; GEORGOPOULOS AP, 1991, ANNU REV NEUROSCI, V14, P361, DOI 10.1146/annurev.ne.14.030191.002045; GRAFTON ST, 1992, BRAIN, V115, P565, DOI 10.1093/brain/115.2.565; KALASKA JF, 1992, SCIENCE, V255, P1517, DOI 10.1126/science.1549781; KAWASHIMA R, 1994, J NEUROSCI, V14, P3462; Neter J, 1990, APPL LINEAR STAT MOD; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; PARSONS LM, 1995, NATURE, V375, P54, DOI 10.1038/375054a0; PERENIN MT, 1988, BRAIN, V111, P643, DOI 10.1093/brain/111.3.643; REDDING GM, 1985, COGNITIVE PSYCHOL, V17, P1, DOI 10.1016/0010-0285(85)90002-7; REDDING GM, 1988, PERCEPT PSYCHOPHYS, V44, P59, DOI 10.3758/BF03207476; SELTZER B, 1980, BRAIN RES, V192, P339, DOI 10.1016/0006-8993(80)90888-4; STEPHAN KM, 1995, J NEUROPHYSIOL, V73, P373, DOI 10.1152/jn.1995.73.1.373; Talairach J., 1988, COPLANAR STEREOTAXIC; THACH WT, 1992, ANNU REV NEUROSCI, V15, P403, DOI 10.1146/annurev.neuro.15.1.403; WELCH RB, 1974, J EXP PSYCHOL, V103, P700, DOI 10.1037/h0037152; WILKINSON DA, 1971, J EXP PSYCHOL, V89, P250, DOI 10.1037/h0031162; Woods R. P., 1996, QUANTIFICATION BRAIN, P353, DOI [10.1016/B978-012389760-2/50070-0, DOI 10.1016/B978-012389760-2/50070-0]; WOODS RP, 1993, J COMPUT ASSIST TOMO, V17, P536, DOI 10.1097/00004728-199307000-00004; WOODS RP, 1992, J COMPUT ASSIST TOMO, V16, P620, DOI 10.1097/00004728-199207000-00024; [No title captured]	30	324	326	0	23	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1996	383	6601					618	621		10.1038/383618a0	http://dx.doi.org/10.1038/383618a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM755	8857536				2022-12-24	WOS:A1996VM75500052
J	Teng, SC; Kim, B; Gabriel, A				Teng, SC; Kim, B; Gabriel, A			Retrotransposon reverse-transcriptase-mediated repair of chromosomal breaks	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; CRITHIDIA-FASCICULATA; TY1; RECOMBINATION; ELEMENT; RNA; TRANSPOSITION; LOCUS; YEAST; SITE	THE abundance of short and long interspersed nuclear sequences (SINEs and LINEs) and pseudogenes in eukaryotic genomes indicates that reverse transcriptase (RT)-mediated phenomena are important in genome evolution. However, the mechanisms involved in their spread are largely unknown. We have developed a selection system in the yeast Saccharomyces cerevisiae to test whether RT-mediated events could be linked to the repair of double-strand breaks (DSBs). Here we show that DSBs can be fixed by the insertion of complementary DNAs at the break site. In the presence of functional RT (from human L1, yeast Ty1 or Crithidia CRE1), and in the absence of homologous recombination, an HO endonuclease-induced DSB at the mating type (MAT) locus is the primary site at which a marked cDNA is observed among surviving cells. The structure and junctional sequences of these insertions suggest that repair occurs primarily by nonhomologous recombination. Our data support a role for endogenous retroelements in the repair of chromosomal breaks.			Teng, SC (corresponding author), RUTGERS STATE UNIV,DEPT MOL BIOL & BIOCHEM,PISCATAWAY,NJ 08855, USA.			TENG, SHU-CHUN/0000-0002-6492-2560				BOEKE JD, 1988, SCIENCE, V239, P280, DOI 10.1126/science.2827308; BOEKE JD, 1985, CELL, V40, P491, DOI 10.1016/0092-8674(85)90197-7; Broach J.R., 1992, MOL CELLULAR BIOL SA, P583; CURCIO MJ, 1994, GENETICS, V136, P1245; CURCIO MJ, 1991, P NATL ACAD SCI USA, V88, P936, DOI 10.1073/pnas.88.3.936; DERR LK, 1993, NATURE, V361, P170, DOI 10.1038/361170a0; DERR LK, 1991, CELL, V67, P355, DOI 10.1016/0092-8674(91)90187-4; DOMBROSKI BA, 1994, MOL CELL BIOL, V14, P4485, DOI 10.1128/MCB.14.7.4485; GABRIEL A, 1991, P NATL ACAD SCI USA, V88, P9794, DOI 10.1073/pnas.88.21.9794; GABRIEL A, 1990, MOL CELL BIOL, V10, P615, DOI 10.1128/MCB.10.2.615; George JA, 1996, GENETICS, V142, P853; GLETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425; HABER JE, 1995, BIOESSAYS, V17, P609, DOI 10.1002/bies.950170707; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; MATHIAS SL, 1991, SCIENCE, V254, P1808, DOI 10.1126/science.1722352; MONOKIAN GM, 1994, GENE, V139, P9, DOI 10.1016/0378-1119(94)90517-7; Moore JK, 1996, NATURE, V383, P644, DOI 10.1038/383644a0; Moore JK, 1996, MOL CELL BIOL, V16, P2164, DOI 10.1128/mcb.16.5.2164; Nissley DV, 1996, NATURE, V380, P30, DOI 10.1038/380030a0; Roth D., 1988, GENETIC RECOMBINATIO, P621; SHARON G, 1994, MOL CELL BIOL, V14, P6540, DOI 10.1128/MCB.14.10.6540; SHEEN FM, 1994, P NATL ACAD SCI USA, V91, P12510, DOI 10.1073/pnas.91.26.12510; ZIMMERLY S, 1995, CELL, V82, P545, DOI 10.1016/0092-8674(95)90027-6; ZOU S, 1995, P NATL ACAD SCI USA, V92, P920, DOI 10.1073/pnas.92.3.920; [No title captured]	25	199	205	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1996	383	6601					641	644		10.1038/383641a0	http://dx.doi.org/10.1038/383641a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM755	8857543				2022-12-24	WOS:A1996VM75500059
J	ONeill, P; Kelly, P				ONeill, P; Kelly, P			Postal questionnaire study of disability in the community associated with psoriasis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEALTH SURVEY QUESTIONNAIRE; OUTCOME MEASURE; SF-36; SMOKING; INDEX	Objective-To study the disability caused by psoriasis in patients recorded as having psoriasis by their general practitioner, Design-Postal questionnaire survey using the psoriasis disability index and SF-36. Setting-Five general practices in Cleveland. Subjects-Of 767 patients identified, 546 completed the questionnaire and 435 were eligible and gave informed consent. Main outcome measures-scores on SF-36 and psoriasis disability index. Results-The psoriasis disability index score was highly negatively correlated with all eight of the SF-36 health measures (P<0.0001 for each), and the manual social classes scored higher than the non-manual social classes (P<0.0001). The manual social class group scored significantly lower scores than the controls on all the SF-36 scales, and the non-manual group scored significantly lower for physical and mental role limitation (P<0.0004 and P=0.026), mental health (P<0.0001), energy and vitality (P<0.0004), and health perception (P<0.0001). Also, the manual group had poorer health perception on five of the SF-36 variables when compared with the non-manual group. Conclusions-Patients with psoriasis have an overall lower perception of their quality of life than healthy controls, and those in the lower social classes suffer a greater degree of disability from their disease than the higher social classes.	UNIV TEESSIDE, CTR HLTH & MED RES, MIDDLESBROUGH TS1 3BA, CLEVELAND, ENGLAND	University of Teesside	ONeill, P (corresponding author), NORTON MED CTR, STOCKTON ON TEES TS20 1AN, ENGLAND.							BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; FINLAY AY, 1990, BRIT J DERMATOL, V123, P751, DOI 10.1111/j.1365-2133.1990.tb04192.x; FINLAY AY, 1995, BRIT MED J, V310, P1673, DOI 10.1136/bmj.310.6995.1673; FINLAY AY, 1987, CLIN EXP DERMATOL, V12, P8, DOI 10.1111/j.1365-2230.1987.tb01844.x; FINLAY AY, 1995, BRIT J DERMATOL, V132, P236; GARRATT AM, 1993, BMJ-BRIT MED J, V306, P1440, DOI 10.1136/bmj.306.6890.1440; HIGGINS EM, 1994, BRIT MED J, V308, P1572, DOI 10.1136/bmj.308.6943.1572c; HUNTER JAA, 1989, CLIN DERMATOL, P2; JENKINSON C, 1993, BRIT MED J, V306, P1437, DOI 10.1136/bmj.306.6890.1437; JOBLING RG, 1976, CLIN EXP DERMATOL, V1, P233, DOI 10.1111/j.1365-2230.1976.tb01424.x; LYONS RA, 1995, J PUBLIC HEALTH MED, V17, P46; REA JN, 1976, BRIT J PREV SOC MED, V30, P107; STANKLER L, 1981, CLIN EXP DERMATOL, V6, P303, DOI 10.1111/j.1365-2230.1981.tb02308.x; WEINGARTEN S, 1995, BRIT MED J, V310, P1076, DOI 10.1136/bmj.310.6986.1076a; WILLIAMS HC, 1994, BMJ-BRIT MED J, V308, P428, DOI 10.1136/bmj.308.6926.428	15	65	65	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 12	1996	313	7062					919	921						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM754	8876097				2022-12-24	WOS:A1996VM75400028
J	Schubart, DB; Rolink, A; KoscoVilbois, MH; Botteri, F; Matthias, P				Schubart, DB; Rolink, A; KoscoVilbois, MH; Botteri, F; Matthias, P			B-cell-specific coactivator OBF-1/OCA-B/Bob1 required for immune response and germinal centre formation	NATURE			English	Article							BINDING TRANSCRIPTION FACTORS; IMMUNOGLOBULIN GENES; PROMOTER ACTIVITY; PROTEIN; OCT-2; MICE; ACTIVATION; EXPRESSION; MECHANISM; DEFICIENT	THE B-lymphocyte-specific transcriptional factor called Oct binding factor (OBF)-1, OCA-B or Bob1 (refs 13) is thought to be involved in the transcription of immunoglobulin genes through recruitment to the highly conserved octamer site of immunoglobulin promoters, mediated by either Oct-1 or Oct-2. To define the in vivo role of OBP-1 we have used gene targeting in embryonic stem cells to generate mice lacking the coactivator OBP-1. Such OBF-1(-/-) mice are born normally, are fertile and seem healthy, and surprisingly, rearrangement and transcription of immunoglobulin genes are largely unaffected. However, mice deficient in OBF-1 have reduced numbers of mature B cells and a severe reduction in the number of recirculating B cells, but otherwise show normal B-cell differentiation. Serum IgA and particularly IgG levels are greatly reduced. If mutant mice are immunized with either a thymus-independent or a thymus-dependent antigen, their immune responses are dramatically weakened. Strikingly, germinal centres completely fail to develop after immunization with thymus-dependent antigen. Our results demonstrate that in vivo OBF-1 is not required for initial transcription of immunoglobulin genes or for B cell development, but instead is essential for the response of B cells to antigens, and is required for the formation of germinal centres.	FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND; BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND; GLAXO INST MOL BIOL SA,CH-1228 PLAN LES OUATES,SWITZERLAND	Friedrich Miescher Institute for Biomedical Research; GlaxoSmithKline			Schubart, Daniel/AAV-6487-2021	Schubart, Daniel/0000-0002-8069-0122				Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; CASTIGLI E, 1994, P NATL ACAD SCI USA, V91, P12135, DOI 10.1073/pnas.91.25.12135; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; CORCORAN LM, 1994, IMMUNITY, V1, P635, DOI 10.1016/1074-7613(94)90035-3; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; DREYFUS M, 1987, EMBO J, V6, P1685, DOI 10.1002/j.1460-2075.1987.tb02418.x; FELDHAUS AL, 1993, EMBO J, V12, P2763, DOI 10.1002/j.1460-2075.1993.tb05937.x; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; HUMPHREY JH, 1984, EUR J IMMUNOL, V14, P859, DOI 10.1002/eji.1830140916; JENUWEIN T, 1991, GENE DEV, V5, P932, DOI 10.1101/gad.5.6.932; Kelsoe G, 1996, IMMUNITY, V4, P107, DOI 10.1016/S1074-7613(00)80675-5; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; LUO Y, 1995, MOL CELL BIOL, V15, P4115; MASON JO, 1985, CELL, V41, P479, DOI 10.1016/S0092-8674(85)80021-0; MIZUSHIMASUGANO J, 1986, P NATL ACAD SCI USA, V83, P8511, DOI 10.1073/pnas.83.22.8511; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; PFISTERER P, 1994, EMBO J, V13, P1655; ROLINK A, 1994, INT IMMUNOL, V6, P1257, DOI 10.1093/intimm/6.8.1257; ROLINK A, 1995, IMMUNOLOGIST, V3, P125; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; Schubart DB, 1996, NUCLEIC ACIDS RES, V24, P1913, DOI 10.1093/nar/24.10.1913; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; STREF A, 1994, J IMMUNOL, V152, P3378; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; WOOD SA, 1993, P NATL ACAD SCI USA, V90, P4582, DOI 10.1073/pnas.90.10.4582; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6	30	238	242	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1996	383	6600					538	542		10.1038/383538a0	http://dx.doi.org/10.1038/383538a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL755	8849727				2022-12-24	WOS:A1996VL75500054
J	Jory, WC				Jory, WC			Refractive surgery	LANCET			English	Editorial Material											Jory, WC (corresponding author), LONDON CTR REFRACT SURG,LONDON W1N 1PD,ENGLAND.							CHOYCE DP, 1996, AM SOC CAT REFR SURG; GARTRY DS, 1995, BRIT MED J, V310, P979, DOI 10.1136/bmj.310.6985.979; JORY W, 1995, EUR J IMPLANT REFRAC, V7, P17; KRIEGEROWSKI M, 1996, AM SOC CAT REF SURG; ROBIN JB, 1991, REFRACT CORNEAL SURG, V1, P112; ROSEN ES, 1994, EUR J IMPLANT REF SU, V6, P309; *ROYAL COL OPHTH, 1995, EXC LAS PHOT KER BES; WILLIAMS DK, 1966, UK IR SOC CAT REF SU	8	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 5	1996	348	9032					904	905		10.1016/S0140-6736(05)65332-9	http://dx.doi.org/10.1016/S0140-6736(05)65332-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL097	8843803				2022-12-24	WOS:A1996VL09700003
J	Olson, BR; Forman, MR; Lanza, E; McAdam, PA; Beecher, G; Kimzey, LM; Campbell, WS; Raymond, EG; Brentzel, SL; GuttschesEbeling, B				Olson, BR; Forman, MR; Lanza, E; McAdam, PA; Beecher, G; Kimzey, LM; Campbell, WS; Raymond, EG; Brentzel, SL; GuttschesEbeling, B			Relation between sodium balance and menstrual cycle symptoms in normal women	ANNALS OF INTERNAL MEDICINE			English	Article							PREMENSTRUAL-SYNDROME; ALDOSTERONE; PROGESTERONE; VASOPRESSIN; PREGNANCY	Objective: To determine whether sodium balance affects expression of menstrual symptoms. Design: Prospective study of menstrual symptoms during three cycles: a baseline month (usual intake of sodium, 115 mmol/d) followed by 2 months of sodium restriction (intake of sodium, 73.0 mmol/d). Added salt was allowed during the last month, Investigators were aware of the diet sequence. Setting: Outpatient. Meals were prepared by a metabolic kitchen during the 2 months that the participants received salt-restricted diets. Participants: 13 healthy menstruant women. Measurements: Plasma sodium levels, urinary sodium excretion, and plasma renin activity were measured for five time periods during the baseline cycle and the two cycles of salt-restricted diet. Eleven women completed a questionnaire assessing somatic symptoms and sensory cravings at the same time every day during the 3-month study period. Results: Sodium restriction was associated with a mean decrease (+/- one half of the 95% CI) in plasma sodium levels of 0.9 +/- 0.9 mmol/L from a mean of 139.3 mmol/L during the baseline cycle (P = 0.018), a decrease in urinary sodium excretion of 40.3 +/- 18 mmol/d from a mean of 117 mmol/d during the baseline cycle (P = 0.001), and an increase in plasma renin activity of 0.14 +/- 0.08 ng/(L - s) from a mean of 0.28 ng/(L s) during the baseline cycle (P = 0.008). During the luteal phase of the sodium restriction cycle, significant decreases in plasma sodium levels of 1.23 +/- 0.5 mmol/L (from values of 138.8 mmol/L during the follicular phase) and increases in urinary sodium excretion of 27.2 +/- 10 mmol/d (from values of 65.5 mmol/d during the follicular phase) preceded periods when menstrual symptoms were most severe. Ratings of breast tenderness increased sixfold to eightfold in the late luteal phase (P < 0.001) and those of swelling or bloating increased twofold to threefold during early menses (P < 0.001) compared with nadir symptom ratings during each cycle. Sodium cravings increased in the luteal phase of all cycles but were not accompanied by increased sodium intake when access to added salt was allowed. Conclusions: Breast tenderness and bloating did not result from sodium retention in the luteal phase of the menstrual cycle. During normal and sodium-restricted diet cycles, women actually had urinary sodium loss, not retention, during the luteal phase; severity of menstrual symptoms was unchanged.	USDA, BELTSVILLE, MD 20705 USA; NCI, NIH, BETHESDA, MD 20892 USA	United States Department of Agriculture (USDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								DAVISON JM, 1988, J CLIN INVEST, V81, P798, DOI 10.1172/JCI113386; FROLICH M, 1976, ACTA ENDOCRINOL-COP, V81, P548, DOI 10.1530/acta.0.0810548; FRYE CA, 1994, PHYSIOL BEHAV, V55, P193, DOI 10.1016/0031-9384(94)90031-0; HALBREICH U, 1985, CAN J PSYCHIAT, V30, P489, DOI 10.1177/070674378503000706; KATZ FH, 1972, J CLIN ENDOCR METAB, V34, P819, DOI 10.1210/jcem-34-5-819; LANDAU RL, 1958, J CLIN ENDOCR METAB, V18, P1237, DOI 10.1210/jcem-18-11-1237; MICHELAKIS AM, 1975, AM J OBSTET GYNECOL, V123, P724, DOI 10.1016/0002-9378(75)90495-0; MUNDAY MR, 1981, CLIN ENDOCRINOL, V14, P1, DOI 10.1111/j.1365-2265.1981.tb00359.x; OBRIEN PMS, 1979, BRIT J OBSTET GYNAEC, V86, P142; RUBINOW DR, 1984, AM J PSYCHIAT, V141, P684; SAGNELLA GA, 1989, AM J PHYSIOL, V256, pR1171, DOI 10.1152/ajpregu.1989.256.6.R1171; SCHMIDT PJ, 1991, NEW ENGL J MED, V324, P1174, DOI 10.1056/NEJM199104253241705; Schnurr PP, 1989, PSYCHOL ASSESSMENT, V1, P277; SMEATON TC, 1977, J CLIN ENDOCR METAB, V44, P1; SPRUCE BA, 1985, CLIN ENDOCRINOL, V22, P37, DOI 10.1111/j.1365-2265.1985.tb01062.x; STEINER M, 1980, ACTA PSYCHIAT SCAND, V62, P177, DOI 10.1111/j.1600-0447.1980.tb00605.x; SUNDSFJORD JA, 1970, ACTA ENDOCRINOL-COP, V64, P452, DOI 10.1530/acta.0.0640452; THOMPSON CJ, 1988, CLIN ENDOCRINOL, V28, P629, DOI 10.1111/j.1365-2265.1988.tb00237.x; VOKES TJ, 1988, AM J PHYSIOL, V254, pR641, DOI 10.1152/ajpregu.1988.254.4.R641; WHIPP GT, 1978, AUST J EXP BIOL MED, V56, P545, DOI 10.1038/icb.1978.60	20	25	27	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1996	125	7					564	567		10.7326/0003-4819-125-7-199610010-00005	http://dx.doi.org/10.7326/0003-4819-125-7-199610010-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VJ653	8815755				2022-12-24	WOS:A1996VJ65300005
J	He, S; Cavanagh, P; Intriligator, J				He, S; Cavanagh, P; Intriligator, J			Attentional resolution and the locus of visual awareness	NATURE			English	Article							LATERAL MASKING; CORTEX; OBJECTS; HUMANS; FIELDS	VISUAL spatial resolution is limited by factors ranging from optics to neuronal filters in the visual cortex(1,2), but it is not known to what extent it is also limited by the resolving pow er of attention. To investigate this, we studied adaptation to lines of specific orientation, a process that occurs in primary visual cortex(3). When a single grating is presented in the periphery of the visual field, human observers are aware of its orientation, but when it is flanked by other similar gratings ('crowding'), its orientation becomes impossible to discern(4,5). Nevertheless, we show that orientation-specific adaptation is not affected by crowding, implying that spatial resolution is limited by an attentional filter acting beyond the primary visual cortex. Consistent with this, we find that attentional resolution is greater in the lower than in the upper visual field, whereas there is no corresponding asymmetry in the primary visual cortex. We suggest that the attentional filter acts in one or more higher visual cortical areas to restrict the availability of visual information to conscious awareness(6).			He, S (corresponding author), HARVARD UNIV,DEPT PSYCHOL,33 KIRKLAND ST,CAMBRIDGE,MA 02138, USA.							BLAKEMORE C, 1969, J PHYSIOL-LONDON, V203, P237, DOI 10.1113/jphysiol.1969.sp008862; BOUMA H, 1970, NATURE, V226, P177, DOI 10.1038/226177a0; BUTLER BE, 1986, PSYCHOL RES-PSYCH FO, V48, P201, DOI 10.1007/BF00309084; CAMPBELL FW, 1966, J PHYSIOL-LONDON, V186, P558, DOI 10.1113/jphysiol.1966.sp008056; CHAMBERS L, 1983, B PSYCHONOMIC SOC, V21, P459, DOI 10.3758/BF03330008; CHASTAIN G, 1983, PSYCHOL RES-PSYCH FO, V45, P147, DOI 10.1007/BF00308666; CHRISTMAN SD, 1993, B PSYCHONOMIC SOC, V31, P275; CRICK F, 1995, NATURE, V375, P121, DOI 10.1038/375121a0; DEYOE EA, 1988, P NATL ACAD SCI USA, V93, P2382; GAZZANIGA MS, 1987, NEUROPHYSIOLOGICAL N, P203; HE S, 1995, INVEST OPHTH VIS SCI, V36, P2010; HORTON JC, 1991, ARCH OPHTHALMOL-CHIC, V109, P816, DOI 10.1001/archopht.1991.01080060080030; INTRILIGATOR J, 1991, INVEST OPHTH VIS SCI, V32, P1040; KOLB FC, 1995, NATURE, V377, P336, DOI 10.1038/377336a0; MAUNSELL JHR, 1987, ANNU REV NEUROSCI, V10, P363, DOI 10.1146/annurev.ne.10.030187.002051; POSNER MI, 1994, NEUROPSYCHOL REHABIL, V4, P183, DOI 10.1080/09602019408402280; PREVIC FH, 1990, BEHAV BRAIN SCI, V13, P519, DOI 10.1017/S0140525X00080018; PYLYSHYN Z W, 1988, Spatial Vision, V3, P179, DOI 10.1163/156856888X00122; Rubin N, 1996, SCIENCE, V271, P651, DOI 10.1126/science.271.5249.651; SERENO MI, 1995, SCIENCE, V268, P889, DOI 10.1126/science.7754376; TAYLOR SG, 1972, PERCEPT PSYCHOPHYS, V12, P97, DOI 10.3758/BF03212851; TOET A, 1992, VISION RES, V32, P1349, DOI 10.1016/0042-6989(92)90227-A; TREISMAN A, 1988, Q J EXP PSYCHOL-A, V40, P201, DOI 10.1080/02724988843000104	23	736	748	4	53	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 26	1996	383	6598					334	337		10.1038/383334a0	http://dx.doi.org/10.1038/383334a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VJ439	8848045				2022-12-24	WOS:A1996VJ43900044
J	Kitson, J; Raven, T; Jiang, YP; Goeddel, DV; Giles, KM; Pun, KT; Grinham, CJ; Brown, R; Farrow, SN				Kitson, J; Raven, T; Jiang, YP; Goeddel, DV; Giles, KM; Pun, KT; Grinham, CJ; Brown, R; Farrow, SN			A death-domain-containing receptor that mediates apoptosis	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; TNF RECEPTOR; CELL-DEATH; PROTEIN; INTERACTS; FAS; SYSTEM; YEAST	THE cell-killing effects of the cytokines TNF-alpha and Fast are mediated by the distinct cell-surface receptors TNFR1, TNFR2 and Fas (also known as CD95/APO-1), which are all members of a receptor superfamily that is important for regulating cell survival(1-4). The cytoplasmic regions of TNFR1 and Fas contain a conserved 'death' domain which is an essential component of the signal pathway that triggers apoptosis and activation of the transcription factor NF-kappa B (refs 5, 6). Here we report the isolation of a 54K receptor that is a new member of the TNFR superfamily, using the death domain of TNFR1 in a yeast two-hybrid system(7,8). This protein, WSL-1, is most similar to TNFR1 itself, particularly in the death-domain region, The gene wsl-1 is capable of inducing apoptosis when transfected into 3T3 and 293 cells, and can also activate NF-kappa B in 293 cells, Like TNFR1, WSL-1 will homodimerize in yeast. WSL-1 also interacts specifically with the TNFR1-associated molecule TRADD(9). The tissue distribution is very restricted and significantly different from that of Fas and TNFR1.	GLAXO WELLCOME MED RES CTR,CELL BIOL UNIT,STEVENAGE SG1 2NY,HERTS,ENGLAND; TULARIK INC,S SAN FRANCISCO,CA 94080	GlaxoSmithKline				Pun, Tao/0000-0001-5241-2187				Baker SJ, 1996, ONCOGENE, V12, P1; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; ITOH N, 1993, J BIOL CHEM, V268, P10932; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SONG HY, 1994, J BIOL CHEM, V269, P22492; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; WARD AC, 1990, NUCLEIC ACIDS RES, V18, P5319, DOI 10.1093/nar/18.17.5319; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	22	285	329	2	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1996	384	6607					372	375		10.1038/384372a0	http://dx.doi.org/10.1038/384372a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV271	8934525				2022-12-24	WOS:A1996VV27100053
J	Tinsley, JM; Potter, AC; Phelps, SR; Fisher, R; Trickett, JI; Davies, KE				Tinsley, JM; Potter, AC; Phelps, SR; Fisher, R; Trickett, JI; Davies, KE			Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene	NATURE			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; ORAL SODIUM PHENYLBUTYRATE; MUSCLE-SPECIFIC EXPRESSION; SKELETAL ACTIN GENE; EXTRACELLULAR-MATRIX; FULL-LENGTH; THERAPY; PROTEIN; COMPLEX; MOUSE	DUCHENNE muscular dystrophy (DMD) is a severe, progressive muscle-wasting disease that causes cardiac or respiratory failure(1,2) and results in death at about 20 years of age, Replacement of the missing protein, dystrophin, using myoblast transfer in humans or viral/liposomal delivery in the mouse DMD model is inefficient and short-lived(3,4). One alternative approach to treatment would be to upregulate the closely related protein, utrophin(5,6), which might be able to compensate for the dystrophin deficiency in all relevant muscles(7,8). As a first step to this approach, we have expressed a utrophin transgene at high levels in the dystrophin-deficient mdx mouse. Our results indicate that high expression of the utrophin transgene in skeletal and diaphragm muscle can markedly reduce the dystrophic pathology. These data suggest that systemic upregulation of utrophin in DMD patients may lead to the development of an effective treatment for this devastating disorder.	UNIV OXFORD,DEPT BIOCHEM,GENET LAB,OXFORD OX1 3QU,ENGLAND	University of Oxford								Blake DJ, 1996, BRAIN PATHOL, V6, P37, DOI 10.1111/j.1750-3639.1996.tb00781.x; BRENNAN KJ, 1993, J BIOL CHEM, V268, P719; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; COLLINS AF, 1995, BLOOD, V85, P43, DOI 10.1182/blood.V85.1.43.bloodjournal85143; COX GA, 1993, NATURE, V364, P725, DOI 10.1038/364725a0; DOVER GJ, 1994, BLOOD, V84, P339; EMERY AEH, 1993, OXFORD MONOGR MED GE, V24; Hoffman EP, 1996, BRAIN PATHOL, V6, P49, DOI 10.1111/j.1750-3639.1996.tb00782.x; HOFFMAN EP, 1994, NAT GENET, V8, P311, DOI 10.1038/ng1294-311; Hogan B., 1986, MANIPULATING MOUSE E; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; LOVE DR, 1989, NATURE, V339, P55, DOI 10.1038/339055a0; MATSUMURA K, 1994, MUSCLE NERVE, V17, P2, DOI 10.1002/mus.880170103; MORGAN JE, 1994, HUM GENE THER, V5, P165, DOI 10.1089/hum.1994.5.2-165; MUSCAT GEO, 1987, MOL CELL BIOL, V7, P4089, DOI 10.1128/MCB.7.11.4089; NHUYEN TM, 1991, J CELL BIOL, V155, P1695; PARTRIDGE TA, 1995, BRIT MED BULL, V51, P123, DOI 10.1093/oxfordjournals.bmb.a072942; PHELPS SF, 1995, HUM MOL GENET, V4, P1251, DOI 10.1093/hmg/4.8.1251; RAFAEL JA, 1994, HUM MOL GENET, V3, P1725, DOI 10.1093/hmg/3.10.1725; ROBERDS SL, 1993, J BIOL CHEM, V268, P23739; SHERRATT TG, 1992, BIOCHEM J, V287, P755, DOI 10.1042/bj2870755; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; TINSLEY JM, 1993, NEUROMUSCULAR DISORD, V3, P537, DOI 10.1016/0960-8966(93)90111-V; TINSLEY JM, 1992, NATURE, V360, P591, DOI 10.1038/360591a0; TINSLEY JM, 1994, P NATL ACAD SCI USA, V91, P8307, DOI 10.1073/pnas.91.18.8307; WELLS DJ, 1995, HUM MOL GENET, V4, P1245, DOI 10.1093/hmg/4.8.1245	27	394	418	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1996	384	6607					349	353		10.1038/384349a0	http://dx.doi.org/10.1038/384349a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV271	8934518				2022-12-24	WOS:A1996VV27100046
J	Levy, JA				Levy, JA			Infection by human immunodeficiency virus CD4 is not enough	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											Levy, JA (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,SAN FRANCISCO,CA 94143, USA.							Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Berson JF, 1996, J VIROL, V70, P6288, DOI 10.1128/JVI.70.9.6288-6295.1996; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; ENDRES MJ, IN PRESS CELL; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Levy JA, 1994, HIV PATHOGENESIS AID; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0	15	28	45	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 14	1996	335	20					1528	1530		10.1056/NEJM199611143352011	http://dx.doi.org/10.1056/NEJM199611143352011			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT340	8890107				2022-12-24	WOS:A1996VT34000011
J	Wu, LJ; Gerard, NP; Wyatt, R; Choe, H; Parolin, C; Ruffing, N; Borsetti, A; Cardoso, AA; Desjardin, E; Newman, W; Gerard, C; Sodroski, J				Wu, LJ; Gerard, NP; Wyatt, R; Choe, H; Parolin, C; Ruffing, N; Borsetti, A; Cardoso, AA; Desjardin, E; Newman, W; Gerard, C; Sodroski, J			CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; HUMAN MONOCLONAL-ANTIBODY; ENVELOPE GLYCOPROTEINS; T-CELL; BINDING; CD4; INFECTION; IDENTIFICATION; EPITOPES; FUSION	FOR efficient entry into target cells, primary macrophage-tropic and laboratory-adapted human immunodeficiency viruses type 1 (HIV-1) require particular chemokine receptors, CCR-5 and CXCR-4, respectively, as well as the primary receptor CD4 (refs 1-6). Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1 alpha and MLP-1 beta (refs 7, 8). The apparent affinity of the interaction between gp120 and CCR-5 was dramatically lower in the absence of soluble CD4. Additionally, in the absence of gp120, an interaction between a two-domain CD4 fragment and CCR-5 was observed. A gp120 fragment retaining the CD4-binding site and overlapping epitopes was able to interact with CCR-5 only if the V3 loop, which can specify HIV-1 tropism and chemokine receptor choice(2,9-11), was also present on the molecule. Neutralizing antibodies directed against either CD4-induced or V3 epitopes on gp120 blocked the interaction of gp120-CD4 complexes with CCR-5. These results suggest that HIV-1 attachment to CD4 creates a high-affinity binding site for CCR-5, leading to membrane fusion and virus entry.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT PATHOL,DIV HUMAN RETROVIOROL,BOSTON,MA 02115; LEUKOSITE INC,CAMBRIDGE,MA 02142; CHILDRENS HOSP,INA SUE PERLMUTTER LAB,BOSTON,MA 02115; BETH ISRAEL HOSP,DEPT MED,BOSTON,MA 02115; BETH ISRAEL HOSP,DEPT PEDIAT,BOSTON,MA 02115; UNIV PADUA,INST MICROBIOL,I-35121 PADUA,ITALY; DANA FARBER CANC INST,DIV HEMATOL MALIGNANCIES,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; University of Padua; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard T.H. Chan School of Public Health			borsetti, alessandra/K-4103-2016	borsetti, alessandra/0000-0002-5401-135X				Akhatib G., 1996, SCIENCE, V272, P1955; ARTHOS J, 1989, CELL, V57, P469, DOI 10.1016/0092-8674(89)90922-7; BACHELDER RE, 1995, J VIROL, V69, P5734, DOI 10.1128/JVI.69.9.5734-5742.1995; BURKLY LC, 1992, J IMMUNOL, V149, P1779; CHENGMAYER C, 1990, J VIROL, V64, P4390, DOI 10.1128/JVI.64.9.4390-4398.1990; CHESEBRO B, 1991, J VIROL, V65, P5782, DOI 10.1128/JVI.65.11.5782-5789.1991; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CULP JS, 1991, BIO-TECHNOL, V9, P173, DOI 10.1038/nbt0291-173; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GERARD NP, 1989, J BIOL CHEM, V264, P1760; GERSHONI JM, 1993, FASEB J, V7, P1185, DOI 10.1096/fasebj.7.12.7690724; HEALEY D, 1990, J EXP MED, V172, P1233, DOI 10.1084/jem.172.4.1233; HELSETH E, 1991, J VIROL, V65, P2119, DOI 10.1128/JVI.65.4.2119-2123.1991; HWANG SS, 1991, SCIENCE, V253, P71, DOI 10.1126/science.1905842; IVEYHOYLE M, 1991, P NATL ACAD SCI USA, V88, P512, DOI 10.1073/pnas.88.2.512; Moore JP, 1996, J VIROL, V70, P1863, DOI 10.1128/JVI.70.3.1863-1872.1996; MOORE JP, 1995, J VIROL, V69, P122, DOI 10.1128/JVI.69.1.122-130.1995; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; POSNER MR, 1991, J IMMUNOL, V146, P4325; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SULLIVAN N, 1995, J VIROL, V69, P4413, DOI 10.1128/JVI.69.7.4413-4422.1995; THALI M, 1993, J VIROL, V67, P3978, DOI 10.1128/JVI.67.7.3978-3988.1993; TRUNEH A, 1991, J BIOL CHEM, V266, P5942; WYATT R, 1993, J VIROL, V67, P4557, DOI 10.1128/JVI.67.8.4557-4565.1993; WYATT R, 1995, J VIROL, V69, P5723, DOI 10.1128/JVI.69.9.5723-5733.1995	29	1059	1131	3	55	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 14	1996	384	6605					179	183		10.1038/384179a0	http://dx.doi.org/10.1038/384179a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT336	8906795				2022-12-24	WOS:A1996VT33600069
J	Hall, W; Sannibale, C				Hall, W; Sannibale, C			Are there two types of alcoholism?	LANCET			English	Editorial Material							MEN		CENT SYDNEY AREA HLTH SERV,DRUG & ALCOHOL SERV,SYDNEY,NSW,AUSTRALIA		Hall, W (corresponding author), UNIV NEW S WALES,NATL DRUG & ALCOHOL RES CTR,SYDNEY,NSW 2052,AUSTRALIA.		Hall, Wayne D/A-3283-2008	Hall, Wayne D/0000-0003-1984-0096				CLONINGER CR, 1981, ARCH GEN PSYCHIAT, V38, P861; FILLMORE KM, 1988, DRUGS SOC, V2, P69; LITTRELL J, 1988, J STUD ALCOHOL, V49, P491, DOI 10.15288/jsa.1988.49.491; PENICK EC, 1990, ALCOHOL CLIN EXP RES, V14, P623, DOI 10.1111/j.1530-0277.1990.tb01213.x; SEARLES JS, 1988, J ABNORM PSYCHOL, V97, P153, DOI 10.1037/0021-843X.97.2.153; Sigvardsson S, 1996, ARCH GEN PSYCHIAT, V53, P681	6	7	7	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 9	1996	348	9037					1258	1258		10.1016/S0140-6736(05)65754-6	http://dx.doi.org/10.1016/S0140-6736(05)65754-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VR555	8909376				2022-12-24	WOS:A1996VR55500006
J	Barhanin, J; Lesage, F; Guillemare, E; Fink, M; Lazdunski, M; Romey, G				Barhanin, J; Lesage, F; Guillemare, E; Fink, M; Lazdunski, M; Romey, G			K(v)LQT1 and IsK (minK) proteins associate to form the I-Ks cardiac potassium current	NATURE			English	Article							RECTIFIER K+ CHANNEL; XENOPUS-OOCYTES; SK PROTEIN; EXPRESSION; CLONING; MEMBRANE; HEART; HERG; SENSITIVITY; ARRHYTHMIA	IN mammalian cardiac cells, a varlets of transient or sustained K+ currents contribute to the repolarization of action potentials(1). There are two main components of the delayed-rectifier sustained K+ current, I-Kr (rapid) and I-Ks (slow)(2). I-Kr is the product of the gene HERG(3,4), which is altered in the long-QT syndrome, LQT2 (ref. 5). A channel with properties similar to those of the I-Ks channel is produced when the cardiac protein IsK is expressed in Xenopus oocytes(6-8). However, it is a small protein with a very unusual structure for a cation channel(9-15). The LQT1 gene is another gene associated with the LQT syndrome, a disorder that causes sudden death from ventricular arrhythmias(16). Here we report the cloning of the full-length mouse K(v)LQT1 complementary DNA and show that K(v)LQT1 associates with IsK to form the channel underlying the I-Ks cardiac current, which is a target of class-III anti-arrhythmic drugs and is involved in the LQT(1) syndrome.	CNRS,INST PHARMACOL MOL & CELLULAIRE,F-06560 VALBONNE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur			Lesage, Florian/D-5097-2011; Lesage, Florian/P-9780-2019	Lesage, Florian/0000-0002-4406-7106; Lesage, Florian/0000-0002-4406-7106				ATTALI B, 1993, NATURE, V365, P850, DOI 10.1038/365850a0; ATTALI B, 1993, J BIOL CHEM, V268, P24283; BenEfraim I, 1996, J BIOL CHEM, V271, P8768, DOI 10.1074/jbc.271.15.8768; BLUMENTHAL EM, 1994, J NEUROSCI, V14, P3097; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Deal KK, 1996, PHYSIOL REV, V76, P49, DOI 10.1152/physrev.1996.76.1.49; Fink M, 1996, J BIOL CHEM, V271, P26341, DOI 10.1074/jbc.271.42.26341; FOLANDER K, 1990, P NATL ACAD SCI USA, V87, P2975, DOI 10.1073/pnas.87.8.2975; FREEMAN LC, 1993, CIRC RES, V73, P968, DOI 10.1161/01.RES.73.5.968; GUILLEMARE E, 1992, BIOCHEMISTRY-US, V31, P12463, DOI 10.1021/bi00164a024; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HICE RE, 1994, PFLUG ARCH EUR J PHY, V426, P139, DOI 10.1007/BF00374681; HONORE E, 1991, EMBO J, V10, P2805, DOI 10.1002/j.1460-2075.1991.tb07829.x; HONORE E, 1992, BIOCHEM BIOPH RES CO, V184, P1135, DOI 10.1016/S0006-291X(05)80001-4; LESAGE F, 1993, RECEPTOR CHANNEL, V1, P143; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; NUSS HB, 1994, J PHYSIOL-LONDON, V479, P265, DOI 10.1113/jphysiol.1994.sp020294; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; TZOUNOPOULOS T, 1995, P NATL ACAD SCI USA, V92, P9593, DOI 10.1073/pnas.92.21.9593; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; ZHANG ZJ, 1994, P NATL ACAD SCI USA, V91, P1766, DOI 10.1073/pnas.91.5.1766	24	1287	1324	2	36	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1996	384	6604					78	80		10.1038/384078a0	http://dx.doi.org/10.1038/384078a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR219	8900282				2022-12-24	WOS:A1996VR21900058
J	Simon, R; Igeno, MI; Coupland, G				Simon, R; Igeno, MI; Coupland, G			Activation of floral meristem identity genes in Arabidopsis	NATURE			English	Article							CELL FATE; INITIATION; APETALA1; THALIANA	THE Arabidopsis floral meristem identity genes APETALA1 (AP1) and LEAFY (LFY) confer floral identity on developing floral primordia(1-4), whereas TERMINAL FLOWER (TFL) is required to repress their expression within shoot and inflorescence meristems(1,5). LFY and AP1 are expressed in floral primordia in response to environmental conditions, such as day length, which regulate the onset of flowering, and presumably also in response to the action of genes that influence flowering time. However, the relationship between these flowering-time genes and the floral meristem-identity genes has been difficult to assess because flowering time is determined by several interacting genetic pathways(6,7). Here we describe a method to regulate expression of the flowering-time gene CONSTANS (CO) and demonstrate that CO expression is sufficient to trigger flowering, irrespective of day length. In response to CO expression, transcription of LFY and TFL is initiated rapidly, whereas transcription of AP1 occurs much later. We propose that CO acts within a genetic pathway that is sufficient to activate LFY and TFL transcription, but that rapid activation of AP1 requires an additional pathway.	JOHN INNES CTR PLANT SCI RES,NORWICH NR4 7UH,NORFOLK,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center			Coupland, George/AAP-8609-2020; Simon, Rudiger/T-6755-2018	Coupland, George/0000-0001-6988-4172; Igeno, M. Isabel/0000-0003-4745-3827; Simon, Rudiger/0000-0002-1317-7716				AOYAMA T, 1995, PLANT CELL, V7, P1773, DOI 10.1105/tpc.7.11.1773; Bradley D, 1996, NATURE, V379, P791, DOI 10.1038/379791a0; BRADLEY D, 1993, CELL, V72, P85, DOI 10.1016/0092-8674(93)90052-R; COUPLAND G, 1995, TRENDS GENET, V11, P393, DOI 10.1016/S0168-9525(00)89122-2; GUSTAFSONBROWN C, 1994, CELL, V76, P131, DOI 10.1016/0092-8674(94)90178-3; HEMPEL FD, 1994, PLANTA, V192, P276, DOI 10.1007/BF01089045; KOORNNEEF M, 1991, MOL GEN GENET, V229, P57, DOI 10.1007/BF00264213; LLOYD AM, 1994, SCIENCE, V266, P436, DOI 10.1126/science.7939683; MANDEL MA, 1992, NATURE, V360, P273, DOI 10.1038/360273a0; MANDEL MA, 1995, NATURE, V377, P522, DOI 10.1038/377522a0; Martinez-Zapater JM, 1994, ARABIDOPSIS, P403; MCDANIEL CN, 1992, DEV BIOL, V153, P59, DOI 10.1016/0012-1606(92)90091-T; PUTTERILL J, 1995, CELL, V80, P847, DOI 10.1016/0092-8674(95)90288-0; REDEI GP, 1962, GENETICS, V47, P443; SHANNON S, 1991, PLANT CELL, V3, P877, DOI 10.1105/tpc.3.9.877; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; WEIGEL D, 1995, NATURE, V377, P495, DOI 10.1038/377495a0	17	257	280	1	33	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1996	384	6604					59	62		10.1038/384059a0	http://dx.doi.org/10.1038/384059a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR219	8900276				2022-12-24	WOS:A1996VR21900052
J	Higgins, RM; Bevan, DJ; Carey, BS; Lea, CK; Fallon, M; Buhler, R; Vaughan, RW; ODonnell, PJ; Snowden, SA; Bewick, M; Hendry, BM				Higgins, RM; Bevan, DJ; Carey, BS; Lea, CK; Fallon, M; Buhler, R; Vaughan, RW; ODonnell, PJ; Snowden, SA; Bewick, M; Hendry, BM			Prevention of hyperacute rejection by removal of antibodies to HLA immediately before renal transplantation	LANCET			English	Article							LYMPHOCYTOTOXIC ANTIBODIES; IMMUNOADSORPTION; RECIPIENTS; CROSSMATCH; ALLOGRAFTS; EPISODES	Background Many patients with circulating antibodies to human leucocyte antigens (anti-HLA) are highly sensitised against renal transplantation and are liable to immediate graft loss through hyperacute rejection. Our aim was to find out whether removal of anti-HLA immediately before renal transplantation prevented hyperacute graft rejection. Methods 13 highly sensitised patients underwent cadaveric renal transplants immediately after immunoadsorption (IA) treatment to remove anti-HLA. Before IA, 12 patients had a positive crossmatch against donor cells either by cytotoxic or flow-cytometric assay; results for one patient were equivocal. Findings Renal biopsy samples were obtained 20 min after removal of the Vascular clamps in nine patients. There was no evidence of hyperacute rejection in six of the nine patients; the other three patients showed glomerular thrombosis but no other evidence of hyperacute rejection. Two of these three grafts were functioning at 31 months of follow-up. Six episodes of acute rejection occurred in five patients during the first month after transplantation and overall there were 13 rejection episodes in nine patients. At latest follow-up (median 26 months, range 9-42), 12 of 13 patients were alive and seven of 13 grafts were surviving with a median plasma creatinine concentration of 185 mu mol/L (range 106-296) in the functioning grafts. No graft was lost as a result of classic hyperacute rejection. Interpretation Immediate pretransplant IA can prevent hyperacute rejection and provide an opportunity for successful transplantation in highly sensitised patients.	UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT MED,RENAL GRP,LONDON SE5 9PJ,ENGLAND; GUYS HOSP,S THAMES REG TISSUE TYPING LAB,LONDON SE1 9RT,ENGLAND; UNIV LONDON KINGS COLL HOSP,DEPT HISTOPATHOL,LONDON,ENGLAND; UNIV LONDON KINGS COLL HOSP,RENAL UNIT,LONDON,ENGLAND	University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London								ALMOND PS, 1991, TRANSPLANTATION, V52, P253, DOI 10.1097/00007890-199108000-00013; Bevan DJ, 1996, TRANSPLANT INT, V9, P155, DOI 10.1111/j.1432-2277.1996.tb00871.x; BEVAN DJ, 1995, NEPHROL DIAL TRANSPL, V10, P744; BEVAN DJ, 1996, IN PRESS TRANSPL S1, V9; ESNAULT V, 1990, TRANSPLANTATION, V50, P449, DOI 10.1097/00007890-199009000-00018; GASTON RS, 1994, TRANSPLANTATION, V57, P47, DOI 10.1097/00007890-199401000-00010; GJORSTRUP P, 1991, TRANSPLANT P, V23, P392; HEISSE C, 1992, NEPHROL DIAL TRANSPL, V7, P944; Higgins RM, 1996, NEPHRON, V74, P53, DOI 10.1159/000189281; KARUPPAN SS, 1992, TRANSPLANTATION, V53, P666, DOI 10.1097/00007890-199203000-00033; KUPIN WL, 1991, TRANSPLANTATION, V51, P324, DOI 10.1097/00007890-199102000-00010; LAZDA VA, 1988, TRANSPLANTATION, V45, P562, DOI 10.1097/00007890-198803000-00012; PALMER A, 1989, LANCET, V1, P10; PATEL R, 1969, NEW ENGL J MED, V280, P735, DOI 10.1056/NEJM196904032801401; PORTER KA, 1992, PATHOLOGY KIDNEY, P1799; REISAETER AV, 1995, TRANSPLANTATION, V60, P242, DOI 10.1097/00007890-199508000-00006; ROSS CN, 1993, TRANSPLANTATION, V55, P785, DOI 10.1097/00007890-199304000-00019; TAUBE DH, 1984, LANCET, V1, P824; TAYLOR CJ, 1989, TRANSPLANTATION, V48, P953, DOI 10.1097/00007890-198912000-00011; THOROGOOD J, 1991, TRANSPLANTATION, V52, P831, DOI 10.1097/00007890-199111000-00015; WELSH KI, 1988, TRANSPLANT INT, V1, P190, DOI 10.1111/j.1432-2277.1988.tb01814.x	21	98	117	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 2	1996	348	9036					1208	1211		10.1016/S0140-6736(96)03452-6	http://dx.doi.org/10.1016/S0140-6736(96)03452-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ467	8898038				2022-12-24	WOS:A1996VQ46700012
J	Lamarche, N; Tapon, N; Stowers, L; Burbelo, PD; Aspenstrom, P; Bridges, T; Chant, J; Hall, A				Lamarche, N; Tapon, N; Stowers, L; Burbelo, PD; Aspenstrom, P; Bridges, T; Chant, J; Hall, A			Rac and Cdc42 induce actin polymerization and G1 cell cycle progression independently of p65(PAK) and the JNK/SAPK MAP kinase cascade	CELL			English	Article							GTP-BINDING-PROTEIN; ADP-RIBOSYLATION; TARGET PROTEINS; NADPH OXIDASE; STRESS FIBERS; SMALL GTPASES; RHO; ACTIVATION; TRANSFORMATION; PURIFICATION	Rac and Cdc42 regulate a variety of responses in mammalian cells including formation of lamellipodia and filopodia, activation of the JNK MAP kinase cascade, and induction of G1 cell cycle progression. Pac is also one of the downstream targets required for Ras-induced malignant transformation. Pac and Cdc42 containing a Y40C effector site substitution no longer intact with the Ser/Thr kinase p65(PAK) and are unable to activate the JNK MAP kinase pathway. However, they still induce cytoskeletal changes and G1 cell cycle progression. Rac containing an F37A effector site substitution, on the other hand, no longer interacts with the Ser/Thr kinase p160(ROCK) and is unable to induce lamellipodia or G1 progression. We conclude that Pac and Cdc42 control MAP kinase pathways and actin cytoskeleton organization independently through distinct downstream targets.	UNIV LONDON UNIV COLL,DEPT BIOCHEM,CRC ONCOGENE & SIGNAL TRANSDUCT GRP,MRC LAB MOL CELL BIOL,LONDON WC1E 6BT,ENGLAND; HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138	MRC Laboratory Molecular Biology; University of London; University College London; Harvard University			Burbelo, Peter D./B-1027-2009; Stowers, Lisa/K-6137-2015	Stowers, Lisa/0000-0002-4403-1269; Tapon, Nicolas/0000-0001-5267-6510	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; ASPENSTROM P, 1995, METHOD ENZYMOL, V256, P228; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; EATON S, 1995, J CELL BIOL, V131, P151, DOI 10.1083/jcb.131.1.151; Foster R, 1996, MOL CELL BIOL, V16, P2689; GILLMORE AP, 1996, NATURE, V381, P531; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HARTWIG JH, 1995, CELL, V82, P843; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MORII N, 1992, J BIOL CHEM, V267, P20921; Murphy AM, 1996, J CELL BIOL, V133, P617, DOI 10.1083/jcb.133.3.617; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; REID T, 1996, IN PRESS J BIOL CHEM; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; UEDA T, 1990, J BIOL CHEM, V265, P9373; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; YAMAMOTO M, 1993, J BIOL CHEM, V268, P21509; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	56	534	536	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 1	1996	87	3					519	529		10.1016/S0092-8674(00)81371-9	http://dx.doi.org/10.1016/S0092-8674(00)81371-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VQ466	8898204	hybrid			2022-12-24	WOS:A1996VQ46600017
J	Chee, M; Yang, R; Hubbell, E; Berno, A; Huang, XC; Stern, D; Winkler, J; Lockhart, DJ; Morris, MS; Fodor, SPA				Chee, M; Yang, R; Hubbell, E; Berno, A; Huang, XC; Stern, D; Winkler, J; Lockhart, DJ; Morris, MS; Fodor, SPA			Accessing genetic information with high-density DNA arrays	SCIENCE			English	Article							HUMAN MITOCHONDRIAL-DNA; ENZYMATIC AMPLIFICATION; SEQUENCE; HYBRIDIZATION; EVOLUTION; GENOME; DISEASE; ORIGIN	Rapid access to genetic information is central to the revolution taking place in molecular genetics. The simultaneous analysis of the entire human mitochondrial genome is described here, DNA arrays containing up to 135,000 probes complementary to the 16.6-kilobase human mitochondrial genome were generated by light-directed chemical synthesis, A two-color labeling scheme was developed that allows simultaneous comparison of a polymorphic target to a reference DNA or RNA. Complete hybridization patterns were revealed in a matter of minutes. Sequence polymorphisms were detected with single-base resolution and unprecedented efficiency, The methods described are generic and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability.			Chee, M (corresponding author), AFFYMETRIX, 3380 CENT EXPRESSWAY, SANTA CLARA, CA 95051 USA.			Hubbell, Earl/0000-0001-7301-3759	NHGRI NIH HHS [5RO1HG00813] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000813] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; AQUADRO CF, 1983, GENETICS, V103, P287; BAINS W, 1988, J THEOR BIOL, V135, P303, DOI 10.1016/S0022-5193(88)80246-7; BROWN MD, 1992, FASEB J, V6, P2791, DOI 10.1096/fasebj.6.10.1634041; BUTZOW JJ, 1965, BIOPOLYMERS, V3, P95, DOI 10.1002/bip.360030110; CANN RL, 1984, GENETICS, V106, P479; CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0; CHENG S, 1994, NAT GENET, V7, P350, DOI 10.1038/ng0794-350; DRMANAC R, 1989, GENOMICS, V4, P114; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; GILL P, 1985, NATURE, V318, P577, DOI 10.1038/318577a0; GREENBERG BD, 1983, GENE, V21, P33, DOI 10.1016/0378-1119(83)90145-2; HACIA J, UNPUB; HORAI S, 1995, P NATL ACAD SCI USA, V92, P532, DOI 10.1073/pnas.92.2.532; HUFF JW, 1964, BIOCHEMISTRY-US, V3, P501, DOI 10.1021/bi00892a006; HUTCHIN T, 1995, P NATL ACAD SCI USA, V92, P6892, DOI 10.1073/pnas.92.15.6892; LOCKHART D, IN PRESS NATURE BIOT; LYSOV YP, 1988, DOKL AKAD NAUK SSSR, V303, P1508; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MELCHIOR WB, 1973, P NATL ACAD SCI USA, V70, P298, DOI 10.1073/pnas.70.2.298; PEASE AC, 1994, P NATL ACAD SCI USA, V91, P5022, DOI 10.1073/pnas.91.11.5022; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1992, GENOMICS, V13, P1008, DOI 10.1016/0888-7543(92)90014-J; STONEKING M, 1991, AM J HUM GENET, V48, P370; TRULSON MO, UNPUB; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WALLACE RB, 1979, NUCLEIC ACIDS RES, V6, P3543, DOI 10.1093/nar/6.11.3543; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0; WODICKA L, COMMUNICATION; ZEVIANI M, 1990, AM J HUM GENET, V47, P904	31	1213	1670	2	96	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 25	1996	274	5287					610	614		10.1126/science.274.5287.610	http://dx.doi.org/10.1126/science.274.5287.610			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN919	8849452				2022-12-24	WOS:A1996VN91900050
J	Hanes, DP; Schall, JD				Hanes, DP; Schall, JD			Neural control of voluntary movement initiation	SCIENCE			English	Article							FRONTAL EYE FIELD; NEURONS; MACAQUE; MONKEY; PONS	When humans respond to sensory stimulation, their reaction times tend to be long and variable relative to neural transduction and transmission times. The neural processes responsible for the duration and variability of reaction times are not understood. Single-cell recordings in a motor area of the cerebral cortex in behaving rhesus monkeys (Macaca mulatta) were used to evaluate two alternative mathematical models of the processes that underlie reaction times. Movements were initiated if and only ii the neural activity reached a specific and constant threshold activation level. Stochastic variability in the rate at which neural activity grew toward that threshold resulted in the distribution of reaction times. This finding elucidates a specific link between motor behavior and activation of neurons in the cerebral cortex.	VANDERBILT UNIV,DEPT PSYCHOL,NASHVILLE,TN 37240	Vanderbilt University					NEI NIH HHS [P30-EY08126] Funding Source: Medline; NIMH NIH HHS [F31-MH11178, R01-MH55806] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY008126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [F31MH011178, R01MH055806] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Brooks V.B., 1986, NEURAL BASIS MOTOR C; BRUCE CJ, 1985, J NEUROPHYSIOL, V54, P714, DOI 10.1152/jn.1985.54.3.714; BUTTNERENNEVER JA, 1988, J COMP NEUROL, V267, P307, DOI 10.1002/cne.902670302; CARPENTER RHS, 1995, NATURE, V377, P59, DOI 10.1038/377059a0; Carpenter RHS, 1988, MOVEMENTS EYES; Carpenter RHS, 1991, EYE MOVEMENTS; DEJONG R, 1990, J EXP PSYCHOL HUMAN, V16, P164, DOI 10.1037/0096-1523.16.1.164; Dias EC, 1995, J NEUROPHYSIOL, V74, P2744, DOI 10.1152/jn.1995.74.6.2744; GRATTON G, 1988, J EXP PSYCHOL HUMAN, V14, P331, DOI 10.1037/0096-1523.14.3.331; GRICE GR, 1968, PSYCHOL REV, V75, P359, DOI 10.1037/h0026287; HANES DP, 1995, VISUAL NEUROSCI, V12, P929, DOI 10.1017/S0952523800009482; HANES DP, 1995, EXP BRAIN RES, V103, P85; LEGENDY CR, 1985, J NEUROPHYSIOL, V53, P926, DOI 10.1152/jn.1985.53.4.926; LOGAN GD, 1984, PSYCHOL REV, V91, P295, DOI 10.1037/0033-295X.91.3.295; Luce RD, 1986, RESPONSE TIMES THEIR; MCCLELLAND JL, 1979, PSYCHOL REV, V86, P287, DOI 10.1037/0033-295X.86.4.287; MEYER DE, 1988, BIOL PSYCHOL, V26, P3, DOI 10.1016/0301-0511(88)90013-0; NAZIR TA, 1991, PSYCHOL RES-PSYCH FO, V53, P281, DOI 10.1007/BF00920481; PACUT A, 1977, BIOL CYBERN, V28, P63, DOI 10.1007/BF00335286; RATCLIFF R, 1978, PSYCHOL REV, V85, P59, DOI 10.1037//0033-295X.85.2.59; SAYER RJ, 1990, J NEUROSCI, V10, P826; Schall J. D., 1991, VISION VISUAL DYSFUN, V4, P388; SEGRAVES MA, 1992, J NEUROPHYSIOL, V68, P1967, DOI 10.1152/jn.1992.68.6.1967; VONHELMHOLTZ HLF, 1853, PHILOS MAG, V6, P313; Wurtz R. H, 1989, NEUROBIOLOGY SACCADI	25	857	862	2	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1996	274	5286					427	430		10.1126/science.274.5286.427	http://dx.doi.org/10.1126/science.274.5286.427			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	VN173	8832893				2022-12-24	WOS:A1996VN17300056
J	Tatsuno, I; Homma, M; Oosawa, K; Kawagishi, I				Tatsuno, I; Homma, M; Oosawa, K; Kawagishi, I			Signaling by the Escherichia coli aspartate chemoreceptor tar with a single cytoplasmic domain per dimer	SCIENCE			English	Article							LIGAND-BINDING DOMAIN; BACTERIAL CHEMOTAXIS RECEPTOR; CROSS-LINKING; SALMONELLA-TYPHIMURIUM; ETHYLENE-GLYCOL; TRANSDUCTION; COMPLEX; REPELLENTS; PROTEINS; GLYCEROL	Many transmembrane receptors are oligomeric proteins. Binding oi a ligand may alter the oligomeric state of the receptor, induce structural changes within the oligomer, or both. The bacterial aspartate chemoreceptor Tar forms a homodimer in the presence or absence of ligands. Tar mediates attractant acid repellent responses by modulating the activity of the cytoplasmic kinase CheA. In vivo intersubunit suppression was used to show that certain combinations of full-length and truncated mutant Tar proteins complemented each other to restore attractant responses to aspartate. These results suggest that heterodimers with only one intact cytoplasmic domain are functional. The signaling mechanism may require interactions between dimers or conformational changes within a single cytoplasmic domain.	NAGOYA UNIV,GRAD SCH SCI,DIV BIOL SCI,CHIKUSA KU,NAGOYA,AICHI 46401,JAPAN; NAGOYA UNIV,GRAD SCH POLYMATH,CHIKUSA KU,NAGOYA,AICHI 46401,JAPAN	Nagoya University; Nagoya University			Oosawa, Kenji/K-6610-2013; Tatsuno, Ichiro/GQP-8401-2022	Tatsuno, Ichiro/0000-0003-4053-9695				BIEMANN HP, 1994, BIOCHEMISTRY-US, V33, P629, DOI 10.1021/bi00169a002; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BOYD A, 1981, CELL, V26, P333, DOI 10.1016/0092-8674(81)90202-6; CHERVITZ SA, 1995, J BIOL CHEM, V270, P24043, DOI 10.1074/jbc.270.41.24043; CHERVITZ SA, 1995, BIOCHEMISTRY-US, V34, P9722, DOI 10.1021/bi00030a010; Cochran AG, 1996, SCIENCE, V271, P1113, DOI 10.1126/science.271.5252.1113; Gardina PJ, 1996, SCIENCE, V274, P425, DOI 10.1126/science.274.5286.425; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; KAWAGISHI I, UNPUB; KIM SH, 1992, COLD SPRING HARB SYM, V57, P17, DOI 10.1101/SQB.1992.057.01.004; LEE GF, 1995, P NATL ACAD SCI USA, V92, P3391, DOI 10.1073/pnas.92.8.3391; LEE L, 1990, J BACTERIOL, V172, P377, DOI 10.1128/JB.172.1.377-382.1990; LONG DG, 1992, BIOCHEMISTRY-US, V31, P9904, DOI 10.1021/bi00156a007; MADDOCK JR, 1993, SCIENCE, V259, P1717; MANSON MD, 1992, ADV MICROB PHYSIOL, V33, P277, DOI 10.1016/S0065-2911(08)60219-2; MANSON MD, UNPUB; MARUYAMA IN, 1995, J MOL BIOL, V253, P530, DOI 10.1006/jmbi.1995.0571; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MILLIGAN DL, 1991, SCIENCE, V254, P1651, DOI 10.1126/science.1661030; OKUMURA H, UNPUB; OOSAWA K, 1983, J BACTERIOL, V154, P104, DOI 10.1128/JB.154.1.104-112.1983; OOSAWA K, 1984, J BACTERIOL, V157, P576, DOI 10.1128/JB.157.2.576-581.1984; OOSAWA K, 1986, P NATL ACAD SCI USA, V83, P6930, DOI 10.1073/pnas.83.18.6930; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; SCOTT WG, 1993, J MOL BIOL, V232, P555, DOI 10.1006/jmbi.1993.1411; STOCK JB, 1991, ANNU REV BIOPHYS BIO, V20, P109, DOI 10.1146/annurev.bb.20.060191.000545; TATSUNO I, 1994, MOL MICROBIOL, V14, P755, DOI 10.1111/j.1365-2958.1994.tb01312.x; TATSUNO I, UNPUB; WOLFE AJ, 1987, J BACTERIOL, V169, P1878, DOI 10.1128/jb.169.5.1878-1885.1987; WOLFE AJ, 1994, J BACTERIOL, V176, P4483, DOI 10.1128/JB.176.15.4483-4491.1994; Wu JG, 1996, BIOCHEMISTRY-US, V35, P4984, DOI 10.1021/bi9530189; YEH JI, 1993, J BIOL CHEM, V268, P9787; 1996, P NATL ACAD SCI USA, V93, P2545	36	65	65	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1996	274	5286					423	425		10.1126/science.274.5286.423	http://dx.doi.org/10.1126/science.274.5286.423			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN173	8832891				2022-12-24	WOS:A1996VN17300054
J	Traub, RD; Whittington, MA; Stanford, IM; Jefferys, JGR				Traub, RD; Whittington, MA; Stanford, IM; Jefferys, JGR			A mechanism for generation of long-range synchronous fast oscillations in the cortex	NATURE			English	Article							CAT VISUAL-CORTEX; NEURONAL RESPONSES; RAT HIPPOCAMPUS; SYNCHRONIZATION; CELLS; AREAS; FIELD	SYNCHRONOUS neuronal oscillations in the 30-70 Hz range, known as gamma oscillations, occur in the cortex of many species(1-6). This synchronization can occur over large distances, and in some cases over multiple cortical areas(7,8) and in both hemispheres(2); it has been proposed to underlie the binding of Several features into a single perceptual entity(4). The mechanism by which coherent oscillations are generated remains unclear, because they often show zero or near-zero phase lags over long distances, whereas much greater phase lags would be expected from the slow speed of axonal conduction. We have previously shown that interneuron networks alone can generate gamma oscillations(9,10); here we propose a simple model to explain how an interconnected chain of such networks can generate coherent oscillations. The model incorporates known properties of excitatory pyramidal tells and inhibitory interneurons; it predicts that when excitation of interneurons reaches a level sufficient to induce pairs of spikes in rapid succession (spike doublets), the network will generate gamma oscillations that are synchronized on a millisecond timescale from one end of the chain to the other. We show that in rat hippocampal slices interneurons do indeed fire spike doublets under conditions in which gamma oscillations are synchronized over several millimetres, whereas they fire single spikes under other conditions. Thus, known properties of neurons and local synaptic circuits can account for tightly synchronized oscillations in large neuronal ensembles.	COLUMBIA UNIV,DEPT NEUROL,NEW YORK,NY 10032; ST MARYS HOSP,IMPERIAL COLL,SCH MED,DEPT PHYSIOL & BIOPHYS,LONDON W2 1PG,ENGLAND; UNIV BIRMINGHAM,SCH MED,DEPT PHYSIOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	Columbia University; Imperial College London; University of Birmingham	Traub, RD (corresponding author), IBM CORP,DIV RES,TJ WATSON RES CTR,YORKTOWN HTS,NY 10598, USA.		Jefferys, John/E-6132-2012; Jefferys, John G R/AAF-1164-2021	Jefferys, John/0000-0003-0106-4412; Jefferys, John G R/0000-0003-0106-4412; Whittington, Miles Adrian/0000-0002-0247-1362	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSEN P, 1978, BRAIN RES, V144, P11, DOI 10.1016/0006-8993(78)90431-6; BAUER R, 1995, BRAIN RES, V669, P291, DOI 10.1016/0006-8993(94)01273-K; BRAGIN A, 1995, J NEUROSCI, V15, P47; BUHL EH, 1994, J NEUROPHYSIOL, V71, P1289, DOI 10.1152/jn.1994.71.4.1289; Bush P, 1996, J COMPUT NEUROSCI, V3, P91, DOI 10.1007/BF00160806; EECKMAN FH, 1990, BRAIN RES, V528, P238, DOI 10.1016/0006-8993(90)91663-2; ENGEL AK, 1991, P NATL ACAD SCI USA, V88, P6048, DOI 10.1073/pnas.88.14.6048; ENGEL AK, 1991, SCIENCE, V252, P1177, DOI 10.1126/science.252.5009.1177; FRIEN A, 1994, NEUROREPORT, V5, P2273, DOI 10.1097/00001756-199411000-00017; Gray C M, 1994, J Comput Neurosci, V1, P11, DOI 10.1007/BF00962716; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; INNOCENTI GM, 1980, ARCH ITAL BIOL, V118, P124; KISVARDAY ZF, 1993, J COMP NEUROL, V327, P398, DOI 10.1002/cne.903270307; Konig P, 1991, NEURAL COMPUT, V3, P155, DOI 10.1162/neco.1991.3.2.155; MURAKOSHI T, 1993, NEUROSCI LETT, V163, P211, DOI 10.1016/0304-3940(93)90385-X; RIBARY U, 1991, P NATL ACAD SCI USA, V88, P11037, DOI 10.1073/pnas.88.24.11037; Salin PA, 1996, J NEUROPHYSIOL, V75, P1589, DOI 10.1152/jn.1996.75.4.1589; SIK A, 1995, J NEUROSCI, V15, P6651; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.ne.18.030195.003011; SOLTESZ I, 1993, J NEUROPHYSIOL, V70, P97, DOI 10.1152/jn.1993.70.1.97; Traub RD, 1995, J COMPUT NEUROSCI, V2, P291, DOI 10.1007/BF00961441; TRAUB RD, 1994, J PHYSIOL-LONDON, V481, P79, DOI 10.1113/jphysiol.1994.sp020420; Traub RD, 1996, J PHYSIOL-LONDON, V493, P471, DOI 10.1113/jphysiol.1996.sp021397; ULNAS RR, 1991, P NATL ACAD SCI USA, V88, P897; WHITTINGTON MA, 1995, NATURE, V373, P612, DOI 10.1038/373612a0; Wilson MA, 1991, NEURAL COMPUT, V3, P498, DOI 10.1162/neco.1991.3.4.498; WONG RKS, 1981, J NEUROPHYSIOL, V45, P86, DOI 10.1152/jn.1981.45.1.86	27	515	523	0	30	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1996	383	6601					621	624		10.1038/383621a0	http://dx.doi.org/10.1038/383621a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM755	8857537				2022-12-24	WOS:A1996VM75500053
J	Duncan, R				Duncan, R			Application of image-based brain analysis to research and clinical problems	LANCET			English	Editorial Material											Duncan, R (corresponding author), SO GEN HOSP,INST NEUROL SCI,GLASGOW G51 4TF,LANARK,SCOTLAND.							COOK MJ, 1992, BRAIN, V115, P1001, DOI 10.1093/brain/115.4.1001; COWELL PE, 1994, J NEUROSCI, V14, P4748; DAVIS PC, 1994, AM J ROENTGENOL, V162, P1267, DOI 10.2214/ajr.162.6.8191980; Murphy DGM, 1996, ARCH GEN PSYCHIAT, V53, P585; MURPHY DGM, 1993, LANCET, V342, P1197, DOI 10.1016/0140-6736(93)92184-U; Wang GJ, 1996, J COMPUT ASSIST TOMO, V20, P423, DOI 10.1097/00004728-199605000-00020; Zijdenbos Alex P., 1994, Critical Reviews in Biomedical Engineering, V22, P401	7	2	2	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 12	1996	348	9033					974	975		10.1016/S0140-6736(05)64921-5	http://dx.doi.org/10.1016/S0140-6736(05)64921-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM027	8855849				2022-12-24	WOS:A1996VM02700005
J	Calleja, M; Moreno, E; Pelaz, S; Morata, G				Calleja, M; Moreno, E; Pelaz, S; Morata, G			Visualization of gene expression in living adult Drosophila	SCIENCE			English	Article							SIGNALING MOLECULE; WING DEVELOPMENT; NERVOUS-SYSTEM; VENTRAL CELLS; PROTEIN; DORSAL; PATTERN; HEDGEHOG; BOUNDARY; ORGANS	To identify genes involved in the patterning of adult structures, Ga14-UAS (upstream activating site) technology was used to visualize patterns of gene expression directly in living flies. A large number of Ga14 insertion lines were generated and their expression patterns were studied. In addition to identifying several characterized developmental genes, the approach revealed previously unsuspected genetic subdivisions of the thorax, which may control the disposition of pattern elements. The boundary between two of these domains coincides with localized expression of the signaling molecule wingless.	UNIV AUTONOMA MADRID, CSIC, CTR BIOL MOL, E-28049 MADRID, SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)			Moreno, Eduardo/D-7262-2011; Pelaz, Soraya/F-3431-2015	Pelaz, Soraya/0000-0001-7699-9330; moreno, eduardo/0000-0001-5040-452X; Morata, Gines/0000-0003-3274-5173	CSR NIH HHS [RG-372/94] Funding Source: Medline	CSR NIH HHS		ARIAS AM, 1988, DEVELOPMENT, V103, P157; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BRAND A, 1994, METHOD CELL BIOL, P435; BRAND AH, 1993, DEVELOPMENT, V118, P401; CALLEJA M, UNPUB; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CARROLL SB, 1994, SCIENCE, V265, P109, DOI 10.1126/science.7912449; Cohen Stephen M., 1993, P747; DAMBLYCHAUDIERE C, 1992, INT J DEV BIOL, V36, P85; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P1661; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; Garcia-Bellido A, 1975, GENETIC CONTROL WING; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GEYER PK, 1986, EMBO J, V5, P2657, DOI 10.1002/j.1460-2075.1986.tb04548.x; GomezSkarmeta JL, 1996, CELL, V85, P95, DOI 10.1016/S0092-8674(00)81085-5; HAENLIN M, COMMUNICATION; Heitzler P, 1996, GENETICS, V143, P1271; INGHAM PW, 1985, GENETICS, V111, P463; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; Lawrence P., 1992, MAKING FLY GENETICS; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MCALPINE JF, 1987, 28 RES BRANCH AGR CA, V2; MLODZIK M, 1987, CELL, V48, P465, DOI 10.1016/0092-8674(87)90197-8; MORATA G, 1977, NATURE, V265, P211, DOI 10.1038/265211a0; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NG M, 1995, DEVELOPMENT, V121, P589; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; RODRIGUEZ I, 1990, EMBO J, V9, P3583, DOI 10.1002/j.1460-2075.1990.tb07569.x; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; STERN CURT, 1954, AMER SCI, V42, P213; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TIONG SYK, 1995, DEVELOPMENT, V121, P1649; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0	38	408	412	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 11	1996	274	5285					252	255		10.1126/science.274.5285.252	http://dx.doi.org/10.1126/science.274.5285.252			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM671	8824191				2022-12-24	WOS:A1996VM67100045
J	Goedert, M; Jakes, R; Spillantini, MG; Hasegawa, M; Smith, MJ; Crowther, RA				Goedert, M; Jakes, R; Spillantini, MG; Hasegawa, M; Smith, MJ; Crowther, RA			Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans	NATURE			English	Article							PAIRED HELICAL FILAMENTS; NEUROFIBRILLARY TANGLES; HEPARAN-SULFATE; AMYLOID PROTEIN; DISEASE BRAIN; PHOSPHORYLATION; ISOFORMS; BINDING; IDENTIFICATION; CYTOSKELETON	THE paired helical filament (PHF) is the major component of the neurofibrillary deposits that form a defining neuropathological characteristic of Alzheimer's disease (reviewed in refs 1,2). PHFs are composed of microtubule-associated protein fan, in a hyperphosphorylated state(3-8). Hyperphosphorylation of tau results in its inability to bind to microtubules(9,10) and is believed to precede PHF assembly(11). However, it is unclear whether hyperphosphorylation of tau is either necessary or sufficient for PHF formation. Here we show that non-phosphorylated recombinant tau isoforms with three microtubule-binding repeats form paired helical-like filaments under physiological conditions in vitro, when incubated with sulphated glycosaminoglycans such as heparin or heparan sulphate. Furthermore, heparin prevents tau from binding to microtubules and promotes microtubule disassembly. Finally, we show that heparan sulphate and hyperphosphorylated Lau coexist in nerve cells of the Alzheimer's disease brain at the earliest known stages of neurofibrillary pathology. These findings, with previous studies which show that heparin stimulates tau phosphorylation by a number of protein kinases(12-14), indicate that sulphated glycosaminoglycans may be a key factor in the formation of the neurofibrillary lesions of Alzheimer's disease.			Goedert, M (corresponding author), MRC,MOL BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.							BRAAK E, 1994, ACTA NEUROPATHOL, V87, P554, DOI 10.1007/s004010050124; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; BRANDT R, 1994, J BIOL CHEM, V269, P11176; CROWTHER RA, 1991, P NATL ACAD SCI USA, V88, P2288, DOI 10.1073/pnas.88.6.2288; CROWTHER RA, 1992, FEBS LETT, V309, P199, DOI 10.1016/0014-5793(92)81094-3; CROWTHER RA, 1994, FEBS LETT, V337, P135, DOI 10.1016/0014-5793(94)80260-2; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; GOEDERT M, 1995, NEUROSCI LETT, V189, P167, DOI 10.1016/0304-3940(95)11484-E; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; Hasegawa M, 1996, FEBS LETT, V384, P25, DOI 10.1016/0014-5793(96)00271-2; JAKES R, 1991, EMBO J, V10, P2725, DOI 10.1002/j.1460-2075.1991.tb07820.x; KATO T, 1991, NEUROSCI LETT, V122, P33, DOI 10.1016/0304-3940(91)90186-W; KONDO J, 1988, NEURON, V1, P827, DOI 10.1016/0896-6273(88)90130-4; LEE VMY, 1995, CURR OPIN NEUROBIOL, V5, P663, DOI 10.1016/0959-4388(95)80073-5; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; MAWALDEWAN M, 1992, J BIOL CHEM, V267, P19705; MERCKEN M, 1992, ACTA NEUROPATHOL, V84, P265, DOI 10.1007/BF00227819; PERRY G, 1991, J NEUROSCI, V11, P3679; SCHWEERS O, 1995, P NATL ACAD SCI USA, V92, P8463, DOI 10.1073/pnas.92.18.8463; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SNOW AD, 1989, ACTA NEUROPATHOL, V78, P113, DOI 10.1007/BF00688198; SNOW AD, 1990, AM J PATHOL, V137, P1253; SPILLANTINI MG, 1990, P NATL ACAD SCI USA, V87, P3947, DOI 10.1073/pnas.87.10.3947; STRITTMATTER WJ, 1994, EXP NEUROL, V125, P163, DOI 10.1006/exnr.1994.1019; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; YANG SD, 1994, J NEUROCHEM, V63, P1416; YOSHIDA H, 1993, J NEUROCHEM, V61, P1183, DOI 10.1111/j.1471-4159.1993.tb03642.x	33	828	842	5	50	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1996	383	6600					550	553		10.1038/383550a0	http://dx.doi.org/10.1038/383550a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL755	8849730				2022-12-24	WOS:A1996VL75500057
J	Kanyo, ZF; Scolnick, LR; Ash, DE; Christianson, DW				Kanyo, ZF; Scolnick, LR; Ash, DE; Christianson, DW			Structure of a unique binuclear manganese cluster in arginase	NATURE			English	Article							RAT-LIVER ARGINASE; NITRIC-OXIDE BIOSYNTHESIS; HYDROXY-L-ARGININE; INTERMEDIATE; MACROPHAGES; INDUCTION; PROGRAM	EACH individual excretes roughly 10 kg of urea per year, as a result of the hydrolysis of arginine in the final cytosolic step of the urea cycle(1). This reaction allows the disposal of nitrogenous waste from protein catabolism, and is catalysed by the liver arginase enzyme(2). In other tissues that lack a complete urea cycle, arginase regulates cellular arginine and ornithine concentrations for biosynthetic reactions(3), including nitric oxide synthesis: in the macrophage, arginase activity is reciprocally coordinated with that of NO synthase to modulate NO-dependent cytotoxicity(4-9). The bioinorganic chemistry of arginase is particularly rich because this enzyme is one of very few that specifically requires a spin-coupled Mn2+-Mn2+ cluster for catalytic activity in vitro and in vivo(10). The 2.1 Angstrom-resolution crystal structure of trimeric(11) rat liver arginase reveals that this unique metal cluster resides at the bottom of an active-site cleft that is 15 Angstrom deep. Analysis of the structure indicates that arginine hydrolysis is achieved by a metal-activated solvent molecule which symmetrically bridges the two Mn2+ ions.	UNIV PENN,DEPT CHEM,PHILADELPHIA,PA 19104; TEMPLE UNIV,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140	University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NIGMS NIH HHS [R01 GM067788] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067788] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBINA JE, 1995, J IMMUNOL, V155, P4391; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CAVALLI RC, 1994, BIOCHEMISTRY-US, V33, P10652, DOI 10.1021/bi00201a012; CHENAIS B, 1993, BIOCHEM BIOPH RES CO, V196, P1558, DOI 10.1006/bbrc.1993.2429; Christianson DW, 1996, ACCOUNTS CHEM RES, V29, P331, DOI 10.1021/ar9501232; CHRISTIANSON DW, 1989, J AM CHEM SOC, V111, P6412, DOI 10.1021/ja00198a065; CORRALIZA IM, 1995, BIOCHEM BIOPH RES CO, V206, P667, DOI 10.1006/bbrc.1995.1094; DAGHIGH F, 1994, BIOCHEM BIOPH RES CO, V202, P174, DOI 10.1006/bbrc.1994.1909; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; HERZFELD A, 1976, BIOCHEM J, V153, P469, DOI 10.1042/bj1530469; JABRI E, 1995, SCIENCE, V268, P998, DOI 10.1126/science.7754395; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KANYO ZF, 1992, J MOL BIOL, V224, P1175, DOI 10.1016/0022-2836(92)90479-4; KELLER R, 1991, CELL IMMUNOL, V134, P249, DOI 10.1016/0008-8749(91)90348-F; KLATT P, 1993, J BIOL CHEM, V268, P14781; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krebs HA, 1932, H-S Z PHYSIOL CHEM, V210, P33, DOI 10.1515/bchm2.1932.210.1-2.33; KUHN NJ, 1991, ARCH BIOCHEM BIOPHYS, V286, P217, DOI 10.1016/0003-9861(91)90031-D; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Nyborg J., 1977, ROTATION METHOD CRYS, P139; Park IS, 1996, BIOCHEMISTRY-US, V35, P5345, DOI 10.1021/bi952894j; RARDIN RL, 1991, NEW J CHEM, V15, P417; RECZKOWSKI RS, 1992, J AM CHEM SOC, V114, P10992, DOI 10.1021/ja00053a064; RECZKOWSKI RS, 1994, ARCH BIOCHEM BIOPHYS, V312, P31, DOI 10.1006/abbi.1994.1276; YIP MCM, 1972, BIOCHEM J, V127, P893, DOI 10.1042/bj1270893	27	376	380	6	71	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1996	383	6600					554	557		10.1038/383554a0	http://dx.doi.org/10.1038/383554a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL755	8849731				2022-12-24	WOS:A1996VL75500058
J	Bauer, MF; Sirrenberg, C; Neupert, W; Brunner, M				Bauer, MF; Sirrenberg, C; Neupert, W; Brunner, M			Role of Tim23 as voltage sensor and presequence receptor in protein import into mitochondria	CELL			English	Article							INNER MEMBRANE; YEAST MITOCHONDRIA; DYNAMIC INTERACTION; CRYSTAL-STRUCTURE; TRANSLOCATION; HSP70; PRECURSOR; SUPPRESSOR; MACHINERY; TRANSPORT	Tim23, an essential component of the protein import machinery of the inner membrane of mitochondria (TIM complex), forms dimers that display a dynamic behavior. Dimer formation is promoted by the membrane potential Delta psi. Binding of a matrix targeting sequence to Tim23 triggers dimer dissociation. Monomeric Tim23 is present when a preprotein chain is in transit across the TIM complex. Dimerization of Tim23 is dependent on the second half of its N-terminal hydrophilic domain, which is exposed to the intermembrane space. This segment contains a heptad leucine repeat motif with a predicted capacity for dimer formation. We propose that Tim23 exerts a key function in protein import: Tim23 dimers formed in response to Delta psi act as receptors for matrix targeting sequences on the surface of the inner membrane. The ensuing dissociation of Tim23 dimer triggers opening of the TIM channel and insertion of the preprotein.			Bauer, MF (corresponding author), UNIV MUNICH,INST PHYSIOL CHEM,GOETHESTR 33,D-80336 MUNICH,GERMANY.			Brunner, Michael/0000-0001-9798-3047				BERTHOLD J, 1995, CELL, V81, P1085, DOI 10.1016/S0092-8674(05)80013-3; BLOM J, 1996, EUR J BIOCHEM, V232, P309; DEKKER PJT, 1993, FEBS LETT, V330, P66, DOI 10.1016/0014-5793(93)80921-G; EMTAGE JLT, 1993, J CELL BIOL, V122, P1003, DOI 10.1083/jcb.122.5.1003; FRIEDMAN AM, 1995, SCIENCE, V268, P1721, DOI 10.1126/science.7792597; Glick B, 1991, Trends Cell Biol, V1, P99, DOI 10.1016/0962-8924(91)90037-A; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; HORST M, 1995, EMBO J, V14, P2293, DOI 10.1002/j.1460-2075.1995.tb07223.x; HOVLAND P, 1989, GENE, V83, P57, DOI 10.1016/0378-1119(89)90403-4; HWANG S, 1989, J CELL BIOL, V109, P487, DOI 10.1083/jcb.109.2.487; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; KRONIDOU NG, 1994, P NATL ACAD SCI USA, V91, P12818, DOI 10.1073/pnas.91.26.12818; KUBRICH M, 1994, FEBS LETT, V349, P222, DOI 10.1016/0014-5793(94)00670-9; KUBRICH M, 1995, CURR GENET, V27, P393, DOI 10.1007/BF00311207; LITHGOW T, 1995, TRENDS BIOCHEM SCI, V20, P98, DOI 10.1016/S0968-0004(00)88972-0; Lupas A, 1996, METHOD ENZYMOL, V266, P513; MAARSE AC, 1992, EMBO J, V11, P3619, DOI 10.1002/j.1460-2075.1992.tb05446.x; MAARSE AC, 1994, FEBS LETT, V349, P215, DOI 10.1016/0014-5793(94)00669-5; MARTIN J, 1991, J BIOL CHEM, V266, P18051; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; MAYER A, 1995, EMBO J, V14, P4204, DOI 10.1002/j.1460-2075.1995.tb00094.x; PFANNER N, 1992, CELL, V68, P999, DOI 10.1016/0092-8674(92)90069-O; PFANNER N, 1985, EMBO J, V4, P2819, DOI 10.1002/j.1460-2075.1985.tb04009.x; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; RASSOW J, 1994, J CELL BIOL, V127, P1547, DOI 10.1083/jcb.127.6.1547; RYAN KR, 1994, MOL BIOL CELL, V5, P529, DOI 10.1091/mbc.5.5.529; RYAN KR, 1993, J BIOL CHEM, V268, P23743; SCHLEYER M, 1984, J BIOL CHEM, V259, P3487; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; STUBER D, 1990, IMMUNOLOGICAL METHOD, V4, P121; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; Ungermann C, 1996, EMBO J, V15, P735, DOI 10.1002/j.1460-2075.1996.tb00409.x; Voos W, 1996, EMBO J, V15, P2668, DOI 10.1002/j.1460-2075.1996.tb00627.x; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0	35	237	238	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1996	87	1					33	41		10.1016/S0092-8674(00)81320-3	http://dx.doi.org/10.1016/S0092-8674(00)81320-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VL695	8858146	Bronze			2022-12-24	WOS:A1996VL69500006
J	Umar, A; Buermeyer, AB; Simon, JA; Thomas, DC; Clark, AB; Liskay, RM; Kunkel, TA				Umar, A; Buermeyer, AB; Simon, JA; Thomas, DC; Clark, AB; Liskay, RM; Kunkel, TA			Requirement for PCNA in DNA mismatch repair at a step preceding DNA resynthesis	CELL			English	Article							CELL NUCLEAR ANTIGEN; NUCLEOTIDE EXCISION-REPAIR; PROTEIN-PROTEIN INTERACTIONS; SIMPLE REPETITIVE DNA; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; REPLICATION FORK; 2-HYBRID SYSTEM; SHUTTLE VECTORS; TUMOR-CELLS	A two-hybrid system was used to screen yeast and human expression libraries for proteins that interact with mismatch repair proteins. PCNA was recovered from both libraries and shown in the case of yeast to interact with both MLH1 and MSH2. A yeast strain containing a mutation in the PCNA gene had a strongly elevated mutation rate in a dinucleotide repeat, and the rate was not further elevated in a strain also containing a mutation in MLH1. Mismatch repair activity was examined in human cell extracts using an assay that does not require DNA repair synthesis. Activity was inhibited by p21WAF1 or a p21 peptide, both of which bind to PCNA, and activity was restored to inhibited reactions by addition of PCNA. The data suggest a PCNA requirement in mismatch repair at a step preceding DNA resynthesis. The ability of PCNA to bind to MLH1 and MSH2 may reflect linkage between mismatch repair and replication and may be relevant to the roles of mismatch repair proteins in other DNA transactions.	OREGON HLTH SCI UNIV,DEPT MOL & MED GENET,PORTLAND,OR 97201	Oregon Health & Science University	Umar, A (corresponding author), NIEHS,MOL GENET LAB,RES TRIANGLE PK,NC 27709, USA.		Kunkel, Thomas A./D-5088-2019; Umar, Asad/AAI-4560-2020; Buermeyer, Andrew/AAW-4099-2020	Kunkel, Thomas A./0000-0002-9900-1788; Umar, Asad/0000-0002-6239-8494; Buermeyer, Andrew/0000-0003-4502-4666	NIGMS NIH HHS [GM45413-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045413] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; BENDIXEN C, 1994, NUCLEIC ACIDS RES, V22, P1778, DOI 10.1093/nar/22.9.1778; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BOYER JC, 1995, CANCER RES, V55, P6063; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; FANG WH, 1993, J BIOL CHEM, V268, P11838; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FUKUDA K, 1995, J BIOL CHEM, V270, P22527, DOI 10.1074/jbc.270.38.22527; HALL PA, 1995, ONCOGENE, V10, P2427; HAWN MT, 1995, CANCER RES, V55, P3721; HEALE SM, 1995, CELL, V83, P539, DOI 10.1016/0092-8674(95)90093-4; HENDERSON ST, 1992, MOL CELL BIOL, V12, P2749, DOI 10.1128/MCB.12.6.2749; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Iaccarino I, 1996, CURR BIOL, V6, P484, DOI 10.1016/S0960-9822(02)00516-X; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; KOLODNER R, 1996, IN PRESS GENES DEV; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LEVINSON G, 1987, NUCLEIC ACIDS RES, V15, P5323, DOI 10.1093/nar/15.13.5323; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; Mellon I, 1996, SCIENCE, V272, P557, DOI 10.1126/science.272.5261.557; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, pU3559; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; ROBERTS JD, 1993, GENETICS, V2, P295; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH M, 1994, SCIENCE, V226, P1376; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; Thomas David C., 1995, Methods (Orlando), V7, P187, DOI 10.1006/meth.1995.1024; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Umar A, 1996, EUR J BIOCHEM, V238, P297, DOI 10.1111/j.1432-1033.1996.0297z.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; WARD AC, 1990, NUCLEIC ACIDS RES, V18, P5319, DOI 10.1093/nar/18.17.5319	51	486	501	9	114	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1996	87	1					65	73		10.1016/S0092-8674(00)81323-9	http://dx.doi.org/10.1016/S0092-8674(00)81323-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VL695	8858149	Bronze			2022-12-24	WOS:A1996VL69500009
J	Danielian, PS; McMahon, AP				Danielian, PS; McMahon, AP			Engrailed-1 as a target of the Wnt-1 signalling pathway in vertebrate midbrain development	NATURE			English	Article							INT-1 PROTOONCOGENE; MOUSE DEVELOPMENT; EXPRESSION; MICE; DELETION; PHENOTYPE; OUTGROWTH; EMBRYOS; DOMAINS; FAMILY	A SECRETED Signalling molecule encoded by the Wnt-1 gene is required for development of the central nervous system. In mouse embryos homozygous for a Wnt-1-null allele, the midbrain and anterior hindbrain fail to develop(1,2). This corresponds to the region where two transcription factors encoded by the mouse engrailed genes (En-1 and En-2) are normally expressed(3,4). Studies of the Drosophila orthologue of Wnt-1, wingless, indicate that Wingless signal is required to maintain engrailed expression in neighbouring cells of the developing epidermis(5-7). Here we report that expression of En-1 in the developing midbrain of Wnt-1 null embryos is sufficient to rescue early midbrain and anterior hindbrain development. This suggests that a key role of Wnt-1 signalling is to maintain En expression and that this aspect of the Wnt-1/engrailed interaction has been conserved from flies to mice.	HARVARD UNIV, BIOL LABS, DEPT MOL & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA	Harvard University			McMahon, Andrew P/ABE-7520-2020	Danielian, Paul/0000-0003-2651-0386				ARIAS AM, 1988, DEVELOPMENT, V103, P157; ASANO M, 1992, MECH DEVELOP, V39, P29, DOI 10.1016/0925-4773(92)90023-D; Crossley PH, 1996, NATURE, V380, P66, DOI 10.1038/380066a0; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DAVIS CA, 1991, DEVELOPMENT, V111, P287; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FRITZSCH B, 1995, J NEUROBIOL, V27, P457, DOI 10.1002/neu.480270403; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; KLINGENSMITH J, 1995, REV BIOL, V170, P636; KNECHT AK, 1995, DEVELOPMENT, V121, P1927; MAHMOOD R, 1995, CURR BIOL, V5, P797, DOI 10.1016/S0960-9822(95)00157-6; MASTICK GS, IN PRESS J COMP NEUR; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; PARR BA, 1993, DEVELOPMENT, V119, P247; ROWITCH DH, 1995, MECH DEVELOP, V52, P3, DOI 10.1016/0925-4773(95)00380-J; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; WURST W, 1994, DEVELOPMENT, V120, P2065	23	238	240	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 26	1996	383	6598					332	334		10.1038/383332a0	http://dx.doi.org/10.1038/383332a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VJ439	8848044				2022-12-24	WOS:A1996VJ43900043
J	Cumano, A; DieterlenLievre, F; Godin, I				Cumano, A; DieterlenLievre, F; Godin, I			Lymphoid potential, probed before circulation in mouse, is restricted to caudal intraembryonic splanchnopleura	CELL			English	Article							HEMATOPOIETIC STEM-CELLS; IN-VITRO DIFFERENTIATION; MURINE FETAL LIVER; EMBRYONIC YOLK-SAC; B-CELL; PARAAORTIC SPLANCHNOPLEURA; BONE-MARROW; PRECURSORS; PROGENITORS; ONTOGENY	Emergence of hemopoietic stem cells in the mammalian embryo has yet to be definitively allocated. Previously, we detected multipotent hemopoietic precursors in the region surrounding the dorsal aorta (paraaortic splanchnopleura) beginning at 8.5 days postcoitum (dpc). However, as circulation is already established, it remained unclear whether hemopoietic precursors arise in situ or are blood-delivered. By adding an organotypic step to our former culture system, we now detect lymphocyte and multipotent myeloid precursors from the intraembryonic splanchnopleura as early as 7.5 dpc. Under identical conditions, yolk sacs from the same embryos are unable to generate lymphoid progeny and have a reduced potential for myeloid differentiation and maintenance. Thus, if isolated before circulation, the yolk sac does not produce multipotent precursors and therefore does not contribute to definitive hemopoiesis in the mouse.	COLL FRANCE, F-75024 PARIS, FRANCE; INST PASTEUR, INSERM, U277, UNITE BIOL MOL GENE, F-75024 PARIS, FRANCE	UDICE-French Research Universities; PSL Research University Paris; College de France; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Cumano, A (corresponding author), CNRS, INST EMBRYOL CELLULAIRE & MOL, F-75024 PARIS, FRANCE.		GODIN, Isabelle/K-5769-2013	GODIN, Isabelle/0000-0001-8577-8388; Cumano, Ana/0000-0002-4578-959X				BEAUPAIN D, 1979, BLOOD, V53, P212; BROTHERTON TW, 1979, P NATL ACAD SCI USA, V76, P2853, DOI 10.1073/pnas.76.6.2853; COLLINS LS, 1987, J IMMUNOL, V138, P1082; CUMANO A, 1992, EMBO J, V11, P593, DOI 10.1002/j.1460-2075.1992.tb05091.x; CUMANO A, 1993, P NATL ACAD SCI USA, V90, P6429, DOI 10.1073/pnas.90.14.6429; CUMANO A, 1992, NATURE, V356, P612, DOI 10.1038/356612a0; Delassus S, 1996, IMMUNITY, V4, P97, DOI 10.1016/S1074-7613(00)80302-7; DIETERLENLIEVRE F, 1975, J EMBRYOL EXP MORPH, V33, P607; DOWNS KM, 1993, DEVELOPMENT, V118, P1255; GARCIAPORRERO JA, 1995, ANAT EMBRYOL, V192, P427; GODIN I, 1995, P NATL ACAD SCI USA, V92, P773, DOI 10.1073/pnas.92.3.773; Godin I, 1995, Semin Immunol, V7, P131, DOI 10.1016/1044-5323(95)90041-1; GODIN IE, 1993, NATURE, V364, P67, DOI 10.1038/364067a0; HAMILTON HL, 1952, LILLIES DEV CHICK IN; HARRISON DE, 1979, BLOOD, V54, P1152; HOMBACH J, 1988, EMBO J, V7, P3451, DOI 10.1002/j.1460-2075.1988.tb03219.x; HUANG H, 1994, EXP HEMATOL, V22, P19; JENKINSON EJ, 1992, J EXP MED, V176, P845, DOI 10.1084/jem.176.3.845; Kanatsu M, 1996, DEVELOPMENT, V122, P823; KEE BL, 1994, INT IMMUNOL, V6, P401, DOI 10.1093/intimm/6.3.401; LAWSON KA, 1991, DEVELOPMENT, V113, P891; LEDER A, 1992, DEVELOPMENT, V116, P1041; LI YS, 1993, J EXP MED, V178, P951, DOI 10.1084/jem.178.3.951; LIU CP, 1991, DEVELOPMENT, V113, P1315; Medvinsky AL, 1996, BLOOD, V87, P557, DOI 10.1182/blood.V87.2.557.bloodjournal872557; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; METCALF D, 1971, FRONT BIOL, V24, P173; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; MULLER AM, 1994, IMMUNITY, V1, P291, DOI 10.1016/1074-7613(94)90081-7; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; OGAWA M, 1988, EMBO J, V7, P1337, DOI 10.1002/j.1460-2075.1988.tb02949.x; PAIGE CJ, 1979, J EXP MED, V150, P548, DOI 10.1084/jem.150.3.548; PALACIOS R, 1993, P NATL ACAD SCI USA, V90, P6581, DOI 10.1073/pnas.90.14.6581; PARAMESWARAN M, 1995, DEV GENET, V17, P16, DOI 10.1002/dvg.1020170104; SAINTRUF C, 1994, SCIENCE, V266, P1208, DOI 10.1126/science.7973703; SONODA T, 1983, DEV BIOL, V97, P89, DOI 10.1016/0012-1606(83)90066-0; TOLES JF, 1989, P NATL ACAD SCI USA, V86, P7456, DOI 10.1073/pnas.86.19.7456; TYAN ML, 1968, J IMMUNOL, V101, P446; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WEISSMANN I, 1978, COLD SPRING HARB SYM, V5, P33; WONG PMC, 1986, P NATL ACAD SCI USA, V83, P3851, DOI 10.1073/pnas.83.11.3851	41	447	451	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	1996	86	6					907	916		10.1016/S0092-8674(00)80166-X	http://dx.doi.org/10.1016/S0092-8674(00)80166-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VJ443	8808626	Bronze			2022-12-24	WOS:A1996VJ44300009
J	Pollard, VW; Michael, WM; Nakielny, S; Siomi, MC; Wang, F; Dreyfuss, G				Pollard, VW; Michael, WM; Nakielny, S; Siomi, MC; Wang, F; Dreyfuss, G			A novel receptor-mediated nuclear protein import pathway	CELL			English	Article							PORE-TARGETING COMPLEX; HNRNP PROTEINS; SACCHAROMYCES-CEREVISIAE; HUMAN HOMOLOG; T-ANTIGEN; TRANSPORT; IDENTIFICATION; LOCALIZATION; SEQUENCE; INTERACTS	Targeting of most nuclear proteins to the cell nucleus is initiated by interaction between the classical nuclear localization signals (NLSs) contained within them and the importin NLS receptor complex. We have recently delineated a novel 38 amino acid transport signal in the hnRNP A1 protein, termed M9, which confers bidirectional transport across the nuclear envelope. We show here that M9-mediated nuclear import occurs by a novel pathway that is independent of the well-characterized, importin-mediated classical NLS pathway. Additionally, we have identified a specific M9-interacting protein, termed transportin, which binds to wild-type M9 but not to transport-defective M9 mutants. Transportin is a 90 kDa protein, distantly related to importin beta, and we show that it mediates the nuclear import of M9-containing proteins. These findings demonstrate that there are at least two receptor-mediated nuclear protein import pathways. Furthermore, as hnRNP A1 likely participates in mRNA export, it raises the possibility that transportin is a mediator of this process as well.			Pollard, VW (corresponding author), UNIV PENN, SCH MED, HOWARD HUGHES MED INST, DEPT BIOCHEM & BIOPHYS, PHILADELPHIA, PA 19104 USA.		McDermott, Michael Francis/GZM-5330-2022; Dreyfuss, Gideon/D-1218-2013	Dreyfuss, Gideon/0000-0001-8129-8774				ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; CORTES P, 1994, P NATL ACAD SCI USA, V91, P7633, DOI 10.1073/pnas.91.16.7633; CUOMO CA, 1994, P NATL ACAD SCI USA, V91, P6156, DOI 10.1073/pnas.91.13.6156; DAVIS LI, 1995, ANNU REV BIOCHEM, V64, P865, DOI 10.1146/annurev.bi.64.070195.004245; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; DUVERGER E, 1995, J CELL SCI, V108, P1325; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FISCHER U, 1991, J CELL BIOL, V113, P705, DOI 10.1083/jcb.113.4.705; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; IMAMOTO N, 1995, FEBS LETT, V368, P415; Iovine MK, 1995, J CELL BIOL, V131, P1699, DOI 10.1083/jcb.131.6.1699; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KILEDJIAN M, 1994, RNA PROTEIN INTERACT, P127; KUSSEL P, 1995, J CELL BIOL, V129, P1491, DOI 10.1083/jcb.129.6.1491; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; Michael WM, 1995, COLD SPRING HARB SYM, V60, P663, DOI 10.1101/SQB.1995.060.01.071; MICHAEL WM, 1995, CELL, V83, P415; MICHAUD N, 1991, J CELL BIOL, V112, P215, DOI 10.1083/jcb.112.2.215; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P6572, DOI 10.1073/pnas.93.13.6572; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; NAKIELNY S, 1996, IN PRESS J CELL BIOL; ONEILL RE, 1995, VIROLOGY, V206, P116, DOI 10.1016/S0042-6822(95)80026-3; Pante N, 1995, INT REV CYTOL, V162B, P225; Pante N, 1996, CURR OPIN CELL BIOL, V8, P397, DOI 10.1016/S0955-0674(96)80016-0; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Pinol-Roma Serafin, 1993, Trends in Cell Biology, V3, P151, DOI 10.1016/0962-8924(93)90135-N; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SCHAAFFGERSTENSCHLAGER I, 1995, YEAST, V11, P79, DOI 10.1002/yea.320110110; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; TOROK I, 1995, J CELL BIOL, V129, P1473, DOI 10.1083/jcb.129.6.1473; Visa N, 1996, CELL, V84, P253, DOI 10.1016/S0092-8674(00)80980-0; WEIGHARDT F, 1995, J CELL SCI, V108, P545; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640	54	585	591	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	1996	86	6					985	994		10.1016/S0092-8674(00)80173-7	http://dx.doi.org/10.1016/S0092-8674(00)80173-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VJ443	8808633	hybrid			2022-12-24	WOS:A1996VJ44300016
J	Neumann, S; Doubell, TP; Leslie, T; Woolf, CJ				Neumann, S; Doubell, TP; Leslie, T; Woolf, CJ			Inflammatory pain hypersensitivity mediated by phenotypic switch in myelinated primary sensory neurons	NATURE			English	Article							NERVE GROWTH-FACTOR; RAT SPINAL-CORD; SUBSTANCE-P; DORSAL HORN; RECEPTOR ACTIVATION; FACTOR CONTRIBUTES; MESSENGER-RNAS; INJURY; REFLEX; SENSITIZATION	PAIN is normally evoked only by stimuli that are sufficiently intense to activate high-threshold A delta and C sensory fibres, which relay the signal tp the spinal cord, Peripheral inflammation leads to profoundly increased pain sensitivity: noxious stimuli generate a greater response and stimuli that are normally innocuous Elicit pain. Inflammation increases the sensitivity of the peripheral terminals of A delta and C fibres at the site of inflammation(1). It also increases the excitability of spinal cord neurons(2,3), which now amplify all sensory inputs including the normally innocuous tactile stimuli that are conveyed by low-threshold A beta fibres. This central sensitization has been attributed to the enhanced activity of C fibers(4), which increase the excitability of their postsynaptic targets by releasing glutamate and the neuropeptide substance P5-7. Here we show that inflammation results in A beta fibres also acquiring the capacity to increase the excitability of spinal cord neurons. This is due fa a phenotypic switch in a subpopulation of these fibres so that they, like C-fibres, now express substance P. A beta fibres thus appear to contribute to inflammatory hypersensitivity by switching their phenotype to one resembling pain fibres, thereby enhancing synaptic transmission in the spinal cord and exaggerating the central response to innocuous stimuli.			Neumann, S (corresponding author), UNIV LONDON UNIV COLL,DEPT ANAT & DEV BIOL,GOWER ST,LONDON WC1E 6BT,ENGLAND.		Woolf, Clifford/A-9784-2010	doubell, timothy/0000-0003-1054-5592				AVERILL S, 1995, EUR J NEUROSCI, V7, P1484, DOI 10.1111/j.1460-9568.1995.tb01143.x; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; DONNERER J, 1992, NEUROSCIENCE, V49, P693, DOI 10.1016/0306-4522(92)90237-V; FITZGERALD M, 1985, BRAIN RES, V332, P131, DOI 10.1016/0006-8993(85)90396-8; HEATH MJS, 1994, J NEUROPHYSIOL, V72, P1192, DOI 10.1152/jn.1994.72.3.1192; LESLIE TA, 1995, NEUROSCIENCE, V67, P753, DOI 10.1016/0306-4522(95)00101-N; LEWIN GR, 1994, EUR J NEUROSCI, V6, P1903, DOI 10.1111/j.1460-9568.1994.tb00581.x; MA QP, 1995, J PHYSIOL-LONDON, V486, P769, DOI 10.1113/jphysiol.1995.sp020852; Ma QP, 1996, PAIN, V67, P97, DOI 10.1016/0304-3959(96)03105-3; MANTYH PW, 1995, SCIENCE, V268, P1629, DOI 10.1126/science.7539937; MCMAHON SB, 1995, NAT MED, V1, P774, DOI 10.1038/nm0895-774; NOGUCHI K, 1995, J NEUROSCI, V15, P7633; Reeh PW, 1994, CELLULAR MECH SENSOR, V79, P119; ROBERTSON B, 1991, J NEUROCYTOL, V20, P387, DOI 10.1007/BF01355535; THOMPSON SWN, 1990, EUR J NEUROSCI, V2, P638, DOI 10.1111/j.1460-9568.1990.tb00453.x; THOMPSON SWN, 1994, J NEUROSCI, V14, P3672; TOREBJORK HE, 1992, J PHYSIOL-LONDON, V448, P765, DOI 10.1113/jphysiol.1992.sp019069; URBAN L, 1984, BRAIN RES, V290, P336, DOI 10.1016/0006-8993(84)90952-1; VERGE VMK, 1995, J NEUROSCI, V15, P2081, DOI 10.1523/JNEUROSCI.15-03-02081.1995; WARDEN MK, 1988, J COMP NEUROL, V272, P90, DOI 10.1002/cne.902720107; WOOLF CJ, 1986, J NEUROSCI, V6, P1433; WOOLF CJ, 1990, J NEUROSCI, V10, P2717; WOOLF CJ, 1994, PAIN, V58, P141, DOI 10.1016/0304-3959(94)90195-3; WOOLF CJ, 1983, NATURE, V306, P686, DOI 10.1038/306686a0; WOOLF CJ, 1987, J COMP NEUROL, V261, P105, DOI 10.1002/cne.902610109; WOOLF CJ, 1991, PAIN, V44, P293, DOI 10.1016/0304-3959(91)90100-C; WOOLF CJ, 1994, NEUROSCIENCE, V62, P327, DOI 10.1016/0306-4522(94)90366-2; XU XJ, 1992, EUR J PHARMACOL, V216, P337, DOI 10.1016/0014-2999(92)90428-7	28	426	438	0	23	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1996	384	6607					360	364		10.1038/384360a0	http://dx.doi.org/10.1038/384360a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV271	8934522				2022-12-24	WOS:A1996VV27100050
J	Fletcher, CF; Lutz, CM; OSullivan, TN; Shaughnessy, JD; Hawkes, R; Frankel, WN; Copeland, NG; Jenkins, NA				Fletcher, CF; Lutz, CM; OSullivan, TN; Shaughnessy, JD; Hawkes, R; Frankel, WN; Copeland, NG; Jenkins, NA			Absence epilepsy in tottering mutant mice is associated with calcium channel defects	CELL			English	Article							TYROSINE-HYDROXYLASE GENE; PROGRAMMED CELL-DEATH; CA2+ CHANNELS; INTRACELLULAR CALCIUM; SELECTIVE INCREASE; CENTRAL NEURONS; PURKINJE-CELLS; SPIKE-WAVE; MOUSE; EXPRESSION	Mutations at the mouse tottering (tg) locus cause a delayed-onset, recessive neurological disorder resulting in ataxia, motor seizures, and behavioral absence seizures resembling petit mal epilepsy in humans. A more severe allele, leaner (tg(la)), also shows a slow, selective degeneration of cerebellar neurons. By positional cloning, we have identified an alpha(1A) voltage-sensitive calcium channel gene that is mutated in tg and tg(la) mice. The alpha(1A) gene is widely expressed in the central nervous system with prominent, uniform expression in the cerebellum. alpha(1A) expression does not mirror the localized pattern of cerebellar degeneration observed in tg(la) mice, providing evidence for regional differences in biological function of alpha(1A) channels. These studies define the first mutations in a mammalian central nervous system-specific voltage-sensitive calcium channel and identify the first gene involved in absence epilepsy.	JACKSON LAB,BAR HARBOR,ME 04609; UNIV CALGARY,FAC MED,DEPT ANAT,CALGARY,AB T2N 4N1,CANADA; UNIV CALGARY,FAC MED,NEUROSCI RES GRP,CALGARY,AB T2N 4N1,CANADA	Jackson Laboratory; University of Calgary; University of Calgary	Fletcher, CF (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,MAMMALIAN GENET LAB,ABL BASIC RES PROGRAM,FREDERICK,MD 21702, USA.		Hawkes, Richard/F-7971-2011					ADACHI K, 1975, IRCS (International Research Communications System) Medical Science Library Compendium, V3, P329; ANDERSON VE, 1991, GENETIC STRATEGIES E, P89; ANNEGERS JF, 1991, GENETIC STRATEGIES E, P139; AUSTIN MC, 1992, MOL BRAIN RES, V15, P227, DOI 10.1016/0169-328X(92)90113-P; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; CHAUDHARI N, 1992, J BIOL CHEM, V267, P25636; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; CHRISTAKOS S, 1987, METHOD ENZYMOL, V139, P534; de Curtis M, 1994, Funct Neurol, V9, P307; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; GALLI C, 1995, J NEUROSCI, V15, P1172; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GHOSH A, 1994, J NEUROBIOL, V25, P294, DOI 10.1002/neu.480250309; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GREEN MC, 1962, J HERED, V53, P79; Green MC., 1989, GENETIC VARIANTS STR, P12; HAUSER JF, 1991, GENETIC STRATEGIES E, P45; HAWKES R, 1991, PROG NEUROBIOL, V36, P309, DOI 10.1016/0301-0082(91)90004-K; HECKROTH JA, 1994, BRAIN RES, V658, P93, DOI 10.1016/S0006-8993(09)90014-2; HELLAR AH, 1983, EPILEPSIA, V2, P25; HERRUP K, 1982, NEUROSCIENCE, V7, P2185, DOI 10.1016/0306-4522(82)90129-4; HESS EJ, 1991, NEURON, V6, P123, DOI 10.1016/0896-6273(91)90127-L; HILLE B, 1992, IONIC CHANNELS EXCIT, P83; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; KATER SB, 1991, J NEUROSCI, V11, P891; KILBOURNE EJ, 1992, J BIOL CHEM, V267, P7563; KOELLER DM, 1995, GENOMICS, V28, P508, DOI 10.1006/geno.1995.1182; KOH JY, 1992, BRAIN RES, V587, P233, DOI 10.1016/0006-8993(92)91002-V; KRAWCZAK M, 1992, HUM GENET, V90, P41; LENNON VA, 1995, NEW ENGL J MED, V332, P1467, DOI 10.1056/NEJM199506013322203; LEVITT P, 1981, P NATL ACAD SCI-BIOL, V78, P4630, DOI 10.1073/pnas.78.7.4630; LIMBRICK DD, 1995, BRAIN RES, V690, P145, DOI 10.1016/0006-8993(95)00552-2; LLINAS R, 1989, P NATL ACAD SCI USA, V86, P1689, DOI 10.1073/pnas.86.5.1689; LLINAS RR, 1989, ANN NY ACAD SCI, V560, P103, DOI 10.1111/j.1749-6632.1989.tb24084.x; MARESCAUX C, 1992, J NEURAL TRANSM-SUPP, V35, P37; MEIER H, 1971, J HERED, V62, P297, DOI 10.1093/oxfordjournals.jhered.a108176; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; Nishimura Y, 1975, ADV NEUROL SCI, V19, P670; NOEBELS JL, 1979, SCIENCE, V204, P1334, DOI 10.1126/science.572084; NOEBELS JL, 1984, NATURE, V310, P409, DOI 10.1038/310409a0; NOEBELS JL, 1984, ANN NEUROL, V16, pS18, DOI 10.1002/ana.410160705; ORRENIUS S, 1994, J NEURAL TRANSM-SUPP, V43, P1; PEREZREYES E, 1995, KIDNEY INT, V48, P1111, DOI 10.1038/ki.1995.395; PTACEK LJ, 1994, CELL, V77, P863; QIAN F, 1995, GENOMICS, V28, P66, DOI 10.1006/geno.1995.1107; QIAO XX, 1991, BRAIN RES, V555, P43, DOI 10.1016/0006-8993(91)90857-R; Rettig J, 1996, P NATL ACAD SCI USA, V93, P7363, DOI 10.1073/pnas.93.14.7363; ROSS ME, 1990, P NATL ACAD SCI USA, V87, P4189, DOI 10.1073/pnas.87.11.4189; RYAN SG, 1995, NAT GENET, V10, P4, DOI 10.1038/ng0595-4; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; SNEAD OC, 1995, ANN NEUROL, V37, P146, DOI 10.1002/ana.410370204; Spitzer Nicholas C., 1994, Current Opinion in Neurobiology, V4, P70, DOI 10.1016/0959-4388(94)90034-5; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; STEA A, 1994, P NATL ACAD SCI USA, V91, P10576, DOI 10.1073/pnas.91.22.10576; TAKAHASHI T, 1993, NATURE, V366, P156, DOI 10.1038/366156a0; TANG SQ, 1993, J BIOL CHEM, V268, P13026; TESSAROLLO L, 1995, METHOD ENZYMOL, V254, P419; TSAKIRIDOU E, 1995, J NEUROSCI, V15, P3110, DOI 10.1523/jneurosci.15-04-03110.1995; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; URADE Y, 1991, P NATL ACAD SCI USA, V88, P1069, DOI 10.1073/pnas.88.3.1069; USOWICZ MM, 1992, NEURON, V9, P1185, DOI 10.1016/0896-6273(92)90076-P; Volsen SG, 1995, MOL BRAIN RES, V34, P271, DOI 10.1016/0169-328X(95)00234-J; Wheeler DB, 1995, PROG BRAIN RES, V105, P65; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; ZHANG JF, 1993, NEUROPHARMACOLOGY, V32, P3075; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0	68	600	614	0	25	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1996	87	4					607	617		10.1016/S0092-8674(00)81381-1	http://dx.doi.org/10.1016/S0092-8674(00)81381-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VU035	8929530	Bronze			2022-12-24	WOS:A1996VU03500004
J	Wannamethee, SG; Whincup, PH; Shaper, G; Walker, M				Wannamethee, SG; Whincup, PH; Shaper, G; Walker, M			Influence of fathers' social class on cardiovascular disease in middle-aged men	LANCET			English	Article							ISCHEMIC-HEART-DISEASE; BIRTH-WEIGHT; ADULT LIFE; SOCIOECONOMIC-STATUS; LIVING-CONDITIONS; BRITISH MEN; CHILDHOOD; RISK; MORTALITY; GROWTH	Background The independent effect of early life circumstances on adult cardiovascular risk is still unresolved. We assessed the associations of father's social class with cardiovascular risk factors and with risk of ischaemic heart disease and stroke in adult life. Methods We did a longitudinal study of cardiovasular disease in 5934 men aged 40-59 years at enrolment. A cross-sectional measurement survey was done between 1978 and 1980 and a follow-up questionnaire was completed in 1992. The main endpoints were non-fatal myocardial infarction and stroke based on general practitioners' reports obtained between screening and 1992 and on recall of physician-diagnosed ischaemic heart disease in the 1992 questionnaire. Findings Father's social class was strongly associated with social class in adulthood (fathers' occupation was manual for 41.3% of professionals [I] vs 89.1% for unskilled manual workers [VI]) and was significantly related to height (nonmanual vs manual 175.4 cm [SE 0.2] vs 172.9 cm [0.1], p < 0.0001) and obesity (213 [14.1%] vs 804 [20.1%], p < 0.0001) irrespective of adult social class; no association was found with blood glucose (log, 1.69 [0005] vs 1.70 [0.003], p = 0.22) or cholesterol (6.4 [0.03] vs 6.29 mmol/L [0.02], p = 0.16. Men whose fathers' social class was manual had significantly higher rates of non-fatal myocardial infarction (342/4006 vs 92/1510) and self-reported physician-diagnosed ischaemic heart disease (686/4006 vs 192/1510) than men whose fathers' social class was nonmanual, even after adjustment for adult social class and other established risk factors (relative odds 1.3 [95% CI 1.0-1.7], p < 0.05 and 1.3 [1.1-1.6], p < 0.01, respectively). The influence of father's social class on non-fatal myocardial infarction and ischaemic heart disease was only seen in men whose adult social class was non-manual. No association was seen between father's social class and non-fatal stroke. Interpretation Father's social class is strongly associated with adult social class. The higher risk of non-fatal myocardial infarction and self-reported physician-diagnosed ischaemic heart disease seen in men whose father's social class was manual suggests that socioeconomic status early in life has some persisting influence on ischaemic heart disease risk in adult life.			Wannamethee, SG (corresponding author), ROYAL FREE HOSP,SCH MED,DEPT PRIMARY CARE & POPULAT SCI,LONDON NW3 2PF,ENGLAND.		Lennon, Lucy/ABB-9433-2020	Lennon, Lucy/0000-0002-1738-1351; Wannamethee, Sasiwarang/0000-0001-9484-9977; Whincup, Peter/0000-0002-5589-4107				ARNESEN E, 1985, J EPIDEMIOL COMMUN H, V39, P210, DOI 10.1136/jech.39.3.210; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; BARKER DJP, 1993, BRIT MED J, V307, P1524, DOI 10.1136/bmj.307.6918.1524; BARKER DJP, 1986, LANCET, V1, P1077; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BARTLEY M, 1994, BMJ-BRIT MED J, V309, P1475, DOI 10.1136/bmj.309.6967.1475; BRUCE NG, 1988, J HYPERTENS, V6, P375; ELFORD J, 1991, INT J EPIDEMIOL, V20, P833, DOI 10.1093/ije/20.4.833; FALL CHD, 1995, BRIT MED J, V310, P17, DOI 10.1136/bmj.310.6971.17; FORSDAHL A, 1977, BRIT J PREV SOC MED, V31, P91; FORSDAHL A, 1978, J EPIDEMIOL COMMUN H, V32, P34, DOI 10.1136/jech.32.1.34; GLIKSMAN MD, 1995, J EPIDEMIOL COMMUN H, V49, P10, DOI 10.1136/jech.49.1.10; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; KAPLAN GA, 1990, BRIT MED J, V301, P1121, DOI 10.1136/bmj.301.6761.1121; LYNCH JW, 1994, LANCET, V343, P524, DOI 10.1016/S0140-6736(94)91468-0; Office of Population Censuses and Surveys, 1980, CLASS OCC COD IND; PANETH N, 1995, BRIT MED J, V310, P411, DOI 10.1136/bmj.310.6977.411; PECK MN, 1994, SOC SCI MED, V39, P553; PETERS TJ, 1983, BRIT J OBSTET GYNAEC, V90, P1040, DOI 10.1111/j.1471-0528.1983.tb06442.x; POCOCK SJ, 1987, LANCET, V2, P197; RODRIGUEZ C, 1995, J EPIDEMIOL COMMUN H, V49, P38, DOI 10.1136/jech.49.1.38; RONA RJ, 1981, BRIT MED BULL, V37, P265, DOI 10.1093/oxfordjournals.bmb.a071713; SHAPER AG, 1991, BRIT HEART J, V66, P384; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; STRACHAN DP, 1995, BRIT MED J, V310, P423, DOI 10.1136/bmj.310.6977.423; STRONG JP, 1969, J ATHEROSCLER RES, V9, P251, DOI 10.1016/S0368-1319(69)80020-7; WALKER M, 1984, J ROY COLL GEN PRACT, V34, P365; WANNAMETHEE G, 1995, BRIT HEART J, V74, P324; WILCOX MA, 1995, ACTA OBSTET GYN SCAN, V74, P15, DOI 10.3109/00016349509009936	31	183	184	1	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 9	1996	348	9037					1259	1263		10.1016/S0140-6736(96)02465-8	http://dx.doi.org/10.1016/S0140-6736(96)02465-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR555	8909377				2022-12-24	WOS:A1996VR55500007
J	Gorina, S; Pavletich, NP				Gorina, S; Pavletich, NP			Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2	SCIENCE			English	Article							WILD-TYPE P53; CELL-CYCLE CONTROL; P53-DEPENDENT APOPTOSIS; GENE AMPLIFICATION; MUTANT P53; BINDING; PROTEIN; DNA; TRANSCRIPTION; INHIBITION	Mutations in the p53 tumor suppressor are among the most frequently observed genetic alterations in human cancer and map to the 200-amino acid core domain of the protein. The core domain contains the sequence-specific DNA binding activity and the in vitro 53BP2 protein binding activity of p53. The crystal structure of the p53 core domain bound to the 53BP2 protein, which contains an SH3 (Src homology 3) domain and four ankyrin repeats, revealed that (i) the SH3 domain binds the L3 loop of p53 in a manner distinct from that of previously characterized SH3-polyproline peptide complexes, and (ii) an ankyrin repeat, which forms an L-shaped structure-consisting of a 3 hairpin and two ct helices, binds the L2 loop of p53. The structure of the complex shows that the 53BP2 binding site on the p53 core domain consists of evolutionarily conserved regions that are frequently mutated in cancer and that it overlaps the site of DNA binding. The six most frequently observed p53 mutations disrupt 53BP2 binding in vitro. The structure provides evidence that the 53BP2-p53 complex forms in vivo and may have a critical role in the p53 pathway of tumor suppression.			Gorina, S (corresponding author), MEM SLOAN KETTERING CANC CTR, CELLULAR BIOCHEM & BIOPHYS PROGRAM, 1275 YORK AVE, NEW YORK, NY 10021 USA.				NATIONAL CANCER INSTITUTE [R01CA065698] Funding Source: NIH RePORTER; NCI NIH HHS [CA65698] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BRUNGER AT, 1991, X PLOR SYSTEM CRYSTA; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; *EUR MOL BIOL LAB, 1995, DAT P53 MUT; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARPER JW, 1993, CELL, V75, P805; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; THOMPSON CC, 1991, SCIENCE, V253, P253; THUKRAL SK, 1994, MOL CELL BIOL, V14, P8315, DOI 10.1128/MCB.14.12.8315; TONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489; WU XD, 1995, STRUCTURE, V3, P215, DOI 10.1016/S0969-2126(01)00151-4; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	38	386	411	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 8	1996	274	5289					1001	1005		10.1126/science.274.5289.1001	http://dx.doi.org/10.1126/science.274.5289.1001			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR792	8875926				2022-12-24	WOS:A1996VR79200055
J	Hyatt, BA; Lohr, JL; Yost, HJ				Hyatt, BA; Lohr, JL; Yost, HJ			Initiation of vertebrate left-right axis formation by maternal Vg1	NATURE			English	Article							LEFT-RIGHT ASYMMETRY; XENOPUS-EMBRYOS; MESODERM; PROTEIN; RNA; EXPRESSION; INDUCTION; CLONING	IN the development of the three-dimensional vertebrate body plant the left-right axis is linked to the dorsoventral and anterioposterior axes(1,2). In humans, altered left-right development results in severe cardiovascular and visceral abnormalities in individuals and in conjoined twins(3,4). Although zygotically transcribed genes that are asymmetrically expressed have been identified(5-8), the mechanism by which left-right asymmetries are established during embryogenesis is unknown(9). Here we show that the Xenopus maternal gene Vg1, a member of the TGF-beta family of cell-signalling molecules which are implicated in dorsoanterior development(10), initiates left-right axis formation. Altered expression of Vg1 on the right side of 16-cell embryos or disruption of endogenous Vg1 signalling on the left side randomizes cardiac and visceral left-right orientation and alters expression of Xnr-1, a nodal-related molecular marker for left-right developments, Furthermore, the orientation of the left-right asis in conjoined twins is dependent upon which cell-signalling molecule initiated twin formation and on whether the secondary axis is on the left or right side of the primary embryonic axis, implicating a molecular pathway leading to the formation of conjoined twins.	UNIV MINNESOTA, DEPT CELL BIOL & NEUROANAT, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT PEDIAT, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities								ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; BOTERENBROOD EC, 1973, ROUX ARCH DEV BIOL, V173, P319, DOI 10.1007/BF00575837; Bowers PN, 1996, PROG PEDIATR CARDIOL, V6, P53, DOI 10.1016/1058-9813(96)00171-3; BURN J, 1991, CIBA F SYMP, V162, P282; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; DALE L, 1989, EMBO J, V8, P1057, DOI 10.1002/j.1460-2075.1989.tb03473.x; DALE L, 1993, EMBO J, V12, P4471, DOI 10.1002/j.1460-2075.1993.tb06136.x; DANOS MC, 1995, DEVELOPMENT, V121, P1467; Danos MC, 1996, DEV BIOL, V177, P96, DOI 10.1006/dbio.1996.0148; Dohrmann CE, 1996, DEV BIOL, V175, P108, DOI 10.1006/dbio.1996.0099; GERHART J, 1989, DEVELOPMENT, V107, P37; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HEMMATIBRIVANLOU A, 1995, DEV GENET, V17, P78, DOI 10.1002/dvg.1020170109; Henry GL, 1996, DEVELOPMENT, V122, P1007; JONES CM, 1995, DEVELOPMENT, V121, P3651; KESSLER DS, 1995, DEVELOPMENT, V121, P2155; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; Meno C, 1996, NATURE, V381, P151, DOI 10.1038/381151a0; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; Spemann H, 1919, ARCH ENTWICKLUNG ORG, V45, P371, DOI 10.1007/BF02554405; TANNAHILL D, 1989, DEVELOPMENT, V106, P775; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; YISRAELI JK, 1989, METHOD ENZYMOL, V180, P42; YOSH HJ, 1995, CELL, V82, P689; YOSH HJ, 1992, NATURE, V357, P158	28	136	140	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 7	1996	384	6604					62	65		10.1038/384062a0	http://dx.doi.org/10.1038/384062a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR219	8900277				2022-12-24	WOS:A1996VR21900053
J	Slupphaug, G; Mol, CD; Kavli, B; Arvai, AS; Krokan, HE; Tainer, JA				Slupphaug, G; Mol, CD; Kavli, B; Arvai, AS; Krokan, HE; Tainer, JA			A nucleotide-flipping mechanism from the structure of human uracil-DNA glycosylase bound to DNA	NATURE			English	Article							CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; EXCISION; SPECIFICITY; REFINEMENT; SUBSTRATE; DYNAMICS; BASE	ANY uracil bases in DNA, a result of either misincorporation or deamination of cytosine, are removed by uracil-DNA glycosylase (UDG), one of the most efficient and specific of the base-excision DNA-repair enzymes(1). Crystal structures of human(2,3) and viral(4) UDGs complexed with free uracil have indicated that the enzyme binds an extrahelical uracil. Such binding of undamaged extra-helical bases has been seen in the structures of two bacterial methyltransferases(5,6) and bacteriophage T4 endonuclease V (ref. 7). Here we characterize the DNA binding and kinetics of several engineered human UDG mutants and present the crystal structure of one of these, which to our knowledge represents the first structure of any eukaryotic DNA repair enzyme in complex with its damaged, target DNA. Electrostatic orientation along the UDG active site, insertion of an amino acid (residue 272) into the DNA through the minor groove, and compression of the DNA backbone flanking the uracil all result in the flipping-out of the damaged base from the DNA major groove, allowing specific recognition of its phosphate, deoxyribose and uracil moieties. Our structure thus provides a view of a productive complex specific for cleavage of uracil from DNA and also reveals the basis for the enzyme-assisted nucleotide flipping by this critical DNA-repair enzyme.	Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA; NORWEGIAN UNIV SCI & TECHNOL, UNIGEN CTR MOL BIOL, N-7005 TRONDHEIM, NORWAY	Scripps Research Institute; Norwegian University of Science & Technology (NTNU)			Slupphaug, Geir/AAN-3794-2020; Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429; Slupphaug, Geir/0000-0002-7498-3500				AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; DAVIS ME, 1990, CHEM REV, V90, P509, DOI 10.1021/cr00101a005; DELORT AM, 1985, NUCLEIC ACIDS RES, V13, P319, DOI 10.1093/nar/13.2.319; DOMENA JD, 1988, BIOCHEMISTRY-US, V27, P6742, DOI 10.1021/bi00418a015; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; ENSLON HCM, 1996, CHEM BIOL, V3, P419; Kavli B, 1996, EMBO J, V15, P3442, DOI 10.1002/j.1460-2075.1996.tb00710.x; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KROKAN H, 1981, NUCLEIC ACIDS RES, V9, P2599, DOI 10.1093/nar/9.11.2599; KUBAREVA EA, 1995, GENE, V157, P167, DOI 10.1016/0378-1119(94)00771-J; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; MOL CD, 1995, CELL, V82, P701, DOI 10.1016/0092-8674(95)90467-0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OTWINOWSKI Z, 1990, P CCP4 STUD WEEK JAN, V29, P56; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; Sawa R., 1995, NATURE, V373, P487; SAWA R, 1995, NAT STRUCT BIOL, V2, P752; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; VARSHNEY U, 1991, BIOCHEMISTRY-US, V30, P4055, DOI 10.1021/bi00230a033; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6	25	480	487	4	53	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1996	384	6604					87	92		10.1038/384087a0	http://dx.doi.org/10.1038/384087a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR219	8900285				2022-12-24	WOS:A1996VR21900061
J	Zakany, J; Duboule, D				Zakany, J; Duboule, D			Synpolydactyly in mice with a targeted deficiency in the HoxD complex	NATURE			English	Article							GENE; DISRUPTION; HOMEOSIS	THE morphogenesis of mammalian digits requires the function of several genes of the HoxD complex during development of limb buds(1-4). Using embryonic stem (ES) cells and a site-specific recombination system (loxP/Cre), we have induced a deficiency(5,6) that eliminates the products of the Hoxd-13, Hoxd-12 and Hoxd-11 genes simultaneously. A Hoxd-11/lacz reporter gene replaced the deleted region in order to monitor the effect of this triple inactivation at the cellular level. Mice homozygous for this deficiency showed small digit primordia, a disorganized cartilage pattern and impaired skeletal mass. These alterations are similar to the defects seen in a human synpolydactyly(7,8), suggesting that this syndrome, which is associated with a subtle mutation in HOXD13 (ref. 8), may involve the loss of function of several Herd genes. These results indicate the existence of a functional hierarchy among these genes and provide us with an animal model to study human digit malformations.	UNIV GENEVA, DEPT ZOOL & ANIM BIOL, CH-1211 GENEVA 4, SWITZERLAND	University of Geneva				duboule, denis/0000-0001-9961-2960				AKARSU AN, 1995, J MED GENET, V32, P435, DOI 10.1136/jmg.32.6.435; Davis AP, 1996, DEVELOPMENT, V122, P1175; DAVIS AP, 1994, DEVELOPMENT, V120, P2187; DOLLE P, 1993, CELL, V75, P431, DOI 10.1016/0092-8674(93)90378-4; DUBOULE D, 1994, TRENDS GENET, V10, P358, DOI 10.1016/0168-9525(94)90132-5; FAVIER B, 1995, P NATL ACAD SCI USA, V92, P310, DOI 10.1073/pnas.92.1.310; Forrest D, 1996, EMBO J, V15, P3006, DOI 10.1002/j.1460-2075.1996.tb00664.x; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; KONDO T, IN PRESS DEVELOPMENT; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Muragaki Y, 1996, SCIENCE, V272, P548, DOI 10.1126/science.272.5261.548; Nelson CE, 1996, DEVELOPMENT, V122, P1449; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; SARFARAZI M, 1995, HUM MOL GENET, V4, P1453, DOI 10.1093/hmg/4.8.1453; SORDINO P, 1995, NATURE, V375, P678, DOI 10.1038/375678a0; vanderHoeven F, 1996, CELL, V85, P1025, DOI 10.1016/S0092-8674(00)81303-3	17	173	177	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 7	1996	384	6604					69	71		10.1038/384069a0	http://dx.doi.org/10.1038/384069a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR219	8900279				2022-12-24	WOS:A1996VR21900055
J	Contreras, D; Destexhe, A; Sejnowski, TJ; Steriade, M				Contreras, D; Destexhe, A; Sejnowski, TJ; Steriade, M			Control of spatiotemporal coherence of a thalamic oscillation by corticothalamic feedback	SCIENCE			English	Article							NUCLEUS-RETICULARIS THALAMI; IN-VITRO; SYNCHRONIZED OSCILLATIONS; MECHANISMS; CAT	The mammalian thalamus is the gateway to the cortex for most sensory modalities, Nearly all thalamic nuclei also receive massive feedback projections from the cortical region to which they project, In this study, the spatiotemporal properties of synchronized thalamic spindle oscillations (7 to 14 hertz) were investigated in barbiturate-anesthetized cats, before and after removal of the cortex, After complete ipsilateral decortication, the long-range synchronization of thalamic spindles in the intact cortex hemisphere changed into disorganized patterns with low spatiotemporal coherence. Local thalamic synchrony was still present, as demonstrated by dual intracellular recordings from nearby neurons. In the cortex, synchrony was insensitive to the disruption of horizontal intracortical connections, These results indicate that the global coherence of thalamic oscillations is determined by corticothalamic projections.	UNIV LAVAL,FAC MED,NEUROPHYSIOL LAB,QUEBEC CITY,PQ G1K 7P4,CANADA; SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,LA JOLLA,CA 92037; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	Laval University; Howard Hughes Medical Institute; Salk Institute; University of California System; University of California San Diego			Sejnowski, Terrence/AAV-5558-2021	Destexhe, Alain/0000-0001-7405-0455				AMZICA F, 1995, J NEUROSCI, V15, P4658; [Anonymous], [No title captured]; AVENDANO C, 1988, J COMP NEUROL, V278, P1, DOI 10.1002/cne.902780102; BAL T, 1993, J PHYSIOL-LONDON, V468, P669, DOI 10.1113/jphysiol.1993.sp019794; BAL T, 1995, J PHYSIOL-LONDON, V483, P641, DOI 10.1113/jphysiol.1995.sp020612; Contreras D, 1996, J PHYSIOL-LONDON, V490, P159, DOI 10.1113/jphysiol.1996.sp021133; CONTRERAS D, 1995, J NEUROSCI, V15, P604; DESTEXHE A, 1994, NEUROREPORT, V5, P2217, DOI 10.1097/00001756-199411000-00003; Destexhe A, 1996, J NEUROPHYSIOL, V76, P2049, DOI 10.1152/jn.1996.76.3.2049; Golomb D, 1996, J NEUROPHYSIOL, V75, P750, DOI 10.1152/jn.1996.75.2.750; Jones EG, 1985, THALAMUS; KIM U, 1995, J NEUROPHYSIOL, V74, P1301, DOI 10.1152/jn.1995.74.3.1301; KOCH C, 1987, NEUROSCIENCE, V23, P399, DOI 10.1016/0306-4522(87)90064-9; MORISON RS, 1945, J NEUROPHYSIOL, V8, P309, DOI 10.1152/jn.1945.8.5.309; Morison RS, 1943, AM J PHYSIOL, V138, P0297, DOI 10.1152/ajplegacy.1943.138.2.297; NICOLELIS MAL, 1993, P NATL ACAD SCI USA, V90, P2212, DOI 10.1073/pnas.90.6.2212; Press W.H., NUMERICAL RECIPES AR, Vthird; SILLITO AM, 1994, NATURE, V369, P479, DOI 10.1038/369479a0; STERIADE M, 1984, J COMP NEUROL, V229, P531, DOI 10.1002/cne.902290407; STERIADE M, 1987, J NEUROPHYSIOL, V57, P260, DOI 10.1152/jn.1987.57.1.260; STERIADE M, 1985, J NEUROPHYSIOL, V54, P1473, DOI 10.1152/jn.1985.54.6.1473; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; Steriade M., 1988, CELLULAR THALAMIC ME, P51; Steriade M, 1972, CORTICOTHALAMIC PROJ, P221; STERIADE M, 1990, THALAMIC OSSCILLATIO; TIMOFEEV I, IN PRESS J NEUROPHYS; VONKROSIGK M, 1993, SCIENCE, V261, P361, DOI 10.1126/science.8392750	27	348	353	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1996	274	5288					771	774		10.1126/science.274.5288.771	http://dx.doi.org/10.1126/science.274.5288.771			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ145	8864114				2022-12-24	WOS:A1996VQ14500039
J	Hicks, KA; Millar, AJ; Carre, IA; Somers, DE; Straume, M; MeeksWagner, DR; Kay, SA				Hicks, KA; Millar, AJ; Carre, IA; Somers, DE; Straume, M; MeeksWagner, DR; Kay, SA			Conditional circadian dysfunction of the Arabidopsis early-flowering 3 mutant	SCIENCE			English	Article							DARK CYCLES; DROSOPHILA; BEHAVIOR; LIGHT	Photoperiodic responses, such as the daylength-dependent control of reproductive development, are associated with a circadian biological clock. The photoperiod-insensitive early-flowering 3 (elf3) mutant of Arabidopsis thaliana lacks rhythmicity in two distinct circadian-regulated processes, This defect was apparent only when plants were assayed under constant light conditions. elf3 mutants retain rhythmicity in constant dark and anticipate light/dark transitions under most light/dark regimes. The conditional arrhythmic phenotype suggests that the circadian pacemaker is intact in darkness in elf3 mutant plants, but the transduction of light signals to the circadian clock is impaired.	UNIV OREGON,INST MOL BIOL,EUGENE,OR 97403; UNIV VIRGINIA,NSF,CTR BIOL TIMING,DEPT BIOL,CHARLOTTESVILLE,VA 22903; UNIV VIRGINIA,NSF,CTR BIOL TIMING,DEPT MED,CHARLOTTESVILLE,VA 22908	University of Oregon; National Science Foundation (NSF); NSF - Center for Biological Timing; University of Virginia; National Science Foundation (NSF); NSF - Center for Biological Timing; University of Virginia			Kay, Steve A/F-6025-2011; Millar, Andrew J/G-2423-2012; Somers, David E/A-9209-2010; CARRE, Isabelle A/D-8802-2011	Kay, Steve A/0000-0002-0402-2878; Millar, Andrew J/0000-0003-1756-3654; CARRE, Isabelle A/0000-0002-0548-7378; Hicks, Karen/0000-0003-2785-0614	NIGMS NIH HHS [1R01GM46006] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brandes C, 1996, NEURON, V16, P687, DOI 10.1016/S0896-6273(00)80088-4; Deitzer G.F., 1987, MANIPULATION FLOWERI, P241; HAMBLENCOYLE MJ, 1992, J INSECT BEHAV, V5, P417, DOI 10.1007/BF01058189; Hicks KA, 1996, SEMIN CELL DEV BIOL, V7, P409, DOI 10.1006/scdb.1996.0051; HICKS KB, UNPUB; KOORNNEEF M, 1991, MOL GEN GENET, V229, P57, DOI 10.1007/BF00264213; Loros J J, 1986, J Biol Rhythms, V1, P187, DOI 10.1177/074873048600100302; LUMSDEN PJ, 1991, ANNU REV PLANT PHYS, V42, P351, DOI 10.1146/annurev.pp.42.060191.002031; MILLAR AJ, 1992, PLANT CELL, V4, P1075, DOI 10.1105/tpc.4.9.1075; MILLAR AJ, 1995, SCIENCE, V267, P1161, DOI 10.1126/science.7855595; MILLAR AJ, UNPUB; SOMERS DE, UNPUB; THOMPSON NJ, 1993, DATABASE, V16, P6; Wetherell D. F., 1990, PULVINUS MOTOR ORGAN, P72; WHEELER DA, 1993, J BIOL RHYTHM, V8, P67, DOI 10.1177/074873049300800106; ZAGOTTA MT, 1996, PLANT J, V10, P101	16	290	301	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1996	274	5288					790	792		10.1126/science.274.5288.790	http://dx.doi.org/10.1126/science.274.5288.790			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ145	8864121				2022-12-24	WOS:A1996VQ14500046
J	Lydall, D; Nikolsky, Y; Bishop, DK; Weinert, T				Lydall, D; Nikolsky, Y; Bishop, DK; Weinert, T			A meiotic recombination checkpoint controlled by mitotic checkpoint genes	NATURE			English	Article							SYNAPTONEMAL COMPLEX PROTEIN; DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE; CHROMOSOME SYNAPSIS; DROSOPHILA-MELANOGASTER; YEAST; MEIOSIS; REPAIR; DNA; MUTANTS	IN budding yeast, meiotic recombination occurs at about 200 sites per cell and involves DNA double-strand break (DSB) intermediates(1-3). Here we provide evidence that a checkpoint control requiring the mitotic DNA-damage checkpoint genes RAD17, RAD24 and MEC1 ensures that meiotic recombination is complete before the first meiotic division (MI). First, RAD17, RAD24 and MEC1 are required for the meiotic arrest caused by blocking the repair of DSBs with a mutation in the recA homologue DMC1. Second, mec1 and rad24 single mutants (DMC1(+)) appear to undergo MI before all recombination events are complete. Curiously, the mitosis-specific checkpoint gene RAD9 is not required for meiotic arrest of dmc1 mutants(4), This shows that although mitotic and meiotic control mechanisms are related, they differ significantly, Rad17 and Rad24 proteins may contribute directly to formation of an arrest signal by association with single-strand DNA in mitosis and meiosis.	UNIV ARIZONA,DEPT MOL & CELLULAR BIOL,TUCSON,AZ 85721; UNIV CHICAGO,DEPT RADIAT & CELLULAR ONCOL,DEPT MOL GENET & CELL BIOL,CHICAGO,IL 60638	University of Arizona; University of Chicago								ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; BAKER BS, 1972, GENETICS, V71, P255; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; GAME JC, 1980, GENETICS, V94, P51; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; KLAPHOLZ S, 1985, GENETICS, V110, P187; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; Lydall D, 1996, CURR OPIN GENET DEV, V6, P4, DOI 10.1016/S0959-437X(96)90003-9; MALONE RE, 1981, MOL CELL BIOL, V1, P891, DOI 10.1128/MCB.1.10.891; OGAWA T, 1993, COLD SPRING HARB SYM, V58, P567, DOI 10.1101/SQB.1993.058.01.063; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SCHWACHA A, 1994, CELL, V76, P51, DOI 10.1016/0092-8674(94)90172-4; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; Sun ZX, 1996, GENE DEV, V10, P395, DOI 10.1101/gad.10.4.395; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; SYM M, 1994, CELL, V79, P283, DOI 10.1016/0092-8674(94)90197-X; WEBER L, 1992, GENETICS, V131, P55; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; WEINERT TA, IN PRESS DNA DAMAGE; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; WU TC, 1994, SCIENCE, V263, P515, DOI 10.1126/science.8290959; XU L, IN PRESS GENES DEV	30	269	278	1	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 31	1996	383	6603					840	843		10.1038/383840a0	http://dx.doi.org/10.1038/383840a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ144	8893012				2022-12-24	WOS:A1996VQ14400068
J	Lapham, EV; Kozma, C; Weiss, JO				Lapham, EV; Kozma, C; Weiss, JO			Genetic discrimination: Perspectives of consumers	SCIENCE			English	Article								In a study of the perceptions of 332 members of genetic support groups with one or more of 101 different genetic disorders in the family, it was found that as a result of a genetic disorder 25 percent of the respondents or affected family members believed they were refused life insurance, 22 percent believed they were refused health insurance, and 13 percent believed they were denied or let go from a job. Fear of genetic discrimination resulted in 9 percent of respondents or family members refusing to be tested for genetic conditions, 18 percent not revealing genetic information to insurers, and 17 percent not revealing information to employers. The level of perceived discrimination points to the need for more information to determine the extent and scope of the problem.	ALLIANCE GENET SUPPORT GRP,CHEVY CHASE,MD 20815		Lapham, EV (corresponding author), GEORGETOWN UNIV,CHILD DEV CTR,3307 M ST NW,WASHINGTON,DC 20007, USA.				NHGRI NIH HHS [R01-HG00786-03] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000786] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ANDREWS L, 1994, ASESSING GENETIC RIS; BILLINGS PR, 1992, AM J HUM GENET, V50, P476; COLLINS FS, 1991, J CLIN ETHIC, V2, P4; COOKDEEGAN RM, 1991, BIOMEDICAL POLITICS, P148; Geller G, 1993, J Law Med Ethics, V21, P238, DOI 10.1111/j.1748-720X.1993.tb01246.x; KAHN MJE, 1995, OVERVIEW HUMAN GENOM; KASS NE, 1992, HASTINGS CENT REP, V22, pS12; KASS NE, 1992, HASTINGS CENT REP, V22, pS6; KASS NE, 1992, HASTINGS CENT REP, V22, pS15; MURRAY TH, 1991, C ETH LEG IMPL GEN T; *NIH, 1993, GEN INF HLTH INS REP; *NIH NAT CTR HUM G, 1995, NIH PUBL; OSTRER H, 1993, AM J HUM GENET, V52, P565; ROTHENBERG KH, 1995, J LAW MED ETHICS, V23, P313; *US C, 1990, OTABA455; WERTZ DC, 1993, ETHICAL ISSUES GEN 1, P33; 1995, AM J HUM GENET, V56, P325; 1995, AM J HUM GENET, V56, P327	18	223	224	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 25	1996	274	5287					621	624		10.1126/science.274.5287.621	http://dx.doi.org/10.1126/science.274.5287.621			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	VN919	8849455				2022-12-24	WOS:A1996VN91900053
J	Gray, R; Rajan, AS; Radcliffe, KA; Yakehiro, M; Dani, JA				Gray, R; Rajan, AS; Radcliffe, KA; Yakehiro, M; Dani, JA			Hippocampal synaptic transmission enhanced by low concentrations of nicotine	NATURE			English	Article							HIGH-CALCIUM PERMEABILITY; ACETYLCHOLINE-RECEPTORS; ALPHA-BUNGAROTOXIN; NEURONS; RAT; CHANNEL; BLOCKADE; FACILITATION; RECORDINGS; DENDRITES	NICOTINE obtained from tobacco can improve learning and memory on various tasks and has been linked to arousal, attention, rapid information processing, working memory, and longterm memories that can cause craving years after someone has stopped smoking(1,2). One likely target for these effects is the hippocampus, a centre for learning and memory that has rich cholinergic innervation and dense nicotinic acetylcholine receptor (nAChR) expression(3-6). During Alzheimer's dementia there are fewer nAChRs and the cholinergic inputs to the hippocampus degenerate(7). However, there is no evidence for fast synaptic transmission mediated by nAChRs in the hippocampus, and their role is not understood(8,9). Nicotine is known to act on presynaptic nAChRs within the habenula of chick to enhance glutamatergic transmission(10); here we report that a similar mechanism operates in the hippocampus. Measurements of intracellular Ca2+ in single mossy-fibre presynaptic terminals indicate that nAChRs containing the alpha 7 subunit can mediate a Ca2+ influx that is sufficient to induce vesicular neurotransmitter release. We propose that nicotine from tobacco influences cognition by enhancing synaptic transmission. Conversely, a decreased efficacy of transmission may account for the deficits associated with the loss of cholinergic innervation during Alzheimer's disease.	BAYLOR COLL MED, DIV NEUROSCI, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT MED, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine				Gray, Richard/0000-0002-5890-1819				ALKONDON M, 1991, J RECEPTOR RES, V11, P1001, DOI 10.3109/10799899109064693; ALKONDON M, 1992, MOL PHARMACOL, V41, P802; ALKONDON M, 1993, J PHARMACOL EXP THER, V265, P1455; CASTRO NG, 1995, BIOPHYS J, V68, P516, DOI 10.1016/S0006-3495(95)80213-4; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; Dani JA, 1996, NEURON, V16, P905, DOI 10.1016/S0896-6273(00)80112-9; HENNINGFIELD JE, 1993, DRUG ALCOHOL DEPEN, V33, P23, DOI 10.1016/0376-8716(93)90030-T; KASA P, 1986, PROG NEUROBIOL, V26, P211, DOI 10.1016/0301-0082(86)90016-X; LEVIN ED, 1992, PSYCHOPHARMACOLOGY, V108, P417, DOI 10.1007/BF02247415; LEVRAM V, 1992, J NEUROPHYSIOL, V68, P1167, DOI 10.1152/jn.1992.68.4.1167; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; MAGEE JC, 1995, J PHYSIOL-LONDON, V487, P67, DOI 10.1113/jphysiol.1995.sp020862; MCGEHEE DS, 1995, SCIENCE, V269, P1692, DOI 10.1126/science.7569895; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; NORDBERG A, 1994, NEUROCHEM INT, V25, P93, DOI 10.1016/0197-0186(94)90059-0; OHNO M, 1993, PHARMACOL BIOCHEM BE, V45, P89, DOI 10.1016/0091-3057(93)90091-7; RAE J, 1991, J NEUROSCI METH, V37, P15, DOI 10.1016/0165-0270(91)90017-T; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; SEGUELA P, 1993, J NEUROSCI, V13, P596; STEVENS CF, 1995, NEURON, V14, P795, DOI 10.1016/0896-6273(95)90223-6; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; VERNINO S, 1994, J NEUROSCI, V14, P5514; VERNINO S, 1992, NEURON, V8, P127, DOI 10.1016/0896-6273(92)90114-S; VIJAYARAGHAVAN S, 1992, NEURON, V8, P353, DOI 10.1016/0896-6273(92)90301-S; WADA E, 1989, J COMP NEUROL, V284, P314, DOI 10.1002/cne.902840212; WONNACOTT S, 1990, CIBA F SYMP, V152, P87; WOOLF NJ, 1991, PROG NEUROBIOL, V37, P475, DOI 10.1016/0301-0082(91)90006-M; WU LG, 1994, J NEUROSCI, V14, P645; ZAREI MM, 1995, J NEUROSCI, V15, P1446; ZORUMSKI CF, 1992, MOL PHARMACOL, V41, P931	30	827	840	2	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 24	1996	383	6602					713	716		10.1038/383713a0	http://dx.doi.org/10.1038/383713a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN918	8878480				2022-12-24	WOS:A1996VN91800052
J	Hirth, RA; Turenne, MN; Woods, JD; Young, EW; Port, FK; Pauly, MV; Held, PJ				Hirth, RA; Turenne, MN; Woods, JD; Young, EW; Port, FK; Pauly, MV; Held, PJ			Predictors of type of vascular access in hemodialysis patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AREA VARIATIONS; UNITED-STATES; POLYTETRAFLUOROETHYLENE; COMPLICATIONS; SURVIVAL; FISTULA; GRAFTS; MORBIDITY; THERAPY; VEIN	Objective.-Complications from vascular access account for 15% of hospital admissions among US hemodialysis patients, Complications are less frequent with arteriovenous fistulas than with synthetic grafts, We assessed clinical and nonclinical predictors of whether patients with end-stage renal disease (ESRD) starting hemodialysis receive a fistula or graft, We also investigated changes in practice between 1986-1987 and 1990, Design.-Cross-sectional study. Setting.-United States hemodialysis population, Patients.-Random, national samples of ESRD patients who started hemodialysis in 1986-1987 (n=2741) or 1990 (n=1409) from United States Renal Data System Special Studies, Main Outcome Measure.-Type of permanent vascular access (arteriovenous fistula vs synthetic graft), analyzed using multivariate logistic regression, Results.-Clinical and demographic factors as well as socioeconomic status, region of residence, and year starting hemodialysis predicted the type of vascular access, Overall, 56% of patients had grafts 30 days after starting dialysis, but graft use increased from 51% in 1986-1987 to 65% in 1990 (adjusted odds ratio [AOR], 1.67 for 1990 vs 1986-1987; 95% confidence interval [CI], 1.43-1.95; P<.001), Graft use (relative to fistula) varied by region of residence (ranging from AOR, 0.20; 95% CI, 0.14-0.28; P<.001 [New England], to AOR, 2.69; 95% CI, 2.03-3.58; P<.001 [East South Central]; both relative to the national average), Conclusions.-This national study documents large variations in the relative use of fistulas and grafts and a trend away from fistulas, The prevalence of comorbid conditions fails to explain these findings, Presentation and referral of patients early in the process of their ESRD, teaching surgeons to place fistulas, and training dialysis nurses to access fistulas may increase their use.	UNIV MICHIGAN, DEPT ECON, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT EPIDEMIOL, ANN ARBOR, MI 48109 USA; VET AFFAIRS MED CTR, ANN ARBOR, MI USA; UNIV PENN, DEPT HLTH CARE SYST, PHILADELPHIA, PA 19104 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Pennsylvania	Hirth, RA (corresponding author), UNIV MICHIGAN, SCH PUBL HLTH, DEPT HLTH MANAGEMENT & POLICY, 109 S OBSERV, ANN ARBOR, MI 48109 USA.				NIDDK NIH HHS [N01-DK-3-2202] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [N01DK032202] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albers F J, 1994, Adv Ren Replace Ther, V1, P107; BAKER LD, 1976, T AM SOC ART INT ORG, V22, P382; BENNION RS, 1993, VASCULAR SURG COMPRE, P606; BLEYER AJ, 1995, J AM SOC NEPHROL, V6, P483; BRESCIA MJ, 1966, NEW ENGL J MED, V275, P1089, DOI 10.1056/NEJM196611172752002; BROTMAN DN, 1994, J AM COLL SURGEONS, V178, P431; CHAZAN JA, 1995, NEPHRON, V69, P228, DOI 10.1159/000188461; CHURCHILL DN, 1992, AM J KIDNEY DIS, V19, P214, DOI 10.1016/S0272-6386(13)80002-9; COBURN MC, 1994, J VASC SURG, V20, P896, DOI 10.1016/0741-5214(94)90226-7; CONNALL TP, 1995, VASCULAR SURG, P1233; CONNOLLY JE, 1984, ARCH SURG-CHICAGO, V119, P1325; FAN PY, 1992, J AM SOC NEPHROL, V3, P1; FELDMAN HI, 1993, KIDNEY INT, V43, P1091, DOI 10.1038/ki.1993.153; GOLDWASSER P, 1994, AM J KIDNEY DIS, V24, P785, DOI 10.1016/S0272-6386(12)80672-X; Greene, 2003, ECONOMETRIC ANAL, P1241; HELD PJ, 1994, AM J KIDNEY DIS, V24, P974, DOI 10.1016/S0272-6386(12)81108-5; Held PJ, 1996, KIDNEY INT, V50, P550, DOI 10.1038/ki.1996.348; HOLAHAN J, 1990, HEALTH AFFAIR, V9, P166, DOI 10.1377/hlthaff.9.4.166; HURT AV, 1983, AM J SURG, V146, P844, DOI 10.1016/0002-9610(83)90356-2; JENKINS AM, 1980, SURGERY, V88, P667; JENSEN B V, 1990, Ugeskrift for Laeger, V152, P2169; KHERLAKIAN GM, 1986, AM J SURG, V152, P238, DOI 10.1016/0002-9610(86)90249-7; LUNDIN AP, 1989, REPLACEMENT RENAL FU, P1133; McEwen D R, 1994, AORN J, V59, P225; MCLAUGHLIN CG, 1989, MED CARE, V27, P507, DOI 10.1097/00005650-198905000-00006; MCMAHON LF, 1989, MED CARE, V27, P623, DOI 10.1097/00005650-198906000-00005; MILLER ME, 1995, MED CARE RES REV, V52, P252, DOI 10.1177/107755879505200205; MUNDA R, 1983, JAMA-J AM MED ASSOC, V249, P219, DOI 10.1001/jama.249.2.219; PALDER SB, 1985, ANN SURG, V202, P235, DOI 10.1097/00000658-198508000-00015; PHELPS CE, 1992, J ECON PERSPECT, V6, P23, DOI 10.1257/jep.6.3.23; PHELPS CE, 1990, MED CARE, V28, P703, DOI 10.1097/00005650-199008000-00004; Prischl FC, 1995, J AM SOC NEPHROL, V6, P1613; RIORDAN S, 1994, AUST NZ J SURG, V64, P763, DOI 10.1111/j.1445-2197.1994.tb04535.x; SANDS JJ, 1995, J AM SOC NEPHROL, V6, P501; Sommer B G, 1992, ASAIO J, V38, P743; SWEDBERG SH, 1989, CIRCULATION, V80, P1726, DOI 10.1161/01.CIR.80.6.1726; TURENNE MN, 1995, J AM SOC NEPHROL, V6, P504; *US REN DAT SYST, 1992, 1992 USRDS NIH NAT I; *US REN DAT SYST, 1996, 1996 USRDS NIH NAT I; *US REN DAT SYST, 1995, 1995 USRDS NIH NAT I; WEHRLI H, 1989, HELV CHIR ACTA, V56, P621; WENNBERG J, 1973, SCIENCE, V182, P1102, DOI 10.1126/science.182.4117.1102; WENNBERG JE, 1987, LANCET, V1, P1185, DOI 10.1016/s0140-6736(87)92152-0; Windus D W, 1994, Adv Ren Replace Ther, V1, P148; WINDUS DW, 1993, AM J KIDNEY DIS, V21, P457, DOI 10.1016/S0272-6386(12)80391-X; WINDUS DW, 1992, AM J KIDNEY DIS, V19, P448, DOI 10.1016/S0272-6386(12)80953-X; WINSETT OE, 1985, SOUTHERN MED J, V78, P513, DOI 10.1097/00007611-198505000-00004; YOUNG EW, 1995, J AM SOC NEPHROL, V6, P569; ZIBARI GB, 1988, SURGERY, V104, P681	49	182	184	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	1996	276	16					1303	1308						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM825	8861988				2022-12-24	WOS:A1996VM82500032
J	Smith, DS; Catalona, WJ; Herschman, JD				Smith, DS; Catalona, WJ; Herschman, JD			Longitudinal screening for prostate cancer with prostate-specific antigen	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARCINOMA; SERUM; COST; MEN	Objective.-To determine for the first 4 years of serial prostate-specific antigen (PSA)-based screening trends in compliance, prevalence of abnormal screening test results, cancer detection rates, and stage and grade of cancers detected. Design.-A community-based study of serial screening for prostate cancer with serum PSA measurements. Setting.-University medical center. Subjects.-A total of 10 248 male volunteers at least 50 years old who were screened at 6-month intervals for a minimum of 48 months. Main Outcome Measures.-The proportion of men who returned for serial screening, the proportion with elevated PSA levels, the proportion with newly elevated PSA levels, prostate cancer detection rates, and the distribution of tumor stages and grades at diagnosis. Results.-At 48 months, 79% of volunteers returned for screening. During this interval there was a decrease in the proportion of volunteers with serum PSA levels higher than 4.0 ng/mL (from 10% to 6%-7%), in cancer detection rates (from 3% to <1%), and in the proportion with clinically advanced cancer (from 6% to 2%). In men who underwent surgery, the proportion with high-grade cancer decreased (from 11% to 6%), and the proportion with pathologically advanced cancer was proportionately reduced but not significantly reduced (from 33% to 27%). Conclusions.-With serial PSA-based screening, the proportion of men with abnormal test results decreased, and the prostate cancer detection rate decreased to near the reported population-based incidence rate, There was also a shift to detection of cancers at an earlier clinical stage and detection of lower-grade cancers. If PSA screening is ultimately shown to be beneficial, then appropriate cost-benefit analyses will be required to determine how the shifts in cancer detection rate and cancer stage will affect the economics of serial PSA-based screening.			Smith, DS (corresponding author), WASHINGTON UNIV,SCH MED,DEPT SURG,DIV UROL SURG,4960 CHILDRENS PL,ST LOUIS,MO 63110, USA.				NATIONAL CANCER INSTITUTE [P20CA058193] Funding Source: NIH RePORTER; NCI NIH HHS [P20 CA58193] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRAWER MK, 1993, J UROLOGY, V150, P106, DOI 10.1016/S0022-5347(17)35409-5; BRAWER MK, 1992, J UROLOGY, V147, P841, DOI 10.1016/S0022-5347(17)37401-3; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CATALONA WJ, 1993, JAMA-J AM MED ASSOC, V270, P948, DOI 10.1001/jama.270.8.948; CATALONA WJ, 1994, J UROLOGY, V151, P1283, DOI 10.1016/S0022-5347(17)35233-3; COLBERG JW, 1993, J UROLOGY, V149, P507, DOI 10.1016/S0022-5347(17)36130-X; DEMARKWAHNEFRIED W, 1995, UROLOGY, V46, P346, DOI 10.1016/S0090-4295(99)80218-0; GANN PH, 1995, JAMA-J AM MED ASSOC, V273, P289, DOI 10.1001/jama.273.4.289; GILLILAND F, 1994, CANCER EPIDEM BIOMAR, V3, P105; Gleason DF, 1977, UROLOGIC PATHOLOGY P, P171; HUMPHREY PA, 1996, J UROLOGY, V156, P816; JACOBSEN SJ, 1995, JAMA-J AM MED ASSOC, V274, P1445, DOI 10.1001/jama.274.18.1445; LITTRUP PJ, 1993, CA-CANCER J CLIN, V43, P134, DOI 10.3322/canjclin.43.3.134; LUBKE WL, 1994, J NATL CANCER I, V86, P1790, DOI 10.1093/jnci/86.23.1790; LUYAO GL, 1994, LANCET, V343, P251, DOI 10.1016/S0140-6736(94)91109-6; METTLIN C, 1994, J UROLOGY, V152, P1737, DOI 10.1016/S0022-5347(17)32373-X; MILLER BA, 1992, NIH PUBLICATION; MONTIE JE, 1995, CANCER, V75, P1814, DOI 10.1002/1097-0142(19950401)75:7+<1814::AID-CNCR2820751610>3.0.CO;2-B; OPTENBERG SA, 1990, UROL CLIN N AM, V17, P719; POTOSKY AL, 1995, JAMA-J AM MED ASSOC, V273, P548, DOI 10.1001/jama.273.7.548; SMITH DS, 1994, J UROLOGY, V152, P1732, DOI 10.1016/S0022-5347(17)32372-8; THOMPSON IM, 1995, ONCOLOGY S, V11, P141; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; WOOLF SH, 1995, NEW ENGL J MED, V333, P1401, DOI 10.1056/NEJM199511233332107	24	160	167	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	1996	276	16					1309	1315		10.1001/jama.276.16.1309	http://dx.doi.org/10.1001/jama.276.16.1309			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM825	8861989				2022-12-24	WOS:A1996VM82500033
J	Zerangue, N; Kavanaugh, MP				Zerangue, N; Kavanaugh, MP			Flux coupling in a neuronal glutamate transporter	NATURE			English	Article							ARACHIDONIC-ACID; GLIAL-CELLS; RAT-BRAIN; ASPARTATE; SYNAPTOSOMES; INHIBITION; SUBTYPES; ISCHEMIA; RELEASE; CORTEX	SYNAPTIC transmission is commonly terminated by diffusion and reuptake of neurotransmitter from the synaptic cleft. Glutamate reuptake prevents neurotoxicity and sets the lower limit for the concentration of extracellular glutamate, so it is important to understand the thermodynamics of this process. Here we use voltage clamping with a pH-sensitive fluorescent dye to monitor electrical currents and pH changes associated with flux of glutamate mediated by the human neuronal glutamate transporter EAAT3. In contrast to a previous model(1), we find that three sodium ions and one proton are cotransported viith each glutamate ion into the cell, while one potassium ion is transported out of the cell. This coupling can support a transmembrane glutamate concentration gradient ([Glu](In)/[Glu](out)) exceeding 10(6) under equilibrium conditions, and would allow the transporter to continue removing glutamate over a wide range of ionic conditions.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201	Oregon Health & Science University								ARRIZA JL, 1994, J NEUROSCI, V14, P5559; BARBOUR B, 1989, NATURE, V342, P918, DOI 10.1038/342918a0; BARBOUR B, 1988, NATURE, V335, P433, DOI 10.1038/335433a0; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Billups B, 1996, NATURE, V379, P171, DOI 10.1038/379171a0; BILLUPS B, IN PRESS J NEUROSCI; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; BURGER PM, 1989, NEURON, V3, P715, DOI 10.1016/0896-6273(89)90240-7; CHAN PH, 1983, J NEUROCHEM, V40, P309, DOI 10.1111/j.1471-4159.1983.tb11284.x; CHAUDHRY FA, 1995, NEURON, V15, P711, DOI 10.1016/0896-6273(95)90158-2; Eliasof S, 1996, P NATL ACAD SCI USA, V93, P4153, DOI 10.1073/pnas.93.9.4153; ERECINSKA M, 1983, J BIOL CHEM, V258, P9069; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; HANSEN AJ, 1985, PHYSIOL REV, V65, P101, DOI 10.1152/physrev.1985.65.1.101; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P3949, DOI 10.1021/bi00612a011; Larsson HP, 1996, BIOPHYS J, V70, P733, DOI 10.1016/S0006-3495(96)79613-3; NELSON PJ, 1983, BIOCHEMISTRY-US, V22, P5459, DOI 10.1021/bi00292a030; PATNEAU DK, 1990, J NEUROSCI, V10, P2385; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; SAUGSTAD JA, 1995, EXCITATORY AMINO ACI, P77; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; SZATKOWSKI M, 1994, TRENDS NEUROSCI, V17, P359, DOI 10.1016/0166-2236(94)90040-X; TRUSSELL LO, 1989, NEURON, V3, P209, DOI 10.1016/0896-6273(89)90034-2; VOLTERRA A, 1994, J NEUROSCI, V14, P2924; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; WEBB DJ, 1981, J CELL BIOL, V91, P562, DOI 10.1083/jcb.91.2.562; ZERANGUE N, 1995, J BIOL CHEM, V270, P6433, DOI 10.1074/jbc.270.12.6433; Zerangue N, 1996, J PHYSIOL-LONDON, V493, P419, DOI 10.1113/jphysiol.1996.sp021393	30	664	676	1	32	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1996	383	6601					634	637		10.1038/383634a0	http://dx.doi.org/10.1038/383634a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM755	8857541				2022-12-24	WOS:A1996VM75500057
J	Kim, U; Qin, XF; Gong, SC; Stevens, S; Luo, Y; Nussenzweig, M; Roeder, RG				Kim, U; Qin, XF; Gong, SC; Stevens, S; Luo, Y; Nussenzweig, M; Roeder, RG			The B-cell-specific transcription coactivator OCA-B/OBF-1/Bob-1 is essential for normal production of immunoglobulin isotypes	NATURE			English	Article							BINDING PROTEINS; REGION GENES; ACTIVATION; EXPRESSION; MOUSE; PROMOTERS; MECHANISM	OCA-B was initially identified as a B-cell-restricted coactivator that functions with octamer binding transcription factors (Oct-1 and Oct-2) to mediate efficient cell type-specific transcription of immunoglobulin promoters in vitro(1-3). Subsequent cloning studies led to identification of the coactivator as a single polypeptide, designated either as OCA-B (ref. 3), OBF-1 (ref. 4) or Bob-1 (ref. 5). OCA-B itself does not bind to DNA directly, but interacts with either Oct-1 or Oct-2 to potentiate transcriptional activation(1-5). To determine the biological role of OCA-B, we generated OCA-B-deficient mice by gene targeting. Mice lacking OCA-B undergo normal antigen-independent, B-cell differentiation, including appropriate expression of both immunoglobulin genes and other early B-cell-restricted genes. However, antigen-dependent maturation of B cells is greatly affected. The proliferative response to surface IgM crosslinking is impaired, and there is a severe deficiency in the production of secondary immunoglobulin isotypes including IgG1, IgG2a, IgG2b, IgG3, IgA and IgE in BCA-B-deficient B cells. This defect is not due to a failure of the isotype switching process, but rather to reduced levels of transcription from normally switched immunoglobulin heavy-chain loci. In accord dth the defective isotype production, germinal centre formation is absent in these mutant mice.	ROCKEFELLER UNIV,HOWARD HUGHES MED INST,BIOCHEM & MOL BIOL LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,LAB MOL IMMUNOL,NEW YORK,NY 10021	Howard Hughes Medical Institute; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University			Nussenzweig, Michel/AAE-7292-2019	QIN, FRANK XIAOFENG/0000-0002-5395-0304				BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522; BOTTARO A, 1994, EMBO J, V13, P665, DOI 10.1002/j.1460-2075.1994.tb06305.x; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; COGNE M, 1994, CELL, V77, P737, DOI 10.1016/0092-8674(94)90057-4; DARIAVACH P, 1991, EUR J IMMUNOL, V21, P1499, DOI 10.1002/eji.1830210625; DEFRANCO AL, 1982, J EXP MED, V155, P1523, DOI 10.1084/jem.155.5.1523; GOLD MR, 1994, ADV IMMUNOL, V55, P221; Gong SC, 1996, SCIENCE, V272, P411, DOI 10.1126/science.272.5260.411; GRANT PA, 1995, EMBO J, V14, P4501, DOI 10.1002/j.1460-2075.1995.tb00129.x; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; LI SC, 1994, INT IMMUNOL, V6, P491, DOI 10.1093/intimm/6.4.491; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; LUO Y, 1995, MOL CELL BIOL, V15, P4115; LUTZKER S, 1988, MOL CELL BIOL, V8, P1849, DOI 10.1128/MCB.8.4.1849; MCLENNAN IC, 1994, ANNU REV IMMUNOL, V12, P117; PARKER DC, 1993, ANNU REV IMMUNOL, V11, P331, DOI 10.1146/annurev.immunol.11.1.331; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; QIN XF, 1994, EMBO J, V13, P5967, DOI 10.1002/j.1460-2075.1994.tb06942.x; RAJEWSKY K, 1992, CURR OPIN IMMUNOL, V4, P171, DOI 10.1016/0952-7915(92)90008-3; ROLINK A, 1993, ADV IMMUNOL, V53, P123, DOI 10.1016/S0065-2776(08)60499-X; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; STAVNEZER J, 1988, P NATL ACAD SCI USA, V85, P7704, DOI 10.1073/pnas.85.20.7704; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Wang HY, 1996, IMMUNITY, V4, P113, DOI 10.1016/S1074-7613(00)80676-7; YANCOPOULOS GD, 1986, ANNU REV IMMUNOL, V4, P339, DOI 10.1146/annurev.iy.04.040186.002011; YANCOPOULOS GD, 1985, CELL, V40, P271, DOI 10.1016/0092-8674(85)90141-2	27	205	212	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1996	383	6600					542	547		10.1038/383542a0	http://dx.doi.org/10.1038/383542a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL755	8849728				2022-12-24	WOS:A1996VL75500055
J	Ball, S				Ball, S			Antenatal screening of thyroid antibodies	LANCET			English	Editorial Material							POSTPARTUM THYROIDITIS				Ball, S (corresponding author), ROYAL VICTORIA INFIRM,DEPT MED,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND.							GERSTEIN HC, 1990, ARCH INTERN MED, V150, P1397, DOI 10.1001/archinte.150.7.1397; HALL R, 1995, BAILLIERE CLIN ENDOC, V9, P137, DOI 10.1016/S0950-351X(95)80883-3; HARRIS B, 1992, BMJ-BRIT MED J, V305, P152, DOI 10.1136/bmj.305.6846.152; Lazarus JH, 1996, QJM-INT J MED, V89, P429; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; OTHMAN S, 1990, CLIN ENDOCRINOL, V32, P559, DOI 10.1111/j.1365-2265.1990.tb00898.x	6	16	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 5	1996	348	9032					906	907		10.1016/S0140-6736(05)65334-2	http://dx.doi.org/10.1016/S0140-6736(05)65334-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL097	8843805				2022-12-24	WOS:A1996VL09700005
J	Glover, V; Fisk, N				Glover, V; Fisk, N			For debate - Do fetuses feel pain? We don't know; Better to err on the safe side from mid-gestation	BRITISH MEDICAL JOURNAL			English	Article							RESPONSES				Glover, V (corresponding author), QUEEN CHARLOTTES & CHELSEA HOSP,ROYAL POSTGRAD MED SCH,INST OBSTET & GYNAECOL,DEPT PAEDIAT,LONDON W6 0XG,ENGLAND.		Fisk, Nicholas M/B-2126-2009; Glover, Vivette/M-2711-2016	Fisk, Nicholas M/0000-0003-0031-7975; Glover, Vivette/0000-0001-6543-1651				ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; BENNETT P, 1994, LANCET, V344, P615; DERBYSHIRE SWG, 1994, LANCET, V344, P615, DOI 10.1016/S0140-6736(94)92001-X; FITZGERALD M, 1993, PAIN RES CLIN MANAGE, V5, P19; GIANNAKOULOPOULOS X, 1994, LANCET, V344, P77, DOI 10.1016/S0140-6736(94)91279-3; GLOVER V, 1995, BAILLIERES CLIN PAED, P495; GREENFIELD SA, 1995, JOURNEY CENTRES MIND; Hepper P.G., 1994, J REPROD INFANT PSYC, V12, P143, DOI [10.1080/02646839408408880, DOI 10.1080/02646839408408880]; JONES AKP, 1991, P ROY SOC B-BIOL SCI, V244, P39, DOI 10.1098/rspb.1991.0048; MEANEY MJ, 1993, CELL MOL NEUROBIOL, V13, P321, DOI 10.1007/BF00711576; ROGERS MC, 1992, NEW ENGL J MED, V326, P55, DOI 10.1056/NEJM199201023260109; TADDIO A, 1995, LANCET, V345, P291, DOI 10.1016/S0140-6736(95)90278-3; Teixeira J, 1996, LANCET, V347, P624, DOI 10.1016/S0140-6736(96)91327-6	13	27	29	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1996	313	7060					796	796						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK566	8842075				2022-12-24	WOS:A1996VK56600029
J	Rothe, MJ; GrantKels, JM				Rothe, MJ; GrantKels, JM			Diagnostic criteria for atopic dermatitis	LANCET			English	Editorial Material							FEATURES				Rothe, MJ (corresponding author), UNIV CONNECTICUT,CTR HLTH,DIV DERMATOL,FARMINGTON,CT 06030, USA.							HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; KANWAR AJ, 1991, PEDIATR DERMATOL, V8, P114, DOI 10.1111/j.1525-1470.1991.tb00297.x; KANWAR AJN, 1996, PEDIAT DERMATOL, V13, P10; RUDZKI E, 1994, DERMATOLOGY, V189, P41, DOI 10.1159/000246781; TADA J, 1994, ACTA DERM-VENEREOL, V74, P129; Williams HC, 1996, ARCH DERMATOL, V132, P51, DOI 10.1001/archderm.132.1.51; WILLIAMS HC, 1995, DERMATOL CLIN, V13, P649, DOI 10.1016/S0733-8635(18)30070-6	7	23	23	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 21	1996	348	9030					769	770		10.1016/S0140-6736(05)65206-3	http://dx.doi.org/10.1016/S0140-6736(05)65206-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH989	8813980				2022-12-24	WOS:A1996VH98900006
